<SEC-DOCUMENT>0001558370-23-016393.txt : 20231012
<SEC-HEADER>0001558370-23-016393.hdr.sgml : 20231012
<ACCEPTANCE-DATETIME>20231012145049
ACCESSION NUMBER:		0001558370-23-016393
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		186
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20231012
DATE AS OF CHANGE:		20231012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		231322499

	BUSINESS ADDRESS:	
		STREET 1:		7900 E. UNION AVENUE
		STREET 2:		SUITE 920
		CITY:			DENVER
		STATE:			CO
		ZIP:			80237
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		7900 E. UNION AVENUE
		STREET 2:		SUITE 920
		CITY:			DENVER
		STATE:			CO
		ZIP:			80237

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>aytu-20230630x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/12/2023 5:27:11 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: 5e6d252d-a01a-4df9-8b03-acad12866831 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:aytu="http://aytubio.com/20230630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" xs:nil="true" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_mrEuTDctZU6eyaOEDuRFiQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" xs:nil="true" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_2-s3_3j2KUSm_aQnUWHO0g"></ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_rIBeRtWFvEGJfXJe_l62nQ">http://fasb.org/us-gaap/2023#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="Hidden_BJqygzVGsUWKb9RG-yTu9g">http://fasb.org/us-gaap/2023#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_yQ9teocmrEaukVqlK0qQGA">http://aytubio.com/20230630#ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_ENsPMegNIk2YzYHeCFNu_Q">http://aytubio.com/20230630#ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_llgInfKn_U2zW9dlBCNJSA">http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_FMHpnXdokUSkB93aoVfALQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_IYKQ6G4kC0q2f0Eo8FxG9w">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_l0zNFg108E-x9CeMtWe_cQ">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_uaGaFPSQFEWqA3PDf3QHEg">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_9O13ml59skCUuFb3DYly5g">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityCentralIndexKey" id="Tc_703MTevAkUC44Zd3mOLqdQ_2_1">0001385818</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_RXGs4pIy6k-rOMRza_dEmQ_3_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AmendmentFlag" id="Tc_jOglyZgiXkS8Q-yZN_UixQ_4_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_8_9_2022_3F2Ccz3Wck6721wKJ-0A4Q" name="us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList" id="Hidden_lJyJinKATUWpgR-69fgRWA">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_8_2023_eNIKHDa7GEyCxQqlAVN61w" name="us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList" id="Hidden_Gk_K9Y9VnUGpM3yHOr25gQ">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lW0IGwUkb02QvnOBc2Pj2g" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_3RYmrqdPpkulAM_puxB6GA">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_ClJODWq5GkytcMX5yJ4VSA" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_uFqyeNkqnUqdeYZoziKJTg">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_723PZapFN067HORqlV5P5w" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_tV4Cb9jIzEmzHK0NDzFEuA">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_tW-XdTep1EiTmzvuYPs2Tg" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_yRGseizAxkmA67HfSaHhJA">http://aytubio.com/20230630#ConsumerHealthMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_vn_CdUbVbUCIdczuM-TVqA" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_z6eyzX-6U0S2IpXwpmIt5w">http://aytubio.com/20230630#ConsumerHealthMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" xs:nil="true" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:PreferredStockValue" id="Hidden_LYG5MF9ZSUmaFm4UmaMR2g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" xs:nil="true" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:PreferredStockValue" id="Hidden_GVVL6pelS0SESYOcJDmIMg"></ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_hVXynGx4zUyImHk6UmwuZQ">http://fasb.org/us-gaap/2023#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="Hidden_BSDhkQqovkW5-zz8We4mCQ">http://fasb.org/us-gaap/2023#ProductMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_G-ii9jXEiUerH3aNSGrgcw">0.05</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_r6wyCx8FVUSn4nYPEIcZkw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_ZU0GSZmRRU6mHNeNM31yuQ">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QrBZlgHdA022QUl02C4sgg" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_QQYcc8br-EqS2gjQlclZQg">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_9ibQ5VWhQku-IfGQmqL7sg" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_BkyMcFO_ukqYjCCDP1gOew">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="Hidden_6fUhpC-LoUCZ1c2RWfvzow">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:AccountsReceivableCreditTermsLowEndOfRange" id="Hidden_b9ThaH63FEyijuGZHHcAxg">P40D</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_wY87TqPOnkW6ipA7FPw71Q" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_g-cbh5-g8Eq9t2stexXsqA">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_jqeMvRIcF0KKaWLkShVnzg" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_K8_3hQR_I0yTd3PB8O7Q8Q">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_opCVDrrQuEy8HCC-ycOUCw" name="us-gaap:ReportingUnitNameOfSegmentExtensibleList" id="Hidden_3ehiKXD22k2GoV9XNE777Q">http://aytubio.com/20230630#RxMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_kMk3CteVXE-sj0ReN6tePA">http://fasb.org/us-gaap/2023#AssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_oCFrnX1cZEKlI0YfWFbvaQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_uO7hW3tJ10-9Y4OnbKB2gw">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_kiHw9kJlzEqfvdcIxL-40Q">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_unXTBH375Ue8ldFNegISKg">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_rmlxlXZlBUmyfb7kJxK3Ag">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg" name="aytu:SupplyAndDistributionAgreementTerm" id="Hidden_jJl8Ok9bXUO0qTue9ytzzw">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_Ed_wMja5SES4fIWHM8Ndsg">http://fasb.org/us-gaap/2023#AssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_Yi-wD1QAw027O6Gw0MqnzA">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_YynIzFLXAkeAX8AGtpTUAQ">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" name="us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList" id="Hidden_iwcBQPje9UyI7pXQKxPUyQ">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Hidden_fR7I1KmwmUOKA79OdXpBSQ">2022-09-07</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_n6ygMXZYX06DicD4TeTCsg" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Hidden_Hl9WG5ycz0COuiafV-9j_g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_rz01dYXMbkqXZMuUYv3ppA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_RhAn5e9yTkGo43QiNn8L3A">0.3333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7YsSuAEDpU6Jmd-xM6h7wA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_76J9aX39Y0KMdQ7sa8ZTdA">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3m-PBbKuhE65KlFLmBEPew" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_ZQWV1d3orUOWhJfxpy8Wrw">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_qA7uEawIfEG6yPQLwo5_4A" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Kew6LAzlW0Subej7uXg45g">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_cOsjlAaax0iq1gy16Unhnw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_atRctttF5kGizw3GS0D_sg">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_M8QzGlI3w0ei7UlfZaBHGg" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_UM8ORUgeAkeglLMdGPU3ZQ">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_fx_an4UdW0Kqxay6f5AycA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_fyBILllLnk6bWwcWwYApTw">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_3jn_JzaekUCCqwhh5fzJaA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Ez33FFSqI0uGMSU9NaITRQ">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_tWk3vNLTpUG0H2Wvl2eRBA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_ZiVqmCiNWEOf8STK7ZK6yw">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eYzcqI0yOkiPlqcLPWgNGg" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_aDjYmXhr_0y36dQjawXmwQ">0.3333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SIgXTNQCeUCoZSwIwFVNNw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Cdi3hkXdc0OpPArxBtSwhA">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5WcZTEx5b0iBMqbaHODblw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_w_FAzbQnJkiomaZGu2gnqw">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_eHsxoU6HEUOy3QGc61-17Q" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_RQWy15Pb2k-QNuwGzup_XQ">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_-w-9won20kO7uoXOtbDR1w" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Pb5UtpvkmEGcCA2EitT1Fg">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_l1yBXDDsXkSmrgaCSj0xrw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_NOkVRpcVoUuTSnoKpinAAQ">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_lAg5efzSNE2sQ24FnyN9IA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_pnnHcg3G30GLFzKZerZfyA">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_0KUsBxJuTkW5bP-8Li0HvA" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Zf0xvLUMsEy4X0ESjua5-w">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_FUWMCFz5JEWq94W9ci2zcw" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_SjR6CETviEC4J8qxQetREw">0.0833</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_9EV35llWm0G5Ej7R_H5Kdw">0.05</ix:nonFraction><ix:nonNumeric contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Hidden_u-AypRtbtUiKizPrtwHpzw">2022-09-07</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Hidden_JDyjzzB8SUiDT9RhDuHhaw">P5Y6M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="aytu-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_9_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_1cn0JRM84U6rdzEe3qxCig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_QByDhdR18kWOtQNXuaKWXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-06</xbrli:startDate><xbrli:endDate>2023-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0Kak6DTDzkyr-6pUSkAZgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yekhljvbxU-rrnE2lH9ydw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O4CwaXSKW0-EnAiW9BgQ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_ThApNN5hSEC7yAWt4I3olg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_WlYHSncbxkyESoDclR_i5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_YRN694O3EEKsSKs55s-uVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_se_2_5-8wkmfy3FsWYR-eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_n6ygMXZYX06DicD4TeTCsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_q294pgLXSkiw4_mNpKB8fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_t8eRN6kS_EqT7DiyJIMG7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_13_2020_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_L2WFGiNHUUeTtcgD-Tt5cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_8cakf67lD06PgvsYxOk2qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_Hq8jU58mP0yXy0NLI2hCtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_19_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_5bokif2CVU27ubsvFSCIGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_c91ZRffRLEe9Xlg8BIIOcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_VVTadRrGBUuL-6oQmtuGQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_2_2021_To_8_2_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_6Su9NkIAvUOaA057CsgVYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2021-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7YsSuAEDpU6Jmd-xM6h7wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3m-PBbKuhE65KlFLmBEPew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_rz01dYXMbkqXZMuUYv3ppA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_M8QzGlI3w0ei7UlfZaBHGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_fx_an4UdW0Kqxay6f5AycA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_tWk3vNLTpUG0H2Wvl2eRBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_qA7uEawIfEG6yPQLwo5_4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_cOsjlAaax0iq1gy16Unhnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_3jn_JzaekUCCqwhh5fzJaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SIgXTNQCeUCoZSwIwFVNNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5WcZTEx5b0iBMqbaHODblw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eYzcqI0yOkiPlqcLPWgNGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_l1yBXDDsXkSmrgaCSj0xrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_lAg5efzSNE2sQ24FnyN9IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_FUWMCFz5JEWq94W9ci2zcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_eHsxoU6HEUOy3QGc61-17Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_-w-9won20kO7uoXOtbDR1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_0KUsBxJuTkW5bP-8Li0HvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-17</xbrli:startDate><xbrli:endDate>2022-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_-jV0TussHES3Y8yd6y1Z7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_amdkmNT3rEWFjdSSoepO6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_S6HC2MMrH0iNwu4ujLgsNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_bgnuDzVZ90GHs01Kz4agwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_gPGJ0H3cakSZg1nXXAX0Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_trxd6492bkmdu5cEs_LDOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_CQLYBsBbXECCphRQy0MWNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_us-gaap_NonUsMember_LkBwlL2700aENO-vthtouA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_ny4Ioj3TaUWAHDoTez-dHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_country_US_eQR9LbH5NkuCUdtmvO2k4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_7PrD9QVnpUeLAEO5GWzdCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_cXbnpjXPukexCAFy3_LFIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_Ei3dfZNp9kKN-0D3nbjFKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_zUCpOHor3EKdIXUHOlnNXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_country_US_rIjPJISGDEi3pzssDPn3HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_YxGJ1VVEdEyw5ny5-XgKFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_-wVTRKUC6ECEuGno8N9RJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_723PZapFN067HORqlV5P5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_ClJODWq5GkytcMX5yJ4VSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_vn_CdUbVbUCIdczuM-TVqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lW0IGwUkb02QvnOBc2Pj2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_opCVDrrQuEy8HCC-ycOUCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_jqeMvRIcF0KKaWLkShVnzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_tW-XdTep1EiTmzvuYPs2Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_wY87TqPOnkW6ipA7FPw71Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_r6wyCx8FVUSn4nYPEIcZkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_9ibQ5VWhQku-IfGQmqL7sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QrBZlgHdA022QUl02C4sgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_9jIFl-JbSUSy2-E0dwOfCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_5MqaEaeetUGtGEYDAHXg8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_7mJbheQk9E-fPv17qgwvgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_CSjduuCOFUWc6w0vdHoF3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_kQajJzeLJkCdUTJlMSe9iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_bUb-E6CVMEW0AkWN12ZTNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_qTHTkenh9EuSbsPXngyU5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_NGXHsoRLLUW-TllyXMODGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_y5gGC1vDBUWYv1EcPoN6Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MBlO3K9Y5E-CNimpZftBwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q2AFXDkUOEyEfmyAK7PljQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Svctda3Et0O2kTjOc-zi0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_Y4i8_JEJe0SvA0HJFtx-NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_gcPJdm_wtE65EZK74cL6oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_4QygS4Rlv0O5YI7SfAsGHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_8Yuqe19JIk2B29trNymR7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_db-vGfL3fUmxvIexRiVKVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_lv1AQVTl0keo4ZlP9CVIgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_NeosTherapeuticsIncMember_jE3g0rsLqEWv2jo6veaozw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NeosTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_ThMW95wZjkCdP_ru56uSmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_ZolpiMistMember_dJH0ndjeUEaT4pdit6AumQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ZolpiMistMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_TussionexMember_zVcKQ1_g1UWXhUn0779uOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:TussionexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_CefaclorMember_mhqlF9Qs0UWCJpWeLPVIJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:CefaclorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AciphexMember_qGDcQ6lLy0ulHTbXHsPakA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AciphexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_17kGrCVmQEOjFdEV5C2_zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_DxeLmfrDLkiqMKsp5HRFVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_g8KZkdeDqk-U60JJxrNmOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_F_kE5Lxwtky7YSEDVzN1hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_JXn5-Xzq2kiOE7uPypp10Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_fwYbk0T1rkuVqkxgYwDegA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_Sbisw7Ka2U-eJeK-plm2KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_96lPa_UH3EC_sxZ01SDNgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_kEPlwQ3Z5EajARrt_81BZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_pvg1LRUhb0W16a7tuQUDyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_i3pgtEL-p0az9jQE1IUGqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_KFT-owhYG0KTW-8HwcgXlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentValueRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_AfRtXHFQ9USFYETLv0hWfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentValueRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_4vybuWwiOkecBLkUHT6SMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_N8QRmflkVEK0aXHJHlg2eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UpGaGbRyLEqoaYVRkRx8cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_eNIKHDa7GEyCxQqlAVN61w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2022_3F2Ccz3Wck6721wKJ-0A4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wTfWp6Qu5kuUcvqKqDdSvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Z12qpqcVkkK_jr6qZ_cGBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_IsVh2msT0EmhmcrW0JvYbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lzWJ_F-ZrUaSzSfq1TNUiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LRQAfaW_D0auL9YBkk-kXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_3CSXkEWhhkC8dtO67-wH2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_V5QFAOw8DUmhBp4aYi7M0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_psdJZSxrqEyjZhoFMF-3Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_OU6-ZAL7g068xkL0XGt6CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_uyAuyq8iF02T8ekDM7p7Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9VU0MObsYUWsSE7KNqA2LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BwVbhIEKsk-sG7dxwmlpBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lHN7htztVE6wijIYRnB1CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LU7VfbLrpkCDkceqmLfiUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7aP_mPOQnEm0PE5wFOYT_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_RUN5j4oRMUyMIuo84vuTaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:SixPercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_x_PrG4pcs06d9XTkn5jk5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_iQ5ElZ-9mkCBPVrJJm9cng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_hvi9wwMyG02M4YOpOzDNtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_sWQv2CL_9karqaYLUrXPDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_-JXzqrvuMU6CA_7Lj0xMKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_BL_kOTzSHEKA4ccnDQIqTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7x7PFK5f0kiltq3YkU0RXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_WbJzKLlmzki6AlcwWXPsyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_1tT0xZNkt0etJpk7fTLLPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_M0-TXPTse0mGHnAuhWTPYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_bt9P46zN4Uul011WiS7arg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gPuRFu8KH0SGqG1C9lGBcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MuRUdcU6WUG7NmDnhiTGRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dmuRzfJ_1EO6Agna7CZtLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_pYyR9VketkCher0rQtHN3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_DezRVWJ-AU2jRVzIgJxVKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dI9JDG4GZ0q2nb3uqscqxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_dyFD-8ah2kCovq17PPt-2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fubd0D8AXkeZ3HKcrke_bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MpUuzivE-kWKg5ULjMW2Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__8vHwioqrU-ElY0VqMElLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_G2AveL47mkeAW3hRAHiUWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TdsGYshoqUijifsxflxvYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U52ccDTbd0SLphyOs_tA1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_bb-F103xJEKObyLwN9P9hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_jJVCcTYbiUaIJ-QiKtx9tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_BMNvc2gmyU2xEU7d2Lo8uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_aUf6uQX8JkCRV6eBvCg8Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_25_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_Y2L8pKkibkq2ytqbielQJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_ik8BrUrWiUqfXRn4qxLh-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_I38l4DudfUG9B_ywzeXUNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_hHbd5LNmMkO0y394Oj5L5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_tKH_DOG2x0SbdakkNDfEwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2022_To_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_8BPUJ7pkK0qSQNua439-Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ZXAfman6vk2Sxgjn7SWz_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201613Member__qlcvv9uqkqtL2K0Bw_iFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q9trfMe7pUqct3050BPKPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_uaS8GvqRBE6WifGw2IAIyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j3RI5vFShkKJU2UzYtHHnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember__yHJIt2Q9UOXX-nN6ZJg3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_btNydZdRJUeurgcuPy8Ayw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_sbvAUga0FkCVwaanOZG6qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Z3wjagFy1kWhlKur4kTO9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember_GoexjV6gxkqMDtQcdeO1uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_m2S0-xKuZ06BhQoPKWEIIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_G4vMM4ms7UyTRxItSf21Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lWZtLtuZq0aBxZRyaXV8jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_M9qxYqENEUmjeBlE_Zjf2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_xlpXGmnCE0q9N4hnP11C0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_l930vcslY0aPIpci-ZFhFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AwSMEA2VYkySNlTWV-Mg5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_95MKJo-V6E6JsQfGaBmnxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_vnaTWWbZJUOh5Za0C4EoQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_30_2022_Hh0hfMIawkOJO2Wn8Wo4kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2023_ra_B9a0R50O4AefrE3gZZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SupplyAndDistributionAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SupplyAndDistributionAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_6_30_2020_uXBqmTqkjkG4C-vVf43Sxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_t8Ed9oXcc0ahpFotmKPoCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_28_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_biR4fT1tx0yl6OmCteqbJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2020_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfMember_g5mEjHtQiUyvG-DIxyhSLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_1u8MB_0WKUqOOhFJoTnpRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpirationOfSubleaseMember_qJVnAen4DEKJ5nCT7EWV2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:ExpirationOfSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpansionDateMember_OStY-vIWGkihjBhiDOXvUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:ExpansionDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_PuGTLMkWzEGYXoqXlmsEWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_qxV92QOxs02EZ-8Z3YXlNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:ProductContingentLiabilityNovalereFluticareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:ProductContingentLiabilityNovalereFluticareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_srt_RangeAxis_srt_MinimumMember_0H_yp89jtUqG89f48FDrpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_O8YhH2nEYUOb-JVw1s0Yfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2017_To_10_31_2017_us-gaap_TypeOfArrangementAxis_aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_1wb-z3AmGEG4sOa28Qj_VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LicenseAgreement2017ShireLlcNewDrugApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2016_To_2_29_2016_us-gaap_TypeOfArrangementAxis_aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_eC9Z_MBaeUGsNuYWxQQb7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementsAr101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementsAr101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LicensingAgreementCedarsSinaiMedicalCenterHealightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_wh8-haFGq0ilyzEd2ep6MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_vUpSuynmCUCGZ3WZlbjUuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_86YG5A0Um0yo8qgGtK-dHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_45L0yjrLA06cm11dTTlAbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_WKARek3HGUePLpa2Lv1yQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_KrFIpmKuVEO1-6ai2hZCKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_7wtjA0AipUW_t_5VDehRxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_psb5HJRJGUmm-pY27HkHJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_5qxxQfplJUCrdZsaKXc-bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Z0XzDKGO6UGmhcRPSeKd1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_12_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_jDvZD8q0Y0el44FFCfCVRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_12_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_2wCCGQMMCUmH4iUajN7RIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_UOFSRPaFi0u7A5wpcioV4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_m0FsqjSjeUaa1vPcTxPTlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_kws3beaygUG87BjJP1LOuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-26</xbrli:startDate><xbrli:endDate>2022-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-JITEKUA0GmzvfgKWJObg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_G4Ig525OfkKi6bpvihM7ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_XqoLyaAyJkqUthh4KeWIOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_v1uEDB4Qe0ChX25O408Kdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputMarketRiskPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputLeveragedBetaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6RWMQBcVTkKXBXn5bPIjLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_vlDLGuQ7RU6fpglPTudPkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_z3pQQ5Ly3kepba66l3j4ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_j9upZ0K_wkaSqBsZ35fPUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputMarketRiskPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_32pYQVd-O0683kHB-OxqJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputLeveragedBetaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_umMfg0XoZ0-AYDOK8yZ-LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_4_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_6bo-99QlKEWBnykXi0Nj8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_LnhBuUfFUU2Q1TN_RRlvNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-08</xbrli:startDate><xbrli:endDate>2023-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg"><xbrli:measure>aytu:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w"><xbrli:measure>aytu:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw"><xbrli:measure>aytu:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA"><xbrli:measure>aytu:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ"><xbrli:measure>aytu:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg"><xbrli:measure>aytu:payment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_JfZ2PWRCJ0apFPM0xMjerg"><xbrli:measure>aytu:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg"><xbrli:measure>aytu:plan</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:24.48pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_370856b8_ed8e_496d_965c_2ac1c5ca8c82"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentType" id="Narr_ydSwSaK_l0CGsnK35sfYiw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3364e9fe_1e96_4372_a67d_c6f74888ab41"></a><a id="Tc_WMLkz1kBKEaTsOKRfaAEpw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentAnnualReport" id="Tc_xz9_IZehKkWAbAbfM-SWTQ_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentPeriodEndDate" id="Narr_F0D7lfQbBEKbXiNDfH3-Jg"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:CurrentFiscalYearEndDate" id="Narr_uerQKjMF5kWskO-7t5g1Rg"><b style="font-size:7.5pt;font-weight:bold;">June 30</b></ix:nonNumeric><b style="font-size:7.5pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentFiscalYearFocus" id="Narr_pZ83pVOZrEGQtDJtiAH5ig"><b style="font-size:7.5pt;font-weight:bold;">2023</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8da8b47f_a929_4739_91b5_8b25b38a164a"></a><a id="Tc_pQpbkdleqEeN5X31qhv0Bg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:DocumentTransitionReport" id="Tc_thWcF5m650uNbPRFJSOykA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityFileNumber" id="Narr_kOV_pSMc6km0gZ5lAtaduQ"><b style="font-size:7.5pt;font-weight:bold;">001-38247</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="aytu-20230630x10k001.jpg" alt="Graphic" style="display:inline-block;height:24.48pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:112.32pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityRegistrantName" id="Narr_9Rv2Yw5Yok2-DNcoF68sAg"><b style="font-weight:bold;">AYTU BIOPHARMA,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a18aa377_f5c8_456a_8da5_f94b93dad489"></a><a id="Tc_IgbLJ63wDUWReunOx2Z7GQ_2_0"></a><a id="Tc_FPZ1kxkJA0OVdV8HfO4kJg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_M5QOELngpEKNb3MQ1lkBqQ_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityTaxIdentificationNumber" id="Tc_SamGF8uPV0CsM4nla8u4cA_1_2"><b style="font-size:8pt;font-weight:bold;">47-0883144</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of incorporation</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">or organization)</b></p></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification Number)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_98c32ba2_85f1_4e24_b7c5_0135bc8596ac"></a><a id="Tc_HDtjeAT_fkG_H5GBmbTjTw_1_0"></a><a id="Tc_rf8MzIXdWEmBHsEE416bIg_2_0"></a><a id="Tc_Ie0YKaVs7kqcMCGN2jnmvg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityAddressAddressLine1" id="Narr_U66rSZNGNEuJWjDZyYeNMg"><b style="font-size:8pt;font-weight:bold;">7900 East Union Avenue</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityAddressAddressLine2" id="Narr_JWzYxWuPdUeHgqKqQ-w_xA"><b style="font-size:8pt;font-weight:bold;">Suite&#160;920</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityAddressCityOrTown" id="Narr_jBnhrLMSYU29RjpTiRsX9A"><b style="font-size:8pt;font-weight:bold;">Denver</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityAddressStateOrProvince" id="Narr_2ewQ9oRrtkCKYdmdv2l6hw"><b style="font-size:8pt;font-weight:bold;">Colorado</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityAddressPostalZipCode" id="Tc_Cus_K2-iUE2JzbcrxVJNNQ_1_2"><b style="font-size:8pt;font-weight:bold;">80237</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:middle;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:CityAreaCode" id="Narr_DwNQv4hypUOwn-Skhq5XNQ"><b style="font-size:8pt;font-weight:bold;">720</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:LocalPhoneNumber" id="Narr_h7n72GSvOUiqz35HYYGcWQ"><b style="font-size:8pt;font-weight:bold;">437-6580</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_7815c751_19be_4c64_a81c_b67875d0cec7"></a><a id="Tc_0gcsbtCsHUWwDcIOwFnQDA_1_0"></a><a id="Tc_zHxuaSciD0K3baXaTxek0A_1_1"></a><a id="Tc_WIIxOKpE30Whw_aLsMuJmA_1_2"></a><a id="Tc_LhJjAtB3ZUWfO_lQtu-6wg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:31.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">registered</b></p></td></tr><tr><td style="vertical-align:top;width:31.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:Security12bTitle" id="Tc_HE2FRogN4ECSq2YP1ReJkg_2_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, par value </b><b style="font-size:8pt;font-weight:bold;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" format="ixt:numdotdecimal" scale="0" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" name="dei:EntityListingParValuePerShare" id="Narr_8FAVmQ39Qkylj2JRVowEkA">0.0001</ix:nonFraction></b><b style="font-size:8pt;font-weight:bold;"> per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:TradingSymbol" id="Tc_fRZEZy_pB0qf5Q_vXc-EEg_2_1"><b style="font-size:8pt;font-weight:bold;">AYTU</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">The </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:SecurityExchangeName" id="Narr_gWLiYz6hPE-GCjY4k_Hv2Q"><b style="font-size:8pt;font-weight:bold;">NASDAQ</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_0pVncOb2gUeNY6C1iJQYng"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. Yes </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityVoluntaryFilers" id="Narr_ENUspgn5fEKci7ikmDuogQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by a check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityCurrentReportingStatus" id="Narr_GSHL-lDTLEGE6GJWVUk3Gw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7.5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityInteractiveDataCurrent" id="Narr_4d7y6gZcgkyvYGEzoeKdaw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:7.5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act. (check one):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_25cdc6c5_764f_4193_b0ee_f796c0c3a9a3"></a><a id="Tc_fbgj8viSB0ynjztJoCNhLA_1_0"></a><a id="Tc_D7yjF9YWNUKkSsXjNT15MA_1_1"></a><a id="Tc_wP1_e76eMk2tfj74n-b1zA_1_3"></a><a id="Tc_qvEgcYGFhUehBfOCTvWPhw_1_4"></a><a id="Tc_xydFQW47B06e0NXyB5r8BA_2_1"></a><a id="Tc_ed2cSpNsnUi7pCO0WYbuJg_2_3"></a><a id="Tc_mAknGZsOuUiiOyuLz5PJBA_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:45.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:24.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:top;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityFilerCategory" id="Tc_k6YzN7-XmUaVugMZfIr7Ow_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntitySmallBusiness" id="Tc_enzPHWmqqk6PfTKekZJz8w_2_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:19.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityEmergingGrowthCompany" id="Tc_63k51YX0WkihSnILVdhvhw_3_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;background:#ffffff;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_k9BuwhWH2E6oN_B7IgOHow"><span style="font-family:'Segoe UI Symbol';font-size:8pt;background:#ffffff;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:EntityShellCompany" id="Narr_u5Oei-wlkUqBgw2kquw4WQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt;">The aggregate market value of common stock held by non-affiliates of the Registrant as of December&#160;30, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_12_30_2022_Hh0hfMIawkOJO2Wn8Wo4kA" decimals="-5" name="dei:EntityPublicFloat" id="Narr_DPYargVTMUqFcd7nvOFMXg">12.3</ix:nonFraction> million based on the closing price of $3.80 as of that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;">As of September 20, 2023, there were </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_9_20_2023_ra_B9a0R50O4AefrE3gZZw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_FGbhoC608Eu52Cc_3aJxAA">5,530,027</ix:nonFraction></span><span style="font-size:8pt;"> shares of common stock issued and outstanding</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4fb39a80_4ac7_4af7_8f2c_afd33f5064fb"></a><a id="_46566"></a><a id="TABLEOFCONTENTS_296149"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PAGE</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_288341"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_572453"><span style="font-style:normal;font-weight:normal;">Item&#160;1</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_572453"><span style="font-style:normal;font-weight:normal;">BUSINESS</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_545192"><span style="font-style:normal;font-weight:normal;">Item&#160;1A</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_545192"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_256339"><span style="font-style:normal;font-weight:normal;">Item&#160;1B</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_256339"><span style="font-style:normal;font-weight:normal;">UNRESOLVED STAFF COMMENTS</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_819204"><span style="font-style:normal;font-weight:normal;">Item&#160;2</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_819204"><span style="font-style:normal;font-weight:normal;">PROPERTIES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_332346"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_332346"><span style="font-style:normal;font-weight:normal;">LEGAL PROCEEDINGS</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_822048"><span style="font-style:normal;font-weight:normal;">Item&#160;4</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_822048"><span style="font-style:normal;font-weight:normal;">MINE SAFETY DISCLOSURES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_350944"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_459290"><span style="font-style:normal;font-weight:normal;">Item&#160;9A</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_459290"><span style="font-style:normal;font-weight:normal;">CONTROLS AND PROCEDURES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_33867"><span style="font-style:normal;font-weight:normal;">Item&#160;9B</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_33867"><span style="font-style:normal;font-weight:normal;">OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJ"><span style="font-style:normal;font-weight:normal;">Item 9C</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJ"><span style="font-style:normal;font-weight:normal;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_810231"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Item&#160;10</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_611473"><span style="font-style:normal;font-weight:normal;">Item&#160;11</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_611473"><span style="font-style:normal;font-weight:normal;">EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsRelatedTransac"><span style="font-style:normal;font-weight:normal;">Item&#160;13</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsRelatedTransac"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_131801"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandConsolidatedFinancialSt"><span style="font-style:normal;font-weight:normal;">Item&#160;15</span></a></p></td><td style="vertical-align:top;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandConsolidatedFinancialSt"><span style="font-style:normal;font-weight:normal;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16_10K_SUMMARY"><span style="font-style:normal;font-weight:normal;">Item 16</span></a></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16_10K_SUMMARY"><span style="font-style:normal;font-weight:normal;">FORM 10-K SUMMARY</span></a></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:80%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_374122"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2a14deb0_e46b_440f_a743_b09da9c63983"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or Annual Report, includes forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;suggest,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the markets for our approved products and our plans for our approved products, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, the potential future commercialization of our product candidates, our anticipated future cash position and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including without limitation the risks described in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report. These risks are not exhaustive. Other sections of this Annual Report include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless otherwise indicated or unless the context otherwise requires, references in this Form&#160;10-K to the &#8220;Company,&#8221; &#8220;Aytu,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; are to Aytu BioPharma,&#160;Inc. and its wholly owned subsidiaries.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">This Annual Report on Form 10-K refers to trademarks, such as Aytu, Adzenys XR-ODT, Cotempla XR-ODT,  FlutiCare, Innovus Pharma, Neos, OmepraCare, Poly-Vi-Flor, Regoxidine, and Tri-Vi-Flor which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-K also contains trademarks, service marks, copyrights and trade names of other companies which are the property of their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-K may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We obtained statistical data, market and product data, and forecasts used throughout this Form&#160;10-K from market research, publicly available information and industry publications. While we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified the data, and we do not make any representation as to the accuracy of the information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_39f7eccf_5e90_4373_b7b4_b8c54a246186"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Summary of Risk Factors </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following list summarizes what we believe to be the principal risks relevant to our company. The following summary is further elaborated on by the full text of the risk factors provided in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for the year ended June 30, 2023. All capitalized terms in this section not defined herein shall have the meanings given to them elsewhere in this Annual Report. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Business and Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We have incurred losses since our inception and may incur continued losses in the future. We may never achieve or maintain profitability, and we may require additional capital to fund our operations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our failure to comply with the covenants or other terms of the loan and security agreement with Avenue Capital and our secured revolving loans with Eclipse could result in a default under those agreements that could materially and adversely affect the ongoing viability of our business.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>Our credit facility agreements contain restrictions that limit our flexibility in operating our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We have indefinitely suspended development of our AR101 (enzastaurin) clinical development program and shifted our strategic focus towards accelerating the growth of our commercial business.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we are unable to successfully commercialize our commercial prescription products, our business, financial condition and results of operations may be materially adversely affected, and the price of our common stock may decline.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The commercial success of our commercial prescription products will depend upon their acceptance by multiple stakeholders, including physicians, patients, and healthcare payors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we are unable to differentiate our commercial prescription products from current and future products or existing methods of treatments or if the market opportunities for our commercial prescription products are smaller than we believe, our ability to successfully commercialize our commercial prescription products would be adversely affected and our revenue may be adversely affected.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we or our contract manufacturing organizations (&#8220;CMOs&#8221;) fail to manufacture sufficient quantities of our attention deficit/hyperactivity disorder (&#8220;ADHD&#8221;) prescription products, we may be unable to meet market demand and our ability to generate revenues could be affected.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We may encounter manufacturing problems resulting in insufficient quantities being produced or not having access to the requisite supplies.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we do not secure collaborations with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful revenues.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If third-party payors do not reimburse pharmacies or patients for our commercial prescription products or if reimbursement levels are set too low for us to sell our commercial prescription products at a profit, our ability to successfully commercialize our commercial prescription products and our results of operations will be harmed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we cannot implement and maintain effective patient affordability programs or improve formulary access for our commercial prescription products in the face of increasing payor pressures, the adoption of our commercial prescription products by physicians and patients may decline.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other applicable regulatory authorities approve generic or similar products that compete with our commercial prescription products, or if the FDA or other applicable regulatory authorities change or create new pathways that may expedite approval of such products, it could decrease our expected sales of our commercial prescription products.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Even though we have obtained regulatory approval for our commercial prescription products, we still face extensive FDA regulatory requirements and may face future regulatory difficulties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our relationships with physicians, patients, payors, and pharmacies in the U.S. are subject to applicable anti-kickback, fraud and abuse laws and regulations. Our failure to comply with these laws could expose us to criminal, civil and administrative sanctions, reputational harm, and could harm our results of operations and financial conditions.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate to protect our technology, our commercial prescription products or our other product candidates, our competitors could develop and commercialize technology similar to ours, and our competitive position could be harmed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We may become involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which could be uncertain and could harm our business.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Our Organization, Structure and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our efforts to expand and transform our business may require significant investments and may be unsuccessful.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We may have difficulties integrating acquired businesses and as a result, our business, results of operations and/or financial condition may be materially adversely affected.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Securities Markets and Investment in Our Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>The price of our common stock may be volatile, and you may lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Future issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our business and operations would suffer in the event of system failures or security breaches whether such failure or breach was physically affected or affected via a cybersecurity failure.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Our sales force and other employees, third party logistics partners, CMOs, contract research organizations (&#8220;CROs&#8221;), principal investigators, collaborators, independent contractors, consultants and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in this Annual Report on Form 10-K. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our securities to decline and could cause you to lose all or part of your investment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_43d70da4_1841_4641_9f78_7e91f8a0697e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">AYTU BIOPHARMA,&#160;INC.</p><a id="PARTI_288341"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_572453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">COMPANY OVERVIEW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; the &#8220;Company&#8221;, &#8220;we&#8221;) is a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the &#8220;Consumer Health Portfolio&#8221;). We were originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and were re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;) in March 2021 (the &#8220;Neos Acquisition&#8221;), we changed our name to Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses in each year since inception. Our net loss was $17.1 million for the year ended June 30, 2023, and as of June 30, 2023, we had an accumulated deficit of $304.1 million. We expect to continue to incur significant expenses in connection with our ongoing activities, including the integration of our acquisitions, although we do expect to become profitable following that integration and through continued growth of our commercial business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective January 6, 2023, we effected a 1-for-20 reverse stock split of our outstanding shares of common stock. Unless specifically provided otherwise herein, the share and per share information that follows in this Annual Report, other than in the historical financial statements and related notes included elsewhere in this Form 10-K, assumes the effect of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RECENT BUSINESS DEVELOPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our ongoing strategic evaluation and go-forward operating plan, we are prioritizing growing our Rx Segment given the encouraging prescription trends for both our attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) Portfolio and Pediatric Portfolio, and the current market trends supporting our products&#8217; growth. We believe focusing resources on our most profitable, rapidly growing products and business segments provides the most effective pathway to achieve near-term companywide profitability and continued growth. As part of our plan, we expect to monetize, divest, or otherwise discontinue the Consumer Health Segment in order to maximize profitability and, if a divestiture is made, provide us with non-dilutive capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In fiscal year 2023, we recorded net revenue of $73.8 million in our Rx Segment, the highest revenue achieved in our history. During the year, the ADHD market encountered several supply chain interruptions, causing a shortage of medications for these patients. We were able to increase the production of our ADHD medications, Adzenys XR-ODT (&#8220;Adzenys&#8221;), and Cotempla XR-ODT (&#8220;Cotempla&#8221;) to provide patients with alternative solutions to products that have experienced supply chain interruptions. As a result, we recorded the highest prescription levels for both Adzenys and Cotempla in 2023.  Our Pediatric Portfolio products, Poly-VI-Flor, Tri-Vi-Flor and Karbinal, also recorded record prescriptions in our fiscal 2023, which was largely attributable to sales force execution and our Aytu Rx Connect program. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently manufacture both Adzenys and Cotempla in our facility in Grand Prairie, Texas. In an effort to reduce costs, we are in the process of transferring the manufacture of these products to a third-party manufacturer. In April 2023, we received approval from the U.S. Food &amp; Drug Administration (&#8220;FDA&#8221;) of the Adzenys Prior Approval Supplement (&#8220;PAS&#8221;), which enables the transfer of manufacturing of Adzenys to a third-party manufacturer. In June 2023, we submitted the Cotempla PAS to the FDA. We expect to have a six-month review process for the Cotempla PAS. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AR101 (enzastaurin) is a development-stage asset we had been developing as an investigational treatment for Vascular Ehlers-Danlos Syndrome (&#8220;VEDS&#8221;), a rare connective tissue disorder for which there are no approved treatments. AR101 has received Orphan Drug Designation from both the FDA and from the European Commission, thus making AR101 eligible for market exclusivity upon product approval. AR101 also received Fast Track Designation from the FDA given the urgent, unmet need in VEDS. We do not expect the development of AR101 to advance until we are able to either fund development through operating cash flows, or through an out-license or sale to a strategic partner as we focus our resources to commercial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we entered into a licensing agreement with Cedars-Sinai Medical Center (&#8220;Cedars-Sinai&#8221;) to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational ultraviolet light-based medical device platform being investigated as a prospective treatment for severe respiratory infections. The licensing agreement with Cedars-Sinai grants us a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. We terminated the Healight license on May 9, 2023 and are in the process of returning materials and transferring all intellectual property to Cedars-Sinai as we shift our resources to commercial purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, we entered into an Exclusive License Agreement (&#8220;NeuRx License&#8221;) with NeuRx Pharmaceuticals LLC (&#8220;NeuRx&#8221;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx&#8217;s proprietary compound designated as NRX 101, subsequently referred to as NT0502. NT0502 is a new chemical entity that was being developed for the treatment of sialorrhea, which is excessive salivation or drooling. In April 2023, and in order to focus our resources on commercial operations, we returned the NT0502 rights to NeuRx in exchange for royalties and milestone payments on monies received by NeuRx from future licensing agreements, asset sales or revenue generated on NT0502.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Debt and Equity Financings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Avenue Capital Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, we entered into a Loan and Security Agreement (the &#8220;Avenue Capital Agreement&#8221;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. (the &#8220;Avenue Capital Lenders&#8221;), collectively (&#8220;Avenue Capital&#8221;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0&#160;million loan. The interest rate on the loan is the greater of the prime rate and&#160;3.25%, plus&#160;7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of existing debt, which was assumed through the acquisition of Neos Therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 13, 2023, in conjunction with the equity financing described below, we announced that the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. The interest-only period now extends to the January 26, 2025 maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eclipse Loan Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the Avenue Capital Agreement, we entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (&#8220;Eclipse&#8221;), dated as of January 26, 2022 (the &#8220;Eclipse Loan Agreement&#8221;). Pursuant to the Eclipse Loan Agreement, we, among other things, extended the maturity date of the Eclipse Loan Agreement to January 26, 2025 and reduced the maximum availability under the Eclipse Loan Agreement from $25.0&#160;million to $12.5&#160;million minus a $3.5&#160;million availability block.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 24, 2023, the Company and certain of its subsidiaries entered into Amendment No. 4 (the Eclipse Amendment&#8221;) to the Loan and Security Agreement dated October 2, 2019. The Eclipse Amendment, among other things, increased the maximum amount available under the revolving credit facility provided under the Eclipse Loan </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Loan Agreement remains subject to a borrowing base and reserve, and availability blockage requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Financings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, we raised gross proceeds of $10.0 million from the issuance of (i) 1,075,290 shares of our common stock, and in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock (the &#8220;Pre-Funded Warrants&#8221;), and (ii) accompanying warrants (the &quot;Common Warrants&quot;) to purchase 1,265,547 shares, as adjusted, of our common stock. We received $9.1 million in proceeds net of underwriting fees and other expenses. In August 2022, the Pre-Funded Warrants were exercised in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we raised gross proceeds of $4.0 million from the issuance of (i) 1,743,695 shares of our common stock, and (ii) in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of common stock and (iii), accompanying Tranche A warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock. We received approximately $3.4 million in proceeds net of underwriting fees and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">COMMERCIAL BUSINESS OVERVIEW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We operate through two business segments (i) the Rx Segment, consisting of various prescription pharmaceutical products sold through third parties, and (ii) the Consumer Health Segment, which consists of various consumer health products sold directly to consumers. We generate revenue by selling our products through third party intermediaries in our marketing channels as well as directly to our customers. We currently manufacture our ADHD products at our facility in Grand Prairie, Texas, and use third party manufacturers for our other prescription and consumer health products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rx Segment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Rx Segment consists of our ADHD Portfolio and our Pediatric Portfolio. Our prescription products are sold solely in the United States and are distributed through multiple channels, including sales to pharmaceutical wholesalers and pharmacies, using third-party logistics enterprises. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We acquired our ADHD Portfolio in March 2021 with the acquisition of Neos Therapeutics. These commercial ADHD products are extended-release (&#8220;XR&#8221;) medications formulated in patient-friendly, orally disintegrating tablets (&#8220;ODT&#8221;) that utilize the Neos-developed microparticle modified-release drug delivery technology platform. Products containing amphetamine or methylphenidate are the most commonly prescribed medications in the United States for the treatment of ADHD. Adzenys (for patients six years of age and above) and Cotempla (for patients six to seventeen years of age) are the first and only FDA-approved amphetamine and methylphenidate extended-release, orally disintegrating tablets, respectively, for the treatment of ADHD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our prescription Pediatric Portfolio includes Karbinal&#174; ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above and Poly-Vi-Flor&#174; and Tri-Vi-Flor&#174;, two complementary prescription fluoride-based multi-vitamin product lines containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency (Karbinal ER, Poly-Vi-Flor and Tri-Vi-Flor are collectively the &#8220;Pediatric Portfolio&#8221;). These products serve established pediatric markets and offer distinct clinical features and patient benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We commercialize our Rx Portfolio through our internal commercial organization that includes approximately forty sales territories for our ADHD Portfolio and approximately six sales territories for our Pediatric Portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our Aytu RxConnect&#8482; patient support program operates through a network of approximately 1,000 pharmacies to offer affordable, predictable copays and hassle-free availability to all commercially insured patients, regardless of their individual insurance plan. In addition, RxConnect seeks to significantly reduce the challenges and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">frustrations that health care professionals and their office staff can face when prescribing branded medications, including our medications, for their patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, we entered into an exclusive collaboration, distribution and supply agreement with Medomie Pharma Ltd, (&#8220;Medomie&#8221;) a privately owned pharmaceutical company, for Medomie to sell Adzenys and Cotempla in Israel and the Palestinian Authority. We will supply Adzenys and Cotempla to Medomie and Medomie will seek local regulatory approvals and marketing authorizations for each. This agreement represents Aytu&#8217;s first international commercial agreement for Adzenys and Cotempla.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consumer Health Segment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Consumer Health Segment is dedicated to commercializing safe and effective &#8220;over-the-counter&#8221; (&#8220;OTC&#8221;) medicines, personal care products, and dietary supplements to improve health and vitality. Our core products compete in categories such as hair loss, digestive health, urological health, diabetes management, and allergy. All products are intended to be used by consumers on a regular basis, and as such, we offer a monthly subscription program to allow for ongoing use and to simplify product ordering and use by patients. We acquired our Consumer Health Segment, previously known as Innovus Pharmaceuticals, Inc., in February 2020 (the &#8220;Innovus Acquisition&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Segment currently sells directly to consumers primarily in the United States through e-commerce platforms, including branded websites and Amazon.com which utilize marketing strategies focused on search engine optimization, search marketing and affiliate marketing. Additionally, the segment sells products through direct mail solicitations and advertisements, allowing consumers to purchase directly through business reply mail, through call centers, or online with shipment directly to their homes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to monetize, divest, or otherwise discontinue the Consumer Health Segment in order to maximize profitability and, if a divestiture is made, provide us with non-dilutive capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Development Portfolio &#8211; AR101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2021, we entered into an asset purchase agreement with Rumpus VEDS, LLC, Rumpus Therapeutics, LLC, and Rumpus Vascular, LLC (together &#8220;Rumpus&#8221;) pursuant to which we acquired commercial global licenses, relating primarily to the pediatric-onset rare disease development asset enzastaurin, or AR101. AR101 is initially being studied for the treatment of VEDS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AR101 is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K and AKT pathways. AR101 has been studied in more than 3,300 patients across a range of solid and hematological tumor types in trials previously conducted by Eli Lilly &amp; Company. Harry &#8220;Hal&#8221; C. Dietz III, M.D. developed the first preclinical model that mimics the human condition and recapitulates VEDS, and this model serves as the basis for the plausible clinical benefit and rationale for conducting a clinical trial with AR101 in VEDS. This novel knock-in mouse model has the same genetic mutation most prevalent in VEDS patients and is representative of the human condition in both the timing and location of VEDS-related vascular events. The model has generated identical structural histology and mechanical characteristics, and unbiased findings demonstrated that vascular structure alone does not lead to vascular events. Objective comparative transcriptional profiling by high-throughput RNA sequencing of the aorta displayed a molecular signature for excessive PKC/ERK cell signaling that is the purported driver of disease. PKC inhibitors proved efficacious in multiple pre-clinical and murine (mice) models and indeed prevented death due to vascular rupture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have secured exclusive global rights to AR101 in the fields of rare genetic pediatric onset or congenital disorders outside of oncology. AR101 is protected by a suite of pending patents being pursued in major markets globally which have been licensed from The Johns Hopkins University (&#8220;Johns Hopkins&#8221;) and have an earliest priority date of March 2017. In December 2021, the FDA granted Orphan Drug Designation (&#8220;ODD&#8221;) to AR101 for the treatment of EDS, inclusive of VEDS, allowing for seven years of marketing exclusivity in the United States. The FDA has cleared the IND application for AR101, although, we do not expect to advance development of AR101 until we are able to either fund development through operating cash flows or through an out-license or sale to a strategic partner.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OUR STRATEGY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our goal is to become a leading pharmaceutical company that improves the lives of patients and healthcare consumers. We will do this by employing a focused approach of in-licensing, acquiring, developing, and commercializing novel prescription therapeutics and consumer health products. Our primary focus is on commercializing innovative prescription products that address conditions frequently developed or diagnosed in childhood, including ADHD. We also commercialize consumer healthcare products through efficient e-commerce and direct-to-patient platforms, although we expect to monetize, divest, or discontinue the Consumer Health Segment in favor of focusing on the Rx Segment and attaining profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategic priorities are to continue to increase revenues from our Rx Segment and enhance our financial performance through operational and manufacturing efficiencies and portfolio prioritization. Specifically, we intend to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to grow our commercial branded, revenue-generating products, by increasing product sales and improving patient access. Our primary commercial objective is to drive revenue growth of our ADHD and pediatric brands, which consists of Adzenys, Cotempla, Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. We expect to increase market share using our internal commercial organization and leveraging our advanced analytics platform to optimize sales force performance and increase both the breadth, or number of healthcare professionals (&#8220;HCPs&#8221;) prescribing our medicines, and the depth, or the number of appropriate patients per HCP for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our novel Aytu RxConnect patient support platform, which is designed to reduce access barriers to medicines facing patients and HCPs by providing coverage for all commercially insured patients, regardless of their individual insurance plan, thus establishing an affordable and predictable monthly co-pay for patients, and eliminating many of the hassles facing HCPs and their staffs by improving availability of Aytu products at participating pharmacies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve gross margins for our ADHD product franchise through the manufacturing transfer of Adzenys and Cotempla to a contract manufacturing organization, a transition that is expected to occur in early calendar 2024;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our history of acquiring companies and in-licensing and acquiring products and pipeline assets, along with our success in building out commercial organizations and executing product launch and growth strategies, is a distinct competitive advantage. Our transactional adeptness and execution orientation enable us to continue to seek growth opportunities through both organic growth and opportunistic in-licensing or strategic acquisitions. Further, our commercial infrastructure and distribution capability is scalable and lends itself to additional on-market assets and future product candidates that fit within our core therapeutic focus or within our commercial capabilities and infrastructure. As such, in the near term, we may seek to leverage our commercial model and infrastructure by expanding our commercial portfolio with external product opportunities as we have done since our inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OUR PRODUCTS AND MARKETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Prescription Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADHD Portfolio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ADHD Market and Treatment Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ADHD is a neurobehavioral disorder characterized by a persistent pattern of inattention and/or hyperactivity/impulsivity that interferes with functioning and/or development. ADHD can have a profound impact on an individual&#8217;s life, causing disruption at school, work, home and in relationships. It is one of the most common developmental disorders in children and often persists into adulthood. The Centers for Disease Control and Prevention (&#8220;CDC&#8221;) reported that six million children in the United States ages 3 to 17 had previously received an ADHD diagnosis </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">between 2016-2019, up 36% since 2003. Current ADHD treatment guidelines recommend a multi-faceted approach that uses medications in conjunction with behavioral interventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2022, approximately 83.5 million prescriptions for medications with ADHD labeling were written in the United States generating $21.2 billion in sales. Approximately 91% of these prescriptions were for stimulant medications, such as amphetamine and methylphenidate, which are and have remained the standard of care for several decades. The market for ADHD medications outside of the United States is less developed, but we believe it will continue to grow as recognition and awareness of the disorder increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Extended-release, or long-acting, dosage forms of stimulant medications are the standard of care for treating ADHD, making up approximately 43% of ADHD prescriptions. The most prescribed extended-release medications for ADHD, Adderall XR&#174; and Concerta&#174; (and each of their generic equivalents), are long-acting versions of previously short-acting amphetamine and methylphenidate medications, respectively. Most of these extended-release dosage forms allow for once-daily dosing in the morning, which eliminates the need to re-dose during the day. Our products, Adzenys XR-ODT and Cotempla XR-ODT, are extended-release orally disintegrating tablets that allow for once-daily dosing based upon our internally developed proprietary microparticle delivery technology and are the only approved extended-release orally disintegrating tablet formulations of amphetamine and methylphenidate for the treatment of ADHD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant competition in the ADHD market, including from well-established companies, many of whom have substantially greater financial, technical and commercial resources than we do, and entrenched existing ADHD products. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Extended-release amphetamine products are currently marketed in the United States by (i) Takeda Pharmaceutical Company Limited under the brand names Adderall XR&#174;, Vyvanse&#174; and Mydayis&#174; and (ii) Tris Pharma, Inc. (&#8220;Tris&#8221;), under the brand names Dyanavel&#174; XR, Dyanavel&#174; XR tablets; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Extended-release methylphenidate products are marketed in the United States by (i) Janssen Pharmaceuticals, Inc. under the brand name Concerta&#174;, (ii) Tris under the brand names Quillivant XR&#174; and QuilliChew ER&#174;, (iii) Rhodes Pharmaceuticals LP under the brand name Aptensio XR&#174;, (iv) Ironshore Pharmaceuticals Inc. under the brand name Jornay PM&#174;, (v) Alora Pharmaceuticals under the name Methylphenidate HCl ER 72 mg Tablets, (vi) Novartis under the brand names Focalin XR&#174; and Ritalin LA&#174; and (vii) Azstarys</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, a product developed by KemPharm (now Zevra Therapeutics) and sold by Corium; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-stimulant treatment for ADHD was approved by the FDA and commercially launched by Supernus in the U.S in 2021 is being sold under the brand name Qelbree&#174;.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, makers of branded drugs could also enhance their own formulations in a manner that competes with our enhancements of these drugs. We are also aware of efforts by several pharmaceutical companies with ADHD medications in clinical development, including Cingulate Therapeutics, NLS Pharma and Neurovance, a subsidiary of Otsuka Pharmaceutical Co., Ltd. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our ADHD Product Portfolio</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our modified-release drug delivery technology platform has enabled us to create extended-release ODT formulations of amphetamine and methylphenidate. This was achieved by developing an extended-release profile that allows for once daily dosing and an ODT formulation that allows for easier administration and ingestion and twelve-hour duration of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adzenys XR-ODT and Cotempla XR-ODT are the first and only XR-ODT products for the treatment of ADHD. These XR-ODT products offer unique attributes to ADHD patients and caregivers, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ease of administration and ingestion because they disintegrate rapidly in the mouth and may be taken without water;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">taste-masking of bitter ADHD medications, with pleasant-tasting flavor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevention of &#8220;cheeking,&#8221; the practice of hiding medication in the mouth and later spitting it out rather than swallowing it; and</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adzenys XR-ODT: Amphetamine XR-ODT for the treatment of ADHD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adzenys XR-ODT is approved by the FDA for the treatment of ADHD in patients six years and older and is the first FDA-approved amphetamine XR-ODT for the treatment of ADHD. The New Drug Application (&#8220;NDA&#8221;) for Adzenys XR-ODT relies on the efficacy and safety data that formed the basis of FDA approval for the reference listed drug, Adderall XR, 30 mg, together with bioequivalence, bioavailability, and aggregate safety data from the Adzenys XR-ODT clinical program. Adzenys XR-ODT contains amphetamine loaded onto a mixture of immediate-release and polymer-coated delayed-release resin particles, which are formulated and compressed into an ODT along with other tableting excipients using our patented Rapidly Disintegrating Ionic Masking (&#8220;RDIM&#8221;) technology. The result is amphetamine with an <i style="font-style:italic;">in vivo</i> extended-release profile delivered through a tablet that quickly disintegrates in the mouth without the need for water. Adzenys XR-ODT is available in 30-day supply, child-resistant blister packs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The suite of composition-of-matter patents for Adzenys XR-ODT are scheduled to expire in 2026 and 2032. These patents are listed in the FDA&#8217;s publication of approved drug products with therapeutic equivalence evaluations (the &#8220;Orange Book&#8221;). In addition, we entered into a settlement agreement with Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;) (acquired by Teva Pharmaceutical Industries), which resolved all ongoing litigation involving Adzenys XR-ODT patents and Actavis&#8217; ANDA with the FDA for a generic version of Adzenys XR-ODT. Under the agreement with Actavis, Actavis has the right to manufacture and market its approved generic version of Adzenys XR-ODT under the ANDA beginning on September 1, 2025, or earlier under certain circumstances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the approval of the Adzenys XR-ODT NDA, the FDA has required us to conduct certain clinical studies in preschool (age four to five years) children with ADHD as a post-marketing requirement. A pharmacokinetic study in this population was completed in 2018, and we are in discussions with the FDA to further clarify the design protocols required to conduct the remaining studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cotempla XR-ODT: Methylphenidate XR-ODT for the treatment of ADHD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA approved Cotempla XR-ODT for the treatment of ADHD in patients six to seventeen years old. The Cotempla XR-ODT NDA relies on the efficacy and safety data that formed the basis of FDA approval for the reference listed drug, Metadate CD&#174;, together with bioavailability/bioequivalence data and efficacy/safety data from the Cotempla XR-ODT clinical program. The results of the Cotempla XR-ODT Phase 3 clinical efficacy and safety trial showed a statistically significant improvement in ADHD symptom control compared to placebo across the school day. Onset of effect was observed within one hour post-dose and persisted through 12 hours. No serious adverse events were reported during the study, and the adverse event profile was consistent with the drug&#8217;s mechanism of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cotempla XR-ODT contains methylphenidate loaded onto a mixture of immediate-release and polymer-coated delayed-release resin particles, which are formulated and compressed into an ODT along with other tableting excipients using our RDIM technology. The result is methylphenidate with an <i style="font-style:italic;">in vivo</i> extended-release profile delivered through a tablet that quickly disintegrates in the mouth. Cotempla XR-ODT is available in 30-day supply, child-resistant blister packs. Cotempla XR-ODT is the first FDA-approved methylphenidate XR-ODT for the treatment of ADHD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We hold composition-of-matter patents in the U.S. which we expect will provide Cotempla XR-ODT intellectual property protection until 2032, and a method-of-use patent was issued which will extend protection until 2038. These patents are listed in the Orange Book. In addition, Neos entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;), which resolved all ongoing litigation involving the Cotempla XR-ODT patents and Teva&#8217;s ANDA with the FDA for a generic version of Cotempla XR-ODT. Under the agreement with Teva, Neos granted Teva the right to manufacture and market its approved generic version of Cotempla XR-ODT under the ANDA beginning on July 1, 2026, or earlier under certain circumstances. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the approval of the Cotempla XR-ODT NDA, the FDA required us to perform additional clinical studies in preschool (age four to five years) children with ADHD as a post-marketing requirement. A pharmacokinetic study in this population was completed in 2019. In light of a new draft guidance for industry that was published in May 2019, &#8220;Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,&#8221; we remain in discussions with the FDA to gain concurrence on the design of the protocols required to meet the remaining post-marketing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Pediatric Portfolio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Poly-Vi-Flor and Tri-Vi-Flor: Our fluoride-based multivitamin prescription supplement product line for infants and children</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Poly-Vi-Flor and Tri-Vi-Flor are two complementary prescription fluoride-based supplement product lines containing combinations of vitamins and sodium fluoride in various oral formulations. These prescription supplements are prescribed for infants and children to treat or prevent fluoride deficiency due to poor diet or low levels of fluoride in drinking water and other sources while also providing multi-vitamin support and folic acid supplementation. Because these products contain at least .25 mg of sodium fluoride, Poly-Vi-Flor and Tri-Vi-Flor are classified as products that should be administered under the supervision of a licensed prescriber.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fluoride supplementation has been proven to protect teeth from decay. Community water fluoridation prevents tooth decay by providing frequent and consistent contact with low levels of fluoride. By keeping the teeth strong and solid, fluoride stops cavities from forming and can rebuild the tooth&#8217;s surface. Community water fluoridation began in the United States in 1945 and is the process of adjusting the amount of fluoride in drinking water to a level recommended for preventing tooth decay. As of 2016, more than 200 million people, or nearly 3 in 4 Americans who use public water supplies, drank water with enough fluoride to prevent tooth decay. However, Americans living in municipalities that do not fluoridate the water supply or in rural areas that rely on well water supplies do not receive recommended levels of fluoride through fluoridation. Therefore, many children living in these areas often require daily fluoride supplementation as part of their mineral and vitamin intake. In many instances, physicians prescribe fluoride-based multi-vitamins (Vitamins A, B, C, D and folic acid) regularly to supplement their fluoride intake and enable convenient supplementation. Infants are prescribed easier-to-take multi-vitamin drops while older children are prescribed tablet formulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2022, 8 million multi-vitamin prescriptions were written in the U.S. Of those prescriptions, multi-vitamins containing sodium fluoride accounted for 1.1 million total prescriptions. Common multi-vitamin combinations contain vitamins A, B, C, D and E, but no other prescription pediatric multi-vitamin products contain Metafolin, which makes the Poly-Vi-Flor and Tri-Vi-Flor product lines distinct, single-source brands. Other brands include Tri-Vite (marketed by Method Pharmaceuticals), Floriva (marketed by BonGeo Pharmaceuticals) and Quflora (marketed by Carwin Pharmaceutical Associates).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Poly-Vi-Flor is available in both chewable tablet and oral liquid suspension multivitamin formulations in six different product presentations: Poly-Vi-Flor Chewable Tablets .25 mg, .50 mg, and 1 mg tablets, Poly-Vi-Flor Chewable Tablets with Iron, Poly-Vi-Flor Oral Suspension and Poly-Vi-Flor Oral Suspension with Iron. Poly-Vi-Flor contains Vitamin A, Vitamins B1, B2, B3, and B6, Vitamin C, Sodium Fluoride in various doses and Metafolin, a proprietary, trademarked L-methylfolate form of folic acid developed by and licensed from Merck &amp; Cie (&#8220;Merck&#8221;). Beginning in the second half of fiscal 2023, we introduced Poly-Vi-Flor and Tri-Vi-Flor containing Arcofolin, Arcofolin offers an improved profile over Metafolin as a body ready L-methylfolate. Arcofolin&#8217;s low water content and low molecular weight of the counterion yield higher levels of assayed folate than other forms of L-methylfolate currently available on the market. It also has an improved purity profile, enhanced water solubility and an excellent overall stability profile. The addition of Arcofolin also broadens the brands&#8217; IP protection and extends the patent life and provides further differentiation with this novel ingredient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Tri-Vi-Flor is available as an oral liquid suspension in two different strengths (.25 mg and .50 mg fluoride) containing Vitamin A, Vitamin C, Vitamin D3, Sodium Fluoride, Sodium Benzoate and L-methylfolate. By virtue of its </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">L-methylfolate content, Tri-Vi-Flor offers a similar clinical profile: a fluoride-based multivitamin containing a proprietary, body-ready L-methylfolate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arcofolin&#174;, which we also licensed exclusively in our field of use, is Merck&#8217;s manufactured calcium salt of L-5-methyltetrahydrofolic or L-methylfolate. It is a &#8216;body ready&#8217; alternative to folic acid and offers good stability, solubility, and bioavailability. Folic acid supplementation is recommended in various patient groups, but a significant number of patients have difficulty metabolizing folate due to an enzymatic deficiency caused by a genetic mutation affecting the enzyme methylenetetrahydrofolate reductase, or MTHFR. MTHFR converts ingested folate (such as supplemented folic acid) into L-methylfolate, the body&#8217;s usable form. Clinical studies have demonstrated that 75% of patients may have at least one MTHFR genetic mutation while 40% may have two mutations. These mutations lead to impaired function of the enzyme and result in folate deficiency. Both Arcofolin and Metafolin are unaffected by the MTHFR mutation, thereby directly delivering bioavailable L-methylfolate, and offering a distinct clinical advantage over other folic acid supplements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The core family of patent covering Arcofolin has a priority date of March 31, 2017 and describes a crystalline sodium salt of 5-methyl-(6S)- tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as a process of obtaining the same. Upon issuance, the standard 20-year exclusivity for this patent would expire in 2037.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The prescription multi-vitamin market is dominated by generic products, with brands accounting for 9.5% of the multivitamin plus fluoride market for the year ending December 31, 2022. Poly-Vi-Flor and Tri-Vi-Flor primarily compete in the generic prescription multi-vitamin fluoride market and with the branded products FLORIVA and QFLORA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Karbinal ER: Extended release carbinoxamine oral suspension for the treatment of seasonal and perennial allergies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Karbinal&#174; ER (carbinoxamine maleate extended-release oral suspension) is an H1 receptor antagonist (antihistamine) indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and food, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled, and amelioration of the severity of allergic reactions to blood or plasma for patients two years of age and above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Over 50 million Americans suffer from allergies in any given year, and allergies are the sixth leading cause of chronic illness in the U.S. Numerous allergy treatments exist to address allergies and allergic symptoms depending upon the symptom(s). Oral antihistamines are considered a mainstay of allergy treatment, and the prescription antihistamine market is a large category with approximately 52 million prescriptions written in 2021. The prescription antihistamine category is dominated by generic products and consists of first generation and second-generation molecules. Generally, first-generation antihistamines block both histaminic and muscarinic receptors and pass the blood-brain barrier. Second-generation antihistamines mainly block histaminic receptors, but they do not pass the blood-brain barrier. First generation antihistamines, which are generally characterized as more sedating, accounted for 6% of 2021 total prescriptions, while non-sedating, second generation antihistamines accounted for 94% of total prescriptions. The most widely prescribed oral, second-generation antihistamines are cetirizine (brand name Zyrtec&#174;) and loratadine (brand name Claritin&#174;). Diphenhydramine (brand name Benadryl&#174;) is the most widely prescribed first-generation molecule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Karbinal ER is the only FDA-approved, 12-hour carbinoxamine oral suspension and is an effective antihistamine with a broad range of indications. Karbinal ER is positioned as a second-line allergy treatment for patients who continue to suffer from allergic symptoms following initial treatment with a second-generation, non-sedating antihistamine. Further, as Karbinal ER is an oral suspension formulation, children are the primary target patient given their preference for liquid treatments and, in many cases, their inability to swallow tablets or capsules. Karbinal ER is indicated for children as young as two years of age. Karbinal has a pleasant strawberry-banana taste and is available in 480 mL bottles.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through a supply and distribution agreement with Tris, we own exclusive rights to distribute Karbinal ER in the U.S. through August 2032, unless the agreement is terminated earlier pursuant to the termination provisions in the agreement. As part of the agreement, we pay sales-based royalties based on net revenue. Additionally, we are committed to make annual minimum payments to Tris through 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Two core patents protect Karbinal ER in the U.S., and both parents are listed in the FDA&#8217;s Orange Book. The first patent describes a coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin. The priority date for this family is March 29, 2009, so the standard 20-year exclusivity for this patent will expire in 2029. The second patent describes an aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core molecule complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated ion exchange resin complex. The priority date for this family is June 15, 2007, so the standard 20-year exclusivity for this patent will expire in 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Karbinal ER faces competition from OTC products such as non-sedating antihistamines, sedating antihistamines as well as nasal steroids, nasal antihistamines, and anticholinergics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consumer Health Segment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We acquired our consumer health business through the acquisition of Innovus Pharmaceuticals, Inc. in February 2020. The consumer health business is focused on OTC medicines and consumer health products designed to address common conditions. Now doing business as Aytu Consumer Health, we commercialize numerous products in the U.S. and Canada through two distinct marketing channels: e-commerce platforms including our websites and Amazon.com and via direct mail campaigns. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We classify our products into three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ANDA/Medical Device OTC products, which compete in large consumer health categories and are marketed primarily through Amazon.com;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OTC monograph products, which compete in large consumer health categories; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dietary supplements and personal care products, which are proprietary products with strong scientific evidence and clinical support.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following represents the core Aytu Consumer Health OTC medicines, which are expected to be the Consumer Health Segment&#8217;s primary profit drivers:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regoxidine&#174; - for Men &amp; Women &#8211; proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">OmepraCareDR&#174; - acid reducer to treat frequent heartburn.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EsomepraCareDR&#174; - acid reducer to treat frequent heartburn.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the company&#8217;s shift in focus and objective of generating near-term profitability, we expect to divest, monetize, or discontinue the Consumer Health operations by the end of fiscal 2024 or shortly thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We own over 200 trademarks for products in our Consumer Health Portfolio and own or license patents covering 9 of these products, some of which we plan to either license, sell, or discontinue as part of the planned divestiture, sale, or discontinuation of the Consumer Health Segment. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MANUFACTURING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADHD Product Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the production of our ADHD products, we lease a manufacturing site in Grand Prairie, Texas. This facility has 77,112 square feet of manufacturing and laboratory space and contains dedicated current Good Manufacturing Practices (&#8220;cGMP&#8221;) manufacturing suites for both Adzenys XR-ODT and Cotempla XR-ODT. We hold U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) manufacturing and analytical licenses and maintain storage and use of Schedule II through IV controlled substances. The manufacture of our products is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are in the process of transferring the manufacturing of our ADHD products to a contract manufacturing organization (&#8220;CMO&#8221;). The transfer of the manufacturing of pharmaceutical products requires several steps including knowledge and method transfer, manufacturing of materials for feasibility studies and confirmation batch materials, bioequivalence studies, inspections from regulatory agencies, and regulatory filings. We have completed the required activities, including the successful completion of bioequivalence studies, which are required in order to enable the transfer of both Adzenys XR-ODT and Cotempla XR-ODT. The Adzenys XR-ODT Prior Approval Supplement (&#8220;PAS&#8221;) was approved by the FDA in April 2023, and the Cotempla XR-ODT PAS was submitted to the FDA in June 2023. We expect to receive approval for the Cotempla XR-ODT PAS by early calendar 2024. Thus, we expect the CMO to begin manufacturing both ADHD products in early calendar 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with transferring the manufacturing of our ADHD products to a CMO, we entered into an agreement with AMT Manufacturing Solutions, LLC, a newly established, full service CMO, to sublease 22,909 square feet of our Grand Prairie, Texas manufacturing facility. This sublease represents over 30% of our facility. In addition, commencing as early as April 1, 2024, but no later than December 31, 2024, the sublease will be expanded to include the remaining portion of the manufacturing facility. This agreement enables us to reduce costs associated with exiting the facility and allows for increased supply chain flexibility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pediatric Product Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We contract with CMOs for the manufacture and testing of our Pediatric Portfolio products. We have entered into the following key supply agreements for the commercial manufacture and supply of certain of these products:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Poly-Vi-Flor and Tri-Vi-Flor drops are purchased through a supply agreement with a CMO based in the U.S., and we expect to add our multivitamin chewable tables to this supply agreement. Until that time, the chewable tablets are being produced and purchased without a supply agreement specifically covering those purchases. Merck &amp; Cie is responsible for providing Metafolin and Arcofolin to our designated CMO. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A supply agreement with Tris Pharma for the supply of Karbinal. This agreement terminates in August 2033, subject to earlier termination or extension in accordance with the terms of the agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe the third-party manufacturers of our Pediatric Portfolio products have adequate capacity to manufacture sufficient quantities of these products to meet anticipated commercial demands. As we rely on CMOs, we employ personnel with extensive technical, manufacturing, supply chain management, and analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consumer Health Segment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Segment maintains relationships with a number of manufacturers and brokers from which it obtains its products. We attempt to work with a variety of manufacturers to broaden our supplier base and to optimize product acquisition costs and delivery schedules. For our OTC medicines we have relationships with three primary suppliers and one broker through which we source our consumer health products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RESEARCH AND DEVELOPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have indefinitely suspended product candidate research and development activities in favor of focusing our resources on our commercialization efforts. With this re-focusing on commercial operations, development of our lead product candidate, AR101, is on indefinite hold. We are pursuing strategic partnerships in order to advance this program but have no assurance that a partnership will be consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Development Pipeline: AR101 (enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS))</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AR101 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the protein kinase C (&#8220;PKC&#8221;) beta, PI3K and AKT pathways. AR101 has been studied in more than 3,300 patients across a range of solid and hematological tumor types. AR101 was originally developed by Eli Lilly and Company (&#8220;Lilly&#8221;), and worldwide rights were acquired by Denovo Biopharma in September 2014 following Lilly&#8217;s discontinuation of the enzastaurin development program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. VEDS is the severe subtype of Ehlers-Danlos Syndrome, affecting 1 in 50,000 people worldwide. VEDS results from pathogenic variants in the COL3A1 gene, which encodes the chains of type III procollagen, a major protein in vessel walls and hollow organs. Twenty-five percent of VEDS patients have a first complication by the age of 20 years, and more than 80 percent have at least one complication by the age of 40. VEDS patients have a median lifespan of 51 years. There are currently no FDA approved treatments for VEDS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research underpinning the application of enzastaurin for the treatment of VEDS has been conducted by Dr. Harry (Hal) Dietz and his research colleagues. Dr. Dietz is the Victor A. McKusick Professor of Genetics in the departments of medicine, pediatrics, and molecular biology and genetics at The Johns Hopkins University School of Medicine and director of the William S. Smilow Center for Marfan Syndrome Research. He has also been an investigator at Howard Hughes Medical Institute since 1997. Dr. Dietz is a leading scientist in the field of genetic connective tissue disorders and developed the first preclinical model that mimics the human condition and recapitulates VEDS. His group&#8217;s research findings were published in the Journal of Clinical Investigation in February 2020. The VEDS knock-in murine (mouse) preclinical model from Dr. Dietz has the same genetic mutation most prevalent in VEDS patients and is representative of the human condition in both the timing and location of vascular events. The model has generated identical structural histology and mechanical characteristics, and unbiased findings demonstrated that structure alone does not lead to vascular events. Objective comparative transcriptional profiling by high-throughput RNA sequencing of the aorta displayed a consistent molecular signature for excessive PKC/ERK cell signaling that is now known to be the driver of disease. Based on the scientific rationale for intervention along the PKC/ERK pathway, PKC inhibition and treatment with PKC&#946; inhibitors proved efficacious in multiple pre-clinical and murine studies and indeed prevented death due to vascular rupture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In fiscal 2022 we received Orphan Drug Designation for AR101 in Ehlers-Danlos Syndrome including VEDS and in Europe, allowing for seven years&#8217; marketing exclusivity in the United States and ten years in Europe. We also received Fast Track designation for AR101 in VEDS by the FDA, allowing for an accelerated review timeline upon submission of the New Drug Application (&#8220;NDA&#8221;) and more frequent interaction with the FDA during the development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">AR101 is protected by a suite of five pending patents being pursued in major markets globally which have been licensed from Johns Hopkins and have an earliest priority date of March 2017. The cornerstone of the intellectual </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">property family surrounds enzastaurin initially targeting the treatment of VEDS focused on the U.S. and certain foreign jurisdictions which include Europe, Japan, China, Brazil, Mexico, Canada, Israel, Australia, New Zealand, and South Korea. This pending patent provides compositions and methods for treating VEDS and associated connective tissue disorders and has a priority date of October 2018. The second pending patent provides methods and compositions for the diagnosis, treatment, and prevention of Marfan syndrome and related diseases, disorders and conditions and has a priority date of March 2017, in select geographies. The third pending patent, titled &#8220;Targeted Epigenetic Therapy for Inherited Aortic Aneurysm Conditions,&#8221; broadens the coverage of the potential therapeutic application of AR101/Enzastaurin and has a priority date of September 2017. The fourth pending patent, titled &#8220;Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome&#8221;, and the fifth pending patent, titled &#8220;Endothelin-1 Signaling Contributes to Vascular Rupture Risk&#8221;, deepens the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome and are highly confirmatory of the therapeutic approach for AR101/Enzastaurin. These pending patents have priority dates of September 2020 and February 2022 respectively. Additional molecule intellectual property is afforded through the license with Denovo whose pending patent provides methods and compositions for the prediction of the activity of enzastaurin and has a priority date of September 1, 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">INTELLECTUAL PROPERTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek trademark protection in the United States when appropriate. We currently own or license registered trademarks for Aytu, Aytu Biopharma, Neos Therapeutics, Innovus Pharma, Healight, Poly-Vi-Flor, Adzenys, Adzenys XR-ODT, Adzenys ER and Cotempla XR-ODT in the United States, as well as trademarks related to our DTRS technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may find it necessary or prudent to obtain licenses from third party intellectual property holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GOVERNMENT REGULATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies. The FDCA and the FDA&#39;s implementing regulations set forth, among other things, requirements for the testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record-keeping, reporting, distribution, import, export, sale, advertising and promotion of our products and product candidates. We may seek approval for, and market, our products in other countries in the future. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Development and Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the FDCA, FDA approval of an NDA is required before any new drug can be marketed in the U.S. NDAs in the case of new drugs, or PMAs or 510(k)s in the case of medical devices, may require extensive studies and submission of a large amount of data by the applicant, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Testing</i>. Preclinical testing generally includes laboratory evaluation of product chemistry and formulation, as well as toxicological and pharmacological studies in several animal species to assess the toxicity and dosing of the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i>. Clinical trials involve the administration of a drug to healthy human volunteers or to patients, under the supervision of a qualified investigator. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trials involve the initial administration of the investigational drug to humans, typically to a small group of healthy human subjects, but occasionally to a group of patients with the targeted disease or disorder. Phase 1 clinical trials generally are intended to evaluate the safety, metabolism and pharmacologic actions of the drug, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 clinical trials generally are controlled studies that involve a relatively small sample of the intended patient population and are designed to develop initial data regarding the product&#39;s effectiveness, to determine dose response and the optimal dose range, and to gather additional information relating to safety and potential AEs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3 clinical trials are conducted after preliminary evidence of effectiveness has been obtained and are intended to gather the additional information about safety and effectiveness necessary to evaluate the drug&#39;s overall risk-benefit profile, and to provide a basis for physician labeling. Generally, Phase 3 clinical development programs consist of expanded, multi-site, large-scale studies of patients with the target disease or disorder to obtain statistical evidence of the efficacy and safety of the drug at the proposed dosing regimen. Phase 3 data often form the core basis on which the FDA evaluates a drug&#8217;s safety and effectiveness when considering the product application.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Post-Approval Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once approved, drug products are subject to continuing regulation by the FDA. If ongoing regulatory requirements are not met or if safety or manufacturing problems occur after the product reaches the market, the FDA may at any time withdraw product approval or take actions that would limit or suspend marketing. Additionally, the FDA may require post-marketing studies or clinical trials, changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, or the implementation of other risk management measures, including distribution-related restrictions, if there are new safety information developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DEA Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ADHD products are considered a &#8220;controlled substance&#8221; as defined in the Controlled Substances Act of 1970, or CSA, because Adzenys XR-ODT contains amphetamine and Cotempla XR-ODT contains methylphenidate. Because amphetamine and methylphenidate are Schedule II controlled substances, the DEA has Adzenys XR-ODT and Cotempla XR-ODT listed and regulated as Schedule II controlled substances. None of our pediatric products (Poly-Vi-Flor, Tri-Vi-Flor and Karbinal ER) are considered &#8220;controlled substances.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The DEA establishes annually an aggregate quota for how much of a controlled substance may be produced in and/or imported into the U.S. based on the DEA&#8217;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. Our or our manufacturers&#8217; quotas of an active ingredient may not be sufficient to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by the DEA in establishing our or our manufacturers&#8217; quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual states also independently regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution of these products, including, for example, state requirements for licensures or registration. Additionally, we use third-party logistics firms to inventory and fill sales orders for our commercial portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We contract with third parties for the manufacture and testing of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. Poly-Vi-Flor and Tri-Vi-Flor are not supplied under any contract. We have entered into the following key supply agreements for the commercial manufacture and supply of certain of these products:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A supply agreement with Tris for the supply of Karbinal. This agreement terminates in August 2033, subject to earlier termination or extension in accordance with the terms of the agreement.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Poly-Vi-Flor and Tri-Vi-Flor drops are produced under a supply agreement with a CMO based in the U.S., and we expect to expand that agreement to include the chewable tablet formations. Until that time, the Ploy-Vi-Flor chewable tablets are produced by the same CMO on a purchase order-to-purchase order basis, Merck &amp; Cie is responsible for providing Metafolin and Arcofolin to our designated CMO.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our third-party manufacturers have adequate capacity to manufacture sufficient quantities of these products to meet anticipated commercial demands. Because we rely on CMOs, we employ personnel with extensive technical, manufacturing, supply chain management, and analytical and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record-keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among other activities. Our systems and our contractors are required to comply with these regulations, and we assess this compliance regularly through monitoring of performance and a formal audit program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the production of our ADHD products, we lease one manufacturing site in Grand Prairie, Texas. This facility has 77,112 square feet of manufacturing and laboratory space, and contains dedicated cGMP manufacturing suites for both Adzenys XR-ODT and Cotempla XR-ODT. We hold DEA manufacturing and analytical licenses, and maintain storage and use of Schedule II through IV controlled substances. The manufacture of our products is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel, and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are in the process of a technology transfer to outsource the manufacturing of our ADHD products to a CMO. The transfer of the manufacturing of pharmaceutical products requires several steps including knowledge and method transfer, manufacturing of materials for feasibility study and confirmation batch materials, bioequivalence studies and regulatory filings. We have completed the required activities, including the successful completion of bioequivalence studies, which are required in order to enable the transfer of both Adzenys XR-ODT and Cotempla XR-ODT. The Adzenys XR-ODT Prior Approval Supplement (&#8220;PAS&#8221;) was approved by the FDA in April 2023, and the Cotempla XR-ODT PAS was submitted to the FDA in June 2023. We expect to receive approval for the Cotempla XR-ODT PAS by early calendar 2024. We expect the CMO to begin manufacturing both ADHD products in early calendar 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HUMAN CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, we employed 150 full-time employees, including 53 who are involved in operations, 5 who are directly involved in research and development, 60 who are involved in commercialization and 32 who are involved in general and administrative activities. All of our colleagues are located in the U.S. Of these colleagues, 45% are female and 55% are male. Our colleagues are not represented by a labor union. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our values &#8211; team-oriented, hard-working, relentlessly determined, integrity, visionary, entrepreneurial, and servant-minded - are built on the foundation that the colleagues we hire and the way we treat one another promote creativity, innovation, and productivity, which spur our success. This culture depends in large part on our ability to attract, retain and develop a diverse population of talents and high-performing employees at all levels of our organization. Providing market competitive pay and benefit programs, opportunities to participate in the success they help create, while engaging colleagues in important dialogue regarding organization performance, we create a culture of inclusion in which all colleagues have the opportunity to thrive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">AVAILABLE INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 7900 East Union Avenue, Suite&#160;920, <ix:nonNumeric contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ" name="dei:AuditorLocation" id="Narr_TY185D_aO0SKlSLF09sLFA"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="dei:AuditorLocation" id="Narr_nlXP349EK0O7HCt66apVyA"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AuditorLocation" id="Narr_pxKbRHW7Mk6OfOkrQQiNkA">Denver, Colorado</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> 80237 USA, and our phone number is (720) 437-6580.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We maintain a website on the internet at <i style="font-style:italic;">http://aytubio.com</i>. We make available, free of charge, through our website, by way of a hyperlink to a third-party site that includes filings we make with the SEC website (<i style="font-style:italic;">www.sec.gov)</i>, our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">those reports electronically filed or furnished pursuant to Section&#160;15(d)&#160;of the Exchange Act. The information on our website is not, and shall not be deemed to be, a part of this Annual Report on Form&#160;10-K or incorporated into any other filings we make with the SEC. In addition, the public may read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room&#160;at 100 F Street, N.E., Washington D.C., 20549. Information on the operation of the Public Reference Room&#160;may be obtained by calling the SEC at 1-800-SEC-0330.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CODE OF ETHICS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of ethics that applies to our officers, directors, and employees, including our principal executive officer and principal accounting officer. We intend to disclose any amendments to, or waivers from, our code of ethics that are required to be publicly disclosed pursuant to rules&#160;of the SEC by filing such amendment or waiver with the SEC. This code of ethics and business conduct can be found in the corporate governance section of our website, <i style="font-style:italic;">https://investors.aytubio.com/corporate-governance#CorporateGovernance</i>.</p><a id="_cdfa878f_bd49_43df_bffd_d69635eb7e58"></a><a id="Item1ARiskFactors_545192"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investing in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other information contained in this Annual Report on Form 10-K. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our securities to decline and could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RISKS RELATED TO OUR BUSINESS AND FINANCIAL POSITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We have incurred losses to date and can give no assurance of profitability.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have incurred losses in each year since our inception. As of the filing of this Annual Report on Form 10-K, there is a substantial doubt regarding our ability to continue as a going concern. Our net loss for the years ended June 30, 2023 and 2022 was $17.1 million and $108.8 million, respectively. We have not demonstrated the ability to be a profit-generating enterprise to date. Even though we expect to have revenue growth in the next several fiscal years, it is uncertain that the revenue growth will be significant enough to offset our expenses and generate a profit in the future. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered by healthcare businesses, many of which will be beyond our control. These risks include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>uncertain market acceptance of our products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>difficulties in maintaining coverage and reimbursement for our products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>lack of sufficient capital;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>U.S. and foreign regulatory approval of our products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>unanticipated problems, delays, and expense relating to product development and implementation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>lack of sufficient intellectual property;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the ability to attract and retain qualified employees;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>competition; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>technological changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result of the increasingly competitive nature of the markets in which we compete, our historical financial data is of limited value in anticipating future operating expenses. Our planned expense levels will be based in part on our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expectations concerning future operations, which is difficult to forecast accurately based on our historical strategy of product and/or business acquisition to develop our product and business portfolio. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary shortfall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To obtain revenues from our products, we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing products, manufacturing, marketing and selling our existing products, satisfying any post-marketing requirements, and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, as applicable, may not be successful in these activities and, even if we or our collaborators do, we may never generate revenues that are sufficient to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We have not established sources of ongoing revenue sufficient to cover operating costs and allow us to continue as a going concern. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since our inception, we have had significant operating losses. As of June 30, 2023, we had accumulated deficit of $304.1 million. Even though we plan to mitigate the conditions that raise substantial doubt about our ability to continue as a going concern, we may continue to incur net losses, and our ability to generate positive cash flows from operating activities is uncertain for the foreseeable future. We have not established an ongoing source of revenue sufficient to cover operating costs. Our ability to continue as a&#160;going&#160;concern&#160;is dependent on our continued operational improvements, refinancing, or obtaining adequate capital to fund operating losses until we become profitable. If we are unable to generate sufficient cash flows or obtain adequate capital, we may be unable to develop and commercialize our product offerings and we could be forced to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our product expansion efforts or other operations. Further, future sales and issuances of our common stock or rights to purchase common stock will result in dilution of the percentage ownership of our existing stockholders and could cause our stock price to fall.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are expending resources to commercialize our prescription products and to service our debt obligations. We may require additional funding through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. As of June 30, 2023, our cash and cash equivalents totaled $23.0 million. During the year ended June 30, 2023, we raised approximately $15.6 million, net of fees, from a combination of common stock offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our operating plans may change as a result of many factors currently unknown to us, and we could need additional capital in the future to continue our operations and may need to seek additional funds sooner than planned. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we sell common stock, convertible securities or other equity securities in more than one transaction, any such sales may result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to those of our existing common stockholders. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock to decline. Any future grants of securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could also have an adverse effect on the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. The incurrence of additional indebtedness would result in increased fixed payment obligations and we may be required to agree to additional restrictive covenants, such as further limitations on our ability to incur additional debt, additional limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unable to obtain funding on a timely basis, we may be unable to expand the market for our products or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have a $15.0 million term loan with Avenue Capital and up to $14.5 million of secured revolving loans with Eclipse. As of June 30, 2023, $1.6 million was outstanding under the secured revolving loan. All obligations under our loans are secured by substantially all of our existing property and assets subject to certain exceptions. These debt financings and any future debt financings may create additional financial risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing our outstanding debt obligations at maturity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result, we may not have sufficient funds, or may be unable to arrange for additional financing, to pay the amounts due on our outstanding indebtedness under our debt agreements. Further, funds from external sources may not be available on economically acceptable terms, if at all. For example, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish potentially valuable rights to our products or technologies, or to grant licenses on terms that are not favorable to us. If adequate funds are not available when and if needed, our ability to make interest or principal payments on our debt obligations, and finance our operations and other general corporate activities would be significantly limited and we may be required to delay, significantly curtail, or eliminate one or more of our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Failure to satisfy our current and future debt obligations under our loan agreements with Avenue Capital or Eclipse could result in an event of default and, as a result, our lenders could accelerate all of the amounts due. In the event of an acceleration of amounts due under one or both of our debt agreements as a result of an event of default, we may not have sufficient funds or may be unable to arrange for additional financing to repay our indebtedness. In addition, our lenders could seek to enforce their security interests in any collateral securing such indebtedness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The loan agreements with Avenue Capital and Eclipse subject us to financial covenants and restrictions on our ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the lender. Failure to comply with such covenants could permit the lenders to declare our obligations under the loan agreements, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These restrictive covenants could limit our flexibility in operating our business and our ability to pursue business opportunities that we or our stockholders may consider beneficial. Any declaration by the lender of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay these outstanding obligations at the time any event of default occurs. Further, if we raise any additional capital through debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">We recently announced that we have been engaged in discussions with various parties regarding potential strategic transactions and potential financing options. There can be no assurance that this process will result in the pursuit or consummation of any potential transaction, or that any such potential transaction, if implemented, will provide sufficient funding to continue our operations.</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We recently announced that we are engaged in discussions with various parties regarding potential strategic transactions and potential financing, which could include a financing, sale or licensing of assets, acquisition, merger, business combination, and/or other strategic transaction or series of related transactions. This process, including any uncertainty created by this process, involves a number of risks which could impact our business and our stockholders, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant fluctuations in our stock price could occur in response to developments relating to the process or market speculation regarding any such developments;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may encounter difficulties in hiring, retaining and motivating key personnel during this process or as a result of uncertainties generated by this process or any developments or actions relating to it;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may incur substantial increases in general and administrative expense associated with increased legal fees and the need to retain and compensate third-party advisors; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience difficulties in preserving the commercially sensitive information that may need to be disclosed to third parties during this process or in connection with an assessment of our strategic options.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The review process also requires significant time and attention from management, which could distract them from other tasks in operating our business or otherwise disrupt our business. Such disruptions could cause concern to our suppliers, strategic partners or other constituencies and may have a material impact on our business and operating results and volatility in our share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There can be no assurance that this process will result in the pursuit or consummation of any potential transaction or strategy, or that any such potential transaction or strategy, if implemented, will provide sufficient funding to conduct our operations. Any outcome of this process would be dependent upon a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, regulatory approvals, and the availability of financing on reasonable terms. The occurrence of any one or more of the above risks could have a material adverse impact on our business, financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We have indefinitely suspended development of our AR101 (enzastaurin) clinical development program and shifted our strategic focus towards accelerating the growth of our commercial business. If we fail to execute successfully on this reprioritized strategic focus, our business, results of operations and financial condition could be materially and adversely affected.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have indefinitely suspended our AR101 (enzastaurin) clinical development program and shifted our focus towards accelerating the growth of our commercial business and achieving operating cash flows. Though we expect that the suspension of this program will save over $20 million in projected future study costs over the next three fiscal years, the process of reorienting our business strategy may be costly, time consuming and complex, and we have incurred, and may in the future incur, costs related to this strategic shift. Our strategic reprioritization may result in unexpected expenses or liabilities and/or write-offs. There is no assurance that we will be successful at executing on our revised strategy or that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated, lead to increased stockholder value, or achieve the anticipated results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unable to execute successfully on our reprioritized strategic focus, our cash resources may not last as long as estimated and our business, results of operations and financial condition could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2023, we had federal net operating loss carryforwards of approximately $504.0 million. The available net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2024 and, except for certain indefinite-lived net operating loss carryforwards, will completely expire in 2037. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) and the regulations promulgated thereunder, including, without limitation, the consolidated income tax return regulations, various corporate ownership changes could limit our ability to use our net operating loss carryforwards and other tax attributes to offset our income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An &#8220;ownership change&#8221; (generally a 50% change in equity ownership over a three-year period) under Section 382 of the Code could limit our ability to offset, post-change, our U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. We believe that the June 2021 acquisition of Neos caused an ownership change of Neos, resulting in a limitation in our ability to use their pre-acquisition net operating loss carryovers. We also believe that the financing transactions in fiscal 2022 and 2023 may have caused, together with equity ownership changes in the past three years, an ownership change resulting in a limitation of our ability to use our pre-acquisition net operating loss carryovers. The ownership change scenario could result in an increased future tax liability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management conducted an assessment of the effectiveness of our internal controls over financial reporting for the quarter ended September 30, 2022, and concluded that a certain control was not effective. We concluded that we had a material weakness in internal control over financial reporting related to accounting for complex warrant issuances and the classification of these issued warrants. In addition, we concluded that we had a material weakness in internal control over financial reporting for the year ended June 30, 2023 related to our analysis for the accounting for valuation of our inventory. Our Audit Committee conducted an internal investigation to identify and determine plans to remediate the material weaknesses and to enhance our overall control environment. We will not consider the material weaknesses remediated until our enhanced control is operational for a sufficient period of time and tested, enabling management to conclude that the enhanced controls are operating effectively. Our remediation plan includes the implementation of controls over the process of reviewing significant and complex contracts and agreements and we believe that the issues have been remediated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If in the future we were to conclude that our internal controls over financial reporting were not effective, we cannot be certain as to the timing of completion of our evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could require us to restate our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unable to conclude that we have effective internal controls over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an attestation report on the effectiveness of internal controls over financial reporting as required by Section 404 of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to maintain listing on the NASDAQ Capital Market. Due to our current filing status, we are not required to have our independent registered public accounting firm deliver an attestation report on the effectiveness of our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">We have been and in the future may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> We and certain of our officers and directors have been and may in the future become defendants in one or more stockholder derivative actions or other class-action lawsuits. For example:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two putative class action lawsuits were filed on February 9, 2022 and March 7, 2022 derivatively and on behalf of all Aytu stockholders, challenging the grant in 2021 of certain stock option awards to directors and officers, and seeking rescission of the awards, unspecified damages to stockholders as a result of the awards, and attorneys&#8217; fees.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A shareholder derivative suit was filed on September 12, 2022, derivatively and on behalf of all Aytu stockholders, against certain of our current and former directors and stockholders, alleging breaches of fiduciary duties in connection with certain acquisitions, and seeking unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Part I, Item 3. Legal Proceedings for more information on these lawsuits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These lawsuits can divert our management&#8217;s attention and resources from our ordinary business operations, and we would likely incur significant expenses associated with their defense (including, without limitation, substantial attorneys&#8217; fees and other fees of professional advisors and potential obligations to indemnify current and former officers and directors who are or may become parties to such actions). In connection with these lawsuits, we may be required to pay material damages, consent to injunctions on future conduct and/or suffer other penalties, remedies or sanctions, or issue additional shares upon the exercise of certain warrants, which may cause additional dilution. In addition, any such future lawsuits could adversely impact our reputation and/or ability to launch and commercialize our products, thereby harming our ability to generate revenue. Accordingly, the ultimate resolution of these matters and any future matters could have a material adverse effect on our business, financial condition, results of operation and cash flow and, consequently, could negatively impact the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RISKS RELATED TO COMMERCIALIZATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We are heavily dependent on the commercial success of our commercial products. To date, we have not generated sufficient revenues from the sales of these products to achieve profitability and we may never achieve or maintain profitability. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to become profitable depends upon our ability to generate increased revenues from sales of our prescription and consumer health product portfolios. While we have been selling pharmaceutical products for several years, we have limited commercial experience selling our current lineup of pharmaceutical products, having only generated revenues from the sale of our pediatric products since acquiring that portfolio in November 2019 and from our ADHD products since acquiring that portfolio in March 2021. None of our marketed prescription or consumer health products have thus far generated product sales revenues at levels sufficient for us to attain profitability. We have not generated any revenues from product sales of any other product candidates and, to date, have incurred significant operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have incurred, and anticipate continuing to incur, significant costs associated with commercialization of our approved products and, if approved, any other product candidates that we may develop. It is possible that we will never attain sufficient product sales revenues to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If we are unable to differentiate our products from branded drugs or existing generic therapies for similar treatments, or if the FDA or other applicable regulatory authorities approve additional generic products that compete with any of our products, our ability to successfully commercialize such products would be adversely affected.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We expect to compete against branded drugs with distinct clinical attributes and to compete with their generic counterparts that will be sold for a lower price. Although we believe that our Rx Portfolio is or will be differentiated from branded drugs and their generic counterparts, if any, including through clinical efficacy or through improved patient compliance, ease of administration, and our patient support programs, it is possible that such differentiation will not impact our market position. If we are unable to achieve significant differentiation for our products and accompanying support services against other drugs, the opportunity for our products to achieve premium pricing and be commercialized successfully would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">After a New Drug Application (&#8220;NDA&#8221;), including a 505(b)(2) application, is approved, the covered product becomes a &#8220;listed drug&#8221; that, in turn, can be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. The FDCA, implementing regulations and other applicable laws provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use, or labeling as our product candidate and that the generic product is bioequivalent to ours, meaning it is absorbed in the body at the same rate and to the same extent as our product candidate. These generic equivalents, which must meet the same quality standards as the listed drugs, would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product, such as our Rx Portfolio products, can be lost to the generic version. Accordingly, competition from generic equivalents to our products could materially adversely impact our revenues, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in our products. For example, on July 25, 2016, Neos received a paragraph IV certification from Actavis advising them that Actavis filed an ANDA with the FDA for a generic version of Adzenys XR-ODT. On October 17, 2017, Neos entered into a Settlement Agreement and a Licensing Agreement with Actavis (which is now owned by Teva), pursuant to which Neos granted Actavis the right to manufacture and market its now approved generic version of Adzenys XR-ODT under the ANDA beginning on September 1, 2025, or earlier under certain circumstances. On October 31, 2017, Neos received a paragraph IV certification from Teva advising them that Teva filed an ANDA with the FDA for a generic version of Cotempla XR-ODT. On December 21, 2018, Neos entered into a Settlement Agreement and a Licensing Agreement with Teva, pursuant to which we have granted Teva the right to manufacture and market its now approved generic version of Cotempla XR-ODT under the ANDA beginning on July 1, 2026, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">While we expect to wind down or monetize our Consumer Health Segment, the Consumer Health Segment relies heavily on obtaining products that change from a prescription to over the counter through an FDA approval process. Any delays in this process might impact the financial performance of our consumer Health Segment.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our Consumer Health Segment has pursued opportunities where existing prescription drugs have recently, or are expected to, change from a prescription to over-the-counter. Historically the FDA has highly scrutinized any product application submitted to switch a product from prescription to unsupervised over-the-counter use by the general public. The continued expansion of Rx-to-OTC switches is important to our Consumer Health Segment&#8217;s future growth. Reluctance of FDA to approve Rx-to-OTC switches in new product categories could impact that growth and could impact the financial performance of our Consumer Health Segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our pharmaceutical and consumer health products may prove to be difficult to effectively commercialize as planned or on the timeframes we announce and expect.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Various commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues from sales of our pharmaceutical and consumer health product offerings. Moreover, we have limited </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">experience selling some of our current products given their acquisition from other companies or their recent approval. We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory, and other product development objectives and, from time to time, we may publicly announce the expected timing of some of these milestones. The achievement of many of these milestones may be outside of our control and if we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our products may be delayed and our business, prospects and results of operations may be harmed. Specifically, we may encounter difficulty by virtue of the following, each of which could be negatively impacted if expected timeframe goals are not achieved:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our available capital resources;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our inability to have clear proprietary rights to the products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our inability to manufacture or cost-effectively manufacture the products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our inability to adequately market and increase sales of any of these products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>existence of adverse side effects that make using the products less desirable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our inability to attract and retain a skilled support team, marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance for our products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our inability to secure continuing prescribing of any of these products by current or previous users of the product;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our inability to effectively transfer and scale manufacturing as needed to maintain an adequate commercial supply of these products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">reimbursement and medical policy changes that may adversely affect the pricing, profitability or commercial appeal of pharmaceutical products; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our inability to effectively identify and align with commercial partners outside the U.S., or the inability of those selected partners to gain the required regulatory, reimbursement, and other approvals needed to enable commercial success of our products.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We rely on limited sources of supply for our products, and any disruption in the chain of supply may impact production and sales of our products, and cause delays in developing and commercializing our currently manufactured and commercialized products. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Some of our products are produced in single annual production lots by single-source suppliers. Due to the limited production quantities, production of these lots may not be prioritized by the third-party manufacturer, and may not be scheduled and produced at all. We are reliant on a limited number of suppliers for resin, drug compounds, coating and other component substances of our final products. If any of these single source suppliers were to breach or terminate its supply agreement, if any, with us or otherwise not supply us, we would need to identify an alternative source for the supply of component substances for our products. If we fail to procure supply of our products, we could lose potential revenue and our business, financial condition, results of operation and reputation could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Identifying an appropriately qualified source of alternative supply for any one or more of the component substances for our products could be time consuming, and we may not be able to do so without incurring material delays in the development and commercialization of our approved products or a decrease in sales of our approved products, which could harm our financial position and commercial potential for our products. Any alternative vendor would also need to be qualified through an FDA Prior Approval Supplement process which could result in further delay. The FDA, DEA, or other regulatory agencies outside of the United States may also require additional studies if we enter into </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">agreements with new suppliers for the manufacture of our ADHD products that differ from the suppliers used for clinical development of such products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These factors could cause the delay of commercialization of our products, cause us to incur higher costs and prevent us from commercializing them successfully. Furthermore, if our suppliers fail to deliver the required commercial quantities of components and APIs on a timely basis and at commercially reasonable prices, including if our suppliers did not receive adequate DEA quotas for the supply of certain scheduled components, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, commercialization of our ADHD products may be delayed or we could lose potential revenue and our business, financial condition, results of operation and reputation could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We rely on third parties manufacture certain products, and third-party manufacturing risks and inefficiencies may result in costs and delays that prevent us from successfully commercializing products and adversely affect our ability to produce our products.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ADHD products are currently manufactured in our own production facility in Grand Prairie, Texas. We are in the process of outsourcing the manufacturing of our ADHD products to a third-party manufacturer to produce commercial quantities of our ADHD products beginning in late calendar 2023 or early calendar 2024. If the third party is not successful or does not meet our expectations (for example, timeliness of production, quantity of production, maintenance of needed documentation or regulatory compliance), we may have to find a different manufacturer and incur expenses and delays in the process. Manufacturers of our ADHD products must comply with good manufacturing practice (&quot;GMP&quot;) requirements enforced by the FDA, NMPA, EMA and other comparable foreign health authorities through facilities inspection programs. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our FDA regulated products may be unable to comply with these GMP requirements and with other FDA, NMPA, EMA, DEA, state, and foreign regulatory requirements. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our drugs, which would seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For all other products and any future product, we expect to use third-party manufacturers because we do not expect to have our own manufacturing capabilities. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing our current products, there could be significant differences between our estimates and the actual amounts of product we require. If we do not effectively maintain our supply agreements, we will face difficulty finding replacement suppliers, which could harm sales of those products. If we fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>reliance on third parties for regulatory compliance and quality assurance;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">possible breaches of manufacturing agreements by the third parties because of factors beyond our control;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>possible regulatory violations or manufacturing problems experienced by our suppliers; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further, if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition to a third-party CMO for our ADHD products. We may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">not be able to meet the demand for our products if one or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers for any of our products in a timely manner and on terms acceptable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The manufacturing processes and facilities of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer will be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>administrative or judicially imposed sanctions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>injunctions or the imposition of civil penalties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>recall or seizure of the product in question;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>total or partial suspension of production or distribution;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the FDA&#8217;s refusal to grant pending future clearance or pre-market approval;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>withdrawal or suspension of marketing clearances or approvals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>clinical holds;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>warning letters;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>refusal to permit the export of the product in question; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims, and harm our reputation with customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our products. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If we or our contract manufacturer fail to manufacture our ADHD products in sufficient quantities and at acceptable quality and pricing levels, or fail to obtain adequate DEA quotas for controlled substances, or to fully comply with cGMP regulations, we may face delays in the commercialization of these products, or be unable to meet market demand, and may be unable to generate potential revenues. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls, and the use of specialized processing equipment. Pharmaceutical companies often encounter difficulties in manufacturing, particularly in scaling up production of their products. These problems include manufacturing difficulties relating to production costs and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state, and foreign regulations. If we are unable to demonstrate stability in accordance with commercial requirements, or if our raw material manufacturers were to encounter difficulties or otherwise fail to comply with their obligations to us, our ability to obtain FDA approval and market our products would be jeopardized. We purchase raw materials and components from various suppliers in order to manufacture our ADHD products. If we are unable to source the required raw materials from our suppliers, or if we do not obtain DEA quotas or receive inadequate DEA quotas, we may experience delays in manufacturing our ADHD products, and may not be able to meet customer demand for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we and our contract manufacturer must comply with federal, state, and foreign regulations, including cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. We may be unable to comply with these cGMP requirements and with other FDA and foreign regulatory requirements. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or voluntary recall, or withdrawal of product approval. If the safety of any of our products is compromised due to failure to adhere to applicable laws or for other reasons, we may not be able to obtain, or to maintain once obtained, regulatory approval for such products or successfully commercialize such products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay in commercialization of our products, entail higher costs or adversely impact our commercialization of our products. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If our manufacturing facility becomes damaged or inoperable or we decide to or are required to vacate our facility, our ability to manufacture our ADHD products may be jeopardized. Our inability to continue manufacturing adequate supplies of our products could adversely affect our ability to generate revenues. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While we are in the process of transferring manufacturing at our Grand Prairie, Texas facility to a third-party manufacturer, all of our ADHD products manufacturing capabilities are currently housed in our sole manufacturing facility located in Grand Prairie, Texas. Our facility and equipment could be harmed or rendered inoperable by natural or manmade disasters, including war, fire, tornado, power loss, communications failure or terrorism, any of which may render it difficult or impossible for us to operate our drug delivery technology platform and manufacture our products for some period of time. While we seek to maintain finished goods inventory of our products outside of this facility, it is unlikely that the level of such inventory would be sufficient if we were to sustain anything other than a short-term disruption in our ability to manufacture our products at our Grand Prairie, Texas facility. The inability to manufacture our products if our facility or our equipment is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our facility and the equipment we use to manufacture our products could become damaged and time consuming to repair or replace. It would be difficult, time consuming and expensive to rebuild our facility or repair or replace our equipment or to complete the transfer of our proprietary technology to a third party, particularly in light of the requirements for a DEA registered manufacturing and storage facility like ours and FDA site change requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all. An </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">inability to continue manufacturing adequate supplies of our ADHD products at our Grand Prairie, Texas facility could result in a disruption in the supply of our products to physicians and pharmacies, which would adversely affect our ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In conjunction with transferring the manufacturing of our ADHD products to a CMO, we entered into an agreement with AMT Manufacturing Solutions, LLC to sublease approximately 30% of our Grand Prairie, Texas manufacturing facility. Commencing as early as April 1, 2024, but no later than December 31, 2024, the sublease will be expanded to include the remaining portion of the manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If we do not secure collaborations with strategic partners to test, commercialize and manufacture products, we may not be able to successfully develop products and generate meaningful revenues.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may enter into collaborations with third parties to commercialize and manufacture our products. If we are able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety are demonstrated. Further, the economic environment at any given time may result in potential collaborators electing to reduce their external spending, which may prevent us from developing our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Collaboration agreements typically provide for the ownership of intellectual property. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration and we may be limited in our ability to use, make or sell these inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize our products. Collaborations involving our products pose a number of risks, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may not have sufficient resources or may decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">collaborators may delay the development or commercialization of our products in favor of developing or commercializing their own or another party&#8217;s products; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>collaborators may decide to terminate or not to renew the collaboration for these or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a result, collaboration agreements may not lead to development or commercialization of our products in the most efficient manner or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Collaboration agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&#8217;s objectives and meet our expectations, we may be unable to advance our products and may not generate meaningful revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We face substantial competition from companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The biopharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We compete with companies that design, manufacture and market already-existing and new products. We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and/or our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. Our competitors may be more successful in acquiring new products than we are. If we fail to acquire new products, implementation of our business plan would be delayed, which could have a negative adverse effect on our business and prospects. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">expand the market for our approved products, especially our pharmaceutical and devices regulated by the FDA;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>successfully commercialize our products alone or with commercial partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>discover and develop products that are superior to other products in the market;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>obtain required regulatory approvals;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>attract and retain qualified personnel; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>obtain patent and/or other proprietary protection for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Established pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our products obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the products we are developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We compete with companies that design, manufacture and market treatments that compete with our products. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are more effective or less costly than that of our products or any product candidate that we are currently developing or that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We anticipate that we will face increased competition in the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to become profitable. If we are not able to compete effectively against our current and future competitors, our business will not grow, and our financial condition and operations will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our or our collaborators&#8217; ability to set a price we believe is fair for our approved products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our ability to generate revenue from our approved products and achieve profitability; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the availability of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Patient Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act, significantly impacted the provision of, and payment for, health care in the U.S. Various provisions of these laws are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the U.S., could influence the purchase of medicines and medical devices and reduce demand and prices for our products, if approved. This could harm our or our collaborators&#8217; ability to market any approved products and generate revenues. As we expect to receive significant revenues from reimbursement of our Rx Portfolio products by commercial third-party payors and government payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products approved in the future, and could cause an increase in our compliance, manufacturing or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, in some foreign countries, the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched in the EU do not follow price structures of the U.S. and generally tend to have significantly lower prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our financial results will depend on the acceptance among clinicians, third-party payors and the medical community of our products.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Physicians may not choose to prescribe our products if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to existing medicines or treatments. Our future success depends on the acceptance by our target customers, third-party payors, and the medical community that our products are reliable, safe, and cost-effective. We cannot predict the degree of market acceptance of any of our approved products. Many factors may affect the market acceptance and commercial success of our products, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our ability to convince our potential customers of the advantages, safety and economic value our products and product candidates over existing technologies and products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the approved labeling for the product and any required warnings;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the prevalence and severity of adverse events or publicity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>potential product liability claims</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the relative convenience and ease of our products over existing technologies and products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the introduction of new technologies and competing products that may make our products less attractive for our target customers;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our success in training medical personnel on the proper use of our products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the willingness of third-party payors to reimburse our target customers that adopt our products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>increases in rebate payments with payors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the acceptance in the medical community of our products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the extent and success of our manufacturing, marketing, and sales efforts; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>general economic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our future products fail to gain market access and acceptance, this will have a material adverse impact on our ability to generate revenue to provide a satisfactory, or any, return on our investments. Even if some therapies achieve market access and acceptance, the market may prove not to be large enough to allow us to generate significant revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While our pharmaceutical products are approved and generating revenues in the U.S., they may not receive, or continue to receive, clinician or patient acceptance, or they may not maintain adequate reimbursement from third party payors. In the future, we might possibly sell other products to target customers substantially all of whom receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&#8217;s determination that use of a product is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>a covered benefit under its health plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>appropriate and medically necessary for the specific indication;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>cost effective; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>neither experimental nor investigational.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third-party payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures and devices deemed to be experimental.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Obtaining coverage and reimbursement approval for a product from each government or third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a profit or even cover their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our products, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs are complex and may involve subjective decisions. Any failure to comply with those obligations could subject us to penalties and sanctions</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a condition of reimbursement by various federal and state health insurance programs, pharmaceutical companies are required to calculate and report certain pricing information to federal and state agencies. The regulations governing the calculations, price reporting and payment obligations are complex and subject to interpretation by various government and regulatory agencies, as well as the courts. Reasonable assumptions have been made where there is a lack of regulations or clear guidance and such assumptions involve subjective decisions and estimates. Pharmaceutical companies are required to report any revisions to their calculations, price reporting and payment obligations previously reported or paid. Such revisions could affect liability to federal and state payers and also adversely impact reported financial results of operations in the period of such restatement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Uncertainty exists as new laws, regulations, judicial decisions, or new interpretations of existing laws, or regulations related to our calculations, price reporting or payments obligations increases the chances of a legal challenge, restatement or investigation. If a company becomes subject to investigations, restatements, or other inquiries concerning compliance with price reporting laws and regulations, it could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on the business, financial condition and results of operations. In addition, it is possible that future healthcare reform measures could be adopted, which could result in increased pressure on pricing and reimbursement of products and thus have an adverse impact on financial position or business operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Further, state Medicaid programs may be slow to invoice pharmaceutical companies for calculated rebates resulting in a lag between the time a sale is recorded and the time the rebate is paid. This results in a company having to carry a liability on its consolidated balance sheets for the estimate of rebate claims expected for Medicaid patients. If actual claims are higher than current estimates, the company&#8217;s financial position and results of operations could be adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to retroactive rebates and the potential for 340B Program refunds, if a pharmaceutical firm is found to have knowingly submitted any false price information related to the Medicaid Drug Rebate Program to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), it may be liable for civil monetary penalties. Such failure could also be grounds for CMS to terminate the Medicaid drug rebate agreement, pursuant to which companies participate in the Medicaid program. In the event that CMS terminates a rebate agreement, federal payments may not be available under government programs, including Medicaid or Medicare Part B, for covered outpatient drugs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, if a pharmaceutical company overcharges the government in connection with the FSS program or Tricare Retail Pharmacy Program, whether due to a misstated Federal Ceiling Price or otherwise, it is required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against a company under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our collaborators are also subject to similar requirements outside of the U.S. and thus the attendant risks and uncertainties. If our collaborators suffer material and adverse effects from such risks and uncertainties, our rights and benefits for our licensed products could be negatively impacted, which could have a material and adverse impact on our revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our future profitability may depend, in part, on our ability to commercialize our products in foreign markets for which we intend to primarily rely on collaboration with third parties such as the agreement we entered into with Medomie Pharma Ltd. in July 2023 to sell Adzenys and Cotempla in Israel and the Palestinian Authority. If we commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our inability to directly control commercial activities because we are relying on third parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>different medical practices and customs in foreign countries affecting acceptance in the marketplace;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>import or export licensing requirements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>longer accounts receivable collection times;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>longer lead times for shipping;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>language barriers for technical training;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to our products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>foreign currency exchange rate fluctuations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our customers&#8217; ability to obtain reimbursement for our products in foreign markets; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Foreign sales of our products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have adopted a Code of Business Conduct and Ethics that mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. We cannot ensure, however, that our employees and third party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any such action will likely result in a materially significant diversion of management&#39;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to various health care fraud and abuse and reimbursement laws pertaining to the marketing of our approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential patients to request our products and services. Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations, Physician Payments Sunshine Act, and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payer, not only the Medicare and Medicaid programs, and do not contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction of our products, which may have a material adverse effect on our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adzenys XR-ODT and Cotempla XR-ODT contain controlled substances, and their manufacture, use, sale, importation, exportation, prescribing and distribution are subject to regulation by the DEA. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Adzenys XR-ODT and Cotempla XR-ODT, (collectively, our &#8220;Controlled Substance Products&#8221;), which are approved by the FDA, are regulated by the DEA as Schedule II controlled substances. Before any commercialization of any product candidate that contains a controlled substance, the DEA determines the controlled substance schedule of a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">drug, taking into account the recommendation of the FDA. Our Controlled Substance Products are, and our other future products may, if approved, be regulated as &#8220;controlled substances&#8221; as defined in the Controlled Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to distributors, prescribers, and dispensers of our products. For example, Schedule II controlled substances are subject to various restrictions, including, but not limited to, mandatory written prescriptions and the prohibition of refills. The DEA regulates the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled substances. State-controlled substance laws and regulations may have more extensive requirements than those determined by the DEA and FDA. Though state-controlled substances laws often mirror federal law because the states are separate jurisdictions, they may schedule products separately. While some states automatically schedule a drug when the DEA does so, other states require additional state rulemaking or legislative action, which could delay commercialization. Some state and local governments also require manufacturers to operate a drug stewardship program that collects, secures, transports, and safely disposes of unwanted drugs. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances are considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Amphetamine and methylphenidate, which are the active ingredients in our Adzenys XR-ODT and Cotempla XR-ODT products, respectively, are listed by the DEA as a Schedule II controlled substance under the CSA. Scheduled controlled substances are subject to DEA regulations relating to supply, procurement, manufacturing, storage, distribution, and physician prescription procedures. We currently manufacture these products in our own facilities, which are registered with and inspected by the DEA. Our planned contract manufacturer is also registered with and inspected by the DEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Registered entities are subject to DEA inspection and also must follow specific labeling and packaging requirements, and provide appropriate security measures to control against diversion of controlled substances. Security requirements vary by controlled substance schedule with the most stringent requirements applying to Schedule I and Schedule II controlled substances. Required security measures include background checks on employees and physical control of inventory through measures such as vaults and inventory reconciliations. Failure to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of a DEA registration. The DEA also has a production and procurement quota system that controls and limits the availability and production of Schedule I or II controlled substances. If we or any of our suppliers of raw materials that are DEA classified as Schedule I or II controlled substances are unable to receive any quota or a sufficient quota to meet demand for our products, if any, our business would be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because of their restrictive nature, these laws and regulations could limit commercialization of our products containing controlled substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees, criminal and civil penalties, and state actions, among other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The design, development, manufacture, supply and distribution of our products are highly regulated processes and technically complex. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to extensive regulation of the preparation and manufacture of our products for commercial sale. Components of a finished therapeutic product approved for commercial sale or used in late stage clinical trials must be manufactured in accordance with cGMPs and equivalent foreign standards. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our products that may not be detectable in final product testing. The development, manufacture, supply, and distribution of our approved products as well as any of our future potential products, are highly regulated processes and technically complex. We, along with our third-party suppliers, must comply with all applicable regulatory requirements of the FDA and foreign authorities. For instance, because each of our ADHD products is a regulated drug product and subject to the DEA and state-level regulations, we have had to, and will continue to, need to secure state licenses from each required state in which we intend to sell such product allowing us to distribute a regulated drug product in such state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Regulatory authorities also may audit our manufacturing facilities. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we may be required to take remedial measures that may be costly and/or time consuming for us to implement and that may include the temporary or permanent suspension of commercial sales or the temporary or permanent closure of our facility. Any such remedial measures imposed upon us could materially harm our business. If we fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or revocation of a pre-existing approval, or civil or criminal penalties. As a result, our business, financial condition and results of operations may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">There is a risk we may be unable to sell and distribute certain of our products if we cannot continue to comply with the serialization requirements of the Drug Quality and Security Act within the necessary time frames. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Title II of the Drug Quality and Security Act of 2013 provided increased FDA oversight over tracking and monitoring of the sale and distribution of prescription drugs. We are required to provide product identification information, or serialization, at the manufacturing batch, or lot level. In addition, we are required to track and verify wholesaler and pharmacy authentication and verification. By the end of 2023 we will be required to conduct unit level tracking throughout the entire supply chain. We are now serializing our products and are compliant with the Drug Quality and Security Act, but there is no guarantee that we will be able to continue to satisfy each ever-stringent product identification requirements. Failing to do so could result in a delay or inability to sell our products within the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Failure to comply with health and data protection laws and regulations could lead to U.S. federal and state government enforcement actions, including civil or criminal penalties, private litigation, and adverse publicity and could negatively affect our operating results and business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We and any potential collaborators may be subject to U.S. federal and state data protection laws and regulations, such as laws and regulations that address privacy and data security. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, we may obtain health information from third parties, including research institutions which are subject to privacy and security requirements under HIPAA, as amended by Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;). To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers, the federal government, and media outlets with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Depending on the facts and circumstances, we could be subject to significant civil, criminal, and administrative penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Compliance with U.S. and foreign privacy and data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time-consuming and costly.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our research and development processes may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We are dependent on our relationships and license agreements, and we rely on the intellectual property rights granted to us pursuant to the license agreements. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A number of our patent and trademark rights are derived from our license agreements with third parties. Pursuant to these license agreements, we have licensed rights to various patents, patent applications, trademarks and trademark applications within and outside of the United States. We may lose our rights to this intellectual property if we breach our obligations under such license agreements, including, without limitation, our financial obligations to the licensors. If we violate or fail to perform any term or covenant of the license agreements, the licensors may terminate the license agreements upon satisfaction of applicable notice requirements and expiration of any applicable cure periods. Additionally, any termination of license agreements, whether by us or the licensors may not relieve us of our obligation to pay any license fees owing at the time of such termination. If we fail to retain our rights under these license agreements, we will not be able to commercialize certain products subject to patent or patent application or trademark or trademark application, and our business, results of operations, financial condition and prospects would be materially adversely affected. In addition, the licensor may not be able to obtain valid and enforceable patents that protect the licensed products and may not be able to prevent third parties from infringing on those rights. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time we may renegotiate the terms of our existing licensing agreements or other material contracts. There can be no guarantee that the terms of the renegotiated license agreement will be viewed favorably by the market although the renegotiated terms might be advantageous to our business or that the other party would agree to material changes to benefit the Company. For example, in May 2022, we negotiated to terminate the License, Development, Manufacturing and Supply agreement with Tris. The negotiations resulted in reducing the future minimum payments we owed to Tris by approximately $8 million. If we were unable to renegotiate the terms of the agreement, it would have had a material negative impact on our cash flows and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The expiration or loss of patent protection may adversely affect our future revenues and operating results.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The suite of composition-of-matter patents for Adzenys XR-ODT are scheduled to expire in 2026 and 2032. The composition-of-matter patents in the U.S. for Cotempla XR-ODT expire in 2032, and the method-of-use patent expires in 2038. There is no guarantee that we will be able to extend the life of these patents or to obtain additional patents, licenses, or other instruments that can provide us with a comparable level of exclusivity to the intellectual property underlying the expiring patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We rely on patent, trademark and other intellectual property protection in the discovery, development, manufacturing and sale of our products. In particular, patent protection is, in the aggregate, important in our marketing of products in the United States. Patents covering our products normally provide market exclusivity, which is important for the profitability of many of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As patents for certain of our products expire, we may face competition from lower priced generic or bioequivalent products. In general, the expiration or loss of patent protection for a product may allow market entry by substitute products that could significantly reduce sales for the original product in a short amount of time. If our competitive position is compromised because of generic or bioequivalent products or otherwise, it could have a material adverse effect on our business and results of operations. In addition, proposals emerge from time to time for legislation to further encourage the early and rapid approval of generic or bioequivalent products. Any such proposals that are enacted into law could increase the negative effect of generic competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our ability to compete may decline if we do not adequately protect or enforce our intellectual property rights.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our success depends in part on our ability to manufacture, use, sell and offer to sell our products and in obtaining and maintaining intellectual property rights in our products, proprietary know-how and technology advances. We rely on patent protection, as well as a combination of trademark and trade secret laws to protect and prevent others from making, using and/or selling our compounds, processes, apparatuses and technology. While a presumption of validity exists with respect to patents issued to us in the U.S., there can be no assurance that any of our patents will not be challenged, invalidated, circumvented or rendered unenforceable. Such means may afford only limited protection of our intellectual property and may not (i) prevent our competitors from duplicating our inventions; (ii) prevent our competitors from gaining access to our proprietary information and technology; or (iii) permit us to gain or maintain a competitive advantage. In addition, our competitors or other third parties may obtain patents that restrict or preclude our ability to lawfully practice, produce or sell our products in a competitive manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Obtaining and maintaining a patent portfolio entails significant expense and resources. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer. In addition, the patent scope can be limited in prosecution or by the courts after issuance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal actions to enforce our patent rights and administrative challenges at the U.S. Patent and Trademark Office can be expensive and may involve the diversion of significant management time. In addition, these actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to patent protection, because we operate in the highly technical field of development of therapies and medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In addition, some countries allow patents to be challenged by third parties in administrative proceedings, which may result in a reduction in scope or cancelation of some or all of the claims.  Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There is significant litigation in the pharmaceutical industry regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products infringe </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the intellectual property rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions or devices that relate to our prescription and consumer health business. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies or universities involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation, wrongful disclosure of confidential information, or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could lead to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#8217;s intellectual property rights;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">we or our collaborators having to enter into license arrangements that may not be available on commercially reasonable or acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business, prospects and financial condition. As a result, we could be prevented from commercializing our products.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RISKS RELATED TO OUR ORGANIZATION, STRUCTURE AND OPERATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our efforts to expand and transform our businesses may require significant investments; if our strategies are unsuccessful, our business, results of operations and/or financial condition may be materially adversely affected.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We continuously evaluate opportunities for expansion and change. These initiatives may involve making acquisitions, entering into partnerships and joint ventures, divesting assets, restructuring our existing operations and assets, creating new financial structures and building new facilities&#8212;any of which could require a significant investment and subject us to new kinds of risks. We may incur additional indebtedness to finance these opportunities. If our strategies for growth and change are not successful, we could face increased financial pressure, such as increased cash flow demands, reduced liquidity and diminished access to financial markets, and the equity value of our businesses could be diluted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The implementation of strategies for growth and change may create additional risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>diversion of management time and attention away from existing operations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">requiring capital investment that could otherwise be used for the operation and growth of our existing businesses;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>disruptions to important business relationships;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>increased operating costs;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>limitations imposed by various governmental entities; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>difficulties due to lack of or limited prior experience in any new markets we may enter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our inability to mitigate these risks or other problems encountered in connection with our strategies for growth and change could have a material adverse effect on our business, results of operations and financial condition. In addition, we may fail to fully achieve the savings or growth projected for current or future initiatives notwithstanding the expenditure of substantial resources in pursuit thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We may have difficulties integrating acquired products and businesses and as a result, our business, results of operations and/or financial condition may be materially adversely affected.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have completed a number of acquisitions, and we intend to continue to acquire additional products and businesses through mergers, asset purchases or in-licensing, businesses or products, or form strategic alliances as part of our business strategy. Such growth strategies involve risks, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>inability to efficiently operate new businesses or to integrate acquired products and businesses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">inability to accurately predict delays in realizing the costs and benefits of acquisitions, partnerships, or joint ventures;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>unexpected losses of customers or suppliers of an acquired or existing business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>difficulties in retaining key employees of acquired businesses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>difficulties in realizing projected synergies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>failure of the acquired business to produce the expected value;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">exposure to unanticipated liabilities, including unexpected environmental exposures, litigation challenging a merger, product liability or illegal activities conducted by an acquired company or a joint venture partner.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our inability to address these risks in a timely manner or at all could cause us to fail to realize the anticipated benefits of such acquisitions or joint ventures and could have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">In fiscal 2023, the great majority of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially and adversely affect our results of operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Three customers contributed greater than 10% of our gross revenue during the years ended June 30, 2023 and 2022. During the years ended June 30, 2023 and 2022, three customers accounted for 78% of gross revenue, respectively. The loss of one or more of our significant customers could have a material adverse effect on our business, operating results or financial condition. Any reduction, delay or cancellation of an order from these customers or the loss of any of these customers could cause our revenue to decline. If we are unable to diversify our customer base, we will continue to be susceptible to risks associated with customer concentration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our accounts receivable subjects us to credit risk.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are also subject to credit risk from our accounts receivable related to our product sales. As of June 30, 2023, three customers accounted for 83% of gross accounts receivable. Our profitability and cash flow are dependent on receipt of timely payments from customers. Any delay in payment by our customers may have an adverse effect on our profitability, working capital and cash flow. There is no assurance that we will be able to collect all or any of its trade receivables in a timely matter. If any of our customers face unexpected situations such as financial difficulties, we may not be able to receive full or any payment of the uncollected sums or enforce any judgment debts against such clients, and our business, results of operations and financial condition could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our success depends to a significant degree upon the technical and management skills of our directors, officers, and key personnel. Any of our directors could resign from our board at any time and for any reason. Although our named executive officers Joshua Disbrow and Mark Oki have employment agreements, the existence of an employment agreement does not guarantee the retention of the executive officer for any period of time, and each agreement obligates us to pay the officer lump sum severance of two and a half years and one year, respectively, of salary if we terminate him without cause, as defined in the agreement, which could hurt our liquidity. The loss of the services of either of these individuals would likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key personnel. The loss of any of our directors or key executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We compete for such personnel, including directors, against numerous companies, including larger, more established companies with significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We will be exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of therapeutic candidates. Any failure of future therapeutic candidates by us and our corporate collaborators may expose us to liability claims as may the potential sale of any therapies approved in the future. These claims might be made by patients who use our therapies, healthcare providers, pharmaceutical companies, our corporate collaborators or other third parties that research or sell our therapies. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our future therapeutic candidates or any prospects for commercialization of our future therapeutic candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical, medical device, dietary supplement and personal care products. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration of a patient&#8217;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business, financial condition and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although we maintain general liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition, insurance coverage is increasingly expensive and difficult to obtain. For example, we have experienced increasing difficulty in procuring insurance coverage for our products, in particular, our ADHD products, due to their status as controlled substances. Inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm our reputation, which may adversely affect our collaborators&#8217; ability to commercialize our products successfully. A successful product liability claim or series of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to the Company.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted by Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:98.28%;"><tr style="height:15pt;"><td style="vertical-align:top;width:7.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#9679;</p></td><td style="vertical-align:top;width:88.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">we may, in our discretion, indemnify other officers, employees and agents in those circumstances where indemnification is permitted by applicable law;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:7.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#9679;</p></td><td style="vertical-align:top;width:88.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">we are required to advance expenses, as incurred, to our directors and executive officers in connection with defending a proceeding, except that such directors or executive officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:7.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#9679;</p></td><td style="vertical-align:top;width:88.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">we will not be obligated pursuant to our bylaws to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by our Board of Directors, (iii) such indemnification is provided by us, in our sole discretion, pursuant to the powers vested in the corporation under applicable law or (iv) such indemnification is required to be made pursuant to our amended and restated bylaws;</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:7.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#9679;</p></td><td style="vertical-align:top;width:88.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">the rights conferred in our bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:7.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#9679;</p></td><td style="vertical-align:top;width:88.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">we may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a result, if we are required to indemnify one or more of our directors or executive officers, it may reduce our available funds to satisfy successful third-party claims against us, may reduce the amount of money available to us and may have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Public concern over the abuse of medications that are controlled substances, including increased legislative, legal and regulatory action, could negatively affect our business.</b><b style="font-weight:bold;background:#ffff00;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Products containing controlled substances may generate public controversy. Certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of controlled substances such as opioids in the United States. State and local governmental agencies have commenced investigations into pharmaceutical companies and others in the supply chain in connection with the distribution of opioid medications. For example, on March 7, 2018 and April 18, 2019, Neos Therapeutics, which we now own, received citations advising Neos that the County of Harris Texas and the County of Walker Texas filed lawsuits on December 13, 2017 and January 11, 2019, respectively, against Neos and various other alleged manufacturers, promoters, sellers and distributors of opioid pharmaceutical products. Through these lawsuits, each of Harris County and Walker County seek to recoup as damages some of the expenses they allegedly have incurred to combat opioid use and addiction. Each of Harris County and Walker County also seeks punitive damages, disgorgement of profits and attorneys&#8217; fees. In addition, multiple lawsuits have been filed against pharmaceutical companies alleging, among other claims, failures to provide effective controls and procedures to guard against the diversion of controlled substances, negligence by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failures to report suspicious orders of controlled substances in accordance with regulations. Certain cases noted above have recently been settled, some for hundreds of millions of dollars. In the future, political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or restrict, the introduction and marketing of our products, the withdrawal of currently approved products from the market, or result in other legal action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we are aware of other legislative, regulatory or industry measures to address the misuse of prescription opioid medications which could affect our business in ways that we may not be able to predict. Liabilities for taxes or assessments under any such laws will likely have an adverse impact on our results of operations, unless we are able to mitigate them through operational changes or commercial arrangements where permitted and may result in us ceasing to continue to sell our products in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certain of our stockholders own a significant percentage of our stock and may and their interests may conflict with yours.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2023, one stockholder holds approximately 20% of our outstanding common stock and holds warrants which can be exercised to purchase additional shares of our common stock resulting in ownership of approximately 40% of our currently outstanding common stock. Accordingly, this stockholder will be able to exert a significant degree of influence over our management and affairs and over matters requiring security holder approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, in connection with our recent public offering of securities in June 2023, this stockholder has been granted the right to designate an individual to join our board of directors, who has since joined the board of directors, and to nominate an additional candidate who is acceptable to us to be elected to the Board, subject to Nasdaq regulations. The interests of this stockholder could conflict with the interests of our other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our business could be negatively affected as a result of the actions of activist stockholders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Proxy contests have been waged against many companies in the pharmaceutical industry over the last several years. It is possible that one or more of our stockholders may publicly voice opposition to certain aspects of our corporate governance and strategy, or undertake a proxy contest to reconstitute our board. If faced with a proxy contest or other type of stockholder activism, we may not be able to respond successfully to the contest or other type of activism which would be disruptive to our business. Even if we are successful, our reputation and/or business could be adversely affected by a proxy contest or other form of stockholder activism because:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived uncertainties as to our company and future strategic direction may result in the loss of potential financing, acquisitions, collaboration, in-licensing or other business opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if individuals are elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any or all of these activities could cause our stock price to decline or experience periods of volatility, and could be particularly problematic as our company seeks to transition to a commercial enterprise in a challenging environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RISK RELATED TO SECURITIES MARKETS AND INVESTMENT IN OUR SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our common stock. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement, the exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting notification, we anticipate that we would take actions to restore our compliance with applicable exchange requirements, such as stabilize our market price, improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&#8217;s minimum bid price requirement, or prevent future non-compliance with such exchange&#8217;s listing requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Effecting a reverse stock split, if determined by the Board in its discretion, may not achieve one or more of our objectives.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have effected five reverse stock splits since June 8, 2015, each of which has impacted the trading liquidity of the shares of our common stock. There can be no assurance that the market price per share of our common stock after a reverse stock split will remain unchanged or increase in proportion to the reduction in the number of shares of our common stock outstanding before the reverse stock split. The market price of our shares may fluctuate and potentially decline after a reverse stock split. Accordingly, the total market capitalization of our common stock after a reverse stock split may be lower than the total market capitalization before the reverse stock split. Moreover, the market price of our common stock following a reverse stock split may not exceed or remain higher than the market price prior to the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, there can be no assurance that a reverse stock split will result in a per-share market price that will attract institutional investors or investment funds or that such share price will satisfy investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve. Further, if a reverse stock split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus, these factors include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the success of products we acquire for development or commercialization relative to the success of our competitors;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>product safety;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">conditions or trends in the healthcare, biotechnology and pharmaceutical industries, including healthcare payment systems;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">our ability to effectively manage operations, financial decisions, internal controls over financial reporting or disclosure controls, performance relative to projections, and attract and retain employees;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>our dependence on third parties, including CROs and scientific and medical advisors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>adverse regulatory decisions or changes in laws or regulations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>general political and economic conditions and effects of natural or man-made catastrophic events; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>other events or factors, many of which are beyond our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our common stock. You might not be able to resell your shares at or above the price you paid for them.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any trading market for our common stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our business. We cannot control the number of securities and industry analysts who publish research on us, the extent of their coverage or the content of their reports. Downgrades of our stock or publishing inaccurate or unfavorable research about our business, would likely lead to a decline in our stock price. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose market visibility and demand for our stock could decrease, which might cause our stock price and any trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Some provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of our stockholders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Provisions in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the authorization of 50.0 million shares of &#8220;blank check&#8221; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>limiting the removal of directors by the stockholders;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>allowing for the creation of a staggered board of directors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</span></span>eliminating the ability of stockholders to call a special meeting of stockholders; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#9679;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired by or beneficial to our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">We do not intend to pay cash dividends on our capital stock in the foreseeable future.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any payment of cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">We are and may continue to be subject to short selling strategies.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Short sellers of our stock may be manipulative and may attempt to drive down the market price of shares of our Common Stock. Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is therefore in the short seller&#8217;s best interests for the price of the stock to decline, many short sellers (sometime known as &#8220;disclosed shorts&#8221;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum and generate profits for themselves after selling a stock short. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by blogging have allowed many disclosed shorts to publicly attack a company&#8217;s credibility, strategy and veracity by means of so-called &#8220;research reports&#8221; that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market, on occasion in large scale and broad base. Issuers who have limited trading volumes and are susceptible to higher volatility levels than large-cap stocks, can be particularly vulnerable to such short seller attacks. These short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the United States, are not subject to certification requirements imposed by the SEC and, accordingly, the opinions they express may be based on distortions or omissions of actual facts or, in some cases, fabrications of facts. In light of the limited risks involved in publishing such information, and the enormous profit that can be made from running a successful short attack, unless the short sellers become subject to significant penalties, it is more likely than not that disclosed short sellers will continue to issue such reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:13.5pt;"> </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Significant short selling of a company&#8217;s stock creates an incentive for market participants to reduce the value of that company&#8217;s common stock. Short selling may lead to the placement of sell orders by short sellers without commensurate buy orders because the shares borrowed by short sellers do not have to be returned by any fixed period of time. If a significant market for short selling our common stock develops, the market price of our common stock could be significantly depressed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">The Sabby litigation may result in the issuance of additional shares on the exercise of certain of our warrants and cause dilution to existing shareholders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A complaint was filed on February 22, 2023 by holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrantholders may receive, and that the Company failed to provide prompt notice to the warrantholders of such adjustment. The complaint seeks, among other things, a declaratory judgment of the warrant share calculation such that 2,325,581 warrant shares be due to the warrantholders on the exercise of the warrants rather than 1,265,547 shares. While we believe that this lawsuit is without merit and we intend to vigorously defend against it, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations. If this lawsuit is successful and the warrantholders exercise their warrants, it will result in significant dilution of the percentage ownership of our existing stockholders and could cause our stock price to fall. See Part I, Item 3. Legal Proceedings for more information on this lawsuit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">GENERAL RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Our business and operations would suffer in the event of system failures, cybersecurity attacks or other security breaches.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate cybersecurity attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the confidentiality, availability, and integrity of our data. There can be no assurance that we will be successful in preventing cyber attacks or successfully mitigating their effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from such cybersecurity attacks, including computer viruses, unauthorized access, ransomware attacks, phishing expeditions, natural disasters, terrorism, war and telecommunication and electrical failures. Such an event could cause interruption of our operations. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could suffer reputational harm or face litigation or adverse regulatory action and the development of our products could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our sales force and other employees, third party logistics partners, CMOs, CROs, principal investigators, collaborators, independent contractors, consultants and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Major bank failure or sustained financial market illiquidity, could adversely affect our business, financial condition and results of operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We face certain risks in the event of a sustained deterioration of domestic or international financial market liquidity. In particular:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to access funds in our deposit accounts on a timely basis. Any resulting need to access other sources of liquidity or short-term borrowing would increase our costs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the event of a major bank failure, we could face major risks to the recovery of our bank deposits. A substantial portion of our cash and cash equivalents are either held at banks that are not subject to insurance protection against loss or exceed the deposit insurance limit. While we are not currently aware of any liquidity issues directly impacting the financial institutions where we hold cash deposits or securities, if financial liquidity deteriorates, there can be no assurance we will not experience an adverse effect, which may be material, on our ability to access capital and on our business, financial condition and results of operations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e62b31d9_cea3_45df_b6d8_e8e37fe5be12"></a><a id="Item1BUnresolvedStaffComments_256339"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_cd3c47b8_fcb8_4d7b_bbb4_d9cc741b16ab"></a><a id="Item2Properties_819204"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease or sublease various properties, including office buildings, manufacturing, research and development facilities and sales offices within the U.S. We continuously review and evaluate our facilities as a part of our strategy to optimize our business operations. The following table sets forth a list of our properties as of June 30, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.74%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:52.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leased/Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:52.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purpose</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Englewood, CO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate headquarters</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grand Prairie, TX</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Administrative offices, Laboratory and Manufacturing facilities</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Berwyn, PA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office</p></td></tr><tr><td style="vertical-align:bottom;width:37.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Oceanside, CA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leased</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:52.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warehouse</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ffc9eca9_36c8_453a_b6fc_4a818203f5ca"></a><a id="Item3LegalProceedings_332346"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">ITEM&#160;3. LEGAL PROCEEDINGS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Witmer Class-Action Securities Litigation. </i>A shareholder derivative suit was filed on September 12, 2022 in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua Disbrow, Gary </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint drops Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enrichment and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in as insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While we believe that this lawsuit is without merit and have vigorously defended against it, we have agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Sabby Litigation.</i> A complaint was filed on February 22, 2023 in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrantholders may receive, and that the Company failed to provide prompt notice to the warrantholders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. While we believe that this lawsuit is without merit and we intend to vigorously defend against it, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Stein Litigation.</i> Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on February 1, 2023 in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which is pending. Due to the early stage of litigation, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations, and intend to vigorously defend this case in the event it is not dismissed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ed64c62d_1b9a_4739_b384_0ae800d0ae84"></a><a id="Item4MineSafetyDisclosures_822048"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4. MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_85ae8477_4ed3_45f0_83d7_2ded9eb01540"></a><a id="PARTII_350944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock has been listed on the NASDAQ Capital Market under the symbol &#8220;AYTU&#8221; since October&#160;20, 2017. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 6, 2023, we effected a 1-for-20 reverse stock split of our outstanding shares of common stock. Unless specifically provided otherwise herein, the share and per share information that follows in this Annual Report on Form 10-K other than in the historical financial statements and related notes included elsewhere in this Form 10-K, assumes the effect of the reverse stock split. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;20, 2023, the closing price as reported on the Nasdaq of our common stock was $1.585, and there were 190 holders of record of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Equity Compensation Plan Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On May 18, 2023, our stockholders approved the adoption of the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the &quot;2023 Equity Incentive Plan&#8221;). Prior to our adoption of the 2023 Equity Incentive Plan, we awarded equity incentive grants to our directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (&#8220;Aytu 2015 Plan&#8221;) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (&#8220;the Neos 2015 Plan&#8221;) (collectively the &#8220;2015 Plans&#8221;).  For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,155 shares available for grant under the 2015 Plans be &#8220;rolled over&#8221; to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table displays equity compensation plan information as of June&#160;30, 2023 relating to securities reserved for future issuance upon exercise.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Available&#160;for&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance&#160;under&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;be&#160;Issued&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">upon&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plans&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Column&#160;C&#160;-&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Options,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Excluding&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">and&#160;Rights&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;and&#160;Rights&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reflected&#160;in&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Column&#160;A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Column&#160;B)</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Column&#160;(A))</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 94,302</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 84,560</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity compensation plans not approved by security holders<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">127.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,595</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 98,721</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,155</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It reflects the weighted-average exercise prices of options outstanding. Restricted stocks and restricted stock units (RSUs) do not have exercise prices </span><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">(see Note 15 - Equity Incentive Plan).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It reflects the equity plan we assumed pursuant to the Neos Acquisition and restricted stock previously issued outside of the Aytu 2015 Plan (see Note 15 - Equity Incentive Plan).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have never declared or paid any dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors. Our ability to pay dividends on our common stock is limited by restrictions under the terms of our credit facility with Avenue Capital. In addition, any future indebtedness that we may incur could preclude us from paying dividends. Investors should not purchase our common stock with the expectation of receiving cash dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6b79b6b9_88b9_407e_8b8f_e79b2db67fac"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;7.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing strategy, includes forward-looking statements that involve risks and uncertainties. You should read the &#8220;Risk Factors&#8221; section of this Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">OBJECTIVE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purpose of the Management Discussion and Analysis (the &#8220;MD&amp;A&#8221;) is to present information that management believes is relevant to an assessment and understanding of our results of operations and cash flows for the fiscal year ended June 30, 2023 and our financial condition as of June 30, 2023. The MD&amp;A is provided as a supplement to, and should be read in conjunction with, our financial statements and notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OVERVIEW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. We operate through two business segments (i) the Rx Segment, consisting of various prescription pharmaceutical products sold through third party wholesalers (the Rx Portfolio&#8221;), and (ii) the Consumer Health Segment, which consists of various consumer health products sold directly to consumers. We generate revenue by selling our products through third party intermediaries in our marketing channels as well as directly to our customers. We currently manufacture our products for the treatment of ADHD at our manufacturing facility in Grand Prairie, Texas and use third party manufacturers for our other prescription and consumer health products. We also have a product candidate in development, AR101 (enzastaurin) for the treatment of VEDS, for which the development has been indefinitely suspended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses in each year since inception. Our net losses were $17.1 million and $108.8 million for the years ended June 30, 2023 and 2022, respectively. As of June 30, 2023 and 2022, we had an accumulated deficit of approximately $304.1 million and $287.1 million, respectively. We expect to continue to incur significant expenses in connection with our ongoing activities, including the integration of our acquisitions and the commercialization of our product pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNIFICANT DEVELOPMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Environment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have continued to experience significant inflationary pressure and supply chain disruptions related to the sourcing of raw materials, energy, logistics and labor during fiscal 2023. While we do not have sales or operations in Russia or Ukraine, it is possible that the conflict or actions taken in response, could adversely affect some of our markets and suppliers, economic and financial markets, costs and availability of energy and materials, or cause further supply chain disruptions. We expect that inflationary pressures and supply chain disruptions could continue to be significant across the business throughout the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Commercial Products </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 23, 2022, our newly issued US patent No. 11,166,947 for Cotempla XR-ODT was listed in the U.S. FDA publication &quot;Approved Drug Products with Therapeutic Equivalence Evaluations&quot;, commonly known as the &quot;Orange Book.&quot; The Cotempla XR-ODT patent covers methods of use for the effective pediatric dosing of methylphenidate for the treatment of attention deficit hyperactivity disorder. The Orange Book listing extends the exclusivity period for Cotempla XR-ODT to 2038. Teva Pharmaceuticals USA, Inc. has the right to manufacture and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">market its generic version of Cotempla XR-ODT under its ANDA beginning on July 1, 2026, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Development Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">AR101</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 7, 2021, the FDA granted Orphan Drug Designation (&#8220;ODD&#8221;) to AR101 for the treatment of Ehlers-Danlos Syndrome, a group of rare inherited connective tissue disorders that includes the severe subtype VEDS. The FDA grants ODD status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. ODD affords us with certain financial incentives to support clinical development and the potential for up to seven years of market exclusivity in the U.S. upon regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 13, 2021, the FDA cleared the IND application for AR101 in VEDS to enable the initiation of the AR101 PREVEnt Trial in VEDS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2022, the European Commission granted orphan designation to AR101 (enzastaurin) for the treatment of Ehlers-Danlos Syndrome. The European Medicines Agency orphan designation affords us with certain benefits and incentives, including clinical protocol assistance, differentiated evaluation procedures for Health Technology Assessments in certain countries, access to a centralized marketing authorization procedure valid in all EU member states, reduced regulatory fees and 10 years of market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 19, 2022, we were notified by the FDA that AR101 received Fast Track designation. Fast Track is a process designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet medical need. Fast Track addresses a broad range of serious conditions, and the request can be initiated by a pharmaceutical company at any time during the development process. FDA reviews the request and decides based on whether or not the drug fills an unmet medical need in a serious condition. Once a drug receives Fast Track designation, early and frequent communication between the FDA and the sponsor is encouraged throughout the entire drug development and review process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we announced the indefinite suspension of the development of AR101 to focus on our commercial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Healight</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, we received U.S. Patent Number 11,179,575, titled &quot;Internal Ultraviolet Therapy,&quot; which is the first issued patent protecting the Healight investigational device and covers methods of treating a patient for an infectious condition inside the patient&#39;s body through the insertion of a UV-light-emitting delivery tube inside a respiratory cavity of the patient at specific UV-A light wavelengths. The term of this patent extends to August of 2040.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, our preclinical pilot study showed that administration of Healight delayed the time to development of VAP in a novel porcine model. The proof-of-concept study was conducted at Hospital Clinic de Barcelona under the supervision of principal investigator Antonio Torres, M.D., Ph.D., FERS, FCCP, ATSF, Senior Consultant, Pulmonology Department - one of the only centers in the world with access to this well-characterized porcine model of VAP caused by oropharyngeal secretions colonized by Pseudomonas aeruginosa. In the study, administration of the Healight UV-A endotracheal catheter resulted in a 46% reduction in multidrug-resistant Pseudomonas aeruginosa (&#8220;PA C1-17&#8221;) versus controls following two separate 20-minute treatments. Based on these positive data, Hospital Clinic de Barcelona and we conducted a second, larger porcine VAP study to guide the future development of Healight for patients with VAP. We have since terminated the license agreement with Cedars-Sinai Medical Center (&#8220;CSMC&#8221;) and have discontinued development of Healight.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Debt and Equity Financings </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 26, 2022, we entered into the Avenue Capital Agreement with the Avenue Capital, pursuant to which Avenue Capital provided the Company and certain of its subsidiaries with a secured $15.0&#160;million loan. The interest rate on the loan is the greater of the prime rate and&#160;3.25%, plus&#160;7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the Deerfield Facility</span>, which was otherwise due and payable on May 11, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In connection with the Avenue Capital Agreement, we entered into an amendment to the Eclipse Loan Agreement. Pursuant to the amendment, the Company, among other things, extended the maturity date of the Eclipse Loan Agreement to January 26, 2025 and reduced the maximum availability under the Eclipse Loan Agreement from $25.0&#160;million to $12.5&#160;million minus a $3.5&#160;million availability block.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, we entered into an Amendment No. 4 (the &#8220;Eclipse Amendment&#8221;) to the Loan and Security Agreement dated October 2, 2019. The Eclipse Amendment, among other things, provided for an aggregate increase of $2.0 million to the Eclipse Lender&#8217;s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, upon closing of an underwritten public offering, we raised gross proceeds of $7.6 million from the issuance of (i) 151,500 shares of our common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock. We received $6.8 million in proceeds net of underwriting fees and other expenses. In April 2022, the pre-funded warrants were exercised in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2022, upon the closing of an underwritten public offering, we raised proceeds of $10.0 million from the issuance of (i) 1,075,290 shares of our common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of our common stock, and (ii) accompanying warrants to purchase 1,265,547 shares of our common stock. We received $9.1 million in proceeds net of underwriting fees and other expenses. In August 2022, the pre-funded warrants were exercised in full. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 6, 2023, we effected a 1-for-20 reverse stock split of our common stock. All share and per share amounts in this quarterly report have been adjusted to reflect the effect of the Reverse Stock Split. Aytu&#8217;s Board of Directors implemented the reverse stock split with the objective of regaining compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Market. On January 23, 2023, Nasdaq confirmed we regained compliance with this listing rule. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A cash payment was made to each stockholder in lieu of any fractional interest in a share to which each stockholder would otherwise be entitled as a result of the reverse stock split. The reverse stock split reduced the number of shares of outstanding common stock from approximately 68.8 million shares to approximately 3.4 million shares. As a result of the reverse stock split, proportional adjustments were also made to outstanding warrants and options, and to the shares available for grant in our equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2023, we entered into a securities purchase agreement with certain institutional investors named therein and a placement agency agreement with Maxim Group LLC, pursuant to which the Company agreed to issue and sell to investors in the offering an aggregate of 1,743,695 shares of the Company&#8217;s common stock, pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, accompanying Tranche A warrants to purchase 2,173,912 shares of common stock, and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The common warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. The gross proceeds were $4.0 million and net proceeds were approximately $3.4 million after deducting offering expenses. The offering closed on June 13, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, we issued 699,929 shares of common stock under the ATM Sales Agreement (as defined below) with total gross proceeds of approximately $3.0 million before deducting commissions of 3% and other offering expenses including legal and audit fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Discontinued Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our realization of post-acquisition synergies and product prioritization, we have implemented a portfolio rationalization plan whereby we will discontinue or divest five non-core products in our Rx Segment: Cefaclor Oral Suspension, Flexichamber, Tussionex, Tuzistra XR, and ZolpiMist. These products, collectively, contributed $1.6 million and $2.1 million in net revenue during the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;years ended June&#160;30, 2023 and 2022</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 107,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,730</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40,767</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 44,386</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,619)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66,632</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 52,283</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,349</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Advertising and direct marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,217</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,589</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,372)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other selling and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,231</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,124</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,107</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,167</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,537)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,095</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,567)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Goodwill impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (65,802)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,705</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,951)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,788</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,844</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,056)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain from contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (969)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,655)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 686</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 162,189</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (78,492)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,065)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (109,906)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 92,841</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,779)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (757)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,022)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 169</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (169)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,793</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,605</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,188</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,017</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,003)</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,051)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (108,889)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 91,838</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax (benefit) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (110)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 110</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,051)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (108,779)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 91,728</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue by segment</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:52.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net revenue by segment:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 73,799</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 61,121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,678</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Consumer Health Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,548</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,948)</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 107,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 96,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,730</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, net product revenue increased b<span style="background:#ffffff;">y $10.7 </span>million, or 11% compared to the year ended June 30, 2022. The increase in our Rx Segment product lines was primarily due to higher volume due to shortages of competing ADHD products, the effectiveness of our Aytu Rx Connect program, and the effectiveness of our sales and marketing programs. The decrease in the Consumer Health Segment&#8217;s net revenue was due to the reduction of our direct mailing business to focus our efforts on the higher profitability of our e-commerce business. We expect the revenue from our Consumer Health Segment to continue to decrease in fiscal 2024 as we look to monetize or discontinue this segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gross margin by segment</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin by segment:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">71%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">56%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15%</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Consumer Health Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">43%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">51%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(8)%</p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total gross margin by segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">62%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">54%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, gross margins increased by 8% compared to the year ended June 30, 2022. The improvement in Rx Segment gross margin percentage was primarily due to the greater volumes resulting in greater utilization of our manufacturing facilities. The lower gross margin in our Consumer Health Segment was due to the focus on our e-commerce business, which has lower gross margins, but higher contribution margins than our direct mailing business. In addition, we recorded an inventory impairment write-off of $2.1 million in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising and direct marketing (Consumer Health Segment)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, advertising and direct marketing expenses decreased by $2.4 million, or 12%, compared to the year ended June 30, 2022. Advertising and direct marketing expense include direct-to-consumer marketing, advertising, sales, and customer support and processing fees related to our Consumer Health Segment. The reduction in advertising and direct marketing costs were due to our focus on our e-commerce business during fiscal 2023. We expect advertising and direct marketing expenses to decrease from 2023 levels as we continue to reduce our direct mailing business and monetize or discontinue our Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other selling and marketing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, other selling and marketing expense increased $5.1 million, or 27%, compared to the year ended June 30, 2022. The increase was primarily driven by higher commission expense, a result of the higher subscriptions generated by our sales force. In addition, we incurred increased commercial marketing program fees due to the higher volumes generated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, general and administrative expense decreased by $2.5 million or 8%, compared to the year ended June 30, 2022. The decrease was primarily due to reductions of redundancies from the Neos and Innovus acquisitions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and development </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">AR101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,880</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,673</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,793)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">ADHD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,803</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 702</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,101</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Healight</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 926</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (676)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 361</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (199)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,095</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (8,567)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, research and development expense decreased by $8.6 million, or 68%, compared to the year ended June 30, 2022. Our research and development costs were primarily associated with our AR101 product candidate and support of our ADHD products, Adzenys and Contempla, and to a lesser extent, the development of our Healight product candidate, and support for our commercialized products. In October 2022, we announced the suspension of the development of AR101 and Healight to focus on our commercial operations, resulting in the decrease in expenses in fiscal 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, we recognized total impairment expense of $5.7 million, consisting of (i) $5.6 million intangible assets, and (ii) $0.1 million other assets. The impairments were due to increased focus on our commercial efforts in the Rx Segment and discontinued product distributions in the Consumer Health Segment. See Note 7 &#8211; Goodwill and Other Intangible Assets in the accompanying consolidated financial statements for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, we recognized total impairment expense of $75.5 million, consisting of (i) $65.8 million in goodwill, (ii) $7.1 million intangible assets, (iii) $2.0 million inventory, (iv) $0.4 million other assets and (v) $0.2 million property and equipment. The impairment expense related to write-down of assets was due to the discontinuation of commercializing certain products and products not marketed. See Note 7 &#8211; Goodwill and Other Intangible Assets in the accompanying consolidated financial statements for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amortization of intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, amortization expense of intangible assets, excluding amounts included in cost of sales, decreased by $1.1 million, or 18%, compared to the&#160;year ended June 30, 2022. The decreases were primarily related to the smaller intangible asset base due to the impairments of certain intangible assets during fiscal year 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain or loss from contingent consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We fair value our acquisition-related contingent considerations based on our projected results, any changes are reflected through income or expense. During the year ended June 30, 2023, the gain from contingent considerations decreased by $0.7 million, or 41%, compared to the&#160;year ended June 30, 2022. The decrease was primarily due to the contingent considerations (including CVRs) expiring or winding down during the fiscal year of 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other (expense) income, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, other expense, net increased by $4.0 million compared to the year ended June 30, 2022. Other expense, net, includes interest expense, accretion from fixed payment arrangements, and other income. In the fiscal year ended June 30, 2022, we received payments related to the divestiture of Natesto, which was recorded as other income. Starting the third quarter of fiscal 2023, we did not receive such payments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unrealized gain or loss on derivative warrant liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We fair value our derivative warrant liabilities using either the Monte Carlo simulation model or the Black-Scholes option pricing model. Derivative warrant liabilities are revalued at each reporting period and changes are reflected through income or expense. During the year ended June 30, 2023, the net gain from derivative warrant liability increased by $3.2 million when compared to the&#160;year ended June 30, 2022. The net increase was primarily due to higher fair values of derivative liabilities from warrants issued during fiscal year 2023. See Note 14 &#8211; Stockholders&#8217; Equity and Note 12 &#8211; Fair Value Considerations in the accompanying consolidated financial statements for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income tax benefit</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year ended 2023, there was no income tax benefit, primarily driven by the Internal Revenue Code Section 382 limitation on net operating loss utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year ended 2022, the impairment of the Rx Segment book goodwill decreased the net deferred tax liability by $0.1 million resulting in an income tax benefit of $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">LIQUIDITY AND CAPITAL RESOURCES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the primary sources and uses of cash for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,129)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,823)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,694</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (117)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,248)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,131</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,871</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,530</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,341</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities during these periods primarily reflected our net losses, partially offset by changes in working capital and non-cash charges including goodwill and intangible asset impairment, inventory write-down, changes in fair values of various liabilities, stock-based compensation expense, depreciation, amortization and accretion, and other charges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2023, net cash used in operating activities totaled $5.1 million. The decrease in net cash used was primarily the result of the decrease in operating loss, and increases in accounts payable and accrued liabilities, partially offset by an increase in accounts receivable, inventory, and prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2022, net cash used in operating activities totaled $28.8 million. The use of cash was approximately $81.4 million less than the net loss primarily due to non-cash charges of depreciation, amortization and accretion, impairment of goodwill and intangible assets, stock-based compensation, inventory and other assets write-downs and loss on debt extinguishment. These charges were offset by gains from change in fair values of contingent consideration and contingent value rights. In addition, our use of cash decreased due to changes in working capital including decreases in accounts receivable, inventory and prepaids, offset by a decrease in accrued liabilities and accounts payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities is generally related to our merger and acquisitions as well as purchase of assets to support our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $0.1 million during the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities of $3.2 million during the year ended June 30, 2022, was primarily due to $3.2 million payment of contingent consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net Cash from Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities of $8.9 million during the year ended June 30, 2023, was primarily from $3.4 million of net proceeds from our securities purchase agreement in June 2023, $9.1 million of net proceeds from our August 2022 equity raise, and $2.9 million net proceeds from our sales under the ATM Sales Agreement; partially offset by $2.3 million of net payments made under our short-term line of credit, and fixed payment arrangements totaling $4.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities of $1.5 million during the year ended June 30, 2022, was primarily from $15.0 million proceeds from long-term debt and $11.7 million net proceeds from issuance of our common stock, partially offset by $16.1 million full repayment of long-term debt, $4.1 million net reduction in our revolving loan, $4.4 million in payments of fixed payment arrangements and $0.5 million payment of debt issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sources of Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have obligations related to our loan agreements, contingent considerations related to our acquisitions, milestone payments for licensed products and manufacturing purchase commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We finance our operations through a combination of sales of our common stock and warrants, borrowings under our line of credit facility and cash generated from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shelf Registrations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 28, 2021, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the &#8220;2021 Shelf&#8221;). As of June 30, 2023, approximately $82.4 million remains available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitations of Form S-3. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2020, the Company filed a shelf registration statement (the &#8220;2020 Shelf&#8221;), which was declared effective by the SEC on June 17, 2020, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. The 2020 Shelf expired in June 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, under the 2020 Shelf, we initiated an at-the-market offering program (&quot;ATM&quot;), which allows us to sell and issue shares of our common stock from time-to-time. On June 2, 2021, we terminated our &#8220;at-the-market&#8221; sales agreement with a sales agent, and on June 4, 2021, we entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with a sales agent, pursuant to which we agreed to sell up to $30.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2020 Shelf. During the year ended June 30, 2023, we issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. As of June 30, 2023, we had approximately $3.0 million of capacity under the ATM Sales Agreement due to baby self-limitations. As our market capitalization increases, these limitations will be adjusted and we will be able to issue additional ATM sales. We terminated the Controlled Equity Offering in July 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Underwriting &amp; Placement Agency Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June 8, 2023, we entered into a securities purchase agreement with certain institutional investors named therein and a placement agency agreement with Maxim Group LLC, pursuant to which the Company agreed to issue and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sell to investors in the offering an aggregate of 1,743,695 shares of the Company&#8217;s common stock, pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, accompanying Tranche A warrants to purchase 2,173,912 shares of common stock, and accompanying Tranche B warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The common warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. The gross proceeds were $4.0 million, and net proceeds were approximately $3.4 million after deducting offering expenses. The offering closed on June 13, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 11, 2022, we closed an underwritten public offering, pursuant to which we sold an aggregate of (i) 1,075,290 shares of its common stock, (ii), pre-funded warrants to purchase 87,500 shares of its common stock, and (ii) accompanying warrants to purchase 1,265,547 shares of our common stock. The shares of common stock (or pre-funded warrants) and the accompanying common warrants were issued separately but could only be purchased together. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant is $8.58, which equals the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants are exercisable at any time after the date of issuance for a period of five years from the date such common warrants are first exercisable. The number of shares of common stock issuable upon exercise of the common warrants is subject to adjustment in certain circumstances, including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock. The Company received gross proceeds of $10.0 million and net proceeds were approximately $9.1 million, after deducting underwriting discounts and commissions and estimated offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, we closed on an underwritten public offering, pursuant to which, we sold (i) 151,500 shares of our common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable six months after the date of issuance and have a term of five years from the date of exercisability. We raised gross proceeds of $7.6 million before commission and other costs of $0.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Avenue Capital Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, we entered into the Avenue Capital Agreement, pursuant to which the Company received $15.0 million loan. The interest rate on the loan is the greater of the prime rate and 3.25%, plus 7.4%, payable monthly in arrears. We met certain milestones which resulted in monthly payments consisting of interest only. The principal amount will become due on the maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of outstanding debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event we prepay the outstanding principal prior to the maturity date, we will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, we shall pay to Avenue Capital a non-refundable fee in the amount of $0.6 million (&#8220;Final Payment&#8221;). See Note 11 &#8211; Long-term Debt in the accompanying consolidated financial statements for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eclipse Loan Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Eclipse Loan Agreement, as amended, provides us with up to $14.5 million in Revolving Loans, of which up to $2.5 million may be available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans bore interest at Secure Overnight Financing Rate (&#8220;SOFR&#8221;), plus 4.50% through April 2022. Beginning in May 2022 through maturity, the Revolving Loans bear interest at the SOFR plus 4.50%. In addition, we are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">required to pay an unused line fee of 0.50% of the average unused portion of the maximum Revolving Loans amount during the immediately preceding month. Interest is payable monthly in arrears. The maturity date under the Eclipse Loan Agreement, as amended, is January 26, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, we are required to pay a fee equal to&#160;(i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. We may permanently terminate the Eclipse Loan Agreement with at least five business&#160;days prior notice. See Note 10 &#8211; Line of Credit in the accompanying consolidated financial statements for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contractual Obligations, Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of our acquisitions and licensing agreements, we are contractually and contingently obliged to pay, when due, various fixed and contingent milestone payments. See Note 18 &#8211; Commitments and Contingencies in the accompanying consolidated financial statements for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 related to Tuzistra (the &#8220;Tuzistra License Agreement&#8221;). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6&#160;million to $9&#160;million, which reduced our total liability for minimum payments by approximately $8.0&#160;million from the original License Agreement. The settlement payment will be paid in&#160;three&#160;installments from December 2022 through July 2024, with a provision that allows for the Company to pay interest on any principal amounts due but remaining unpaid past the scheduled payment date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the acquisition of a line of prescription pediatric products from Cerecor, Inc. in October 2019, we assumed payment obligations that require us to make fixed and product milestone payments. As of June 30, 2023, up to $3.8 million of fixed and product milestone payments remain through 2026 and are expected to be paid from the revenue generated by Karbinal ER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the February 2020 acquisition of Innovus Pharmaceuticals, Inc. (the &#8220;Innovus Acquisition&#8221;), all of Innovus&#8217;s shares were converted to our common stock and contingent value rights (&#8220;CVRs&#8221;), which represents contingent additional consideration of up to $16.0 million payable to satisfy future performance milestones. As of June 30, 2023, up to $5.0 million of potential CVR milestone payments remain, which we do not expect to pay. These CVR milestone payments expire on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with our Innovus Acquisition, we assumed a contingent obligation which required us to make milestone payment of $0.5 million, between fiscal year 2026 through fiscal year 2033 to Novalere, if and when certain levels of FlutiCare sales are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with our acquisition of the Rumpus assets, upon satisfaction of milestones, we may be required to pay up to $67.5 million in regulatory and commercial-based earn-out payments to Rumpus. Under the licensing agreement with Denovo Biopharma LLC (&#8220;Denovo&#8221;), we are required to make a payment of $0.6 million for a license fee in April 2022 and upon achievement of regulatory and commercial milestones, up to $101.7 million. Under the licensing agreement with Johns Hopkins University (&#8220;JHU&#8221;), upon achievement of regulatory and commercial milestone, we may be required to pay up to $1.6 million to JHU. In fiscal 2022, two milestones payable to Rumpus were achieved totaling $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CRITICAL ACCOUNTING ESTIMATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). The preparation of our financial statements requires us to make estimates and judgments </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that affect the reported amounts of assets and liabilities and the disclosure of any contingent assets and liabilities at the date of the financial statements, as well as reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note 2 &#8211; Summary of Significant Accounting policies to the notes to our audited financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generate revenue from product sales through our Rx Segment and Consumer Health Segment. We evaluate our contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations and if they are distinct; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net product sales in the Rx Segment consist of sales of prescription pharmaceutical products under the Rx Portfolio, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#8220;Gross to Net&#8221; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gross to Net adjustments include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Savings offers </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Prompt payment discounts </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prompt payment discounts are based on standard provisions of wholesalers&#8217; services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesale distribution fees </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Rebates </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesaler chargebacks </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217; end customers.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Returns </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wholesalers&#8217; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. Our periodic adjustments of our estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. We continually monitor these provisions and do not believe variances between actual and estimated amounts have been material. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A 10% increase or decrease in these estimates impacts net sales by a corresponding increase or decrease of approximately $3.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We generate Consumer Health Segment product revenue from sales of various consumer health products through e-commerce platforms and direct mail. Revenue is generally recognized &#8220;free-on-board&#8221; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by us from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impairment of Long-lived Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We assess impairment of long-lived assets annually and when events or changes in circumstances indicates that their carrying value amount may not be recoverable. Long-lived assets consist of property and equipment, net and goodwill and other intangible assets, net. Circumstances which could trigger a review include but are not limited to: (i) significant decreases in the market price of the asset; (ii) significant adverse changes in the business climate or legal or regulatory factors; (iii) changes in business plans or (iv) expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than the carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. Such estimates involve projections of future sales and costs, which may vary from actual results.</span> <span style="font-size:10pt;">Declines in the outlook for the related products, particularly soon after fair-value measurement upon acquisition or prior impairment, can negatively impact our ability to recover the carrying value and can result in an impairment charge.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to continue building our portfolio of revenue-generating products by leveraging our commercial team&#8217;s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating prescription products, we have decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, we incurred an impairment charge of $2.6 million related to NT0502 and have terminated the licensing agreement. We also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $3.0 million due to discontinuance of products in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the Rx Segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million impairment expense for the write-down of intangible assets consisting of (i) $2.6 million for AcipHex Sprinkle, (ii) $1.4 million for ZolpiMist, (iii) $0.5 million for Tussionex, (iv) $0.2 million for Cefaclor and (v) $0.2 million for the Neos tradename. Additionally, our Consumer Health Segment recorded an impairment of $2.2 million related to products no longer being marketed and products that have been underperforming.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Goodwill is recorded as the difference between the fair value of the purchase consideration and the fair value of the net identifiable tangible and intangible assets acquired. As described in Note 2 &#8211;  Summary of Significant Accounting Policies to our financial statements, Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. If, after assessing events or circumstances, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying amount, we perform a quantitative impairment test by comparing the fair value of the reporting unit with the carrying value. If the fair value of a reporting unit is less than the carrying amount, an impairment charge is recorded in the amount of the difference. The fair value of a reporting unit is estimated using a combination of a market multiple and a discounted cash flow approach. Determining the fair value of a reporting unit requires the use of estimates, assumptions and judgment. The principal estimates and assumptions that we use include prospective financial information (revenue growth, operating margins, and capital expenditures), future market conditions, weighted average costs of capital, a terminal growth rate, comparable multiples of publicly traded companies in our industry, and the earnings metrics and multiples utilized. We believe that the estimates and assumptions used in impairment assessments are reasonable. We have determined that we have two reporting units that require periodic review for goodwill impairment, the Rx Segment, and the Consumer Health Segment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the fiscal year 2022, our market capitalization significantly declined. The decline was considered a qualitative factor that led us to assess whether an impairment had occurred. The evaluation indicated that the goodwill related to one of the reporting units within the Rx Segment and Consumer Health Segment was potentially impaired. We performed a quantitative impairment test. As a result, we recorded an impairment charge of $65.8 million for the year ended June 30, 2022. At June 30, 2022, we had no goodwill recorded on our balance sheet. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Equity classified warrants are valued using a Black-Scholes options pricing model at issuance and are not remeasured. Liability classified warrants are carried at fair value using either the Black-Scholes option pricing or Monte Carlo simulation model. Changes in the fair value of liability classified warrants in subsequent periods are recorded as a gain or loss on remeasurement and reported as a component of cash flows from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2791878b_ddf4_4964_9aeb_b438c784e9ab"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;7A.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_91e2d9f5_8328_482e_9eae_60d16f66f21a"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;8.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The financial statements required by this item are identified in Item&#160;(a)(1)&#160;of Part&#160;IV and begin at page&#160;F-1 of this Annual Report on Form&#160;10-K and are incorporated herein by reference.</p><a id="_bde44b12_4ee5_46db_8212_4e9e4b81bc62"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;9.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d9b6f09d_758d_4868_aa88_4e46e1cdcae2"></a><a id="Item9AControlsandProcedures_459290"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;9A.&#160;&#160;&#160;CONTROLS AND PROCEDURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of June 30, 2023, our principal executive officer and principal financial officer concluded that our controls were not effective as of the end of the period covered by this report. Notwithstanding the material weakness, our management believes that the financial statements included elsewhere in this report present fairly, in all material respects, our financial position, results of operations, changes in stockholders&#8217; equity and cash flows in conformity with GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the preparation of our financial statements for the period ended June 30, 2023, we concluded that we had a material weakness in internal control over financial reporting related to our analysis for the accounting for valuation of our inventory. At year end, it was determined that the analysis of over/under absorbed manufacturing costs was not performed, which could have led to material misstatement of our financial statement. If not addressed, the deficiency could result in a material misstatement in the future. In response, we have incorporated the process for quantifying any over or under absorbed manufacturing costs, and having the appropriate level of management evaluate the analysis and materiality of any over or under absorption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules&#160;13a-15(f)&#160;under the Exchange Act). Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2023. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in <i style="font-style:italic;">Internal Control-Integrated Framework (2013)</i>. Our management has concluded that, as of June 30, 2023, our internal control over financial reporting is effective based on these criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant Thornton, LLP, the independent registered public accounting firm that audited our financial statements included in this Annual Report on Form&#160;10-K, was not required to issue an attestation report on our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Previous Disclosure of Material Weakness in Internal Controls Over Financial Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">As disclosed in our September 30, 2022 Form 10-Q/A, we identified a material weakness in controls over the accounting for complex warrant issuances and the classification of these issued warrants. This material weakness resulted in the failure to prevent material adjustments in accounting for the warrants as equity classification when the warrants should have been classified as liabilities and marked to market each reporting period. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements, other literature, and consultation with third-party experts, we did not classify the warrants correctly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Remediation Plan </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Our Audit Committee conducted an internal investigation to identify and determine a plan to remediate the material weakness described above and to enhance our overall control environment. We will not consider the material weakness remediated until our enhanced control is operational for a sufficient period of time and tested, enabling management to conclude that the enhanced controls are operating effectively. Our remediation plan includes the implementation of controls over the process of reviewing significant and complex contracts and agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Changes in Internal Control Over Financial Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">Except for the material weakness noted above, there have been no changes in the Company&#8217;s internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2023, that have material effect, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f58b7552_382c_48bf_90a8_97b368ee3b56"></a><a id="Item9BOtherInformation_33867"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;9B.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_9610a9fe_69df_4972_9222_ebf1e7d4601d"></a><a id="ITEM9CDISCLOSUREREGARDINGFOREIGNJ"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">ITEM 9C.  DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENT INSPECTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d3fbbf44_6f74_4838_8361_f4046374b6e5"></a><a id="PARTIII_810231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsandExecutiveOfficersandCo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;10.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">DIRECTORS AND EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the names and ages of all of our directors and executive officers. Our Board of Directors is currently comprised of five members, who are elected annually to serve for one&#160;year or until their successor is duly elected and qualified, or until their earlier resignation or removal. We have two executive officers that serve at the discretion of the Board of Directors and are appointed by the Board of Directors.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Joshua R. Disbrow</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chairman and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Mark Oki</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chief Financial Officer, Secretary, and Treasurer</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Greg Pyszczymuka</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chief Commercial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carl C. Dockery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">John A. Donofrio, Jr.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Abhinav Jian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:39.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vivian H. Liu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a biographical summary of the experience of our executive officers and directors during the past five&#160;years, and an indication of directorships held by the directors in other companies subject to the reporting requirements under the federal securities law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Joshua R. Disbrow&#160;&#8211; Chairman and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr. Disbrow has been employed by us since April 16, 2015 and a member of our Board of Directors since January 2016. Prior to the closing of the merger between Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. that formed Aytu BioPharma, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow jointly served as the Chief Operating Officer of Ampio Pharmaceuticals, Inc. (&#8220;Ampio&#8221;) from December 2012 until April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, LLC (&#8220;Arbor&#8221;), a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company&#8217;s second full-time employee. Mr. Disbrow led the company&#8217;s commercial efforts from inception to the company&#8217;s acquisition in 2010 and growth to over $127 million in net sales in 2011 and to over $250 million in net sales in 2012. By the time Mr. Disbrow departed Arbor in late 2012, he handled the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 26 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, sales management, marketing, commercial operations, commercial strategy, and business development. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience Inc., an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake Forest University School of Business and BS in Management from North Carolina State University. Mr. Disbrow&#8217;s experience in executive management and commercialization within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should serve as a member of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mark K. Oki&#160;&#8211; Chief Financial Officer, Secretary, and Treasurer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Mr. Oki has served as our Chief Financial Officer since January 2022 and as our Secretary and Treasurer since May 5, 2022. From October 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC, (formerly Vivus Inc.) a commercial-stage pharmaceutical company. Vivus was a Nasdaq listed company up to December 2020. From April 2006 to October 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at life science companies, Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation). Mr. Oki began his career in public accounting at Deloitte &amp; </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration &#8211; Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Greg Pyszczymuka &#8211; Chief Commercial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Mr. Pyszczymuka has served as our Chief Commercial Officer since January 2022. Prior to joining the Company, at the closing of the company&#8217;s merger with Neos Therapeutics in March 2021, Greg Pyszczymuka served as Vice President, Commercial at Neos Therapeutics since June 2020. He previously served as Vice President, Commercial Strategy &amp; Market Access at Neos from November 2018 to June 2020, and as Executive Director of Channel Strategy &amp; Access Programs. Prior to joining Neos, Greg had served in roles of increasing responsibility over a 15-year career including sales management, brand management, channel strategy, managed markets and new products planning. Greg joined Neos most recently from Aqua Pharmaceuticals (an Almirall company), and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">John A. Donofrio,&#160;Jr.&#160;- Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mr. Donofrio joined our Board of Directors in July 2016. He is a senior pharmaceutical executive with over 30 years of experience in the industry across a broad range of areas, including President, Chief Financial Officer, and Chief Operating Officer positions. Mr. Donofrio has significant finance experience in consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and business development. Since March 2022 Mr. Donofrio has served as Executive Vice President, Chief Operating Officer of Novan Inc., a publicly held specialty dermatology company, and as President of Novan Inc.&#8217;s wholly owned subsidiary EPI Health, a specialty pharmaceutical company commercializing products in the dermatology market. From March 2019 until its acquisition by Novan, Inc in March 2022, Mr. Donofrio served as EPI Health&#8217;s President. Mr. Donofrio previously served as Chief Financial Officer and Head of Business Development at TrialCard from March of 2018 to March 2019. TrialCard is a technology-driven pharmaceutical services company providing patient access and support programs to the pharmaceutical and biotechnology industries. Prior to joining TrialCard, Mr. Donofrio was the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, from August 2013 to March 2018. Merz is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the United States and Canada. At Merz, Mr. Donofrio was accountable for financial performance, cost management, business development and strategic business planning and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013. In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for the Global Dermatology Business Unit. Mr. Donofrio served as a director of Vyrix from February 2014 to April 2015. Mr. Donofrio holds a degree in Accounting from North Carolina State University. Mr. Donofrio&#8217;s broad executive leadership experience and financial expertise along with experience in the pharmaceutical industry led to the conclusion that he should serve as a member of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Carl C. Dockery&#160;&#8211; Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Mr. Dockery joined our Board of Directors in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance industry and more recently since 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC. Mr. Dockery&#8217;s career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd&#8217;s and the London Underwriting Centre brokering various types of reinsurance placements. From September 2014 through September 2019, Mr. Dockery served as a director of CytoDyn Inc. (OTCQB: CYDY), and a publicly-traded biotechnology company focused on the development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV and cancers. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities. Mr. Dockery&#8217;s financial expertise and experience, as well as his experience as a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">director of a publicly traded biopharmaceutical company led to the conclusion that he should serve as a member of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Abhinav &#8220;Abi&#8221; Jain - Director</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Mr. Jain joined our Board of Directors in June 2023. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management and is focused on investments in various sectors, including specialty and generic pharmaceuticals. From 2015-2017, Mr. Jain was an Associate at Angelo, Gordon &amp; Co., an alternative asset manager. At Angelo, Gordon &amp; Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.  Mr. Jain&#8217;s financial expertise and experience led to the conclusion that he should serve as a member of our Board of Directors. Mr. Jain was appointed pursuant to a board designation right granted to Nantahala Capital Management, LLC to appoint one director to our Board of Directors, pursuant to the Securities Purchase Agreement dated June 8, 2023 with Nantahala and other investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Vivian H. Liu - Director</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Ms. Liu joined our Board of Directors in July 2022. Ms. Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited, a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Ms. Liu served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc., a publicly listed consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack  Pharmaceuticals, Inc. From 2017-2018, she served as the Chief Operating Officer and a member of the Board of Directors of Cesca Therapeutics, Inc. Previously, Vivian served as Managing Director of OxOnc Services Company, an oncology development company, and prior to that, Ms. Liu co-founded and served as President, Chief Executive Officer, and board director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Ms. Liu served in several executive capacities, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from the University of California, Berkeley. Ms. Liu&#8217;s experience in executive management within the pharmaceutical industry, as a director of a publicly traded biotech company and in corporate finance led to the conclusion that she should serve as a member of our Board of Directors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Family Relationships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Jarrett T. Disbrow, our Chief Business Officer is the brother of Joshua R. Disbrow, our Chairman and Chief Executive Officer. There are no other family relationships among or between any of our current or former executive officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Involvement in Certain Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-indent:36pt;margin:0pt 25.95pt 0pt 0pt;">Mr. Oki was the Chief Financial Officer of Vivus, Inc. at the time a Chapter 11 petition was filed under the Federal bankruptcy laws in July 2020. Mr. Donofrio was Executive Vice President, Chief Operating Officer of Novan, Inc. at the time a Chapter 11 petition was filed under the Federal bankruptcy laws in July 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-indent:36pt;margin:0pt 25.95pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our directors or executive officers have not been involved in any legal proceedings in the past 10&#160;years that would require disclosure under Item&#160;401(f)&#160;of Regulation S-K promulgated under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Section&#160;16(a)&#160;of the Securities Exchange Act requires our officers and directors and persons who own more than 10% of our outstanding common stock to file reports of ownership and changes in ownership with the Securities </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and Exchange Commission. These officers, directors and stockholders are required by regulations under the Securities Exchange Act to furnish us with copies of all forms they file under Section&#160;16(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based solely on our review of the copies of forms we have received, we believe that all such required reports have been timely filed, except for one late filing of a Form 4 by Josh Disbrow relating to a rescission of 80,000 shares of restricted common stock on December 20, 2022, which was inadvertently filed one day late on December 23, 2022, and two late filings of Form 4s by Greg Pyszczymuka, one of which related to the conversion of 833 restricted stock units to shares of common stock on April 25, 2023, which was inadvertently filed late on June 20, 2023, and the second of which related to the conversion of 208 restricted stock units to shares of common stock on June 30, 2023, which was inadvertently filed late on July 6, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Code of Ethics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item&#160;regarding our Code of Ethics is found in Part&#160;I, Item&#160;1, under the caption &#8220;Code of Ethics.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Board Committees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has established an Audit Committee, Compensation Committee and a Nominating and Governance Committee. Our Audit Committee consists of Mr. Donofrio (Chair), Mr. Dockery, Mr. Jain, and Ms. Liu. Our Compensation Committee consists of Ms. Liu (Chair), Mr. Dockery, Mr. Jain, and Mr. Donofrio. Our Nominating and Governance Committee consists of Mr. Dockery (Chair), Mr. Donofrio, Mr. Jain, and Ms. Liu. The independence of our directors is discussed in Part&#160;III, Item&#160;13 under the caption &#8220;Director Independence.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each of the above-referenced committees operates pursuant to a formal written charter. The charters for these committees, which have been adopted by our Board, contain a detailed description of the respective committee&#8217;s duties and responsibilities and are available on our website at http://www.aytubio.com under the &#8220;Investor Relations&#8212;Corporate Governance&#8221; tab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board has determined Mr.&#160;Donofrio qualifies as an audit committee financial expert, as defined in Item&#160;407(d)(5)&#160;of Regulation S-K promulgated by the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stockholder Proposals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our bylaws establish procedures for stockholder nominations for elections of directors and bringing business before any annual meeting or special meeting of stockholders. A stockholder entitled to vote in the election of directors may nominate one or more persons for election as directors at a meeting only if written notice of such stockholder&#8217;s intent to make such nomination or nominations has been delivered to our Corporate Secretary at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary of the prior&#160;year&#8217;s annual meeting. In the event that the date of the annual meeting is more than 30&#160;days before or more than 60&#160;days after the anniversary date of the prior&#160;year&#8217;s annual meeting, the stockholder notice must be given not more than 120&#160;days nor less than the later of 90&#160;days prior to the date of the annual meeting or, if it is later, the 10th day following the date on which the date of the annual meeting is first publicly announced or disclosed by us. These notice deadlines are the same as those required by the SEC&#8217;s Rule&#160;14a-8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the bylaws, a stockholder&#8217;s notice must set forth among other things: (a)&#160;as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules&#160;and regulations thereunder; and (b)&#160;as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There have been no changes to these nominating procedures since the adoption of the bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_18c3bc1f_dd5a_406e_95fe_d9fe0e4df621"></a><a id="Item11ExecutiveCompensation_611473"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;11.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with Item 402 of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation of our Company&#8217;s named executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In establishing executive compensation, our Board is guided by the following goals:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the executive officers for work required for a company of our size and scope;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">compensation should align the executive officers&#8217; interests with the long-term interests of stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">compensation should assist with attracting and retaining qualified executive officers and directors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current compensation package for non-employee directors, effective July 1, 2020, consists of: an annual cash retainer of $70,000 for the non-executive Board chair, $40,000 for each other director, $20,000 for each audit committee and compensation committee chair, $10,000 for nominating and governance committee chair, and $10,000 for each other committee member of the audit and compensation committees and $5,000 for each other committee member of the nominating and governance committee; a grant of 6,500 restricted shares of stock or restricted stock units upon appointment to the Board; and an annual stock option grant of 1,500 shares thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides information regarding all compensation paid to non-employee directors of Aytu during the fiscal&#160;year ended June 30, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fees&#160;Earned&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">or&#160;Paid&#160;in&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carl C. Dockery (1)(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 70,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 70,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">John A. Donofrio Jr. (1)(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 90,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Abhinav Jian (1)(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,306</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vivian H. Liu (1)(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 63,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25,870</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 89,620</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">As of June 30, 2023, the number of restricted shares held by each non-employee director was as follows: 3,893 restricted shares for Mr. Dockery and 762 restricted shares for Mr. Donofrio, both adjusted for the recission of shares from the Aponowicz and Paguia settlement (for more information, see Stipulation of Compromise and Settlement in Note 15 to the Consolidated Financial Statements included in Aytu&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2023). Ms. Liu held 6,825 restricted shares.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">As of June 30, 2023, the number of stock options held by each non-employee director was as follows: (i) 200 shares for Mr. Dockery; (ii) 200 shares for Mr. Donofrio. </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Executive Officer Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth all cash compensation earned, as well as certain other compensation paid or accrued for the&#160;years ended June 30, 2023 and 2022 to each of the following named executive officers. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change&#160;in&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pension&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value&#160;and&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Equity&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nonqualified&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incentive&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All&#160;Other&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Salary&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Bonus&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Award</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Award&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Earnings&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Compensation&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(c)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(d)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(e)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(f)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(g)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(h)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(i)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(j)</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Named Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Joshua R. Disbrow</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 590,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 118,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 708,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><i style="font-style:italic;">since December&#160;2012</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 590,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 590,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Mark K. Oki</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><i style="font-style:italic;">Chief Financial Officer, Secretary</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 415,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,840</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 522,840</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><i style="font-style:italic;">and Treasurer since January 2022</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 183,558</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 135,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 368,558</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;">Greg Pyszczymuka</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><i style="font-style:italic;">Chief Commercial Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 375,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,046</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 540,046</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">Option awards are reported at fair value at the date of grant.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. Executives are reimbursed for business expenses directly related to our business activities, such as travel, primarily for business development as we grow and expand our product lines. On average, each executive incurs between $1,000 to $3,000 of out-of-pocket business expenses each month. The executive management team meets weekly and determines which activities they will work on based upon what we determine will be most beneficial to the Company and our stockholders. No interest is paid on amounts reimbursed to the executives.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Outstanding Equity Awards at Fiscal&#160;Year-End 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The following table contains certain information concerning unexercised options for the Named Executive Officers as of June 30, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:46.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option&#160;Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:29.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;Awards</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Incentive&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Incentive&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards:&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards:&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Market</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;or&#160;Payout&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Incentive&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Market</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unearned&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unearned&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards:&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Value&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">or&#160;Units&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;or&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units&#160;or&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units&#160;or&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Securities&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;Stock&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Units&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">That&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rights&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rights&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercised&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercised&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Have&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">That&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">That&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">That&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercised&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Not&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Have&#160;Not&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Have&#160;Not&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Have&#160;Not&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unearned&#160;Options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Expiration&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vested&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vested&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vested&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Vested&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Named Executive Officers:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;">Joshua R. Disbrow</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 290.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">6/8/2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,227</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21,334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 563</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 901</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 375</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 125</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 16,163</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 25,861</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;">Mark K. Oki</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,917</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,667</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,917</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,667</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;">Greg Pyszczymuka</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,031</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;">10/1/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,335</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,336</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><i style="font-style:italic;">Chief Commercial Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 7,031</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,335</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,336</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> &#8212;</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Based on $1.60 per share which was the closing price of our common stock on NASDAQ on June 30, 2023, the last trading day of that fiscal year.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Joshua R. Disbrow&#160;Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 13, 2023, we entered into an amended and restated employment agreement with Mr. Disbrow. The agreement supersedes any prior employment agreements or amendments with the Company. The agreement was amended to: (i) provide for one-year employment terms with auto-renewal; (ii) modify the acceleration provision in connection with a change of control such that he would need to be terminated within 12 months following a change of control for &#8220;Cause&#8221; or resign for &#8220;Good Reason&#8221;; and (iii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his employment to willful malfeasance or willful misconduct; and (b) change material breach of the employment agreement to willful and deliberate breach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Mark K. Oki&#160;Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 13, 2023, we entered into an amended and restated employment agreement with Mr. Oki. The agreement supersedes any prior employment agreements with the Company. The agreement was amended to: (i) modify the equity acceleration provision to conform to Mr. Disbrow&#8217;s agreement relating to the equity awards referenced and acceleration language; and (ii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his other agreements with the Company to willful malfeasance or willful misconduct; (b) make conforming changes related to Mr. Oki&#8217;s unintended but material breach of the agreement instead of a material and repeated breach; and (c) change gross negligence in connection with his employment to willful malfeasance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Greg Pyszczymuka Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 21, 2023, we entered into an amended and restated employment agreement with Mr. Pyszczymuka. The agreement supersedes any prior employment agreements with the Company. The agreement was amended to: (i) modify the equity acceleration provision to conform to Mr. Disbrow&#8217;s agreement relating to the equity awards referenced and acceleration language; and (ii) provide associated changes to the &#8220;Cause&#8221; definition to (a) change material misconduct in connection with his other agreements with the Company, to willful malfeasance or willful misconduct; (b) make conforming changes related to Mr. Pyszczymuka&#8217;s unintended but material breach of the agreement, instead of a material and repeated breach; and (c) change gross negligence in connection with his employment to willful malfeasance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Payments Provided Upon Termination for Good Reason or Without Cause</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the employment agreements, in the event employment is terminated without Cause by us or the officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and, in the case of Mr. Disbrow, (i) a lump sum payment equal to two and one half (2.5) times his base salary in effect at the date of termination; (ii) continued participation in the health and welfare plans for up to two&#160;years; and (iii) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year. Messrs. Oki and Pyszczymuka shall receive, (i) a payment equal to his base salary in effect at the date of termination; (ii) immediate vesting of all stock-based awards; (iii) continued participation in the health and welfare plans for up to 12 months; and (iv) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Good Reason&#8221; means (i) there is a material reduction of the level compensation (excluding any bonuses) except where there is a general reduction applicable to the management team generally; (ii) there is a material reduction in overall responsibilities or authority, or scope of duties; or (iii) without the officer&#8217;s written consent, a material change in the principal geographic location at which the officer must perform his services (it being understood that the relocation of the officer to a facility or a location within forty (40) miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of the employment agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Cause&#8221; means (i) willful malfeasance or willful misconduct in connection with his employment; (ii) conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii) willful and deliberate violation of a Company policy, (iv) unintended but material breach of any written policy applicable to all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of Directors within thirty (30) business days after notice thereof; (v) the unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#8217;s relationship with the Company, or (vi) the willful and deliberate breach of the employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Payments Provided Upon a Change in Control</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event the officer&#8217;s employment is terminated within 12 months of a Change in Control of us, all stock options, restricted stock, and other stock-based grants granted or may be granted in the future by us to the officers will immediately vest and become exercisable. In addition, Mr. Disbrow shall be paid a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year. In addition, Mr. Oki shall receive (i) a payment equal to his base salary in effect at the date of the Change in Control; (ii) continued participation in the health and welfare plans for up to 12 months; and (iii) a pro-rata amount of the target bonus determined by the percentage of time he was employed during the fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;Change in Control&#8221; means: the occurrence of any of the following events:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale of all of the stock of the Company to an unrelated person, entity or group thereof acting in concert; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_69df689b_4fff_4cbd_adec_06e02fd93dea"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;12.</b><span style="font-size:10pt;">&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information with respect to the beneficial ownership of our common stock as of August&#160;31, 2023 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">each beneficial owner of more than 10% of our outstanding common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">each of our director and named executive officers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">all of our directors and executive officers as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC. These rules&#160;generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60&#160;days of August&#160;31, 2023. The&#160;percentage ownership information shown in the table is based upon 5,530,027 shares of common stock outstanding as of August&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In computing the number of shares of common stock beneficially owned by a person and the&#160;percentage ownership of that person, we deemed outstanding shares of common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60&#160;days of August&#160;31, 2023. We did not deem these shares outstanding, however, for the purpose of computing the&#160;percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the tables below are based on information known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the table </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">below, addresses of the director, executive officers and named beneficial owners are in care of Aytu BioPharma,&#160;Inc., 7900 East Union Avenue, Suite&#160;920, Denver, Colorado 80237.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beneficially&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Beneficially&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5% or more Beneficial Owners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:10pt;">Nantahala Capital Management, LLC </span>(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,086,812</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Carl C. Dockery(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,402</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">John A. Donofrio Jr.(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 962</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vivian H. Liu(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,825</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Named Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Joshua R. Disbrow(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 71,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Mark K. Oki (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,500</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Greg Pyszczymuka (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,143</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">All directors and executive officers as a group, including those named above (eight persons) (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 190,951</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.45</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Represents beneficial ownership of less than 1%.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">The number of shares is from a schedule 13D/A filed by Nantahala Capital Management with the SEC on June 16, 2023. Based on such filing, Nantahala Capital Management are deemed to have the voting and dispositive power with respect to 1,086,812 shares of common stock. Nantahala Capital have their principal business office at 130 Main St. 2</span><sup style="font-size:7.12pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup><span style="font-size:9.5pt;"> Floor, Nan Canaan, CT 06840.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(2)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">Consists of (i) 4,259 shares of common stock, (ii) 3,893 unvested restricted shares, and (iii) 200 shares of common stock issuable upon the exercise of vested options, (iv)&#160;50 shares of common stock held by Alpha Venture Capital Partners, L.P Mr.&#160;Dockery is the President of the general partner of Alpha Venture Capital Partners,&#160;L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners,&#160;L.P.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(3)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">Consists of (i) 762 unvested restricted shares, (ii) 200 shares of common stock issuable upon the exercised of vested options.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:9.5pt;white-space:pre-wrap;">(4)   Consists of 6,825 unvested restricted shares.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(5)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">Consists of (i) 55,428 shares of common stock, (ii) 16,163 unvested restricted shares, (iii) 375 shares of common stock issuable upon the exercise of vested options. Does not include 116 shares of common stock held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&#8217;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a 8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(6)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">Consists of (i) 6,583 shares of common stock, (ii) 2,917 shares of unvested restricted shares.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:9.5pt;white-space:pre-wrap;">(7)   Consists of (i) 20,267 shares of common stock, (ii) 1,876 shares of unvested restricted shares.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">(8)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9.5pt;">In addition to the above stated for directors and officers, includes (i) 63,941 shares of common stock, and (ii) 7,212 shares of unvested restricted shares.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_918dd826_61ff_4d49_8eaa_688d5fcfa79c"></a><a id="Item13CertainRelationshipsRelatedTransac"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;13.</b><span style="font-size:10pt;">&#160;&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We describe below all transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal&#160;years, to which we were a party or will be a party, in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed $120,000; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Jarrett T. Disbrow, the brother of Joshua R. Disbrow, our Chief Executive Officer, is employed by us as Chief Business Officer and President, Consumer Health. His total annual salary and other cash compensation was approximately $427,000, which consists of $365,000 base salary plus $62,000 cash bonus during the year ended June 30, 2023, and he receives benefits consistent with other employees serving in the same capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Review, Approval or Ratification of Transactions with Related Persons</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon its adoption in July 2016, pursuant to the Audit Committee Charter, the Audit Committee is responsible for reviewing and approving all related party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and other improprieties. Our policies and procedures for review and approval of transactions with related persons are in writing in our Code of Conduct and Ethics available on our website at http://www.aytubio.com under the &#8220;Investor Relations&#8212;Corporate Governance&#8221; tab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of the Audit Committee Charter, and due to the small size of our company, we did not have a formal written policy regarding the review of related party transactions, and relied on our Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviewed any such transaction in light of the particular affiliation and interest of any involved director, officer or other employee or stockholder and, if applicable, any such person&#8217;s affiliates or immediate family members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock is listed on the NASDAQ Capital Market. Therefore, we must comply with the exchange rules&#160;regarding director independence. Audit Committee members must satisfy the independence criteria set forth in Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered to be independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Four of our five directors are independent under the definition of NASDAQ. Josh Disbrow is not independent under either definition due to being an executive officer of our Company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_53bec7dc_3d6e_4978_aff1_c790839ec88a"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;14.&#160;&#160;</b><b style="font-size:9.5pt;font-weight:bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AuditorName" id="Narr_j9eCIITPCkmhazNWU4tJmg"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AuditorName" id="Narr_Ol-RsCTtQUWoKI81RCSOTg">Grant Thornton, LLP</ix:nonNumeric></ix:nonNumeric>, or Grant Thornton has served as our independent auditor since December 2022 and has been appointed by our Audit Committee to continue as our independent auditor for the fiscal&#160;year ending June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="dei:AuditorName" id="Narr_Jf9baTOy50-KKuiIau7myg"><ix:nonNumeric contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ" name="dei:AuditorName" id="Narr_cmByUOAwbEO32GOkU0Eg1w">Plante &amp; Moran, PLLC</ix:nonNumeric></ix:nonNumeric>, or Plante Moran has served as our independent auditor until December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents aggregate fees for professional services rendered by our principal independent registered public accounting firms, Grant Thornton for the fiscal year ended June 30, 2023, and Plante Moran for the year ended June 30, 2022, for the audit of our annual financial statements. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 940</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 547</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit related fees*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 940</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 579</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">*</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Audit-related fees for both fiscal years 2023 and 2022 were comprised of fees related to registration statements, including S-1, S-3 and S-8 filings, our registered offerings, and at-the-market (ATM) offerings. </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">In </span>addition to the amounts above, $0.1 million in professional services was rendered by Plante Moran as our principal independent auditor for the financial statements included in our Form 10&#8211;Q and 10-Q/A during the fiscal year ended June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Dismissal of Independent Registered Public Accountants.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">On December 12, 2022, the Audit Committee of the Board of Directors of Aytu BioPharma, Inc. (the &#8220;Company&#8221;) dismissed Plante &amp; Moran, PLLC (&#8220;Plante Moran&#8221;), as the Company&#8217;s independent registered public accounting firm.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">The reports of Plante Moran on the Company&#8217;s consolidated financial statements for the fiscal years ended June 30, 2022 and 2021 did not contain any adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except for Plante Moran&#8217;s report on the financial statements for the year ended June 30, 2022, which contained an explanatory paragraph expressing substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">During the fiscal years ended June 30, 2022 and 2021, and through the date of Plante Moran&#8217;s dismissal, there were (i) no &#8220;disagreements&#8221; (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Plante Moran on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of Plante Moran would have caused Plante Moran to make reference to the subject matter of the disagreement in connection with its reports on the Company&#8217;s consolidated financial statements for such years and (ii) no &#8220;reportable events&#8221; as that term is defined in Item 304(a)(1)(v) of Regulation S-K, except for the material weakness in the Company&#8217;s internal control over financial reporting previously reported in Part II, Item 9A &#8220;Controls and Procedures&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2021, as amended.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">The Company concluded that it had a material weakness in its internal control over financial reporting related to the analysis for the accounting for the impairment of long-lived assets, including goodwill and other intangible assets. The Company performs an assessment to determine if an impairment of long-lived assets has occurred annually or when circumstances indicate an impairment may have occurred. This assessment was prepared by internal staffing and reviewed by the Chief Financial Officer. At the June 30, 2021 fiscal year end, it was determined that the Company improperly aggregated certain assets when performing this assessment. This resulted in an incorrect conclusion that no impairment had occurred. This deficiency did not result in a revision of any of the Company&#8217;s previously issued financial statements. However, if not addressed, the deficiency could have resulted in a material misstatement in the future. In response, the Company incorporated utilization of third-party providers to review its assumptions and computations in the Company&#8217;s impairment analysis for completeness and accuracy. The Company believes that its controls are now designed properly and operating effectively.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">The material weakness was discussed with the Audit Committee. The Company has authorized Plante Moran to respond fully to inquiries of Grant Thornton LLP (&#8220;Grant Thornton&#8221;), the Company&#8217;s successor accountant as described below, concerning the material weaknesses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Engagement of New Independent Registered Public Accountants.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">On December 12, 2022, the Audit Committee appointed Grant Thornton LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ended June 30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:32.4pt;"></span><span style="font-size:9.5pt;">During the fiscal years ended June 30, 2021 and 2022 and the subsequent interim period through December 12, 2022, neither the Company nor anyone on its behalf has consulted with Grant Thornton with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Grant Thornton concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_262cd331_f345_43a3_8bfd_bbc10dda5358"></a><a id="PARTIV_131801"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandConsolidatedFinancialSt"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;15.</b><span style="font-size:10pt;">&#160;&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:34pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">(a)(1)</b></span><b style="font-size:9.5pt;font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following documents are filed as part of this Form&#160;10-K, as set forth on the Index to the Consolidated Financial Statements found on page&#160;F-1.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Reports of Independent Registered Public Accounting Firms</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of June 30, 2023 and 2022</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the years ended June 30, 2023 and 2022</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity for the years ended June 30, 2023 and 2022</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the years ended June 30, 2023 and 2022</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:34pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">(a)(2)</b></span><b style="font-size:9.5pt;font-weight:bold;">Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:34pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:bold;">(a)(3)</b></span><b style="font-size:9.5pt;font-weight:bold;">Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:44.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date Filed</b></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:middle;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419010889/aytu_ex21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of September 12, 2019, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">09/18/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419011717/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated October 10, 2019, by and between Aytu Bioscience, Inc. and Cerecor Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10/15/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2.3</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020042028/ea131376ex2-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of December 10, 2020, by and among Aytu BioScience, Inc., Neutron Acquisition Sub, Inc. and Neos Therapeutics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">12/10/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2.4</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249110.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated April 12, 2021, by and among Aytu BioPharma, Inc., Rumpus VEDS LLC, Rumpus Therapeutics LLC, Rumpus Vascular LLC, Christopher Brooke and Nathaniel Massari.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">05/17/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">2.4</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation effective, June 3, 2015.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/09/15</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation, effective June 1, 2016.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/02/16</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation, effective June 30, 2016.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">07/01/16</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation, effective August 25, 2017.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">08/29/17</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Restated of Certificate of Incorporation, effective August 10, 2018.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">08/10/18</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495420013283/aytu_ex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Restated Certificate of Incorporation, effective December 8, 2020.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">12/08/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390021016775/ea138107ex3-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation, effective March 22, 2021.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">03/22/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923001400/tm231530d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation, effective January 6, 2023.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/25/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022007674/aytu-20220504xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">05/09/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/ea119575ex4-2_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">03/13/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/ea119575ex4-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/13/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/ea119842ex4-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/20/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/ea119842ex4-2_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/20/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/ea123752aex4-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Wainwright Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">07/02/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022002837/aytu-20220302xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Prefunded Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/04/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022002837/aytu-20220302xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/04/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465922088699/tm2222304d3_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">08/10/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465922088699/tm2222304d3_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">08/10/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">06/05/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex4-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche A Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">06/05/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Tranche B Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">06/05/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022014652/aytu-20220630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">09/27/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">07/28/16</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420417038709/v471569_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2015 Stock Option and Incentive Plan, as amended on July 26, 2017.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">07/27/17</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">08/16/17</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-31_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License Agreement, dated June 11, 2018, between Aytu BioScience, Inc. and Magna Pharmaceuticals, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">09/06/18</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419001148/aytu_ex105.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Purchase Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">02/07/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419001148/aytu_ex102.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License, Development, Manufacturing and Supply Agreement, dated November 2, 2018.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">02/07/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419005839/aytu_ex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease Agreement, dated April 4, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/14/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419005839/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement with Joshua R. Disbrow, dated April 16, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/14/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419008769/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and restated License and Supply Agreement with Acerus Pharmaceuticals, dated July 29, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">08/02/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419010889/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Contingent Value Rights Agreement.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">09/18/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1467652/000110465919052850/a19-19348_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan and Security Agreement, by and between Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, and Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, and Encina Business Credit, LLC, dated October 2, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10/3/2019</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419011716/aytu_ex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated October 11, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10/15/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419012301/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Asset Purchase Agreement with Cerecor, Inc., dated November 1, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">11/04/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419012301/aytu_ex102.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement with Cerecor, Inc., dated November 1, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">11/04/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419012301/aytu_ex107.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Transition Services Agreement, dated November 1, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">11/04/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419012347/aytu_ex106.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent and Limited Waiver Agreement, dated November 1, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">11/04/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419012492/aytu_ex106.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent and Limited Waiver Agreement, dated November 1, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">11/07/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000165495419013481/aytu_ex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Waiver and Amendment to the July 29, 2019 Amended and Restated License and Supply Agreement, dated November 29, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">12/02/19</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/ea123752aex10-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Cancelation and Exchange Agreement.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">07/02/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390020042028/ea131376ex10-3_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commitment Letter, dated as of December 10, 2020, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc. and Encina Business Credit, LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">12/10/20</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390021016775/ea138107ex10-2_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent, Waiver and Amendment No. 1 to Loan and Security Agreement, by and among Aytu BioScience, Inc., Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, and Encina Business Credit, LLC, dated March 19, 2021.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">03/22/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249111.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Termination and Transition Agreement between Aytu BioPharma, Inc. and Acerus Pharmaceuticals Corporation, dated March 31, 2021.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/17/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249029.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Aytu BioPharma, Inc. and Christopher Brooke, dated April 12, 2021</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/17/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_249686.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Option Agreement between Rumpus VEDS, LLC and Denovo Biopharma LLC, dated December 21, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/17/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000143774921012543/ex_250530.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement between Rumpus VEDS, LLC and Johns Hopkins University, dated December 20, 2019.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">05/17/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000121390021031096/ea142150ex1-1_aytubio.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Controlled Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Sales Agreement, dated June 4, 2021, by and between the registrant and Cantor Fitzgerald &amp; Co.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">06/04/21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837021012825/aytu-20210630xex10d79.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated July 1, 2021 by and between Aytu BioPharma, Inc. and UAB &#8220;Caerus Biotechnologies.&#8221;</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">9/28/2021</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;">10.79</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.31</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837021012825/aytu-20210630xex10d80.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Termination Agreement, dated June 29, 2021 by and between Aytu BioPharma, Inc. and Avrio Genetics, LLC.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">9/28/2021</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.80</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.33&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement between Aytu BioPharma, Inc. and Mark Oki, effective January 17, 2022.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">02/14/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.34&amp;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Loan and Security Agreement dated January 26, 2022 between the registrant and the Avenue Capital Lenders and Avenue Capital Agent.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">02/14/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.35&amp;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent, Joinder and Second Amendment to Loan and Security Agreement dated January 26, 2022 between the registrant and Eclipse Business Capital LLC.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">02/14/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.36</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated January 26, 2022 between Aytu and each of the warrant holders.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">02/14/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.37&amp;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022001110/aytu-20211231xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">02/14/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38#&amp;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022008952/aytu-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Settlement and Termination of License Agreement between the Registrant and TRIS Pharma, Inc., dated May 12, 2022.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">05/16/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837022010509/aytu-20220629xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">07/01/22</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837023009367/aytu-20230331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 4 to Loan and Security Agreement by and among Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Neos Therapeutics Commercial, LLC, PharmaFab Texas, LLC, Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Delta Prime Savings Club, Inc. and Eclipse Business Capital LLC, dated March 24, 2023.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">05/11/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000155837023009367/aytu-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Loan Documents by and among Avenue Capital Management II L.P., certain lenders and Aytu BioPharma, Inc., dated March 24, 2023.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">05/11/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex10-42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agency Agreement</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/05/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.42</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.38&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="https://www.sec.gov/Archives/edgar/data/1385818/000110465923068133/tm2313999d4_ex10-43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/05/23</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">10.43</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.45&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement by and between the Company and Joshua R. Disbrow dated February 13, 2023</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.46&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d46.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement by and between the Company and Mark Oki dated February 13, 2023</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.47</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sublease Agreement by and between the Company and AMT Manufacturing Solutions, LLC dated April 27, 2023</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial Lease Agreement dated June 10, 1999, between Walstib, L.P. and Pharmafab, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.49</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d49.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease dated September 1, 2002, between Walstib, L.P. and PFAB, LP</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.50</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d50.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease dated September 4, 2003, between Teachers Insurance and Annuity Association of America and PFAB, LP</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.51</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d51.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease dated October 1, 2003, Between TIAA and PFAB, LP</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.52</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d52.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Lease dated May 1, 2009, between TIAA and Neos Therapeutics, LP (formerly PFAB, LP)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.53</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d53.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Lease dated April 5, 2010, between TIAA and Neos Therapeutics, LP</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.54</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d54.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to Lease dated August 14, 2013, between Riverside Business Green, LP and Neos Therapeutics, LP</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10.55&#8224;</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex10d55.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement by and between the Company and Greg Pyszczymuka dated March 21, 2023</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Plante &amp; Moran, PLLC, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Grant Thornton, LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#SIGNATURES_374122"><span style="font-style:normal;font-weight:normal;">Power of Attorney (contained on signature page hereto)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aytu-20230630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of the Chief Executive Officer of Aytu BioScience,&#160;Inc. pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aytu-20230630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of the Chief Financial Officer of Aytu BioScience,&#160;Inc. pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a>.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:8pt;" href="aytu-20230630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioScience,&#160;Inc. pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 INS</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 SCH</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inline XBRL Taxonomy Schema Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 CAL</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inline XBRL Taxonomy Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 DEF</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inline XBRL Taxonomy Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 LAB</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inline XBRL Taxonomy Labels Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">101 PRE</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Inline XBRL Taxonomy Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">Indicates is a management contract or compensatory plan or arrangement.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">#</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">The company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">&amp;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9.5pt;">Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (1) the omitted information is not material and (2) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.</span></p></td></tr></table><a id="_57cea837_dc21_45a9_8aef_c11723b30026"></a><a id="ITEM16_10K_SUMMARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">ITEM&#160;16.</b><span style="font-size:10pt;">&#160;&#160;&#160;&#160;</span><b style="font-size:9.5pt;font-weight:bold;">FORM 10-K SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_12910b56_24f4_4045_b95d_7fd5322f74db"></a><a id="SIGNATURES_374122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">AYTU BIOPHARMA,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:middle;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Date: October&#160;12, 2023</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">By:</span></p></td><td style="vertical-align:bottom;width:46.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">/s/ Joshua R. Disbrow</span></p></td></tr><tr><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Joshua R. Disbrow</span></p></td></tr><tr><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">Chairman and Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:47.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">(Principal Executive Officer)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We the undersigned directors and officers of Aytu BioPharma, Inc. (the &#8220;Company&#8221;), hereby severally constitute and appoint Joshua R. Disbrow and Mark Oki, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, to file any and all amendments to this Annual Report on Form 10&#8209;K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys&#8209;in&#8209;fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys&#8209;in&#8209;fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities indicated, on October 12, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Title</b></p></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ Joshua R. Disbrow</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Chairman and Chief Executive Officer</span></p></td></tr><tr style="height:7.9pt;"><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Joshua R. Disbrow</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ Mark K. Oki</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Chief Financial Officer</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Mark K. Oki</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-18pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-size:9.5pt;font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ John A. Donofrio, Jr.</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Lead Independent Director</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John A. Donofrio, Jr.</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ Carl C. Dockery</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Director</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Carl C. Dockery</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ Abhinav Jain</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Director</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abhinav Jain</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:9.5pt;">/s/ Vivian H. Liu</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Director</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vivian H. Liu</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1c9aae83_21ad_4e5f_9dc8_d9270139fcf7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Reports of Independent Registered Public Accounting Firms</span></a><span style="font-size:9.5pt;"> (PCAOB ID </span><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AuditorFirmId" id="Narr_G0eqJ4_NGEqyFDuV1uOfJw"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="dei:AuditorFirmId" id="Narr_iOTpeBBSqkmPiSf_3i7lrg"><span style="font-size:9.5pt;">248</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:9.5pt;"> &amp; </span><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" name="dei:AuditorFirmId" id="Narr_lXT4WL3BU0eJTUwTtUnEuw"><ix:nonNumeric contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ" name="dei:AuditorFirmId" id="Narr_mNQei-bDb0WN4OhJ5XW_XA"><span style="font-size:9.5pt;">166</span></ix:nonNumeric></ix:nonNumeric><span style="font-size:9.5pt;white-space:pre-wrap;">)  </span></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">1</span></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#ConsolidatedBalanceSheets_740306"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#ConsolidatedStatementsofOperations_25979"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#ConsolidatedStatementsofStockholdersEqui"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#ConsolidatedStatementsofCashFlows_690293"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">7</span></p></td></tr><tr><td style="vertical-align:top;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="font-size:9.5pt;" href="#NotestotheFinancialStatements_740843"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="font-size:9.5pt;">F-</span><span style="font-size:9.5pt;">9</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d26f8705_33f6_4de9_ac04_00b6e2efb073"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Board of Directors and Stockholders </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the financial statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">We have audited the accompanying consolidated balance sheet of Aytu BioPharma, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of June 30, 2023, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the year then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&#8217;s net loss was $17.1 million and cash used in operating activities was $5.1 million for the year ended June 30, 2023, and as of that date, the Company&#8217;s accumulated deficit was $304.1 million. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Basis for opinion </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><b style="font-weight:bold;">Critical audit matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The critical audit matter<span style="color:#0000ff;"> </span>communicated below is a<span style="color:#0000ff;"> </span>matter<span style="color:#0000ff;"> </span>arising from the current period audit of the financial statements that was<span style="color:#0000ff;"> </span>communicated or required to be communicated to the audit committee and that: (1) relates<span style="color:#0000ff;"> </span>to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the financial statements, taken as a whole, and we are not, by communicating the critical audit matter<span style="color:#0000ff;"> </span>below, providing an opinion<span style="color:#0000ff;"> </span>on the critical audit matter or on the accounts or disclosures to which it<span style="color:#0000ff;"> </span>relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Variable consideration in contracts with customers</i><i style="font-style:italic;"><br /></i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As described in Note 2 to the financial statements, the Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales. A key source of information used by management to develop the estimate for the ADHD portfolio savings offerings and commercial rebates (collectively the &#8220;GtN adjustments&#8221;) is inventory levels in the distribution channel as of the balance sheet date. We identified this key source of information as a critical audit matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The principal considerations for our determination that those inventory levels in the distribution channel as of the balance sheet date are a critical audit matter are (a) the inherent limitations over management&#8217;s visibility and insight into the underlying details of the source data, which requires management to depend and rely on external data from multiple sources and (b) the extent to which the external data is used by management to develop the estimate of GtN adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audit procedures related to this critical audit matter included the following, among others. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the relevance and reliability of the external data used by management to develop the estimate of inventory levels in the distribution channel as of the balance sheet date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 64.8pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:28.8pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We tested management&#8217;s process of reconciling the external data from multiple sources used to develop the estimate of inventory levels in the distribution channel as of the balance sheet date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 64.8pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">We evaluated the appropriateness and consistency in the application of the inventory levels in the distribution channel as of the balance sheet date as it relates to management&#8217;s methods and assumptions used in developing the estimate of GtN adjustments.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:18pt 0pt 18pt 0pt;">/s/ GRANT THORNTON LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:14.0pt;margin:0pt 0pt 14.19pt 0pt;">We have served as the Company&#8217;s auditor since 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denver, Colorado</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">October 12, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Board of Directors and Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheet of Aytu BioPharma, Inc. (the &#8220;Company&#8221;) as of June 30, 2022; the related consolidated statements of operations, stockholders&#39; equity, and cash flows for the year then ended; and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2022, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#39;s management is responsible for these financial statements. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.2pt 0pt 0pt 0pt;">/s/ Plante &amp; Moran, PLLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">Denver, Colorado</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">September 27, 2022, except for Note 2, as to which the date is October 12, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">We served as the Company&#8217;s auditor from 2015 to 2022.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e291c61f_6a96_4fb1_a8d3_2eb4bd3354a3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><a id="ConsolidatedBalanceSheets_740306"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except shares and per-share amounts)</b></p><a id="_5f4bc554_874b_4b1d_974c_d95bf6cd799c"></a><a id="Tc_4EnsU_WPl0SjaTmwnDbw5g_1_2"></a><a id="Tc_KF-Tg2AT50OyKl0KGrn8Ew_2_2"></a><a id="Tc_nBsGC-L2JEm40pmjDjzngQ_2_5"></a><a id="Tc_-arANZ7py02ea_nEHzQG6w_3_0"></a><a id="Tc_2PRxacSADkipUJgJYjRjRQ_4_0"></a><a id="Tc_BkGyk-0g_EmPULILP0vs6Q_5_0"></a><a id="Tc_jj5IC6DKYkCQTpyPTWzkEg_5_2"></a><a id="Tc_Znep8fsyvEuDymvIB1jfZA_5_5"></a><a id="Tc_b9NbhVV8LUu1gYDJnWsdOQ_6_0"></a><a id="Tc_t4DsS_In30-jFpxvQ_txTw_7_0"></a><a id="Tc_byI5di8R-UWhYPmLQYhaGw_8_0"></a><a id="Tc_Wy7CUHML90m8m_PUiDcF9w_9_0"></a><a id="Tc_AQ3PPc_tS0yNffZZgLaPlw_10_0"></a><a id="Tc_Wsw6Hnf-HUa11qvck-Z6xA_11_0"></a><a id="Tc_OndhdwRsxUm2n7icf-jBSw_12_0"></a><a id="Tc_Qj3tU1I6zEmIO8TIILKtaQ_13_0"></a><a id="Tc_f8fohDdN6U2f0ASTBgFJWg_14_0"></a><a id="Tc_mD73ulplPkSz3pE0LwS96w_15_0"></a><a id="Tc_IqEj57lJI0CwOkgz7kzFOQ_16_0"></a><a id="Tc_0xfRwNkeY06F7V2OfX58lw_16_2"></a><a id="Tc_YWzKQvraMEewFjyUjrh7qw_16_5"></a><a id="Tc_DB1Xnr5clkCS-EPQkm_APg_18_0"></a><a id="Tc_f3XphJDseUSmnpwfGLPrWA_19_0"></a><a id="Tc_52oa_NaNdEaXw8X008XcLg_20_0"></a><a id="Tc_KLI-LtB8_0GtumNeXV7udA_20_2"></a><a id="Tc_xRgMdXndq0GP2xANk2LhLw_20_5"></a><a id="Tc_KqToFrKG7keH1wiGo8X4eA_21_0"></a><a id="Tc_SV5_SDiWJ0iY58IGwVH5kA_22_0"></a><a id="Tc_GLwS1PywekennS8A5JeBDA_23_0"></a><a id="Tc_xkswgM48a0OiwaUeChDpEg_24_0"></a><a id="Tc_lQwZOLOQ4kGb6Oy4ouEZrw_25_0"></a><a id="Tc_a9F8d5AZuE6NjJawRhis0g_27_0"></a><a id="Tc_obz8ETxrLkOERYpkoN_wMQ_28_0"></a><a id="Tc_F0rDcSBcH0WR0t34AlCKxw_29_0"></a><a id="Tc_PXKH2Oy0jES-FYVpbWNVyA_30_0"></a><a id="Tc_cIPUPSiaSECJ3BSSyoToAg_32_0"></a><a id="Tc_vm1CJxN4oUe2y0Sgpz5YdA_34_0"></a><a id="Tc_-WL8GmZFxk-lAolfhJHYvg_35_0"></a><a id="Tc_oh4YT8NOx0-6hbi3fyeGVw_36_0"></a><a id="Tc_wnn8m20zAECXgaDJ8d5nGg_36_6"></a><a id="Tc_Re7IRuUNV0u3owLS8P63kA_37_0"></a><a id="Tc_RXVoJAzQfkK2EQ-rv2lbeg_38_0"></a><a id="Tc_d4inicxwwEyJAT-id-HzjQ_39_0"></a><a id="Tc_sbEaPxBx-kGw_7Uk4GHTsQ_41_0"></a><a id="Tc_fZkVez641UOiQew_euW5EQ_41_2"></a><a id="Tc_8MxDkvaGW0ix1rCgfjA5nA_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_jxaFgWU1mUy0lrTMqukEMA_5_3">22,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_5CeuEphqkk2kZSmKZjhX6A_5_6">19,360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_cGSHHvIuj0ecoTlf4TX9cQ_6_3">28,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_vOKt5b4LSkGt1-hDCoP7Tg_6_6">21,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Yhq3hP8gLUaPvGf-x18RaQ_7_3">11,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_TQJRHAs2CUi_gH3huFRktw_7_6">10,849</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_u8bOVLmXR0ekGc7WlMYG3g_8_3">8,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_qbibpmKNzkagLcT9eIcLIg_8_6">7,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_ymLFc-QeQk-iOvQo3n_m7Q_9_3">868</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_gAV2EDUIz0i4sPQ9cFa0UQ_9_6">633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_wUHKDf_-v0iTaUV2DqEdbg_10_3">72,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_k---mgN-VUGsdg_dBho2rw_10_6">59,929</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_4xUKXBUY3k62FW0S5haezw_11_3">1,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_oe2F7hiHWE23q_nO2Pxr9A_11_6">3,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_W7F2EPUp9Ue7Bgd3_1SBLA_12_3">2,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_3inkJHrtWEmsXlgZ-3rDQw_12_6">3,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Intangible assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_x3N2JMRFC0mHIQp6XDMo8w_13_3">58,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_HIl7f2s1dEWlmuDWF6x4SA_13_6">70,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_y9aoaBp3N0OcSyhCGeQ_XQ_14_3">792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_BEXN3kzaGk2cvMV6sNDtog_14_6">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_JfH7z2ilME6YtcfQy9RRRw_15_3">63,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_lMVBr_e0ukCcyPZzxtc9zQ_15_6">77,694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_lDFhVeezPUmlI5S67yXyCg_16_3">136,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_83cf_mo_5UK0wCNQ6WnDPw_16_6">137,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="Tc_eioZYdGLPUGLoXteGI1Aww_20_3">13,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="Tc_MYoS-XAqrUGmNx0HIsMcgA_20_6">10,987</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_CRk1-vJFWUeN_Db0pXY0mA_21_3">46,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_WVxbq3_03kaybeo4_hV2Dw_21_6">44,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Short-term line of credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Tc_lZwH1O52HkyDM4zYC11UPg_22_3">1,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="3" id="Tc_n7Gv8-VUEESAVp3OrkHO0g_22_6">3,813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="Tc_rJqcoGyg30We6IU3Ppgmmg_23_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="Tc_jNTikVHIlk2SUFyzdmyTXA_23_6">96</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_Rcf5b2uLc0eppA_xL7druQ_24_3">7,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_x5s5SCdBJ0yaTmAqxW3lhA_24_6">5,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Y_IppyT3VkKgvRZNsXDXQQ_25_3">69,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_MeMPjRctA02ES2pQU5fLOQ_25_6">64,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Debt, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="Tc_3II5-YNWFE2bZBPOa6jxhg_27_3">14,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="Tc_Ho44jxVPd0OeOWMTg3-g9Q_27_6">14,279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_HHTboVsxGUKTpNPEtp-xZQ_28_3">6,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_aZKNVAp5A06bPyD63Lm--w_28_6">1,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_a7aivwG-vEuJFK0YebXkRg_29_3">6,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_gXWovIB7kUmt-ghiwU-BZg_29_6">12,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_DkGHxNAV_UqN9xwQzTn_0A_30_3">97,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_bLU78J1xGUGh5n83ZJHF6g_30_6">93,315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Commitments and contingencies (Note 18)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Preferred Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_H3h-6bkjxU2j9W81_n1jcA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_mlpIGW7O6Uyj5TWoWwqzYQ">.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_V6oRMiNRS0qBm8Y1r_khjw"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_L70UI7W9gEuRky3i3TXsvw">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_g78d1nWdukKRf3JMLtPuDw"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_pe3kGEwXjkmOJHI75BRUkQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Liq8un8UJke8D3CqwZWNNQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_bkjwuZzFuk-Mk2X7aICZuw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June&#160;30,&#160;2023 and June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_LYG5MF9ZSUmaFm4UmaMR2g;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_GVVL6pelS0SESYOcJDmIMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Common Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_uyds8Cb8L0yLZxSNlY8pqA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_RhqjUV4eRUWg-QNhrqvaow">.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_iPYn2euFQESGKFW5m3ZQMw"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_FH30OJCZtECSwC-7_bFDqQ">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; shares issued and outstanding <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_tENZx5gqHkKoRosVhccIWQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_kp33oo2NJ0ST4FhgtHh9rA">5,517,174</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_yoDeoU95U0-FNYlw-y4s5w"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_cIpesK9j1kGMUQrw1SuHEw">1,928,941</ix:nonFraction></ix:nonFraction>, respectively, as of June&#160;30,&#160;2023 and June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_vCRW8PUzrUGp-ZHx2ejtww_36_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_dGMINa_-gU2u5AeRdiDhzg_37_3">343,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_Q6d3IXjNzEazeQaT9zci-A_37_6">331,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_HFtuDWE7Wk6XbqBxfKw7cg_38_3">304,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_NP8YNKEeTkSj1UTP7tW2kQ_38_6">287,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VsV60TDfF02AY5_w0dyuTg_39_3">39,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r9zcFYMbEU2m34VWo9GWxQ_39_6">44,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_C1kzlMb6g0ib7-LnJ1GXNw_41_3">136,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_m84IY9evtEaUhIcxEvQskw_41_6">137,623</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9.5pt;">See the accompanying Notes&#160;to the Consolidated Financial Statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b1dc079a_907c_4805_89cd_8f46afae4869"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><a id="ConsolidatedStatementsofOperations_25979"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per-share amounts)</b></p><a id="_ba0da4b6_2032_4189_b4c2_d1273961e711"></a><a id="_741b343a_ee67_4d8a_91a5_78bfcdd726ab"></a><a id="Tc_TI-ZeLtxrUactqY1BVtO9Q_1_2"></a><a id="Tc_XrTXWz6jLkyMCq47jdGZMw_2_2"></a><a id="Tc_-Do7C-QcvU2GBk7zRj4EZw_3_2"></a><a id="Tc_FahyuuqHlUaD_Bvuo6YRvQ_3_5"></a><a id="Tc_HMhP3FbkkE28Vyg5nmKVeg_4_2"></a><a id="Tc_y-1waZkntUyfRduwuzh6ZA_4_5"></a><a id="Tc_XRCZtUaXsUKABpuzwoi2ng_6_0"></a><a id="Tc_zFjnuBA4C0Oo4Q8Mynl_8g_8_0"></a><a id="Tc_1doba6uQ0Ey2iXVQymSwiA_9_0"></a><a id="Tc_mCjmiQtVD0eiEf7b9S5eTg_10_0"></a><a id="Tc_TxIoU5cJpEGJ4F-vghgc5g_11_0"></a><a id="Tc_IMSW13PYA0eDacMtabZ9Vw_12_0"></a><a id="Tc_phEIIDUvLEejneVzqRWJpw_12_3"></a><a id="Tc_CqZJUfrigkSGO6omCNS8mg_13_0"></a><a id="Tc_ovsPmTAp40iX4sz8VYOMQw_14_0"></a><a id="Tc_snjyOx5y6kyB5mnPBv9ztw_15_0"></a><a id="Tc_1E8BoePGT028C52wHBiutA_16_0"></a><a id="Tc_O13h8yf89kqowZs4M7DfVQ_18_0"></a><a id="Tc_1aEm170X-kKI5BvP2WbZhg_20_0"></a><a id="Tc_xoHwL52keUiF4hs4Z9L32A_21_0"></a><a id="Tc_rHG896uFY0eZPDlHRenpdw_22_0"></a><a id="Tc_MsDWs4dzP0Od7Hin7uyJMQ_22_3"></a><a id="Tc_gN0HxgpKzU6fKSbGyoEN4w_23_0"></a><a id="Tc_XDFtRa21TEqB__85qasEMg_24_0"></a><a id="Tc_p-zGeWcpHE-Q9SZpChMunw_25_0"></a><a id="Tc_OXOmqXMl3EyMrgfu0Mnw_Q_26_0"></a><a id="Tc_Zb-98sWff0KhesU9otjs2g_26_3"></a><a id="Tc_WfvnY6p-EU-Xk_9g5MdMBA_27_0"></a><a id="Tc_HYWb3u6adk-QBlfdiAlG0w_27_2"></a><a id="Tc_Hz7J0eV5gUK8gX6Eypsfyw_27_5"></a><a id="Tc_Uy4PVogB40uflfbo-wIY5A_29_0"></a><a id="Tc_G-Jw7H1qGEqo5Ljib9BW6w_31_0"></a><a id="Tc_tMdnCulwA0OLkJzuMnRFXw_31_2"></a><a id="Tc_gg0MW9yy2kmHJhlQuZc7LA_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_hVXynGx4zUyImHk6UmwuZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product revenue, net</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_eCLDru7pjkeAnwWOfEbXXw_4_3">107,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_oitzDVCdLUqttoUrhWxmyw_4_6">96,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_BSDhkQqovkW5-zz8We4mCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cost of sales</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_LB7QZFr-ZkSx1pT0foJvSg_5_3">40,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_uavk07mi0EePiLREN2s2WQ_5_6">44,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_NCDQ4DnpJU-mUG5CQddZ4A_6_3">66,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_ewmwibn-rkypmGfadbSMHg_6_6">52,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_YSpuCr0DmkazqSzksjpnIQ_9_3">41,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="3" id="Tc_Cg1MQedr9EGoKQoKoctAsQ_9_6">38,713</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_eoz5H9-GUk2zBgg8CnBhZg_10_3">28,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_FjMGB_8C7kuFtXM8Pj9uMQ_10_6">31,167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_3xgM9FfhhUGytwT0eyJXgA_11_3">4,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_QWAbJyxYzEi68D2kUUcwVA_11_6">12,662</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Tc_b0nmCqn7ek-mP6J2y4R1Xg_12_6">65,802</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="Tc_OT28EWnZi0iOcrUhPBrXkg_13_3">5,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetImpairmentCharges" scale="3" id="Tc_DMVxlPYw3k2eOoR8_67f9A_13_6">9,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_fu8WIDXQzk2ygEQJpKT_fQ_14_3">4,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_zBNubYvT00qEZQ1ZK9I2iA_14_6">5,844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain from contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="3" id="Tc_imZc2JLo40OZDlNM3tixFg_15_3">969</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="3" id="Tc_W19JwYyo3kOsdzjn_1DIfA_15_6">1,655</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_a7SG-mRv-UaQwHfIG2syUA_16_3">83,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_xxmpz0z_REiSxvZn4i7jFg_16_6">162,189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_8RJ9lFhPb0qxpp2F5lmfnQ_18_3">17,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SB8E720G4UO0YU9jXC5TTg_18_6">109,906</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_COgPa6FPk0SQWDo3SGF2Vw_21_3">4,779</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_esw74XjBkEKYqn9eRQ5-zg_21_6">757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_ZoZujx6F4Uab7VoVEd8EFA_22_6">169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_mUwIMFqqq0mQJLg1J_fgOg_23_3">4,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_IdRyJOHY-EC1wPKuHbfPdw_23_6">1,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_AEGfvDDwqU-USrdkJHCcoQ_24_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_a3v6tt3MkUCXJlNOtd-ifA_24_6">1,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_OFAQ3-tTREC-1IgActXM8A_25_3">17,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_s6E5ZP-ixkKBctaTi5Wh4Q_25_6">108,889</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_UzHGzmO6-kiNGk7m9yU5Eg_26_6">110</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jmqVALIWQEGUVVG4pt1VwA_27_3">17,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tHzi2yFfF0ezGiAk2fSRKg_27_6">108,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_7ar8-RFP_kKgqtHw9Q9T4A_29_3"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7ar8-RFP_kKgqtHw9Q9T4A_29_3_2">3,339,906</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_rjo6NH4I2kiwh6TbnG30xg_29_6"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_rjo6NH4I2kiwh6TbnG30xg_29_6_2">1,469,875</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_yzHKA9Cnz0qeyh3x52hrDg_31_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_yzHKA9Cnz0qeyh3x52hrDg_31_3_2">5.11</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_59LZ7I_jD0KdR22F3DKdtg_31_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_59LZ7I_jD0KdR22F3DKdtg_31_6_2">74.01</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See the accompanying Notes&#160;to the Consolidated Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_23758a7a_360c_463e_94bb_fe0e54a5ccbe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><a id="ConsolidatedStatementsofStockholdersEqui"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equit</b><b style="font-weight:bold;">y</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except shares)</b></p><a id="_fa9df51a_9e0e_4bc0_aa4b_902a207d33ca"></a><a id="Tc_S1tTe5EhL0-V20ugw3Eu9w_2_12"></a><a id="Tc_mMixlIQ7iEGcj3jQWottQQ_2_18"></a><a id="Tc_FTZoP5xQwkCNLs8o5aOhQA_3_2"></a><a id="Tc_lETLl-6jc0mhKSgzfJhkfQ_3_7"></a><a id="Tc_GXAJfp6mU0a03cX4V7YcOQ_3_12"></a><a id="Tc_B0NRMH8MW0Gq1K-7nsrzjQ_3_15"></a><a id="Tc_RatuqdUn6kOh5v4gUGwUug_3_18"></a><a id="Tc_8nPUO9EMHkaPY9zzuvTZlg_4_2"></a><a id="Tc_WXEU_v6f_E29fuA6Qsoufg_4_4"></a><a id="Tc_Ga_DXhNdXUO7EYOPrc9OWA_4_7"></a><a id="Tc_JWAJiv7FZ0SnhtPQtWNaCQ_4_9"></a><a id="Tc_ZynD-BiDZUiz2NNUMna6Qw_4_12"></a><a id="Tc_c9ZG6vtVzkSQBQ00wrQsow_4_15"></a><a id="Tc_xO6KfPNMBEyjPJ5Og6bepA_4_18"></a><a id="Tc_ieQwXNTsW0iZKDsk0Hz0DA_5_0"></a><a id="Tc_ZlqsnOIwYkSLJ3EYvm_LUA_5_2"></a><a id="Tc_HNkCAoHGHUaw0mfy58SkbA_5_4"></a><a id="Tc_oLFta3K4Tk2_scM-8n3mJA_5_5"></a><a id="Tc_sFAZ4yZ71EOnA52L4hP8vA_5_9"></a><a id="Tc_KJQx1QCllkmmVI62xkuYYg_5_10"></a><a id="Tc_rIjP6-cSyEKfXHacNXL9AQ_5_12"></a><a id="Tc_8RHWIrohs0OFq86W3Don9A_5_15"></a><a id="Tc_LIHBRPPBn0CMvUqsUHNEZg_5_18"></a><a id="Tc_tcvldYYoC0qKASRprP6xJQ_7_0"></a><a id="Tc_ZQVhwOOegE-z_rCqWCmPnA_7_2"></a><a id="Tc_d2CVnJ0Uf06qBud5Ek4APw_7_5"></a><a id="Tc_FKP3sSZbF0ekChnyf5ibHg_7_10"></a><a id="Tc_6Pk28N3bKESFZedbeUlO0Q_7_16"></a><a id="Tc_L60qFK5yOEiLMw0xQJwrMQ_8_0"></a><a id="Tc_5C9MFUMMJU2fpM2DWkHXaw_8_2"></a><a id="Tc_kPV00gScVEKlNr4H4b4jDQ_8_5"></a><a id="Tc_A5zTR7aDFkuYRQk8nA7LLQ_8_16"></a><a id="Tc_I46i6a4ZN0-GzTCprpLXSw_9_0"></a><a id="Tc_s0BDqq8hWEiip_0NnxE7ow_9_2"></a><a id="Tc_ZXl138w7pk-DKuZ3yfvBMQ_9_5"></a><a id="Tc_eq3YdcJpBkyjYwnA-PmePA_9_7"></a><a id="Tc_plq2h5OMskajWUeZxtieiQ_9_10"></a><a id="Tc_1GFBh00BvE2KtJxLiPHaCg_9_13"></a><a id="Tc_pOiCD7m_P0qIDmaRz7jByw_10_0"></a><a id="Tc_56sA-GP4NUqsEmxisDCvNw_10_2"></a><a id="Tc_LIdJWc3uaUav0AsNXsESdQ_10_4"></a><a id="Tc_g_t4sIjXjEGSlxdOZwwWFg_10_5"></a><a id="Tc_KKowceMsrkScT_MrYRcFtA_10_9"></a><a id="Tc_itI0tz-XjUOTR6GYiNtmrw_10_12"></a><a id="Tc_1m63s3c9qUC2Mf3kCfaerQ_10_15"></a><a id="Tc_gh451l9b0kqrk9gYYwApxw_10_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td colspan="19" style="vertical-align:bottom;white-space:nowrap;width:67.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_gQaAZGIiikeN4nI6dQI1GA_5_7">1,928,941</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_e-Lh3LYkpUSqJ1LTvbvSzw_5_13">331,386</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_tQKGj6lqK0Ov1T0bkOzd6Q_5_16">287,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_1xNXJy9wn0uiQqJ1Bgff_A_5_19">44,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" sign="-" scale="0" id="Tc_JnSs312g8k6PPQYqroYKaw_7_7">18,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_ytirZT7kq02ODb1OHHJqjg_7_13">6,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_notlcwGH-UibiRfTI5tA5g_7_19">6,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" scale="3" id="Narr_09TTy0nAY0axDo-Q4AoHDw">1,004</ix:nonFraction> issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_51JL-qaQcE2L8nF4B2A8yQ_8_7">3,606,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_-VxUjEnIYE-6YGtIquq2_A_8_10">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ni3tm6Hw402p_fh2kgHb-w_8_13">6,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_8riVQxjfJEmrS8M4k4e1Fg_8_19">6,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q2AFXDkUOEyEfmyAK7PljQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Az2JTgMOK0que8JNxT6l4g_9_16">17,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_etmgmNBh80OTokOXbf3lSw_9_19">17,051</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_Er9CQTIVM0-Ncb1R3iewnw_10_7">5,517,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_o9jyiV513UG3LoqQOPsjMg_10_10">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yekhljvbxU-rrnE2lH9ydw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_qACDcG4sjUSo8TUSAT-2aQ_10_13">343,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0Kak6DTDzkyr-6pUSkAZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_j4QYZ_Uy7EOcvXnDa0rSFA_10_16">304,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_PELp_kvh2UCfg7-j6pHiQQ_10_19">39,357</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bd6396c3_3f87_4751_b4b6_4ff1bbc21686"></a><a id="Tc_EbE-Txg4sUunZQpmPcdevw_2_12"></a><a id="Tc_MqPj94uL00m9tc3KvLKJVA_2_18"></a><a id="Tc_3umsuI4MS0GcU6Fualu5YQ_3_2"></a><a id="Tc_kH-3wUd5C0-CveFwvREvog_3_7"></a><a id="Tc_LWMB4A6jsE6sSJYZ7ajVjg_3_12"></a><a id="Tc_wdAYWcnxsEWL39QPMgJSnA_3_15"></a><a id="Tc_QVaxsdmZQ0aDPWtUBnqVPA_3_18"></a><a id="Tc_RCyp37nKGEuSULMroSYvhA_4_2"></a><a id="Tc_THCoggY1H06pNwAJkB0e3A_4_4"></a><a id="Tc_s7T35WjFa0WVo-SPqrnPGQ_4_7"></a><a id="Tc_Rzz5hvzs4U23JqtQXRVkXQ_4_9"></a><a id="Tc_4rdLufkTlUCscnKY4vaqnw_4_12"></a><a id="Tc_jRBcEDv68ke3jE0kyHB8SQ_4_15"></a><a id="Tc_sGEPTedRZ0qLpkxgphcZdw_4_18"></a><a id="Tc_UmeIfqgLzkWtTHj9RoOx0A_5_0"></a><a id="Tc_jsS7J70nSESupMIV84T1rQ_5_2"></a><a id="Tc_rUZw6Tec2UuSbhI1cn4XIQ_5_4"></a><a id="Tc_0pGSJ445fkOGolhdBLN30A_5_5"></a><a id="Tc_bVZYKMb00kO24dWfstwqHg_5_9"></a><a id="Tc_uIAhlUx8NUeqfWyVKwuaJg_5_10"></a><a id="Tc_jvK6BytdTU-16MCtuxYvxQ_5_12"></a><a id="Tc_yMOMl0R2qk6SMLfK0770NA_5_15"></a><a id="Tc_AJovmxv96E6prKDQgSAj7A_5_18"></a><a id="Tc_29t0cjsswEeV5UndcfWIOw_7_0"></a><a id="Tc_ijip2_yNSUOKM6EPWp-eCQ_7_2"></a><a id="Tc_vDXm4hgAF0qQSxY9NhGUeQ_7_5"></a><a id="Tc_sCvpPi2HfE26B2FZR36F8g_7_10"></a><a id="Tc_hhiXWPgW6EihnA2HspCudA_7_16"></a><a id="Tc_Oy6Q3-xM_UyW7n-Q_f9TDA_8_0"></a><a id="Tc_rM2LVZNv10OJqVR2niJPYA_8_2"></a><a id="Tc_LfwGXKLpuEmfDeTHmSJoQw_8_5"></a><a id="Tc_5xZjqdeOxkGE2lsGeuk84Q_8_10"></a><a id="Tc_SIZ-vIk_aUyqiU3-2VOHqw_8_16"></a><a id="Tc_A2Vs409fukmhfw44yUThtw_9_0"></a><a id="Tc_--XeWZQRjU2rAEeCz6Qxfg_9_2"></a><a id="Tc_1MTPy_uw7kWuy-bbT-TuFg_9_5"></a><a id="Tc_qoWMnBFw8E2kt2cH2Q9RjA_9_10"></a><a id="Tc_Qo4aVp-5TEigGJnrviNgIg_9_16"></a><a id="Tc_NlekrMBP9k-lXuGaHLnB3Q_10_0"></a><a id="Tc_-r5LEreyQ0O3dMleQhxrjw_10_2"></a><a id="Tc_O7QIsc2IWkGrXoEdcX52mg_10_5"></a><a id="Tc_SNSd3Wpjfkq7G0rXomnsdA_10_7"></a><a id="Tc_ctqddokL1E-SQmBHOZQYxw_10_10"></a><a id="Tc_pIgSFaXKu0mvR2wi9g5uVg_10_16"></a><a id="Tc_VivnrNlb2Eigy8TrARzTWQ_11_0"></a><a id="Tc_ulYQLbFxx0SprIMNXFLbMg_11_2"></a><a id="Tc_ahjolyJXkE-I5GteK1apaw_11_5"></a><a id="Tc_Z10Pj0UkD0mAVHtu1pZl0w_11_7"></a><a id="Tc_gcy2ZimlXkKE-TgfUV0Vyw_11_10"></a><a id="Tc_UDX-ZBeWbES7aULMmb3dSw_11_13"></a><a id="Tc_guAChy-TwUWdz-91iMJycg_12_0"></a><a id="Tc_h1TBQT4AkEGoltAa9-TC0Q_12_2"></a><a id="Tc_rIFHllJnTkepr5TkmPyUvg_12_4"></a><a id="Tc_BNueSdtvPkO3rnvdtG35fQ_12_5"></a><a id="Tc_CHkNSJH_2keDUfN7O2uo0Q_12_9"></a><a id="Tc_EO_HH0wNMkW8hqNwfGjDtQ_12_10"></a><a id="Tc_1RqXhMbAYkOMakLmGsZRuw_12_12"></a><a id="Tc_R90vjbXokUyf3e935jlYyg_12_15"></a><a id="Tc_7oZg8BFyBkm6hoDEfAAxHA_12_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="19" style="vertical-align:bottom;white-space:nowrap;width:67.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U52ccDTbd0SLphyOs_tA1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_PsFqxn3odEiAJmxyycsVMQ_5_7">1,374,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_eQLHIlKyh0OOu8wiDD7RXQ_5_13">315,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O4CwaXSKW0-EnAiW9BgQ0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_jAz-jja0A0egsJ0uBZVtCA_5_16">178,299</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_onXUGjUMNkifW4Dr0lDv_Q_5_19">137,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_QXCngTdc1U2TKhtpgyNOzg_7_7">20,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_fgvp5gHK1k635YCX7GIlMQ_7_13">5,248</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_BYkkI89bW0iXSukrMu-gqg_7_19">5,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" scale="3" id="Narr_Up9c7MfqXECoEVPtx_P9rg">1,048</ix:nonFraction> issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_5XN20idhr0aWijzbk74gXw_8_7">424,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_gReb4xSNN0i58Ukrd92YEQ_8_13">8,854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_qGDCoEli8ka0fGne-eyOuw_8_19">8,854</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock related to milestone payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ" decimals="INF" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodSharesMilestonePayments" scale="0" id="Tc_LqMGV3RGHkaIWUexYigEOg_9_7">109,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow" decimals="-3" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodValueMilestonePayments" scale="3" id="Tc_54hu1ENw-EuyO3SvCiSCdg_9_13">1,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodValueMilestonePayments" scale="3" id="Tc_Y8BIrMdyB0u52lCTNkw4fg_9_19">1,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax withholding for stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_xijFjmXeckmwZPuYvgLimg_10_13">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_mljM8fHAkEe0cKtajM8h_w_10_19">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Svctda3Et0O2kTjOc-zi0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_stlmFUUk40u9Rj3z-Z2tdw_11_16">108,779</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XR1FAWbgQUm1HyU7kIiGLQ_11_19">108,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_Ln9mCn6WJUC3R5ZSsir0pw_12_7">1,928,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_w7-pErbdVkCA255sCjreDw_12_13">331,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_z03D_WPPzkyuysESyQcPCQ_12_16">287,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_5B2X8XBkak66zg3W-XmENg_12_19">44,308</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See the accompanying Notes&#160;to the Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_03184c1b_c4e1_4609_a67c_af6007cfd42f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><a id="ConsolidatedStatementsofCashFlows_690293"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_1b9212dc_7297_434e_8e67_9adf2e7f899c"></a><a id="Tc_tDDCLJJlwUmmd0Ne8827-g_1_2"></a><a id="Tc_2tJYJbeK10WdGaIa1I61dQ_2_2"></a><a id="Tc_wR0HPFOcV06XIr08eK7Meg_3_2"></a><a id="Tc_p9QctcdsuESjCnOz_TQ35A_3_5"></a><a id="Tc_gNFMlXQttkqY_tgNwdNu2g_4_0"></a><a id="Tc_LmiOu_MuvUGdMydKbNKemg_5_0"></a><a id="Tc_90GKI30YqkWdcsJUi9sdCg_5_2"></a><a id="Tc_8LW5HwsJP0Wi3nWos_bpUg_5_5"></a><a id="Tc_1xQ_yk-zn0-LPGRiDXN-Bw_6_0"></a><a id="Tc_c7_4OkFqcUWJW2N6Lz0TpQ_7_0"></a><a id="Tc_4O7rl-2aVkOeKTJWs8oiYg_8_0"></a><a id="Tc_7e8quXkxbUaKfqsR973ytw_9_0"></a><a id="Tc_o4Axe-LyfEiJwV7hsHYRXw_10_0"></a><a id="Tc_AWS8kwA8q0uWZAN7E4pCtg_11_0"></a><a id="Tc_FxeqPuQjUk6vv-vWEw7rKw_12_0"></a><a id="Tc_6GzU7KOdbEGGeDWc7WfygA_13_0"></a><a id="Tc_Nx9kzhPjREywZe15euAY1g_14_0"></a><a id="Tc_WLeoCflrMk-adCzNA_DM5Q_14_3"></a><a id="Tc_xCmlAHx7N0OR5z6ThamSCg_15_0"></a><a id="Tc_h5Tf1I0nP0q0eu_G35xSTw_15_3"></a><a id="Tc_WoE7CQFH_UuNxO8feoW64A_16_0"></a><a id="Tc_dZrPHQx6W0e1aZweJsEMGQ_17_0"></a><a id="Tc_yy8B7Lou6Uir_f8mwGCFfQ_18_0"></a><a id="Tc_eg4W1ZV_U0KaR2BFVtYbgQ_19_0"></a><a id="Tc_fkGbxdaM7UOidFbPH2CnEw_20_0"></a><a id="Tc_ghHmicdSNkaPKqKy7FwdzQ_21_0"></a><a id="Tc_vwuFc7IY4kehd68J5XjFhg_22_0"></a><a id="Tc_mkXqyORnlk-d4RF65d5xZw_23_0"></a><a id="Tc_hFNHAl5rHUCDHgZs0j5TqQ_24_0"></a><a id="Tc_O-lp4HnS6EitmrBK_QSJJg_25_0"></a><a id="Tc_yShlE_tn_0yq-VJGOMxe_g_26_0"></a><a id="Tc_iKypBnBke0uluLB2psdJxQ_27_0"></a><a id="Tc_BIrGVQYuTUuh-QEUaJK4UQ_28_0"></a><a id="Tc_Jansn1JRK0qYW6c8ufuyfA_29_0"></a><a id="Tc_B8LCaIv53kGF15obbVzPJw_30_0"></a><a id="Tc_iqAjyUbbzEe5qOfAz1jLwg_31_0"></a><a id="Tc_pOIyopVoFEuf33m3WC-Lvw_32_0"></a><a id="Tc_3OLga9rMGEeNRj8sjH_C7g_33_0"></a><a id="Tc_VcDfkuxPxUuVEnBdA6em-w_34_0"></a><a id="Tc_79kPR9J0ykOByy4y4jrQMw_34_3"></a><a id="Tc_WhFbvJeF0k6uPNH9EhR4nQ_35_0"></a><a id="Tc_yT5j8bE2I0qsihQ_lZQAwg_36_0"></a><a id="Tc_xuxdlc3ttU-7MUC-cmOJ9A_36_3"></a><a id="Tc_0XE6JKVbOkKy0jDeEPT1Mw_37_0"></a><a id="Tc_6VZ3dWlsHkyEN6b3LSmO2w_38_0"></a><a id="Tc_bMiqGI7HFUuDNSqYfMxd7w_39_0"></a><a id="Tc_80RhO_OpUESBAfhiWiRQKA_40_0"></a><a id="Tc_Kv32DsnCikSSQoGKMIJLSA_40_2"></a><a id="Tc_Mj0e_uABTEm3VDxAfz3Y9g_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Operating Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_-WimGYmArUGz_fyVwH-UcQ_5_3">17,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_D2q3pVyvAECU2EYgzILghA_5_6">108,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Depreciation, amortization and accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_K5kVlVD5J0WVkJ_k50vRbA_7_3">8,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_jJUleTGrZ0CSqDpvwPQCkg_7_6">10,146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="Tc_yGqfSX8AYUCzYse6gy9s_A_8_3">5,705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="Tc_nGusxjVteUO2hBiwEuTVUw_8_6">75,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Inventory write-down</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_92IsAzRr8kqehayaLlaQUw_9_3">2,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="3" id="Tc_P2uLWq2MNEGcpz_e-m913Q_9_6">2,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4SoO1cWpT0a2V6K_Do9tNA_10_3">6,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gsmtU7xQCEy08Ot8hWO_4g_10_6">5,248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_UwQ3H9XLC0q-N7KD30otwQ_11_3">4,793</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_-3go8rfxo0yKVblHB7qupA_11_6">1,605</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Gain from contingent considerations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="3" id="Tc_WHsp9F9wnEqWCrTd4HJrPg_12_3">969</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="3" id="Tc_4uln7FHU10WA-bK0D_5EVA_12_6">1,655</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Amortization of senior debt (premium) discount </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_uVrGKol3SEqHpiWUVpE0sw_13_3">559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" sign="-" scale="3" id="Tc_mHBJjmyGX0uQoSWiIITzFg_13_6">126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Shares issuance related to milestone payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:IssuanceOfStockForMilestonePayments" scale="3" id="Tc_X2kzGBUnfEGWsS9B4RniNg_14_6">1,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Gain on debt extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:WriteOffOfDeferredDebtIssuanceCostNet" sign="-" scale="3" id="Tc_fXnD9XBkQ0WTcMCMQzp35w_15_6">193</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other noncash adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="Tc_GZ3iRXJHH0KpdSmKfJW0_A_16_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" sign="-" scale="3" id="Tc_QeBqPq7KlUy0j_c_lpSJsQ_16_6">65</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_Kcj5zcSR9UKvrz4kETEN1g_18_3">7,153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_IboMADXq8kqt5WSIg9yrbQ_18_6">6,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_HjUYiqpq70617Wgj266Ncw_19_3">3,609</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_joLz-Gmwj0ukTJRSdyGRkA_19_6">1,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_S34nscFr_US3esQqEkDUww_20_3">914</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_ZS5KK8JW_UKG60X_KiiLIw_20_6">2,228</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accounts payable and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_-Ej2-_xBT06IELL0K2GT4w_21_3">2,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_8iWl1OJFvU2cFtC6mb2prw_21_6">7,681</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_LDw-15gqc0O2URwiYnwkZg_22_3">3,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_gKFU6VeGVUqlkz2hHpvIBg_22_6">13,292</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other operating assets and liabilities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="3" id="Tc_BdEPYkZByky0dphTIa7_zQ_23_3">111</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" sign="-" scale="3" id="Tc_0OBeAliXDUCcJOB_I1UybQ_23_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_DdV3GoQ5_USI0XTP27O4Zw_24_3">5,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_54OKLD2nUk2UsFlB--0Qsg_24_6">28,823</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Contingent consideration payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" scale="3" id="Tc_ao3cVIsdPku0VYuEu0p_0w_26_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" scale="3" id="Tc_BZV8xlpGoUG4npSnROJa9Q_26_6">3,178</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_a2NwHXAzgUe4rPR-5HRNdw_27_3">112</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_zPb0ULJlMk2vEjERmjkK5w_27_6">70</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_6deLNnjcXES96Q6VZVuMEQ_28_3">117</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_kSdnVeC-00yBCs0PTnJw9w_28_6">3,248</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net proceeds from issuance of stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_2__pYzx3gUuGC_URL47ObQ_30_3">15,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_e7okxOJCmk61YW7-QgN18g_30_6">11,694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Payment made to fixed payment arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:PaymentsForFixedPaymentArrangement" scale="3" id="Tc_X4FfL5B-LkiVb_qt4xafuA_31_3">4,266</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:PaymentsForFixedPaymentArrangement" scale="3" id="Tc_uucOUvwu3kCgCnMurDhYBA_31_6">4,409</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Net payments made on short-term line of credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" sign="-" scale="3" id="Tc_rqSAoUJLlEi08LvPaS7FuQ_32_3">2,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" sign="-" scale="3" id="Tc_k5jTTyNLn0GWwFW6iAF6Nw_32_6">4,121</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Payments made to borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" scale="3" id="Tc_R0EyVv7nuU6ZqSpEem_aVQ_33_3">96</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" scale="3" id="Tc_s5VVi6E9A06LQCl62JWh-A_33_6">16,101</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Proceeds from borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" scale="3" id="Tc_9yMaRL6Sq0mmUg75VLdxQw_34_6">15,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Payment for debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_0lj5N6HMd06nSwMjP9WALQ_35_3">92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_3TPc5FchckePH4tHwkgyqg_35_6">526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 24pt;">Other financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="3" id="Tc_VQ9YJe7SYEO-PS3BI_QYeg_36_6">7</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ro5SQrlJ5U-JjG6Bgl0UhA_37_3">8,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_AanWo5PGDkyNkAEL-p7SaA_37_6">1,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_ELplbpDBQUG_pkenDQaSGg_38_3">3,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_mnXFaCT7TEu7qL80n4yAfQ_38_6">30,541</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Cze1VIVGo0-VxQ3LK9VfzQ_39_3">19,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_jdg3AWVDe0GrQsSQIDfQCw_39_6">49,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_jL3zu54rmkK9amfIPD8wTw_40_3">22,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_VmgmGEXwbUubomEyubpEyA_40_6">19,360</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See accompanying Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_00cecc03_7206_43f8_a393_a15d7038d1ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows, Cont&#8217;d</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_016567e7_2c77_4164_a173_1febb487b1df"></a><a id="Tc_ITvWlMpV10-v5qIluhS3Bg_1_2"></a><a id="Tc_OYvgpQ4BckeGnZ_0p_6XOg_2_2"></a><a id="Tc_DviYajcH9UyGNFgw1MHipg_3_2"></a><a id="Tc_T4H0k-b4qEmtlYbNTKW4Ig_3_5"></a><a id="Tc_Q7nIwHOVkUOuouSiKYe_gw_4_0"></a><a id="Tc_wFMgFO1h5kyWBBeamwRaJg_5_0"></a><a id="Tc_1sw2xfcsF0ewKd-CCGuPGw_5_2"></a><a id="Tc_yPdola2cQU63DC1Bf2pK_Q_5_5"></a><a id="Tc_fzc61J_Y7UCSxwFKcw81Hw_6_0"></a><a id="Tc_oR6a7SH8B0-kRov_5VYNUg_7_0"></a><a id="Tc_4tpJnAsZHkaBFVbdUXTBSQ_7_2"></a><a id="Tc_oEMOhc16W0-n6IDm89vZQg_7_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_wXagSifDcke_qZY0VgbyEg_5_3">3,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_jIxNHY7M8E21cfs0_CAt2w_5_6">3,148</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other noncash investing and financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" id="Tc_2Yi5BOonAUOYr76oGgYj2Q_7_3">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" id="Tc_w1eC0yV_u0yemwQyDILYzw_7_6">54</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2ab6a82d_07b8_4198_a67b_854fa76d5b08"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to the Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="NotestotheFinancialStatements_740843"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="Tb_lLDed2bMo06Zoh4lRF_7vg" continuedAt="Tb_lLDed2bMo06Zoh4lRF_7vg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; or the &#8220;Company&#8221;), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through <ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_ulzzFY8eV0mnW7Td7VJe7g">two</ix:nonFraction> business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the &#8220;Consumer Health Portfolio&#8221;). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;) in March 2021, (the &#8220;Neos Acquisition&#8221;) the Company changed its name to Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every <span style="-sec-ix-hidden:Hidden_G-ii9jXEiUerH3aNSGrgcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span> shares held (&#8220;Reverse Stock Split&#8221;). Where applicable, all share and per share amounts in this annual report have been adjusted to reflect the effect of the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Rx Segment primarily consists of <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="INF" format="ixt-sec:numwordsen" name="aytu:NumberOfProductPortfolios" scale="0" id="Narr_2Zl-0z9GwUWkspqXg4qMvw">two</ix:nonFraction> product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) together the &#8220;ADHD Portfolio&#8221;, and the &#8220;Pediatric Portfolio&#8221; consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Portfolio consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, urological health and general wellness, commercialized through direct mail and e-commerce marketing channels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic and consumer markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development program AR101 (enzastaurin), and has terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr_IwYYokjKTUuOrt1g1CLJBg">23.0</ix:nonFraction> million of cash and cash equivalents and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_fBW9Jb33PEGz5XqVprXPQQ">28.9</ix:nonFraction> million in accounts receivable. The Company incurred a net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_g6rkUPg3vU6u5dJyRDi8oA">17.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_fdXC_Zkd_EOrsCEBeSRLgw">108.8</ix:nonFraction> million during the years ended June 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_yiOFmokvyUG9MyyHvem9cA">304.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_dQQk13dPgkWioGysunDmvA">287.1</ix:nonFraction> million as of June 30, 2023 and 2022, respectively. Cash used in operations was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_ZCLA537P9kOOwsFxvhiAGw">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_HXTAgZ6vGk2WBAQYqIDPUA">28.8</ix:nonFraction> million during the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has non-operating liabilities that are scheduled to, or may become current in the eighteen months following the filing of this 10-K, most notably the maturity of the $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_55m8hmaRO020GQ_6Zffq1Q">15</ix:nonFraction> million Avenue Capital term note (the &#8220;Avenue Note&#8221;). The Company expects to refinance the Avenue Note in the event it does not have sufficient cash on hand to retire it. As a result, there exists substantial <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt:booleantrue" name="us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear" id="Narr_x73fgisUGkKpPN7Nbqsv3g">doubt</ix:nonNumeric> about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on i) eliminating expenses for clinical development, ii) winding down or monetizing the Consumer Health Segment, which has generated negative cash flows since its acquisition in 2021, iii) refinancing its $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_24EbhjzYokGb_42x4OLNQQ">15</ix:nonFraction> million Avenue Note (see Note 11 &#8211; Long-term Debt) to extend its maturity date, and, if necessary iv) raising additional capital through public or private equity, debt offerings, or monetizing additional assets in order to meet its obligations. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lLDed2bMo06Zoh4lRF_7vg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_0JCBIz-QSUKv_SmxuW8OXw" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_Nw1ZCKszEE21VEVKnV8M3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principals of Consolidation</span><i style="font-style:italic;">. </i>The Company&#8217;s consolidated financial statements include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_2wE1xyoDF06MJrFa4vKsTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span><i style="font-style:italic;">.</i> The Company&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Use of estimates</span><i style="font-style:italic;white-space:pre-wrap;">.  </i>The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for doubtful accounts; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, long-lived assets, and goodwill; purchase price allocations, and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="Tb_k0VNfs5H9EKjrFjorTZifw" continuedAt="Tb_k0VNfs5H9EKjrFjorTZifw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Prior Period Reclassification</span><i style="font-style:italic;">. </i>Certain prior year amounts in the consolidated statements of operations and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of amortization of intellectual property, and a reclassification of fair value adjustment from contingent consideration. Amortization of intellectual property was previously included in research and development expenses and is currently recorded in amortization of intangible assets expenses on the consolidated statements of operations. Gain or loss from the fair value of contingent consideration was previously included in Other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the fiscal years ended June 30, 2023 and 2022 or its financial position as of June 30, 2023 or June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Financial Statements</span><i style="font-style:italic;">. </i>The classification of certain of the Company&#8217;s warrants was previously recorded as equity. These warrants according to U.S. GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the audited financial statements as of June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; and the Financial Accounting Standards Board (&#8220;FASB&#8221;), Statement of Financial Accounting Concepts No. 2 &#8220;Qualitative Characteristics of Accounting Information&#8221; indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company&#8217;s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_729c3dc9_5bb3_4f12_8a7e_fd12014cb90c"></a><a id="Tc_XgmC10N2GEuOb7Yny4mOag_1_2"></a><a id="Tc_nDFppolOGk6W52kSL6HnEw_2_2"></a><a id="Tc_TtrA7UY0nUW6AOLkp8gS5w_3_2"></a><a id="Tc_uWFLX7PgEEKTZyfUkoUyDQ_3_5"></a><a id="Tc_JewaaYOlq0Wes3kHuzt_FA_3_8"></a><a id="Tc_k6dBuMqIB0OHzg3RlFQdZA_4_2"></a><a id="Tc_rjrO1WFE4UucKeBmaIiyxg_5_0"></a><a id="Tc_e_7gyrEsDEGWXXqNw7ZE9g_6_0"></a><a id="Tc_fGqFesMGQUqlD-4OEOVhKA_6_2"></a><a id="Tc_BZI-hyZbkE279KwUmhp3lA_6_3"></a><a id="Tc_1oujIJy9sUaLbeJxcn6myA_6_5"></a><a id="Tc__wklC-ATpUyrm0v-olW9RQ_6_8"></a><a id="Tc_Uwk6Ak9RxkCdHcgzJRmJ_g_7_0"></a><a id="Tc_vLOqYA8LWEmoRsHwwzjxYQ_7_2"></a><a id="Tc_Jqd0_mPuQUWuYvXA8wnaDg_7_5"></a><a id="Tc_zYMhdGx1hEClPNHYVCAYmg_7_8"></a><a id="Tc_BMWLeTYw20anHiz8TjpR0A_8_0"></a><a id="Tc_djq4R1BUoEuic224WeBVfg_8_2"></a><a id="Tc_xwuwwMffK025HUhtS67fhA_8_5"></a><a id="Tc_9m1Zh7IfG02dFAPvWlvdYQ_8_8"></a><a id="Tc_SpP810doqUCm1rKHA1xXtg_9_0"></a><a id="Tc_peeP2ZFR8kG31gJkLlTkXA_9_2"></a><a id="Tc_A3swgzOnMkydzfr_nATXjA_9_5"></a><a id="Tc_3FmC-x_E0kG0l3v_f7Ubog_9_8"></a><a id="Tc_rF6al9tEZEuHZtMro_dcWw_10_0"></a><a id="Tc_vr7RpyWl2ke1lBumxRiwcw_10_2"></a><a id="Tc_PmQpQI-jQE--0xOF8sMR7w_10_5"></a><a id="Tc_-ruoXkGL7Uy8hGWUxI5igw_10_8"></a><a id="_16ef4086_e6bf_41d8_9b78_6cdc6c2f156e"></a><a id="_2fd5927e_a7f2_479a_b52c_cf973287bdc4"></a><a id="Tc_PSZ3AW79DEmPMJgCu0M1ZA_1_2"></a><a id="Tc_F97TT0lvLU25_G5diearnw_2_2"></a><a id="Tc_UH-xmEYZmUyHnJnIBLSYEA_3_2"></a><a id="Tc_RDl2UkOxiEu7ex5W_d-mqw_4_2"></a><a id="Tc_oVlwFkF8nki_N2MobZ18hw_4_5"></a><a id="Tc_EEmIFz8YO0W4-dj5Phvw7Q_4_8"></a><a id="Tc_VTt7Ul1upEqWzQirVXCwzg_5_2"></a><a id="Tc_mEzot3HC3kCkCNNZgANJhQ_6_0"></a><a id="Tc_2wIZDpacf0SKGXm9FvXrzA_7_0"></a><a id="Tc_McisWNSq0kOgGJ6z3AlfhQ_7_2"></a><a id="Tc_rpMP6LytfkyWtsBGJqteZQ_7_5"></a><a id="Tc_uLVloxsCJ0u6rWYBOrGMVA_7_8"></a><a id="Tc_tf6-FlogJk6n0uneI_Xyaw_8_0"></a><a id="Tc_wCGipLgD-kOd1UGAyxtIiA_8_2"></a><a id="Tc_g1zFX6MVgU-auzJiXcC9fw_8_5"></a><a id="Tc_vHmp0gJPc0ibtl_T9-Ussw_8_8"></a><a id="Tc_fz8_XBmjZkiUlYmSdKPnow_9_0"></a><a id="Tc_x8aby6VXBkG8ar9jiIq3WQ_9_2"></a><a id="Tc_YnzPf9HyQECLnf56J16muw_9_5"></a><a id="Tc_vFCypvSbiUS2l2S-dbTARw_9_8"></a><a id="Tc_2pnqHsOA5EKftSnSXkQC9A_10_0"></a><a id="Tc_jZySGleqk0qsePFEtcWMBQ_10_2"></a><a id="Tc_y_ns8B1XwE63BJ4I7N4Gzg_10_5"></a><a id="Tc_2m9Bl2x4fU-UVG-Wr7wZEQ_10_8"></a><a id="Tc_xZirXFGZ60eCOTbA63Kz_Q_11_0"></a><a id="Tc_DTef9wb0KU-Uvn0jhu0CIw_11_2"></a><a id="Tc_rPa52nQFI0mQgxVps8pcQw_11_5"></a><a id="Tc_UKyeuy0SHUizEcC2c40PSA_11_8"></a><a id="Tc_m_srcsoNtEWK3AMZXVw4cw_13_0"></a><a id="Tc_Aej87nVAJEKHds-LGqy-tA_14_0"></a><a id="Tc_oFSeCTSvQEaZc-KT7MApFw_14_2"></a><a id="Tc_7WiToDE4uU-JSbmCdsFfLg_14_5"></a><a id="Tc_M38T3ebqJ0KGr92ATBhoNA_14_8"></a><a id="Tc_00WrxXjCME-tY8zllyDGUw_16_0"></a><a id="Tc_m_GUCTPfTEyl_alRkfXhLQ_17_0"></a><a id="Tc_mfsIedJvBUmJv3rmXYHmTA_17_2"></a><a id="Tc_8n15HGlC0kiNzUtHrfsJtg_17_5"></a><a id="Tc_8ystF6jJlkyg0Eh7DKnw5Q_17_8"></a><a id="Tc_vIakjzUjHUqF3Q9VVaQZrQ_18_0"></a><a id="Tc_z4n53d_J0kGzqNrUmfKRuA_18_2"></a><a id="Tc_oP14y5IFy0K096wnWSHtkQ_18_5"></a><a id="Tc_U_QqpUDQDEyzBpGsygqrWA_18_8"></a><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont1" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont2"><ix:continuation id="Tb_k0VNfs5H9EKjrFjorTZifw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="Tb_dr53aXMAz06VkwWQ9zlD2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance Sheet data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_DfARo3xXl0W861xTHM6MeA_6_6">1,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_hRlDgZLtGUSpEwcrF8QoNg_6_9">1,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_iaAwqnU0aESfci90rsiM5A_7_3">91,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc__wLpXilUr0-Wzq0K69-rIQ_7_6">1,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_NIDbJKYdTkGHlcV4GRLHaw_7_9">93,315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_gPRDDlDYn0-LlHvsNNSZLg_8_3">334,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" sign="-" scale="3" id="Tc_FO8y68xFv0C3YpAm7zG9_w_8_6">3,174</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_GxcbO7DJCE6NKsybkV200g_8_9">331,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_auhIfS8Ah0udpJTUo_Z-ZQ_9_3">288,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_tNFVHpAkV0K8IYwz4EtFOg_9_6">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_4w0oUf8Hu06zPYrG981LJg_9_9">287,078</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_EWL9yme1pk2IQ9orL6gZyQ_10_3">46,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_dAMogO1Kp0KswgLPC4NUbg_10_6">1,784</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_NdWwp9CxrkGCbPrj6QHRng_10_9">44,308</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Twelve Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Operation data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_UoAuahPxpkOvsboZiREMqA_7_3">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_QeoQ-oemkEWy0atiO5847A_7_6">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_mGUng9kUEEmXRBFt7gtsXw_7_9">1,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">Total other income, net </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_4IbcAzG5Ik2kaZlZ5FBEXw_8_3">1,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_u_4HfJ1Jq0mR2gEinKmdkg_8_6">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_6KgV9pvEbU2gMSxH-D8Jvg_8_9">1,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_rSZu5MPy_ECI-wqzPDSQ2Q_9_3">110,283</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_OFBy14Dr2EWusoLFQ0oSnA_9_6">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_-34Fd-zVrEuiDgj3dXgIqA_9_9">108,889</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jGR3j_HBq0KRoLMrcVROiQ_10_3">110,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_o4EVWspbiE-iAyw-ZT96og_10_6">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jK8xe9A3JkyYPrT7TFbrPQ_10_9">108,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UBRBk4bsPEuDny4JQtxs7Q_11_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_UBRBk4bsPEuDny4JQtxs7Q_11_3_2">75.00</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_qXgVfDEOoE6_NTEAP_xekg_11_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_qXgVfDEOoE6_NTEAP_xekg_11_6_2">0.99</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_HaimNf7oIE2_5ClgsfRdgQ_11_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_HaimNf7oIE2_5ClgsfRdgQ_11_9_2">74.01</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Stockholders&#39; Equity data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ClPDFZjy9EmkpIQzG9Z7cQ_14_3">11,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" sign="-" scale="3" id="Tc_Y37fH9yE8UGTnZG_o6X91w_14_6">2,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_KHmc3GC-l0yrtK8t7FAceQ_14_9">8,854</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Cash Flow data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_UsIemhWy3kan4qz4U2gUYA_17_3">110,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_wDmFvHFs0U-6XwTtYEjihQ_17_6">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc__nI2WhbllUSHVO8DBR7-Sw_17_9">108,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_pMduOxIli0Sij-CW8unSMw_18_3">211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_32beKxjbGUKD4seuQq1MXA_18_6">1,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_pzGTwPQwyUulo8V5yWErFw_18_9">1,605</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Includes reclassification of gain or loss from the fair value of contingent consideration. See </span><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Prior Period Reclassification </i><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">in Note 2 &#8211; Summary of Significant Accounting Policies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Segment Information</span><i style="font-style:italic;">. </i>During the year ended June 30, 2023, the Company identified an omission regarding the disclosure of certain key metrics of its reportable segments under ASC 280 related to the year ended June 30, 2022. During the year ended June 30, 2022, the Company inappropriately reported the net income of each of its <ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_3septTjjREmgQyfLAMnvLw"><ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_kQpeuspLFEKCUjXf9ZCcCw">two</ix:nonFraction></ix:nonFraction> segments as opposed to operating income which more closely aligns with the adjusted EBITDA metric that is utilized by its chief operating decision maker. The impact on June 30, 2022 was that $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="6" id="Narr_Q2voKGjeC0KUx0nN6geGhA">92.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="6" id="Narr_-Cq4_zkt106_OasFhbXL2g">17.5</ix:nonFraction> million of operating loss relating to the Rx Segment and Consumer Health segment, respectively, should have been reported as a separate line. The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99. The Company concluded that the omission was not material to any of the previously issued consolidated financial statements and began reporting operating results by segment in accordance with ASC 280 on a prospective basis starting with the year ended June 30, 2023</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_HA8hUeckg0SWpkRFwkO2Kw" continuedAt="Tb_HA8hUeckg0SWpkRFwkO2Kw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span><i style="font-style:italic;">.</i> The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to FDIC (the &#8220;Federal Deposit Insurance Corporation&#8221;) insurance limits, and cash balances in the money market funds are not FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6db70792_9ff4_48bf_b5b4_e6e2c200f38c"></a><a id="Tc_RPZSsCIndEOef30mwwt9Tw_1_3"></a><a id="Tc_kHU8Zh0q50SM_Qa8S64bBA_2_3"></a><a id="Tc_7MY07Dwpi0afDnKLVBxa1A_3_0"></a><a id="Tc_mkaxfvtOrEyCmWtmUR3PPg_3_2"></a><a id="Tc_7I8-y52uE0qalGzew0MXiQ_4_0"></a><a id="Tc_BWBp1KkgSkqe7_p5S8x6Ag_5_0"></a><a id="Tc_VghldPiaLk-yxJnYm7DqVQ_5_2"></a><a id="Tc_M6vIygn_0kS2Dr8J_9Q3Aw_7_0"></a><a id="Tc_JUQdwkV9-k-fEe7Z1NBMXg_7_2"></a><a id="Tc_Bb1n1tmYzEaN43N8nF2V-Q_8_0"></a><a id="Tc_ABo5Mnd7lEWCAFcD6BLaCw_9_0"></a><a id="Tc_HopcPWSvTkShIYiN3PiX6g_9_2"></a><a id="_fa6d0eb3_3308_4e7f_b87f_04e0dd001dea"></a><a id="Tc_741a_gp17UmxcHXXvy88OA_1_3"></a><a id="Tc_WH-9rwkW3UmUEddnoQhAkQ_1_6"></a><a id="Tc_KmYG33ebwU-uBWpxXHQVEA_1_9"></a><a id="Tc_omwynBHAUECr7G-34v_gEg_2_3"></a><a id="Tc_we3hpU2DDU-boYKCZmAofg_4_0"></a><a id="Tc_jvZT9kZ8D0GDv6m9UDyd8w_4_2"></a><a id="Tc_LNzeZ5Q1X0G7sFYkbYAqXA_4_5"></a><a id="Tc_ObgHzsBjgkGYwJ4zyG0ADA_4_8"></a><a id="Tc_rrYv8txlvkKbhCsnkCeYnw_5_0"></a><a id="Tc_D1dvDdrLQkWzGlzIXVzp9w_6_0"></a><a id="Tc_piK7GLVQvkuMUM3aTlvaDw_7_0"></a><a id="Tc_wPVy-QC7BECrdwwp0V4amA_7_2"></a><a id="Tc_7QnJTmMGQEassUBrOlcf3w_7_5"></a><a id="Tc_kPl7hA8_R0ee-YUAUbK4iQ_7_8"></a><a id="Tc_z7hr-xjnTUS-hIvy-14MHQ_8_0"></a><a id="Tc_nddYEfzamEyE8e9Z6V9Nvg_9_0"></a><a id="Tc_Eyy8LcTCcE2C9w5pdxjobg_10_0"></a><a id="Tc_JecGVTPwLE6weXWajKDY0w_10_2"></a><a id="Tc_vRIw9Pqumk2qkm3KeM-ZnA_10_5"></a><a id="Tc__aZfeQynaUOpT_0AWwhn7A_10_8"></a><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont2" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont3"><ix:continuation id="Tb_HA8hUeckg0SWpkRFwkO2Kw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_MnQGfPN3ZEaGsou-N9hAwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, net</span><i style="font-style:italic;">. </i>Accounts receivable represent amounts due from customers less allowances for doubtful accounts, discounts and pricing chargebacks. An allowance for doubtful accounts, when needed, is based upon the financial condition and payment history of customers; collections experience on other accounts; and economic factors or events expected to affect future collections. The allowance for doubtful accounts was <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt-sec:numwordsen" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" scale="0" id="Narr_1qW2S5EPxU-BUjC4xEvrcQ"><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt-sec:numwordsen" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" scale="0" id="Narr_HYNLeXTGBU6bWMA07q9lMA">zero</ix:nonFraction></ix:nonFraction> for both years ended June 30, 2023 and 2022. The allowance for discounts was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" scale="6" id="Narr_EZq5dIMX4EyEQ-mXFTGCtQ">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" scale="6" id="Narr_LYrEvsNgBEaHrIVW4Fs1jw">1.3</ix:nonFraction> million for the years ended June 30, 2023 and 2022, respectively. The allowance for chargebacks was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" scale="6" id="Narr_3IL-Ux3juEmgGPpeeEzAgg"><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" scale="6" id="Narr__aXIaaDFBkO4iUNWSYf3gA">1.2</ix:nonFraction></ix:nonFraction><span style="white-space:pre-wrap;"> million for both years ended June 30, 2023 and 2022.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below presents the opening and closing balances of receivables from customers.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="Tb_e1AZ1nmVMUSkZI88tipI9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accounts Receivable, gross</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="3" id="Tc__UtmmxJwGk6_yNjVi6hLLQ_3_3">24,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="3" id="Tc_kU1gaj7pz0C4GIMI4Jj3jQ_4_3">31,927</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" scale="3" id="Tc_3dWAho8b_UOQpWijCywQVQ_5_3">7,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="3" id="Tc_-yKoPSaqBEOVAyk_WRYk0Q_7_3">30,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="3" id="Tc__yiWFmYc2EG8EfGUfpBQyQ_8_3">24,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Decrease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" sign="-" scale="3" id="Tc_Nx_Y1_jhZkK8YkzUkMXjdg_9_3">6,106</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="Tb_SWBxAQBa_E-tQV2AOmroPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Chargeback</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Allowance</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" scale="3" id="Tc_xXanAlCNmEi2Ot-U3CmNeA_4_3">1,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" scale="3" id="Tc_7Zmky8xk0UOVX9qWTZQ4RA_4_6">1,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="Tc__8TD4x9RI0ux6wOg8xvxrQ_4_9">2,149</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" scale="3" id="Tc_5r_Yl-1TNUCngO5RzxtYPA_5_3">6,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" scale="3" id="Tc_CpW30nOaS0aYk4uijOjEDA_5_6">4,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_lx-kuZPEYkK0ylzHaDSJNw_5_9">11,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" scale="3" id="Tc_b5Ztrg0NuUakrKNI1qCI1Q_6_3">6,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" scale="3" id="Tc_1-Y_Gi6nPEqcVz26pfmcVA_6_6">4,408</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="Tc_ic_G2farSU-ttlIps4cYoA_6_9">11,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" scale="3" id="Tc_-WvzMp7hc0yqkjHFxhFP1g_7_3">1,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" scale="3" id="Tc_sfokl32GbEiBFHskPXgGbA_7_6">1,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="Tc_IvcT1SP_oUyuPL4HiAyA2Q_7_9">2,507</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" scale="3" id="Tc_dShS2KbwNU-7UJFIKRpWxQ_8_3">9,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" scale="3" id="Tc_ePr_v-V1V0SjeBWywguWCQ_8_6">4,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_YkVngKnqqkuwth4p9YyuWg_8_9">13,628</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" scale="3" id="Tc_us2qu_F2EUydShITxcSedQ_9_3">8,597</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" scale="3" id="Tc_aS3Ey4ZssEGepoLwy3D2AQ_9_6">4,548</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="3" id="Tc__55LCZzrNE-jQPn5-vVeCA_9_9">13,145</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" scale="3" id="Tc_RqdayOcF70GxH4rwGGw_Ew_10_3">1,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" scale="3" id="Tc_pNXajGtlNkWOkGM_PLawIQ_10_6">1,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="Tc_iAD0u7P9zkqIu-c4e557OA_10_9">2,990</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:InventoryPolicyTextBlock" id="Tb_kcex6NCQJ0ajZapHjCW1sg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span><i style="font-style:italic;">.</i> Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:GoingConcernPolicyTextBlock" id="Tb_uPk3zQ9itECEI7nts0F_YQ" continuedAt="Tb_uPk3zQ9itECEI7nts0F_YQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Determination</span><i style="font-style:italic;">.</i> In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the financial statements are issued.<span style="font-size:11pt;"> </span>The evaluation is based on relevant conditions and events that are known and reasonably knowable within one year after the date that the financial statements are issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont3" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont4"><ix:continuation id="Tb_uPk3zQ9itECEI7nts0F_YQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_cOU7r61nCUiS5OBfYdLaGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and equipment, net</span><i style="font-style:italic;">. </i>Property and equipment are recorded at cost less accumulated depreciation. <span style="-sec-ix-hidden:Hidden_ZU0GSZmRRU6mHNeNM31yuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Furniture</span></span> and <span style="-sec-ix-hidden:Hidden_QQYcc8br-EqS2gjQlclZQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">equipment</span></span> are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:Hidden_BkyMcFO_ukqYjCCDP1gOew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to <ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_y69yBKt-akOWeNQFV5QWCA">seven years</ix:nonNumeric>. Leasehold improvements are amortized over the <span style="-sec-ix-hidden:Hidden_6fUhpC-LoUCZ1c2RWfvzow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shorter of the estimated useful life</span></span> or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_QAwfrtlvkk6Oq10ok9kQKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span><i style="font-style:italic;">.</i> At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Fair Value of Financial Instruments</span>.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:BusinessCombinationsPolicy" id="Group_ejEQd9vV30WVduYnfaNOhg" continuedAt="Group_ejEQd9vV30WVduYnfaNOhg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisitions</span><b style="font-weight:bold;">. </b>In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does not result in goodwill. Contingent consideration is accounted for Acquired in-process research and development with no alternative future use is charged to expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:WarrantsPolicyTextBlock" id="Tb_Yto7i2Hb2kilJdTEyKM9xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants. </span>The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC 815,including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability classified warrants are valued using the Monte Carlo simulation model or the Black-Scholes option pricing model at issuance, and for each reporting period. Equity classified warrants are valued using the Black-Scholes model.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_6_KEa9LpOEikjv55QWzBIw" continuedAt="Tb_6_KEa9LpOEikjv55QWzBIw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span><i style="font-style:italic;">. </i>The Company generates revenue from product sales through its prescription pharmaceutical products segment (&#8220;Rx Segment&#8221;) and its consumer healthcare products segment (&#8220;Consumer Health </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont4" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont5"><ix:continuation id="Tb_6_KEa9LpOEikjv55QWzBIw_cont1" continuedAt="Tb_6_KEa9LpOEikjv55QWzBIw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Segment&#8221;). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rx Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rx product revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#8220;Gross to Net&#8221; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gross to Net adjustments include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Savings offers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Prompt payment discounts</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Prompt payment discounts are based on standard provisions of wholesalers&#8217; services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesale distribution fees </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Rebates </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesaler chargebacks</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217; end customers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Returns</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Wholesalers&#8217; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior </span></td></tr></table></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63921f7e_c4ff_4213_8452_9bb475fac904"></a><a id="Tc_o2GFpKs0vEym4kvDKB4bgw_1_2"></a><a id="Tc_juZsXDJDnk-hjG1bGmCLJA_1_8"></a><a id="Tc_H-_qbHSQw0GIE45FLCLJGg_2_2"></a><a id="Tc_IyrJz5__JkaRb5A97KelUg_3_2"></a><a id="Tc_CxWJN-vDb0S53mEvMMtjMw_3_5"></a><a id="Tc_oyI9dqWRB020dAJTfEelig_3_8"></a><a id="Tc_EQJrqsND_0aiHx3O--rIbg_3_11"></a><a id="Tc_jfPmLjbXw0SppiSalNJjhw_4_0"></a><a id="Tc_isWdKKVAlEqd6Cs-CoQB0g_4_3"></a><a id="Tc_ylILmJqp_kytHbYtVCOCew_4_6"></a><a id="Tc_cgKgVnvMckWnCGVyndMSQQ_4_9"></a><a id="Tc_yCExgUYRQ0qJ_Z-vNuPWsQ_4_12"></a><a id="Tc_IwzEM7KYq0Sr2Xtr9FeWjg_5_0"></a><a id="Tc_lE4pe3T9P0upWbBOd4HgvQ_5_3"></a><a id="Tc_S6h_6xWSdEWG6FPEbAlKGA_5_6"></a><a id="Tc_w-4ZA4APg0mAcmhWqIv0hQ_5_9"></a><a id="Tc_g0Xo9s24-ke3bBYqhNB-lw_5_12"></a><a id="Tc_pJHtiM8kJUOfmLcQEu2ACA_6_0"></a><a id="Tc_Ro2QlGsqtkWwKZh5Nly5kw_6_3"></a><a id="Tc_SS7mkj7dOk2dWMPeLdG5Zw_6_6"></a><a id="Tc_aUVa5iu7CEmoqQY7dRcJvA_6_9"></a><a id="Tc_i2eL51WfZEunV6B_CNrSQg_6_12"></a><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont5" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont6"><ix:continuation id="Tb_6_KEa9LpOEikjv55QWzBIw_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consumer Health Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized &#8220;free-on-board&#8221; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:CustomerContractCostsPolicyTextBlock" id="Tb_mCGBMhirFkCF9VMPrQbAWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Customer Contract Costs</span><i style="font-style:italic;">.</i> The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one&#160;year.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_JGGAzLzJZUaid3oOl7qefQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span><i style="font-style:italic;">. </i>Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:Hidden_b9ThaH63FEyijuGZHHcAxg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt-sec:durwordsen" name="aytu:AccountsReceivableCreditTermsHighEndOfRange" id="Narr_ZHq54zwB8kWWTYsdBnsx7Q">sixty days</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents customers that contributed more than 10% of gross revenue and accounts receivable<i style="font-style:italic;">: </i></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Tb_0xJtTbrvqkq_rzaQeHatSw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of gross revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of accounts receivable</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_3sWZGJwLWkqe1X7WwsXfYQ_4_2">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__8vHwioqrU-ElY0VqMElLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_ep6HrZtjm0uAnjAd9Q2QGQ_4_5">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_DezRVWJ-AU2jRVzIgJxVKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_3wPSisoblU2OC1TJGCI1Fg_4_8">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_G2AveL47mkeAW3hRAHiUWA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_k2s3FPaviEKOwyiA5OV4nw_4_11">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dmuRzfJ_1EO6Agna7CZtLg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_MENtZYpdTkqjuxDwTCYNSg_5_2">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fubd0D8AXkeZ3HKcrke_bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_EYBfI9BRA028yEClvJQCPw_5_5">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_pYyR9VketkCher0rQtHN3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_S0cbeTJxMEazLVEVGBAT1A_5_8">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MpUuzivE-kWKg5ULjMW2Nw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_b1K7IK46eUiG01KIJUALeQ_5_11">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gPuRFu8KH0SGqG1C9lGBcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_dE5upl6qzUeUNaH4HqO-mA_6_2">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dI9JDG4GZ0q2nb3uqscqxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_B8QjfBkhVkuxvbYOQ20yGA_6_5">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MuRUdcU6WUG7NmDnhiTGRA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_J8RKKHg-lU26CJJEtIGoFg_6_8">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_dyFD-8ah2kCovq17PPt-2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Tc_-ucTuvZ_Vk-fVCxS0Ra34g_6_11">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:CostOfSalesPolicyTextBlock" id="Tb_sPk512Dfb0Ce-CdYOBcibw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Costs of Sales</span><i style="font-style:italic;">. </i>Costs of sales consists primarily of manufactured product cost, products acquired from third-party manufacturers, freight, production, and indirect manufacturing overhead costs and FDA fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that may require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company&#39;s third-party logistics companies are included in costs of sales.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_R9n6bWUBdU2EBtDFvNKAAg" continuedAt="Tb_R9n6bWUBdU2EBtDFvNKAAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span><i style="font-style:italic;">.</i> The Company accounts for share-based payments compensation expense using a fair value based model. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont6" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont7"><ix:continuation id="Tb_R9n6bWUBdU2EBtDFvNKAAg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn&#8217;t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. </p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_XmzERv2OjkeX7CaDGMtF8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span>. Research and development costs are expensed as incurred and include salaries and benefits, facilities costs, overhead costs, raw materials, laboratory and clinical supplies, clinical trial costs, contract services, milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates and other related costs.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="Tb_G7F2N8w470eHdMfbOMdeOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;">.</i> The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Tb_QeswFbOM-ESvFSlICrmk3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-lived Assets and Goodwill</span><i style="font-style:italic;">.</i> The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company&#8217;s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry forecasted financial performance indicate that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company&#8217;s industry.</p></ix:nonNumeric><ix:continuation id="Group_ejEQd9vV30WVduYnfaNOhg_2" continuedAt="Group_ejEQd9vV30WVduYnfaNOhg_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span><i style="font-style:italic;">. </i>The consideration for our acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income<span style="font-size:12pt;">.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="Tb_rd4bfo9mDUi3S0_cvwJwJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising Costs</span><i style="font-style:italic;">. </i>Advertising costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="Narr_Fp4s9ANJdE-vuuRRK_UB1Q">11.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="Narr_wRvmVzIMR0GZtAlsV7s-IQ">13.6</ix:nonFraction> million of advertising costs for the&#160;years ended June 30, 2023 and 2022, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_RINByVsHTUGChkIL-PTLTA" continuedAt="Tb_RINByVsHTUGChkIL-PTLTA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span><i style="font-style:italic;">.</i> The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont7" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont8"><ix:continuation id="Tb_RINByVsHTUGChkIL-PTLTA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of  to be sustained upon an examination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:DebtPolicyTextBlock" id="Tb_5a9l8N2auU6IRxWXfZ4BWA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt issuance costs, discounts (premiums)</span><i style="font-style:italic;">. </i>Debt issuance costs reflect fees paid to lenders and third parties directly related to issuing debt. Debt issuance costs and discounts (premiums) related to term loans are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense. Debt issuance costs related to a line of credit facility are classified as assets and subsequently amortized over the term of the line of credit as additional interest expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_g0FAgyCZb0yXsX1Z7lt3bA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span><i style="font-style:italic;">. </i>The Company&#8217;s operating segments engage in business activities from which it may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker, who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has <ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_xIF_EQ0eOE2W6x1gzd0hGg"><ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_jUAOnzudo0ehxTwRBUVlKQ">two</ix:nonFraction></ix:nonFraction> reportable segments: the Rx Segment and the Consumer Health Segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:LegalCostsPolicyTextBlock" id="Tb_vxtNcY32uUmOQ8O4cUsiYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paragraph IV litigation costs</span><i style="font-style:italic;">. </i>Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p></ix:nonNumeric><ix:continuation id="Group_ejEQd9vV30WVduYnfaNOhg_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Contingent considerations</span><i style="font-style:italic;">. </i>The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_XgmMMSIPAEyNeBG1kRCbYA" continuedAt="Tb_XgmMMSIPAEyNeBG1kRCbYA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Common Share</span><i style="font-style:italic;">.</i> Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For the years ended June 30, 2023 and 2022, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f40dc20a_396b_4650_973a_a6c530febdf8"></a><a id="Tc_YEn9bW8YtUau7ptmhbX9AA_1_4"></a><a id="Tc_qEUIPvwnyk-HVuUipRlrZA_2_4"></a><a id="Tc_JvIz2vPeo0KwNqmbnZxJPQ_2_6"></a><a id="Tc_rdEmKhpzG0eJjfIIIXg35Q_3_0"></a><a id="Tc_zGKcUaM4bEupQ1FyTQYpvA_3_2"></a><a id="Tc_aP2P1iCM5ky4oksJ1Rv7Zw_4_0"></a><a id="Tc_2ONZ2-zoYkOH_Gs47sEGVA_4_2"></a><a id="Tc_LX8FtYLT4UCWLJhGy5y8AA_5_0"></a><a id="Tc_DXJLlCZn_kyzArMrnk4hwg_5_2"></a><a id="Tc_nh9m9NLIU0S92b0OV5QLyQ_6_0"></a><a id="Tc_kHAnF7EkzUiKK4IGD4H4OQ_6_2"></a><a id="Tc_7Chpybc1YUCqWjOrzpxtYA_7_0"></a><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont8" continuedAt="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont9"><ix:continuation id="Tb_XgmMMSIPAEyNeBG1kRCbYA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets-forth securities excluded from the calculation of diluted earnings per share.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_K9tBrhzgYkuZLYim_7aOCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember__yHJIt2Q9UOXX-nN6ZJg3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8i4nbpdYAESIwQ5OkFLRiw_3_4">6,538,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember_GoexjV6gxkqMDtQcdeO1uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_bs08VeY2yUmh-NX8H25XoA_3_6">434,328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j3RI5vFShkKJU2UzYtHHnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_pQ9-mMserUmOJELtVZNS8Q_4_4">52,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Z3wjagFy1kWhlKur4kTO9w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_HU40fJVoBUiomcyxffnSMA_4_6">3,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_uaS8GvqRBE6WifGw2IAIyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qZKw3_S6hkCjUPzixrntwQ_5_4">40,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_sbvAUga0FkCVwaanOZG6qA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_hHGtrfL4g02vZGc5FFCxgQ_5_6">85,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q9trfMe7pUqct3050BPKPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_G2Usblda7kK3mDSFAZf9kg_6_4">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_btNydZdRJUeurgcuPy8Ayw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wwl_dSaFAUutYBtC500yyw_6_6">8,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Q1Yw_vVifEurZt8Xm14hxA_7_4">6,636,773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_DT6DzbGiRUe43IhtNXmrHw_7_6">532,104</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_q7p9Omqxj0uIZjaTTjCn5g" continuedAt="Tb_q7p9Omqxj0uIZjaTTjCn5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reference Rate Reform.</span> In March 2020, the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standard Update (&#8220;ASU&#8221;) 2020-04, <i style="font-style:italic;">Reference Rate Reform (Topic 848)</i>: <i style="font-style:italic;">&#8220;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&#8221;</i>, which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective July 1, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earnings Per Share.</span> In May 2021, the FASB issued ASU 2021-04,<i style="font-style:italic;"> &#8220;Earnings Per Share (Topic260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#8221;.</i> The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="Narr_TEfoD2s_xUyVNRDyUlWsew">adoption</ix:nonNumeric> of ASU 2021-04 and related updates did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt&#8212;Debt with Conversion and Other Options.</span> In August 2020, the FASB issued ASU No. 2020-06,<i style="font-style:italic;"> Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8212; &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (&#8221;SEC&#8221;), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ZXAfman6vk2Sxgjn7SWz_g" format="ixt:booleanfalse" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="Narr_BoBl-vV5Jk-jP9arZV8O2A">adopt</ix:nonNumeric> the guidance on July 1, 2024 and does not expect the adoption of the standard to have any material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial Instruments&#160;</span>&#8211;<span style="font-style:italic;font-weight:bold;"> Credit Losses.</span> In June&#160;2016, the FASB issued <i style="font-style:italic;">ASU 2016-13, &#8220;Financial Instruments&#160;&#8211; Credit Losses&#8221;</i> requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard is effective for smaller reporting companies for fiscal periods beginning after December&#160;15, 2022. In May 2019, the FASB issued ASU 2019-05, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses</i>&#8221;, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0JCBIz-QSUKv_SmxuW8OXw_cont9"><ix:continuation id="Tb_q7p9Omqxj0uIZjaTTjCn5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures</i>&#8221; which eliminates the accounting guidance for troubled debt restructurings by creditors and adds disclosure requirements for current period gross write-offs by year of origination for financing receivables and net investments in leases. The Company had <ix:nonNumeric contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201613Member__qlcvv9uqkqtL2K0Bw_iFw" format="ixt:booleanfalse" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="Narr_NTK1Kv_lXEG58vhq9WBfpg">adopted</ix:nonNumeric> ASU 2016-13 and ASU 2019-05 for the fiscal&#160;year ended June&#160;30, 2024. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:36pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_PNK2R7OmYkuMxFoZn3-QeA_1_2"></a><a id="Tc_yEnRbSSvlEq3w2oUWj53QQ_2_2"></a><a id="Tc_POkCK6HsiEu_THNR39b3NA_3_2"></a><a id="Tc_cZ8UotPY2Ea3uRldz46AWA_3_5"></a><a id="Tc_3_VECx_xhUyy2W4jX5ts4w_4_2"></a><a id="Tc_HnZ_XOKbHkaa38VHEmelJg_5_0"></a><a id="Tc_NIMHsbxN_UC2h8QIJmw-EQ_5_2"></a><a id="Tc_uvXcTGaoG0SeG38BNFP8hg_5_5"></a><a id="Tc_FC-U_57RG0CdYltcnT0V4Q_6_0"></a><a id="Tc_Uid4xHiZ7k-0PLrSgwakBg_7_0"></a><a id="Tc_eCH-06TF9kinRIeBDV8Dkg_7_2"></a><a id="Tc_3MV1wPTwbE2wmtmVRl150g_7_5"></a><a id="Tc_8zDvzwwei06a3_cBt0PYgg_1_2"></a><a id="Tc_MJD-zDJagEeGhzoH2-WwPg_2_2"></a><a id="Tc_-Ww4dfT4eUq2PWi0TYOgUg_3_2"></a><a id="Tc_aVOzG_Gn5k6lXyYRw4YOeg_3_5"></a><a id="Tc_nnfGbMix6ES5qdGZd9NtIQ_4_0"></a><a id="Tc_KWQTtj5f2U2W7te9Su7KDQ_4_2"></a><a id="Tc_L2R2PLKA50eYC_XU06c-Zg_5_2"></a><a id="Tc_wfK9Oohsi0uLvKtJouZnWg_5_5"></a><a id="Tc_8djf9fp9ikWDGyNQQAPbNg_8_2"></a><a id="Tc_Pht6GU6bw06Flj4FR9tgRw_8_5"></a><a id="_3afe8f5a_a2ec_4820_a575_e9c4a9ef5f3d"></a><a id="_3afe8f5a_a2ec_4820_a575_e9c4a9ef5f3d_2"></a><a id="_3afe8f5a_a2ec_4820_a575_e9c4a9ef5f3d_3"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_zbb6jCGUKEm5-gf4VfxJIQ" continuedAt="Tb_zbb6jCGUKEm5-gf4VfxJIQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Revenues from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company disaggregates its revenue into <ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_qhAVrN6m4EOy2xekF-E5hA">two</ix:nonFraction> segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys XR-ODT and Cotempla XR-ODT; and the Pediatric Portfolio, comprised of Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. The Consumer Health portfolio is comprised of over <ix:nonFraction unitRef="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w" contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_srt_RangeAxis_srt_MinimumMember_0H_yp89jtUqG89f48FDrpg" decimals="INF" format="ixt-sec:numwordsen" name="aytu:NumberOfProducts" scale="0" id="Narr_FXJGhPwr5UaRwDgBK6MrAg">ten</ix:nonFraction> consumer health products competing in large healthcare categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Revenues by Segment</i>: Net revenue disaggregated by segment for the years ended June 30, 2023 and 2022 were as follows.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_dXUWpVwtzUy1ED8k1-GtcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_4DOAZ_3bv0amAZTxfHD03A_5_3">73,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_8FXXj2QZ_kSex6KrDHAfDQ_5_6">61,121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consumer Health Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ZJFfZAB_5UKkNH8S40VM2g_6_3">33,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ncagX6gZHE2W79vSMm3K7g_6_6">35,548</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Consolidated revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_yW-Qq9Jmt0igTDVY72ntHw_7_3">107,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_HhJXDSi_gE-cxpfZjG_RkQ_7_6">96,669</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues by Product Portfolio</i>: Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2023 and 2022 were as follows. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="Tb_CYCucMC-2EWWkuIQGk-DLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_g-cbh5-g8Eq9t2stexXsqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADHD </span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_cXbnpjXPukexCAFy3_LFIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_90GX6lWEhEC9pVn7a0iRRQ_5_3">46,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_-wVTRKUC6ECEuGno8N9RJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_8zhtwt3oakOodQ9bbGHBmA_5_6">42,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_K8_3hQR_I0yTd3PB8O7Q8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pediatric</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_7PrD9QVnpUeLAEO5GWzdCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_uzdCbs0HnUK3rn4a-WS8iA_6_3">25,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_YxGJ1VVEdEyw5ny5-XgKFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_XRBHABSlwkS22g61QwGw4w_6_6">16,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_3ehiKXD22k2GoV9XNE777Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_ny4Ioj3TaUWAHDoTez-dHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_MzpU8574t06cY0HGakMinw_7_3">1,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_zUCpOHor3EKdIXUHOlnNXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_wmtxjlkvQEmsoB0xfZPusQ_7_6">2,182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Jw6pJXl6zkmi6gHapozHdw_8_3">73,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_JNkGY-QvvEuLcJCEPeBikQ_8_6">61,121</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-IfvocbP_U-loKxAyH8rrA_1_2"></a><a id="Tc_4m5OiiXkQE-4WMBfrNJy8g_2_2"></a><a id="Tc_iNn-Yojfqkml3lVkl1dxXA_3_2"></a><a id="Tc_EoDbbGGqwEmvOcvU49L-JA_3_5"></a><a id="Tc_cy47ljfVRU6UUsn4tMps6w_4_2"></a><a id="Tc_c_vt1zuKW0GbimK7wd7GpA_5_0"></a><a id="Tc_KINvlM9ah0SEUCbS7-t5yA_5_2"></a><a id="Tc_Pu6txCuvEk6htuX2PNWhwA_5_5"></a><a id="Tc_phYgjjJcQEq5LQ0-R1u2kw_6_0"></a><a id="Tc_qlf0AfrCX0Wflxo8w75wVw_7_0"></a><a id="Tc_XZwDG6wWO0OLbV8-2O2ikA_7_2"></a><a id="Tc_RTTr5R_4iUeEg9Htdvd2Dg_7_5"></a><ix:continuation id="Tb_zbb6jCGUKEm5-gf4VfxJIQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues by Geographic location. </i>The following table reflects product revenues by geographic location as determined by the billing address of the Company&#8217;s customers:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="Tb_9HrBp8MjGk-BwBTF-B0jrg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_country_US_eQR9LbH5NkuCUdtmvO2k4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_TrRzpCK170OrxgFIvxstkA_5_3">106,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_country_US_rIjPJISGDEi3pzssDPn3HA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_IrFrNGCAo0GOA5vriQZduw_5_6">94,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">International</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_us-gaap_NonUsMember_LkBwlL2700aENO-vthtouA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_ueDMjNafXkOwr1LrW32ZRA_6_3">481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_Ei3dfZNp9kKN-0D3nbjFKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_XzZfiqrM70qhU1MzYeJWcQ_6_6">2,063</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_g9MGZZjslUySnhtjWHgSrQ_7_3">107,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_HENg5CJtAkCr6gPk9FH1pg_7_6">96,669</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9595214d_f320_45dc_9914_0c75fba7e210"></a><a id="Tc_vOrYsvD1Bku7kH3b8f3eBQ_1_2"></a><a id="Tc_zdWvir28JEC_zusvTRriKQ_1_5"></a><a id="Tc_g-e9d-oDk0yLcD3kbfis9Q_2_2"></a><a id="Tc_33IIFZFavUi_6zRXpYe3Bg_2_5"></a><a id="Tc_8kxP3z3L7EKF2xkJUy-kqQ_3_1"></a><a id="Tc_QHvbP5GX0kq7UgA-sxajcQ_4_0"></a><a id="Tc_-Kr45DiaoUGkdK_6aeUkPA_4_2"></a><a id="Tc_M54wjxiae0evg-gmsGKM4Q_4_5"></a><a id="Tc_4HdRKOb2ok-6l-oXfAmWcg_5_0"></a><a id="Tc_LVzqmyWV00KhgEV-f13biA_6_0"></a><a id="Tc_Hs3P1FVkUUO8_6sYmZi8hQ_7_0"></a><a id="Tc_zLqHkZs5r0GKO2KYFv3QcQ_7_2"></a><a id="Tc_Qp_g6F_Kckq98VWtuL18XQ_7_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_nO66R__FHkO6NX-l828IMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories consist of the following:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_EiBmaBMYN02w7kzSK7n5Xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:23.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_BLuN2TlVp0quw-FiPjxtjA_4_3">1,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_2og4V6tS2kShfLBNz_cjTA_4_6">1,814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_SsFqyCOFoka_j3ev4xyifA_5_3">2,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_NU8maN4BDkOrivAVqK364A_5_6">1,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_1YwjZGrk9kOjqGn_nf0Rkw_6_3">7,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_vMO6CtNdm0-W6wnZbbEduA_6_6">7,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_vnKXT5VpnUegicphLDxaqA_7_3">11,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Dd0nRXGiGkui4t2waJ91TQ_7_6">10,849</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred charges of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_9Kx_gOp80UWH3jrhvwIMQQ">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="aytu:InventoryWriteDownAndImpairment" scale="6" id="Narr_T1Zq0VDKiUuHLZ9bYIdoJg">4.2</ix:nonFraction> million to reduce the carrying value of inventory to net realizable value during the years ended June 30, 2023 and 2022, respectively, primarily as a result of unsalable and slow-moving products. </p></ix:nonNumeric><a id="_e7335cfe_f90a_4bed_b4e7_eb2cbe24aae7"></a><a id="Tc_yr43BDw0UkyK18LZZnrHzA_1_2"></a><a id="Tc_crufcY4ztU-Xs2GifJ4k5Q_1_5"></a><a id="Tc_BBp2_o1vHUmKNzTPb14AaA_2_2"></a><a id="Tc_LFqMrXh22UqJwKJ7Pc5YCg_2_5"></a><a id="Tc_Cu_zISeUwEGv2O1dyVlUzQ_3_2"></a><a id="Tc_9BCZ2u9v-U675U4JlN77Fw_4_0"></a><a id="Tc_7NcOLPzXR0mTCTw66ck1og_4_2"></a><a id="Tc_Lv8UEgrrjUyukKujryNSWw_4_5"></a><a id="Tc_63r7qNLP50mUJwDtWDGnRA_5_0"></a><a id="Tc_wxQIZNqWtESmEjiZL8Z17w_6_0"></a><a id="Tc_QRk9nUAJsEmfFdODfEMZ0Q_7_0"></a><a id="Tc_TVmVefa_DkOM0Wt4Xthz9Q_8_0"></a><a id="Tc__DI9uRZnN0etyZhNNcbHnA_8_6"></a><a id="Tc_Z5iJg1n88kSZH0qmzOVeFw_9_0"></a><a id="Tc_vW3g_M0N0kW1X8LuDUmaNg_10_0"></a><a id="Tc_ZOwuLRHwrkmth2fiJr9Vog_11_0"></a><a id="Tc_4E47396foU6O9L8HJJsI_Q_11_2"></a><a id="Tc_3mWwJBCk6UezhHOIGwjgaQ_11_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_qrGQDah-a06IpVQgRxe6jA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consist of the following:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_75VIdKH3REylWC1YYnJsFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_7mJbheQk9E-fPv17qgwvgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_Dy5tGLi_t06jn-E66TgrTQ_4_3">2,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_qTHTkenh9EuSbsPXngyU5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_9lx2hJOuWkiZCO8TZ77Xow_4_6">2,487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_EAn2hHYqLEumK7V3KbrKRg_5_3">999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_kQajJzeLJkCdUTJlMSe9iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_9KWp4d9Wgkyp42eyXZn_HQ_5_6">999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment, furniture and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_5MqaEaeetUGtGEYDAHXg8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_3o0K8uVqG0i8yUhk9I_eNA_6_3">1,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_bUb-E6CVMEW0AkWN12ZTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_rh47EP2NR0Gbju7crN0zYg_6_6">1,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_CSjduuCOFUWc6w0vdHoF3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_3YrVUD7ZbEWCiig37MNi0A_7_3">832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_NGXHsoRLLUW-TllyXMODGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_28N9PI1eOkq-JpttKi2Kjw_7_6">832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets under construction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_9jIFl-JbSUSy2-E0dwOfCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_AyyopxAY7EyEnpU2xTLB1A_8_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_e1FENN_96EKkFm6wtwimfQ_9_3">5,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="Tc_lNJCc5kGGEyAaocgJc499Q_9_6">5,446</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_xERXY8INZEGcixIwFy4qKA_10_3">3,681</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="Tc_DqruiKiXikqeOOROeEhbfw_10_6">2,421</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_G0lOu_jdVUm9GY5DPlnz4w_11_3">1,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="Tc_aDYlPh2s0kSAkUQhlp23Hw_11_6">3,025</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_pvfFCp60h0iXraz0t0TSVA">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_EdKZegyPlkyLJqy-0yC6rw">1.6</ix:nonFraction> million for the&#160;years ended June 30, 2023 and 2022, respectively. During the year ended June 30, 2022, the Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="Narr_4vmo9yJmsUCf4EE7Q6AIOg">0.1</ix:nonFraction> million on the disposal of equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended June 30, 2022, in connection with the decision to divest Tussionex, the Company recorded a $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="Narr_NzeNAbxgU0KxKojnwXrZoQ">0.2</ix:nonFraction> million <span style="-sec-ix-hidden:Hidden_kMk3CteVXE-sj0ReN6tePA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment</span></span> charge related to manufacturing equipment associated with this product. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:LeaseDisclosureTextBlock" id="Tb_b9APaADJL06Fa4YQP7oD0w" continuedAt="Tb_b9APaADJL06Fa4YQP7oD0w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases are for equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LNVcoja5p0ybSPuEJgSYyw_1_2"></a><a id="Tc_9-IvFMIsLk2G_04gQSnYQA_2_2"></a><a id="Tc_VTjDaAYh4UmHSI00uxQQIw_3_2"></a><a id="Tc_1TpgTuwH40ypO0nUS10UvQ_3_5"></a><a id="Tc_IKAQR1imKkSR6J2G5c6y8w_3_8"></a><a id="Tc_4w8uWoJ4pkaMQ2I4__oqsg_4_2"></a><a id="Tc_yOihL7NCnUefS6xIRiltuw_5_0"></a><a id="Tc_O41_pDBR1UGEZe_JnR9aBw_6_0"></a><a id="Tc_vq7NIHCzdUeslH0dwyKEAg_6_2"></a><a id="Tc_ZAGas1SaIUGb2MJuH9qScg_6_5"></a><a id="Tc_wfsjfXNYJ0-5n2rztytQ9A_6_8"></a><a id="Tc_6k1s1tMagU-E7MQBdBKqnA_7_0"></a><a id="Tc_O3ZcLRDLKEG5urn-2qefMw_7_8"></a><a id="Tc_AK86xoYnJUqy-y2doj3T7g_8_0"></a><a id="Tc_oXR5fauutk-SwphwkDnpYQ_9_0"></a><a id="Tc_FJn92gi0UEy-odRepg7v4g_9_8"></a><a id="Tc_ob18Ua3SaEGUMOHPEZpXtA_10_0"></a><a id="Tc_MWIVk9rQEUORxr9PIh33uQ_10_8"></a><a id="Tc_JpjZqJsR8E--_HatdBO5uQ_11_0"></a><a id="Tc_LibGJH-IrkykxuqVFF72ZA_11_2"></a><a id="Tc_YE5yB50uDUGNYECGWfgrKg_11_5"></a><ix:continuation id="Tb_b9APaADJL06Fa4YQP7oD0w_cont1" continuedAt="Tb_b9APaADJL06Fa4YQP7oD0w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">option provisions under which the parties may extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#8217;s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_Uz2BvkIxHUiCW8Xxm8dFTQ"><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_WckY8X4nZ0yQIAA8QILgOA">3.5</ix:nonFraction></ix:nonFraction> million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does not provide an implicit rate, a borrowing rate of <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_0IjcUi3KdU-9tB6508Onsw">6.7</ix:nonFraction>% was used to determine the present value of future lease payments. The finance leases are related to equipment finance leases with fixed contract terms and an implicit interest rate of approximately <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="Narr_JmhrR4Ha0kq3BNt7qwJkPQ">5.9</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company entered into an agreement with a manufacturing company to sublease <ix:nonFraction unitRef="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A" contextRef="As_Of_4_30_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_LnhBuUfFUU2Q1TN_RRlvNw" decimals="INF" format="ixt:numdotdecimal" name="aytu:AreaOfSubleaseProperty" scale="0" id="Narr_mn-lJefBG0Gizls-WIwrJw">22,909</ix:nonFraction> square feet of the Company&#8217;s manufacturing facility in Grand Prairie, Texas (the &#8220;Sublease Agreement&#8221;). The sublease commenced in May 2023 and will terminate on December 31, 2024. The Sublease Agreement provides the sublessee an <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_HdkvYzf7dEikeSaxOiXIyQ">option to expand</ix:nonNumeric> the subleased property to include the remaining <ix:nonFraction unitRef="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A" contextRef="As_Of_5_31_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_PuGTLMkWzEGYXoqXlmsEWA" decimals="INF" format="ixt:numdotdecimal" name="aytu:RemainingAreaOfSubleaseProperty" scale="0" id="Narr_R_hfThftwU6lvQIPdlu0Gg">54,203</ix:nonFraction> square feet of the Company&#8217;s manufacturing facility. The expansion date may commence as early as April 1, 2024 but no later than December 31, 2024 (the &#8220;Expansion Date&#8221;). Under the terms of the Sublease Agreement, the sublessee will pay base rent of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpansionDateMember_OStY-vIWGkihjBhiDOXvUQ" decimals="0" format="ixt:numdotdecimal" name="aytu:RentReceivableFromSubleaseProperty" scale="0" id="Narr_VSZhLaYvskqO29Utrp5ZUA">20,500</ix:nonFraction> per month through the Expansion Date. Beginning on the Expansion Date, base rent will be $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpirationOfSubleaseMember_qJVnAen4DEKJ5nCT7EWV2g" decimals="0" format="ixt:numdotdecimal" name="aytu:RentReceivableFromSubleaseProperty" scale="0" id="Narr_1PoCG1Um3Em7wwBwxBzexA">70,686</ix:nonFraction> per month through the expiration of the sublease. In addition to the base rent, the sublessee will pay the Company certain operating expenses incurred by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2023, in addition to the sublease mentioned above, the Company entered into an operating lease agreement to relocate its principal office (See Note 18 &#8211; Commitments and Contingencies). During the fiscal year ended June 30, 2022, the Company commenced a <ix:nonNumeric contextRef="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_wivHl2P1lUaCWG0R1iFqDw">five-year</ix:nonNumeric> operating lease and recorded an ROU of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_zpDRuwxyPESgw5idCr7btg">0.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of lease expenses are as follows;</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_cBRSLFix3UGQUyDf5cAjVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statement of Operations Classification</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_9XyDOetEt0uXHOEvvGpzww_6_3">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_rg6ByUAPzEidh2GCzOKAIQ_6_6">1,299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_S6PwGJL40USStDsznbT9_A_7_3">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="3" id="Tc_uU2InoX3B0iii87S-uEDQg_7_6">152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_JmhuFS6pYUaF9p1kHKvMKQ_9_3">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_qSjZVWywF021hViCYIbjFw_9_6">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_0z_E29ZFR0-UUvJqjA8WYQ_10_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_B34z6o6GyEG9Sj9JY8SqKQ_10_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (expense), net</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total net lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_ig-VAd067kagRvlqUZEnpA_11_3">1,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_oxHJ4WEG40y7gbmUEChXhA_11_6">1,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_sTPTtvb_GEOCifgiwXrRDA_1_2"></a><a id="Tc_i9XA5GfByEa_2sw68pGDLg_1_5"></a><a id="Tc_ngZK5X7viUmZrJK_x-SPVA_1_8"></a><a id="Tc_35slbYbP5EmAyaOCGuqvZQ_2_2"></a><a id="Tc_plCe78HvPEeyeqW9-nO1sw_2_5"></a><a id="Tc_1mz7J4gcKkmb9T97b2itmg_3_2"></a><a id="Tc_B-6-MqNRp0y9P9Yp3PO23g_4_0"></a><a id="Tc_IV7tJwVtG02zgw-MrCq7JQ_5_0"></a><a id="Tc_xvDJM9PGEkSmYZBbgaXAug_5_2"></a><a id="Tc_UaB-VkLxuUWGdl3xr7YZHg_5_5"></a><a id="Tc_hKtiEUsZYE-7y9GN-XH84Q_5_8"></a><a id="Tc_nOpo8UeCFkyuZaeKFdFyqA_6_0"></a><a id="Tc_rCQpdSgL1UydCSdkahRm5w_7_0"></a><a id="Tc_2g-UqflM-EWLoDiPt9Mnrw_7_2"></a><a id="Tc_1C9HJUM900eBywDfmj00uw_7_5"></a><a id="Tc_TKQ8VF_vSUO9uUwoDucr7A_8_0"></a><a id="Tc_rMyio6A_hU-adC4VEjMu2Q_9_0"></a><a id="Tc_4Nqf7772X0eWXweC7WLIcA_10_0"></a><a id="Tc_YJbf-nyw_E2n3-a3IyvonA_10_2"></a><a id="Tc_vuVVEc8-h0CPlKL34gXTYA_10_5"></a><a id="Tc_3J34FtDa6EO5vYa8KjRfTA_11_0"></a><a id="Tc_FDWrueOrME-AXh8RcXx2Xw_12_0"></a><a id="Tc_UXl2154KTUOFpkCaCbj2Sg_13_0"></a><a id="Tc_Qw46_4Ie5UuHkL4k1LbU0A_14_0"></a><a id="Tc_N7mdHBwwFUOYsh8JGkgSoQ_14_3"></a><a id="Tc_2RdgcQ3Jd0OHtJn4drDGzw_15_0"></a><a id="Tc_ErXrvLO9w0q9sfiiWS2LTg_15_2"></a><a id="Tc_BpIeTaxO8UCQo3qJY_pOTg_15_5"></a><a id="Tc_bQ-nx5vDXEC_psG-tEh28Q_1_2"></a><a id="Tc_BeWyCB9RtEKwdu3rNdZEig_1_5"></a><a id="Tc_qzk8azkhbkK7qyWg4HpdVg_2_2"></a><a id="Tc_ovD_V7AW3kWgDhPsI2s89g_2_5"></a><a id="Tc_1cO1q4Q7T0WXp3WOlrtUQA_3_0"></a><a id="Tc_v9QVgadQgUiBRKWlDNkqGg_4_0"></a><a id="Tc_p4bMEgWsoEWGbhbTVV5rEA_5_0"></a><a id="Tc_MK_lItZllUCvCqCXaavA9g_6_0"></a><a id="Tc_HuWmWlWJ50euhHUbfQ9V1w_7_0"></a><a id="Tc_yyycEf-xcE2WEJuH8CE1Iw_7_4"></a><a id="Tc_OPGxgvQ7ZEGVnkwoC5g3cA_7_7"></a><a id="Tc_OT8XeXxdc0ynezp_4avc_g_8_0"></a><a id="Tc_tLN5zVi9qUOYxBZNrZchRg_8_4"></a><a id="Tc_03ez4gVSbECWQ1TXQlwldg_8_7"></a><a id="Tc_OEQetxOLOECL2XyJWoqnKA_1_2"></a><a id="Tc_RA8y3yc4m0WLUf2g70-omA_2_2"></a><a id="Tc_VmVHBu5eLUyCc_py0WFTtg_3_2"></a><a id="Tc_UgQi1QprLk2w1cUhsQlQ-w_3_5"></a><a id="Tc_D3MKXoQOgEmaMo7epSNsBQ_4_2"></a><a id="Tc_7THb-2bF4kSVQ9-FCij-tg_5_0"></a><a id="Tc_iVlYLMMpGkqiob36YAYhUw_6_0"></a><a id="Tc_UqFZLufOkUqzVnt6GNL8cw_6_2"></a><a id="Tc_iF7Wmzt5L0ajdKlq2skXxA_6_5"></a><a id="Tc_RH2L8SP10EiecHutX3KMbw_7_0"></a><a id="Tc_vr_PWurGoEi1jzACsaPm7A_7_2"></a><a id="Tc_CqK6DpuPp0OI_nDivCO-OA_7_5"></a><a id="Tc_tGl67G2dJ0S-wy-QcMIJcg_8_0"></a><a id="Tc_4xLSc1xNa0WwU5LrKNpDKQ_8_2"></a><a id="Tc_Ow9LxZLQ1kWCP6vKkazQnQ_8_5"></a><a id="_e8b88457_15a5_467b_ac8f_3ee3fdb3d8ee"></a><a id="Tc_q-UQXZGLM0mHq4FBq6rUdQ_1_2"></a><a id="Tc_WM2qDYm-tEu3XRmcqQ88pA_1_5"></a><a id="Tc_Xx13TvXXt0uCffhEaQ71Dw_2_2"></a><a id="Tc_GdyYJxP8ikSzrQJF-Kcdrg_3_0"></a><a id="Tc_gVdx1biGXkyoQi6xRYr-mA_3_2"></a><a id="Tc_xs3u2kjnkUCxe75lbfS2Jw_3_5"></a><a id="Tc_5-IUpArTLkOikRc8ongSOw_4_0"></a><a id="Tc_O1B_-r0Br0yVqZ7YgncHUg_4_6"></a><a id="Tc_a3ZWtSGd60unqz2xRozpVg_5_0"></a><a id="Tc_hzpazQwZo0ie2rNnHO-41A_5_6"></a><a id="Tc_IbssJOuJVUagOSvn3T74wA_6_0"></a><a id="Tc_m6wBlNRBD0WOTR_fhxA9Fg_6_6"></a><a id="Tc_TStwPx-rP0KeLhuFz6TyTA_7_0"></a><a id="Tc_DKIfaunfp0iWeTNCpUlpLg_8_0"></a><a id="Tc_v7R9Z3yWk0OHH0uLAtRKwg_9_0"></a><a id="Tc_rCGoOl1TsU2y44I_elu6kA_9_2"></a><a id="Tc_cJ7gQoE7kk-_bC0bB_dCCw_9_5"></a><ix:continuation id="Tb_b9APaADJL06Fa4YQP7oD0w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information related to leases is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:AssetsAndLiabilitiesLesseeTableTextBlock" id="Tb_2RIBQxO6bEu-0EFils-cMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_gWfMT6nNJk6wB-1vlkAoeA_5_3">2,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_92w77hdz-EykL3RAbJ2yyg_5_6">3,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_oPVc18wEwkGz7b-Mr1SOag_6_3">159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_u3b_qmj0eUyFOBYgehE4Tw_6_6">256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_oCFrnX1cZEKlI0YfWFbvaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset" scale="3" id="Tc_yLIwYIxvJEqI6jQU26s6Rw_7_3">2,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset" scale="3" id="Tc_X_D9XzalNEWun4ka--CIzw_7_6">3,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_DhKTZxpdeUGlsmFUshwUeA_10_3">1,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_Xq2FeY931EumhHF3xYzQ6Q_10_6">1,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uO7hW3tJ10-9Y4OnbKB2gw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_zReWlrKuNEW4snuH6KtUgw_11_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_6mEXers4b0iHgxCRf4gvuQ_11_6">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_kiHw9kJlzEqfvdcIxL-40Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of debt</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Y9oqriihw0ifT87xtJlzkQ_13_3">832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_FBSsXKpoMkKE6BBZF5D-2g_13_6">2,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_unXTBH375Ue8ldFNegISKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_YGey-S9tvk2DwlrbmpWsdQ_14_6">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_rmlxlXZlBUmyfb7kJxK3Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Debt, net of current portion</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:OperatingLeaseAndFinanceLeaseLiability" scale="3" id="Tc__6-m1H1ZtEOJIYZVHzjQ-A_15_3">2,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:OperatingLeaseAndFinanceLeaseLiability" scale="3" id="Tc_ElbxzpB590WDw5J3_ZJisw_15_6">3,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Remaining lease terms and discount rates used are as follows;</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:RemainingLeaseTermAndDiscountRateTableTextBlock" id="Tb_6AR3TaJNhk6ICvNyb5ZAHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Remaining Lease Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_2DIFE68cek6OIrB3MH1OQg_4_3"> 1.72</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_1HsvhlR4G0qTxcnZPeqMxw_4_6"> 2.63</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Zc-jgYDUD0Sczl9YFxztIA_5_3"> 0.87</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_LiVbjKaPRk-ux7_txiPYPw_5_6"> 1.73</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_ah5P6RORyUqb-1dJidQ8zw_7_3">7.78</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_PWoYZl_RCkWNcHQMSHltvA_7_6">7.48</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_NfzTAC7BTEy63L4Cs5Ur0g_8_3">6.54</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_IrFZMSuuzEOMzHZ-4cVrgA_8_6">6.43</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to leases is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:LesseeLeasesCashFlowInformationTableTextBlock" id="Tb_t3utrfuUTkOEPPkzIP3ETw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow classification of lease payments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_N-lp9_MTKkuSRjm13LwbsA_6_3">1,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_3HXfh3cmnUSGCfm2fOzDxA_6_6">1,016</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_hTfiUPeITkOyKSIPvFyK7Q_7_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="Tc_RjXd3eVhWEKmb18WNj0UeQ_7_6">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_sq42lPqjCEaCHba-NsEMAg_8_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_C8V7FYeC-Uub0gMB2X_MAw_8_6">102</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the maturities of the Company&#8217;s future minimum lease payments were as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_CTIwg1Yipk2Y3guACLPUFQ" escape="true"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_4tfBFwMukUeexMdsfiup5g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_yrZ-jVr1m0W8DeIblIbl2A_3_3">1,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_7bT3YxxR806RJ08tR-3iSQ_3_6">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_yS8N-9zYw0uyhtu6n1iY7Q_4_3">749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_EUJM-lNeEEig-CYiC6NWFg_5_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_hDk-sglwrECzS7cYIG_-Yg_6_3">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_KwSyrkoaxk6ZSDjm64xrsQ_7_3">2,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_U2DXgsLn5kaEaGu0bQAafA_7_6">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_aJKu84akFkym2GS-_pJ4rQ_8_3">173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_tHXeZ8C2akaxSBLYgFiuvg_8_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_7Upy1OlO_UGRnVuLnl2ulA_9_3">2,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_Ob4t4A76_0WkNwWADqKQgA_9_6">85</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e83e5af6_e32b_4c70_854e_ab77629316d7"></a><a id="Tc_B9SV1t9t-Ea6GZnrxVuRXw_1_2"></a><a id="Tc_1--I5vlXzkuvFpwzZAHckw_1_5"></a><a id="Tc_SbSXH4-YwUu2hwA5VLqk9g_1_8"></a><a id="Tc_s_z861O6QkCOfn_Iz4RPtg_2_2"></a><a id="Tc_Y1YMgDBc7UatbdFjcQFMkw_4_0"></a><a id="Tc_0zrVDTwYu0e-bORUZD6T8A_4_2"></a><a id="Tc_0_LWYce4_0ieU75wROtwOw_4_5"></a><a id="Tc_Y6WtXDHffUesxBHC89uBSg_4_8"></a><a id="Tc_M6QzqZMb80-lo6hDsARkZA_5_0"></a><a id="Tc_z2hTG6f9XEiIDwH6oGndkA_6_0"></a><a id="Tc_VkHz33a4WUaa_drHksl9DA_6_2"></a><a id="Tc_TaX06VD3YkicW6lO8XLNTg_6_3"></a><a id="Tc_UDJOq3gNgUuXZ5WgEEGrRg_6_5"></a><a id="Tc_be_1mCCumEOIixiV0nzgbw_6_6"></a><a id="Tc_34rRaXLjE0Sr5YPvjYsTUQ_6_8"></a><a id="Tc_5mDHlVyZ5EWlODc3Z1zl2Q_6_9"></a><a id="_4912a9ee_7356_458c_aabb_0a681d924598"></a><a id="Tc_PRelkpKBKkm7oPLD3-L2hw_1_2"></a><a id="Tc_o5k9ffDbQ0qMb_P7iYdfGw_2_14"></a><a id="Tc_hWIgm6KnWkSwR5oqLPVi4A_3_11"></a><a id="Tc_ghhU6oE450ubwgFUhHsMOQ_3_14"></a><a id="Tc_Aid0b7y0s0OleiJJUKR8OA_4_2"></a><a id="Tc_yMxJbjYWrEayr1TNoQGigA_4_5"></a><a id="Tc_hWFvGQ8q_EqO3ZWwC6VfEw_4_11"></a><a id="Tc_6x-Lm9O4J02ceIEwVsLk_g_4_14"></a><a id="Tc_aDVQ2jdu70KcOC11Fg7erQ_5_2"></a><a id="Tc_kLhOwwD9SUK0mZrHEHJnGw_5_5"></a><a id="Tc_v_XcDRXJKEmusJnZrRJBJQ_5_8"></a><a id="Tc_6KUxwh65REO8gWBRLBvVdg_5_11"></a><a id="Tc_1g17Q_Ti002qNX3iEpGKng_5_14"></a><a id="Tc_Ekh3aCwBU0usA3-zSTe5jg_6_2"></a><a id="Tc_6r8u9vPiF0K1hWynYYEugQ_7_0"></a><a id="Tc_x5XzmhzCL0Wq_OSBRZl5yQ_8_0"></a><a id="Tc_L39tz8cA7EW10CJ7w8PeXQ_8_2"></a><a id="Tc_umzeNJgGFUeqU7yjw3tHcg_8_5"></a><a id="Tc_np1ehXjnNkaC1SLrMqf4XQ_8_8"></a><a id="Tc_wiZhQG8RoEGgeGqDFFTZRQ_8_9"></a><a id="Tc_iQOO4L2Tukmy9M9T0b0lCQ_8_11"></a><a id="Tc_YwaR-0dXFkKxHCLcFmhsgg_9_0"></a><a id="Tc_1PfQY-4gqk2xHdPgJ2xFmw_9_9"></a><a id="Tc_BKVIUuLYtE6_QINvk3uHyg_10_0"></a><a id="Tc_Se4PsMRjyEam3qZiKtm47g_12_0"></a><a id="Tc_NlmD5oew9k6Cb28acaxrNw_13_0"></a><a id="Tc_TpLdobGcYUCJvzuqSyauJw_13_6"></a><a id="Tc_5QDb5m1NVkWWj214sVZ7jw_13_12"></a><a id="Tc_0L_x2JGC7kyP8yHf9mrspg_13_14"></a><a id="Tc_mO4WOu7mB0OIY-dVcaf-hA_14_6"></a><a id="Tc_8Cr0so_8WE-nt8C7xW09pg_14_12"></a><a id="Tc_YyKpRWRhqUuPgW64HfN06A_15_0"></a><a id="Tc_fCRC7t0suUefKnGSfWqzog_15_2"></a><a id="Tc_U2lxPSk3SkCwWxbTuFrtOA_15_5"></a><a id="Tc_nFXp8Wr6tUOMic2sw-SFQA_15_8"></a><a id="Tc_eOM03L_b7Um_2Hb1RwAcGg_15_11"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_T7ypsdbv6UeBIuIi5bBfAA" continuedAt="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Goodwill and Other Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-style:normal;font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:Goodwill" scale="3" id="Narr_5hsItURkcUC0EfQvDNBBbg"><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:Goodwill" scale="3" id="Narr_5YQa8Io5r0qqt5R8Jk7naA">no</ix:nonFraction></ix:nonFraction> goodwill carrying amounts in the consolidated balance sheets as of June 30, 2023 and 2022. The carrying amount of goodwill by reportable segment and changes during the year ended June 30, 2022 are as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfGoodwillTextBlock" id="Tb_tznAQ8bCvEy1mdfPX-Stbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rx Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consumer Health Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_17kGrCVmQEOjFdEV5C2_zQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_97_hvBR8RkqQe2EhmkQonA_4_3">57,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_DxeLmfrDLkiqMKsp5HRFVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_ivcxCvAu0kS4sj1ZYi-s1w_4_6">8,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_oQm-u0CZkE2Y4uZfw87ZCQ_4_9">65,802</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Tc_OcXr5qGPPEGu6SjbfYnECg_5_3">57,165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Tc_k5V2L5lMakm_T31POfIj3Q_5_6">8,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="Tc_zFiTVNwYbk2Nv5Hfq2AIlA_5_9">65,802</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">During the year ended June 30, 2022, the Company&#8217;s market capitalization significantly declined. The decline was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management&#8217;s evaluation indicated that the goodwill related to its reporting units in both the Rx and Consumer Health segments were potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. Using a risk adjusted weighted-average discount rate, the fair value of the reporting units was less than its carrying value. The Company recognized an impairment charge of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="Narr__uVUsTPe5UaYURJyoZ6ZCQ">57.2</ix:nonFraction></span><span style="background:#ffffff;">&#160;million in the Rx Segment, associated with the Cerecor and Neos acquisition and a </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="Narr_9vSQqo5sAUuy4BXONrNOKA">8.6</ix:nonFraction></span><span style="background:#ffffff;"> million impairment charge in the Consumer Health Segment related to the goodwill associated with the Innovus Acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tables below provide the summary of the Company&#8217;s intangible assets as of June 30, 2023 and June 30, 2022, respectively. Carrying amounts are net of any impairment charges from prior periods. Intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_d7o3ZyjumEimiuBY5m6XRw" continuedAt="Tb_d7o3ZyjumEimiuBY5m6XRw_cont1" escape="true"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="Tb_L5PfZQ9uQEiWLUg67l8_tg" continuedAt="Tb_L5PfZQ9uQEiWLUg67l8_tg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_FXVb9lwuDE-GnLe2hO70Xw_8_3">42,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_mC_kW24p-065BPc2__Rp0A_8_6">10,881</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_cRjqtxmfu0m5PWYy5HNBvQ_8_12">31,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_fwYbk0T1rkuVqkxgYwDegA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc__zYUKfuDuEKVxJprb4TE8A_8_14"> 11.49</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_48U5t-o8S0KsS01brkLXnA_9_3">30,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_WzPdZtkOHUOA4aw5wAv3iA_9_6">4,054</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_VLTwnbnLn0-LPMgSv0CDkg_9_12">26,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_JXn5-Xzq2kiOE7uPypp10Q" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_nffGe_yCok2Ws78zpapGAQ_9_14"> 14.75</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_7tUsCzeFgE6W0jV69_QGTg_10_3">9,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_kiQGx8yvLEy11kyF90Mr4g_10_6">4,678</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_sDz9Aoyu6kqXnj94ny3LLw_10_9">2,975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_Xz8OAcIP9kKZI0u_SZsP5g_10_12">1,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_Sbisw7Ka2U-eJeK-plm2KA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_9VWOJ3OpDUWjx8wj4FURIQ_10_14"> 1.00</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_M9_7-bGnBUuSZYPmN1f68Q_11_3">81,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_04yQ6AaZZECQgMNwRnXfEA_11_6">19,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_j58iyTnL20WE8aq8rzm-jA_11_9">2,975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_FKj-TPAHDEOtJSIt0A0emQ_11_12">58,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_AXxCxwbeEke0JvoM4O2DCA_11_14"> 12.67</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_RxaRw3eo9EqdOu9idOlFNQ_13_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" scale="3" id="Tc_5VbDQ_-V_ke__ZAHFuuAbQ_13_9">2,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc__pai3Jnm20OBCcHNvulH1Q_14_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" scale="3" id="Tc_3REJajl-60WJb8vcjryaEQ_14_9">2,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_jlYtKFQIF02q_s1KSgpT2w_15_3">84,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_hJEHWpqxZUSUszoGFzEh1w_15_6">19,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" scale="3" id="Tc_0o4pzEp6kE68zSB-5axSSg_15_9">5,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_X7XI21yoEE6d3raobJOz2g_15_12">58,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_uEv_zrha9UO0Phtyr5BwNQ_15_14"> 12.67</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8a2208c0_829c_47ac_82a5_a5b152ac3d2e"></a><a id="Tc_h7KjFC_7t0iQ2_B451UI9w_1_2"></a><a id="Tc_MdFsNL64WEGkB_0C-pmVdg_2_14"></a><a id="Tc_WIBJe-E44USlWGVCFkmoNQ_3_14"></a><a id="Tc_u7KLwJo8X0ma9Wsctg5HzQ_4_2"></a><a id="Tc_1vSaGuzQh0WZ22XZLR2fkQ_4_5"></a><a id="Tc_lKUL_ZhnikWGkjGAGkpWRg_4_12"></a><a id="Tc_0tGa3FKun0qU-OYIxaR40g_4_14"></a><a id="Tc_LGXDBPHO-Ey6LHKBQwu8dQ_5_2"></a><a id="Tc_2g_mhjSDyUO7abAHsbUDXA_5_5"></a><a id="Tc_9RL4WHFZwUK3WBkQH6kZKA_5_8"></a><a id="Tc_HWvvm3DmfkiOf9oHwcBEQA_5_11"></a><a id="Tc_4rgpp-dSG0eHemr9mU-EiQ_5_14"></a><a id="Tc_BzcpuNKfz0Kqz6QxlqADvw_6_2"></a><a id="Tc_TnP8kno6I06xvMZt4rs8Bg_7_0"></a><a id="Tc_mGCcPQvrwEa3qocAiDg5Rg_8_0"></a><a id="Tc_45UssLVSakOkp3i7osNfTw_9_0"></a><a id="Tc_QBeAn5HPtkyaX4gVKyrN2g_9_9"></a><a id="Tc_sAMPq_ad0kWZBoHfumPqrw_10_0"></a><a id="Tc_QkWetRU_g0uzIDAN1emuVQ_11_0"></a><a id="Tc_tBgRq6O-v061BNEOD-EWig_11_12"></a><a id="Tc_FWxBky4wUUy5gkSHjcXmeg_11_14"></a><a id="Tc_o_1W3cpiIE2jMjFZOA_m7A_13_0"></a><a id="Tc_3R_cCbgYD0yZe236ibPm9g_14_0"></a><a id="Tc_2h5shPNnik2cHnF9am8pug_14_6"></a><a id="Tc_PYV-wpHAZUWN-6sa5uTOUw_14_9"></a><a id="Tc_ORzfHTJURk6_40UbklfpYA_14_14"></a><a id="Tc_ixZ5qaVxfk-2QO2UHr8eyg_15_6"></a><a id="Tc_Gnb3Yg02GE2ESI5ha0dVug_15_9"></a><a id="Tc_vF8m8pH89kK6bJ5lttnZqg_16_0"></a><a id="Tc_rwcBYLb1_06V3aeOOiIlGw_16_2"></a><a id="Tc_xeUik1EQ8EewY5SYFjMtBg_16_5"></a><a id="Tc_m8GHheJIY0SX296tbsE_5Q_16_8"></a><a id="Tc_a_zOs8EM8ECCQ1rxZQGVwg_16_11"></a><a id="_3b0cc766_485d_4bef_857c_41d0d31e7d89"></a><a id="Tc_QKsD-A7tpkKzedDzKr9BVA_1_2"></a><a id="Tc_KzEvgWSdvU6mkmVyRnk3HA_2_2"></a><a id="Tc_jXHam5Jfa0qOzR5xtFH6gQ_3_0"></a><a id="Tc_Ve0UrseD9k2LSx8hcuwS4A_3_2"></a><a id="Tc_qtZOTEhPh0WNtMy6VSgAmA_4_0"></a><a id="Tc_R_9oBK-mPEKvTqeShLhP2g_5_0"></a><a id="Tc_1JbgCOZoKUiDDRlaaAntLQ_6_0"></a><a id="Tc_opjDeWH1JEG-Omtt4MqMkg_7_0"></a><a id="Tc_IGU7ERTjBkKoL4hv4IR-Hg_8_0"></a><a id="Tc__6p87ym8fU6VSs_o-XCcKw_9_0"></a><a id="Tc_MYldHVebtEaK80Hft70m5w_9_2"></a><ix:continuation id="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont1" continuedAt="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont2"><ix:continuation id="Tb_d7o3ZyjumEimiuBY5m6XRw_cont1"><ix:continuation id="Tb_L5PfZQ9uQEiWLUg67l8_tg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_0mQ62Ku7GkChUywATDd85A_8_3">45,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_LFaoP2g7sEq1XO15aBGtRQ_8_6">7,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_b5C7V03tvkuEok1vQ-yBQw_8_9">3,224</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_RFTprqVpUU2cTKHaD5Y3gQ_8_12">34,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_kEPlwQ3Z5EajARrt_81BZw" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_2aW9MnwVpUW4t0MCvqMVSA_8_14"> 12.33</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_tT3JSxsDr0WVozFgmtxn7g_9_3">30,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_bJcrknao00eAo9M996ew9w_9_6">2,278</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_H4j2oJjeU0KQikfzajtDjA_9_12">27,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_96lPa_UH3EC_sxZ01SDNgw" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_z4R9yHEviUWs-dsuLZ7Zrg_9_14"> 15.75</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_H7H8FUyzIEyuVQF_9QqteQ_10_3">11,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_OMhj2enZAkGPd2HZIsiW9A_10_6">3,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_MRxjDv585ke9EjF1iPpr1A_10_9">2,172</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_7q4AmmzdPU-5EIILbHbiqA_10_12">5,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_pvg1LRUhb0W16a7tuQUDyA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_K50XtBmGX02UwPEpQjI8Xg_10_14"> 7.60</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_bcsK_VLFCUmzl1ix5KzE7g_11_3">4,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_OBmD7LxAr0Kf8TSSDCg5gw_11_6">3,004</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_KFkKUlm2RE6258lD-Bp9hQ_11_9">1,662</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_ZlRx7UIK-0GlWJ5W2vtBQw_12_3">91,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_EyAmMn9g80COz0CcC-r94w_12_6">16,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment" scale="3" id="Tc_qdaMjoim3UeRJUcGvnYxLg_12_9">7,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_R1eq8D6UBkW7jeh4kzSQLg_12_12">68,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_84ZwRSzXakqgcnasQnALRw_12_14"> 13.35</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_uSw_GyGe6UmQAUT2jvF6mg_14_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_1b4k0Sgm5U-KJt0cL8yJbg_14_12">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_TIKgaew6BUu-pCQt_ETP8w_15_3">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_FRmpk2NC80S-s9NAAAX90g_15_12">2,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_8kya9YJUp0Gt3xnSitiDGg_16_3">94,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_EnU5a59CTEiELzPmDIjpJQ_16_6">16,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" scale="3" id="Tc_A2reA1_LQ06cToz4CV5HXQ_16_9">7,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_SXyjP7DJr0yl6ck5d5WtHA_16_12">70,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Tc_2OxvXI6ot0moH3h0qoVizA_16_14"> 13.35</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated future amortization expense to be recognized over the next&#160;five years and periods thereafter:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_LNnYlDApI0aJcecWM2MUGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_HUCOW20tF0eE7ClK4kn4KA_3_3">6,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_VVpDYNDbOUearS4bExg85A_4_3">4,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_y2HXNQbilE-H-qS7PwkgOg_5_3">4,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_rkIW8PzQI0qUQASipWZZYA_6_3">4,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_3VrJV4N81Ey3RvobUR4oNw_7_3">4,989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="Tc_wgScfDfAMUinAGEaYFHkEg_8_3">32,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_l7BySZssSkWq6eCNKN_m8g_9_3">58,970</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Product Technology Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquired Product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Karbinal&#174; ER. </i>The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris for the exclusive rights to commercialize Karbinal&#174; ER in the United States (the &#8220;Tris Karbinal Agreement&#8221;). The Tris Karbinal Agreement&#8217;s initial term terminates in August&#160;of 2033, with an optional initial <span style="-sec-ix-hidden:Hidden_jJl8Ok9bXUO0qTue9ytzzw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20-year</span></span> extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Poly-Vi-Flor&#160;and Tri-Vi-Flor.</i> The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the &#8220;Poly-Tri Agreements&#8221;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ADHD Portfolio.</i> As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is <ix:nonNumeric contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_F_kE5Lxwtky7YSEDVzN1hA" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_-PCsno29MEejOrsc1lBH7g">17 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Technology Right</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">TRRP Technology.</i> As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (&#8220;TRRP&#8221;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont2" continuedAt="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology underlines each of Neos&#8217; core products and can potentially be used in future product development initiatives as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Product Distribution Rights (and customer list)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Innovus Acquisition, the Company obtained <ix:nonFraction unitRef="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w" contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw" decimals="INF" format="ixt:numdotdecimal" name="aytu:NumberOfProductsAcquired" scale="0" id="Narr_6J0Y0BQ0yUOdR-pPXZRZhA">35</ix:nonFraction> products with a combination of over <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw" decimals="INF" format="ixt:numdotdecimal" name="aytu:NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" scale="0" id="Narr_k78-1D_kK0WeaTsMlATLuQ">300</ix:nonFraction> registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. During the fiscal year ended June 30, 2023, this intangible asset was impaired by $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_4Zx8g9aLAU6WMV8l0JF04A">3.0</ix:nonFraction> million due to the discontinuance of products in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired In-Process R&amp;D</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IPR&amp;D &#8211; NT0502.</i> As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&amp;D will begin amortizing on a straight-line over the life of the product. During the fiscal year ended June 30, 2023, the Company fully impaired the IPR&amp;D of NT0502 due to the termination of its development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Other </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other intangible assets consist of customer lists, trade names and other technology and licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA" format="ixt-sec:duryear" name="aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" id="Narr__YSEQWq-PEy9Z_yj-i2Jrw">1</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_UOFSRPaFi0u7A5wpcioV4g" format="ixt-sec:durwordsen" name="aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" id="Narr_P0H4qBF8TUOFzSAXvPvEjQ">20 years</ix:nonNumeric> depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDeferredCharges" scale="6" id="Narr_XykXM9XXnEazU_Lj1k8tHw">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDeferredCharges" scale="6" id="Narr_DzCjWlESK02tb5BAMk0IrA">7.8</ix:nonFraction> million during the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, the Company incurred an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_NeosTherapeuticsIncMember_jE3g0rsLqEWv2jo6veaozw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_uV9A2nLLZk2ZjT0aeUs9ow">2.6</ix:nonFraction> million related to NT0502 and terminated the licensing agreement. The Company also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_piFzsqROiUGHM_CWbra-mQ">3.0</ix:nonFraction> million due to discontinuance of products in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the Rx Segment that have minimal revenue and gross margin contribution, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_Y6CIcUFk30OrmB28acZ6xw">4.9</ix:nonFraction> million <span style="-sec-ix-hidden:Hidden_Ed_wMja5SES4fIWHM8Ndsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment</span></span> expense for the write-down of intangible assets consisting of (i) $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AciphexMember_qGDcQ6lLy0ulHTbXHsPakA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_s72sdyA1dUirQQRxxLtMpw">2.6</ix:nonFraction> million for AcipHex, (ii) $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_ZolpiMistMember_dJH0ndjeUEaT4pdit6AumQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_qk5iPZKxdUO4tCWS9Gs76g">1.4</ix:nonFraction> million for ZolpiMist, (iii) $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_TussionexMember_zVcKQ1_g1UWXhUn0779uOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_XST4vpwgFUSHghz3vgbFNQ">0.5</ix:nonFraction> million for Tussionex, (iv) $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_CefaclorMember_mhqlF9Qs0UWCJpWeLPVIJw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_roKihFkX506kW8UVN_GyOQ">0.2</ix:nonFraction> million for Cefaclor and (v) $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_ThMW95wZjkCdP_ru56uSmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_9O5AIIBwNEmjtkOrIVRbMQ">0.2</ix:nonFraction> million for the Neos tradename. Additionally, the Company&#8217;s Consumer Health Segment recorded an impairment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr__6MK8NcMO0eQlmaCvxs_MQ">2.2</ix:nonFraction> million related to products no longer being marketed and products that have been underperforming.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_T7ypsdbv6UeBIuIi5bBfAA_cont3"></ix:continuation><a id="_6b37e2d3_43d7_46ba_8806_a5ff96e44733"></a><a id="Tc_L88a6paty0eNpl595bC46Q_1_2"></a><a id="Tc_DIMxhBv7BE-H4UGyiVpgJw_1_5"></a><a id="Tc_QLZG1qudaU6S9nmEVw7TCg_2_2"></a><a id="Tc_ha77ibHzR0iKbcVze6DrVA_2_5"></a><a id="Tc_P1MMMTY_UEqmB3pQkAfrMg_3_2"></a><a id="Tc_HQ_1HOyaSEuBTZCmS3sweQ_5_0"></a><a id="Tc_-IQY3ohC_UO0qkgQZdYAkA_5_2"></a><a id="Tc_h2WjHtOpukeEcAhJruYlmQ_5_5"></a><a id="Tc_IIztm3Zke062hGmKo6t9ag_6_0"></a><a id="Tc_7P4WH5tSFEOSnOh_o2UgeQ_7_0"></a><a id="Tc_Z2gvtIGKnkO6x9974sEAmA_8_0"></a><a id="Tc_KSedz6vAX0yeYvhsbHYtqA_9_0"></a><a id="Tc_CavuSwCrOEKRQnWqtp4pMg_10_0"></a><a id="Tc_m9LvLEWa5keYI-syOWrXQQ_11_0"></a><a id="Tc_r1TqsKq8DkGrvWxAG6K0hA_11_2"></a><a id="Tc_soEpYv0kH0GlGIoAGkejJA_11_5"></a><a id="_dbd8f7e6_1fd6_4b50_aa4b_3789a57b3ec8"></a><a id="Tc_VUMDi-fRvUm6MSLCvVbHNg_1_3"></a><a id="Tc_u9PsHbblMU-sjQ0lY5qrQQ_2_3"></a><a id="Tc_6fr7NJIDd0W7Ctk9_8QR1w_4_0"></a><a id="Tc_UKQQ4gr1j0CpeOqcjl3-aQ_4_2"></a><a id="Tc_um91M4Ybk0ONisgqY3fNKQ_5_0"></a><a id="Tc_d5WXv5Cw906UQByyXcnkSQ_6_0"></a><a id="Tc_VriFBWhUf0ehUiHj5gjusg_7_0"></a><a id="Tc_8YFLC-q9zUCw7OmEy3MzIg_7_2"></a><a id="Tc_gSgHAhfC60KORtHXvYXSSA_8_0"></a><a id="Tc_DrpNQ867TEKWzS9wsKrWDA_9_0"></a><a id="Tc_O2ipkMxETkieBKuoli3s-g_10_0"></a><a id="Tc_VI7rB8kHGku_Lw4NCoA7_g_10_2"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_Jw2VE9-mZEeFwBZHyFHOYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Accrued liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_4q8h_ziWZE6KlmZnvxo9uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued savings offers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedSavingOffers" scale="3" id="Tc_Biv37Sg8l0OX2HQ8NiuPyg_5_3">15,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedSavingOffers" scale="3" id="Tc_4ChCNSeO2kir23lisjhviA_5_6">12,711</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued program liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedProgramRelatedLiabilities" scale="3" id="Tc_tO2DlVMi4EOY7dNd5ln8jw_6_3">11,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedProgramRelatedLiabilities" scale="3" id="Tc_0coiT-GeWku93xglb-1UmA_6_6">9,468</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_0trivw-JcEWex_Dbskma8Q_7_3">5,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_3TFJzt1DQUWUXChExVfTBA_7_6">4,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued customer and product related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedCustomerAndProductRelatedFeesCurrent" scale="3" id="Tc_gNe1CQJq2EqwwFAOmfk17g_8_3">6,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:AccruedCustomerAndProductRelatedFeesCurrent" scale="3" id="Tc_LgAn9cHKBUiZodsux8hZaA_8_6">7,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserveCurrent" scale="3" id="Tc_eSP5DYHhe0Cb1l3ThrJoJQ_9_3">5,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserveCurrent" scale="3" id="Tc_7FHhc6VYGkCtlcFx1I4boA_9_6">5,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_ITDjx6h8ukOqE9tg9lK9cg_10_3">2,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_9U0LNLF-N0eHcncmudTsyA_10_6">3,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_qGAzwgVKsker1Yx0AvYHsw_11_3">46,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_4zLSW3CCk0aUSSkkyNCDfw_11_6">44,187</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table details the change in return reserve for the periods presented:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:ScheduleOfReturnReserveTableTextBlock" id="Tb_0LTX1jleq0KOlv8oyAJ6jg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Return Reserve</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserve" scale="3" id="Tc_vdv0d_sxlEOkmnlbK-GT7Q_4_3">6,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserveChargesToExpense" scale="3" id="Tc_OuINFg4oNE6ctnfGtNNbKQ_5_3">8,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReservePayments" scale="3" id="Tc_KAGjWjEGVE2sWEEu7aZNaA_6_3">9,165</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserve" scale="3" id="Tc_YXeNpUrJz0CIXu-cP7Sksw_7_3">5,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserveChargesToExpense" scale="3" id="Tc_e_gxnzpJzUOspW8iOBAW2A_8_3">8,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReservePayments" scale="3" id="Tc_x5UGaLHjRkCJrlZfxz7KNQ_9_3">8,346</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:ReturnReserve" scale="3" id="Tc_RffxJBfUWEqng_q37GmTBA_10_3">5,777</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers represent programs for the Company&#8217;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Program liabilities include government and commercial rebates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Other accrued liabilities consist of accrued license fees, professional fees, credit card liabilities, taxes payable, legal settlements, and samples expense, none of which individually represent greater than five&#160;percent<span style="font-size:12pt;">.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_OT7zI7d9LEWrimJmmC7OYg_1_2"></a><a id="Tc_u_2uWV1_jUySFCw_lWh-9w_1_5"></a><a id="Tc_4xCIlqrTzkGatHQlAjc4Zg_2_2"></a><a id="Tc_kbbRBxEwfkyUIqpTCjYXgg_2_5"></a><a id="Tc_8sgBv3DQiEmie_Uk2E_uVQ_3_2"></a><a id="Tc_rsB6aTQx5Uage6NjjGug1g_5_0"></a><a id="Tc_Fjjtwo9kN0qSjrOkQfm77Q_5_2"></a><a id="Tc_gAx3i3gvI0W4pE33zo3ymw_5_5"></a><a id="Tc_hqknRoAX3kaukTbgmmrDXg_6_0"></a><a id="Tc_xiArL7DWXkWkGS_tX_wcHg_7_0"></a><a id="Tc_n10LsrMNekKHmQzTsYp9FQ_7_3"></a><a id="Tc_GNa1FyvCa0icb16IS9s_YA_8_0"></a><a id="Tc_qAR4qyis1EqOfX77O2AauQ_8_3"></a><a id="Tc_IJb8TapdJk6MiIHMjgcYbA_9_0"></a><a id="Tc_TGmNjqHmAku_jXdQ-iyk0A_10_0"></a><a id="Tc_AW-pU_ddHEOHjAKZspqGyg_11_0"></a><a id="Tc_4V4XQOzQSkC0eFqIhp6u6A_12_0"></a><a id="Tc_hk0lJdwuBkyJzfoeNoiFuw_12_2"></a><a id="Tc_7cFXeCSjjE-u5xfbmmA4Aw_12_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="Tb_Hw6whEvvyEGtV9CUMVTETQ" continuedAt="Tb_Hw6whEvvyEGtV9CUMVTETQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Other Liabilities</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:OtherLiabilitiesTableTextBlock" id="Tb_j8nub6fNxU6KDJZTtS6FxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed payment arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="3" id="Tc_QKeHN_9bpkeikgBvC5LNJw_5_3">10,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="3" id="Tc_YMYPpkGDo0C1smJjVftIBA_5_6">13,051</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_l1uctFXRvUqSv8lqMU5YLg_6_3">2,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_L9sHK35yRkiij_l2tEmROg_6_6">3,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent value rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsLiabilitiesFairValueDisclosure" scale="3" id="Tc_05q3Pcl9PEKTsaR8a-2euA_7_6">578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" scale="3" id="Tc_SFAoMfecD0SdWuyYAcsPyQ_8_6">396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSundryLiabilities" scale="3" id="Tc_sMS5siaEaEyrWIeH9JkWDQ_9_3">1,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherSundryLiabilities" scale="3" id="Tc_m57yABtW9UG5rl5RuonKIg_9_6">815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_g8qmDnit5EiciwUPFraHHA_10_3">14,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="Tc_173iIK_TQ0yHID2OBsExow_10_6">18,157</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_6ww-8TS9tEelBHXXSJdWAA_11_3">7,090</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_Hj7Dc7COWUCxbJG2eiru_A_11_6">5,359</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_iOhEQ_hxZEugs8N3XJsCtg_12_3">6,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_p1XwGZmoMEuU_JVq4jxE8g_12_6">12,798</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fixed payment arrangements.</span> Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyPaymentAmount" scale="6" id="Narr_MTy9cSL0XkqnjQdA53nujw">0.1</ix:nonFraction> million from November 2019 through January 2021 plus $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" id="Narr_HlVob6xEQESpZcqkMW6keA">15.0</ix:nonFraction> million due in January 2021, of which $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid" scale="6" id="Narr_EQjRe7dJvkqFjItzy0TqOg">15.0</ix:nonFraction> million was paid down early in March 2020. Monthly variable payments due to the same investor are equal to <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q" decimals="3" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" scale="-2" id="Narr_I8fe6myAC0er2OWOVfkLJQ">15.0</ix:nonFraction>% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" scale="6" id="Narr_1685SqeCz0CkshOmbNmcOw">0.1</ix:nonFraction> million, except for January 2021, when a one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_vUpSuynmCUCGZ3WZlbjUuw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" scale="6" id="Narr_kTHG6dSySEaBNsEmhy4_6Q">0.2</ix:nonFraction> million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" scale="6" id="Narr_WVkgmO-MqkmPkZnEIuUQjg">9.3</ix:nonFraction> million have been made or (ii) February 12, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsPaymentAmountPaid" scale="6" id="Narr_CR4MjCyZjE6dgHUZRpD5Uw">2.8</ix:nonFraction> million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_TUB46cHwhUqOn7l4VzYczA">3.0</ix:nonFraction> million in <ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" scale="0" id="Narr_VcqmJ1BnWUShZvGqW70hwQ">six</ix:nonFraction> equal quarterly payments of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmount" scale="6" id="Narr_0yC0h5_f4EmbXrUIM0mpEw">0.5</ix:nonFraction> million each over <ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" scale="0" id="Narr_oLDIhGOwgEatEjMlpPVPkg">six</ix:nonFraction> quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg" format="ixt-sec:durwordsen" name="aytu:SupplyAndDistributionAgreementTerm" id="Narr_MX637d94yUO5S69r8JN3bw">20 years</ix:nonNumeric>. The Company will pay Tris a royalty equal to <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="3" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" scale="-2" id="Narr_SifhmLT3fkaNq5kGOqDVbg">23.5</ix:nonFraction>% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="INF" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" scale="0" id="Narr_gUXFDG0Y_kOPSXU_1JdxZA">70,000</ix:nonFraction> units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="0" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" scale="0" id="Narr_w6AtlU2HXkif_9Q-eT8rPw">30</ix:nonFraction> for each unit under the <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="INF" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" scale="0" id="Narr_ixHqboZfnE-0FNeTZVus0A">70,000</ix:nonFraction>-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" scale="6" id="Narr_sMsiohkqXkKN5YnzeEWk5A">2.1</ix:nonFraction> million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" scale="6" id="Narr_eMZxPNAhQEm_l_mBAvbcTg">3.0</ix:nonFraction> million based on cumulative net sales, the first of which is triggered at $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" scale="6" id="Narr_rEjupwffm0KYJZHcK1a4Yw">40.0</ix:nonFraction> million of net revenues. As of June 30, 2023, the fixed payment arrangement balance was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsCurrent" scale="6" id="Narr_Kvm8iG7Ac0mSlwiQHVUQtw">1.7</ix:nonFraction> million in other current liabilities and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsNoncurrent" scale="6" id="Narr_eXv80IgScES4DIz2_ugIvg">2.1</ix:nonFraction> million in other non-current liabilities on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the &#8220;License Agreement&#8221;). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_5_12_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_jDvZD8q0Y0el44FFCfCVRA" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_iOT0uEUP6kSdJ3zkbCfoTw">6.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_5_12_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_2wCCGQMMCUmH4iUajN7RIg" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_L0ydbeVGVEWF5MhE-NgWkQ">9.0</ix:nonFraction>&#160;million, which reduced our total liability for minimum payments by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_7wtjA0AipUW_t_5VDehRxw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsLiabilityReduction" scale="6" id="Narr_jDM7vFCSrEuwQ0IltZxUBQ">8.0</ix:nonFraction>&#160;million from the original License Agreement. The settlement payment will be paid in&#160;<ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_psb5HJRJGUmm-pY27HkHJg" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsInstallmentPaymentsNumber" scale="0" id="Narr_wkLlF7NoeUW5MV5blIUbMg">three</ix:nonFraction>&#160;installments from December 2022 through July 2024. As of June 30, 2023, the balance was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_5qxxQfplJUCrdZsaKXc-bA" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_0avsFGgvu0yyH8XCtjD3JQ">6.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingent value rights.</span> Contingent value rights (&#8220;CVRs&#8221;) represent contingent consideration related to the Company&#8217;s 2020 acquisition of Innovus of up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" scale="6" id="Narr_2fxOL0AfrUKPptf7ySeCmg">16.0</ix:nonFraction> million payable upon attainment of future performance milestones. Consideration can be satisfied in up to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg" decimals="INF" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" scale="0" id="Narr_MtYVsD5620KUjrm-2Klw-g">470,000</ix:nonFraction> shares of the Company&#8217;s common stock, or cash either upon the option of the Company or in the event there are insufficient shares available to satisfy such obligations. In the fiscal years ended June 30, 2020 and 2021, the Company issued to the CVR holders <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2019_To_6_30_2020_uXBqmTqkjkG4C-vVf43Sxg" decimals="INF" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts" scale="0" id="Narr_3tSpedh7nE6RjgyFZbPFwQ">6,191</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ" decimals="INF" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts" scale="0" id="Narr_RNyfuMqqKESVjeTrCMwlww">5,160</ix:nonFraction> shares of common stock, respectively, upon achievement of specified revenues. No milestones were met during the fiscal years ended June 30, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Hw6whEvvyEGtV9CUMVTETQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2022 and 2023. As of June 30, 2023, up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" scale="6" id="Narr_AXRWFkYwyEGA-bCJwQw7dg">5.0</ix:nonFraction> million of future milestone payments potentially remain. During the years ended June 30, 2023 and 2022, the Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_O9FJOcTGtUCFRN7aqVKAng">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_CW0akrgCqUWARSJ487H4nw">0.8</ix:nonFraction> million, respectively, in the consolidated statements of operations related to the changes in fair values of CVRs. As of June 30, 2023 and 2022, the CVRs balance was <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt-sec:numwordsen" name="aytu:ContingentValueRightsLiabilitiesFairValueDisclosure" scale="6" id="Narr_ABpQCDBdFEODwj7-dIUxjQ">zero</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsLiabilitiesFairValueDisclosure" scale="6" id="Narr_R0n27RIIRUe953QjlZxBtQ">0.6</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span><i style="font-style:italic;">. </i>Contingent consideration represents the fair value of potential future payments in connection with acquisitions that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Subsequent changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s 2020 acquisition of Innovus, the Company recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" scale="6" id="Narr_6HH18D7bH0m1QRVefKO8fw">0.2</ix:nonFraction> million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ" decimals="INF" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" scale="-2" id="Narr_3jhy3_Glp0OvJzgcB-uz6w">30</ix:nonFraction>% discount rate based on the estimated risk that the milestones are achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the Company&#8217;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR<i style="font-style:italic;">. </i>The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#8220;Tris&#8221;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#8211; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" scale="6" id="Narr_tah0LLOT3kGuzpi61kgaGg">8.5</ix:nonFraction> million and recorded a liability of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" scale="6" id="Narr_jJRftOTkg0qD4nV79RfSqw">7.6</ix:nonFraction> million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#8217;s estimated borrowing rate. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_H2jGxblBRUSs4BAxMIxEww">0.9</ix:nonFraction> million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (&#8220;Magna&#8221;) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. In 2022, the Company reversed the remaining contingent consideration liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" scale="6" id="Narr_dJgZSbir-0moIGmerpieoQ">0.6</ix:nonFraction> million and recorded the $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_y5gGC1vDBUWYv1EcPoN6Uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Narr_qGObHRKSWk2VA8eCYSR64Q">50,000</ix:nonFraction> payment due for termination of the Manga licensing agreements in other current liabilities. The Company recognized a $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_fhwSnyYIMEKV_FKQLBR8Dw">0.6</ix:nonFraction> million gain from termination of the contingent consideration liability in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023 and 2022, the Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_fHMhOQDwRU-bk-ZP3DQ6rw">0.4</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" sign="-" scale="6" id="Narr_4QgcIsXp_0exEFNOvwaRAw">0.5</ix:nonFraction> million, respectively, from the changes in fair values of contingent considerations. As of June 30, 2023 and 2022, the contingent consideration balance was <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_hKAJRc3i4kWCN2bSYhyINA">zero</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_yI-1XKuvXkeQyeP1R0YopQ">0.4</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other.</span><i style="font-style:italic;"> </i>Consist of taxes payable and deferred cost related to our technology transfer.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ShortTermDebtTextBlock" id="Tb_DAnpWFqktUqu91B5A6lW_w" continuedAt="Tb_DAnpWFqktUqu91B5A6lW_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Line of Credit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (&#8220;Eclipse&#8221;) as agent for the lenders (the &#8220;Eclipse Loan Agreement&#8221;).&#160;Under the Eclipse Loan Agreement, Eclipse extended up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_-jJh6sgANEmLwmE9hfXLcQ">25.0</ix:nonFraction> million in secured revolving loans to Neos (the &#8220;Revolving Loans&#8221;), of which up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_IJocGHKCpkuqS12GITQfww">2.5</ix:nonFraction> million was available for short-term swingline loans, against <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg" decimals="INF" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" scale="-2" id="Narr_8mvTlATNJ0u1ufkSedhS9w">85</ix:nonFraction>% of eligible accounts receivable. The Revolving Loans thereunder accrued variable interest through maturity at the one-month Secure Overnight Financing Rate (&#8220;SOFR), plus <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_2DKLxDqdr06N0vvvIHYuxg">4.50</ix:nonFraction>%. The Eclipse Loan Agreement included an unused line fee of <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_Y4i8_JEJe0SvA0HJFtx-NQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="Narr_Ham05tgxf0-zIV98-cxCVg">0.50</ix:nonFraction>% of the average unused portion of the maximum revolving facility amount during the immediately preceding&#160;month. Interest is payable&#160;monthly in arrears. The original maturity date under the Eclipse Loan Agreement was <ix:nonNumeric contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_8J7zG4q4M0ytdoTSmIHoQQ">May 11, 2022</ix:nonNumeric>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DAnpWFqktUqu91B5A6lW_w_cont1" continuedAt="Tb_DAnpWFqktUqu91B5A6lW_w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Avenue Capital Agreement, described in Note 12 &#8211; Long Term Debt, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the &#8220;Eclipse Second Amendment&#8221;). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_M0-TXPTse0mGHnAuhWTPYA" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr__uEIVawkL0eQQodqQGUtvg">January 26, 2025</ix:nonNumeric>, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_enrhqtQMQk6XlM85KBb4mA">25.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_pxYhKHjl70qXmxSE8_eKVA">12.5</ix:nonFraction> million minus a $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag" decimals="-5" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" scale="6" id="Narr_oUszNLhUPkqOfcM0Zn2IvQ">3.5</ix:nonFraction> million availability block, (vii) increased the availability block from $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw" decimals="-5" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" scale="6" id="Narr_gOaSACDOukuzaK0qfBDaOw">1.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag" decimals="-5" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" scale="6" id="Narr_MnNVkJPo2kGwfrkzoGnaag">3.5</ix:nonFraction> million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNoncurrentGross" scale="6" id="Narr_tj4989TZd0WDShqcAipcGw">0.1</ix:nonFraction> million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNoncurrentGross" scale="6" id="Narr_GgoRb8DC2EmAe3IW2v_l_Q">0.1</ix:nonFraction> million as of June 30, 2022 was included in other noncurrent assets in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the Eclipse Amendment&#8221;) to the Loan and Security Agreement dated October 2, 2019 (as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, and the Eclipse Amendment (the &#8220;Eclipse Agreement&#8221;). The Eclipse Amendment, among other things, provided for an aggregate increase of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_O8YhH2nEYUOb-JVw1s0Yfg" decimals="-5" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" scale="6" id="Narr_WdAf5ichIU6CgNjGkkf0Mg">2.0</ix:nonFraction> million to the Eclipse Lender&#8217;s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_gcPJdm_wtE65EZK74cL6oQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_feDoOV7RwU-EZpzW7QpAAQ">14.5</ix:nonFraction> million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="3" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" scale="-2" id="Narr_I9tdPQZocEi2wZu5-2YTWA">2.0</ix:nonFraction>% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="3" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" scale="-2" id="Narr__Ouvr-8HCkKH68MwRVzAZw">1.0</ix:nonFraction>% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="3" format="ixt:numdotdecimal" name="aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" scale="-2" id="Narr_fewN9fuvwkyILHERn36lmw">0.5</ix:nonFraction>% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least <ix:nonFraction unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="INF" format="ixt-sec:numwordsen" name="aytu:DebtInstrumentTerminationBusinessDaysNoticePeriod" scale="0" id="Narr_4Pzg_-0zkkCsuSOPgWIADA">five</ix:nonFraction> business&#160;days prior notice to Eclipse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The&#160;Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#8217;s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company&#8217;s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Total interest expense on the Revolving Loans, including amortization of deferred financing costs, were $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_8Yuqe19JIk2B29trNymR7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_OY7D6fi6nE6HYRZCBwkOUw">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_db-vGfL3fUmxvIexRiVKVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_jay4gFNX90CiOBtSNW6sIA">0.4</ix:nonFraction> million&#160;for the years ended June 30, 2023 and 2022. As of June 30, 2023 and 2022, the outstanding Revolving </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DAnpWFqktUqu91B5A6lW_w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loans under the Eclipse Loan Agreement, as amended, were $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="Narr_JCx9TRwkEEqbvlntn95f1A">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="Narr_2BZvtR0jR0-5Ahej9Jxq9w">3.8</ix:nonFraction> million, respectively. Unused line of credit amount as of June 30, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="Narr_-rx869EdSUO_iRP0Us4RHQ">9.3</ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:LongTermDebtTextBlock" id="Tb_K-2nfJoreEm7CCdJ211PQA" continuedAt="Tb_K-2nfJoreEm7CCdJ211PQA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Long-term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deerfield Debt.</span> Upon closing of the Neos Acquisition, the Company assumed a senior secured term credit facility (the &#8220;Deerfield Facility&#8221;) with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P. (collectively, &#8220;Deerfield&#8221;) with an outstanding balance of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_DG1iuhq1pkyYKkGSV8ylFQ">16.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated and determined&#160;that the&#160;fair value of the remaining outstanding debt was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="Narr_SRkP8S6N00edGDCFMEnmOQ">17.4</ix:nonFraction> million as of the March&#160;19, 2021 acquisition date. Accordingly, the Company recorded a premium&#160;of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="6" id="Narr_SxvAjCDptEm84ehiNJ2VrQ">0.8</ix:nonFraction> million, which was the difference between carrying amount and the fair value of the debt&#160;and was being amortized into interest expense using the effective interest method over the remaining term of the debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_g8KZkdeDqk-U60JJxrNmOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_-Bjqd6K0UUqbTQRXinhieA">0.2</ix:nonFraction> million during the year ended June 30, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_4QygS4Rlv0O5YI7SfAsGHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="Narr_Sp3pWEVBVEu80knRrACSTA">0.8</ix:nonFraction> million for the period from July 1, 2021 through full repayment on January 26, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Avenue Capital Loan. </span>On January 26, 2022 (&#8220;Closing Date&#8221;), the Company entered into a Loan and Security Agreement (the &#8220;Avenue Capital Agreement&#8221;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#8220;Avenue Capital Lenders&#8221;), and Avenue Capital Management II, L.P. as administrative agent (the &#8220;Avenue Capital Agent&#8221;), collectively (&#8220;Avenue Capital&#8221;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_VG5CX8zXlU23NZ3iKfvHMg">15.0</ix:nonFraction> million loan. The interest rate on the loan is the greater of the prime rate and <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" decimals="4" format="ixt:numdotdecimal" name="aytu:DebtInstrumentMinimumVariableRateBeforeBasisSpread" scale="-2" id="Narr_7u8R_E5Fn0SSMbI85Vu_Eg">3.25</ix:nonFraction>%, plus <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_rl9dLvE1Zk2nbxz2BkifRQ">7.4</ix:nonFraction>%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the Deerfield Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" format="ixt-sec:durwordsen" name="aytu:DebtInstrumentInterestPaymentTerm" id="Narr_oIw4p6yKk0mETQ82v2-9eg">18 months</ix:nonNumeric> following the Closing Date (&#8220;Interest-only Period&#8221;). The Interest-only Period could be extended automatically without any action by any party for <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" format="ixt-sec:durwordsen" name="aytu:DebtInstrumentInterestPaymentExtensionTerm" id="Narr_rFGTHI0Tx06LJmNYL7C2Ow">six months</ix:nonNumeric> provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (&#8220;Interest-only Milestone 1&#8221;). The Interest-only Period could further be extended automatically without any action by any party for an additional <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" format="ixt-sec:durwordsen" name="aytu:InterestOnlyPeriodFurtherExtensionTerm" id="Narr_0sl7doU5kUWpxngGbe_bbg">six months</ix:nonNumeric> provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" format="ixt-sec:durwordsen" name="aytu:DebtInstrumentTermOfTrailingMonthsRevenue" id="Narr_jAwLrMjFuke0Tg56aD9OWg">12 months</ix:nonNumeric> revenue as of the date of determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA" decimals="3" format="ixt:numdotdecimal" name="aytu:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_owA6mN01UE2W8MRG8KI0ZA">3.0</ix:nonFraction>% of the loan if such event occurs on or before January 26, 2023, (ii) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_kws3beaygUG87BjJP1LOuQ" decimals="3" format="ixt:numdotdecimal" name="aytu:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_gZFSXCpugkyn6r0Ia0q81A">2.0</ix:nonFraction>% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_m0FsqjSjeUaa1vPcTxPTlA" decimals="3" format="ixt:numdotdecimal" name="aytu:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_BWLSfoyAJUi6bHuVVhlmdQ">1.0</ix:nonFraction>% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_6av_ngfYxU2gEfqwhwoB_A">0.6</ix:nonFraction> million (&#8220;Final Payment&#8221;). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s obligations under Avenue Capital Agreement are secured by substantially all of the Company&#8217;s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_BKwxzhsgYkuORlZF9am3Tg_1_2"></a><a id="Tc_xvAtdPRUckmmeuM0evoRUQ_2_2"></a><a id="Tc_l1nlW_n4pUiCRYz8G7I1lQ_3_2"></a><a id="Tc_Sm3tlslE1EKwTAydCMSL1A_4_0"></a><a id="Tc_ZaFI7qSsQUawkieVORyo0A_4_2"></a><a id="Tc_enySOxnJfUi5h8tQHJTqbA_5_0"></a><a id="Tc_-vjgskC9wEmbtjBH5aJzdw_6_0"></a><a id="Tc_rkiaQ-9MvU6A5JmI1PsFjQ_7_0"></a><a id="Tc_1BpwXYwfM0OBRNqPKmExUw_8_0"></a><a id="Tc_eod9x3jma0uWBOShlDN3hA_9_0"></a><a id="Tc_HUUz5AiiJka0wwczL64Qkg_10_0"></a><a id="Tc_aLqVir6j2kuFfYNZw7choA_10_2"></a><ix:continuation id="Tb_K-2nfJoreEm7CCdJ211PQA_cont1" continuedAt="Tb_K-2nfJoreEm7CCdJ211PQA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company&#8217;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On <ix:nonNumeric contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_8BPUJ7pkK0qSQNua439-Bg" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_zvxlTTXXoUa7OClHJdUU4Q">January 26, 2022</ix:nonNumeric> (&#8220;Issuance Date&#8221;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_o1yFif9FI0Svb8iezicq0g">24.20</ix:nonFraction> per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_29_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_hHbd5LNmMkO0y394Oj5L5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_iIGnoLx3WECfd2tERxz7iA">24.20</ix:nonFraction> prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_a1p_1XuT7EGBwNeNtEFSPA">0.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On <ix:nonNumeric contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_tKH_DOG2x0SbdakkNDfEwA" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_RhXEyDdY-0Kq2Pi6iKzfFg">March 7, 2022</ix:nonNumeric>, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 15 &#8211; Stockholders Equity, at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_Ibqu0Ue0V0CPHBTOf6tOhA">25.00</ix:nonFraction> per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_q6ZY16eGNUK9vboJa4yrAg">24.20</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#8220;Avenue&#8221;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_10_25_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_Y2L8pKkibkq2ytqbielQJA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_qDwDgTFoUUmVKTPBMSz9-Q">8.60</ix:nonFraction>, corresponding to the warrant exercise price associated with the Company&#8217;s August 2022 equity financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 &#8211; Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. The interest-only period now extends to the January 26, 2025 maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the debt discounts discussed above, the Company also incurred $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LoanProcessingFee" scale="6" id="Narr_jvM9XE01XUio9DyRXBZydA">0.4</ix:nonFraction> million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_bt9P46zN4Uul011WiS7arg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_8NJFd-pSMU6ZkUrzgcE1bA">16.59</ix:nonFraction>%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_wly_pBvKnkK2hJgq5kcyOg">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_lv1AQVTl0keo4ZlP9CVIgA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_A4W5_QoB40uDV_O508W7UQ">0.9</ix:nonFraction> million for the years ended June 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following;</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_L0WOECD2Nk6e5USgzFUEAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, due on January 26, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_hIwOOubZDUiVkmnloXgmtA_4_3">15,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term, final payment fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="Tc_5BWjWyNuhkOZcRL0UnWv0A_5_3">638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="Tc_X4FHmihnek-AobFfEAKGbA_6_3">925</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing leases, maturing through May 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_iYOfwuWDwEex1Tb25SmumA_7_3">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="3" id="Tc_R8xL3jmS-0S570wd2BNs1Q_8_3">14,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="Tc_4MP8Qp89sUWZw3P4Tpn1wA_9_3">85</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="Tc_gnsy8EPmaEier7y9ozKuJw_10_3">14,713</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_9jQx-PTG5UOEO4h_-S3n8g_1_2"></a><a id="Tc_wi9pK8er-U-SyV9xVi1JQw_2_2"></a><a id="Tc_tdnH3RQy40SYWqM5mqvhag_3_0"></a><a id="Tc_zTGuCXyI7UKEm0YKgGyLtw_3_2"></a><a id="Tc_RzpCxTHUcEGqKx9-TO1W6w_4_0"></a><a id="Tc_A9UyCXzyzE-NN4DjKwCaEg_5_0"></a><a id="Tc_ZGAqJnKMgk2xnnxjMEw1SQ_6_0"></a><a id="Tc_ys3-wV76s02RWf23pGMXpg_7_0"></a><a id="Tc_bQvt5d3NjEyQzYKINmf6IA_8_0"></a><a id="Tc_4o-iVysEBk-hXO5NIkLi7A_8_2"></a><ix:continuation id="Tb_K-2nfJoreEm7CCdJ211PQA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future principal payments of long-term debt, including financing leases, are as follows;</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_kEu4cO8CqkaJfW-oA31pQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" scale="3" id="Tc_lJuUa4gsHU6mkkEEbsi2Dg_3_3">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" scale="3" id="Tc_3lDbQCY3KEONY3r4YgZl_Q_4_3">15,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future principal payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:LongTermDebtAndFinanceLeaseLiabilityGross" scale="3" id="Tc_TNMCtW29c0WpwDnEo9TGXQ_5_3">15,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_U3bq9t-vxUCNo4QeeOS7Zw_6_3">925</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="Tc_yR9r2JykRUWKMkXnnokhAw_7_3">85</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="Tc_mlT1e9sNfE6gR-VhowsOdg_8_3">14,713</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_xE0VuuBj8kutHU4XH7Gk3w" continuedAt="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">12. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determine the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 1:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 2:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 3:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Unobservable inputs that are supported by little or no market activity.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities</span>,<span style="font-size:10pt;"> contingent consideration liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_306d13bc_35de_4b42_8756_d61a51c701da"></a><a id="Tc_48R3nW5_YkC4UFfv1Ax3Lw_1_5"></a><a id="Tc_bA-zAu7D2UywifeOctkKvA_2_2"></a><a id="Tc_1mm9wzxrXkef75UqPljVDg_3_2"></a><a id="Tc_kvvc3KJeTk6GkKSi7ort5g_3_5"></a><a id="Tc_qIWmdRVZT0aruinS2NBfSw_3_8"></a><a id="Tc__T3Q1b2fY02KR1QlYVnstA_3_11"></a><a id="Tc_0Rd96Q-9OEiYDG0-pSOJXA_4_2"></a><a id="Tc_vBFb9DS6UkG1y6VjcZk4QA_5_0"></a><a id="Tc_pIFWi7fpEUCgZcuyoupWKw_6_2"></a><a id="Tc_xhPYYzjyKkO79jOnzKVOIQ_6_5"></a><a id="Tc_SqL9frHUS06pFKAnswR2eA_6_6"></a><a id="Tc_7fdciMaok0qTGmtg7Kwqcg_6_8"></a><a id="Tc_K8x17dv0tE2yExjjjpMDXQ_6_9"></a><a id="Tc_JFg6d3B3O0Coyfy4S31BwA_6_11"></a><a id="Tc_x3UMF1cF20Gos1PxrssloQ_7_0"></a><a id="Tc_wTY31lTwXUCS2LwQCSS2eg_7_2"></a><a id="Tc_4Oxhhql_9U22iWLKQqYd4g_7_5"></a><a id="Tc_lKVzMk-7_0SQSpEMOMftow_7_6"></a><a id="Tc_4MGXAwcFKE6KNAeY0fr7TA_7_8"></a><a id="Tc_E4hBGFRTbk2Jl_j5Q5s63g_7_9"></a><a id="Tc_TvGGQLZjxU615JGp3kYheA_7_11"></a><a id="_d002c309_f506_4b03_8523_b1bfb7fbcf7d"></a><a id="Tc_k5YhXUJGK0S2JA7ms0VWiQ_1_5"></a><a id="Tc_98B6SKpICk6gZwbMtjqD1w_2_2"></a><a id="Tc_XYRCtcHp90qt03VEttAejQ_3_2"></a><a id="Tc_eVXpokzgG0WbLH9Ua1wiYA_3_5"></a><a id="Tc_HzvyVGT7tEOBfAd3M3I6_Q_3_8"></a><a id="Tc_UWXbKzO560aZTq750F_CbA_3_11"></a><a id="Tc_j2taXLnPEEWZJMoflxQN7A_4_2"></a><a id="Tc_EXHz14ZSJE2-MJtrMU8uCw_5_0"></a><a id="Tc_QW3Ma94ue0-3b_Fngr_CXQ_6_0"></a><a id="Tc_nYYFXnm570qbQW48j275VQ_6_2"></a><a id="Tc_hksUP68mbkq1KAjFkuSDgw_6_5"></a><a id="Tc_UtOJEdwiIkaycJ2YKtB7eg_6_6"></a><a id="Tc_8pzN4q3fgUKkxwmWDP9tfQ_6_8"></a><a id="Tc_E1vmYkjG5ECKr7HIE3h5ng_6_9"></a><a id="Tc_OBM3KHUnvUOo5cmjRB_coQ_6_11"></a><a id="Tc_28eT7OjHcUGxxhUEGAap8A_7_0"></a><a id="Tc_VwgGML22BUSpAwE8M2rjnQ_7_6"></a><a id="Tc_OibVJtvxsk6z-bvfOmGqqg_7_9"></a><a id="Tc_Ws-umQN9VE-W5RgDZu5Ovg_8_6"></a><a id="Tc_FqUZqSGQ10ubqxckQcxU1g_8_9"></a><a id="Tc_6F8dFMVjEUu1mq92OZzLuw_9_0"></a><a id="Tc_Nfqo07IW3kqTZLC0VisGjg_9_2"></a><a id="Tc_HCawFmpHPEyuVjMNUQ9V6g_9_5"></a><a id="Tc_YC0yTbZVp0GhGdgv4HHRpg_9_6"></a><a id="Tc_DafIIjJAkE261kNjPNM6bw_9_8"></a><a id="Tc_fKLmi3LUTkmLOydetS6zhw_9_9"></a><a id="Tc_sounoE8UOkmsBx21cV7SsQ_9_11"></a><ix:continuation id="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont1" continuedAt="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the Company&#8217;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2023 and 2022, by level within the fair value hierarchy:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_0fQuHK8GzEKd155MIjpOFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_Yi-wD1QAw027O6Gw0MqnzA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_OagLZFhYJ0etkdeK0ruIqg_6_3">6,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_iu4xgb2F1EOxpRBxCTYiRw_6_12">6,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_6mLCpyVGgkyyifgXVPDzRQ_7_3">6,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_Fr70Bfbo7UyOE-Cm0f4zTg_7_12">6,403</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A" decimals="-3" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" scale="3" id="Tc_D47XN0c61EWvXskUVSNEIA_6_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg" decimals="-3" format="ixt:numdotdecimal" name="aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" scale="3" id="Tc_STEJEQ04LU6uFt8kuqGkJQ_6_12">396</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsLiabilitiesFairValueDisclosure" scale="3" id="Tc_bf2NChayy0m-eGlSdm2Xgw_7_3">578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg" decimals="-3" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsLiabilitiesFairValueDisclosure" scale="3" id="Tc_nBkzOOv4ckOZyT0n6WuQag_7_12">578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_YynIzFLXAkeAX8AGtpTUAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_oB70SXezh02hJ6fjQl1vcw_8_3">1,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_9r48odMk1UShmkN2hLcYNw_8_12">1,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_iClno79Yl0-xp17NCP070A_9_3">2,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_LOebDGcsg0CZemIWRFe-aQ_9_12">2,770</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds, and reflect their fair value at Level 1 in the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Recurring Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended June 30, 2023 and 2022, were fixed payment arrangements, goodwill and intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_WKARek3HGUePLpa2Lv1yQw" decimals="3" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMeasurementInput" scale="-2" id="Narr_K187N8DzkEm5BHkAZ1PAPw">10.0</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_KrFIpmKuVEO1-6ai2hZCKQ" decimals="3" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMeasurementInput" scale="-2" id="Narr_svdMiSP530aTLMCdhdkTqg">15.4</ix:nonFraction>%, and are classified as Level 3 inputs in the fair value hierarchy. In May 2022, the Company recognized a fixed payment arrangement liability of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_5_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Z0XzDKGO6UGmhcRPSeKd1g" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_GF1g1X4ZI0GWcvBW9pxi9g">7.6</ix:nonFraction> million relating to the termination of the License, Development, Manufacturing and Supply Agreement with Tris. See Note 9 &#8211; Other Liabilities for further information on fixed payment arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on the Company&#8217;s impairment analyses for fiscal years 2023 and 2022, the Company recorded an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="Narr_xvSqIJNyCkWCNpBxc58Ayg">5.6</ix:nonFraction> million on intangible assets during the year ended June 30, 2023; and an impairment charge of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="Narr_Gjw2uEHuPUG5RDO4G0ro6A">7.1</ix:nonFraction> million on intangible assets and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="Narr_-PwKd-5qEUmlvfLtogUjpg">65.8</ix:nonFraction><span style="white-space:pre-wrap;"> million on goodwill for the year ended June 30, 2022. Valuation of goodwill and intangible assets involves significant Level 3 inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted EBITDA margins, and the selection of a discount rate. These assumptions may be affected by expectations about future market or economic conditions. See Note 7 -  Goodwill and Other Intangible Assets and Note 2 - Summary of Significant Accounting Policies, for further discussion on the fair value measurement of goodwill and other intangible assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9509697a_9bbd_4b7e_a7a2_955214f021ba"></a><a id="Tc_F26ey1iZnUOTP0zbkcXR9Q_1_2"></a><a id="Tc_IFNkFcZrq0mVj9T4i-6nxg_1_5"></a><a id="Tc_pHjtBwx2dkm4zaQk7e5Tog_1_9"></a><a id="Tc_b5R_SQmvxEK-3kyLxKRLfQ_2_2"></a><a id="Tc_VStaKIO3yUqSC8nR2EYh1g_2_5"></a><a id="Tc_HcdXHzSek0ODeIWK3QCuag_2_9"></a><a id="Tc_jqC4haivM0-kV92MT7zL8w_3_2"></a><a id="Tc_Az7wKujKzUK0b6uP2YGdaA_4_0"></a><a id="Tc_FR7Y0xQql0ynfhsf_4vOaA_4_2"></a><a id="Tc_BBpW7ToNY0iDWaTqmRj5JQ_4_5"></a><a id="Tc_ePzjhINiqUmdx5LotlsA-A_4_8"></a><a id="Tc_oQWDuD5PckeT12iRJ2pdjg_5_0"></a><a id="Tc_CVEFr8SQC0exZdTQ8MqO9A_6_0"></a><a id="Tc_9JvnRhw1VkC9XD2l5TVPLg_7_0"></a><a id="Tc_pGaA5H8eeEOmoLMutDli1w_7_3"></a><a id="Tc_x5fyDekwwE-VDVfm_9Vfag_7_6"></a><a id="Tc_mhat-TciPU-ztUT6tfdC2g_8_0"></a><a id="Tc_MZTKwV5dCUG_UA0_BxzGgA_8_3"></a><a id="Tc_WfQ9HcAmQU2DoYidhMepnA_8_9"></a><a id="Tc_RFByxz1rnk-Kokzobk2UFQ_9_0"></a><a id="Tc_69KzdNoKzUO_ri3jOdzM4A_9_2"></a><a id="Tc_-UiycTx-t0ipmUYfE6zYyA_9_3"></a><a id="Tc_Wl-b6rcbFk255QI7XkSU0A_9_5"></a><a id="Tc_CD8pjBf6vEiQ_rFKkWRt4w_9_6"></a><a id="Tc_RajMQjHJ60WFn7Yp6-9Orw_9_8"></a><a id="_a2d0e402_f1ea_4c48_a790_fafaaff5b3bc"></a><a id="Tc_08_tOF-Hukedf41MDzTrHA_1_2"></a><a id="Tc_qYAN_dZZZUKaUyJi1nbjYQ_2_2"></a><a id="Tc_CGZ1fjdcKkaBWCr6a2Dhnw_2_5"></a><a id="Tc_gToPSa7KSkCOq7V_bd6A5A_3_0"></a><a id="Tc_BkJzhWF42UGmfKPvVK8yxQ_4_0"></a><a id="Tc_42z6UyaClUerkiXuK_z4Fw_4_3"></a><a id="Tc_dGOhh_k_rUG1Di0RH2-Gqg_4_6"></a><a id="Tc_PpoUsGBdF02FSATs0twocg_5_0"></a><a id="Tc_Zz9eXXCgU0ChSwBQDzcIIg_5_3"></a><a id="Tc_3T4IapFLG0CaMBWnRwzbaA_5_6"></a><a id="Tc_aJtZfccdyU2Gibr0v2c6dQ_6_0"></a><a id="Tc_wQIK4GiER0OrdnFSbGX6uw_6_3"></a><a id="Tc_njnhmImvvkWV54097SevDQ_6_6"></a><a id="Tc_gehnx-oUck6qVzWe6cvbLA_7_0"></a><a id="Tc_hvJ-uIQEpkWz4Ux0jwjoYQ_7_3"></a><a id="Tc_0xZKAmN1D0iyPO7J4IodcA_7_6"></a><a id="_a6297a91_1298_4bf0_8a8b_ec35a5c6e385"></a><a id="_a6297a91_1298_4bf0_8a8b_ec35a5c6e385_2"></a><a id="_a6297a91_1298_4bf0_8a8b_ec35a5c6e385_3"></a><a id="_58990d50_8b66_401c_9d0d_428e78bd549a"></a><a id="Tc_Ma6eXGung0ia0PY1HR4fzQ_1_2"></a><a id="Tc_9RyrP35fFEuK-TDWW7WcMQ_2_2"></a><a id="Tc_-LIWgvCPmEmZL11_U7SVBg_3_0"></a><a id="Tc_FiVckRfsMEWYAaeoGXtAUQ_3_3"></a><a id="Tc_tqhfOX9A3U-qtm6qwTflFA_4_0"></a><a id="Tc_K-zbIzccrU2ZktGL_5ZOGw_5_0"></a><a id="Tc_-vTDDdF_QUmDtBsUQvrSBw_5_3"></a><a id="Tc_m1iI5Zy4pE2s8gRaRSqLaQ_6_0"></a><a id="Tc_aUcN9O6p_UmRFoWTmN62ZA_6_3"></a><a id="_3b5978dc_2156_4267_b1e0_79334725b1f7"></a><a id="Tc_xepDBhkYGE-5_noMRJApEA_1_2"></a><a id="Tc_FTSp8u0tYEaBgQ0dzRdnnA_2_2"></a><a id="Tc_bD3cViaTHkW3Exc4ptIpiw_3_0"></a><a id="Tc_50hipTxxQUWMnUKprvCKSQ_3_3"></a><a id="Tc_sVBO_12xS0O5Az6_s7ZFSg_4_0"></a><a id="Tc_WESOGPb8RUuRG4XGLPX87g_5_0"></a><a id="Tc_VNKgs6b4zE2eHh2XSKixSw_5_3"></a><a id="Tc_FKzIxfDfpkKXa4Z69qn7UQ_6_0"></a><a id="Tc_Zo7P5GvGD0WC5CfJVvD8Fw_6_3"></a><ix:continuation id="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont2" continuedAt="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Level 3 Input Changes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the&#160;year ended June 30, 2023:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_rwYMkNUfOEqq5g9bJrW_lw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CVR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_pREYRHxAC02w7LKKoGWLhw_4_3">578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_AfRtXHFQ9USFYETLv0hWfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_xgJZWAdAykeVZyVSwKhuGg_4_6">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_KFT-owhYG0KTW-8HwcgXlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_KEQaDa4ldUCZrG19iD-p0A_4_9">1,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Included in earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_ZFpgwZhkqUyRl3zlMAqdiw_5_3">578</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_cXnfGMkH6EyXv-Fz8sqpEw_5_6">391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="Tc_Wf-8xld3FUS6QvmVZbVqvA_5_9">6,391</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases, issues, sales and settlements:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_tdxxPEX1e0uf4NzO0Pesnw_7_9">10,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Settlements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="Tc_wM3pmftTB0ygGEduaXmRnQ_8_6">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_i3pgtEL-p0az9jQE1IUGqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_RRCPbu8y90yBCsaliGqc5Q_9_9">6,403</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3 Inputs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the fair value of contingent liabilities in subsequent periods are recorded as a gain or loss in the consolidated statements of operations. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_9T5Pro5tD0yyXwNzqFFJug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in valuing the CVRs were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leveraged Beta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ" decimals="2" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="0" id="Tc_dshqxwsz9UGkqLEQv96ncg_3_2">0.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_32pYQVd-O0683kHB-OxqJw" decimals="2" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="0" id="Tc_mwSjWMkq2ECt5aQ0CeFI_A_3_5">0.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market risk premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_v1uEDB4Qe0ChX25O408Kdg" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_y51y1A5viEOBAM11NMGDCQ_4_2">6.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_j9upZ0K_wkaSqBsZ35fPUA" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_2fWEwDSpGUmsnBRuTEIrqA_4_5">6.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-JITEKUA0GmzvfgKWJObg" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_ZrkfroQAH0qZ_Pw06W-SNw_5_2">5.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6RWMQBcVTkKXBXn5bPIjLQ" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_ZW8t7n6Hp0-sTJwXwQEGZQ_5_5">2.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_G4Ig525OfkKi6bpvihM7ow" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_TpCmS5Lokk-1FXP-SgR1nw_6_2">22.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_vlDLGuQ7RU6fpglPTudPkA" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_WzE49ZmVkESc_wMzf9STCw_6_5">20.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company specific discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_XqoLyaAyJkqUthh4KeWIOQ" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_9V-e_ia6skWcWqq-vCAM4Q_7_2">10.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_z3pQQ5Ly3kepba66l3j4ig" decimals="4" format="ixt:numdotdecimal" name="aytu:ContingentValueRightsMeasurementInput" scale="-2" id="Tc_cDMES5KkPkuEsgHy6E5P8g_7_5">10.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb__kF3gv0r2U6suYK6GyS6Kg" continuedAt="Tb__kF3gv0r2U6suYK6GyS6Kg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 9,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BwVbhIEKsk-sG7dxwmlpBg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_1FyOmwd0MUyMGPhTgLFPOw_3_2">89.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw" contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lHN7htztVE6wijIYRnB1CQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_jx0jZ1oLs0qhVYWJJRnzJA_4_2">4.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9VU0MObsYUWsSE7KNqA2LQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_bsi_l92ld0GiZrJsUK9Mew_5_2">3.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LU7VfbLrpkCDkceqmLfiUg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_f5nDLccMwE2aZZJCsJaqhg_6_2">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 8,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_psdJZSxrqEyjZhoFMF-3Bg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_-0NTYcg9cEWJ3P1t1rExYw_3_2">83.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw" contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_OU6-ZAL7g068xkL0XGt6CA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_qY3XN_iAzEiiz0uqMRfasA_4_2">5.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_V5QFAOw8DUmhBp4aYi7M0Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_rqRistxa90KkrjPTsRwoDA_5_2">3.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_uyAuyq8iF02T8ekDM7p7Ig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_lwA3U4zbmkerxG3nWZCKFQ_6_2">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b54535c3_87ac_495a_b81d_7c38538892ed"></a><a id="Tc_VgH5z26v3EOSGeOFivdlCw_1_2"></a><a id="Tc_S8MqgrQDGE2hznmHcT4JdQ_2_2"></a><a id="Tc_CLQvkN7G5E-avk-op19swA_3_0"></a><a id="Tc_A4TuLnqjaUqmJI9-TnrlBA_3_3"></a><a id="Tc_QpFB6_1CVUGCn_Yx0TS7jQ_4_0"></a><a id="Tc_hXb1bAFcL0uuxrTeT9PoeA_4_2"></a><a id="Tc_jED9MNetiU2nkQTJAKhlow_5_0"></a><a id="Tc_j8ng8Duq7UuZsPMOa0af-Q_5_2"></a><a id="Tc_qaR5Eu6QsUe-15UCz0u6hQ_5_3"></a><a id="Tc_TjrrCZ2tRku--LJ8yyI9cQ_6_0"></a><a id="Tc_X4DGd_QOHUO1fA0QTWdi-Q_6_3"></a><ix:continuation id="Tb_xE0VuuBj8kutHU4XH7Gk3w_cont3"><ix:continuation id="Tb__kF3gv0r2U6suYK6GyS6Kg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in <span style="-sec-ix-hidden:Hidden_iwcBQPje9UyI7pXQKxPUyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">valuing</span></span> the derivative warrant liabilities, marked to market, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LRQAfaW_D0auL9YBkk-kXw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_z9WsiKOjbUiIzjzdrrKoMQ_3_2">83.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Z12qpqcVkkK_jr6qZ_cGBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_n5TOuB2JXUKERCwunA9NqQ">3.59</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lzWJ_F-ZrUaSzSfq1TNUiA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_5bKZ-Iz_b0qhWCN6kcIWzA">4.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wTfWp6Qu5kuUcvqKqDdSvA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_XC0szhTIuUmojD7ah7a2GQ">4.13</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_IsVh2msT0EmhmcrW0JvYbQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_8_7NkBpvOEWVnLsRgfDDsw">4.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_3CSXkEWhhkC8dtO67-wH2A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_QeFxWp4Z8EiJF8r0TYcMhg_6_2">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">              Expected volatility was based primarily on historical volatility. The Company chose to use a two-year lookback on historical volatility to avoid the effects of COVID-19 and the Innovus acquisition. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term of these warrants, and will not differ materially. If expected volatility by the active market is higher than estimated, the derivative may result in a greater fair value. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_dVnRG1a2Skak1Geepo5a8Q" continuedAt="Tb_dVnRG1a2Skak1Geepo5a8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year of 2023, there was <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_Hz4nRry6PEKxKZkLXrpYaA">no</ix:nonFraction> income tax benefit, primarily driven by Section 382 limitation on post-TCJA (&#8220;Tax Cuts and Jobs Act&#8221;) net operating loss (&#8220;NOL&#8221;) utilization, further described below. As of June 30, 2023, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_1tT0xZNkt0etJpk7fTLLPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="Narr_QurA6XKqrUGSrdGkhRXvAg">0.1</ix:nonFraction> million deferred tax asset (DTA) included in other non-current assets, $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="Narr_-atlxU1Gd0CMcy3q4Q5kjw">0.1</ix:nonFraction> million deferred tax liability (DTL) included in other long-term liabilities, and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="Narr_AKPEG3Pb6kq5eJ4MAe6TNw">0.1</ix:nonFraction> million income tax payable in accrued liabilities in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Section 382 Limitation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, substantial changes in the Company&#8217;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the Company&#8217;s Section 382 analysis, an ownership change was determined to have occurred in March 2022 at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-6" format="ixt:numdotdecimal" name="aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" scale="6" id="Narr_HGEfR3fBSkW-kIRterpt_Q">12</ix:nonFraction> million) is determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation. The Company also determined that ownership change occurred in June 2023 at a time that the Company was in a net unrealized loss position. As a result of the Section 382 analysis, the Company had estimated $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" scale="6" id="Narr_6ui3hPEfukqbOxTDTGixIw">0.3</ix:nonFraction> million of disallowed recognized built-in loss and had carried forward as an operating loss as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had federal net operating losses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_xUNKi9L0qkeWVmaa3mtIBg">504.0</ix:nonFraction> million as of June 30, 2023, that subject to limitation (as described above), may be available in future tax years to offset taxable income. Of the available federal net operating losses, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_PcP-Lq9S1061U6uuOAncvQ">172.0</ix:nonFraction> million can be carried forward indefinitely, while the remaining balance will begin to expire in 2024 and completely expire in 2027. As of June 30, 2023, the Company had research and development credits of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_o8xXzGVuRkuQ739dJAopiA">3.0</ix:nonFraction> million, which begin to expire in 2024. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2039. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_b13-nM0E30Wr2B7SJyYRPA_1_2"></a><a id="Tc_03tZP0hu7kaeh-0BPrm44Q_2_2"></a><a id="Tc_XI-PnAji3Uqm_D5m3egenw_2_5"></a><a id="Tc_FV76-D6_4U-tRt_CvKeEcg_3_2"></a><a id="Tc_evhEtxbmsUGya78QXehz0Q_4_0"></a><a id="Tc_IqjctDAyGEmec1OIEexehg_5_0"></a><a id="Tc_MED37rGHJ0yOzBSP-usPhw_5_2"></a><a id="Tc_m6JorDmBKkOdydCGyD0-8g_5_5"></a><a id="Tc_il_oclKl5EaEZF5Na7i8zw_5_6"></a><a id="Tc_XDhlXV__60Oc4RlT4LsWhg_6_0"></a><a id="Tc_hoch0-zBmk2AQpWA1A4uJA_7_0"></a><a id="Tc_hXRDBC-r80Op1X37owqUaQ_8_0"></a><a id="Tc_9ZTQP4IZJke2Adny87gZfQ_9_0"></a><a id="Tc_2A2XSmNAsUKxYd-BWiEqdA_10_0"></a><a id="Tc__vCbJz151EKgb5ZE9dZtLg_11_0"></a><a id="Tc_NhH95F5JhEqW2LMYVsvaHw_12_0"></a><a id="Tc_sv69yPtIfEilgi8gTGIRqw_12_2"></a><a id="Tc_sJ-u_yXpd0COWoeM0fqJPg_12_3"></a><a id="Tc_D951EepYOU-hJ4l84XqYMg_12_5"></a><a id="Tc_t_ZJYq_31kKCDL0nyfu0dA_1_2"></a><a id="Tc_IilO_6VUlkOy_c4CRm4YJQ_2_2"></a><a id="Tc_PCdXlPPOsEGqlq5pfPD_fA_2_8"></a><a id="Tc_XPF6Bw2Cn0GQNm-TYyDY6g_3_2"></a><a id="Tc_DpC8satpxE6Uoo8PMf8smQ_4_0"></a><a id="Tc_OOA9iFZD3ES9JUAXB8eKdQ_4_2"></a><a id="Tc_BAqsp1v5bU-6yQmTIELacQ_4_6"></a><a id="Tc_Drja7szk806fKvWzuLeE5A_4_8"></a><a id="Tc_N_KzoHvBvUmrgvkljcJfCQ_4_12"></a><a id="Tc_X98cuq3Xq0u1UslwtNmWWg_5_0"></a><a id="Tc_r6lELJ3jYEKPgicWEFbqmg_5_6"></a><a id="Tc_5nDstXV2FEqXIcVvwcVdcg_5_12"></a><a id="Tc_ZdSlZoMCpk6n3lQT1OIsxg_6_0"></a><a id="Tc_eXb3JOaKWUCBMnCG7Fdf0A_6_3"></a><a id="Tc_Hiz72J2nwUuRMTivjQxuTw_6_5"></a><a id="Tc_AVoOS9aIDEKmEYmJ4b-o-w_6_6"></a><a id="Tc_CpO2EvFVv0S3a1JXS2H-aA_6_9"></a><a id="Tc_lRu5zIl6eUKRvrD1v9XmmQ_6_11"></a><a id="Tc_6-sS7fZ1v0eyAtztiaFN4Q_6_12"></a><a id="Tc_NyCqdRfgEE-yP8OmuK4AKg_7_0"></a><a id="Tc_kojSBsOiqkiRLDTJr7peCw_7_3"></a><a id="Tc_HC1ZZwxjnEm9OGKfUQLHAQ_7_5"></a><a id="Tc_hFEs85UaqUaTizJdbrhaow_7_6"></a><a id="Tc_Qh-t234XMES0yBeMFD60HA_7_12"></a><a id="Tc_xP5ilX17t0aLydxrkYP8rg_8_0"></a><a id="Tc_iLf2T9C5lUuXy6eBdzylJA_8_6"></a><a id="Tc_0LTCcEfi6kG6NBL3m-R_BQ_8_12"></a><a id="Tc_GUBAg7EBg0WhT_90Olfbkg_9_0"></a><a id="Tc_m0-55UQ_6UaeAye_pDcvTQ_9_3"></a><a id="Tc_ZQEUY34woUi3RSN5Na21Nw_9_5"></a><a id="Tc_CzmqKWzSXkCRV59hqvyDaA_9_6"></a><a id="Tc_kCJvGd9jFUKGtQNWnQDUnw_9_12"></a><a id="Tc_toyoHD1EZkSWAhcuKWdbSQ_10_0"></a><a id="Tc_7-wxsUDL_UuntNfLc6WrDg_10_3"></a><a id="Tc_dGwBNMPO4UiCob94FSZCqQ_10_5"></a><a id="Tc_6L9L_hr0PEim_pakJfuLSg_10_6"></a><a id="Tc_G7sZthmlUk-hQ6-hcCMkqw_10_12"></a><a id="Tc_YuarBw0pIkulS7F49RAPvg_11_0"></a><a id="Tc_xq_c_EWE40ihP1Lt6cT8lw_11_3"></a><a id="Tc_Ewu9PFnxP0msqCxrMZ_sjQ_11_5"></a><a id="Tc_xCs1lAAG5kK6kUS1FKTyVg_11_6"></a><a id="Tc_EOlG8kRj7kmvI8GbI6jeIA_11_9"></a><a id="Tc_KfwlsTlrX0yfhG9FmbvSVg_11_11"></a><a id="Tc_jPUJ1YrNykKFsVRAGIhxrw_11_12"></a><a id="Tc_ZaTCMGFJokq9yQxiu2LIZA_12_0"></a><a id="Tc_ceUN9h0hD0S_gza6M20ioA_12_3"></a><a id="Tc_lqg8is6zlUapni6W_WY1wQ_12_5"></a><a id="Tc_H4Y-Wu-UFkGxB4Qp1mp8rg_12_6"></a><a id="Tc_ysTVR__l80CpOzH9du9djQ_12_9"></a><a id="Tc_JTn3dSeaAU-kI-gar0tqjg_12_11"></a><a id="Tc_KZSak8iGZ06r6nTt6OzOeg_12_12"></a><a id="Tc_JB4rBuxFdkSfpxNTHXy1uw_13_0"></a><a id="Tc_xVpJXfr0z0KvHkBN7_8hGA_13_3"></a><a id="Tc_kb1iQRaiyEmeEqdKA5Ywcg_13_5"></a><a id="Tc_PPyVBtP_SE62yHB4jxZ8bA_13_6"></a><a id="Tc_Eh6_lKia0E6e4ycb3h4xew_13_9"></a><a id="Tc_N_XFzzJs00apUkoLjXuo8Q_13_11"></a><a id="Tc_t572Gw4mIU-JWnRDmZMzOw_13_12"></a><a id="Tc_fN5enSixmkSCBRkMuKV5GQ_14_0"></a><a id="Tc_EghXgLJegUa0sWb90aVySQ_14_3"></a><a id="Tc_YFFlhQd6uEq8CXiPRj7NBA_14_5"></a><a id="Tc_SOGTDvW8XUaFBtcgeCKzSw_14_6"></a><a id="Tc_IuCB-2MnM0m9r_BZdNZjdA_14_9"></a><a id="Tc_GClGdyOfOUmyUR5ubmUEsg_14_11"></a><a id="Tc_WFjrcqHY8EClIFGWC_qMsg_14_12"></a><a id="Tc_PD4AzZYycUOcjaSC3jxGZw_15_0"></a><a id="Tc_i4WM7xBrtEi5ePmctxI6eQ_15_3"></a><a id="Tc_rmHAYCaIfk2TOuAjI8X9Mw_15_5"></a><a id="Tc_i7EbT3DVqkmph1bpDyKEqw_15_6"></a><a id="Tc_MHh6Mbn_pkienTMF2VxDtA_15_9"></a><a id="Tc_VF4QujLpi0WqfsSAsOeErw_15_11"></a><a id="Tc_ZlIhzX5E_Ua2n1uqmqMRGg_15_12"></a><a id="Tc_CjK7UWWEQk2fYAZRooW5Ew_16_0"></a><a id="Tc_j7ER87qFt0yG7ABEFK6DNg_16_6"></a><a id="Tc_6xmskaXg002-vflX_Cedqg_16_12"></a><a id="Tc_vvSa-vhjSke6YdqT_6CtNw_17_0"></a><a id="Tc_uIcLUyjeIkGURoIlGuXrkw_17_3"></a><a id="Tc_oWe-Pj7NNEizBCfdAJKpGQ_17_5"></a><a id="Tc_4vyslU12F0iIH-NeqEDQPg_17_6"></a><a id="Tc_t90zmCJwv0CfUcj4insC-g_17_9"></a><a id="Tc_WRcVX_WPgUu_LDMJ4rfPTw_17_11"></a><a id="Tc_FYZLatCF2kOg4CTte0WP6A_17_12"></a><a id="Tc_wsgh56ja8EC7xMA9a16NNQ_18_0"></a><a id="Tc_2aSkLvskiUyg9yX_bTAySw_18_6"></a><a id="Tc__s3xiXI1PUuMoTyFIgccsA_18_12"></a><a id="Tc_FPhRFE9uHUWu7XKGQtrp4Q_19_0"></a><a id="Tc_u1mrKssDiE6GJruHvSx9xA_19_2"></a><a id="Tc_-RNpfRnTJ0u3sH7OwRVWvA_19_3"></a><a id="Tc_C7SLVNaQh0OqWLeteRSM5g_19_6"></a><a id="Tc_pgiTW04u_EOKYoSW8OlFgw_19_8"></a><a id="Tc_-DYAzD90Kk6FwTSkRuqsTA_19_12"></a><ix:continuation id="Tb_dVnRG1a2Skak1Geepo5a8Q_cont1" continuedAt="Tb_dVnRG1a2Skak1Geepo5a8Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized.  Generally, it is not appropriate to use zero as an applicable tax rate and rather, a deferred tax asset should be recorded at the applicable tax rate and a valuation of an equal amount would be provided.  However, under certain circumstances it may be appropriate to follow an alternative approach and use a zero rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross deferred tax assets disclosed.  The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and not apply a zero rate to NOL carryforwards expected to expire unutilized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In review of the Company&#8217;s consolidated deferred position excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and not utilized against a net DTL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes consisted of the following:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_nGAwGj7mDUizmofVdGqGjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_DEPGXwkuNEG_Z7JPfN-uww_5_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_D0l-UutydkGhYn0m4fqQPQ_6_3">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_oVrmDNspkUeD7svrQiM9sQ_6_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_HOaPGdkd3EysY0-Rp95Rxw_7_3">126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_Zt22Yieb1Uiku3DlpBIzMw_7_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Xuz2bKGQM0mpN1n3kmmsGw_9_3">109</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Rkum4b-UO02PMNSuvD5wSA_9_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ONrGF_sMN0mC0nWozo7ONw_10_3">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_tnQahNnDrECmrIpM5aph2w_10_6">26</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_7iWvqELPkEa6ENm1Ezwn9Q_11_3">126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_3qKMKzBHiEOlXnZuVKIPYQ_11_6">117</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_9JENLb4gP06vVVwCaHgthw_12_6">110</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax benefit resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and various states) differs from the income tax provision (benefit) in the financial statements. Reconciliation of the U.S. federal statutory income tax rates to our effective tax rate is as follows.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_1ATgvjyrfUm8S__kcj2rsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_mOrsxZwNmU2zY5Uy5VFOzQ_4_3">3,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" sign="-" scale="-2" id="Tc_Ny5iKXGeIEGbHFdcepNRJg_4_5">22.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_pcUxmGWp6EmU-LqXWQZjOQ_4_9">23,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" sign="-" scale="-2" id="Tc_3rf-NMpfPU2-UD1t21BPiQ_4_11">21.00</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="Tc_7NpCzkRXw0ShKLOjdn1Yig_5_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" scale="-2" id="Tc_hYQf2EGQwkCgOICe43N9lQ_5_5">0.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="Tc_N492SKHJ2kyk7EdMV9phEg_5_9">601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" scale="-2" id="Tc_D_R6A_e5ZEisfVH5--273w_5_11">0.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="Tc_irU92--3JUmiVzwxuINgZQ_7_9">273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_ryXkfrod7U2P6gUVbpbU5w_7_11">0.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:IncomeTaxReconciliationContingentConsideration" sign="-" scale="3" id="Tc_jesCxAUj-kCZOe51SRYuCA_8_3">193</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration" sign="-" scale="-2" id="Tc_TCJBWymQFka0jonopWQRHg_8_5">1.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:IncomeTaxReconciliationContingentConsideration" sign="-" scale="3" id="Tc_lXXuXJcN7UmKPwsQPmNlDw_8_9">155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration" sign="-" scale="-2" id="Tc_wN4OMTTj40KvixLRqKqgmA_8_11">0.14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" scale="3" id="Tc_gSHJZ3NpSkqhbl5R8FVc5w_9_9">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" scale="-2" id="Tc_EZfR-daUj0inLEhWdxM3iA_9_11">0.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="3" id="Tc_0S_liwaUG0WYOv8ogEGwfg_10_9">9,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="Tc_SjMlqGV83USD3j61QxLbXw_10_11">8.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of phased-in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on debt extinguishment and interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_O0CsLdM6nUaEAsJn4tgxxQ_16_3">3,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_QgnwKTRJC0uVFzCFRmkQBw_16_5">22.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_wn3M7KseAEi6b2roebnPPQ_16_9">12,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_Xp2ARINILkKWeKqK7RG7mQ_16_11">11.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="Tc_F0bvqNWkuUS4skPfO2nGsg_18_3">117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_n4FdCNnSAk-wZzczMTtsYw_18_5">0.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="Tc_VNDIhl_rYUSgjRtd2cZj-w_18_9">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_RDA_zpXRkkuSW-XSdIq3CA_18_11">0.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_yUkShCc21k-2p_d-qBgJ2w_19_5">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Ude9sxTfx06jnzcEEKU3mw_19_9">110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_kFBzyxv4AUWRp9G-xPxDtw_19_11">0.09</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b7e561cf_1753_46f0_81cd_0e33b8385cc1"></a><a id="Tc_awpxFxHEwUqgV05YbEFr6A_1_2"></a><a id="Tc_xcT7CBtAkkeWPVch3CGy6w_2_2"></a><a id="Tc_zTM5WhkSj02Wzsfipl7Xbw_2_5"></a><a id="Tc_TIEa89bGTkGSIsiG4kPmwA_3_2"></a><a id="Tc_Vl-qHsq8RkmpHzSPWkJDPQ_4_0"></a><a id="Tc_B41d2IMcm0elcXJqjdfWiw_5_0"></a><a id="Tc_fsfspbbgjEidCurx602ulQ_5_2"></a><a id="Tc_TQYYG8EnckOxMZBYy05akQ_5_5"></a><a id="Tc_zkQjQs8E-UmsrQIeS1UibQ_6_0"></a><a id="Tc_yJoSop_gKUCoqo2yuUwJOQ_7_0"></a><a id="Tc_Sp0Q5ZlWFUuRlUxwoirjWA_8_0"></a><a id="Tc_9_k4XY-GGkKYANdAxwnJYQ_9_0"></a><a id="Tc_VV8FVq1K9kGpBSHFQIjAeg_10_0"></a><a id="Tc_3C8i-5X7pki0NFlUK-RbZQ_11_0"></a><a id="Tc_StF1qUFyX0m1poH85CIkng_11_6"></a><a id="Tc_yA1uvMXMeEmyJ4WT2X7RMA_12_0"></a><a id="Tc_ssofm4mfCECkYRHSwNMBFg_12_6"></a><a id="Tc_WW1zhp9pWkmQBqikCtuBtg_13_0"></a><a id="Tc_KFMnKdhpCEeNPuQ_y83jLQ_14_0"></a><a id="Tc_9nZxoXqQXk-HHSRmsxNMuA_15_0"></a><a id="Tc_qTaUQksnokKDoSBKOPG_iw_16_0"></a><a id="Tc_2QD6gMlz_UW6GOPcd_1PTw_17_0"></a><a id="Tc_kBUOReJPcEWby8Y28zg9RA_18_0"></a><a id="Tc_oBtfQMdLIkymV9j4Ijq5Hg_19_0"></a><a id="Tc_uhSxGcSW4UqO1KO6iJ68Fw_20_0"></a><a id="Tc_0SJOqUkzsEyIa-YgSzHeyA_21_0"></a><a id="Tc_edX8kgH15kKttnXOK4LIBQ_22_0"></a><a id="Tc_YGu_2k7ZZ0OuYA9BXCco0Q_23_0"></a><a id="Tc_iBIGdujRrkKJi2zrsX8E4g_24_0"></a><a id="Tc_UYTu44BD7Ei36N_qv291Rg_24_2"></a><a id="Tc_oa7VHojBYkuKmS68Lq0Rvg_24_3"></a><a id="Tc_4j3q_XL-AU-7Bsf211vLfw_24_5"></a><ix:continuation id="Tb_dVnRG1a2Skak1Geepo5a8Q_cont2" continuedAt="Tb_dVnRG1a2Skak1Geepo5a8Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_5R6b5SIDXk2JyLkltqb8bQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_I3_BfWX1LE-jfjNGku9EYg_5_3">114,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_YySYEJNfQUuqcQffRWX58w_5_6">114,443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsAccruedRebates" scale="3" id="Tc_Zua6k96kGEWeJUXXBp9qtQ_6_3">6,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsAccruedRebates" scale="3" id="Tc_CcP0CpYrAEuLWdmX_oNHvQ_6_6">5,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_ycQUsyUo7EKoIUpnOhYagA_7_3">4,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_SOWtCQ_Oaka8zorbKHDQMw_7_6">2,773</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_A5eAlkYaEEW2v28ATbz7lA_8_3">758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_PajtVnPBPk2vBPuqKNx4LA_8_6">817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_lIfyVqGwcUGEGii372NnmQ_9_3">2,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_Renrsfxt60SCDOZkMR4Jaw_9_6">2,423</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsInterest" scale="3" id="Tc_mE4EbTx_HEiuzOEORT-tag_10_3">4,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsInterest" scale="3" id="Tc_JiVs2oDrw0aEkUEyc0n0nQ_10_6">2,975</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="Tc_GgiqeaArcUCI8hMCmmYhxg_11_3">1,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" scale="3" id="Tc_FOE5hVtymEi-4lTO2jR0aQ_12_3">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_6xU8zWaPe0GznpSkIgkW2w_13_3">743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="Tc_D3zRloraPUKY37_cZt60YA_13_6">1,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_ReUNN-vFI0Kr-EYCudI1cA_14_3">492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_mbyJXI8LbEKwJuOkD8a_QQ_14_6">799</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_wYACH3EYpUWF1XR7JqAxtg_15_3">1,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_c8z6NALaH0uEmOwOe_p9Fg_15_6">1,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_b_OPMSvm8ki10vNqFUniMQ_16_3">137,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_vtSzJ87t9kymxbuX2kt6LA_16_6">132,652</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_4uQLZwpU4UyKkSMKmi_bMA_17_3">136,400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_R1zm5UicGkCvhDj-YZUW4Q_17_6">128,966</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_zGsgTVmpmkqzSpRPezMrMg_18_3">1,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_z432LUx-10uFWRyoW0-38w_18_6">3,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_6-ssxNpR7UiMWW7KzSn1Wg_20_3">845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="Tc_HPjAOCUrIEKztjY4-zDEAg_20_6">2,717</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_9U67NEqITUmsnMgUy0vBZw_21_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_mfsZTExzHE-y8f_UHwDHgg_21_6">308</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_huk88KhnXEuGEKbivxle7g_22_3">483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="aytu:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="Tc_AoLppWwgZ0qUk-AGIQyXlQ_22_6">788</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_ipmcDWc9iEiF6CDgt9sMjQ_23_3">1,378</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_WnTJtQYPWEyqFtUpKRT9rg_23_6">3,813</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="Tc_RwdOHhiVZ0SeXpR2deRQHw_24_6">127</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In fiscal year 2022, the impairment of goodwill decreased net deferred tax liabilities by $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" scale="6" id="Narr_dovBdmKCGUSW_ygJkhEIfw">0.1</ix:nonFraction> million resulting in an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" scale="6" id="Narr_mV1rNYrK8EGmst-FoeihXA">0.1</ix:nonFraction> million. As of June 30, 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="Narr_e4DBSh5kTEqMT2r-m0cZaw">0.1</ix:nonFraction> million deferred tax liabilities included in other long-term liabilities in the consolidated balance sheet. The Company had federal net operating losses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MBlO3K9Y5E-CNimpZftBwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_1DbaP_MKI0SnciYiimOEEg">503.2</ix:nonFraction> million as of June 30, 2022, subject to Section 382 limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_3yM3ByFDYEa6yI1CHnUJ2g">136.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_Iwg-8a7u_U-k1DPd4AgMnQ">129.0</ix:nonFraction> million at June 30, 2023 and 2022, respectively, to reserve its net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not, that it will realize the benefits of these deductible differences, net of the valuation allowance provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#8217;s net operating loss carryforward, interest expense carryover or research and development credit carryover and therefore do not require recognition. As a result of these timing differences, at June 30, 2023 and 2022, the Company had gross unrecognized tax benefits related to uncertain tax positions of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr__mYQmGaEgkuw4wYPVyq3MQ">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_UeHPbuQhlUmuhV1U1TR61g">2.8</ix:nonFraction> million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_64131230_c542_4c6a_8466_dd9f3d697ad3"></a><a id="Tc_8OswRDy87E6zgvlibf_73A_1_2"></a><a id="Tc_18ACsGZl3EGlA5xtTwSxng_2_2"></a><a id="Tc_jwApRzgeH0KG-jmJaddWzw_2_5"></a><a id="Tc_23MIAMnf6EORZmSmcenvhA_3_2"></a><a id="Tc_MHGhwJOgp0aHbK6hSQLwrA_4_0"></a><a id="Tc_mxCzq2XUd0GPCAcjJe69nw_4_2"></a><a id="Tc_phBtLaxCPkKpm8c4Hmn3dw_4_5"></a><a id="Tc_eecuy20JhESNNw6SzvR2YQ_5_0"></a><a id="Tc_HRtFJDMBYkCoZbaj3QQwkQ_5_3"></a><a id="Tc_L_v9TTWqSkiTLJhACqzj8Q_5_6"></a><a id="Tc_fMvLFRTpCUqU8KFNwMuuZA_6_0"></a><a id="Tc_RnZUzBNDfECrqSK58q1pUA_7_0"></a><a id="Tc_WJOrcQ0TMk2BL6jfbKuqag_8_0"></a><a id="Tc_jjd7k5qXbkGIRGfFEWeE7g_8_2"></a><a id="Tc_2-ex-dlH6U2hMSUEoZBZAA_8_5"></a><ix:continuation id="Tb_dVnRG1a2Skak1Geepo5a8Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A tabular roll-forward of the Company&#8217;s gross unrecognized tax benefits is below.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_bYYoqHwQPU-tJHIMISvylw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_mkQ0zv49GUCxUUWdckWSow_4_3">2,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_DcxP_RGPK0uxePVIff_OLw_4_6">3,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from prior period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_uPot53ItE0mH_7Y7g_8ueA_6_3">246</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_thkEsFB9JUqD9fyR3klajQ_6_6">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_wSGdzj1NLEmOIBWMwpPXtQ_7_3">120</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_zKbLXLa4wUGxPLCNSxIDpA_7_6">647</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_yjx2mtp_P0mhZogoGcLXqQ_8_3">2,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_yi306P61NEOrBJywxNxd9w_8_6">2,822</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The change in the Company&#8217;s gross unrecognized tax benefits relates to the acquisition of Neos, whereby historic tax positions of Neos were inherited in the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to 2004 being subject to examination.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_qQQw_6nLjUiAKYLpp-U1RQ" continuedAt="Tb_qQQw_6nLjUiAKYLpp-U1RQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_9_VzCTVtZUe_BY4C2oqPPQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_AuMZhG0Bq02W3TE7v4m8TA">200.0</ix:nonFraction></ix:nonFraction> million shares of common stock authorized with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_FSSgZbDcIk2zWuST0x5jKw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_vLtWntjLskOsH0lzwFKc7g">0.0001</ix:nonFraction></ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_ey0MIKy6pUGnp2vHUSeWJQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_EOkG_E2G8kWu09VBYgy3yQ">50.0</ix:nonFraction></ix:nonFraction> million shares of preferred stock authorized with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Rx3IQpJCrEmOtyrniMgwNg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Zj_dPmSkC0eVXRVHrHNwdg">0.0001</ix:nonFraction></ix:nonFraction> per share. As of June 30, 2023 and 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_apxGfm4LWku_3-j0CGjUWg"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_z1qe5EoP7U6lCNdGXyIvqA">5,517,174</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_z-cqLgvOpEiG02wRuAV3hQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_lS57SBx50UKbHnfLborsKg">1,928,941</ix:nonFraction></ix:nonFraction> common shares issued and outstanding, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_ge_CWWasykSQ75IqYWhYJg"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_F75a8ifL3EqzAjCpDAKIsw"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_oQAccj4dvkSX1CUOLPZhuQ"><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_6S818-YZY0muWmq5954NsA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred shares issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Included in the common stock outstanding are <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TdsGYshoqUijifsxflxvYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_R--OjroIkE-nEm3gQ5x1xA">40,996</ix:nonFraction> shares of unvested restricted stock issued to executives, directors, and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2020, the Company filed a shelf registration statement (the &#8220;2020 Shelf&#8221;), which was declared effective by the SEC on June 17, 2020, covering up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_17_2020_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfMember_g5mEjHtQiUyvG-DIxyhSLA" decimals="-5" format="ixt:numdotdecimal" name="aytu:ShelfRegistrationAmountAuthorized" scale="6" id="Narr_A3ebeaE-rkyWcL-2KHjL1w">100.0</ix:nonFraction> million of its common stock, preferred stock, debt securities, warrants, rights, and units. On June 4, 2021, the Company entered into an agreement with an agent for the sale of up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_4_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_6bo-99QlKEWBnykXi0Nj8w" decimals="-5" format="ixt:numdotdecimal" name="aytu:AtmSalesAgreementAmountAuthorized" scale="6" id="Narr_wWCNeotl702fk2MuWKVAzQ">30.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2020 Shelf (the &#8220;ATM Sales Agreement&#8221;). During the year ended June 30, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ze6ZSJWgA0KnI_-dMdd42g">699,929</ix:nonFraction> shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr__od4kflCtUm3wxjY1te-2w">3.0</ix:nonFraction> million before deducting underwriting discounts, commissions, and other offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A" decimals="-5" format="ixt:numdotdecimal" name="aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" scale="6" id="Narr_PdwMHqxqxkKorRlsvdXE_Q">0.1</ix:nonFraction> million. The 2020 Shelf expired in June 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 28, 2021, the Company filed a shelf registration statement (the &#8220;2021 Shelf&#8221;), which was declared effective by the SEC on October 7, 2021, covering up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_9_28_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_biR4fT1tx0yl6OmCteqbJw" decimals="-5" format="ixt:numdotdecimal" name="aytu:ShelfRegistrationAmountAuthorized" scale="6" id="Narr_T57JElUAwEKY3U1fra_vJA">100.0</ix:nonFraction> million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2023, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_t8Ed9oXcc0ahpFotmKPoCw" decimals="-5" format="ixt:numdotdecimal" name="aytu:ShelfRegistrationRemainingAmountAvailableForSale" scale="6" id="Narr_0WqzyCvkgUasB9TWACnENA">82.4</ix:nonFraction> million remain available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. The 2021 Shelf expires in October 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_t5IWsTWUe06II53YZRBf3g">151,500</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KyVLLDBRykuK9nfZvX9jDw">151,500</ix:nonFraction> shares of common stock, and (iii) common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1CHTv40zdkK3YS7uoe7Z8w">333,300</ix:nonFraction> shares of common stock (the &#8220;March 2022 Offering&#8221;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_1czrUMCo2U6i7MU7buKz0Q">1.1</ix:nonFraction> shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_o9VmgfFSUEiXatjNkOi0vg">0.002</ix:nonFraction> per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CAwpursoU0qpGQR5oQh8WA">26.00</ix:nonFraction> per share of common stock and are exercisable <span style="-sec-ix-hidden:Hidden_fR7I1KmwmUOKA79OdXpBSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span></span> after the date of issuance and have a term of <ix:nonNumeric contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_9u7YqFng-kCVTA6JqhESHg">five years</ix:nonNumeric> from the date of exercisability. The Company raised gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA" decimals="-5" format="ixt:numdotdecimal" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="6" id="Narr_rbx_aD2ev0iH0N6XxWsfpg">7.6</ix:nonFraction> million through the March 2022 Offering before commission and other costs of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA" decimals="-5" format="ixt:numdotdecimal" name="aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" scale="6" id="Narr_el8GYwKeNkGWg8LlYT6DfA">0.8</ix:nonFraction> million. The pre-funded and common warrants have a combined fair value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_bAadN-Ex1EW_8qD9_Q9QAA">2.8</ix:nonFraction> million at issuance, and are classified as a derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see Note 16 - Warrants).</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qQQw_6nLjUiAKYLpp-U1RQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On <ix:nonNumeric contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_FQ-7_5jVYEOW0V9xTQzqgw">August 11, 2022</ix:nonNumeric>, the Company closed on an underwritten public offering (the &#8220;August 2022 Offering&#8221;) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_M3X9oG45kkSLnt29N-cBOA">1,075,290</ix:nonFraction> shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_fGeqUiuEok6jlRXP4uY0RA">87,500</ix:nonFraction> shares of its common stock, and (iii) accompanying warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_YHyrFgDghkqz-hzG1rrPEQ">1,265,547</ix:nonFraction> shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_9gverrxbKUK9oYHeXUrkaQ">one</ix:nonFraction> common warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_YHsl-ggX1EeVYlFjYgd-3Q">one</ix:nonFraction> share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1c-ygVpo4EypcsU4CkVa0Q">8.60</ix:nonFraction>, and the combined offering price for each pre-funded warrant and accompanying common warrant was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightOfferingPrice" scale="0" id="Narr_zpL9LAwFgEWkyzaL3EgtHA">8.58</ix:nonFraction>, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_31_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_ik8BrUrWiUqfXRn4qxLh-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_mtq_QBFKCE2CHe1McTWa5A">0.001</ix:nonFraction> per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_15YFYDxNtUyzsB00zTEIRg">8.60</ix:nonFraction> per share of common stock and are exercisable for a period of <ix:nonNumeric contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_3k35P_CB-kqDhMvTpDPyVQ">five years</ix:nonNumeric> from issuance. The Company raised $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA" decimals="-5" format="ixt:numdotdecimal" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="6" id="Narr_C9GA9eA2n0Ce62RWRbQSHg">10.0</ix:nonFraction> million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA" decimals="-5" format="ixt:numdotdecimal" name="aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" scale="6" id="Narr_DyizO_kNREajBZnsLJHANA">0.9</ix:nonFraction> million. The pre-funded and common warrants have a combined fair value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_oxD6_ah7TkWS9YeM_bj2Hw">6.0</ix:nonFraction> million at issuance, and are classified as derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (See Note 16 &#8211; Warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_WKAf8oEmU0a1hF7jdibpNw">June 8, 2023</ix:nonNumeric>, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell an aggregate of (i) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_iyiG3Egjd0SwGOQUwt26OQ">1,743,695</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants in lieu of shares to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_l347MGO4HUapGRyzMJxwlw">430,217</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), (iii) accompanying Tranche A Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_TL1iizNZa0OPs8BRWHFklA">2,173,912</ix:nonFraction> shares of common stock, (iv) and accompanying Tranche B Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Dx-Rw7bmCk-fw79wNUAAew">2,173,912</ix:nonFraction> shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ADLK7Xhw2Eqcw02LX3tiwg">0.0001</ix:nonFraction> per share in the same form as the Pre-Funded Warrant (the &#8220;Exchange Warrants&#8221;). Each Pre-Funded Warrant will be exercisable for <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_80dVEL80M06emJg-qEzWag">one</ix:nonFraction> share of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_TBcydqPWNUizj0YiY9Ya7A">0.0001</ix:nonFraction> per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q" decimals="2" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="Narr_z9IX80Xr3kC5lBvtIK562Q">1.59</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="4" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="Narr_rWvbkZEBp0WHR61t2LxWjw">1.5899</ix:nonFraction> per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <ix:nonNumeric contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_1MJaSgshBU2H9zP1-S7ywg">five years</ix:nonNumeric> after the date of issuance, and (ii) <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q" format="ixt-sec:durwordsen" name="aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" id="Narr_1swSRuMuC0KpHNn19h9Szw">30 days</ix:nonNumeric> following the closing price of the Company&#8217;s common stock equaling <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" scale="-2" id="Narr_K_Xa-1a8UEGRzIIhw9W2bA">200</ix:nonFraction>% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) <ix:nonNumeric contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_9JHEPMy8zkaJKdK1rIXEsQ">five years</ix:nonNumeric> after the date of issuance, and (y) <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA" format="ixt-sec:durwordsen" name="aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" id="Narr_1OAzFbCXq0eu3zQmCMVMMA">30 days</ix:nonNumeric> following the Company&#8217;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA" decimals="-6" format="ixt:numdotdecimal" name="aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="Narr_vItENKF_sUKk4LvK1E6NvA">12</ix:nonFraction> million. The Company raised $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="6" id="Narr_BLltnzEieki3Xlb2G_xf3Q">4.0</ix:nonFraction> million in gross proceeds and net proceeds were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" scale="6" id="Narr_NQo5Ok_7xUCXRiQzMQouxw">3.4</ix:nonFraction> million after deducting offering expenses. The warrants have a combined fair value of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_QByDhdR18kWOtQNXuaKWXg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_8DorV8Q5TkajnchYXDJMGA">5.0</ix:nonFraction> million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" scale="6" id="Narr_wdY71VAp-E-02C9s4zQn0w">0.6</ix:nonFraction> million in the consolidated financial statement of operations (See Note 16 &#8211; Warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Pg8hqGz--UmWV1_lwbwGKg" continuedAt="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Equity Incentive Plan.</i><span style="white-space:pre-wrap;"> On May 18, 2023, the Company&#8217;s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the &#8220;2023 Equity Incentive Plan&#8221;). Prior to the Company&#8217;s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (&#8220;Aytu 2015 Plan&#8221;) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (&#8220;the Neos 2015 Plan&#8221;) (collectively the &#8220;2015 Plans&#8221;).  For the 2023 Equity Incentive Plan, the stockholders approved (a) </span><ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_gVKcaUJ1CECD_fzk8wUn2Q">200,000</ix:nonFraction> new shares, (b) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_n0rO3WOrfk6Pemz7ClLddg">87,155</ix:nonFraction> shares available for grant under the 2015 Plans be &#8220;rolled over&#8221; to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_q294pgLXSkiw4_mNpKB8fg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_wfMLQhCXU0iptJnSOffSSw">no</ix:nonFraction> additional <span style="-sec-ix-hidden:Hidden_Hl9WG5ycz0COuiafV-9j_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">awards</span></span> will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. As of June 30, 2023 the Company had <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_se_2_5-8wkmfy3FsWYR-eQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_GgQ6HngVLU6KZEjP1zLtnA">287,155</ix:nonFraction> shares that are available for grant under the 2023 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Aytu 2015 Plan.</i> On June&#160;1, 2015, the Company&#8217;s stockholders approved the Aytu 2015 Plan, which, as amended in July&#160;2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_eb20d59b_d470_4851_bd9f_0f1ad003df35"></a><a id="Tc_fxzhxxV86EW-bXqGumYW8Q_1_7"></a><a id="Tc_fBwmSjIcEU6xGf3oegvlFw_2_7"></a><a id="Tc_AmRTDkK1Wk24MmayGHz_HA_3_4"></a><a id="Tc_Drkb2pdY_ESiCxG3UCdGAQ_3_7"></a><a id="Tc_uvUPcQJ-30mbnuSb_OXVsA_4_2"></a><a id="Tc_k2OEgB3CRkGTiw7pn8zfWQ_4_4"></a><a id="Tc__5sAIJhwuEepITiVkqBWQg_4_7"></a><a id="Tc_-JhSKhjSuEKr9mEJd6N-BA_5_2"></a><a id="Tc_tO4cw1E3dU-NamoJ-2vP1A_5_4"></a><a id="Tc_ZdIujpKsE0-h_d_4ssSRZg_5_7"></a><a id="Tc_ovLhLAXfq0OBuz-_PZnG4g_6_0"></a><a id="Tc_IO1BGahBWUG-gs9jAP98Zg_6_4"></a><a id="Tc_mWs-_PXpbU-EbJmB9nw0vA_7_0"></a><a id="Tc_T0UWltpDkk-Y7ISCWniVPg_8_0"></a><a id="Tc_Y83yozJXUEGyGwBMkoWZGQ_9_0"></a><a id="Tc_qRCPjbwKDkWvZmt2e0kkRQ_10_0"></a><a id="Tc_UoyDCbG1i0aN_L57kcYvxQ_10_4"></a><a id="Tc_6h40EAftI0ScO31XnY_AHQ_12_0"></a><a id="Tc_x_8s4UFVoEmCb4-Q4CtkNw_12_4"></a><a id="_5e8480e7_2951_42aa_ac8d_6cce9d3f3556"></a><a id="Tc_4W6AtjKsoUi03qQEnsvZ8g_1_8"></a><a id="Tc_tbF21F1zRkmMBnENamSJ0Q_2_8"></a><a id="Tc_I9OhKGhS1EOemYgRlJZEtQ_3_8"></a><a id="Tc_UhEVPzPPm0Ozex-zcCDQ5w_4_5"></a><a id="Tc_HnjcmdacbU2rBw6r5FXleg_4_8"></a><a id="Tc_dM619BvGS0a4QG5BOfJGgw_5_0"></a><a id="Tc_ItEYfyaGeUGklL1uaWDTCQ_5_3"></a><a id="Tc_6mYsf9Zg2EWYaDmgRNdNCw_5_5"></a><a id="Tc_L_hODLMWwUOmbLzsM4s_nw_5_8"></a><a id="Tc_XKDEXNLPR0mC0tYC3Onp7A_5_10"></a><a id="Tc_9_7cCRSUUUC6VE_QnMEn4g_5_12"></a><a id="Tc_aV2m83_aV06Qg5-WP2l15g_6_0"></a><a id="Tc_4VrMD61lT0-2ESGUlr2gDw_6_3"></a><a id="Tc_lQjZEJ8c50WX5RB7iVizPA_6_5"></a><a id="Tc_FsiGC3jfjUOFhTY2QzFdiA_6_8"></a><a id="Tc_3io_s-CrN0iiq_rUlwqmLA_6_10"></a><a id="Tc_mgEJvcUXkkWOzQMtG34N5A_6_12"></a><a id="Tc_xn9WmXnPNUyMCkMrdJJ7Kg_7_0"></a><a id="Tc_5UJfEOMfT0Cc3bBmRgzUdw_7_3"></a><a id="Tc_dXq7lR9jRkCGANKyuxMc2w_7_5"></a><a id="Tc_KzzV_Rz4zUCkrWumz_55yQ_7_8"></a><a id="Tc_ttQSBg2qLUK4qB1qwIVcaA_7_10"></a><a id="Tc_itj2FU5n-0y3juQVbTwVIA_7_12"></a><a id="Tc_E4Z6vb0L40S5BYwc71xdAg_8_0"></a><a id="Tc_rFrQ0Ol0F06fshr2Fl5IBA_8_5"></a><a id="Tc_LqbO-VJVWEqqkzAU4hMAwQ_8_10"></a><a id="Tc_LqVI3MQKtEqAHSZyykCZJA_8_12"></a><a id="Tc_2XT_70Kgw0iASI-RlwG8Cw_8_13"></a><a id="Tc_MwSuGnuzCkqnFQEQIAnPMw_9_0"></a><a id="Tc_OPNRcMPDqEa9CXlhMj75Fw_9_1"></a><a id="Tc_cG8IP5x8YUO6wUtIrycfZQ_9_5"></a><a id="Tc_utmMi-FJ3EeiOII8iPr_9w_9_12"></a><a id="Tc_SKHAQ9YVp0CCyt_Bh9-ffw_10_5"></a><a id="Tc_joBvJ3SZtkOs7CcmTQk_Dw_10_12"></a><ix:continuation id="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont1" continuedAt="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">equity awards. On February&#160;13, 2020, the Company&#8217;s stockholders approved an increase to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_13_2020_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_L2WFGiNHUUeTtcgD-Tt5cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_Nmtr81akKkK56wGSvh11bg">250,000</ix:nonFraction> total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_Hq8jU58mP0yXy0NLI2hCtg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_R2PmUspq6U6jgY86bsNAFg">10 years</ix:nonNumeric> from the grant date and a vesting period ranging from <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_S6HC2MMrH0iNwu4ujLgsNA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fjrEZtpkc0OZPz93klhDiQ">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_trxd6492bkmdu5cEs_LDOQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_asrubAa0tUqqVXoC_daDpA">4 years</ix:nonNumeric>. The restricted stock awards have a vesting period ranging from <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_-jV0TussHES3Y8yd6y1Z7g" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Dskadpd_R06WW2e6PVlEHw">4</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_bgnuDzVZ90GHs01Kz4agwg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_5snPOueX70eHaExI2beQFA">10 years</ix:nonNumeric>, and the restricted stock units have a vesting period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_CQLYBsBbXECCphRQy0MWNg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fyiIY54YokC2cD3lNn7XWw">4 years</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Neos 2015 Plan.</i> Pursuant to the Neos Acquisition, the Company assumed <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_YRN694O3EEKsSKs55s-uVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_uQI604C_TkeYiO_sz_I92w">3,486</ix:nonFraction> stock options and <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_19_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_5bokif2CVU27ubsvFSCIGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Narr_1zS6sAZT2k2LR4MrWSxYaQ">1,786</ix:nonFraction> restricted stock units (RSUs) previously granted under Neos plan. Accordingly, on April 19, 2021, the Company registered <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_4_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_t8eRN6kS_EqT7DiyJIMG7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_E5gE3D45xE2Rx35QRVQOBw">5,272</ix:nonFraction> shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities will stay the same as they were under the previous Neos plan. The Company allocated costs of the replacement awards attributable to pre- and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_8cakf67lD06PgvsYxOk2qA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_92pSw_z9OUmsIinEuYfMPw">10 years</ix:nonNumeric> from the grant date and a vesting period ranging from <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_amdkmNT3rEWFjdSSoepO6g" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_WMd7pMp29k6gCn-ZqhjCYA">1</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_gPGJ0H3cakSZg1nXXAX0Cw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ND7fYs_6EUeL766wpVWijA">4 years</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_nBwUQDCSfkSj3yLRlNJtVQ">49,212</ix:nonFraction> stock options were granted. The weighted-average grant date fair value of options granted during the year ended June 30, 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_lMdwQe1_JkyaWgGXXc9TMQ">4.00</ix:nonFraction>. As of June 30, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_Mi_pfHqtFEmzsLK2pBeTXw">0.1</ix:nonFraction> million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UpGaGbRyLEqoaYVRkRx8cg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_6QB6wNGmekycm9ucFueYrA">2.2</ix:nonNumeric> years. <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_MdKa1movyUWCm5QC_RPPCg">No</ix:nonFraction> options were granted during the fiscal year 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option activity is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_gBpj7yXvA0uZ8ANagrf3LQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kCgy_M0jJUK2jnXUyhVaXA_6_2">3,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_V7EJLKiMHUGdz2f9Lva4hw_6_5">209.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_TXCBuMgAXkWf8RiTiVucuQ_6_7"><span style="font-size:8pt;"> 7.77</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Dk85phsw90aLN29XxrBFTQ_7_2">49,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_phnx6LJWekedBSNVnEOqvA_7_5">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_o-AGRrE69UanSY3yK8hKSg_8_2">172</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6Sx9BbLNA0GbqGHTzJEvlQ_8_5">128.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_4pUcl346gUWdYVUvufLfQA_9_2">177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_e5lX1_vXQkWGiE3O-SQp9g_9_5">131.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_GwXSAFgLuEy4P8jE3N0WiQ_10_2">52,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0GuEJERaxECj5A8oBEJ4JQ_10_5">18.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_a7fRJljo8kyzZGUP_mALEg_10_7"><span style="font-size:8pt;"> 9.06</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercisable at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_5ysC1AilDEixEzsQPxeA0g_12_2">3,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_kZfjSwpVtUGw0BzSo_ARjg_12_5">225.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_cAIbx4D4CEyrM_TOuYWJtQ_12_7"><span style="font-size:8pt;"> 6.17</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table details the options outstanding at June 30, 2023 by range of exercise prices:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_3HvAr78fFESSuShpsSvzqA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_wYfOGVOEkE6R_whPigkyBg_8_1">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc__n4OMu58u0COQ7iGY9TmtQ_8_3">49,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_NjgXz0YB1UyPdiQk9CD2Ww_8_6">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_5yM4PQVgnUGKwvtcrGkWFQ_8_8"> 9.26</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_ThApNN5hSEC7yAWt4I3olg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Narr_72VrYP2pKkiM1h0_z-Di5g">123.16</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_WlYHSncbxkyESoDclR_i5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Narr_rct_7xD5FUOa4dbLI5B3gQ">290.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_NjHCOnGqNEW_r7c3dXPguA_9_3">3,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_f4dom1HmNkaRqz6P2v_MNw_9_6">217.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_R0AplVHYPE256NcvwZAgUQ_9_8"> 6.26</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_oJyHTvDdX02LyjTYi268Sg_9_10">3,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_zTBqu3TSkE2DBxsBUinPtg_9_13">225.74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_pIg8Yy8BKEeeazQx4mKM_Q_10_3">52,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Tc_QyJaQjIzWUC60_gCyUGDXg_10_6">18.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_KCcIDrlYDEyDE9YbfRbaOQ_10_8"> 9.06</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_WscpoTD1gUqRN-70faLYxQ_10_10">3,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Tc_-9U7atAj0kKrbN8chUvJlw_10_13">225.74</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4180e82c_37f6_4901_9e7e_bb9462359f21"></a><a id="Tc_BMq3qVfkWUyvDOEF1GG8qQ_1_4"></a><a id="Tc_PE_aVvRAFUWDApXclvgcgQ_2_4"></a><a id="Tc_EUvXaDMsm0GXdHuEWgEmlA_3_2"></a><a id="Tc_tOh2Gtufu0Wq9WVXsAuhQQ_3_4"></a><a id="Tc_YzwX5xHLZkyyq-o_2dv2Sw_4_2"></a><a id="Tc_mxKzjjTcwUqHzQQaDVRLug_4_4"></a><a id="Tc_wGO-hsaCQkCs3r2znKbR9Q_5_0"></a><a id="Tc_7GmhBgcuH0uP5GmrLKqMMw_5_4"></a><a id="Tc_HA8cxy05dk2g6cHQmNw1Kg_6_0"></a><a id="Tc_bFr9NtFgR0qD4Gne2ZzGpg_7_0"></a><a id="Tc_8be-0adB3kWZrBWIxiSTdQ_8_0"></a><a id="Tc_CuYwDp2qjUuaH_MHOwYw5Q_9_0"></a><a id="Tc_U4gLYSXMhU6t8cMp9n_Eww_9_4"></a><a id="_9bb4f79f_4c36_48cf_9cce_d069cd1487a4"></a><a id="Tc_eORl7zd_IkK3YWvmZLN6Ug_2_4"></a><a id="Tc_NKLlYtKh9kiU0qY70Nja8g_3_4"></a><a id="Tc_rq2czlWIUU6SpT9d7Bl12A_4_2"></a><a id="Tc_mpKWSwCaeU-XWlxN-e5zQA_4_4"></a><a id="Tc_0ufaNEYrGkeq6rKYqp7q5A_5_2"></a><a id="Tc_tkyc32LqREuGa1Hs_HlU-A_5_4"></a><a id="Tc_NvtLhkNJKEOcNondN2J-XA_6_0"></a><a id="Tc_m1SEBSHKJEKCgpQ8ulO2EQ_6_4"></a><a id="Tc_ManYcJsJUkGIR1zb1XhU7A_7_0"></a><a id="Tc_I0ptHYIs_kGEgFLIltWm9g_8_0"></a><a id="Tc_XIAFTLqd8UekA2agu8N0Qg_8_4"></a><ix:continuation id="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont2" continuedAt="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, as a result of the change in members of the Company&#8217;s board, the Company accelerated unvested shares for <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_1u8MB_0WKUqOOhFJoTnpRQ" decimals="INF" format="ixt-sec:numwordsen" name="aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" scale="0" id="Narr_qOL2DHNPmU-nmhQ34QjLBg">two</ix:nonFraction> former members and recorded $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_m2S0-xKuZ06BhQoPKWEIIg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_JR105v7VHkyNfZkwS64oCQ">1.5</ix:nonFraction> million of non-cash equity compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2022, the Company entered into a Stipulation of Compromise and Settlement (the &#8220;Stipulation&#8221;). As a part of the terms of the Stipulation, the Company agreed to rescind <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ" decimals="INF" format="ixt:numdotdecimal" name="aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" scale="-2" id="Narr_mNQAjAQKRUScPl2KxXy-IA">25</ix:nonFraction>% of the aggregate 2021 grants to board members. As a result of the recission of the shares, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_k0LRZr6SIU22bwLF2nri4A">0.6</ix:nonFraction> million in non-cash compensation during the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, the Company granted a total of <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_8_2_2021_To_8_2_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_6Su9NkIAvUOaA057CsgVYQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_W8SPtPtkt0qX3W8o-gGssQ">6,825</ix:nonFraction> shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which <span style="-sec-ix-hidden:Hidden_RhAn5e9yTkGo43QiNn8L3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> vest on the grant date and <span style="-sec-ix-hidden:Hidden_76J9aX39Y0KMdQ7sa8ZTdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/12</span></span> <span style="-sec-ix-hidden:Hidden_ZQWV1d3orUOWhJfxpy8Wrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span></span> <span style="-sec-ix-hidden:Hidden_Kew6LAzlW0Subej7uXg45g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span></span> <span style="-sec-ix-hidden:Hidden_atRctttF5kGizw3GS0D_sg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span></span> day of <span style="-sec-ix-hidden:Hidden_UM8ORUgeAkeglLMdGPU3ZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each</span></span> <span style="-sec-ix-hidden:Hidden_fyBILllLnk6bWwcWwYApTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarter</span></span> <span style="-sec-ix-hidden:Hidden_Ez33FFSqI0uGMSU9NaITRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereafter</span></span>, <span style="-sec-ix-hidden:Hidden_ZiVqmCiNWEOf8STK7ZK6yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject</span></span> to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_c91ZRffRLEe9Xlg8BIIOcQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_29pFoY08jk6I6sIstLuYog">3.31</ix:nonFraction> per-share to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_VVTadRrGBUuL-6oQmtuGQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_PCu0GjFosEe6BFI-a6IRUg">13.4</ix:nonFraction> per-share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock activity under the Aytu 2015 Plan is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_IwOCWfvFhkinZ4ur6dWlVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_mtMIfcJgOkmi7ZryXuvtXg_5_2">80,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_TCCfk10TxEG5ZG862v1qdg_5_5">148.91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_gaPkLrfcsEOcx0MuxrV-jQ_6_2">6,825</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_FPML5s2Uc0WNB1JEcTGjDA_6_5">3.79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_EL4jHeHBpEm1kzdN9fS2fA_7_2">42,434</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_A7EQi8wYR0ijwPm3pMpVbw_7_5">126.98</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_qKHLy8sMU0aVRAU8KRBHJQ_8_2">6,689</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_zd4iUBhxNki_ZW9fGa7trA_8_5">135.66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_-R0j_avDvkivZwXFdx0o5w_9_2">38,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_LLgTuBN-3UimVt6uxfkF_Q_9_5">142.20</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_o7uJh5pXqkKwxiF0v1DPYA">3.6</ix:nonFraction> million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_ZaGAMXoutkWZbqSmR8QHfA">2.0</ix:nonNumeric> years. The total fair value of restricted stock vested during the year ended June 30, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_23nvJXDXLkuXBhoG4e-x3g">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously issued <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_F2hovHPtGEavzcSlfSHVYA">4</ix:nonFraction> shares of restricted stock outside of the Aytu 2015 Plan, which vest in July&#160;2026. On January 17, 2022, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_HJzqFgT2yk2YpqE--Tq1AQ">5,000</ix:nonFraction> shares of restricted stock to a member of its management team outside of the Aytu 2015 Plan, of which <span style="-sec-ix-hidden:Hidden_aDjYmXhr_0y36dQjawXmwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> vest on January 17, 2023 and <span style="-sec-ix-hidden:Hidden_Cdi3hkXdc0OpPArxBtSwhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/12</span></span> <span style="-sec-ix-hidden:Hidden_w_FAzbQnJkiomaZGu2gnqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each</span></span> <span style="-sec-ix-hidden:Hidden_RQWy15Pb2k-QNuwGzup_XQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarter</span></span> <span style="-sec-ix-hidden:Hidden_Pb5UtpvkmEGcCA2EitT1Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereafter</span></span>, <span style="-sec-ix-hidden:Hidden_NOkVRpcVoUuTSnoKpinAAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject</span></span> <span style="-sec-ix-hidden:Hidden_pnnHcg3G30GLFzKZerZfyA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span></span> <span style="-sec-ix-hidden:Hidden_Zf0xvLUMsEy4X0ESjua5-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing</span></span> <span style="-sec-ix-hidden:Hidden_SjR6CETviEC4J8qxQetREw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employment</span></span> with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_o-sEaFANTUuOWHw2NkSUHQ">27.00</ix:nonFraction> per-share. As of June 30, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_4vybuWwiOkecBLkUHT6SMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_Wfdh4BN4KEOR7mcXsgtWUw">0.4</ix:nonFraction> million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_N8QRmflkVEK0aXHJHlg2eQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_gbOhtH7RQ0G988VflExXDg">1.56</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended June 30, 2023, the Company did not grant restricted stock units (&#8220;RSU&#8221;). RSU activity is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="Tb_XeWi9L6vHUyAEdsppsu6eA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_77OPaXYOVE-QYXLQE3fEGQ_6_2">8,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_C6L8joOvFk-zltZpd7_D6w_6_5">25.88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_aQKKw3Ipm0Gf2Qr7ameJRA_7_2">3,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_z-RaxzHie06qVjm_niF-Qw_7_5">26.26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_eQPtgqhtNkekUyv-xBXcAg_8_2">4,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Nck03Jxf2E-qE9zFKLPL4w_8_5">25.62</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dee4b06b_fb02_4f04_a1ac_bdbac5e06431"></a><a id="Tc_4_3tCQk3m0OnV98JcZN8KA_1_2"></a><a id="Tc_y3vu2TqURUm9XuuXiEYM8A_2_2"></a><a id="Tc_ttV1iWNt90u7tNjA5-2NHg_3_2"></a><a id="Tc_3n-HbBMAh06C0zEiDNdW_w_3_5"></a><a id="Tc_oJ2-w0-alkm5-VOPDM3PZQ_4_2"></a><a id="Tc_FXpI6fTXaEKHIdI5h_Gd6g_5_0"></a><a id="Tc_A2KfvrUVAkSf7VFb4On-IQ_5_2"></a><a id="Tc_ywNwgdNlRkCjXht2QsH4IA_5_5"></a><a id="Tc_LCRufM3opkGFtOOelgrlUw_6_0"></a><a id="Tc_DaGRURd5O0CswM0MvhpQvw_7_0"></a><a id="Tc_A4ax6b2HKkuBtXYo_lYFBA_8_0"></a><a id="Tc_zQJ4wlBisEKVblytvg8pPw_9_0"></a><a id="Tc_kS5CjpCrxU6k-2MiruOxLA_9_2"></a><a id="Tc_v4824nKLeky5RTLkWPY2JA_9_5"></a><ix:continuation id="Tb_Pg8hqGz--UmWV1_lwbwGKg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_xV6yLhjZ00-rgDo5smqhqw">0.1</ix:nonFraction> million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#8217;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_I8_JoPgwBkGOqw4paOPDhQ">1.6</ix:nonNumeric> years. The total fair value of RSUs vested during the year ended June 30, 2023 was immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Tb_CCKVPkiDGUCVIxlMV-dD8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_xlpXGmnCE0q9N4hnP11C0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wHniP4IAvEiqZ9ZiwcX2lg_5_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_vnaTWWbZJUOh5Za0C4EoQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ejmRkBXGcUadmZF_vX_O0A_5_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lWZtLtuZq0aBxZRyaXV8jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_FlNsYSjS8Eu02N3FcklJAQ_6_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AwSMEA2VYkySNlTWV-Mg5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CObVIUIbIkei6NH1RnTgAQ_6_6">536</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_G4vMM4ms7UyTRxItSf21Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nGXvfv3RxE2OVpFHf2QYMg_7_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_l930vcslY0aPIpci-ZFhFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uwXRydtHYEGmpHVTNMO_Mw_7_6">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and Administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_M9qxYqENEUmjeBlE_Zjf2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GxRPWdmh40S2J7NKsSpRtg_8_3">5,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_95MKJo-V6E6JsQfGaBmnxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_giBiMzvU90enecHxB6FUCw_8_6">4,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_3ynmSVfO40OmLENH14bGzw_9_3">6,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2axJkolD9EeNFZkMcy_cvA_9_6">5,248</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:WarrantsOrRightsDisclosureTextBlock" id="Tb_rjrj-z_qAk6uRXIw0W-e-Q" continuedAt="Tb_rjrj-z_qAk6uRXIw0W-e-Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liability Classified Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation valuation model, and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_5YRQvHTdVkqMabm3tRUsNw">June 8, 2023</ix:nonNumeric>, the Company entered into a securities purchase agreement (the &#8220;Security Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell an aggregate of (i) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_0RBmHp2Uw0OOa4M1A4u_0Q">1,743,695</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants in lieu of shares to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Fgz0rN7wGk2fcxTPEqaCzQ">430,217</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), (iii) accompanying Tranche A Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_oE6Vur2X9U-Y4JjQIhW-GA">2,173,912</ix:nonFraction> shares of common stock, (iv) and accompanying Tranche B Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_CdUxa4E8H0yT35xydlOIKA">2,173,912</ix:nonFraction> shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_GWlJoVu3MkyEu-vTQLAF0g">0.0001</ix:nonFraction> per share in the same form as the Pre-Funded Warrant (the &#8220;Exchange Warrants&#8221;). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lbAgpVHhWUG8h-6KGjZojQ">0.0001</ix:nonFraction> per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="Narr_zwyyy4DEg0KPqPqkhigYpA">1.59</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" scale="0" id="Narr_566DdUFrG0CK_pFGw1ibcw">1.5899</ix:nonFraction> per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) <ix:nonNumeric contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_4i7GfGIHhES2neYNNfqSxA">five years</ix:nonNumeric> after the date of issuance, and (ii) <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q" format="ixt-sec:durwordsen" name="aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" id="Narr_s34h3acVVEq2jD3j4rr-UQ">30 days</ix:nonNumeric> following the closing price of the Company&#8217;s common stock equaling <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" scale="-2" id="Narr_T4cCuUu8OEe3kpfb7FVF2Q">200</ix:nonFraction>% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) <ix:nonNumeric contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_54nFkxRZF0GcbsIOYVSraw">five years</ix:nonNumeric> after the date of issuance, and (y) <ix:nonNumeric contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA" format="ixt-sec:durwordsen" name="aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" id="Narr_InUZnx2QXEGVzjBqszyDyA">30 days</ix:nonNumeric> following the Company&#8217;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Security Purchase Agreement) of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA" decimals="-6" format="ixt:numdotdecimal" name="aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="Narr_zKv3iNkqxUKHpXR-RTP7Rw">12</ix:nonFraction> million (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On <ix:nonNumeric contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="Narr_iZGrfOCMykufN4CaI03JSA">August 11, 2022</ix:nonNumeric>, the Company closed on the August 2022 Offering, pursuant to which, the Company issued pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Dw9b6q8otEWR1BSf0ScZyQ">87,500</ix:nonFraction> shares of its common stock and common warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_pC922mw5YUGKn4U_dZGAfQ">1,265,547</ix:nonFraction> shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_NIqMM-l6o0engU-QPuU5KA">one</ix:nonFraction> common warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_aWuWpiTXy0aGfhcl_QLDyw">one</ix:nonFraction> share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vW6JO9r8YkWxu0LCe7yS-Q">0.02</ix:nonFraction> per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0jIlk3KreEayH748-wms4Q">8.60</ix:nonFraction> per share of common stock and are exercisable for a period of <ix:nonNumeric contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_3QVrTmKSG0iG_eAf3oV4Lw">five years</ix:nonNumeric> from issuance. The common warrants provide that </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_TcLrWCfm-EOPwuEvlDE-5w"></a><ix:continuation id="Tb_rjrj-z_qAk6uRXIw0W-e-Q_cont1" continuedAt="Tb_rjrj-z_qAk6uRXIw0W-e-Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#8220;Stock Combination Event&#8221;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the <ix:nonFraction unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt-sec:numwordsen" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" scale="0" id="Narr_yTr7ahOmqkiP5O75iSCXRQ">five</ix:nonFraction> lowest trading days during the <ix:nonFraction unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" scale="0" id="Narr_exFpJRTVAkOPXppGvAZHmA">20</ix:nonFraction> consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt-sec:numwordsen" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" scale="0" id="Narr_xevQ7rePkUmnj8FNSDZpqg">five</ix:nonFraction>; or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" scale="0" id="Narr_ip3C37vVLE6hW7JaWdUJwg">2.32</ix:nonFraction> and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" scale="0" id="Narr_bgcTfWqX3UWn4dxBrgbrPQ">2,325,581</ix:nonFraction> shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" scale="0" id="Narr_MZoGvqd0-EWEOPDdlD-Jcg">2.32</ix:nonFraction> (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_nloDuUge50CFnuMzgZuDDg">8.60</ix:nonFraction>. As a result, the associated common warrants exercise price was adjusted to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_X5m1-383nU2pNiIPZ7Z52g">3.30</ix:nonFraction>. On January 6, 2023, the Company consummated a <span style="-sec-ix-hidden:Hidden_9EV35llWm0G5Ej7R_H5Kdw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span></span> to 1 reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest <ix:nonFraction unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg" decimals="INF" format="ixt-sec:numwordsen" name="aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" scale="0" id="Narr_cAX_BPxc6Uqak8pSVZ4BkA">five</ix:nonFraction> trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_aUf6uQX8JkCRV6eBvCg8Kg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_TBfoAypBm0Simi7yu5IX1w">2.32</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SaDgg6Qq5E2r4cu2QPofHw">151,500</ix:nonFraction> shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_hja6sBKjTk2ySbal5PtYlQ">151,500</ix:nonFraction> shares of common stock, and (iii) common warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_IOE35FvSiU65Rox2o42YLQ">333,300</ix:nonFraction> shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_5n_jf809wUSZRkBdUi244g">1.1</ix:nonFraction> shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_405GdyEFWUW4ausAedY58A">0.002</ix:nonFraction> per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BvM6GuCUoUuhOJ_tKZnWDg">26.00</ix:nonFraction> per share of common stock and are exercisable <span style="-sec-ix-hidden:Hidden_u-AypRtbtUiKizPrtwHpzw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span></span> after the date of issuance and have a term of <ix:nonNumeric contextRef="As_Of_9_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_1cn0JRM84U6rdzEe3qxCig" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_draYYP28eU2LmR6eO4wvEQ">five years</ix:nonNumeric> from the date of exercisability (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, as consideration for entering into the Avenue Capital Agreement as described in Note 11 &#8211; Long-term Debt, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_4KgesRw2i0-1kF7uBkeatA">24.20</ix:nonFraction> per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WI8r53mWSkuzomIzqSqd4A">24.20</ix:nonFraction> prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the issuance (see Note 11 &#8211; Long-term Debt for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 &#8211; Fair Value Considerations).</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_JoG-7vr0HEW7thIw4ixgIw_1_7"></a><a id="Tc_A7Q_kRoqXkCjJ7tACgSppA_2_7"></a><a id="Tc_0LO-YrLJBUS086Z_R_EW2Q_3_4"></a><a id="Tc_JiMySnu-K0GYOIitR2YUdw_3_7"></a><a id="Tc_VlRHD9BSk0qD0bBi2Qblww_4_2"></a><a id="Tc_d0AYx7wobUWIDu6-V_Goag_4_4"></a><a id="Tc_74Y8_r9z4EG8VWQFB2rjRQ_4_7"></a><a id="Tc_PKq5dLpMOUa8WSKmOsY69w_5_2"></a><a id="Tc_32faPgh35EaJEWBGliNyVQ_5_4"></a><a id="Tc_3teYBv8Lu0uZ6SnBRFR2qA_5_7"></a><a id="Tc_zaPMsoL8sEGdzsg4xwmvqw_6_0"></a><a id="Tc_ZxI2NXLph0aEYpfIHFjHUA_6_4"></a><a id="Tc_RbxRR8wZi0KyrKD80gXN2w_7_0"></a><a id="Tc_2IZsUONef0K6Se_Vc95kiQ_8_0"></a><a id="Tc_iIYW7Ol1C0mQuDQMlVUf2Q_9_0"></a><a id="Tc_G9uBmvFITkGYpSHZM2bd9g_10_0"></a><a id="Tc_cZbEYLyUEki_1XDM7z-5lA_10_7"></a><a id="Tc_UnesRPMpYUWOf4bOF8Gmdw_11_0"></a><a id="Tc_1WUBP9XVBkmdknyqwLMfLg_11_4"></a><ix:continuation id="Tb_rjrj-z_qAk6uRXIw0W-e-Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of warrants is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:ClassOfWarrantOrRightActivityTableTextBlock" id="Tb_GOBxCT94X0aBUr8KSQWKoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_jJVCcTYbiUaIJ-QiKtx9tQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_rKTE6eucqEK5QxlPZhR3KA_6_2">434,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_I38l4DudfUG9B_ywzeXUNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_9KTn_FOOW0KVQ4Oge1pKVA_6_5">92.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_umMfg0XoZ0-AYDOK8yZ-LA" format="ixt-sec:duryear" name="aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="Tc_osSpHnqOHkS-3NEBNS4Q-g_6_7"> 4.8</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" id="Tc_aXTtoPnaQE2yjLhhmkLQxQ_7_2">6,028,331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig" decimals="2" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" id="Tc_8f8bOVu6QUedh2__W1OvBw_7_5">1.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" format="ixt-sec:duryear" name="aytu:ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" id="Tc_Pd6xLpEXgEW94oRCrAijGQ_7_7"> 5.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" id="Tc_Jrd8YVzQDUKNPWYMXdOUzg_8_2">87,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig" decimals="2" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" scale="0" id="Tc_5bUk4Fbyf0O_4suFDsn8Zw_8_5">0.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" format="ixt-sec:duryear" name="aytu:ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" id="Tc_jk2UhLEZCEu6nWDVG2GY4w_8_7"> 5.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant adjusted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightAdjusted" scale="0" id="Tc_KLOhqu3Dx0mVN9Synwvbfw_9_2">181,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig" decimals="2" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" scale="0" id="Tc_RD-HBzO68UeG5aEUEslt-g_9_5">5.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" format="ixt-sec:duryear" name="aytu:ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" id="Tc_U-nHE1XskUKzGN_Z5PNX6Q_9_7"> 3.9</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" decimals="INF" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExpiredDuringPeriod" scale="0" id="Tc_cxoR3DSqcUimXqL2LZSWPA_10_2">18,568</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig" decimals="2" format="ixt:numdotdecimal" name="aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" scale="0" id="Tc_UQTub2H15Eu4Ij7laHhVKg_10_5">2,011.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_bb-F103xJEKObyLwN9P9hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_WABu2D6s10ONQSgatHs6qg_11_2">6,538,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA" contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_BMNvc2gmyU2xEU7d2Lo8uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_PI8G8Zlp10uA2cwp7NMPDA_11_5">4.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw" format="ixt-sec:duryear" name="aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" id="Tc_7-62lKfWv0e-B9kauOgs0w_11_7"> 4.71</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:DefinedContributionPlanTextBlock" id="Tb_bN60I1qwZkCKCdgwmvA7uQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the merger with Neos, Aytu had <ix:nonFraction unitRef="Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="aytu:NumberOfEmployeeBenefitPlan" scale="0" id="Narr_xko3OSBjrU6wxRF381eExA">two</ix:nonFraction> 401(k)&#160;plans the (&#8220;Neos Plan&#8221;) and the (&#8220;Aytu Plan&#8217;) both plans allow participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Neos Plan matched <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_etSVEI1u90m3Rja62GDizQ">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_pyz_4HmoL0CArxy0ldN2ag">3</ix:nonFraction>% contributed by employees and matched <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7aP_mPOQnEm0PE5wFOYT_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_ukvnM_48nEGhg1ASJwyh6Q">50</ix:nonFraction>% on the next <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_x_PrG4pcs06d9XTkn5jk5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_7JQ7DwZaEki0o6tD24xmOQ">4</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_hvi9wwMyG02M4YOpOzDNtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_OKg7_lpWnUiW31Jrf_8Cfg">5</ix:nonFraction>% contributed by the employees. The Company&#8217;s match for the Neos Plan was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7x7PFK5f0kiltq3YkU0RXQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_sm2nesUTWUGpsf3g5x1i3A">0.4</ix:nonFraction> million for the year ended June 30, 2022. The Aytu Plan matched <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_joJYichnT0aw60wR-HPr4A">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_zC4d3OxdGkS0Ebx4498-ww">6</ix:nonFraction>% contributed to the plan by employees. The Company&#8217;s match for the Aytu Plan was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_WbJzKLlmzki6AlcwWXPsyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_j9PGM3rps0GAm7q9pY5zfA"><ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_-JXzqrvuMU6CA_7Lj0xMKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_30n6aYcAEU-Dtx071s5W3Q">0.2</ix:nonFraction></ix:nonFraction> million for both years ended June 30, 2023 and 2022. In July 2022, the Company transferred the Neos Plan into the Aytu BioPharma Employee Retirement Plan and in February 2023 the Company transferred the Aytu Plan into the Aytu BioPharma Employee Retirement Plan. The Aytu BioPharma Employee Retirement Plan matches <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_TAio2oAoNEOWjsZ2z8jL7w">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_3h2lIeryIkm0aKNJofBhlA">3</ix:nonFraction>% contributed by employees and matches <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_RUN5j4oRMUyMIuo84vuTaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_r5eoR2I4Y0WDgSTnNHB17A">50</ix:nonFraction>% of the next <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_iQ5ElZ-9mkCBPVrJJm9cng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_I_M62FD7b0assrWbXNZdvQ">4</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_sWQv2CL_9karqaYLUrXPDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_H4RSmUPP6UyZYWkySK9xLg">5</ix:nonFraction>% contributed by the employees. The Company&#8217;s match for the Aytu BioPharma Employee Retirement Plan was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_BL_kOTzSHEKA4ccnDQIqTA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_i91xEzwhyEGBSg3HM_EI8g">0.7</ix:nonFraction><span style="white-space:pre-wrap;"> million during the year ended June 30, 2023.  </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_8vJuHKURM0q014nem4TrSQ" continuedAt="Tb_8vJuHKURM0q014nem4TrSQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric Portfolio Fixed Payments and Product Milestone</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assumed <ix:nonFraction unitRef="Unit_Standard_agreement_JfZ2PWRCJ0apFPM0xMjerg" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_wh8-haFGq0ilyzEd2ep6MQ" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber" scale="0" id="Narr_ZZvBBitf10W0nE5pzA8biQ">two</ix:nonFraction> fixed, periodic payment obligations to an investor (the &#8220;Fixed Obligation&#8221;). Under the first fixed obligation, the Company was to pay monthly payment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyPaymentAmount" scale="6" id="Narr_jTOMpvcOiUGi52hKHcs6Hw">0.1</ix:nonFraction> million beginning November&#160;1, 2019 through January&#160;2021, with a balloon payment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsBalloonPaymentAmount" scale="6" id="Narr_iKYxVc0oqEK15IVuVc24_g">15.0</ix:nonFraction> million that was to be due in January&#160;2021 (&#8220;Balloon Payment Obligation&#8221;). A second fixed obligation requires the Company pay a minimum of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_45L0yjrLA06cm11dTTlAbg" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" scale="6" id="Narr_fYAeHQf8hEKvd7lgCuD4OA">0.1</ix:nonFraction> million&#160;monthly through February&#160;2026, except for $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_86YG5A0Um0yo8qgGtK-dHg" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" scale="6" id="Narr_x9Sd2tJGhEiCVP4qPs1xzQ">0.2</ix:nonFraction> million paid in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the &#8220;Early Payment Agreement&#8221;) pursuant to which the Company agreed to pay $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid" scale="6" id="Narr_M6anEiW0q02SCrP7m-qLtw">15.0</ix:nonFraction> million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsPaymentAmountPaid" scale="6" id="Narr_tHMQO3Lo_06crOaBPaZyOA">2.8</ix:nonFraction> million to the investor in satisfaction of the second fixed obligation. The company agreed to pay the remaining fixed obligation of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangements" scale="6" id="Narr_fWdtSh-vokO3ROru15LHaA">3.0</ix:nonFraction> million in <ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" scale="0" id="Narr_xui9x2jLuEqFAFXISXcrHQ">six</ix:nonFraction> equal quarterly payments of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="-5" format="ixt:numdotdecimal" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmount" scale="6" id="Narr_8sdkuI-sVEibU8OSA0x0_A">0.5</ix:nonFraction> million over the next <ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA" decimals="INF" format="ixt-sec:numwordsen" name="aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" scale="0" id="Narr_4gxoyPElnkGxcJQ2d2xwBQ">six</ix:nonFraction> quarters commencing September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8vJuHKURM0q014nem4TrSQ_cont1" continuedAt="Tb_8vJuHKURM0q014nem4TrSQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company acquired a Supply and Distribution Agreement with Tris (the &#8220;Tris Karbinal Agreement&#8221;), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Tris Karbinal Agreement was <ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg" format="ixt-sec:durwordsen" name="aytu:SupplyAndDistributionAgreementTerm" id="Narr_fKlih06XxEWLOyGyCHMtrw">20 years</ix:nonNumeric>. The Company will pay Tris a royalty equal to <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="3" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" scale="-2" id="Narr_8JMwGTJO4EuOY-R3t2jVbw">23.5</ix:nonFraction>% of net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial&#160;year that spans from August&#160;1 through July&#160;31, of <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="INF" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" scale="0" id="Narr_xv9JaA04r069-O9Jpkzs4g">70,000</ix:nonFraction> units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="INF" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" scale="0" id="Narr_di7cglqOH0OitT4_iw23zQ">30</ix:nonFraction> for each unit under the <ix:nonFraction unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="INF" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" scale="0" id="Narr_dqDxdOx5kEGZ7hmBMzFQcg">70,000</ix:nonFraction>-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" scale="6" id="Narr_bEb5OErYb0SclMJZK74CjA">2.1</ix:nonFraction> million&#160;each&#160;year. The annual payment is due in August&#160;of each&#160;year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" scale="6" id="Narr_4voELNJipkmBqeNV3fRXug">3.0</ix:nonFraction> million based on cumulative net sales, the first of which is triggered at $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw" decimals="-5" format="ixt:numdotdecimal" name="aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" scale="6" id="Narr_gI9iALEjdkKwu5oJor2sCQ">40.0</ix:nonFraction> million of net revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the Company&#8217;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR<i style="font-style:italic;">. </i>The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#8220;Tris&#8221;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#8211; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" scale="6" id="Narr_Am_eoXtdW0Sby-iqnghKrw">8.5</ix:nonFraction> million and recorded a liability of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" scale="6" id="Narr_L7bkW2s8ckGEcZdOtmr2nw">7.6</ix:nonFraction> million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#8217;s estimated borrowing rate. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA" decimals="-5" format="ixt:numdotdecimal" name="aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" scale="6" id="Narr_vHnV5Kegh0e9n-9ZpTQKfw">0.9</ix:nonFraction> million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product Contingent Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make <ix:nonFraction unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg" contextRef="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw" decimals="INF" format="ixt-sec:numwordsen" name="aytu:ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" scale="0" id="Narr_GRHx97hEN0-GewB1bmyTPQ">five</ix:nonFraction> additional payments of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw" decimals="-5" format="ixt:numdotdecimal" name="aytu:ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" scale="6" id="Narr_LCWbz09Ock-GOEOtWoF9qw">0.5</ix:nonFraction> million when certain levels of FlutiCare sales are achieved. In fiscal year 2023, the manufacturer associated with this contingent liability filed for bankruptcy. There were <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_qxV92QOxs02EZ-8Z3YXlNA" decimals="-3" format="ixt-sec:numwordsen" name="aytu:ProductContingentLiabilityMilestonePayment" scale="0" id="Narr_rGoc0Ps-rEqpIVsxx4tgNw">no</ix:nonFraction> payments required in fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rumpus Earn Out Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (&#8220;Denovo&#8221;) and Johns Hopkins University (&#8220;JHU&#8221;), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" scale="6" id="Narr_GnFCaBnWakGjtdIH_EfcLQ">67.5</ix:nonFraction> million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company&#8217;s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:LicenseAgreementAnnualMaintenanceFee" scale="0" id="Narr_jGgoHTrZ6UaOELqDVbAr-A">25,000</ix:nonFraction>, a license option fee of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementLicenseOptionFee" scale="6" id="Narr_Uyk8xuwp-EiW9lEG5hJKFQ">0.6</ix:nonFraction> million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementEscalatingRoyaltiesMaximum" scale="6" id="Narr_zrDN0drfh06YKVMjtqWQVQ">101.7</ix:nonFraction> million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" scale="0" id="Narr_iO0z4KmipUygwJrTsa9CRw">5,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" scale="0" id="Narr_qhfA4kqlo02Rm1FCZIZEIQ">20,000</ix:nonFraction> beginning in calendar year 2022, royalties of <ix:nonFraction unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ" decimals="INF" format="ixt:numdotdecimal" name="aytu:LicenseAgreementRoyaltiesPercentageOfNetProductSales" scale="-2" id="Narr__xGwZP-fy0aQhb8neVzqHg">3.0</ix:nonFraction>% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" scale="6" id="Narr_KO_Db7DyJUaKPHfXJp5NoA">1.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, AR101 received Orphan Drug Designation (&#8220;ODD&#8221;) and Fast Track designation from the FDA, resulting in total milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementMilestonePaymentPaidCashAndCommonStock" scale="6" id="Narr_Dn4Hed91gUy47UMp_WY4Rw">4.0</ix:nonFraction> million, which were paid in <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w" decimals="INF" format="ixt:numdotdecimal" name="aytu:StockIssuedDuringPeriodSharesMilestonePayments" scale="0" id="Narr_Yl0hQcJ3Pka7DFG6dFtNyw">109,447</ix:nonFraction> shares of common stock and $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementMilestonePaymentPaidCash" scale="6" id="Narr_ZoYT_K80cUaCNIh0HZWTQA">2.6</ix:nonFraction> million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In May 2023, the Company entered into an operating lease agreement to relocate its principal office within Denver, Colorado. The lease has a commencement date of October 1, 2023 with an initial term of <span style="-sec-ix-hidden:Hidden_JDyjzzB8SUiDT9RhDuHhaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five and a half years</span></span>. Undiscounted minimum monthly rent payments average approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw" decimals="0" format="ixt:numdotdecimal" name="aytu:AverageUndiscountedMinimumMonthlyRentPayments" scale="0" id="Narr_-YkIWZmzuE-t8-QlNGpasg">15,500</ix:nonFraction> over the initial term of the lease. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8vJuHKURM0q014nem4TrSQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has one <ix:nonNumeric contextRef="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_sXznGw8oeEC13_w3exEjhg">five-year</ix:nonNumeric> renewal option through March 2034.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-indent:36pt;margin:0pt;">Legal Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Witmer Class-Action Securities Litigation. </i>A shareholder derivative suit was filed on September12, 2022 in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint drops Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enrichment and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in as insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While we believe that this lawsuit is without merit and have vigorously defended against it, we have agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Sabby Litigation.</i> A complaint was filed on February 22, 2023 in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrantholders may receive, and that the Company failed to provide prompt notice to the warrantholders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Frm2bQ0htkKBpEuFVgDY8A">575,000</ix:nonFraction> warrant shares be due to Sabby on exercise of its warrants rather than <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg" decimals="INF" format="ixt:numdotdecimal" name="aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_a1wzoDEgf06sSpbd1Qh9eg">312,908</ix:nonFraction> shares, and that <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_V1MIjbgcuE6OXafBxrzfuw">100,000</ix:nonFraction> warrant shares be due to Walleye on exercise of its warrants rather than <ix:nonFraction unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw" contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA" decimals="INF" format="ixt:numdotdecimal" name="aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_j4SdMPOyOkmQB1wluVfjAw">54,146</ix:nonFraction> shares. While we believe that this lawsuit is without merit and we intend to vigorously defend against it, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Stein Litigation.</i> Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on February 1, 2023 in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which is pending. Due to the early stage of litigation, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations, and intend to vigorously defend this case in the event it is not dismissed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="aytu:LicensingAgreementsTextBlock" id="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ" continuedAt="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19. License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Healight</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw" format="ixt-sec:durwordsen" name="aytu:LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" id="Narr_uADRIr7iU0moUQex6jaNEw">ten years</ix:nonNumeric> after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ_cont1" continuedAt="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the agreement, the Company paid an initial $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementInitialLicenseFeePaid" scale="6" id="Narr_r_R8lClrhUuE6JSWu9ptSw">0.3</ix:nonFraction> million license fee and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementPatentProsecutionFeesPaid" scale="6" id="Narr_73fFvwG1mE6Jml_sgVwzzA">0.1</ix:nonFraction> million in earlier patent prosecution fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Company&#8217;s focus on the revenue growth of its commercial business, the Company had terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NeuRx</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, Neos entered into an Exclusive License Agreement (&#8220;NeuRx License&#8221;) with NeuRx Pharmaceuticals LLC (&#8220;NeuRx&#8221;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx&#8217;s proprietary compound designated as NRX-101, referred to by Neos as NT0502. NT0502 is a new chemical entity that is being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Teva</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (&#8220;ANDA&#8221;) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Actavis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shire</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the &#8220;2014 License Agreement&#8221;) with Shire LLC (&#8220;Shire&#8221;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#8217; New Drug Application (the &#8220;NDA&#8221;) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid a lump sum, non-refundable license fee of an amount less than $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_TypeOfArrangementAxis_aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_eC9Z_MBaeUGsNuYWxQQb7w" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" scale="6" id="Narr__OTM38tUq0C5VWh9TlF9pg">1.0</ix:nonFraction> million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expires May of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2017, Neos entered into a License Agreement (the &#8220;2017 License Agreement&#8221;) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos&#8217; NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_10_1_2017_To_10_31_2017_us-gaap_TypeOfArrangementAxis_aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_1wb-z3AmGEG4sOa28Qj_VA" decimals="-5" format="ixt:numdotdecimal" name="aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" scale="6" id="Narr_FpkWKYtnXkG080NfqhHvNQ">1.0</ix:nonFraction> million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_Ux4Tm8Q4YkO1yOWEt24EkQ_1_0"></a><a id="Tc_u2sMmjas-kyNaw_YG6yDuw_1_2"></a><a id="Tc_Hn3jsRKpl0ucyBifyrcXFg_1_5"></a><a id="Tc_IoB5VxkCqkiMZRlEntOtsA_1_8"></a><a id="Tc_PxIVaMI-xE-QZfwlE5iJAw_3_0"></a><a id="Tc_rFpRfItpl0-BAdWEcWmmug_5_0"></a><a id="Tc_EG8MCl0EiUWZK8sBzYh1Ug_5_1"></a><a id="Tc_YOQddDQBmkWsSR5DODhazw_5_4"></a><a id="Tc_gH4ChEFs5E-TV39evvuP6A_5_7"></a><a id="Tc__4Lv6mLJ9kKBu_xgPIs9tQ_6_0"></a><a id="Tc_oWa9rfUNQUS5oYhscjF-FQ_6_1"></a><a id="Tc_3XPFmjn7jUCT-A9lkOxg7Q_6_4"></a><a id="Tc_XM-mRwnmUkmB2QCMWNUbXQ_6_7"></a><a id="Tc_Bvx2H-3XwU2g4eXq-Qx4Hg_8_0"></a><a id="Tc_gSZrLqIWb0GxqzQV8jbkaw_8_1"></a><a id="Tc_GeJFGX5wykWwivPV45wvhg_8_4"></a><a id="Tc_UPVCRtlw7UKPfgPiJ_kKdA_8_7"></a><a id="Tc_UBW1YScFakq9zW5ZGkFjBQ_9_0"></a><a id="Tc_KSjrLK1Eu0i9BmbqpnO0HA_9_1"></a><a id="Tc_ydyfB2pc5U-CvyE5WZcstA_9_4"></a><a id="Tc_54RBX8WxTE2uNQOXKH3QuQ_9_7"></a><a id="Tc_2OYKJuclUk-9zQq28ykXfg_10_0"></a><a id="Tc_dio_asuHck2dNq6waq-h1Q_10_1"></a><a id="Tc_kOax5PhR6U2qL8S7JKlGtg_10_4"></a><a id="Tc_3DA5HvI5nEuADZZ0kdMfbA_10_7"></a><a id="Tc_uSf-qxTLzESh8uE6AL_JgA_12_0"></a><a id="Tc_OEwyaHdwmkOkX16yf7COrw_14_0"></a><a id="Tc_j8yN6gK7zkeIBmEk1EPKAQ_14_1"></a><a id="Tc_J-EL1i344Um-D3yry2qznA_14_4"></a><a id="Tc_TiiPvOgZN0yCxPVJDbHBdQ_14_7"></a><a id="Tc_vGCFgRk6DEaEiy3hvj-Emw_15_0"></a><a id="Tc_O0PxsCOxOUqSN43VeUBuHA_15_1"></a><a id="Tc_XQjEKLTfEEO6McAlEvQI8Q_15_4"></a><a id="Tc_LGTr9TX_O02wQZo6brc20g_15_7"></a><a id="Tc_3sadZuTJ_U2oFtht2A30qA_17_0"></a><a id="Tc_cNRnnERqQ0qI97ABT0dfCA_17_1"></a><a id="Tc_rpADJ8ee0EKHgp8Z3VXgAQ_17_4"></a><a id="Tc_cATLklWq2EaoonZTWOk0-w_17_7"></a><a id="Tc_PoxCNZ6gUUmcfqhZoeHxfA_18_0"></a><a id="Tc_rCMDXHoAzEqKQROnCi6ESw_18_1"></a><a id="Tc_QRLx3otsr0yEpeOOdGiAOA_18_4"></a><a id="Tc_5K2C_utV9kiwBcycG5QrfA_18_7"></a><a id="Tc_iUZTjoTfqUKHmsNFy9npdA_19_0"></a><a id="Tc_t490xIPWjEmhHSN59IHeEA_19_1"></a><a id="Tc_8E8rUD6Kq0Sp09OUl1fwRA_19_4"></a><a id="Tc_P8ExXjbQSk-EHGK2HNzQPw_19_7"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_ipo8m4jKIEqHP9X-_u4W8Q" continuedAt="Tb_ipo8m4jKIEqHP9X-_u4W8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20. Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Company&#8217;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages and aggregates its&#160;operational and financial information in accordance with <ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_eQ6VniBnDkaFJkNA8oFKxg"><ix:nonFraction unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_AqJ_LheuAUiLGFwBlkdfkg">two</ix:nonFraction></ix:nonFraction> reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#8217;s prescription products. The Consumer Health Segment contains the Company&#8217;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, the Rx Segment recognized an impairment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_7wD0JB03EkGB-VLeOwHsSg">2.6</ix:nonFraction> million due to ceasing active development of the NT0502 product candidate as a result of the Company&#8217;s increased focus on commercial efforts. The Consumer Health Segment recognized an impairment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_DbmCjF1DFUmzjmAnhyhOSA">3.0</ix:nonFraction><span style="white-space:pre-wrap;"> million from intangible assets  (see Note 7 &#8212; Goodwill and Other Intangible Assets) and an inventory write-off of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr__TJAvx4e2k-n0g3ODQBxvA">2.1</ix:nonFraction> million due to the discontinuance of its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, the Rx Segment recognized a total impairment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_V94qmKJbh0ynmEeDSxHV2Q">64.6</ix:nonFraction> million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, the Consumer Health Segment recognized $<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_772gIuyHOUaqBSRYkyYUzg">10.8</ix:nonFraction><span style="white-space:pre-wrap;"> million of goodwill and intangible assets write downs (see Note 7 &#8212;  Goodwill and Other Intangible Assets).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Select financial information for these segments is as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_tM4nQgRop0OvztR26hcM-g" continuedAt="Tb_tM4nQgRop0OvztR26hcM-g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rx</p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consumer Health</p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2023:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_418TiD4Nl0SX-8hhvDTSww_5_2">73,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_K-52NcA0yEGpUMYw9w-Qcg_5_5">33,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_rc4IaK7j6EyOVLG7PGBgfw_5_8">107,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_SMvWtKTy70-hvOR_lbGGBQ_6_2">7,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_5axHKRmulUmVPVXgDgPq8A_6_5">9,707</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_gUZY9PMPIUKBl30LH953MA_6_8">17,065</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_3e3f5s5SoEuLZZikBedx9Q_8_2">6,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_uIRWD2swOEGfyr9HQRS0tQ_8_5">1,116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_wq6yK_oGSEanExsr1jXDnw_8_8">7,387</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment and write-off expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_dvvWLxXKG0iuqnmbUv4c3A_9_2">2,730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_yO6avAYh2kiJxNv2nFKKnQ_9_5">5,094</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_NTFrpkpXZU6g-kGns0po0g_9_8">7,824</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_4ByAYsqi0kqs0wXT6gRS3Q_10_2">5,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qFCbwf2sKUi9yeqmLiPsEA_10_5">324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_b7Te6RfRHUagMgB02PWpbQ_10_8">6,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2022:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_5RyzjyyOI0qRKPda4DmrkQ_14_2">61,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_pmV4XhAXCEqvbfXI2Dgw4g_14_5">35,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_v3qXR0yQZ0KVPiIvoshjiw_14_8">96,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_zfl_ViY_hkm0Gn7cEHCK6w_15_2">92,441</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_CLksWEYiPUiXq3B9fQhZCA_15_5">17,465</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_dkmHreii4UO8OtH7t8PQYQ_15_8">109,906</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_iw0II8EaSU-VhB4-m0J1kQ_17_2">7,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_hV6u3U1BtkKHQnYuaFoGCQ_17_5">1,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_YdYOqScem021Fr8n85nWCA_17_8">9,378</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_Vv-hi233f02PU_ZZxhgpsA_18_2">64,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_uaQl9tf5bk2RpvfzARsP5A_18_5">10,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="aytu:AssetImpairmentAndWriteoffCharges" scale="3" id="Tc_EBilxIQsqkaVQJFVgvHSzA_18_8">75,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_OOu0W5mxoEW8EJ5VXZvHbg_19_2">5,190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_q1YtC4StBEOZYtaDRYO9ig_19_5">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ" contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Qn4g4k5vM0qAQsDCdPWv6w_19_8">5,248</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ipo8m4jKIEqHP9X-_u4W8Q_cont1"><ix:continuation id="Tb_tM4nQgRop0OvztR26hcM-g_cont1"></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Dyr68U9KxEqJYBid-VkKQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distribution and Supply Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with a privately-owned pharmaceutical company for Adzenys XR-ODT and Cotempla XR-ODT product lines. The pharmaceutical company will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT; and will focus on distributing and selling these products for patients in Israel and the Palestinian Authority. The Company will commit to product supply based on forecasts and provide product training. Due to the nascency of the collaboration, estimates of its financial effect cannot be made. This agreement represents the Company&#8217;s first international commercial agreement for Adzenys and Cotempla.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>2
<FILENAME>aytu-20230630xex10d45.htm
<DESCRIPTION>EX-10.45
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.45</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDED AND RE-STATED EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10.19pt 0pt;"><font style="font-size:11pt;">This Amended and Re-Stated Employment Agreement (the &quot;Agreement&quot;), is effective as of February 13, 2023 (the &#8220;Effective Date&#8221;), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the &quot;Company&quot;), and Joshua R. Disbrow (&#8220;Employee&quot;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.04pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS, </b><font style="font-size:11pt;">the Company is a duly organized Delaware corporation, with its principal place of business within the State of Colorado, and is in the business of developing and marketing pharmaceutical products; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><font style="font-size:11pt;">, the Company and Employee originally entered into an Employment Agreement on April 16, 2019, which was amended on July 1, 2020, and again on April 7, 2021; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS, </b><font style="font-size:11pt;">the Company and Employee desire to amend and re-state the Employment Agreement; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS,</b><font style="font-size:11pt;"> the Company desires assurance of the continued association and services of the Employee in order to continue to retain the Employee&#8217;s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Employee&#8217;s services on the terms and conditions set forth in this Agreement; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS,</b><font style="font-size:11pt;"> Employee desires to be in the continued employ of the Company, and is willing to accept such continued employment on the terms and conditions set forth in this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOW, THEREFORE,</b><font style="font-size:11pt;"> the parties hereto agree to the terms and conditions of this Agreement as follows:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">1.  Employment Term.  </b><font style="font-size:11pt;white-space:pre-wrap;">The Company hereby agrees to continue to employ Employee and Employee hereby accepts such continued employment with the Company for a period of 12 months beginning on the Effective Date (the &#8220;Continued Term&#8221;).  Upon the expiration of the Continued Term, the Agreement shall automatically renew for successive terms of 12 months each (with each such successive term constituting a &#8220;Renewal Term,&#8221; together with the Continued Term, the &#8220;Term&#8221;), unless terminated in accordance with the provisions of the Agreement.  The termination of Employee&#39;s employment under the Agreement shall end the Term but shall not terminate Employee&#8217;s or the Company&#8217;s other obligations that are intended to survive the termination of this Agreement (including without limitation, the payments under Section 7 and 8 and Employee&#8217;s obligations under Section 9).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">2.  Position and Duties.</b><font style="font-size:11pt;white-space:pre-wrap;">  During the Term, Employee shall serve as Chairman of the Board (Chairman) and Chief Executive Officer (CEO) of the Company, and perform such duties as are consistent with this position. The Employee shall report to the Board of Directors of the Company.  During the Term, Employee shall also hold such additional positions and titles as the Board of Directors of the Company (the &quot;Board&quot;) may determine from time to time.  During the Term, Employee shall devote as much time as is necessary to satisfactorily perform his duties as CEO of the Company.  Employee may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company During the Term of this Agreement, Employee agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Employee to be adverse or antagonistic to the Company, its business or prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">provision shall encompass any advisory boards of which Employee is or becomes a member of during the term hereof. Employee shall provide written disclosure to the Compensation Committee of the Company&#8217;s Board of Directors as to all advisory boards on which Employee sits, and will provide the Company with written notice within 10 business days of Employee agreeing to sit on any additional advisory boards. On termination of Employee&#8217;s employment, regardless of the reason for such termination, Employee shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Employee may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">3. Compensation.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(a)   Base Salary.</b><font style="font-size:11pt;white-space:pre-wrap;">  The Company shall pay Employee a base salary of $590,000 per annum, payable at least monthly on the Company&#39;s regular pay cycle for professional employees (the &#8220;Base Salary&#8221;). Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the Compensation Committee of the Board and ratified by the Compensation Committee or a majority of the independent members of the Board.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(b)  Annual Review.</b><font style="font-size:11pt;white-space:pre-wrap;">  The Base Salary shall be reviewed at the end of each fiscal year (the first such review to occur at the end of fiscal year 2020).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(c)  Equity Compensation.</b><font style="font-size:11pt;white-space:pre-wrap;">  Employee acknowledges that, pursuant to his original </font><font style="font-size:11pt;white-space:pre-wrap;">Employment Agreement dated April 16, 2019, the First Amendment to the Employment Agreement dated July 1, 2020, and the Second Amendment to the Employment Agreement dated April 7, 2021, Employee received equity and restricted shares, as well as a one-time cash payment in lieu of additional equity.  Employee continues to participate in the Stock Incentive Plan and his Awards under the Stock Incentive Plan are governed by the terms thereof.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(d)  Other and Additional Compensation.</b><font style="font-size:11pt;white-space:pre-wrap;">  Subsections (a) and (c) above establish Employee&#8217;s compensation during the Term which shall not preclude the Board from awarding Employee a higher salary or any bonuses or stock options, restricted stock or other forms of additional equity awards in the discretion of the Board during the Term at any time. The Employee shall be eligible for an annual discretionary bonus (hereinafter referred to as the &#8220;Bonus&#8221;) with a target amount of sixty percent (60%)&#160;of the Base Salary</font><b style="font-size:11pt;font-weight:bold;">, </b><font style="font-size:11pt;">subject to standard deductions and withholdings, based on the Compensation Committee&#8217;s determination, in good faith, and based upon the Employee&#8217;s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Employee has met such performance milestones as are established for the Employee by the Board or the Compensation Committee, in good faith, in consultation with the Employee (hereinafter referred to as the &#8220;Performance Milestones&#8221;). The Performance Milestones will be based on certain factors including, but not limited to, the Employee&#8217;s performance and the Company&#8217;s financial and operational performance. The Employee&#8217;s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Employee&#8217;s written consent. The Employee must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">4.  Employee Benefits.</b><font style="font-size:11pt;white-space:pre-wrap;">  During the Term, Employee shall be entitled to participate at the same level as other senior executive officers of the Company in any group insurance, hospitalization, medical, health</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">and accident, disability, fringe benefit and tax-qualified retirement plans or programs of the Company now existing or hereafter established to the extent that he is eligible under the general provisions thereof.  For the term of this Agreement, Employee shall be entitled to paid time off at the rate of (5) weeks per annum.  In accordance with Company policy, unused paid time off may not be carried over from year to year.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">5.  Expenses.</b><font style="font-size:11pt;white-space:pre-wrap;">  The Company shall reimburse Employee for actual, reasonable out-of-pocket expenses incurred by him in the performance of his services for the Company upon the receipt of appropriate documentation of such expenses which shall be submitted in such form, and with such supporting documentation, as called for or required by Company policy.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">6.  Termination.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(a)  General.  </b><font style="font-size:11pt;white-space:pre-wrap;">The Term shall end immediately upon Employee&#39;s death.  Employee&#8217;s employment may also be terminated by the Company with or without Cause or as a result of Employee&#8217;s Disability, as defined in Section 7 or by Employee with or without Good Reason (as such terms are defined below).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(b)  Notice of Termination.</b><font style="font-size:11pt;white-space:pre-wrap;">  Either party shall give written notice of termination to the other party.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(c)  Notification of New Employer</b><font style="font-size:11pt;white-space:pre-wrap;">.  In the event that Employee leaves the employ of the Company, Employee grants consent to notification by the Company to Employee&#8217;s new employer about his rights and obligations under this Agreement and the PIA (hereinafter defined).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">7.  Severance Benefits.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(a)  Cause Defined.</b><font style="font-size:11pt;white-space:pre-wrap;">  &#8220;Cause&#8221; means (i) willful malfeasance or willful misconduct by Employee in connection with his employment; (ii) Employee&#8217;s conviction of, or entry of a plea of guilty to, or entry of a plea of </font><i style="font-size:11pt;font-style:italic;">nolo contendere</i><font style="font-size:11pt;"> with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii) Employee&#8217;s willful and deliberate violation of a Company policy, (iv) Employee&#39;s unintended but material breach of any written policy applicable to all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of Directors within thirty (30) business days after notice thereof; (v) the Employee&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the Employee owes an obligation of nondisclosure as a result of the Employee&#8217;s relationship with the Company, or (vi) the Employee&#8217;s willful and deliberate breach of his obligations under this Agreement..</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(b)  Disability Defined.  </b><font style="font-size:11pt;white-space:pre-wrap;">&quot;Disability&quot; shall mean (i) Employee&#39;s incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation, that results in Employee being substantially unable to perform his duties hereunder for six consecutive months (or for six months out of any nine month period) or (ii) a qualified independent physician mutually acceptable to the Company and Employee determines that Employee is incapacitated due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation so as to be unable to regularly perform the duties of his position and such condition is expected to be of a permanent or near-permanent duration.  Until such time as Employee is terminated for Disability under this paragraph (b), Employee shall continue to receive his Base Salary hereunder, provided that if the Company provides Employee with disability insurance coverage, payments of Employee&#39;s Base Salary shall be reduced by the amount of any disability insurance payments received by Employee due to such coverage.  The Company shall give Employee written notice of termination due to Disability which shall take effect sixty (60) days after the</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">date it is sent to Employee unless Employee shall have returned to the performance of his duties hereunder during such sixty (60) day period (whereupon such notice shall become void).  In the event that the Company terminates Employee&#8217;s employment as a result of his Disability, Employee shall be entitled to the same benefits as if his employment had been terminated by the Company without Cause.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(c)  Good Reason Defined. </b><font style="font-size:11pt;white-space:pre-wrap;">For purposes of this Agreement. &#8220;Good Reason&#8221; shall mean:  : (i) there is a material reduction of the level of Employee&#8217;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may the Base Salary be reduced below the amount stated in Section 3(a)), (ii) there is a material reduction in Employee&#8217;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in Employee&#8217;s responsibilities or authority); or (iii) without Employee&#8217;s written consent, a material change in the principal geographic location at which Employee must perform his services (it being understood that the relocation of Employee to a facility or a location within forty (40) miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of this Agreement).  No event shall be deemed to be &#8220;Good Reason&#8221; if the Company has cured the event (if susceptible to cure) within 30 days of receipt of written notice from Employee specifying the event or events which, absent cure, would constitute &#8220;Good Cause.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(d)  Accrued Compensation Defined.  </b><font style="font-size:11pt;white-space:pre-wrap;">Accrued Compensation shall mean an amount which shall include all amounts earned or accrued by Employee through the date of termination of this Agreement but not paid as of such date, including (i) Base Salary, (ii) reimbursement for business expenses incurred by the Employee on behalf of the Company, pursuant to the Company&#8217;s expense reimbursement policy in effect at such time, (iii) any expense allowance pursuant to Company policy, (iv) accrued but unused vacation pay per Company policy, and (v) bonuses and incentive compensation earned and awarded prior to the date of termination.  Accrued Compensation shall be paid on the first regular pay date after the date of termination (or earlier, if required by applicable law).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(e)  Termination.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">(i) Cause; Without Good Reason; Death; Disability.</b><font style="font-size:11pt;white-space:pre-wrap;">  If the Company ends the Term for Cause, if Employee resigns as an employee of the Company for reasons other than an event of Good Reason, the Employee dies or Disability occurs , then the Company shall pay to Employee the Accrued Compensation but shall have no obligation to pay Employee any amount, whether for salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the Term, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be forfeited immediately upon the end of the Term.  For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date the Company ends the Term for Cause, or the date of Employee&#8217;s death, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the Employee or his personal representative or executor.  For the avoidance of doubt, Employee shall receive the payments specified in this Section 7(e)(i) and shall not be entitled to any other compensation that would have been made for the remainder of a Continued Term or Renewal Term or payments under any other severance plan. For example, if the Employment Period has been automatically renewed for twelve (12) months starting April 7, 2025 and Employee resigns as an employee of the Company for reasons other than an event of Good Reason on July 7, 2025, Employee shall not be entitled to receive payments for the period of July 7, 2025 through April 7, 2026; Employee will receive only the payments noted in this Section 7(e)(i).  In no case shall Employee be entitled to payment for any period Employee</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">is not performing services under this Agreement beyond the payments provided for under this Section 7(e)(i).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">(ii) Without Cause; Good Reason.</b><font style="font-size:11pt;white-space:pre-wrap;">  In the event that the Company terminates Employee&#8217;s employment hereunder without Cause, or the Employee terminates his employment with Good Reason, he shall be entitled to the Accrued Compensation and, subject to Section 21 and 22 below,</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">(A) A lump sum payment equal to two and one half (2.5) times his Base Salary in effect at the date of termination, less applicable withholding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">(B) Continued participation (via state or federal insurance continuation laws such as COBRA, to the extent available) in the health and welfare plans (or comparable plans, if continued participation in the Company&#8217;s plans is not available) provided by the Company to Employee at the time of termination for a period of two years from the date of termination or, if earlier, until he is eligible for comparable coverage with a subsequent employer.  The Company agrees to reimburse the payments Employee makes for such coverage, whether via continuation or separate comparable policy.  Premium reimbursements shall be made by the Company to Employee consistent with the Company&#8217;s normal expense reimbursement policy, provided that Employee submits documentation to the Company substantiating his payments for insurance coverage.  Employee shall give the Company prompt notice of his eligibility for comparable coverage.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">(C)  Any severance payments and/or other separation benefits contemplated by this Agreement are conditional on Employee: (i) continuing to comply with the terms of this Agreement and the PIA (as defined herein); (ii) delivering prior to or contemporaneously with any such severance payments, and not revoking, (x) a customary general release of claims relating to Employee&#8217;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their respective directors, officers and stockholders and (y) a customary affirmation of Employee&#8217;s continuing obligations hereunder and under the PIA.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">(D)  In the event of a termination Without Cause or Change in Control, Employee shall be paid a pro-rata amount of the target bonus determined by the percentage of time Employee was employed during the fiscal year.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">(E)  For the avoidance of doubt, Employee shall receive the payments specified in this Section 7(e)(ii) and shall not be entitled to any other compensation that would have been made for the remainder of a Continued Term or Renewal Term or payments under any other severance plan. For example, if the Employment Period has been automatically renewed for twelve (12) months starting April 7, 2025 and Employee resigns as an employee of the Company for an event of Good Reason on July 7, 2025, Employee shall not be entitled to receive payments for the period of July 7, 2025 through April 7, 2026; Employee will receive only the payments noted in this Section 7(e)(ii).  In no case shall Employee be entitled to payment for any period Employee is not performing services under this Agreement beyond the payments provided for under this Section 7(e)(ii).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Unless otherwise required by law, no severance payments and/or benefits under this Agreement will be paid and/or provided until after the expiration of any relevant revocation period.  Subject to the</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">effectiveness of the release, the severance payments shall be paid on the first payroll date that begins 30 days after Employee&#8217;s termination of employment.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">8.  Change in Control Payments.</b><font style="font-size:11pt;white-space:pre-wrap;">  The provisions of this paragraph 8 set forth the terms of an agreement reached between Employee and the Company regarding Employee&#39;s rights and obligations upon the occurrence of a &quot;Change in Control&quot; (as hereinafter defined) of the Company during the Term.  These provisions are intended to assure and encourage in advance Employee&#39;s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such Change in Control.  The following provisions shall apply in the event of a Change in Control, in addition to any payment or benefit that may be required pursuant to Section 7.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(a)  Equity.  </b><font style="font-size:11pt;white-space:pre-wrap;">If within 12 months after a Change in Control, Employee&#8217;s employment is terminated by the Company without Cause or by the Employee for Good Reason, all stock options, restricted stock and other stock-based grants to Employee by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse.  All stock options shall remain exercisable from the date of such employment termination until the expiration of the term of such stock options.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(b)  Definitions.</b><font style="font-size:11pt;white-space:pre-wrap;">  For purposes of this paragraph 8, the following terms shall have the following meanings:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;Change in Control,&#8221; also referred to as a &#8220;Sale Event&#8221; in the Company&#8217;s Restricted Stock Award Agreement, shall mean any of the following:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">(i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">(ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">(iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">(iv) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of a the acquisition of securities directly from the Company.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">9.  Proprietary Information and Inventions Agreement</b><font style="font-size:11pt;white-space:pre-wrap;">.  As a condition of Employee&#8217;s employment with the Company, Employee agrees to sign the Company&#8217;s standard form of Proprietary Information and Inventions Agreement (&#8220;PIA&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">10.  Successors and Assigns.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(a)  Employee.</b><font style="font-size:11pt;white-space:pre-wrap;">  This Agreement is a personal contract, and the rights and interests that the Agreement accords to Employee may not be sold, transferred, assigned, pledged, encumbered, or hypothecated by him.  All rights and benefits of Employee shall be for the sole personal benefit of</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Employee, and no other person shall acquire any right, title or interest under this Agreement by reason of any sale, assignment, transfer, claim or judgment or bankruptcy proceedings against Employee.  Except as so provided, this Agreement shall inure to the benefit of and be binding upon Employee and his personal representatives, distributees and legatees.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">(b)  The Company.</b><font style="font-size:11pt;white-space:pre-wrap;">  This Agreement shall be binding upon the Company and inure to the benefit of the Company and of its successors and assigns, including (but not limited to) any Company that may acquire all or substantially all of the Company&#39;s assets or business or into or with which the Company may be consolidated or merged.  Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#8220;successor&#8221; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">11.  Entire Agreement.</b><font style="font-size:11pt;white-space:pre-wrap;">  This Agreement (together with the equity award agreements referred to herein) represents the entire agreement between the parties concerning Employee&#39;s employment with the Company and supersedes all prior negotiations, discussions, understanding and agreements, whether written or oral, between Employee and the Company relating to the subject matter of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">12.  Amendment or Modification, Waiver.</b><font style="font-size:11pt;white-space:pre-wrap;">  No provision of this Agreement may be amended or waived unless such amendment or waiver is agreed to in writing signed by Employee and by a duly authorized officer of the Company.  No waiver by any party to this Agreement or any breach by another party of any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">13.  Notices.</b><font style="font-size:11pt;white-space:pre-wrap;">  Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">If to Employee:                      </font><font style="display:inline-block;width:3.4pt;"></font><font style="font-size:11pt;">3631 East 7</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Avenue Parkway</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">         </font><font style="display:inline-block;width:8.49pt;"></font><font style="font-size:11pt;">Denver, CO 80206</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">If to the Company:</font><font style="display:inline-block;width:18.12pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Aytu BioPharma, Inc.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">373 Inverness Parkway</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Suite 206</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;">Englewood, Colorado 80112</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">14.  Severability.</b><font style="font-size:11pt;white-space:pre-wrap;">  If any provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction or arbitrator acting pursuant to Section 19 below to be invalid and unenforceable to any extent, the remainder of this Agreement or the application of such provision to such person or circumstances other than those to which it is so determined to be invalid and unenforceable shall not be affected, and each provision of</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">this Agreement shall be validated and shall be enforced to the fullest extent permitted by law.  If for any reason any provision of this Agreement containing restrictions is held to cover an area or to be for a length of time that is unreasonable or in any other way is construed to be too broad or to any extent invalid, such provision shall not be determined to be entirely null, void and of no effect; instead, it is the intention and desire of both the Company and Employee that, to the extent that the provision is or would be valid or enforceable under applicable law, any court of competent jurisdiction or arbitrator acting pursuant to Section 19 below shall construe and interpret or reform this Agreement to provide for a restriction having the maximum enforceable area, time period and such other constraints or conditions (although not greater than those contained currently contained in this Agreement) as shall be valid and enforceable under the applicable law.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">15.  Survivorship.</b><font style="font-size:11pt;white-space:pre-wrap;">  The respective rights and obligations of the parties hereunder shall survive any termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">16.  Headings.</b><font style="font-size:11pt;white-space:pre-wrap;">  All descriptive headings of sections and paragraphs in this Agreement are intended solely for convenience of reference, and no provision of this Agreement is to be construed by reference to the heading of any section or paragraph.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">17.  Withholding Taxes.</b><font style="font-size:11pt;white-space:pre-wrap;">  All salary, benefits, reimbursements and any other payments to Employee under this Agreement shall be subject to all applicable payroll and withholding taxes and deductions required by any law, rule or regulation of and federal, state or local authority.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">18.  Counterparts.</b><font style="font-size:11pt;white-space:pre-wrap;">  This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together constitute one and same instrument. The parties agree that facsimile signatures shall have the same force and effect as original signatures.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">19.  Applicable Law; Arbitration.</b><font style="font-size:11pt;white-space:pre-wrap;">  The validity, interpretation and enforcement of this Agreement and any amendments or modifications hereto shall be governed by the laws of the State of Colorado, as applied to a contract executed within and to be performed in such State.  The parties agree that any disputes shall be definitively resolved by binding arbitration before the American Arbitration Association in Denver, Colorado in accordance with its rules of arbitration procedure then in effect. The parties consent to the jurisdiction to the federal courts of the District of Colorado or, if there shall be no jurisdiction, to the state courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto.  Each party shall choose one arbitrator and the two arbitrators shall choose a third arbitrator.  All costs and fees related to such arbitration (and judicial enforcement proceedings, if any) shall be borne by the Company unless Employee&#8217;s claim is deemed to be frivolous by the arbitrator(s) or judge.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">20.  Legal Fees.</b><font style="font-size:11pt;white-space:pre-wrap;">  The Company shall pay the reasonable expenses of Employee&#8217;s counsel in negotiating this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">21.  Section 409A.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">(a)  Anything in this Agreement to the contrary notwithstanding, if at the time of Employee&#8217;s separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the Company determines that Employee is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after Employee&#8217;s separation from service, or (B) Employee&#8217;s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">(b)  All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">(c)  To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#8217;s termination of employment, then such payments or benefits shall be payable only upon Employee&#8217;s &#8220;separation from service.&#8221;  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A 1(h).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">(d)  The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A 2(b)(2).  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;white-space:pre-wrap;">22.  Application of Internal Revenue Code Section&#160;280G. </b><font style="font-size:11pt;">If any payment or benefit Employee would receive pursuant to a Change in Control from the Company or otherwise (&#8220;</font><i style="font-size:11pt;font-style:italic;">Payment</i><font style="font-size:11pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><i style="font-size:11pt;font-style:italic;">Excise Tax</i><font style="font-size:11pt;">&#8221;), then such Payment shall be equal to the Reduced Amount. The &#8220;Reduced Amount&#8221; shall be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#8220;parachute payments&#8221; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x)&#160;in the preceding paragraph is subject to the</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Excise Tax, Employee agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y)&#160;in the preceding paragraph, Employee will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Unless Employee and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Employee and the Company within fifteen (15)&#160;calendar days after the date on which Employee&#8217;s right to a Payment is triggered (if requested at that time by the Employee or the Company) or such other time as requested by Employee or the Company.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-size:11pt;font-weight:bold;">Indemnification.</b><font style="font-size:11pt;"> As a condition to the effectiveness of this Agreement, the Company and Employee shall enter into a mutually acceptable indemnification agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:11pt;"> the parties hereto have executed this Agreement as of the date first written above.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">AYTU BIOPHARMA, INC.</b><font style="display:inline-block;width:15.06pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">EMPLOYEE</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">By:  __________________________                       ______________________________</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name: VIVIAN LIU</font><font style="display:inline-block;width:16.3pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Name:  JOSHUA R. DISBROW</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chairwoman of the Compensation Committee</font><font style="display:inline-block;width:29.45pt;"></font><font style="font-size:11pt;">Chairman and Chief Executive Officer</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Board of Directors</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>3
<FILENAME>aytu-20230630xex10d46.htm
<DESCRIPTION>EX-10.46
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.46</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDED AND RE-STATED EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This Amended and Re-stated Employment Agreement (the &quot;Agreement&quot;), is effective as of February 13, 2023 (the &#8220;Effective Date&#8221;), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the &quot;Company&quot;), and Mark Oki (&#8220;Executive&quot;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 2.04pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS, </b><font style="font-size:11pt;">the Company is a duly organized Delaware corporation, with its principal place of business within the State of Colorado, and is in the business of developing and marketing pharmaceuticals, medical devices, and other healthcare products; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS,</b><font style="font-size:11pt;"> the Company desires Executive&#8217;s continued experience, skills, abilities, background and knowledge, and is willing to engage Executive&#8217;s services on the terms and conditions set forth in this Agreement; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS,</b><font style="font-size:11pt;"> Executive desires to continue to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-size:11pt;white-space:pre-wrap;">.  The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the &#8220;Term&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position and Duties</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, the Executive shall serve as the Chief Financial Officer of the Company, and shall have supervision and control over and responsibility for the day-to-day business and affairs of the Company and shall have such other powers and duties as may from time to time be prescribed by the Chief Executive Officer (&#8220;CEO&#8221;) of the Company, provided that such duties are consistent with the Executive&#8217;s position or other positions that he may hold from time to time.  The Executive shall devote his full working time and efforts to the business and affairs of the Company.  Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the CEO, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive&#8217;s performance of his duties to the Company as provided in this Agreement.  During the Term, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Executive to be adverse or antagonistic to the Company, its business or prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of which Executive is or becomes a member of during the term hereof. Executive shall provide written disclosure to the Compensation Committee (&#8220;Compensation Committee&#8221;) of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) as to all advisory boards on which Executive sits, and will provide the Company with written notice within 10 business days of Executive agreeing to sit on any additional advisory boards. On termination of Executive&#8217;s employment, regardless of the reason for</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation and Related Matters</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, the Executive&#8217;s initial annual base salary shall be four hundred fifteen thousand dollars ($415,000.00), less applicable deductions and withholdings.  The Executive&#8217;s base salary shall be reviewed at least annually by the Compensation Committee or a majority of the independent members of the Board, and the base salary may be increased only by the Compensation Committee or a majority of the independent members of the Board.  The base salary in effect at any given time is referred to herein as &#8220;Base Salary.&#8221;  The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for senior executives.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bonus Compensation</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the &#8220;Bonus&#8221;) with a target amount of forty percent (40%) of the Base Salary, subject to standard deductions and withholdings, based on the Compensation Committee&#8217;s determination, in good faith, and based upon the Executive&#8217;s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the Compensation Committee, in good faith, in consultation with the Executive (hereinafter referred to as the &#8220;Performance Milestones&#8221;). The Performance Milestones will be based on certain factors including, but not limited to, the Executive&#8217;s performance and the Company&#8217;s financial and operational performance. The Executive&#8217;s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Executive&#8217;s written consent. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signing Bonus</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive shall receive a bonus upon signing this agreement in the amount of fifty thousand dollars and zero cents ($50,000.00) less applicable deductions and withholdings (hereinafter referred to as the &#8220;Signing Bonus&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Grant</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Company shall grant to Executive a stock grant of 100,000 shares, which will vest over a (3) year period of employment with the Company beginning with one third (1/3) of the stock vesting on the one-year anniversary of the Effective Date of this Agreement, and the remaining stock vesting in equal quarterly tranches for two years.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relocation Expenses</u><font style="font-size:11pt;">. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses associated with relocating to the Denver, Colorado area inclusive of travel, hotel and other lodging, expenses associated with travel to and from Denver for home searches and moving and packing of household items.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Benefits</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, the Executive shall be eligible to participate in or receive benefits under the Company&#8217;s employee benefit plans in effect from time to time, subject to the terms of such plans.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacations</u><font style="font-size:11pt;white-space:pre-wrap;">.  For the term of this Agreement, Executive shall be entitled to paid time off at the rate of twenty-one (21) days per annum.  In accordance with Company policy, unused paid time off may not be carried over from year to year.  The Executive shall also be entitled to all paid holidays given by the Company to its executives.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, the Executive&#8217;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Death</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive&#8217;s employment hereunder shall terminate upon his death.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Company may terminate the Executive&#8217;s employment if he is disabled and unable to perform the essential functions of the Executive&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.  If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#8217;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#8217;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.  The Executive shall cooperate with any reasonable request of the physician in connection with such certification.  If such question shall arise and the Executive shall fail to submit such certification, the Company&#8217;s determination of such issue shall be binding on the Executive.  Nothing in this Section&#160;3(b) shall be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><i style="font-size:11pt;font-style:italic;">et&#160;seq.</i><font style="font-size:11pt;"> and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><i style="font-size:11pt;font-style:italic;">et&#160;seq.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Company for Cause</u><font style="font-size:12pt;">(d)</font><font style="display:inline-block;width:27.7pt;"></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u><font style="font-size:11pt;white-space:pre-wrap;">  The Company may terminate the Executive&#8217;s employment hereunder for Cause.  For purposes of this Agreement, &#8220;Cause&#8221; shall mean any of the following:  (i)&#160;the Executive&#8217;s willful and deliberate breach of any agreement with the Company, including the Confidentiality and Intellectual Property Agreement, dated November 28, 2021 (the &#8220;Confidentiality Agreement&#8221;), the provisions of Section&#160;8 of this Agreement, the Code of Conduct or any other material policy that may result in material injury to the Company, including Executive&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the Employee owes an obligation of nondisclosure as a result of the Employee&#8217;s relationship with the Company; (ii)&#160;the Executive&#8217;s conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendre with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii)&#160;the Executive&#8217;s act of fraud or intentional misrepresentation in connection with the Executive&#8217;s duties or otherwise in connection with the business of the Company, that may result in material injury to the Company; (iv)&#160;the Executive&#8217;s unintended but material breach in the performance of duties under this Agreement, including insubordination or failure to implement or follow a lawful policy or directive of the Company, provided that if such failure is curable, it is not cured within 30&#160;days following written notice thereof from the Board; or (v)&#160;the Executive&#8217;s willful malfeasance or willful misconduct in the performance of the Executive&#8217;s employment.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Without Cause</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Company may terminate the Executive&#8217;s employment hereunder at any time without Cause.  Any termination by the Company of the Executive&#8217;s</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">employment under this Agreement which does not constitute a termination for Cause under Section&#160;3(c) and does not result from the death or disability of the Executive under Section&#160;3(a) or (b) shall be deemed a termination without Cause.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Executive</u><font style="font-size:12pt;">(q)</font><font style="display:inline-block;width:23.49pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason.  For purposes of this Agreement, &#8220;Good Reason&#8221; shall mean, without the Executive&#8217;s consent, the occurrence of any of the following:  (i)&#160;the Company materially breaches any term of this Agreement, and such breach causes or is likely to cause material harm to the Executive; (ii)&#160;there is a change in the Executive&#8217;s responsibilities that represents a material and adverse change from the Executive&#8217;s overall responsibilities, taken as a whole; (iii)&#160;there is a Change in Control that results in a change in the Executive&#8217;s responsibilities that represents a material and adverse change from the Executive&#8217;s overall responsibilities, taken as a whole; (iv)&#160;the Executive&#8217;s Base Salary is substantially reduced or diminished; or (v)&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">the Executive&#8217;s place of employment is relocated by the Company more than a 50-mile radius from Englewood, CO (it being understood and agreed that the Executive may be required to travel in connection with Company business and none of such travel shall constitute or give rise to &#8220;Good Reason&#8221;).  The Executive&#8217;s voluntary termination shall be deemed to have occurred for Good Reason for purposes of this Agreement only if (x)&#160;the Executive provides written notice to the Company within 30&#160;days after the Executive becomes aware of circumstances giving rise to Good Reason, (y)&#160;the Company fails to correct the circumstances giving rise to Good Reason within 30&#160;days following the receipt of such notice (the &#8220;Cure Period&#8221;) and (z)&#160;the Executive resigns within 30&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">days following the end of the Cure Period.  If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(r)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Termination</u><font style="font-size:11pt;white-space:pre-wrap;">.  Except for termination as specified in Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">3(a), any termination of the Executive&#8217;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(s)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u><font style="font-size:11pt;white-space:pre-wrap;">.  &#8220;Date of Termination&#8221; shall mean:  (i)&#160;if the Executive&#8217;s employment is terminated by his death, the date of his death; (ii)&#160;if the Executive&#8217;s employment is terminated on account of disability under Section&#160;3(b) or by the Company for Cause under Section&#160;3(c), the date on which Notice of Termination is given; (iii)&#160;if the Executive&#8217;s employment is terminated by the Company under Section&#160;3(d), the date on which a Notice of Termination is given; (iv)&#160;if the Executive&#8217;s employment is terminated by the Executive under Section&#160;3(e) without Good Reason, 30&#160;days after the date on which a Notice of Termination is given, (v)&#160;if the Executive&#8217;s employment is terminated by the Executive under Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period, and (vi) if the Executive&#8217;s employment is terminated by Executive for a Bona Fide Retirement, 30 days after the date on which a Notice of Termination is given.  Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Upon Termination</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Generally</u><font style="font-size:11pt;white-space:pre-wrap;">.  If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i)&#160;any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section&#160;2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">event more than 30&#160;days after the Executive&#8217;s Date of Termination; and (ii)&#160;any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#8220;Accrued Benefit&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Company Without Cause, by the Executive with Good Reason</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, if the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section&#160;3(d), or the Executive terminates his employment for Good Reason as provided in Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">3(e), then the Company shall pay the Executive his Accrued Benefit.  In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the &#8220;Separation Agreement and Release&#8221;) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:25.34pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">the Company shall pay the Executive an amount equal to the Executive&#8217;s annual Base Salary plus any pro-rated incentive compensation earned (as determined by the Board or the Compensation Committee) but unpaid as of the Date of Termination (the &#8220;Severance Amount&#8221;).  Notwithstanding the foregoing, if the Executive breaches any of the provisions of the Confidentiality Agreement, or Section&#160;8 of this Agreement, all payments of the Severance Amount shall immediately cease; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:11pt;">Notwithstanding anything to the contrary in the applicable stock-based award agreement, the underlying shares of the stock-based award will immediately vest following the expiration of the revocation period as set forth in Separation Agreement and Release; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:20.01pt;"></font><font style="font-size:11pt;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12&#160;months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:19.34pt;"></font><font style="font-size:11pt;">the amounts payable under this Section&#160;4(b) shall be paid out in substantially equal installments in accordance with the Company&#8217;s payroll practice over 12&#160;months commencing within 60&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&#160;1.409A-2(b)(2); and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Payment</u><font style="font-size:11pt;white-space:pre-wrap;">.  The provisions of this Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive&#8217;s rights and obligations upon the occurrence of a Change in Control of the Company.  These provisions are intended to assure and encourage in advance the Executive&#8217;s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event.  These provisions shall apply in lieu of, and expressly supersede, the provisions of Section&#160;4(b) regarding severance pay and benefits upon a termination of employment, if such termination of</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">employment occurs within 12&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">months after the occurrence of the first event constituting a Change in Control.  These provisions shall terminate and be of no further force or effect beginning 12&#160;months after the occurrence of a Change in Control.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:11pt;white-space:pre-wrap;">.  During the Term, if within 12&#160;months after a Change in Control, the Executive&#8217;s employment is terminated by the Company without Cause as provided in Section&#160;3(d) or the Executive terminates his employment for Good Reason as provided in Section&#160;3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release effective all within the time frame set forth in the Separation Agreement and Release,</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:25.34pt;"></font><font style="font-size:11pt;">the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A)&#160;the Executive&#8217;s then current Base Salary (or the Executive&#8217;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B)&#160;the Executive&#8217;s target annual incentive compensation for the then- current year; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options, restricted stock and other stock-based grants to Executive by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions thereon shall lapse.  All stock options shall remain exercisable from the date of such employment termination until the expiration of the term of such stock options; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:20.01pt;"></font><font style="font-size:11pt;">if the Executive was participating in the Company&#8217;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12&#160;months or the Executive&#8217;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:19.34pt;"></font><font style="font-size:11pt;">The amounts payable under this Section&#160;5(a) shall be paid or commence to be paid within 60&#160;days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For the avoidance of doubt, all stock options and other stock-based awards held by the Executive as of the Effective Date shall be treated as indicated in the applicable award agreements.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitation</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:25.34pt;"></font><font style="font-size:11pt;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&#160;280G of the Code and the applicable regulations thereunder (the &#8220;Aggregate Payments&#8221;), would be subject to the excise tax imposed by Section&#160;4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section&#160;4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;white-space:pre-wrap;">receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">280G of the Code:  (1)&#160;cash payments not subject to Section&#160;409A of the Code; (2)&#160;cash payments subject to Section&#160;409A of the Code; (3)&#160;equity-based payments and acceleration; and (4)&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas.  Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c)&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">shall be reduced before any amounts that are subject to calculation under Treas.  Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:11pt;">For purposes of this Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">5(b), the &#8220;After Tax Amount&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#8217;s receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:20.01pt;"></font><font style="font-size:11pt;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#8220;Accounting Firm&#8221;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.  Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:11pt;white-space:pre-wrap;">.  For purposes of this Section&#160;5, the following terms shall have the following meanings:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;Change in Control&#8221; shall mean the consummation of any of the following:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:25.34pt;"></font><font style="font-size:11pt;">A sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:22.68pt;"></font><font style="font-size:11pt;">A merger, reorganization or consolidation in which the outstanding shares of common stock of the Company are converted into or exchanged for shares of the successor entity and the holders of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity immediately upon the completion of such transaction; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:20.01pt;"></font><font style="font-size:11pt;">The sale of all or a majority of the common stock of the Company to an unrelated person or entity; or</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:19.34pt;"></font><font style="font-size:11pt;">Any other transaction in which the holders of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity in the transaction immediately upon the completion of such transaction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;409A</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#8217;s separation from service within the meaning of Section&#160;409A of the Code, the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive&#8217;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section&#160;409A(a) of the Code as a result of the application of Section&#160;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&#160;six months and one day after the Executive&#8217;s separation from service, or (B)&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">the Executive&#8217;s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;white-space:pre-wrap;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#8217;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#8217;s &#8220;separation from service.&#8221;  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&#160;1.409A-1(h).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:11pt;">The parties intend that this Agreement will be administered in accordance with Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&#160;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">1.409A-2(b)(2).  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&#160;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:11pt;">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&#160;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any confidential</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;">information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to the Company&#8217;s or any of its affiliates&#8217; actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by the Executive (whether alone or jointly with others) while employed by the Company and its affiliates, whether before or after the date of this Agreement (collectively referred to as &#8220;Work Product&#8221;), are the property of the Company or such affiliated companies.  The Executive shall promptly disclose such Work Product to the Board and, at the Company&#8217;s expense, perform all actions reasonably requested by the Board (whether during or after the period of employment) to establish and confirm such ownership (including, without limitation, executing and delivering assignments, consents, powers of attorney and other instruments).  The Executive acknowledges that all Work Product shall be deemed to constitute &#8220;works made for hire&#8221; under the U.S. Copyright Act of 1976, as amended.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information, Noncompetition and Cooperation</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Executive agrees that he continues to be bound by the terms of the Confidentiality Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">The Executive agrees that all property (including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts and computer- generated materials) furnished to or created or prepared by the Executive incident to the Executive&#8217;s employment belongs to the Company and shall be promptly returned to the Company upon termination of the Executive&#8217;s employment.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;white-space:pre-wrap;">Upon termination of the Executive&#8217;s employment, the Executive shall be deemed to have resigned from any and all offices and directorships then held with the Company and its affiliates.  Following any termination of employment, the Executive shall reasonably cooperate with the Company (i)&#160;in the winding up of pending work on behalf of the Company and the orderly transfer of work to other employees, and (ii)&#160;in the defense of any action brought by any third party against the Company that relates to the Executive&#8217;s employment by the Company; provided, that in each case the Company shall reimburse the Executive for any reasonable and documented out-of-pocket fees and expenses incurred by the Executive in connection with such cooperation.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;white-space:pre-wrap;">The Executive acknowledges that in the course of the Executive&#8217;s employment with the Company, the Executive will become familiar with the Company&#8217;s and its affiliates&#8217; trade secrets and with other confidential and proprietary information and that the Executive&#8217;s services will be of special, unique and extraordinary value to the Company and its affiliates.  Therefore, the Executive agrees that the Executive shall not, during the Term and for a period of one (1)&#160;year thereafter, directly or indirectly, either for himself or for any other person or entity or otherwise, (i)&#160;participate in any business or enterprise (including, without limitation, any division, group or franchise of a larger organization), engaged, anywhere within North America at the time of termination (the &#8220;Restricted Territory&#8221;), in the business of developing or commercializing controlled release, ion exchange resin based pharmaceutical products or any therapeutic agent being studied for or approved for the treatment of vascular Ehlers-Danlos Syndrome (VEDS) or an associated connective tissue disorder, or any other business in which the Executive would be required to employ, reveal or otherwise utilize trade secrets of the Company and its affiliates used prior to termination that may result in a material injury to the Company (with it being understood that the term &#8220;participate in&#8221; shall include, without limitation, having any direct or indirect interest in any person or entity, whether as a sole proprietor, owner, stockholder, partner, joint venturer, creditor or otherwise, or rendering any direct or indirect service or assistance to any person or entity -whether as a director, officer, manager, supervisor, employee, agent, consultant, advisor or otherwise); provided that, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the outstanding stock of any class of an entity which is publicly traded so long as the Executive has no active participation in the business of</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">such corporation; (ii)&#160;induce or attempt to induce any customer, supplier, licensee or other business relation of the Company or any of its subsidiaries to cease doing business with the Company or any such subsidiary or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and the Company and any such subsidiary; or (iii)&#160;induce or attempt to induce any employee of the Company or its affiliates to leave the employ of the Company or any such affiliated company, or in any way interfere with the relationship between the Company and any of its affiliates and any employee thereof, or hire or otherwise engage any person who was an employee of the Company or any of its affiliated companies within one year before any such hiring would take place.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:11pt;white-space:pre-wrap;">The Executive agrees that he will not directly or indirectly, individually or in concert with others, make any statement calculated or likely to have the effect of undermining or disparaging the business or the business reputation of the Company or its affiliates or their respective employees, officers, directors, customers, suppliers, successors and assigns, including, without limitation, negative comments about any such person or company, its management methods, policies and/or practices.  Notwithstanding the foregoing, nothing herein shall prohibit the Executive from responding accurately and fully to any question, inquiry or request made in connection with any governmental inquiry, investigation, review, audit or proceeding, any legal proceeding or claim (whether in court, arbitration or otherwise) of any nature, or as otherwise required by law.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:11pt;">If, at the time of enforcement of this Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law.  Because the Executive&#8217;s services are unique and because the Executive has access to confidential and proprietary information of the Company and its business, the parties hereto agree that money damages would not be an adequate remedy for any breach of Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8 of this Agreement.  Therefore, in the event of a breach or threatened breach of Section&#160;8 of this Agreement, the Company or its successors or assigns may, in addition to other rights and remedies existing in their favor and notwithstanding anything herein to the contrary, apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief in order to enforce or prevent any violations of, the provisions hereof (without posting a bond or other security).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:11pt;">The Executive acknowledges that the provisions of this Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8 are in consideration of the Executive&#8217;s employment with the Company and additional good and valuable consideration as set forth in this Agreement.  The Executive agrees and acknowledges that the restrictions contained in Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8 do not preclude the Executive from earning a livelihood, nor do they unreasonably impose limitations on the Executive&#8217;s ability to earn a living.  The Executive acknowledges (i)&#160;that the business of the Company and its affiliates will be conducted throughout the Restricted Territory, (ii)&#160;notwithstanding the state of formation or principal office of the Company and its affiliates, or any of their respective executives or employees (including the Executive), it is expected that the Company will have business activities and have valuable business relationships within its industry throughout the Restricted Territory, and (iii)&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">as part of the Executive&#8217;s responsibilities, the Executive may be traveling throughout the Restricted Territory in furtherance of the Company&#8217;s and its affiliates&#8217; business and its relationships.  The Executive acknowledges that the potential harm to the Company of the non-enforcement of Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8 outweighs any potential harm to the Executive of its enforcement by injunction or otherwise.  The Executive acknowledges that the Executive has carefully read this Agreement and has given careful consideration to the restraints imposed upon the Executive by this Agreement and is in full accord as to their necessity for the reasonable and proper protection of confidential and proprietary information of the Company and its subsidiaries now existing or to be</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;">developed in the future.  The Executive acknowledges that each and every restraint imposed by this Agreement is reasonable with respect to scope, duration, and geographical area.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration of Disputes</u><font style="font-size:11pt;white-space:pre-wrap;">.  Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive&#8217;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (&#8220;AAA&#8221;) in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators.  In the event that any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity&#8217;s agreement.  Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.  This Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">8 shall be specifically enforceable.  Notwithstanding the foregoing, this Section&#160;8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section&#160;9.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent to Jurisdiction</u><font style="font-size:11pt;white-space:pre-wrap;">.  To the extent that any court action is permitted consistent with or to enforce Section&#160;</font><font style="font-size:11pt;white-space:pre-wrap;">9 of this Agreement, the parties hereby consent to the jurisdiction of the District Court of Douglas County, Colorado and the United States District Court for the District of Colorado.  Accordingly, with respect to any such court action, the Executive (a)&#160;submits to the personal jurisdiction of such courts; (b)&#160;consents to service of process; and (c)&#160;waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</u><font style="font-size:11pt;white-space:pre-wrap;">.  This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that the Confidentiality Agreement remains in full force and effect.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;white-space:pre-wrap;">.  All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor to the Executive</u><font style="font-size:11pt;white-space:pre-wrap;">.  This Agreement shall inure to the benefit of and be enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees.  In the event of the Executive&#8217;s death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive&#8217;s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u><font style="font-size:11pt;white-space:pre-wrap;">.  If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">15.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-size:11pt;white-space:pre-wrap;">.  The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the terms contained herein.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">16.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-size:11pt;white-space:pre-wrap;">.  No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party.  The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">17.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:11pt;white-space:pre-wrap;">.  Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;white-space:pre-wrap;">If to Executive:   </font><font style="display:inline-block;width:26.69pt;"></font><font style="font-size:11pt;">To the address specified in the payroll records of the Company.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:108pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">If to the Company:</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:11pt;">Aytu BioPharma, Inc., 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">18.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:11pt;white-space:pre-wrap;">.  This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">19.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:11pt;white-space:pre-wrap;">.  This is a Colorado contract and shall be construed under and be governed in all respects by the laws of the State of Colorado, without giving effect to the conflict of laws principles of such State.  With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the District of Colorado.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">20.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:11pt;white-space:pre-wrap;">.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">21.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor to Company</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place.  Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">22.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Gender Neutral</u><font style="font-size:11pt;white-space:pre-wrap;">.  Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:11pt;"> the parties hereto have executed this Agreement as of the date first written above.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">AYTU BIOPHARMA, INC.</b><font style="display:inline-block;width:15.06pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">EXECUTIVE</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">By:  __________________________                       ______________________________</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name: VIVIAN LIU</font><font style="display:inline-block;width:16.3pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Name:  MARK OKI</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chairwoman of the Compensation Committee</font><font style="display:inline-block;width:29.45pt;"></font><font style="font-size:11pt;">Chairman and Chief Executive Officer</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Board of Directors</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>4
<FILENAME>aytu-20230630xex10d47.htm
<DESCRIPTION>EX-10.47
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.47</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBLEASE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">THIS SUBLEASE (this &#8220;Sublease&#8221;) is dated for reference purposes as of May 15, 2023, and is made by and between Neos Therapeutics, LP, a Texas limited partnership (&#8220;Sublessor&#8221;), and AMT Manufacturing Solutions, LLC, a Delaware limited liability company (&#8220;Sublessee&#8221;). &#160;Sublessor and Sublessee hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</u><font style="font-size:11pt;">: &#160;This Sublease is made with reference to the fact that Riverside Business Green, LP, a Delaware limited partnership, as Landlord, as successor-in-interest to Walstib, L.P. (&#8220;Master Lessor&#8221;), and Sublessor, as successor-in-interest to PharmaFab, Inc., as tenant, entered into that certain Commercial Lease Agreement, dated as of June 29, 1999, as amended by that certain First Amendment to Lease dated as of September 1, 2002 (the &#8220;First Amendment&#8221;), that certain Interim Amendment to Lease dated as of September 4, 2003 (the &#8220;Second Amendment&#8221;), that certain Third Amendment to Lease dated as of October 1, 2003 (the &#8220;Third Amendment&#8221;), that certain Fourth Amendment to Lease effective as of May 1, 2009 (the &#8220;Fourth Amendment&#8221;), that certain Fifth Amendment to Lease dated as of April 5, 2010 (the &#8220;Fifth Amendment&#8221;), and that certain Sixth Amendment to Lease dated as of August 14, 2013 (the &#8220;Sixth Amendment&#8221;; together with the Original Lease, First Amendment, Second Amendment, Third Amendment, Fourth Amendment, and Fifth Amendment, the &#8220;Master Lease&#8221;), with respect to premises consisting of approximately 97,282 rentable square feet of space, located at 2490 N. Highway 360, Grand Prairie, Texas (the &#8220;Premises&#8221;) consisting of approximately 77,112 rentable square feet in Suites 100 and 200 (the &#8220;Suites 100 and 200 Premises&#8221;) and approximately 20,170 rentable square feet located in Suite 400). &#160;A copy of the Master Lease is attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Premises</u><font style="font-size:11pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">A.</font></font><font style="font-size:11pt;">Commencing on the Commencement Date, Sublessor hereby subleases to Sublessee, and Sublessee hereby subleases from Sublessor, a portion of the Premises consisting of approximately 22,909 rentable square feet of space located in Suite 200 of the Premises (hereinafter, the &#8220;Subleased Premises&#8221;). &#160;The Subleased Premises are more particularly described as the area outlined in red on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:11pt;"> attached hereto. &#160;Commencing as early as April 1, 2024 but no later than December 31, 2024, which date shall be designated by Sublessor by written notice to Sublessee not less than thirty (30) days prior to the date of expansion (such date, the &#8220;Expansion Date&#8221;), the Subleased Premises shall be expanded to include the remainder of the Suites 100 and 200 Premises (other than Sublessor&#8217;s server room therein) outlined in green on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:11pt;"> attached hereto (the &#8220;Expansion Space&#8221;). If Sublessee needs additional space during the period of time preceding the Expansion Date, Sublessor and Sublessee shall work in good faith to accommodate such request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">B.</font></font><font style="font-size:11pt;">Notwithstanding the foregoing, within thirty (30) days of the Commencement Date, subject to receipt of Master Lessor&#8217;s consent, Sublessee, at its sole cost and expense, shall construct a wall or fence as reasonably determined by Sublessor in the location shown in yellow-green dividing the initial Subleased Premises from the Expansion Space on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:11pt;"> attached hereto in accordance with the terms of Paragraph 13 below and the terms of the Master Lease. Sublessee shall only be entitled to access the office area within the Subleased Premises until the date upon which the wall or fence is fully constructed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">C.</font></font><font style="font-size:11pt;">Sublessor shall have the exclusive right to use, and Sublessor&#8217;s security and information technology personnel may enter the Subleased Premises at any time to access the server room which is accessible from within the Subleased Premises. Sublessor shall make commercially reasonable effort to notify Sublessee of such access.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-size:11pt;">: &#160;The term (the &#8220;Term&#8221;) of this Sublease shall be for the period commencing on the date which is one (1) business day after the date by which Sublessor has received consent of the Sublease from both Master Lessor and Sublessor&#8217;s lender (the &#8220;Lender&#8221;) in a form acceptable to Sublessor (the &#8220;Commencement Date&#8221;) and ending on December 31, 2024 (the &#8220;Expiration Date&#8221;), unless this Sublease is sooner terminated pursuant to its terms or the Master Lease sooner expires pursuant to its terms. &#160;For the avoidance of doubt, the Subleased Premises shall be deemed delivered when Sublessor vacates the Subleased Premises and provides Sublessee keys or other means of access thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent</u><font style="font-size:11pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">A.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u><font style="font-size:11pt;">. &#160;Sublessee shall pay to Sublessor base rent for the Subleased Premises for each month during the period commencing on the Commencement Date and expiring on December 31, 2023 the amount of Twenty Thousand Forty-Five Dollars ($20,045) per month, and during the period commencing on January 1, 2024 until the day preceding the Expansion Date the amount of Twenty-One Thousand Dollars ($21,000) per month and during the period commencing on the Expansion Date until the Expiration Date the amount of Seventy Thousand Six Hundred Eighty-Six Dollars ($70,686) per month (&#8220;Base Rent&#8221;). &#160;Base Rent and Additional Rent, as defined in Paragraph 4.B below, shall be paid on or before the first (1st) day of each month. &#160;Base Rent and Additional Rent for any period during the Term hereof which is for less than one (1) month of the Term shall be a pro rata portion of the monthly installment based on a thirty (30) day month. &#160;Base Rent and Additional Rent shall be payable without notice or demand and without any deduction, offset, or abatement, in lawful money of the United States of America. &#160;Base Rent and Additional Rent shall be paid directly to Sublessor by ACH pursuant to instructions provided by Sublessor, or by such other means as may be designated in writing by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">B.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Rent</u><font style="font-size:11pt;">. &#160;All monies other than Base Rent required to be paid by Sublessor under the Master Lease as to the Subleased Premises, including, without limitation, any amounts payable by Sublessor to Master Lessor as &#8220;Operating Expenses&#8221; (as defined in Section 4.2 of the Master Lease), shall be paid by Sublessee hereunder as and when such amounts are due under the Master Lease, as incorporated herein. &#160;Sublessee shall also pay to Sublessor (i) any gross receipts or rent tax payable with respect to this Sublease, (ii) all costs directly incurred by or at the request of Sublessee with respect to its use of the Subleased Premises and (iii) the share allocable to the Subleased Premises as reasonably determined by Sublessor of the actual, reasonable costs incurred by Sublessor with respect to the Premises, including to perform its obligations under the Master Lease, including with respect to utilities and roof and Building system maintenance, or to provide the services, including security, described herein to the extent not included in Operating Expenses. Sublessee shall pay to Sublessor all such amounts within thirty (30) days of invoice therefor. All such amounts shall be deemed additional rent (&#8220;Additional Rent&#8221;). &#160;Base Rent and Additional Rent hereinafter collectively shall be referred to as &#8220;Rent&#8221;. &#160;Sublessee and Sublessor agree, as a material part of the consideration given by Sublessee to Sublessor for this Sublease, that Sublessee shall pay all costs, expenses, taxes, insurance, maintenance and other charges of every kind and nature arising in connection with this Sublease, the Master Lease as to the Subleased Premises or the Subleased Premises, such that Sublessor shall receive, as a net consideration for this Sublease, the Base Rent payable under Paragraph 4.A hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit</u><font style="font-size:11pt;">: &#160;Upon execution hereof by Sublessee, Sublessee shall deposit with Sublessor the sum of Ninety Thousand Seven Hundred Thirty-One Dollars ($90,731) (the &#8220;Security Deposit&#8221;), in cash, as security for the performance by Sublessee of the terms and conditions of this Sublease. &#160;Upon the full execution and delivery by Sublessee and Master Lessor of a lease of all of Suites 100 and 200 of the Building commencing upon the termination of this Sublease and Master Lessor&#8217;s agreement that the Premises does not need to be restored by Sublessor, and Sublessee&#8217;s delivery of a copy thereof to Sublessor, if Sublessee is not then in default under this Sublease, Sublessor shall apply (a)&#160;an amount equal to $20,045 to Base Rent next coming due under this Sublease and (b)&#160;the remainder of the Security Deposit to Base Rent due in December 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holdover</u><font style="font-size:11pt;">: &#160;The parties hereby acknowledge that the expiration date of the Master Lease is December 31, 2024 and that it is therefore critical that Sublessee surrender the Subleased Premises to Sublessor no later than the Expiration Date in accordance with the terms of this Sublease. &#160;In the event that Sublessee does not surrender the Subleased Premises by the Expiration Date in accordance with the terms of this Sublease, Sublessee shall indemnify, defend, protect and hold harmless Sublessor from and against all loss and liability resulting from Sublessee&#8217;s delay in surrendering the Subleased Premises and pay Sublessor holdover rent as provided in Section 16.9 of the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repairs</u><font style="font-size:11pt;">: &#160;The parties acknowledge and agree that Sublessee is subleasing the Subleased Premises on an &#8220;as is&#8221; basis, and that Sublessor has made no representations or warranties with respect to the condition of the Subleased Premises. &#160;Sublessor shall have no obligation whatsoever to make or pay the cost of any alterations, improvements or repairs to the Subleased Premises, including, without limitation, any improvement or repair required to comply with any law; provided, however, subject to reimbursement by Sublessee under Paragraph 4.B, Sublessor shall maintain the roof and certain systems serving the Subleased Premises. &#160;Master Lessor shall be solely responsible for performance of any repairs required to be performed by Master Lessor under the terms of the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Cure Defaults</u><font style="font-size:11pt;">: &#160;If Sublessee fails to pay any sum of money under this Sublease, or fails to perform any other act on its part to be performed hereunder, then Sublessor may, but shall not be obligated to, after passage of any applicable notice and cure periods, make such payment or perform such act. &#160;All such sums paid, and all reasonable costs and expenses of performing any such act, shall be deemed Additional Rent payable by Sublessee to Sublessor upon demand, together with interest thereon at the interest rate set forth in Section 16.2 of the Master Lease (the &#8220;Interest Rate&#8221;) from the date of the expenditure until repaid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment and Subletting</u><font style="font-size:11pt;">: &#160;Sublessee may not assign this Sublease, sublet the Subleased Premises, transfer any interest of Sublessee therein or permit any use of the Subleased Premises by another party (collectively, &#8220;Transfer&#8221;), without the prior written consent of Sublessor and Master Lessor. &#160;Sublessee acknowledges that the Master Lease contains a &#8220;recapture&#8221; right in Section 12.2, and that Sublessor may withhold consent to a proposed Transfer in its sole discretion unless Master Lessor confirms in writing that the recapture right does not apply to the Subleased Premises or otherwise waives such right. &#160;A consent to one Transfer shall not be deemed to be a consent to any subsequent Transfer. &#160;Any Transfer without such consent shall be void and, at the option of Sublessor, shall terminate this Sublease. &#160;Sublessor&#8217;s waiver or consent to any assignment or subletting shall be ineffective unless set forth in writing. &#160;Any Transfer shall be subject to the terms of Section 12 of the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use</u><font style="font-size:11pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">A.</font></font><font style="font-size:11pt;">Sublessee may use the Subleased Premises only for the uses identified in Section&#160;1.8 of the Master Lease, as modified by Section 7 of the Fifth Amendment. &#160;All use of the Subleased Premises by Sublessee shall comply with all applicable laws and regulations and shall not violate any laws administered by the U.S. Drug Enforcement Administration or the U.S. Food and Drug Administration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">B.</font></font><font style="font-size:11pt;">Sublessee shall not do or permit anything to be done in or about the Subleased Premises that would (i) injure the Subleased Premises; or (ii) vibrate, shake, overload, or impair the efficient operation of the Subleased Premises or the sprinkler systems, heating, ventilating or air conditioning equipment, or utilities systems located therein. &#160;Sublessee shall not store any materials, supplies, finished or unfinished products or articles of any nature outside of the Subleased Premises. &#160;For purposes of this Sublease and Sections 2.4 and 16.20 of the Master Lease, Sublessee shall comply with all reasonable rules and regulations promulgated from time to time by Sublessor and Master Lessor, including with respect to security measures imposed by Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Conveyance</u><font style="font-size:11pt;">: &#160;As used in this Sublease, the term &#8220;Sublessor&#8221; means the holder of the tenant&#8217;s interest under the Master Lease. &#160;In the event of any assignment, transfer or termination of the tenant&#8217;s interest under the Master Lease, which assignment, transfer or termination may occur at any time during the Term hereof in Sublessor&#8217;s sole discretion, Sublessor shall be and hereby is entirely relieved of all covenants and obligations of Sublessor hereunder, and it shall be deemed and construed, without further agreement between the parties, that any transferee has assumed and shall carry out all covenants and obligations thereafter to be performed by Sublessor hereunder. &#160;Sublessor may transfer and deliver any security of Sublessee to the transferee of the tenant&#8217;s interest under the Master Lease, and thereupon Sublessor shall be discharged from any further liability with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery and Acceptance</u><font style="font-size:11pt;">: &#160;If Sublessor fails to deliver possession of the Subleased Premises to Sublessee on or before the Commencement Date for any reason whatsoever, then this Sublease shall not be void or voidable; provided, however, that in such event, Rent shall abate until Sublessor delivers possession of the Subleased Premises to Sublessee. &#160;By taking possession of the Subleased Premises, Sublessee conclusively shall be deemed to have accepted the Subleased Premises in their as-is, then-existing condition, without any warranty whatsoever of Sublessor with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvements</u><font style="font-size:11pt;">: &#160;No alteration or improvements shall be made to the Subleased Premises, except in accordance with the Master Lease, and with the prior written consent of both Master Lessor and Sublessor, provided Sublessor has conceptually approved of the alterations described under Paragraph 2.B. above, subject to Master Lessor&#8217;s consent and its review of more detailed plans therefor, including the design and materials for such alterations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u><font style="font-size:11pt;">: &#160;Sublessee shall obtain and keep in full force and effect, at Sublessee&#8217;s sole cost and expense, during the Term the insurance required under Section 8.2 of the Master Lease. &#160;Sublessee shall name Master Lessor and Sublessor as additional insureds under its liability insurance policy. &#160;The release and waiver of subrogation set forth in Section 8.4 of the Master Lease, as incorporated herein, shall be binding on the parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">15.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default</u><font style="font-size:11pt;">: &#160;Sublessee shall be in default under this Sublease if Sublessee commits any act or omission which constitutes a default under the Master Lease, which has not been cured after delivery of written notice and passage of the applicable grace period provided in the Master Lease as modified, if at all, by the provisions of this Sublease. &#160;In the event of any default by Sublessee, Sublessor shall have all remedies provided pursuant to the Landlord&#8217;s Remedies Addendum attached to the Master Lease and by applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">16.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender</u><font style="font-size:11pt;">: &#160;Prior to expiration of this Sublease, Sublessee shall remove all of its trade fixtures and shall surrender the Subleased Premises to Sublessor in the condition required under the Master Lease, provided Sublessor shall remain responsible for the removal of its signs from the Subleased Premises prior to the expiration of the Master Lease. &#160;If the Subleased Premises are not so surrendered, then Sublessee shall be liable to Sublessor for all liabilities Sublessor incurs as a result thereof, including costs incurred by Sublessor in returning the Subleased Premises to the required condition, plus interest thereon at Interest Rate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">17.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker</u><font style="font-size:11pt;">: &#160;Sublessor and Sublessee each represents to the other that it has dealt with no real estate brokers, finders, agents or salesmen in connection with this transaction. &#160;Each party agrees to hold the other party harmless from and against all claims for brokerage commissions, finder&#8217;s fees or other compen&#173;sation made by any other agent, broker, salesman or finder as a consequence of such party&#8217;s actions or dealings with such agent, broker, salesman, or finder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">18.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:11pt;">: &#160;Unless at least five (5) days&#8217; prior written notice is given in the manner set forth in this paragraph, the address of each party for all purposes connected with this Sublease shall be that address set forth below its signature at the end of this Sublease. &#160;All notices, demands or communications in connection with this Sublease shall be (a) personally delivered; or (b) properly addressed and (i) submitted to an overnight</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">courier service, charges prepaid, or (ii) deposited in the mail (certified, return receipt requested, and postage prepaid). &#160;Notices shall be deemed delivered upon receipt, if personally delivered, one (1) business day after being submitted to an overnight courier service and three (3) business days after mailing, if mailed as set forth above. All notices given to Master Lessor under the Master Lease shall be considered received only when delivered in accordance with the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">19.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="font-size:11pt;">: &#160;Sublessee and Sublessor each represent and warrant to the other that each person executing this Sublease on behalf of such party is duly authorized to execute and deliver this Sublease on behalf of that party. &#160;Capitalized terms used but not defined in this Sublease shall have the meanings ascribed to such terms in the Master Lease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">20.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Sublease Terms</u><font style="font-size:11pt;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">A.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incorporation by Reference</u><font style="font-size:11pt;">. &#160;Except as set forth below, the terms and conditions of this Sublease shall include all of the terms of the Master Lease and such terms are incorporated into this Sublease as if fully set forth herein, except that: (i)&#160;each reference in such incorporated sections to &#8220;Lease&#8221; shall be deemed a reference to &#8220;Sublease&#8221;; (ii)&#160;each reference to the &#8220;Premises&#8221; shall be deemed a reference to the &#8220;Subleased Premises&#8221;; (iii)&#160;each reference to &#8220;Landlord&#8221; and &#8220;Tenant&#8221; shall be deemed a reference to &#8220;Sublessor&#8221; and &#8220;Sublessee&#8221;, respectively, except as otherwise expressly set forth herein; (iv)&#160;with respect to work, services, repairs, restoration, insurance, indemnities, representations, warranties or the performance of any other obligation of Master Lessor under the Master Lease, the sole obligation of Sublessor shall be to request the same in writing from Master Lessor as and when requested to do so by Sublessee, and to use Sublessor&#8217;s reasonable efforts (without requiring Sublessor to spend more than a nominal sum) to obtain Master Lessor&#8217;s performance; (v) with respect to any obligation of Sublessee to be performed under this Sublease, wherever the Master Lease grants to Sublessor a specified number of days to perform its obligations under the Master Lease, except as otherwise provided herein, Sublessee shall have three (3) fewer days to perform the obligation, including, without limitation, curing any defaults; (vi)&#160;with respect to any approval required to be obtained from the &#8220;Landlord&#8221; under the Master Lease, such consent must be obtained from both Master Lessor and Sublessor, and the approval of Sublessor may be withheld if Master Lessor&#8217;s consent is not obtained; (vii) in any case where the &#8220;Landlord&#8221; reserves or is granted the right to manage, supervise, control, repair, alter, regulate the use of, enter or use the Premises or any areas beneath, above or adjacent thereto, perform any actions or cure any failures, such reservation or right shall be deemed to be for the benefit of both Master Lessor and Sublessor; (viii) in any case where &#8220;Tenant&#8221; is to indemnify, release or waive claims against &#8220;Landlord&#8221;, such indemnity, release or waiver shall be deemed to cover, and run from Sublessee to, both Master Lessor and Sublessor; (ix) in any case where &#8220;Tenant&#8221; is to execute and/or deliver certain documents or notices to &#8220;Landlord&#8221;, such obligation shall be deemed to run from Sublessee to both Master Lessor and Sublessor; (x)&#160;all payments shall be made to Sublessor; (xi) Sublessee shall pay all consent and review fees set forth in the Master Lease to each of Master Lessor and Sublessor; (xii) Sublessee shall not have the right to terminate this Sublease due to casualty or condemnation unless Sublessor has such right under the Master Lease; (xiii) Sublessor&#8217;s obligations under Section 4.2 are limited to forwarding statements and refunds provided by Master Lessor, and Sublessee shall have no right to dispute or audit such statements; and (xiv) &#8220;Sublessee&#8217;s Share&#8221; shall mean, initially, 23.55% of the Premises, 20.17% of the Building and 10.68% of the Industrial Park, and such amounts shall be increased pro rata based on the increased square footage of the Subleased Premises on the Expansion Date to 79.27% of the Premises, 67.88% of the Building and 35.93% of the Industrial Park. Under no circumstances shall rent abate under this Sublease except to the extent that rent correspondingly abates under the Master Lease as to the Subleased Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;">Notwithstanding the foregoing, the following provisions of the Master Lease shall not be incorporated herein: Sections 1.1, 1.2 (the first sentence only), 1.3-1.7, 1.10, 1.11, 3.1, 3.2, 4.2(b) (first two sentences), 4.2(d) (the reference to Paragraph 1.6 only), 4.2(e), 4.2(f), 5 (the reference to Paragraph 1.7 only), 6.2 (the third and fourth sentences and the first clause in the fifth sentence only), 6.5, 7.3 (the second sentence only), 11 (reference to paying utilities directly instead of to Sublessor), 12.1(c), 16.6, 16.7, 16.18(c) and 16.27;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Guaranty of Lease; Tenant Improvements Addendum; Option to Extend Addendum; Additional Security Deposit Addendum; Exhibit A; First Amendment (except the first sentence of Section 5); Second Amendment; Third Amendment; Fourth Amendment (except Sections 5(b), 6 (except that the reference to &#8220;July 1, 2009&#8221; in Section 6(b) shall mean the Commencement Date), 7, 8 and 9); Fifth Amendment (except Section 7); Sixth Amendment (except Section 7). &#160;In addition, notwithstanding subpart (iii) above, (a) references in the following provisions to &#8220;Landlord&#8221; shall mean Master Lessor only: Sections 2.2-2.5, 4.2(a), 6.4 (the first reference only), 7.1 (the first instance only), 7.2, 8.1, 8.3, 9.1, 10.1-10.4, 12.1(a) (the penultimate sentence), 14, and 16.20 (the last instance only); Fourth Amendment (Section 5(a) only); (b) references in the following provisions to &#8220;Landlord&#8221; shall mean Master Lessor and Sublessor: Sections 6.1 and 6.18(a) and Fourth Amendment (Section 6(c) only); and (c) the terms of the second sentence of Section 10.3 shall also apply to any improvements currently located in the Subleased Premises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">B.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of Obligations</u><font style="font-size:11pt;">. &#160;This Sublease is and at all times shall be subject and subordinate to the Master Lease and the rights of Master Lessor thereunder. &#160;Sublessee hereby expressly assumes and agrees: (i)&#160;to comply with all provisions of the Master Lease which are incorporated hereunder; and (ii)&#160;to perform all the obligations on the part of the &#8220;Tenant&#8221; to be performed under the terms of the Master Lease during the Term of this Sublease that are incorporated hereunder. &#160;In the event the Master Lease is terminated for any reason whatsoever, this Sublease shall terminate simultaneously with such termination (unless Master Lessor or a successor tenant agrees to permit Sublessee to continue to occupy the Subleased Premises on the terms of this Sublease for the remainder of the Term), without any liability of Sublessor to Sublessee except to the extent such termination is due to the violation by a party of the terms of this Sublease. &#160;In the event of a conflict between the provisions of this Sublease and the Master Lease, as between Sublessor and Sublessee, the provisions of this Sublease shall control. &#160;In the event of a conflict between the express provisions of this Sublease and the provisions of the Master Lease, as incorporated herein, the express provisions of this Sublease shall prevail.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">21.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent</u><font style="font-size:11pt;">: &#160;This Sublease and Sublessor&#8217;s and Sublessee&#8217;s obligations hereunder are conditioned upon the written consent of Master Lessor and the Lender. &#160;Each party shall use commercially reasonable efforts to obtain such consent, including by promptly signing Master Lessor&#8217;s and Lender&#8217;s commercially reasonable the consent forms. &#160;If Sublessor fails to obtain Master Lessor&#8217;s or Lender&#8217;s consent within thirty (30) days after execution of this Sublease by Sublessor, then Sublessor or Sublessee may terminate this Sublease by giving the other party written notice thereof prior to the date such consent is received, and Sublessor shall return to Sublessee its payment of the first month&#8217;s Rent paid by Sublessee pursuant to Paragraph 4 hereof and the Security Deposit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">22.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination; Recapture</u><font style="font-size:11pt;">: &#160;Notwithstanding anything to the contrary herein, Sublessee acknowledges that, under the Master Lease, both Master Lessor and Sublessor have certain termination and recapture rights, including, without limitation, in Sections 9, 12.2 and 14. &#160;Nothing herein shall prohibit Master Lessor or Sublessor from exercising any such rights and neither Master Lessor nor Sublessor shall have any liability to Sublessee as a result thereof. &#160;In the event Master Lessor or Sublessor exercise any such termination or recapture rights as to the Subleased Premises, this Sublease shall terminate without any liability to Master Lessor or Sublessor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">23.</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Furniture, Fixtures and Equipment</u><font style="font-size:11pt;">: &#160;Upon execution hereof by Sublessee, Sublessee shall pay to Sublessor the sum of One Hundred Thousand Dollars ($100,000) (the &#8220;Purchase Price&#8221;). Upon receipt of the Purchase Price, Sublessor shall transfer all of its right, title and interest in those assets identified on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="font-size:11pt;"> attached hereto (the &#8220;FF&amp;E&#8221;), and Sublessee shall accept the FF&amp;E in their &#8220;AS IS, WHERE IS&#8221; condition, without representation or warranty whatsoever, pursuant to and in accordance with the form bill of sale attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u><font style="font-size:11pt;">. &#160;Sublessee shall be responsible for payment of all sales tax for the FF&amp;E.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF, the parties have executed this Sublease as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">SUBLESSOR:</font><font style="display:inline-block;width:186.59pt;"></font><font style="font-size:11pt;">SUBLESSEE:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">NEOS THERAPEUTICS, LP, </font><font style="display:inline-block;width:115.41pt;"></font><font style="font-size:11pt;">AMT MANUFACTURING SOLUTIONS, LLC,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a Texas limited partnership </font><font style="display:inline-block;width:129.21pt;"></font><font style="font-size:11pt;">a Delaware limited liability company</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">f/k/a PFAB LP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">By: ___________________________</font><font style="display:inline-block;width:84.86pt;"></font><font style="font-size:11pt;">By: ___________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Name:_________________________</font><font style="display:inline-block;width:85.18pt;"></font><font style="font-size:11pt;">Name: _________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Its: ___________________________</font><font style="display:inline-block;width:86.69pt;"></font><font style="font-size:11pt;">Its: ____________________________</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Address:  c/o Aytu BioPharma, Inc.</font><font style="display:inline-block;width:94.66pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Address:  2490 N. Highway 360, Suite 200</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">373 Inverness Parkway, Suite 206</font><font style="display:inline-block;width:102pt;"></font><font style="font-size:11pt;">Grand Prairie, TX 75052</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Englewood, CO 80112</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Attn:  Chief Financial Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Email:  CFO@aytubio.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">MASTER LEASE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit A</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">SUBLEASED PREMISES, EXPANSION SPACE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">AND LOCATION OF DEMISING WALL</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;"><img src="aytu-20230630xex10d47001.jpg" alt="Graphic" style="display:inline-block;height:364.5pt;width:662.25pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit B</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.55%;margin-right:4.55%;margin-top:30pt;page-break-after:always;width:90.91%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT C</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Furniture, Fixtures and Equipment Listing</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:90%;"><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Major Type</b></p></td><td style="vertical-align:top;width:14.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Fixed asset group</b></p></td><td style="vertical-align:top;width:14.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Fixed asset number</b></p></td><td style="vertical-align:top;width:31.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Area</b></p></td><td style="vertical-align:top;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Locaton/Comments</b></p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1923</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Sanimatic  (Liquids CIP SYSTEM)</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1982</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Type (316) Air-Powe (diaphragm pump)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55042</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Purified Water Syst</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">47</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55046</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kugler Linofill Mac</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55047</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Kugler Reservoir -  100 Liter Hopper </font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55048</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Level Regulation Sy - part of the kugler</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55049</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Addl Rotory Piston - Kugler Pumps</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55060</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">McBrady- Orbit Bottle Rinser</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55145</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kaps All Surge Tabl</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55154</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Load cells - for  Tank 55213</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55126</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP 500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55204</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Joni Electric Tilting Kettle</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55213</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Atmos Open Top Tank 2000L</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55215</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Brawn Mixer BGMF300 - installed on Tank 55213</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1640</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heavy Duty floor scale</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">7008</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Heavy Duty floor scale</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55223</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">B-Tek Heavy Duty floor scale</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55283</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diaphragm pump</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55447</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kugler Pump Svc Cart</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55448</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Kugler Pump Svc Cart</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55526</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Positive Displacement Pump</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55540</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Handheld Oxygen Analyzer</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55206</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Bottle turntable</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55211</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Surge table</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55417-1</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Upack Conveyor</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55210</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pack Off Table</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1639</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Liquid packoff  table &amp; conveyor</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55040</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">12&#39; Conveyor - new</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55408</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sneeze Guards for Kugler</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55409</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sliding Cover for Kugler</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55441</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">BellatRx Chuck Capper</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55513</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">NJM Labeler Trotter W127</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55542</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Nitrogen Purge System</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_5Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55417</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liquid Line U-Pack</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_5Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55493</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liquid Line U-Track</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">C06H07318</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ACH-1 10-60 ton trane Chiller </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">outside</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OfficeEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Warehouse racking (S/R and R1 - R4)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">200 warehouse</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OfficeEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conference Table</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">office area</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OfficeEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Office desk sets (5 total)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">office area</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">OfficeEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cubicles (13 Total)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">office area</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_5Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55407</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Conveyor  </font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">50</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55123</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55124</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1652</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diaphragm pump</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1653</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Load cells - for Tank 1840</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1840</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">500 Gallon tank </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55196-1</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dayton Mixer on tank 1840</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Exhibit C</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:90%;"><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2018</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diaphram Pump (Liquids)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54 - In blue cabinet</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">7006</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diaphragm Pump - 1/2&quot; PTFE </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55036</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diaphragm Pump - 1/2&quot; PTFE </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55541</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Drum Pump - Finish Thompson STTS440</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55261</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">100L mixing tank  and SPX Air mixer</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55043</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;"> Drum Heating Oven</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Shipping warehouse</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55144</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Moyno Cavity Pump</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55146</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MPS Pack-Off Table and Conveyor</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55154</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Lynx Batch - old Controller for  load cells</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55180</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP 500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55127</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP 500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55198</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP 500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55128</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SP 500 VFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55182</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Portable Mixer 2hp</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sold with Groen Kettle - June 22</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55186</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">30G Stainless Steel</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55189</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Portable Mixer 1/2 HP </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55190</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Portable Mixer 1/2 HP </p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55200</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Moyno Cavity Pump</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55060-02</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Chg Prts 125ML&amp;90ML</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55226-01</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">AC Tech Inverter - LenzeVFD</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55243</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Brawn Mixer BGMF150</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On a shelf in shipping dock.</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55243.02</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17 AF# Impeller</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On a shelf in shipping dock.</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55243.03</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">15# A35 Impeller</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On a shelf in shipping dock.</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55243.04</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">SS Polished Shaft</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On a shelf in shipping dock.</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MfgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55266</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&quot;2&quot;&quot; Diaphragm Pump&quot; NT Mfg</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54 - in blue cabinet</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">ME_COG_7Yr</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Presuure Tank PC-37</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stainless Steel Lidding &amp; Foil Racks</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55224</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">Eastey  - Tape Machine</font></p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2473</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stability Chamber</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2474</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stability Chamber</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2475</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stability Chamber</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">LAB</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2308</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Incubator</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Scate Conveyors (3 Total)</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PkgEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55026</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">VideoJet Data Flex Controller</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Suite200</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:top;width:12.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WE_COG_42M</p></td><td style="vertical-align:top;width:14.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">QA Label /Rejection</p></td><td style="vertical-align:top;width:31.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cage Material</p></td><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">WhseEquip</p></td><td style="vertical-align:top;width:14.18%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">200 warehouse</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Exhibit C</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT D</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FORM BILL OF SALE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BILL OF SALE</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">FOR VALUE RECEIVED, the sufficiency of which is hereby acknowledged, Neos Therapeutics, LP, a Texas limited partnership (&#8220;Seller&#8221;), does hereby transfer, assign, sell and convey to AMT Manufacturing Solutions, LLC, a Delaware limited liability company (&#8220;Purchaser&#8221;), all of the furniture, equipment and other personal property described on Exhibit C attached hereto (the &#8220;Assets&#8221;), which are currently located a portion of Suite 200 of in those certain premises at 2490 N. Highway 360, Grand Prairie, Texas.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Seller warrants and represents that it currently holds title to the Assets free and clear of any liens or encumbrances.  EXCEPT AS STATED IN THE PRECEDING SENTENCE, SELLER MAKES NO WARRANTY OR REPRESENTATION WHATSOEVER REGARDING THE ASSETS AND EXPRESSLY EXCLUDES ANY SUCH WARRANTY OR REPRESENTATION, EITHER EXPRESS OR IMPLIED, AS TO THE MANUFACTURE, FITNESS, MERCHANTABILITY, QUALITY, CONDITION, CAPACITY, SUITABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE ASSETS.  THE ASSETS ARE SOLD TO PURCHASER AS IS, WHERE IS, AND WITH ALL FAULTS AND DEFECTS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">WHEREFORE, Seller has executed this Bill of Sale as of the ___ day of ________, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">NEOS THERAPEUTICS, LP,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">a Texas limited partnership</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:164.11pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Print Name:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:126.54pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Title:</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:10.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Exhibit C</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>5
<FILENAME>aytu-20230630xex10d48.htm
<DESCRIPTION>EX-10.48
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.48</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">TRAMMELL CROW COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">COMMERCIAL LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">Landlord</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">PHARMAFAB, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">Tenant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.&#160;&#160;&#160;&#160;BASIC PROVISIONS</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.1.Parties</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.2.Premises</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.3.Term</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.4.Base Rent</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.5.Tenant&#8217;s Share of Operating Expenses</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.6.Tenant&#8217;s Estimated Monthly Rent Payment</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.7.Security Deposit</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.8.Permitted Use</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.9.Guarantor</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.10.Addenda and Exhibits</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">1.11.Address for Rent Payments</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.&#160;&#160;&#160;&#160;PREMISES, PARKING AND COMMON AREAS</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2.1.Letting</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2.2.Common Areas - Definition</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2.3.Common Areas - Tenant&#8217;s Rights</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2.4.Common Areas - Rules and Regulations</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2.5.Common Area Changes</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.&#160;&#160;&#160;&#160;TERM</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">3.1.Term</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">3.2.Delay in Possession</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">3.3.Commencement Date Certificate</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.&#160;&#160;&#160;&#160;RENT</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">4.1.Base Rent</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">4.2.Operating Expenses</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.&#160;&#160;&#160;&#160;SECURITY DEPOSIT</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.&#160;&#160;&#160;&#160;USE</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">6.1.Permitted Use</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">6.2.Hazardous Substances</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">6.3.Tenant&#8217;s Compliance with Requirements</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">8</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">6.4.Inspection; Compliance with Law</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">6.5.Existing Environmental Conditions</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.&#160;&#160;&#160;&#160;MAINTENANCE, REPAIRS, TRADE FIXTURES AND ALTERATIONS</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">7.1.Tenant&#8217;s Obligations</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">7.2.Landlord&#8217;s Obligations</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">7.3.Alterations</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">7.4.Surrender/Restoration</p></td><td style="vertical-align:top;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.&#160;&#160;&#160;&#160;INSURANCE; INDEMNITY</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.1.Payment of Premiums</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.2.Tenant&#8217;s Insurance</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.3.Landlord&#8217;s Insurance</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.4.Waiver of Subrogation</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.5.Indemnity</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.6.Exemption of Landlord from Liability</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">8.7.Breach of Lease by Landlord</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.&#160;&#160;&#160;&#160;DAMAGE OR DESTRUCTION</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">9.1.Termination Right</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">12</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">9.2.Damage Caused by Tenant</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.&#160;&#160;REAL PROPERTY TAXES</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">10.1.Payment of Real Property Taxes</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">10.2.Real Property Tax Definition</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">10.3.Additional Improvements</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">10.4.Joint Assessment</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">13</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">10.5.Tenant&#8217;s Property Taxes</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.&#160;&#160;UTILITIES</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.&#160;&#160;ASSIGNMENT AND SUBLETTING</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">12.1.Landlord&#8217;s Consent Required</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">14</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">12.2.Rent Adjustment</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.&#160;&#160;DEFAULT; REMEDIES</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">13.1.Default</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">15</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">13.2.Remedies</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">13.3.Late Charges</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.&#160;&#160;CONDEMNATION</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.&#160;&#160;ESTOPPEL CERTIFICATE AND FINANCIAL STATEMENTS</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">15.1.Estoppel Certificate</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">16</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">15.2.Financial Statement</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.&#160;&#160;ADDITIONAL COVENANTS AND PROVISIONS</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.1.Severability</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.2.Interest on Past-Due Obligations</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.3.Time of Essence</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.4.Landlord Liability</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.5.No Prior or Other Agreements</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.6.Notice Requirements</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">17</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.7.Date of Notice</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.8.Waivers</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.9.Holdover</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.10.Cumulative Remedies</p></td><td style="vertical-align:top;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.11.Binding Effect; Choice of Law</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.12.Landlord</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">18</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.13.Attorneys&#8217; Fees and Other Costs</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.14.Landlord&#8217;s Access; Showing Premises; Repairs</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.15.Signs</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.16.Termination; Merger</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.17.Quiet Possession</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.18.Subordination; Attornment; Non-Disturbance</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.19.Financing by Tenant</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">20</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.20.Rules and Regulations</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.21.Security Measures</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.22.Reservations</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.23.Conflict</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.24.Offer</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.25.Amendments</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.26.Multiple Parties</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">16.27.Authority</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGNATURES</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">22</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT A</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT B</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT C</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBIT D</p></td><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">GLOSSARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following terms in the Lease are defined in the paragraphs opposite the terms.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TERM</u></p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DEFINED IN PARAGRAPH</u></p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional Rent</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Applicable Requirements</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.3</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assign</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.4</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic Provisions</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building Operating Expenses</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2(b)</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Code</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commencement Date</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.3</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commencement Date Certified</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Areas</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Area Operating Expenses</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2(b)</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Condemnation</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Default</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiration Date</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.3</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HVAC</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2(a)</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hazardous Substance</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indemnity</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8.5</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Industrial Center</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Entities</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.2(c)</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lenders</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.4</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mortgage</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.18</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Party/Parties</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Use</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.8</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prevailing Party</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.13</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Real Property Taxes</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reportable Use</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Requesting Party</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Responding Party</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rules and Regulations</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.4</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security Deposit</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.7</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant Acts</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9.2</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant&#8217;s Share</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.5</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.3</p></td></tr><tr><td style="vertical-align:top;width:73.16%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use</p></td><td style="vertical-align:top;width:26.83%;margin:0pt;padding:0pt 2.9pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">INDUSTRIAL MULTI-TENANT LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Basic Provisions</b> (&#8220;Basic Provisions&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>: This Lease (&#8220;Lease&#8221;) dated June ____, 1999, is made by and between WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;) and PHARMAFAB, INC., a Texas corporation (&#8220;Tenant&#8221;) (collectively the &#8220;Parties,&#8221; or individually a &#8220;Party&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Premises</u>: A portion, outlined on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> attached hereto (&#8220;Premises&#8221;), of the building (&#8220;Building&#8221;) located at 360 Riverside Business Center (Building B) in the City of Grand Prairie, State of Texas. &#160;The Building is located in the industrial center commonly known as 360&#160;Riverside Business Center (the &#8220;Industrial Center&#8221;). &#160;Tenant shall have non-exclusive rights to the Common Areas (as defined in Paragraph&#160;2.3 below), but shall not have any rights to the roof exterior walls or utility raceways of the Building or to any other buildings in the Industrial Center. &#160;The Premises, the Building, the Common Areas, the land upon which they are located and all other buildings and improvements thereon are herein collectively referred to as the &#8220;Industrial Center.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>: The period (&#8220;Term&#8221;) commencing on July&#160;15, 1999, subject to the provisions of Section&#160;3.2 below (&#8220;Commencement Date&#8221;), and ending July&#160;31, 2006 (&#8220;Expiration Date&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>: Initially, the sum of $28,930.00 per month, subject to adjustment as set forth below (&#8220;Base Rent&#8221;). &#160;The first installment of Base Rent in the amount of $28,930.00 shall be payable on execution of this Lease. &#160;The Base Rent shall be as follows:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:57.49%;" align="center"><tr><td style="vertical-align:top;width:33.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Months</u></p></td><td style="vertical-align:top;width:30.64%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net PSF</u></p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly</u></p></td></tr><tr><td style="vertical-align:top;width:33.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1-12</p></td><td style="vertical-align:top;width:30.64%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$7.89</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$28,930.00</p></td></tr><tr><td style="vertical-align:top;width:33.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13-60</p></td><td style="vertical-align:top;width:30.64%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$8.70</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$31,900.00</p></td></tr><tr><td style="vertical-align:top;width:33.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">61-72</p></td><td style="vertical-align:top;width:30.64%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$9.58</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$35,126.67</p></td></tr><tr><td style="vertical-align:top;width:33.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">73-84</p></td><td style="vertical-align:top;width:30.64%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$9.98</p></td><td style="vertical-align:top;width:35.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$36,593.33</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Share of Operating Expenses</u> (&#8220;Tenant&#8217;s Share&#8221;):</p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:69.54%;"><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:top;width:70.66%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Industrial Park</p></td><td style="vertical-align:top;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20.5</p></td><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="vertical-align:top;width:70.66%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building</p></td><td style="vertical-align:top;width:13.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38.7</p></td><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Estimated Monthly Rent Payment</u>: Following is the estimated monthly Rent payment to Landlord pursuant to the provisions of this Lease. This estimate is made at the inception of the Lease and is subject to adjustment pursuant to the provisions of this Lease:</p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:66.76%;"><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent (Paragraph&#160;4.1)</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28,930.00</p></td></tr><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses (Paragraph&#160;4.2; <br>excluding Real Property Taxes and <br>Landlord Insurance)</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,283.33</p></td></tr><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(c)</p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Insurance (Paragraph&#160;8.3)</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">183.33</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:66.76%;"><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)</p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Real Property Taxes (Paragraph&#160;10)</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,300.00</p></td></tr><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.72%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.05%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated Monthly Payment</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:18.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33,696.66</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit</u>: $38,000.00 (&#8220;Security Deposit&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</u>: Manufacturing, storage and distribution of pharmaceutical products (&#8220;Permitted Use&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guarantor</u>: Bruce K. Montgomery and Darlene Ryan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Addenda and Exhibits</u>: Attached hereto are the following Addenda and Exhibits, all of which constitute a part of this Lease:</p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:72.32%;"><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(a)</p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Addenda:</p></td><td colspan="2" style="vertical-align:top;width:71.79%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remedies Addendum</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:71.79%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant Improvements Addendum</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:71.79%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Option To Extend Addendum</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:71.79%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additional Security Deposit Addendum</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(b)</p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibits:</p></td><td style="vertical-align:top;width:23.07%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>:</p></td><td style="vertical-align:top;width:48.71%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diagram of Premises.</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.07%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>:</p></td><td style="vertical-align:top;width:48.71%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commencement Date Certificate.</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.07%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u>:</p></td><td style="vertical-align:top;width:48.71%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signage Criteria</p></td></tr><tr><td style="vertical-align:top;width:8.97%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.23%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.07%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u>:</p></td><td style="vertical-align:top;width:48.71%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subordination Agreement</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Address for Rent Payments</u>: All amounts payable by Tenant to Landlord shall until further notice from Landlord be paid to WALSTIB, L.P., a Delaware limited partnership at the following address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">c/o Trammell Crow Dallas/Fort Worth</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">801 Avenue H East, Suite 101</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">Arlington, Texas 76011</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Premises, Parking and Common Areas</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Letting</u>. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the Premises upon all of the terms, covenants and conditions set forth in this Lease. &#160;Any statement of square footage set forth in this Lease or that may have been used in calculating Base Rent and/or Operating Expenses is an approximation which Landlord and Tenant agree is reasonable and the Base Rent and Tenant&#8217;s Share based thereon is not subject to revision whether or not the actual square footage is more or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Areas - Definition</u>. &#8220;Common Areas&#8221; are all areas and facilities outside the Premises and within the exterior boundary line of the Industrial Center and interior utility raceways within the Premises that are provided and designated by the Landlord from time to time for the general non-exclusive use of Landlord, Tenant and other tenants of the Industrial Center and their respective employees, suppliers, shippers, tenants, contractors and invitees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Areas - Tenant&#8217;s Rights</u>. Landlord hereby grants to Tenant, for the benefit of Tenant and its employees, suppliers, shippers, contractors, customers and invitees, during the Term of this Lease, the non-exclusive right to use, in common with others entitled to such use, the Common Areas as they exist from time to time, subject to any rights, powers, and privileges reserved by Landlord under the terms hereof or under the terms of any rules and regulations or covenants, conditions and restrictions governing the use of the Industrial Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Areas - Rules and Regulations</u>. Landlord shall have the exclusive control and management of the Common Areas and shall have the right, from time to time, to establish, modify, amend and enforce reasonable Rules and Regulations with respect thereto in accordance with Paragraph&#160;16.19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Area Changes</u>. Landlord shall have the right, in Landlord&#8217;s sole discretion, from time to time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>To make such changes to the Common Areas as Landlord, in the exercise of sound business judgment, may deem to be appropriate, including, without limitation, changes in the locations, size, shape and number of driveways, entrances, parking spaces, parking areas, loading and unloading areas, ingress, egress, direction of traffic, landscaped areas, walkways and utility raceways; provided, however, that no such changes shall result in access to the Premises or the parking areas or loading areas adjacent to the Premises being denied to Tenant, and in any event Landlord shall use reasonable efforts to minimize the extent to which any such changes in the Common Areas will impede or interfere with access to the Premises, including the use of parking spaces and loading areas adjacent to the Premises and the use of driveways providing ingress and egress to and from the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>To close temporarily any of the Common Areas for maintenance purposes so long as reasonable access to the Premises remains available;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To designate other land outside the boundaries of the Industrial Center to be a part of the Common Areas;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>To add additional buildings and improvements to the Common Areas;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>To use the Common Areas while engaged in making additional improvements, repairs or alterations to the Industrial Center, or any portion thereof; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>To do and perform such other acts and make such other changes in, to or with respect to the Common Areas and Industrial Center as Landlord may, in the exercise of sound business judgment, deem to be appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Term</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. The Commencement Date, Expiration Date and Term of this Lease are as specified in Paragraph&#160;1.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay in Possession</u>. If for any reason Landlord cannot deliver possession of the Premises to Tenant by the Commencement Date, Landlord shall not be subject to any liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">therefor, nor shall such failure affect the validity of this Lease or the obligations of Tenant hereunder. &#160;In such case, Tenant shall not, except as otherwise provided herein, be obligated to pay Rent or perform any other obligation of Tenant under the terms of this Lease until Landlord delivers possession of the Premises to Tenant. &#160;The term of the Lease shall commence on the earlier of (a)&#160;the date upon which Tenant takes possession of the Premises, or (b)&#160;ten (10) days following notice to Tenant that the Leasehold Improvements (as defined in the Tenant Improvements Addendum) are substantially complete (as such term is defined in the Tenant Improvements Addendum) and Landlord is prepared to tender possession of the Premises to Tenant. &#160;If possession of the Premises is not delivered to Tenant within sixty (60) days after the receipt of a building permit in respect of the Premises from the City of Grand Prairie and such delay is not due to Tenant&#8217;s acts, failure to act or omissions, then Tenant shall be entitled, as its sole remedy, to receive one (1) day&#8217;s rental abatement (effective as of the Commencement Date) for each day of delay beyond such sixty (60) day period. &#160;If possession of the Premises is not delivered to Tenant within ninety (90) days after the receipt of a building permit in respect of the Premises from the City of Grand Prairie and such delay is not due to Tenant&#8217;s acts, failure to act or omissions, then Tenant shall be entitled, as its sole remedy, to receive two (2) days&#8217; rental abatement (effective as of the Commencement Date) for each day of delay beyond such ninety (90) day period. &#160;If possession of the Premises is not delivered to Tenant within one hundred twenty (120) days after the receipt of a building permit in respect of the Premises from the City of Grand Prairie and such delay is not due to Tenant&#8217;s acts, failure to act or omissions, then Tenant may, as its sole remedy, cancel this Lease by notice in writing to Landlord within ten (10) days after the end of said one hundred twenty (120) day period, and in such event the parties shall be discharged from all obligations hereunder. &#160;If such written notice from Tenant is not received by Landlord within said ten (10) day period, Tenant&#8217;s right to cancel this Lease shall terminate. &#160;If the Commencement Date is after August 1, 1999, and is not the first day in a calendar month, then the Term shall end, and the Expiration Date shall be, the last day of the eighty-four (84) month period that begins on the first day of the first full calendar month of the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commencement Date Certificate</u>. At the request of Landlord, Tenant shall execute and deliver to Landlord a completed certificate (&#8220;Commencement Date Certificate&#8221;) in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Rent</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>. Tenant shall pay to Landlord Base Rent and other monetary obligations of Tenant to Landlord under the terms of this Lease (such other monetary obligations are herein referred to as &#8220;Additional Rent&#8221;) in lawful money of the United States, without offset or deduction, in advance on or before the first day of each month. &#160;Base Rent and Additional Rent for any period during the term hereof which is for less than one full month shall be prorated based upon the actual number of days of the month involved. &#160;Payment of Base Rent and Additional Rent shall be made to Landlord at its address stated herein or to such other persons or at such other addresses as Landlord may from time to time designate in writing to Tenant. &#160;Base Rent and Additional Rent are collectively referred to as &#8220;Rent&#8221;. &#160;All monetary obligations of Tenant to Landlord under the terms of this Lease are deemed to be rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Expenses</u>. Tenant shall pay to Landlord on the first day of each month during the term hereof, in addition to the Base Rent, Tenant&#8217;s Share of all Operating Expenses in accordance with the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;Operating Expenses&#8221; are all costs incurred by Landlord relating to the ownership and operation of the Industrial Center, Building and Premises including, but not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>The operation, repair, maintenance and replacement in neat, clean, good order and condition of the Common Areas, including parking areas, loading and unloading areas, trash areas, roadways, sidewalks, walkways, parkways, driveways, landscaped areas, striping, bumpers, irrigation systems, drainage systems, lighting facilities, fences and gates, exterior signs and tenant directories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Water, gas, electricity, telephone and other utilities servicing the Common Areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>Trash disposal, janitorial services, snow removal, property management and security services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>Reasonable reserves set aside for maintenance, repair and replacement of the Common Areas and Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(v)<font style="display:inline-block;width:24.34pt;"></font>Real Property Taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(vi)<font style="display:inline-block;width:21.56pt;"></font>Premiums for the insurance policies maintained by Landlord under Paragraph&#160;8 hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(vii)<font style="display:inline-block;width:18.78pt;"></font>Environmental monitoring and insurance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(viii)<font style="display:inline-block;width:16pt;"></font>Monthly amortization of capital improvements to the Common Areas and the Building, it being agreed that the monthly amortization of any given capital improvement shall be equal to the quotient obtained by dividing the cost of the capital improvement by Landlord&#8217;s estimate of the number of months of useful life of such improvement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ix)<font style="display:inline-block;width:21.56pt;"></font>Maintenance of the Building including, but not limited to, painting, caulking and repair and replacement of Building components, including, but not limited to, roof, elevators, mechanical, systems, and fire detection and sprinkler systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(x)<font style="display:inline-block;width:24.34pt;"></font>If Tenant fails to maintain the Premises, any expense incurred by Landlord for such maintenance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant&#8217;s Share of Operating Expenses that are not specifically attributed to the Premises or Building (&#8220;Common Area Operating Expenses&#8221;) shall be that percentage shown in Paragraph&#160;1.5(a). &#160;Tenant&#8217;s Share of Operating Expenses that are attributable to the Building (&#8220;Building Operating Expenses&#8221;) shall be that percentage shown in Paragraph&#160;1.5(b). &#160;Landlord in its reasonable discretion shall determine which Operating Expenses are Common Area Operating Expenses, Building Operating Expenses or expenses to be entirely borne by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The inclusion of the improvements, facilities and services set forth in Subparagraph&#160;4.2(a) shall not be deemed to impose any obligation upon Landlord to either have said improvements or facilities or to provide those services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Tenant shall pay monthly in advance on the same day as the Base Rent is due Tenant&#8217;s Share of estimated Operating Expenses in the amount set forth in Paragraph&#160;1.6. &#160;Landlord shall deliver to Tenant within ninety (90) days after the expiration of each calendar year a reasonably detailed statement showing Tenant&#8217;s Share of the actual Operating Expenses incurred during the preceding year. &#160;If Tenant&#8217;s estimated payments under this Paragraph&#160;4(d) during the preceding year exceed Tenant&#8217;s Share as indicated on said statement, Tenant shall be credited the amount of such overpayment against Tenant&#8217;s Share of Operating Expenses next becoming due. &#160;If Tenant&#8217;s estimated payments under this Paragraph&#160;4.2(d) during said preceding year were less than Tenant&#8217;s Share as indicated on said statement, Tenant shall pay to Landlord the amount of the deficiency within ten (10) days after delivery by Landlord to tenant of said statement. &#160;At any time Landlord may adjust the amount of the estimated Tenant&#8217;s Share of Operating Expenses to reflect Landlord&#8217;s estimate of such expenses for the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Notwithstanding anything contained herein to the contrary, the Controllable Operating Expenses (as hereinafter defined) payable by Tenant for each calendar year after 2000 shall not be more than the sum of (i)&#160;the aggregate amount of Controllable Operating Expenses for the year 2000 and (ii)&#160;the product obtained by multiplying (A) .15, times (B) the number of complete calendar years that have elapsed between January 1 of the year 2000 and January 1 of the year for which such calculation is being made, times (C) the aggregate amount of Controllable Operating Expenses for the year 2000. &#160;For purposes of this Lease, the term &#8220;Controllable Operating Expenses&#8221; shall mean all items of Operating Expenses which are within the reasonable control of Landlord; thus, excluding Real Property Taxes, insurance, utilities, and other costs beyond the reasonable control of Landlord. &#160;The limit on the increases in Controllable Operating Expenses shall continue during any renewal or extended Term, using the year 2000 as the base year to calculate the applicable limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>After giving Landlord thirty (30) days&#8217; prior written notice thereof, Tenant may inspect or audit Landlord&#8217;s records relating to Operating Expenses for any periods of time within one year before the audit or inspection; however, no audit or inspection shall extend to periods of time before the Commencement Date. &#160;If Tenant fails to object to the calculation of Operating Expenses on an annual Operating Expense statement within thirty (30) days after the statement has been delivered to Tenant, then Tenant shall have waived its right to object to the calculation of Operating Expenses for the year in question and the calculation of Operating Expenses set forth on such statement shall be final. &#160;Tenant&#8217;s audit or inspection shall be conducted only during business hours reasonably designated by Landlord. &#160;Tenant shall pay the cost of such audit or inspection, including $100 per hour of Landlord&#8217;s or the building manager&#8217;s employee time devoted to such inspection or audit, to reimburse Landlord for its overhead costs allocable to the inspection or audit, unless the total Operating Expenses charged to Tenant for the time period in question is determined to be in error by more than five percent (5 %) in the aggregate, in which case Landlord shall pay the audit cost. &#160;Tenant may not conduct an inspection or have an audit performed more than once during any calendar year. &#160;If such inspection or audit reveals that an error was made in the Operating Expenses previously charged to Tenant, then Landlord shall refund to Tenant any overpayment of any such costs, or Tenant shall pay to Landlord any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">underpayment of any such costs, as the case may be, within thirty (30) days after notification thereof. &#160;Tenant shall maintain the results of each such audit or inspection confidential and shall not be permitted to use any third party to perform such audit or inspection, other than an independent firm of certified public accountants reasonably acceptable to Landlord which agrees with Landlord in writing to maintain the results of such audit or inspection confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Security Deposit</b>. Tenant shall deposit with Landlord upon Tenant&#8217;s execution hereof the Security Deposit set forth in Paragraph&#160;1.7 as security for Tenant&#8217;s faithful performance of Tenants obligations under this Lease. &#160;If Tenant fails to pay Base Rent or Additional Rent or otherwise defaults under this Lease (as defined in Paragraph&#160;13.1), Landlord may use the Security Deposit for the payment of any amount due Landlord or to reimburse or compensate Landlord for any liability, cost, expense, loss or damage (including attorney&#8217;s fees) which Landlord may suffer or incur by reason thereof. &#160;Tenant shall on demand pay Landlord the amount so used or applied so as to restore the Security Deposit to the amount set forth in Paragraph&#160;1.7. &#160;Landlord shall not be required to keep all or any part of the Security Deposit separate from its general accounts. &#160;Landlord shall, at the expiration or earlier termination of the term hereof and after Tenant has vacated the Premises, return to Tenant that portion of the Security Deposit not used or applied by Landlord. &#160;No part of the Security Deposit shall be considered to be held in trust, to bear interest, or to be prepayment for any monies to be paid by Tenant under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Use</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</u>. Tenant shall use and occupy the Premises only for the Permitted Use set forth in Paragraph&#160;1.8. &#160;Tenant shall not commit any nuisance, permit the emission of any objectionable noise or odor, suffer any waste, or make any use of the Premises which is contrary to any law or ordinance, or which would invalidate any of Landlord&#8217;s insurance, or which would increase the premiums for any insurance carried by Landlord which is typically carried by landlords of properties comparable to the Industrial Center. &#160;Tenant shall not service, maintain or repair vehicles on the Premises, Building or Common Areas. &#160;Tenant shall not store foods, pallets, drums or any other materials outside the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Substances</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reportable Uses Require Consent</u>. The term &#8220;Hazardous Substance&#8221; as used in this Lease shall mean any product, substance, chemical, material or waste whose presence, nature, quantity and/or intensity of existence, use, manufacture, disposal, transportation, spill, release or effect, either by itself or in combination with other materials expected to be on the Premises, is either: &#160;(i)&#160;potentially injurious to the public health, safety or welfare, the environment, or the Premises; (ii)&#160;regulated or monitored by any governmental authority; or (iii)&#160;a basis for potential liability of Landlord to any governmental agency or third party under any applicable statute or common law theory. &#160;Hazardous Substance shall include, but not be limited to, hydrocarbons, petroleum, gasoline, crude oil or any products or by-products thereof. &#160;Landlord acknowledges and agrees that Tenant will be using the Premises for the manufacture, storing and distribution of pharmaceutical and related materials (some of which may contain Hazardous Substances) in the ordinary course of Tenant&#8217;s business (collectively, &#8220;Tenant&#8217;s Products&#8221;). &#160;Nothing contained in this Lease shall be construed to prohibit Tenant from bringing Tenant&#8217;s Products upon the Premises; provided, however, that Tenant must comply with all Applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Requirements in respect of Tenant&#8217;s Products. &#160;With the exception of Tenant&#8217;s Products, Tenant shall not, without the prior written consent of Landlord, generate, possess, store, use, transport, or dispose of a Hazardous Substance (i)&#160;that requires a permit from, or with respect to which a report, notice, registration or business plan is required to be filed with, any governmental authority, or (ii)&#160;with respect to which any Applicable Requirements require that a notice be given to persons entering or occupying the Premises or neighboring properties. &#160;Furthermore, Tenant shall not install or use any above or below ground storage tank in the Industrial Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duty to Inform Landlord</u>. If Tenant knows that a Hazardous Substance is located in, under or about the Premises or the Building in violation of Applicable Requirements, Tenant shall immediately give Landlord written notice thereof, together with a copy of any statement, report, notice, registration, application, permit, business plan, license, claim, action, or proceeding given to, or received from, any governmental authority or private party concerning the presence, spill, release, discharge of, or exposure to, such Hazardous Substance. &#160;Tenant shall not cause or permit any Hazardous Substance to be spilled or released in, on, under or about the Premises (including, without limitation, through the plumbing or sanitary sewer system) in violation of Applicable Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. Tenant shall indemnify, protect, defend and hold Landlord, Landlord&#8217;s affiliates, Lenders, and the officers, directors, shareholders, partners, employees, managers, independent contractors, attorneys and agents of the foregoing (&#8220;Landlord Entities&#8221;) and the Premises, harmless from and against any and all damages, liabilities, judgments, costs, claims, liens, expenses, penalties, loss of permits and attorneys&#8217; and consultants&#8217; fees arising out of or involving any Hazardous Substance brought onto the Premises by or for Tenant or by any of Tenant&#8217;s employees, agents, contractors or invitees. &#160;Tenant&#8217;s obligations under this Paragraph&#160;6.2(c) shall include, but not be limited to, the effects of any contamination or injury to person, property or the environment created or suffered by Tenant, and the cost of investigation (including consultants&#8217; and attorneys&#8217; fees and testing), removal, remediation, restoration and/or abatement thereof, or of any contamination therein involved. &#160;Tenant&#8217;s obligations under this Paragraph&#160;6.2(c) shall survive the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Compliance with Requirements</u>. Tenant shall, at Tenant&#8217;s sole cost and expense, fully, diligently and in a timely manner, comply with all &#8220;Applicable Requirements,&#8221; which term is used in this Lease to mean all laws, rules, regulations, ordinances, directives, covenants, easements and restrictions of record, permits, the requirements of any applicable fire insurance underwriter or rating bureau, and the recommendations of Landlord&#8217;s engineers and/or consultants, relating in any manner to the Premises (including but not limited to matters pertaining to (i)&#160;industrial hygiene, (ii)&#160;environmental conditions on, in, under or about the Premises, including soil and groundwater conditions, and (iii)&#160;the use, generation, manufacture, production, installation, maintenance, removal, transportation, storage, spill or release of any Hazardous Substance), now in effect or which may hereafter come into effect. &#160;Tenant shall, within five (5)&#160;days after receipt of Landlord&#8217;s written request, provide Landlord with copies of all documents and information evidencing Tenant&#8217;s compliance with any Applicable Requirements and shall immediately upon receipt, notify Landlord in writing (with copies of any documents involved) of any threatened or actual claim, notice, citation, warning, complaint or report pertaining to or involving failure by Tenant or the Premises to comply with any Applicable Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inspection; Compliance with Law</u>. In addition to Landlord&#8217;s environmental monitoring and insurance program, the cost of which is included in Operating Expenses, Landlord and the holders of any mortgages, deeds of trust or ground leases on the Premises (&#8220;Lenders&#8221;) shall have the right to enter the Premises at any time in the case of an emergency, and otherwise at reasonable times, for the purpose of inspecting the condition of the Premises and for verifying compliance by Tenant with this Lease and all Applicable Requirements. &#160;Landlord shall be entitled to employ experts and/or consultants in connection therewith to advise Landlord with respect to Tenant&#8217;s installation, operation, use, monitoring, maintenance, or removal of any Hazardous Substance on or from the Premises. &#160;Any inspection of the Premises conducted by Landlord or Lenders (other than in the event of an emergency) shall be done in compliance with any applicable requirements of the federal Food and Drug Administration (the &#8220;FDA&#8221;) or any requirements imposed by Tenant in order to comply with requirements of the FDA. &#160;The cost and expenses of any such inspections shall be paid by the party requesting same unless a violation of Applicable Requirements exists or is imminent or the inspection is requested or ordered by a governmental authority. &#160;In such case, Tenant shall upon request reimburse Landlord or Landlord&#8217;s Lender, as the case may be, for the costs and expenses of such inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing Environmental Conditions</u>. Prior to the execution of this Lease, Landlord has delivered to Tenant an environmental report (the &#8220;Environmental Report&#8221;) in respect of the Building commissioned by Landlord. &#160;Landlord represents to Tenant that as of the date hereof Landlord has no actual knowledge of any environmental matters affecting the Property other than those disclosed in the Environmental Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Maintenance, Repairs, Trade Fixtures and Alterations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Obligations</u>. Subject to the provisions of Paragraph&#160;7.2 (Landlord&#8217;s Obligations), Paragraph&#160;9 (Damage or Destruction) and Paragraph&#160;14 (Condemnation), Tenant shall, at Tenant&#8217;s sole cost and expense and at all times, keep the Premises and every part thereof in good order, condition and repair (whether or not such portion of the Premises requiring repair, or the means of repairing the same, are reasonable or readily accessible to Tenant and whether or not the need for such repairs occurs as a result of Tenant&#8217;s use, the elements or the age of such portion of the Premises) including, without limiting the generality of the foregoing, all equipment or facilities specifically serving the Premises, such as heating, ventilating and air conditioning (&#8220;HVAC&#8221;), plumbing, electrical, lighting facilities, boilers, fired or unfired pressure vessels, fire hose connectors if within the Premises, fixtures, interior walls, interior surfaces of exterior walls, ceilings, floors, windows, doors, plate glass, and skylights, but excluding any items which are the responsibility of Landlord pursuant to Paragraph&#160;7.2 below. &#160;Heating, ventilation and air conditioning systems serving the Premises shall be operated at Tenant&#8217;s sole expense and shall be maintained, at Tenant&#8217;s sole expense, pursuant to maintenance service contracts entered into by Tenant; provided, however, that the scope of services and contractors under such maintenance contracts shall be reasonably approved by Landlord. &#160;Tenant shall be responsible for removal of snow and ice from the sidewalks adjacent to the Premises. &#160;Tenant&#8217;s obligations shall include restorations, replacements or renewals when necessary to keep the Premises and all improvements thereon or a part thereof in good order, condition and state of repair. &#160;Landlord shall grant Tenant the benefit of any assignable warranty covering the equipment serving the Premises for which Tenant is responsible hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Obligations</u>. Subject to the provisions of Paragraph&#160;6 (Use), Paragraph&#160;7.1 (Tenant&#8217;s Obligations), Paragraph&#160;9 (Damage or Destruction) and Paragraph&#160;14 (Condemnation), Landlord at its expense and not subject to reimbursement pursuant to Paragraph&#160;4.2, shall keep in good order, condition and repair the foundations and exterior walls of the Building and utility systems outside the Building. &#160;Landlord, subject to reimbursement pursuant to Paragraph&#160;4.2, shall keep in good order, condition and repair the Common Areas and the roof of the Building. &#160;Landlord&#8217;s obligation to keep the Common Areas in good order, condition and repair shall include, without limitation, the obligation to keep the driveways and parking areas included in the Common Areas adequately paved, to keep such parking areas adequately striped, and to provide adequate drainage to the Common Areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alterations</u>. Tenant shall not make nor cause to be made any alterations or installations in, on, under or about the Premises without the prior written consent of Landlord, which consent shall not be unreasonably withheld. &#160;Notwithstanding the foregoing, Tenant shall not be required to obtain Landlord&#8217;s consent for alterations totaling less than $20,000 in any single instance or series of related alterations performed within a six (6) month period, provided that such alterations do not (a)&#160;involve penetration of the roof of the Building or any load-bearing walls or exterior glass panes in the Building, (b)&#160;affect any structural elements of the Building, (c)&#160;affect the configuration or location of any exterior or load-bearing interior walls of the Building, or (d)&#160;affect any mechanical systems in the Building (including, without limitation, the electrical and plumbing systems in the Building).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender/Restoration</u>. Tenant shall surrender the Premises by the end of the last day of the Lease term or any earlier termination date, clean and free of debris and in good operating order, condition and state of repair ordinary wear and tear excepted. &#160;Without limiting the generality of the above, Tenant shall remove all personal property, trade fixtures and floor bolts, patch all floors and cause all lights to be in good operating condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">Insurance; Indemnity</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Premiums</u>. The cost of the premiums for the insurance policies maintained by Landlord under this Paragraph&#160;8 shall be a Common Area Operating Expense pursuant to Paragraph&#160;4.2 hereof. &#160;Premiums for policy periods commencing prior to, or extending beyond, the term of this Lease shall be prorated to coincide with the corresponding Commencement Date or Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Insurance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>At its sole cost and expense, Tenant shall maintain in full force and effect during the Term of the lease the following insurance coverages insuring against claims which may arise from or in connection with the Tenant&#8217;s operation and use of the leased premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Commercial General Liability with minimum limits of $1,000,000 per occurrence; $2,000,000 general aggregate for bodily injury, personal injury and property damage. &#160;If required by Landlord, liquor liability coverage will be included.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Workers&#8217; Compensation insurance with statutory limits and Employers Liability with a $1,000,000 per accident limit for bodily injury or disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:21pt;"></font>Automobile Liability covering all owned, non-owned and hired vehicles with a $1,000,000 per accident limit for bodily injury and property damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>Property insurance against all risks of loss to any tenant improvements or betterments and business personal property on a full replacement cost basis with no coinsurance penalty provision; and Business Interruption Insurance with a limit of liability representing loss of at least approximately six (6) months of income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall deliver to Landlord certificates of all insurance reflecting evidence of required coverages prior to initial occupancy; and annually thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>All insurance required under this Paragraph&#160;8.2: (i)&#160;shall be primary and non-contributory, (ii)&#160;shall provide for severability of interests, (iii)&#160;shall be issued by insurers licensed to do business in the state in which the Premises are located and rated A:VII or better by Best&#8217;s Key Rating Guide, (iv)&#160;shall be endorsed to include Landlord and such other persons or entities as Landlord may from time to time designate, as additional insureds (Commercial General Liability only), and (v)&#160;shall be endorsed to provide at least thirty (30)days prior notification of cancellation or material change in coverage to said additional insureds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Insurance</u>. Landlord may, but shall not be obligated to, maintain all risk, including earthquake and flood, insurance covering the buildings within the Industrial Center, Commercial General Liability and such other insurance in such amounts and covering such other liability or hazards as deemed appropriate by Landlord. &#160;The amount and scope of coverage of Landlord&#8217;s insurance shall be determined by Landlord from time to time in its sole discretion and shall be subject to such deductible amounts as Landlord may elect. &#160;Landlord shall have the right to reduce or terminate any insurance or coverage. &#160;Premiums for any such insurance shall be a Common Area Operating Expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Subrogation</u>. To the extent permitted by law and without affecting the coverage provided by insurance required to be maintained hereunder, Landlord and Tenant each waive any right to recover against the other on account of any and all claims Landlord or Tenant may have against the other with respect to property insurance actually carried, or required to be carried hereunder, to the extent of the proceeds realized from such insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity</u>. Subject to Section&#160;8.6, Tenant shall indemnify, defend, and hold harmless Landlord, its successors, assigns, agents, employees, contractors, partners, directors, officers and affiliates (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Parties</u>) from and against all fines, suits, losses, costs, liabilities, claims, demands, actions and judgments of every kind or character (a)&#160;arising from Tenant&#8217;s failure to perform its covenants hereunder, (b)&#160;recovered from or asserted against any of the Indemnified Parties on account of any Loss (defined below) to the extent that any such Loss is caused by a Tenant Party or any other person entering upon the Premises under or with a Tenant Party&#8217;s express or implied invitation or permission, (c)&#160;arising from or out of the occupancy or use by a Tenant Party or arising from or out of any occurrence in the Premises, or (d)&#160;suffered by, recovered from or asserted against any of the Indemnified Parties by a Tenant Party, regardless of whether Landlord&#8217;s negligence caused such loss or damage. &#160;However, such indemnification of the Indemnified Parties by Tenant shall not be applicable if such loss, damage, or injury is caused by the gross negligence or willful misconduct of Landlord or any of its duly</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">authorized agents or employees. &#160;The provisions of this Paragraph&#160;8.5 shall survive the termination of this Lease with respect to any claims or liability accruing prior to such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exemption of Landlord from Liability</u>. Landlord shall not be liable to Tenant or those claiming by, through, or under Tenant for any injury to or death of any person or persons or the damage to or theft, destruction, loss or loss of use of any property or inconvenience (a &#8220;Loss&#8221;) caused by casualty, theft, fire, third parties, or any other matter (including Losses arising through repair or alteration of any part of the Building, or failure to make repairs, or from any other cause), regardless of whether the negligence (other than gross negligence) of either party caused such Loss in whole or in part, Landlord and Tenant each waives any claim it might have against the other for any damage to or theft, destruction, loss, or loss of use of any property, to the extent the same is insured against under any insurance policy maintained by it that covers the Building, the Premises, Landlord&#8217;s or Tenant&#8217;s fixtures, personal property, leasehold improvements, or business, or is required to be insured against by the waiving party under the terms hereof, regardless of whether the negligence or fault of the other party caused such loss; however, Landlord&#8217;s waiver shall not apply to any deductible amounts maintained by Landlord under its insurance. &#160;Each party shall cause its insurance carrier to endorse all applicable policies waiving the carrier&#8217;s rights of recovery under subrogation or otherwise against the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breach of Lease by Landlord</u>. Nothing contained in Section&#160;8.5 or Section&#160;8.6 above shall be construed to limit the remedies for breach of contract which Tenant may have for breach of this Lease by Landlord (it being agreed, however, that such remedies shall in all events be subject to other applicable provisions of this Lease, including, without limitation, Section&#160;16.4 hereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Damage or Destruction</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Right</u>. Tenant shall give Landlord immediate written notice of any damage to the Premises. &#160;Thereafter, Landlord shall send Tenant written notice (the &#8220;Estimated Time Notice&#8221;) of the estimated period of time, as determined by Landlord&#8217;s architect, that repair of such damage will substantially interfere with the conduct of Tenant&#8217;s business at the Premises. &#160;Subject to the provisions of Paragraph&#160;9.2, if the damage to the Premises is such that, in the opinion of Landlord&#8217;s architect as set forth in the Estimated Time Notice, there will be substantial interference with the conduct by Tenant of its business at the Premises for a period exceeding ninety (90) consecutive days, then Tenant may terminate this Lease by sending Landlord written notice thereof within ten (10) days after Tenant receives the Estimated Time Notice (time being of the essence), which termination shall be effective thirty (30) days after delivery of such notice of termination to Landlord. &#160;If the Estimated Time Notice states that repair of damage will not interfere with the conduct of Tenant&#8217;s business at the Premises for more than ninety (90)&#160;consecutive days, but such repair does in fact interfere with the conduct of Tenant&#8217;s business at the Premises for a period in excess of ninety (90) days (excluding delays caused by events of force majeure), then Tenant may terminate this Lease by sending Landlord written notice thereof within ten (10) days after the expiration of such ninety (90) day period (time being of the essence), which termination shall be effective thirty (30) days after delivery of such notice of termination to Landlord. &#160;No such termination shall excuse the performance by Tenant of those covenants which under the terms hereof survive termination. &#160;Rent shall be abated in proportion to the degree of interference during the period that there is such substantial interference with the conduct of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tenant&#8217;s business at the Premises. &#160;Abatement of rent and Tenant&#8217;s right of termination pursuant to this provision shall be Tenant&#8217;s only remedies for failure of Landlord to keep in good order, condition and repair the foundations and exterior walls of the Building, Building roof, utility systems outside the Building, the Common Areas and HVAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Damage Caused by Tenant</u>. Tenant&#8217;s termination rights under Paragraph&#160;9.1 shall not apply if the damage to the Premises or Building is the result of any act or omission of Tenant or of any of Tenant&#8217;s agents, employees, customers, invitees or contractors (&#8220;Tenant Acts&#8221;). &#160;Any damage resulting from a Tenant Act shall be promptly repaired by Tenant. &#160;Landlord at its option may at Tenant&#8217;s expense repair any damage caused by Tenant Acts. &#160;Tenant shall continue to pay all rent and other sums due hereunder and shall be liable to Landlord for all damages that Landlord may sustain resulting from a Tenant Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Real Property Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Real Property Taxes</u>. Landlord shall pay the Real Property Taxes due and payable during the term of this Lease and, except as otherwise provided in Paragraph&#160;10.3, any such amounts shall be included in the calculation of Operating Expenses in accordance with the provisions of Paragraph&#160;4.2. &#160;The amount of Real Property Taxes included in Operating Expenses shall take into account fully any tax abatement in effect with respect to the Industrial Center, such that Tenant derives its proportionate share of the benefit of any such tax abatement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Real Property Tax Definition</u>. As used herein, the term &#8220;Real Property Taxes&#8221; is any form of tax or assessment, general, special, ordinary or extraordinary, imposed or levied by any governmental authority or by any owners&#8217; association upon the Industrial Center or any interest of Landlord in the Industrial Center. &#160;Real Property Taxes include (a)&#160;any tax or charge which replaces or is in addition to any of such above-described &#8220;Real Property Taxes,&#8221; (b)&#160;any charge or assessment imposed upon the Industrial Center by an owners&#8217; association or similar entity, and (c)&#160;any fees, expenses or costs (including attorney&#8217;s fees, expert fees and the like) incurred by Landlord in protesting or contesting any assessments levied or any tax rate. &#160;Real Property Taxes for tax years commencing prior to, or extending beyond, the term of this Lease shall be prorated to coincide with the corresponding Commencement Date or Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Improvements</u>. Operating Expenses shall not include Real Property Taxes attributable to improvements placed upon the Industrial Center by other tenants or by Landlord for the exclusive enjoyment of such other tenants. &#160;Notwithstanding Paragraph&#160;10.1 hereof, Tenant shall, however, pay to Landlord at the time Operating Expenses are payable under Paragraph&#160;4.2, the entirety of any increase in Real Property Taxes if assessed by reason of improvements placed upon the Premises by Tenant or at Tenant&#8217;s request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint Assessment</u>. If the Building is not separately assessed, Real Property Taxes allocated to the Building shall be based upon the assessed value of the Building and the land associated with the Building relative to the total assessed value of all of the land and improvements included within the tax parcel assessed (it being agreed that Tenant shall be responsible for payment of Tenant&#8217;s Share of taxes allocated to the Building, as set forth in Section&#160;1.5(b) of the Basic Provisions). &#160;In the absence of manifest error, Landlord&#8217;s allocation of Real Property Taxes to the Building shall be binding upon Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Property Taxes</u>. Tenant shall pay prior to delinquency all taxes assessed against and levied upon Tenant&#8217;s improvements, fixtures, furnishings, equipment and all personal property of Tenant contained in the Premises or stored within the Industrial Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Utilities</b>. Tenant shall pay directly for all utilities and services supplied to the Premises, including but not limited to electricity, HVAC, telephone, security, gas and cleaning of the Premises, together with any taxes thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Assignment and Subletting</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Consent Required</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Except as otherwise provided in Paragraph&#160;12.1(c) below, Tenant shall not assign, transfer, mortgage or otherwise transfer or encumber (collectively, &#8220;assign&#8221;) or sublet all or any part of Tenant&#8217;s interest in this Lease or in the Premises without Landlord&#8217;s prior written consent, which consent shall not be unreasonably withheld. &#160;Relevant criteria in determining reasonableness of consent include, but are not limited to, credit history of a proposed assignee or sublessee, references from prior landlords, any change or intensification of use of the Premises or the Common Areas and any limitations imposed by the Internal Revenue Code and the Regulations promulgated thereunder relating to Real Estate Investment Trusts. &#160;Any assignment or subletting shall not release Tenant from its obligations hereunder. &#160;Tenant shall not (i)&#160;sublet or assign or enter into other arrangements such that the amounts to be paid by the sublessee or assignee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of the sublessee or assignee; (ii)&#160;sublet the Premises or assign this Lease to any person in which Landlord owns an interest, directly or indirectly (by applying constructive ownership rules set forth in Section&#160;856(d)(5) of the Internal Revenue Code (the &#8220;Code&#8221;); or (iii)&#160;sublet the Premises or assign this Lease in any other manner which could cause any portion of the amounts received by Landlord pursuant to this Lease or any sublease to fail to qualify as &#8220;rents from real property&#8221; within the meaning of Section&#160;856(d) of the Code, or which could cause any other income received by Landlord to fail to qualify as income described in Section&#160;856(c)(2) of the Code. &#160;The requirements of this Section&#160;12.1 shall apply to any further subleasing by any subtenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>A change in the control of Tenant shall constitute an assignment requiring Landlord&#8217;s consent. &#160;The transfer, on a cumulative basis, of twenty-five percent (25%) or more of the voting or management control of Tenant shall constitute a change in control for this purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Notwithstanding the provisions of Paragraph&#160;12.1(a), Landlord agrees that during the twelve (12) month period after the Commencement Date, Tenant may assign this Lease, without obtaining the consent of Landlord, to a limited partnership (to be named PFab LP) in which the partners (general and limited) are entities owned or controlled by PharmaFab, Inc., Bruce K. Montgomery or Darlene Ryan (or a combination thereof). &#160;However, Tenant shall promptly notify Landlord of such assignment. &#160;No such assignment shall relieve Tenant of its obligations under this Lease or relieve Bruce K. Montgomery or Darlene Ryan of their obligations as guarantors of the obligations of Tenant under this Lease. &#160;Upon the request of Landlord, Tenant shall (i)&#160;cause the assignee to execute an instrument reasonably satisfactory to Landlord evidencing the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">assumption by such assignee of all of Tenant&#8217;s obligations under this Lease, and (ii)&#160;cause each guarantor of this Lease to execute a ratification of his or her guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent Adjustment</u>. If, as of the effective date of any permitted assignment or subletting the then remaining term of this Lease is less than three (3) years, Landlord may terminate this Lease as of the date of assignment or subletting subject to the performance by Tenant of those covenants which under the terms hereof survive termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Default; Remedies</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default</u>. The occurrence of any one of the following events shall constitute an event of default on the part of Tenant (&#8220;Default&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The abandonment of the Premises by Tenant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Failure to pay any installment of Base Rent, Additional Rent or any other monies due and payable hereunder for a period of three (3) days after Landlord has delivered to Tenant written notice thereof; provided, however, that a Default shall immediately occur hereunder, without Landlord first having to give Tenant written notice, if Tenant is more than three (3) days delinquent in paying any Base Rent, Additional Rent or any other monies due under this Lease and Landlord has given Tenant written notice under this Paragraph&#160;13.1(b) on more than one (1) occasion during the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>A general assignment by Tenant or any guarantor for the benefit of creditors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The filing of a voluntary petition in bankruptcy by Tenant or any guarantor, the filing of a voluntary petition for an arrangement, the filing of a petition, voluntary or involuntary, for reorganization, or the filing of an involuntary petition by Tenant&#8217;s creditors or guarantors;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Receivership, attachment, of other judicial seizure of the Premises or all or substantially all of Tenant&#8217;s assets on the Premises;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Failure of Tenant to maintain insurance as required by Paragraph&#160;8.2;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Any breach by Tenant of its covenants under Paragraph&#160;6.2;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>Failure in the performance of any of Tenant&#8217;s covenants, agreements or obligations hereunder (except those failures specified as events of Default in other Paragraphs of this Paragraph&#160;13.1 which shall be governed by such other Paragraphs), which failure continues for 10 days after written notice thereof from Landlord to Tenant provided that, if Tenant has exercised reasonable diligence to cure such failure and such failure cannot be cured within such ten (10) day period despite reasonable diligence, Tenant shall not be in default under this subparagraph&#160;unless Tenant fails thereafter diligently and continuously to prosecute the cure to completion; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>The default of any guarantors of Tenant&#8217;s obligations hereunder under any guaranty of this Lease, or the attempted repudiation or revocation of any such guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u>. In the event of any Default by Tenant, Landlord shall have the remedies set forth in the Addendum attached hereto entitled &#8220;Landlord&#8217;s Remedies in Event of Tenant Default&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Late Charges</u>. Tenant hereby acknowledges that late payment by Tenant to Landlord of rent and other sums due hereunder will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain. &#160;Such costs include, but are not limited to, processing and accounting charges. &#160;Accordingly, if any installment of rent or other sum due from Tenant shall not be received by Landlord or Landlord&#8217;s designee within 10 days after such amount shall be due, then, without any requirement for notice to Tenant, Tenant shall pay to Landlord a late charge equal to 5% of such overdue amount. &#160;The parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant. &#160;Acceptance of such late charge by Landlord shall in no event constitute a waiver of Tenant&#8217;s Default with respect to such overdue amount, nor prevent Landlord from exercising any of the other rights and remedies granted hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">Condemnation</b>. If the Premises or any portion thereof are taken under the power of eminent domain or sold under the threat of exercise of said power (all of which are herein called &#8220;condemnation&#8221;), this Lease shall terminate as to the part so taken as of the date the condemning authority takes title or possession, whichever first occurs. &#160;If more than ten percent (10%) of the floor area of the Premises, or more than twenty-five (25%) of the portion of the Common Areas designated for Tenant&#8217;s parking, is taken by condemnation, Tenant may, at Tenant&#8217;s option, to be exercised in writing within ten (10) days after Landlord shall have given Tenant written notice of such taking (or in the absence of such notice, within ten (10) days after the condemning authority shall have taken possession) terminate this Lease as of the date the condemning authority takes such possession. &#160;If Tenant does not terminate this Lease in accordance with the foregoing, this Lease shall remain in full force and effect as to the portion of the Premises remaining, except that the Base Rent shall be reduced in the same proportion as the rentable floor area of the Premises taken bears to the total rentable floor area of the Premises. &#160;No reduction of Base Rent shall occur if the condemnation does not apply to any portion of the Premises. &#160;Any award for the taking of all or any part of the Premises under the power of eminent domain or any payment made under threat of the exercise of such power shall be the property of Landlord, provided, however, that Tenant shall be entitled to any compensation, separately awarded to Tenant for Tenant&#8217;s relocation expenses and/or loss of Tenants trade fixtures. &#160;In the event that this Lease is not terminated by reason of such condemnation, Landlord shall to the extent of its net severance damages in the condemnation matter, repair any damage to the Premises caused by such condemnation authority. &#160;Tenant shall be responsible for the payment of any amount in excess of such net severance damages required to complete such repair.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">Estoppel Certificate and Financial Statements</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Estoppel Certificate</u>. Each party (herein referred to as &#8220;Responding Party&#8221;) shall within 10 days after written notice from the other Party (the &#8220;Requesting Party&#8221;) execute, acknowledge and deliver to the Requesting Party, to the extent it can truthfully do so, an estoppel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">certificate in the form attached hereto, plus such additional information, confirmation a/or statements as be reasonably requested by the Requesting Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statement</u>. If Landlord desires to finance, refinance, or sell the Building, Industrial Center or any part thereof, Tenant and all Guarantors shall deliver to any potential lender or purchaser designated by Landlord such financial statements of Tenant and such Guarantors as may be reasonably required by such lender or purchaser, including but not limited to Tenant&#8217;s financial statements for the past 3 years. &#160;All such financial statements shall be received by Landlord and such lender or purchaser in confidence and shall be used only for the purposes herein set forth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">Additional Covenants and Provisions</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. The invalidity of any provision of this Lease, as determined by a court of competent jurisdiction, shall not affect the validity of any other provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest on Past-Due Obligations</u>. Any monetary payment due Landlord hereunder not received by Landlord within 10 days following the date on which it was due shall bear interest from the date due at twelve percent (12%) per annum, but not exceeding the maximum rate allowed by law in addition to the late charge provided for in Paragraph&#160;13.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of Essence</u>. Time is of the essence with respect to the performance of all obligations to be performed or observed by the Parties under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Liability</u>. Tenant, its successors and assigns, shall not assert nor seek to enforce any claim for breach of this Lease against any of Landlord&#8217;s assets other than Landlord&#8217;s interest in the Industrial Center. &#160;Tenant agrees to look solely to such interest for the satisfaction of any liability or claim against Landlord under this Lease. &#160;In no event whatsoever shall Landlord (which term shall include, without limitation, any general or limited partner, trustees, beneficiaries, officers, directors, or stockholders of Landlord) ever be personally liable for any such liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Prior or Other Agreements</u>. This Lease contains all agreements between the Parties with respect to any matter mentioned herein, and supersedes all oral, written prior or contemporaneous agreements or understandings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice Requirements</u>. All notices required or permitted by this Lease shall be in writing and may be delivered in person (by hand or by messenger or courier service) or may be sent by regular, certified or registered mail or U.S. Postal Service Express Mail, with postage prepaid, or by facsimile transmission during normal business hours, and shall be deemed sufficiently given if served in a manner specified in the Paragraph&#160;16.6. &#160;The addresses noted adjacent to a Party&#8217;s signature on this Lease shall be that Party&#8217;s address for delivery or mailing of notice purposes. &#160;Either Party may by written notice to the other specify a different address for notice purposes, except that upon Tenant&#8217;s taking possessing of the Premises, the Premises shall constitute Tenant&#8217;s address for the purpose of mailing or delivering notices to Tenant. &#160;A copy of all notices required or permitted to be given to Landlord hereunder shall be concurrently transmitted to such party or parties at such addresses as Landlord may from time to time hereafter designate by written notice to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Notice</u>. Any notice sent by registered or certified mail, return receipt requested, shall be deemed given on the date of delivery shown on the receipt card, or if no delivery date is shown, the postmark thereon. &#160;If sent by regular mail, the notice shall be deemed given 48&#160;hours after the same is addressed as required herein and mailed with postage prepaid. &#160;Notices delivered by United States Express Mail or overnight courier that guarantees next day delivery shall be deemed given 24 hours after delivery of the same to the United States Postal Service or courier. &#160;If any notice is transmitted by facsimile transmission or similar means, the same shall be deemed served or delivered upon telephone or facsimile confirmation of receipt of the transmission thereof, provided a copy is also delivered via hand or overnight delivery or certified mail. &#160;If notice is received on a Saturday or a Sunday or a legal holiday, it shall be deemed received on the next business day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u>. No waiver by Landlord or Tenant of a default by the other party shall be deemed a waiver of any subsequent default by such defaulting party or a waiver of any other term, covenant or condition hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holdover</u>. Tenant has no right to retain possession of the Premises or any part thereof beyond the expiration or earlier termination of this Lease. &#160;If Tenant holds over with the consent of Landlord: &#160;(a)&#160;the Base Rent payable shall be increased to one hundred fifty percent (150%) of the Base Rent applicable during the month immediately preceding such expiration or earlier termination; (b)&#160;Tenant&#8217;s right to possession shall terminate on thirty (30) days notice from Landlord and (c)&#160;all other terms and conditions of this Lease shall continue to apply. &#160;Nothing contained herein shall be construed as a consent by Landlord to any holding over by Tenant. &#160;Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims, demands, actions, losses, damages, obligations, costs and expenses, including, without limitation, attorneys&#8217; fees incurred or suffered by Landlord by reason of Tenant&#8217;s failure to surrender the Premises on the expiration or earlier termination of this Lease in accordance with the provisions of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cumulative Remedies</u>. No remedy or election hereunder shall be deemed exclusive but shall, wherever possible, be cumulative with all other remedies in law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect; Choice of Law</u>. This Lease shall be binding upon the Parties, their personal representatives, successors and assigns and be governed by the laws of the State in which the Premises are located. &#160;Any litigation between the Parties hereto concerning this Lease shall be initiated in the county in which the Premises are located.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord</u>. The covenants and obligations contained in this Lease on the part of Landlord are binding on Landlord, its successors and assigns, only during and in respect of their respective period of ownership of such interest in the Industrial Center. &#160;In the event of any transfer or transfers of such title to the Industrial Center, Landlord (and in case of any subsequent transfers or conveyances, the then grantor) shall be concurrently freed and relieved from and after the date of such transfer or conveyance, without any further instrument or agreement, of all liability with respect to the performance of any covenants or obligations on the part of Landlord contained in this Lease thereafter to be performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attorneys&#8217; Fees and Other Costs</u>. If any Party brings an action or proceeding to enforce the terms hereof or declare rights hereunder, the Prevailing Party (as hereafter defined) in any such proceeding shall be entitled to reasonable attorneys&#8217; fees. &#160;The term &#8220;Prevailing Party&#8221; shall include, without limitation, a Party who substantially obtains or defeats the relief sought. &#160;Landlord shall be entitled to attorneys&#8217; fees, costs and expenses incurred in preparation and service of notices of Default and consultations in connection therewith, whether or not a legal action is subsequently commenced in connection with such Default or resulting breach. &#160;Tenant shall reimburse Landlord on demand for all reasonable legal, engineering and other professional services expenses incurred by Landlord in connection with all requests by Tenant for consent or approval hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.14.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Access; Showing Premises; Repairs</u>. Landlord and Landlord&#8217;s agents shall have the right to enter the Premises at any time, in the case of an emergency, and otherwise at reasonable times upon reasonable notice for the purpose of showing the same to prospective purchasers, lenders, or tenants, and making such alterations, repairs, improvements or additions to the Premises or to the Building, as Landlord may reasonably deem necessary. &#160;Any inspection of the Premises conducted by Landlord or Landlord&#8217;s agents (other than in the event of an emergency) shall be done in compliance with any applicable requirements of the FDA or any requirements imposed by Tenant in order to comply with requirements of the FDA. &#160;Landlord may at any time place on or about the Premises or Building any ordinary &#8220;For Sale&#8221; signs and Landlord may at any time during the last one hundred eighty (180) days of the term hereof place on or about the Premises any ordinary &#8220;For Lease&#8221; signs. &#160;All such activities of Landlord shall be without abatement of rent or liability to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.15.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signs</u>. Tenant shall not place any signs at or upon the exterior of the Premises or the Building, except that Tenant may, with Landlord&#8217;s prior written consent, install (but not on the roof) such signs as are reasonably required to advertise Tenant&#8217;s own business so long as such signs are in a location designated by Landlord and comply with sign ordinances and the sign age criteria established for the Industrial Center by Landlord. &#160;The sign age criteria of Landlord is attached hereto as Exhibit C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.16.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination; Merger</u>. Unless specifically stated otherwise in writing by Landlord, the voluntary or other surrender of this Lease by Tenant, the mutual termination or cancellation hereof, or a termination hereof by Landlord for Default by Tenant, shall automatically terminate any sublease or lesser estate in the Premises; provided, however, Landlord shall, in the event of any such surrender, termination or cancellation, have the option to continue any one or all of any existing subtenancies. &#160;Landlord&#8217;s failure within ten (10) days following any such event to make a written election to the contrary by written notice to the holder of any such lesser interest, shall constitute Landlord&#8217;s election to have such event constitute the termination of such interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.17.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quiet Possession</u>. Upon payment by Tenant of the Base Rent and Additional Rent for the Premises and the performance of all of the covenants, conditions and provisions on Tenant&#8217;s part to be observed and performed under this Lease, Tenant shall have quiet possession of the Premises for the entire term hereof subject to all of the provisions of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.18.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subordination; Attornment; Non-Disturbance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subordination. This Lease shall be subject and subordinate to any ground lease, mortgage, deed of trust, or other hypothecation or mortgage (collectively, &#8220;Mortgage&#8221;) now or hereafter placed by Landlord upon the real property of which the Premises are a part, to any and all advances made on the security thereof and to all renewals, modifications, consolidations, replacements and extensions thereof. &#160;Tenant agrees that any person holding any Mortgage shall have no duty, liability or obligation to perform any of the obligations of Landlord under this Lease. &#160;In the event of Landlord&#8217;s default with respect to any such obligation, Tenant will give any Lender, whose name and address have previously in writing been furnished Tenant, notice of a default by Landlord. &#160;Tenant may not exercise any remedies for default by Landlord unless and until Landlord and the Lender shall have received written notice of such default and a reasonable time (not less than sixty (60) days) shall thereafter have elapsed without the default having been cured. &#160;If any Lender shall elect to have this Lease superior to the lien of its Mortgage and shall give written notice thereof to Tenant, this Lease shall be deemed prior to such Mortgage. &#160;The provisions of a Mortgage relating to the disposition of condemnation and insurance proceeds shall prevail over any contrary provisions contained in this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Attornment. Subject to the non-disturbance provisions of subparagraph&#160;C of this Paragraph&#160;16.18, Tenant agrees to attorn to a Lender or any other party who acquires ownership of the Premises by reason of a foreclosure of a Mortgage. &#160;In the event of such foreclosure, such new owner shall not: &#160;(i)&#160;be liable for any act or omission of any prior landlord or with respect to events occurring prior to acquisition of ownership, (ii)&#160;be subject to any offsets or defenses which Tenant might have against any prior Landlord, or (iii)&#160;be liable for security deposits or be bound by prepayment of more than one month&#8217;s rent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Non-Disturbance. With respect to Mortgage entered into by Landlord after the execution of this Lease, Tenant&#8217;s subordination of this Lease shall be subject to receiving assurance (a &#8220;non-disturbance agreement&#8221;) from the Mortgage holder not disturbing Tenant&#8217;s possession of the Premises so long as this Lease is in full force and effect and Tenant is not in default under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Self-Executing. The agreements contained in this Paragraph&#160;16.18 shall be effective without the execution of any further documents; provided, however, that upon written request from Landlord or a Lender in connection with a sale, financing or refinancing of Premises, Tenant and Landlord shall execute such further writings as may be reasonably required to separately document any such subordination or non-subordination, attornment and/or non-disturbance agreement as is provided for herein. &#160;Landlord is hereby irrevocably vested with full power to subordinate this Lease to a Mortgage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.19.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing by Tenant</u>. Landlord acknowledges and agrees that Tenant may grant a security interest in the personally, furniture, trade fixtures and inventory owned by Tenant in the Premises to an institutional lender. &#160;Upon the grant of such security interest, Landlord shall, upon the request of Tenant, execute and deliver to Tenant a subordination agreement in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u> attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.20.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules and Regulations</u>. Tenant agrees that it will abide by, and to cause its employees, suppliers, shippers, customers, tenants, contractors and invitees to abide by all reasonable rules and regulations (&#8220;Rules and Regulations&#8221;) which Landlord may make from time to time for the management, safety, care, and cleanliness of the Common Areas, the parking and unloading of vehicles and the preservation of good order, as well as for the convenience of other occupants or tenants of the Building and the Industrial Center and their invitees. &#160;Landlord shall not be responsible to Tenant for the non-compliance with said Rules and Regulations by other tenants of the Industrial Center; provided, however, that Landlord agrees to use reasonable efforts to attempt to enforce the Rules and Regulations on a uniform basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.21.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Measures</u>. Tenant acknowledges that the rental payable to Landlord hereunder does not include the cost of guard service or other security measures. &#160;Landlord has no obligations to provide same. &#160;Tenant assumes all responsibility for the protection of the Premises, Tenant, its agents and invitees and their property from the acts of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.22.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservations</u>. Landlord reserves the right to grant such easements that Landlord deems necessary and to cause the recordation of parcel maps, so long as such easements and maps do not reasonably interfere with the use of the Premises by Tenant. &#160;Tenant agrees to sign any documents reasonably requested by Landlord to effectuate any such easements or maps.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.23.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflict</u>. Any conflict between the printed provisions of this Lease and the typewritten or handwritten provisions shall be controlled by the typewritten or handwritten provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.24.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offer</u>. Preparation of this Lease by either Landlord or Tenant or Landlord&#8217;s agent or Tenant&#8217;s agent and submission of same to Tenant or Landlord shall not be deemed an offer to lease. &#160;This Lease is not intended to be binding until executed and delivered by all Parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.25.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</u>. This Lease may be modified only in writing, signed by the parties in interest at the time of the modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.26.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiple Parties</u>. Except as otherwise expressly provided herein, if more than one person or entity is named herein as Tenant, the obligations of such persons shall be the joint and several responsibility of all persons or entities named herein as such Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.27.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u>. Each person signing on behalf of Landlord or Tenant warrants and represents that she or is authorized to execute and deliver this Lease and to make it a binding obligation of Landlord or Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signatures appear on following page]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The parties hereto have executed this Lease at the place and on the dates specified above their respective signatures.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:top;width:46.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab, Inc.</p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Landlord&#8217;s Remedies Addendum In Event</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Tenant Default</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (State of Texas)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Upon any Default, Landlord may, in addition to all other rights and remedies afforded Landlord hereunder or by Applicable Requirements, take any of the follow actions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Terminate this Lease by giving Tenant written notice thereof, in which event, Tenant shall pay to Landlord the sum of (A) all unpaid past due rent accrued hereunder through the date of termination, (B) all amounts due under paragraph&#160;(b) below, and (C) an amount equal to (1) the total rent that Tenant would have been required to pay for the remainder of the Term discounted to a present value at a per annum rate equal to the &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prime Rate</b>&#8221; as published on the date this Lease is terminated by The Wall Street Journal, Southwest Edition, in its listing of &#8220;<b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Money Rents</b>&#8221;, minus (2) the then present fair rental value of the Premises for such period, as determined by Landlord in good faith, similarly discounted; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Terminate Tenant&#8217;s right to possess the Premises and change the door locks to the Premises without terminating this Lease, with or without notice thereof to Tenant, and without judicial proceedings, in which event Tenant shall pay to Landlord (A) all unpaid past due rent and other amounts accrued hereunder to the date of termination of possession, (B) all amounts due from time to time under paragraph&#160;(b) below, and (C)&#160;all rent and other sums required hereunder to be paid by Tenant during the remainder of the Term, diminished by any net sums thereafter received by Landlord through reletting the Premises during such period. &#160;Tenant shall not be entitled to the excess of any consideration obtained by reletting over the rent due hereunder. &#160;Reentry to Landlord in the Premises shall not affect Tenant&#8217;s obligations hereunder for the unexpired Term; rather, Landlord may, from time to time, bring action against Tenant to collect amounts due by Tenant, without the necessity of Landlord&#8217;s waiting until the expiration of the Term. &#160;Unless Landlord delivers written notice to Tenant expressly stating that it has elected to terminate this Lease, all actions taken by Landlord to exclude or dispossess Tenant of the Premises shall be deemed to be taken under this paragraph&#160;(a)(ii). &#160;If Landlord elects to proceed under this paragraph&#160;(a)(ii), it may at any time elect to terminate this Lease under paragraph&#160;(a)(i) above. &#160;Landlord and Tenant hereby confirm that the terms and provisions of this addendum supersedes Section&#160;93.002 of the Texas Property Code to the extent of any conflict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall pay to Landlord all reasonable costs and expenses incurred by Landlord (including court costs and reasonable attorney&#8217;s fees and expenses) in (i)&#160;obtaining possession of the Premises, (ii)&#160;removing and storing Tenant&#8217;s or any other occupant&#8217;s property, (iii)&#160;renovating, repairing and altering the Premises for a new tenant or tenants, (iv)&#160;if Tenant is dispossessed of the Premises and this Lease is not terminated, reletting all or any part of the Premises (including brokerage commissions, reasonable cost of tenant finish work, and other costs incidental to such reletting), (v)&#160;performing Tenant&#8217;s obligations which Tenant failed to perform, and (vi)&#160;enforcing, or advising Landlord of its rights, remedies, and recourses. &#160;Landlord&#8217;s acceptance of rent following the occurrence of a Default shall not waive Landlord&#8217;s rights regarding such Default. &#160;Landlord&#8217;s receipt of rent with knowledge of any Default by Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">hereunder shall not be a waiver of such Default, and no waiver by Landlord of any provision of this Lease shall be deemed to have been made unless set forth in writing and signed by Landlord. &#160;No waiver by Landlord of any violation or breach of any of the terms contained herein shall waive Landlord&#8217;s rights regarding any future violation of such term or violation of any other term. &#160;If Landlord repossesses the Premises pursuant to the authority herein granted, then Landlord shall have the right to (A) keep in place and use or (B) remove and store, at Tenant&#8217;s expense, all of the furniture, fixtures, equipment or other property, deemed abandoned by Tenant in the Premises, including that which is owned by or leased to Tenant at all times before any foreclosure thereon by Landlord or repossession thereof by any lessor thereof or third party having a lien thereon. &#160;Landlord may relinquish possession of all or any portion of such furniture, fixtures, equipment and other property to any person (a &#8220;Claimant&#8221;) who presents to Landlord a copy of any instrument represented by Claimant to have been executed by Tenant (or any predecessor of Tenant) granting Claimant the right under various circumstances to take possession of such furniture, fixtures, equipment or other property, without the necessity on the part of Landlord to inquire into the authenticity or legality of the instrument. &#160;The rights of Landlord herein stated are in addition to any and all other rights that Landlord has or may hereafter have at law or in equity, and Tenant agrees that the rights herein granted Landlord are commercially reasonable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">INDUSTRIAL MULTI-TENANT LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Tenant Improvements Addendum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Landlord shall construct the leasehold improvements in the Premises (the &#8220;Leasehold Improvements&#8221;) in substantial accordance with plans and specifications (the &#8220;Plans&#8221;) which have been mutually approved in writing by Landlord and Tenant. &#160;Landlord and Tenant will endeavor to agree upon the Final Plans not later than June&#160;10, 1999. &#160;Tenant shall be responsible for the costs of preparing the Final Plans and any other architectural and design costs in respect of the Leasehold Improvements (which costs may be paid from the Tenant Allowance, as hereinafter defined).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>After the Plans have been approved by Landlord and Tenant, Landlord shall competitively bid the job to a minimum of three (3) qualified general contractors reasonably acceptable to Landlord and Tenant. &#160;Landlord shall contract with the lowest qualified bidder, or such other bidder as is agreed upon by Landlord and Tenant (the &#8220;Contractor&#8221;), to construct the Leasehold Improvements in the Premises; provided, however, that if the lowest bid (or such other bid agreed upon by Landlord and Tenant) is more than Nine Hundred Thousand Dollars ($900,000), Landlord and Tenant shall revise the Plans in such a manner that the cost of constructing the Leasehold Improvements reflected in the Plans, as revised, is not more than Nine Hundred Thousand Dollars ($900,000). &#160;Landlord shall cause the Contractor to construct the Leasehold Improvements in substantial accordance with the approved Plans and in a good and workmanlike manner utilizing all new materials. &#160;The contract with the Contractor shall obligate the Contractor to obtain necessary permits and approvals from local governmental authorities in respect of the construction of the Leasehold Improvements and to construct the Leasehold Improvements in accordance with all applicable laws, codes and regulations (it being expressly agreed that it shall be the responsibility of Tenant to cause any requirements of the FDA to be incorporated into the approved Plans). &#160;During the construction period, Tenant shall have access to the Premises during reasonable times to observe the progress and quality of the work; provided, however, that Tenant shall at all time when visiting the Premises comply with Contractor&#8217;s safety requirements. &#160;Any changes which the Tenant may request during the construction of Leasehold Improvements shall be submitted to the Landlord in written form, and change orders shall be subject to the written approval of both Landlord and Tenant. &#160;Thereupon, Landlord shall prepare a written change order for Tenant&#8217;s review and approval, which, when signed by Tenant and Landlord, shall authorize Landlord to make such change in the Leasehold Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>The Leasehold Improvements shall be deemed to be &#8220;substantially complete&#8221; and ready for delivery to Tenant at such time as a certificate of occupancy for the Premises is secured from the City of Grand Prairie. &#160;At such time as the Leasehold Improvements are substantially complete, Landlord, Tenant and Contractor shall walk the Premises for the purpose of preparing a &#8220;punch list&#8221; of items needing correction. &#160;Thereafter, the architect for construction of the Leasehold Improvements shall issue a certificate of substantial completion to which the &#8220;punch list&#8221; shall be attached. &#160;Landlord shall cause the Contractor to correct or complete the items on the &#8220;punch list&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as soon as reasonably practicable, but in no event later than thirty (30) days after the date upon which the Leasehold Improvements are substantially complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>Tenant shall be responsible for the payment of all costs associated with the construction of the Leasehold Improvements, including, but not limited to, the following: &#160;(a)&#160;all costs, including professional fees, of the architect and all other design and planning costs; (b)&#160;the costs of labor and material associated with the construction of the Leasehold Improvements; and (c)&#160;a fee to Trammell Crow Dallas Fort Worth equal to four percent (4%) of the sum of all design, planning and construction costs associated with the construction of the Leasehold Improvements. &#160;It is understood and agreed that the Tenant Allowance, as hereinafter defined, may be used to pay the costs described in clauses (a), (b) and (c) of the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>Notwithstanding anything to the contrary contained herein, Landlord grants to Tenant an allowance (the &#8220;Tenant Allowance&#8221;) in the amount of Seven Hundred Ninety-Two Thousand Dollars ($792,000) to be applied to the cost of the Leasehold Improvements and other costs described in Paragraph&#160;4 above. &#160;In the event that the bid for the Leasehold Improvements exceeds the Tenant Allowance, Tenant shall prepay to Landlord the amount of such excess prior to the time Landlord enters into the construction contract with Contractor, it being agreed that the Tenant Allowance shall be advanced before such funds deposited by Tenant are used to pay for construction of the Leasehold Improvements. &#160;If the cost of constructing the Leasehold Improvements is less than the Tenant Allowance, Tenant may, within the twelve (12) month period after the Commencement Date, apply the unused portion of the Tenant Allowance towards the cost of additional construction in the Premises or an upgrade of the tenant finish work in the Premises. &#160;In the event that any portion of the Tenant Allowance remains unused upon the expiration of the twelve (12) month period after the Commencement Date, Landlord shall have no obligation to pay such unused portion to Tenant or otherwise allow Tenant the benefit thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>Tenant shall cooperate with the Contractor to promote the efficient and expeditious completion of the Leasehold Improvements. &#160;Tenant agrees that in the event of default in payment hereunder, including, but not limited to, those payments due under Paragraph&#160;5 above, Landlord, in addition to any and all other remedies at law or in equity, shall have the same rights and remedies against Tenant as in the event of default in payment of rent under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>It is understood and agreed that any delay in construction of the Leasehold Improvements caused by Tenant shall not operate to delay the Commencement Date. &#160;Any of the following shall constitute a delay caused by Tenant: &#160;(a)&#160;Tenant&#8217;s failure to have preliminary plans prepared or Tenant&#8217;s failure to approve the plans in a timely manner; (b)&#160;any delay resulting from Tenant&#8217;s changes in the Plans; (c)&#160;any delay resulting from Tenant&#8217;s request for materials, finishes or installations which are not readily available; or (d) any delay in the construction of the Leasehold Improvements otherwise caused by Tenant.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant:</p></td></tr><tr><td style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab, Inc.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">INDUSTRIAL MULTI-TENANT LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Option To Extend Addendum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Option To Extend Addendum is a part of the Lease dated __________, 1999 by and between WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;) and PharmaFab, Inc., a Texas corporation (&#8220;Tenant&#8221;) for the premises commonly known as 360 Riverside Business Center (Building B).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Option to Extend</b>. Landlord hereby grants to Tenant the option to extend the term of this Lease for the following periods (&#8220;Option Periods&#8221;) commencing when the prior term expires:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Months 85 &#8211; 145 &#8220;Period One&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Months 145 &#8211; 205 &#8220;Period Two&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Exercise Dates</b>. For purposes of Paragraph&#160;5 of this Addendum:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>the Earliest Exercise Date is12 months prior to the date that the applicable Option Period would commence; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>the Last Exercise Date is 9 months prior to the date that the applicable Option Period would commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Monthly Base Rent</b>. The monthly Base Rent for each month of an Option Period shall be the amount calculated in accordance with the alternative selected below (&#8220;Rent Adjustment Alternative&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">[X] Market rent (&#8220;Market Rent Adjustment&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Conditions to Exercise of Option</b>. Tenant&#8217;s right to extend is conditioned upon and subject to each of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In order to exercise an option to extend, Tenant must give written notice of such election to Landlord and Landlord must receive the same by the Last Exercise Date but not prior to the Earliest Exercise Date. &#160;If proper notification of the exercise of an option is not given and/or received, such option shall automatically expire. &#160;Options (if there are more than one) may only be exercised consecutively. &#160;Failure to exercise an option terminates that option and all subsequent options. &#160;Tenant acknowledges that because of the importance to Landlord of knowing no later than the Last Exercise Date whether or not Tenant will exercise the option, the failure of Tenant to notify Landlord by the Last Exercise Date will conclusively be presumed an election by Tenant not to exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall have no right to exercise an option (i)&#160;if Tenant is in Default. &#160;or (ii)&#160;if during the twelve (12) month period immediately preceding the exercise of the option, three (3) or more Defaults have occurred which were not cured within any applicable notice or grace period. &#160;The period of time within which an option may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise an option because of the provisions of this paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>All of the terms and conditions of this Lease except where specifically modified by this Addendum shall apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The options are personal to Tenant, cannot be assigned or exercised by anyone other than Tenant and only while Tenant is in full possession of the Premises and without the intention of thereafter assigning or subletting. &#160;For purposes of the preceding sentence only, the term &#8220;Tenant&#8221; shall include any entity to which Tenant assigns the Lease pursuant to Section&#160;12.1(c) of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Calculation of Rent Adjustment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Rent Adjustment</u>. Four months prior to the commencement of each Option Period, if the selected Rent Adjustment Alternative is the Market Rent Adjustment, the Parties shall negotiate in good faith to determine the Base Rent for the Option Period. &#160;If agreement cannot be reached within 30 days, then Landlord and Tenant shall each, no later then 90 days prior to the commencement of the Option Period, make a reasonable determination of the fair market rental for the Premises for the Option Period and submit such determination, in writing, to arbitration in accordance with the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>No later than 90 days prior to the commencement of the Option Period, Landlord and Tenant shall each select an industrial leasing broker to act as an arbitrator. &#160;The two arbitrators so appointed shall, no later then 75 days prior to the commencement of the Option Period, select a third mutually acceptable industrial leasing broker to act as a third arbitrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>The three arbitrators, acting by a majority, shall no later then 75 days prior to the commencement of the Option Period, determine the actual fair market rental for the Premises for the Option Period. &#160;The decision of a majority of the arbitrators shall be binding on the parties. &#160;The fair market rental determination of Landlord or Tenant which is closest to the fair market rental as determined by the arbitrators shall be the Base Rent for the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iii)<font style="display:inline-block;width:21pt;"></font>If either of the parties fails to appoint an arbitrator within the period required by this Addendum, the arbitrator timely appointed shall determine the Base Rent for the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>The entire cost of such arbitration shall be paid by the party whose fair market rental submission is not selected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signatures appear on following page]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab, Inc.</p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P.,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">INDUSTRIAL MULTI-TENANT LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Security Deposit Addendum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Additional Security Deposit Addendum is a part of the Lease dated ______________, 1999 by and between WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;) and PharmaFab, Inc., a Texas corporation (&#8220;Tenant&#8221;) for the premises commonly known as 360&#160;Riverside Business Center (Building B).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Tenant agrees to pay Landlord an Additional Security Deposit in the amount of $80,000.00 that can be held in the form of a Certificate Of Deposit or Letter Of Credit. &#160;Such Additional Security Deposit shall be refunded after five (5) years, unless during the first five (5) years of occupancy there have occurred three (3) or more Defaults which were not cured within any applicable notice or grace period. &#160;If the Additonal Security Deposit is in the form of a Certificate Of Deposit or Letter Of Credit and the Premises are sold, Tenant shall, at its expense, cause the Certificate Of Deposit or Letter Of Credit, as the case may be, to be reissued in the name of the purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab, Inc.</p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GUARANTY OF LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;), and PharmaFab, Inc., a Texas corporation (&#8220;Tenant&#8221;) are about to execute a lease (&#8220;Lease&#8221;) dated ___________________ 1999, for the premises commonly known as 360 Riverside Business Center (Building B).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Bruce K. Montgomery and Darlene Ryan (each a &#8220;Guarantor&#8221;) have a financial interest in Tenant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Landlord would not execute the Lease if Guarantor did not execute and deliver to Landlord this Guaranty of Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the execution of the foregoing Lease by Landlord and as a material inducement to Landlord to execute the Lease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Guarantor hereby jointly, severally, unconditionally and irrevocably guarantee the prompt payment by Tenant of all rents and all other sums payable by Tenant under the Lease and the faithful and prompt performance by Tenant of each and every one of the terms, conditions and covenants of the Lease to be kept and performed by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The terms of the Lease may, without the consent of or notice to Guarantor, be modified by Landlord and Tenant or by a course of conduct and this Guaranty shall guarantee the performance of said Lease as so modified. &#160;The Lease may be assigned by Landlord or any assignee of Landlord without consent or notice to Guarantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>This Guaranty shall not be released, modified or affected by the failure or delay on the part of Landlord to enforce any of the rights or remedies of the Landlord under the Lease, whether pursuant to the terms thereof or at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>No notice of default need be given to Guarantor. &#160;The guaranty of the undersigned is a continuing guaranty under which Landlord may proceed immediately against Tenant and/or against any Guarantor (or each Guarantor) following any breach or default by Tenant or for the enforcement of any rights which Landlord may have against Tenant under the terms of the Lease or at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>Landlord shall have the right to proceed against any Guarantor (or each Guarantor) hereunder following any breach or default by Tenant without first proceeding against Tenant and without previous notice to or demand upon either Tenant or any Guarantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>Each Guarantor hereby waives (a)&#160;notice of acceptance of this Guaranty, (b)&#160;demand of payment, presentation and protest, (c)&#160;any right to require the Landlord to proceed against the Tenant or any other Guarantor or any other person or entity liable to Landlord, (d) any right to require Landlord to apply to any default any security deposit or other security it may hold under the Lease, (e) any right to require Landlord to proceed under any other remedy Landlord may have before proceeding against Guarantor and (f) any right of subrogation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>Each Guarantor does hereby subrogate all existing or future indebtedness of Tenant to such Guarantor to the obligations owed to Landlord under the Lease and this Guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font>If a Guarantor is married, such Guarantor expressly agrees that recourse may be had against his or her separate property for all of the obligations hereunder. &#160;If there is more than one Guarantor, the obligations of each Guarantor hereunder shall be joint and several.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font>The obligations of Tenant under the Lease to execute and deliver estoppel certificates and financial statements shall be deemed to also require each Guarantor hereunder to do and provide the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font>The term &#8220;Landlord&#8221; refers to and means the Landlord named in the Lease and also Landlord&#8217;s successors and assigns. &#160;So long as Landlord&#8217;s interest in the Lease, the leased premises or the rents, issues and profits therefrom, are subject to any mortgage or deed of trust or assignment for security, no acquisition by Guarantor of the Landlord&#8217;s interest shall affect the continuing obligation of Guarantor under this Guaranty which shall nevertheless continue in full force and effect for the benefit of the mortgagee, beneficiary, trustee or assignee under such mortgage, deed of trust or assignment and their successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font>The term &#8220;Tenant&#8221; refers to and means the Tenant named in the Lease and also Tenant&#8217;s successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font>In the event any action be brought by said Landlord against Guarantor hereunder to enforce the obligation of Guarantor hereunder, the unsuccessful party in such action shall pay to the prevailing party therein a reasonable attorney&#8217;s fee which shall be fixed by the court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font>After three (3) years, provided Tenant has not had an uncured Default as described in the Lease, the aggregate liability of the Guarantors hereunder shall be limited to the sum of $380,000.00 on a joint and several basis (i.e. the liability of Bruce K. Montgomery hereunder shall be limited to $380,000, and the liablity of Darlene Ryan hereunder shall be limited to $380,000, but the maximum aggregate amount Landlord can recover from the Guarantors under this Guranty shall be limited to a total of $380,000). &#160;If no uncured Default has occurred under the Lease at the expiration of the fifth (5th) year of Tenant&#8217;s occupancy, this Guaranty shall terminate. &#160;It is agreed that if a Default occurs under the Lease which continues beyond the expiration of any applicable grace or cure period, Landlord may condition its acceptance of any cure of such Default upon keeping this Guaranty in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Executed on the ______ day of June, 1999.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:50%;"><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:22.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:77.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8220;GUARANTOR&#8221;</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bruce K. Montgomery</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:77.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:92.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td colspan="2" style="vertical-align:top;width:83.3%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:50%;"><tr><td colspan="3" style="vertical-align:top;width:16.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:83.3%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Darlene Ryan</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:22.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:77.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">on:</p></td><td colspan="4" style="vertical-align:top;width:92.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td colspan="3" style="vertical-align:top;width:85.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:85.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Exhibit A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">Diagram of Premises</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="aytu-20230630xex10d48001.jpg" alt="Graphic" style="display:inline-block;height:479.54pt;left:0.13%;padding-bottom:0pt;position:relative;top:0pt;transform:rotate(270deg);width:519.81pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">COMMENCEMENT DATE MEMORANDUM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:96.33%;"><tr><td style="vertical-align:top;width:19.25%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">LANDLORD:</p></td><td style="vertical-align:top;width:80.74%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">WALSTIB, L.P., DELAWARE UNITED PARTNERSHIP</p></td></tr><tr><td style="vertical-align:top;width:19.25%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TENANT:</p></td><td style="vertical-align:top;width:80.74%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PHARMAFAB, INC.</p></td></tr><tr><td style="vertical-align:top;width:19.25%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">LEASE DATE: </p></td><td style="vertical-align:top;width:80.74%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">_____________, 1999</p></td></tr><tr><td style="vertical-align:top;width:19.25%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PREMISES:</p></td><td style="vertical-align:top;width:80.74%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">360 Riverside Business Center (Building B)<br>Grand Prairie, Texas 75050</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant hereby accepts the Premises as being in the condition required under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Commencement Date of the Lease is ______________________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Expiration Date of the Lease is ______________________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tenant:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab, Inc.</p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;">Signage Criteria</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Per Paragraph&#160;16.15, Tenant can install the sign described hereunder, provided that upon removal of such sign, Tenant shall make all repairs and maintenance to the building (i.e., repairing holes, texture, paint, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sign criteria for the project shall consist of internally illuminated channel letters attached to a single raceway centered on each building entrance. &#160;The raceway will be located on the top facade band directly above the reveal, and the raceway shall be confined to a 40 foot maximum length with an 8 inch height. &#160;The copy shall be limited to 30 inches in height with 5 inch painted returns. &#160;Raceway and return colors will be specified by Landlord along with electrical specifications. &#160;Tenant shall replace the raceway face to its original condition upon vacating the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Subordination Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD&#8217;S SUBORDINATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, WALSTIB, L.P. (hereinafter referred to as &#8220;Landlord&#8221;) is the owner and/or lessor of the following premises (hereinafter referred to as &#8220;Premises&#8221;) which are leased to the following tenant (hereinafter referred to as &#8220;Tenant&#8221;) pursuant to that certain lease executed by and between Landlord and Tenant on or about the ___day of _________________, 1999, as same may have been amended from time to time (hereinafter referred to as the &#8220;Lease&#8221;);</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:70.47%;"><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises:</p></td><td style="vertical-align:top;width:43.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.42%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:43.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.42%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant:</p></td><td style="vertical-align:top;width:43.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:56.57%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.42%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Summit National Bank, N.A. (&#8220;Lender&#8221;) has or is about to loan funds to Tenant, and to secure such loan Tenant has or will grant a security interest to Lender on personalty, furniture, trade fixtures and inventory owned by Tenant and located in the Premises, as described on Exhibit &#8220;A&#8221; attached hereto (the &#8220;Property&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, all or a portion of the Property may from time to time be located at the Premises or may become wholly or partially affixed to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, for and in consideration of the covenants contained herein, it is hereby agreed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Except as limited in this Agreement, Landlord subordinates to the interest of Lender any and all liens, claims or other rights which Landlord may have in or to the Property now or hereafter located in or on the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Except if Tenant is a debtor in a proceeding under Title 11 of the United States Code, to the extent of the subordination provided for herein, Landlord agrees that upon prior written notice to Landlord, Lender, through its authorized representatives or agents, may enter upon the Premises at any time mutually agreeable to Lender and Landlord after three (3) days written notice for the purpose of inspecting, repairing, or removing the Property, and Landlord agrees not to hinder or prevent Lender from taking any such action; provided, however, that nothing herein shall release Lender from, and Lender agrees to be responsible for, any and all damages resulting to the Premises as a result of any such entry or removal. &#160;Lender agrees to indemnify and hold Landlord harmless from any and all claims arising from or related to the removal of the Property from the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Within ten (10) business days after Landlord notifies Lender that Tenant is in default under the Lease and Landlord has notified Lender of which remedy Landlord has pursued under the lease between Landlord and Tenant, Lender must notify Landlord of Lender&#8217;s election to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Remove the Property from the Premises within ten (10) business days of such election; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>With Landlord&#8217;s approval, retain the Property at the Premises for a period of time to be mutually determined by Landlord and Lender and pay to Landlord rental for such use of the Premises, as set forth in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>Any notice pursuant to this Agreement shall be deemed to have been given, whether or not received, when deposited in the United States mail, postage prepaid, certified mail, return receipt requested, at the following addresses:</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:80%;"><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Lender:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:49.99%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Landlord:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.99%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>This Agreement shall be binding upon and inure to the benefit of the heirs, representatives, successors and assigns of Landlord and Lender.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>: &#160;THIS LANDLORD&#8217;S SUBORDINATION AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signatures and acknowledgments appear on following pages]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNED this ____ day of ________________, 19___.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Landlord:</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Lender:</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">SUMMIT NATIONAL BANK, N.A.</p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB Venture, L.L.C.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited liability company</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="2" style="vertical-align:top;width:39.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TCDFW Development, Ltd.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Administrative Member</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:46.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trammell Crow DFW Development, Inc.,</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware corporation</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:top;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td colspan="2" style="vertical-align:top;width:39.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Facsimile:</p></td><td colspan="3" style="vertical-align:top;width:39.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Executed at:</p></td><td style="vertical-align:top;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">on:</p></td><td colspan="5" style="vertical-align:top;width:45.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">ACKNOWLEDGMENTS</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:96.33%;"><tr><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">STATE OF TEXAS</p></td><td style="vertical-align:top;width:66.31%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#167;</p></td></tr><tr><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COUNTY OF _____</p></td><td style="vertical-align:top;width:66.31%;margin:0pt;padding:0pt 5.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#167;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This instrument was acknowledged before me on the ______ day of __________, 19___, by ____________________, the _______________ of _________________________________.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notary Public</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commission Expires:</p></td><td style="vertical-align:top;width:31.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Printed Name:</p></td><td colspan="2" style="vertical-align:top;width:37.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>6
<FILENAME>aytu-20230630xex10d49.htm
<DESCRIPTION>EX-10.49
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.49</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">FIRST AMENDMENT TO LEASE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This First Amendment to Lease (this &#8220;Amendment&#8221;) is made to be effective as of September&#160;1,&#160;2002, by and between WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;), and PFAB, LP, a Texas limited partnership (&#8220;Tenant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</font></font>Landlord and PharmaFab, Inc., a Texas corporation (&#8220;PharmaFab&#8221;), entered into that certain Commercial Lease Agreement dated on or about June&#160;29,&#160;1999, and having a Commencement Date as of October&#160;25,&#160;1999 (as same may have been amended and assigned, the &#8220;Lease&#8221;) regarding certain premises (the &#8220;Premises&#8221;) located at 360 Riverside Business Center in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</font></font>Pursuant to that certain Assignment of Lease dated on or about June 29, 1999, to be effective as of July&#160;1,&#160;1999, PharmaFab assigned its right, title and interest in the Lease to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C.</font></font>Pursuant to that certain Guaranty of Lease (the &#8220;Original Guaranty&#8221;), Bruce K. Montgomery and Darlene M. Ryan guaranteed the obligations of Tenant under the Lease, subject to certain limitations set forth in said Original Guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">D.</font></font>Landlord and Tenant have agreed to amend the Lease as hereinafter set forth, and Darlene M. Ryan has agreed to execute a new guaranty of Tenant&#8217;s obligations under the Lease as hereinafter set forth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the premises, Landlord and Tenant agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defined Terms</u>. &#160;All capitalized terms not defined herein shall have the meanings set forth for such terms in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion of Premises</u>. &#160;Landlord and Tenant agree that the Premises shall be expanded to include the space comprised of approximately 50,000 rentable square feet in Building A of the Industrial Center that is denoted on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u> attached hereto and made a part hereof (and herein referred to) as the &#8220;Expansion Space&#8221;. &#160;Tenant acknowledges that Tenant has inspected the Expansion Space and agrees to accept the Expansion Space in &#8220;as is&#8221; condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. &#160;Landlord and Tenant agree that the Expiration Date of the term of the Lease shall be November 30, 2010 (rather than October 31, 2006).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>: &#160;Landlord and Tenant agree that the Base Rent shall be as follows:</p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70%;"><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Monthly</p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Months</u></p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u></p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">September 1, 2002 &#8212;March 31, 2003</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$31,900.60</p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">April 1, 2003 &#8212; April 30, 2003</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$45,962.50</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70%;"><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">May 1, 2003 &#8212; October 31, 2004</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$49,608.33</p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">November 1, 2004 &#8212; October 31, 2005</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$52,835.00</p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">November 1, 2005 &#8212; March 31, 2008</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$54,301.66</p></td></tr><tr><td style="vertical-align:bottom;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">April 1, 2008 &#8212; November 30, 2010</p></td><td style="vertical-align:top;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$56,697.50</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment in Tenant&#8217;s Share</u>. &#160;As used in the Lease, the term &#8220;Building&#8221; shall refer to Building A and Building B. &#160;Landlord and Tenant agree that, as a result of adding the Expansion Space to the Premises, Tenant&#8217;s Share is as follows:</p><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:70%;"><tr><td style="vertical-align:bottom;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">(a)</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Industrial Park</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">43.8%</p></td></tr><tr><td style="vertical-align:bottom;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">(b)</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building A</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">49.5%</p></td></tr><tr><td style="vertical-align:bottom;width:5.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 1pt;">(c)</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building B</p></td><td style="vertical-align:top;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">38.7%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Refurbishment Allowance</u>. &#160;On December&#160;1,&#160;2005, Landlord shall provide to Tenant an allowance (the &#8220;Refurbishment Allowance&#8221;) of Two Hundred Fifty Thousand Dollars ($250,000) to be used by Tenant to design and construct improvements in the Premises; provided, however, that Landlord shall have no obligation to provide the Refurbishment Allowance if at such time (a) Tenant is the subject of a bankruptcy proceeding or any other insolvency proceeding, or (b) Tenant is in Default, or any circumstance exists which, with the giving of notice or the passage of time, or both, would constitute a Default. &#160;All improvements constructed with the Refurbishment Allowance shall be subject to the provisions of the Lease governing alterations to the Premises, and, unless waived in writing by Landlord, Trammell Crow Dallas Fort Worth (or its designee) shall serve as the construction manager for such improvements. &#160;The Refurbishment Allowance shall be used only for payment of the following: &#160;(i) costs, including professional fees, of the architect and other design and planning costs in connection with tenant improvements constructed in the Premises; (ii) the costs of labor and material associated with the construction of the tenant improvements in the Premises; and (iii) a fee equal to four percent (4%) of the sum of all design, planning and construction costs associated with the construction of the tenant improvements in the Premises, unless Landlord has waived in writing the requirement that Trammell Crow Dallas Fort Worth (or its designee) serve as construction manager, in which event no fee shall be owed. &#160;Landlord shall have the right to require, as a condition to any disbursement of any portion of the Refurbishment Allowance requested by Tenant, that Tenant provide Landlord copies of invoices and/or similar evidence that the requested disbursement is for one of the purposes set forth in the foregoing clauses (i), (ii) or (iii). &#160;In no event shall Landlord have any obligation to make any disbursement of the Refurbishment Allowance requested after May 1, 2006, it being agreed that after such date any unused portion of the Refurbishment Allowance shall be deemed forfeited by Tenant. &#160;Each payment of the Refurbishment Allowance shall be made within thirty (30) days after Landlord has received a request therefor together with all other documents reasonably required by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Offer</u>. &#160;Tenant shall have a right of first offer with respect to the space in Building A shown on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</u> attached hereto and made a part hereof (the &#8220;Offered Space&#8221;), under the following terms and conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Subject to the provisions of Section 7(d) below, if at any time during the term of the Lease any lease for any portion of the Offered Space shall expire and if Landlord intends to market the Offered Space to prospects for lease with third parties (a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;Proposed Tenant&#8221;) other than the tenant then occupying such space (or its affiliates), Landlord shall first allow Tenant the right to include the Offered Space within the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Such offer shall be made by Landlord to Tenant in a written notice (hereinafter called the &#8220;Offer Notice&#8221;) which notice shall designate the space being offered and shall specify the terms for such Offered Space that Landlord intends to submit to prospective tenants in an effort to market the Offered Space. &#160;Tenant may accept the offer set forth in the Offer Notice by delivering to Landlord an unconditional acceptance (hereinafter called &#8220;Tenant&#8217;s Notice&#8221;) of such offer within five (5) business days after delivery by Landlord of the Offer Notice to Tenant. &#160;Time shall be of the essence with respect to the giving of Tenant&#8217;s Notice. &#160;If Tenant does not accept (or fails to timely accept) an offer made by Landlord pursuant to the provisions hereof with respect to the Offered Space designated in the Offer Notice, Landlord shall be under no further obligation whatsoever respect to such space. &#160;In order to send the Offer Notice, Landlord does not need to have negotiated a lease with any particular Proposed Tenant but may merely have determined on what basis it will market the Offered Space to Proposed Tenants. &#160;Tenant must make its decision with respect to the Offered Space as long as it has received a description of such material economic terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Tenant must accept all Offered Space offered by Landlord at any one time if it desires to accept any of such Offered Space and may not exercise its right with respect to only part of such space. &#160;In addition, if Landlord desires to lease more than just the Offered Space to one tenant. &#160;Landlord may offer to Tenant pursuant to the terms hereof all such space which Landlord desires to lease, and Tenant must exercise its rights hereunder with respect to all such space and may not insist on receiving an offer for just the Offered Space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If Tenant at any time declines any Offered Space offered by Landlord, Tenant shall be deemed to have irrevocably waived all further rights under this Addendum, and Landlord shall be free to lease the Offered Space to any Proposed Tenant including on terms which may be less favorable to Landlord than those set forth in the Offer Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Tenant shall not have the benefit of the foregoing right of first offer if Tenant is in Default at the time the Offer Notice is to be sent, or if at such time any circumstance exists which, with the giving of notice or the passage of time, or both, would constitute a Default. &#160;The period of time Tenant&#8217;s right of first offer may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise such right because of the provisions of this paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option to Extend</u>. &#160;The addendum to the Lease captioned &#8220;Option to Extend&#8217; Addendum&#8221; is hereby deleted in its entirety. &#160;Landlord hereby grants to Tenant the options to extend the term of this Lease for the periods (the &#8220;Option Periods&#8221;) (1) from December&#160;1,&#160;2010 to November&#160;30,&#160;2015, and (2) from December&#160;1,&#160;2015 to November&#160;30,&#160;2020, under the following terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In order to exercise an option to extend, Tenant must give written notice of such election to Landlord and Landlord must receive the same by no later than twenty four</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">(24) months prior to the date (the &#8220;Last Exercise Date&#8221;) that the applicable Option Period would commence, but not earlier than thirty (30) months prior to the date that the applicable Option Period would commence. &#160;If proper notification of the exercise of an option is not given and/or received, such option shall automatically expire. &#160;The renewal options may only be exercised consecutively. &#160;Failure to exercise an option terminates that option and all subsequent options. &#160;Tenant acknowledges that because of the importance to Landlord of knowing no later than the Last Exercise Date whether or not Tenant will exercise the option, the failure of Tenant to notify Landlord by the Last Exercise Date will conclusively be presumed an election by Tenant not to exercise the option. &#160;Upon the exercise of an option to extend, both parties shall execute an amendment to the Lease evidencing the renewal thereof and setting forth the new Base Rent (as determined pursuant to Section 8(c) below) no later than eighteen (18) months prior to the date that the applicable Option Period would commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall have no right to exercise an option (i) if Tenant is in Default. &#160;or (ii) if during the twelve (12) month period immediately preceding the exercise of the option, three (3) or more Defaults have occurred which were not cured within any applicable notice or grace period. &#160;The period of time within which an option may be exercised shall not be extended or enlarged by reason of Tenant&#8217;s inability to exercise an option because of the provisions of this paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If an option to extend is exercised, all of the terms and conditions of this Lease shall apply, except that (i) Landlord shall not be required to grant any allowance or perform any tenant improvement work in the Premises, and (ii) for each Option Period, Base Rent shall be adjusted to equal fair market rent. &#160;After an option to renew is exercised, Landlord and Tenant shall negotiate in good faith to determine the Base Rent for the applicable Option Period. &#160;If agreement cannot be reached within thirty (30) days, then Landlord and Tenant shall each, no later than sixty (60) days after the date of exercise of the option, make a reasonable determination of the fair market rental for the Premises for the applicable Option Period and submit such determination, in writing, to arbitration in accordance with the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>No later than ninety (90) days after the option to renew is exercised, Landlord and Tenant shall each select an industrial leasing broker to act as an arbitrator. &#160;The two arbitrators so appointed shall, no later then one hundred twenty (120) days after the option to renew is exercised, select a third mutually acceptable industrial leasing broker to act as a third arbitrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>The three arbitrators, acting by a majority, shall no later then one hundred fifty (150) days after the option to renew is exercised, determine the actual fair market rental for the Premises for the Option Period. &#160;The decision of a majority of the arbitrators shall be binding on the parties. &#160;The fair market rental determination of Landlord or Tenant which is closest to the fair market rental as determined by the arbitrators shall be the Base Rent for the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iii)<font style="display:inline-block;width:21pt;"></font>If either of the parties fails to appoint an arbitrator within the period required by this Addendum, the arbitrator timely appointed shall determine the Base Rent for the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>The entire cost of such arbitration shall be paid by the party whose fair market rental submission is not selected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The renewal options set forth herein are personal to Tenant, cannot be assigned or exercised by anyone other than Tenant and only while Tenant is in full possession of the Premises and without the intention of thereafter assigning or subletting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guaranty</u>. &#160;Concurrently with the execution hereof, Tenant shall cause Darlene M. Ryan to execute and deliver to Landlord a guaranty in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</u> attached hereto and made a part hereof, which shall supersede the Original Guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commission Agreement</u>. &#160;Attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D</u> is a copy of the Commission Agreement (herein so called) executed between Landlord, as &#8220;Owner,&#8221; and Fobare Commercial, as &#8220;Agent,&#8221; in connection with the Lease. &#160;The Commission Agreement shall remain in full force and effect, except that in connection with this Amendment (and this Amendment only) the compensation paid to Agent shall be as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;E</u> attached hereto. &#160;The Commission Agreement, as modified with respect to this Amendment only in the manner described on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;E</u>, shall be deemed included as a provision of this Lease in compliance with Section&#160;62.022 of the Texas Property Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. &#160;The parties may execute this Amendment in any number of counterparts with the same effect as if all parties to this Amendment had signed the same document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. &#160;The Lease, as amended hereby, shall be governed and construed in accordance with the laws of the State of Texas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continued Effect</u>. &#160;The Lease, as amended hereby, is ratified and confirmed and shall continue in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Amendment to be effective as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Landlord</b>:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Tenant</b>:</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">WALSTIB, L.P.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PFAB, L.P.</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td></tr><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">AMB Property, L.P.</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab Texas, LLC,</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Delaware limited partnership</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited liability company</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its sole general partner</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its General Partner</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:42.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:41.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name: &#160;Doug McGregor</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:41.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Darlene M. Ryan, Manager</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Its Vice President</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:49.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date of Execution:</p></td><td style="vertical-align:top;width:34.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:14.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date of Execution:</p></td><td style="vertical-align:top;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion Space</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="aytu-20230630xex10d49001.jpg" alt="Graphic" style="display:inline-block;height:276.73pt;width:563.1pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offered Space</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="aytu-20230630xex10d49002.jpg" alt="Graphic" style="display:inline-block;height:284.86pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:554pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GUARANTY OF LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Guaranty of Lease (this &#8220;Guaranty&#8221;) is made to be effective as of September&#160;1,&#160;2002, by DARLENE M. RYAN (&#8220;Guarantor&#8221;) for the benefit of WALSTIB, L.P., a Delaware limited partnership (&#8220;Landlord&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</font></font>Landlord and PharmaFab, Inc., a Texas corporation (&#8220;PharmaFab&#8221;), entered into that certain Commercial Lease Agreement dated on or about June 29, 1999, and having a Commencement Date as of October&#160;25,&#160;1999 (as same may have been amended and assigned, the &#8220;Original Lease&#8221;) regarding certain premises located at 360 Riverside Business Center in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Original Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</font></font>Pursuant to that certain Assignment of Lease dated on or about June&#160;29,&#160;1999, to be effective as of July&#160;1,&#160;1999, PharmaFab assigned its right, title and interest in the Original Lease to PFab, LP, a Texas limited partnership (&#8220;Tenant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">C.</font></font>Pursuant to that certain Guaranty of Lease (the &#8220;Original Guaranty&#8221;), Bruce K. Montgomery (&#8220;Montgomery&#8221;) and Guarantor guaranteed the obligations of Tenant under the Original Lease, subject to certain limitations set forth in said Original Guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">D.</font></font>Landlord would not have executed the Original Lease if Montgomery and Guarantor had not executed and delivered the Original Guaranty to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">E.</font></font>Landlord and Tenant have entered into that certain First Amendment to Lease of even date herewith (the &#8220;First Amendment&#8221;) providing for, among other things, the expansion of the premises demised by Landlord to Tenant (the Original Lease, as amended by the First Amendment, being herein referred to as the &#8220;Lease&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">F.</font></font>In connection with the First Amendment, Guarantor (who owns an interest in Tenant) has agreed to execute and deliver to Landlord, and Landlord has agreed to accept, this Guaranty as a replacement of the Original Guaranty, it being understood that Landlord is not willing to execute the First Amendment if Guarantor does not execute and deliver this Guaranty to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the execution of the First Amendment by Landlord and as a material inducement to Landlord to execute the First Amendment:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Guarantor hereby unconditionally and irrevocably guarantees the prompt payment by Tenant of all rents and all other sums payable by Tenant under the Lease and the faithful and prompt performance by Tenant of each and every one of the terms, conditions and covenants of the Lease to be kept and performed by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The terms of the Lease may, without the consent of or notice to Guarantor, be modified by Landlord and Tenant or by a course of conduct and this Guaranty shall guarantee the performance of said Lease as so modified. &#160;The Lease may be assigned by Landlord or any assignee of Landlord without consent or notice to Guarantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>This Guaranty shall not be released, modified or affected by the failure or delay on the part of Landlord to enforce any of the rights or remedies of the Landlord under the Lease, whether pursuant to the terms thereof or at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>No notice of default need be given to Guarantor. &#160;The guaranty of the undersigned is a continuing guaranty under which Landlord may proceed immediately against Tenant and/or against Guarantor following any breach or default by Tenant or for the enforcement of any rights which Landlord may have against Tenant under the terms of the Lease or at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>Landlord shall have the right to proceed against Guarantor hereunder following any breach or default by Tenant without first proceeding against Tenant and without previous notice to or demand upon either Tenant or Guarantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>Guarantor hereby waives (a) notice of acceptance of this Guaranty, (b) demand of payment, presentation and protest, (c) any right to require Landlord to proceed against Tenant or any other person or entity liable to Landlord, (d) any right to require Landlord to apply to any default any security deposit or other security it may hold under the Lease, (e) any right to require Landlord to proceed under any other remedy Landlord may have before proceeding against Guarantor, and (f) any right of subrogation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>Guarantor does hereby subrogate all existing or future indebtedness of Tenant to such Guarantor to the obligations owed to Landlord under the Lease and this Guaranty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font>If a Guarantor is married, such Guarantor expressly agrees that recourse may be had against his or her separate property for all of the obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font>The obligations of Tenant under the Lease to execute and deliver estoppel certificates and financial statements shall be deemed to also require Guarantor to do and provide the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font>The term &#8220;Landlord&#8221; refers to and means the Landlord named in the Lease and also Landlord&#8217;s successors and assigns. &#160;So long as Landlord&#8217;s interest in the Lease, the leased premises or the rents, issues and profits therefrom, are subject to any mortgage or deed of trust or assignment for security, no acquisition by Guarantor of the Landlord&#8217;s interest shall affect the continuing obligation of Guarantor under this Guaranty which shall nevertheless continue in full force and effect for the benefit of the mortgagee, beneficiary, trustee or assignee under such mortgage, deed of trust or assignment and their successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font>The term &#8220;Tenant&#8221; refers to and means the Tenant named in the Lease and also Tenant&#8217;s successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font>In the event any action be brought by said Landlord against Guarantor hereunder to enforce the obligation of Guarantor hereunder, the unsuccessful party in such action shall pay to the prevailing party therein a reasonable attorney&#8217;s fee which shall be fixed by the court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font>Provided Tenant has not had an uncured Default as described in the Lease, as of October&#160;25,&#160;2002, the liability of Guarantor hereunder shall be limited to the sum of $760,000.00. &#160;If no uncured Default has occurred under the Lease as of October&#160;25,&#160;2004, then this Guaranty</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shall terminate. &#160;It is agreed that if a Default occurs under the Lease which continues beyond the expiration of any applicable grace or cure period, Landlord may condition its acceptance of any cure of such Defauit upon keeping this Guaranty in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font>This Guaranty shall supersede the Original Guaranty in its entirety, it being specifically agreed that Montgomery shall no longer have any liability as a guarantor of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Executed to be effective as of the date and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="4" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">&#8220;<b style="font-weight:bold;">GUARANTOR</b>&#8221;</p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:50.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:50.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:50.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Darlene M. Ryan</p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Executed at:</p></td><td colspan="2" style="vertical-align:bottom;width:39.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Address:</p></td><td colspan="3" style="vertical-align:bottom;width:43.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:5.85pt;"><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:43.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:43.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:43.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">STATE OF TEXAS</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#167;</p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#167;</p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">COUNTY OF TARRANT</p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#167;</p></td><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This instrument was acknowledged before me on August __ 2002, by DARLENE M. RYAN.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notary Public - State of Texas</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.6pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[Seal]</p></td><td style="vertical-align:top;width:23.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">My Commission Expires:</p></td><td style="vertical-align:top;width:26.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copy of Commission Agreement</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMMISSION AGREEMENT BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOBARE COMMERCIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS CONTRACT OF AGREEMENT</b>, entered into by and between <b style="font-weight:bold;">Walstib, L.P., a Delaware limited partnership</b> hereinafter referred to as &#8220;Owner,&#8221; and <b style="font-weight:bold;">Fobare Commercial</b> hereinafter referred to as &#8220;Agent.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">W I T N E S S E T H:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Agent has assisted or is assisting Owner in negotiating and consummating a Lease Agreement between Owner and <b style="font-weight:bold;">PharmaFab, Inc</b>., hereinafter referred to as &#8220;Prospect,&#8221; covering an approximate 44,000 square foot facility located at (in) <b style="font-weight:bold;">360 Riverside Business Park (Building&#160;B)</b> (the &#8220;Project&#8221;) for a term of 84 months beginning <b style="font-weight:bold;">June 1, 1999</b> with rentals being due to Owner as therein provided, to which lease reference is hereby made, and the same is hereby incorporated herein for all purposes; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Agent and Owner hereby and herein desire to agree upon a commission to which Agent shall be entitled for such services based on rentals actually received by Owner, as hereinafter provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is mutually agreed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. REGISTRATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Registration of the Prospect requires either (a) this Registration Letter from Agent naming the Prospect and a face-to-face meeting with a decision maker representing the Prospect or (b) a duly executed and authorized letter from the Prospect designating Agent as its exclusive Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>This Registration and Agreement is effective for sixty (60) days after the date hereof and may be extended for another sixty (60) days if the Agent shows evidence satisfactory to Owner that Agent is actively pursuing the execution of a Lease Agreement between Owner and the Prospect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>If at any time following the registration of the Prospect pursuant to (a) or (b) above, Agent loses control of the Prospect as evidenced by a letter from the Prospect designating some other Agent as the Prospect&#8217;s Agent, then upon notification of such event to Agent by Owner, this Registration Letter and Commission Agreement shall become null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Agent has satisfied the aforesaid initial registration requirements of Owner and accordingly Owner agrees to recognize <b style="font-weight:bold;">PharmaFab, Inc.</b> as Agent&#8217;s Prospect and agrees to pay</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a commission to Agent if a lease of space of the Project is consummated between the Prospect and Owner during the term of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. CASH COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Primary Term</u>. &#160;(1) If Agent requests a front-end cash-out of commission obligation hereunder, and if Prospect in Owner&#8217;s opinion has sufficient credit to meet all of Prospect&#8217;s obligations under the lease, Owner shall, as set forth in d. below, pay Agent as the Commission hereunder four and one-half percent (4-1/2%) of the total Rentals as hereafter payable for the entire initial term of the lease up to ten (10) years. &#160;Financial statements and other information necessary to determine credit risk are to be provided by Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal</u>. &#160;If Agent requests a front-end cash-out of the commission obligation hereunder with respect to a renewal option contained in the lease which has been duly exercised, and if Prospect in Owner&#8217;s opinion then has sufficient credit to meet all of Prospect&#8217;s obligations under the lease during the renewal term, Owner shall pay Agent the then prevailing market commission for a renewal, based upon the total Rentals payable for the renewal term, up to ten (10) years, providing that Agent is instrumental in assisting Owner in obtaining such renewal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion</u>. &#160;If Agent requests a front-end cash-out of the commission obligation hereunder with respect to an Option to Expand contained in the Lease Agreement which has been duly exercised prior to the termination of the Lease Agreement and if Prospect in Owner&#8217;s opinion then has sufficient credit to meet all of Prospect&#8217;s obligations under the lease as so expanded, Owner may pay Agent a commission of four and one-half percent (4-1/2%) of the total Rentals payable for the expansion space providing that Agent is instrumental in assisting Owner in obtaining such expansion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of Payment</u>. &#160;(1) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term</u>. &#160;One-half (1/2) upon execution of the lease by Owner and Prospect, delivery thereof to both parties and receipt by Owner of first full month&#8217;s rent and any security deposit; and the balance upon occupancy by Prospect, delivery to Owner of satisfactory commencement letter executed by Prospect. &#160;In addition, no payment shall be payable until contingencies relating to the actual consummation or cancellation of the agreement by Prospect (including but not limited to contingencies regarding zoning, restrictive covenants, permitting, plan approvals and finish cost limits) are satisfactorily eliminated by the parties to the Lease Agreement. &#160;In addition for Build-to-Suit facilities no commission will be payable until Owner has received interim financing for the project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal Term</u>. &#160;If a renewal commission is due pursuant to Paragraph 2.b. above, the commission shall be payable upon written exercise of the renewal option and payment of the rental for the first full month of the renewal term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cancellation</u>. &#160;Notwithstanding the above provisions, where Prospect individually or Prospect and Owner, jointly, have the right to cancel the lease, a commission shall only be paid to Agent for the period up to the date on which the lease may be canceled. &#160;If the lease is not then canceled, Owner shall pay the balance of the commission due for the remainder of the period covered under the lease at the time the Prospect&#8217;s right to cancel expires, provided Prospect remains in occupancy of the space and is not in default under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">f.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Lease</u>. &#160;In the event Agent furnishes Owner written authorization to represent Prospect and negotiates and consummates a new Lease Agreement between Owner and Prospect covering an expansion or relocation facility, Owner shall pay Agent a commission based on the above provisions for the expansion or relocation premises, but Agent&#8217;s commission under the original Lease Agreement shall be terminated as of the commencement date of the new Lease Agreement and any unearned commission paid to the Agent with respect to the original Lease Agreement shall be netted out of commission payable for the new Lease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. GENERAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale of Premises</u>. &#160;In the event of sale of the premises and assignment of the Lease Agreement by Owner, Owner agrees to provide a copy of this Commission Agreement to the Purchaser and to use its reasonable efforts to obtain from the purchaser or assignee an agreement whereby such purchaser or assignee assumes the obligation to pay to Agent under the terms and provisions hereof, and Owner shall be released from all liability for all future payments of commissions as may thereafter become due under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;&#8220;Rentals&#8221; shall mean the base monthly cash rent, and shall not include any amounts payable by Prospect to Owner for reimbursement of costs and expenses passed through to Prospect, such as real estate taxes, insurance premiums, utilities, janitorial and common area maintenance, or any operating expense escalations or amortization of tenant finish costs above Owner&#8217;s building standard allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition rentals shall be reduced by the cost of any lease takeover obligations to Owner, free rent or other considerations by Owner to the benefit of Prospect, whether agreed to in the Lease Agreement or other written instrument. &#160;Rentals for the purposes of this Commission Agreement, does not include that portion of Prospect&#8217;s payments that relate to costs to Owner that are separately amortized because the cost of such improvements are above Owner&#8217;s building standard allowance, relate to extraordinary items or otherwise would not be considered within the ordinary course of rental payments in an industrial facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u>. &#160;Except as otherwise herein provided, all rights and obligations hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and personal representatives of the Owner and Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. &#160;Except as expressly herein provided, Owner shall have no obligation to pay, and Agent shall have no right to receive, any commission or other payment with respect to the Lease or any transactions between Owner and Prospect, unless such right or obligation is set forth in writing and signed by Owner and Prospect after the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance</u>. &#160;This agreement is intended to be an offer, and if not accepted and returned to Owner in writing within three business days from the date hereon, it is hereby withdrawn. &#160;If not received by said date, this offer is null and void. &#160;This Agreement is not valid unless fully signed by both Owner and Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">f.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Owner&#8217;s Interest</u>. &#160;Broker shall look solely to Owner&#8217;s interest in the Project for the recovery of any judgement against Owner for failure to perform under this Agreement, and Owner</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(and Its partners, shareholders and agents) shall not be personally liable for any such judgement therefore.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EXECUTED BY OWNER this ___________ day of _______________, 1999.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:48.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP</b></p></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">WALSTIB Venture, L.L.C., a Delaware limited liability company</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its sole general partner</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">TCDFW Development, Ltd., a Texas limited partnership</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its Administrative Member</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Trammell Crow DFW Development, Inc., a Delaware corporation</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its sole general partner</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its:</p></td><td colspan="3" style="vertical-align:bottom;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Executive Vice President</p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Telephone:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="background:#000000;">(214) 979-6180</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:89.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Facsimile:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="background:#000000;">(214) 979-6355</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:89.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Executed At:</p></td><td colspan="2" style="vertical-align:bottom;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">2200 Ross Avenue, Suite 3700</p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">On:</p></td><td colspan="4" style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td colspan="2" style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">EXECUTED BY AGENT this _________ day of _________, 1999.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">FOBARE COMMERCIAL</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td style="vertical-align:bottom;width:47.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Title:</p></td><td style="vertical-align:bottom;width:47.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit E</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Commission with Respect to this Amendment Only</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Capitalized terms used in this exhibit which are not defined in the Amendment to which this exhibit is attached shall have the same meanings attributed to such terms in the Commission Agreement. &#160;Upon the execution of the Amendment by Landlord and Tenant, Agent shall be paid, in full, the commission due to Agent by reason of the existence of the Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The foregoing timing of the payment due to Agent applies only with respect to the Amendment to which this exhibit is attached and Landlord reserves the right to insist hereafter upon strict compliance with the terms of the Commission Agreement. &#160;The terms of the Commission Agreement shall remain in full force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;">First Amendment to Lease &#8211; Page 16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMMISSION AGREEMENT BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOBARE COMMERCIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS CONTRACT OF AGREEMENT</b>, entered into by and between <b style="font-weight:bold;">Walstib, L.P.,</b> a <b style="font-weight:bold;">Delaware limited partnership</b> hereinafter referred to as &#8220;Owner,&#8221; and <b style="font-weight:bold;">Fobare Commercial</b> hereinafter referred to as &#8220;Agent.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">W I T N E S S E T H:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Agent has assisted or is assisting Owner in negotiating and consummating a Lease Agreement between Owner and <b style="font-weight:bold;">PharmaFab, Inc.,</b> hereinafter referred to as &#8220;Prospect,&#8221; covering an approximate 44,000 square foot facility located at (in) <b style="font-weight:bold;">360 Riverside Business Park (Building&#160;B)</b> (the &#8220;Project&#8221;) for a term of 84 months beginning <b style="font-weight:bold;">June 1, 1999</b> with rentals being due to Owner as therein provided, to which lease reference is hereby made, and the same is hereby incorporated herein for all purposes; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Agent and Owner hereby and herein desire to agree upon a commission to which Agent shall be entitled for such services based on rentals actually received by Owner, as hereinafter provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is mutually agreed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. REGISTRATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Registration of the Prospect requires either (a) this Registration Letter from Agent naming the Prospect and a face-to-face meeting with a decision maker representing the Prospect or (b) a duly executed and authorized letter from the Prospect designating Agent as its exclusive Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>This Registration and Agreement is effective for sixty (60) days after the date hereof and may be extended for another sixty (60) days if the Agent shows evidence satisfactory to Owner that Agent is actively pursuing the execution of a Lease Agreement between Owner and the Prospect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>If at any time following the registration of the Prospect pursuant to (a) or (b) above, Agent loses control of the Prospect as evidenced by a letter from the Prospect designating some other Agent as the Prospect&#8217;s Agent, then upon notification of such event to Agent by Owner, this Registration Letter and Commission Agreement shall become null and void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Agent has satisfied the aforesaid initial registration requirements of Owner and accordingly Owner agrees to recognize PharmaFab, Inc. as Agent&#8217;s Prospect and agrees to pay a commission to Agent if a lease of space of the Project is consummated between the Prospect and Owner during the term of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. CASH COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Primary Term</u>. &#160;(1) If Agent requests a front-end cash-out of commission obligation hereunder, and if Prospect in Owner&#8217;s opinion has sufficient credit to meet all of Prospect&#8217;s obligations under the lease, Owner shall, as set forth in d. below, pay Agent as the Commission hereunder four and one-half percent (4-1/2%) of the total Rentals as hereafter payable for the entire initial term of the lease up to ten (10) years. &#160;Financial statements and other information necessary to determine credit risk are to be provided by Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal</u>. &#160;If Agent requests a front-end cash-out of the commission obligation hereunder with respect to a renewal option contained in the lease which has been duly exercised, and if Prospect in Owner&#8217;s opinion then has sufficient credit to meet all of Prospect&#8217;s obligations under the lease during the renewal term, Owner shall pay Agent the then prevailing market commission for a renewal, based upon the total Rentals payable for the renewal term, up to ten (10) years, providing that Agent is instrumental in assisting Owner in obtaining such renewal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion</u>. &#160;If Agent requests a front-end cash-out of the commission obligation hereunder with respect to an Option to Expand contained in the Lease Agreement which has been duly exercised prior to the termination of the Lease Agreement and if Prospect in Owner&#8217;s opinion then has sufficient credit to meet all of Prospect&#8217;s obligations under the lease as so expanded, Owner may pay Agent a commission of four and one-half percent (4-1/2%) of the total Rentals payable for the expansion space providing that Agent is instrumental in assisting Owner in obtaining such expansion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of Payment</u>. &#160;(1) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Term</u>. &#160;One-half (1/2) upon execution of the lease by Owner and Prospect, delivery thereof to both parties and receipt by Owner of first full month&#8217;s rent and any security deposit; and the balance upon occupancy by Prospect, delivery to Owner of satisfactory commencement letter executed by Prospect. &#160;In addition, no payment shall be payable until contingencies relating to the actual consummation or cancellation of the agreement by Prospect (including but not limited to contingencies regarding zoning, restrictive covenants, permitting, plan approvals and finish cost limits) are satisfactorily eliminated by the parties to the Lease Agreement. &#160;In addition for Build-to-Suit facilities no commission will be payable until Owner has received interim financing for the project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal Term</u>. &#160;If a renewal commission is due pursuant to Paragraph 2.b. above, the commission shall be payable upon written exercise of the renewal option and payment of the rental for the first full month of the renewal term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cancellation</u>. &#160;Notwithstanding the above provisions, where Prospect individually or Prospect and Owner, jointly, have the right to cancel the lease, a commission shall only be paid to Agent for the period up to the date on which the lease may be canceled. &#160;If the lease is not then canceled, Owner shall pay the balance of the commission due for the remainder of the period covered under the lease at the time the Prospect&#8217;s right to cancel expires, provided Prospect remains in occupancy of the space and is not in default under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">f.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">New Lease</u>. &#160;In the event Agent furnishes Owner written authorization to represent Prospect and negotiates and consummates a new Lease Agreement between Owner and Prospect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">covering an expansion or relocation facility, Owner shall pay Agent a commission based on the above provisions for the expansion or relocation premises, but Agent&#8217;s commission under the original Lease Agreement shall be terminated as of the commencement date of the new Lease Agreement and any unearned commission paid to the Agent with respect to the original Lease Agreement shall be netted out of commission payable for the new Lease Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. GENERAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale of Premises</u>. &#160;In the event of sale of the premises and assignment of the Lease Agreement by Owner, Owner agrees to provide a copy of this Commission Agreement to the Purchaser and to use its reasonable efforts to obtain from the purchaser or assignee an agreement whereby such purchaser or assignee assumes the obligation to pay to Agent under the terms and provisions hereof, and Owner shall be released from all liability for all future payments of commissions as may thereafter become due under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;&#8220;Rentals&#8221; shall mean the base monthly cash rent, and shall not include any amounts payable by Prospect to Owner for reimbursement of costs and expenses passed through to Prospect, such as real estate taxes, insurance premiums, utilities, janitorial and common area maintenance, or any operating expense escalations or amortization of tenant finish costs above Owner&#8217;s building standard allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition rentals shall be reduced by the cost of any lease takeover obligations to Owner, free rent or other considerations by Owner to the benefit of Prospect, whether agreed to in the Lease Agreement or other written instrument. &#160;Rentals for the purposes of this Commission Agreement, does not include that portion of Prospect&#8217;s payments that relate to costs to Owner that are separately amortized because the cost of such improvements are above Owner&#8217;s building standard allowance, relate to extraordinary items or otherwise would not be considered within the ordinary course of rental payments in an industrial facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u>. &#160;Except as otherwise herein provided, all rights and obligations hereunder shall be binding upon and inure to the benefit of the successors, assigns, heirs, administrators and personal representatives of the Owner and Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. &#160;Except as expressly herein provided, Owner shall have no obligation to pay, and Agent shall have no right to receive, any commission or other payment with respect to the Lease or any transactions between Owner and Prospect, unless such right or obligation is set forth in writing and signed by Owner and Prospect after the date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance</u>. &#160;This agreement is intended to be an offer, and if not accepted and returned to Owner in writing within three business days from the date hereon, it is hereby withdrawn. &#160;If not received by said date, this offer is null and void. &#160;This Agreement is not valid unless fully signed by both Owner and Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">f.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Owner&#8217;s Interest</u>. &#160;Broker shall look solely to Owner&#8217;s interest in the Project for the recovery of any judgement against Owner for failure to perform under this Agreement, and Owner (and Its partners, shareholders and agents) shall not be personally liable for any such judgement therefore.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EXECUTED BY OWNER this _________ day of ___________, 1999.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:48.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP</b></p></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">WALSTIB Venture, L.L.C., a Delaware limited liability company</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its sole general partner</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">TCDFW Development, Ltd., a Texas limited partnership</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its Administrative Member</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Trammell Crow DFW Development, Inc., a Delaware corporation</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its sole general partner</p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Its:</p></td><td colspan="3" style="vertical-align:bottom;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Executive Vice President</p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Telephone:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="background:#000000;">(214) 979-6180</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:89.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Facsimile:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="background:#000000;">(214) 979-6355</font></p></td><td colspan="2" style="vertical-align:bottom;width:48.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:89.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Executed At:</p></td><td colspan="2" style="vertical-align:bottom;width:41.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">2200 Ross Avenue, Suite 3700</p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="6" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">On:</p></td><td colspan="4" style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td colspan="2" style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">EXECUTED BY AGENT this _________ day of _________, 1999.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><b style="font-weight:bold;">FOBARE COMMERCIAL</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">By:</p></td><td style="vertical-align:bottom;width:47.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;">Title:</p></td><td style="vertical-align:bottom;width:47.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 1pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>7
<FILENAME>aytu-20230630xex10d50.htm
<DESCRIPTION>EX-10.50
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.50</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">INTERIM AMENDMENT TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This INTERIM AMENDMENT TO LEASE (this &#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;) is made and entered into as of September 4, 2003, by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (hereinafter referred to as &#8220;<font style="font-style:italic;font-weight:bold;">Landlord</font>&#8221;), and PFAB LP, a Texas limited partnership (hereinafter referred to as &#8220;<font style="font-style:italic;font-weight:bold;">Tenant</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BACKGROUND:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Walstib, L.P. &#160;(&#8220;<font style="font-style:italic;font-weight:bold;">Walstib</font>&#8221;) and PharmaFab, Inc., a Texas corporation (&#8220;<font style="font-style:italic;font-weight:bold;">PharmaFab</font>&#8221;), entered into that certain Commercial Lease Agreement dated on or about June 29, 1999, and having a Commencement Date as of October 25, 1999 (as same may have been amended and assigned, the &#8220;<font style="font-style:italic;font-weight:bold;">Lease</font>&#8221;) regarding certain premises (the &#8220;<font style="font-style:italic;font-weight:bold;">Premises</font>&#8221;) located at 360 Riverside Business Center in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to that certain Assignment of Lease dated on or about June 29, 1999, to be effective as of July 1, 1999, PharmaFab assigned its right, title and interest in the Lease to Tenant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Walstib and Tenant amended the Lease pursuant to that certain First Amendment to Lease dated effective as of September 1, 2002 (the &#8220;<font style="font-style:italic;font-weight:bold;">First Amendment</font>&#8221;) pursuant to which the Premises were expended from approximately 44,000 square feet of space in Suite 100 of Building B of the industrial Center (the &#8220;<font style="font-style:italic;font-weight:bold;">Suite 100 Space&#8221;</font>) to include approximately 50,000 additional square feet in Suite 100 of Building A of the Industrial Canter (the &#8220;<font style="font-style:italic;font-weight:bold;">Building A Space</font>&#8221;) and Bruce K. Montgomery was released from his Guaranty of Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord succeeded to the interest of Walstib under the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant are currently negotiating a Second Amendment to Lease (the &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment</font>&#8221;) relocating a portion of the Premises.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant desire to amend the Lease on an interim basis, to allow entry by Tenant into the space located at 2940 North Highway 360, Grand Prairie, Texas (the &#8220;<font style="font-style:italic;font-weight:bold;">Expansion Premises</font>&#8221;) for the purpose of installing Tenant&#8217;s equipment and telecommunications equipment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u>. All capitalized terms which are not otherwise defined herein shall have the meaning set forth in the Lease, as amended hereby.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion</u>. As of September 4, 2003 (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Date&#8217;&#8217;</font>, the term &#8220;Premises&#8221; as used In the Lease shall include the Expansion Premises, Tenant&#8217;s occupancy of the Expansion Premises is under all terms and conditions of the Lease, as modified hereby.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term - Expansion Premises</u>. The term of the Lease with regard to the Expansion Premises is month to month (&#8216;<font style="font-style:italic;font-weight:bold;">Temporary Expansion Term</font>&#8221;). &#160;The Temporary Expansion Term shall expire upon the earlier of (i) full execution of the Second Amendment and fulfillment of the contingency set forth therein, or (ii) 15 days after written notice of termination by either party to the other party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rental</u>. The Rent for the Expansion Premises is $1,000 per month, payable as provided in the Lease. &#160;Tenant shall not be responsible for payment of Tenant&#8217;s Share of Operating Expenses with regard to the Expansion Premises during the Temporary Expansion Term. &#160;Rent for any partial calendar month shall be prorated on a per diem basis.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance of Premises</u>. Tenant accepts the Expansion Premises in their &#8220;AS IS, WHERE IS&#8221; condition, and Landlord has no obligation to Improve, repair, restore, or refurbish the Premises. &#160;Tenant&#8217;s occupancy of any portion of the Premises is conclusive evidence that Tenant: &#160;(A) accepts such portion of the Premises as suitable for the purposes for which they are leased; (B) accepts such portion of the Premises as being in a good and satisfactory condition; (C) waives any defects in the Premises; and (D) having been provided an opportunity to inspect and measure each portion of the Premises, agrees that the square footage numbers specified in this Amendment are accurate, binding, and conclusive for all purposes. &#160;Neither Landlord nor any other Landlord Entity has made, and Tenant waives, any express or implied representation or warranty with respect to the Premises or any other portion of the Industrial Center including, without limitation, any representation or warranty with respect to the suitability or fitness of the Premises or any other portion of the Industrial Center for the conduct of Tenant&#8217;s business. &#160;Landlord expressly recognizes, covenants and agrees that notwithstanding the terms of this Paragraph 4 or Paragraph 7, to the contrary, nothing in this Paragraph 4 relieves Landlord of any of its obligations pursuant to the Lease. &#160;Including, without limitation, Paragraph 7.2 of the Lease and Paragraph 16.17 of the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokerage Mutual Indemnities</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Tenant warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than Trammel Crow Company and CB Richard Ellis (collectively, &#8220;<font style="font-style:italic;font-weight:bold;">Brokers</font>&#8221;). &#160;Tenant shall indemnify, defend, and hold Landlord harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent other than Brokers claiming by, through, or under Tenant with respect to this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Landlord Warrants that it has had no dealing; with any broker or agent in connection with the negotiation or execution of this Amendment other than Brokers. &#160;Landlord</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shall indemnify, defend, and hold Tenant harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent, including Brokers, claiming by, through or under Landlord with respect to this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>Any brokerage commissions payable to Brokers are payable by Landlord pursuant to the terms of separate agreements between Landlord and Broker.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Offsets</u>. Tenant hereby represents to Landlord that to the best of Tenant&#8217;s knowledge, as of the date of this Amendment. &#160;Tenant has no defenses to or offsets against the full and timely payment and performance of each and every covenant and obligation required to be performed by Tenant under the terms of the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts</u>. The terms of this Amendment prevail if there is a conflict with the terms of the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. The headings or captions of the paragraphs in this Amendment are for convenience only and shall not act and shall not be implied to act to limit or expand the construction and intent of the contents of the respective Paragraph.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u>. This Amendment is binding upon and shall inure to the benefit of the parties and their respective successors and assigns (but this reference to assigns shall not be deemed to act as a consent to an assignment by Tenant).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification</u>. The Lease, as amended and modified hereby, is ratified and confirmed by the parties as being in full force and effect.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EXECUTED as of the date first above written.</p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101%;"><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TEACHERS INSURANCE AND ANNUITY|</b></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ASSOCIATION OF AMERICA,</b></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a New York Corporation</p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:45.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:36.3%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As Its:</p></td><td style="vertical-align:top;width:36.3%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PFAB LP,</b></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a Texas limited partnership</p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PharmaFab Texas, LLC,</p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">its general partner</p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By<b style="font-weight:bold;">:</b></p></td><td colspan="2" style="vertical-align:top;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Print Name: &#160;Darlene M. Ryan</p></td></tr><tr><td style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:45.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As Its: &#160;Sole Manager</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT &#8220;A&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">to Interim Amendment to Lease by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Teachers Insurance and Annuity Association of America, as Landlord</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PFAB LP, as Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">FLOOR PLAN OF THE EXPANSION PREMISES</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.51
<SEQUENCE>8
<FILENAME>aytu-20230630xex10d51.htm
<DESCRIPTION>EX-10.51
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.51</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIRD AMENDMENT TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This THIRD AMENDMENT TO LEASE (this <font style="font-style:italic;font-weight:bold;">&#8220;Amendment&#8221;</font>) is made and entered into as of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">_______________</u>, 2003, by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (hereinafter referred to as &#8220;<font style="font-style:italic;font-weight:bold;">Landlord&#8221;</font>), and PFAB LP, a Texas limited partnership (hereinafter referred to as <font style="font-style:italic;font-weight:bold;">&#8220;Tenant&#8221;</font>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BACKGROUND:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Walstib, L.P. &#160;(</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Walstib&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) and PharmaFab, Inc., a Texas corporation (</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;PharmaFab&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), entered into that certain Commercial Lease Agreement dated on or about June 29, 1999, and having a Commencement Date as of October 25, 1999 (as same may have been amended and assigned, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Lease&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) regarding certain premises (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Premises&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) located at 360 Riverside Business Center in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to that certain Assignment of Lease dated on or about June 29, 1999, to be effective as of July 1, 1999, PharmaFab assigned its right, title and interest in the Lease to Tenant.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Walstib and Tenant amended the Lease pursuant to that certain First Amendment to Lease dated effective as of September 1, 2002 (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;First Amendment&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) pursuant to which the Premises were expanded from approximately 44,000 square feet of space in Suite 100 of Building B of the Industrial Center (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Suite 100 Space&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) to include approximately 50,000 additional square feet in Suite 100 of Building A of the Industrial Center (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Building A Space&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) and Bruce K. Montgomery was released from his Guaranty of Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord succeeded to the interest of Walstib under the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord and Tenant amended the Lease on a short term basis pursuant to an Interim Amendment to Lease, dated September 4, 2003.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">F.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord and Tenant desire to further amend the Lease as hereinafter set forth to include, without limitation, the release of Darlene M. Ryan from any guaranty of the Lease.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;All capitalized terms which are not otherwise defined herein shall have the meaning set forth in the Lease, as amended hereby.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relocation</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;As of the respective Effective Dates set forth below, the Building A Space will be relocated to 2940 N. Highway 360, Building B, Suite 400 (</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Suite 400 Space&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) consisting of approximately 20,170 square feet of space and 2940 N. Highway 360, Building B, Suite 200 consisting of approximately 33,112 square feet of space (</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Suite 200 Space&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) for a total of approximately 53,282 square feet of space.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Lease will terminate as to the Building A Space [except with regard to liabilities due and outstanding as of the Suite 400 Effective Date (hereinafter defined)] and Tenant will relocate from the Building A Space to the Suite 400 Space on September 9, 2003 (the <font style="font-style:italic;font-weight:bold;">&#8220;Suite 400 Effective Date&#8221;</font>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Upon vacating the Building A Space, Tenant shall surrender such space in accordance with the terms of the Lease, as though the Lease had expired with respect to the Building A Space. &#160;Tenant is solely responsible for all costs of relocating from the Building A Space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Subject to the satisfaction of the contengency set forth in Paragraph 10 of this Amendment, effective 5 days after the date SmartMail, LLC (<font style="font-style:italic;font-weight:bold;">&#8220;SmartMail&#8221;</font>), the current tenant of Suite 200 of Building B, vacates Suite 200 (the <font style="font-style:italic;font-weight:bold;">&#8220;Suite 200 Effective Date&#8221;</font>), the Premises shall be deemed to include the Suite 200 Space. &#160;From and after the Suite 200 Effective Date, the term <font style="font-style:italic;font-weight:bold;">&#8220;Premises&#8221;</font> shall be deemed to refer to the Suite 100 Space, the Suite 200 Space and the Suite 400 Space for a total of approximately 97,282 square feet of space, all as more fully described on <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment A</b> hereto.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Lease, as amended hereby shall expire on November 30, 2010 (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Expiration Date&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rental</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon the Suite 400 Effective Date, monthly Base Rent is payable as follows:</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Suite 400 Space</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;From the Suite 400 Effective Date through the date prior to the Suite 200 Effective Date, Monthly Base Rent for the Suite 400 Space is $19,867.45. &#160;From the Suite 200 Effective Date until May 9, 2004, Base Rental for the Suite 400 Space is abated. &#160;Thereafter, Monthly Base Rental for the Suite 400 Space is as follows:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:211.7pt;text-indent:-211.7pt;margin:0pt 0pt 0pt 72pt;">5/9/04 - 4/30/09<font style="display:inline-block;width:75.21pt;"></font>$16,505.78</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:211.7pt;text-indent:-211.7pt;margin:0pt 0pt 0pt 72pt;">5/1/03 - 11/30/10<font style="display:inline-block;width:70.21pt;"></font>$18,774.91</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Suite 200 Space</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;From the Suite 200 Effective Date through the date prior to the fifth anniversary thereof, Monthly Base Rental for the Suite 200 Space is $21,633.17. &#160;From and after the fifth anniversary of the Suite 200 Effective Date through the Expiration Date, the Monthly Base Rental for the Suite 200 Space is $23,702.67.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Suite 100 Space</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Monthly Base Rental for the Suite 100 Space is as follows:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:36.36%;"><tr><td style="vertical-align:bottom;width:68.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9/1/03 - 10/31/04</p></td><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$28,930.00</p></td></tr><tr><td style="vertical-align:bottom;width:68.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/1/04 - 10/31/05</p></td><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$35,126.67</p></td></tr><tr><td style="vertical-align:bottom;width:68.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/1/05 - 11/30/10</p></td><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$36,593.33</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Landlord and Tenant agree to execute and deliver a memorandum setting forth the actual dates and rental rates once such dates are determined.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant shall be liable for Tenant&#8217;s Share of Operating Expenses for each portion of the Premises on the applicable Effective Date for such portion, payable as provided in the Lease. &#160;Tenant&#8217;s Share of Operating Expenses for the Industrial Park and Building is determined on a per square foot basis by dividing the number of square feet in the Premises (or applicable portion thereof) by the total number of square feet in the Industrial Park or Building, as applicable. &#160;From the Suite 400 Effective Date through the date prior to the Suite 200 Effective Date, Landlord estimates Tenant&#8217;s Share of Operating Expenses as follows:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Industrial Park<font style="display:inline-block;width:48.84pt;"></font>29.90%</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Building<font style="display:inline-block;width:73pt;"></font>56.49%</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Upon the Suite 200 Effective Date, Landlord estimates Tenant&#8217;s Share of Operating Expenses as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Industrial Park<font style="display:inline-block;width:48.84pt;"></font>45.33%</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Building<font style="display:inline-block;width:73pt;"></font>85.64%</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If during the Lease Term, Suite 300 of Building B is available for lease and Landlord enters into a letter of intent with a third party covering all of the essential terms (collectively, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Third Party Terms&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) for any of such space (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;First Refusal Space&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), then Landlord shall deliver a notice to Tenant (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;First Refusal Notice&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) offering to lease the First Refusal Space to Tenant under the Third Party Terms (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;ROFR Terms&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). &#160;As used in this Paragraph 6 only, the term available for lease means that the First Refusal Space is neither: &#160;(i) subject to any rights of third parties existing as of the date of this Amendment, including, without limitation, previously granted rights of first notice, expansion rights, extension rights, options to lease, or other previously granted rights, nor (ii) subject to renewal by its current tenant, Statewide, whether or not such renewal is pursuant to an option to renew set forth in its lease as of the date of this Amendment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tenant may elect to lease the First Refusal Space under the ROFR Terms by delivering a notice (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Response Notice&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) to Landlord within 5 business days after the date Tenant receives the First Refusal Notice. &#160;If (i) Landlord does not receive the Response Notice within the 5 business day period or (ii) in the Response Notice Tenant elects not to lease the First Refusal Space under the ROFR Terms, then Tenant is deemed to waive its right to lease the First Refusal Space and Tenant has no further rights under this Paragraph 6. &#160;Notwithstanding the foregoing, however, if Landlord does not then execute a lease for the First Refusal Space with</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">any third party, under economic terms no more than 5% different from those set forth in the Third Party Terms, then this Paragraph 6, and the parties&#8217; rights and obligations hereunder, will be reinstated in their entirety.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Tenant timely delivers a Response Notice electing to lease First Refusal Space under the ROFR Terms, then Landlord shall promptly prepare, and deliver to Tenant an amendment to the Lease adding the First Refusal Space to the Premises upon the ROFR Terms, which amendment will be in a form substantially similar to this Amendment. &#160;Landlord and Tenant shall execute and deliver such amendment within 5 business days thereafter.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord is not obligated to offer the First Refusal Space to Tenant, and Tenant may not exercise its option to lease the First Refusal Space, if Tenant is in default under the Lease at the time Landlord would otherwise be obligated to give notice to Tenant under this Paragraph.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Right of First Offer set forth in Section 7 of the First Amendment is hereby deleted and shall be of no further force and effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit; Release of Guaranties</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon execution of this Amendment, Tenant shall deposit the amount of $48,706.56 as in increase in the Security Deposit currently held by Landlord under Section 5 of the Lease for a total Security Deposit of $86,706.57. &#160;The Security Deposit shall be held and applied by Landlord as provided in the Lease. &#160;Upon execution of this Amendment by Landlord, Darlene M. Ryan is and shall automatically without any further action be deemed released from and shall have no further liability pursuant to the guaranties previously executed by her in connection with the Lease, including without limitation, that certain Guaranty of Lease dated June 29, 1999 and that certain Guaranty of Lease dated effective September 1, 2002. &#160;It is further recognized and agreed that pursuant to the terms of the First Amendment, Bruce K. Montgomery, was previously released from any and all guaranties previously executed by him in connection with the Lease, including, without limitation, that certain Guaranty of Lease Dated June 29, 1999.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance of Premises</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant accepts the Premises including Suites 200 and 400 in their &#8220;AS IS, WHERE IS&#8221; condition, and Landlord, subject to its obligations under </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment B</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, has no obligation to improve, repair, restore, or refurbish the Premises. &#160;Tenant&#8217;s occupancy of any portion of the Premises is conclusive evidence that Tenant: &#160;(A) accepts such portion of the Premises as suitable for the purposes for which they are leased; (B) accepts such portion of the Premises as being in a good and satisfactory condition; (C) waives any defects in the Premises; and (D) having been provided an opportunity to inspect and measure each portion of the Premises, agrees that the square footage numbers specified in this Amendment are accurate, binding, and conclusive for all purposes. &#160;Neither Landlord nor any other Landlord Entity has made, and Tenant waives, any express or implied representation or warranty with respect to the Premises or any other portion of the Industrial Center including, without limitation, any representation or warranty with respect to the suitability or fitness of the Premises or any other portion of the Industrial Center for the conduct of Tenant&#8217;s business. &#160;Landlord expressly recognizes, covenants and agrees that notwithstanding the terms of this Paragraph 8 or Paragraph 13, to the contrary, nothing in this Paragraph 8 relieves Landlord of any of its obligations pursuant to the Lease, including, without limitation, Paragraph 7.2 of the Lease and Paragraph 16.17 of the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Finish-Out of Premises</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Landlord agrees to provide Tenant with a finish-out allowance of $301,036 for costs incurred in connection with renovations to the Premises. &#160;Tenant hereby waives any rights it may have to approximately $250,000 in additional tenant improvements to be made to the Building A Space. &#160;Tenant must perform all Tenant Finish Work in accordance with the terms of the Lease and </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment B</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to this Amendment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contingency</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Suite 200 Space is currently subject to a lease dated February 25, 2000 by and between Landlord, as successor in interest to Walstib and SmartMail (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;SmartMail Lease&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) The effectiveness of this Amendment is contingent on Landlord executing an amendment to the SmartMail Lease in form and substance satisfactory to Landlord, relocating SmartMail to the Building A Space. &#160;If Landlord and SmartMail fail to so amend the SmartMail Lease on or before October 2, 2003, Landlord shall notify Tenant in writing and this Amendment shall be terminated and of no further force and effect.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokerage; Mutual Indemnities</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tenant warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than Trammell Crow Company and CB Richard Ellis (collectively, </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Brokers&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). &#160;Tenant shall indemnify, defend, and hold Landlord harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent other than Brokers claiming by, through, or under Tenant with respect to this Amendment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than Brokers. &#160;Landlord shall indemnify, defend, and hold Tenant harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent, including Brokers, claiming by, through or under Landlord with respect to this Amendment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any brokerage commissions payable to Brokers are payable by Landlord pursuant to the terms of separate agreements between Landlord and Broker.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Offsets</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant hereby represents to Landlord that to the best of Tenant&#8217;s knowledge, as of the date of this Amendment, Tenant has no defenses to or offsets against the full and timely payment and performance of each and every covenant and obligation required to be performed by Tenant under the terms of the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The terms of this Amendment prevail if there is a conflict with the terms of the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">14.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The headings or captions of the paragraphs in this Amendment are for convenience only and shall not act and shall not be implied to act to limit or expand the construction and intent of the contents of the respective paragraph.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;This Amendment is binding upon and shall inure to the benefit of the parties and their respective successors and assigns (but this reference to assigns shall not be deemed to act as a consent to an assignment by Tenant).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Lease, as amended and modified hereby, is ratified and confirmed by the parties as being in full force and effect.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement of Option to Extend</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Landlord recognizes, covenants and agrees that the Option to Extend set forth in Paragraph 8 of the First Amendment remains in full force and effect and applies and shall continue to apply to the Premises as defined herein.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">EXECUTED as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA,</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a New York corporation</p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:50.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As Its:</p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TENANT:</b></p></td><td style="vertical-align:bottom;width:40.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:bottom;width:12.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PFAB LP,</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Texas limited partnership</p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:50.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PharmaFab Texas, LLC,</p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">its general partner</p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:47.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Darlene M. Ryan</p></td></tr><tr><td style="vertical-align:bottom;width:46.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As Its:</p></td><td style="vertical-align:bottom;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sole Manager</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT &#8220;A&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">to Third Amendment to Lease by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Teachers Insurance and Annuity Association of America, as Landlord,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PFAB LP, as Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">FLOOR PLAN OF THE PREMISES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">to Third Amendment to Lease by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Teachers Insurance and Annuity Association of America, as Landlord,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PFAB LP, as Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">TENANT FINISH CONSTRUCTION</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plans and Specifications</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: &#160;Tenant shall submit to Landlord at least 30 days prior to commencement of any remodeling in the Premises complete initial plans and specifications (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Initial Construction Documents&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) for the remodeling of the Premises. &#160;The Initial Construction Documents must include, without limitation:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">General Notes Sheet</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Demolition Plan</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New Construction Plan with details of all new improvements</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Finishes Plan</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Electrical, Mechanical and Plumbing Plan</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Within 15 days after receipt of the Initial Construction Documents, Landlord shall deliver to Tenant a notice either approving or disapproving them. &#160;Any disapproval must specify in reasonable detail the reasons for the disapproval. &#160;If Tenant does not receive a notice from Landlord disapproving the Initial Construction Documents within the 15-day period, Landlord is deemed to approve the Initial Construction Documents. &#160;If Landlord disapproves the Initial Construction Documents, Tenant shall revise them to conform to Landlord&#8217;s objections and deliver complete copies of the revised Initial Construction Documents to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The approved Initial Construction Documents are referred to as the <font style="font-style:italic;font-weight:bold;">&#8220;Construction Documents&#8221;</font> and all work to be performed by Tenant pursuant to the Construction Documents is referred to as the <font style="font-style:italic;font-weight:bold;">&#8220;Tenant Finish Work&#8221;</font><i style="font-style:italic;">. &#160;</i>Landlord&#8217;s approval of the Construction Documents is not a warranty that the Construction Documents comply with Applicable Laws.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Finish Work</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant shall pay the Actual Cost (defined below) of all Tenant Finish Work. &#160;Within 45 days of completion of the Tenant Finish Work, and presentation to Landlord of (i) receipts and invoices marked &#8220;paid&#8221; (ii) lien releases executed by all parties performing Tenant Finish Work, including without limitation, the general contractors,</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">materialmen and other vendors performing any portion of the Tenant Finish Work or supplying any materials used in connection therewith, and (iii) the Architect&#8217;s Certificate of Substantial Completion, Landlord will reimburse Tenant for a portion of the Tenant Finish Work, up to the amount of $301,036.00 (the <font style="font-style:italic;font-weight:bold;">&#8220;Work Allowance&#8221;</font>). &#160;The term <font style="font-style:italic;font-weight:bold;">&#8220;Actual Cost&#8221;</font> means the cost of all labor and materials and all hard and soft costs relating to the Tenant Finish Work, together with the Building Service Fee of 4% of all hard costs of the Tenant Finish Work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Tenant, at its cost and risk (subject to reimbursement of the Work Allowance by Landlord), shall construct or cause to be constructed the Tenant Finish Work in substantial accordance with the Construction Documents. &#160;Tenant shall allow Landlord access to the Premises at all times to inspect the Tenant Finish Work. &#160;Landlord has no obligation to inspect the Tenant Finish Work. &#160;No inspection by Landlord of the Tenant Finish Work is a warranty that the Tenant Finish Work complies with the Construction Documents or any Applicable Laws.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">General.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any changes to the Construction Documents must first be submitted to Landlord for review and approval prior to the work reflected in such amended Plans being undertaken by Tenant.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Workmanship and materials to be used in the Tenant Finish Work shall be of best quality. &#160;Any approval by Landlord of the Plans shall not in any way constitute a representation or warranty of Landlord as to the adequacy of sufficiency of the Plans; such approval shall merely be the consent of Landlord as may be required hereunder in connection with the Tenant Finish Work in accordance with the Plans under the terms of the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tenant shall perform the Tenant Finish Work consistent with Building Rules and Regulations, in a manner to minimize noise and other interference with tenants of the Industrial Center and shall remove all trash and debris from the Premises on a daily basis.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upon completion of the construction of Tenant Finish Work, Tenant shall promptly restore any area of the Industrial Center damaged as a result of Tenant&#8217;s construction of the Tenant Finish Work to the condition existing prior to the commencement of such construction.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All contractors, subcontractors, suppliers, service providers, moving companies, and others performing work of any type for Tenant in the Industrial Center shall carry the insurance listed below with companies acceptable to Landlord:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Commercial General Liability Insurance (ISO Form CG00010798 or its equivalent), written on an &#8220;occurrence&#8221; basis, with minimum limits of $1,000,000 per occurrence; $3,000,000 general aggregate for bodily injury, personal injury and property damage. &#160;If required by Landlord, liquor liability coverage will be included.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Workers&#8217; Compensation insurance with statutory limits and Employers Liability with a $1,000,000 per accident limit for bodily injury or disease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Automobile Liability covering all owned, non-owned and hired vehicles with a $1,000,000 per accident limit for bodily injury and property damage.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Tenant shall deliver to Landlord, do Trammell Crow Company (<font style="font-style:italic;font-weight:bold;">&#8220;Manager&#8221;</font>), 2200 Ross Avenue, Suite 3700, Dallas, Texas 75201, Attention: Betty Venator, duly executed certificates of all insurance (Acord Form 27, modified as necessary to cover liability insurance) and additional insured endorsements reasonably satisfactory to Landlord (on ISO Form 2026 or its equivalent, without modification) prior to entering the Premises and annually thereafter, reflecting evidence of required coverages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All insurance required under hereunder (i) shall be primary and non-contributory (ii) shall provide for severability of interests, (iii) shall be issued by insurers, licensed to do business in the state in which the Premises are located and which are rated A:IX or better by Best&#8217;s Key Rating Guide, (iv) shall be endorsed to include Landlord and such other persons or entities as Landlord may from time to time designate, as additional insureds without restriction (Commercial General Liability only), and (v) shall be endorsed to provide at least 30-days prior notification of cancellation or material change in coverage to said additional insureds. &#160;Each policy must be endorsed to waive any rights of subrogation against Landlord, its officers, directors, employees, agents, partners and assigns.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.52
<SEQUENCE>9
<FILENAME>aytu-20230630xex10d52.htm
<DESCRIPTION>EX-10.52
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.52</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FOURTH AMENDMENT TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This FOURTH AMENDMENT TO LEASE (this <b style="font-weight:bold;">Amendment</b>) is made and entered into as of June ___, 2009 (the <b style="font-weight:bold;">Execution Date</b>), to be effective as of May 1, 2009 (the <b style="font-weight:bold;">Effective Date</b>), by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (<b style="font-weight:bold;">Landlord</b>), and NEOS THERAPEUTICS, LP, a Texas limited partnership, formerly known as PFAB LP (<b style="font-weight:bold;">Tenant</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BACKGROUND:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Walstib, L.P., a Delaware limited partnership (</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Walstib</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), and PharmaFab, Inc., a Texas corporation (</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">PharmaFab</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">), entered into that certain Commercial Lease Agreement dated on or about June 29, 1999, and having a Commencement Date as of October 25, 1999 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Original Lease</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) regarding certain premises containing approximately 44,000 square feet in Suite 100 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Original Premises</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) of Building B (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Building</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) in the industrial complex commonly known as 360 Riverside Business Center located at 2940 N. Highway 360 in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Original Lease (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Industrial Center</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to that certain Assignment of Lease dated on or about June 29, 1999, to be effective as of July 1, 1999, PharmaFab assigned its right, title and interest in the Original Lease to PFAB LP, a Texas limited partnership (</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">PLP</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Walstib and PLP amended the Original Lease pursuant to that certain First Amendment to Lease dated effective as of September 1, 2002 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">First Amendment</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) pursuant to which (i) the Original Premises were expanded to include approximately 50,000 additional square feet in Suite 100 of Building A of the Industrial Center (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Building A Premises</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) and (ii) Bruce K. Montgomery was released from his Guaranty of Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord succeeded to the interest of Walstib under the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord and PLP further amended the Original Lease on a short term basis pursuant to an Interim Amendment to Lease dated September 4, 2003 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Second Amendment</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">F.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord and PLP further amended the Original Lease pursuant to that certain Third Amendment to Lease dated October 1, 2003 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Third Amendment</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) pursuant to which (i) the Building A Premises were relocated to Suites 200 and 400 of the Building such that the Premises (as defined in the Original Lease) consist of (1) approximately 77,112 square feet of space in Suites 100 and 200 of the Building (collectively, the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Renewal Premises</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) and (2) approximately 20,170 square feet of space in Suite 400 of the Building (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Suite 400 Space</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) and (ii) Darlene M. Ryan was released from her Guaranty of Lease. &#160;The Original Lease, as amended by the First Amendment, Second Amendment and Third Amendment, is referred to herein as the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Lease</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">G.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June 22, 2007, Tenant changed its name to Neos Therapeutics, LP.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">H.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Landlord and Tenant desire to further amend the Lease to extend the Term of the Lease for the Renewal Premises and modify certain provisions of the Lease as hereinafter set forth, but not otherwise.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;All capitalized terms which are not otherwise defined herein shall have the meaning set forth in the Lease, as amended hereby.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Term for the Renewal Premises is extended to expire on December 31, 2019 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Expiration Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). &#160;The Term for the Suite 400 Space shall expire on November 30, 2010. &#160;Commencing December 1, 2010, the term &#8220;Premises&#8221; shall refer to the Renewal Premises only.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;From the Effective Date through the Expiration Date, the Base Rent payable with respect to the Renewal Premises and the Suite 400 Space, as applicable, is as follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:94.9%;"><tr style="height:53.05pt;"><td style="vertical-align:top;width:22.92%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Period</u></p></td><td style="vertical-align:top;width:27.09%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent/SF</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Renewal Premises &#8211; <br>77,112 square feet)</p></td><td style="vertical-align:top;width:27.09%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent/SF</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Suite 400 Space &#8211; <br>20,170 square feet</p></td><td style="vertical-align:top;width:22.87%;background:#f2f2f2;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Base </u><font style="text-decoration-line:none;"><br></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent</u></p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/1/09 - 9/30/09</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$0.00</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$11.17</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$18,774.91</p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/1/09-11/30/10</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$7.50</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$11.17</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$66,969.91</p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/1/10-4/30/11</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$7.50</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$48,195.00</p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/1/11 -12/31/13</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$8.50</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$54,621.00</p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/1/14-12/31/16</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$9.00</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$57,834.00</p></td></tr><tr><td style="vertical-align:middle;width:22.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/1/17 -12/31/19</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$9.50</p></td><td style="vertical-align:middle;width:27.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:22.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$61,047.00</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All other terms of the Lease regarding the payment of Base Rent remain unchanged. &#160;Tenant shall continue to pay all other amounts payable under the Lease; provided, however, Tenant&#8217;s Share shall be amended in accordance with Section 5 of this Amendment.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance of Premises</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant accepts the Premises in their &#8220;AS-IS&#8221; condition and Landlord shall have no obligation to improve, repair, restore or refurbish the Renewal Premises except as otherwise specifically provided in this Amendment. &#160;Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty, except as otherwise expressly provided in this Amendment, with respect to the Renewal Premises or any other portion of the Industrial Center including, without limitation, any representation or warranty with respect to the suitability or fitness of the Renewal Premises or any other portion of the Industrial Center for the conduct of Tenant&#8217;s business. &#160;Nothing in this Paragraph 4 shall negate or diminish Landlord&#8217;s repair or restoration obligations under the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating </u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 2</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant shall be liable for Tenant&#8217;s Share of Operating Expenses for the Premises, payable as provided in the Lease. &#160;Tenant&#8217;s Share for the Industrial Center and the Building is determined on a per square foot basis by dividing the number of square feet in the Premises (or applicable portion thereof) by the total number of square feet in the Industrial Center or the Building, as applicable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">From the Effective Date through November 30, 2010, Tenant&#8217;s Share of Operating Expenses is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Industrial Center<font style="display:inline-block;width:40.52pt;"></font>45.33%<br>(b)<font style="display:inline-block;width:24.34pt;"></font>Building<font style="display:inline-block;width:73pt;"></font>85.64%</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">From December 1, 2010 through the Expiration Date, Tenant&#8217;s Share of Operating Expenses is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Industrial Center<font style="display:inline-block;width:40.52pt;"></font>35.93%<br>(b)<font style="display:inline-block;width:24.34pt;"></font>Building<font style="display:inline-block;width:73pt;"></font>67.88%</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the Effective Date, Section 4.2 of the Lease is amended by adding the following:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For purposes of determining Tenant&#8217;s Share of Operating Expenses, Controllable Operating Expenses (defined below) for any calendar year will not increase over the amount of Controllable Operating Expenses during the previous year (calculated upon a base equal to the actual expenses incurred for calendar year 2009) by more than 8% per year on a cumulative basis, compounded annually. &#160;For example, the maximum amount of Controllable Operating Expenses that may be included in the calculation of such Additional Rent for each calendar year after 2009 shall equal the product of the <b style="font-weight:bold;">Controllable Operating Expenses</b> incurred for calendar year 2009 and the following percentages for the following calendar years: &#160;108% for 2010, 116.64% for 2011, 125.97% for 2012, etc. &#160;The term Controllable Operating Expenses means all Operating Expenses except costs and expenses for taxes, insurance, property management fees (except for property management fees paid to affiliates of Landlord), utilities, costs to Landlord resulting from compliance with Applicable Requirements, and any increases in service contract fees and expenses resulting from government-mandated wage increases.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Insurance</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon the Effective Date, Section 8.2 of the Lease is deleted and the following substituted therefor:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>At its sole cost and expense, Tenant shall maintain in full force and effect during the Term of this Lease the following insurance coverages insuring against claims which may arise from or in connection with the Tenant&#8217;s operation and use of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Commercial General Liability Insurance (ISO Form CG00010798 or its equivalent), written on an &#8220;occurrence&#8221; basis, with minimum limits of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 3</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">$1,000,000 per occurrence; $2,000,000 general aggregate for bodily injury, personal injury and property damage and excess umbrella liability insurance in the amount of $5,000,000. &#160;Tenant&#8217;s Commercial General Liability Insurance must cover business carried on, in or from the Premises and Tenant&#8217;s use and occupancy of the Premises (including contractual liability and must have no deductible).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>Workers&#8217; compensation insurance complying with statutory requirements of the State of Texas and employers liability insurance in amounts not less than $500,000 bodily injury per accident/$500,000 disease each employee/$500,000 disease policy limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iii)<font style="display:inline-block;width:21pt;"></font>Automobile Liability covering all owned, non-owned and hired vehicles with a $1,000,000 per accident limit for bodily injury and property damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 72pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>Property insurance against all risks of loss to any tenant improvements or betterments and business personal property on a full replacement cost basis with no coinsurance penalty provision and a deductible not to exceed $25,000; and Business Interruption Insurance with a limit of liability representing loss of at least approximately six months of income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Tenant shall deliver to Landlord duly executed certificates of all insurance (Acord Form 28, modified as necessary to cover liability insurance) and additional insured endorsements reasonably satisfactory to Landlord (on ISO Form 2026 or its equivalent, without modification) prior to July 1, 2009 and annually thereafter, reflecting evidence of required coverages together with endorsements required under this Section 8.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>All insurance required under Paragraph 8.2 (i) shall be primary and non- contributory, (ii) shall provide for severability of interests, (iii) shall be issued by insurers, licensed to do business in the state in which the Premises are located and which are rated A-:IX or better by Best&#8217;s Key Rating Guide, (iv) shall be endorsed to include Landlord, Landlord&#8217;s property manager and such other persons or entities as Landlord may from time to time designate, as additional insureds without restriction (Commercial General Liability and excess umbrella liability insurance only), (v) shall be endorsed to endeavor to provide at least 30-days prior notification of cancellation or material change in coverage to said additional insureds, and (vi) shall be endorsed to waive any rights of subrogation against Landlord, its officers, directors, employees, agents, partners and assigns. &#160;All deductibles shall be at Tenant&#8217;s sole risk and shall be paid by, assumed by and for the account of Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If Tenant fails to comply with the insurance requirements, Landlord may obtain the required insurance on behalf of Tenant and Tenant shall pay the cost thereof as Additional Rent.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Subrogation</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon the Effective Date, Section 8.4 of the Lease is deleted and the following substituted therefor:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 4</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Each party waives all claims that arise or may arise in its favor against the other party, or anyone claiming through or under them, by way of subrogation or otherwise, during the Lease Term or any extension or renewal thereof, for all losses of, or damage to, any of its property (<b style="font-weight:bold;">WHETHER OR NOT THE LOSS OR DAMAGE IS CAUSED IN WHOLE OR IN PART BY THE FAULT OR NEGLIGENCE OR STRICT LIABILITY OF THE OTHER PARTY OR ANYONE FOR WHOM THE OTHER PARTY IS RESPONSIBLE</b>), which loss or damage is covered by valid and collectible Special Form Property insurance policies or would have been covered by such insurance policies had the party maintained such insurance. &#160;The party incurring the loss or damage will be responsible for any deductible or self-insured retention under its property insurance. &#160;These waivers are in addition to, and not in limitation of, any other waiver or release in this Lease with respect to any loss or damage to property of the parties. &#160;Each party shall immediately give each insurance company issuing to it policies of Special Form Property insurance written notice of the terms of these mutual waivers, and have the insurance policies properly endorsed, if necessary, to prevent the invalidation of the insurance coverages by reason of these waivers.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon the Effective Date, Section 8.5 of the Lease is amended by adding the following:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">THE INDEMNITY IN THIS SECTION WILL APPLY EVEN IF THE LOSS OR DAMAGE IS CAUSED OR ALLEGED TO BE CAUSED IN WHOLE OR IN PART BY THE NEGLIGENCE OR STRICT LIABILITY OF A LANDLORD ENTITY BUT WILL NOT APPLY TO THE EXTENT THE DAMAGE OR LOSS IS CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF SUCH LANDLORD ENTITY.</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exemption of Landlord from Liability</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon the Effective Date, Section 8.6 of the Lease is deleted and the following substituted therefor:</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Landlord Entities shall not be liable for and Tenant waives any claims against Landlord Entities (<b style="font-weight:bold;">EVEN IF SUCH CLAIMS ARE CAUSED SOLELY OR IN PART BY THE NEGLIGENCE OF LANDLORD ENTITIES BUT NOT TO THE EXTENT CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF LANDLORD ENTITIES</b>) for injury or damage to the person or the property of Tenant, Tenant&#8217;s employees, contractors, invitees, customers or any other person in or about the Premises, Building or Industrial Center from any cause whatsoever, including, but not limited to, damage or injury which is caused by or results from (i) fire, steam, electricity, gas, water or rain, or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires, appliances, plumbing, air conditioning or lighting fixtures or (ii) from the condition of the Premises, other portions of the Building or Industrial Center. &#160;Landlord shall not be liable for any damages arising from any act or neglect of any other tenant of Landlord nor from the failure by Landlord to enforce the provisions of any other lease in the Industrial Center. &#160;<b style="font-weight:bold;">NOTWITHSTANDING LANDLORD&#8217;S NEGLIGENCE OR BREACH OF THIS LEASE, LANDLORD SHALL UNDER NO CIRCUMSTANCES BE LIABLE FOR INJURY TO TENANT&#8217;S BUSINESS, FOR ANY LOSS OF INCOME OR PROFIT THEREFROM OR ANY INDIRECT, CONSEQUENTIAL OR PUNITIVE DAMAGES.</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Right of First Refusal covering Suite 300 of the Building as set forth in Section 6 of the Third Amendment, remains in full force and effect during the</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 5</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Term as extended by this Amendment, and may be exercised by Tenant during such extended Term in accordance with Section 6 of the Third Amendment.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security Deposit</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Upon execution of this Amendment, Tenant shall deposit the amount of $48,195.00 (the </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Security Deposit Increase</b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">) which shall be added to and become part of the Security Deposit currently held by Landlord under Section 5 of the Lease for a total Security Deposit of $134,901.57. &#160;The Security Deposit, as increased by the Security Deposit Increase, shall be held and applied by Landlord as provided in the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contingency</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord acknowledges that in anticipation of the execution of this Amendment, Tenant is withholding payment of Base Rent and Operating Expenses for the months of May and June, 2009 (the <b style="font-weight:bold;">Deferred Rent</b>). &#160;Subject to the terms of this Paragraph 12, such failure to make Base Rent and Operating Expense payments is not a default under the Lease, and Landlord will not assess interest or a late charge as provided under the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant is currently negotiating a Venture Capital Agreement (the <b style="font-weight:bold;">VC Agreement</b>) with third parties. &#160;Tenant shall notify Landlord in writing on or before July 2, 2009 (the <b style="font-weight:bold;">Notification Date</b>) whether the VC Agreement was fully executed (the <b style="font-weight:bold;">Tenant&#8217;s Notice</b>). &#160;If Tenant fails to timely deliver the Tenant&#8217;s Notice on or prior to the Notification Date, Tenant shall be deemed to have executed the VC Agreement, and this Amendment shall remain in full force and effect. &#160;If Tenant delivers the Tenant&#8217;s Notice on or prior to the Notification Date advising Landlord that the VC Agreement was not fully executed on or before July 1, 2009, then (i) this Amendment shall automatically terminate without further action by Landlord or Tenant, (ii) within twenty (20) days of receipt of such Tenant&#8217;s Notice, Landlord will return the Security Deposit Increase to Tenant and (iii) within five (5) business days after the date of such Tenant&#8217;s Notice, Tenant shall pay the Deferred Rent. &#160;Failure to pay such Deferred Rent within such 5-business day period shall constitute a Default under the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option to Extend</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant may extend the Term subject to all of the following conditions:</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Tenant is not in default under the Lease at the time of the exercise of this option or at the commencement of the extended Term, Tenant may extend the Term for 2 extension terms of 5 years each (each, an <b style="font-weight:bold;">Extension Term</b>), commencing on the next day after the then-current Expiration Date, by giving Landlord an extension notice at least 9 months, but not more than 12 months, prior to the then-current Expiration Date (the <b style="font-weight:bold;">Extension Notice Period</b>).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Tenant gives a valid extension notice, then subject to this Section 13, the Term is extended for 5 years upon the same terms as in the Lease (as amended hereby), except that the Rent and other applicable terms adjust based on the Market Rate (defined and determined below), and Tenant has no further option to extend the Term after both options set forth in this Section 13 are exercised. &#160;If Tenant does</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 6</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">not give an extension notice during the applicable Extension Notice Period, then this option expires automatically at the end of the applicable Extension Notice Period.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within 30 days after Landlord receives Tenant&#8217;s extension notice, Landlord shall deliver a notice to Tenant specifying the Market Rate (the <b style="font-weight:bold;">Market Rate Notice</b>). &#160;The term <b style="font-weight:bold;">Market Rate</b> means the minimum rent, refurbishment allowance, and other economic terms that a non-encumbered, non-equity tenant, having a credit standing substantially similar to that of Tenant as of the date of the Lease and requiring substantially the same space and terms as Tenant, would be able to obtain from a willing landlord comparable to Landlord, in arms-length negotiations for comparable space located within the Industrial Center and other comparable buildings in the Grand Prairie/Arlington markets, and leased at the time in question for a comparable period of time, as determined by Landlord in its reasonable discretion based upon current market conditions for comparable space located within the Industrial Center and other comparable buildings in the Grand Prairie/Arlington markets. &#160;In determining Market Rate, Landlord shall consider, among other things and in addition to base rent and refurbishment allowance: &#160;(i) Operating Expense treatment, (ii) rental abatement concessions, lease takeover payments, (iv) whether or not brokerage commissions are involved, and (v) other allowance, inducements, and concessions.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant shall notify Landlord within 15 days after the date of the Market Rate Notice whether it approves Landlord&#8217;s designation of Market Rate (the <b style="font-weight:bold;">Response Notice</b>), and if Tenant does not timely give a Response Notice, Tenant is deemed to approve the Market Rate specified in the Market Rate Notice. &#160;If Tenant gives a valid Response Notice that it disapproves of Landlord&#8217;s designation of Market Rate, then Landlord and Tenant shall negotiate in good faith for a period of 20 days after the date of the Response Notice to reach agreement on the Market Rate. &#160;If Landlord and Tenant do not reach agreement on the Market Rate within the 20-day period, then Tenant, as its sole remedy, may either (i) revoke its exercise notice by delivering a <b style="font-weight:bold;">Revocation Notice</b> (herein so called) to Landlord within 5 days after the end of the 20-day negotiation period (the <b style="font-weight:bold;">Revocation Period</b>), or (ii) deliver an <b style="font-weight:bold;">Arbitration Notice</b> (herein so called) to Landlord before the end of the Revocation Period, notifying Landlord of its election to submit the determination of Market Rate to arbitration, to be conducted by the American Arbitration Association office located in Dallas, Texas, in accordance with Section 13(e) below. &#160;If Tenant does not deliver a Revocation Notice or an Arbitration Notice before the end of the Revocation Period, then Tenant is deemed to have given a timely Revocation Notice.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">e.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Tenant gives a valid Arbitration Notice, then Landlord, or its designated representative, and Tenant shall each place in a separate sealed envelope their final proposal as to Market Rate (as to each party individually, <b style="font-weight:bold;">Final Proposal</b>) and shall meet with each other within 10 days after the last day of the Revocation Period (the <b style="font-weight:bold;">Meeting Date</b>). &#160;At the meeting, Landlord and Tenant shall exchange and then open the envelopes in each other&#8217;s presence. &#160;If Landlord and Tenant do not mutually</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">agree upon the Market Rate within 5 days after the Meeting Date, then the Market Rate will be submitted to baseball-style arbitration, and within 15 days after the Meeting Date, Landlord and Tenant shall agree upon and jointly appoint a 3&#160;-&#160;member arbitration panel (the <b style="font-weight:bold;">Panel</b>) to conduct the arbitration. &#160;In appointing the Panel, Landlord and Tenant shall choose real estate professionals (excluding appraisers and attorneys) with knowledge of the Grand Prairie and Arlington markets for industrial space comparable to the Industrial Center. &#160;If Landlord and Tenant do not agree upon and appoint a 3- member Panel within 15 days after the Meeting Date, then within 5 days, Landlord and Tenant shall each appoint one panel member, and within 5 days thereafter, the two appointed members shall select the third. &#160;The determination of the Panel will be limited solely to the issue whether Landlord&#8217;s or Tenant&#8217;s Final Proposal is closer to the actual Market Rate for the Premises as determined by the Panel. &#160;The Panel may hold hearings and require briefs from Landlord and Tenant as the Panel, in its sole discretion, determines is necessary. &#160;In addition, Landlord or Tenant may submit to the Panel and the other party, within 5 days after the appointment thereof, any market data and additional information that the party deems relevant to the determination of Market Rate (<b style="font-weight:bold;">MR Data</b>), and the other party may submit a reply in writing within 5 days after receipt of such MR Data. &#160;The Panel shall, within 30 days after its appointment, notify Landlord and Tenant whether Landlord&#8217;s or Tenant&#8217;s Final Proposal is closer to the actual Market Rate for the Premises as determined by the Panel. &#160;The Panel&#8217;s decision is binding upon Landlord and Tenant. &#160;The cost of arbitration shall be paid by Landlord and Tenant equally, except that each party will be responsible for its own legal fees and costs of experts in connection with its presentation of information and evidence to the Panel.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If the Term is extended under this Section 13, Landlord shall prepare, and Landlord and Tenant shall promptly execute and deliver, an amendment to the Lease to reflect the extension of the Term and, if applicable, the modification of the Premises.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">g.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Option to Extend contained in Section 8 of the First Amendment is hereby deleted in its entirety.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">14.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokerage; Mutual </u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Indemnities.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than CB Richard Ellis, Inc. and Jackson &amp; Cooksey, Inc. (collectively, <b style="font-weight:bold;">Brokers</b>). &#160;Tenant shall indemnify, defend, and hold Landlord harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent other than Brokers claiming by, through, or under Tenant with respect to this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than Brokers. &#160;Landlord shall indemnify, defend, and hold Tenant harmless against all costs, expenses,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 8</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent, including Brokers, claiming by, through or under Landlord with respect to this Amendment.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any brokerage commissions payable to Brokers are payable by Landlord pursuant to the terms of separate agreements between Landlord and Broker.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">15.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Offsets</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;Tenant hereby represents to Landlord that to the best of Tenant&#8217;s knowledge, as of the date of this Amendment, Tenant has no defenses to or offsets against the full and timely payment and performance of each and every covenant and obligation required to be performed by Tenant under the terms of the Lease, as amended hereby.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">16.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The terms of this Amendment prevail if there is a conflict with the terms of the Lease.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">17.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The headings or captions of the paragraphs in this Amendment are for convenience only and shall not act and shall not be implied to act to limit or expand the construction and intent of the contents of the respective paragraph.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">18.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;This Amendment is binding upon and shall inure to the benefit of the parties and their respective successors and assigns (but this reference to assigns shall not be deemed to act as a consent to an assignment by Tenant).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">19.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification</u><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. &#160;The Lease, as amended and modified hereby, is ratified and confirmed by the parties as being in full force and effect.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Remainder of page intentionally left blank.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 9</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EXECUTED as of the date first above written.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD:</b></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA,</b></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a New York corporation</p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:43.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:35.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As Its:</p></td><td style="vertical-align:top;width:35.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:36.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT:</b></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEOS THERAPEUTICS, LP, </b><b style="font-weight:bold;"><br></b>a Texas limited partnership</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PharmaFab Texas, LLC,</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Texas limited liability company,</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">its manager</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As Its:</p></td><td style="vertical-align:top;width:36.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FOURTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 10</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.53
<SEQUENCE>10
<FILENAME>aytu-20230630xex10d53.htm
<DESCRIPTION>EX-10.53
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.53</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FIFTH AMENDMENT TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This FIFTH AMENDMENT TO LEASE (this <b style="font-weight:bold;">Amendment</b>) is made and entered into as of April ___., 2010 (the <b style="font-weight:bold;">Execution Date</b>), by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (<b style="font-weight:bold;">Landlord</b>), and NEOS THERAPEUTICS, LP, a Texas limited partnership, formerly known as PFAB LP (<b style="font-weight:bold;">Tenant</b>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BACKGROUND:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Walstib, L.P., a Delaware limited partnership (<b style="font-weight:bold;">Walstib</b>), and PharmaFab, Inc., a Texas corporation (<b style="font-weight:bold;">PharmaFab</b>), entered into that certain Commercial Lease Agreement dated on or about June 29, 1999, and having a Commencement Date as of October 25, 1999 (the <b style="font-weight:bold;">Original Lease</b>), regarding certain premises containing approximately 44,000 square feet in Suite 100 (the <b style="font-weight:bold;">Original Premises</b>) of Building B (the <b style="font-weight:bold;">Building</b>) in the industrial complex commonly known as 360 Riverside Business Center located at 2940 N. Highway 360 in the City of Grand Prairie, Tarrant County, Texas, as more particularly described in the Original Lease (the <b style="font-weight:bold;">Industrial Center</b>).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to that certain Assignment of Lease dated on or about June 29, 1999, to be effective as of July 1, 1999, PharmaFab assigned its right, title and interest in the Original Lease to PFAB LP, a Texas limited partnership (<b style="font-weight:bold;">PLP</b>).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Walstib and PLP amended the Original Lease pursuant to that certain First Amendment to Lease dated effective as of September 1, 2002 (the <b style="font-weight:bold;">First Amendment</b>) pursuant to which (i) the Original Premises were expanded to include approximately 50,000 additional square feet in Suite 100 of Building A of the Industrial Center (the <b style="font-weight:bold;">Building A Premises</b>) and (ii) Bruce K. Montgomery was released from his Guaranty of Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord succeeded to the interest of Walstib under the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and PLP further amended the Original Lease on a short term basis pursuant to an Interim Amendment to Lease dated September 4, 2003 (the <b style="font-weight:bold;">Second Amendment</b>).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and PLP further amended the Original Lease pursuant to that certain Third Amendment to Lease dated October 1, 2003 (the <b style="font-weight:bold;">Third Amendment</b>) pursuant to which (i) the Building A Premises were relocated to Suites 200 and 400 of the Building such that the definition of the premises (as defined in the Original Lease and as amended by the Third Amendment) consist of (1) approximately 77,112 square feet of space in Suites 100 and 200 of the Building (collectively, the <b style="font-weight:bold;">Suite 100 Space</b>) and (2) approximately 20,170 square feet of space in Suite 400 of the Building (the <b style="font-weight:bold;">Suite 400 Space</b>) (collectively, the <b style="font-weight:bold;">Premises</b>) and (ii) Darlene M. Ryan was released from her Guaranty of Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">On June 22, 2007, Tenant changed its name to Neos Therapeutics, LP.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">H.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant further amended the Original Lease pursuant to that certain Fourth Amendment to Lease effective as of May 1,,2009 (the <b style="font-weight:bold;">Fourth Amendment</b>), whereby the Term was extended for the Suite 100 Space. &#160;The Original Lease, as amended by the First</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Amendment, Second Amendment, Third Amendment and Fourth Amendment, is referred to herein as the Lease.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant desire to further amend the Lease to extend the Term of the Lease for the Suite 400 Space and modify certain provisions of the Lease as hereinafter set forth, but not otherwise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u>. &#160;All capitalized terms which are not otherwise defined herein shall have the meaning set forth in the Lease, as amended hereby.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. &#160;The Term for the Suite 400 Space is hereby extended to expire on December 31, 2019 (the <b style="font-weight:bold;">Expiration Date</b>). &#160;Therefore, in accordance with the Fourth Amendment and this Amendment, the Term for the entire Premises (consisting of the Suite 100 Space and the Suite 400 Space) expires on the Expiration Date.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>. &#160;From March 1, 2010 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) through the Expiration Date, the Base Rent payable with respect to the Suite 400 Space only is as follows:</p></td></tr></table><div style="padding-left:35.75pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:95%;"><tr><td style="vertical-align:top;width:27.8%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Period</u></p></td><td style="vertical-align:top;width:34.72%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent/SF</u></p></td><td style="vertical-align:top;width:37.46%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Base Rent</u></p></td></tr><tr><td style="vertical-align:top;width:27.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/1/10 - 5/31/11</p></td><td style="vertical-align:top;width:34.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$8.00</p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$13,446.67</p></td></tr><tr><td style="vertical-align:top;width:27.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/1/11 - 1/31/14</p></td><td style="vertical-align:top;width:34.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$10.05</p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$16,892.38</p></td></tr><tr><td style="vertical-align:top;width:27.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2/1/14 - 1/31/17</p></td><td style="vertical-align:top;width:34.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$10.55</p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$17,732.79</p></td></tr><tr><td style="vertical-align:top;width:27.8%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2/1/17 - 12/31/19</p></td><td style="vertical-align:top;width:34.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$11.05</p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$18,573.21</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">All other terms of the Lease regarding the payment of Base Rent remain unchanged. &#160;Tenant shall continue to pay all other amounts payable under the Lease; provided, however, Tenant&#8217;s Share shall be amended in accordance with Section 5 of this Amendment.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceptance of Premises</u>. &#160;Tenant accepts the Premises in their &#8220;AS-IS&#8221; condition and Landlord shall have no obligation to improve, repair, restore or refurbish the Premises except as otherwise specifically provided in this Amendment. &#160;Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty, except as otherwise expressly provided in this Amendment or the Lease, with respect to the Premises or any other portion of the Industrial Center including, without limitation, any representation or warranty with respect to the suitability or fitness of the Premises or any other portion of the Industrial Center for the conduct of Tenant&#8217;s business. &#160;Nothing in this Paragraph 4 shall negate or diminish Landlord&#8217;s repair or restoration obligations under the Lease, as amended.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Expenses</u>. &#160;From the Effective Date through Expiration Date, Tenant&#8217;s Share of Operating Expenses is as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 2</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Industrial Center<font style="display:inline-block;width:4.52pt;"></font><font style="display:inline-block;width:36pt;"></font>45.33%</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Building<font style="display:inline-block;width:73pt;"></font>85.64%</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Finish-Out of Premises</u>. &#160;Landlord agrees to provide Tenant with a finish-out allowance of $500,000.00 for costs incurred in connection with renovations to the Premises. &#160;The Tenant Finish Work will be performed and the allowance applied in accordance with <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment A</b> attached to this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</u>. &#160;Upon the Execution Date, Section 1.8 of the Lease is hereby deleted and the following substituted therefor:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;1.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</u>: &#160;Manufacturing, storage and distribution of pharmaceutical products in compliance with all Applicable Requirements, including use of portions of the Premises as laboratory space for research and manufacturing purposes in connection with Tenant&#8217;s business.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>. &#160;The Right of First Refusal covering Suite 300 of the Building, as set forth in Section 6 of the Third Amendment, (i) remains in full force and effect during the Term as extended by this Amendment, and (ii) may be exercised by Tenant during such extended Term in accordance with Section 6 of the Third Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option to Extend</u>. &#160;The Option to Extend set forth in Section 13 of the Fourth Amendment (i) remains in full force and effect and (ii) shall include and be applicable to the entire Premises (including the Suite 400 Space).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokerage; Mutual Indemnities</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:39.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than CB Richard Ellis, Inc. and Jackson &amp; Cooksey, Inc. &#160;(collectively, the <b style="font-weight:bold;">Brokers</b>). &#160;Tenant shall indemnify, defend, and .hold Landlord harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent other than Brokers claiming by, through, or under Tenant with respect to this Amendment,</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:39.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord warrants that it has had no dealings with any broker or agent in connection with the negotiation or execution of this Amendment other than Brokers. &#160;Landlord shall indemnify, defend, and hold Tenant harmless against all costs, expenses, attorneys&#8217; fees, or other liability for commissions or other compensation or charges claimed by any broker or agent, including Brokers, claiming by, through or under Landlord with respect to this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:39.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any brokerage commissions payable to Brokers are payable by Landlord pursuant to the terms of separate agreements between Landlord and Broker.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Offsets</u>. &#160;Tenant hereby represents to Landlord that to the best of Tenant&#8217;s knowledge, as of the date of this Amendment, Tenant has no defenses to or offsets against the full and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 3</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">timely payment and performance of each and every covenant and obligation required to be performed by Tenant under the terms of the Lease, as amended hereby.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts</u>. &#160;The terms of this Amendment prevail if there is a conflict with the terms of the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">13.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. &#160;The headings or captions of the paragraphs in this Amendment are for convenience only and shall not act and shall .not be implied to act to limit or expand the construction and intent of the contents of the respective paragraph.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u>. &#160;This Amendment is binding upon and shall inure to the benefit of the parties and their respective successors and assigns (but this reference to assigns shall not be deemed to act as a consent to an assignment by Tenant).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">15.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification</u>. &#160;The Lease, as amended and modified hereby, is ratified and confirmed by the parties as being in full force and effect.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page intentionally left blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 4</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 24pt 0pt;">EXECUTED as of the date first above written.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LANDLORD</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TEACHERS INSURANCE AND ANNUITY</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">ASSOCIATION OF AMERICA,</b></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a New York corporation</p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:47.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:44.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name:</p></td><td style="vertical-align:top;width:31.4%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As Its:</p></td><td style="vertical-align:top;width:31.4%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEOS THERAPEUTICS, LP</b><b style="font-weight:bold;"><br></b>a Texas limited partnership</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PharmaFab Texas, LLC,</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A Texas limited liability company,</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its manager</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:36.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:36.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:36.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 5</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ATTACHMENT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">to Fifth Amendment to Lease by and between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Teachers Insurance and Annuity Association of America, as Landlord,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Neos Therapeutics, LP, as Tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TENANT FINISH WORK</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plans and Specifications</u>: &#160;Tenant shall submit to Landlord within thirty (30) days following the Execution Date initial plans and specifications (the &#8220;<font style="font-style:italic;font-weight:bold;">Initial Construction Documents</font>&#8221;) for the remodeling of the Premises. &#160;The Initial Construction Documents must include, without limitation:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">General Notes Sheet</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Demolition Plan</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">New Construction Plan with details of all new improvements</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Finishes Plan</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Electrical, Mechanical and Plumbing Plan</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Within 15 days after receipt of the Initial Construction Documents, Landlord shall deliver to Tenant a notice either approving or disapproving them. &#160;Landlord shall not unreasonably withhold, condition or delay its approval of any plans, changes to such plans, designation of contractors or other matters related to the Tenant Finish Work; provided, if the Tenant Finish Work affects the structural portions of the Building or the Building systems, Landlord&#8217;s approval shall be in its commercially reasonable discretion. &#160;Any disapproval must specify in reasonable detail the reasons for the disapproval. &#160;If Tenant does not receive a notice from Landlord disapproving the Initial Construction Documents within the 15-day period, Landlord is deemed to approve the Initial Construction Documents. &#160;If Landlord disapproves the Initial Construction Documents, Tenant shall revise them to conform to Landlord&#8217;s reasonable objections and deliver copies of the revised Initial Construction Documents to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The approved Initial Construction Documents are referred to as the &#8220;<font style="font-style:italic;font-weight:bold;">Construction Documents</font>&#8221; and all work to be performed by Tenant pursuant to the Construction Documents is referred to as the &#8220;<font style="font-style:italic;font-weight:bold;">Tenant Finish Work</font>&#8221;. &#160;Landlord&#8217;s approval of the Construction Documents is not a warranty that the Construction Documents comply with Applicable Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 6</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Finish Work</u>. &#160;Tenant, at its cost and risk (subject to reimbursement of the Work Allowance by Landlord), shall construct or cause to be constructed the Tenant Finish Work in substantial accordance with the Construction Documents. &#160;Tenant shall solicit bids from three contractors approved by Landlord for performance of the Tenant Finish Work, and Tenant shall select one of the three contractors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Tenant shall pay the Actual Cost (defined below) of all Tenant Finish Work subject to reimbursement by Landlord as specified below of a work allowance not to exceed a maximum of $500,000.00 (the &#8220;<font style="font-style:italic;font-weight:bold;">Work Allowance</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The term &#8220;<font style="font-style:italic;font-weight:bold;">Actual Cost</font>&#8221; means the cost of all labor and materials and all hard and soft costs relating to the Tenant Finish Work (including thirty-party, out-of-pocket costs incurred by Tenant in designing and constructing Tenant Finish Work [i.e. preparation and revisions of Tenant&#8217;s space plan, preparation and revisions of the Construction Documents and Initial Construction Documents, Tenant&#8217;s working drawings, space planning, interior architect, engineering, all construction and materials costs of Tenant&#8217;s contractor and all subcontractors, relocation, and cabling, and any and all other hard and soft costs incurred by Tenant in connection with the Tenant Finish Work]), together with the Building Service Fee of 5% of all hard costs of the Tenant Finish Work</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Tenant shall allow Landlord access to the Premises at all times to inspect the Tenant Finish Work. &#160;Landlord has no obligation to inspect the Tenant Finish Work. &#160;No inspection by Landlord of the Tenant Finish Work is a warranty that the Tenant Finish Work complies with the Construction Documents or any Applicable Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Work Allowance is available for Tenant&#8217;s use from the date of this Amendment through February 28, 2011, after which Tenant&#8217;s right to same will expire and be of no further force and effect.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DISBURSEMENT OF WORK ALLOWANCE</u>. &#160;Landlord shall pay to Tenant the Actual Cost of the Tenant Finish Work, up to the total Work Allowance, as follows:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">On or about the 15th of each month (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Submittal Date</font>&#8221;), Tenant shall deliver to Landlord the following (the &#8220;<font style="font-style:italic;font-weight:bold;">Payment Conditions</font>&#8221;): &#160;(a) a request for reimbursement to Tenant of a specified portion of the Work Allowance (the &#8220;<font style="font-style:italic;font-weight:bold;">Disbursement</font>&#8221;), showing the schedule, by trade, of the percentage of completion of the Tenant Finish Work, describing with specificity the portion of the Tenant Finish Work completed since the previous Submittal Date (the &#8220;<font style="font-style:italic;font-weight:bold;">Completed Work</font>&#8221;) (the Completed Work shall be summarized on AIA form G-702 &#8212; Contractor&#8217;s Application for Payment, or its equivalent), and substantiating, to Landlord&#8217;s reasonable satisfaction, the amount of the Disbursement in relation to the Completed Work; (b) executed, unconditional, and recordable lien waivers and releases reasonably satisfactory to Landlord covering all of the Completed Work; (c) paid receipts for all items of the Completed Work in excess of $1,000; and (d) all other information reasonably required by Landlord, including copies of all operating manuals and service manuals that Tenant has received relating to the Tenant Finish Work, if any.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within 30 days after each Submittal Date (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Reimbursement Date</font>&#8221;), if Tenant has fully complied with Paragraph C(1) above, Landlord shall pay Tenant the lesser of: &#160;(a) the applicable Disbursement, less a 10% retainage (all of which are collectively the &#8220;<font style="font-style:italic;font-weight:bold;">Retainage</font>&#8221;) (except to the extent Tenant&#8217;s payments to its contractor, architect, engineer, etc., already reflect a 10% retainage), and (b) the balance of any remaining available portion of the Work Allowance (not including the Retainage). &#160;The final disbursement of the Work Allowance by Landlord (not including the Retainage) will be adjusted, if necessary, so that the total Retainage is 10% of the total available Work Allowance.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within five (5) business days after each Submittal Date, Landlord will give Tenant written notice of any missing or incomplete Payment Conditions, information or documentation reasonably required by Landlord in order to process Tenant&#8217;s reimbursement request. &#160;The applicable Reimbursement Date shall be automatically extended by the number of days beyond the five (5) business day notice period taken by Tenant to submit the missing or incomplete documentation. &#160;Further, upon Tenant&#8217;s written request, Landlord may omit payment for costs with incomplete documentation and make immediate payment on only that portion of the reimbursement request that the parties agree is complete, with the balance of such payment request to be paid along with Tenant&#8217;s next monthly reimbursement request, subject to Tenant&#8217;s submittal of all missing or incomplete documentation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within 30 days after the completion of the Tenant Finish Work, if Tenant has fully complied with Paragraph C(1) above with respect to all of the Tenant Finish Work, Landlord shall pay the Retainage to Tenant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Landlord fails to pay all or any portion of the Work Allowance to Tenant when due, and if Tenant has fully complied with this Paragraph C, then Tenant shall notify Landlord in writing of the failure (the &#8220;<font style="font-style:italic;font-weight:bold;">Delinquency Notice</font>&#8221;), and Landlord shall have 30 days after it receives the Delinquency Notice to cure the failure. &#160;If Landlord does not cure the failure within that 30-day period, then Tenant may, at its option, pay all or any portion of the amounts due and offset those payments, plus interest at 6% per annum (but not to exceed the highest rate allowable under applicable law), against the next due installments of Base Rent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any material changes to the Construction Documents must first be submitted to Landlord for review and approval prior to the work reflected in such amended Construction Documents being undertaken by Tenant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Workmanship and materials to be used in the Tenant Finish Work shall be of best quality. &#160;Any approval by Landlord of the Construction Documents shall not in any way constitute a representation or warranty of Landlord as to the adequacy or sufficiency of the Construction Documents; such approval shall merely be the consent of Landlord as may be required hereunder in connection with the Tenant</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 8</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Finish Work in accordance with the Construction Documents under the terms of the Lease.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Tenant shall perform the Tenant Finish Work consistent with Building Rules and Regulations, in a manner to minimize noise and other interference with tenants of the Industrial Center and shall remove all trash and debris from the Premises on a daily basis.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon completion of the construction of Tenant Finish Work, Tenant shall promptly restore any area of the Industrial Center damaged as a result of Tenant&#8217;s construction of the Tenant Finish Work to the condition existing prior to the commencement of such construction.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Any entry upon the Premises by Tenant and its agents and contractors shall be deemed to be under all of the terms, the covenants provisions and conditions of the Lease.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All contractors, subcontractors, suppliers, service providers, moving companies and others (the &#8220;<font style="font-style:italic;font-weight:bold;">Service Providers</font>&#8221;) performing work of any type for Tenant in the Industrial Center shall (i) carry the insurance listed below with companies acceptable to Landlord, and (ii) furnish certificates of insurance to Landlord evidencing required coverages at least 10 days prior to entry on the Industrial Center and annually thereafter;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Commercial general liability insurance written on the most current form of ISO CG 00 01 (occurrence basis) or its equivalent, have a minimum each occurrence limit of $1,000,000, a minimum general aggregate limit of $2,000,000, and not exclude the Lease from the definition of &#8220;Insured Contract&#8221; under the contractual liability provisions;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Workers&#8217; compensation insurance complying with statutory requirements of the State of Texas and employers liability insurance in amounts not less than $500,000 bodily injury per accident/$500,000 disease each employee/$500,000 disease policy limit;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Business automobile insurance for claims arising out of ownership, maintenance, or use of owned, non-owned, and hired motor vehicles at, upon, or away from the Industrial Center. &#160;The minimum limits must be $1,000,000 each occurrence; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:75.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:32.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Excess/umbrella liability insurance, applying on at least a &#8220;following form&#8221; (or primary) basis, in excess of commercial general liability, employers liability, and business automobile liability, with a minimum limit of $3,000,000 each occurrence and aggregate, where applicable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Landlord, Landlord&#8217;s designated property management firm, and all Landlord Entities shall be named additional insureds on each of said policies (excluding the worker&#8217;s compensation policy) and said policies shall be issued by an insurance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 9</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">company or companies authorized to do business in the State and which have policyholder ratings not lower than &#8220;A-&#8221; and financial ratings not lower than &#8220;IX&#8221; in Best&#8217;s Insurance Guide (latest edition in effect as of the date of the Lease and subsequently in effect as of the date of renewal of the required policies). &#160;EACH OF SAID POLICIES SHALL ALSO INCLUDE A WAIVER OF SUBROGATION PROVISION OR ENDORSEMENT IN FAVOR OF LANDLORD AND THE LANDLORD ENTITIES, AND AN ENDORSEMENT PROVIDING THAT LANDLORD SHALL RECEIVE THIRTY (30) DAYS PRIOR WRITTEN NOTICE OF ANY CANCELLATION OF, NON-RENEWAL OF, REDUCTION OF COVERAGE OR MATERIAL CHANGE IN COVERAGE ON SAID POLICIES. &#160;In addition, all policies of the Service Providers shall be endorsed to be primary, with the policies of all Landlord Entities being excess, secondary and non-contributing. &#160;Each Service Provider hereby waives its right of recovery against any Landlord indemnitee of any amounts paid by it or on its behalf to satisfy applicable worker&#8217;s compensation laws. The policies or duly executed certificates showing the material terms for the same, together with satisfactory evidence of the payment of the premiums therefor, shall be deposited with Landlord on the date each Service Provider first enters the Industrial Center and upon renewals of such policies not less than fifteen (15) days prior to the expiration of the term of such coverage. &#160;If certificates are supplied rather than the policies themselves, each Service Provider shall allow Landlord, at all reasonable times, to inspect its policies of insurance required herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">With respect to insurance coverages, except worker&#8217;s compensation, maintained hereunder by each Service Provider and insurance coverages separately obtained by Landlord, all insurance coverages afforded by policies of insurance maintained by each Service Provider shall be primary insurance as such coverages apply to Landlord, and such insurance coverages separately maintained by Landlord shall be excess, and each Service Provider shall have its insurance policies so endorsed. &#160;The amount of liability insurance under insurance policies maintained by each Service Provider shall not be reduced by the existence of insurance coverage under policies separately maintained by Landlord. &#160;Each Service Provider shall be solely responsible for any premiums, assessments, penalties, deductible assumptions, retentions, audits, retrospective adjustments or any other kind of payment due under its policies.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FIFTH AMENDMENT TO LEASE</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">PAGE 10</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.54
<SEQUENCE>11
<FILENAME>aytu-20230630xex10d54.htm
<DESCRIPTION>EX-10.54
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:48 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.54</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIXTH AMENDMENT TO LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Sixth Amendment to Lease (&#8220;Amendment&#8221;) is made effective as of August ____, 2013, by and between RIVERSIDE BUSINESS GREEN, LP, a Delaware limited partnership (&#8220;Landlord&#8221;) and NEOS THERAPEUTICS, LP, a Texas limited partnership (&#8220;Tenant&#8221;), with reference to the following facts and circumstances.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord is the owner of that certain building located at 2940 N. Highway 360, Grand Prairie, Texas (the &#8220;Building&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Walstib, L.P., predecessor in interest to Landlord, and PharmaFab, Inc. predecessor in interest to Tenant, entered into a certain Commercial Lease Agreement dated June 29, 1999, as amended by that certain First Amendment to Lease dated September 1, 2002, that certain Interim Amendment to Lease dated September 4, 2003, that certain Third Amendment to Lease dated October 1, 2003, that certain Fourth Amendment to Lease dated May 1, 2009 and that certain Fifth Amendment to Lease dated April 5, 2010 (collectively, the &#8220;Lease&#8221;), for (i) certain premises containing approximately 77,112 rentable square feet located in Suites 100 and 200 of the Building (the &#8220;Suite 100 Space&#8221;) and certain premises containing approximately 20,170 rentable square feet located in Suite 400 f the Building (the &#8220;Suite 400 Space&#8221;). &#160;The Suite 100 Space and Suite 400 Space shall be known collectively herein as the &#8220;Premises&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord and Tenant desire to amend the Lease upon terms and conditions hereinafter set forth.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the foregoing facts and circumstances, the mutual covenants and promises contained herein and after good and valuable consideration, the receipt and sufficiency of which is acknowledged by each of the parties, the parties do hereby agree to the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;Each capitalized term used in this Amendment shall have the same meaning as is ascribed to such capitalized term in the Lease, unless otherwise provided for herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>. &#160;The term of the Lease is hereby extended for the period commencing on January 1, 2020, and ending on December 31, 2024 (the &#8220;Extended Term&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">During the Extended Term, monthly installments of Base Rent for the Suite 100 Space shall be as follows:</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Months</u></p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Installment</u></p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual</u></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2020 - December 31, 2020</p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$64,260.00</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$771,120.00</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2021 - December 31, 2021</p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$64,260.00</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$771,120.00</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2022 - December 31, 2022</p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$67,473.00</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$809,676.00</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 1 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">January 1, 2023 - December 31, 2023</p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$67,473.00</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$809,676.00</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">January 1, 2024 - December 31, 2024</p></td><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$70,686.00</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$848,232.00</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:50.4pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">During the Extended Term, monthly installments of Base Rent for the Suite 400 Space shall be as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Months</u></p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Installment</u></p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual</u></p></td></tr><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2020 - December 31, 2020</p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$19,497.67</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$233,972.00</p></td></tr><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2021 - December 31, 2021</p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$19,497.67</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$233,972.00</p></td></tr><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2022 - December 31, 2022</p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$20,472.55</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$245,670.60</p></td></tr><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2023 - December 31, 2023</p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$20,472.55</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$245,670.60</p></td></tr><tr><td style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;">January 1, 2024 - December 31, 2024</p></td><td style="vertical-align:top;width:33.7%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$21,514.67</p></td><td style="vertical-align:top;width:20.16%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">$258,176.00</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provided that Tenant has faithfully performed all of the terms and conditions of this Lease, Landlord agrees to abate Tenant&#8217;s obligation to pay Base Rent for months of August, September, October, November, and December of 2013 and January of 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Work</u>. &#160;Landlord shall, at Landlord&#8217;s expense, (i) add seven (7) speed bumps around the Building to be located in the area mutually and reasonably agreed upon by Landlord and Tenant and (ii) install a fence or comparable barrier on the north side of the Building, which shall be mutually and reasonably acceptable to Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option to Extend</u>. &#160;The Option to Extend as set forth in Section 13 of that certain Fourth Amendment to Lease dated May 1, 2009, shall remain in full force during the Extended Term and effect and shall be applicable to the entire Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>. &#160;The Right of First Refusal covering Suite 300 of the Building, as set forth in Section 6 of that certain Third Amendment to Lease dated October 1, 2003 (the &#8220;Third Amendment&#8221;) (i) shall remain in full force and effect during the Term and the Extended Term, and (ii) may be exercised by Tenant during the Term or the Extended Term in accordance with Section 6 of the Third Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment and Subletting: &#160;Effective as of the full execution of this Amendment, Section 12</u>.1(b) of the Lease is hereby deleted and replaced with the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">&#8220;(b) A change in control of Tenant shall constitute an assignment requiring Landlord&#8217;s consent. &#160;The transfer, on a cumulative basis of a majority of the voting or management control of Tenant shall constitute a change in control for this purpose. &#160;So long as such change in control does not result in a material decline in Tenant&#8217;s credit, in the event that Landlord fails to provide written consent to an assignment that arises from a change in control, Landlord&#8217;s sole remedy for such assignment shall be to provide Tenant with forty-eight (48) months prior written notice of termination of the Lease.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 2 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord acknowledges that Landlord has or may have access to and gain knowledge of confidential and proprietary information of Tenant and its Affiliates and business partners, including, but not limited to, business practices, discoveries, ideas, formulations, costs and pricing data, techniques, programs, marketing plans, strategies and tactics, research and development information, data relating to the approval, administration, use or experience relating to any product of Tenant or any of its Affiliates or business partners (whether marketed or in development), and financial and technical information, all of which information is considered confidential by Tenant (&#8220;Confidential Information&#8221;). &#160;For the purposes of this Lease, the term &#8220;Affiliates&#8221; shall mean all entities controlling, controlled by or under common control with Tenant. &#160;The term &#8220;control&#8221; shall mean the ability to vote fifty percent (50%) or more of the voting securities of an entity or otherwise having the ability to influence and direct the policies and direction of an entity. &#160;Landlord agrees that Landlord will not use or disclose Confidential Information for any reason other than to carry out the purpose of this Lease without the prior written consent of Tenant. &#160;Notwithstanding the foregoing, Landlord is expressly permitted to disclose tenant&#8217;s financial and other related information to Landlord&#8217;s Affiliates, agents, employees, lenders (both current and potential and any potential buyer of the Building. &#160;The foregoing restrictions on use and disclosure shall not apply to information which Landlord can prove was or became public knowledge through no fault of Landlord.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Landlord may disclose Confidential Information (i) in response to a valid order of a court or any governmental agency or regulatory body or (ii) as otherwise required by law; provided that the Landlord promptly notifies Tenant of such pending order or requirement and lends Tenant all reasonable assistance, so that the Tenant may seek a protective order or other appropriate remedy; and provided further that in the event that no such protective order or other remedy is obtained, the Landlord will furnish only that portion of the Confidential Information which it is legally required to furnish in order to comply. &#160;Notwithstanding the foregoing, information required to be disclosed pursuant this Section 8(b) will continue to be considered Confidential Information for all other purposes.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recover Reconciliation</u>. &#160;Except for a $44,738.77 credit due Tenant for the 2012 Recovery Reconciliation as shown in more detail on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>, attached hereto, Tenant hereby represents to Landlord that, to the best of Tenant&#8217;s knowledge, as of the date of this Amendment, that Tenant has no defenses, offsets or counterclaims that could be asserted in an action by Landlord to enforce Landlord&#8217;s remedies under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Defenses</u>. &#160;Tenant affirms that, to the best of its knowledge, as of the date of execution of this Amendment: &#160;(a) no default or breach by Landlord exists under the Lease; (b) all tenant improvements to be constructed by Landlord prior to the date of this Amendment, if any, are complete and Tenant has accepted the Premises in &#8220;as is, where is&#8221; condition as of the date of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 3 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">this Amendment; and (c) Landlord has fully funded or Tenant has waived any unfunded tenant improvement allowances payable under the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker</u>. &#160;Tenant represents to Landlord that except for CB Richard Ellis, Inc. and Jackson and Cooksey (the &#8220;Brokers&#8221;), Tenant has not dealt with any real estate broker, salesperson or finder in connection with this Amendment, and no other such person initiated or participated in the negotiation of this Amendment or is entitled to any commission in connection herewith. &#160;Tenant hereby agrees to indemnify, defend and hold Landlord, its property manager and their respective employees harmless from and against any and all liabilities, claims, demands, actions, damages, costs and expenses (including attorneys fees) arising from either (a) a claim for a fee or commission made by any broker, other than the Brokers, claiming to have acted by or on behalf of Tenant in connection with this Amendment, or (b) a claim of, or right to lien under the statutes of the state in which the Premises are located relating to real estate broker liens with respect to any such broker retained by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Submission</u>. &#160;Submission of this Amendment by Landlord to Tenant for examination and/or execution shall not in any manner bind Landlord and no obligations on Landlord shall arise under this Amendment unless and until this Amendment is fully signed and delivered by Landlord and Tenant; provided, however, the execution and delivery by Tenant of this Amendment to Landlord shall constitute an irrevocable offer by Tenant of the terms and conditions herein contained, which offer may not be revoked for ten (10) days after such delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification</u>. &#160;A modification of any provision herein contained, or any other amendment to this Amendment, shall be effective only if the modification or amendment is in writing and signed by both Landlord and Tenant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. &#160;This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number and Gender</u>. &#160;As used in this Amendment, the neuter includes masculine and feminine, and the singular includes the plural.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u>. &#160;Headings at the beginning of each Section and subsection are solely for the convenience of the parties and are not a part of this Amendment. &#160;Except as otherwise provided in this Amendment, all exhibits referred to herein are attached hereto and are incorporated herein by this reference. &#160;Unless otherwise indicated, all references herein to Articles, Section, subsections, paragraphs, subparagraphs or provisions are to those in this Amendment. &#160;Any reference to a paragraph or Section herein includes all subparagraphs or subsections thereof. &#160;In the event any portion of this Amendment shall be declared by any court of competent jurisdiction to be invalid, illegal or unenforceable, such portion shall be deemed severed from this Amendment, and the remaining parts hereof shall remain in full force </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 4 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">and effect, as fully as though such invalid, illegal or unenforceable portion had never been part of this Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration of Other Agreements</u>. &#160;This Amendment, the Lease and prior amendments set forth the entire agreement and understanding of the parties with respect to the matters set forth herein and supersedes all previous written or oral understandings, agreements, contracts, correspondence and documentation with respect thereto.<font style="display:inline-block;width:26.53pt;"></font>Any oral representation or modifications concerning this Amendment shall be of no force or effect.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">f.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duplicate Originals; Counterparts</u>. &#160;This Amendment may be executed in any number of duplicate originals, all of which shall be of equal legal force and effect. &#160;Additionally, this Amendment may be executed in counterparts, but shall become effective only after a counterpart hereof has been executed by each party; all said counterparts shall, when taken together, constitute the entire single agreement between parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">g.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</u>. &#160;No failure or delay of either party in the exercise of any right given to such party hereunder shall constitute a waiver thereof unless the time specified herein for exercise of such right has expired, nor shall any single or partial exercise of any right preclude other or further exercise thereof or of any other right. &#160;No waiver by any party hereto of any breach or default shall be considered to be a waiver of any other breach or default. &#160;The waiver of any condition shall not constitute a waiver of any breach or default with respect to any covenant, representation or warranty.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">h.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u>. &#160;Landlord and Tenant each agree to execute any and all other documents and to take any further actions reasonably necessary to consummate the transactions contemplated hereby.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">i.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</u>. &#160;Except as otherwise provided herein, no person or entity shall be deemed to be a third party beneficiary hereof, and nothing in this Amendment, (either expressed or implied) is intended to confer upon any person or entity, other than Landlord and/or Tenant (and their respective nominees, successors and assigns), any rights, remedies, obligations or liabilities under or by reason of this Amendment.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">j.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Full Force and Effect</u>. &#160;The Lease, as amended hereby, shall continue in full force and effect, subject to the terms and provisions thereof and hereof. &#160;In the event of any conflict between the terms of the Lease and the terms of this Amendment, the terms of this Amendment shall control.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 5 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, this Amendment is executed as of the day and year aforesaid.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIVERSIDE BUSINESS GREEN, LP<b style="font-weight:bold;"><br></b>a Delaware limited partnership</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:43.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Printed Name:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NEOS THERAPEUTICS, LP<br>a Texas limited partnership</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:43.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Printed Name:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:12.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 6 -</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.55
<SEQUENCE>12
<FILENAME>aytu-20230630xex10d55.htm
<DESCRIPTION>EX-10.55
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:50 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.55</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDED AND RE-STATED</b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.7pt;margin:0pt;"><font style="font-size:12pt;">This Amended and Re-Stated Employment Agreement (the &quot;Agreement&quot;), is effective as of March 21, 2023 (the &quot;Effective Date&quot;), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the &quot;Company&quot;), and Greg Pyszczymuka as (&quot;Executive&quot;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS, </b><font style="font-size:12pt;">the Company is a duly organized Delaware corporation, with its principal place of business within the State of Colorado, and is in the business of developing and marketing pharmaceuticals, medical devices, and other healthcare products; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS, </b><font style="font-size:12pt;">the Company desires assurance of the continued association and services of the Executive in order to continue to retain the Executive&#39;s experience, skills, abilities, background and knowledge, and is willing to engage the Executive&#39;s services on the terms and conditions set forth in this Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS, </b><font style="font-size:12pt;">Executive desires to be in the continued employ of the Company, and is willing to accept such continued employment on the terms and conditions set forth in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NOW, THEREFORE, </b><font style="font-size:12pt;">in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.25pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.2pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-size:12pt;">. The Company hereby agrees to employ Executive and Executive hereby accepts such employment with the Company for the period of 12 months beginning on the Effective Date, with automatic renewal of the employment period every 12 months. &#160;. The Term of this Agreement (the &#8220;Term&#8221;) shall continue until the termination of Executive&#39;s employment in accordance with the provisions of this Agreement. The termination of Executive&#39;s employment under this Agreement shall end the Term but shall not terminate Executive&#39;s or the Company&#39;s other obligations that are intended to survive the termination of this Agreement (including without limitation, the payments under Section 4 and 5 and Executive&#39;s obligations under Section 8).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.1pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position and Duties</u><font style="font-size:12pt;">. During the Term, the Executive shall serve as the Chief Commercial Officer, and shall have supervision and control over and responsibility for the day-to-day business and affairs of the commercial operational aspects of the Company and shall have such other powers and duties as may from time to time be prescribed by the Chief Executive Officer (&quot;CEO&quot;) of the Company, provided that such duties are consistent with the Executive&#39;s position or other positions that he may hold from time to time. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the CEO, or engage in religious, charitable or other</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive&#39;s performance of his duties to the Company as provided in this Agreement. During the Term, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Executive to be adverse, competitive, or antagonistic to the Company, its business or prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of which Executive is or becomes a member of during the term hereof. Executive shall provide written disclosure to the Compensation Committee (&quot;Compensation Committee&quot;) of the Company&#39;s Board of Directors (the &quot;Board&quot;) as to all advisory boards on which Executive sits, and will provide the Company with written notice within 10 business days of Executive agreeing to sit on any additional advisory boards. On termination of Executive&#39;s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation and Related Matters</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.95pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u><font style="font-size:12pt;">. During the Term, the Executive&#39;s initial annual base salary shall be three hundred seventy-five thousand dollars ($375,000.00), less applicable deductions and withholdings. The Executive&#39;s base salary shall be reviewed at least semi-annually by the Compensation Committee or a majority of the independent members of the Board, and the base salary may be increased only by the Compensation Committee or a majority of the independent members of the Board. The base salary in effect at any given time is referred to herein as &quot;Base Salary.&quot; The Base Salary shall be payable in a manner that is consistent with the Company&#8217;s usual payroll practices for senior executives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bonus Compensation</u><font style="font-size:12pt;">. The Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the &quot;Bonus&quot;) with a target amount of forty percent (40%) of the Base Salary, subject to standard deductions and withholdings, based on the Compensation Committee&#39;s determination, in good faith, and based upon the Executive&#39;s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the Compensation Committee, in good faith, in consultation with the Executive (hereinafter referred to as the &quot;Performance Milestones&quot;). The Performance Milestones will be based on certain factors including, but not limited to, the Executive&#39;s performance and the Company&#39;s financial and operational performance. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Bonus Compensation</u><font style="font-size:12pt;">. In recognition of Executive&#39;s significant contributions in securing the Rumpus Therapeutics asset purchase and success in integrating the Company&#39;s commercial operations following the Neos Therapeutics merger (the &quot;Transactions&quot;), Executive acknowledges prior receipt of a one-time, discretionary bonus (the &quot;Transaction Bonus&quot;) in the amount of one hundred thousand dollars </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">($100,000.00).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Grant</u><font style="font-size:12pt;">. Executive acknowledges previous receipt of &#160;a sign on restricted stock grant of 75,000 shares, scheduled to vest over a (3) year period of employment with the Company beginning on October 1, 2021, and performance-based restricted stock units of 50,000 shares scheduled to vest over a (3) year period of employment with the Company beginning on the grant date of the performance-based award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u><font style="font-size:12pt;">. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Benefits</u><font style="font-size:12pt;">. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company&#39;s employee benefit plans in effect from time to time, subject to the terms of such plans.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacations</u><font style="font-size:12pt;">. For the term of this Agreement, Executive shall be entitled to paid time off at the rate of five (5) weeks per annum. In accordance with Company policy, unused paid time off will accrue up to a maximum accrual of 240 hours, which is considered the maximum accrual amount. Current accrued PTO of Executive, at the time of this employment agreement execution, shall not be impacted and remain unchanged. The Executive shall also be entitled to all paid holidays given by the Company to its executives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.7pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="font-size:12pt;">. During the Term, the Executive&#39;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Death</u><font style="font-size:12pt;">. The Executive&#39;s employment hereunder shall terminate upon his death.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.05pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.05pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u><font style="font-size:12pt;">. The Company may terminate the Executive&#39;s employment if he is disabled and unable to perform the essential functions of the Executive&#39;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#39;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#39;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company&#39;s determination of such issue shall be binding on the Executive. Nothing in this Section 3{b) shall be construed to waive the Executive&#39;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;260 I </font><i style="font-size:12pt;font-style:italic;">et seq. </i><font style="font-size:12pt;">and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><i style="font-size:12pt;font-style:italic;">et seq.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.1pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.8pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Company for Cause</u><font style="font-size:12pt;">. The Company may terminate the Executive&#39;s employment hereunder for Cause. For purposes of this Agreement, &quot;Cause&quot;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">shall mean any of the following: (i) the Executive&#39;s material breach of any agreement with the Company, including the Confidentiality and Intellectual Property Agreement, dated 10/04/2021 (the &quot;Confidentiality Agreement&quot;), the provisions of Section 8 of this Agreement, the Code of Conduct or any other material policy that may result in material injury to the Company; (ii) the Executive&#39;s conviction of , or entry of a plea of guilty to, or a plea of nolo contender with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iii) the Executive&#39;s act of fraud or intentional misrepresentation in connection with the Executive&#39;s duties or otherwise in connection with the business of the Company, that may result in material injury to the Company; (iv) the Executive&#39;s unintended but material breach in the performance of duties under this Agreement, including insubordination or failure to implement or follow a lawful policy or directive of the CEO or Company, provided that if such failure is curable, it is not cured within 30 days following written notice thereof from the CEO or Board; or (v) the Executive&#39;s willful malfeasance or willful misconduct in the performance of the Executive&#39;s duties for the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72.1pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.8pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.35pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Without Cause</u><font style="font-size:12pt;">. The Company may terminate the Executive&#39;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#39;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.15pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Executive</u><font style="font-size:12pt;">. The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, &quot;Good Reason&quot; shall mean, without the Executive&#39;s consent, the occurrence of any of the following: (i) the Company materially breaches a material term of this Agreement, and such breach causes or is likely to cause material harm to the Executive; (ii) there is a change in the Executive&#39;s responsibilities that represents a material and adverse change from the Executive&#39;s overall responsibilities, taken as a whole; (iii) there is a Change in Control that results in a change in the Executive&#39;s responsibilities that represents a material and adverse change from the Executive&#39;s overall responsibilities, taken as a whole; (iv) the Executive&#39;s Base Salary is substantially reduced or diminished; or (v) the Executive&#39;s place of employment is relocated by the Company more than a 50-mile radius from Philadelphia, Pennsylvania (it being understood and agreed that the Executive may be required to travel in connection with Company business and none of such travel shall constitute or give rise to &quot;Good Reason&quot;). The Executive&#39;s voluntary termination shall be deemed to have occurred for Good Reason for purposes of this Agreement only if (x) the Executive provides written notice to the Company within 30 days after the Executive becomes aware of circumstances giving rise to Good Reason, (y) the Company fails to correct the circumstances giving rise to Good Reason within 30 days following the receipt of such notice (the &quot;Cure Period&quot;) and (z) the Executive resigns within 30 days following the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.15pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Termination</u><font style="font-size:12pt;">. Except for termination as specified in Section 3(a), any termination of the Executive&#39;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a &quot;Notice of Termination&quot; shall mean a notice, which shall indicate the specific termination provision in this Agreement relied upon.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.95pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.2pt;"><font style="color:#3d3d3d;font-family:'Times New Roman','Times','serif';font-size:11.5pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u><font style="font-size:12pt;">. &quot;Date of Termination&quot; shall mean: (i) if the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Executive&#39;s employment is terminated by his death, the date of his death; (ii) if the Executive&#39;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#39;s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive&#39;s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive&#39;s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period, 30 days after the date on which a Notice of Termination is given. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 71.95pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Upon Termination</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:41.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Generally</u><font style="font-size:12pt;">. If the Executive&#39;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive&#39;s Date of Termination in a lump sum payment; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &quot;Accrued Benefit&quot;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.8pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by the Company Without Cause, by the Executive with Good Reason</u><font style="font-size:12pt;">. During the Term, if the Executive&#39;s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e), then the Company shall pay the Executive his Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the &quot;Separation Agreement and Release&quot;) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.55pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:33.82pt;"></font><font style="font-size:12pt;">The Company shall pay the Executive an amount equal to the Executive&#39;s annual Base Salary plus any pro-rated incentive compensation earned (at target amount of forty percent (40%) of the Executive&#39;s Base Salary) but unpaid as of the Date of Termination (the &quot;Severance Amount&quot;). In the event the Company determines that bonus payouts for Company executives will not be paid in full for the fiscal year during which the Executive&#39;s termination occurs, at the Company&#39;s sole determination, Executive&#39;s pro-rated incentive compensation may be reduced below forty percent (40%) commensurate with such other executive bonuses paid for that fiscal year. Notwithstanding the foregoing, if the Executive breaches any of the provisions of the Confidentiality Agreement or Section 8 of this Agreement, all payments of the Severance Amount sha11 immediately cease; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.35pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:31.19pt;"></font><font style="font-size:12pt;">Notwithstanding anything to the contrary in the applicable Restricted Stock Agreement, the issued restricted stock will immediately vest following the expiration of the revocation period as set forth in Separation Agreement and Release; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:27.16pt;"></font><font style="font-size:12pt;">If the Executive was participating in the Company&#39;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive&#39;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:27.87pt;"></font><font style="font-size:12pt;">The amounts payable under this Section 4(b) shall be paid out in a substantially equal insta11ments in accordance with the Company&#39;s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately fol1owing the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section l.409A-2(b)(2)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.3pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Payment</u><font style="font-size:12pt;">. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive&#39;s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive&#39;s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control. Regardless of change in employment status following Change in Control, all stock options and other stock-based awards held by the Executive and granted after the Effective Date shall immediately accelerate and become fully exercisable or non-forfeitable as of the Date of Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:12pt;">. During the Term, if within 12 months after a Change in Control, the Executive&#39;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release effective all within &#160;the time frame set forth in the Separation Agreement and Release,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.55pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:32.62pt;"></font><font style="font-size:12pt;">The Company shall pay the Executive a lump sum in cash in an amount equal to one time the sum of (A) the Executive&#39;s then current Base Salary (or the Executive&#39;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive&#39;s target annual incentive compensation for the then- </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36.9pt;"><font style="font-size:12pt;">current year; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.75pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:28.89pt;"></font><font style="font-size:12pt;">Notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards held by the Executive and granted after the Effective Date shall immediately accelerate and become fully exercisable or non-forfeitable as of the Date of Termination; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:25.51pt;"></font><font style="font-size:12pt;">If the Executive was participating in the Company&#39;s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive&#39;s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:25.97pt;"></font><font style="font-size:12pt;">The amounts payable under this Section S(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.5pt;margin:0pt;"><font style="font-size:12pt;">For the avoidance of doubt, all stock options and other stock-based awards held by the Executive as of the Effective Date shall be treated as indicated in the applicable award agreements.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitation</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:67.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:39.12pt;"></font><font style="font-size:12pt;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &quot;Aggregate Payments&quot;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; I .280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.2800-1, Q&amp;A-24(b) or(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.55pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:31.89pt;"></font><font style="font-size:12pt;">For purposes of this Section 5(b), the &quot;After Tax Amount&quot; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#39;s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 107.55pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:27.71pt;"></font><font style="font-size:12pt;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &quot;Accounting Finn&quot;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:12pt;">. For purposes of this Section 5, the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">&quot;Change in Control&quot; shall mean the consummation of any of the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.3pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(i)</font><font style="display:inline-block;width:33.17pt;"></font><font style="font-size:12pt;">A sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(ii)</font><font style="display:inline-block;width:29.19pt;"></font><font style="font-size:12pt;">A merger, reorganization or consolidation in which the outstanding shares of common stock of the Company are converted into or exchanged for shares of the successor entity and the holders of the Company&#39;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity immediately upon the completion of such transaction; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iii)</font><font style="display:inline-block;width:26.01pt;"></font><font style="font-size:12pt;">The sale of all or a majority of the common stock of the Company to an unrelated person or entity; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">(iv)</font><font style="display:inline-block;width:26.62pt;"></font><font style="font-size:12pt;">Any other transaction in which the holders of the Company&#39;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity in the transaction immediately upon the completion of such transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.1pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#39;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &quot;specified employee&quot; within the meaning of Section 409A(a){2)(B)(i) of the Code, then to the extent any payment or benefit </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">that the Executive becomes entitled to under this Agreement on account of the Executive&#39;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#39;s separation from service, or (B) the Executive&#39;s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72.1pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year sha11 not affect the in-kind benefits to be provided or the expenses eligible for &#160;reimbursement &#160;in any other taxable year (except for any lifetime or other aggregate limitation &#160;applicable &#160;to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">To the extent that any payment or benefit described in this Agreement constitutes &quot;non-qualified deferred compensation&quot; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#39;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#39;s &quot;separation from service.&quot; The determination of whether and when a separation from service has occurred sha11 be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A- 1(h).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.95pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section l.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.55pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u><font style="font-size:12pt;">. The Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, &#160;methods, &#160;designs, &#160;analyses, drawings, reports, patent applications, copyrightable work and &#160;mask &#160;work (whether or not including any confidential information) and all registrations or applications &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">related &#160;thereto, &#160;all other proprietary information and all similar or related information (whether or not &#160;patentable) which relate to the Company&#39;s or any of its affiliates&#39; actual or anticipated business, research and development or existing or future products or services and which &#160;are conceived, &#160;developed &#160;or made by the Executive (whether alone or jointly &#160;with &#160;others) &#160;while employed &#160;by the Company and its affiliates, whether before or after the date of this Agreement (collectively referred to as &quot;Work Product&quot;), are the property of the Company or such affiliated companies. The &#160;Executive shall promptly disclose such Work Product to the Board and, at the Company&#39;s &#160;expense, perform &#160;all actions reasonably requested by the Board &#160;(whether &#160;during &#160;or after the period of employment) to establish and confirm such ownership (including, without limitation, executing and delivering assignments, consents, powers of attorney and other instruments). &#160;The Executive acknowledges that all Work Product shall be deemed to constitute &quot;works made for hire&quot; under the U.S. Copyright Act of 1976, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.75pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information, Noncompetition and Cooperation</u><font style="font-size:12pt;">. The Executive agrees that he continues to be bound by the terms of the Confidentiality Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:71.8pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The Executive agrees that all property (including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts and computer&#173; generated materials) furnished to or created or prepared by the Executive incident to the Executive&#39;s employment belongs to the Company and shall be promptly returned to the Company upon termination of the Executive&#39;s employment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Upon termination of the Executive&#39;s employment, the Executive shall be deemed to have resigned from any and all offices and directorships then held with the Company and its affiliates. Following any termination of employment, the Executive shall reasonably cooperate with the Company (i) in the winding up of pending work on behalf of the Company and the orderly transfer of work to other employees, and (ii) in the defense of any action brought by any third party against the Company that relates to the Executive&#39;s employment by the Company; provided, that in each case the Company shall reimburse the Executive for any reasonable and documented out-of-pocket fees and expenses incurred by the Executive in connection with such cooperation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">The Executive acknowledges that in the course of the Executive&#39;s employment with the Company, the Executive will become familiar with the Company&#39;s and its affiliates&#39; trade secrets and with other confidential and proprietary information and that the Executive&#39;s services will be of special, unique and extraordinary value to the Company and its affiliates. Therefore, the Executive agrees that the Executive shall not, during the Term and for a period of one (1) year thereafter, directly or indirectly, either for himself or for any other person or entity or otherwise, (i) participate in any business or enterprise (including, without limitation, any division, group or franchise of a larger organization), engaged, anywhere within North America at the time of termination (the &quot;Restricted Territory&quot;), in the business of developing or commercializing controlled release, ion exchange resin based pharmaceutical products, developing or commercializing ADHD products, or developing or commercializing any products addressing Vascular Ehlers-Danlos Syndrome, or any other business in which the Executive would be required to employ, reveal or otherwise utilize trade secrets of the Company and its affiliates used prior to termination that may result in a material injury to the Company (with it being understood that the term &quot;participate in&quot; shall include, without limitation, having any direct or indirect interest in any person or entity, whether as a sole proprietor, owner, stockholder, partner, joint venturer, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">creditor or otherwise, or rendering any direct or indirect service or assistance to any person or entity -whether as a director, officer, manager, supervisor, employee, agent, consultant, advisor or otherwise); provided that, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the outstanding stock of any class of an entity which is publicly traded so long as the Executive has no active participation in the business of such corporation; (ii) induce or attempt to induce any customer, supplier, licensee or other business relation of the Company or any of its subsidiaries to cease doing business with the Company or any such subsidiary or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and the Company and any such subsidiary; or (iii) induce or attempt to induce any employee of the Company or its affiliates to leave the employ of the Company or any such affiliated company, or in any way interfere with the relationship between the Company and any of its affiliates and any employee thereof, or hire or otherwise engage any person who was an employee of the Company or any of its affiliated companies within one year before any such hiring would take place.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:65.05pt;margin:0pt 0pt 0pt 6.95pt;"><font style="display:inline-block;text-indent:0pt;width:44.65pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">The Executive agrees that he will not directly or indirectly, individually or in concert with others, make any statement calculated or likely to have the effect of undermining or disparaging the business or the business reputation of the Company or its affiliates or their respective employees, officers, directors, customers, suppliers, successors and assigns, including, without limitation, negative comments about any such person or company, its management methods, policies and/or practices. Notwithstanding the foregoing, nothing herein shall prohibit the Executive from responding accurately and fully to any question, inquiry or request made in connection with any governmental inquiry, investigation, review, audit or proceeding, any legal proceeding or claim (whether in court, arbitration or otherwise) of any nature, or as otherwise required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:70.65pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.55pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">If, at the time of enforcement of this Section 8, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law. Because the Executive&#39;s services are unique and because the Executive has access to confidential and proprietary information of the Company and its business, the parties hereto agree that money damages would not be an adequate remedy for any breach of Section 8 of this Agreement. Therefore, in the event of a breach or threatened breach of Section 8 of this Agreement, the Company or its successors or assigns may, in addition to other rights and remedies existing in their favor and notwithstanding anything herein to the contrary, apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief in order to enforce or prevent any violations of, the provisions hereof (without posting a bond or other security).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:70.65pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72.05pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:12pt;">The Executive acknowledges that the provisions of this Section 8 are in consideration of the Executive&#39;s employment with the Company and additional good and valuable consideration as set forth in this Agreement. The Executive agrees and acknowledges that the restrictions contained in Section 8 do not preclude the Executive from earning a livelihood, nor do they unreasonably impose limitations on the Executive&#39;s ability to earn a living. The Executive acknowledges (i) that the business of the Company and its affiliates will be conducted throughout the Restricted Territory, (ii) notwithstanding the state</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">of formation or principal office of the Company and its affiliates, or any of their respective executives or employees (including the Executive), it is expected that the Company will have business activities and have valuable business relationships within its industry throughout the Restricted Territory, and (iii) as part of the Executive&#39;s responsibilities, the Executive may be traveling throughout the Restricted Territory in furtherance of the Company&#39;s and its affiliates&#39; business and its relationships. The Executive acknowledges that the potential harm to the Company of the non-enforcement of Section 8 outweighs any potential harm to the Executive of its enforcement by injunction or otherwise. The Executive acknowledges that the Executive has carefully read this Agreement and has given careful consideration to the restraints imposed upon the Executive by this Agreement and is in full accord as to their necessity for the reasonable and proper protection of confidential and proprietary information of the Company and its subsidiaries now existing or to be developed in the future. The Executive acknowledges that each and every restraint imposed by this Agreement is reasonable with respect to scope, duration, and geographical area.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.85pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration of Disputes</u><font style="font-size:12pt;">. Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive&#39;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (&quot;AAA&quot;) in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity&#39;s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties consent to the jurisdiction to the federal courts of the District of Colorado or, if there shall be no jurisdiction, to the state courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto. This Section 8 shall be specifica1ly enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 9.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.45pt;text-align:justify;text-indent:-0.45pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:37.55pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.75pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent to Jurisdiction</u><font style="font-size:12pt;">. To the extent that any court action is permitted consistent with or to enforce Section 9 of this Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the State of Colorado and the United States District Court for the District of Colorado. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.85pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</u><font style="font-size:12pt;">. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that the Confidentiality Agreement remains in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.75pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:12pt;">. All payments made by the Company to the Executive under </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:44pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor to the Executive</u><font style="font-size:12pt;">. This Agreement shall inure to the benefit of and be enforceable by the Executive&#39;s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive&#39;s death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive&#39;s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.3pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.35pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">14.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u><font style="font-size:12pt;">. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.35pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">15.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-size:12pt;">. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#39;s employment to the extent necessary to effectuate the terms contained herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.3pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.45pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">16.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-size:12pt;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.8pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">17.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:12pt;">. Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:129.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.75pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#3f3f3f;font-size:11.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">If to Executive: To the address specified in the payroll</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;">records of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:129.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="color:#3f3f3f;font-size:11.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">If to the Company:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.1pt;margin:0pt 0pt 0pt 166.5pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aytu BioPharma, Inc</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0.1pt;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;">373 Inverness Parkway</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;">Suite 206</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 166.5pt;"><font style="font-size:12pt;">Englewood, Colorado 80112</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:35.75pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:46.05pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">18.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</u><font style="font-size:12pt;">. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:45.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">19.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:12pt;">. This is a Colorado contract and shall be construed under and be governed in all respects by the laws of the State of Colorado, without giving effect to the conflict of laws principles of such State. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the Tenth Circuit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.2pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">20.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:12pt;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.8pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">21.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successor to Company</u><font style="font-size:12pt;">. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.35pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 220.5pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a name="_Hlk146202121"></a><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AYTU BIOPHARMA, INC</b><font style="font-size:12pt;">.</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: Vivian Lu</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Its: Chairwoman of the Compensation Committee Board of Directors</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Executive</b></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Greg Pyszczymuka</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>13
<FILENAME>aytu-20230630xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:27:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF AYTU BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:88.66%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of Subsidiary</b></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">State Jurisdiction</b></p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aytu Therapeutics, LLC</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Innovus Pharmaceuticals, Inc.</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nevada</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Semprae Laboratories, Inc</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplement Hunt, Inc.</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nevada</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delta Prime Savings Club, Inc</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nevada</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neos Therapeutics, Inc.</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neos Therapeutics Brands, LLC</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neos Therapeutics, LP</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Texas</p></td></tr><tr><td style="vertical-align:top;width:8.64%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</div><div style="display:table-cell;padding:0pt;"></div></div></div></td><td style="vertical-align:top;width:58.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PharmaFab Texas, LLC</p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Texas</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>14
<FILENAME>aytu-20230630xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:28:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;">We hereby consent to the incorporation by reference in Aytu BioPharma, Inc. Registration Statements on Form S-8 (No. 333-255325, 333-205462, 333-236598 and 333-272897), Form S-3 (Nos. 333-259862, 333-235548, 333-236599, 333-239010 and 333-265479) and Form S-1 (File Nos. , 333-212100, 333-213489, 333-222994, 333-223385, 333-227243, 333-227706 and 333-271556) of our report dated September 27, 2022, except for Note 2, as to which the date is October 12, 2023,  relating to the consolidated financial statements as of and for the year ended June 30, 2022 that appear in this Annual Report on Form 10-K.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-top:12pt;background:#ffffff;margin:0pt;">/s/Plante &amp; Moran, PLLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Denver, Colorado </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">October 12, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>15
<FILENAME>aytu-20230630xex23d2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:28:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have issued our report dated October 12, 2023, with respect to the consolidated financial statements included in the Annual Report of Aytu BioPharma, Inc. on Form 10-K for the year ended June 30, 2023. We consent to the incorporation by reference of said report into the Registration Statements of Aytu BioPharma, Inc. on Forms S-1 (File Nos. 333-212100, 333-213489, 333-222994, 333-223385, 333-227243, 333-227706 and 333-271556), on Forms S-3 (File Nos. 333-259862, 333-235548, 333-236599, 333-239010 and 333-265479) and on Forms S-8 (File Nos. 333-255325, 333-205462, 333-236598 and 333-272897).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">/s/ GRANT THORNTON LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Denver, Colorado</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">October 12, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>16
<FILENAME>aytu-20230630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:28:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AYTU BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Joshua R. Disbrow, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this report on Form 10-K for the year ended June 30, 2023 of Aytu BioPharma, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8212;15(e) and 15d&#8212;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8212;15(f) and 15d&#8212;15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date: October 12, 2023</b></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joshua R. Disbrow</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Joshua R. Disbrow</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer (Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>17
<FILENAME>aytu-20230630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:28:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AYTU BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Mark Oki, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this report on Form 10-K for the year ended June 30, 2023 of Aytu BioPharma, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8212;15(e) and 15d&#8212;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8212;15(f) and 15d&#8212;15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:26.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date: October 12, 2023</b></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mark Oki</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Mark Oki</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>18
<FILENAME>aytu-20230630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 10/12/2023 05:28:25 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S. C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I Joshua R. Disbrow, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10&#8209;K of Aytu BioPharma, Inc. for the fiscal year ended June 30, 2023 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><b style="font-weight:bold;">Date: October 12, 2023</b></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joshua R. Disbrow</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Joshua R. Disbrow</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer (Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I Mark Oki, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10&#8209;K of Aytu BioPharma, Inc. for the fiscal year ended June 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><b style="font-weight:bold;">Date: October 12, 2023</b></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mark Oki</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Mark Oki</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>aytu-20230630x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20230630x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J )8# 2(  A$! Q$!_\0
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M-&R. RL-I!Z$&ORUUG]C[]H+]EWXU:MXG^""+K&CWYD6)X)( 1 [A_L\\$K
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&P]** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>aytu-20230630xex10d47001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20230630xex10d47001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +9!2T# 2(  A$! Q$!_\0
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M@:GBG_"1:K_T$[S_ ,"'_P :/^$AU7_H)WG_ ($/_C7MW@#X5:%X<?0=3O\
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M!.\_\"'_ ,:/^$AU7_H)WG_@0_\ C6?119!<T/\ A(=5_P"@G>?^!#_XT?\
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MBBR"YH?\)#JO_03O/_ A_P#&C_A(=5_Z"=Y_X$/_ (UGT4607-#_ (2'5?\
MH)WG_@0_^-'_  D.J_\ 03O/_ A_\:SZ*+(+FA_PD.J_]!.\_P# A_\ &C_A
M(=5_Z"=Y_P"!#_XUGT4607-#_A(=5_Z"=Y_X$/\ XT?\)#JO_03O/_ A_P#&
ML^BBR"YH?\)#JO\ T$[S_P "'_QH_P"$AU7_ *"=Y_X$/_C6?119!<T/^$AU
M7_H)WG_@0_\ C1_PD.J_]!.\_P# A_\ &L^BBR"YH?\ "0ZK_P!!.\_\"'_Q
MH_X2'5?^@G>?^!#_ .-9]%%D%S0_X2'5?^@G>?\ @0_^-'_"0ZK_ -!.\_\
M A_\:SZ*+(+FA_PD.J_]!.\_\"'_ ,:/^$AU7_H)WG_@0_\ C6?119!<T/\
MA(=5_P"@G>?^!#_XT?\ "0ZK_P!!.\_\"'_QK/HHL@N:'_"0ZK_T$[S_ ,"'
M_P :/^$AU7_H)WG_ ($/_C6?119!<T/^$AU7_H)WG_@0_P#C1_PD.J_]!.\_
M\"'_ ,:SZ*+(+FA_PD.J_P#03O/_  (?_&C_ (2'5?\ H)WG_@0_^-9]%%D%
MS0_X2'5?^@G>?^!#_P"-'_"0ZK_T$[S_ ,"'_P :SZ*+(+FA_P )#JO_ $$[
MS_P(?_&C_A(=5_Z"=Y_X$/\ XUGT4607-#_A(=5_Z"=Y_P"!#_XT?\)#JO\
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MD.J_]!.\_P# A_\ &C_A(=5_Z"=Y_P"!#_XUGT4607-#_A(=5_Z"=Y_X$/\
MXT?\)#JO_03O/_ A_P#&L^BBR"YH?\)#JO\ T$[S_P "'_QH_P"$AU7_ *"=
MY_X$/_C6?119!<T/^$AU7_H)WG_@0_\ C1_PD.J_]!.\_P# A_\ &L^BBR"Y
MH?\ "0ZK_P!!.\_\"'_QH_X2'5?^@G>?^!#_ .-9]%%D%S0_X2'5?^@G>?\
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M:/\ A(=5_P"@G>?^!#_XUGT4607-#_A(=5_Z"=Y_X$/_ (T?\)#JO_03O/\
MP(?_ !K/HHL@N:'_  D.J_\ 03O/_ A_\:/^$AU7_H)WG_@0_P#C6?119!<T
M/^$AU7_H)WG_ ($/_C1_PD.J_P#03O/_  (?_&L^BBR"YH?\)#JO_03O/_ A
M_P#&C_A(=5_Z"=Y_X$/_ (UGT4607-#_ (2'5?\ H)WG_@0_^-'_  D.J_\
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MZ=>SVLZA9X)&BD .0&4X//?D5#0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.],1Y/THKH?%NB_8I_M,*XAD/('\)KGJ "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&=V=N#NQP>#GCDZ*8!1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ****  =:[WQ?KU_HL?A];*X\E9='MRX,:-G!?'W@:X(=:Z[XA
MG(\-?]@:#_T)Z3W&9W_"<:Y@#[:,#H/L\7_Q-;=KK-[K7@?Q!)>S>>Z&)5.Q
M5P-Z_P!T"N'KJ]"_Y$/Q'_O0_P#H:T-#1RE%%%,D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M22U-K6XD]+'(44451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6QX+_Y'/P__ -A*V_\ 1JUCUL>"_P#D<_#_ /V$K;_T:M Q/&'_ "-FM?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBM"_P!
MO=/: -"THF@CG5H59AM=0P!..N#R* ,^BKFKZ7-HM_)9W!0RH%)V$D?,H8=0
M.Q%4Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNK7ZZ;82SD\@84>IKS*21I9&=CEF.2:8AM%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %;'@O\ Y'/P_P#]A*V_]&K6/4MI=36-W!<V\ABN
M()%ECD7JK*<J1]" :!FEXO\ ^1LUK_K]F_\ 1C5D5)=74M[<RW$\AEGE<R.[
M=68G))_&HZ!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%%  .M=5X\_U?AO_ +!$/_H3URHZUU7CS_5^&_\ L$0_^A/2
MZC.5KKM"_P"2<^)O^N]K_-JY&NNT+_DG/B;_ *[VO\VH8(Y&BBBF(**** "B
MBB@#VG4_LRZ?H)<PASID!.XVP/0_\](V;]<5RGQ)P=$T H4,>ZXV[#&1U7/W
M%"_D*Z;6?$5II5EH4,VH26KG3(&V+-<(.AYQ&0/ZU2O[71OB!9Z3:_\ "36]
MI<Q2.B),LTLDA=A@9;GMW-9+N:'E%%6]8T\Z3JMY9&02FWF:+>!@-M)&<?A5
M2M3,**ZGPEX,MO$6EZA?WFL1:1;V<D<;/-$S@E]V.G3[OZU?;P-X;7_F>+$_
M2VDI70['#'I7N'B8VXOX?,:'=]E@SO:U!_U:_P!^,M^9KBF\">&B/E\=6)^M
MK(*Z?7?&^D->HMOK+-''#%'F*:Z1250 \(0.W:I;N]"EH<_\6@@@\,>6%"&Q
M8_)LQ_K&_N +^0KSZN_^*]TE[;^&)XY3,CV+$2,SL3^\/=_F_.N JH[">X44
M44R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ****  =:^@M+NVBT+1E5R!_9]OP)]O_ "S7M]H3_P!!KR'0
MO"EEJ&E?VAJ.O6^C0M,88Q-;R2ER "?N=/O"O1T\<:%I]G96<7B&.1;:VB@+
MQPSA6*J 2!M]JB6NQ<=#SOXF-O\ '&J-ZLAY.?\ EFON?YGZUS%=-\27$OC7
M4G#;PWEL&YY!C4YYKF:I;$O<****8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K8\&_\C;HW_7Y#_P"ABL>N]T'PQI>AW>C:EJ/B>SL;
MC$5[]CDM9F(7.X#<HP<XZTF-'K6DWCG6;9=S8,P&/M&>_I]J/_H)^E?-4W^N
MD_WC_.O?/#GC;3-1\16-K!K*W$TLX5(Q', QSTY&/SKP.;_72?[Q_G4Q*D-H
MHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#IO".MBWD^QS-B-C\A/8^E=C-$EQ$T;J&1A@
M@UY0"0<C@BNP\.^*5=5MKQMK#A9#W^M %#6_"DMH[2VP,L/7:.JUS[*5.""#
MZ&O600P!!R#W%0?\(];:S=PP&W1I9I%C4].20!D_C0!Y93HXVE8*BEF/8"OJ
M+6/V>O ED-4TB#7)QXHTZU%Q)#=(([>0X!*HQQGKQC_&O*[73+6R \F!$/KC
MFDG<;5CE]"\)/(RSWB[4'(C[GZUV("QH!PJJ/P H=UC4L[!5'4FN-\1^*/M
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MT,&N_P#?RQ_PH^LX?_GXOO#VU#_GY'[T?/-%?0__  S[X(QG_A(-=_[^V/\
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M[I%QG/0#\:@'PZ\(&4G[!=&+[3Y_EB2WW!/^>.[SON_AGWKG^NQ_DE_X"_\
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M/RB_PH^NP_EE_P" O_(?UM?\^Y_^ R_R/#J*]P_X4'H><?V]>Y_W8O\ "@?
M/0><^(+T?\ B/]*/KL/Y9?\ @+_R#ZVO^?<__ 9?Y'A]%>X'X!Z",8\07I_X
M!%_A2_\ "@-#()77KUE'4[(@/Y4?78?RR_\  7_D'UM?\^Y_^ R_R/#J*]X/
M[.>D[-PUN^(_W8?\*</V<]&V MKU^I/;RXC1]>A_++_P%_Y!];7_ #[G_P"
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MTS9Y9A,G5?[I;J1^-<=4Q5BF[FCJ6O7>J<2R;8^R+P*SJ**HD**** "BBB@
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M^ DM+_8FE?\ 0QVW_@++26F[!A9SR2^%M9$DCN!-;8W,3WDJ&T _X1G4^/\
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MOKP6]%P/2O:XOAE\/4L[ZU36_P#6,'NI/[6B,F >C-CA=Q&1W.,UR'Q.\/\
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M1M3Z8KA\5TOQ#4IXJN065OD0Y7IRH-<W36PF)BC%+15 7M '_$^TW_KYB_\
M0Q70_$+6O,U*XTRW3RK>*4O,1UEE[D^P[5S^@?\ (>TW_KYB_P#0Q5OQH<^*
M]4/K.U3U'T,3%&*6BJ$)BO0_!E__ &;X1:7*(9+_ ,H,ZDX)CXZ<\D"O/:ZB
MWO7L_A_^["[SJ897/5"J @CWJ7J-'27]SKOAQM0N]5TF]-I).9(I%G 5%!P
M0"< Y%9OB/Q3>:%J5Y!;+$%OK&!9/,&\@;.Q^A-++XSN=2T.>\UF&WNH6<PP
M6ZAE,C<,V6W'"C"Y Z\"L3QQ/]HUJ.38L8:UA(5,X'R#@9J4NX-EWPY!XCU?
MPQ>Z9I5@+JPDE!F<;=P/!P"S#T%0_P#"L/%'_0&F_P"_D?\ \54?@WQ3>:'?
M06RZE)I^G33*;@QJI('0G)4GI7LOB5FT/P]=W_\ ;NI(ZPLT)=HR"^T[ 1Y7
M<XZXH;:8TDT>!ZMHUYH5X;2_MVMK@*',;$$X/0\$BNM^"$H@^*&AL5W R,"
M<9&TY&:Y+5M9O=>O#=ZA<-<W)4(9& !P.@X %=5\%@#\3M"!.T&4Y)[?*:Z:
M/\2-^Z-L-_'AZK\SSCPS-X6UJ:.!?##P*ML\SRR:@[JBK&6)(P,]/6N'P#V%
M=KJ>FVWA;PA"=(F&K1:A&L5QJ\1Q&H !\E4^\A. 26ZXX[UQ=?:(^[8F!Z48
M'I2T4Q"8'H*,#TI:* $Q1BEHH *3%+10 F*,4M% "8HP/2EHH 3 ]!4EL/\
M2(O]X?SIE26__'Q%_O#^= SK/BWS\0-3Q_TS_P#0%K*D\$Z[#X?77'TN<:2P
MR+K@KC.,XSD#/?&*]@E_X0#_ (2GQ ?%YM1=":(PF<S9\ORESCR^.OK7JA\'
M:%+H(TTV2MI1B""W,LFS9U_O9_K63GRI&G+>Y\845Z7\5U\ KIEC_P (@;;[
M7YY^T>09B=FTXSOXZXZ5YI6B=U<S:L%=CH/_ "3/Q5_U\6G_ *$U<=78Z#_R
M3/Q5_P!?%I_Z$U#&CC:6BBF2%%%% !1110 4F*6B@!,4M%% !1110!Z=K_\
MR1G1?]]?_0YJ\QKT[7AGX+Z*?^FBC_QZ7_&O,:Y*'QU?\7_ML3EH_P 2K_B7
M_I,0HHHKK.H**** "BBB@ HHHH **Z;P=\-_$'CWSO[%L#=+"0'8L% )Z#)K
MJ?\ AFOX@?\ 0%'_ '^%,9YA17I__#-?Q _Z H_[_"@_LV?$  DZ,,#_ *;"
M@1YA16QXH\(ZMX-U$6.KVC6EP5WA2<AAZ@BL>D 4444 %%%% !1110 4444
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M/<O)")@\110 21CG_=J5-M[%.-CPOP__ ,A[3?\ KYB_]#%6_&7_ "-.I_\
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MQA1110 4AZ4M(>E 'I$0Q:6?S%O]&BY+AL?(./;Z=NE+0IS:67.?]&B'4'^
M>G_Z_6BOCL3_ !Y^K_,^(Q?^\5/5_F%%%%<QR!1110 AZ5UWQ!.3HO!&+%1S
MWYZUR)Z5UWQ 4*=%QWLE)^N:GJ!R5&:**H S114L%G<70)AMY9@O!,<;-C\A
M0!8T3_D-Z=_U\Q?^ABK'BOCQ/JO_ %\O_.MOP;X9D2ZAU/4+6X6"*=$AB\IM
MTDFX8.,?='4FLWQ1I5])XDU-EL[EU-PY#+ Y!YZCBIOJ'0P>M!&#@\&NG\#Z
M9>1>+-->2SN$19,EGA8 <'N16JF@B[\8ZQ/?0-]A5Y(PSQ':SOE$Q@=B=V1T
MVYHN.QE>#X);K2O$D4,;2RM9J%1 2Q_>#L*[:?Q/X@_LFZTR/1YI8XK9(H\(
M^6RNTG ';-<_X>T^YTOPGXMAN8)()4C4?,I7D$]_2L^::1(_$#+(ZL+>V((8
MY'S)4O5AL4O'BE/$4BD$%88@01@@[!7/@X/!P?:ND^(85?%5P%+$;(_O=?NB
MN;JUL(7S'_OM_P!]&D)+=23]3FBBF!?T#_D/:;_U\Q?^ABK?C3_D:]5_Z[M5
M30/^0]IO_7S%_P"ABK7C/_D:M3_Z[M2ZAT-3P[\3M8\+Z4FGV2VIMT9G!EB9
MFRQR>0PKT[X?_$%_$.F7,VKW=C:S)-L10XBRNT'.&;GFO!*0@'J ?J*EQ3&I
M-'TWJOBFQL]*O9[?4K)YXH))(T^TH=S!20,!N>0.*\D/QN\1$$%+#D?\\6_^
M+KS_ &C^Z/RI:2@D-R;$;[I^E=IKNAWFO^++>VM+>2Y86=NSK'C(3:H)Y^M<
M6WW3]*[W4_%%UX5\7Q7=HL+.UA!$WGJ6 !12>A'I5/R)-.P\&W-MJZ*/!UTD
M'F&,W!O<C8<J6QCT)I?!_@_4O#.NZ\EQ;2^0_A_5_*FV<./L4V.G0^QKT^'Q
M+I<NDC4Q>QFPS@W #;>.O;->:^$O'.I^*=<U:6Y:.!K?P[JX3[*&0'_0Y2">
M3R,<5T8)MXB'JCT<$DL52]4?,0) P2<T9/K707%VWB?2+BYN KZG9*KO.!AI
MXB0I+^K*2.>I!YZ5S]?:'V(4444 %%%% !1110 4444 %7-&C675[%& 96GC
M!!&01N%4ZLZ7.EMJ5I,YVI',CL<= &!- ST3Q+\1#HFOZEIT7AW0GCM;AX5=
M[/YB%8@$\]>*S4^+,J9_XIOP^V?[UEG^M+K_ (=TOQ%K.JW]CXHT^>69IKM;
M58)@V "Y&2N.@ZUQ%F(C>6XGQY!D7S,]-N1G],U*2&VSN?\ A;LVW'_",^'<
M?]>/_P!>F-\692,?\(UX?'N+/_Z]=AXSL_A-'X9U4Z'<6+ZNL1^RK'<SLQ?(
MQ@,<'C/6O%*2L^@W==3U>;QT(/!=GJ__  C^AO/->26Y1K(;0JJI!&#G/-5;
M/XZZO!'%:PZ7I4%ONP(XHG55R>< -46B>'+CQ5X$\.Z;:Q2.\VKSB1HE!9(]
MD>Y\$C.!DTOCKX22^$+*VU&S74;BT60+<R7ENL0BR5"GACD$MC-+W=F/7<U?
MB%\19M%\77]F-%T>[$94^==6@>1LJ#R>_6N=_P"%M3_]"YX?_P# %:U/B!X
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MF?\ BF_%GW/^/./J#N_U@Z=L>N?:N6/6DA] HHHIB"I5N[B-0J7$R*.BK*P
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M$C8.@&>OK4<SO8JRL<'HW@?7[?6+"632KA(TN(V9CMP &!)ZUG>,O^1IU/\
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MAS5YC7)0^*I_B_\ ;8G+1_B5?\2_])B%%%%=9U!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ='#_P D_N_^O^+_ - >
MN<KHX?\ DG]W_P!?\7_H#USE8TMGZL]'&_%#_!'\@HHHK8\X**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ZWX5:99ZKX[TR#4/LIL@7DE2
M]($;J%)P<\=<=:]%^.OAWPW9>&;*YT*#1[6:.ZVRBQ,?F.I4X^Z>@([UX80&
M&" 1Z$5TOPW\-V7BCQA9:=>JZVTH<OY!"MPA/7'M4M:W*3TL,T#PK9:U8&XN
M/%&CZ-()"GV:_:02$ #YOE4C!SZ]C5'Q!HUOHEXD-OJ]CK*,@8SV!8HIR?E.
MX YXS^(KKY=4^'$,BI#HVLR(HP3)<*"QRV>A]Q_WR/?(=8^'+\G1=67D':)5
M/<'&=_3M^-%PLC*\#:@MCIGB42PBZMWLE\R!G90X$B]P>#R>:QM;TZW@2WO+
M%G:QN@=J2'+Q./O(Q[XR"#W!%>I^#9?!E\FI_P!BZ+J-Q=+:@36UTT;1RKYB
M]%+=>G4XXJEXQ;P]#96L6I^'-2T>W\QFC^PK!&'8@9S@MG@#TI7U';0\EKHO
M OAV;Q%KL,<(5FA=9F5U5E90P+ AN#QGCOTJ]O\   7_ %7B)F_ZZ0 ?R-:W
MACQ=X1\)7S7=C;ZV9&0H?->%A@_A3;TT$D4O$OPPOM/UR:TM7B<@;V$SI'@E
MF 50"<X"G\JYC5_#UWHD4$EP]NZ3%E1K>82<J%)SCIPR_G7J ^)6B:SK4,T%
MKK1U!V"1"(P9)^< #*X_Y:,.G8&J_C?2;?4?#<]U<66K6<UBAECFOY8")F=D
M4@[!EC@9]3SS23?4;2Z'DM%%%60%%%% !1110 5Z%^SU_P EQ\#_ /85@_\
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M _8 Q.'^_P"O3K1=AH:4NA:C8>!&L-1EM[61'<Q^=,-NP[".?J#^=1S:4O\
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M^_=)_P (?KG_ $"KK_OBM3_A:'B+_GZA_P# :/\ PI#\4/$7_/S!_P" T?\
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M .BVKAZ[CX+''Q%TW_=E_P#1;4I;,:W,KP$[+XQM%CD,4TIEAA<(7(D>-E3
M ))W$=!7H/B'PWXMT#P_JEUK^J3W.G_9VC\N6SE0%VP%Y9 !R?6O+M T^;4]
M>MX(%1I/,,A#RB)=JY9LN>G"GFNO\=Z;-K,LUYIZV%G9Q0EY;.VU1)<X.<A
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M&=:_X1W7K+4O(%R+=]_DEMN[@CK@XZUF5H>'(8[CQ!ID4L:RQ/=1*Z.,A@7
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M,YRBBBJ)"BBB@ HHHH *]!_9\_Y+?X(_["L'_H5>?5Z#^SY_R6_P1_V%8/\
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M"/\ D7O&?_8,'_HP5J]C-;FF?C'-G_D5]!_[\/\ _%4'XQS$8_X1?0?P@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!T</_ "3^[_Z_XO\
MT!ZYOK720_\ )/[O_K_B_P#0'K0U*[L);RUTF]M8(K=K6 1WD$866%VC4[B1
M]]<GD'WQ6%+9^K/2QOQ0_P ,?R.,HKII8$\&1(L]K!<ZQ+E@+A=Z6Z9(4[>A
M9L9YZ#'K4'C^WCM?&6K1PQI#&)LA$& ,@'IVZUM<\ZQ@4444Q!1110 4444
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M&/L<V1@#WKLPC_?P]4=V!7^U4_5'RN.@I:0=!2U]D?9!1110 45H:1X=U7Q
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MY(08XS2;ML-(\C9=K$>E=;X)'_%/^,_^P8/_ $8*Y.7_ %K?6NM\$?\ (O\
MC/\ [!@_]&"J>Q*W.0/6BO;?AIX#^'_B?P]I2ZA=))X@N!)YEI'J)20D.^,1
M@\?( ?IS7=?\,_>"O^?*\_\  Z2I<TG9E*#9\L45]':G\,?A9HMVUKJ%\EC<
MJ QAN-69' /0X)[UY5\5]&\*Z-J-@GA6[CN[=XF:9H[O[1AMW'/;CM34DQ.-
MC*\0_#CQ%X5TN#4=4TXVMG,55)/-1CDC(! )(X'>N;KI/$'Q"UKQ/IXLK^6%
MX-ZR$1PA"2 0.?Q->K^ ?AO\//%&C:<KW N=:DMEDN+:'46#JV!N^0'C!-%^
M5:A:[T/!**^I_P#AG[P5_P ^5Y_X'25@W?P[^$MA=36USJ<-O<0N4DBEU<JR
M,."",\$5/M$/D9Y!\+/^2@Z+_P!=6_\ 1;5SE_\ \?US_P!=&_F:]$TNQT?3
M?C=9VV@3+<:2DP\F1)O.!S!EOG[_ #%J\[O_ /C^N?\ KHW\S5K5DG4?#\9L
MO%?_ &!KC^0KFM,T^35M3M;*%E66YE2%&<X4%F &<=N:Z;X??\>7BS_L"W']
M*Y2VNIK*ZBN+>1H9XG#QR+U5@<@CZ&@#U/\ X9K\3?\ /_I'_?Z3_P"-T?\
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M/_1R5SM=)X5_Y 7BK_KQ3_T<E)@CFZ***8@HHHH **** "O0/V??^2W^!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ/EB?QUJ6H*N2/M-O(^T^VZL#PQ_R!O$O_7D/_1J5SIZU-M;E7T.O&A>$/\
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M+W!70GBWXG7OB[2183V-M;1^:LN^)W)R,\<GWJAX+@CNIM5BEN$M8WL7#32
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M+*\;Q;X4D6*5)=HUVR!8!AT_?_0?C7RED^M&3ZFG_9M#N_O7^0O[,PO9_?\
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M+Q1XVE#:?J"Z5<ZA*CWT-LS(J^8P)#8V\$$?A2>XUL2#X7V8/_(YZ%_W^_\
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MI_\ 0&KTOP%\1]2A\4WGAV?6+'1='@ENI$N9[>,L&\TMM+.P!R6;\JY[P?\
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MV%TS(9DO)BR?*3D9/M7!74:PW4T:YVHY49] :T1+)](%@=1A_M,W L>?,-J
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M/TYZ5RMO(L-Q%(\8E1&#-&3@, >1^-=?\3)A<W>F2*A1'M050@# )Z<<5+W
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M'X*L$W$EO,OIW))/7/%11?%330X\SP7ISQ_Q*MY.I(^O:O/:*^IM!_8C_P"
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M-JSDD]%LVO(\?\<ZE=Q>,M;1+J=$6\E 596  W'@#-8?]K7W_/[<_P#?YO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/ECLX'N&C1) S!5+$#(QGBESQ'RL\IKHO"__ "!?$_\ UXI_Z.2N=KHO"_\
MR!?$_P#UXI_Z.2FQ+<YVBBBF(**** "BBB@ KOO@#_R6SP3_ -A6#_T(5P-=
M]\ ?^2V>"?\ L*P?^A"HG\#]")_"S#^(W_)0/$G_ &$)_P#T,USM=%\1O^2@
M>)/^PA/_ .AFN=K'"_P*?^%?D<^$_P!VI_X5^04445TG6%%%% !2'I2TAZ4
M>DHNVTLOEVYMHC]W;_ .??Z]Z*;$,6=G]S_CWB^XI'\ ZY[^I[TZOC<3_'GZ
MO\SXC%_[Q4]7^84445SG(%%%% "'I77?$)0IT3'>Q4G\ZY$]*]0\03Z5:Z=I
M=QJ=D+H?9TB3:I8C@G^^M2]T-'F%%=E_;GA/_H#/_P!^S_\ 'J/[<\)_] :3
M_OV?_CU%Q'&UT'AWPU!JMN;R>]C2&%SYML,^<Z@9PGJ3R!QUK>23P])I<FH+
MH3FU1MI?9SG@=/.SU(JK'XG\+VEY'/;^'9EDB(9)!<E"&'\6,G'/N:5[CL:4
M-Y97OP]Q)]H@MHWD141UF91E"<$[<#)Z5!+=Z1]DNX2U\';288V8(F!&#&P(
M&>O3CZUJ7>J0>*/"$LEI:BW =T\NZGXR"A^]Z'H:S9]&N)(M0D6ULA&^G11B
M07'$9VQC'WNGN?;GFI&9WCT1C3_#0B+M%]@&TR !B.,9 XS7'UZ5XCU72=-L
M=$AU#18M0E%FN"D[!8QQD*0>1[U2TZ?0]3MI[B+PDOD0<R/]M(QQDX!//']*
MI.R$T<%17H"'P^^EMJ T)OLBG&\K@\''3SO7^M4?[<\)_P#0&D_[]G_X]3N%
MCCE4NP5068G  ZFNO^).DOHO[/\ 96\S W!\2(\BC^ FU?Y?KC&:GM?$WABQ
MN$G@TETF0Y5O)S@^N#-1\5[RUU#X%6US:1&&*7Q(KD.I#%OL\H)/S-Z#O7I9
M<_\ :8^C_(];*O\ >5Z/\F> 4445]4?5A1110 4444 %%%% !1110 5W_P %
M'\OQ>Y_Z=V ^I90*X"N]^#'_ "-K\9_T<C_Q].:TA\<?5'1A_P"-#U7YEZ;/
MG29&#N/%;OAKP+JOBRWFFT](&2)@C>;,$.<9]*PIN)GYS\QYK9\-^,=4\,MY
M=E=FWMI)%>91&K;@.O4$]/2O@)7Z'YL]]3<_X4UXF_YY6?\ X%C_  K#\2^#
M-3\)" ZBD*^?NV>5*'Z8SGTZBO6-0^,>@-970M+BZ6Y,;B$FU. ^#MZ^^*\A
MUSQ7JOB40C4[LW/DYV9C5<9QG[H'H*E.3W&[="_\/3CQ!,0"W_$MO^!_UZ35
MXE7MGP^_Y&";#;?^);?\_P#;I-7B=?3Y;_!?K^B/J<K_ -W?J_R05Z;!_P B
MKX=_Z]6_]'25YE7IL'_(J^'?^O5O_1TE=.._W:?R_-'5CO\ =:GR_-$)('4@
M?6C<O]X?G74>"/&[>#)+MEL(K[[2$7$KE=NTGV/K^E>X[]9-KY_V'2MNS?C?
M+G&,_P#/.OCW*Q\8E<^9@0>A!^AKO_@/_P E8T'_ +>?_26:J'C3XB/XST^V
MMFTV&Q$4GF[XY"Q/RD8^Z/6K_P !_P#DK&@_]O/_ *2S5V83_>*?^)?FCLP'
M^^4?\4?S1XMX]_Y';7?^OV7_ -#-85;OCW_D=M=_Z_9?_0S6386-QJE];V=I
M"UQ=7#B**)/O.Q. !]:^P6Q]J]S2\*^$M0\9:D;'31";@)OQ/*(QC('4]\D5
M#XE\.7OA/69]+U 1"[A"EQ#)O7D CGZ&OHGX1_"^UT;P];7FJ:9/8:^3*DK?
M:)$?9O.T$*^W& /TKC_CA\-=0N==34=&TFZN;?[+ON[@2&0 KGJ7;/"@=*A3
M5[%N-E<\3KK?A1_R/VF?27_T4]<B#D5UWPG&?'VF?27_ -%/5O9D+<H>$;<W
M7B)8_M:V0*L3(RQL#[%9"%(]CZ>M=%X'EMHG\9R:FEQ=VHM"9TWJ)9!YO.6!
M(S[@D5R>B:NFB:L;F2V%VFQD,1DV9SQUP?Y=ZV_!WE_V)XT\I#'%_9OR(S;B
MH\P8!.!GZX%#&C6L;SX>ZCJ%O:Q:!JR-/(L89[Q< DXSQVI=4E^'^D:E=64V
MB:L\MO(T3-'=+M)!QD9-<5X<_P"1BTS_ *^8_P#T(5;\=?\ (Z:Y_P!?DO\
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MQ>:8O[">/<-P'WB<9^:N97XE2J"#X=\/-GN=/''ZTDV-I''T5V:_$Z149?\
MA&O#G/?^S^1_X]2'XER%0/\ A&_#HQW&G]?_ !ZG=BT.-HKKA\1Y0/\ D7]
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M\:Z44'K17:= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXJ7_ (26WEB@6XT>SN9(HEB\UWE!8*,#.' Z"LW4]0.IWLEPT:0EL 1QD[5
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MP.*[[X#C/Q9T'_MY_P#26:NG"_[Q3_Q+\T=V _WRC_BC^:/%O'G_ ".NN_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:QNH8FM#*EH\<\T0<M'O4$X.".,GH/2J>M Z["MEJOQ#N+V(.'%O<V\A^;!
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M'\B^X^@]A1_D7W(]Y_X7SX!_Z)[J?_@XL_\ Y7T-\<OAK(Q9_A?J#,>I_MZ
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MYI-]R6W+=G.UVF@_%";1-'MM/DT#1M42W!6.:^CE,@4L6V_+(HQDGM6;X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD[?NX]NM>.$\U[M>:?X?U?3M26VU*QL\6+6_[F[@:) S[BS $'DD\Y[UP/\
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MM&<G4C:Z_5'MY;A:U"4W5C:Z_5'SM177?\(AH/\ T.-G_P" S_XT?\(AH/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<J,EL<_>_"[XB)<SF&*\-NKMY9.J+G9DX_Y:>E< ^N:H&(;4KW(X_P"/E_\
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M0<%@#@YXJ?Q3\7/$>D>)=4L;>2T$%O<R1('M58A0Q R<\TM=K!IW/,OL\O\
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MM:7+7 F$GFR*I12 CX7!Z]%;/'IVJVK(E;G!R_ZUOK75^"O^0!XR_P"P8/\
MT8*Y27_6M]:ZGP-=62VGB&RO+^#3S?60@BEN-VS=O!YV@GI5O8E;F+X=Y\0Z
M;CD_:8^O^\*M^.F#^,]<88(-Y*>/]XUK6/@VZM]6TB71KVS\07$MT5BAM&9
M71?,(+.%'0'O_.M/6/A'XYUC5KR^?P\T;7,K2E!=0D#)SC.^INKCLSSJBO<M
M>^ 21^"K:72K"[D\1A8S-$]TFPDXW@ D*,9)Z]J\^U#X0>+]+L9[RZT9XK:!
M#))(9XCM4#). ^>E"DF#BT0^,O\ D!>$O^P<?_1K5RE=_J'AC4_%=CX3LM)M
M3>70TMY3&'5<*)B"<L0.X_.H?^%(^-_^@$__ ($0_P#Q=":069PU==H; ?#;
MQ,.-QN[3COC]Y_\ 6KT;Q5\ HHO"EM)H=C>2ZZ!'YT<ETI5B0-^ 2 ,')X/;
M%<=<> _&'ACP;K4-YH)BL9#'<37)N8SY2QY_A#G/WJ7,F.S1C?"S_DH.B_\
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M&=QJ.E:';QZMIBO96S0R;KE>29&;(YZ8(H=6'\R&L)B/^?;^YGD] ZUW%_\
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M8H >"P&26;KCH!UJ7NBT8\OB_1+.\=8_!NE/Y4A"R">?G!X(^;CIFMYO'O\
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M+H9NB:H^AZQ8ZC'&LLEI.DZHY(#%6! )'/:O6O\ AJ#6/^@'8?\ ?^6O-_\
MA /$O_0"O_\ OP:/^$ \2<YT.^&!GF$TFHO<$VMA?'?C*X\>>(&U:YMHK25H
MDB\N%F9<+G!RW/>N? )( &2>PKH!\/O$QQ_Q(;_DX_U#5HZ=I-_X(L;W5]0T
M^:TOTV0V/VF/&V1LYD /4JJG'N0>U.Z6P:]2]J.@ZFOPJTY#IUT'CU&29U,+
M95#'PQ&.![UR_A#Q++X0\1V6L001W,MJ6*Q2DA6RI7DCGO7J%[KNI6_P2T[4
MH[VZ6_\ M2'[5O;>3YDO5N_TKB-:\,ZGXE^QZQIFE2SI>P"2<6D6468,ROP.
MF=N['O4I]QOR.V_X:=U;_H Z=_W^EKSGQ_XTN/'FLOJ=S:Q6<GDB+RX69EP,
M\Y//>D/@#Q*!DZ%?@>OD&@_#WQ.Z/MT'4#P>D#4THK5";;.P\0>+Y_ WQ6?5
M[>VBNY8[6.,13,54[H5!.1S6O_PT[JW_ $ =._[_ $M8'Q*\'ZYJGBZXFM-)
MN[F+RH5WQQ$C(C4$?I7,1?#[Q))*B'1;U 6"EFA.!SC)J;1:U'=K8ZOPWK6H
M>/?BUI^NMIQB4W$0E^SJ[QQX 498],X'6N2L+C3;3QNLVL0-=:6EZ[7,*KN+
MIN.0!D9[=Q7I'@#5)5^*4.AVCR1Z3IQ>".W4D*[(0&D8#JQ()R>E<#J7@+Q'
M/J5W)'H=\\;3.598#@C<>::!['MFG_M >"M*L;>SM+;4X+6W01Q1+:C"*!@
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MN<'Y>Q)_.MGXE?#_ %#Q)J$^LZ982B8.8;FW="A8K\JRQEL!E90.,Y!K@/\
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M !I/[6OO^?ZY_P"_S?XU5HI^RA_*ON%]<Q/_ #]E][+?]KW^,?;KK'_79O\
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M#M_IZ]3_ ,L$_P *1?BQXF7I?I_X#QG^E2XW=RD[:%OX,HK^,1&ZAD>!U96
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M!D;>+:$<>GW*-1Z$&@3^'!K^FF.VU-'^U1;6DGBV@[QC/'2J/CK_ )'37O\
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MU!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!?U;_ER_Z]H_ZU0K:UK3)8M-TZ^+1F&2)(MJM\RL%S
MR/0BL6L:/P(]#'_[Q+Y?D@HHHK8\\**=%&9I4C7&YB%&:O:YHDV@WBV\TL$Y
M9-ZO;ON4C)'7 Z%2*!F?1110(*U+SQ/J>H:6FG7-VTUHCJX5U4ME00N6QN.
M2!DUEU8T^RDU._MK2(J);B18D+G !8X&3Z<T#*]%6M3T]]+O9+9Y(YF0*=\+
M91@5# @_0BJM @HHHH U?"2[_%>BKN5<WL(RQP!\XZT_QE_R-^M_]?T__HPU
M'X5./%&CG_I\A_\ 0Q5[QEI=X?%^ME;2X*F]F((A8Y&\^U<;_P!Z7^%_FCB?
M^]Q_PO\ -'.T5:_LJ]_Y\KG_ +\M_A4,]K-;$":&2$GH)$*Y_.NP[2.BBB@
MHHJPNFWCJ&6TN&4C((A8@_I0!7HI9(VA<I(IC=>JN,$?4&FY]Z %HHHH 0]*
M[SXJG)\.<@XTU!QVY_G7!D@#D@?6O6_&G@;5O%-OH=QIT5NT,.GQJYEN4C.<
M;LX)ST[^Q]*EZ-%+8\EKI?"G_("\5_\ 8/7_ -&K5O\ X53K_P#U#O\ P8P_
M_%5I6/@S4O#?ACQ3<7IM?+>R"#R+I)3GS%/13T]Z=T"3//:]>^'V@WFN>%X#
M8B&XDCBG5H%F42YR_P#!UQ\Z\^]>11)YTJ1J1N<A1D]S7=^$+K4/AYK5Q=V6
MK^'1>>6]K)'=W)8+\PR, #G*#O2EJM CN>C>$OV>=(O?#ME-K::G9ZHZ$SP+
M<(H1LG QM/;'>M&]_9P\+I9W#P-JDEPL;&-3<H=S8X'W/6L+2OC#XJU'7--T
MY=0\,R?;)A$7M$DF,8ZEBH<=@:U_&/Q*U_P]?0Q6FN>')X)(]P?4+>2U?.2"
M I<Y'O67O7W-/=ML>9>'? ^K^$]3>;7])NM/M9K*Z7<=@9P(26"X)YQZU/J&
MO^'M+M-.2T?Q%;J]LC+'!>(BE-[@$X'WNOZ5K#Q[K7C^QFN-4?2HK:UM;T1)
M;YCED<P$-@$MD 8]*\\U2YCMI-!E=(YT2RB8Q2'Y7 EDX/L:T5V]2'IL=%X%
MFTR;QYIK:=#>1?NYO-^URK(6;RVY! %<MIWB;6-%B>'3M6OK"%G+M';7#QJ6
MZ9(!'. /RK:^&<\<GCVT<!(E;SB$4\+E&P![=JY-NI/:JZDFV_COQ+*C(_B'
M571A@JU[(01Z=:Z;P!;Z==>"/$\>JW$]K8^;;,\UO&'9>6QP?<BO/-R_WA^=
M=MX7(/PV\88(/S6W3_KI2:T&F2-HW@#/R^(M4(][$?XUIZ)X&\%:_+.EKXCO
M@((_-D>:V6)57<%Y+'U(KS.M;PSJT.E7TBW:-+87436UTB_>,;=Q[@@,/I0T
M^X7.A\>^#-#\,Z?:SZ5K8U2668QM&&0[5"YS\I/? KB*W==\)C2-/AU&VU"T
MU+3IY3%'-;Y#;@,X92/E.*PJ:V$PHHHIB$*J>J@_A2T44 %%%% !1110!Z;X
M.^)'BC498;$30?V=;(&NIFMU^2) .6/K@ #N3BN-\;ZF-;\4:A>;9%$S XEC
M\MON@<KVK7\-^*I-1L(?#&I,G]F2'9!*BA'@DR2C$C&]=QY#9X/&,5B>+?M'
M_"17HNI(9K@. [VX(0G Z9J4K,IO0Z>P^(T&N0'3/%EG'>:>YW+<VL2QS0.>
MKC'7W]?>I#X _P"$:NO[?%S%J?AVVC-U#=QGB5@0(XV'8[RN?8&O/,YKH/"?
MC2_\)3N("MQ93<7%E.-T4HZ'(['W'Z]*+6V"_<W-7NI?#O@*&UDS_:?B"3[;
M<N?O"$$[ ?\ >)+5PE;7C#Q+)XKUZ?4&C\B)L)#!G(BC485?RK&4!F +!03C
M<QP![FFA,V-.6&PT:]N+JR,IND\FUE8957# L?4$#&#]167:VLU]<Q6]O&TT
M\KA(XUZLQ. !^-:?B658+I=-M[Q[NQLQMC+8(#'E\$=1NS70?#""+3Y]3\27
M(#0:1!OC0_QS-D(/;O\ I1?2X^MA/B3=)IJZ9X9MB?)TJ$"8[L[IV^9^GIG]
M:XBIKV\EU"[FNIVWS3.9';U).34(ZTTK">I=?0]2BLA>/I]VEF0&%PT#B,@]
M#NQC!K<\#S74$>J&SF\B<I %?)QDSQCG')%;]Y9RGPC=7INY3'_9MI;BV).P
M?)"V[KU[=*SOA5:P7VI:A;W,44T#VZ[HYCA3^\7'X^GOBHOI<:6I=^(_B35[
M#4=+BMM5O;:-M+MG9(;AU!8IR< ]369\,O$VG^%]2OY-1EGAAN+4P*]O$'8$
MLIZ$$= >H->F3?#B]\1^/M(U%+2TN-$LHX(;B*=U&54'CRS]X8(KL?'GPOTO
M5/"E_:Z'H6E6^J2!/)E6&.$KAP3\^.. :CF6Q?*]SC$^*OA.XE1(YKY7;*C_
M $)<9.[!^[VW#_OD>^<+QAX@O_$.N>(_"TA2143-C&J ,70JY3/<D;L#V%>;
MWNC77ASQ*VFWJHMU:SJD@C?<N>#P>_6O9-8U;X9V7B"];7K.\;7$N7:6:!9^
M#NRA!1P.%V]!562V%=O<YG2O$^I>$OA98W6GR"&?[;)$P=,C!SG(/?BNI^%.
ML^(OB*FHO)K<>G&U,8 AL(WW[MW7)&/NUC_%;Q+I/BGP4MUHIF:RCO8XLSHR
MN7V.6)W$D]5Y)IGP$^(5IX?<>'I;*XGN=3OU,<\978F45?F!Y/*GIZTFKQO8
M:WL>H:I\-]6UVSFLKKQ8YAN$,3[-+B4E3C(SN]J^=O"7C+5O"-]/9:=<JMO<
MSJDJO&&WX8KGVX)KZO\ %GB"/PCX?O-7N+>:>&V4,T<6 QRP'!/'>ODOQ)K\
M/BCQW-JMO ]M#<W,;K%(1N7[HYQQVI0UW">FQ[S\.?%\5EX@\7:9?7UG9VT&
MH&6$SS+$S,^=W+,,_=7H.*[W_A+=&_Z#FG?^!T7_ ,57R+\0USXWUO< 3]J?
MKSWKG?+7^ZOY4_9IZASVT/:OB7XF?7[GQF1+!<6]E%9V\$D#;@R>;OY8$@G<
MS<BO>=&;[?H]C<FW5#-!')M"9 W*#C./>OD?PX/^*)\68' 6U_\ 1M<QYT@_
MY:R#_@9H<+Z"4K:GUW\7X OPS\0GR@N+8\[,?Q"O-_!VGB]^,7AYV)S;:%',
M%"Y#?NV3!_[[S^%>%O*[*09'8$="Y(KK_B:Q76-**L5/]D6O*G'\)IJ-M YK
MZGU[]G'_ #Q'_?'_ -:O!/$]@+#XP>),$GSM&EEP5QMS$!C]*\/\Z7_GK)_W
MV:[#X8L6U?5"S%C_ &5=<DY_@I*'+K<'*Y6^'7B77O"U]<7>@V'VZ9X1%(#:
MO.%4D'HIXY6OI#Q!\08K7PS=7&F&2XU=(=T4#:?<$,_'&-@]^]?-O@/XCZM\
M/3=/I:6S-=*BR?:8V?A<XQAAZFNN;]I+Q?*IC\K3#O&W MY,\_\ ;2B46W<(
MNR,[1/$=UXMO?&FJWHB%S/HLVX0*53A5 P"3V [UA^#OAOK?CR*ZETF.V=+9
ME63SYQ'R02,9'/2MKP?X;O=&T7Q//=(D:MH\\?E^8#(IV@X91T./6N[^'7Q;
M\%>$?"MA9R)-;:B(@+M[>P)\QP3R6'WN#UIMV^$27<\,U739]&U.[T^Y"BYM
M96@E"-N7<I(.#W&1UJK77_%37]'\3>+Y]0T2,QVDL:ER8/)+R<EV([DD]>]<
MA6BU1+-KP;X6F\:>([71[>XBM9K@.1+,"5&U"QR!SVJ?QUX+N/ >N?V9=74-
MW+Y2R^9 K!<'/'S<]JU_A3XZTSP#JUU?:AIDFH2M&%@>$)OA/.X@MTR#CBI_
MBU\0],^(5UIUS8:7-83P+(LTL^PM*#MVC*]=N&Z_WJF[YO(>EC0U[_DBNB_]
M=A_Z%)7F%>GZ]_R131?^NP_]"DKS"N:A\=7_ !?^VQ..C_$J_P")?^DQ"BBB
MNLZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM2.>)C_\10W[0\3,3_PAVGC/;[4V/_0*\<HH^HT>\O\ P.?_ ,D'U*E_-/\
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MXK-Y$G)&#N(4YP>?8U6FU=M-6WMKG0;>"6*;SV%Q 4>12Q(0[@#MYQ]!78>
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M,%V?Q??D(K-OO!?A[Q1'9W6IRWZW$&GV2-Y+(J*C1X7J#Z'-8USX"\!V]W#
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MZ;.WB+2IVL[2>V\J=BH)ED60GA3@KMVXJ;LI)'#^ '$_@3Q?(9DDD^S3E@9
M7;,8^;'4].M>;GK7O'B>ZT;79_%&M:?J]A=32:));FRLSG8%!._) ^F,=Z\'
M/6JB2PHHHJB0HHHQ0!Z?KQ_XLMHH[^:#_P"/2_X5YA7I^OC_ (LOHI_Z:*/_
M !^7_&O,*Y*'QU?\7_ML3EH_Q*O^)?\ I,0HHHKK.H**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL;3_DD>I?]AF#_ -%2
M5QU=YX8O]%M_A[>6^N0WLMM-JD;+]A=%<,L3==W;FN3$_8_Q(X\3]C_$C@Z*
M[;[1\//^?/Q#_P!_H?\ "C[1\/,?\>7B'/\ UVA_PKJN=MBO>+_Q:K3F_P"H
MK(/_ "'7(UZ-)XC\"2:##I)M-?\ LL4[7 'F0[MY&.OIBJ N/AWWLO$/X3P_
MX4DQV.(HKMC<?#S)_P!#\0X[?OH?\*/M'P\Q_P >7B'/_7:'_"G<5CB:*['4
M],\,:EH-_=:#%JD-U8^7)(MZZ,K1LVTXV],$@YI=+T_PK8^'=/N];AU2:ZNS
M*1]BDC5%56V@88=:+A8XVBNV^T?#S_GR\0_]_H?\*/M'P\_Y\_$/_?Z'_"BX
M6#P%$NA:7JOBF; >S3[/9 _Q7#C&1_N@Y_&M;P5=?#-?#\/_  D\%W+K&YS*
M\8G((W';]Q@.F*CNO$W@6ZT2RTHV6O1V=J[2*J2P@N[=6;U/;Z5FF?X>$?\
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MDD4VSHO^$XO/^@?HW_@K@_\ B:9K7C*ZUS1;;39K6S@B@G:<-:P+#DE<8(7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]=E>6Y/K1FCZM6_Y_2^Z/_R(>PK_ //]_='_ .1/4?\ A#_AK_T.%S_WR/\
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MCC+)&"*W=)B^'^B2RRV>HZ-')+$\#DZG<L"C###!C].]>$Y/K1D^IH^KUO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5
M!11@^A_*C!]#^5 !11@^A_*C!]#^5 !11@^A_*C!]#^5 'WI8_"W3;VU@E33
M'?S$# B; /7/?U!_*GS_  KTRW@>5],D6-/O,9LXY ]?4C\ZFLO$CVEM#&+>
MT<(FW,D 8GKU/?K^@]*D;Q(]RAA-O:H)&'S) %8<@\'MT_4^M<1UGJO_  S%
MX#_Y\[[_ ,#3_A1_PS%X#_Y\[[_P-/\ A7IR:E9OJ+V"W<#7Z1B=K42KYJQE
MB Y3.0I((SC&015K:>>#Q0!Y/_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\
MP-/^%>L$$=1BDH \H_X9B\!_\^=]_P"!I_PH_P"&8O ?_/G??^!I_P *]-NM
M4LK&ZM+:YO+>WN+MS';0S2JCSL%+%44G+$ $D#/ )K-O?'7AK3/[4^V>(M(M
M/[+*#4/M%_#']C+_ '/.RP\O=D8W8SGB@#A/^&8O ?\ SYWW_@:?\*/^&8O
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M?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\
M T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\
MGSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT
M4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.
M^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q>
M _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^
M%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_
M .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?
M\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\
MP-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS
M%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_
M (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GS
MOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y
M1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_
M\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@
M/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO
M10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^
M?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\
M#,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_
MX5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q
M> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X
M4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO
M_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4
M?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\
M T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\
MGSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT
M4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.
M^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q>
M _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^
M%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_
M .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?
M\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\
MP-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS
M%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_
M (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GS
MOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y
M1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_
M\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@
M/_GSOO\ P-/^%>KT4 >4?\,Q> _^?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO
M10!Y1_PS%X#_ .?.^_\  T_X4?\ #,7@/_GSOO\ P-/^%>KT4 >4?\,Q> _^
M?.^_\#3_ (4?\,Q> _\ GSOO_ T_X5ZO10!Y1_PS%X#_ .?.^_\  T_X4?\
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M'':BV7[+;B&-!LV_)&#A0.R@X XS6!<> ;V,>$)-.UJ2RNO#\(M/-FLQ.MU
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I6_*OD.B@#Z\V-_=;\J\C_: 4A=!R".;CJ/\ KE7C]4]0_@_'^E '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>aytu-20230630xex10d48001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20230630xex10d48001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /!!!(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !12,2!P,GTSBG4 )1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %!(4$D@ =2:*#R/44 %%%% !113%GC:1HQ(I=<;E!!(S
MTR.U #Z*6DH I7.I/$=L5E<7![E %'YL1G\*9'JLV?WFFW2+_> 5L?@#FM#
M]*,"@"""]AN6*HV' R4<;6'U!YJ>JNH0L8O.AVK<1C*L0,D#DK]",U95@ZJP
MZ,,B@!:*** "BBB@ I)"0C$8!Q2T4 ?/'@/P;^TB-4N/^$Q^)'@Y-)6<F--'
MT!WNGARW&]V5$8#;CY'!YSZU[KX<W?V):,TKSO(@=I7&&<GG)';Z5I8R".QX
MK&\,SF.T-A*^ZXM&,1/KCH?RQ0!LT444 ,N(TF@D21!+&RE61AD,#P0:I>'_
M  [IOA31K32-'L8--TRSC$5O:6R;(XD'15'8<U>D?9M&0&8X /?U_2G4 <_K
MGP^\-^);JXN=4T.QO[BX2&*:6>$,TB1.7B5CW"LS$#U)K&\$? _P)\-]334?
M#'ABPT2]2R&G+-:(5(M@YD$0YQMWDM]:[FB@#G;OX<^%;ZXU.>X\-Z5-/JDD
M,U]*]FA:[>$@Q-*<9<H0"I.<8&*T;K1OM6N6.I?;[V$6L<L?V.*;;;S;]OS2
M)CYF7;\IR,9/K6C10 4V5#+$Z!VC+*1O0X9<CJ/>G44 >*Z?^S(=,MWA@^*W
MQ-(;DM+XB$K%N26^:$X)ST''M56]_9GU\K*=/^.GQ,LI''R^;>V5PJG.> UJ
M./;->Z44 ?/FL?LV?$'7)Q+/^T1XZMB&#;;"TTZW7( '18.G'3H22:YS4OV.
M?'>N::+'5/VDOB%=0I<?:(Q$EM;G/. SQJKLO/3<![#BOJ:B@#X^N_\ @G]J
MVJ0P1ZA\??B/<+$JJ%2]V(-O3 W'CZDG'>LN;_@F+HTRJ5^,'Q'MG"; MMJG
MEQ+UQM3H,9/'3K7VK10!\=K_ ,$Q? JP*G_"Q?B=D+M('B/Y#]5\O^M5G_X)
MNBVMO*T_X\?%2U#2;G276C)$Z$8*E.!^-?9M% 'Q++_P3+CU8&'6OCE\2=5L
MF;<]J^I81^,<@LP^G''O6I#_ ,$J_@Q);8U*[\7:M>GE[^YUQUE8X/.%4#OG
MD'IZ<5]C44 ?'NH_\$L?@OJ4A9I_%,8XX75@6Z8^^T9?_P >[^E(_P#P2I^!
M7DS)%;>)8/,5%W)KTIVXZG!!!SW!!'H!7V'10!\?O_P2K^ [3O(EAK\&^'RF
M2+6I%4MMP9",<L3\QS\N2>,<5:M_^"8_PCMK!K1+[Q8(73RI5&K@>8G]TXC^
M[[# KZVHH ^/+;_@E5\#[02")/$JB12K@:MC<#U!PE(?^"5'P-\M8PGB58US
MA!J_'/7^"OL2B@#XMO?^"3?P9G_X]-3\7:;P0?(U2-@_H6#PG..?SK%/_!(?
MX9&;_D;_ !;]G# K");9<#'()$74^H _&ONRB@#XJU'_ (),_!R>V5=/U3Q7
MI=PBX22/4(I%#=FVM#U';!&*Q;O_ ()%?#^9@8O'GC! "2!++!)MSC[N4^7O
MTZ\>E?=]% 'PA9?\$N+K1GC;1_CUXXTLPMF#R3CRP#\HXD'(]1CZ"J-Y^P]^
MT;IUA>V6D_M.:M)9P$1V$%T]TA>'G_62*[,K#@?+NSZCI7W[10!^><'[$G[4
M&FZ3.++]HZXDN)@H:":]O]APV<>:VYEZGD+STZ=&C]E']LJ&,QVWQ^M?G&6>
M74[IL'T&ZV)_$5^AU% 'Y\)^S!^VI$Z.?CYICXZH;V;!_P#)2K$W[*W[7Z3S
MB#]H*"YAC97MVDO)XC-SSO @.S [98-[8K[_ ** /@B/]EO]KZ;3Y!-^T);6
MET\Q)6*:68% AVX8P+M.\ 8 Z$DDXP9M-_98_:[@M$D;]I*&&^5T/D/;O<Q,
M#MWDNT0(V_-@;2#@<KGC[QHH ^-YOV:OVI)VAG;]IZ,2(,%8_#<:(0.>5!Y)
MQSFL>?X$_M=Q+//<?&/3==F>X*&UMYCIH\E02DBLMLX5B3\R8X 'S'-?<%%
M'P':? _]M73;F:[M?BEI3ORL5M>ZI]H0(P().;,9(SD'L<>E;5MX*_;E\,:+
M-9V_C;P)XC)<>5<WJ;KJ-=@'WS$B'D?Q*3DDU]Q44 ?"*-^WJ'A#IX"944!B
M)807/J>/;MCJ?:K"W7[><0>4VOP[E$:[A$9$S+A@2N<C!(!7/ P3WP:^YJ*
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M?:;D%(&@^S"7]P<L&WE.[C& ?0D5=HHH **** "BBB@ HHHH **** "BBB@
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M=>6(+L8DR3\P((_"OT=%?FQ^S>(X?VI_@G&0KR'PE? .H/07&J Y]\BOTGH
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MQP/6@#VFBO(M!_::\*>(M)^'VIVT.I1VGC2SOKRQ,]L$, M(C+,LX+91@%8
M#()4\CK63\$_VN/#GQNU^UTFS\->*O#DNH:8=8TJ?Q#I@MH=3M%95:2W8.P8
M#S(R<XX<=: /<Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***",@C)&>,B@ HH' '?ZT4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;B-?&%F97)"[-G '!SG(^F*O2_&WX\Q6OGC]G02L6 \B+QK9&3&.I!4#CZT
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M **** "BBB@ HHHH **** "B@G ]>:.E !1110 4444 %%%% !1110 4444
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M22.6Q^,UK;+%CY66>RA<G_OJ =/6OUE4DYS_ 'C_ #H 6BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***"0.IQ0 9Q17@_P"UA\4M4^'>E> 8] UN'2M1U+QII%A=*YC+26,D
MY6=2K]%(&"PZ>HKW=75P2I!'M0 M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$GCR(A3CQ[X1"[>"/^);,3GV_P :_2H#&?J?YT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 44= 3VHS0 4&BD89! ZGUH P_"/CKP_P"/;*[O
M/#VKVFL6MI=R6,\MG*'6*>,X>-L=&'&1[UM2S1PQL[NJ(HR68@ "OACXU?LW
M:]\#_#7Q6^)MA\<?&>A6\ES=:S;Z3IIC,32RJBHD@?[[L^U=P (7:!R,U\7:
M+\2OCO\ %^9O!6G>,_%_C*35$9KC28Y8W\V$%?,+-M!5 #SAAV'>@#]NZ*9
MI6"-3D$*!@_2GD@=: "BFB13T8?G0\R1J69PJCJQ.!0 ZOG3XH_%CQ7X_P#B
MR_P@^%U[;Z5JEA;)?>)_%LL2W"Z+"Y(C@BB/RO<R8R W"CD@]O:O''C*S\&>
M#=:U^9EFBTVRFO3$DBJTOEQL^U23C)VX_&OB7X<ZO>:1^S]X1T'P9J:7GQ<^
M,.KFYU_6["]2>XT]I0)[RY9ER%,%LR(J\;6=>,T ,^(GPJ_8T\!:T]O\2O&
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M\&[2PU!H/V8M*:(0,4-S:Z;&D@.,H656QQG[N>GO7K_PG\9^._AUHUE'\/\
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MBBB@ HHHH **** "BBB@ W#..<]>E%%% !1110 4444 %%%% !1110 4444
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MU&8W7RR3RN&97R/[F.]:% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6_$#_A6NB_%_P3J'BJVN9K"RL$@NR)4CWM*6E$6SS%"DF/<W1AN&*_63X5>
MK?X7?#CPWX1M;F6\M]%L8K%+F?&^78N-YQP,G)QVH ^"?VTX$MO$?C&2-6##
MXC>&)BV>C'27R?\ QT5^CZ# /^\?YFOS5_;>0OKWQ$VR$LGCGPD\8W<;CI<R
MG_T$5^E?K]: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_;L^ L=RT!^)^@EU1Y"RW!*$(<$!@,$^@SD]LU!;_M[? >Z91#\1--D+2+&
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MTY I:^MDW.8ANF49<=5Z]1Z53A\;^'[BV^T1ZWI[V^&/FK=(5PN=W.>V#^5
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M=M 'S[?_ +9?C>YL;6"Q^*GA'[0EU$TMR? ^M*7ASEU*E& R.,<=."*H:?\
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MSB>^:4#S7V(58!1@ G*E3QS0!XEI7[.'Q?5KN*Y^&GQ"NG:X><W5]\6%A7&
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M54<GUK:2)(AA0$'MQF@#Y<M?^"@7A?5-"&H:9X!^(>HW#VQNHK.+PW,&D4$
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M-V\/F@@[1Y@D)&"1SCG;^- '*M^PSX#N6EDOO$'CO4KJ5][W-SXMO/,/M\K
M8_"JFH?L ?"S5%6.]N?%MW;*ZN;:?Q1>21M@\ JSGBNC\._!3XIZ7K<MWJ/Q
MVU35[-X)HELW\/V<05F0A'W#^)&(8<8.W!X-%I^S[XT_M6ZO;WXW^+;P7&GS
MV)@6VM(8XS(K!9D"Q\2(Q# \] .E &9H_P"P'\ =%FNI(?ASILWGR>9MN9)I
M1'P!M0%_E7C./4FM>S_8L^!&F0&*'X6^&MA)8F:R$I_-B3^%5O _[,&H^'M%
M\1:=KOQ;\=>*1J]LEJL]Q?K;R6:AMQ:%D7*NW0MUVY'O5C3/V3/#UAX7UW0)
M_%_CO5+'6&MVG:^\2SO+&(F+ 12##(&SAL'Y@!0!KZ1^S!\&M#>5['X:>%(#
M*!O/]E1-G'3J#BKTWP.^$EH5>7P+X1MR3M5GTNW7)]!E:Y6W_8X\!VWA/4O#
MR7GBG[#?W,-U([>);QIE>,.%"2%]RKAVRHX/&>@J^/V0OA=-X4@\.:CH$^N:
M7!>G4(TU?4KJZ=)S&L98.TFX?*H&,XZG'- '>1R^#/#JPW2'0]-60A(IE$,0
M;'  88SCT'2C6_BOX-\.:*VL:KXJT>PTM=W^F7%[&D7RD!OF)QP2 ?K7%P?L
MD?!Z+P_9:&_P]T2YTJRFEN+>UNH#.L4DFWS&7>203L3/^Z*TX/V:/A1;Z;I^
MGCX=>&I++3Y)9;2";38Y$MVD(,A0,#MW$ G'H* &7?[3OPFL+6PNKGXC>&X+
M;4(6N+6:34HE2:-7*,RG." RE?J#3=8_:=^$F@H&U#XD>&K7,"7(635(@S1.
M R.!NR0001Z@U;N_V<_A9?VNG6US\._#$]OIT9ALXI-*A98$+%RJ KP"S%B/
M4DU>U#X(?#S5;>6"\\"^'+F&6VCLW232H"&@C_U<9^7[J]AT% $#_'OX;1:^
MNAOX\\/)K+,BBP;4XA,2X!4;=V<D,I'KD4:;\>_AMK.O1Z'8>//#UYK,DS6Z
M6$&IQ/.TBYR@0-DL,'CVI-4^ 'PSUS6EU?4/ 'AJ]U-1$JW=QI4+R 1 ",;B
MO10 !Z  =A6KIOPJ\%Z-KDFM:?X1T.QUB1S(]_;Z="DY<DDMO"YR222<T <K
MH7[4/PK\57>JVFC>-])U:[TRSFO[N"SG\YXH(O\ 6,57)./0<UF^%_VK_ 'C
M2T\0SZ')K&I-H=L+R>&+0[L2S1%MNZ!#&#+R1]S/6O4M/\+Z/I%S)<6.E6-E
M<29+RV]LD;MDY.2H!/-:6T'U/U- 'AUA^U;I&L^'M6U:P\#>/;E=.>-9+8^&
M;E)I ^[!C5P"PRH!QTW GCFHXOVH;V?P5J7B&/X1?$0FSO4LUTHZ.%O)PT8<
MS*A?_5K]TG/7M7NV/<T8'^30!X5!^TMKEUX-@\10_!?X@M&]X]HVFM8PK>H
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M#;((VV')X'..M>:_L?>(=<\5_LT?#S5_$MY-J&NW>EK+=W5P09)'WN,G  Z
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MEF2!-[MM7(&?J<"@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444  & ?KFBBB@ HHHH *175]VT@[3@X[&EI%14+%5"[CDX&,GUH 6BBB@
MHHHH ***#P,XS[4 (74=2*;Y\?\ ?'YU\4Z]_P $_P#QWXI\>:UK.I_M$^+E
MT_4;J:=K.R62%HU<_+&I$WE@ ;1P@X':OGG]IG]GJ\_9F\3_  [MH/B%\1/'
M47B._DANM+MM5E@N945X1Y<!5\%W,I49[D4 ?JG=:Q8V,?F7%W! G3=)(JCI
MGJ3Z _E64/B)X7.<>(=+XZ_Z9'Q_X]7Y8WWP[N;Z'[%??LH?%#58(Y"8VO\
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MAZ&37=<MFBW6=P(U\Z53AH^&SV(YKU*R9'M8FC8NC*&#G^('O^/6@">BBB@
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MUY^SY\1]*%[-%#->75K"(+8,P#.S>8#M7DGC.!TKZ4H **** "BBB@ HHHH
M***P_'6@7OBGP;KFCZ=JLNAW]_936L&IP+NDM'="JRJ,C)4G(Y[4 ;E%9/A+
M1[OP]X8TK3+_ %2;6[VSM8X)M2N$5)+IU4 R,%X!;&3CUK6H **** "BBB@
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MP2!DQDCV(H [>EKS'PA\7+OQ7^SK8?$I-*2*\O/#?]NIIGG;E#^091%OQTR
M,XIGPX^,)^)O[.VD?$>PMUMIM2T$ZF+>3YECF$3%D]P'4CW% 'J%%>>_!;QS
MJ7CSX%>#_%FJB :MJFAV^H7'V=2L7FO$'.T$Y S7-_L??$[7?C+^SGX0\8>)
M)89M9U-)S.]M'Y:';<R(N%R<?*HH ]FI:\2_9*^*>N_%OX::IK/B&>"ZO;?Q
M%JNG1R6T7EJ88+EDCXR>=H S[5)^S-XN\6>)Q\3[3QAJ<.J7VA>-;W2[66VA
M$4:6JPV\D2 #T$O).3G/- 'M%%>2?L\>*=7\3Z?\03K&H2:A)I_C35]/MFD
M!BMXY@(HQ@=%!P*B^ 'C/6?%NL_%N'5KYKV+1O&EWIMBK*!Y-NL$#+'P.0"S
M')YYH ]@S17C?P$\5ZUXB\:_&RTU;4)+RWTCQB;+3XWQBWM_L%I((UXZ;G=O
MJQIOP5\=ZUXI^+WQPTC4KMKC3] UZSM-.A8 "")["&1E&!R"Y9N?6@#V7<-V
MW//I2UX/X \9ZOJ'[87Q8\-W>J7,ND:?H.BW5CITA'E1M)YWFR(.N20H-;_C
M+QEK6F?M)_#7PS:WOE:'JNB:W=WMIY8/FR0-9B)MW4;?.?IUR<T >LU\=?\
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M.H:*2OO_ &<.?Y?E7>?%6Y\;Q77@U/!L,9B;Q%:+K4DJJRC3-LAN",D$$80
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M^->D7NJ_%KX(36]C+<6UCXCNI[B>.,LL"_V;<*&8_P ();&?6L_]J*81Z_\
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M6=[HJ:VEJ<>:(V@$P3KC=@XZXS4?PK^)=K\5OA9X=\;V-G<65GK6GQZA#:W
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MUM^S+8VFF6EDOC[Q^ZP"1/.D\0,TL@=PWS-LYVXP/0$BO9*#V^H_G0!\*_\
M!+ZT73?^%Q6:RO-Y.O0IOF<N[X64%F)ZDX))[G-?5'Q_TGP=K'PC\0IX_FEM
M_"-I''J%_-"[HT:6\J3*P*#=PT:G ZU\9_\ !,V]FB^,?QKT]I9)(_.2X*J<
M1[OMUVF<>N!CZ5]F_M ^'])\5_!+QOH^O:TGAS1[[2+BWNM6EP5M(V7!E()
M.WKU% '!1^'[*;]MNS\0I<O+/-X :)(6M6VHGVU2'$N< G.-N,UV?POU"YNO
M$'C^PO\ Q7I7B26TU;9]BTZQ$']F1O$)$@F.YO,?8P)8X^E>47.GP6__  4%
M\*3JSR._PVN$21#\C;;Q!S[$'(KU#X5Z=-H_CWXG6B^$].\/Z<VKP7%MJ-B
M'U5I+5&EFE'_ #T#Y7W&* ,K2OB[X-^*OP \0^)-*U'4_#7A2TAOK)]0LH#!
M<V:VS-&\D*!3C&W*@*>.W:O7-)EBGTNSD@F:XA>%&29_O.I4$,?<CFO"_AH-
M/L?V;/$'_"%WGASPBL;:N\.HVERU_IUG,)Y2\[NX!.""SJ>%.1R!7LO@FXGO
M/!VA7%SJ5OK-Q+8P22:E:+MANV,:DRH,G"N26 ST(H VJ*** "JFL:M::!I-
M[J>H3I:V%E ]S<3O]V.-%+,Q]@ 35NF7%O%=P20S1I-#(I1XW&592,$$=P:
M/*H?VJ_A7<0I+'XQL6C=0RG)Y!Y':BNN7X4>"44*O@WP^J@8 &E0<#_OBB@#
MJJ*** "BBB@#YU^//Q(^,7@OQQ;0>#T^'[:#<)%%!!XCU9[6]N)B?GVC 4 #
M( Y)Z^U>^Z)/=W6E6DU_%%!>R0H\T4$GF1HY4%@K8&Y0<X.!D<U^>7_!0S2M
M(E^-GAFSUS0O#;Z?KJVEM)J-E$]]XFVJYP8+8N%";@J;@&)W'OQ7Z$>&[>&S
M\/Z;!;0O;VT5M%'%#(FQD4( %*]B!P1VQ0!I45\__&C]LCPS\"/B'IGACQ/X
M?\20V^H2PQ0ZY#IY:P8OUQ)GYBF1N !(_"OH <Y]N* /R'_X*$K)<?M1>-)!
M- HM=&TP;&E5'(:/'RJ3ESELD#.!S7Z;_L\G/P#^&QZ_\4WIW_I-'7YK?MZZ
M7?W/[2'Q5N+*\@@AM?#NC3WD$L"R/-$9(8P$<_ZLAV0Y'49'2OTK_9\!'P$^
M&P;;D>&M-SMZ?\>L= &S\3;NYT_X=>*+JR:)+R#2[J6%IRHC$@A<KNW$+MSC
M.XXQG-9'P%TV[TCX+^"+/4(8+:^AT>U6>"U@2"*-_*4LJ)&2BJ"< *2,8Q7/
M?M=W]]8?LT_$;^S; :G>7.C3V26A21_-\Y3$5 C5F)PYQQC.,D#)KNOAII_]
ME?#KPO9>3+;?9]*M(?(G^_'MA1=K>XQ@^] %GQSKT/A;P9KVL7.[[/I^GW%W
M)M/.V.)G./? KR_]BJSGLOV4_A='=1M%.VAP2E'&" ^7&?P85I?M9ZA%I7[,
MGQ6NIG5(T\*ZFN6.!N:V=5'XD@?C7;?#6W-I\._"\#  Q:5:(0!@#$*#I0!T
M=%%% '@G[9%EK=[\//#D>@^(H/#%Z?%>D%KVXU'["K1^?\T6_(WEN!Y?\73!
MZ5QWC[6_B!;?MCZFGP_T71]8NSX%LQ<G6KY[6*!?[0N-A!1&+%B'&,<8!KIO
MVQ[/Q%JVC_#?3_#F@S:[.WC;2KFY M1/#!;Q2%G>8-P%Y&#V(KA?BCKOQ!T3
M]N2WL/AW8:'>WNJ^ D>Y37[B2&)HX+Z4AD=%8[@TXR,=#VH ZF'X@?M.*'DE
M^%W@M]LI"PQ^*"&E7U4F+ _'!]J^D;-I7M8FG013E09$#;@K8Y /< ]Z^;+O
M4/VL_P"T(Y(-(^&0LD^_;F^NR\G'9R@V\^QZ5]*6AF-I";D(MP47S%C.5#8Y
M /IG.* (]3T^#5M.NK&Y3S;:YB>&5-Q7<C AAD$$<'J#FO@9_P!@#XNZ3I.H
M^'-'^)'AR7P]/ITV@V5Q?:?,+W3-,DE:66. H=N^4MB1CEF"CYJ^^M12ZDT^
MZ6RECAO6B8023(71),':64$9 .,C(KYTD\%_M27-Z7;XB?#^UMS)C;#H5RY$
M>.O,G7/;..>M 'PY\7]$^(?PR^)'C70;Z]\.>)ET*/PU?7-O'8O;1:A8_:(K
M>TTS&XB*V20*[)_$W)/.*]C^#.HZMJ/[3_PH%[96>I)_:GB"34/&-NZ?\3S5
M!8[+GR4&&%K;#%NAZ'9Q[\;^T?X7\3Z!XC^/L?CC7K;Q-JEUX&\/RR76DV!M
M0L']L1ILCB+-^\&QR#GEF'2I/AWIXTW]ISX+ZA86>MZ1>6&HII-SH[./L7AR
MQFLI3:Z<W'S7<B(\\Y'1GP><4 ?;G[1OB*/P???"K5%L!>7DWC6QTN%WN)(E
MA%U'-#(Y53A\*3A6XS@]J\Z_X**76K:/\)O"&LZ-<?9+S2O&.F7(N5=5DB!,
MD6Y,]6S(!WX8\8S74?M@%OL7P=0'"O\ $K0PW&<C=*>/3D"L?_@H?IMK??L[
MO-<QAC:^(=&FC8C+1M]NC0E?0[78?B: .B_;GMH)_P!D_P"))F@BF\K3O-C\
MU00CK*FUAGH0>0?6M?\ :?C\_P#92^)2%3*7\*7@P.^;8UG?MO$)^R?\4';[
ML>CR2GV"NK?TKL/']O8>/_@'K\2RLVF:QX;GVS)\K&*2U8AAZ'!!H H?#)[7
MQC^S7X:,R17UGJ7A2W61"#Y<RO9A64@\X/(KA_V:;:Z\;_L)^"[%K@S7FH>"
MQ9>=,V3N-NT0R?;I^%=-^S:YD_9.^';]2?"-F<_]NPK-_8EB\K]D#X4[0 Q\
M.6YQVR5)_F: ,/\ 9-U35/'_ .PWX3BN'CN]7.@7.CC8 BL\/FVT:^G1$!/?
MK5G]@*XU!_V3? ]CJH<:AI0NM(GCE8%HS;W4L.PX_NA-OX4?L!I*O[*'@@G:
M"TU^QR.WVZ>KO[$1CD^ %G,A),VO:W*Y/=CJESF@"A^P7I=MH?P &FV>\6UE
MXEUVUCWG)VIJEPJ_^.A1^%1?L(RW\?P@UW3K]V\S3/&6NV:1,P(B07[ML!'8
M%V_.KW[$)#?!C4BG(/B[Q%@G_L*W%2?L@30S>'OB,85V1CXA:^%7T_TO)_4T
M 0_L1;IO@"0) S'Q#KH!]/\ B9W'%5O^"?VL1ZE^R_X:M%22.?2+N_TNY608
M_?17DN_'M\PJ?]A2ZCN?@5(BG+0^)]>C<>C#4YS_ %%'[$Z11^ _'"P\(/'_
M (B '8#^T).E $W[&MY+JG[.D7GRE_\ B=:_;H6_A0:I=JH_ 5F?L%WMCX@_
M8\\&Z=9W*.;2VN=+N0IR8IEFD#*WO\RG\16A^P[$&_9XLTD'S_\ "0:\'3^Z
M?[6N@17+?\$Y=,71O@IXETV-V>&R\;:S;1,XPQ1+A57([' Z4 1_\$Z;1]!_
M93336?<=,U;6;0'C'[JY=>/Q!-<O\%?B!=?#_P#X)FZ9KVEJ3JYL;FTLL_\
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MN?\ VH;QM6_87\8W@!D,_A-)SQG.8XF.?;UJQ\3_ +3XF_8-\2-8127=Q?\
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M(LF4[N%XZ5U&H_M??$/X]?#;XS>%_%2Z(=+L=#FNXY-.M9(I8VCU*VB16R[
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M-P )P.M;'AW2;BT_:_\ &&JM!,+&Z\%Z/$+DH?+,J7E[N0-T)"E21[UY);>
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MFZ/?Q:=HT6F3F N#,L5NL3E !GY@#@=><#F@#TW]F8X_9)^'.<C'A&SZ\?\
M+L*X_P#X)[:]/XF_8]\#":6!WLK2;2U-NK#:L,CQJ&S_ !X SCC/2N2T3_@H
M9^S=\/O#FC^&-)\0W+:-I]C!;6R6VG7,\<,(3"QLVT_,H # \@GFLOX:?MZ_
MLM?"KPNN@^%M7N]&TB.::Z2T&EW9"O)(7?&Y2>6)(';M0!Z?^P#>P7'[*O@Z
MWCD5I;*:_M9D!!*2+>S$JWH<$=>>:UOV,--O-*^ ]E!?6TUI-_;>LN()X]C(
MC:G<%>/3!!S[UXIX*_X*-_L]^"X;ZRM/$&J2VUSJ,]VNW06B2%9&W%5$<:Y4
M'/)!<YY)I=._X*A_ 30IKV.R3Q$JW=W+=22?V?,XDD8@M(-Q) .!\HP!Z"@#
MUW]BAXH?A5X@LD=3/8^,_$,,\.?FB<ZG.X5AV)5U;Z,*7]CN V_AOXB(2"1\
M0?$'(_Z^Z\,^'O\ P43_ &?? !\0Q:4FOPC6-5N-:E1='F8R3S%2YSDY)*]>
M!VXQ6-HG_!3_ .#_ ((DU&R\(^ ?$KVM[J$]_,T$2+Y]S/)NDDVO)N!=CG''
MH!0![M^PEI<NA^"?B1I<^5FLOB)KT;QDY"9G5@%]L,#]2:\;^'?[7WA;]F;1
M-:TWQ'I>J7HU?QWXGN!/IT2NMO''J95BX)!_BS@9X!JKX>_X*/>"_!]MKAT#
MX,^.[2XU._FU6Z068VS74I'F2%F<[2=J^WM7S/\ &3XE?#'XH:9XC?2_@QXW
M\/\ B2^DO=0M]7GNG\H75PPDDWQ L-I(8A0.I]\@ ^[?^">\TH\(?$VT^VRW
M=G:^/-3^R+(V5BAE9)@%] WF;L>K&MG]A-43P!\0!&28_P#A86O[<\_\O0_K
MFOG3X1?MOZ!\+]$UP>'/@5XYMHKV]&HZ@UM;*83.8HXV<#I&"(P0OX]36SX-
M_;YT7X=+<:7I'[/_ (\T:#4]0N-2E@BM ?-FG<L\F"<Y8\D#@=J /7/^"=M\
MTOPS\>Z>S G3?'FM0!/XHPTPDP1VY;/XUXSX(\//X@^.O@2WNK6>;3;+XQ^-
M+UA&&$2211B2%GQP,.#C/H?>F^&_V\8O!OB3Q.?!_P"SWXY>\\0:B=6U))DV
M-)=-&D9=4P<96-<].?K7-_#_ /;V\<:0_BB/P?\ L^W4L%UKEWJ-VD$MU(R7
M$K_O?.*Q.%EW@[@, = !0!]5?L<:0WAFZ^-VD#F&T^(FH-&-VXXD@MYN3@?\
M]*\%UR:ZT?5=5\,WBJ'T[]H;3;M94?*R1W<:W2 \<$!\'WIGP[_:-^.NDIXA
MUKP[^R_J(B\3:F^JW4TNHR@O.42(ML>($#;$HQP.,]ZYWX@>*OC]\4M6M]G[
M,)TGR?$MAXFEE>Z*/=W-H $\U\ '* )GT H ^J/V7D\KQQ^T G#'_A8-PY([
M;K&U(KY]^)/[4.H?LP>//C5K&G:%:Z[-JGCNUL/+O+LVZ1A=%@DW9"MD_+C'
MO5[3/BQ^U%X5U/Q%?Z9^S;I-I>:Q<?;KZ>WU+)N)1&J!F&?F?:JCC&<53\5>
M&?VJO&EI?7EQ\(/A?.-9F:Y>QOVBFN+9GA\G=*SN%=Q& N>N!CB@#TW]C_QZ
M_P 3_C7\5?%TVG_V;)KV@^%M1-L)/,$6^SDR@; S@]Z]1\,>$M8LOVL/'7B*
M73I8]"O_  II%I!?D8CEGBN+LR(#W*JZ$_[PKY>\%_"3]LSP-X0TK3-!U#X?
M:/;V-G#91VXC$D[1Q@A%DDQAL GH<#M74CP?^W%) Y/C/X?1N.BK;,2?;[N*
M /HFR\#ZQ'^TWK'C"2 +H4_A.TTJ*;S 2;A+R:1UV]1A74Y]ZYZYT;6K/]MJ
MTUJ/2+J;0+[P"]A)J8_U$5Q%?^8L>?[Q63./QKQEO /[;=[ KGXC>!-/EP08
MX[)C]#G8>?\ &HKWP%^VG##&T_Q2\ V:_)")_L9!+,P Y*8R3@>^>E 'TIK?
MP^N9OV@O#'CBVM&ECMM"O-%NIFN5188Y)8IE(CVEG8M$!D$ #/7BLSQ]\*-2
M\2_M$?"SQY:SVZZ;X9M-5MKZ*5B)#]HCC$90=\,ASTP*\%D^&/[;"W8V_%;P
M4T8(&#8$ ^^/+S3'_8V_:#OM1DN[S]I_58FD?S76VTX*JDG)"KD #T% 'U-X
MQ\)ZKKOCCP/K%CK"6.F:)=74^H6)3)OEDMGBC3..-KL'[=*Q?C+HGBS7-9\!
MIX:U*?2K./59CJ]U;LFZ.V:RG16VN#N(E:(@>H&>,U\_Q?L1?&+4+5H-3_:B
M\4[?,+C[)8*ASVY#@]>W2L_Q'^PSJ5CX:U75/B9^TCXYU'0-,@:]>:"86*VR
MH"SR.0S9 7/IB@#PW]G?P?\ '/4?VJ-,@\4ZQK5S_P ([?VVL:PNN:FJ(]J1
M-#"ZQ\KN*/(=J@'&<\XK[^^.W@>S^-?P^N?#%CXI30KY;ZTN5OK:<[X6AF21
ME(5U)W*K+@G'S=#BO ?"O_!-#X8:G91:S<>-/&WB1;^WCEM]0DU@H[PLH93O
M5<L""",GCM6A:_\ !,3X*^;<&WN_$XEE<O+)#KS[V]FPO/KSS0!U?[9_Q@\$
MG]ESXB6L?BK2);K5=%O;.Q@BO$>2YG *&-%!RS!N"!WKN?BI+H/Q)_9_\3^'
MSXFT[1%UKPW-:?;+V55%J);?&^1201MSDCK7BFE_\$R_V>X[K[)!%J=QJ$:E
MF ULF7KRQ"CCG'.*E;_@FU^SSJ.L7-BUKJ-QJBCS)[<Z[(\H!(^9ADG!)')]
M: .M\4_%?X6:]^S[K_P]MOB?X4:_?PY/X>$L^IQ*GG?9#"&.6SC=@YJYX4^.
MOPCT?X,Z5X/U3XH^%XKBQ\/6VEWDUOJD3!6^S")F7GGG.*\W_9I_8Q^ OC[X
M2V/B&Y^'<=X]]=W:#^U[Z2XE18+J6!0&4H O[K.,=^<UZSI_[!WP!TU$6'X8
M:*VUMP,PDD.??<YS]* .)B_:/_9W\(_ >+P$_P 4]#U+1]/\/?V(S&59YIH5
M@\G)B3EB1SM'6L^U_P""@O[-\?@^W\.CQF4TT62Z=LCTVY3$0B\O &SY1MZ>
ME>L:;^QC\#])OK6\M?ACX?CN;5_,B8VVX!LYR020?Q!KMO\ A2WP_P Y_P"$
M'\.?^"F#_P")H _'?QY??!2QTCP2GAGXGW>KR>'!!8BT;0IXQ/:_VE/<22M*
MP'SI%,HP!\S+QU KZZ^#G[<W[._[/?PX?PYHGBO7O$D":C=WL8;1YA,?/G:4
MKRH7"EL9XSZ5]HQ_"'P);)&$\&>'XTB4HF-+@^12<D#Y.A->4Z38)\// %_K
M'C;X;Z=K6H_V]=P6MGX2T&*[D2R,[_9F9$4G(C"[CV)YP: /"?A7^W]\ ?A)
MI.JZ9H=MXMALK_5[S5S%/I,C"*2>3>ZIZ)G) [9I?"'_  4:^&'A"'Q):>$_
M _C#5+674[O56CL-(V*HD*R2S,6<\-(78DXQGH!BOL'QWJ5GX0\*?VQ9^![S
MQ3*&C"Z7I%E"UR0_5MKE1QWYS4^HZ^?#\&@26/@O4;H:O)'%<)8P0J;!6 ):
MX!8?*N2#MW=#0!\9?#G]NWP[X$AUS^R/A!\3+B+7-7NM>E,FFJP$L[!I A!^
MYE>*\Y_9I_;I;X7W/C2PF\&^(/$VB:UK5QKNF6FC6RS7-B]S,[RQ2X/.25(/
MKN'I7Z.^,?&%[X5%D;+PQJWB-)Y"DATL1DVXXPSAW4X.3]W/0U^'FD?$;Q;\
M&OB%=Z]X<U:[T+6[#49TGA$A5)RMPV^*=>C*>ASTSD8- 'W1\/\ ]M:T^'3:
MEIGA+]F_Q_I]OJ^K3:E-!':85KB8C>X!X7) ^7.!6IX?_:1^-?@NRO+'PS^R
M-JFEVUW>3WA1+UD5II7+/(P\L\L3D\]:^H?A!\9(_C5X7\*>)?#UEYWA[5K"
M66\NC<J)+&Z0HOV9H_O%LF0$]M@]15KXCWGQ-M-8L$\"Z3X;U#33&3=OK5_+
M;RJ^[[J!(V!!7N2.: /A_P")US\=?B=X+\0Z3<?LM6&G3ZTUQ.FJ1WL<MU:7
M$ZHLDZAAG>1&N<$9"CTKJO!/B']KCP;8-;Z'\"_"%BLJ0BXD;4XTFN7CA2,2
M3%9!ERJ*"3[#M7WO&&\M=ZJ'P-P7D ]Z\.O_  MX^T#Q7XUO?AY<65U=ZSK,
M-U>IXNDF2VMXQ9Q1J+/RPVY<H2WW1N+4 ?(.N?MO_M.>"_BL? .L> /"Z^*[
M^:$66E&=ONRK^[59%<JVXHQR2.<BO2]%UC]L?4Y/$MS:?#+P-X4U74EMI/M]
MQ=@R,539AMKGS2 .-Q&T-CFIO^"A7[-E_P"*_!6G?%W1'^S^/O!]M%/>?V>I
MQ<PQN'+IQNW0OEU[[=PKU7]GGXV>,/VC_P!G?0O%>@WN@:;XJ^VRVFJK<P2S
M6R-&[!E558,&93$X.<8:@#R>!?VZH+2=#;?#UY7!Q+D*X., _?P2/>LZTTG]
MKT^+KFUM/$OPITWQ5/8P76HVT41-W<1KF..:7') Y4'H,8%?7.O^'?'NN?#V
MVL+3Q5IWA[Q<"K3ZM;::;BV."=P6%W! (QR6XP:\<OO"7BR\^*2Z%IGQ/T"S
M^*%MX:AEU'4SX3+SW-G]KEV'/G!5CW$#9DG*[NAH X67P[^W''(@3Q'\.9UQ
M_K#;R#;_ )XJ$:)^W2DK;M<^'4D?)^6%^?;K7TM)X.^(UU\-+726\?6-GXO2
M<-+X@@T0/%)&&)V_9VE&"5P,[NW2M6P\.>-(_A_<Z7>>+;.?Q2X=8M=CTK9$
MF6&TFW\PY(&?X^30!^>'PY_:#_:H\8>/KWX;:%KWAJY\4:2+E+N/6;14?=!)
MM?\ >!P'.6&,*/EP:]/UZP_;,N(K >(-=^&.AP)=PK#=W* AYBP$: -N^8GC
MY<'G@UR?[6_PW\7?LP^./!GQ_L=;@\3>)(;XV&KRBP%E#=!HBL6Z-&;!= \;
M-GDB,X&*^I_B)\4O!7CKX+>"_&LNJ:1;^'-3U32KRTN-;LWN(S(TP*(JJ05F
M#!E#=%8'(H \"G_91_:<N?$(UG_A9/@2.Y%G+8F)-"VPM%)(DCJT?D[6RZ*<
MMG!'N:V_$'P"_:V\5>'=1T;5?C#X2O=-U&WDL[NU;26420NI5ER(LC()K[:4
M86EH ^+(OV?_ -K&XL+6QG^.N@Z1:VRJD7]EZ/N;:JX 8E.@ KQ+P?\ #7XN
M^//VA_&_AZR_:!DL?B!H5K;0W-W/I,EO)?6R,6"K&4 *1O(>0#GS <X-?J!7
MYC?MD^*=;^#'[<MEXU\,3,FI+I5C=S1R?-'/'^\@EA*\?*\<8^C 'M0!VWP^
M_9Z^-/Q3\+S^(M&_:6U1DFNYHF/]ER6Q::*0Q2JZ,JE<%"!QV':MZ^_8?^.N
MH:<UM/\ M/Z[*KXW1BS,8/'W=RN&Q[\9KZK^"_Q6T#XS>!8/$WAN*Y@TV:XG
M@$=W;F"0.DA5\K]><]Z[J@#\N/C]^Q=XP^!WP>UKQOJOQJ\8^(M0L;FTC2WM
M+NXAA$#.L3%\RDY (PW &!G.:[;X$_L7Z3\:_ASH_C?2_C9\3;>UU2"2.:TG
MU/\ ?0LKLDD+$,0"",<?45]Z>._!FF_$3P=K7AG68S+I6KV<ME<HIP?+D4J2
M#V(Z@]B!7P[^P%XONO@_\7/B+\ M<DEE>SOKB]TN\G4QF;RPJ.-K'^./RI1@
M8/SF@!OP/_9 T?Q=\0?']AJ'Q6^(]Z/!_B'^SOLG]NRQB:,V\<B,S!B<Y=QQ
MC[HXKW-_V#_ $D[2MK_CLLS;F_XJR[Y/_?54/V6?E^/W[2B^4Z[O$UM)YC<*
MW[AAQ]".O^%?3M 'S?=?\$^_@[?:5_9MQINN369E^T-%)X@O&1Y2VXR%3)M+
MDDDMC.23UK \:?L<?"CX(_!_XHZ]X2\,FTUAO"FJ0K=SW<UP\:-;.&5-[$+G
M&#@9KZOKA?CPJ/\  _XAJXRA\/:@"/\ MW>@!OP"E6;X%?#J1&#JWAS32&4Y
M!_T6.N\KR#]C^2VE_9<^%;6D<D</_".V8"R')!$8#?AD''MBO7Z "BBB@ HH
MHH Y7Q?\4_!W@/S/^$C\2Z5HQC",RWMTD;*&.%."<\FN';]L#X*"$R?\+-\,
M[ S+D:@AY'7O71^.?@'\./B5K*ZMXJ\%:)KVJ+$(!>7UFDDNP9PNX\X&3CZU
M8T?X'?#OP_IT5CI_@;P[:VD0(2)-+A( SGJ5)ZT <,_[:_P01U0?$?0G) .4
MN-PYZ<@5\X_MB_&_P1\5M5^#G_" ^(]&\3^(M-\:6MQ'9P72J[*0%V;R/E5G
MV GH#C/2ON*P\$>'--C*66@Z7:QL<E8+*) 3] M?'?\ P4@\.Z!;Z7\(K::.
MVT;3[SQA##?75HBV\J0E#YC"51E"!DY[$ ]J /8?@-X:\:W?QC^)'CSQ;X8M
M_"$&M6NFZ?9:?%J$5V["V^T%I6,?RKN\]>.ORU[_ %X-^R[HOPNT"V\2?\*T
M\77_ (GM99HI+TWNL27Z0/AMI4O]W<,YP>=H]*]X5U89!!'7(H 6O(_VC/#"
M>)K#P"'OIK'[!XTT?4%\JUDG\TQ3$^6VP'8&SR[?*N.:]7:[@1<M*BCU+ "O
M%_VG=/\ $GC;X;Z=!X#\36^CWZ:WI]Q/>IJ*VR_94F_? OGD$$ K_%TH ]L5
MMPSC'M2UCW/B[1+$R"YU:RA\O;O,EPB[=V=N<GO@X^AIC>./#Z6OVIM;T\6^
MX)YINDV[B,@9SUQS0!X38W(M/^"A&HQ%6;[;\.(65E&0ACU"0$-Z9W<>O->I
M?'SP?9>/_@SXR\.ZC#J%S8:CI<T$T.E;/M4BD?=BW_+N..,\5YS\1O%?A?PM
M^T/\./%;>(-$TFVO=-U#1[^[GU"*-[Q287M(0I;+[96<C XWG^]5GXS_ !<^
M%OQ*^''B[P1_PM/P_HEWJ^FW5A]J34HO,MB592^T.#E2#D9'0T >V>'[6*QT
M/3[:!&BAAMXXXT?AE55  /N ,5H5XMX7_::^$&E:'I.EQ?$SP]=O;V$>)&U&
M,%XXXU!=LGC( //K4\G[7OPC%Q?6\'C?3;^ZL2GGV]BYN)$#2I%NVH"2H:1<
MD< ')XH ]BK,\3V\-WX<U2"XA2Y@EM94DAD?RUD4HP*EOX01D$]J\4L?VYOA
M%J,.JS0ZY?&'39XK>>0Z5<XW2,ZIM^3Y@3&W(XZ>HJ;PO^U=\,_C-HVK66D7
M6KW$+6ET)5?1[F,LB0%I N8_F;8>%')/ % 'H_P;M+2P^$_@^VL+.'3[&'2;
M5+>TM[S[7'#&(EV*LW_+10,88=:[&OG7X=_M#_#_ ,!?";2M-L+3Q8VG^'-(
M@MDBNO#MVMRT<1CME!7RQER2IP.Q)Z"NCU7]JWPIH\%E+/HGC%Q=6\5P@A\+
MWLFT2)N56VQG#8ZKU&>: /9Z#7C?B']IK3M#OX+2#P1XZU9I'5#)9>&[DHA9
M%899E _B XS@@@]*H:S^T9XA:XLT\._![QOK<<DPCGFEM([)(E!(8_OG4D@C
MTP1SF@#JO@%XG\/>)?!5X/#7V,6>GZUJ6GSI96KVT:7$=U)YHV-SG<<ENC$D
MC@BO2:^:?A[XRUSX>Q7EAX<_9_\ $>EVVJ7UQJUV(]1M'!NYFW2LY,YVDG''
M&.PK??XS?%J37I+:#X&ZF=-4;A>2ZY9(6'&0%W]>3CGM0![O2CJ*\ \'^/\
MX_ZGKNI1Z]\+M#TG2DNXEM)D\0))(]N9<2,P4'#+'\V.YXK<\%>(/C7JEMJ1
M\0^%O"NCSQWI2T\C5I)UFMA'(?,)$?!+^2 .N"Y(& " ?.?[&DI/[;G[2 ?
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MXD>Q2-66\U^\BTX%B.1\V1P>."3[5<A^-/[0L\TX_P"&?X(T1/DW^*;;+/\
MEC;^M>:^)/CU\7].^,?CF'3KBRU3PY<2:]H/A[28;-3/;ZG8Z>ES S'<&D63
M+YP,9 '&17H?[&WQQUCXJ:EXZT/4]:/B>'03I\T&L36!L9F-S 7D@>+ '[J1
M' 8=0?44 0ZQ\0_VJ;O1]NF?"3PEI^HF0'?=^)%F14R<@J N3C'.:]4_9XU?
MQOKGPVANOB%X:M?"?BC[;=QSZ=8Y,(43-LD4Y.0X^;/?.:],/0G%>9_!WQU)
MXP\2?%&RDL;BS&@^*'TQ))KAI5N%%I;R;T!&$'[S&T<9!/<T >FX!ZC-&!Z4
M44 & 2,^M?CI\(M(M]?_ &^M7\.7T4=UI.L^)->TV_MI$&R6VE2X#IC''W5(
M/4%0:_8LG R.U?D_X-T:V\.?\%2VL;0/]G'BR\D +<J9+1Y6_#=(WX4 >D_L
MR>,KO]B/X_:W\#_&UT6\,>(;J*[\/ZL(R5:69A'&7../,"A&[+(GHU?HN#D9
MKY<_;N_9@?X^?#2#5M )MO&WAF.2ZTUXCM:YCQN>WW#D$E0R'LZCU-=!^Q1^
MTK;_ +1WPF@NKD&W\4:*(['6('_BEV#$R_[,F"?9@P[4 ?0=>._#?X>7WAW]
MH#XK^)+KQ2FJQZ]%ICV^C[G+Z8D<<BX()V@.02-N,X.>E>Q5YMX:TWQI#\=/
M&M]J,Y/@6;2M-CTF$LA NE:;[2P ^8<&+.>#V[T >C3PI<1-'(BR1L"&1AD,
M",$$=Q7YZ>!KVY_89_;(NO!D\CV7PA\>RB?3'NI?W-I<N,#9V&)"(FS_  M%
MZ9K]#J\2_:\_9YL?VB_@[JNAF",>(+6-KO1;LC#PW2C(4-U"N/D8>X/4"@#V
MU?F4'I7D]IX8M;?]J+4?$/V>&.[N/"<-B;G^T4,DBK=,X3[+C<H&2?,S@YQC
M(S7FO[ 7[0=]\9_A9=:/XEF)\9>%)QIFHB4;99$ Q%(ZGD-\K(W^TC>M>AZE
M\&='D_:@T?XGM-J/]M)X>N-&6*.$-9B,2*^7?JK_ #G"GK@GM0!Z_1110!RO
MQ2^&VB?%WP%K'A+Q#:K=:5J<)BD!ZQMU213V9& 8'U%?G#\!-<GTKP?XU^!_
MC@65[JOP^UR/Q%IEOJ]ZVGVZ1VMP6G9IPK (I9)@F!E93^'ZD&OSH_X*B? C
M[!]B^*^B6XB%PHTK7A"YC:0L-MO*Q!Y!QY3>H*9SB@#]%('\V&-_E)90V5.1
MSSP:?7(_"/Q_IOQ1^&?AGQ5I/RV.JV$-PD?>(E0&C/NK!E/N*ZZ@ KXJ_:5^
M"NF?&7]JV'0[P&6]O_AW>S:<RMY;6EY;WD?DR!AU!,A5@01MSZU]JU\]>("%
M_;N\&-C##P%JO/K_ *=;T >6?\$S?BPVL^$?%'P\U.!++6?#MZ]XL.?G,4[M
MY@8>L<RNA]BM?;%?D_XMO[C]DS]KC2/&^F>5HWA35-6NK;5DCU47R-&;@&[6
M5E4>6P66.<1\LNWKUK]6;"^M]3LK>[M)TN;6>-98IHVW+(C %6![@@@T 3U\
M&?MZ^$=0^$'Q7\"_M!Z$5N3IM[:Z=J.GN2N\CS/+8$=F1I(SGN4-?>=<C\3_
M (7:%\7? >L>$?$D,MUH^J*!.L<GER+M8.I1ARI#*"#0!\W?L-^.+#XC_%C]
MH+Q)I%Q-<:-J6N6=S9M.C(1&T#_P-RO(/%?7]?&?['W@FS^$/[3WQW\"V$5W
M96-O_9UY86GF"6 6KH=C%SEO,RS=3TK[,H *YWXD:/\ \)%\//%&E>8(?MVE
M75KYA&0N^%USCVS715G>)#M\/:H2,XM9N/7Y&H \B_8EN%N?V3?A7(H*C^P;
M=<$YZ9']*]NKPO\ 89;=^R-\*CMV_P#$CBX_X$U>Z4 %%%% !1110!Y9\7OA
MAXV\>:E93^%OB=J'@.VA@>*>WM-,@NA,Q.0^9.5(''%>?:7^R%KZ6<7]I_'C
MXCWFH@?O9[>[MX(F/;$?E-CCW->F_%3XD>+?!%W90>&_AMJWCA9T+R3Z?=VT
M,<!!P%;S9%))Z\ C'>N ;XT_&W6ITCT;X$S6*(I::3Q!KUM;@GLL?EE\GKUQ
M0!:3]D.QNK*&/5?B9\2-3NDR&N/^$A:W+C/ *Q*J\?3/O7S)^V[\#XOAD/A;
M)H'B;Q1J>J:EXHBM+<Z_K,EY'!)L!1T#J=K951G!XSP<U]':EXS_ &D[ZS0Z
M?\-?"&FW ?YUO?$C297CILCQ^O:OF7]NL?&-OAKX=UOX@Z?X9T;3]*UN)K>\
M\.:A<3744[HZJRAD&, $Y!SD"@#Z/\$_LW>(=;N/&)\=ZE=Z19ZRK6Z:9X8\
M02-:F)VW/A3;QF(C 4;#T9N:Z/3_ -DCPYIMK]EC\7^/7M%41QV\GB:XV1(
M0%7&#C!QR3T%4_V7_%O@[7)]?MO"OB_QEXM(6&::7Q5%,%@'("Q,\,8YY) R
M>!7OM 'BNA_LA?#K2-*.FSP:SK-EYQN$BU77+N?8QB\IL'S <%  0<C@5PWQ
MJ_9=\#^!O@KKT?@3X::=JFH/)9QII<QN)XWC:\@\W">;D83<_P I'* ]J^HZ
M\G_:F\1CPG\#_$&I'0H_$OER62#3)9'C64O>0H"63YAM+!N/[O/% #[;]ECX
M1P:6^GCP!HD]I*8RZ7-OYQD*%BA9G)+;=S8R>,FM)/V=_AC'!# O@+P\+>&X
M6Z2'^SH_+$JQ^6K[<8R$^7..E>ACICTHH ^?_B5H?A_3OV@?@SH(\+Z!+9:G
M%K;OYVE0N\30V\#H8V*_)R.<=<#TKT;Q'\)?"L^C:DUGX6T9-2>WF,-Q'IMM
MYJRLK$,I=-N[<<Y;C)YKS_XM<?M7_ ,YR#:^(U*XZ?Z+"<_TKW'4GECTVZ>"
M/SIUA<QQXSN;:<#\30!YU\*?AUHS_#?PT=7T+2KK5#IL*W4LEK:S,[[!NW/%
M&$?TRH"GM7<:;X2T;1[I[JPTJQLKEAAIK>UCC<CN,JH..!^5<Y\##KA^#W@_
M_A)=+@T37_[,A^W:=;0K#';S;?F18UX4 ]ATKN: (TMXHW9UC16;&6"@$_4T
MUX 87CB_=]00GR]1[=*FIA15.X* 2P+'U]Z //\ X Z?K.D_";0K'7]?_P"$
MFU:W6:*?507_ 'Q6>0#E@"=H 7) SMS7H?XG\Z\^^!&E>*=%^&]I:^,M4&L>
M(%N[QI;M9%D#1FZE,*[E 'RQ%%]L8[5Z#0 '\?SIKJ"#D9IU(WW3GI0!Q'PU
M\'6?A6]\936IOMVL:]/J<PO75E#O'$I\K!XC_=@@'G.:[C ':N"^%?@&^\"7
MOCF:\U+^TH_$'B.XUNV&6_T:*2*!!#SZ&)CQQ\U=[0 4'H:*#R* /@WX/6ZV
M?_!4;XI106*V,1TF:1P&SYCLEDS2^VXG.*^X?$HLCX=U0:DGF:<;67[2F"=T
M6P[QQ_LYKXH\#?N/^"K'CH!CB?PV&*Y_Z86A_I7VMXFBM9_#FJQWTC0V3VDR
MSR)]Y8RC!B/<#- 'RU<:MX)E^+_[*T?AJQB72[G2=2.A.\LJRVMH+%2J[,$-
ME<+\YR"*]LT)=*'Q[\5-#>:S)K!T/3Q<6DZO_9\<0DG\MX3C;YA)8. <X"YK
MRO2[[P-X>U#]F-?#-RVJ:'>QW&EZ!>S6L4LC0_V>\@D:9P'0E8L'8.2W->K:
M%KMW+\=?$^CR^*+6[M(-$L+N/PZL!$]F[23*T[28P5DV@ 9XV'IW )?A5XD?
M7-9^(UN-(ETM-+\22V8EEE=Q>'[-;OYRAONK\^S:O&4)[FNQ\-:I>:UHEM>7
M^ESZ+=R[M]C<NC2188@9*$KR #P>]9GA3Q]I/C34_%&G:9)(USX>U$Z7?!XR
M@6?RHY<*3]X;)4.16;\%=8@U[X<:;>6VM:EX@A:6Y0:AJUO]GN9"L\BD,FU<
M!2"HXY"@\YS0!W%%%% !1110 4444 %%%% !1110!X7^T?KEA9^(/AS:77B'
MP?I$8UZ.XOK;Q4L+O<681MZVPDSMD+;0&%>8_M_?L\Z%\8O \&LZ9J>AZ+XO
ML/+?^T]7U(V\1T[#"1>NU1EU8-C^'K7BO_!130/&UM\8=4N?#OA9O$6G^(O#
M,&EW%RWAQ]1:T"M/E(92-L;-YFXE>047/:O0OCY\!/"_CG4-/BU?X)>)_&4U
MOH%CIZ>(--U2.U<*(0 BPR2CYEYSE<9X.: .<_:5\#Z'!\=?AC=2^#IO%8U"
M#1=-LO$-OXS^SW,?[T(C1P %F"_ZPR#AB2<@\U^@]G;I:6L4",S)$H12[%F(
M P,D\D\=37P#\6/A)IFG_M,?!$:5X/3Q=J*:+IEI>Z9J1<3Z7#;31K%=RO$Q
M5650_#?(QB.,DU^@@Z'ZT ?FO_P4XO7M_B%=Z<L<,O\ :GA&Q1C(Q#IY>J,P
M* ##$D@')&,]Z^W_ -FO6D\0_L^_#J_26WF$N@V8WVI8Q_+$JX!8 \;<<CJ#
M7P7_ ,%.9F/QKL2NHBS\GPS:*]D2<WRM?S,,=OW;1ACGU%?;?['UM]A_9;^%
M\94+_P 4_:OA>G*;OZT &G^(;;4OVL=5TI=/NH[K2_"43/>M9#R)!-<Y"+/N
MSN&P_N]N#USP:]BKPGX+_$"+QO\ M$_'"UM=1N[BUT.32M,-G<!ECMYTBG\U
MHP>,,2O(ZE:]U"X)()R: /"6MA/^W&9@2'MOAT%Q_P!=-4_^U'\Z]WKPGX7Q
M?;?VKOC=>38DFM+#P_96\C'+11&":5HU_NJ6;<0.IYKW:@ HHH)Q0!X#X@\)
M:/??ML>%_$$L=Q_;5EX4N(8734+<1;#*^0UN3YQ;]XV' V\^H->=_MP>'/\
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M?!8L<R.2S<L>IH Z#Z]*^=O&/[*WP774[_7M?GO[2XN+EIYYY_%5Y"JRNQ/
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M/;01R9W%<%6E!![\]J]FP/048'I0!X;JO[1/B;3M#:ZC^"_CJZU!/*+6$-M
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M9P,C-.IKG '..0/UH \X_9]BUVW^'21>(]!L_#>I)J.H*+"PMU@A$/VN7RI
MBDC+IM<GN6)[UZ37D7[*_C$>.?A'!J@L)M-4ZKJEOY$]V]TW[N^F0MO?YL'&
M0O1>@X KUTF@#S_XU?'3PC\ /"T/B#QA?/9V,]REI"L,+32RRL"0J(H)/ )/
MH!7">*?VWOA-X5O?"=O=:_).GB6T@O[2XM;622**VGD$<,LS ?NE9C@%L=#7
MD?[8MEXW\6:II6N77@N[?PQ\/?&-C?QW&FDW$^I6#P9GF6(+G]VY52!G//I7
MDGQ>^ <T7[-WPDMY$\1:=X_U7PS9>'7TC2--$T.H,DT4\4-[)C]TL;$-N)&,
M-UQB@#W[P1J@TO\ X*3_ !&TJ!A,FJ^#+"YN/D(\J2!T50&Z-E9">.G%?6E?
M"GP=UBXUG_@IO\1+J73;_3[9/#TVGV[WT+()Q;&SC9XB1AD+!B"/7/>ON@SQ
MC_EHOYT /HJ!K^V0D-<1 CL7%03:YI\#1K)>VZ&1Q&@:51N;!.!SR>#Q0!>K
MD/#7@GP[H?Q!\8^(M-8'7]<%FNK 3!L>1$R0?)_#\C'Z]:MM\2/"JRR1-XBT
ML21DAT-Y'E2#@@_-7E/@[5_A[X+^+WQ'\9'X@Z!*_BU].1K3[;&K6[VL#1$$
M[N=V0>G&* />J*\M\2?M2?"7PC%'+JWQ#\/6<<C%4+:A&=Q R1@&L!_VWO@4
MD4DG_"S_  Z42/S#MO%)QTX'<^W6@#W&ORM_;PT^33_V[?"%T)H-MT=!DPK;
MFC"WA3YU[9QD>HK[;TO]NCX#ZQ)*D/Q-T&-HP"?/N1%D'TW8S^%?!G[<OQ-\
M&^.?VH_ 'B?P[XITG5])M+?3OM=W9$,MMY5^68RN.ORG('4 'UH _6KN?J:"
M,BO!]4_;B^#.EQQ2'Q<EY%,&99+&TFN$ 'J40@?C64G[=7@35&E;P_HGC#Q/
M;1$(UUI/AVZEBWXSMSL'/0?C0!XQ_P %$_A3KO@_Q;X3_:#\&6T/]H>%GB&J
MG.PE4E'DROC!=/G:)_164]%KZ+^!_P <--^.G]AZ]HT%\FG7VBO+,KV@\FUN
M8[@1R0/-G(D!SA,8*_-WKDO$O[3&@?$'PIJ6A7OPK^(>KZ?J<#V5W9GPM<?Z
MMU(.00,_AWP:^*/V4OB?=?LE_'[5_#NK>$/%&IVWB&&.VM(9=-D@U+(9FBD2
MT+8(DVD,1SE <XS0!^MM%?+>O?MB>-+'6#%I?[/7Q&U/3=@(NWL5A8GT",<X
M^M%I^V-XUF,?F_LY?$I-_ Q:0G'YN* /J0@,,'I7PU^VSX*O_@9\5_"O[2_A
MFWDN4TB>*R\1Z;:Q*K7%LV8_,+>K!_+);IB/TKUV^^.GQF:V@ET_X :I(9&)
M*7.N643*I^[D;SSZCM7)^/OBW\1O%_AR]\'^,O@!?OI_B.WET_[';^(;)I+@
M%"7$>7!+*JELCD8SVH ^E/ 'CG2?B5X,T?Q/H=RMWI6J6R7,$JL#PPR5.#PR
MG*D=B"*Z"OS)_94^/GQ#^ .K:G\"4^&]YJNN+>RWVBZ9J>I06<\,,B^:T<C-
M\K97+@IG)+CM7U7-\9?CW&_R_ 173&01XGM<_0^] 'T77-_$LWR_#GQ4VF6J
M7VI#2;LVMK+&)%FE\E]B%?X@S8!'?.*\1/QJ^/Z[3_PS_NW=O^$GM?EY[\5%
M=_'3X\V5O+<S_ %DMXE9Y&_X2>T^51R3^5 'I'A_P7'\3OV<M$\->,=-2T&L
M>&K:UU.P@B^SB!WMU#HB#_5[&Z ?=V@=J^7_ /@G%XQOO /B3XA? WQ-J9DU
M+PWJ$DNFPSR<M&&*SK&#T7)CEP/^>QKTM?CA^T)XDT[3)= ^"-E!%?,CI?:A
MXD@>W$#+GS/W>3R"",9[U\W_ +5'@_XH?#CXB>&OC[J/A'PYHVHZ3>V\5T=&
MU"6=+J3+!&G C7:K*?+9LG.4ST% 'Z:5\^?'(_\ &47[. *;A]MUXEO[H_LT
MBN7^&OQ _:1^*G@+1/%6D6WPTM]/U2%+J$27EW(QB89P=J$*P/RD9X(-8OQ;
MN/V@-/U?P5>ZGJWPH\,WTFKC3-,O[A+JYD>>XC91%'N0;"X4@XZXH ]Q^&NB
M>)],^+_Q1NM7\0P:MH%]/83:-8(ZF33E%N5EC90,@%@&!).<G&*\\_X*"?"!
M/BG^SQK-U!"&U;PUG6K5TCW2,D8/GQ*1R-\>>G=%KA?#_AK]JF3X@^,=/M/$
MO@&TFLULGEUB70)XEU(O&Y50XY<QA=IR3MW #O74WWP[_:OO+>56^(WP^?S+
M.2!H&T6?RVD.,$Y)SQD>G^R<T =3^P[\8!\8OV?-!N[J\>]UO2 =(U*25B7>
M6+&V1B>27C,;9[DFO?\ -?E3X"T'XK_LY_M,)\'[3Q]I7A5_%TD5Z^IV^C++
M:32F!]@B1RI4;T,6 < [<=<5]FP_!GX[2).EQ\=[=593Y;V_A:(.K=CS(1C/
MM0!PW@R.>#_@IQX_=H=L-SX/MGCD?C<H^S@E?494@XK["KXA\*Z9XO\  G_!
M0OPGI?B7QD/&-UJ?@FZ5[N73X[0K&LA?RT5"?XTW9/."1Z5]O4 %'<?6BCN/
MJ* /!_V)E:/X"VD3*5,>N:ZASZC5;JO>*^9/V"=>O=5\ ^/K"ZD+0Z1XYUJT
MMHRH!CC:X\TJ2.OSR.<GUQVKZ;H **** "BBB@#@/B]\-=:^).FV%MHWCO6?
M LMM,99+C1XXG:=2N-C>8I& >>*\MM?V.S-$X\2_&+XB:W(UPTT;1ZN+((6
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MOACP[%X6T,V*R7/B&26*6[::)991$1P0F[:2,\COTKZ97) SU]J^,?BKXO\
MC'X:_:CM8?AK+JGB#12ELGB*QUZW6#1K;<8U4VT[;3O9-S%5+?-D8.<#[-CZ
M$Y)R3UH _+S_ (*%VMG=_%#XOW$D,<UU9>$O#LD#L,M$6U"4,5/;*DCWK[O\
M+:DGAW]E?2+^X::..Q\%PSR/;.$E4)8!B48\!L#@GH<5\3_\%&;6"Q\4?$Z=
M8HXY[SPYX80LF=[K]OO\@]O^6*]/05]5_%66V@_8FN;>[U6?0X;WPI::;]NM
MK<SR1&XBBMUQ&/O9,H7\?:@#MOV9=$MO#W[/WP^L;-+A+5=&MY(EO)5EFVNG
MF#>Z?*S?/R1Q7>>)-9M_#GAW5-6O#MM+"UENYCG&$C0NWZ TGAK28] \/Z;I
M</\ JK&VBM4^B(%'\JX7]IW5(]%_9O\ BI>R.J"+PMJ9!8X!8VL@4?4D@?C0
M!S'[#ZR_\,J_#F>:)H3<Z<UT$<8(66>21?\ QUQ7N=<C\(+#^R_A-X*LBNPV
MVAV,.W'3;;H/Z5UU !0WW3]**#V^M 'S[^SIKTVK_&;X^6T^AP:<]EXCMX4U
M"&*1#?1_9@%9]Q*LR[2-RX!##(K._;MM-"N?AYX%D\3I9MX?@\=Z(]^;_'DB
M!IRDF\GHNUB#[9K0_8]\:)\2-%\>^(?-U;S#XLOK VNIZC]K6 0,%7RL*OEH
MP;.SG'J:S_V[KC1;7X=^!9/$IMO^$;7QYH;:F+P P&V$Y+^8.A7 Y^E ',OX
M+_8TNY_M4EO\./-.7R+F)1]=H?'?TKZ'^$4/@FV\":?!\/&TP^$XS(+4:.X:
MV4EB7"D$C[Q.1[U\ZW7Q0_8VNUGM+B7X;L-V'4V4 R3_ ,!KWCX#R?#>;P!%
M-\*QI \)RW,K)_8@ @,V0).G\7 !^@H ]$KP/XF_&3]GOP?XWO\ 2_&EYX3A
M\3QA6NDOK&*2XY0%=S%"2=N._I7OAZ5\Y_&;]JGX(?"CQN^E^+DCN/$D#".;
MR=$>ZEA!4,"SB,X!!'>@#Y\^.7QO^$OCOXE_";PI\+7T9M9E\5"TNY+/2!%
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MVCO D_[27BRS;6O"D.GIX;TV6'74O(Q/=.TUSN@:3=AE0*& ZCS/>MD?L)?
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M1C58KG-F?*1\+RVX_*.[5F?\%!YM2\/? W1M?T80BVT'Q3I&HWUD0%2[A6X
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M>.-2DN9CIOA>PO)KV PF-1-<1S,P591E"!QD+W/% 'ZWW/B#3+,*9M0M80Q
M7?,HR>P'-9NI?$+PQI"PM?:_IMH)I/)C\ZZ1=[X)VC)Y. ?RK\EOC+^PIX@^
M#OPI'C3QU\1='M=0B "Z)=7$\K/)@[88)2QW28 Z  <\UQ=[J>AW/['EHJ^
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ML#<'D3IC&9,G.*]PU^PU(?M'>#[R+P];W.DCP]JD,^N%"9;23S[5DA!S@+(
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MV6ABZUDSQW-I,)'U)?(B7[1*!]Q_E*;3V0'O0!VU%%% !1110 4444 %%%%
M!1110!^?O_!1GXRZKX'\5Z+H4=QX:\3Z9=1K<'PKJ6D2W5S!*B.4EWQL"!(?
MD&,8!/49K[UT69KK2+*9X1;/)!&[0J,",E02N/;I7Q[^TK=?$.R_:/\ #T_P
MVU46-VL<"ZK'XIDMTT5XVP(UA#@2M+]XMY9./E]:^SER5&[&>^/6@#X8_:RT
M_P +7/[27P]L[[XJS1:[+K-C?IX'UN1_[(:(2! <Q >7(2I*"0D,W'%?<Z @
M'/J>:_/GXZ> )IOVQ)[+PKINK:QI^LW_ (?U7Q>]OHYO&T^2"X\RT,4[-^[2
M7R\.HX4*3[5^@RY&[/!R: /S-_X*3R23>+O&4:8VC2_#D3GU/F:NX%?0?[7.
ML7&A_LY?#KPQ L*R>)-;T#0I8Y4#KY1DC>0;3U&(L<>M?,O_  47GDF\?_$1
M0<>6GAN(8/4?9M4?^9KZ-^,^I'Q1I_[)FEW=K'+JVJ>)-,U-H9&9=@@T]I93
MD>A8<=\8H ^NT7:"!P 2 /:O!_VY+,ZG^S+XLL N\7TVG69C/1Q)J%NA4^Q!
MP:]Z'3/K7&_%;X7Z/\7/#4&A:W-=0VL=_:Z@C6DWEMYL$HEC![,N5Y4]?J!0
M!U\$"6T*Q1((XT&U448"@< #Z"GT+R,^O-% !0:*"=HSZ<T >&?L@^)M+\7_
M  [US4]*:.:W?Q+J<;3QZ5'I_FLLV"?+0D,>,;R<MCG%<I_P41MFC^ %KJ[/
M"EMHGB;1]2N/M"Y0Q+=HK9'.?OYQW -=;^QS'H:?!Y_^$?@TJ"P.M:B2NCW<
MES$9#<-O)>15;=GJ,8'&.*ROV]KZVTS]FS5KR\YM+;5M'GF^0O\ NUU&W9OE
M')X!X[T <Z_QG_96EO)]0N?^$.%S+*)9+B?2D#%@VY6),?7H:]S^$7BSP1XS
M\(+J/P^FTV?P\;B1%;2HECA\W(,G"@#.2"?K7D-Y^VA\%)4,=R]]-$S'._PW
M<LI'8G,6,8KU+X,_%/P5\4/#US=>!W_XEMG<FWDC%@]GLD*AON,J]00<XH ]
M!KQ/XI_M#^$OA]XPN=!U3PMXCUK4[>V2X,FF>'IKR-D89 $BH5]NO!KVRO*?
MB1\=KGX?>)?[)A^'GC/Q.@B65K[0M+:XMP6S\N_(RPQR!TR* /GSXA?M(6/Q
M>?X1VEKX(\7^&;8?$71U%QK6DM;6_P DC *'^[DDC"]>#7'_ +#WC/XJ6OPA
M\>>'_ VC^&]<&@:_=P6B:A?/;N))6$A)(4JR99B.0<#'O3_VV?VCM6\3?#SP
M[!:_#WQOX5^Q^*=,O8]<U?3S:0V\T<V44$G)9LD#C%=U_P $Y]*@T2_^/%C:
MQ""UM_'%Q%#$!C8@4A5Q[#C\* /77?\ :$E\+J(XO 4&OBV4,S3W3V[3B7D_
M<!"F,].S+W!K$N[3]J231G,%_P##2'4@(U5&CO&0G!\QB<#'.,#'KS7T510!
MX3J.D_M&7,G^A:]\/K&/R8!^^LKN5O,\I?.Z,!CS-^W_ &<9YKA?%H^/&K_$
M:R\(6/Q0\(:'XCETJ35%M+;P_/(C6R2QQ-(978@-O8 +Z9KZPKRK5[KPSIG[
M2N@R7M_HMOXEO?#=S965M+<.NHW$?GK*PCC^ZT0\MB3]X$>E '*ZG\-/CUJ&
MGVJP_%K1-/O%NW::2#P]N1X/+C5  TF0VY9&/;+^@K+U7X-_M"-JR3:?\<=.
M6RBE+)!/X:3YT+$A7PYS@$#@CI7TG10!\WZY\(?V@K_6;"XL/C-I>GVD>F+!
M<1#00XEN@I!E"EN 3@]>,=*YOQCX6^+?@+5_"4>M?'F[:3Q#K<&C6<5AX6MV
MC$K0O)F3=("%/E/G'J/>OK2O+/CCXMTSPKJ7PX;4;S2K)KSQ3;6ELVIVCSN\
MKQRJ$@V_ZN4C(#MP 6]J .?\(_ [XD:#XK?5M3^-^K:]8S3QRR:5-HMM%#Y8
M)+1J5.5W# SSBHM/_9V\;6,]Q*_QS\778D\T)'-:V>R/=&RJ>(\DJ6##GJHK
MW=00H!I: /G^]_9F\6ZQX6&C:E\;_&4Y6*1%N[9+:VE\PNK(Y9$R=H!&W(!W
M'->7_'KX9Q?!SPIX/GU;XH?$C5[S4=9L="W6>M16\DIE;;O">7@X&21G..<G
M%?:%>9?M!:SI>A^#-+N-6N#:P/K^EV\<@L$O#YLEW&B#8_"Y)QO'*YR.E '-
M:S^RY_:EKI]O!\3OB!8164LC_N-70O/N()#L8\D#&!Z FJVH?LHOJ\MJ;SXK
M_$-X(K8VLD$.K1Q"9<MM+,L8.X!@-PY.T5[WW/UHH ^)?VH?V<M&T'Q%\+=7
MC\4>,)'U/QYI5A):S:V\D2;T=?,C!&8W7RP0R]RWK4'[9OP!M_AW^S+XIN=+
M\2>,=5\W4=,-VNI:W)=!H/M:(ZX88"XDSQW5?2O8/VO91%)\$MQ 4_$W1\D_
M[EP:P/\ @I!>/:_LN:J@C61+C6-*A?<#E5^VQ$D8Z'Y<?C0!K67[!_PLMXI!
M)%XCN6>&6(M/XCO&(\P<GAQR/R]0:W?^&+O@U)ID&GS^"XKJUA0($GOKI\@'
M/.9>><GZDU[:IRHQTXHH \8D_8V^#,MN\#>!+(0OMW(MQ<+G P.DGI7$_MD_
ML]>"?$_P)U]X]'\.:3K%FRW%CK&K?NHK662XA$KM)U!<#'.<DBOIVO*OVH-"
M\7>)?@GXATWP++%!XGG-L+9YS&$"BYB:3_6 K]P-U'TYQ0!O6OP9\"-::>)?
M!?AV1[2-5A/]F0D1<ECLRO W%FX[G-7[CX6>#+MX7F\):%*T$/V>(OID#;(L
M8V+E>%QVZ5TL*E8E!.2!UI] &*O@GP^LKRC0]-$KQK$S_8X]S( %"D[<D
M#T&*AN/ /A^2VU".+1M.MWO8FBGDCLH<R \_-\N&P<'#9&0*Z"C&: //?A!X
M'\/^&_!UG:6/V759[3=9W.J'3H+:6ZDB=E9G6-%7(8$<#'&17<Q:;:VX BMX
MH@',@V1A<,1@L,#KCC/6N#^ ^B>,] \$W5MXZO3?ZTVL:C-%(75B+1[J1K9<
MKQQ$4&.W0]*]%H 39[M^=&W /)_$TM% 'E_P6TV31=8^(MG_ &1-IUM)XFN;
MY)Y[Z*Y-TTP5GD54YB7(&$?YJ]0VCTKQ/X#?#32?A[\2_C-=:=/K$\^N^((]
M3N_[1MC' LDD.[%N_P#RT0;B">Q 7M7ME &'XZ;78_!FNMX82VD\2+8S'34O
M#B%KG8?*#G^[NQFOGOXP?M#>+?A'X9^"NEZK=Z%:?$/Q/JFFV>L:8\3R)*CN
MD=W]G*G *,X.6.,=,U]05\^_&_X%^._B[\0_#,Z^(/#UKX'T;6-.UA+*?36D
MU 26\HDD"39PH?:!P.G!H ^6/^"AOQ2\7?#S]JCP)=:-J$%L=,TI;O3,6"W$
ML4L[SV\SX^](0F2J9P" <<U]K_LWW<NH?#&UOI/B*OQ/BN96EAUQ;:.W_=X4
M"(JA(W+@YSSDG(KY^_;KU"VOOB[\%/#FG:OI.B>++[Q!:/9WSZ<9]1MHS.5,
ML4A^3RP3AHV^\2*]_P#V?/@</@9X?UVSGUZ7Q'JFMZM+J]]?/:I:H\KHB82%
M/E0;8USCJ<DT ?-GQ(^.GQ%L/VGO$$^F^(HK?PEX9U_2O#'_  C1B4QWIN[*
M:>2XD;[ZLK*H7'''L:\@^&7Q6^-6L_!7X@ZI=^++[6;KQ)IFD^,%.C1&2^TN
MRN-0EM[V*V4\ K#"S*HZ8R.<U]G^-_V2/#GC3X]:-\49=6U&SO+)[::YTJW"
M?9+Z6W$@A>48R2HE<=^*QOAQ^Q;X?^$LGQ#?PQXJUS2O^$KMOL=LT4B9T:#S
M991':YS@!IGQGI0!YI^R_-X@_:/_ &:/B?\ #VZ\7ZW;"QUFYT'3O$FH0%=3
M^PLL<L?G(Q!$FQRIY!P17#_LZ_"V;X<?MD7OPY\1>+?$-[-X2TBUOO#,EM>M
M!9W-A'"$,$UJN4 !DSG.25K[,^!WP;TGX%>$)=!L-4O];N;J\EO[W5=6E$EY
M>3R8R\C]6(5549Z!0*\A^(/PD\#1_MK^ O%\FHZ]IWB[6M-NG5-/N%2RNELU
MC&V?^(@K(HV#(;8,XQ0!/\)=2U'Q%XG_ &G]!F\07RW%MX@DAL9//W2Z?%)I
ML10Q _< 8L5XQD>N:[K]CGQ%JGBS]F+X;ZMK6HRZMJMUHT,ES>SON>63+ EC
MW/ KI/#_ ,)/!?A7XB>+?%VG6BP>)?%:0Q:K,9B?/$:E4&S.%X/..M;_ ,/_
M  #H7PO\'Z9X8\-6*Z;HFG1F*VM48L$!8L>3R222>?6@#H:_.'_@L [1/\*7
M0C<%U4X)]$@/3\*_1ZOSB_X*]KNE^%H'&(]5//\ NP<4 >7?"'XS3?L,?%/4
M].M[/4_%OAOQ'H&FWS642JKKJ,UG'-$%8X7'[QD;OM*G''/Z3_!7X[>'?C;H
M]U+I3RVFLZ8R0:QHMVI2ZTVX*Y,4JGOUP1P<9%?GMXOAT[QKX"\1^#WTB+5O
M$NM7'AN'1)+B\6TATZXB\/P/),\[G:!Y>1M_CS@=./9?^"9'C#0KFS\7>$9?
M#>F:+XXT'RH;_4;)M[ZI"'=%>1\MN=&4J2"0=P(ZT >E?'_X;_ K]IOQMJ_@
M3Q)?6UG\2-'LH@MW"_DWEM$_SQ[2WRRIE\E3G[W;-?!'P[\:>-_V+OVD8?!.
MD:U?^,])T[55AN_#^CJ[PZBLD*%VBBY(D56!P.-R5]S?M7_L Z'^T=XKMO%N
MG:Y+X6\4K$EO<W8B,T5S&G"$J&4HZCC<IY& >E9/PM_9,O?V48O"UQX6E?QE
MXFUKQ590:]K5Y9[GMM*\N7S1'EB8P&VDOG)+<]J /E?]HOXLVOQ6_:CAU+Q/
MX,\9ZA:V&EB/PKX)O](9&NK\QMEWC)SY1?:[$9+>6%.!U[OX4>,?!'[/O[+W
M_"&?&GX7>*IHM<U>6?4!>Z"R6\L[G,81\C[B1KM(((P<5^B7CB\L/#6@ZGXJ
MNK"*\GT2PN;Q',:F8(D3.RHQ&5W!<<&OSG^,WC_QO^T)\%%T/XF6^D>&M5&L
M>&-<TG4+&4M:PZ?J<L]NK3Y8Y:,"3=R!TH X?]DGXL7?P]_:(UZU^$VC>-?%
MWPUFBGF?PY'$))XP47RI65R A63<N[(++C.<5O>"?A3\2M<_;BT3XA:Y\,_$
MN@Z!?>+7U5I;R!<6JM&X0R,I( 4E<X[5]R?LA?!#PK\$OA+86'AZXT[6;J\7
MSM1\0:?\RZE,&8;]V3\H' 7H,'WKSG]H7Q5\2]?^/GP^\%6_@Z31_!]MXGT_
M5;7QKYSRVTYBBD+VTR1CY"[,R#<<9"D\&@#Q+]HVS\7?L*_$OQEXU\&6(U'P
M%X_L+B&6RD!6VTO4VVA6(48P=SE1QG<5SP*L_![0?B)^P>R+KNB7WB?X2^)M
M-M9+ZYTN+[1<:5J+6JAR\298J6'EDC@@*1SD5^B&J:38ZYI\UCJ%I!?V4P D
MM[J)9(W .1E6!!Y -6E4(H4< # QQ0!^2/@[1K?P3^S)\,_#'C%O^$/\(_$'
MQ??7WB&\D7R+J?3;.$/% Y.,!W0KANS# YKTSX":Q\2?@E\+=9^*?A3X5_V_
MI_COQ(]^VE6\1@NM.TE=PMPL2@DA]Y*@#:O4_>X_0WQ#X1T/Q=;);Z[H]AK4
M$;;TBU"V2=5;&,@,#@XK1AMH[6".&!$AB0!$1%"JH P  .@QB@#\Z/AEX/N/
MCM9>&E\2Z-+X;_9Y\"V]](DNIWPB>]?!R9'7!.QRP)7"@*1DDUC_ !H_:>;X
MC?LY^*?!OPU^%NLI\*-(LHK"7Q/<MM@@@CGC$31J<F12$YR<@$$]Z/B3HU_X
M>\%_";]GS3O$,\VB>,?%6J0ZU?M;&U\R :B%: "0;@ SD@CAL#'!K[-^//A[
M1O!'[)WC[0='M;;2])LO"U]:6EJF$CC46[A5&>Y]>I)S0!\Z_&+XL:GX6_9J
M^$W@V&X\/Z3HWBSP)*E[J7B%YEBW1V,&RWC:/I(X=MN>NS'-?)?A;X[Z[_PH
M[0O!FN1Q:A;>#O&6@:MI5C?Q%)3:-+/OA<'!9%<+@XXW@'M7K_P^^,GQ-B^
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M?6\[Z2L.FK*[?8=MI\V5(VJ7)W?+G(QGFO4*\\\"OXJ;XI?$A=97'AM9]/\
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M@L_B#\9]:_X2SXE>.O%J3:@NGZCX?TKP;.B_85NA<1VPD8?*GF*C9&20,C-
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M1XFVGJ/MJ$C]*W_VZ-0M=/\ @KIINI?*63Q9H"*Q7(R-2A8Y/8;5;G_&JO\
MP4$@CG_9FUDR2QH4U?2602(&+M_:$ VKGHQ!/(YZT ?2'0GTHHS\Q^M&: "O
M%_VQ]:UGPY^SAXUU/0='BU[4[2VBFBL)XI)$D"S(S$K&0QV@%N#VKVC-<C\7
M_$EGX/\ A1XRUW4/MOV#3='N[R?^SFVW/EI"S-Y1[/@'!]<4 :?@?5[GQ!X+
MT#5+V(0WE[I]O<SQA2 DCQ*S#!Y&"3P:VZQ?!.JV^N>#-!U*U\_[+>V%O<P_
M:CF78\:LN\]VP1GWS6UF@ HHR*C:>,.4+@/UVYY_*@#S7]G?7O&/B/P!<WGC
MBV:UUG^V=3BBC>(1-]D2[D6W) ]8PO/<<]Z].KS7X(R_8=%\0Z9+I=EH@L-=
MOHX[>UU)KWS$:02>:[-RC,9"2G1> .*[^36+&)Y4>[@22( NC2*"H)P,C/'/
M% %N@]#68?$^DA2QU&T"@9),ZX Z^OL:RM4^*'A'1]'GU2\\2Z5;Z= "9+I[
MR,1H!C.3GW'YT >8_ CP]=:5\;_CS?SZW;:I;ZCK=B\%I#<F1[$+9J#&Z'B,
MDG< .H.:]VKYA^'/Q]T'PUX[^)>K^+_B-X;'A75M3M[CPLRZA <V@A6*7[OS
M?ZX,/FR<@]J](UO]JGX2>'+2UN=1^(&A6L-U&LL+O>+^\1MVUACL=K<^QH ]
M6KPW]M+QWXF^&O[/'B/Q%X5OSI6HV<EKYVH)"LSVULTZ)/*B'AF5&) ]:UG_
M &L_A'%HO]KMXZTD::)OLYN?.^02;!)M)]=I!_&O,OCY^T7\!OBA\/[OP'KW
MC-VL/$L8@6ZTFVDG:%E=65]RH0A#!2"WO0!\F:7XA3QC\0])\::_XD\0>*3X
M?^(WA_1K'6?$-HME)%;SAYYD%L%#*?,"<G^$KQ7I_P 7O%OQ@\"_&+XOZU_P
MEGBK2K/1)H-0\.VC::DVAW%J[6\;QRR8!SF5L*"#P3FO./BAK?PU\,7D5O:?
M&KQ;X[U6]US3=3O+-M*CFCO9X9X(A)YPC&PI%'MPAR< <]#] ?%2P^#?Q(^,
MUIXBU0_$.^O'M+:^ETC2K2^_LR_\H;XQ+&J;2X"C*<?=P><T >,Z%^U%\2;3
MQ;IWPRU?Q5=7NOZ;XOUW2[Z_:U\I-4L/L\PC=3M&WRIE(&TY'R\G%>9^%/$G
MC'XS?LD>-_$&N?$G7[.^^&>FV\6F66GW[PF^\PE_/NGSOD;+>6.< 1]R37V'
M>^'/A?>?$G1;>?P=X_NM0T77[[5K6^?2;AX)I[X_OU:79S$"^X#( V]:YG0?
M@A\%?$WA%/#L/PL^(5Y:Z*1I;F6WNK66:&2>:X"O@H)HXWSC()4.OK0!6E^#
ML'@W5_V>_B)9>,/&5WJ7BKQ!I4-[9:CK<DUKY<^GRNXV?[R ^G-?-:^%;OXF
M7_\ 8TOC37;;6/!W@;6-8\.7+7,CNUU;:K=;F>3.>8HU4^N1_=Q7WAX?\<2>
M)=$T.SG^!'C"PMO"MRLFB6^I1Q1F)[>U<0R*3)P2I,8W=WYKC1I.G^&;[1]9
MTK]GR\MO$^H6>I:(FFW.M6T$[6+N)I %:;#^8TTI(&67!Z#% 'R3X>\1^(/#
M?QST?Q7K5Z^J73^,M'FG\6:CK+Q!5NK.&5K7[ A(,8\['F 8'%?K\!@8].*^
M,/$GP5U'Q#H^D>)D_9I\+W/B[3#;M:VM]KT:2!8&\J)'=<ARL21L-V1QC.1S
MZAIGCC]H77M&N6?X:^&O#>I1R0&%-1U_SXY8SDS<Q(2&'R@=N3Z4 >_U^<7_
M  5[&7^&'R[L0ZMD?\!@KZFU'6_VB)M1L_L/ACP/;68G(N//U>=V,6%P1B(8
M(.[UZ"OB[_@I7+X[N)/AQ'XVL]$@DBLM2,<NC7$D@>0F,/D.HPH41XZY);IB
M@#V_]E;PWX5^)>M_%#P?XGT"PUJT%GX7U'['>P!X]K:/%&K*#T8&-N1S\U>8
M?M(?!?QI^RE\2W^./PVT+0M#\):'-#;W&EZ')*KW=HY&\W,;#:%+80E3Q\C=
MC7L'P*^&GQ7TJSC\:>'].\#V$^O:!HD1NKBYNY)KN&"%%3S5 VHPC+?=!R<#
MGK7I\OPS^-&MZ9JNG:Y\0/"UW8WSR P_\(ZSJ(7BD7RF5I<,NYHSSU"D=Z /
M3?A7\2]#^,'@/2/%OAR[%WI6I1>9&P^\A'#(P[,K J1ZBN8^.OB&?P_>_#+[
M/IDFI_;?&5E92F.61/LR/%/F8A#\P& -K?+\V3T%?#/@#1?B'^R/\:F^#5[\
M13X:\,>*R;GP_KW]C+/;37S^6I0(S_N06RI&2,E3_%7V+J/P7^)>K^$(]+N_
MC/>VFH% 'U:PT>"*0OY[/D L0 4*QX_V<]Z /0_'G@27QS/H\<FO7>G:1;23
M?VCID"*8]3ADA>(PRD\A1OW?+W KP[X>?L9S?#?P/XNTG_A);/QE?ZEI]EHV
MF?\ "2:8LEG9Z?:LS06[PJ?WF#++\V0>1Z5TNK?L\?$#4_"=SI8^.?B*'4))
M;66+4X]/ME>+RE=77 &")-RDY[H/4U%J'[.7Q!OH;(#X\>*(9TF0W+PV-JBS
M0A K(J[3M<D9WY/)/% ';?L]?"0_!#X:6WA=[VUO'6\N[TFQMOLUO&9YFE,<
M49)VHN[ &>@J_P#&[3O$>L?#RZM?"6JIHVN->6+)>/($"Q"[B,RY(QEHPZCU
MW8KB?$'[,U]K6M"_7XL^/;& ,SFRMKZ!8^6+$9\K..<#T%? _P 3];^)'P_^
M/WB'X:^(?B+XUG2>XL8O#6\Q2+?QRWD 0L/+QG89<,,8>+G% 'ZU%U!/(H#J
M>XKQ.T_9GN;::\)^*GCZ5)\J$DU"$^6-ZL-I\KJ-N,^A-6K?]F_[->WEVGQ(
M\=^;<S1S;7U.-DBVONVJIBP%.=I'<4 >Q;AZBFO( .,$Y'%>,Z3^SC>Z)JMQ
M>6WQ2\<2I<3I-+;75[#*AP6+*,Q?*K!L<=,"L77/@78?#?0;[Q'J?Q6^(0TO
M32NH7C2:A'-^ZCR6&T0YVX.3CGB@#'\7_LB7'QG\%V=G\0?%=XOBG2/$5]JV
MC^(-&<)/:027)D@A&Y>B((QCL4!!.*O6/[&VBZ[ L7Q$\;^)_B;:PSB>.QUF
M\$5H"!T>*$*)![,2/:O-_P!DKX>:C\6_!&M>([WXF>/+NT;Q%?0V%Q_:2""[
MLHII(XWC.PDJRD9/&&3BO9-!_9(\+^'?#$^B6OB'QC]GN&W74TGB&9YKG]V4
M(9SDJ,,3A=O/- 'KVDZ=I>@:5:Z;IL5M86%G"L,%O!A8XHU& JCH !7@7[2'
MPZ\4:S\"?BI96WB5_%<FM)$VEZ7<K!;)9*+A&>,2@@%<#J_3;UKJ/"_[(_P^
M\+:?J=I"NO7PU&SFL)Y-0UZ[F?R)=N]%S)A?NC#  CGGFO)?VJOV<_!?PU_9
M:\=W'AW2=1D6TM(IY;>75[N<-;I=0R3*%>0C[B-V]: /"_V#=:_X1S]HC4="
M\:Z[+I%SX4T&ZT_2=(O94\F!);F-[B,29Y *QL@R1M8XX%?H5=_%KP786ZS7
M'BK1X8F<1AWO8P"QY SFOS?_ &]_@UX"^%VK_"OQ-X6\&VC:!<6[27FC096.
MYBBDBF7?@[AO65XBY/5E'I7W/X(^#_P>^(G@7P]K-E\/O#,VFW5C#-;(=/A?
MRT9 0A(!R5SM)R3D&@#O+GXJ>#[,6YG\3Z3$+B1H8B]Y&/,<$ JO/)!91CW%
M4Y/C3X$36(-(;Q=HPU.?=Y5I]MC\Q]N=V!G/&UL_0U6E^ /PVGL]/M)/ OA]
MK?3Y&EM(SI\9$#DJ2R\<$E5)/?:/2M6W^%7@NSO5O8/".A0WBEB+F/3(%D!;
M.[Y@F>=S9]<GUH ^*?B'X3^'&F_ML?"+Q9X-\0QZIKGB?Q'/>:O!%?I/&@^Q
MJ(F1!]P,#G.3FOOY?NCZ5\G?M-> ]!\+?&C]F[7=+T2PTYHO&(TV3[!;Q0,Z
M26KB,-@#*IY8P.PSBOK&/[B_2@!:**#0!X5\)R/^&JOCT/+P?L_ATE_7_19N
M*]UKYU^&NMR6O[;?QFT0INAN]!T/4%DSRK(LD17\0RG\#7T50 4444 %%%%
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M-7^*5QXEMR+^*RNI8RB:G"&W2*/* \A2#[ U^MJ0I'NV+M!8D[>,DGD__7H
M\#L/VPM*UJ^AATKP!X_U&WE!Q=1>')UC!&<@[@#V/:M+4/CYXNB\0"ULO@UX
MMU'1GBBE35$-O&&#HC']V\@<%=Q!!&<J:]M''<_G374$?B/YT ?-OPS^.OBK
M5[G5[70OAGK^N:3!XCO;.;79IK*WA(6]>.4HBN&?9AL?+N;;R<Y-=5HWQ2^+
M>HVM])<_!YK&9+OR[2&37+;,L&QR)7.?E.X1J5Y/SGTKI_@?K>GZ_P"$KZXT
MZ;2[B./6M3MY'TBW:"#S4NY%<%6Y\P$?.W1FW$<&O0\4 ?&O[5GC/XG^(/V3
M_&/_  D?PYL_#DLYAC>,ZW#/Y2?:(#&QP!G<^%P.G6O1+CXC_'2"VL+5_!'@
MVVUZXMYI%TV;Q*=\S(P&V/\ =_W3DG.!W-2?M[L8_P!E'QNP' ;3LGT']H6^
M37I7BCX4^$/$7CCP[X[U>Q$NN>&8[@Z=?M.RK;)*/WIP#M((]>U 'B]CX\_:
M)UC5-=M$TWX:Z1+I$<,MS!<:Q/,\ >+S-LFQ/E[G)P"!D9'-9\OQ:^,C3>'H
MT\6_" 2:Q)FVA74+AFN8=X7=%\HWG.X<=ZI_LHWTWQ*^,G[24_B*WTF>/4KO
M3K22#2[M;JWDM1:/%&#(O4M%C=Z$D5Q/Q&\$?#']ECXQ>$9D\->'=?\ #ES%
MINC6_A^4B75M'F%S(8;RW5R2\;22DOC!RH/- 'O&HVG[0-O/;3/XF\ 66F1*
MS7L[6-VS*@9CO7) X3&02.0>:YEO'WQ+;3[;7HOBU\,%\,7$7V2WU![67RY[
M\+@H&\S;@L#P"2!VKK_VV[+6=2_9/^*%OH G;5&T:8HML<2,@93*!_VS$F?;
M-?FOKD?PNA^$7G>1?3_#C^T/$7]@I>B;R1J3:'9"%5X'_+U]H*D\9!H _0;P
MKHOQ)\.?$WQ#9ZI\5?!UQJFNPV]U9::NE%+D!>'<1^;EE"AE4Y/3)Z8J;0K7
MQM!K?B;P-J'QSLKOQ=#!#K"E=!C1]/L"TB9*^9@AFV_,3QM/7-?%C-=M^U-\
M%; V=_<>.]OA2\BOW#&5-/&E(MU$23D#>)G88_O9.:_0/XV_"WPS?^$?B/XE
M;3ECU[5?"=WI%U?H[+(]JD,KHG!XPQSD<T <9_PK[Q]I.D:9=ZW^T8T7VX^5
M#/'H]G%#.\@R@CW,<GCCDYS6E_PJ'Q-<077A/5_CUK]UJ]_9M-$+:VL[6Z1%
MF0F5 %)P/N$]/FKX?_:$\6:-J7P6_9TU&[M_[;TU_ MS:::5#&!-91;5$W <
M!E\N5<GH37U?HUVUM^V+\)!>B5KRZ^%UQ"9)4)=Y1/;NVX]CA6)SWH =K?['
MU]J'BC0(-1^,GCN^L#:W,%U;OK0M9IG 5HWC\M!G;SN'/&*[[4?V2/"^LI;K
M?^(_&MT8&WHY\27*,#@#/R$ _='6NK\87NN1_%_X?VUCH,%_H<\6I_VAJ[P[
MI+"18HS"%;^ 2'>I/? %>B4 >0-^R=\-;Q;5M3T:ZUNZM9GN(;W4]4NIIXI&
M;<75S)\IR!TQC%7(_P!E[X71:_I^M_\ "&:=)JM@@CMKF4R2-$HW<#<Q'\;9
M]<\UZG10!^=_[<WPG\&?#+XB? 63PKX8TW0I+G6_(G-A (S)'%+:>6IQUQDX
MK]#VY5N_)KXB_P""I?VG1?!7PU\5VDD"7.C>) T0DAWN9#$9$^;/"Y@Y'?(]
M*^U[68W%E%*V,R1JYQTR1G^M 'PK\8? NI:;\*/VH[WQ1X:U35M)O_%MMJ>G
MV:R/']IMXXK7]Y&X#%4!5LG&!M-?2OC)[8>./@P!X4DU5&OIS#?K(P&C?\2Z
M7$C <-N&8^>[ ]:^9OBQ?^(_B9\%OVN])U?4]1EM= \0@Z9'&H!AMH88)O+0
MDKE"5)/)X+=>E?2GB>WL-+\0_!2VFU?6+.:.]>&TCMD:6*](T^0&.Z88 7:"
MX8CEU% &IJ6O:5%^T1X?T>5H/[9F\-7]U$C669! MS;JY$^?E&YDS'CG@Y&*
M^1O''QC\:W7QKU32_BMXPUKX)>%+35V70VTK26,>L0(VT-+>,&49&TXQQN/I
M7V%J4%BWQR\/S36&DMJ7]AWB07TEX5U!8S/"9(XX<?-$<(6?/#!1WK\U/%VO
M_'[XC^+?BG<0^*/$<?A;0Y];O+6X;3EFT^3[#-($ME^0@DC*\YY'>@#];D(9
M%(.00"#ZTM5M,=I--M'<Y=H49CC')49JS0 4444 %%%% !1110 5Y[\6?C[X
M!^"!TP>-_$=IX?&I^8+4W9($NS&_! [;E_.O0J\)_:=^&7Q ^(K>&_\ A"$\
M%31VIG^W1^,=--V"&";##A3M/!STSQ0!XWXZ^-/['_B0:_<:UXGTK4)=?FEG
MOWMII7:21[46KMA/NDPJ%'Y]:]#M/V_/V?- TG3X(O'ME#;"W18;<12%XXPH
M505VY' '6OCD_'2Z\-ZWXCT#7;OX46FH:;>261^R>!9KFWNGC.U]KH!RK[EP
M1U4]JX;Q5^U5XDUG7 \GA3X:ZY9)&L$,DWA4QAXU^[\K,'4#L#TH _0F#_@H
M7\ ;B%I!\1-/C53C$JNC'C/ *UI6G[=_P'O+>29/B7H:K&^PB2?:2?8'DCWK
MX)\*?&U?$6D7G]J1_ GPQ-;7,DD>F:OX=F$KN%&UU*;E*G&,@GITK:^%5WKO
MQL\5QZ+X5\(_ ;Q#K#:9_:UQ&FE2Q^2/,561@P^^I<9 XPPYH Y']LO5_"?Q
MI\?_ !1\?>'O$D6J:;IVGZ):64EG,HAG>5+A9DY&791&" ,8&XU]Z?LQ:S=:
MA\4?B%I[NL=IH^B^&;-+8B/>CMI_FLP*J'V%70 .3RK8P*^-_CG+XIT/X*?&
M/X?>(_"W@70;_P .76B:I)+X5L2B217;3*J@G!$BE1\Q_A9ACFOLG]CL1ZIJ
M?Q:UU1N:X\16^GK*8P"4M=,M(@F<\A6WC\Z /I#O7A/A34X=4_;,\?10RI*V
MF^#M&MIE4Y\IWNKN3:?0E2#^->['H:\(^ \$$_QT_:$OUBC-Q_PD6GV;3@#<
MR1Z5;,%)]FD;CW- 'N]%%% !4=S"+BWEC+%0ZE2R]1D8R*DH/2@#YK_8CFU7
MPMX9\8?#;Q)K;:YX@\(:_=0-<2S/-*]K*WF6[N[$_,03\H/RXQ7TI7S;\6_"
M7C'X=_'?1?BSHOB"]G\$I9O9>)O#BQO<;TX$4EK!&N6E9R@)Y/'IP/??#?BC
M2_%FG+>Z5>PWL.=CF)PQC<?>1@.C \$'D4 :N !7S+HFJV>G_P#!1#Q+87#E
M+S4OA_9-; QGYQ#>2&4!L8. Z&OIJOG#]I*[;X>_&OX*_$5[AK728M3G\+:O
M*$4JMO?(OE%V/*K]HABY[9]^0#Z/-?,$>D0> ?\ @H-/JEW*YA\>^##!:ET&
MT7-C-&7C#9ZF)@^/K7T\O*CZ5YA\>O@?#\9M'T=[35YO#/BG0+Y=2T77K6,/
M):3!2K J<;HW4E67N,>E 'I[*-IX&2/2OS7U7X_:W^R'^UA\;M4USP!KFLV7
MBZ\M)M,N+5-L<D4.\;E8C!!WX^JFOH;2?VK?$/PGU)-"^/'AAO"C'<+;Q;IN
MZ?1KO:N<LXYA8]=K#C.,U]#^&O%.@>.M)@U+1=2LM9L)E65)K:594((RIXSS
MSF@#XMTW_@IQJ.O?N]'^"/B_5;H#<T-JJN0O3=QVSQ6C%_P40\7B*=KC]G?Q
MY"X0&+_1LAF[ACC@5]MI&B?= 7MQQ3L?YS0!\&1_\%)/',DP@/[.WBX7'!\L
M!LX_[X^E7M1_;.^*EQK.G7TG[./CR!K(2L((90(9@Z ?O%V?-CJ.1@U]RX^O
MYU\K?M]?&*#X9>&/ EA_PEVI^$I=7\10I=3Z+'YMZUBB-]H,:[6S@M%V[B@#
M@8/V\/C/<%@O[-/B.,[U10[2Y^;IG]W5M?VV?CD;M4'[,WB"1%P9=DK@@'IC
M,>#WKSS2OV@=.U"YN8=!_:MUC0K6UV,MOXN\.1^8V3T\PJF\<<@ $ UW5M^T
M%X]OY;-?#G[0'PC\174LQ4V-]#):%EP3@%9&(/MB@"I<?MG?M'3:#-!!^S;J
MUOK1)V7,AD:!5W9!*!=Q.W X/6L?0_VIOVO=3UB.Q7X%P2-+G89X)K:,8!Y:
M1SM'X]:]:@_:!^,MBEO:P^%/ _C:\CC+32Z#XJ2(S'DD1Q2@'.,=?SJ9_P!J
MCXKZ%,AUO]GGQ'/!*N4.@W]OJ#!@1G>%;Y1S0!QD_P 9?VS'L6\OX*^'HIU;
M[YU0/D$<87<,X^M45^+G[;,UZ(XOA%X9A0 $F2\&TY_VO,_2O2[3]N?3K65H
MO$7PN^(7AIT5"YNM!DE4$[MXS'GA0H.>^>.AJQ<_\%"?@YIS0'4=1U;2XY95
MA$U]HUS#&K'U9DP* /-=8\:?MNWVFS6\?P^\*:>\JX^UV>H1O+$,C)57DVEL
M=,\5S-A8_MZ7-S:6T\OAR!)@':[N$MV2+()VN%DSD8QP#7U=H_[5_P '=>G>
M&Q^)'ARXD2+SF47\8PF<9Y/K79:9\3?"6LM MCXETF[:?'E+#>1L7STP >:
M/CW3/"_[<][#(;CQ'X&T]M[*%N8 S$ X##82,'J,\^N*L/X-_;B9<?\ "8>
MQ@8^6V//OS7VW%=P39\N:-\==K U)N'K0!^?'CWX$_MC_%'2TTCQ#XJ\'2:9
M]JM[L10H%5989%EC?[I) =%.._2N5_:B\%_M0>'_ (,WM_\ $7QWX3UCPM;W
MM@]S;V=J4EW_ &I/*<L5& KE&;&#M4XK],0P/<9KY6_X*:^(H-$_9'\2V<L4
MDLFKW5KI\10 A'\SS=S>VV)OQ(H ZWPM\/OCI_:L-UK'Q3T"ZTYKB.X:*QT
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M"0 !SZ5?ATNSMT1(K2")4^ZJ1* OTP.*\IF_:\^#$%T;9_B=X66<?P'5(O\
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M'7:VTLI/4'ZU[#7YS:I+8_L:_M.>&_BG87<VG_!WXHQ--J-JL1"6$\D:RH7
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ME1Y4C<B8EMQ555VR"7 R0*[FT^%UB-5N;4?LGZ(FG&95CNGN-..\;@"Y4OD
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M>-E93D$%!@@U\._\%'OAU>Z1^S-'J.I>,-9UB[T_4;>-UG,<<%WYLK8\R)%
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MA(TDB^2!!-#(H"]0V)GR>F *9X<\/Z#-X+N+R3X7Z=K%II[L+[5Y?$WV=II
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M^'?%OQ/T[4=6_9Q\6:AK&GR12IXE\/-' S-(H>0M)%(K.59F!)YR#SS7S_\
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MBR[L-&AM+KQ5(9=9FB+!KQO+,>6YX^4D<8ZDUS&J_LR?#[6/A-HGPWN-(?\
MX1+1I8)[*T2X<-$\3ET._.3@LW7UH YKQ_L7]L#X2,5_>/X>\0IN[X#6AQ61
M\$H;>W_:8_:0\032>6(+[2+!\DD".+3EF+?G*>/;WKV/6?AS8ZW\1_#OC&>2
M1=0T.SO;*WC7&QDN?*WEN^1Y0Q]35#P=\);'PAXQ^('B!)VNG\8WT%[=6TB
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MF-[>Q@T*,00M&<H44Q]1USP<U-#^R!^TI=ZH]QJ'[2=S#&P(/V.SR>3G 4J
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M,WC:'D,-(TE\^Q>]']*[RO*?#5^?^&F/'EDXP#X:T:9,GJ//OE/'UH _+?\
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M?]KKP+\-?@IIWA'6WUJ;6[6[OYWAL='GN$6(SE@0\:D$?-C/KP: /T$H_/\
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MS:RPVS6<4R)DK)CS&5N.C<5<TC]I3]H&PU+XEV<WASP?XIE\/W@A06.K"V9
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M\2]9U"$^*OA+<:5H\]G-=PZKHNJPZE$_EQ[U4!.29,@)CJ: /?-H/84!0.@
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M.BDE#CK\HKR_4;C41^P%\(M%N)HX%\>:YIEE?F/YBMIJ&H27#JG^UM91GZT
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MX8LL<@=N,!>^>*[3P5^U_P##3QKH#ZLFKSZ/;Q7%K:2_VS9R692:X)6)/W@
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M'% 'Z,"16. P)]J<.>E>!:[^R_K5]XAO=7T;XO>,?#<EU;6UN]K:20RVZF%
M@94D4[=P&2!W)Y-4%_9A^(2YQ^T/XSY.>;*S/_LE 'T;7S[^T'JU_P#%3Q+8
M_!3PU=-;R:I"MYXLU"!]KZ=HY)4HI'26X(,:^B[V[5 O[-?Q'0%5_:&\6E&X
M;=IUF3CV.WBN^^"_P4M_A#;ZS//K=]XJ\1:W=?:]3U[5 OVBY8*$C3"\*B*,
M*HX&2>] '<>&O#FG>$= T_1=(M(K#3-/@2VM;:%<)%&H"JH'L!5^2".5XW>-
M':,[D9E!*G!&1Z<$C\:?10 4444 %%%% !1110 444B;L'=@')Z'M0 M%%%
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M@!@D<9K'^)GC;P7K'@7Q/HU[XNTJQCO-&NEEE^U(S10O P,NW/( .[WQ7*?
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MEZC!;2:A*^IWER([K3B;<*#;IUD+YVMCH.: /2A10** "BBB@ HHHH ****
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M;1?\%#[NW$FU9_AE"QCQ]XKJ;\_@"?SKZ/KY<OW>/_@I1IO9)/AK(O!ZXO\
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MLIO*_>R0,FK,'[14,=IXAM_'7@'Q%X6ATO38[ZY%Y9B[@N(G<1LD9BW"0AG
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M(/>OJ;_@G6I3]D[PCGJ\M_)],WDW^% 'TK1110 4444 %%%% !1110 4444
M%%%% !1110 4449% !11FB@ -?/GB/\ ;R^"WA37]<T74O%T<.H:-,]O>1"V
ME;9(C['4$+AMK<'%?0>?YU^<WB7X+?$?PKXL^(]\G@&^N[6&#Q"UCJ.E);W4
MFHR:AJ=M<0%8I.I1$(.X9 !Q0!]JP?M#?#FX\(1^)U\9:.-$D0NMT;I0/N>9
MC&<[MISMZU4\/_M,_#'Q/)HL=AXSTF1]9MYKJP#W 3SXXI#'(R[L?=8$'Z&O
M@'X9?LW>,O OQB\-:AK7@K7M7L;301<WA718I+..Y;2=BA8L[9)XYOW>2 3C
M)/-=3??LL^)OB!^SM\&K*^\!R7&LVOC*YN-6ANK>.VNH-+FNYI'#@'Y%8,I*
M*>,\4 ?H@?%6C!Y$.JV0:-%E<&X7*HV-K'G@'(P?<5!;^./#UU'</#K=A(EO
M<M:2LMPA"3*NXQDY^\%YQZ5^2/B;]B/XT7DOQ U!="U72K>WL9#IEJ+XW4M_
M +B-+>Q#*V<)$%;GIY0K8^*GPU\1Z#\&_&>GZ1X3UJQ.E_$Z6<QV5M(72&72
MDA\T=2P+EANYY<>M 'ZPWGB#3-.THZG=:A;6^GA!+]JEE58]A&0VXG&#5JVO
M(+RVBN()DFMY5#QRQL&5U(R"".HK\CKF#XA_%.PU#1OB58W^C6O@7PDDEEH3
M:9=+:,UM<6@@CG53^_\ M";E.W)4$GM7U]\<M;U>'_@GS8ZQX;T:^\+ZBFD:
M5=P6&CRR++I:^9"S;3@L5C7.01R!S0!]:SW$5M$TDTBQ1J,L[G  ]235:'7-
M.N9($BO[:5YP6B5)E)D'JN#S^%?DUK_C'Q1XY_9O^%7A/4?',MA/KNK7]YJE
MWJES<F[^SF6:..5RJC_1=JMN'KC Q76>%O\ A";;3OV?+G0+!=&\4V?C)+!B
M-9N'EGLOMA0R6RL!YMO(Q<Y(&T9'- 'ZC44 ;>.W-% !1110 4444 %%%% !
M1110 4444 %%%% !1110 444CL57(7<?3- "T444 %%%% !398Q-$\;9VNI4
MX.#@CUIU% %?3K&/3+"WM(2[101K$AD<NV%&!ECR3QU/6K%%%  :I:4+[R93
MJ/D><)Y/+^SYP(MQV9S_ !;<9[9Z5=HH **,BB@ HHHH #R*0*!TI:* //O'
M'P"\!?$.XO[K6O#=G-J%] MM<:C #!=/&"I5?.0A@ 57OV%85U\#=7T+5=6U
M7P9XYU;1[O4)[.1K+4S]OLHT@&UDC1B&3S$ !(/49[UZ]10!X;<>*OCAX4N]
M.^W^#]!\7:;-J3Q7$FAWK17%O:'E)/+E #,.A :MZP^,7A[Q-;:+HWBGP_J6
M@7>OB[1-(U^P)7%ON,@D."@!52PR>1TKU3K4<]O%<QF.:-98R""CC(((((P?
M8D?C0!X/K'[+OP/^*^CVE_IFB:;9":-EM=8\+3_8YBHX8+)$1N'&"#FN3N?V
M:?B_X#T&\B^''QPU"Y8L7MK'Q;9I=HO"@*9@=_8]N]>M>)?V=?!?B"UT2&VL
M9_#@T62:6P.@7#6(@:7F0A(\*<G#8(/-0>'OAKXQ\!P^&;72?&TVM:7I=E<P
MWMMKL(EN-1E8L\4AG!&PJ2%Z'Y?>@#S32OBS\?OAI$L/COX71>-;:.V!_M3P
M5=J\CR*O.Z"0@C)],UIZ/^WE\,IC<)XCEU3P+/ PC>/Q+826J[\ ,@<C:2K'
M:>>W%=OH/C;XA:/9^'X?&/A".XN[LW)U&]\.W'G6UC'&A9&(;#L7P5 4'G'K
M5!_C%\)OBWIVB:)K,ME=KX@$\EGHVOVACDE^SG,I,4HR-A7.3Z4 >GZ'XMT7
MQ-;I/I.K66I1.H=7M;A9 5/0\&M4,&Z&OFK7_P!A?X5^(W35/"1U#P+>R^6Z
MW_A347MU95?=C8"4(//;WJ*\^#/QS^'$D4G@#XG0>*[26Z$UU8^-X-SJ@&-L
M4T0& >^1Z&@#Z;(!Z\TQ[>.12KQJRGJK#(KY:_X:-^-7@37+:R\<?!"_U#3F
MW"35_!UR+^,#'#>7@,/<=:]!\%_M>?##QEJ]GHH\0+HOB&XC+C1]:C:SN5()
M#*5D Y!!_*@"W\8_V4OAC\=Y6N?%WAF"[U,PK FIP.T5S&BDE0K@]!D]0>M>
M%^/O^";7A/7_ !3=S:(=.TOPYJ-W:R7.FFT<36L,:*LJ6LP?"^8%)(92,N37
MV7;W<-U&LD,J2HPR&1@P(]<BI<T ?F<_["_B7P!\:X[7X>:IXQ\ 6$[/::?X
M@C2/4(!&2799&0YBC;"8#*!D<G-7-.\:?M&^%G\4?#CP7XQ\(?$;5(1/&+U)
MH[?6(IR^6DDA?&]E *\@C&.3BOTEK(;P?H3ZS_:YT:P_M;! O_LR"<9&#^\Q
MNZ$CK0!\:WW[44-KXS^$C_$3X;ZOX!AT6:]-_J^N6CQVMC*+-HD\AX_D;S"S
M 9X ]R*U?@.OP]_:,_:*^+/CF73="UJ'3-2TJQT+4DF5YF>WB9S<)C!&XR+S
MWV8.<5Z[:?LXWOA=]<GT#QOK%XM[:20VVD>*&74M.MI&=6\S8P#M@*0 6_B-
M>1>(OA /"VGZ[XA^)?PVTF[&DVL<D/B#X;--:WDVUV)8V\>TH(T&XD[A]: .
M?_9=^#_B?4?BY\5/&_A'QC?>&/#R^/;RWN-#NHDN(=2$1/GEB,,I\Q\*1T4>
MM>[^&O%WQL\+>()+3QMX4T?7M 037#:_X;NF5DB5&94^RO\ .SD@ !<YW>U?
M*/[)FJ:]X:^#:Z[X+^*MOHS76IM+J.D>/M/:.UFN[@EE,-SD,Q=4&6&X$@FO
M=+#]LKQ#X7\9:]X;\<_#Z\F.D10S2:KX-9M5M]LF=I<*-T>X L >< T >O\
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MKE.1&Q5QMVD@[<YS7VK^P/=I<_LI>!508\B*Y@;D')6ZE&>/Y=: /H.BBB@
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M5\G_  EN-6\&_P#!/3XF>-Y-9QK?B*#7_$,5['\K1S3-)'%M)ZDE%(/?<,4
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MR2&;P]\7=#C<-L4?V=J1CX! !S&6[]:FTG]NOPYI=VUA\1O"GB;X9Z@KA/\
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M::]?Z5=Z;H]X+>Q8#47S);.F2!C<#M+X&,!J />^YHH[GZT4 %%%% !1110
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MTS7BVH_L:_#R+P'X^\,>';"7PS%XV2--7N;21GDE"N6)RQ_BW.#SSN- '??
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M%#,FU\9(!!R,BO1DD21048,#R"#F@#C]>^&=GX@\?>#O%<]S*EYX9CO8[>%
M-DOVF)(V+?01C'UJQHWPXTS1/%7B_P 00&;[?XH:W:]W-\H\F#R4V#M\OZUU
M5% 'F4_[/_AM_A'X<^'437,6A:#+I\MHP<&4&SG2:+)QSEHP#[$UT6H?#;2=
M1^)FD^.93,-9TS3+K2H0K?NS#/)'(^1ZYB7'U-=710!P4_P6\.7&C_$'3'CN
M/LWCF6675P)N6:2W2W;8<?+\B+^/-3W/P@\-WG@[PKX9FM9)=+\,S6-QIR-*
M=T<EICR&+=\;1GUKMJ* .9G^'.@W/Q&M/'4MGO\ $MKIDFD17>X_+;/(LC+C
MIRR@YJU#X&T"WTW6]/CTFU6QUN::XU*VV92ZDF&)6<'KO P?6MRB@"G;Z-8V
MEC9V4-I#':6:HMM"J#;"$&U-H[8' QTJ5;&W2Z-TL$8N601F;:-Y49(!;K@$
MDX]ZGHH :D:QYVC;DY./6@1J#G'.<YIU% !7BEY^RKX,\4_%3QEXR\7:+IGB
MB36GL3:0W]L)#9"" 1, 3V8@-BO:Z\!\%_%;7+C]K'XJ^#M5U2W3PQH^DZ3>
MZ?#*%1HGG4[_ )\\ABK<'VH O_'WX>_"?PY\,[S6O%.@:7H^DZ7<VMS_ &A8
M:;$)[>07$?EE<)SE]JD=PQK)\&Z=I^F_MN?$$Q+$+N?P9I#!%A*&*-;BX7 (
M^4@D ^HVBNM_:$\,Z3\9?A%KO@Y/$>FZ<VHM;?Z3-.C*GEW,4AX!ZG9@>Y%<
M7X2L;8?MV>/=0@E$C77@?2]P6=7'%U./NCE> .O7D]#0!W'A[Q&UKX4^)U[?
M7'A^&WTO4M2"R:=&)(XH8XE8&Z0=91\Q<=2,>M<WJ'Q<T'QA^RC:>.K'Q5<>
M'=%N+6U===L+!E>,K<1QL(X&&0'<% N.%>ND^%^B65W:?$ZTO/"0T"ROO$FH
M+<)/(7754:*-7NO99!QC_9->=--/X*_8EA;P':>&=#GL[91IUOJ&H+=Z7 3>
M<YG8X?J2">C8':@#Z85@RAAP#R :6F0LS0QEB"Q4$E>F<<T^@ HHHH ****
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MKCX*?&3Q)XD^"VIZ/IOB.WTC1O#'A@ZI +F:",.ESMF4)NPS*A#.#T7->E^
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M0/''[3WPT^(7A5O"FO:AJVAC6+*"2\DLI##<6,<NF_VF'$B\@+&FTL/XN.]
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M'R I<@G;VSZT ?2& 1SR*JZEI5EK-G+:7]I!>VLH*O!<QB1&!Z@JP(-?&WQ
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M^S=J&A6?Q'TB;Q3H4OAOQ+;VLUS=W5U%>+?S-#&D4J29)#B6)2<<J<9Q5SX
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M6S1M1AA@NLMN2!RR ;CMP2!U7:3[YJY10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !00#UYHHH QO%?@S0O'&EG3O$&DV6L6.]9!!>P+*
M@9>C 'H1ZUYNWP&U'P]KLNK>$O'6NZ6]UJ7]HWNGZA+]NMKA<'_1U#\PQY)^
M[G&?85[#10!X9!\7O$WA#^P-$^*'A!3/J$>H3W>KZ&ANM,M8;5/,5Y2PRI=0
M2%P<$5%J_@WX'?M5>'A)=V.CZ\NJQ23).B""\9%<([AAA\!E49.1P*]W>-9%
M*L,@C!!Z&N%\9_!+PAXXEN+F]TM;74YM+FT<:GI[FWNHK64AG1'7&WYE!'H?
MJ: /&;S]E[QS\-=TOP9^)-UH^GB6&;_A&_$8:^M)&4_O )6)D0,NT8' Q[U'
MJ'[4WCKX,^)+71_BY\/KG[#?SLMEXA\(J]]:% ,GS$QO1AD<8Z<UZ,WP]\<_
M#O1]2'@SQ&NN6]KI4-KI&A^("2!<)(#)++=9+L70N.1P2/2KJ_&F?P^-5/C+
MPQJ/ARVT\V<0U%1]HM;R6?"[8"F6.US@Y [&@"3X>_M+_#/XH*R^'_&&F7-R
MC%'M)9A#/&P&2&C?!!KTU7#C*G(]:\"\?_LJ?!#XY^);G5-4T#3;G7[*5HKJ
MYTNX\B=9&ZB4QD?-QWYZUR#_  5^.WPH\3+<_#OXB6WBOPG;P%(O#'B[.]?F
M)5$N%&>!@!F].: /JPJ&Z@&N&\2?!?P3K_B.#Q1>>&M/?Q'92&Z@U5(0EPL@
M0J"77!;@XP<@UYEX1_;(T2;XAS^!/'6@:C\.O$=O:K.SZRR?8IVVJS)%.#M;
M@Y'J ?2O>],UBPUNQBO+"\@O;290R302!T<'T(H _*/P5XITW7/@-\-O"/B7
MXP:,_ARTO+*\U7POJVBR-<6<=M<[S;1R)G(.-I+ 9'?%=-X8^*OPAF\>/XR\
M :WXH^%>KZ=;7=C#_:&E2ZAI$D3S*Q6,9_=H2@?:I'!]L5^E47@[0H<^7HNG
M1YZ[+2,9_P#':MV^B:=9VC6L%C;0VQSF&.%50_@!B@#\[?AM^W!I$,7Q3T?Q
MY'J_BJTUR\G,.M>%--EELO):TC@>*+*AE(96/S#JU4?B/\=/@;\7_AYX)\,'
MPMXQ=?#4VF)%?Q>'Y?ML5I;E T8F #+N5,$@^X%?=K_"&PT&V\5S^#9%\,:O
MKL&/-BCWVL,X!Q,+?(7<2?FQC=@9KPGQK!\4M/\ # T?QYX,N_%UK#,)+?Q#
M\-+PV=X&#$*SP$@CY3R/F'6@#YNN?C-H'@SXBS^,OASJWQ#M;J/21IP@\1>'
MKC4XKQ//,P4.VUHU#8'>M[X#_&#4[[X'>-?#&L? CQ9K.E>+M4U6ZO8M#L@E
MK$+D)F*/?ALCKG'!KZ'U+6_B5\.O$]II^@?$3P]XM1DCW^&?%SK9:BFY 459
MDX+'/=16]_PUA/X0F2T^(7P[\4>$9A.EL]_':F]L"S#.\319&P8ZG% 'CM_^
MUII.LZUX9\(:E\$O&B:UX9EM-8TRPNO*BG4QHT,<H!8;\*[C'>K$WQ>^)EM\
M6[WX@Z!^SCXI>\U#2+?2)&OKF*$O!%,\BL4&?FS(1R>@%?04.M?!_P#:0T^W
M N-!\5XD)B5V7[3&T;<[>DBD'TQ4UU\%]4MOB=;^+=%\>ZWI]M),KZCH%P5N
M;&XB 'R(K &(\#D$]Z /GBSM?C/K_P *-?\ "</[/NG6.A^)9[Z>_L;_ ,2K
M$[?:Y7DESQE268G';-7M:T']I?QG#X-U ?#OP7X=U7PKJ#W6G_:-:>X"@VLE
MM@@  C9*W?L*]YM?$'Q5L/B,;/4/"ND7G@JXNI!'JNG:@?M-M"$)1I(749)(
M (4G!-/^&?[1WA+XFZO+HUH;[2M>@21Y]+U:SDMIHA&V'SN&#C@\'H<T >%V
M_P /_P!JY[_5M;@OOAIH>MZHEO%/<Q6DKS%(<[59OX@ S8STS6CX1_9I^.?A
M/PM9:!9?&#1['3K=I'^SV_A\,F9)7E?&YN?G<FOJC2]=TW7+?S].O[:^A_YZ
M6TJR+^8-7J /D'4OV)/'WB[Q#HFK>*OCYXAU/^S+_P#M"*"TL8H!%+L*;HCS
MM.UB.0>">.:Z?X!_#SP]\+/VB_B1I46N>(?$GC"^T32M1U#4-<DC<- 9+B.)
M4*@<CRV!R.FVOIBOG"UD33?V_K]/(?=JWP]B99HYAM_T>^<,'3KG]\NT^S4
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M^6_VKOC-=_##XF>#-+M_"^BZZVM:'K<EO=ZA;J\UM<VML9HL$@_(<$,O&=U
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M-J%A=::^X-&;.)5F1L&"-V2W"N>[D?0 _2$<<>]%-0DKD]:=0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 T%M[9 V\8QUIU%% !1110
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M@7]J3]GE,$DOXA8'Z:>.*O>-?^3M?A7[>'->_P#1EE0!\D_\%264?$_X=@R
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M.MDM/&WC91H=MILDUU;7)U"W0@WZM"%#2-CEU*,N.< +ZUR/@]X[CX#>(_\
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MIT>JW\'V<L]M:,&*S$ <*0C'/M7.67Q-_:-OOA%/X_L?C-X&N?!,,S1OKMQ
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M"0SJI /!K8T'QI\0=&TRQ3Q?X0AO;R:\N(Y[CP[<>;#;VZ1[XY65\,2Q#+M
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M @"[1VQ7;BB@##\#^&9/!_A/2]&FU2\UN6R@6!M0U!@T\^/XG(XS_A6Y110
M4444 %%%% !1110 5\N^*IY(O^"BG@52(=DG@2_163/F\7.2']1D+M^K>M?4
M5?.GCYH[?]N'X2%L"2?POKT:G'7$ENV,^W- &A\9B3^TY^SVH'_+WKI)]!_9
MW_UZ?\:[-#^T?^SM=G.]-5UB ?/Q\VE3M]WN?DZ]L>]:?Q3CTW_AH/X)274-
MS)J N-9%F\3 1(?L'SF0'D_*N!CO5'XV0[OV@/V>9\GY-<U6/;V^;2+DY_\
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MTEX-41!%$; PL6DW'S!)N&!CIMQGGUQ0!;HHHH **** "BBB@ HHHH ****
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MX*?"'P_IGPQT7XBZ+=WNEQN7::[C$MQ(S&225R#@LQ?)YH \VT3]H'PC\*/
MGP:AT[X;V6C:5XJ\47MD]F9E*:3<0W36TEPK-D$[\G(Q@9KZ!^$'Q&TKQKXM
M^)VEZ;H/]CS^'/$ TV]N"JJU_-]FBD\\XZY5E )YP!7C/C_X$?!;X@Z3\/\
M2IO'%A;Z/X3UJYU=+0ZC%(MZ+B<SS0R$L/E,AZCH.*]<^$^C>$_"6N_$#7M+
M\5Z?JB^*M;&JSJES'MMF6VA@\L$-SQ"#D_WJ /6J*RSXJT88!U>PR> /M2<_
MK2CQ1HY;;_:MCN]/M*9_G0!IT5G_ /"1Z5T_M*TSZ>>G^- \0Z8Q &H6ISTQ
M.O\ C0!H453_ +9L,X^V6_\ W]7_ !I$UK3Y "M[;L#T(E4_UH SO'GA"V\?
M^#-;\-WL]Q:VFJV<ME+-:2&.9%==I9&'*L,Y!KS[]HOP_P"!?^&?=8T/Q_J[
MZ1X0\BVM)M19_P!Y"PDC$+@\_-O"=>]=YXOOKR]\,:G#X=U>PL-;>W9;.YNR
M'BBE_A9U!Y%<O\<OAY:_'#X->*/!']IVT%YJEB8HKL$,L-PI#1R;?0.JGZ4
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M%R/04 <_XAD^/?B-]$:Y\ ^")C8:E#>J9]4D;RBF[]XGR\, Q /N:P/B%?\
MQMUC7?"TVK_#+PW>IH^L)J&F2VWB,0M)="&5%&UEY&R23CV]J[_]J+7[WP[;
M_"R2SO)K-+GX@:1:7)BD*"2%VE#(Q[J3C([\4O[5NKSZ!X5\&:I;3Q036OC7
M1%5I4+$B6[6%E7'0E9&!/H6% 'E'Q8\8_%36-8^&-OXS^'FG^'M&'CW1'6_M
M-72Y9#Y^U R#N68C(J?_ ()E3.WP6\50NN&C\5WK-QC+-'"QKTW]JPJFB_#D
MDX ^(7AP9_[?UKR3_@F7= ^!OB79DDR6_B^Y)';#(N,'_@)_*@#[+HHHH *I
MZEHUCK,0BO[."^A#!A%<Q+(H/KA@>:N44 <^WP\\+NC(?#FDE&ZK]ABQ_P"@
MU7?X7>#I7W/X4T5VQC<VGQ$G_P =KJ** .3E^$W@J:-XV\(Z&488(_LZ+D>G
MW:QK[]G/X7ZE<-/<^ ?#TTS8R[:?'D_I7HM!.!0!Y7=_LK?"&]CV3?#GP\RY
M#<6*KR/I7->*/V%O@;XNGAFO?A[I<4D8< VBF'.X8.0IYQU'H:]TM6E:!#.J
MI*?O*AR!4M 'S-!_P3A_9_AEW_\ "!V[\YP\\A!YSZUT6@_L,? OP[;2PV_P
MYTB59)/,)N4:4@[0, D\#CI]:]WHH \4'[%?P.#E_P#A6>@[B=Q_<GKC']ZG
MM^QC\$&SGX9Z <C'_'N?\:]HHH ^>=>_8 ^ _B![AI?A_86QFMA;'[(SQ[ "
M3N7!X;GK["N-O/\ @F1\$[30[RWL;+7K'>I??:ZM(KY [#H<XQS7UQ2, 1R,
MXYQ0!^1O@CX3?LX_$#5?AMHNDZYXVN/$WBN]:TN-&BU<M-HQ57+-,2.,%,<=
M<YJ34?V6=*\'?$CPOH/BKP3XWT71/$/B(>'K+7/^$F#O*[NPC?8!D*57/TKU
MS]G3P(NC?\%%?'VABUBL-/\ #+:IK-C&]N!+-]O:U&2_]Q=[;/0$CN:M?M%^
M*?#GBO\ :_\ A%/H7Q237C;>--/M+SP6CADT^>(E6G7'(/52#W:@#R_P_P#L
MZ?!GQ!X>^'E_;ZM\1HK[Q=K]WX?CLGU3Y[6>V\WS1(>F!Y?!'7<*S_AO\&O@
M%\6O$?@+PWX6\?\ CFY\1>)8I6N;-+YBVE%+=I7$YS@$$;..IJW^S[81W?QE
M^"VK'XC_ /"07>L>,=7U.Z\(A54Z1,4G,C,.H=B%![<G%>H?L0_#R\L?VO?B
MA%?B*6V\!K>:38R6UH(D_P!+OGE^9L99@@(!/.WCI0!I?$#_ ()U>"/AOX!\
M0^*M4^(?CJ:QT2PGU&X$.H-O:.)"Y51NZ\'\Z^;_  W\+O!TG@SQQJ.M/\4_
M"M_X9TBUUY=)O=142W=C/+L\Z+#8(7.3]1ZU^I7[0]OH]W\"O'UOX@:]70I=
M$NX[YM.3?<" Q$.8U[L 3@5^=OQ9^(WA3QY;_$C5/ 6HRZ_X<T+X.:?H?VR0
M$L)7U&$1QO\ ]-"H^;W!]* -[0?V2OAKK_C37= TGXD>/-0&F>&(?$[WJ7_^
MCRV\N_8J'=R?E)]!TKF_#OP&\(3?LPR?&Z7QC\1=$L)6\NVTR+4E:YNV-P((
MU7#XR\G !]*](_9LT-/A[^T!\6OAYJDZ6EOIW@G[#HD4F4FFTYGEN4&3][RQ
M<,F[L%YZ5C63Q:I_P2A\%/82I<#1-2L9M197&;?R]5W2%O3:&4_0YH \FM7^
M,M]X-\::OIWC/XA6^O\ A+6;;3=0\.3J))TCFW/%+E<\JJC<,8R1V-=)H_BW
MXN6G[/\ '\2-8^/&N^&;.#7;G1Y-.O-+-Q-%<H2 CE5SR1T(XSBOK3]E74;?
M4_VA/VF;ZSN(;NTG\0::\,]O('1U^Q'D,/H:^?\ XBZG=:K\$/CG9;XFCTKX
MVQ."YP61[RW) !ZG+'CZT 8_Q"^)'QW^!UII4>O_ +0>CR3:E9#5(K<:-+<7
M$<#;2&D54RB_,/O8[UBZ[^TQ\5O"RV@N/VF?!]Q]KLQ=1/;:7+*$5N09"%^0
M]L&OHR:SAOO^"@/Q?%U;17=M'\.8LQR1AU(RA ((]<U\7^ M)UGP#\+=0N_#
M?A73_&W_  F?PUNM5U);]41M)ACGG@>>/(^8C8C>N?I0!^O7PNO]5U7X;^%[
MW6[NTO\ 5KC3;>:ZN[$$03R-&"9$!Y"MG(^M=17(?!V/ROA+X)0/OVZ'8C<>
M^+>/FNOH **** "BBB@ HHHH **** "DQ\V[OC%+10 4444 %!ZC'3O110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>*?M"Q+-X\^ P* L/'&\,3C &EW
M_P#];\J]KKQC]H''_"=_ @D9/_"<8Y[?\2K4/\* .]\?6-M?VFAK<ZC;:;Y>
MKV<T;7*Y$TBOE8EY'SMT'7Z&O//VO[O[)\(;1R%;/BGP\NUAD'.K6O%>@_$"
MR\+WUIH*^*6MUBCUBSDTXW#;?]/#YM]O^UNZ#OTKS3]M$LGP7M&7G;XK\.'\
M/[8M* ,G]N.Y%CX \"WCQ"6*V\?Z!*\9_B NQT_$BM_]KZ$3?"S2QC)'BWP\
MP]B-5MZYS]OO3[NY^ D5Y9D*VF>)=&OG<G&U%OHU+?@7!K<_;$F,7PBLGSAE
M\6:#C_P:V^* +7[4X1M$^'N\ _\ %P/#O4?]/Z5X/_P3*UQ3-\8]",TA:V\1
MM=K"T6$"NTL98/W),7*]L ]Z]A_;8\56?@;X:>&_$>H>9]@TKQGH-[<^4FYQ
M%%?([D#N< \5\[_\$QM;EU/XE_%DQ3O_ &==I;ZC';D84-+<7!#8]=I _"@#
M]"J*** "BBB@ HHHH **** "BBB@ HHHH ,C-&17Q_\ $JSO-%_;C\.VWB3Q
M1K,?ASQGHTUKHMAIFH^5'9W4-NXG,T74JR'<K]G^E?/7@G^W/#'B_P 7:OI?
MQ;UZ#4O"OC2RT+3O#&H:DE^NIVTL]M%(QP?G!69F^7[N/4&@#]1<@]Z >:^'
M_ W[6OC7P=\,?B=JGCZ!]>UG1O%<_A+1ET:T""XN([=VS@G''EEV)^E2?L5_
M$SXF^,?BG?R_$OQ:#/J^A6^IZ;X=%LJV]Q;-'$RW5M(.XW,LB=06!H ^OX/
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MU\8?%;XF_%O4/VOSX.\)>(K'1O#BVB:9!!<0>8/MT^G75TD\@ZE5\D=/;WH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1MKE;N6.*)7#6ZXV2%MN"W?Y<''U-7** "BBB@ HHHH **** "BBB@ HHHH
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M;F^DU82:0]NL<6F>0!Y<F?FDWYR<@#CMDUL444 %%%% !1110 4444 %%%%
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MKB'+)(+EO.N(D_O.7CSCMG'>LG]E3XX:?\2?VCOB_8W'A37]+M?&\MO=6O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O _VYX0?V:?$MWA ^GW6F
MWZ2/TC,6H6[%L]L#=S7OE>(_M7#XDWG@1-*^'W@[0_&D>H"2'5+/7)]B>3@;
M0J_Q9/7TP* /0I?BQX)MBHD\7:'&7'F*&U&(94\@_>[TB?%[P-(,KXQT$_\
M<1A_^*K\^%_9G^.%S<2)+\#OA41$BJGF/QCH ISVK2LOV6OC#:W*M/\  GX2
M7-HIW-!'.5+#'3=F@#[]MOB=X0O98HK?Q3HT\DK%42._B)8CJ -W-:5CXIT;
M5,_8M6L;S!*GR+E'P0<$<'L:^ 8OV;?BK'91N/V?_A9'<*&^>/49$*].1@\<
M9'%<SK?PN\2:/<63ZQ^R]>0O!$8I9_!6OR1I*_4OMW="3GGF@#[V^/$L%_\
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MV4YQZ<4-_P %*_@-&@:3Q1<Q*6"YDL)%QGZCI0!]245\VC_@HI^S^S8'Q"L
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MF@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%([[ ."><<4M
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7 "G'K110 VBBB@ I1110 'K1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>aytu-20230630xex10d49001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20230630xex10d49001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (N!&X# 2(  A$! Q$!_\0
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M*62!VBNXV"R(Q5T.#P58$$=B* -RBLS_ (2?1_\ H+6/_@2G^-'_  D^C_\
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MW+DCIN&>HJS2;02#@9'0T +1110 4444 %%%% !1110 4444 %%%% !1110
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M$=K_ /&Z[RB@#@_^%"?#'_HG/A+_ ,$=K_\ &Z/^%"?#'_HG/A+_ ,$=K_\
M&Z[RB@#R>']D[X-P:/J.EI\,_#0LM0C,5PIT^,LRE!&=KD;D^4=5(.>>O-<;
M_P .\?V<_P#HE6C_ /?R?_XY7T510!\^6G[ '[/E@TC6OPRTRV:2-H7,4]PI
M9&&&4XDY!!((Z$5J^%_V+/@QX(>X;PYX+30&N0HG;2]1N[8RA<[=VR8;L9.,
M],FO;J* /,/^&;? /_0/U3_PH-0_^/T?\,V^ ?\ H'ZI_P"%!J/_ ,?KT^B@
M#Q7Q?^R+X$\6Z4MDEUXIT(K*)?M6C^)[^&8X!&TLTK#:<YQCL*H2_L8>!9?$
MM]K']L>-$6ZA:(:<OBJ^%I#E N^-/,R&&-P))Y)/M7O-% 'S%_P[]\$?]#S\
M3_\ PL[O_&C_ (=^^"/^AY^)_P#X6=W_ (U].T4 ?,7_  []\$?]#S\3_P#P
ML[O_ !KI?"O[(6B^"U*Z3\0/B-""LJ_O_$CW'$GE[_\ 6JW_ #QCQZ8.,;FS
M[Q10!XOX=_9AL_"ANCIOQ$^(,7VDH9?.UWS\[$"+CS(VV_*!TQGJ<GFM6Z^!
MEY+;3)#\3O'<$S(0DO\ :,+;&QPV##S@\XKU.B@#P^[_ &=O$TW@Y=.@^-OC
MJWUX1HIUOS;9LL&!9O(,6WY@",9XSGM7)?\ #*/Q0_Z.>\=?^ %C_P#&Z^G:
M* /F+_AE'XH?]'/>.O\ P L?_C='_#*/Q0_Z.>\=?^ %C_\ &Z^G:* /F+_A
ME'XH?]'/>.O_   L?_C='_#*/Q0_Z.>\=?\ @!8__&Z^G:* /FWP9\.O%GPE
M^*_A.WU_]H75_%3:Q]J2/PYXCLK9%OXXXMS^0T:J1*C-$_4Y02<'DBCX4\5?
M$O5OA+\+/%U_\0U2Y\:0Z5NMK;0+;9;2WD"RG!+9*J21ZFNF_:.T>]TWQEX(
M^(5EX/OO&MYX0L=9ETW3].\PRG4IX(DMP0F2$=5GC+LK*F\$C.VJOA3P/KUG
M^SY^SYHT^E7,6J:&/#W]I6C)\]IY-JJS;QVV,,&@#M?^$!^)/_151_X3MM_\
M57.7F@_$^+P]XDO8/C!I]U/I_P!H\K[+X9BN!$R1[@DL<;%V<'JB#<00 ,D5
MW6D0:XOQM\637!O/^$:?P]HZ60=V-M]J%SJ9N=BYP'V-:;R!DCR\YP,5_!7B
M_47^&UEJ]Q:ZIKM]+J#6SH;..WN-K7Q@\QHU.T)&AWDYR4C+=3B@#SKQM:?%
MO0?&7@/1=/\ B=:21Z_?3P74MSX=AS%%%;23$H WWB4 YXYKG=1B^/\ K7B'
MQG8^&OBCX?M8/#&H):S2:MX961ID:QM;D,HCD&"#/(ISV"^]>\>*_"<NM^-_
M!&KIYGEZ+=74S[ FW$EK)$-V6!'+_P (;GK@<URW@^TGC\6?'!WAD5;C5H&A
M9D($@_L:R7*^HR"..X(H \3TI_VD]5\-^$];'QH\#6UIXH6 Z8L_A"4/*TT)
MF1"!*=K;%8G)Q\IYK5M_#W[3UWXAOM#B^-'@)]5L;:"\N+;_ (1*7,<4S2K$
MV?-P=Q@F'!S\ASC(SU6C:;=I\)?V:X6M9A+:W.DF=#&=T6-)G4[Q_#@D Y[F
MN[\.VLR?M%>/;AH76WD\,Z B2E2$9EN=6+ 'H2 RY';</6@#P+2OB-\=]+^$
M7CWQY_PL#P-XST[PY]KES!HDMN)/[/=VNHHV29E82B-HPY^[G<!GBO3+_P 3
M_&KP_P"-M#\/W5UX'OGU][N6WE6UNT6U2&)&*$>9E\DDY]_:O+/%7PGNM5_X
M)^OX+T_3XIM2\2:E8VXBO[=H4MYKO6X%,[K;+&Q\HR>;N;<3Y>9/,&X-ZOXE
MT35+K]M#P7J<$*G2;7PCJ$=S,]B),.]Q%L"SE#Y1X.0&7<..<4 4K+XD?%^]
M/Q& B\$K_P (9?&RFS%>?Z2?[.M;[<OS_*-MV$P<\H3WKE_$7QF_:%T3X8^'
M/%\/A7P!>#69-(@6R-]=QF*74+E+>-2^""%>>#)QT=N/DY[[P_I]T]G^T/>B
MVE^RZIKD[V4A0@7*Q:%I]K(4]0)[>>/_ 'HVKF/'WA:X\4_#[]FG07F33MWB
M;0[R=I[*.:1?L-A<7_EKO&8F9[-8RZ$,%=ARI96 ,_5/BA^TO:>(-'\.VG@W
MX=7?B"[TR;5+JV;5;N.&V1)EB"B38?,)WJ?NC'(J%?B5^U5-IUU?6W@7X5W=
MM;&9)7@\2W+!7B9ED0GR\!E964@D8((.,&O5&U&VN/VIX;*.4-<V_@Z5Y8\'
M*A[V+:?QVM^55O@WJFF:+\+O%M]K4T%OI,'BGQ,]U+<X\I8_[8O-V[/;'6@#
MQVY^.'[4EG#X1ED^'?PVQXGN4M;#R_$%S(-[6TMR-S*A7'EP/RI89QC(.:MV
M'Q=_:JU+Q;K'AR+X=_#;^T-*MK6ZN-VO7839.91'M/E<G]P^>../6O9_B?I"
M6FO_  =MM.LA#96/BC:L-K%MCMXETG4$4 *,*HRJCH!D#TI?"7_)PWQ(_P"P
M)H7_ *'J% 'GGB[XX?&3PSHDGC%/A_X1O? MAI,E_?36OB=I[F5E1VW0,L.P
MIPG7DC=STINF_%_X^:5J^F^'O$GPW\(/X@U8R7%BVE^(I1;"W@:'[0)-\)8/
MME^7'&>O2JUE_I7[%7@C2'XM=?CT;P_=,/OK;WM[!:S,AZ!Q',Y4D$!@"01P
M?3O&7_)?OAG_ -@S6_\ VSH \\7]ICXGW/C37/#NG? 34-6.C7:V-[J=IXCM
M?LD<S6T5R$RZJY_=SQ<A,9;':LSQ#^UC\5/"OA^TU;4_V;M?MH;G4(=-6'_A
M(K%I5EFEAA@R <8DEG1%.>H;=M !/5*2-"_:<(X/]J3\C_L7--K)^*&MZ%X$
M^ OP9T(0QZ<NL^*/!^EZ9:VD&V+S5O[6Z*X480>5;3'/ R .I% &7_PU;\7?
M[0^P?\,R^(?MWE>?]E_X2?3/-\O.W?MWYVYXSTS5C_AISXS_ /1K?B?_ ,*/
M3O\ XNO3E_Y.9D_[%!?_ $M:NIL;]O'7A'5DM-1@MY99M0TQ+W3)FD\AXIYK
M?(8A")4:/YE'W75E#$ ,0#YWU7]K[XK:)?:/9WO[,OB6WN=8NVL;&,^(=/)G
MF6"6<H,-Q^Z@E;)P/D/<@'9\+_M6>/-<U;4M)N_V??%ECJNG- UU:Q:I83&.
M*7)1RWFJ.0KG S]WMFO2O%7@[4&U;X-(+U;]O#^N-->W=W,$EN%&BZC;[P&)
M+NTDR$J"3C<W12:C\$_\EY^)_P#UY:-_Z!<T <Z/VJK-O D7C,?#OQQ_PC,M
MFE^FH?9;+:8' 97V_:MV"".,9YZ5HW/[1,MGK]AHDWPQ\<IJE_!/<VUN;>QS
M)'"8Q*P/VO VF:+J?XN,\UY/K=EKFL_L&_#'0_#^H1:;?ZY:>&]):>= Z>3/
M+;QRJ<JV 49AD#(SD$&O:O%7_)Q?P[_[%_7O_1VF4 <]8?M2PZI=^)+:T^&/
MQ!N)O#L@AU)8]-M3Y4AB678I^TXE;8RG$>X_,!U(%8^C_MH:5K=K+<1?##XF
MV<,=U:V6_5/#ZV.Z:YE\J!$\^9-^YR%RN0N1NP"*U=$UZ7PKX?\ VA=:@,@G
MTW6;R\C,3*KAH]'LG&TLKJ#E>"RL/4$<5SOBW4H/#7P/^!VAW6CR:%J&K>(O
M#5G;:/;S-?"VDCGBNI(S,!\RI%;RDR$ ';VS0!/XD_;;T7PGKC:-J'PO^*#:
MFJ&5K:R\-B[8(&*;SY,K_*64@-T.#@G%<\?^"C'@M=-EU$_#CXK#3XI7@DNS
MX0E\I)$D,3H7W8#+("A&<A@0>>*]DL8XI/VCM9G2\M9'C\+6<,ELDZF>,_:K
MA@63J%(;@GK@^E>67?\ R:KXP_[''6__ %*;F@"S:?MU>'KFWO9&^%_Q<MS;
MQ"58Y?!-UNG)D1-B8R-V'+<D#:C<YP#MVO[8WA>Y\'W&N-X-^(\%S$Q4:)+X
M+O\ [=)\P&5 C,>.<\R#@'Z5TOB)B/VH_A\,G!\&^)21_P!OVA5VGA'QE:^,
M)-=2V@EA.D:G+I<OFX^>2-48LN"?E.\=>>#0!XWX;_;B^'_B*^93H_C?3-)E
M*BPUV]\)WWV#4][ 1&V>.-RXD!#)E1N4^O%=K_PT=X+_ +GBC_PCM8_^1:\]
MTS0[_P ,?LW?L]:-JMI)8:IIT_A:TN[288>&:..)'1AV(8$'Z5Z'9W6HZA^T
MQJ]M)K%\ND:1X1LI(-(C=5M7GN[VZ$L\B[=SR*MA"J$MA \N!^\)H SY/VKO
MAO%9ZC=O?ZXEKII<7L[>%M5"6I10[^:WV;";5(8[L8!R:Y_P_P#MX_ WQ8)3
MH?C6361$<2'3]%U"?8=CR8.R X^2.1OHC'H#6?XDCC'P&_:5FAO+6\BN&UV0
M-:3K*$(TU%*-C[K J<J>15']KS6]7\->!/!G]@:S?^'I[J:YBDN-+G,,A TV
MX92<<-M8*P# C*@XH Z"\_;M^!^GZN=*NO&<MMJ@MC>FRFT34$G^SB(S&78;
M?=L$2M(6QC:"V<#->L^ OB#H?Q,T$ZSX>N9[O3A/+;>;<6<]JWF1L5D79,B-
M\K J3C&01U!K@_AKI#W7QP^*.IWU_<:A<6*:7H5NL\<*JENEH+@M\D:DNTEW
M,6).,$ !0,5H_LX_\DP;_L/:[_Z=[R@#TZO,?%7_ "<5\.O^P!KW_HW3*].K
MQ#PO;?\ "Q/VF=6\9VEU?3^'O#&B'PY9R17B/87%[+/YMX5C!)WH(K>,OQRK
M YP, 'M]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !116)HGB"\U37-<L+G0[W3(=/EC2
M"]N"AAOE9-V^(JQ.%.5(8 @]J -NBBB@ HHHH *_,S7O&7[+.K^-?&\OQ=\>
M^+;?Q_#XJUNTOH+2YUSRHHH=2N8;5$%LAB 6VC@4!#VYYS7Z9U\=_L1_$_Q]
MKO[-OA[5=.\%R^*+74=0UB]76+[6K>UN+MI=5NY&>2()A7W,V0.,YQQB@"7X
M&I^RKX2^*_A;0/ ^NVWBCQ_>I<7^C7<MW=ZQ-;JUNXF5;IMZ6Y,4<F8G=6Y^
M[EAGZ_KA/#/BSQQJ>MVUMK'@&/1-.?=YM\NMQ7!BPI*_NU0%LL .O&<]J[N@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4
MM% !1110 5%+;0SO"\D22/"_F1LZ@E&VE=R^APS#([$CO4M% $7V:$W N/*3
MSPGEB7:-VW.=N>N,C.*C.FVC6LML;6$VTI9I(3&-CEB2Q(Q@Y))/J2:LT4 %
M1);0I/).L2+-(%5Y H#,!G:">I R<?4U+10!6&FVBVL5L+6$6T15HX1&-B%2
M&4@8P,$ CT(%2/;0R3QS-$C31@A)"H+*#C(![9P,_05+10!!]AMMMROV>+%R
M=TXV#]Z=H7+?WOE4#GL .U4=5\*Z/KDND2:AIMK>-I%T+[3_ #H@WV6<1O$)
M$'\+!)9%![!C6K10!1_L2P_MHZO]EB_M,V_V0W6W]YY.[=LSZ;N<4:-H=AX>
MM)+73;2*RMY+B>[>.%<*TTTKS3.?=Y)'<GN6)J]10!1N=$L+W5+'4I[2*:^L
M5D6VG=<M")  ^WT)"@9ZXR.YHMM$L+/5;W4H+2**_O5C2YN%7#RK&&"!CWV[
MFQ]35ZB@#$A\%:%;Z#I6B1Z5;)I.E-;M8V83]W;F JT)0=MA52/3 J[/HEA=
M:Q9ZK+:Q2:C9PRP6]RR_/%'*4,BJ>P8Q1Y_W!5ZB@#F)?ASH<VE^+=.:WD-K
MXIDEEU1?-;,K26Z6[X.?ES'&@XQTSU-+K?PYT'Q$WA9M0LS<?\(S>IJ&F R,
M!%.D,D*N<'YL)*_!R,X/:NFHH Q+'P5H6F^*]3\36NE6T'B#4X(K:]U%$Q-<
M119\M&;N%W''UK-?X6^'G\'7WAAK63^Q[R^N-1FB\YMS337C7DC;LY ,SLV.
M@!QTKK:* ,>Z\)Z;>>+],\32Q,VKZ=8W>FV\H<A5@N9+>292O0DM:0')Y&TX
MZFE\/^%M.\,/JC:?$T1U.]DU"YW.6W3.%#,,]!A%X'%:]% '+1?#70X_"WAG
MP^8IY=.\.M9O8>;<.\BM; "%G<G<Y&T9+$[N^:TH/"VGVWBR^\21Q,-6O;*W
MT^:4N2K0P2321KMZ AKB4YZG(]!6O10!Y_X?^!7A#PQX&\5^$=/L9HM#\3W%
M_=:G"UR[-+)>9^T$,3E=VXX Z=JG^(OP?T+XGPZ%;:R;@V>DS23);PR;!+OM
MY("K'K@+(3P0<@=J[FB@#EO#WP_L_#GC3Q7XE@O+V6Z\126TEQ;2RY@B,,*P
MJ8TZ E5&3R3QV  \RU7X$?$+0M"N['X>?&&]\-&74;F_BAU30;'4+>$7%Q)/
M*@&Q)#\\K8)D.!US7NU% 'S]IW[/GQ+\1Z5!:?$/XZ:YJXBO?/>+PMIMOH<5
MQ!LV^1*T8>4@DODK(O\ #@ KD^R>"/!&B?#KPO8>'O#UA%INDV,?EPP1#\V8
M]68G)+'DDDFMVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/
MS]CWX9^,]"_9D\&06'[2LG@RVN[6#4;'0QHNBR+I\,\C3SQNTOFR2M(92R.7
M0IN^:/.47[YU35+/1--N]1U&[@L-/M(7N+F[NI!'%#$BEG=W8@*J@$DDX !-
M?GE\&/AO^S;/\(/AE)K/P'\1^(M7O_#NG3:EK-EX!U>Y@:X:"'S9#*L.)0S,
MS[XMZL 2"<J" ?3_ ,*_"'CBU^)UQJ&I?M%R?$'PO''*]OX671-)@F&<*C3W
M-O&&<)N)^1(LML).T%&]XKY1^!OAOX(>&OC='9^ _@AXL\'ZO':2&W\6W/@[
M4=-TZ4% 7@\Z95*DJ6XE15)3 )8H&^KJ "BN#^,WQBTKX)>#G\0:IINKZX/,
M$<6EZ!:BZOKC@LYCAW*7"(K2.0?E1&8\ U\]ZU_P4T\%>'--N-1U;X6_%O2]
M/M[>"[FN[WPJ(8HH)W,<$K.TP 21P51B<,PP"30!]@45\=WG_!3SP+I]U>6U
MU\,?BS;7%E>PZ==0S>%PCP74P!A@<&;*R2 @JAPS9X!KZ2^$7Q0L?C)X!L?%
M>G:7JVBV]U-<V[:=KMK]EO;>6"XDMY4EBW'8PDB<8)SZX/% '94444 %%%%
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M*DB#<JJ^ [,/I7P-XLMO'O@KP_XFLK>YM+/6M/M]2AM[U D\231K(JR*"0'
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MZM_#'QGBOKE+R]3XJ>(5GN8HO*2602QAG"9;:"<G;DXSC)ZUYU_PT+^Q9_T
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M+/&">P)/:N\^#/AV?P?\'_ N@W6[[3I>@V-C+O0HV^.W1&RIY4Y4\'I7AO\
MP4X_Y,A^(G_732O_ $ZVE?4= !7!?#3Q3K'BC7?'/VR>VN='T_67L-->* Q2
M*(XT$R298[BLI8!N,C'%=[7F'P(_X]O'?_8WZI_Z,% 'I]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(_\ XS0!].T5\Q?\+:_:D_Z(#X9_\+B/_P",T?\ "VOVI/\ H@/AK_PN(_\
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M .#6#_XN@#K:*Y+_ (6[X%_Z'7P[_P"#6#_XNC_A;O@7_H=?#O\ X-8/_BZ
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MR37M= '&^,_@_P"$/B'JUEJ/B31DUB>S,1BCN9I3!F.3S8RT(;RWP_S?,IY
M]!3+[X,>"-4\7-XGO?#5C>:TT4L)GN$,B;9$V2'RV)3<ZC:S;<D<$D5VM% '
M'_#?X0^#OA#I]U9>#] M=#M[IHVG$&YFD\N-8XP68EBJ(BJJYPH& !78444
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M]* /O2BLSPSK]MXL\-Z5K=DLZ6>I6D5[ MS$T4HCD0.H=&P5;##*GD'@UIT
M%%%% !1110 4444 %>)_M@?%;7_@Q\&7\2^&I((M4&KZ99!KF(2IY<]Y%%)\
MI[[7.#V->V5\Q?\ !1?_ )-JE_[&+1/_ $XP4 ?3M?->L?MX^$+/Q+KVD:/X
M%^)/C%-%OY=+NM3\->%9KRS^TQ'$L:R C)1OE/ Y'&003](7#%()64X(4D'\
M*^<_^">-])KW[)7@WQ%>) VL^();_5M4NX;=(3=W<M[.9)G"  L< 9QT  X
M% '+:9_P41L+SQ;KFCS_  4^+<"6,-M<6[1>%II;B6.42#?)!P85WQ2*I)8/
ML?&-I%<U^T!^UY=?$3X.^)]"\(_#;XW^'/%4MNMQI.I0>"YXS%>0R+- &;)P
MC/&J/P?E9N#TKZ*\.?\ )T?Q"_[$WPU_Z7:[7JE 'S?^SS^W+X"^-VE^"K2[
MGN?#OBOQ'IRW%O8ZC8S6]M>7";EN8[29QLF$;H1PQ.&7^+<%^D*^3_V1_"VB
MZ=\8_CIIFJZ18:EXT\->+[JYMO$4ELDD\&GZF/MD5I#,P\Q$4R2%D!";I&(S
MN)KZPH **** "BBB@ HHHH **** /'OVM9["U^!]_-JNH?V3ID>L:(]W?_:?
MLWV:$:M:%Y?-R/+VKEM^1MQG(Q7FH\?_ +.^/^3CO_,H2?\ R375?MQ>*H/#
M/P0MXI=%C\22:IXDT6QAT5W53J#_ &^&7[. X*L9!$4PV%PQR>,'R+^W+K_H
MQ%?^_>B?X4 ?1'P-USX>:X=9;P%\1SX_$?DB\_XJAM9%K]_9UD?R]WS>F[;W
MQ7HECX?L]/UK4]5A$HN]1$0G+2LR'RU*KM4G"\$YP!GO7F'[-^KS7^AZO;R_
M!B;X,"*Y606!2S$5YN7'FJ;8XW#;M.X9P%Y/;V&@#Q7XU>)/A9HGBBUC\<_%
M@^!-4>T5HM/_ .$Q?1Q)%O?$ODB5 V6W#?CG;C/%>6:WKWP$\3OH=AIOQNN/
M%.I_V]I-Q9Z1;?$*.]>XGBU"WEB!@GN=DBAT5F49<J#Y8,FP'T_X_P"I0?VO
MIEI<? FX^+:Q0&6.\-K8RQ6I>5%:-3<-D-M4N<#!V(,Y/'B]GKNFQ?$3P/:7
MG[+?_"OOM?B(VMIJOV'2V,F+"^F$G[KYD,;01R\$$!&8$E K 'DOP.\0>!?A
ME^PO!XIE^).J:8NJ:SJ]_I>E:/KL6BWEQ<S2"&&WD>6X?YHP(Y6+R.%#DOY@
M7+6/%OC3XF_!KXA^&=3E\6>-_BWIVK1^';WPQ;>"-4AO4U:WMK(#5UN;,2^8
M1+A)Q+&DD?[U,R N5/N'[!/PU\(>._V+/A+-XE\*Z)XAFM["Y2&35=.ANFB4
MWDQ(4R*< GTKZ8T/X>^%?#&J/J6C^&='TG47MDLVN[&PBAF:!%54B+JH.Q51
M %S@!% ' H _,35_VE/B1JNL^);7Q5XM\<^"-+O=0\3:G;26.BW-NT L]$\Z
M&VB:XDAP(9EG8PB3YY(T5U59 R_3WC7XB_$M_ G[/GC7P[>7E_XFU'18]2UK
M0H(@R:TGV&*>XA2W,D:"8Y=D(((("CKBOI[7/ 'A?Q-IKZ?K'AO2-6L'N3>-
M:WUC%-$TYSF4JRD%^3\W7D\TWQ-\/_#WC'5_#VJ:SID5_?\ A^[-]I<[LP-K
M.4*%UP0"=K$<Y'- 'S3HGQ$U'Q'^QU\7/B%H_BO7[N76+_Q!>Z-<W#^1<Z;"
MEQ);V\%LL@4Q;5A5@K]'=N@X'@/QS\8_$75?BIIFE0>*_BS\-BOB7PMX5DL[
MG4++R7M[Q&2:<O;2SQFZ)CW\-C# E><5]K:Y;_"+QA)KGPKU.&VO=FHG4-1T
M:1)U073,-1>5I  .&DCE8AMJF:)6P9$5O(/%EW^R-X[\00^--:U;2]0U/6-0
M4KJRZE?*#/:S+"DQ9'"Q)%+*JK,=J*7^5N30!XEXR_;(^*'P$^,_BGPOXP\7
M7_BFTTVYU/3H(=.\.Q2;IIK:&70U\Q+>-6GD\V3>N[;NA8 8QN]WUO6_C1X=
M\4Z5X!C\>75]KGCZRMKWP_K-QX>M3_PCBV31OK'VU41%8/'/"D!V']X^QO+X
MD;U'PUXB^#'Q]\2ZNND76D>+=5LY+6XNEP[*_P!EGF6WF0, LL:2F<"1-R;L
M\GBO0-;^'GAWQ'XP\->*M2TN*[\0>&Q=#2;YV8/:?:(Q'/M .#O10#D'IQB@
M#R/XY>._$?P?\;?#76;KQO):^!=US;>(;&30/M#7*0V-Q</=-<QJ?)*B 'RE
M4;^=H."*^9H/^"B7B/QU=W'AJQGN_ 'B[QC=6_\ PAZ^(_"_V>TLM(DDNGCU
M.29KEQ.)($AW-M5%<'8CJ&>OMSQ%\$O"?B[QQ!XIUJTN=4O8(#!'975[*]@,
MI)&SFU+>46,<KH25.58BN,G_ &*/@K=16B3^!X)FLTBBM9I+ZZ::VBC5TCBB
MD,NZ.-5D<"-2%YZ<"@#Q/_@EEXTU3XC^!?BYXIUIK.34]6\=75S<3:=G[-*Y
MMK8,\1/5"02*]8_:#\3_ !4\%?$+P=J'@G6](UC3[J9[=OA]-;QVMQJFV&5W
ME-^YD,2JPB48B"Y=0S -D;O[*7A'1_ /PZUKPYX?L4TS1=,\4:S;6=G&25AB
M6^E"J"Q)X]S6G\2?V8/AC\7_ !78^)?%_A=-:UVP5%M+V2\N(WMMK;E,>R10
MA#<Y4 Y .>* /D+PM^W;XW\-^)_$VD>+[T2ZA_PBT-]-:ZQHSZ%!X=\03M-,
MFF--/&,QI:;'#OYK3>23&6W;*ZK4OVM/&5UXD^'OB#P_XLT?6?"E_P",O#7@
MJ]TRTM8I8KA[^R,MW</.I+"5'D4(B%54Q'<'R17UCX2^#7@[P/8Z]:Z/HRP+
MKS;M5FGN);BXO<1"("6:5VD8+&-J@MA1G&,FJ!_9\^'S^*]-\1R>&XIM5TZ2
M">T:6XF>&*6&'R(91"7,?F)'\JN5W# (.1F@#Q/XV_M'>*?@QX_^(]O=WB'P
M9;^'?M-IK=_';0IHVK203&TMEP2\Z3&%CF1 $8 ;SO"CJ?B/XT\9_#[3?@9+
M=>,+Z>2]U".S\22:5X8;4&U=182W$A2U@CDEB+-;D Q<()6)!"C'J&L?!GPG
MXCU?Q3?ZOIO]J_\ "2Z?#I>I6EW(SVTT$6_:OE9V@_.3N^]TP1BN'^,WQ,^#
M/ARTTV\\:>+[/14\':A9ZE;SP74BM;SM)<VT:?N\^9N-M>1/'\Q CD# 8S0!
M\U67Q<^-GB3XE^"M!L/BY-;6/C3Q%XDTFSEN/!UO:/816-H9;<O;SQB4GS,!
MU?82HP-I.ZJ-G^V#\09-7B\,W'C.2T\7>(-$M]%T_3!X?2]ET_Q1;7:6NIH6
MMXFA= $DG"F5L(P)V!D%>\^!/@C\#O#_ ,1/ -UH>O33>)M*GU#7-'M'U0N6
M.HQO)*9(L8&Z.21T!"L55B-PC.WN/ WP_P#@KXLNTU/P@OA_7IM,U^?Q']HT
MC4A="WU.Y4B6=MDC ,XSP>.N!0!XCKGB7]H+PE\2?$/PK/C.?7]<\2G2[WP=
MXG@\+P&'3-/2>4:O->#;'"QA46Z[0Y9C<V^U09"%]=^,_C;QO\,(_AS+;Z]:
MW44^K:7I>JQGPQ<W!U!I[F&UF=KF*3RK)?W_ )B^8O+QJH8@E3Z?KG@'2=?\
M8^&?%%RMPFL^'A=)9S03LBM%<1A)HI%!PZ,4B?!'#PQD=.<3QO\ !C1OB#XN
MT/7=7U#66329H+B/2;>_:*PGFAD,L,DT0^^R2$..0,HF0=HH ^7/%/\ P4)4
M^)]773K;4/#^B-?OHGA+5-3\/2W.D^)[U;@6[R1WL4I#1AO-9441Y$08S98Q
M+] ?LT?%+5OB-X>\5Z9XBG2_\1^#_$=[X:U#4H+(6D%])"599HH_,?:#')'D
M9X8,!P 36N?V0OAS?^)]9UN^L+K49=0EN+F&UOIA/!IMQ/,D\T]H'4M#(\T8
MD)4XW%L !B*]$^'/P]TKX7^$[;P_H[74MK"\DSW%]<-/<3S2.TDLLCMRSL[,
MQ/J> * /)_VZ='A\5_LVZYX6E65G\2:AI>C1"/>HWS:A;K\TJQ2^2N,_O&1@
M#CAB0I][A3RXD3^ZH'7-?,W[>O\ R*?PC_[*?X=_]*&KZ<H HZYKNG>&-&O=
M6U>_MM+TNRA:>ZO;R58H8(U&6=W8@*H R23658?$?PGJOA)?%-EXFTB[\--$
M\ZZQ#?1O:&-,[W$H;;A=IR<\8-><?M8>,?ASX0^&BW'Q%M+'7;=+VWN--\.7
ME_';_P!IW:S1I"NV1U22-9)8V??N1!\[#Y17QG\1O 7PW\%^$-#UE?&/PT\1
M6 U+6KY/ ]Y=YT2.ZNXPS(D]MO,<D4",!NP&).Q0=H !^F%O=P7=LMQ!-'-
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MKA&4BLGP-^VM8?$K]GGXE?$SP[H-O>77@>34/M>CRZDZ1SQ6H,N]+D6Y!,D
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M$ JN%KZKUK]F#X4>(]$TO2-2\!:-=Z;ID30VENUOA8XVD61EX.6!=%?#9^8
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MA)HD,;)=_#_67N/*N]T4A$MHMXB2AT\J+/E%E1(B"J^9D_;= !1110 4444
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M^)M$U'1[9%LY/M6J:@\PCDF><1;V?S&C,H9RH)7<%)Y"U]!>#O&7CWQQXP\
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M+&4,+J8Q1[6&T[G )7@GG!K=\/:';>&= TS1[,N;33[6*TA\PY;9&@5<GN<
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M317R5\)_VWO%OB?XU:!\.OB'\#M>^&MYXALFN])O6O3J$<^V-)6#@01[ J2
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MC-_T!/ G_@XO?_D6@#HOA<OA]/!MH/#%GJ-CH^^3RH-5M;NVG4[SNW1W:K*
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M (@> O\ A/;&QAC\1:]X8NK*Y6Z@OO#][Y$FX C;(C*\4J$$Y21&7H< @&N
M^%/[*/A;X2>/H?&=CK/B+6_$*:1=:-)=ZW>I<-/%<7YOI9)"(U)D\XG!R %X
MQWH ]/\ ">DZKHND"VUG79/$5[O9C>R6L=N2IZ+LC 7CUKX^^('[8FL>$OCC
MJ_AGQ+XOTWX8W=KX@M-/T?PMK&BSW8UG3"X#:C]JBC88FW,L:(R[#$5<[@V/
MMNO&M0_9BTS4OB.OBR?QSX[D@76(-<3PW/KS3Z4ES$#M"12JS)'N9G\I7"!L
M8 "(% /G3QM\;?VL-.^(NMZ-9^'O"FE&62WTZP@O;F%K2..YN'MX=3\[S Z
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MSQQ@UUWPT\6^-;_QYXN\,^,XO#D<NEVNGWUB^A2SEYH+@W"EYDE&$_>6TBJ
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M7_ 7PIX#\.>%Q<^&?#5SXLTNQMXKG7K/1;>WEGNDB599U*H"A=@S<=-U>F4
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MPV_:9\(V_CW2]?\ B9X3DNY'M;_PW'XONXGTB\A/E3VTD9=F1U9"2&P2&#8
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MJ_C[X7>#_BII2Z;XQ\,:3XGLD8O'%JMG'<>4Y4KOC+ E'PS ,N",G!KS6Y^
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M+:1K<W=EH6DWOAC4X@\LPMG^T6K2LJLL664<%@Z\A0S<AX>TS7+'X16>N_\
M"K_BGX1\+Q"VBT)/AS\5K[49)DFW6\2"TN;@!%5Y8)%41D93YQL#H_T;:?M#
M?";3O&?Q"\6Z/\3?"_B#49=+MK2/0K?5(4EGELXKBXQ"Q8^<'%R!NC5@"C#)
M(8+T&BZPGPX\/? KPYH=^/[+U/41IMT+EHY)7MQH]_=*I8  $2P0_, ,XQT)
M% 'SO>?$#XW^*Y+6'2-8^.7@';+B>Z\0> ]!U9)$*L<JMO!&R[2H!SNSO&!P
M37/^&_VKOB9;6[6&B_&;PWXB\K?<W6K_ !0^'^H:$8P2BI%$UJ5B<9W'E0W/
M5A@+]N>$O%.H:O\ $OQ[H]Q*KZ?I)L!:($ *>9 7DR>IYQUZ5YAHOBC4M<_9
MA^"-SK,@U:Z\20>&X-7;4$$K77GQPM,7S_$S'.>N: .2\._M7>-=:\!3ZEHL
M_P )/'NL6#+;7,6D^,9=/$\^5W[$N;;$> V[#2'@8R3Q7;Z?^T[K-SIT1/PZ
MFO\ 5A;^;)I^C^)M(NY))%3<Z0J+D/)T./E!/' Z5V5OH_@W4?B;K?A5_!.B
MF6QTFRU=KUK*%O-^TS7<>S;LX*FT)W9.=_08Y\('P0^#%Y\+KOQ_>_"70+?6
M;S6Y],>?2$:SG0RZJUAYT<JY9' ??D8YR!C/ !Z!;_MA6.E>$KG7O&7PU^(?
M@B""<0F*_P##\ERQ4[=KYM_,&"S$8SGY3D8Q6[X6_:\^%WBO1H]1BUVXTU)&
M9?L^JZ;<VLXP<9,;Q@@'MZUR>G_LE?"CPM\483I6J>+-%\57UM=ZE;P67B._
M2-8%>..8H-Y1%4W$2A>#AN!@'%B+]G'QKIWQ U?Q#:?&?QKIFCVY7^RM(^WQ
MZA"R?9PLAN$N8GRWF&0J 2  AX(H ]4T;XV?#_Q!IT=]8>--"FMI"RJS7\2'
M*L58%6(((92"".U>??#/XA^!Y_BM\7]:FU_1;?4?[6L-&2\?6V<7%G!IEK<1
M!4DF:- LU_>#]RJ*226!?<Q\3M?AQXZ\1>&_AKXKU/QEX8U#3?'-I8I>Z)K'
M@"RN/-NKRU:64/-$\#K%][IE^.2<FO/6_9,\3ZAXWO?"%M\%/V?I[ZPTFSU3
M4G,.I6RI'=7-[#$D$@WEFV63.695VF0 !MNX@'WY_P +3\%_]#?H/_@SA_\
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M!Y-H6FP2_M7>-[]O,^TP>"M @3$SA-KWVL,V4!VL<QKAB"5^8 @,V?6:\O\
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M/V)/'?@FPT/3K7PMJ.K-?Z=;W[^1?RZA;7,,5PI!^ZH%M(@5@#O0BO;OB_\
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M:WX*U/Q[\)O#'AC7]"O_  [HJ7!AL++589FAEAMEBM,8<NQ5&F '.>2<X!H
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M/_XJO._CE\4_B;+\*O'6GV?P<O?M4FDO;Q2S:W:>5(TZM$ I#99ESR!ZKZT
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MJ% 'P5\*/#W[)?C[Q;IM_P" M,\4^/-.74XK:+3K32=8O- T><_/'(\;Q>1
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M\#_ SXGZ]J]NK:WK^JZK<R2PW"XEMY)S9:?*I3*C%A%8\#!)3YL.S&MKQ?\
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M!^M,UGX?>"/#OAGQA<R>%-/DL=42YO\ 6H(+-"^HDH#+OZ;V8(HY/.!7<44
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MW@K4?%FOZ!J'A#1[W3A%I^OZA:3P1O!Y7[B.*X8'(VF+RP&Z;,=JZOP-X6\
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M^%=JMS%>+'H-N!/"DB(_&>!(JL.O=17ME<M\*O\ DE_@_P#[ UG_ .B$KJ:
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MV#5]7U74D6(F1&@N+N5E5]P&3M.".1[FI/B9X3T_]F+X:ZQXO^&QTCPE;:-
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M#^,.CZ4/%/PP^(/C&"ZO9KWQ%8W<!AO)K=H+>:*2)2%"!4<>7\R]3\U?7E%
M'@/B/X]?#OQMXU\%:/:>(M"U"Q@U*6\OQ=71MI;%[>#S(),,R%?WDD0PP(8/
MT[CJ/ 7B'0/%/Q.^(_BW2=3%];Z?:Z=X>N#;LDL#&WCFO?-CD1CNRNIA""!@
MPGKGCMM;^'OA?Q*;HZMX=TK4GND,<[W5G'(TBE=N&8C)XX^E>7:E^Q1\%[WP
MW>:):>!K+0;.Z97D;0I)+"7(*G(>)E()V@''4<'B@#,0OHO[-OARPL+FUU5O
M%.JVXMH9+994OK*_U#[3-"T4JD'-E)/O5AP%?'0&NS\8^'M)U?XY?#:6-+.'
M7=&@U+459K;]ZUD85MI$20#@>;<6[%20#LSR5%9.F?LN:%H6N>"+W3_%'BV*
MP\)S^=::/=:U+=V<F('@C5HYBV B.VW85/N1Q5WQ;X2^(.C?%>;QEX-7PUKE
MGJ&FVVEWFC:_<7%C)"(7N9!+!=11S@;FG0-&8>1$IWC % &_X1\3W.J2>.M6
MEUFWN-&M=2EMK))HQ"+$6T217"2,0N1Y\<S[B3\K#D 8%FT\6ZOH7AGP1_PD
MNF%_$.KM:V.H1Z8NZ"UNG@9Y6SDXB#HR@Y/5>37RKXQ\5^-?#O[/>D?"G7OA
M3\0=(OM?>+2=7\1Z'86FM64%G)=QC4IBUM--,N;62?8TD 9FP0H(./<](^)?
MA;XG_&C2I_#WC/0=9TC0M)GG8Z3K-O,S7$SK'MEC60MM"+E6V@9)Y[4 >KV^
MOVUSXCOM$19A>6=I;WDK-$PB*3/,B!7Z,V;>3*CD J3]X5I5XGH_Q#U*Q^&7
MQ1\>3W5S/$VMZI'I=B )?L*6;#355"2 R236<EUC Q]I9?FV[FU-5_M?1KSX
M3>#;:Y$-[/=->ZXNG$Q(]I:VKO,ZO@80WLMBI089TE8;2GF8 /6**P+35WO/
M%VJ6NW4+>UTZVBWM- BV<[R%FW1R?>9T"889  =>#G(SM&^*FA:MX#\-^+9'
MN--TS7_L2V:7<)\T273(D$;JFX*Q:15)SM&>3CF@#L*JZEI=GK-F]I?VD%]:
MN5+07,:R(Q5@RDJ00<$ CT(!I%U6R?5)--6[@.HQPK</:"0>:L3,RJY7J%+*
MP!Z94^E64=9!E6##)&0<\@X- '"?&7X1V_QF\,VFBW7B#6_#T%O>+>,VBW"1
MB[ 1T\BY1T99H&WY:)AABJ^E8G[/'P$MO@-X>U:U:_M=8U?5KYKV^U*UTU+
M3G&$#1(S!F5>#*Q:20_,[,V2?6** /*M<^%,5E\/O"G@#2Y;F?2DO+?^TKF]
M!DEOXHW\ZXDN9D4'SYY 9'E^4O([$G+&K=I:3Z_^T1?ZE+%(+'PUX<33K.=%
M*H]Q?7 FNXW)^\4CL=.9=N-HF?.[<-OI5% 'B>A>,=17X7^//'-F=,36M2OK
MRWT1K^%(0TL<AL[*WN'0*7!N5P"6)VR@;AVQ?BC^S[X<\3?\*RT>72FU7Q38
MS6,,OC&:;9KD5C9C?(SW\12Y4R'*EXV&9)^<;C7NNH>'=+U731I]W86\]B)H
M[@6[1C8)$E$J/CU$BJ^?49JBWA.*;QY'XFG\IY[;37TZTV*ZO&DLJR3[COVL
M&,-OM^4%=C\D-@ '@\/PS\8-X]UCPQX$^+7B?3-)T&2SOKA?$B6_B*U=YVFD
METYFN$%W@1BV?<;IF"38&."/,O!O[-NG>'DUGXC:C\.O#<5Y9"\L[2Z^%^J:
MIX1OKJ..<PI"+..6*(.Y4Y;S?G^0#=\M?15[HOB/X:_#7XIZY9VD6O\ BV[D
MU35[&"W629[LB-OL4#* &9@B11;5]  3P:J>,O#"6&D?"[X7V]Q<WMD9K87-
MU>ME[BUTZ-)/GD R)6D2!L@ ':X) ." >#6WQY\;>&3IEWJ_B+Q_X%DU*YET
MJVTWXE^#;74K::4HLL<JS::+=HPJI,&WM)\H8E1@$^J_#W]I;6_%EA:&SL_"
M/CJYN"\"1^#?$D8E,L0/F[H;Q864<$@+O(VMGH"?0[J_;Q'\>K721%!+8^%]
M$_M2<SQ*76[O)9(+5X7Y(*PVVH+("5XGBQNR=GG5G\'OA/XNU?X@^._$6AZ.
M]E9:I<'[9JEG%;+IGV:W2"YE$P?'EMY3.7.W@G(ZF@#I="_:K\(WFJPZ1X@L
M-?\ !&LM:0W4EKXBTF:W2/S.-GG &,D'()#8X)SCFO4-!\6Z'XI\_P#L76M/
MU?R-OF_8+J.?R]V=N[:3C.#C/7!]*^9-/_9B\5_#'X;>"-+\-?$KQAI/B-;"
M'1[V*$_V_HQNY4S/<S6UWR(=XDP5*8\P<=JP]1^!_CD_$>STJ\T'X>^-KJQT
M*VN[KQ'X?O)_".N6TT=RWV<ND!G!67;=&,JJ(S1SJ6C"@2 '3_#;3XM<^,'@
M7Q"SSQPZG<>+=8M8H[B2(J&GL8=DH1@L@X8[6W+G:V-R@CZFKXG_ .%T>!/"
M4?A]XYO%GP9OO!M]=>&[2Z\<Z#)J>D74MVT3S+<7MM)+"0&CW;_M<14JQ8E
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M65[/KEC!,VC:))IMT\)E&522W2)W.X(?++%6 .Y6 KW3_A<?BW_HA7C_ /\
M [P]_P#+6O/OC!\5_$%VO@MM0^$GC70[:V\2V=R9[J;2)_,*"1A$D=M?RR-(
M^-J@)@DC)'6@#Z5KY_\ @7J'CRVTRYT?2=,\*W?AK2]?O;.2]FUN1KPH;II9
M#Y<,,D8<"4@(9>PW%22![)X(\9:7\0O".D>)=%EDFTO5+9+JW::)HGVL,@,C
M %6'0@C((KP-?^">_P *)(+Z.Y;Q/+]NU*YU:X$/B*[MD>YF<L[B.)U0=0O
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MOA8G1Y]9T$:U9K$OB%(XY9!#:L&(\YUB)2-]K-V!P:U/!WQV_P"%N?#77O\
MA8;6OP^T;4;FUT;3->\+^))2T]U."ICAN$2-XIXIE\LKCDCG*GGU_P =?!SP
MO\0]-\*66K6!-OX6U>TUS1XX)6B6VN[4,(&PI&Y5W'Y#P>XKRKP]^R/<:MX;
MO[;XE^-)/&6M76N:?KJW^EZ9%I$,,UG)YD.V",LI+%GWLQ.[(Z$ T =!XG_:
M]^%7P]^*C_#/6O$LEOXDL;..ZO'DMY)(+2-D#*;B<+M1BI0_-C_6)_>K8_X:
M?^%\USX:@M?&.GW[>(M1;2M/-FYE$DZOY1!*CY5\TI%N/!>1%!RPKFOB#^SY
MXGUKQGXQU3PEXNT7P[I?B_3Q;ZS9ZCX<74;A[GRHX&N(IS,A7_1X($$3*T8*
M%RI9C7GT_P#P3A\#>&_@'XP^'?@34;KP[J?B%[5_^$EOE-[<VRPW4-PJ( R$
M+NB)PK+\S;N2* /<OV@?$/BSPO\ "W5M0\&1)_:R;1)=M;M=-8V__+6X2W4$
MSNBY*Q_Q'&> :\^TKPF^J7GA/XA#XT^(_%_A?1!=G6M.U*2UBLI[:6R=626U
MM+6+?*DC6[A)]Q0!\ %N?H&\6X>RN%LY(H;LQL(9)XS)&KX.TLH92P!QD @D
M=QUKY^^"/P6\>>'?B7XW^(OQ'OO#MG?:Y81Z?+X>\"QW/]FW8C8M]ON%F&][
MLJWE *,!%ZN6&T Y+]E'XU?"[1-6UWP9X<\8:F=#O=9<>&]*UC2)[&TL@V[-
ME93RY$R[XY&501MSM50,"O<=:_: \#Z#\5-,^'=WJY_X2B_4%((H7DCA9@3&
MDL@!6-W )16(+8.*^-?@A^SE\6?C5X.AT;Q/XOT6W^ -[JLU_:Z/8Q3)K200
M79:WM?WD*?9,-'N=T;S1EEX)RN[\1/V&O$?B;X>:IXF\6>*=:?Q]JVK)JVO:
M+X,NW;3M1F^VX@ 9XA<%(+5DC0;AL$;$=68@'W1INJV6M6@NM/O+>^MF9E$U
MM*LB$J2&&Y21D$$'W%6J_/&#X6']DC]J6Z\16'PF^(WB+P18:9!8>"[3P'"E
M]:-,T!%]/J*^<'$A>8JDDP^;=(WS>6I%?]M/XT_&77_ G@_POJWA^Z^!%SXJ
M>\M9+T^*K&6T216C4+>72X\NW\AIY&*98ML4*QXH ^W/C3\(M(^-_@&\\+ZQ
M+/:(\L5U:WMJV);2ZB<20S*#\K%'53M8%3C!%<]\#_BW=^*K_7?!'BH?9OB!
MX69(-0#1"!-3B*C;?VT>XGR)"2 >S*0<<5N_"/XH^!OB+I-U8>"?%]GXOC\/
M^187=U:WOVQ@QA1T9ILGS=RD'S 2"P<$[E8#G?V@O@QJ/Q#B\/>)_"%]!HGQ
M&\)WJZAH]_,"L5V@!$NGW3)\_P!FG!VN%.00K8.TJ0#V"O$OVV;*?4_V3?BI
M9VL33W-QH4\442#)=V "@>Y) KH_@3\==#^._A>YU#3D;3=:TJZ?3=<T&XD5
M[C2KV,E9(7*G:XR#MD7Y77!'<"M^U% +KX >-869T$ED$+1L589D49!'(/N*
M .Q^'-A<:7\/?"]E=Q-;W5MI=K#-$XPR.L2AE/N""*Z*HK6W%I;0P*\DBQH$
M#RN7=L#&68\D^I-2T >6_![_ )*'\<O^QQMO_4?T>O4JX'X;>&-3T#QE\5;Z
M_MO(M=;\2PZAI\GF*WG0+H^FVQ? )*_O;>9<-@_)G&"">^H **** "BBB@ H
MHHH **** "BBB@ HHHH X_X;_"GP_P#"J/Q*N@PS1R>(M=O/$6I2SRF1IKRY
M8%V'95"JB*J@#:@SEBS'L*** "BBB@ HHHH **** "BBB@ KS+]IKQH_PZ_9
MZ^(GB1+07SZ=H=U,+=I-@D_=D8W8..OI7IM>5_M36_VO]GOQS!O,9ET]DWA0
MVW+*,X8$'Z$$4 =3\)O^25^#?^P+9?\ HA*M>/O'VA?#+PI?>(_$=^FGZ59K
MEY&!+.QX5$4<N[' "C)).!7SW^QC_;'Q0CU7XK:_XDU2XU26]U'PX-'CD6/3
M([:UN?*@*0*,*Z^4[;AR3/)VVA>VBEF^,7Q^O[:0>=X)\!"-'AEB/E7FM2*'
M!P\(#?9XF4Y20X:8<9% &3I7[4.OZ=XST"V\=_#;4/ OA#Q/)'!HOB"^OH9!
M',T)?RKZ-3_HSN^U(QEMQ)SM(Q6%_P %./\ DQKXG_\ 7*P_].%M71_MW)HK
M_LO>+_[:=$P;4Z?YOF[#J N(_L8;RP6VF?RP>V,YXS7(_P#!2$WY_8$^(/\
M:@MQJ?V/3?M0LRQA$OVZUW^7NYV[LXSSC&: /JVBBN,^+'PRMOBSX2;0[C6M
M:\/NLR75OJ.@WK6MS!,F3&X(X;:V&VL"I*KD'% '9T5\/:'K?[3GPV^.'BKP
M!X9U;2OBIX9\/Z59ZK;_ /"<!K+4;Z&1I-T$%W#'LDG)1D\R;"*2F0 #7IR_
MMKV'@&33K+XV> _$GP;U&\0%+R]C35='DD:1E2)+^S,B[]B[V$B1[1G)Q@L
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M_AWXA?'*S\/7,_B?X4:-<ZI$7=8=!\2J4D0*"JJ)8@=Y.1U Z5[A10!XA?\
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M^BO$])^!7CWP5IFE6WAGXZ>*K_[ _P#J/'&GV&LP7,1#965XH;:Z9LL"'^T
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M\1:_\&?@7\/QXL7PQHFJ^$Y-;UO7;-C:7:V%L;-$M8)-V(F;[9&K39! C8J
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MX<0ZO^T+\4M&^+5U;W&C?#_1K:>+PIIU]"5GU7S@ VIR1N,PHRC$(P'*-N;
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MXY%#*RD8((/4$=J\7^$%S<_#7XH>(_A1=H4T5;4:_P"$F2%EB73BZQ7%FK!
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MP([5\Z_M!:YIOAK]M;]GK5=7U"UTK3+31_%$MQ>WLRPPPH+:WRSNQ"J!ZDT
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M!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC#QOX]U*RU_Q4W@KP5X\N$\->&1KC-I,<T8BG^V($52^9)IP%9F3:Y#;B-U
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MAJ[L;M9)[B+6[FY>YMO^6EN#+(QC#<?,N",=Z /LBBOF+_AW)\$_^@?XD_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2>$OV=/"&F>+]'B\/\ B5%NIK[3($1([:26[FEV(J$JJX<8"G &!VKV.B@
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M#T!)"J!Z3\)?A=H7P5^'&@>"/#4<\>B:+;BWM_M4QEE;DLSNQZLS,S'  !.
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M*\G^)6G6^H?''X1&XCWFW?59XOF(VN+90#P>>">#Q0!ZQ1110 4444 %%%%
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ME4A?WK!LUZKX%^)GA7XF:1#J?A;7['6[.4$J]I,&88QN#+]Y2"0"" 0>#@T
M=-1110 4444 %%%% !1110 4444 %>?^,=%N+WXM?#O4(]OD6*ZD)<YS\\*!
M<<8ZCOBO0*X5_$^HCXX1>'?/']DMX=?4#!L7/G"Y6,-NQG[I(QG% '=4444
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M_@9\!M/^!'AW5]'L?%/BKQ6FIWSZA-=^+-3^W7"RNH#[7V+@$C<<@DL22>:
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MHULCQNIRK*P3(((!!%=K10 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU[KX1_9F^'/@K2/&FG6/A_[7%XS<OXAFU6[FOY]3RA3;-+.[NR@,^%S@%V(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBP^!H/$]R-1UB_BNA%@A[J.,A'(8RRNB@%03N95;U']GOPI\+O"7BB_^'_\
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MWB5F8DA(H[A41<GA5 4#   &*^H:* /E7_AUQ^S%_P!$R_\ *_JG_P DT?\
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M&1U!! +#.&(/I5% 'A5M^Q!\%[3X37?PR@\)W,/@:\U(:M<Z1'KNHJLUR$1
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M].^P7'B/4WUC5'\^23[1=NJJTF'8A,A%&U<+QTKJ*** "BBB@ HHHH ****
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M/A'^T9XTU;PKX#\13ZMK&G6QO7CETVYMEEMU,2M*C2QKPKS(A5MK9!(4K\Q
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M8/A]JMMJ%EJ-C:ZY%KM];O;QW8<DO";%Q(RO(YR&0%=HP""Q](_9>^&WQS^
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M^<Q?V@4D7$MG<GB&387X<[!R=K\(*]E\(?C!^TQ\4/#7B3XTZ'H/@/P'X3U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKX3^"/%GPS^*<D'B'Q_K'CL^)M&-[=0:Q?0>7I=W;R1J_P!DMT2/]S+]I/1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6;JFE76H7VFSP:S?:;%:2F2:UM4@,=XI4CRY3)&[!0>?W;(
MV1R2.*TJS=-\.:;I&I:G?V=HD%YJ4BRW<JDYF95VJ3SV''% &E1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>aytu-20230630xex10d49002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20230630xex10d49002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (\!%@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q5H5QXDTEM/@U2XTF.9
MU%Q/9G;,T7\2(X(,98<;U^8#.,'!&Q10 U$$:*HSA1@9))_,TZBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]T;XC^%=5M-)@-UJ$]GK%O*EI$ Q,DA5R$7"L<GCY3Z5:_X4-\,_^B=^$_\
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M17BUI^U_\-;_ $*PUNUE\67.C7[0K9ZC#X&UQK>Y,KA(A'(+/:Y=F55P3N+
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M_P!IC5;'3KCX90:QJ6NZ=H5[XFD@OQX>N[ZWN)D&E:A(B$V3"9E\V.-B!QE
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M%% !1110 4444 %%%% !1110 5X9^U#P/!/_ %\ZO_Z8=2KW.N+^*GPC\/\
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M*K6^IV=WY'D7<$WGQ>?#Y<@;S(^/G7!Y7YEY''(]:LT %%%% !1110 4444
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M2<U_P\<TS_HD'C__ +YT[_Y+H ^P:*^/O^'CFF?]$@\?_P#?.G?_ "74MO\
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MMO@5^V+H'QW\>2^$;7P5XU\(:L-$7Q#%_P )5IT-HEQ9-,(EDCV3NS L3@X
M^5N>*^)_'_@CQ]\'Y=9'BGQ/\,(_"EQX@@TC58I;S5;?^SC/;QW\]E!%M'F1
M W;R,\;F2X\S]X06:-/2_P!C;4K[4OVS[@ZM%/%K,7PL@BO#?WOG7\C?VGF.
M6[@R?L<KPF%Q:[G,<;1;FW$@ 'Z%4444 %%%% !1110 4444 %%%% !1110
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M#+>(H-0UO4;74-=U<VS^(+Q[JYCMXKZ:"&,LSO@+'"@P&(SN/)8D^X5\[_\
M!/\ T*]T#]E/PC'?1+&UW/J&HP%)4D62WN+Z>>"0%21AHY$;'49P0#D5]$4
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M8J2#]: /&K?]BC]GV[MXIX/A/X0FAE4.DD>GQLKJ1D$$=01WI_\ PQ!\ O\
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M#O2--\?:A9:OXHLT-O<ZG8.Q2]"DA)B&1-CLN"R\@'/S-UKM* /"?BE^QSX
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M;?\ R-7NOP[\90_$'P1HOB"*%;1[ZU26>S\T2-:3X_>V[G ^>-]R," 0RD$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]X'I\P% &'^V+>Z=H/P<@\2:QJ+Z9I'AWQ'H>L7LZHS@01:G;^9E5R2 I+8
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MOQY_\+<__&: /J&BOE[_ (82'_1POQY_\+<__&:/^&$A_P!'"_'G_P +<_\
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MZ-?VU\WV-HS'N$=Q(ASY$>2,9RV O%8_Q2\&_'FV\'^//&7Q%\6^!=,M]/\
M!FJ:9;OX0TFZDF_?F%V+"ZE*?\L%&>>&/&<$ 'UKX(_Y$S0/^P?;_P#HM:VZ
MQ/!'_(F:!_V#[?\ ]%K6W0 4444 %%%% 'D_QC^+WB_X:ZM86WA_X2Z_\0[.
MYA,CWFB7=M&('#8*.LKJ>F"",@\^E>??\-4_$S_HV3QY_P"!MA_\=KN?B]:_
M'N?Q-;M\+M0^'EIX?^R*)D\66E]+=&YWON*F"15\O9Y> 1G.[MBN'_L_]L/_
M *#7P5_\%VK?_'J -S2/VD?&5[86LM]\!/'>G7,E^MO+;DV<OE6Q7+7&Y9L-
M@\;!\QZUQW[,WAO3_B0O[2-GJVC:O8Z=XG\67EK>6>J0FW9HGLXHG5&1\_=R
M"58$-G!XK=L+/]KB*9S>:G\&KB(Q2*JPV>JQ$2%"(V)+ME5;:2N!N (!7.X=
M/^RHGB2/P5XF7QA+I<WB8>*-2^WR:*DB6;2^8,^4LA+A<8^\2: -+X#^+[PV
M>H?#_P 1Z@^H^,O!RPV=[>SG#ZC R9@O "[,?,488L>75Z]7KPS]HFUG^&NH
M:5\:=+>]'_",@0^)[.VE8QWNA%B;AVBVL&DMBWVE2-K;8Y$W8?%>VV=Y!J%I
M!=6L\=S:SHLL4\+ATD1AE65AP000010!-67XGT:3Q#X>U#38;ZXTR>YA:.*]
MM)&26!\?+(I4@\'!QG!Q@\$UC^+_ (J^$_ EU':ZWK4-I=R*'%JBO-,%.<.8
MXPS!201N(QD8S7)W?[5?PHLKQ+67QE:?:'TZ'5UC2&9R;.5 \=Q\J']V58'=
MT['D$4 3_ ;XBZIXOTK7?#_BJ2T'COPEJ#:5K4=J BS?*)+>[2/)*QSPND@S
MP#O49V&O4:^71XY^&?C[XT6/Q:^'WCG2;C5_#VD?8O%T1GD N= D#S1/Y1B8
M[XYMDJ.@7<K,K,59,>A)^UU\(9#>A?&MJQLHDGN@MM.?L\;J61W_ '?RJP!(
M)P"!D4 >P5P'Q]^)-S\'?@QXQ\;V=G#J%QH&G2Z@MI<&0)-Y8R4)C5F7(R V
M, D%B%!(SO"W[3GPO\:>,+7PKHWC&RO?$5U++!#INR1)7DBB,LB891AEC&X@
M\@8/<5UFH:]X4UWQ')X.OKS3+_6HX8M3;1KADDE6-)0T<WEG^[(BD''!"GTH
M ^#_ (,>-?B=\6?AQXDU34/B#XK\.6>@VMMHFFQV5E+%J.O:G;0JL+)]M0Y9
M[B.7SE7&\@B1@BL3T\GQF^+_ (>DUW5_^$OA\<GPK<Z#I$&CZ%]C6'7Y)-&6
M[N[B3$+2#SI9 T9C9%*KA5)!S[-JGPJ_9[_;%TI"^D6'BJT\.WUQ'YFFRW6G
MM:W4CL\Z,T+1,6+LS,I)^9B2,G-5_$.C?LX_"+XA^%GU:UTK2O%_@O0(8=+:
M07,\]CIB*8HGDQN#A!&RK)+N9?GPPW-D Y#]E3XR>.O$OQ7\.^'?$OB.Z\06
M&O?"O2O&\JZA;V\<MI?SW+QRQQ&&*/\ =;<?*X9@5'S=<^@?M$>%9/ 'B*T^
M/7ARWNI_$?AO3QINM6-NGG'5="\[SIH%0_=EC8M+&R8)(*MN! &K^SO=_ ^]
MU+QE)\'HM BO/M,)UY-%MS"8I0ACB1D*CRQB)R$4!=QD;&YW+:OA?]J/X3^.
M/%%OX:T7QQI6HZU<QS2Q62LP:6.+>)6!90"J^5("<XRC#L: /0/"_B73O&7A
MS3-=TBY2\TS4;=+JVGC8,KQNH(.02.]:E?-OP2^*/PK^&%QXE\'P?&/2=8M$
MOKO5-,TZ\N!&NE61<*UM%.[GST24OAMQQN*@ )@;EQ^W5\ ;6UM;F7XJ^'EA
MNE9HF\\G<%8J> ,CD'K0![M7D'[0'PCU7QHFA^+?!4]OIGQ'\,7 N=-O)"8Q
M>V^09]/F<9Q#.  2RL%8*P (R.DTKX[?#W7/A[>^.K#QCI%WX1LH6GNM6CNE
M,,"#J7[J>. 1D\8!R*L>+_C-X$\ :]INB^)/%VCZ)JVHL5M;2^O$BDDPI;."
M?E&%/)P#B@!/@_\ %32?C+X TSQ/I):'[0GEWFGS'%QIUVH GM)UX*2Q/E64
M@<C/0@GM*^>/$UG;?LT?%5O&=@HL/AUXSO!'XFMQ<*EK8:K(P$>IB,KA/-QL
MF96 9BCL"VYC]"HZR*&4AE(R"#D$4 >)?MO_ /)H?Q=_[%R\_P#19KT;X5?\
MDO\ !_\ V!K/_P!$)7#_ +7T-E>_LU^/M/U"62&UU'3FL&:($MF9A&,<'!^;
MJ1@=^*]2T#1H/#F@Z;I-JTCVUA;1VL32D%RB*%!8@ 9P!G@4 7Z^?_V:_#-Q
MI?Q7_:"U>3=Y&J>+8_*RF!^ZLH%;!SSR?PKZ KS/X*?\?_Q)_P"QNNO_ $1;
MT >F4444 %<%-\??AA;RO%+\1_"4<J,5='URU#*1P01YG!KO:_GZ\-:GX<\'
M?#SXD:]XG_9^'Q#TV\\1WFDCQM-K-S:IITA,<D=NJ1@JKJRA_,^4L)3&258J
M0#]Y&^(OA1%T1F\3Z,JZX=NE$ZA$!J!RHQ!\W[WEE^YG[P]:MZ#XLT/Q4+PZ
M+K.GZP+.8VUR;"Z2?R)1UC?83M8?W3S7Y0>+/"UEX&^(?[ >@P^(/[4O('L[
MB:T-Q=R>4LMY PE59I"J(YWH%2-"/)()90BITGQ+^*>D?\$XOVD_CA!I7A^]
M>S\>>'XM6\/_ &F1IXFU0NX*E<@F'S)I&8EPP$1522RX /T8O?CO\-=.O)[2
M[^(?A2UNH)&BF@FUNV1XW4X964OD$$$$'IBKWAOXL>"/&6I?V=H'C+P_KFH;
M#)]ETW5(+B7:.K;$<G R.<=Z_%/Q?^S>GPPUW]G'0[WX9S_$+Q%XCT.\U?5O
M"HO6L[C499#(Z(9X0LB^7&$?!)(*LI."17ONC?!OPAX4^ _QJ\2:U^RKKWPG
MU:Q\-2PV=S%XCOK\7(D90,!Y1@QR+%*WRGY$;G&00#]1;SQ9H>G:M;Z7=ZSI
M]KJ=PRI#9372)-*S!BH5"<DD1N0 .=C>AK5K\"-"\.>!_&W@GX4>#?"_ACQ?
MX3^..J7UO+!X[UJ\DLM.O"SE]R!IF 6-701O$JLVU2>7Q7V;^V7\._$^K?M%
M6WBSQKX/N_C)\*?#.C6VGR>'O".O307VFR2(9);BZMT<2-([ D%3&'00 D["
M" ?I517XN2P>$])_81_:(E\$>+?%+0/KVC^=X-\3PF&\\.L+TJI)$C*YF0*I
M<!2?LP##*X'?67P5TO\ ;"_;AOO!'C+7/%6FZ%H?PZTV]LTTZ[$#I(D=BA">
M8DB^4QN)7X49)SGKD _66BOQZ^-WBCQM\!_V1?BE\,M,\=:S?Z+H?Q(A\)P7
M,A5;IM*ELGN'M?, W!68 '!&1N7A&9#V/[%7AGX6I^T5X*_LGP[\>=&U'3?M
M<FEMXS\E])1W@D$B.$A&S<I<@Y4%E7))(! /U4HHHH **** "BBB@ HHHH *
M**Q_&.O'PMX1UO6EA%RVFV,]X(2VT2>7&S[<X.,[<9Q0!Y7^Q_XZN?B3\&?^
M$AN;[4M0-UKVLB*75I5DN!$FHW"1HQ4!0%50H"@     "M[XO_'2S^&%YI>A
MZ=HM_P"-/&VJ@RV/AC1MAN7@0CS;B1F(6*%.F]R 6(5<DXKGOV)]/TZS_9:^
M'EUIMD-/BU73AJ\T E:3$]RS3RG+'/+R,<# &> !Q3?AIX+2X_:A^,7C6\NS
M>W<46E^';"*>/<UA;K:1W4JQ.22J2R7"LR* "T2L<GH +XF^,_Q1\)VT][-\
M$=1UJU,R1PP:)K5K/<A2A+.Z,5  ((X)ZBNJ^%O[0'@SXNL;;1[^>QUM(O/F
MT#6;9['4H8\\.UO* ^WI\P!'(YKT:O$?VE/A1X"\?V6FW/B;P?KFJ:Y Q_LW
MQ#X2MY%U?2I%^9)8KB(ATVL0ZJVY"R@LK8H ]NHKPG]C7XRZ]\:_A/>:AXEC
ME;5='UBZT5K^XL6L)M1CA"&*[DM2/W#RQR(S1C@$G& 0![M0 4444 %%%% !
M1110 4444 %?*-^G[0#?&CXMGX42_#6/P_\ VY:?:!XRBU!KK[3_ &/I^[8;
M=@OE[/+QGG.[MBOJZOCBZC^#_P 0+GQ_;_$7Q[<:3JE[XGOXM0TNV\37&FHZ
MVL_V>U9H8I%&X06]N-V,ML!.2: /1_ 7_#4T7C#2V\;?\*?NO"OFXU"/0/[5
M@OO+((W1-+O3<I(;:PPP!7<N=P^@*^7O@/\ #G]G_P %_$>SN_A[XSNK_P 2
MS0RP1V3>++N^6>,H6=3#)*RM@)NY'!0'M7U#0!R7Q1;QVO@^Y'PXC\.OXJ9T
M$#^*9)UL8USEV98%+N<# 4%>3DMQ@^/>'7_:YMM:M9=>B^"NI:0K$W%KITNK
MVEQ(N#@),ZRJAS@Y,;< C'.1ZU\6;OPW9^%ED\5>);CPKIGVA +^UU233W,F
M&PGFHRG!&?ESSCVKYZU#XF?L\7=A<P0?M*75E-+$R)=0_$25GA8@@.H>4J2#
MR P(XY!% 'S?^RI;>(M8_;@^%?B+Q/!I^G:UK?@'4_$UQ:6TXV%=2U;4[R/R
M5+%B-ERC;<EE!^;D&OU)KX*_8UT>VLOC_P" @'DO63X#:!/'<7<AFD4R7+LV
MUFR0OSE0!P% 4< "OO"YN8;.!Y[B5((8QN>21@JJ/4D\"@"6JT^F6=U9&SFM
M();1NL#QAHSSG[I&.O-4K?Q;H=W/'#!K.GS32$*D<=U&S,?0 'DU?6]MWGF@
M6XB::$!I8PX+1@]"P[9P>M 'DOQW_:4\!?LVV=I-XFD*7-Q;3/%:6B)YIAAA
MED'WBHVLZ) O/^MN(EX#9')>+_VGOA!X=\7:UX/MM-M/$6OZ+/863:?I]O;8
M>]O;D00VL;R,J>;G+L"0%522<C%7OV@OV1/#O[3WB[PSJGBS6;RY\,Z7%M_L
M.UEEBCN5992Y\R.5<;G-H^=I_P"/4#^/(XW5_P#@G?X.7Q1<^)O#NKWNE:\E
M_I^K6,NH37-_ MY:WANC+<QFX4W&]FD7&Y-HD8\GF@#9\&?MK_"WQ9XP\.>#
M+/1M5L;F_DDTVY6ZTQ8K?1=0_>!M.NCG$<[&.4;5RIV_>^9<^_\ B#P5H'BO
M2K;3-8T:QU/3K6:&X@M+J!7BBDB8-$ZJ1@%" 01TQQ7QKX?_ ."=6L:#\5],
MU6[\:6?B3PM>Z_'XS\3/?61@U"ZUN(NZFV$6$BMWED,FPDLNP+F0'C[DH Y[
MQE\/?#'Q$M;.V\4:!I^OV]G.+JWBU&W698I0" ZA@<'#$9]":RK[X(_#_4]9
MU75KOP9H=QJ>JVSV5_=R6$9DN8'5%>-VQEE*QQ@@]0B^E=M10!\E_LU>!_#W
MP\_;+_:'T7PQHMCH&DQZ9X;E2RT^!88@[PW3.VU0!DDDD]R:]\^('P/^'WQ7
MO+.[\9^#-$\47-FACMY=6L8[AH5)R0I8''//%<K\+=)6+X_?&O4_[-LXWFNM
M*MCJ*RDW,H33XF\ITV8")YA93O))E<;5P"WL5 '/^&_ 'AOP?J&JWVB:%8:5
M>ZK-Y]]<6ENL<ES)DG=(P&6.2>OJ:YK4_P!G;X::Q?>%KN[\$Z-++X718M&
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M+P ^/,;/\"_MP^*OB?X;L-8\$^!H?%4FG>']2UCQ+ICM/8SPO%=K!9QVY"3
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MM'<QREAM*JH&&'S#Z.KS/X[_  XOO'/A[2M5\/3067C3PMJ$>MZ'=SK(4\U
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M?%GP7IGBWPIJ(U;P]J:-):7JQ21"55=D)VR*K#YE8<@=*Z2@ HHHH *^=?\
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MKVI)'IG@K0)=0G&EK<N(+@R +"T84QKN$A;YTXZD?4GP._:"\$?M$^%/[?\
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M,](MXE9YVVV>I"ZM&GF8;?\ 2(6MX&14&PAQN)(.*]C^._PY^)_B[XG66O\
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M,BRSSN 0PS-(W5R3XQ^S7\-_CA\"?#.D> ]"^%'P^\*Z-'<B;4M?AUV><WC
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M)-MXUL=/U"&_LWN9K+3O[5N3IEG/<K(MU-%:>9Y2M,LF'&W;\JD*&RQ]=HH
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M\)=9=02 PU?31GW_ -?3?^%D^.?^B1ZS_P"#C3?_ )(JM_PCGQN_Z*%X _\
M"$OO_ES1_P (Y\;O^BA> /\ P@[[_P"7- '&_'CQGXWU[X,^,].;X5:S:K=:
M7/"9_P"TK&;RP4(W;(YF=L>B@D]A7T+(BRHR.H9&!!5AD$>E>)>+])^+UII$
M::MX]^&ESIUY=VMA/!?>#+Z!)5GG2(H&_M9\NV_"*5PS%5)4'(]OH \,^ ;?
M\*Q\6^)_A#<$16FEN=7\-@A$#:7.[$PHJ1H,02ETP-V%*9/2O;&L;9[E;EK>
M)KA1A92@+CZ'K7E'[07PY;64\.?$#1X+V7Q?X$O!JME%IP#37UID"^L1&P*R
M--;B5(P=N)3&0Z<FO1?!GB_2?B!X2T?Q+H5T+[1M6M([VTN%!&^)U#*2#R#@
M\@\@Y!Y% &S1110!PWCGXF?\('XT\$Z7>Z:SZ+XDNIM-;5UE %G>[ ]M$Z8R
M5FVS*'SPZQK@[\CN:XGXT?#Z'XH?#+7O#SJ_VFX@,EG+$4$D-U&=\$B%P5#+
M(J$$@@8JI\"/B#?_ !(^&>E:EK>GRZ/XF@4V6LZ;/_K+6]B^693\J@@L-P(4
M*0P(R"#0!Z#1110 445YUX<\>7-M\7O$_@K79W-U.B:SH)\D)$^G^5#%+$'P
M-\J7"RNP.2%GCP2,A0#T6O'_ !7\);Z3]IOP/\3-&L-.EC71;[PYXAGNWD-P
M+4LES9M F[8"EPDBL<;B+CN%!3V"B@"&:. ,MQ,L>Z$$K*X&4&.2">G'6G03
MQ7=O'-#(DT$JATDC8,KJ1D$$<$$=Z)X([J"2&9%EAD4HZ,,AE(P01Z5X%\%-
M9/P?^)-_\#M4NI)K5+9]9\'W$EJD0DTW>!+:ET;#/!(Q4 JA,94X.UC0![K%
MHVGP;_*L;:/>I1MD*C*GJ#QTKP_7/V$/@5XC\;7'BN_\!12:S<78OIO+U*\B
MMI)MP8LULDPA(8C+*4PY+%@=QS[Y10!QOQ>^&\7Q9^&VN>$FU6\T%M0A"0ZI
MIS!;BSE5@\<L9[%653Q@XS@CJ.9_9_\ BQ<^/-.USPSXC^S6WQ#\&W?]E^(K
M*U$@BW')M[J+S/F\JXA"3+DDC>5))4D^L5\Y?M.Z/=_"O6]*^//AJ!I=0\.1
M_9/$>FQ#8FJZ0[*)&D*_,TEOS+'P_P#&-AW J =/XCTZRO?VO_ <\]XMY=6?
M@O7)H-/E6%OL+&\TQ/M"?)YBM*KO&26*D184*?,+>S5\F^$=?L/''_!0^T\3
MZ%<#4M O_@S;SVU_ "8I$EUAVC.>VY0Q /\ =/H:^LJ .4^*_AZV\8?#/Q1X
M=NYH[>'6].GTG=+<BW!:X0PHHD*/M+-(J@[&Y(PK'@]77E?[2G_).](_['+P
MG_ZD.GUZI0 4444 <M\3?A?X6^,G@R_\)^,]&@U[P_?!1/9SLR@D$%65D(9&
M! (92".QKQG1_P#@G7^SMH'B;2O$%A\-+.WU32V@>U?[?>-$K1 !&:(S&.0_
M*"2ZDL<ELDDGL?VHKWXG:9\*=4O/A=<^&K34[:WN)K^?Q']I^2U6"0LUL8""
M)PP4J6^7KFOS^^!'QX^*6E?LK>!]+@\=2W'Q3^-OCF>WT;Q#JDKW<FGV4"VU
MI/)+YD;@L&A"J@(.)U93E6  /N_XM?L3?!+XY>,E\5^-O =KK'B 1I$UXEY<
MVIE5#\OF+#*BR$=,N"< #. !5SXF?L>_!WXO^'/#OA_Q/X&LY]#\.^;_ &5I
M^GSSZ=!:>9MW[4MI(Q@[%X.<8XZFO!?A9X?^*?[*W[2?@#P7XM^,&K_&;2_B
M18ZM#%#K,+6HTNXL(8[E)E9I)V8.K21E5*#Y@QW;%%<O\,?B9^T)X[_X*(Z-
MX6\?W>C>$M'\/:-?ZG=^&?#NJ2RVU[9D/#;O,N]P\WF7$#@NL?RQYVJ<"@#Z
M@^$G['WPE^!?BI_$?@GPS<:1K#VSVC7$NLWUV#$Q4LNR>=UY*+SC/'7DUR-C
M_P $YOV?-.\:'Q'#\/K9F+R3'2)[J>;2S*[$F3[([F+@$@)M\M1C" @$9/[<
MO[1?BCX8CP#\._AIJ%I8?$[QYK-OI]C=7=NMQ'8VYD57G="&P-S*-WEN HD.
M 0#7*?"WX@?&CX#_ +2=Q\-OBWXXTCQOX%O="O\ Q/:>*[BQ6SNH8X&#SJRH
M^V-$,C<-O 4)L90"H /M10%  & . !7FOQL_9\\*?']?"4?BS[=);>&M9BUR
MUM[.<1+-/&K*JRG:6*?/G"E3D#G&0?A_4?VCOVG?'_[/'B#]I'1?$_AGP1X*
MT^=YM+\&)I:7IU"RBNGBD>>Y?+J^1Y?RA ^QF BR"WKOC[]L'QC\0M&^%/@/
MX3V%CI'Q<^)'AJV\3+<ZJ_F6&A64D;.\A8H?.?,<BJH0_=+%?NJP![9J?[*_
M@O4OVE])^.0:_M/&6GZ>VG&&U:%+2Z4QR1^;,OE[WD"2[ V\?+'&,87GV*OD
MO]D3XU?%&[^,/Q&^"_QDU71/$'B[PE9V.H6^L:#8R11W<4X+R>:^U(P4$MLJ
MJ(XR?G/S[2P^M* /'OA#^S#X=^!^B>/M.\+:UKD,GC'4;G5;J]N9;>6:TN)E
MVEH 8=@"]5$BN,CYMPXKR#PM_P $O?A7X1U'X>WEGK_C"1_ ^J#5M-CGOK8I
M+,+A)\3 6PW+NC4?+M.,\]Z\)O/VP_CS\7?BCX@7P)X_^%_@F'0=5O+&P\!Z
MU<HU_KBVC.Q$C.A*^8(V7(> 8Z$8WUZ%\0/VSOCAIGBSX(^$+'PSX*\$>*O'
M&C7%WJD'CA+M8-/N83)N!:.5&1'6+*JRL074;CUH ]P_:&_8WT#]HCXK_#/Q
MQJNN7VFS^"KP7(LK>*-X[U5D654)8?)\Z+D_-E<C )W!ND?L9^'M'_:_UCX^
MQZU>OJFHV"VQT4PQB".;R4A:4/C.#'&ORXSN+-N(.T0?LU^/_CYXP\5:O%\3
M--^&[>&[<2107_@S4)9)?-5P$8HTLH*2+E@&,;*!R,\5]&T ?(,__!-'X<>.
M/BO\0?'/Q3N+OXEW?B74!=Z?!=W%W9'2(07Q;J\-R/-0*T2+N "B(   D5Z#
M^Q]^RNW[)/A#Q%X7M?$Z^(M$U'57U6TC;3VMY;-G14>,N9I!(FV.+'"D$.26
MW#;[[7R9^W#^WQ:?L;WGA*TB\)P^-KK6_M9G@36A9/8^2("NY1#*3O$Y(SM^
MYWSP >K_  )^#6H_"KQ+\5]3U"[L[M?%_BJ;7K46N[?%"\,2+')D#Y@8V/&1
MSUKUROCCXN_\%*?"?P=^"GA7Q7J>A&Y\8^)='M]8TWPO;7CR6TT<DP211J"0
M-'E%WL<J"=H&!N!KZ2^"WQ OOBK\*?"_B_4M E\+WFM627KZ1--YS6P?E07V
M)NRN&SM'!H ^=OB'^RS\6-&\5_$:?X5^+/"]SX:^($;2:MI7Q#M)M3-G=-&T
M326Q(8,A0\1S!XQC;L*\5R)_X)[>(/@SI/PX\5?"/Q/:7OQ/\"V-S8%]=CEA
MT_7+5Y)Y5AEBCERC*TQ PX4\%N@Q]V44 ? N@_\ !.O7OBKHOQ9\4_&O6[.Y
M^(OQ"MHBEGH'^CV.D21*C6ZDA27,;HD9^^"B$EI&;<.<UCX!_'#QSXW^"OPG
M^+J^$+'X;^'=3@N-+U[P9;F&XO)K.QDD6(Q,^R-2J.IVPHH*_*,8%?H[7CWQ
MMUQ-!^)OP2=Y+2/[5XEN+0?;+@P@F33;M0$(5MSG/RIQN/&X=: /4]<U6/0M
M%U#4ID:2*SMY+AT3&Y@BEB!GOQ7QA\"?V;M,^.W[/EO\0KZ:+3OB5XIUX>.]
M.\610J]Q:W4<LAT_S8B/+=(XG,;0XV'>Y&'(<?;;HLB,K*&5A@J1D$5\/?#G
M]MCX+?LX:MJ_PKU;QS/K%G8ZC))H^JP WZO'/,[&T80*?):WDW1;6"@J$8=2
M% /4/V8OAO\ $KP_\4OB7XM\<Z)HWA*SUY+&*#1=!OS<6LUS CK/?! H"&;*
M<-E\( Q. :^DZ** "OF7_@GA:7%_^SLWC;48)+36_'WB+5_%>I6Q0I#'//>2
M(/(5OF6(QPQ,NYF)W$[B",>S_&GQ%?\ A#X.>.]>TJ86VJ:7H-_?6DQ17\N:
M.W=T;:P(.&4'!!![UE_LVZ9=:+^SM\+=/O3&;RT\*Z5;SF)PZ>8MI$K88<$9
M!P1P: /1Z\>ET'X<?"#XQ+K#:I!H.O\ BV&_N(]%6W@*7LX6V:]NXR(3.)#'
M;VHD59!&WEJYC,F7KV&OG[XD>"/%UQ^T'<^*M.\-WWB6R/@S_A']'$NJ6]MI
M=C=7%S*][-<*6^T(2D5@/,@1B5#C!(7 !] T5Q'P1\ 77PK^$WA;PE?7T>I7
MFDV*6TUU$) CL,D[?,9GVC. 68D@ DYKMZ "BBB@ HHHH **** /*/A?J]E+
M\9_C-I:7<+:C!J6FW,MH''F)$^FVZHY7J%9HY #W*-Z5ZO7D/CKPI?\ @KXL
MV'Q1T2+SM.DT]M*\6Z=;PM)<7-HA+VUW"B_ZR6W<R K@LT,T@0,Z1HWJNG:E
M::Q8P7MA=0WMG.@DBN+>021R*1D,K D$$$'(H \B^(^F_$7X>^*-8\9_#KPW
MI?CW^U8(8]1\-W^I_P!F7;21?)$]K<,CQ8VNY=)0N< J^?E//:)^V1I7A]8K
M+XQ>$]:^"^MM-]G+:VGVK2)7*E\PZG"I@90FW)<QX9MH!(S7T/535M(L->TZ
M>PU.RM]1L9QMEM;N)98I!G.&5@0>0#SZ4 <II'AKX=^/;"/7],TCPUK]IJ(%
MTNI6]I;W"W'F .'\P [MP8-G/.<]ZN_\*K\%_P#0H:#_ ."R'_XFN-UG]F+P
M9-=W&H>&UO\ P#J\Q=S>^%;IK(%S"(MS0K^Z;"JG5.=HS6(VE_'#X3:,PTF]
MTSXS6-K@1V.KLNDZS+&(%7 NES;R.95+?/&F0YR_ R =_K7P0^'WB"Q-G?>"
M]#E@+I)A+".-@RL&5@R@$$$ Y![5UNV#1M+VQH$MK2'"H"!A%7@98XZ#N?QK
MQVW_ &M/"&B^(K'PW\0;'5_A3XCOG9+6U\66ZQVEUMBCD=H=0A:2T<#S%3'G
M!]V%*@E0>T^,OBM_"WP=\9Z_8K#>36&D75Q$C-E)'6)B%.#W/'% 'Y]_$3XG
M>$O$7C9=/\/S_":?6-;>9;RV\?\ AK7M*2.)D:98GO(Y9[>?*F3)#+&W5"P<
M5KZ9\3]/;[!INC?"3X0?$_6;AG>[G\!?$V*QM$G=I'VBWNHT9"P5VPI<?*QR
M.@^P+WP^GA[QQ\$_ UNL5UINAV-[?I=70;SR;.SCL4QM8+EEU!RVX$<< '!'
M!W/A+X?^#X_CKX^;X>^'=1TKPU;$IIKZ;;HSRV5DT\RK^[8(K[T ;!.<DC@9
M .$U7P;\$+SQ/8_V_P#LI>)YAJ;-YNO0Z)9ZY!#L4#,[V%W<R _= &TGIQ@$
MC3TNW_9$\&>,5T(^$;3P+KEU:^?C5O#>H:*'AR<$RS11K@E3@%N2O%=+>?L@
M^!_#&I^!_">@:#>:7H=Q'>/K%WH=S<6>^5;=525_*<)&7<D\  D #H!7 :5\
M$)?#GA?QMK/ASXQ?$KPQX+TWQ1-I]@MAJ*7LET$%I97!;[6&<>7?QWL?)7(3
M<H92C, =II&B?LI?$2[U/P]HGBWPWJ&I:L6D\C3/%#?:8@L2JWD;9MT8 CW'
M;CDLW5C5ZP_8$^"^J1-+97GBB\B5MI>#QEJ#J#UQD3]>16!XD^ .OZ7\7/"/
MAS1-7\'7L%WIE_JU\?$7@:PF\];::SB$8,"Q,"WVLDMNS\H]:\HUGP%\0M#T
M+QWXJT7X<?"FW\+Z?JNH)?/IVI:OI5U=/;S-!-*L$3-$CMY?R_,< +Z8H ]V
ML_\ @F_\%]/DN9+6V\46SW,GG3M#XJU!#*^ -S$3?,< <GGBK/\ P[R^$?\
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M\FVXB*%C@D9=!A6ZF@#O/^&.-"T?PZVE^$O'?Q!\&/M1%O-.\2SS2*BR22;
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M;S0]&NK]]6L[5+VXM;W2+RR:.%W9$<^?$@PS(X7GG8^,[6P =O1110 4444
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MFU0:D;2$Z@(?LXNC&/-$>=VS=UVYYQ6?JO@K0]9T7Q!I-UIL)L/$$<L>J1Q
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M '=V#W!KK*YGQWXFL_#6GP/>Z%JFO0S2;/(TO37O64@9W,J@X'N: /&?[)^
M_P#T5O4?_#OZM_\ +&C^RO@/_P!%;U'_ ,._JW_RQKKO^%H^'?\ HF_BS_PD
MY?\ XFN'\3>'?@SXSUJ?5]?_ &?KO6=5G"B6]O\ P#YTTFU0J[G:,DX4 #V
MH RO#'AGP%>?M8_#NZ\$^/-6UXZ=X8\0W=W"GC>\UN-\S:7"D<RSW$VV,^<[
M[5V[GAB8Y\L8^JZ^7?A+X;^&6B_M+:6O@7X;W?P]U&'PCJAO53PH-*M[J*6\
MT[RR\H"[G5H9-J8;@R$E<#=]14 %%%% !1110 4444 %%)10 M%%% !2$ ]1
MGO2T4 %%%)0 M%%% !1110!X?^ROX,3PQ8?%'4TNFN&\1_$+7=4>,IM$!6X^
MR; <G<"+4-GC[Y';)]PKR[]G6[@O_!6N7%M-'<02>+/$#)+$X96']JW7((X(
MKU&@#S/Q+_R<9\/_ /L6]?\ _2C2J],K"OO#<EYXUT?7A<PI'86-Y:-;M:1O
M)(9GMV#+,?GC"^0047A]REN46MV@ HHHH R_$6O:+X9TU]1U[4;#2=/C(5KO
M49TAB4DX +N0 2>.M+?ZUHV@Z<NI7M_8Z=8,447=Q,D41+D!!O) ^8D <\DC
M%?"W_!7'X8_VM\%9O%B>,O$EM<B:PTJW\)Q:HL>CWKFY8^:]L5R\P$GWMPP(
MTX^6N/\ ^"A_PHCT#P/\,?&EWXV\92W&H>(M"L(O"<M\LVAP2+;D,Z084Q/M
MB=MX9\LS#: ^5 /T:US6=(\+:=-JNL7UEI%A#CS;Z^F2"*/<0HW.Q &20!D\
MD@5;AFMM2LHY8GBN[2XC#(Z$/'(C#@@]""#^.:^,OVE/V>_"'QG^)/BCQ7JD
M_B#XSV6AZ=_9UQ\+])UCR?[(O61)!=Q;;B+:62%5,)5RSR;N=N%ZO_@F@;R/
M]E/2+.]O+RXFL=3O[,6U_,\LU@L<[*+5F95!,>-I*J%SG '2@#Z8BATKPQH]
MI9Q)9Z3I5N(K.W@0)#!&"5CBB1>% )*HJCN0 .E1Z!X4T3PI'>)HFCV&CI>W
M4E[=+86J0">XD.9)G" ;G8\LQR3W-?D+XHB\;?M1_&OX^:W=_"G7OBMH&@ZA
M)HFEVEIXOGL9-"D21HM]F@5DD<E1-Y;1LJD9(89S[18_%63Q9X/_ &/?A;X$
M\:^,=$T;Q87O=1U"?4"U]):VN_S;%[J(02X5T>%6C"#8JG!P!0!^DU85CX!\
M,:9XNU'Q59^'-)M/%&HQ+!>ZW!8Q)>W4:A0J2S!=[J B !B0 B^@KX$T^5_V
M/?VXM9\&>!K_ %A?AS+X"O/%DWA&^U.6YM1=Q1RY\MYM[H6^RH2Q+-EF&=N%
M'(ZMX/U[]I#]BF[_ &E_$GQ&UOP[\0[:]U'Q!I%UIEU<Q6>C6D,IM1I\,"2%
M54_9M_G(JR%G&\O@E@#],]#\+:+X9;46T?2+#26U&[>_O38VR0FZN7 #S2[0
M-\C!5!=LD[1D\5/K.BZ?XCTF\TK5K&VU33+V)K>YLKR%9H9XV&&1T8$,I!((
M(P0:I>";B6\\&:#//(\T\MA;O)(YRSL8U)))ZDFO"/V^+'XGZA\$K&/X77FO
MV-ZNNVCZW+X5*#5/[+ D\W[/N93O$GD'"LI*A@3M+ @'K7B3X(?#_P 6^"M-
M\'ZMX-T6[\*Z;<P7=EHWV)$M;>2%]\92-0%49R"H&&5G1@5=E-C0OA)X0\,?
M$#Q!XWTG0K>P\4>((88-4U"!F4W:Q9\LNF=FX9^\%W'C).!7P/\ LK^-+GQ-
M^T;HB^$_C;\0KC2[?0[J;Q!X#^+%]+)JDS-%+Y9ME,*Q'8X@D+(VX -SM8@_
M,7P2^+=S\1?#6B_\)I^U_P#$GX:^)+NXN(W6\:]N]/>-.4=;CSHU3@$$$MSC
MIG% '[!Z=\ ? &E^.O&'C"'PW _B#Q?;+9Z[/<RRSQW\"H$$;PNQB"[5 ("C
M(ZYR:SO!7[,7PU^'/PPUKX>>&?#TNB^$-9DEEOK"UU.[5Y6D14DQ-YOFJ&5%
M4A7 QD=SGK?AI8R:9\./"MG+K<_B:6WTFTA?6KI6674"L* W#AB6#28WD$DY
M8Y)KI: .'N_@GX*OOA.OPTGT))/!*Z:FD#3//E'^BHH58_-#^9PJ@;MV[CK5
M;6_@9X5U?X(W?PGAM[G2_!T^DG14@L[@F:"VV; $DDWDD#NV[WS73>-O%4'@
M;P?K7B&ZMKF]MM+M);R2WLH_,FD5%+$(O<X%?F+^P1^VG\=/V@?VC[VQU[7]
M5\0^!K&RO;Z73K/0;!54;&^SQRS)&C1Y. I#$LZ@$8+, #],_AWX!T;X6^!M
M#\)>'H'MM%T:U2SM(I)#(PC48&6/)/<_6M;6-'L?$.D7VE:I9P:CIE] ]K=6
M=U&)(IXG4J\;J>&5E)!!X()KX'^+GQM_:5^&?@Q_C3J_B'P_X3TZ35(H;'X/
M:OI\,DTMC(Z6P=[E2LS7"O-'*R*X11R3@>6?OVRFEN+."6:!K6:2-6>!V5FB
M8C)4E202#QD$CCB@#YG\.?\ !/WP/X:\9:+J$/BCQK-X3\/ZC;ZKH7@6;Q!<
M2Z+IUS#ED=8G9F;$A\P?,,$D'<I(K&^,/_!-KP%\4OB#JWB?3O$?B/P+#XC?
M/BC2?#ET(+761DMETQA7,FUV)#JS G:&)8_7%% 'SAXZ_8-^''B7X?\ @[PO
MX<EUCX>MX-DN9_#VK>'+YDOK&28N[_Z1)OE*&20N5#KDXY  QY5X:_88\/\
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MA'!/..E 'K=%>&Z=^R1X=\,Z!JFF>%O%WCGPN+YWF$UCXEN9#!*P WHLK.O
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MKGOB#XPB\!>#-5UZ6#[4;.+,5MOV>=*Q"11[L';N=E7=@@9R>!70UYG\:/\
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MZHHKR?3OVH/ !T>UO?$6H7?P^GF@6=K#QO8RZ-/'E074>>JI(4)VLT3.@/\
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M&"]P9I@Y8JL86-<'=P?K2OEOP]X4T#XLWVJ67QPBDUO7=6\1W&D6'A+5(O\
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M#/AK5OVGM8@\8^,+:^T7X<6^\^&_"LCO;S7X92O]HWP4AAN5CY4)^XI#,-Q
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M5XD^#?C7QMXQ\:WMGJ%U<VT6GZ+;:?--=M96B_/<G<R*2T[I!E K$"VC4,0
M!VFNW5_X#_9R\1:CK>M?8=6U*.>635)[];!+.6[E\N)_,NE @6/S8R4*%@5*
MK'(^U&]LJMJ>F6>M:==:?J%I!?V%U$T%Q:W,8DBFC889'5@0RD$@@\$&@#X
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ML:[MH%>V44 -C8O&K%2A(!*MC(]CCBG444 %%%% !1110 5R'QB_Y)'XW_[
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MX_#7C_X\ZO:#Q_X>B\"_#RWC<W'A-]0CO+[69B&51=2P$QQP)PXCC=B[;=Y
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MZ3^TKX6@^)VL7/BRX\0_#R".*'1K:U\7V<EEI]Q.JR7#2QSG-N'*DIR^6\L
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MYP(U(VXV^_6NRK@?&?AZYUW7U^R?%+7/"+A(H3I>EC2F4NQ<HQ%S:32;GVL
M-V#Y9P.#0!1\WXQ_\^W@;_P(O/\ XBCS?C'_ ,^W@;_P(O/_ (BH++X8Z_J5
MG!=VGQO\:75K.@DBGAM]"=)$(R&5AIN"".014_\ PJ3Q/_T6CQS_ . FA_\
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M0O\ 3M9G\::->0WENOAZWLKM;NS>,&62Z9H/L\J-M) 1%NE.&&?-'!QQNT4
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MKQ)X#^*_@275[/2O$<.DW-F=9UC2I?[.6Z ""'[48FC=PY"% 3RK#'!KZ ^
MOC"R\?\ P5\#>(=.<26=_H]K*C+ (5_U:@XC  49!P  !V&*\]_9GN-!\9^$
M/B7X2GL9=2M- \<ZYI-ZFKXN%N&:Y-T#EV8N-ES&,M@[@W8 GL/@O^S[X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\3/"'Q)ANIO"7BK1/%,5JRK</HNHPWBPE@2H<QLVTG!QGK@UTM<'\5?@/\
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M[?1;15GO9C-,_P"Z4Y9SR3S7<UXS9^.OB-X8T;1M/A^#DCQQQK:B*R\0V[I
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MPF\#(7S8^3G@ ^@J*^<?^'BO[./_ $532O\ OQ<__&J/^'BO[./_ $532O\
MOQ<__&J /HZBOG'_ (>*_LX_]%4TK_OQ<_\ QJC_ (>*_LX_]%4TK_OQ<_\
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M9XK\,>(['P9I.GZKX8M9K/16LX/(AT^.9MTOE0)B)68D_,%W?,P! 8Y]$HH
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MD!VY..KM[68?M%W]QY3_ &<^%+>,2[3L+?;)R5STS@@X]Z /+?\ AX%\._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXK3HH \DN?@$/#^O#6? /B;4O!DI 6;2$;[5I4X42;5^S2$B( R8_=%,!5
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M=TX. #VZBN?\%>/_  Y\1M'&J>&=9L]:L=Q1I;20-Y;CJKKU1A_=8 ^U=!0
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MBN2Y2V6/X^_&VT,,0C=H?%J$SMN)\Q]UNP#8('R[5PHXSDGDO^"<?@";X9>
M?$>@7_PVUWP7K%O?*+O5-9T^UM5U$B)%Q$T3DR*K*^'"A2&!#,Q:OK^@#YD_
MX8@N/^CB?CI_X5D/_P BT?\ #$%Q_P!'$_'3_P *R'_Y%KZ;HH ^9/\ AB"X
M_P"CB?CI_P"%9#_\BT^']B:Z@F21?VB/CDS(P8!_%,#*2/4&UP1[&OIBB@#P
M?0OV5KW1O$.EZK-\<?BUJJ6.IC5#I]]K=J;:Z;<C-#,J6JEH#L \H,% 9MNW
M<37O%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!YAXY_9P\#^.+V;55T^;PUXG8L\7B;PU.VGZE!(8GB#
MB:/&_"R-\D@=#QN5@,5S>LV?QW^&<-U=:%?Z+\9].#.T6DZVD>A:NNXQA0+R
M%3:RA?WA(-M"<8^9B,'W.B@#R70/VF/"-WJ7]C^)1>^ /$(F,!TKQ1$+5F;+
MX,<H)AE5A&S!D=AC%>L]:IZMHNGZ]:?9=3L;;4;;<&\F[A65,CH=K C->8ZK
M^SY%IRB;X?\ BS6_AQ=1I)MATQTN;"21E(#RVDZO&Q!VDE=K$*!N% 'K=%>%
M:;\1_B[\.-0D@^)'@RR\6:#+=21VOB7X=13S301;D6(WFF2;I5+ N[-;O.%Q
MM*@#>W>_#WXV^!_BF6C\,^)+/4;Q(HYI; L8KN!7W;?,@<"1#^[?AE!&QL]#
M0!W%%%% !1110 4444 %>9Z'_P G*^-/^Q1T+_TLU>O3*\>\$:Q+K/[47Q4C
M$"+;:5H6@:=Y\;2'?+NO[AE;=&JA@MS&<(SC:RDD$E5 /8:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "JTE^L>I061BG+S123"58F,2A"@*L^,*Q\P$*>2%8C[IJS10
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M(^,Z "OUF_X(<?\ (M_%[_K[TS_T"YK\H1IUR=.-_P"2WV02B R]MY!8+]<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB+X'\ > O&]YX&\)_#SPK)I=U;Q^%GN[Z^NTLMGD0N]PJK&/D4EQN)QC'.:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%I?B9^V[XT\$:7\&OAOXI\9Z?:CQ$VL:WK6IQRBW$D2PB0@;1+MEA;8@*!2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPW,%Q%)<Q2/"L3++"4=T.QIFC50T9# ,RN51G!Y?_ATO^T=_T+6E?^#JW_\
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M;SEMS>W$;M&KMG:&*J=N<8R<#.!U(KR;_AX1^SK_ -%6T3\IO_B*Z_\ :2^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPJ<Q%6)+Q[68%S& >(_\$J_"^A^*_P!CGXLZ7J5A!K>D/K]Z%BU&V4AU_L^
M!F0E@I()X!.,D9-8O_!+K]BCX=_$;X-1_$;QO9-XMGO-1GCM=$ORW]GVOE!H
MB[0[MLSMN)W./EPNT C<>Z_99\+_ +1W[.O[+WB/X<2? 5=0\1!IFT6_@U_2
MUMIS.3YAO/\ 2@X,8.5V [P A\O&\]M^P=X=^,7[-?P&F\$^,/@QJL\^G7K3
M6<NCZ]I4\MYY[2.Y*27,:1+'M0$F1F8R#"X#8 /&?V _V4OAM\2/B'\=-1\2
M:%_:EEH7C*[TRPT&65AI<<(>3&ZV&$D(!  ?<%VJ0 1FO'OBWK,7[+G[0'[4
M.J?#?1_^$>O=,L],TC27T=OL\6DI=QQ&:98U4J3\I ) *M)N# CGZR_8C\(?
M&WX'>+OB>WC'X*7UOI7C#6+WQ(EWIWB/2[F2VE(9TM/+,Z[]Y^02;E 8KN"J
M69>4TK]GCXE?$+]H3XXZC\0/@WKFG?#WXJ6UOIAN+#Q%I3WFFI"T0BN)$%S@
M_P"J61E0OMQM E[@'D?[.?@WXL^,OV,I=.\$?L^^'/%<_C);D7WCOQ)XB@FF
MO@LTL.X6TA22-H@@1/WFT&/?M.XBO-_B#\ /C!\$O '[/>G?$N"6VMM-\?W%
MM:6[:G%=I;PS?V>\"($=@%WPWIQ_"2>FX9^O_P!G?PM^U%^QOI>J?#2P^%MA
M\8? 6G7DTNAZU;^);72I3'*P?&R=V*+DN3'LXD=\.ZX)S?V@-#_:!\<^-O@!
MXX\0?!FYU6Z\%7T]_P"(-*T'4;26RG:9HFA2W1KAY'DBC4I(SHJ^8'V,R,KD
M U/^"H=MKOC3XE?LS?#S2[RWMK77_$\]TZ7*X0W$#6J0N7"E@ MS.,#@[AD'
M Q]_U^=G[4OBSQA\6/V@_P!G[Q7H'P5^)LNF> 9Y=?U43Z$D;R13Q6<_DPYE
MVM.@A=&C+*=XVJ6-??'@GQ.?&GA+2M=;1]4\/F_@6<Z7K=N+>]ML_P $T89@
MKCN,F@#\DK+4H_AI_P %I(K_ ,1QSZ;;:AK\\%JSPL3*UY8R6UL0 "=KRS(-
MW09R< $U^Q%?%/\ P4 _8(;]HBV3Q_X F&E?%C2(T>#]]Y*:HD?*1&3($4RX
M_=R$@9 5BH.].2^%7[6'[0WPD\)#PO\ $;]GCQ[XW\6V,DRSZUI0,]O< 0 P
M8D19$8EPJ.4;:H+. S H0#Z=_:VT#PYXH^!?C"WUZ-;Z72M)N]>M-/&H3VC2
MRVL$CH6,$D<A3=@, PZ]>E?F+^P]^R7#^T7^SWXS\5_$?XD>)](^&VEZA=7'
M]B:#=8+7,<"2W-U,)(Y%;,90 !2S$')& &^JM9M_C9XNU3XV>,?B9\+KWPO9
MZIX%G\,^%=%TBX3Q!.MQ+'+N'^B;W4R,5W2%$0 *">,GD?\ @F9K6B>#_A#X
MB^ /Q!T[7=%\<:SJU\T_A^ZT6^CD%G/9P*7>41;(@5#<LZD<'N,@&'_P30_8
MK\(?$OX4Q?$GXB65WXLL[F^O+3P_I&L7*W&F_8HBL*W!MR,B42)<I\QP  0H
MX:K'[3G[+>B_ [7'\ _"VX\2Z?9?$SP[K5PFB1:YY=G87FE"UO;>2$.I.'/V
MA'#/TG;:5 VGM_@ GQ#_ ."?NH>,?ASJ?PJ\9_$7X:7>L7&J>%M>\&PIJMRD
M;+$##<1%X_*&T*>0G[P2[1(K;AZ#\)/"_C;]I+]H^Z^+GQ#\%:OX&\$>'=(F
MT;P;X<U[;'=7#7+21WEW<0K(3$YC14*,NUE>(JS>7N8 \3_82\:Z!X'_ &#K
M_7M!.CR_%7Q+J5QX<A>Z;]_JFL2/+_9]K.X8,3MEW LPVH68D $TO_!.[XNZ
M0G[-/Q=\#?%HV]Y;_#R]GN]5AO!)<$VX9G^=\L)&$T$BJJ<_*N 21G)_97_9
M0^)GPW_;.U2UM=*U.U^!_A?Q7=:E;VNKQF&"XEFT^]AM[VW5D"2^61'&60[E
M\V(@$;F6E\1_V&?$'BW_ (* ZEHWASP_K/AWX,^(%M=3\47\"2+I]ZL;I=2P
M!RR@O)<1QJ A+(7+A2$:@#["_8A^#UGX!^%<?BN;2+O1_$?C)WUF\LKR]-U]
MAAED>2WM8S@!8XXF08"@YSG!X'SA_P %L=0U.W^"W@2UMIKA--N-;D-Y'&3Y
M3E8<Q[^W!)QGWK]&Z\._;+_9O;]J?X%:IX(M]6&C:D9H[ZQN9%W0_:(PVQ)<
M G8VX@E>1G(!QM(!L?LD016W[*OP<2*-(D/@[2'*HH +-9Q,QX[DDDGN2:]5
MF@CN8FCFC66-NJ.H(/X&OS!_8I_:8\6_L=Z7<?"7]H7PQXE\-Z+:S3MH>O3Z
M?<WD:!"%DMD\I7\R'/S(\6Y?F/\ "P(]E^+W[7FA_M!2^%OA_P#"";Q9J<^H
MZQ:7&N:]I7A^_1-(L(IXVD,J/$CN)#B/Y> "Q9A@!@#%\.P+_P %(/C1XSN=
M2UWQ'IGP2^']]!I^D:9I8;3QK>HE6-U)<3ABY" !0B[&"3QD&,[]^#\0O .M
M?L3_ +0GPST/X<^-?%4/@KXJZA+H=SIM]=+>KHET9K79<VSW"2(S;2J[)D=C
M&DP#@NKQM_9XO+C_ ()Q?$#XMZ'\8+W5H/AWK]]!K'AWQ/8Z5<76EO*QF\Z-
M_)5VAN&0191AC%L3NQL+W?B!XZ;]M[]H+X2^(OAO'>1?"KX9:FVM:KXUU9&L
MM/N+LHDT,*0SF.1\&!8S(H)3[23MVX+@'"?LE?$']K#XX_$?XJ>&;3XC6MOX
M=L-4EL[SQMJVC)<O87$+E1'8VH=8P90J[XVRB*Q8$/C=K?"'6?VJ_AU^TKXW
M^#GAKXA^'_BLNG6$&IS:YX]AO6@LPV L?[EV>*1LGY-SJ0F00<UL_P#!*'XF
MZ#]D^,.FZOXF\/IXEO\ Q;=:H;6TOEV3Q$('G@#D,T.]L*Q'0C/-;7[*'Q$T
M+5_^"B/[2:KXCL;O[:MC!IX^V*_G"+"2)%S\VQVP0O0F@".V\8?M"Z;^W'JO
MPB;XRZ7=Q:MX9DUJ*[G\((;73R7=42"V%R&#)GAWF;=@>8KXKS+]D#XQ?M7?
MM;>+_%=EI_QJTG1_#/AR3R;C7X_"]G<?:'8L(O*MWBB<JX1FR^TJ.HSQ7K5U
MKVF'_@KA9W?]HVGV3_A7Q3S_ #UV;O-;C=G&?:O%/^"-7Q+\)>#U^)>BZ[XF
MTK1]7U?4;(:=8WUY'#-=[4N-WEJQ!?&1G'K0!ZO\,OVU?B5\*_B=\9_A'\38
MW^)OC[PO$^I^&_[-L(K!M6MT@$QC?R ZQ%H6BF4;&*[I%9B0JBYX_A^/GB;]
MC?Q)\6O%?Q*U_P"'?C"S6?Q+8>%M%M+6WM;.UC),5I,P3SY2T>22\H +KNC8
MH=WRW\3_ (A^+-1_:N_:#_:2^$ %WI?@U+;34U&2VCNXI':WBL7E0+(04"PS
M3*^&7:J[@I<"L[XV>/OACXG_ &9&U[Q)\9?%WQ"^-6MZ!83KHJ:I*;32R\Q\
M^%O)A,(4&1]T4S;\!0I4L"0#W#XQ_MF?M,_#G]FOX7?$*U;PE>Z!XN@L;<ZQ
M#:,=72^9/-=&B8_9PLHBF52D384'.UBIKHOVH_CW^V'X&^$O_"TC9>#_ (6^
M&;>\B1M C==0U=(IF5(S.TR&-\,1\L01QO.Y,*2OSI\6_&FG_%SX%?L9_"SP
MMXSTB>^:X6+5M.%^ICL;O=;QV[W2IN:/:);@ D9PS\&OKK_@L7(DG[+WA>1&
M5D;QC8L&4Y!'V:[YS0!YK\3OCQ^T7X3_ &A_A?X1N/B[#X?\(_$FVLY].UJ/
MPE:W,=I<7" ?9TA=%E9!.R(IE*.$<%\E6)^E?BEIWQ:G^.W@?P=X&^,^HV-E
M<VC7WB*"^T#3KF2WM(@B>=%*ML%269]P"N"NYF90%41UYC_P5]^'-WXK_9ST
M;QSI$UQ]J\':I'>>=:SI&L<$^V,S9R&)$GD;=AS\Q.,#([7_ ()\W7B?XPZ+
MXF^/OC>VLK?7/&\D=KIUM9H?+M-/M<QA(V,CL$>82MM;!# GD,* /KQ1@ $D
MD=SWI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?BYI6L:[\+?%FFZ ';6+O2[
MB"V6*412,[1D;8Y"0(Y""0KDX5BK'(!%==10!Y;X1D^(WASPQIVCW>F1ZYK%
MI9R7$M_?7D:6LQ:5_)L_M"EIC+%&8P\[6VV7:6&UG*KVMWX@U&TU%[4>&=2O
M(TLUN?MMK-:^0\I?:;==\R2>8!\^614V_P >[Y:W:* .=T[Q1J=]8WEQ-X0U
MK3Y8(]\=K<S61DN#OD78A2Y90V$5_G91ME3G<'5-G3[J6]LXYIK.:PD;.;>X
M*%TY(Y*,R\]>">OX59HH Q9+W4;O5;2)+&_L;:*:9I9F^S-%.BIM53^\+J':
M0,I"@_N2&V@@-I:=<R7NGVUQ-:36$TL2R/:7!0R0L0"4<HS(64\':S#(X)'-
M6** "JM]J,6G"W\U)W\^98%\BWDFPS="VQ3M7U9L*.Y%6J* .<3QYICV>HW(
MMM:$=A?-ITRG0[T.THQEHD,.Z:+YAB:,-&><.<'&];7"W=M%.@=4D0.HEC:-
M@",\JP!4^Q ([U+10 4444 %%%% !1110 4444 %%%% !1110!6U'3X-5LI;
M2Y0O!*,.JN5)&<]0015FBB@ HHHH **** "BBB@ HHHH S9]'\O3M2@TZX?3
MKJ\\QQ=J/-,4S+@2!7RIP0#MQMXZ5I444 %%%% !1110 4444 %%%% !1110
M 4456N[Q[:>SC2TGN%N)3$\D6W; !&[;WRP.TE0GRACN=>,9( +-%%% !111
M0 4444 %%%% !1110 4444 %07%E;W4MM+/!%-);2&6!Y$#&)RK(64G[IVNZ
MY'9B.A-3T4 %%%% %74M1BTJT:YF2=XU95*VUO).^68*/DC5F(R1DXP!DG !
M-5=)\16FM75U;V\5_');$AS=Z?<6R'$LL7R/(BJ_S0N?E)RIC?[DL;-J44 %
M5=,U&+5K&&[@2=(I1E5N;>2"0<X^:.159?Q I;'3X=-BDC@#A'EDF;S)&D.Y
MW+MRQ) RQP!P!P   *LT 5M0NY;*!)(;*>_=IHHS%;M&&56D56D.]E&U Q=L
M'<54[0S84V*6JNJ:;!K&F7=A="0VUU"\$HBE:)]C*5.UT(93@G#*01U!!H -
M3U&+2=-N[Z=9Y(;:)YG6V@>>5E4$D)'&K.[8'"J"Q.  2<59!! /KZTM8VG>
M&8]*T.]TV"_O\7,]W<?:I;@R3Q-<322ML9@<!&E(1<$*JHH&!0!L9HS6/X@\
M.R:]IZ6J:QJ6E,JLOVC3Y424Y4KDEE89&<CCJ!2Z-X>DTC2IK)]8U+46D4*+
MJ]E1IDQ$L>5(4#)*[SQ]YF/0@  U\T9JGHNFMH^DVMD][=:BT$80W=ZX::7'
M\3D  GZ 5=H 3-&:6B@ HHHH 3-&:6B@!,TM%% !24M% "9I:** "BBB@ HH
MHH **** *VI:;::Q83V-_:P7UE<(8YK:YC$D<BGJK*000?0U0N/!V@7?AT>'
MY]#TV;00JH-+DM(VM0JD,H\HC;@$ @8X(%;%% '$?\*.^''_ $3_ ,+?^"6V
M_P#B*:GP+^',6I:;J$/@3PY;WVFW*WEI<6^EPQ/#,H(5U*J#D;CCT.#U -=S
M10!Y[JOPD^%6@Z;<ZAJ?@OP=IVGVL;33W5WI5I%%$B@EG=V0!0 "22< "O@7
M_@F'\"/AI\9/V=M5LO'GA;PGXFFA\137MINO8I[^.-XUC FCC/F0KF%RBR'+
M LP4#:S?H]XV\!^'?B3X=NM!\4Z+9:_H]RI$EG?PK*AR"-PS]U@"<,,$9X(K
MS/PU^QA\$_!WCVW\::'\/-+TKQ+;W3WD-[:M*GE2MG+*@?8H^8_*%P,\ 4 >
M@^&OA9X/\'^#_P#A%-&\,:5I_ALH(WTN*T3R)0%5?G4C#G:B@ELD[1DUEV7P
M#^&VFZ=J%A:^ O#L%GJ'F"[B33(0)@\GF,&^7IO 8#H"!C&!CO:* /#=>_8>
M^ WB:_%YJ/PM\/S7 C2$,D!C&U%"J,(0.@'.,GO5[6/V/?@_XATFWTK5?!<&
MIZ7;E3#97EY<RPQE054JC2%1@$@8' )%>R44 ?'7Q9^(OP<O?@]?_ CX<Z[H
M][X@\67#^%+/PY!'/J4VG,TZVUS/+ ,O MM'YDZF0QI^X!4XYKZO\*>%-'\#
M>'-.T#0-.M](T;3H5M[6RM4"1Q(.@ _4GJ223R:SM'^&/A+0/%.I>)M/\-Z9
M:^(]1=GN]72U3[7,2%!!E(W;<(GRYQ\HXKIZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>R6\3W=NKI#.R@O&KXWA3U .U<^N!5FB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>aytu-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/12/2023 5:27:44 PM-->
<!--Modified on: 10/12/2023 5:27:44 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" elementFormDefault="qualified" targetNamespace="http://aytubio.com/20230630" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:aytu="http://aytubio.com/20230630" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails">
        <link:definition>40206 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails" id="DisclosureInventoriesTabularDisclosureDetails">
        <link:definition>40401 - Disclosure - Inventories - Tabular Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails" id="DisclosureInventoriesInventoryWriteDownDetails">
        <link:definition>40402 - Disclosure - Inventories - Inventory Write-down (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" id="DisclosurePropertyAndEquipmentTabularDisclosureDetails">
        <link:definition>40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails" id="DisclosureLeasesNetLeaseCostDetails">
        <link:definition>40602 - Disclosure - Leases - Net Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" id="DisclosureLeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>40603 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>40606 - Disclosure - Leases - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails" id="DisclosureLeasesOperatingLeasesGrossDifferenceDetails">
        <link:definition>40607 - Disclosure - Leases - Operating Leases - Gross Difference (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>40608 - Disclosure - Leases - Finance Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails" id="DisclosureLeasesFinanceLeasesGrossDifferenceDetails">
        <link:definition>40609 - Disclosure - Leases - Finance Leases - Gross Difference (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails">
        <link:definition>40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>40704 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails">
        <link:definition>40705 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails" id="DisclosureAccruedLiabilitiesGeneralInformationDetails">
        <link:definition>40801 - Disclosure - Accrued Liabilities - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails" id="DisclosureOtherLiabilitiesComponentsDetails">
        <link:definition>40901 - Disclosure - Other Liabilities - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails" id="DisclosureOtherLiabilitiesClassificationDetails">
        <link:definition>40902 - Disclosure - Other Liabilities - Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails" id="DisclosureLongTermDebtCompositionDetails">
        <link:definition>41103 - Disclosure - Long-term Debt - Composition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" id="DisclosureLongTermDebtFuturePrincipalPaymentsDetails">
        <link:definition>41104 - Disclosure - Long-term Debt - Future Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" id="DisclosureFairValueMeasurementsRecurringBasisDetails">
        <link:definition>41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>41306 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails">
        <link:definition>41307 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails">
        <link:definition>41308 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity" id="StatementConsolidatedStatementOfStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statement of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLineOfCredit" id="DisclosureLineOfCredit">
        <link:definition>11001 - Disclosure - Line of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlans" id="DisclosureEquityIncentivePlans">
        <link:definition>11501 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>11601 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>11901 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>12001 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12101 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31203 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansTables" id="DisclosureEquityIncentivePlansTables">
        <link:definition>31503 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>31603 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails" id="DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails">
        <link:definition>40102 - Disclosure - Nature of Business and Financial Condition - Reverse Stock Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" id="DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails">
        <link:definition>40103 - Disclosure - Nature of Business and Financial Condition - Product Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" id="DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails">
        <link:definition>40105 - Disclosure - Nature of Business and Financial Condition - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails">
        <link:definition>40204 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails">
        <link:definition>40205 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40209 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails">
        <link:definition>40211 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails">
        <link:definition>40214 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>40215 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" id="DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails">
        <link:definition>40301 - Disclosure - Revenues from Contracts with Customers - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" id="DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails">
        <link:definition>40302 - Disclosure - Revenues from Contracts with Customers - Revenues by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" id="DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails">
        <link:definition>40303 - Disclosure - Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" id="DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails">
        <link:definition>40304 - Disclosure - Revenues from Contracts with Customers - Revenues by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails" id="DisclosurePropertyAndEquipmentImpairmentDetails">
        <link:definition>40504 - Disclosure - Property and Equipment - Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails" id="DisclosureLeasesGeneralInformationDetails">
        <link:definition>40601 - Disclosure - Leases - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails">
        <link:definition>40701 - Disclosure - Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails">
        <link:definition>40703 - Disclosure - Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails">
        <link:definition>40706 - Disclosure - Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails">
        <link:definition>40707 - Disclosure - Goodwill and Other Intangible Assets - Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails">
        <link:definition>40708 - Disclosure - Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails">
        <link:definition>40710 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails">
        <link:definition>40711 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" id="DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails">
        <link:definition>40903 - Disclosure - Other Liabilities - Fixed Payment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" id="DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails">
        <link:definition>40904 - Disclosure - Other Liabilities - Supply and Distribution Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" id="DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails">
        <link:definition>40906 - Disclosure - Other Liabilities - Contingent Consideration - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" id="DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails">
        <link:definition>40907 - Disclosure - Other Liabilities - Contingent Consideration - Other than Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLineOfCreditDetails" id="DisclosureLineOfCreditDetails">
        <link:definition>41001 - Disclosure - Line of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails" id="DisclosureLongTermDebtNarrativeDetails">
        <link:definition>41101 - Disclosure - Long-term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails" id="DisclosureLongTermDebtWarrantsDetails">
        <link:definition>41102 - Disclosure - Long-term Debt - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" id="DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails">
        <link:definition>41202 - Disclosure - Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" id="DisclosureFairValueMeasurementsValuationAssumptionsDetails">
        <link:definition>41203 - Disclosure - Fair Value Measurements - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails" id="DisclosureFairValueMeasurementsNarrativeDetails">
        <link:definition>41204 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" id="DisclosureIncomeTaxesConsolidatedBalanceSheetDetails">
        <link:definition>41302 - Disclosure - Income Taxes - Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryForwardsDetails">
        <link:definition>41304 - Disclosure - Income Taxes - Operating Loss Carry Forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" id="DisclosureIncomeTaxesTaxCreditCarryForwardsDetails">
        <link:definition>41305 - Disclosure - Income Taxes - Tax Credit Carry Forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails">
        <link:definition>41310 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" id="DisclosureStockholdersEquityRestrictedStockDetails">
        <link:definition>41402 - Disclosure - Stockholders Equity - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails" id="DisclosureStockholdersEquityStockOfferingsDetails">
        <link:definition>41403 - Disclosure - Stockholders Equity - Stock Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>41404 - Disclosure - Stockholders Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails" id="DisclosureEquityIncentivePlansGeneralInformationDetails">
        <link:definition>41501 - Disclosure - Equity Incentive Plans - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" id="DisclosureEquityIncentivePlansRangeOfExercisePricesDetails">
        <link:definition>41503 - Disclosure - Equity Incentive Plans - Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" id="DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails">
        <link:definition>41504 - Disclosure - Equity Incentive Plans - Restricted Stock - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails" id="DisclosureEquityIncentivePlansRestrictedStockActivityDetails">
        <link:definition>41505 - Disclosure - Equity Incentive Plans - Restricted Stock - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" id="DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails">
        <link:definition>41506 - Disclosure - Equity Incentive Plans - Restricted Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" id="DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails">
        <link:definition>41507 - Disclosure - Equity Incentive Plans - Unrecognized Compensation Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails">
        <link:definition>41508 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails" id="DisclosureWarrantsStockIssuedDetails">
        <link:definition>41601 - Disclosure - Warrants - Stock Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails" id="DisclosureWarrantsGeneralInformationDetails">
        <link:definition>41602 - Disclosure - Warrants - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails" id="DisclosureWarrantsWarrantsActivityDetails">
        <link:definition>41604 - Disclosure - Warrants - Warrants Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41701 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" id="DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails">
        <link:definition>41801 - Disclosure - Commitments and Contingencies - Fixed Payment Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" id="DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails">
        <link:definition>41802 - Disclosure - Commitments and Contingencies - Supply and Distribution Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" id="DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails">
        <link:definition>41803 - Disclosure - Commitments and Contingencies - Contingent Consideration Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" id="DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails">
        <link:definition>41804 - Disclosure - Commitments and Contingencies - Product Contingent Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" id="DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails">
        <link:definition>41805 - Disclosure - Commitments and Contingencies - Earn Out Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseDetails">
        <link:definition>41806 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails" id="DisclosureCommitmentsAndContingenciesLegalMattersDetails">
        <link:definition>41807 - Disclosure - Commitments and Contingencies - Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLicenseAgreementsDetails" id="DisclosureLicenseAgreementsDetails">
        <link:definition>41901 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails" id="DisclosureSegmentInformationImpairmentDetails">
        <link:definition>42002 - Disclosure - Segment Information - Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails" id="DisclosureSegmentInformationSelectFinancialInformationDetails">
        <link:definition>42003 - Disclosure - Segment Information - Select Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition" id="DisclosureNatureOfBusinessAndFinancialCondition">
        <link:definition>10101 - Disclosure - Nature of Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers" id="DisclosureRevenuesFromContractsWithCustomers">
        <link:definition>10301 - Disclosure - Revenues from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10401 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10501 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10601 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets" id="DisclosureGoodwillAndOtherIntangibleAssets">
        <link:definition>10701 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>10801 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilities" id="DisclosureOtherLiabilities">
        <link:definition>10901 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>11101 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11201 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11401 - Disclosure - Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11701 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables" id="DisclosureRevenuesFromContractsWithCustomersTables">
        <link:definition>30303 - Disclosure - Revenues from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30403 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30503 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30603 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" id="DisclosureGoodwillAndOtherIntangibleAssetsTables">
        <link:definition>30703 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>30803 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesTables" id="DisclosureOtherLiabilitiesTables">
        <link:definition>30903 - Disclosure - Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>31103 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>32003 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails" id="DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails">
        <link:definition>40101 - Disclosure - Nature of Business and Financial Condition - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails" id="DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails">
        <link:definition>40104 - Disclosure - Nature of Business and Financial Condition - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails">
        <link:definition>40207 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails">
        <link:definition>40208 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails">
        <link:definition>40210 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails">
        <link:definition>40212 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>40213 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails" id="DisclosurePropertyAndEquipmentDepreciationExpenseDetails">
        <link:definition>40502 - Disclosure - Property and Equipment - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails" id="DisclosurePropertyAndEquipmentGainLossOnDisposalDetails">
        <link:definition>40503 - Disclosure - Property and Equipment - Gain (Loss) on Disposal (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails" id="DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails">
        <link:definition>40604 - Disclosure - Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails" id="DisclosureLeasesCashFlowInformationDetails">
        <link:definition>40605 - Disclosure - Leases - Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails" id="DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>40709 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails" id="DisclosureAccruedLiabilitiesReturnReserveDetails">
        <link:definition>40802 - Disclosure - Accrued Liabilities - Return Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails" id="DisclosureOtherLiabilitiesContingentValueRightsDetails">
        <link:definition>40905 - Disclosure - Other Liabilities - Contingent Value Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails" id="DisclosureOtherLiabilitiesContingentConsiderationTotalDetails">
        <link:definition>40908 - Disclosure - Other Liabilities - Contingent Consideration - Total (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails">
        <link:definition>41301 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails" id="DisclosureIncomeTaxesSection382LimitationDetails">
        <link:definition>41303 - Disclosure - Income Taxes - Section 382 Limitation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails">
        <link:definition>41309 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails">
        <link:definition>41311 - Disclosure - Income Taxes - Unrecognized Tax Benefits - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>41312 - Disclosure - Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails" id="DisclosureStockholdersEquityCommonAndPreferredStockDetails">
        <link:definition>41401 - Disclosure - Stockholders Equity - Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails" id="DisclosureEquityIncentivePlansStockOptionsDetails">
        <link:definition>41502 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails" id="DisclosureSegmentInformationGeneralInformationDetails">
        <link:definition>42001 - Disclosure - Segment Information - General Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:element id="aytu_ReturnReserve" name="ReturnReserve" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="aytu_IncomeTaxReconciliationContingentConsideration" name="IncomeTaxReconciliationContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <xsd:element id="aytu_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="aytu_CustomerContractCostsPolicyTextBlock" name="CustomerContractCostsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ZolpiMistMember" name="ZolpiMistMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_LabEquipmentMember" name="LabEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_CustomerAMember" name="CustomerAMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_CustomerBMember" name="CustomerBMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_CustomerCMember" name="CustomerCMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ProductDistributionRightsMember" name="ProductDistributionRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ContingentConsiderationMember" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" />
  <xsd:element id="aytu_PediatricPortfolioMember" name="PediatricPortfolioMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ConsumerHealthPortfolioMember" name="ConsumerHealthPortfolioMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_LicensingAgreementsTextBlock" name="LicensingAgreementsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts" name="StockIssuedDuringPeriodSharesContingentValueRightsPayouts" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_NeosTherapeuticsIncMember" name="NeosTherapeuticsIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_PaymentsForFixedPaymentArrangement" name="PaymentsForFixedPaymentArrangement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="aytu_Neos2015PlanMember" name="Neos2015PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_NonplanMember" name="NonplanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_WarrantsOrRightsDisclosureTextBlock" name="WarrantsOrRightsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element id="aytu_LesseeLeasesCashFlowInformationTableTextBlock" name="LesseeLeasesCashFlowInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ManufacturingEquipmentMember" name="ManufacturingEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_OfficeEquipmentFurnitureAndOtherMember" name="OfficeEquipmentFurnitureAndOtherMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_OperatingLeaseAndFinanceLeaseLiability" name="OperatingLeaseAndFinanceLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="aytu_AccruedProgramRelatedLiabilities" name="AccruedProgramRelatedLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_AccruedSavingOffers" name="AccruedSavingOffers" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" name="ContingentValueRightsLiabilitiesFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="aytu_ContingentValueRightsMeasurementInput" name="ContingentValueRightsMeasurementInput" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" />
  <xsd:element id="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_LicenseAgreementAbstract" name="LicenseAgreementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_MeasurementInputLeveragedBetaMember" name="MeasurementInputLeveragedBetaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_MeasurementInputMarketRiskPremiumMember" name="MeasurementInputMarketRiskPremiumMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="aytu_ShelfRegistrationAmountAuthorized" name="ShelfRegistrationAmountAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" name="EffectiveIncomeTaxRateReconciliationContingentConsideration" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" name="OperatingLeaseAndFinanceLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="aytu_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheFiveMember" name="ShareBasedCompensationAwardTrancheFiveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheSixMember" name="ShareBasedCompensationAwardTrancheSixMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheSevenMember" name="ShareBasedCompensationAwardTrancheSevenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheEightMember" name="ShareBasedCompensationAwardTrancheEightMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShareBasedCompensationAwardTrancheNineMember" name="ShareBasedCompensationAwardTrancheNineMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_NumberOfProducts" name="NumberOfProducts" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ProductTechnologyRightMember" name="ProductTechnologyRightMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_NumberOfProductsAcquired" name="NumberOfProductsAcquired" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_ContingentValueRightsMember" name="ContingentValueRightsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" name="NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock" name="RemainingLeaseTermAndDiscountRateTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_Aytu2015PlanMember" name="Aytu2015PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" name="EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" name="EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element id="aytu_DeferredTaxAssetsAccruedRebates" name="DeferredTaxAssetsAccruedRebates" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="aytu_DeferredTaxAssetsInterest" name="DeferredTaxAssetsInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" name="FiniteLivedIntangibleAssetsAccumulatedImpairment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" name="OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="aytu_ShelfRegistrationRemainingAmountAvailableForSale" name="ShelfRegistrationRemainingAmountAvailableForSale" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfProductPortfolios" id="aytu_NumberOfProductPortfolios" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentMinimumVariableRateBeforeBasisSpread" id="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AvenueCapitalLoanTermLoanMember" id="aytu_AvenueCapitalLoanTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrimaryCarePortfolioMember" id="aytu_PrimaryCarePortfolioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TussionexMember" id="aytu_TussionexMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" id="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" id="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeerfieldFacilityMember" id="aytu_DeerfieldFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentInterestPaymentTerm" id="aytu_DebtInstrumentInterestPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentInterestPaymentExtensionTerm" id="aytu_DebtInstrumentInterestPaymentExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InterestOnlyPeriodFurtherExtensionTerm" id="aytu_InterestOnlyPeriodFurtherExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" id="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentTermOfTrailingMonthsRevenue" id="aytu_DebtInstrumentTermOfTrailingMonthsRevenue" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentPrepaymentFeePercentage" id="aytu_DebtInstrumentPrepaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AciphexMember" id="aytu_AciphexMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CefaclorMember" id="aytu_CefaclorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConsumerHealthMember" id="aytu_ConsumerHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WriteOffOfDeferredDebtIssuanceCostNet" id="aytu_WriteOffOfDeferredDebtIssuanceCostNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueMilestonePayments" id="aytu_StockIssuedDuringPeriodValueMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesMilestonePayments" id="aytu_StockIssuedDuringPeriodSharesMilestonePayments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockAndWarrants" id="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" id="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" id="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccountsReceivableCreditTermsLowEndOfRange" id="aytu_AccountsReceivableCreditTermsLowEndOfRange" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccountsReceivableCreditTermsHighEndOfRange" id="aytu_AccountsReceivableCreditTermsHighEndOfRange" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsToPurchaseCommonStockMember" id="aytu_WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockEquityClassifiedMember" id="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedMember" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AttentionDeficitHyperactivityDisorderPortfolioMember" id="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" id="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" id="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" id="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" id="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShelfRegistrationStatement2021ShelfMember" id="aytu_ShelfRegistrationStatement2021ShelfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatement2020ShelfMember" id="aytu_ShelfRegistrationStatement2020ShelfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" id="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" id="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" id="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" id="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FixedPaymentArrangements" id="aytu_FixedPaymentArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" id="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsMeasurementInput" id="aytu_FixedPaymentArrangementsMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AccruedCustomerAndProductRelatedFeesCurrent" id="aytu_AccruedCustomerAndProductRelatedFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" id="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" id="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" id="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NeosPlanMember" id="aytu_NeosPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AytuPlanMember" id="aytu_AytuPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NextFourPercentAndFivePercentContributionByEmployeesMember" id="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NextFourPercentContributionByEmployeesMember" id="aytu_NextFourPercentContributionByEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NextFivePercentContributionByEmployeesMember" id="aytu_NextFivePercentContributionByEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SixPercentContributionByEmployeesMember" id="aytu_SixPercentContributionByEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstThreePercentContributionByEmployeesMember" id="aytu_FirstThreePercentContributionByEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfEmployeeBenefitPlan" id="aytu_NumberOfEmployeeBenefitPlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExercisePriceRangeOneMember" id="aytu_ExercisePriceRangeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceRangeTwoMember" id="aytu_ExercisePriceRangeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsMonthlyPaymentAmount" id="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsBalloonPaymentAmount" id="aytu_FixedPaymentArrangementsBalloonPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsBalloonPaymentAmountPaid" id="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsQuarterlyPaymentAmount" id="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" id="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" id="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" id="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsPeriodicPaymentObligationsNumber" id="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" id="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" id="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsPaymentAmountPaid" id="aytu_FixedPaymentArrangementsPaymentAmountPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" id="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" id="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" id="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtmSalesAgreementAmountAuthorized" id="aytu_AtmSalesAgreementAmountAuthorized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" id="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" id="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" id="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LongTermDebtAndFinanceLeaseLiabilityGross" id="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" id="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicensingAgreementCedarsSinaiMedicalCenterHealightMember" id="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" id="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAgreement2017ShireLlcNewDrugApplicationMember" id="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" id="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementInitialLicenseFeePaid" id="aytu_LicenseAgreementInitialLicenseFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementPatentProsecutionFeesPaid" id="aytu_LicenseAgreementPatentProsecutionFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" id="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommercialGlobalLicenseAgreementsAr101Member" id="aytu_CommercialGlobalLicenseAgreementsAr101Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" id="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" id="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAgreementMilestonePaymentPaidCashAndCommonStock" id="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementMilestonePaymentPaidCash" id="aytu_LicenseAgreementMilestonePaymentPaidCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" id="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementAnnualMaintenanceFee" id="aytu_LicenseAgreementAnnualMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementLicenseOptionFee" id="aytu_LicenseAgreementLicenseOptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementEscalatingRoyaltiesMaximum" id="aytu_LicenseAgreementEscalatingRoyaltiesMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" id="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" id="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementRoyaltiesPercentageOfNetProductSales" id="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" id="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProductContingentLiabilityNovalereFluticareMember" id="aytu_ProductContingentLiabilityNovalereFluticareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProductContingentLiabilityMilestonePayment" id="aytu_ProductContingentLiabilityMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" id="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" id="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndDistributionAgreementTrisPharmaIncMember" id="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SupplyAndDistributionAgreementTerm" id="aytu_SupplyAndDistributionAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" id="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" id="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" id="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" id="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" id="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" id="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" id="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsInstallmentPaymentsNumber" id="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" id="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsLiabilityReduction" id="aytu_FixedPaymentArrangementsLiabilityReduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" id="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" id="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" id="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" id="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" id="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IssuanceOfStockForMilestonePayments" id="aytu_IssuanceOfStockForMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" id="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="InnovusPharmaceuticalsIncMember" id="aytu_InnovusPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" id="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" id="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" id="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" id="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" id="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoryWriteDownAndImpairment" id="aytu_InventoryWriteDownAndImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" id="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RxMember" id="aytu_RxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" id="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightOfferingPrice" id="aytu_ClassOfWarrantOrRightOfferingPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" id="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" id="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" id="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" id="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FixedPaymentArrangementsNoncurrent" id="aytu_FixedPaymentArrangementsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EclipseLoanAgreementSecuredRevolvingLoansMember" id="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" id="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" id="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" id="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentTerminationBusinessDaysNoticePeriod" id="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" id="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" id="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" id="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" id="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" id="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsPolicyTextBlock" id="aytu_WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FixedPaymentArrangementsCurrent" id="aytu_FixedPaymentArrangementsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClassOfWarrantOrRightActivityTableTextBlock" id="aytu_ClassOfWarrantOrRightActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" id="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExpirationOfSubleaseMember" id="aytu_ExpirationOfSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpansionDateMember" id="aytu_ExpansionDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RentReceivableFromSubleaseProperty" id="aytu_RentReceivableFromSubleaseProperty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AreaOfSubleaseProperty" id="aytu_AreaOfSubleaseProperty" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="RemainingAreaOfSubleaseProperty" id="aytu_RemainingAreaOfSubleaseProperty" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PrincipalOfficeDenverColoradoMember" id="aytu_PrincipalOfficeDenverColoradoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyThreeEquityIncentivePlanMember" id="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightAdjusted" id="aytu_ClassOfWarrantOrRightAdjusted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" id="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" id="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" id="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" id="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" id="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" id="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AytuBiopharmaEmployeeRetirementPlanMember" id="aytu_AytuBiopharmaEmployeeRetirementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingLeaseAgreementMember" id="aytu_OperatingLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AverageUndiscountedMinimumMonthlyRentPayments" id="aytu_AverageUndiscountedMinimumMonthlyRentPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SabbyLitigationMember" id="aytu_SabbyLitigationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SabbyVolatilityWarrantMasterFundLtdMember" id="aytu_SabbyVolatilityWarrantMasterFundLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WalleyeOpportunitiesMasterFundLtdMember" id="aytu_WalleyeOpportunitiesMasterFundLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SecuritiesPurchaseAgreement2023Member" id="aytu_SecuritiesPurchaseAgreement2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" id="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" id="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" id="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" id="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" id="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" id="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" id="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" id="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" id="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" id="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" id="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" id="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReturnReserveCurrent" id="aytu_ReturnReserveCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReturnReserveChargesToExpense" id="aytu_ReturnReserveChargesToExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReturnReservePayments" id="aytu_ReturnReservePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfReturnReserveTableTextBlock" id="aytu_ScheduleOfReturnReserveTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" id="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetImpairmentAndWriteoffCharges" id="aytu_AssetImpairmentAndWriteoffCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" id="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>aytu-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/12/2023 5:27:44 PM-->
<!--Modified on: 10/12/2023 5:27:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aytubio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventoriesTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventoriesInventoryWriteDownDetails" roleURI="http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesNetLeaseCostDetails" roleURI="http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesOperatingLeasesGrossDifferenceDetails" roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesFinanceLeasesGrossDifferenceDetails" roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureAccruedLiabilitiesGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesComponentsDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesClassificationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtCompositionDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://aytubio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637595105262222002" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637595105262222002" xlink:to="us-gaap_AssetsCurrent_638327284584165499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638327284584165499" xlink:to="us-gaap_AccountsReceivableNetCurrent_638327284584165499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638327284584165499" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638327284584165499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638327284584165499" xlink:to="us-gaap_OtherAssetsCurrent_638327284584165499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638327284584165499" xlink:to="us-gaap_InventoryNet_638327284584165499" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638327284584165499" xlink:to="us-gaap_PrepaidExpenseCurrent_638327284584165499" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637595105262222002" xlink:to="us-gaap_AssetsNoncurrent_638327284584165499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284584165499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638327284584165499" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284584165499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638327284584165499" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284584175499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638327284584165499" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638327284584175499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638327284584165499" xlink:to="us-gaap_OtherAssetsNoncurrent_638327284584175499" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637595105262232314" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637595105262232314" xlink:to="us-gaap_StockholdersEquity_638327284584175499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638327284584175499" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638327284584175499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638327284584175499" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638327284584175499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638327284584175499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638327284584175499" xlink:to="us-gaap_PreferredStockValue_638327284584175499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638327284584175499" xlink:to="us-gaap_CommonStockValue_638327284584185496" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637595105262232314" xlink:to="us-gaap_Liabilities_638327284584185496" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638327284584185496" xlink:to="us-gaap_LiabilitiesCurrent_638327284584185496" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638327284584185496" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638327284584185496" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638327284584185496" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638327284584185496" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638327284584185496" xlink:to="us-gaap_ShortTermBorrowings_638327284584185496" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284584185496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638327284584185496" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284584185496" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638327284584185496" xlink:to="us-gaap_OtherLiabilitiesCurrent_638327284584195498" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638327284584185496" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284584195498" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638327284584185496" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638327284584195498" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638327284584185496" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638327284584195498" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284584195498" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638327284584195498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284584195498" xlink:to="us-gaap_OperatingIncomeLoss_638327284584195498" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638327284584195498" xlink:to="us-gaap_GrossProfit_638327284584205496" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638327284584205496" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284584205496" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638327284584205496" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638327284584205496" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638327284584195498" xlink:to="us-gaap_OperatingExpenses_638327284584205496" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_SellingAndMarketingExpense_638327284584205496" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638327284584205496" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638327284584205496" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638327284584205496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_GoodwillImpairmentLoss_638327284584205496" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_OtherAssetImpairmentCharges_638327284584215499" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638327284584215499" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638327284584205496" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284584215499" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284584195498" xlink:to="us-gaap_NonoperatingIncomeExpense_638327284584215499" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638327284584215499" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638327284584215499" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638327284584215499" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284584215499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638327284584215499" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284584215499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638327284584215499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638327284584215499" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_ProfitLoss_638327284584225497" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638327284584225497" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_AssetImpairmentCharges_638327284584225497" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_InventoryWriteDown_638327284584225497" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_ShareBasedCompensation_638327284584225497" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284584225497" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284584225497" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284584235518" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638327284584235518" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IssuanceOfStockForMilestonePayments" xlink:label="aytu_IssuanceOfStockForMilestonePayments_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="aytu_IssuanceOfStockForMilestonePayments_638327284584235518" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WriteOffOfDeferredDebtIssuanceCostNet" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="aytu_WriteOffOfDeferredDebtIssuanceCostNet_638327284584235518" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_638327284584235518" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638327284584235518" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInInventories_638327284584235518" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638327284584235518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638327284584235518" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638327284584245540" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638327284584245540" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284584225497" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_638327284584245540" order="17" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284584245540" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284584245540" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638327284584245540" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284584245540" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638327284584245540" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PaymentsForFixedPaymentArrangement" xlink:label="aytu_PaymentsForFixedPaymentArrangement_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="aytu_PaymentsForFixedPaymentArrangement_638327284584255571" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_638327284584255571" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_638327284584255571" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638327284584255571" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_638327284584255571" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284584255571" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638327284584255571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284584245540" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638327284584255571" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" xlink:type="extended" xlink:title="40206 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_638327284584265524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_638327284584265524" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284584265524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284584265524" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284584265524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284584265524" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventories - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637706853567067810" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638327284584265524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_637706853567067810" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638327284584265524" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638327284584265524" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_637706853567067810" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638327284584265524" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638327284584275521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_637706853567067810" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638327284584275521" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventories - Inventory Write-down (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InventoryWriteDownAndImpairment" xlink:label="aytu_InventoryWriteDownAndImpairment" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638327284584275521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_InventoryWriteDownAndImpairment" xlink:to="us-gaap_InventoryWriteDown_638327284584275521" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638327284584275521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638327284584275521" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638327284584275521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638327284584275521" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Leases - Net Lease Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638327284584275521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638327284584275521" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_638327284584285518" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638327284584285518" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense_638327284584285518" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638327284584285518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638327284584285518" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638327284584285518" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638327284584285518" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638327284584285518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638327284584285518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638327284584295518" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Leases - Operating Leases - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638327284584295518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638327284584295518" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638327284584295518" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638327284584295518" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails" xlink:type="extended" xlink:title="40607 - Disclosure - Leases - Operating Leases - Gross Difference (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638327284584295518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638327284584295518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638327284584305527" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638327284584305527" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40608 - Disclosure - Leases - Finance Leases - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638327284584305527" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638327284584305527" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails" xlink:type="extended" xlink:title="40609 - Disclosure - Leases - Finance Leases - Gross Difference (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638327284584305527" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638327284584305527" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638327284584305527" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_FinanceLeaseLiability_638327284584305527" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638327284584305527" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638327284584305527" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284584315521" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284584315521" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284584315521" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284584315521" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638327284584315521" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284584315521" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638327284584315521" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284584315521" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284584315521" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284584315521" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284584315521" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284584315521" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284584315521" xlink:to="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_638327284584325519" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638327284584325519" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638327284584325519" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638327284584325519" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638327284584325519" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638327284584325519" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638327284584325519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638327284584325519" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accrued Liabilities - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="aytu_ReturnReserveCurrent_638327284584335519" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638327284584335519" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent_638327284584335519" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="aytu_AccruedSavingOffers_638327284584335519" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="aytu_AccruedProgramRelatedLiabilities_638327284584335519" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638327284584335519" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_637649284121461562" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638327284584335519" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other Liabilities - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284584565518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284584565518" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements_638327284584565518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="aytu_FixedPaymentArrangements_638327284584565518" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638327284584565518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiability_638327284584565518" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities_638327284584565518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherSundryLiabilities_638327284584565518" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284584565518" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284584565518" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Other Liabilities - Classification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities_1" xlink:to="us-gaap_OtherLiabilitiesCurrent_638327284584575525" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilities_1" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638327284584575525" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Long-term Debt - Composition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_637595105268612399" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_637595105268612399" xlink:to="us-gaap_FinanceLeaseLiability_638327284584575525" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_637595105268612399" xlink:to="us-gaap_LongTermDebt_638327284584575525" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_637595105268612399" xlink:to="us-gaap_DebtInstrumentFeeAmount_638327284584575525" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638327284584575525" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_637595105268612399" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638327284584575525" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Long-term Debt - Future Principal Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_638327284584585513" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_638327284584585513" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_638327284584585513" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_638327284584585513" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284584585513" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284584585513" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284584585513" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284584585513" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638327284584585513" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities_638327284584585513" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284584595510" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284584595510" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638327284584595510" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284584595510" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638327284584595510" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284584595510" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284584595510" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638327284584595510" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284584595510" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638327284584595510" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41307 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_638327284584595510" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_638327284584595510" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_638327284584595510" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284584605512" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_638327284584605512" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_638327284584605512" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638327284584605512" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284584605512" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638327284584605512" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638327284584605512" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638327284584605512" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638327284584615511" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284584615511" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration_638327284584615511" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_638327284584615511" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_638327284584615511" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284584615511" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638327284584615511" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638327284584615511" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" xlink:type="extended" xlink:title="41308 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet_638327284584625507" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsGross_638327284584625507" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638327284584625507" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="aytu_DeferredTaxAssetsAccruedRebates_638327284584625507" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638327284584625507" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638327284584625507" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638327284584625507" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsInterest" xlink:label="aytu_DeferredTaxAssetsInterest_638327284584625507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="aytu_DeferredTaxAssetsInterest_638327284584625507" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638327284584635508" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_638327284584635508" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsInventory_638327284584635508" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="aytu_DeferredTaxAssetsLeaseLiability_638327284584635508" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsOther_638327284584635508" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638327284584625507" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638327284584635508" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638327284584635508" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638327284584635508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638327284584635508" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638327284584635508" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638327284584645508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638327284584635508" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638327284584645508" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset_638327284584645508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638327284584635508" xlink:to="aytu_DeferredTaxLiabilitiesRightOfUseAsset_638327284584645508" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>aytu-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/12/2023 5:27:44 PM-->
<!--Modified on: 10/12/2023 5:27:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementOfStockholdersEquity" roleURI="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentImpairmentDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLineOfCreditDetails" roleURI="http://aytubio.com/role/DisclosureLineOfCreditDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtWarrantsDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsValuationAssumptionsDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityRestrictedStockDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityStockOfferingsDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockActivityDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsStockIssuedDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsWarrantsActivityDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesLegalMattersDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLicenseAgreementsDetails" roleURI="http://aytubio.com/role/DisclosureLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationImpairmentDetails" roleURI="http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationSelectFinancialInformationDetails" roleURI="http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://aytubio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="aytu-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd#eedm1" roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_1" xlink:title="us-gaap_AssetsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1" xlink:title="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract_1 To us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_DerivativeGainLossOnDerivativeNet" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_2" xlink:title="us-gaap_AssetImpairmentCharges_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_AssetImpairmentCharges_2" order="2" priority="0" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_2" xlink:title="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_2" order="3" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_1" xlink:title="us-gaap_LiabilitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_2" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract_1" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract_1 To us-gaap_DerivativeLiabilitiesNoncurrent_2" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_15" xlink:title="us-gaap_SegmentDomain_15" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_10" xlink:title="aytu_RxMember_10" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_SegmentDomain_15" xlink:to="aytu_RxMember_10" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_SegmentDomain_15 To aytu_RxMember_10" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_10" xlink:title="aytu_ConsumerHealthMember_10" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_SegmentDomain_15" xlink:to="aytu_ConsumerHealthMember_10" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_SegmentDomain_15 To aytu_ConsumerHealthMember_10" order="2" priority="0" />
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="SRT Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://aytubio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis_1" xlink:title="us-gaap_ValuationTechniqueAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_1" xlink:title="us-gaap_ValuationTechniqueDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationTechniqueAxis_1" xlink:to="us-gaap_ValuationTechniqueDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationTechniqueAxis_1 To us-gaap_ValuationTechniqueDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_1" xlink:title="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_1" xlink:title="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_1" xlink:to="us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_1 To us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_1" xlink:title="us-gaap_OtherCommitmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_1" xlink:title="us-gaap_OtherCommitmentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherCommitmentsAxis_1" xlink:to="us-gaap_OtherCommitmentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherCommitmentsAxis_1 To us-gaap_OtherCommitmentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_1" xlink:title="us-gaap_DebtConversionByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_1" xlink:title="us-gaap_DebtConversionNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_1" xlink:to="us-gaap_DebtConversionNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtConversionByUniqueDescriptionAxis_1 To us-gaap_DebtConversionNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_1" xlink:title="us-gaap_RetirementPlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_1" xlink:title="us-gaap_RetirementPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanNameAxis_1" xlink:to="us-gaap_RetirementPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanNameAxis_1 To us-gaap_RetirementPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodValueMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="aytu_StockIssuedDuringPeriodValueMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_StockIssuedDuringPeriodValueMilestonePayments" xlink:to="aytu_StockIssuedDuringPeriodSharesMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMember" xlink:label="aytu_ContingentValueRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="aytu_ContingentValueRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" xlink:type="extended" xlink:title="40103 - Disclosure - Nature of Business and Financial Condition - Product Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductPortfolios" xlink:label="aytu_NumberOfProductPortfolios" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="aytu_NumberOfProductPortfolios" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" xlink:type="extended" xlink:title="40105 - Disclosure - Nature of Business and Financial Condition - Going Concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AvenueCapitalLoanTermLoanMember" xlink:label="aytu_AvenueCapitalLoanTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" xlink:type="extended" xlink:title="40205 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_OperatingIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40209 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" xlink:type="extended" xlink:title="40211 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="aytu_CustomerCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40214 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="aytu_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40215 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202104Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Revenues from Contracts with Customers - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthPortfolioMember" xlink:label="aytu_ConsumerHealthPortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="aytu_ConsumerHealthPortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="aytu_NumberOfProducts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Revenues from Contracts with Customers - Revenues by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PediatricPortfolioMember" xlink:label="aytu_PediatricPortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="aytu_PediatricPortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ManufacturedProductOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthPortfolioMember" xlink:label="aytu_ConsumerHealthPortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ProductMember" xlink:to="aytu_ConsumerHealthPortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitNameOfSegmentExtensibleList" xlink:label="us-gaap_ReportingUnitNameOfSegmentExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ReportingUnitNameOfSegmentExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Revenues from Contracts with Customers - Revenues by Geographic Location (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_ManufacturingEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Property and Equipment - Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="aytu_ManufacturingEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentChargesAbstract" xlink:label="us-gaap_TangibleAssetImpairmentChargesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_TangibleAssetImpairmentChargesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TangibleAssetImpairmentChargesAbstract" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Leases - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="aytu_PrincipalOfficeDenverColoradoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpansionDateMember" xlink:label="aytu_ExpansionDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_ExpansionDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpirationOfSubleaseMember" xlink:label="aytu_ExpirationOfSubleaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_ExpirationOfSubleaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AreaOfSubleaseProperty" xlink:label="aytu_AreaOfSubleaseProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="aytu_AreaOfSubleaseProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RemainingAreaOfSubleaseProperty" xlink:label="aytu_RemainingAreaOfSubleaseProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="aytu_RemainingAreaOfSubleaseProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RentReceivableFromSubleaseProperty" xlink:label="aytu_RentReceivableFromSubleaseProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="aytu_RentReceivableFromSubleaseProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="aytu_ProductTechnologyRightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductDistributionRightsMember" xlink:label="aytu_ProductDistributionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="aytu_ProductDistributionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_OtherIntangibleAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="aytu_ProductTechnologyRightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductDistributionRightsMember" xlink:label="aytu_ProductDistributionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="aytu_ProductDistributionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" xlink:type="extended" xlink:title="40707 - Disclosure - Goodwill and Other Intangible Assets - Estimated Useful Life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="aytu_ProductTechnologyRightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_InnovusPharmaceuticalsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductsAcquired" xlink:label="aytu_NumberOfProductsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aytu_NumberOfProductsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" xlink:type="extended" xlink:title="40710 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrimaryCarePortfolioMember" xlink:label="aytu_PrimaryCarePortfolioMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="aytu_PrimaryCarePortfolioMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AciphexMember" xlink:label="aytu_AciphexMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_PrimaryCarePortfolioMember" xlink:to="aytu_AciphexMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ZolpiMistMember" xlink:label="aytu_ZolpiMistMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_PrimaryCarePortfolioMember" xlink:to="aytu_ZolpiMistMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TussionexMember" xlink:label="aytu_TussionexMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="aytu_PrimaryCarePortfolioMember" xlink:to="aytu_TussionexMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CefaclorMember" xlink:label="aytu_CefaclorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="aytu_PrimaryCarePortfolioMember" xlink:to="aytu_CefaclorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_NeosTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_InnovusPharmaceuticalsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AssetImpairmentChargesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Other Liabilities - Fixed Payment Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsCurrent" xlink:label="aytu_FixedPaymentArrangementsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsNoncurrent" xlink:label="aytu_FixedPaymentArrangementsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsLiabilityReduction" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsLiabilityReduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Other Liabilities - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Other Liabilities - Contingent Consideration - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aytu_InnovusPharmaceuticalsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Other Liabilities - Contingent Consideration - Other than Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureLineOfCreditDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Line of Credit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Long-term Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeerfieldFacilityMember" xlink:label="aytu_DeerfieldFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_DeerfieldFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AvenueCapitalLoanTermLoanMember" xlink:label="aytu_AvenueCapitalLoanTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aytu_AvenueCapitalLoanTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" xlink:label="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" xlink:label="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentTerm" xlink:label="aytu_DebtInstrumentInterestPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_DebtInstrumentInterestPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentExtensionTerm" xlink:label="aytu_DebtInstrumentInterestPaymentExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_DebtInstrumentInterestPaymentExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InterestOnlyPeriodFurtherExtensionTerm" xlink:label="aytu_InterestOnlyPeriodFurtherExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_InterestOnlyPeriodFurtherExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTermOfTrailingMonthsRevenue" xlink:label="aytu_DebtInstrumentTermOfTrailingMonthsRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_DebtInstrumentTermOfTrailingMonthsRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoanProcessingFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Long-term Debt - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMember" xlink:label="aytu_ContingentValueRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="aytu_ContingentValueRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationMember" xlink:label="aytu_ContingentConsiderationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="aytu_ContingentConsiderationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Fair Value Measurements - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputLeveragedBetaMember" xlink:label="aytu_MeasurementInputLeveragedBetaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="aytu_MeasurementInputLeveragedBetaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputMarketRiskPremiumMember" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="aytu_MeasurementInputMarketRiskPremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMeasurementInput" xlink:label="aytu_ContingentValueRightsMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="aytu_ContingentValueRightsMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" xlink:label="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Fair Value Measurements - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="aytu_FixedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Consolidated Balance Sheet (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAbstract" xlink:label="us-gaap_TaxesPayableCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income Taxes - Operating Loss Carry Forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Income Taxes - Tax Credit Carry Forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" xlink:type="extended" xlink:title="41310 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Stockholders Equity - Restricted Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Stockholders Equity - Stock Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_ShelfRegistrationStatement2020ShelfMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_ShelfRegistrationStatement2020ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_ShelfRegistrationStatement2021ShelfMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreement2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_SecuritiesPurchaseAgreement2023Member" xlink:to="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationAmountAuthorized" xlink:label="aytu_ShelfRegistrationAmountAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_ShelfRegistrationAmountAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationRemainingAmountAvailableForSale" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_ShelfRegistrationRemainingAmountAvailableForSale" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AtmSalesAgreementAmountAuthorized" xlink:label="aytu_AtmSalesAgreementAmountAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_AtmSalesAgreementAmountAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Stockholders Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightOfferingPrice" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Equity Incentive Plans - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Neos2015PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Equity Incentive Plans - Range of Exercise Prices (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="aytu_ExercisePriceRangeOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="aytu_ExercisePriceRangeTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Equity Incentive Plans - Restricted Stock - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheSixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheSevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheEightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheNineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Equity Incentive Plans - Restricted Stock - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" xlink:type="extended" xlink:title="41506 - Disclosure - Equity Incentive Plans - Restricted Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_NonplanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheSixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheSevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheEightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_VestingDomain" xlink:to="aytu_ShareBasedCompensationAwardTrancheNineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" xlink:type="extended" xlink:title="41507 - Disclosure - Equity Incentive Plans - Unrecognized Compensation Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_NonplanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41508 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Warrants - Stock Issued (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_ShelfRegistrationStatement2021ShelfMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aytu_SecuritiesPurchaseAgreement2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_SecuritiesPurchaseAgreement2023Member" xlink:to="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Warrants - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails" xlink:type="extended" xlink:title="41604 - Disclosure - Warrants - Warrants Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aytu_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjusted" xlink:label="aytu_ClassOfWarrantOrRightAdjusted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightAdjusted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="aytu_NeosPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuPlanMember" xlink:label="aytu_AytuPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="aytu_AytuPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuBiopharmaEmployeeRetirementPlanMember" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="aytu_AytuBiopharmaEmployeeRetirementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFourPercentContributionByEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFivePercentContributionByEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SixPercentContributionByEmployeesMember" xlink:label="aytu_SixPercentContributionByEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="aytu_SixPercentContributionByEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfEmployeeBenefitPlan" xlink:label="aytu_NumberOfEmployeeBenefitPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="aytu_NumberOfEmployeeBenefitPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Commitments and Contingencies - Fixed Payment Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Commitments and Contingencies - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Commitments and Contingencies - Contingent Consideration Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" xlink:type="extended" xlink:title="41804 - Disclosure - Commitments and Contingencies - Product Contingent Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityNovalereFluticareMember" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="aytu_ProductContingentLiabilityNovalereFluticareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityMilestonePayment" xlink:label="aytu_ProductContingentLiabilityMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="aytu_ProductContingentLiabilityMilestonePayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" xlink:type="extended" xlink:title="41805 - Disclosure - Commitments and Contingencies - Earn Out Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_CommercialGlobalLicenseAgreementsAr101Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:to="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:to="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAnnualMaintenanceFee" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementAnnualMaintenanceFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementLicenseOptionFee" xlink:label="aytu_LicenseAgreementLicenseOptionFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementLicenseOptionFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementEscalatingRoyaltiesMaximum" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementEscalatingRoyaltiesMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_StockIssuedDuringPeriodSharesMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCash" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCash" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended" xlink:title="41806 - Disclosure - Commitments and Contingencies - Operating Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAgreementMember" xlink:label="aytu_OperatingLeaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_OperatingLeaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AverageUndiscountedMinimumMonthlyRentPayments" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_AverageUndiscountedMinimumMonthlyRentPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails" xlink:type="extended" xlink:title="41807 - Disclosure - Commitments and Contingencies - Legal Matters (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="aytu_SabbyLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureLicenseAgreementsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - License Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails" xlink:type="extended" xlink:title="42002 - Disclosure - Segment Information - Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AssetImpairmentChargesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:label="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:to="us-gaap_InventoryWriteDown" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails" xlink:type="extended" xlink:title="42003 - Disclosure - Segment Information - Select Financial Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_RxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentDomain" xlink:to="aytu_ConsumerHealthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RevenuesAbstract" xlink:to="aytu_AssetImpairmentAndWriteoffCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>aytu-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/12/2023 5:27:44 PM-->
<!--Modified on: 10/12/2023 5:27:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Listing, Par Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net carrying amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term line of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt and Lease Obligation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt and Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current portion of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other liabilities, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 18)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2023 and June 30, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 5,517,174 and 1,928,941, respectively, as of June 30, 2023 and June 30, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contract with customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Product and Service</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost, Product and Service [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost, Product and Service</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from contingent consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on derivative warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on derivative warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodValueMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodValueMilestonePayments" xlink:to="aytu_StockIssuedDuringPeriodValueMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to milestone payment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:to="aytu_StockIssuedDuringPeriodSharesMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to milestone payment (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax withholding for stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" xlink:label="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" xlink:to="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued during period, value, new issues, issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and accretion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of senior debt (premium) discount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IssuanceOfStockForMilestonePayments" xlink:label="aytu_IssuanceOfStockForMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfStockForMilestonePayments" xlink:to="aytu_IssuanceOfStockForMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfStockForMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Stock for Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfStockForMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Stock for Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_IssuanceOfStockForMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuance related to milestone payment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WriteOffOfDeferredDebtIssuanceCostNet" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WriteOffOfDeferredDebtIssuanceCostNet" xlink:to="aytu_WriteOffOfDeferredDebtIssuanceCostNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of Deferred Debt Issuance Cost, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Write-off of Deferred Debt Issuance Cost, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Activities, Cash Flow Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncash adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets and Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating assets and liabilities, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Contingent Consideration Liability, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of stock</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PaymentsForFixedPaymentArrangement" xlink:label="aytu_PaymentsForFixedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForFixedPaymentArrangement" xlink:to="aytu_PaymentsForFixedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentsForFixedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Fixed Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentsForFixedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Fixed Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentsForFixedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment made to fixed payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net payments made on short-term line of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments made to borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash and non-cash investing and financing transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow data</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Significant Noncash Transaction, Value of Consideration Given</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncash investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Financial Condition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues from Contracts with Customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LeaseDisclosureTextBlock" xlink:label="aytu_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LeaseDisclosureTextBlock" xlink:to="aytu_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Other Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Note Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsOrRightsDisclosureTextBlock" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsOrRightsDisclosureTextBlock" xlink:to="aytu_WarrantsOrRightsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants or Rights Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAbstract" xlink:label="aytu_LicenseAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementAbstract" xlink:to="aytu_LicenseAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTextBlock" xlink:label="aytu_LicensingAgreementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicensingAgreementsTextBlock" xlink:to="aytu_LicensingAgreementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicensingAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for licensing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicensingAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicensingAgreementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principals of Consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principals of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior Period Reclassification and Previously Reported Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_GoingConcernPolicyTextBlock" xlink:label="aytu_GoingConcernPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GoingConcernPolicyTextBlock" xlink:to="aytu_GoingConcernPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for going concern determination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern Determination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combinations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisitions and Business Combination and Contingent considerations</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsPolicyTextBlock" xlink:label="aytu_WarrantsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsPolicyTextBlock" xlink:to="aytu_WarrantsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerContractCostsPolicyTextBlock" xlink:label="aytu_CustomerContractCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerContractCostsPolicyTextBlock" xlink:to="aytu_CustomerContractCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CustomerContractCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for customer contract costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerContractCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Contract Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CustomerContractCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Contract Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentrations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs of Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs of Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-lived Assets and Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Cost [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs, discounts (premium)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paragraph IV litigation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of the impact of the immaterial correction of an error</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of receivables from customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of allowance for discounts and allowance for chargebacks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of business risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of concentration of business risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from the computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of disaggregation of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of disaggregation of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue by product lines</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product revenues by geographic location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of product revenues by geographic location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expenses</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="aytu_AssetsAndLiabilitiesLesseeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of lessee's assets and liabilities related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities, Lessee [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of balance sheet information related to leases</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of weighted average lease term and discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Lease Term And Discount Rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of remaining lease term and discount rate</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LesseeLeasesCashFlowInformationTableTextBlock" xlink:label="aytu_LesseeLeasesCashFlowInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LesseeLeasesCashFlowInformationTableTextBlock" xlink:to="aytu_LesseeLeasesCashFlowInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LesseeLeasesCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental cash flow information for leases of the lessee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LesseeLeasesCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases, Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LesseeLeasesCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of supplemental cash flow information related to leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of future minimum lease payments, operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of future minimum lease payments, finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Goodwill [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of change in carrying amount of goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of finite lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Indefinite lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ScheduleOfReturnReserveTableTextBlock" xlink:label="aytu_ScheduleOfReturnReserveTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ScheduleOfReturnReserveTableTextBlock" xlink:to="aytu_ScheduleOfReturnReserveTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ScheduleOfReturnReserveTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the return reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ScheduleOfReturnReserveTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Return Reserve [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ScheduleOfReturnReserveTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of the return reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future principal payments of long term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMember" xlink:label="aytu_ContingentValueRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsMember" xlink:to="aytu_ContingentValueRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments, Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in Level 3 inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant assumptions used in valuation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular rollforward of gross unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock units activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightActivityTableTextBlock" xlink:label="aytu_ClassOfWarrantOrRightActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightActivityTableTextBlock" xlink:to="aytu_ClassOfWarrantOrRightActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrant activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment select financial information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split, conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RxMember" xlink:to="aytu_RxMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rx [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rx [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_RxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rx</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_RxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rx Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductPortfolios" xlink:label="aytu_NumberOfProductPortfolios" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfProductPortfolios" xlink:to="aytu_NumberOfProductPortfolios_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NumberOfProductPortfolios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Product Portfolios</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfProductPortfolios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Product Portfolios</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NumberOfProductPortfolios_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of product portfolios</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AvenueCapitalLoanTermLoanMember" xlink:label="aytu_AvenueCapitalLoanTermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AvenueCapitalLoanTermLoanMember" xlink:to="aytu_AvenueCapitalLoanTermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AvenueCapitalLoanTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Avenue Capital Loan, Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AvenueCapitalLoanTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Avenue Capital Loan, Term Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AvenueCapitalLoanTermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Avenue Capital Loan, Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Adjustment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Error Correction, Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revision of Prior Period, Error Correction, Adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Error Corrections and Prior Period Adjustments Restatement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConsumerHealthMember" xlink:to="aytu_ConsumerHealthMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ConsumerHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ConsumerHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ConsumerHealthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total allowance, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total allowance, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowances</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for discount, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for discount, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for discounts</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for chargeback, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for chargeback, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for chargebacks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Opening balance</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:to="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, before Allowance for Credit Loss, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, before Allowance for Credit Loss, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Discounts, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Discounts, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for discount, charges to expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts, Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts, Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for discount, payments</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Pricing Chargebacks, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Pricing Chargebacks, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for chargeback, charges to expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks, Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks, Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for chargeback, payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total allowance, charges to expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Recovery</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total allowance, payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableCreditTermsLowEndOfRange" xlink:label="aytu_AccountsReceivableCreditTermsLowEndOfRange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableCreditTermsLowEndOfRange" xlink:to="aytu_AccountsReceivableCreditTermsLowEndOfRange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableCreditTermsLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Terms, Low End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableCreditTermsLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Terms, Low End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableCreditTermsLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, credit terms, low end of range</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableCreditTermsHighEndOfRange" xlink:label="aytu_AccountsReceivableCreditTermsHighEndOfRange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccountsReceivableCreditTermsHighEndOfRange" xlink:to="aytu_AccountsReceivableCreditTermsHighEndOfRange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccountsReceivableCreditTermsHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Terms, High End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccountsReceivableCreditTermsHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Credit Terms, High End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccountsReceivableCreditTermsHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, credit terms, high end of range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Benchmark [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer Benchmark [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerAMember" xlink:to="aytu_CustomerAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CustomerAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer A</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerBMember" xlink:to="aytu_CustomerBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CustomerBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer B</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerCMember" xlink:to="aytu_CustomerCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CustomerCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer C</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of concentration risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing and Advertising Expense [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advertising costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockMember" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Unvested Restricted Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Unvested Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202104Member" xlink:to="us-gaap_AccountingStandardsUpdate202104Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2021-04 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2021-04</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-13 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-13</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2020-06 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2020-06</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Accounting Principle, Accounting Standards Update, Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthPortfolioMember" xlink:label="aytu_ConsumerHealthPortfolioMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConsumerHealthPortfolioMember" xlink:to="aytu_ConsumerHealthPortfolioMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ConsumerHealthPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ConsumerHealthPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ConsumerHealthPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consumer Health Portfolio</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfProducts" xlink:to="aytu_NumberOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of products</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:to="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attention Deficit Hyperactivity Disorder Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADHD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attention Deficit Hyperactivity Disorder Portfolio</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PediatricPortfolioMember" xlink:label="aytu_PediatricPortfolioMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PediatricPortfolioMember" xlink:to="aytu_PediatricPortfolioMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PediatricPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pediatric Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PediatricPortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pediatric</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturedProductOtherMember" xlink:to="us-gaap_ManufacturedProductOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturedProductOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitNameOfSegmentExtensibleList" xlink:label="us-gaap_ReportingUnitNameOfSegmentExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportingUnitNameOfSegmentExtensibleList" xlink:to="us-gaap_ReportingUnitNameOfSegmentExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReportingUnitNameOfSegmentExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Unit, Name of Segment [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReportingUnitNameOfSegmentExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Unit, Name of Segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-US [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-US</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:label="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:to="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Production Related Impairments or Charges [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InventoryWriteDownAndImpairment" xlink:label="aytu_InventoryWriteDownAndImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_InventoryWriteDownAndImpairment" xlink:to="aytu_InventoryWriteDownAndImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_InventoryWriteDownAndImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down and Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_InventoryWriteDownAndImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Write-down and Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aytu_InventoryWriteDownAndImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down and impairment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ManufacturingEquipmentMember" xlink:to="aytu_ManufacturingEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ManufacturingEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Equipment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment, Furniture and Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment, Furniture and Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Equipment, Furniture and Other</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LabEquipmentMember" xlink:to="aytu_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset under Construction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset under Construction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="us-gaap_DepreciationAndAmortizationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationAbstract" xlink:to="us-gaap_DepreciationAndAmortizationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on sale of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentChargesAbstract" xlink:label="us-gaap_TangibleAssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentChargesAbstract" xlink:to="us-gaap_TangibleAssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible Asset Impairment Charges [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space and Manufacturing Facilities, Grand Prairie, Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space and Manufacturing Facilities, Grand Prairie, Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Space and Manufacturing Facilities, Grand Prairie, Texas</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrincipalOfficeDenverColoradoMember" xlink:to="aytu_PrincipalOfficeDenverColoradoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PrincipalOfficeDenverColoradoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Office, Denver, Colorado [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrincipalOfficeDenverColoradoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Office, Denver, Colorado [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_PrincipalOfficeDenverColoradoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal Office, Denver, Colorado</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpansionDateMember" xlink:label="aytu_ExpansionDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExpansionDateMember" xlink:to="aytu_ExpansionDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ExpansionDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expansion Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExpansionDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expansion Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ExpansionDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expansion date</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpirationOfSubleaseMember" xlink:label="aytu_ExpirationOfSubleaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExpirationOfSubleaseMember" xlink:to="aytu_ExpirationOfSubleaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ExpirationOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Sublease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExpirationOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of Sublease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ExpirationOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration of sublease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, borrowing rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AreaOfSubleaseProperty" xlink:label="aytu_AreaOfSubleaseProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AreaOfSubleaseProperty" xlink:to="aytu_AreaOfSubleaseProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AreaOfSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of sublease property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AreaOfSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Sublease Property</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RemainingAreaOfSubleaseProperty" xlink:label="aytu_RemainingAreaOfSubleaseProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RemainingAreaOfSubleaseProperty" xlink:to="aytu_RemainingAreaOfSubleaseProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RemainingAreaOfSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Area of Sublease Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RemainingAreaOfSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Area of Sublease Property</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RentReceivableFromSubleaseProperty" xlink:label="aytu_RentReceivableFromSubleaseProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RentReceivableFromSubleaseProperty" xlink:to="aytu_RentReceivableFromSubleaseProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RentReceivableFromSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent Receivable from Sublease Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RentReceivableFromSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent Receivable from Sublease Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_RentReceivableFromSubleaseProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent receivable from sublease property</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, operating lease, term of contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Description [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases, interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of leased assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total net lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities, Lessee [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:to="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents right-of-use asset for operating lease and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease and Finance Lease, Right-of-use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total leased assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Current, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance leases, long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:to="aytu_OperatingLeaseAndFinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents operating and finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease and Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets, weighted-average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease assets, weighted-average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets, weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease assets, weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Operating Activities, Lessee [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Investing Activities, Lessee [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows - finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Financing Activities, Lessee [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing cash flows - finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Gross Difference, Amount [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease Liabilities, Gross Difference, Amount [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing leases, maturing through May 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Goodwill [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillRollForward" xlink:to="us-gaap_GoodwillRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductTechnologyRightMember" xlink:to="aytu_ProductTechnologyRightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductTechnologyRightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Technology Right [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductTechnologyRightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Technology Right [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProductTechnologyRightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Technology Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ProductTechnologyRightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired product technology right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Developed Technology Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired technology right</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductDistributionRightsMember" xlink:label="aytu_ProductDistributionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductDistributionRightsMember" xlink:to="aytu_ProductDistributionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductDistributionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Distribution Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductDistributionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Distribution Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ProductDistributionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired product distribution rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsMember" xlink:to="us-gaap_OtherIntangibleAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIntangibleAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible assets, gross carrying amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible assets, accumulated impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible assets, remaining amortization period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Gross (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, gross carrying amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" xlink:to="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets (Excluding Goodwill), Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-Lived Intangible Assets (Excluding Goodwill), Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite-lived intangible assets, accumulated impairment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" xlink:to="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Tris Pharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Tris Pharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Tris Pharma, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementTerm" xlink:to="aytu_SupplyAndDistributionAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:to="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life, Renewable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life, Renewable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-lived intangible asset, useful life, renewable period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_InnovusPharmaceuticalsIncMember" xlink:to="aytu_InnovusPharmaceuticalsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_InnovusPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovus Pharmaceuticals, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_InnovusPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovus Pharmaceuticals, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_InnovusPharmaceuticalsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Innovus Pharmaceuticals, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductsAcquired" xlink:label="aytu_NumberOfProductsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfProductsAcquired" xlink:to="aytu_NumberOfProductsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NumberOfProductsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Products Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfProductsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Products Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NumberOfProductsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of products acquired</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" xlink:to="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Registered Trademarks and or Patent Rights and Customer Lists Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Registered Trademarks and or Patent Rights and Customer Lists Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of registered trademarks and or patent rights and customer lists acquired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible assets, finite-lived</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortizationAbstract" xlink:label="us-gaap_AdjustmentForAmortizationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortizationAbstract" xlink:to="us-gaap_AdjustmentForAmortizationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortizationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="us-gaap_AmortizationOfDeferredCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrimaryCarePortfolioMember" xlink:label="aytu_PrimaryCarePortfolioMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrimaryCarePortfolioMember" xlink:to="aytu_PrimaryCarePortfolioMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PrimaryCarePortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary Care Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrimaryCarePortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary Care Portfolio [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_PrimaryCarePortfolioMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary Care Portfolio</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AciphexMember" xlink:label="aytu_AciphexMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AciphexMember" xlink:to="aytu_AciphexMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AciphexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AcipHex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AciphexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AcipHex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AciphexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AcipHex</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ZolpiMistMember" xlink:label="aytu_ZolpiMistMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ZolpiMistMember" xlink:to="aytu_ZolpiMistMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ZolpiMistMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ZolpiMist [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ZolpiMistMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ZolpiMist [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ZolpiMistMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ZolpiMist</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TussionexMember" xlink:label="aytu_TussionexMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TussionexMember" xlink:to="aytu_TussionexMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_TussionexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tussionex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_TussionexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tussionex [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_TussionexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tussionex</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CefaclorMember" xlink:label="aytu_CefaclorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CefaclorMember" xlink:to="aytu_CefaclorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CefaclorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cefaclor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CefaclorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cefaclor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CefaclorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cefaclor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Names [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Names</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NeosTherapeuticsIncMember" xlink:to="aytu_NeosTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NeosTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos Therapeutics, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NeosTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos Therapeutics, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NeosTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos Therapeutics, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedSavingOffers" xlink:to="aytu_AccruedSavingOffers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccruedSavingOffers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to accrued saving offers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccruedSavingOffers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Saving Offers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccruedSavingOffers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued savings offers</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedProgramRelatedLiabilities" xlink:to="aytu_AccruedProgramRelatedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccruedProgramRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccruedProgramRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Program Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccruedProgramRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued program liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Customer and Product Related Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Customer and Product Related Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued customer and product related fees</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReserveCurrent" xlink:to="aytu_ReturnReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ReturnReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ReturnReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ReturnReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserve" xlink:label="aytu_ReturnReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReserve" xlink:to="aytu_ReturnReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ReturnReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ReturnReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aytu_ReturnReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return reserve, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aytu_ReturnReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return reserve, beginning balance</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserveChargesToExpense" xlink:label="aytu_ReturnReserveChargesToExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReserveChargesToExpense" xlink:to="aytu_ReturnReserveChargesToExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ReturnReserveChargesToExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Charges to Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ReturnReserveChargesToExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Charges to Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ReturnReserveChargesToExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return reserve, charges to expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReservePayments" xlink:label="aytu_ReturnReservePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReturnReservePayments" xlink:to="aytu_ReturnReservePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ReturnReservePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ReturnReservePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return Reserve, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_ReturnReservePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Return reserve, payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesUnclassifiedAbstract" xlink:label="us-gaap_OtherLiabilitiesUnclassifiedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract" xlink:to="us-gaap_OtherLiabilitiesUnclassifiedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesUnclassifiedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Unclassified [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangements" xlink:to="aytu_FixedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CVR liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilities" xlink:to="us-gaap_OtherSundryLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSundryLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Sundry Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSundryLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="us-gaap_OtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:to="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:to="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Periodic Payment Obligations, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Periodic Payment Obligations, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, periodic payment obligations, number</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, monthly payment amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Balloon Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Balloon Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, balloon payment amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Percentage of Net Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Percentage of Net Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, monthly variable payment amount, minimum</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, monthly variable payment amount, one-time payment, paid</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Aggregate Payments to Satisfy Obligation if Paid before 12 February 2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Monthly Variable Payment Amount, Aggregate Payments to Satisfy Obligation if Paid before 12 February 2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Balloon Payment Amount, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Balloon Payment Amount, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, balloon payment amount, paid</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Payment Amount, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Payment Amount, Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, payment amount, paid</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsCurrent" xlink:label="aytu_FixedPaymentArrangementsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsCurrent" xlink:to="aytu_FixedPaymentArrangementsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, current</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsNoncurrent" xlink:label="aytu_FixedPaymentArrangementsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsNoncurrent" xlink:to="aytu_FixedPaymentArrangementsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, noncurrent</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, quarterly payment amount, payments, number</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Quarterly Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Quarterly Payment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, quarterly payment amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issues, fixed payment arrangements</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsLiabilityReduction" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsLiabilityReduction" xlink:to="aytu_FixedPaymentArrangementsLiabilityReduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Liability, Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Liability, Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, liability, reduction</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" xlink:to="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Installment Payments, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Installment Payments, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, installment payments, number</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Royalty, Percentage of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Royalty, Percentage of Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, royalty, percentage of net sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" xlink:to="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Amount, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Amount, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" xlink:to="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Shares, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Shares, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts" xlink:label="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts" xlink:to="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Contingent Value Rights Payouts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Contingent Value Rights Payouts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights payouts (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:to="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights, gain (loss) for change in fair value during period</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination, contingent consideration, product related, milestone payable, amount</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:to="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" xlink:to="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Other than from Business Combination, Liability, Reversed in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Other than from Business Combination, Liability, Reversed in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration other than from business combination, liability, reversed in period</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration other than from business combination, gain (loss) for change in fair value during period</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-Term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Debt [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity, increase (decrease)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, basis spread on variable rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis spread on variable rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused capacity commitment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, maturity date</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Availability Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity, Availability Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Availability block</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, before 26 January 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, before 26 January 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee before 26 January 2023 (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2023, but before 26 January 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2023, but before 26 January 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" xlink:to="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Termination, Business Days, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Termination, Business Days, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense including amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused line of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Cost, Gross, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeerfieldFacilityMember" xlink:label="aytu_DeerfieldFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeerfieldFacilityMember" xlink:to="aytu_DeerfieldFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeerfieldFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Deerfield Facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeerfieldFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deerfield Facility</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" xlink:label="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" xlink:to="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" xlink:label="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" xlink:to="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior secured credit facility, due on May 11, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount of the remaining outstanding debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the remaining outstanding debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized premium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt, Excluding Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" xlink:to="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Minimum Variable Rate before Basis Spread</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Minimum Variable Rate before Basis Spread</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, minimum variable rate before basis spread (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentTerm" xlink:label="aytu_DebtInstrumentInterestPaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentInterestPaymentTerm" xlink:to="aytu_DebtInstrumentInterestPaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentInterestPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payment term in a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentInterestPaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Payment Term</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentExtensionTerm" xlink:label="aytu_DebtInstrumentInterestPaymentExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentInterestPaymentExtensionTerm" xlink:to="aytu_DebtInstrumentInterestPaymentExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentInterestPaymentExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest payment extension term in a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentInterestPaymentExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Payment Extension Term</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InterestOnlyPeriodFurtherExtensionTerm" xlink:label="aytu_InterestOnlyPeriodFurtherExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_InterestOnlyPeriodFurtherExtensionTerm" xlink:to="aytu_InterestOnlyPeriodFurtherExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_InterestOnlyPeriodFurtherExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Further extension term of interest only period in a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_InterestOnlyPeriodFurtherExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Only Period Further Extension Term</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTermOfTrailingMonthsRevenue" xlink:label="aytu_DebtInstrumentTermOfTrailingMonthsRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentTermOfTrailingMonthsRevenue" xlink:to="aytu_DebtInstrumentTermOfTrailingMonthsRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentTermOfTrailingMonthsRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of trailing months revenue in a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentTermOfTrailingMonthsRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term of Trailing Months Revenue</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DebtInstrumentPrepaymentFeePercentage" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment fee percentage in a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Prepayment Fee Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term, final payment fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanProcessingFee" xlink:to="us-gaap_LoanProcessingFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoanProcessingFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Processing Fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, date from which warrants or rights exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, due on January 26, 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt and Lease Obligation, Including Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, and Finance Lease, Liability, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future principal payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less unamortized discount and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1, 2 and 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Net Asset (Liability) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Statement of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationMember" xlink:label="aytu_ContingentConsiderationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationMember" xlink:to="aytu_ContingentConsiderationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentConsiderationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentConsiderationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Included in earnings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputLeveragedBetaMember" xlink:label="aytu_MeasurementInputLeveragedBetaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_MeasurementInputLeveragedBetaMember" xlink:to="aytu_MeasurementInputLeveragedBetaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_MeasurementInputLeveragedBetaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Leveraged Beta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_MeasurementInputLeveragedBetaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Leveraged Beta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_MeasurementInputLeveragedBetaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Leveraged Beta</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputMarketRiskPremiumMember" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_MeasurementInputMarketRiskPremiumMember" xlink:to="aytu_MeasurementInputMarketRiskPremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Market Risk Premium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Market Risk Premium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Market Risk Premium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount for Lack of Marketability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount for Lack of Marketability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Dividend Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMeasurementInput" xlink:label="aytu_ContingentValueRightsMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentValueRightsMeasurementInput" xlink:to="aytu_ContingentValueRightsMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentValueRightsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure contingent value rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentValueRightsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Value Rights, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ContingentValueRightsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent value rights, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" xlink:label="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" xlink:to="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Valuation Technique [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Valuation Technique</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Nonrecurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Nonrecurring</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedPaymentArrangementsMeasurementInput" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Payment Arrangements, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed payment arrangements, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible assets excluding goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAbstract" xlink:label="us-gaap_TaxesPayableCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-change NOL determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disallowed recognized built-in loss, carried forward as an operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards not subject to expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxReconciliationContingentConsideration" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation, Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">162(m) limitation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Provision (Benefit), Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Provision (Benefit), Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State Income Taxes, Net of Federal Benefit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State Income Taxes, Net of Federal Benefit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent consideration, percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">162(m) limitation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income tax provision (benefit) (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forward</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsAccruedRebates" xlink:to="aytu_DeferredTaxAssetsAccruedRebates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxAssetsAccruedRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Accrued Rebates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxAssetsAccruedRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Accrued Rebates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DeferredTaxAssetsAccruedRebates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credits</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsInterest" xlink:label="aytu_DeferredTaxAssetsInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsInterest" xlink:to="aytu_DeferredTaxAssetsInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxAssetsInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxAssetsInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DeferredTaxAssetsInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Derivative Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Derivatives</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" xlink:to="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Section 174 Capitalization, Research or Experimental Expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Section 174 Capitalization, Research or Experimental Expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Section 174 Capitalization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxAssetsLeaseLiability" xlink:to="aytu_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax assets lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="aytu_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right-of-use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Right-of-use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" xlink:label="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" xlink:to="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Decrease during Period, Goodwill Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Decrease during Period, Goodwill Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill impairment, decrease in net deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" xlink:label="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" xlink:to="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Benefit, Decrease in Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Benefit, Decrease in Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit resulting from decreased net deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase resulting from current period tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease resulting from current period tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationStatement2020ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2020ShelfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" xlink:to="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf, ATM Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember" xlink:to="aytu_ShelfRegistrationStatement2021ShelfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreement2023Member" xlink:to="aytu_SecuritiesPurchaseAgreement2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:to="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023, Private Offering, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023, Private Offering, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement, 2023, Private Offering, June 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationAmountAuthorized" xlink:label="aytu_ShelfRegistrationAmountAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationAmountAuthorized" xlink:to="aytu_ShelfRegistrationAmountAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized amount of common stock, preferred stock, debt securities, warrants, rights and units under the shelf registration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration, Amount Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf registration, amount authorized</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationRemainingAmountAvailableForSale" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShelfRegistrationRemainingAmountAvailableForSale" xlink:to="aytu_ShelfRegistrationRemainingAmountAvailableForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration, Remaining Amount Available for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration, Remaining Amount Available for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf registration, remaining amount available for sale</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AtmSalesAgreementAmountAuthorized" xlink:label="aytu_AtmSalesAgreementAmountAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AtmSalesAgreementAmountAuthorized" xlink:to="aytu_AtmSalesAgreementAmountAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AtmSalesAgreementAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market Sales Agreement, Amount Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AtmSalesAgreementAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Sales Agreement, Amount Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AtmSalesAgreementAmountAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market sales agreement, amount authorized</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:to="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuance Costs, Underwriting Discounts, Commissions, and Other Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuance Costs, Underwriting Discounts, Commissions, and Other Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts, commissions, and other offering expenses</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:to="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock and Warrants Issuance Costs, Commissions and Other Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock and Warrants Issuance Costs, Commissions and Other Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commission and other costs</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock and Warrants, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock and Warrants, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock and warrants, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, March 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, August 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, June 2023</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued to purchase shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, number of securities called by warrants or right (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, number of securities called by each warrant or right (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:to="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightOfferingPrice" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightOfferingPrice" xlink:to="aytu_ClassOfWarrantOrRightOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and rights outstanding, term</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:to="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant, term of expiration after closing price of common stock</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, percentage of exercise price equaling common stock</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:to="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Expiration Term on Achievement of
Consolidated Trailing Twelve-Month Adjusted EBITDA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Expiration Term on Achievement of Consolidated Trailing Twelve-Month Adjusted EBITDA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted earnings before interest, taxes, depreciation, and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Aytu2015PlanMember" xlink:to="aytu_Aytu2015PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Aytu2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Aytu2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_Aytu2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Neos2015PlanMember" xlink:to="aytu_Neos2015PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Neos2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos 2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Neos2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos 2015 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_Neos2015PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos 2015 Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Twenty Three Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Thousand Twenty Three Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested outstanding, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested units outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, capital shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price outstanding, ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price outstanding, beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life in years outstanding, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average remaining contractual life (Year)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life in years exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life in years exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeOneMember" xlink:to="aytu_ExercisePriceRangeOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 1</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeTwoMember" xlink:to="aytu_ExercisePriceRangeTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range of exercise prices</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Three</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Four</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Five</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheSixMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Six</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheSevenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Seven</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheEightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eighth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Eight</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:to="aytu_ShareBasedCompensationAwardTrancheNineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ninth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Nine</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NonplanMember" xlink:to="aytu_NonplanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NonplanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonplan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NonplanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonplan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NonplanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Additional Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs, options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs, excluding options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation costs, period for recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" xlink:to="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" xlink:to="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Accelerated Unvested Shares, Former Board Members, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Accelerated Unvested Shares, Former Board Members, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accelerated unvested shares, former board members, number</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Percentage of Grants Rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Percentage of Grants Rescinded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stipulation of compromise and settlement, board members, percentage of 2021 grants rescinded (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, 20 Consecutive Trading Day Period Preceding Trading Day 16, Lowest Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, 20 Consecutive Trading Day Period Preceding Trading Day 16, Lowest Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, Consecutive Trading Days Preceding Trading Day 16</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, Consecutive Trading Days Preceding Trading Day 16</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Maximum Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Maximum Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, maximum shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Equity Offering, Common Stock Price Lower than Warrant Exercise Price Prior to Anniversary Two of Stock Combination Event, Adjusted Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Adjustment, Equity Offering, Common Stock Price Lower than Warrant Exercise Price Prior to Anniversary Two of Stock Combination Event, Adjusted Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, number of warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, number of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants or rights issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issued During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants or rights exercised during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjusted" xlink:label="aytu_ClassOfWarrantOrRightAdjusted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightAdjusted" xlink:to="aytu_ClassOfWarrantOrRightAdjusted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant adjusted (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants or rights expired during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Expired During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired (in shares)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share of warrants or rights issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issued During Period, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights, Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant adjusted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average period of remaining contractual life of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" xlink:to="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average period of remaining contractual life of warrants or rights, issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Issued, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued, weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" xlink:to="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised, weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" xlink:to="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Adjusted, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Adjusted, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant adjusted, weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Defined Benefit Plans Disclosures [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NeosPlanMember" xlink:to="aytu_NeosPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NeosPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent information pertaining to Neos Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NeosPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NeosPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Neos Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuPlanMember" xlink:label="aytu_AytuPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuPlanMember" xlink:to="aytu_AytuPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AytuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent information pertaining to Aytu Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AytuPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuBiopharmaEmployeeRetirementPlanMember" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuBiopharmaEmployeeRetirementPlanMember" xlink:to="aytu_AytuBiopharmaEmployeeRetirementPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu Biopharma Employee Retirement Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu Biopharma Employee Retirement Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aytu Biopharma Employee Retirement Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FirstThreePercentContributionByEmployeesMember" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Three Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Three Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First 3% Contribution by Employees</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Four percent And Five Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Four percent And Five Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next 4% and 5% Contribution by Employees</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFourPercentContributionByEmployeesMember" xlink:to="aytu_NextFourPercentContributionByEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NextFourPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Four percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NextFourPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Four percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NextFourPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next 4% Contribution by Employees</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NextFivePercentContributionByEmployeesMember" xlink:to="aytu_NextFivePercentContributionByEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NextFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Five Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NextFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next Five Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NextFivePercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Next 5% Contribution by Employees</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SixPercentContributionByEmployeesMember" xlink:label="aytu_SixPercentContributionByEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SixPercentContributionByEmployeesMember" xlink:to="aytu_SixPercentContributionByEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SixPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 6% contribution by employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SixPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Six Percent Contribution By Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SixPercentContributionByEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">6% Contribution By Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfEmployeeBenefitPlan" xlink:label="aytu_NumberOfEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfEmployeeBenefitPlan" xlink:to="aytu_NumberOfEmployeeBenefitPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NumberOfEmployeeBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Employee Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfEmployeeBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Employee Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_NumberOfEmployeeBenefitPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employee benefit plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage employer matches of employee's contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employees' salary with employer matching contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plan contribution</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityNovalereFluticareMember" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductContingentLiabilityNovalereFluticareMember" xlink:to="aytu_ProductContingentLiabilityNovalereFluticareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Novalere, FlutiCare [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Novalere, FlutiCare [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Novalere, FlutiCare</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Additional Payments, Number, Certain Sales Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Additional Payments, Number, Certain Sales Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product contingent liability, additional payments, number, certain sales achieved</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Additional Payments, Amount, Certain Sales Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Additional Payments, Amount, Certain Sales Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product contingent liability, additional payments, amount, certain sales achieved</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityMilestonePayment" xlink:label="aytu_ProductContingentLiabilityMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProductContingentLiabilityMilestonePayment" xlink:to="aytu_ProductContingentLiabilityMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProductContingentLiabilityMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Milestone, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProductContingentLiabilityMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Contingent Liability, Milestone, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ProductContingentLiabilityMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product contingent liability, milestone, payment</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:to="aytu_CommercialGlobalLicenseAgreementsAr101Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreements, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreements, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreements, AR101</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" xlink:to="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Denovo Biopharma LLC, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Denovo Biopharma LLC, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Denovo Biopharma LLC, AR101</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" xlink:to="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Johns Hopkins University, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Johns Hopkins University, AR101 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Global License Agreement, Johns Hopkins University, AR101</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" xlink:to="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone, Maximum Earn-out, Cash and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone, Maximum Earn-out, Cash and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, milestone, maximum earn-out, cash and common stock</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAnnualMaintenanceFee" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementAnnualMaintenanceFee" xlink:to="aytu_LicenseAgreementAnnualMaintenanceFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Annual Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Annual Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, annual maintenance fee</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementLicenseOptionFee" xlink:label="aytu_LicenseAgreementLicenseOptionFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementLicenseOptionFee" xlink:to="aytu_LicenseAgreementLicenseOptionFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementLicenseOptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, License Option Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementLicenseOptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, License Option Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementLicenseOptionFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, license option fee</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementEscalatingRoyaltiesMaximum" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementEscalatingRoyaltiesMaximum" xlink:to="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Escalating Royalties, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Escalating Royalties, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, escalating royalties, maximum</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Royalties, Low End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Royalties, Low End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, minimum annual royalties, low end of range</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Royalties, High End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Minimum Annual Royalties, High End of Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, minimum annual royalties, high end of range</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" xlink:to="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Royalties, Percentage of Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Royalties, Percentage of Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, royalties, percentage of net product sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" xlink:to="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Royalties, Achievement of Certain Regulatory and Commercial Milestones, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Royalties, Achievement of Certain Regulatory and Commercial Milestones, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone Payment Paid, Cash and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone Payment Paid, Cash and Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, milestone payment paid, cash and common stock</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCash" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementMilestonePaymentPaidCash" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone Payment Paid, Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Milestone Payment Paid, Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, milestone payment paid, cash</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAgreementMember" xlink:label="aytu_OperatingLeaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OperatingLeaseAgreementMember" xlink:to="aytu_OperatingLeaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OperatingLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OperatingLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_OperatingLeaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Agreement</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AverageUndiscountedMinimumMonthlyRentPayments" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AverageUndiscountedMinimumMonthlyRentPayments" xlink:to="aytu_AverageUndiscountedMinimumMonthlyRentPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average Undiscounted Minimum Monthly Rent Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average Undiscounted Minimum Monthly Rent Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average undiscounted minimum monthly rent payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, operating lease, renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SabbyLitigationMember" xlink:to="aytu_SabbyLitigationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SabbyLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Litigation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SabbyLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Litigation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SabbyLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Litigation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Volatility Warrant Master Fund Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Volatility Warrant Master Fund Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sabby Volatility Warrant Master Fund Ltd</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Walleye Opportunities Master Fund Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Walleye Opportunities Master Fund Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Walleye Opportunities Master Fund Ltd</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case, Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case, Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation case, class of warrant or right, number of securities called by warrants or rights</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" xlink:to="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement, Cedars-Sinai Medical Center, Healight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement, Cedars-Sinai Medical Center, Healight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement, Cedars-Sinai Medical Center, Healight</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" xlink:to="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" xlink:to="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, 2017, Shire LLC, New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, 2017, Shire LLC, New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, 2017, Shire LLC, New Drug Application</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" xlink:to="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Term, after First Bona Fide Commercial Sale of Licensed Product in Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Term, after First Bona Fide Commercial Sale of Licensed Product in Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, term, after the first bona fide commercial sale of such licensed product in a country</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementInitialLicenseFeePaid" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Initial License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Initial License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, initial license fee paid</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Patent Prosecution Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Patent Prosecution Fees Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, patent prosecution fees paid</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" xlink:to="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Up-front, Non-refundable License Fee Paid, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Up-front, Non-refundable License Fee Paid, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement, up-front, non-refundable license fee paid, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Revenue from Segments to Consolidated [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Revenue Reconciling Item [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AssetImpairmentAndWriteoffCharges" xlink:to="aytu_AssetImpairmentAndWriteoffCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AssetImpairmentAndWriteoffCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset impairment and write-off of assets recognized in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AssetImpairmentAndWriteoffCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment And Writeoff Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_AssetImpairmentAndWriteoffCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment and write-off expense</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>aytu-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/12/2023 5:27:44 PM-->
<!--Modified on: 10/12/2023 5:27:44 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://aytubio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedBalanceSheets" roleURI="http://aytubio.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementOfStockholdersEquity" roleURI="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialCondition" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomers" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventories" roleURI="http://aytubio.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipment" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeases" roleURI="http://aytubio.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssets" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureAccruedLiabilities" roleURI="http://aytubio.com/role/DisclosureAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilities" roleURI="http://aytubio.com/role/DisclosureOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLineOfCredit" roleURI="http://aytubio.com/role/DisclosureLineOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebt" roleURI="http://aytubio.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurements" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxes" roleURI="http://aytubio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquity" roleURI="http://aytubio.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlans" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrants" roleURI="http://aytubio.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://aytubio.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLicenseAgreements" roleURI="http://aytubio.com/role/DisclosureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformation" roleURI="http://aytubio.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://aytubio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersTables" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventoriesTables" roleURI="http://aytubio.com/role/DisclosureInventoriesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesTables" roleURI="http://aytubio.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsTables" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureAccruedLiabilitiesTables" roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesTables" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtTables" roleURI="http://aytubio.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesTables" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansTables" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsTables" roleURI="http://aytubio.com/role/DisclosureWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationTables" roleURI="http://aytubio.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" roleURI="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" roleURI="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventoriesTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureInventoriesInventoryWriteDownDetails" roleURI="http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentDepreciationExpenseDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentGainLossOnDisposalDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosurePropertyAndEquipmentImpairmentDetails" roleURI="http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesNetLeaseCostDetails" roleURI="http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails" roleURI="http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesCashFlowInformationDetails" roleURI="http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesOperatingLeasesGrossDifferenceDetails" roleURI="http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLeasesFinanceLeasesGrossDifferenceDetails" roleURI="http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureAccruedLiabilitiesGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureAccruedLiabilitiesReturnReserveDetails" roleURI="http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesComponentsDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesClassificationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentValueRightsDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureOtherLiabilitiesContingentConsiderationTotalDetails" roleURI="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLineOfCreditDetails" roleURI="http://aytubio.com/role/DisclosureLineOfCreditDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtNarrativeDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtWarrantsDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtCompositionDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLongTermDebtFuturePrincipalPaymentsDetails" roleURI="http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsValuationAssumptionsDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesSection382LimitationDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityCommonAndPreferredStockDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityRestrictedStockDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityStockOfferingsDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansStockOptionsDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockActivityDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" roleURI="http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsStockIssuedDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureWarrantsWarrantsActivityDetails" roleURI="http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureCommitmentsAndContingenciesLegalMattersDetails" roleURI="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureLicenseAgreementsDetails" roleURI="http://aytubio.com/role/DisclosureLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationGeneralInformationDetails" roleURI="http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationImpairmentDetails" roleURI="http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="aytu-20230630.xsd#DisclosureSegmentInformationSelectFinancialInformationDetails" roleURI="http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://aytubio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638327284586325542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638327284586325542" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638327284586325542" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638327284586325542" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638327284586325542" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638327284586325542" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638327284586325542" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638327284586325542" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638327284586325542" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638327284586325542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638327284586325542" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638327284586335531" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638327284586335531" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638327284586335531" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638327284586335531" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638327284586335531" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638327284586335531" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638327284586335531" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityListingParValuePerShare_638327284586335531" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638327284586335531" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638327284586335531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638327284586335531" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638327284586345519" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638327284586345519" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638327284586345519" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638327284586345519" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638327284586345519" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638327284586345519" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638327284586345519" order="27" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638327284586345519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638327284586345519" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638327284586355518" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638327284586355518" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638327284586355518" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638327284586355518" order="32" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638327284586355518" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638327284586355518" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638327284586355518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638327284586355518" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638327284586365521" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638327284586365521" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638327284586365521" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637595105262022531" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262022531" xlink:to="us-gaap_AssetsAbstract_638327284586365521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_AssetsCurrentAbstract_638327284586365521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638327284586365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638327284586365521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_AccountsReceivableNetCurrent_638327284586375523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_InventoryNet_638327284586375523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_PrepaidExpenseCurrent_638327284586375523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_OtherAssetsCurrent_638327284586375523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638327284586365521" xlink:to="us-gaap_AssetsCurrent_638327284586375523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284586375523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638327284586375523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284586375523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_OtherAssetsNoncurrent_638327284586375523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_AssetsNoncurrent_638327284586375523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638327284586365521" xlink:to="us-gaap_Assets_638327284586375523" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638327284586375523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262022531" xlink:to="us-gaap_LiabilitiesAbstract_638327284586375523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638327284586375523" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_638327284586385518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638327284586385518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_ShortTermBorrowings_638327284586385518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284586385518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_OtherLiabilitiesCurrent_638327284586385518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638327284586385518" xlink:to="us-gaap_LiabilitiesCurrent_638327284586385518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638327284586375523" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284586385518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638327284586385518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638327284586375523" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638327284586385518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638327284586375523" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638327284586395512" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638327284586375523" xlink:to="us-gaap_Liabilities_638327284586395512" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262022531" xlink:to="us-gaap_CommitmentsAndContingencies_638327284586395512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262022531" xlink:to="us-gaap_StockholdersEquityAbstract_638327284586395512" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_PreferredStockValue_638327284586395512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_CommonStockValue_638327284586395512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638327284586395512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586395512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586395512" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_StockholdersEquity_638327284586405517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638327284586395512" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638327284586405517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637595105262262274" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262262274" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638327284586405517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_PreferredStockSharesAuthorized_638327284586405517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_PreferredStockSharesIssued_638327284586405517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_PreferredStockSharesOutstanding_638327284586405517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637595105262262274" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638327284586415523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_CommonStockSharesAuthorized_638327284586415523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_CommonStockSharesIssued_638327284586415523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284586405517" xlink:to="us-gaap_CommonStockSharesOutstanding_638327284586415523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637595105262282228" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_RevenuesAbstract_638327284586415523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284586415523" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586415523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284586415523" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_638327284586415523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284586415523" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638327284586415523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284586415523" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_638327284586415523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284586415523" xlink:to="us-gaap_GrossProfit_638327284586415523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638327284586415523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_OperatingExpensesAbstract_638327284586415523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_SellingAndMarketingExpense_638327284586425521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638327284586425521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638327284586425521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_GoodwillImpairmentLoss_638327284586425521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_OtherAssetImpairmentCharges_638327284586425521" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638327284586425521" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284586425521" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638327284586415523" xlink:to="us-gaap_OperatingExpenses_638327284586425521" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_OperatingIncomeLoss_638327284586425521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638327284586425521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638327284586425521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284586435520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586435520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638327284586425521" xlink:to="us-gaap_NonoperatingIncomeExpense_638327284586435520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284586435520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638327284586435520" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_NetIncomeLoss_638327284586435520" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638327284586435520" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638327284586435520" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638327284586435520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_EarningsPerShareBasic_638327284586435520" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637595105262282228" xlink:to="us-gaap_EarningsPerShareDiluted_638327284586445517" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637595105262331706" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637595105262331706" xlink:to="us-gaap_StatementTable_638327284586445517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284586445517" xlink:to="us-gaap_StatementEquityComponentsAxis_638327284586445517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638327284586445517" xlink:to="us-gaap_ParentMember_638327284586445517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638327284586445517" xlink:to="us-gaap_CommonStockMember_638327284586445517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638327284586445517" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638327284586445517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638327284586445517" xlink:to="us-gaap_RetainedEarningsMember_638327284586445517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638327284586445517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638327284586445517" xlink:to="us-gaap_EquityComponentDomain_638327284586445517" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284586445517" xlink:to="us-gaap_StatementLineItems_638327284586455522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638327284586455522" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586455522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_CommonStockSharesIssued_638327284586455522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638327284586455522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638327284586455522" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638327284586455522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638327284586455522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638327284586455522" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284586455522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodValueMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodValueMilestonePayments_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="aytu_StockIssuedDuringPeriodValueMilestonePayments_638327284586455522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_StockIssuedDuringPeriodValueMilestonePayments_638327284586455522" xlink:to="aytu_StockIssuedDuringPeriodSharesMilestonePayments_638327284586455522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638327284586455522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_638327284586455522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638327284586465521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_NetIncomeLoss_638327284586465521" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586465521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586465521" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638327284586465521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638327284586455522" xlink:to="us-gaap_CommonStockSharesIssued_638327284586465521" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts" xlink:label="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_638327284586465521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts_638327284586465521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586465521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586465521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586465521" xlink:to="us-gaap_ProfitLoss_638327284586475529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586465521" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638327284586475529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_AssetImpairmentCharges_638327284586475529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_InventoryWriteDown_638327284586475529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_ShareBasedCompensation_638327284586475529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586475529" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284586475529" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638327284586475529" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IssuanceOfStockForMilestonePayments" xlink:label="aytu_IssuanceOfStockForMilestonePayments_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="aytu_IssuanceOfStockForMilestonePayments_638327284586475529" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WriteOffOfDeferredDebtIssuanceCostNet" xlink:label="aytu_WriteOffOfDeferredDebtIssuanceCostNet_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="aytu_WriteOffOfDeferredDebtIssuanceCostNet_638327284586475529" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_638327284586475529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586475529" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_638327284586475529" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586465521" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638327284586485519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInInventories_638327284586485519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638327284586485519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638327284586485519" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638327284586485519" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_638327284586485519" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638327284586485519" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284586485519" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638327284586485519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638327284586485519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638327284586485519" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638327284586485519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638327284586485519" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638327284586495522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638327284586485519" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638327284586495522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284586495522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PaymentsForFixedPaymentArrangement" xlink:label="aytu_PaymentsForFixedPaymentArrangement_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="aytu_PaymentsForFixedPaymentArrangement_638327284586495522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_638327284586495522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_638327284586495522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_638327284586495522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_638327284586495522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638327284586505517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_638327284586505517" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638327284586495522" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638327284586505517" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638327284586505517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638327284586505517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383272845865055171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383272845865055171" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638327284586505517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637595105262461696" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638327284586505517" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638327284586515516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638327284586505517" xlink:to="us-gaap_InterestPaidNet_638327284586515516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638327284586515516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638327284586505517" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638327284586515516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_638327284586515516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638327284586515516" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_638327284586515516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business and Financial Condition" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638327284586525528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_638327284586525528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638327284586525528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638327284586525528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers" xlink:type="extended" xlink:title="10301 - Disclosure - Revenues from Contracts with Customers" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638327284586525528" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638327284586525528" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10401 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638327284586535521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638327284586535521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638327284586535521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638327284586535521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10601 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LeaseDisclosureTextBlock" xlink:label="aytu_LeaseDisclosureTextBlock_638327284586535521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="aytu_LeaseDisclosureTextBlock_638327284586535521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets" xlink:type="extended" xlink:title="10701 - Disclosure - Goodwill and Other Intangible Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638327284586545524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638327284586545524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureAccruedLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - Accrued Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638327284586545524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638327284586545524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilities" xlink:type="extended" xlink:title="10901 - Disclosure - Other Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_638327284586555523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_2" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_638327284586555523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLineOfCredit" xlink:type="extended" xlink:title="11001 - Disclosure - Line of Credit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock_638327284586555523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock_638327284586555523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="11101 - Disclosure - Long-term Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638327284586555523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtTextBlock_638327284586555523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11201 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638327284586565525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638327284586565525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638327284586565525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638327284586565525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11401 - Disclosure - Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638327284586565525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638327284586565525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlans" xlink:type="extended" xlink:title="11501 - Disclosure - Equity Incentive Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638327284586575522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638327284586575522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="11601 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsOrRightsDisclosureTextBlock" xlink:label="aytu_WarrantsOrRightsDisclosureTextBlock_638327284586575522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="aytu_WarrantsOrRightsDisclosureTextBlock_638327284586575522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11701 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock_638327284586575522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock_638327284586575522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638327284586575522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638327284586575522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLicenseAgreements" xlink:type="extended" xlink:title="11901 - Disclosure - License Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAbstract" xlink:label="aytu_LicenseAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTextBlock" xlink:label="aytu_LicensingAgreementsTextBlock_638327284586615517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_LicenseAgreementAbstract" xlink:to="aytu_LicensingAgreementsTextBlock_638327284586615517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="12001 - Disclosure - Segment Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638327284586625516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638327284586625516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12101 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638327284586625516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638327284586625516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638327284586625516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638327284586625516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638327284586625516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638327284586625516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638327284586635515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_638327284586635515" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638327284586635515" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638327284586635515" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638327284586635515" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_GoingConcernPolicyTextBlock" xlink:label="aytu_GoingConcernPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="aytu_GoingConcernPolicyTextBlock_638327284586635515" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638327284586635515" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638327284586635515" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy_638327284586635515" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsPolicyTextBlock" xlink:label="aytu_WarrantsPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="aytu_WarrantsPolicyTextBlock_638327284586635515" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638327284586635515" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerContractCostsPolicyTextBlock" xlink:label="aytu_CustomerContractCostsPolicyTextBlock_638327284586635515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="aytu_CustomerContractCostsPolicyTextBlock_638327284586635515" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638327284586645522" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638327284586645522" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638327284586645522" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638327284586645522" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_638327284586645522" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638327284586645522" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_638327284586645522" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638327284586645522" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638327284586645522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638327284586645522" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638327284586655517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638327284586655517" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock_638327284586655517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock_638327284586655517" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638327284586655517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638327284586655517" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638327284586655517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638327284586655517" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_638327284586655517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_638327284586655517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_638327284586665514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_638327284586665514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_638327284586665514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638327284586665514" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables" xlink:type="extended" xlink:title="30303 - Disclosure - Revenues from Contracts with Customers (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638327284586665514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638327284586665514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_638327284586665514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_638327284586665514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Inventories (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638327284586675520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638327284586675520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638327284586675520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638327284586675520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638327284586685517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="aytu_AssetsAndLiabilitiesLesseeTableTextBlock_638327284586685517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="aytu_RemainingLeaseTermAndDiscountRateTableTextBlock_638327284586685517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LesseeLeasesCashFlowInformationTableTextBlock" xlink:label="aytu_LesseeLeasesCashFlowInformationTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="aytu_LesseeLeasesCashFlowInformationTableTextBlock_638327284586685517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638327284586685517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638327284586685517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Goodwill and Other Intangible Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_638327284586685517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_638327284586685517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638327284586695517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638327284586695517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_638327284586695517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_638327284586695517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638327284586695517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638327284586695517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accrued Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638327284586695517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638327284586695517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ScheduleOfReturnReserveTableTextBlock" xlink:label="aytu_ScheduleOfReturnReserveTableTextBlock_638327284586695517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="aytu_ScheduleOfReturnReserveTableTextBlock_638327284586695517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Other Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock_638327284586705513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_3" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock_638327284586705513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="31103 - Disclosure - Long-term Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638327284586705513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638327284586705513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638327284586705513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638327284586705513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284586705513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284586705513" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638327284586705513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284586705513" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638327284586705513" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638327284586705513" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284586715513" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMember" xlink:label="aytu_ContingentValueRightsMember_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284586715513" xlink:to="aytu_ContingentValueRightsMember_638327284586715513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284586715513" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638327284586715513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284586705513" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284586715513" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284586715513" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638327284586715513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284586715513" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638327284586715513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284586715513" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638327284586715513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638327284586715513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638327284586715513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638327284586725518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638327284586725518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638327284586725518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansTables" xlink:type="extended" xlink:title="31503 - Disclosure - Equity Incentive Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638327284586725518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638327284586725518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638327284586725518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638327284586725518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637599496125156106" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_638327284586725518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31603 - Disclosure - Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightActivityTableTextBlock" xlink:label="aytu_ClassOfWarrantOrRightActivityTableTextBlock_638327284586725518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="aytu_ClassOfWarrantOrRightActivityTableTextBlock_638327284586725518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="32003 - Disclosure - Segment Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638327284586735517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638327284586735517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business and Financial Condition - Segments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586735517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586735517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638327284586735517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586735517" xlink:to="us-gaap_NumberOfReportableSegments_638327284586735517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Nature of Business and Financial Condition - Reverse Stock Split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638327284586745523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails" xlink:type="extended" xlink:title="40103 - Disclosure - Nature of Business and Financial Condition - Product Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638327284586745523" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586745523" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284586745523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284586745523" xlink:to="us-gaap_SegmentDomain_638327284586745523" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586745523" xlink:to="aytu_RxMember_638327284586745523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586745523" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638327284586745523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductPortfolios" xlink:label="aytu_NumberOfProductPortfolios_638327284586745523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586745523" xlink:to="aytu_NumberOfProductPortfolios_638327284586745523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails" xlink:type="extended" xlink:title="40104 - Disclosure - Nature of Business and Financial Condition - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638327284586755514" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract_638327284586755514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract_638327284586755514" xlink:to="us-gaap_AccountsReceivableNetCurrent_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638327284586755514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638327284586755514" xlink:to="us-gaap_NetIncomeLoss_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficitAbstract" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_638327284586755514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficitAbstract_638327284586755514" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586755514" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284586755514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586755514" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638327284586755514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails" xlink:type="extended" xlink:title="40105 - Disclosure - Nature of Business and Financial Condition - Going Concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5" xlink:to="us-gaap_DebtInstrumentTable_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638327284586765517" xlink:to="us-gaap_DebtInstrumentAxis_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638327284586765517" xlink:to="us-gaap_DebtInstrumentNameDomain_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AvenueCapitalLoanTermLoanMember" xlink:label="aytu_AvenueCapitalLoanTermLoanMember_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638327284586765517" xlink:to="aytu_AvenueCapitalLoanTermLoanMember_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638327284586765517" xlink:to="us-gaap_DebtInstrumentLineItems_638327284586765517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284586765517" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284586765517" xlink:to="us-gaap_DebtInstrumentFaceAmount_638327284586765517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586765517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586765517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586765517" xlink:to="srt_RestatementAxis_638327284586775520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638327284586775520" xlink:to="srt_RestatementDomain_638327284586775520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586775520" xlink:to="srt_ScenarioPreviouslyReportedMember_638327284586775520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586775520" xlink:to="srt_RestatementAdjustmentMember_638327284586775520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAdjustmentMember_638327284586775520" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586775520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586765517" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638327284586775520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" xlink:to="us-gaap_Liabilities_638327284586775520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638327284586775520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638327284586775520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586775520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586775520" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638327284586775520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586785514" xlink:to="srt_RestatementAxis_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638327284586785514" xlink:to="srt_RestatementDomain_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586785514" xlink:to="srt_ScenarioPreviouslyReportedMember_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586785514" xlink:to="srt_RestatementAdjustmentMember_638327284586785514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAdjustmentMember_638327284586785514" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586785514" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586785514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_NonoperatingIncomeExpense_638327284586785514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638327284586785514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638327284586785514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_NetIncomeLoss_638327284586785514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_EarningsPerShareBasic_638327284586795518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586785514" xlink:to="us-gaap_EarningsPerShareDiluted_638327284586795518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_8" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586795518" xlink:to="srt_RestatementAxis_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638327284586795518" xlink:to="srt_RestatementDomain_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586795518" xlink:to="srt_ScenarioPreviouslyReportedMember_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586795518" xlink:to="srt_RestatementAdjustmentMember_638327284586795518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAdjustmentMember_638327284586795518" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586795518" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586795518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638327284586795518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586795518" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638327284586795518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_9" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586805514" xlink:to="srt_RestatementAxis_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638327284586805514" xlink:to="srt_RestatementDomain_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586805514" xlink:to="srt_ScenarioPreviouslyReportedMember_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638327284586805514" xlink:to="srt_RestatementAdjustmentMember_638327284586805514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAdjustmentMember_638327284586805514" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586805514" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586805514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586805514" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" xlink:to="us-gaap_ProfitLoss_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586805514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638327284586805514" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638327284586805514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails" xlink:type="extended" xlink:title="40205 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_14" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_14" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586815515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586815515" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284586815515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284586815515" xlink:to="us-gaap_SegmentDomain_638327284586815515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586815515" xlink:to="aytu_RxMember_638327284586815515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586815515" xlink:to="aytu_ConsumerHealthMember_638327284586815515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_638327284586815515" xlink:to="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586815515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract" xlink:label="us-gaap_OperatingIncomeLossAbstract_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_638327284586815515" xlink:to="us-gaap_OperatingIncomeLossAbstract_638327284586815515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638327284586815515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract_638327284586815515" xlink:to="us-gaap_OperatingIncomeLoss_638327284586815515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails" xlink:type="extended" xlink:title="40206 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_13" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_13" xlink:to="us-gaap_AccountsReceivableNetAbstract_638327284586825518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_638327284586825518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts_638327284586825518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284586825518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586825518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails" xlink:type="extended" xlink:title="40207 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_12" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_12" xlink:to="us-gaap_AccountsReceivableNetAbstract_638327284586825518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="us-gaap_AccountsReceivableGross_638327284586825518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease" xlink:label="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_638327284586825518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease_638327284586825518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract_638327284586825518" xlink:to="us-gaap_AccountsReceivableGross_638327284586835518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails" xlink:type="extended" xlink:title="40208 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_10" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_10" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_638327284586835518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal_638327284586835518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery_638327284586835518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_6383272845868355181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts_6383272845868355181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586835518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal" xlink:label="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_638327284586835518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal_638327284586835518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery_638327284586845514" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks" xlink:label="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks_638327284586845514" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_638327284586845514" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638327284586845514" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_638327284586845514" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_6383272845868455141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_638327284586835518" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_6383272845868455141" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40209 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586845514" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586845514" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586845514" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586845514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586845514" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586845514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586845514" xlink:to="us-gaap_EquipmentMember_638327284586855514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586845514" xlink:to="us-gaap_FurnitureAndFixturesMember_638327284586855514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586845514" xlink:to="us-gaap_LeaseholdImprovementsMember_638327284586855514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586845514" xlink:to="srt_RangeAxis_638327284586855514" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284586855514" xlink:to="srt_RangeMember_638327284586855514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284586855514" xlink:to="srt_MinimumMember_638327284586855514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284586855514" xlink:to="srt_MaximumMember_638327284586855514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586845514" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586855514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586855514" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638327284586855514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638327284586855514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586855514" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_638327284586855514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails" xlink:type="extended" xlink:title="40210 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableCreditTermsLowEndOfRange" xlink:label="aytu_AccountsReceivableCreditTermsLowEndOfRange_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="aytu_AccountsReceivableCreditTermsLowEndOfRange_638327284586865515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccountsReceivableCreditTermsHighEndOfRange" xlink:label="aytu_AccountsReceivableCreditTermsHighEndOfRange_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="aytu_AccountsReceivableCreditTermsHighEndOfRange_638327284586865515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails" xlink:type="extended" xlink:title="40211 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638327284586865515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638327284586865515" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638327284586865515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638327284586865515" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638327284586865515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638327284586865515" xlink:to="us-gaap_SalesRevenueNetMember_638327284586865515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638327284586865515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetMember_638327284586865515" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638327284586865515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638327284586865515" xlink:to="us-gaap_AccountsReceivableMember_638327284586875514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638327284586865515" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638327284586875514" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638327284586875514" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638327284586875514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638327284586875514" xlink:to="us-gaap_CustomerConcentrationRiskMember_638327284586875514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638327284586875514" xlink:to="us-gaap_CreditConcentrationRiskMember_638327284586875514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638327284586865515" xlink:to="srt_MajorCustomersAxis_638327284586875514" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638327284586875514" xlink:to="srt_NameOfMajorCustomerDomain_638327284586875514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerAMember" xlink:label="aytu_CustomerAMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638327284586875514" xlink:to="aytu_CustomerAMember_638327284586875514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerBMember" xlink:label="aytu_CustomerBMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638327284586875514" xlink:to="aytu_CustomerBMember_638327284586875514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638327284586875514" xlink:to="aytu_CustomerCMember_638327284586875514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638327284586865515" xlink:to="us-gaap_ConcentrationRiskLineItems_638327284586875514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638327284586875514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638327284586875514" xlink:to="us-gaap_ConcentrationRiskPercentage1_638327284586875514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails" xlink:type="extended" xlink:title="40212 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638327284586885516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638327284586885516" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_638327284586885516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_638327284586885516" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_638327284586885516" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract_638327284586885516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract_638327284586885516" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract_638327284586885516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense_638327284586885516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketingAndAdvertisingExpenseAbstract_638327284586885516" xlink:to="us-gaap_AdvertisingExpense_638327284586885516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" xlink:title="40213 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586895516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284586895516" xlink:to="us-gaap_NumberOfReportableSegments_638327284586895516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40214 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_6" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638327284586895516" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638327284586895516" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638327284586895516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638327284586895516" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" xlink:to="us-gaap_WarrantMember_638327284586895516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_638327284586895516" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_638327284586895516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638327284586895516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" xlink:to="us-gaap_EmployeeStockOptionMember_638327284586895516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" xlink:to="us-gaap_RestrictedStockMember_638327284586905517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638327284586895516" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638327284586905517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638327284586895516" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638327284586905517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638327284586905517" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638327284586905517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40215 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638327284586905517" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638327284586905517" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638327284586905517" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638327284586905517" xlink:to="us-gaap_TypeOfAdoptionMember_638327284586905517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202104Member" xlink:label="us-gaap_AccountingStandardsUpdate202104Member_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638327284586905517" xlink:to="us-gaap_AccountingStandardsUpdate202104Member_638327284586905517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638327284586905517" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_638327284586905517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638327284586905517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638327284586905517" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638327284586905517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_638327284586905517" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638327284586915515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_638327284586915515" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Revenues from Contracts with Customers - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_1" xlink:to="us-gaap_DisaggregationOfRevenueTable_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586915515" xlink:to="srt_ProductOrServiceAxis_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638327284586915515" xlink:to="srt_ProductsAndServicesDomain_638327284586915515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638327284586915515" xlink:to="us-gaap_ProductMember_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthPortfolioMember" xlink:label="aytu_ConsumerHealthPortfolioMember_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284586915515" xlink:to="aytu_ConsumerHealthPortfolioMember_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586915515" xlink:to="srt_RangeAxis_638327284586915515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284586915515" xlink:to="srt_RangeMember_638327284586915515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284586915515" xlink:to="srt_MinimumMember_638327284586915515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638327284586915515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586915515" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638327284586915515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586915515" xlink:to="us-gaap_NumberOfReportableSegments_638327284586925518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProducts" xlink:label="aytu_NumberOfProducts_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586915515" xlink:to="aytu_NumberOfProducts_638327284586925518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Revenues from Contracts with Customers - Revenues by Segment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_3" xlink:to="us-gaap_DisaggregationOfRevenueTable_638327284586925518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586925518" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284586925518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284586925518" xlink:to="us-gaap_SegmentDomain_638327284586925518" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586925518" xlink:to="aytu_RxMember_638327284586925518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586925518" xlink:to="aytu_ConsumerHealthMember_638327284586925518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586925518" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638327284586925518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586925518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586925518" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586925518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638327284586935520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586935520" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284586935520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284586935520" xlink:to="us-gaap_SegmentDomain_638327284586935520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284586935520" xlink:to="aytu_RxMember_638327284586935520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586935520" xlink:to="srt_ProductOrServiceAxis_638327284586935520" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638327284586935520" xlink:to="srt_ProductsAndServicesDomain_638327284586935520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638327284586935520" xlink:to="us-gaap_ProductMember_638327284586935520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284586935520" xlink:to="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_638327284586935520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PediatricPortfolioMember" xlink:label="aytu_PediatricPortfolioMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284586935520" xlink:to="aytu_PediatricPortfolioMember_638327284586935520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturedProductOtherMember" xlink:label="us-gaap_ManufacturedProductOtherMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284586935520" xlink:to="us-gaap_ManufacturedProductOtherMember_638327284586935520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthPortfolioMember" xlink:label="aytu_ConsumerHealthPortfolioMember_638327284586935520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284586935520" xlink:to="aytu_ConsumerHealthPortfolioMember_638327284586935520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586935520" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586945516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitNameOfSegmentExtensibleList" xlink:label="us-gaap_ReportingUnitNameOfSegmentExtensibleList_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" xlink:to="us-gaap_ReportingUnitNameOfSegmentExtensibleList_638327284586945516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Revenues from Contracts with Customers - Revenues by Geographic Location (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_638327284586945516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586945516" xlink:to="srt_StatementGeographicalAxis_638327284586945516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638327284586945516" xlink:to="srt_SegmentGeographicalDomain_638327284586945516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638327284586945516" xlink:to="country_US_638327284586945516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638327284586945516" xlink:to="us-gaap_NonUsMember_638327284586945516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638327284586945516" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586945516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638327284586945516" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284586945516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Inventories - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_637706853138897422" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_637706853138897422" xlink:to="us-gaap_InventoryNetAbstract_638327284586955516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638327284586955516" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638327284586955516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638327284586955516" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638327284586955516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638327284586955516" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638327284586955516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract_638327284586955516" xlink:to="us-gaap_InventoryNet_638327284586955516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Inventories - Inventory Write-down (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:label="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284586955516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284586955516" xlink:to="us-gaap_InventoryWriteDown_638327284586955516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InventoryWriteDownAndImpairment" xlink:label="aytu_InventoryWriteDownAndImpairment_638327284586955516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284586955516" xlink:to="aytu_InventoryWriteDownAndImpairment_638327284586955516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637674797320815863" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637674797320815863" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586965515" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586965515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" xlink:to="aytu_ManufacturingEquipmentMember_638327284586965515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" xlink:to="us-gaap_LeaseholdImprovementsMember_638327284586965515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeEquipmentFurnitureAndOtherMember" xlink:label="aytu_OfficeEquipmentFurnitureAndOtherMember_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" xlink:to="aytu_OfficeEquipmentFurnitureAndOtherMember_638327284586965515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" xlink:to="aytu_LabEquipmentMember_638327284586965515" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586965515" xlink:to="us-gaap_AssetUnderConstructionMember_638327284586965515" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586965515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_638327284586965515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638327284586965515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_638327284586965515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638327284586975515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_638327284586975515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284586975515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract_638327284586965515" xlink:to="us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_638327284586975515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Property and Equipment - Depreciation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="us-gaap_DepreciationAndAmortizationAbstract_638327284586975515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="us-gaap_DepreciationAndAmortizationAbstract_638327284586975515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638327284586975515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAndAmortizationAbstract_638327284586975515" xlink:to="us-gaap_Depreciation_638327284586975515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Property and Equipment - Gain (Loss) on Disposal (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract_638327284586985514" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Property and Equipment - Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586985514" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638327284586985514" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ManufacturingEquipmentMember" xlink:label="aytu_ManufacturingEquipmentMember_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638327284586985514" xlink:to="aytu_ManufacturingEquipmentMember_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638327284586985514" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586985514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentChargesAbstract" xlink:label="us-gaap_TangibleAssetImpairmentChargesAbstract_638327284586985514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638327284586985514" xlink:to="us-gaap_TangibleAssetImpairmentChargesAbstract_638327284586985514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TangibleAssetImpairmentChargesAbstract_638327284586985514" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_638327284586995526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_638327284586995526" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638327284586995526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract_638327284586995526" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638327284586995526" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Leases - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638327284586995526" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638327284586995526" xlink:to="srt_CounterpartyNameAxis_638327284586995526" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638327284586995526" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638327284586995526" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember" xlink:label="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638327284586995526" xlink:to="aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_638327284586995526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrincipalOfficeDenverColoradoMember" xlink:label="aytu_PrincipalOfficeDenverColoradoMember_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638327284586995526" xlink:to="aytu_PrincipalOfficeDenverColoradoMember_638327284586995526" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638327284586995526" xlink:to="srt_StatementScenarioAxis_638327284586995526" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638327284586995526" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638327284586995526" xlink:to="srt_ScenarioUnspecifiedDomain_638327284586995526" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpansionDateMember" xlink:label="aytu_ExpansionDateMember_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284586995526" xlink:to="aytu_ExpansionDateMember_638327284587005516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExpirationOfSubleaseMember" xlink:label="aytu_ExpirationOfSubleaseMember_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284586995526" xlink:to="aytu_ExpirationOfSubleaseMember_638327284587005516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638327284586995526" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638327284587005516" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638327284587005516" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638327284587005516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638327284587005516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="us-gaap_OperatingLeaseLiability_638327284587005516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638327284587005516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AreaOfSubleaseProperty" xlink:label="aytu_AreaOfSubleaseProperty_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="aytu_AreaOfSubleaseProperty_638327284587005516" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RemainingAreaOfSubleaseProperty" xlink:label="aytu_RemainingAreaOfSubleaseProperty_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="aytu_RemainingAreaOfSubleaseProperty_638327284587005516" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RentReceivableFromSubleaseProperty" xlink:label="aytu_RentReceivableFromSubleaseProperty_638327284587005516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="aytu_RentReceivableFromSubleaseProperty_638327284587005516" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638327284587005516" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638327284587015521" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638327284587005516" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638327284587015521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract_638327284587015521" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_638327284587015521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Leases - Net Lease Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587015521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587015521" xlink:to="us-gaap_LeaseCostAbstract_638327284587015521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638327284587015521" xlink:to="us-gaap_OperatingLeaseCost_638327284587015521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638327284587015521" xlink:to="us-gaap_ShortTermLeaseCost_638327284587015521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638327284587015521" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638327284587015521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638327284587015521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638327284587015521" xlink:to="us-gaap_FinanceLeaseInterestExpense_638327284587015521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638327284587015521" xlink:to="us-gaap_LeaseCost_638327284587025520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587025520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587025520" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638327284587025520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638327284587025520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset_638327284587025520" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_638327284587025520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset" xlink:label="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset_638327284587025520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638327284587025520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638327284587025520" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638327284587025520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638327284587025520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638327284587025520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent_638327284587025520" xlink:to="us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638327284587035515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638327284587035515" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent_638327284587035515" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638327284587035515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638327284587035515" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent_638327284587035515" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_638327284587035515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAndFinanceLeaseLiability" xlink:label="aytu_OperatingLeaseAndFinanceLeaseLiability_638327284587035515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_638327284587025520" xlink:to="aytu_OperatingLeaseAndFinanceLeaseLiability_638327284587035515" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587045514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638327284587045514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638327284587045514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638327284587045514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638327284587045514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Leases - Cash Flow Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587045514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638327284587045514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638327284587045514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638327284587045514" xlink:to="us-gaap_OperatingLeasePayments_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_638327284587055515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_638327284587055515" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587045514" xlink:to="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_638327284587055515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_638327284587055515" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Leases - Operating Leases - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587055515" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638327284587055515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638327284587055515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638327284587055515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638327284587055515" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638327284587065518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638327284587055515" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638327284587065518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails" xlink:type="extended" xlink:title="40607 - Disclosure - Leases - Operating Leases - Gross Difference (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587065518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587065518" xlink:to="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587065518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587065518" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638327284587065518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587065518" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638327284587065518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587065518" xlink:to="us-gaap_OperatingLeaseLiability_638327284587065518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40608 - Disclosure - Leases - Finance Leases - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587065518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638327284587065518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587065518" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638327284587065518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638327284587065518" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638327284587075517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638327284587065518" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638327284587075517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails" xlink:type="extended" xlink:title="40609 - Disclosure - Leases - Finance Leases - Gross Difference (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_638327284587075517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638327284587075517" xlink:to="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587075517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587075517" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638327284587075517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587075517" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638327284587075517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638327284587075517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract_638327284587075517" xlink:to="us-gaap_FinanceLeaseLiability_638327284587075517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable_638327284587085518" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable_638327284587085518" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284587085518" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284587085518" xlink:to="us-gaap_SegmentDomain_638327284587085518" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284587085518" xlink:to="aytu_ConsumerHealthMember_638327284587085518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284587085518" xlink:to="aytu_RxMember_638327284587085518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable_638327284587085518" xlink:to="us-gaap_GoodwillLineItems_638327284587085518" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward" xlink:label="us-gaap_GoodwillRollForward_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems_638327284587085518" xlink:to="us-gaap_GoodwillRollForward_638327284587085518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_638327284587085518" xlink:to="us-gaap_Goodwill_638327284587085518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638327284587085518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_638327284587085518" xlink:to="us-gaap_GoodwillImpairmentLoss_638327284587085518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_6383272845870855181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillRollForward_638327284587085518" xlink:to="us-gaap_Goodwill_6383272845870855181" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637649317493494766" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637649317493494766" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587095520" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587095520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" xlink:to="aytu_ProductTechnologyRightMember_638327284587095520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" xlink:to="us-gaap_DevelopedTechnologyRightsMember_638327284587095520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductDistributionRightsMember" xlink:label="aytu_ProductDistributionRightsMember_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" xlink:to="aytu_ProductDistributionRightsMember_638327284587095520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="us-gaap_OtherIntangibleAssetsMember_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587095520" xlink:to="us-gaap_OtherIntangibleAssetsMember_638327284587095520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587095520" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587095520" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587095520" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638327284587095520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638327284587095520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284587105517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284587105517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284587105517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284587105517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638327284587165521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638327284587095520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638327284587165521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587175521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587175521" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587175521" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587175521" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587175521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587175521" xlink:to="aytu_ProductTechnologyRightMember_638327284587175521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587175521" xlink:to="us-gaap_DevelopedTechnologyRightsMember_638327284587175521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductDistributionRightsMember" xlink:label="aytu_ProductDistributionRightsMember_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587175521" xlink:to="aytu_ProductDistributionRightsMember_638327284587175521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587175521" xlink:to="srt_RangeAxis_638327284587175521" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587175521" xlink:to="srt_RangeMember_638327284587175521" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587175521" xlink:to="srt_WeightedAverageMember_638327284587175521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587175521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587175521" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587175521" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587175521" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638327284587185517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638327284587185517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638327284587185517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638327284587185517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638327284587185517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment_638327284587185517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment_638327284587185517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment" xlink:label="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment_638327284587185517" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284587185517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_638327284587185517" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638327284587185517" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_638327284587195518" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638327284587195518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638327284587195518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638327284587195518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638327284587195518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638327284587195518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_638327284587195518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638327284587195518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638327284587195518" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638327284587195518" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587205520" xlink:to="us-gaap_TypeOfArrangementAxis_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284587205520" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587205520" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587205520" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587205520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587205520" xlink:to="aytu_SupplyAndDistributionAgreementTerm_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails" xlink:type="extended" xlink:title="40707 - Disclosure - Goodwill and Other Intangible Assets - Estimated Useful Life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587205520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587205520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587205520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductTechnologyRightMember" xlink:label="aytu_ProductTechnologyRightMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587215522" xlink:to="aytu_ProductTechnologyRightMember_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" xlink:to="srt_ProductOrServiceAxis_638327284587215522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638327284587215522" xlink:to="srt_ProductsAndServicesDomain_638327284587215522" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638327284587215522" xlink:to="us-gaap_ProductMember_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AttentionDeficitHyperactivityDisorderPortfolioMember" xlink:label="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284587215522" xlink:to="aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" xlink:to="srt_RangeAxis_638327284587215522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587215522" xlink:to="srt_RangeMember_638327284587215522" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587215522" xlink:to="srt_MinimumMember_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587215522" xlink:to="srt_MaximumMember_638327284587215522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587205520" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587215522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587215522" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638327284587215522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod" xlink:label="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_638327284587215522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587215522" xlink:to="aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod_638327284587215522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587225522" xlink:to="us-gaap_BusinessAcquisitionAxis_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638327284587225522" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587225522" xlink:to="aytu_InnovusPharmaceuticalsIncMember_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587225522" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284587225522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284587225522" xlink:to="us-gaap_SegmentDomain_638327284587225522" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284587225522" xlink:to="aytu_ConsumerHealthMember_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587225522" xlink:to="us-gaap_BusinessAcquisitionLineItems_638327284587225522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfProductsAcquired" xlink:label="aytu_NumberOfProductsAcquired_638327284587225522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587225522" xlink:to="aytu_NumberOfProductsAcquired_638327284587225522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired" xlink:label="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_638327284587235520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587225522" xlink:to="aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired_638327284587235520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638327284587235520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587225522" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638327284587235520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended" xlink:title="40709 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortizationAbstract" xlink:label="us-gaap_AdjustmentForAmortizationAbstract_638327284587235520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1" xlink:to="us-gaap_AdjustmentForAmortizationAbstract_638327284587235520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="us-gaap_AmortizationOfDeferredCharges_638327284587235520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentForAmortizationAbstract_638327284587235520" xlink:to="us-gaap_AmortizationOfDeferredCharges_638327284587235520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails" xlink:type="extended" xlink:title="40710 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" xlink:to="srt_ProductOrServiceAxis_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638327284587245523" xlink:to="srt_ProductsAndServicesDomain_638327284587245523" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638327284587245523" xlink:to="us-gaap_ProductMember_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_PrimaryCarePortfolioMember" xlink:label="aytu_PrimaryCarePortfolioMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638327284587245523" xlink:to="aytu_PrimaryCarePortfolioMember_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AciphexMember" xlink:label="aytu_AciphexMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_PrimaryCarePortfolioMember_638327284587245523" xlink:to="aytu_AciphexMember_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ZolpiMistMember" xlink:label="aytu_ZolpiMistMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_PrimaryCarePortfolioMember_638327284587245523" xlink:to="aytu_ZolpiMistMember_638327284587245523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TussionexMember" xlink:label="aytu_TussionexMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_PrimaryCarePortfolioMember_638327284587245523" xlink:to="aytu_TussionexMember_638327284587245523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CefaclorMember" xlink:label="aytu_CefaclorMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_PrimaryCarePortfolioMember_638327284587245523" xlink:to="aytu_CefaclorMember_638327284587245523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587245523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638327284587245523" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638327284587245523" xlink:to="us-gaap_TradeNamesMember_638327284587245523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284587245523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284587245523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284587245523" xlink:to="us-gaap_SegmentDomain_638327284587255519" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284587255519" xlink:to="aytu_ConsumerHealthMember_638327284587255519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" xlink:to="us-gaap_BusinessAcquisitionAxis_638327284587255519" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638327284587255519" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587255519" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosTherapeuticsIncMember" xlink:label="aytu_NeosTherapeuticsIncMember_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587255519" xlink:to="aytu_NeosTherapeuticsIncMember_638327284587255519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587255519" xlink:to="aytu_InnovusPharmaceuticalsIncMember_638327284587255519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638327284587245523" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587255519" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638327284587255519" xlink:to="us-gaap_AssetImpairmentChargesAbstract_638327284587255519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638327284587255519" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638327284587255519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638327284587255519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638327284587255519" xlink:to="us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638327284587255519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" xlink:title="40711 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8" xlink:to="us-gaap_Goodwill_638327284587265517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accrued Liabilities - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedSavingOffers" xlink:label="aytu_AccruedSavingOffers_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="aytu_AccruedSavingOffers_638327284587265517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedProgramRelatedLiabilities" xlink:label="aytu_AccruedProgramRelatedLiabilities_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="aytu_AccruedProgramRelatedLiabilities_638327284587265517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638327284587265517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AccruedCustomerAndProductRelatedFeesCurrent" xlink:label="aytu_AccruedCustomerAndProductRelatedFeesCurrent_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="aytu_AccruedCustomerAndProductRelatedFeesCurrent_638327284587265517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserveCurrent" xlink:label="aytu_ReturnReserveCurrent_638327284587265517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="aytu_ReturnReserveCurrent_638327284587265517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638327284587275521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638327284587275521" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638327284587275521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638327284587275521" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Accrued Liabilities - Return Reserve (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserve" xlink:label="aytu_ReturnReserve_638327284587275521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="aytu_ReturnReserve_638327284587275521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserveChargesToExpense" xlink:label="aytu_ReturnReserveChargesToExpense_638327284587275521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="aytu_ReturnReserveChargesToExpense_638327284587275521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReservePayments" xlink:label="aytu_ReturnReservePayments_638327284587275521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="aytu_ReturnReservePayments_638327284587275521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ReturnReserve" xlink:label="aytu_ReturnReserve_6383272845872755211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_1" xlink:to="aytu_ReturnReserve_6383272845872755211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Other Liabilities - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesUnclassifiedAbstract" xlink:label="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="aytu_FixedPaymentArrangements_638327284587285518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="us-gaap_OperatingLeaseLiability_638327284587285518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587285518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284587285518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilities" xlink:label="us-gaap_OtherSundryLiabilities_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="us-gaap_OtherSundryLiabilities_638327284587285518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesUnclassifiedAbstract_638327284587285518" xlink:to="us-gaap_OtherLiabilities_638327284587285518" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Other Liabilities - Classification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="us-gaap_OtherLiabilitiesAbstract_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_1" xlink:to="us-gaap_OtherLiabilitiesAbstract_638327284587285518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_638327284587285518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract_638327284587285518" xlink:to="us-gaap_OtherLiabilities_638327284587285518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract_638327284587285518" xlink:to="us-gaap_OtherLiabilitiesCurrent_638327284587295517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesAbstract_638327284587285518" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638327284587295517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Other Liabilities - Fixed Payment Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_5" xlink:to="us-gaap_OtherCommitmentsTable_638327284587295517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284587295517" xlink:to="us-gaap_OtherCommitmentsAxis_638327284587295517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638327284587295517" xlink:to="us-gaap_OtherCommitmentsDomain_638327284587295517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284587295517" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284587295517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284587295517" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_638327284587295517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284587295517" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_638327284587295517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284587295517" xlink:to="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_638327284587295517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284587295517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284587295517" xlink:to="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284587295517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284587295517" xlink:to="srt_RangeAxis_638327284587305521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587305521" xlink:to="srt_RangeMember_638327284587305521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587305521" xlink:to="srt_MinimumMember_638327284587305521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587305521" xlink:to="srt_MaximumMember_638327284587305521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284587295517" xlink:to="us-gaap_OtherCommitmentsLineItems_638327284587305521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_638327284587305521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_638327284587305521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount_638327284587305521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue_638327284587305521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_638327284587305521" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_638327284587305521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_638327284587305521" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026_638327284587315520" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_638327284587315520" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid_638327284587315520" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangements_638327284587315520" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsCurrent" xlink:label="aytu_FixedPaymentArrangementsCurrent_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsCurrent_638327284587315520" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsNoncurrent" xlink:label="aytu_FixedPaymentArrangementsNoncurrent_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsNoncurrent_638327284587315520" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_638327284587315520" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_638327284587315520" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_638327284587315520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_638327284587315520" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsLiabilityReduction" xlink:label="aytu_FixedPaymentArrangementsLiabilityReduction_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsLiabilityReduction_638327284587325518" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInstallmentPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587305521" xlink:to="aytu_FixedPaymentArrangementsInstallmentPaymentsNumber_638327284587325518" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Other Liabilities - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587325518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587325518" xlink:to="us-gaap_TypeOfArrangementAxis_638327284587325518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284587325518" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587325518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284587325518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284587325518" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementTerm_638327284587335520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_638327284587335520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_638327284587335520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_638327284587335520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_638327284587335520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_638327284587335520" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_638327284587335520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284587325518" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_638327284587335520" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Other Liabilities - Contingent Value Rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_6" xlink:to="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum_638327284587345521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum" xlink:label="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_6" xlink:to="aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum_638327284587345521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts" xlink:label="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_6" xlink:to="aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts_638327284587345521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_6" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587345521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_6" xlink:to="aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod_638327284587345521" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Other Liabilities - Contingent Consideration - Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_8" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587345521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587345521" xlink:to="us-gaap_BusinessAcquisitionAxis_638327284587345521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_638327284587345521" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587345521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InnovusPharmaceuticalsIncMember" xlink:label="aytu_InnovusPharmaceuticalsIncMember_638327284587345521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_638327284587345521" xlink:to="aytu_InnovusPharmaceuticalsIncMember_638327284587345521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_638327284587345521" xlink:to="us-gaap_BusinessAcquisitionLineItems_638327284587355520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587355520" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount_638327284587355520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate" xlink:label="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587355520" xlink:to="aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate_638327284587355520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_638327284587355520" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638327284587355520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Other Liabilities - Contingent Consideration - Other than Business Combination (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_9" xlink:to="us-gaap_OtherCommitmentsTable_638327284587355520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284587355520" xlink:to="us-gaap_OtherCommitmentsAxis_638327284587355520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638327284587355520" xlink:to="us-gaap_OtherCommitmentsDomain_638327284587355520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284587355520" xlink:to="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284587355520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember" xlink:label="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284587355520" xlink:to="aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_638327284587355520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638327284587355520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284587355520" xlink:to="us-gaap_OtherCommitmentsLineItems_638327284587355520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_638327284587365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587355520" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_638327284587365521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638327284587365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587355520" xlink:to="us-gaap_OtherLiabilitiesCurrent_638327284587365521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284587365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284587355520" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284587365521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Other Liabilities - Contingent Consideration - Total (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_10" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284587365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_10" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284587365521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_638327284587365521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_10" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_638327284587365521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLineOfCreditDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Line of Credit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" xlink:to="us-gaap_ShortTermDebtTypeAxis_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_638327284587375517" xlink:to="us-gaap_ShortTermDebtTypeDomain_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_638327284587375517" xlink:to="us-gaap_SecuredDebtMember_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" xlink:to="us-gaap_DebtInstrumentAxis_638327284587375517" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638327284587375517" xlink:to="us-gaap_DebtInstrumentNameDomain_638327284587375517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638327284587375517" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember" xlink:label="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_638327284587375517" xlink:to="aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" xlink:to="us-gaap_VariableRateAxis_638327284587375517" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638327284587375517" xlink:to="us-gaap_VariableRateDomain_638327284587375517" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638327284587375517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638327284587375517" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638327284587375517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638327284587375517" xlink:to="us-gaap_ShortTermDebtLineItems_638327284587385522" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease_638327284587385522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638327284587385522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable_638327284587385522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638327284587385522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_638327284587385522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_DebtInstrumentMaturityDate_638327284587385522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock" xlink:label="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock_638327284587385522" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023_638327284587385522" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_638327284587385522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024_638327284587385522" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024" xlink:label="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024_638327284587395575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod" xlink:label="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod_638327284587395575" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_InterestExpenseDebt_638327284587395575" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_ShortTermBorrowings_638327284587395575" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638327284587395575" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross_638327284587395575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638327284587385522" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentGross_638327284587395575" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Long-term Debt - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_5" xlink:to="us-gaap_DebtInstrumentTable_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638327284587405544" xlink:to="us-gaap_DebtInstrumentAxis_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638327284587405544" xlink:to="us-gaap_DebtInstrumentNameDomain_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeerfieldFacilityMember" xlink:label="aytu_DeerfieldFacilityMember_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638327284587405544" xlink:to="aytu_DeerfieldFacilityMember_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AvenueCapitalLoanTermLoanMember" xlink:label="aytu_AvenueCapitalLoanTermLoanMember_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638327284587405544" xlink:to="aytu_AvenueCapitalLoanTermLoanMember_638327284587405544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638327284587405544" xlink:to="srt_StatementScenarioAxis_638327284587405544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638327284587405544" xlink:to="srt_ScenarioUnspecifiedDomain_638327284587405544" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member" xlink:label="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284587405544" xlink:to="aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member" xlink:label="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284587405544" xlink:to="aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_638327284587405544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638327284587405544" xlink:to="us-gaap_DebtInstrumentLineItems_638327284587405544" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638327284587405544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_638327284587405544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_LongTermDebtFairValue_638327284587405544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_638327284587415546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638327284587415546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread" xlink:label="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread_638327284587415546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638327284587415546" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentFaceAmount_638327284587415546" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentTerm" xlink:label="aytu_DebtInstrumentInterestPaymentTerm_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_DebtInstrumentInterestPaymentTerm_638327284587415546" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentInterestPaymentExtensionTerm" xlink:label="aytu_DebtInstrumentInterestPaymentExtensionTerm_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_DebtInstrumentInterestPaymentExtensionTerm_638327284587415546" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_InterestOnlyPeriodFurtherExtensionTerm" xlink:label="aytu_InterestOnlyPeriodFurtherExtensionTerm_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_InterestOnlyPeriodFurtherExtensionTerm_638327284587415546" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentTermOfTrailingMonthsRevenue" xlink:label="aytu_DebtInstrumentTermOfTrailingMonthsRevenue_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_DebtInstrumentTermOfTrailingMonthsRevenue_638327284587415546" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DebtInstrumentPrepaymentFeePercentage" xlink:label="aytu_DebtInstrumentPrepaymentFeePercentage_638327284587415546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="aytu_DebtInstrumentPrepaymentFeePercentage_638327284587415546" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638327284587425541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentFeeAmount_638327284587425541" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee_638327284587425541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_LoanProcessingFee_638327284587425541" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638327284587425541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638327284587425541" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638327284587425541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_InterestExpenseDebt_638327284587425541" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284587425541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638327284587405544" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638327284587425541" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Long-term Debt - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587435541" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638327284587435541" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638327284587435541" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638327284587435541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638327284587435541" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587435541" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587435541" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587435541" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587435541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587435541" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587435541" xlink:to="srt_RangeAxis_638327284587435541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587435541" xlink:to="srt_RangeMember_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587435541" xlink:to="srt_MinimumMember_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587435541" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284587435541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284587435541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284587435541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" xlink:to="us-gaap_SharePrice_638327284587445541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587435541" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638327284587445541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Long-term Debt - Composition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_638327284587445541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFeeAmount_638327284587445541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638327284587445541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiability_638327284587445541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_638327284587445541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284587445541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284587445541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284587445541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Long-term Debt - Future Principal Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne_638327284587455543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo_638327284587455543" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LongTermDebtAndFinanceLeaseLiabilityGross" xlink:label="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="aytu_LongTermDebtAndFinanceLeaseLiabilityGross_638327284587455543" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638327284587455543" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_638327284587455543" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_638327284587455543" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284587455543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284587455543" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284587455543" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587465542" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587465542" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638327284587465542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638327284587465542" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284587455543" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638327284587465542" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638327284587465542" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638327284587465542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638327284587465542" xlink:to="us-gaap_FairValueInputsLevel12And3Member_638327284587465542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueInputsLevel12And3Member_638327284587465542" xlink:to="us-gaap_FairValueInputsLevel3Member_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638327284587455543" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284587465542" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638327284587465542" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetAssetLiabilityAbstract_638327284587465542" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability" xlink:label="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284587465542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability_638327284587465542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsLiabilitiesFairValueDisclosure" xlink:label="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="aytu_ContingentValueRightsLiabilitiesFairValueDisclosure_638327284587475544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="us-gaap_DerivativeLiabilities_638327284587475544" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638327284587475544" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_638327284587465542" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_638327284587475544" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638327284587475544" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638327284587475544" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638327284587475544" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638327284587475544" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284587475544" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMember" xlink:label="aytu_ContingentValueRightsMember_638327284587475544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284587475544" xlink:to="aytu_ContingentValueRightsMember_638327284587475544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationMember" xlink:label="aytu_ContingentConsiderationMember_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284587475544" xlink:to="aytu_ContingentConsiderationMember_638327284587485525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638327284587475544" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_638327284587485525" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638327284587475544" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638327284587485525" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638327284587485525" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638327284587485525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638327284587485525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638327284587485525" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638327284587485525" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638327284587485525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_638327284587485525" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6383272845874855251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638327284587485525" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6383272845874855251" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Fair Value Measurements - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587495520" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587495520" xlink:to="us-gaap_MeasurementInputTypeAxis_638327284587495520" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638327284587495520" xlink:to="us-gaap_MeasurementInputTypeDomain_638327284587495520" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputLeveragedBetaMember" xlink:label="aytu_MeasurementInputLeveragedBetaMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="aytu_MeasurementInputLeveragedBetaMember_638327284587495520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_MeasurementInputMarketRiskPremiumMember" xlink:label="aytu_MeasurementInputMarketRiskPremiumMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="aytu_MeasurementInputMarketRiskPremiumMember_638327284587495520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638327284587495520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638327284587495520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638327284587495520" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638327284587495520" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638327284587495520" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_638327284587495520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587495520" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_638327284587495520" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587495520" xlink:to="srt_RangeAxis_638327284587505521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587505521" xlink:to="srt_RangeMember_638327284587505521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587505521" xlink:to="srt_MinimumMember_638327284587505521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587505521" xlink:to="srt_MaximumMember_638327284587505521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587495520" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587505521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentValueRightsMeasurementInput" xlink:label="aytu_ContingentValueRightsMeasurementInput_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587505521" xlink:to="aytu_ContingentValueRightsMeasurementInput_638327284587505521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587505521" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638327284587505521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList" xlink:label="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList_638327284587505521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587505521" xlink:to="us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList_638327284587505521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Fair Value Measurements - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" xlink:to="us-gaap_MeasurementInputTypeAxis_638327284587515551" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638327284587515551" xlink:to="us-gaap_MeasurementInputTypeDomain_638327284587515551" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638327284587515551" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638327284587515551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" xlink:to="srt_RangeAxis_638327284587515551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587515551" xlink:to="srt_RangeMember_638327284587515551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587515551" xlink:to="srt_MinimumMember_638327284587515551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587515551" xlink:to="srt_MaximumMember_638327284587515551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587515551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638327284587515551" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638327284587515551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638327284587515551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638327284587515551" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638327284587515551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638327284587515551" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMeasurementInput" xlink:label="aytu_FixedPaymentArrangementsMeasurementInput_638327284587525544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" xlink:to="aytu_FixedPaymentArrangementsMeasurementInput_638327284587525544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements_638327284587525544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" xlink:to="aytu_FixedPaymentArrangements_638327284587525544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638327284587525544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638327284587525544" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638327284587525544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638327284587525544" xlink:to="us-gaap_GoodwillImpairmentLoss_638327284587525544" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587535540" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Consolidated Balance Sheet (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_StatementTable_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284587535540" xlink:to="us-gaap_BalanceSheetLocationAxis_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638327284587535540" xlink:to="us-gaap_BalanceSheetLocationDomain_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638327284587535540" xlink:to="us-gaap_OtherNoncurrentAssetsMember_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638327284587535540" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_638327284587535540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284587535540" xlink:to="us-gaap_StatementLineItems_638327284587535540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638327284587535540" xlink:to="us-gaap_AssetsNoncurrentAbstract_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638327284587535540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638327284587535540" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638327284587535540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638327284587535540" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587545539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587545539" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638327284587545539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrentAbstract" xlink:label="us-gaap_TaxesPayableCurrentAbstract_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638327284587535540" xlink:to="us-gaap_TaxesPayableCurrentAbstract_638327284587545539" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxesPayableCurrentAbstract_638327284587545539" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638327284587545539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Section 382 Limitation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation_638327284587545539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss" xlink:label="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_638327284587545539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss_638327284587545539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income Taxes - Operating Loss Carry Forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638327284587555542" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638327284587555542" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638327284587555542" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638327284587555542" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638327284587555542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638327284587555542" xlink:to="us-gaap_DomesticCountryMember_638327284587555542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638327284587555542" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638327284587555542" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638327284587555542" xlink:to="us-gaap_OperatingLossCarryforwards_638327284587555542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_638327284587555542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638327284587555542" xlink:to="aytu_OperatingLossCarryforwardsNotSubjectToExpiration_638327284587555542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Income Taxes - Tax Credit Carry Forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_638327284587565541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638327284587565541" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638327284587565541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638327284587565541" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638327284587565541" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638327284587565541" xlink:to="us-gaap_ResearchMember_638327284587565541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638327284587565541" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_638327284587565541" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638327284587565541" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638327284587565541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638327284587575542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638327284587575542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638327284587575542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587575542" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587575542" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638327284587575542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587575542" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638327284587575542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587575542" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638327284587575542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638327284587565541" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638327284587575542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41307 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638327284587585540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638327284587585540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284587585540" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration_638327284587585540" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount_638327284587585540" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_638327284587585540" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284587585540" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638327284587585540" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638327284587575542" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638327284587585540" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent_638327284587585540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_638327284587585540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent_638327284587585540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638327284587595547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration_638327284587595547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent_638327284587595547" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638327284587595547" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638327284587595547" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638327284587595547" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638327284587595547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638327284587585540" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638327284587595547" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails" xlink:type="extended" xlink:title="41308 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637668792884821853" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637668792884821853" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638327284587605553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638327284587605553" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638327284587605553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638327284587605553" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638327284587605553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsAccruedRebates" xlink:label="aytu_DeferredTaxAssetsAccruedRebates_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="aytu_DeferredTaxAssetsAccruedRebates_638327284587605553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638327284587605553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638327284587605553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638327284587605553" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsInterest" xlink:label="aytu_DeferredTaxAssetsInterest_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="aytu_DeferredTaxAssetsInterest_638327284587605553" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638327284587605553" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures" xlink:label="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_638327284587605553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures_638327284587605553" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsInventory_638327284587615545" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxAssetsLeaseLiability" xlink:label="aytu_DeferredTaxAssetsLeaseLiability_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="aytu_DeferredTaxAssetsLeaseLiability_638327284587615545" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsOther_638327284587615545" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsGross_638327284587615545" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638327284587615545" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxAssetsNet_638327284587615545" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638327284587605553" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638327284587615545" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638327284587615545" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_638327284587615545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638327284587615545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638327284587615545" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="aytu_DeferredTaxLiabilitiesRightOfUseAsset_638327284587625542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" xlink:to="aytu_DeferredTaxLiabilitiesRightOfUseAsset_638327284587625542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638327284587625542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638327284587615545" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638327284587625542" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638327284587625542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638327284587605553" xlink:to="us-gaap_DeferredTaxLiabilities_638327284587625542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="extended" xlink:title="41309 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment" xlink:label="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet" xlink:label="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet_638327284587635551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails" xlink:type="extended" xlink:title="41310 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_StatementTable_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284587635551" xlink:to="us-gaap_BalanceSheetLocationAxis_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638327284587635551" xlink:to="us-gaap_BalanceSheetLocationDomain_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638327284587635551" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638327284587635551" xlink:to="us-gaap_StatementLineItems_638327284587635551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638327284587635551" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638327284587635551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638327284587635551" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638327284587635551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails" xlink:type="extended" xlink:title="41311 - Disclosure - Income Taxes - Unrecognized Tax Benefits - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638327284587705546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638327284587705546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended" xlink:title="41312 - Disclosure - Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638327284587715548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" xlink:to="us-gaap_UnrecognizedTaxBenefits_638327284587715548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638327284587715548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638327284587715548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638327284587715548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638327284587715548" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6383272845877155481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638327284587715548" xlink:to="us-gaap_UnrecognizedTaxBenefits_6383272845877155481" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Stockholders Equity - Common and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" xlink:to="us-gaap_CommonStockSharesAuthorized_638327284587725549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638327284587725549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" xlink:to="us-gaap_CommonStockSharesIssued_638327284587725549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587715548" xlink:to="us-gaap_CommonStockSharesOutstanding_638327284587725549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" xlink:to="us-gaap_PreferredStockSharesAuthorized_638327284587725549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638327284587725549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" xlink:to="us-gaap_PreferredStockSharesIssued_638327284587725549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638327284587725549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638327284587725549" xlink:to="us-gaap_PreferredStockSharesOutstanding_638327284587725549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Stockholders Equity - Restricted Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587735544" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587735544" xlink:to="us-gaap_AwardTypeAxis_638327284587735544" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587735544" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587735544" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587735544" xlink:to="us-gaap_RestrictedStockMember_638327284587735544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587735544" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587735544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587735544" xlink:to="us-gaap_CommonStockSharesOutstanding_638327284587735544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Stockholders Equity - Stock Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587735544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587735544" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638327284587735544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587735544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638327284587735544" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587735544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfMember_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587735544" xlink:to="aytu_ShelfRegistrationStatement2020ShelfMember_638327284587745551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember" xlink:label="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_ShelfRegistrationStatement2020ShelfMember_638327284587745551" xlink:to="aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_638327284587745551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587735544" xlink:to="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587745551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587745551" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_638327284587745551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587745551" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_638327284587745551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587735544" xlink:to="aytu_SecuritiesPurchaseAgreement2023Member_638327284587745551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_SecuritiesPurchaseAgreement2023Member_638327284587745551" xlink:to="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_638327284587745551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587735544" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationAmountAuthorized" xlink:label="aytu_ShelfRegistrationAmountAuthorized_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_ShelfRegistrationAmountAuthorized_638327284587745551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationRemainingAmountAvailableForSale" xlink:label="aytu_ShelfRegistrationRemainingAmountAvailableForSale_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_ShelfRegistrationRemainingAmountAvailableForSale_638327284587745551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AtmSalesAgreementAmountAuthorized" xlink:label="aytu_AtmSalesAgreementAmountAuthorized_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_AtmSalesAgreementAmountAuthorized_638327284587745551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587745551" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284587745551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638327284587745551" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_638327284587755549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrants_638327284587755549" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses" xlink:label="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_638327284587755549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses_638327284587755549" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638327284587755549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="us-gaap_SharePrice_638327284587755549" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_638327284587755549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_638327284587755549" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts" xlink:label="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_638327284587755549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587745551" xlink:to="aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts_638327284587755549" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Stockholders Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587765550" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638327284587765550" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638327284587765550" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_638327284587765550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587765550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587765550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_638327284587765550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_638327284587765550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284587765550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284587765550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_638327284587775550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284587765550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284587775550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284587775550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_638327284587775550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284587775550" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_638327284587775550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587765550" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284587775550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284587775550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638327284587775550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284587775550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_638327284587775550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_638327284587775550" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightOfferingPrice" xlink:label="aytu_ClassOfWarrantOrRightOfferingPrice_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_ClassOfWarrantOrRightOfferingPrice_638327284587785549" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638327284587785549" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638327284587785549" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587785549" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_638327284587785549" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_638327284587785549" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_638327284587785549" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_638327284587785549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_638327284587785549" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts" xlink:label="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284587775550" xlink:to="aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts_638327284587795556" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Equity Incentive Plans - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" xlink:to="us-gaap_PlanNameAxis_638327284587795556" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587795556" xlink:to="us-gaap_PlanNameDomain_638327284587795556" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587795556" xlink:to="aytu_Aytu2015PlanMember_638327284587795556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Neos2015PlanMember" xlink:label="aytu_Neos2015PlanMember_638327284587795556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587795556" xlink:to="aytu_Neos2015PlanMember_638327284587795556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587795556" xlink:to="aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_638327284587805552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" xlink:to="us-gaap_AwardTypeAxis_638327284587805552" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587805552" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587805552" xlink:to="us-gaap_EmployeeStockOptionMember_638327284587805552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587805552" xlink:to="us-gaap_RestrictedStockMember_638327284587805552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587805552" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638327284587805552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" xlink:to="srt_RangeAxis_638327284587805552" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587805552" xlink:to="srt_RangeMember_638327284587805552" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587805552" xlink:to="srt_MinimumMember_638327284587805552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587805552" xlink:to="srt_MaximumMember_638327284587805552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587795556" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638327284587805552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638327284587805552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638327284587815560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587815560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638327284587815560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638327284587815560" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638327284587815560" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638327284587815560" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638327284587815560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587805552" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638327284587815560" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Equity Incentive Plans - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638327284587825548" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638327284587825548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638327284587825548" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638327284587825548" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383272845878255481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6383272845878255481" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638327284587835547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638327284587835547" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638327284587835547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638327284587835547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6383272845878355471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638327284587825548" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6383272845878355471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638327284587835547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638327284587835547" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638327284587835547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638327284587835547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638327284587835547" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638327284587835547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Equity Incentive Plans - Range of Exercise Prices (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587845546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638327284587845546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638327284587845546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638327284587845546" xlink:to="aytu_ExercisePriceRangeOneMember_638327284587845546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638327284587845546" xlink:to="aytu_ExercisePriceRangeTwoMember_638327284587845546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587845546" xlink:to="srt_RangeAxis_638327284587845546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587845546" xlink:to="srt_RangeMember_638327284587845546" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587845546" xlink:to="srt_MinimumMember_638327284587845546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587845546" xlink:to="srt_MaximumMember_638327284587845546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638327284587855549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638327284587855549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638327284587855549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638327284587855549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638327284587855549" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638327284587855549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587845546" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638327284587855549" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Equity Incentive Plans - Restricted Stock - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="us-gaap_AwardTypeAxis_638327284587865545" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587865545" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587865545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587865545" xlink:to="us-gaap_RestrictedStockMember_638327284587865545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="us-gaap_PlanNameAxis_638327284587865545" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587865545" xlink:to="us-gaap_PlanNameDomain_638327284587865545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587865545" xlink:to="aytu_Aytu2015PlanMember_638327284587865545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="srt_TitleOfIndividualAxis_638327284587865545" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638327284587865545" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587865545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587865545" xlink:to="srt_ManagementMember_638327284587865545" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="us-gaap_VestingAxis_638327284587865545" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638327284587865545" xlink:to="us-gaap_VestingDomain_638327284587865545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638327284587865545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638327284587865545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638327284587875549" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638327284587875549" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheFourMember_638327284587875549" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheFiveMember_638327284587875549" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheSixMember_638327284587875549" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheSevenMember_638327284587875549" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheEightMember_638327284587875549" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587865545" xlink:to="aytu_ShareBasedCompensationAwardTrancheNineMember_638327284587875549" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="srt_RangeAxis_638327284587875549" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284587875549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284587875549" xlink:to="srt_RangeMember_638327284587875549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587875549" xlink:to="srt_MinimumMember_638327284587885550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284587875549" xlink:to="srt_MaximumMember_638327284587885550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587865545" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587885550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587885550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638327284587885550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587885550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587885550" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587885550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Equity Incentive Plans - Restricted Stock - Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587895553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587895553" xlink:to="us-gaap_AwardTypeAxis_638327284587895553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587895553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587895553" xlink:to="us-gaap_RestrictedStockMember_638327284587895553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587895553" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638327284587895553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587895553" xlink:to="us-gaap_PlanNameAxis_638327284587895553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587895553" xlink:to="us-gaap_PlanNameDomain_638327284587895553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587895553" xlink:to="aytu_Aytu2015PlanMember_638327284587895553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587895553" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638327284587905560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587905560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638327284587905560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638327284587905560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6383272845879055601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6383272845879055601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587895553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638327284587905560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587905560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638327284587905560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638327284587905560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638327284587905560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638327284587905560" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638327284587915561" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails" xlink:type="extended" xlink:title="41506 - Disclosure - Equity Incentive Plans - Restricted Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" xlink:to="us-gaap_AwardTypeAxis_638327284587915561" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587915561" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587915561" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587915561" xlink:to="us-gaap_RestrictedStockMember_638327284587915561" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" xlink:to="us-gaap_PlanNameAxis_638327284587915561" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587915561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587915561" xlink:to="us-gaap_PlanNameDomain_638327284587915561" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587915561" xlink:to="aytu_NonplanMember_638327284587925554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" xlink:to="srt_TitleOfIndividualAxis_638327284587925554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638327284587925554" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587925554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638327284587925554" xlink:to="srt_ManagementMember_638327284587925554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" xlink:to="us-gaap_VestingAxis_638327284587925554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638327284587925554" xlink:to="us-gaap_VestingDomain_638327284587925554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638327284587925554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638327284587925554" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638327284587925554" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFourMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFourMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheFourMember_638327284587925554" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheFiveMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheFiveMember_638327284587925554" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSixMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSixMember_638327284587925554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheSixMember_638327284587925554" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheSevenMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheSevenMember_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheSevenMember_638327284587935553" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheEightMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheEightMember_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheEightMember_638327284587935553" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationAwardTrancheNineMember" xlink:label="aytu_ShareBasedCompensationAwardTrancheNineMember_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638327284587925554" xlink:to="aytu_ShareBasedCompensationAwardTrancheNineMember_638327284587935553" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587915561" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587935553" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587935553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638327284587935553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587935553" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638327284587935553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587935553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587935553" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638327284587935553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails" xlink:type="extended" xlink:title="41507 - Disclosure - Equity Incentive Plans - Unrecognized Compensation Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587945554" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587945554" xlink:to="us-gaap_AwardTypeAxis_638327284587945554" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587945554" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587945554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587945554" xlink:to="us-gaap_EmployeeStockOptionMember_638327284587945554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587945554" xlink:to="us-gaap_RestrictedStockMember_638327284587945554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587945554" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638327284587945554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587945554" xlink:to="us-gaap_PlanNameAxis_638327284587945554" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587945554" xlink:to="us-gaap_PlanNameDomain_638327284587945554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanMember" xlink:label="aytu_Aytu2015PlanMember_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587945554" xlink:to="aytu_Aytu2015PlanMember_638327284587945554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NonplanMember" xlink:label="aytu_NonplanMember_638327284587945554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587945554" xlink:to="aytu_NonplanMember_638327284587945554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638327284587945554" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587955556" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638327284587955556" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_638327284587955556" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_638327284587955556" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638327284587955556" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638327284587955556" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638327284587955556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638327284587955556" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638327284587955556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638327284587955556" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638327284587955556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638327284587955556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638327284587955556" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638327284587955556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41508 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" xlink:to="us-gaap_AwardTypeAxis_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638327284587965554" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638327284587965554" xlink:to="us-gaap_RestrictedStockMember_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" xlink:to="us-gaap_PlanNameAxis_638327284587965554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638327284587965554" xlink:to="us-gaap_PlanNameDomain_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember" xlink:label="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587965554" xlink:to="aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember" xlink:label="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638327284587965554" xlink:to="aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_638327284587965554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" xlink:to="us-gaap_IncomeStatementLocationAxis_638327284587965554" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638327284587965554" xlink:to="us-gaap_IncomeStatementLocationDomain_638327284587965554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638327284587965554" xlink:to="us-gaap_CostOfSalesMember_638327284587965554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638327284587965554" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638327284587965554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_638327284587965554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638327284587965554" xlink:to="us-gaap_SellingAndMarketingExpenseMember_638327284587965554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638327284587965554" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638327284587975552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638327284587965554" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638327284587975552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638327284587975552" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber_638327284587975552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638327284587975552" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded_638327284587975552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638327284587975552" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638327284587975552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Warrants - Stock Issued (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587975552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587975552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587975552" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638327284587985553" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfMember" xlink:label="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587985553" xlink:to="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member" xlink:label="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_ShelfRegistrationStatement2021ShelfMember_638327284587985553" xlink:to="aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023Member_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638327284587985553" xlink:to="aytu_SecuritiesPurchaseAgreement2023Member_638327284587985553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member" xlink:label="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_SecuritiesPurchaseAgreement2023Member_638327284587985553" xlink:to="aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638327284587975552" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638327284587985553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638327284587985553" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284587985553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Warrants - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638327284587985553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638327284587985553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587985553" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638327284587995556" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638327284587995556" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638327284587995556" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_638327284587995556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587995556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587995556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587995556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_638327284587995556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_638327284587995556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_638327284587995556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember_638327284587995556" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284588005551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284588005551" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_638327284588005551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_638327284588005551" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284588005551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284588005551" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_638327284588005551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member" xlink:label="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_638327284588005551" xlink:to="aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_638327284588005551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284587985553" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588005551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638327284588005551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588005551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights" xlink:label="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_638327284588005551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights_638327284588005551" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_638327284588015558" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638327284588015558" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_638327284588015558" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638327284588015558" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays_638327284588015558" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16_638327284588015558" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne_638327284588015558" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_638327284588015558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo_638327284588015558" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares_638327284588025555" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice_638327284588025555" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638327284588025555" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock" xlink:label="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock_638327284588025555" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock_638327284588025555" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda" xlink:label="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda_638327284588025555" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_638327284588025555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588005551" xlink:to="aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_638327284588025555" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails" xlink:type="extended" xlink:title="41604 - Disclosure - Warrants - Warrants Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638327284588035553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284588035553" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638327284588035553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638327284588035553" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638327284588035553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WarrantsToPurchaseCommonStockMember" xlink:label="aytu_WarrantsToPurchaseCommonStockMember_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638327284588035553" xlink:to="aytu_WarrantsToPurchaseCommonStockMember_638327284588035553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284588035553" xlink:to="srt_RangeAxis_638327284588035553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638327284588035553" xlink:to="srt_RangeMember_638327284588035553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638327284588035553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638327284588035553" xlink:to="srt_WeightedAverageMember_638327284588035553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638327284588035553" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638327284588045557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriod_638327284588045557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExercisedDuringPeriod_638327284588045557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjusted" xlink:label="aytu_ClassOfWarrantOrRightAdjusted_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightAdjusted_638327284588045557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExpiredDuringPeriod_638327284588045557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6383272845880455571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6383272845880455571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588045557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice_638327284588045557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_638327284588045557" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_638327284588045557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted_638327284588045557" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired" xlink:label="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired_638327284588055553" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638327284588055553" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife_638327284588055553" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife_638327284588055553" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife_638327284588055553" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife" xlink:label="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_638327284588055553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638327284588045557" xlink:to="aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife_638327284588055553" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_638327284588065559" xlink:to="us-gaap_RetirementPlanNameAxis_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis_638327284588065559" xlink:to="us-gaap_RetirementPlanNameDomain_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NeosPlanMember" xlink:label="aytu_NeosPlanMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638327284588065559" xlink:to="aytu_NeosPlanMember_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuPlanMember" xlink:label="aytu_AytuPlanMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638327284588065559" xlink:to="aytu_AytuPlanMember_638327284588065559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AytuBiopharmaEmployeeRetirementPlanMember" xlink:label="aytu_AytuBiopharmaEmployeeRetirementPlanMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain_638327284588065559" xlink:to="aytu_AytuBiopharmaEmployeeRetirementPlanMember_638327284588065559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_638327284588065559" xlink:to="srt_StatementScenarioAxis_638327284588065559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638327284588065559" xlink:to="srt_ScenarioUnspecifiedDomain_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FirstThreePercentContributionByEmployeesMember" xlink:label="aytu_FirstThreePercentContributionByEmployeesMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284588065559" xlink:to="aytu_FirstThreePercentContributionByEmployeesMember_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentAndFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284588065559" xlink:to="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_638327284588065559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFourPercentContributionByEmployeesMember" xlink:label="aytu_NextFourPercentContributionByEmployeesMember_638327284588065559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_638327284588065559" xlink:to="aytu_NextFourPercentContributionByEmployeesMember_638327284588065559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NextFivePercentContributionByEmployeesMember" xlink:label="aytu_NextFivePercentContributionByEmployeesMember_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_638327284588065559" xlink:to="aytu_NextFivePercentContributionByEmployeesMember_638327284588075568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SixPercentContributionByEmployeesMember" xlink:label="aytu_SixPercentContributionByEmployeesMember_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638327284588065559" xlink:to="aytu_SixPercentContributionByEmployeesMember_638327284588075568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_638327284588065559" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_NumberOfEmployeeBenefitPlan" xlink:label="aytu_NumberOfEmployeeBenefitPlan_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" xlink:to="aytu_NumberOfEmployeeBenefitPlan_638327284588075568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638327284588075568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638327284588075568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638327284588075568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems_638327284588075568" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638327284588075568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Commitments and Contingencies - Fixed Payment Arrangements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_OtherCommitmentsTable_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588085560" xlink:to="us-gaap_OtherCommitmentsAxis_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638327284588085560" xlink:to="us-gaap_OtherCommitmentsDomain_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_638327284588085560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember" xlink:label="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_638327284588085560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284588085560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588085560" xlink:to="us-gaap_OtherCommitmentsLineItems_638327284588085560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber" xlink:label="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber_638327284588085560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsMonthlyPaymentAmount_638327284588085560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmount_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmount_638327284588085560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_638327284588085560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum_638327284588085560" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid" xlink:label="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid_638327284588095616" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid_638327284588095616" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsPaymentAmountPaid" xlink:label="aytu_FixedPaymentArrangementsPaymentAmountPaid_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsPaymentAmountPaid_638327284588095616" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangements" xlink:label="aytu_FixedPaymentArrangements_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangements_638327284588095616" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber_638327284588095616" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FixedPaymentArrangementsQuarterlyPaymentAmount" xlink:label="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FixedPaymentArrangementsQuarterlyPaymentAmount_638327284588095616" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_638327284588095616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588085560" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances_638327284588095616" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Commitments and Contingencies - Supply and Distribution Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588105555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588105555" xlink:to="us-gaap_TypeOfArrangementAxis_638327284588105555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284588105555" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588105555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTrisPharmaIncMember" xlink:label="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_638327284588105555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588105555" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementTerm" xlink:label="aytu_SupplyAndDistributionAgreementTerm_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementTerm_638327284588105555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales" xlink:label="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales_638327284588105555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits_638327284588105555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit_638327284588105555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount" xlink:label="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount_638327284588105555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_638327284588105555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation_638327284588105555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount" xlink:label="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588105555" xlink:to="aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount_638327284588115556" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Commitments and Contingencies - Contingent Consideration Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_OtherCommitmentsTable_638327284588115556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588115556" xlink:to="us-gaap_OtherCommitmentsAxis_638327284588115556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638327284588115556" xlink:to="us-gaap_OtherCommitmentsDomain_638327284588115556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember" xlink:label="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284588115556" xlink:to="aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_638327284588115556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588115556" xlink:to="us-gaap_OtherCommitmentsLineItems_638327284588115556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588115556" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod_638327284588115556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod" xlink:label="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284588115556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588115556" xlink:to="aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod_638327284588115556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails" xlink:type="extended" xlink:title="41804 - Disclosure - Commitments and Contingencies - Product Contingent Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_OtherCommitmentsTable_638327284588125553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588125553" xlink:to="us-gaap_OtherCommitmentsAxis_638327284588125553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638327284588125553" xlink:to="us-gaap_OtherCommitmentsDomain_638327284588125553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityNovalereFluticareMember" xlink:label="aytu_ProductContingentLiabilityNovalereFluticareMember_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638327284588125553" xlink:to="aytu_ProductContingentLiabilityNovalereFluticareMember_638327284588125553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638327284588125553" xlink:to="us-gaap_OtherCommitmentsLineItems_638327284588125553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588125553" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved_638327284588125553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved" xlink:label="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588125553" xlink:to="aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved_638327284588125553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ProductContingentLiabilityMilestonePayment" xlink:label="aytu_ProductContingentLiabilityMilestonePayment_638327284588125553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638327284588125553" xlink:to="aytu_ProductContingentLiabilityMilestonePayment_638327284588125553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails" xlink:type="extended" xlink:title="41805 - Disclosure - Commitments and Contingencies - Earn Out Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588135553" xlink:to="us-gaap_TypeOfArrangementAxis_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284588135553" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementsAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementsAr101Member_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588135553" xlink:to="aytu_CommercialGlobalLicenseAgreementsAr101Member_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_CommercialGlobalLicenseAgreementsAr101Member_638327284588135553" xlink:to="aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member" xlink:label="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_CommercialGlobalLicenseAgreementsAr101Member_638327284588135553" xlink:to="aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_638327284588135553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588135553" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock_638327284588135553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAnnualMaintenanceFee" xlink:label="aytu_LicenseAgreementAnnualMaintenanceFee_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementAnnualMaintenanceFee_638327284588135553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementLicenseOptionFee" xlink:label="aytu_LicenseAgreementLicenseOptionFee_638327284588135553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementLicenseOptionFee_638327284588135553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementEscalatingRoyaltiesMaximum" xlink:label="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementEscalatingRoyaltiesMaximum_638327284588145562" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange_638327284588145562" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange" xlink:label="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange_638327284588145562" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales" xlink:label="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales_638327284588145562" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum" xlink:label="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum_638327284588145562" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock_638327284588145562" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_StockIssuedDuringPeriodSharesMilestonePayments" xlink:label="aytu_StockIssuedDuringPeriodSharesMilestonePayments_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_StockIssuedDuringPeriodSharesMilestonePayments_638327284588145562" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementMilestonePaymentPaidCash" xlink:label="aytu_LicenseAgreementMilestonePaymentPaidCash_638327284588145562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588135553" xlink:to="aytu_LicenseAgreementMilestonePaymentPaidCash_638327284588145562" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails" xlink:type="extended" xlink:title="41806 - Disclosure - Commitments and Contingencies - Operating Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588155562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588155562" xlink:to="us-gaap_TypeOfArrangementAxis_638327284588155562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284588155562" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588155562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_OperatingLeaseAgreementMember" xlink:label="aytu_OperatingLeaseAgreementMember_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588155562" xlink:to="aytu_OperatingLeaseAgreementMember_638327284588155562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588155562" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588155562" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588155562" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638327284588155562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AverageUndiscountedMinimumMonthlyRentPayments" xlink:label="aytu_AverageUndiscountedMinimumMonthlyRentPayments_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588155562" xlink:to="aytu_AverageUndiscountedMinimumMonthlyRentPayments_638327284588155562" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638327284588155562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588155562" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638327284588155562" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails" xlink:type="extended" xlink:title="41807 - Disclosure - Commitments and Contingencies - Legal Matters (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588165562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588165562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638327284588165562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588165562" xlink:to="srt_LitigationCaseAxis_638327284588165562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638327284588165562" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638327284588165562" xlink:to="srt_LitigationCaseTypeDomain_638327284588165562" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyLitigationMember" xlink:label="aytu_SabbyLitigationMember_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638327284588165562" xlink:to="aytu_SabbyLitigationMember_638327284588225557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588165562" xlink:to="dei_LegalEntityAxis_638327284588225557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638327284588225557" xlink:to="dei_EntityDomain_638327284588225557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SabbyVolatilityWarrantMasterFundLtdMember" xlink:label="aytu_SabbyVolatilityWarrantMasterFundLtdMember_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638327284588225557" xlink:to="aytu_SabbyVolatilityWarrantMasterFundLtdMember_638327284588225557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_WalleyeOpportunitiesMasterFundLtdMember" xlink:label="aytu_WalleyeOpportunitiesMasterFundLtdMember_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638327284588225557" xlink:to="aytu_WalleyeOpportunitiesMasterFundLtdMember_638327284588225557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588165562" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588225557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588225557" xlink:to="aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588225557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588225557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588225557" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638327284588225557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureLicenseAgreementsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - License Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementAbstract" xlink:label="aytu_LicenseAgreementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aytu_LicenseAgreementAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588235554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588235554" xlink:to="us-gaap_TypeOfArrangementAxis_638327284588235554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638327284588235554" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588235554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember" xlink:label="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588235554" xlink:to="aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_638327284588235554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember" xlink:label="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588235554" xlink:to="aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_638327284588235554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember" xlink:label="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638327284588235554" xlink:to="aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_638327284588235554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638327284588235554" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry" xlink:label="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" xlink:to="aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry_638327284588235554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementInitialLicenseFeePaid" xlink:label="aytu_LicenseAgreementInitialLicenseFeePaid_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" xlink:to="aytu_LicenseAgreementInitialLicenseFeePaid_638327284588235554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementPatentProsecutionFeesPaid" xlink:label="aytu_LicenseAgreementPatentProsecutionFeesPaid_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" xlink:to="aytu_LicenseAgreementPatentProsecutionFeesPaid_638327284588235554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum" xlink:label="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_638327284588235554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638327284588235554" xlink:to="aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum_638327284588235554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Segment Information - General Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284588245552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284588245552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638327284588245552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_638327284588245552" xlink:to="us-gaap_NumberOfReportableSegments_638327284588245552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails" xlink:type="extended" xlink:title="42002 - Disclosure - Segment Information - Impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638327284588255558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638327284588255558" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284588255558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284588255558" xlink:to="us-gaap_SegmentDomain_638327284588255558" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284588255558" xlink:to="aytu_RxMember_638327284588255558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284588255558" xlink:to="aytu_ConsumerHealthMember_638327284588255558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638327284588255558" xlink:to="us-gaap_SegmentReportingInformationLineItems_638327284588255558" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638327284588255558" xlink:to="us-gaap_AssetImpairmentChargesAbstract_638327284588255558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638327284588255558" xlink:to="us-gaap_AssetImpairmentCharges_638327284588255558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductionRelatedImpairmentsOrChargesAbstract" xlink:label="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638327284588255558" xlink:to="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284588255558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638327284588255558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductionRelatedImpairmentsOrChargesAbstract_638327284588255558" xlink:to="us-gaap_InventoryWriteDown_638327284588255558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails" xlink:type="extended" xlink:title="42003 - Disclosure - Segment Information - Select Financial Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_638327284588265559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_638327284588265559" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638327284588265559" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638327284588265559" xlink:to="us-gaap_SegmentDomain_638327284588265559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_RxMember" xlink:label="aytu_RxMember_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284588265559" xlink:to="aytu_RxMember_638327284588265559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_ConsumerHealthMember" xlink:label="aytu_ConsumerHealthMember_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638327284588265559" xlink:to="aytu_ConsumerHealthMember_638327284588265559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_638327284588265559" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_638327284588265559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_638327284588265559" xlink:to="us-gaap_RevenuesAbstract_638327284588265559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284588265559" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638327284588265559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284588265559" xlink:to="us-gaap_OperatingIncomeLoss_638327284588265559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284588265559" xlink:to="us-gaap_DepreciationAndAmortization_638327284588265559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aytu-20230630.xsd#aytu_AssetImpairmentAndWriteoffCharges" xlink:label="aytu_AssetImpairmentAndWriteoffCharges_638327284588265559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284588265559" xlink:to="aytu_AssetImpairmentAndWriteoffCharges_638327284588265559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638327284588275557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638327284588265559" xlink:to="us-gaap_ShareBasedCompensation_638327284588275557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475832112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 20, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOPHARMA,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0883144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7900 East Union Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Denver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">437-6580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,530,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Grant Thornton, LLP<span></span>
</td>
<td class="text">Plante & Moran, PLLC<span></span>
</td>
<td class="text">Plante & Moran, PLLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">166<span></span>
</td>
<td class="text">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Denver, Colorado<span></span>
</td>
<td class="text">Denver, Colorado<span></span>
</td>
<td class="text">Denver, Colorado<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474178480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,985<span></span>
</td>
<td class="nump">$ 19,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">28,937<span></span>
</td>
<td class="nump">21,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">11,995<span></span>
</td>
<td class="nump">10,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,047<span></span>
</td>
<td class="nump">7,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">72,832<span></span>
</td>
<td class="nump">59,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">3,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">58,970<span></span>
</td>
<td class="nump">70,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">63,631<span></span>
</td>
<td class="nump">77,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">136,463<span></span>
</td>
<td class="nump">137,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other</a></td>
<td class="nump">13,478<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">46,799<span></span>
</td>
<td class="nump">44,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term line of credit</a></td>
<td class="nump">1,563<span></span>
</td>
<td class="nump">3,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">7,090<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,015<span></span>
</td>
<td class="nump">64,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Debt, net of current portion</a></td>
<td class="nump">14,713<span></span>
</td>
<td class="nump">14,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">6,403<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">6,975<span></span>
</td>
<td class="nump">12,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">97,106<span></span>
</td>
<td class="nump">93,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2023 and June 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 5,517,174 and 1,928,941, respectively, as of June 30, 2023 and June 30, 2022</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">343,485<span></span>
</td>
<td class="nump">331,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,129)<span></span>
</td>
<td class="num">(287,078)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">39,357<span></span>
</td>
<td class="nump">44,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 136,463<span></span>
</td>
<td class="nump">$ 137,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473526848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470353552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 107,399<span></span>
</td>
<td class="nump">$ 96,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service</a></td>
<td class="text">Product<span></span>
</td>
<td class="text">Product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">$ 40,767<span></span>
</td>
<td class="nump">$ 44,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service</a></td>
<td class="text">Product<span></span>
</td>
<td class="text">Product<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 66,632<span></span>
</td>
<td class="nump">$ 52,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">41,448<span></span>
</td>
<td class="nump">38,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,630<span></span>
</td>
<td class="nump">31,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,095<span></span>
</td>
<td class="nump">12,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of other assets</a></td>
<td class="nump">5,705<span></span>
</td>
<td class="nump">9,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">5,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod', window );">Gain from contingent consideration</a></td>
<td class="num">(969)<span></span>
</td>
<td class="num">(1,655)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">83,697<span></span>
</td>
<td class="nump">162,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,065)<span></span>
</td>
<td class="num">(109,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(4,779)<span></span>
</td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="nump">4,793<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(17,051)<span></span>
</td>
<td class="num">(108,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,051)<span></span>
</td>
<td class="num">$ (108,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">3,339,906<span></span>
</td>
<td class="nump">1,469,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted (in shares)</a></td>
<td class="nump">3,339,906<span></span>
</td>
<td class="nump">1,469,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">$ (5.11)<span></span>
</td>
<td class="num">$ (74.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (5.11)<span></span>
</td>
<td class="num">$ (74.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474135104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,867<span></span>
</td>
<td class="num">$ (178,299)<span></span>
</td>
<td class="nump">$ 137,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">1,374,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">20,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">424,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodValueMilestonePayments', window );">Issuance of common stock related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesMilestonePayments', window );">Issuance of common stock related to milestone payment (in shares)</a></td>
<td class="nump">109,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding for stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,779)<span></span>
</td>
<td class="num">(108,779)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,386<span></span>
</td>
<td class="num">(287,078)<span></span>
</td>
<td class="nump">$ 44,308<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1,928,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="num">(18,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">3,606,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,051)<span></span>
</td>
<td class="num">(17,051)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 343,485<span></span>
</td>
<td class="num">$ (304,129)<span></span>
</td>
<td class="nump">$ 39,357<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,517,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodValueMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodValueMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481086080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts', window );">Stock issued during period, value, new issues, issuance costs</a></td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">$ 1,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473127632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,051)<span></span>
</td>
<td class="num">$ (108,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">8,815<span></span>
</td>
<td class="nump">10,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expense</a></td>
<td class="nump">5,705<span></span>
</td>
<td class="nump">75,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,046<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="num">(4,793)<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod', window );">Gain from contingent consideration</a></td>
<td class="num">(969)<span></span>
</td>
<td class="num">(1,655)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of senior debt (premium) discount</a></td>
<td class="nump">559<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IssuanceOfStockForMilestonePayments', window );">Shares issuance related to milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_WriteOffOfDeferredDebtIssuanceCostNet', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other noncash adjustments</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,153)<span></span>
</td>
<td class="nump">6,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,609)<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(914)<span></span>
</td>
<td class="nump">2,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="num">(7,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">3,605<span></span>
</td>
<td class="num">(13,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities, net</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,129)<span></span>
</td>
<td class="num">(28,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Contingent consideration payment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(3,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="nump">15,575<span></span>
</td>
<td class="nump">11,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_PaymentsForFixedPaymentArrangement', window );">Payment made to fixed payment arrangement</a></td>
<td class="num">(4,266)<span></span>
</td>
<td class="num">(4,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Net payments made on short-term line of credit</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="num">(4,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Payments made to borrowings</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(16,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment for debt issuance costs</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,871<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="num">(30,541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">19,360<span></span>
</td>
<td class="nump">49,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">22,985<span></span>
</td>
<td class="nump">19,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Other noncash investing and financing activities</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfStockForMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Stock for Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfStockForMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsForFixedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Fixed Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsForFixedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WriteOffOfDeferredDebtIssuanceCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of Deferred Debt Issuance Cost, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WriteOffOfDeferredDebtIssuanceCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475830320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Financial Condition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of Business and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Aytu BioPharma, Inc. (&#8220;Aytu,&#8221; or the &#8220;Company&#8221;), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the &#8220;Consumer Health Portfolio&#8221;). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (&#8220;Neos&#8221;) in March 2021, (the &#8220;Neos Acquisition&#8221;) the Company changed its name to Aytu BioPharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every <span style="-sec-ix-hidden:Hidden_G-ii9jXEiUerH3aNSGrgcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span> shares held (&#8220;Reverse Stock Split&#8221;). Where applicable, all share and per share amounts in this annual report have been adjusted to reflect the effect of the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Rx Segment primarily consists of two product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (&#8220;ADHD&#8221;) together the &#8220;ADHD Portfolio&#8221;, and the &#8220;Pediatric Portfolio&#8221; consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Portfolio consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, urological health and general wellness, commercialized through direct mail and e-commerce marketing channels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic and consumer markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development program AR101 (enzastaurin), and has terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had $23.0 million of cash and cash equivalents and $28.9 million in accounts receivable. The Company incurred a net loss of $17.1 million and $108.8 million during the years ended June 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $304.1 million and $287.1 million as of June 30, 2023 and 2022, respectively. Cash used in operations was $5.1 million and $28.8 million during the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has non-operating liabilities that are scheduled to, or may become current in the eighteen months following the filing of this 10-K, most notably the maturity of the $15 million Avenue Capital term note (the &#8220;Avenue Note&#8221;). The Company expects to refinance the Avenue Note in the event it does not have sufficient cash on hand to retire it. As a result, there exists substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on i) eliminating expenses for clinical development, ii) winding down or monetizing the Consumer Health Segment, which has generated negative cash flows since its acquisition in 2021, iii) refinancing its $15 million Avenue Note (see Note 11 &#8211; Long-term Debt) to extend its maturity date, and, if necessary iv) raising additional capital through public or private equity, debt offerings, or monetizing additional assets in order to meet its obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475059872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principals of Consolidation</span><i style="font-style:italic;">. </i>The Company&#8217;s consolidated financial statements include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span><i style="font-style:italic;">.</i> The Company&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Use of estimates</span><i style="font-style:italic;white-space:pre-wrap;">.  </i>The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for doubtful accounts; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, long-lived assets, and goodwill; purchase price allocations, and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Prior Period Reclassification</span><i style="font-style:italic;">. </i>Certain prior year amounts in the consolidated statements of operations and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of amortization of intellectual property, and a reclassification of fair value adjustment from contingent consideration. Amortization of intellectual property was previously included in research and development expenses and is currently recorded in amortization of intangible assets expenses on the consolidated statements of operations. Gain or loss from the fair value of contingent consideration was previously included in Other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the fiscal years ended June 30, 2023 and 2022 or its financial position as of June 30, 2023 or June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Financial Statements</span><i style="font-style:italic;">. </i>The classification of certain of the Company&#8217;s warrants was previously recorded as equity. These warrants according to U.S. GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the audited financial statements as of June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; and the Financial Accounting Standards Board (&#8220;FASB&#8221;), Statement of Financial Accounting Concepts No. 2 &#8220;Qualitative Characteristics of Accounting Information&#8221; indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company&#8217;s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance Sheet data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (288,472)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (287,078)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,784)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,308</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Twelve Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Operation data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">Total other income, net </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,889)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (74.01)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Stockholders' Equity data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,854</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Cash Flow data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (211)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,605)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Includes reclassification of gain or loss from the fair value of contingent consideration. See </span><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Prior Period Reclassification </i><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">in Note 2 &#8211; Summary of Significant Accounting Policies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Segment Information</span><i style="font-style:italic;">. </i>During the year ended June 30, 2023, the Company identified an omission regarding the disclosure of certain key metrics of its reportable segments under ASC 280 related to the year ended June 30, 2022. During the year ended June 30, 2022, the Company inappropriately reported the net income of each of its two segments as opposed to operating income which more closely aligns with the adjusted EBITDA metric that is utilized by its chief operating decision maker. The impact on June 30, 2022 was that $92.4 million and $17.5 million of operating loss relating to the Rx Segment and Consumer Health segment, respectively, should have been reported as a separate line. The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99. The Company concluded that the omission was not material to any of the previously issued consolidated financial statements and began reporting operating results by segment in accordance with ASC 280 on a prospective basis starting with the year ended June 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span><i style="font-style:italic;">.</i> The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to FDIC (the &#8220;Federal Deposit Insurance Corporation&#8221;) insurance limits, and cash balances in the money market funds are not FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, net</span><i style="font-style:italic;">. </i>Accounts receivable represent amounts due from customers less allowances for doubtful accounts, discounts and pricing chargebacks. An allowance for doubtful accounts, when needed, is based upon the financial condition and payment history of customers; collections experience on other accounts; and economic factors or events expected to affect future collections. The allowance for doubtful accounts was zero for both years ended June 30, 2023 and 2022. The allowance for discounts was $1.8 million and $1.3 million for the years ended June 30, 2023 and 2022, respectively. The allowance for chargebacks was $1.2<span style="white-space:pre-wrap;"> million for both years ended June 30, 2023 and 2022.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below presents the opening and closing balances of receivables from customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accounts Receivable, gross</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,927</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,708</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,325</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Decrease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,106)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Chargeback</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Allowance</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,358</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,592)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,628</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,548)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,145)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,990</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span><i style="font-style:italic;">.</i> Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Determination</span><i style="font-style:italic;">.</i> In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the financial statements are issued.<span style="font-size:11pt;"> </span>The evaluation is based on relevant conditions and events that are known and reasonably knowable within one year after the date that the financial statements are issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and equipment, net</span><i style="font-style:italic;">. </i>Property and equipment are recorded at cost less accumulated depreciation. <span style="-sec-ix-hidden:Hidden_ZU0GSZmRRU6mHNeNM31yuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Furniture</span></span> and <span style="-sec-ix-hidden:Hidden_QQYcc8br-EqS2gjQlclZQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">equipment</span></span> are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:Hidden_BkyMcFO_ukqYjCCDP1gOew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to seven years. Leasehold improvements are amortized over the <span style="-sec-ix-hidden:Hidden_6fUhpC-LoUCZ1c2RWfvzow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shorter of the estimated useful life</span></span> or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span><i style="font-style:italic;">.</i> At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Fair Value of Financial Instruments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisitions</span><b style="font-weight:bold;">. </b>In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does not result in goodwill. Contingent consideration is accounted for Acquired in-process research and development with no alternative future use is charged to expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants. </span>The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC 815,including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability classified warrants are valued using the Monte Carlo simulation model or the Black-Scholes option pricing model at issuance, and for each reporting period. Equity classified warrants are valued using the Black-Scholes model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span><i style="font-style:italic;">. </i>The Company generates revenue from product sales through its prescription pharmaceutical products segment (&#8220;Rx Segment&#8221;) and its consumer healthcare products segment (&#8220;Consumer Health </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Segment&#8221;). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rx Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rx product revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#8220;Gross to Net&#8221; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gross to Net adjustments include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Savings offers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Prompt payment discounts</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Prompt payment discounts are based on standard provisions of wholesalers&#8217; services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesale distribution fees </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Rebates </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesaler chargebacks</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217; end customers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Returns</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Wholesalers&#8217; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consumer Health Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized &#8220;free-on-board&#8221; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Customer Contract Costs</span><i style="font-style:italic;">.</i> The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span><i style="font-style:italic;">. </i>Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:Hidden_b9ThaH63FEyijuGZHHcAxg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span> to sixty days. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents customers that contributed more than 10% of gross revenue and accounts receivable<i style="font-style:italic;">: </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of gross revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of accounts receivable</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Costs of Sales</span><i style="font-style:italic;">. </i>Costs of sales consists primarily of manufactured product cost, products acquired from third-party manufacturers, freight, production, and indirect manufacturing overhead costs and FDA fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that may require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company's third-party logistics companies are included in costs of sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span><i style="font-style:italic;">.</i> The Company accounts for share-based payments compensation expense using a fair value based model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn&#8217;t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span>. Research and development costs are expensed as incurred and include salaries and benefits, facilities costs, overhead costs, raw materials, laboratory and clinical supplies, clinical trial costs, contract services, milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates and other related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;">.</i> The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-lived Assets and Goodwill</span><i style="font-style:italic;">.</i> The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company&#8217;s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry forecasted financial performance indicate that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company&#8217;s industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span><i style="font-style:italic;">. </i>The consideration for our acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising Costs</span><i style="font-style:italic;">. </i>Advertising costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $11.1 million and $13.6 million of advertising costs for the&#160;years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span><i style="font-style:italic;">.</i> The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of  to be sustained upon an examination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt issuance costs, discounts (premiums)</span><i style="font-style:italic;">. </i>Debt issuance costs reflect fees paid to lenders and third parties directly related to issuing debt. Debt issuance costs and discounts (premiums) related to term loans are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense. Debt issuance costs related to a line of credit facility are classified as assets and subsequently amortized over the term of the line of credit as additional interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span><i style="font-style:italic;">. </i>The Company&#8217;s operating segments engage in business activities from which it may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker, who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has two reportable segments: the Rx Segment and the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paragraph IV litigation costs</span><i style="font-style:italic;">. </i>Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Contingent considerations</span><i style="font-style:italic;">. </i>The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Common Share</span><i style="font-style:italic;">.</i> Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For the years ended June 30, 2023 and 2022, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets-forth securities excluded from the calculation of diluted earnings per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,538,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 434,328</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,899</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,377</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,500</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,636,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reference Rate Reform.</span> In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (&#8220;ASU&#8221;) 2020-04, <i style="font-style:italic;">Reference Rate Reform (Topic 848)</i>: <i style="font-style:italic;">&#8220;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&#8221;</i>, which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective July 1, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earnings Per Share.</span> In May 2021, the FASB issued ASU 2021-04,<i style="font-style:italic;"> &#8220;Earnings Per Share (Topic260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#8221;.</i> The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt&#8212;Debt with Conversion and Other Options.</span> In August 2020, the FASB issued ASU No. 2020-06,<i style="font-style:italic;"> Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8212; &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (&#8221;SEC&#8221;), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have any material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial Instruments&#160;</span>&#8211;<span style="font-style:italic;font-weight:bold;"> Credit Losses.</span> In June&#160;2016, the FASB issued <i style="font-style:italic;">ASU 2016-13, &#8220;Financial Instruments&#160;&#8211; Credit Losses&#8221;</i> requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard is effective for smaller reporting companies for fiscal periods beginning after December&#160;15, 2022. In May 2019, the FASB issued ASU 2019-05, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses</i>&#8221;, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures</i>&#8221; which eliminates the accounting guidance for troubled debt restructurings by creditors and adds disclosure requirements for current period gross write-offs by year of origination for financing receivables and net investments in leases. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal&#160;year ended June&#160;30, 2024. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:36pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479812544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues from Contracts with Customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Revenues from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company disaggregates its revenue into two segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys XR-ODT and Cotempla XR-ODT; and the Pediatric Portfolio, comprised of Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. The Consumer Health portfolio is comprised of over ten consumer health products competing in large healthcare categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Revenues by Segment</i>: Net revenue disaggregated by segment for the years ended June 30, 2023 and 2022 were as follows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,121</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consumer Health Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,548</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Consolidated revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues by Product Portfolio</i>: Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2023 and 2022 were as follows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_g-cbh5-g8Eq9t2stexXsqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADHD </span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,855</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_K8_3hQR_I0yTd3PB8O7Q8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pediatric</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,084</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_3ehiKXD22k2GoV9XNE777Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,182</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,121</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenues by Geographic location. </i>The following table reflects product revenues by geographic location as determined by the billing address of the Company&#8217;s customers:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,606</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">International</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,063</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479808976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:23.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,814</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,838</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,197</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,849</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred charges of $2.4 million and $4.2 million to reduce the carrying value of inventory to net realizable value during the years ended June 30, 2023 and 2022, respectively, primarily as a result of unsalable and slow-moving products. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034561823776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,487</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 999</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment, furniture and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,128</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets under construction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,681)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,421)</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,025</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense was $1.3 million and $1.6 million for the&#160;years ended June 30, 2023 and 2022, respectively. During the year ended June 30, 2022, the Company recognized a gain of $0.1 million on the disposal of equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended June 30, 2022, in connection with the decision to divest Tussionex, the Company recorded a $0.2 million <span style="-sec-ix-hidden:Hidden_kMk3CteVXE-sj0ReN6tePA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment</span></span> charge related to manufacturing equipment associated with this product. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034575206352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases are for equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">option provisions under which the parties may extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#8217;s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does not provide an implicit rate, a borrowing rate of 6.7% was used to determine the present value of future lease payments. The finance leases are related to equipment finance leases with fixed contract terms and an implicit interest rate of approximately 5.9%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company entered into an agreement with a manufacturing company to sublease 22,909 square feet of the Company&#8217;s manufacturing facility in Grand Prairie, Texas (the &#8220;Sublease Agreement&#8221;). The sublease commenced in May 2023 and will terminate on December 31, 2024. The Sublease Agreement provides the sublessee an option to expand the subleased property to include the remaining 54,203 square feet of the Company&#8217;s manufacturing facility. The expansion date may commence as early as April 1, 2024 but no later than December 31, 2024 (the &#8220;Expansion Date&#8221;). Under the terms of the Sublease Agreement, the sublessee will pay base rent of approximately $20,500 per month through the Expansion Date. Beginning on the Expansion Date, base rent will be $70,686 per month through the expiration of the sublease. In addition to the base rent, the sublessee will pay the Company certain operating expenses incurred by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2023, in addition to the sublease mentioned above, the Company entered into an operating lease agreement to relocate its principal office (See Note 18 &#8211; Commitments and Contingencies). During the fiscal year ended June 30, 2022, the Company commenced a five-year operating lease and recorded an ROU of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The components of lease expenses are as follows;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statement of Operations Classification</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (expense), net</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total net lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information related to leases is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_oCFrnX1cZEKlI0YfWFbvaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uO7hW3tJ10-9Y4OnbKB2gw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_kiHw9kJlzEqfvdcIxL-40Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of debt</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_unXTBH375Ue8ldFNegISKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_rmlxlXZlBUmyfb7kJxK3Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Debt, net of current portion</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Remaining lease terms and discount rates used are as follows;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Remaining Lease Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.63</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.48</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.54</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.43</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to leases is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow classification of lease payments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,016</p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the maturities of the Company&#8217;s future minimum lease payments were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479947152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Goodwill and Other Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><b style="font-style:normal;font-weight:bold;">Goodwill</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no goodwill carrying amounts in the consolidated balance sheets as of June 30, 2023 and 2022. The carrying amount of goodwill by reportable segment and changes during the year ended June 30, 2022 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rx Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consumer Health Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,802</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,165)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,802)</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">During the year ended June 30, 2022, the Company&#8217;s market capitalization significantly declined. The decline was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management&#8217;s evaluation indicated that the goodwill related to its reporting units in both the Rx and Consumer Health segments were potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. Using a risk adjusted weighted-average discount rate, the fair value of the reporting units was less than its carrying value. The Company recognized an impairment charge of </span><span style="background:#ffffff;">$57.2</span><span style="background:#ffffff;">&#160;million in the Rx Segment, associated with the Cerecor and Neos acquisition and a </span><span style="background:#ffffff;">$8.6</span><span style="background:#ffffff;"> million impairment charge in the Consumer Health Segment related to the goodwill associated with the Innovus Acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tables below provide the summary of the Company&#8217;s intangible assets as of June 30, 2023 and June 30, 2022, respectively. Carrying amounts are net of any impairment charges from prior periods. Intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.49</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.33</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.60</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,004)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the estimated future amortization expense to be recognized over the next&#160;five years and periods thereafter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,518</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,496</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Product Technology Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The acquired Product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Karbinal&#174; ER. </i>The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris for the exclusive rights to commercialize Karbinal&#174; ER in the United States (the &#8220;Tris Karbinal Agreement&#8221;). The Tris Karbinal Agreement&#8217;s initial term terminates in August&#160;of 2033, with an optional initial <span style="-sec-ix-hidden:Hidden_jJl8Ok9bXUO0qTue9ytzzw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20-year</span></span> extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Poly-Vi-Flor&#160;and Tri-Vi-Flor.</i> The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the &#8220;Poly-Tri Agreements&#8221;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ADHD Portfolio.</i> As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Technology Right</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">TRRP Technology.</i> As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (&#8220;TRRP&#8221;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology underlines each of Neos&#8217; core products and can potentially be used in future product development initiatives as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired Product Distribution Rights (and customer list)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. During the fiscal year ended June 30, 2023, this intangible asset was impaired by $3.0 million due to the discontinuance of products in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Acquired In-Process R&amp;D</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IPR&amp;D &#8211; NT0502.</i> As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&amp;D will begin amortizing on a straight-line over the life of the product. During the fiscal year ended June 30, 2023, the Company fully impaired the IPR&amp;D of NT0502 due to the termination of its development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Other </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other intangible assets consist of customer lists, trade names and other technology and licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of the Company&#8217;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.1 million and $7.8 million during the years ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team&#8217;s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, the Company incurred an impairment charge of $2.6 million related to NT0502 and terminated the licensing agreement. The Company also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $3.0 million due to discontinuance of products in the Consumer Health Segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the Rx Segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million <span style="-sec-ix-hidden:Hidden_Ed_wMja5SES4fIWHM8Ndsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment</span></span> expense for the write-down of intangible assets consisting of (i) $2.6 million for AcipHex, (ii) $1.4 million for ZolpiMist, (iii) $0.5 million for Tussionex, (iv) $0.2 million for Cefaclor and (v) $0.2 million for the Neos tradename. Additionally, the Company&#8217;s Consumer Health Segment recorded an impairment of $2.2 million related to products no longer being marketed and products that have been underperforming.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479895024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Accrued liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued savings offers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,711</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued program liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,468</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,765</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued customer and product related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,817</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,770</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,187</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table details the change in return reserve for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Return Reserve</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,367</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,568</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,165)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,770</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,346)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,777</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers represent programs for the Company&#8217;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Program liabilities include government and commercial rebates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Other accrued liabilities consist of accrued license fees, professional fees, credit card liabilities, taxes payable, legal settlements, and samples expense, none of which individually represent greater than five&#160;percent<span style="font-size:12pt;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478422192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed payment arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,051</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent value rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 815</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,157</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,359)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,798</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fixed payment arrangements.</span> Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $0.1 million from November 2019 through January 2021 plus $15.0 million due in January 2021, of which $15.0 million was paid down early in March 2020. Monthly variable payments due to the same investor are equal to 15.0% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $0.1 million, except for January 2021, when a one-time payment of $0.2 million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $9.3 million have been made or (ii) February 12, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of June 30, 2023, the fixed payment arrangement balance was $1.7 million in other current liabilities and $2.1 million in other non-current liabilities on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the &#8220;License Agreement&#8221;). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6.0&#160;million to $9.0&#160;million, which reduced our total liability for minimum payments by approximately $8.0&#160;million from the original License Agreement. The settlement payment will be paid in&#160;three&#160;installments from December 2022 through July 2024. As of June 30, 2023, the balance was $6.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingent value rights.</span> Contingent value rights (&#8220;CVRs&#8221;) represent contingent consideration related to the Company&#8217;s 2020 acquisition of Innovus of up to $16.0 million payable upon attainment of future performance milestones. Consideration can be satisfied in up to 470,000 shares of the Company&#8217;s common stock, or cash either upon the option of the Company or in the event there are insufficient shares available to satisfy such obligations. In the fiscal years ended June 30, 2020 and 2021, the Company issued to the CVR holders 6,191 and 5,160 shares of common stock, respectively, upon achievement of specified revenues. No milestones were met during the fiscal years ended June 30, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2022 and 2023. As of June 30, 2023, up to $5.0 million of future milestone payments potentially remain. During the years ended June 30, 2023 and 2022, the Company recognized a gain of $0.6 million and $0.8 million, respectively, in the consolidated statements of operations related to the changes in fair values of CVRs. As of June 30, 2023 and 2022, the CVRs balance was zero and $0.6 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span><i style="font-style:italic;">. </i>Contingent consideration represents the fair value of potential future payments in connection with acquisitions that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Subsequent changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Company&#8217;s 2020 acquisition of Innovus, the Company recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the Company&#8217;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR<i style="font-style:italic;">. </i>The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#8220;Tris&#8221;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#8211; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#8217;s estimated borrowing rate. The Company recognized $0.9 million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (&#8220;Magna&#8221;) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. In 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liabilities. The Company recognized a $0.6 million gain from termination of the contingent consideration liability in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023 and 2022, the Company recognized a gain of $0.4 million and a loss of $0.5 million, respectively, from the changes in fair values of contingent considerations. As of June 30, 2023 and 2022, the contingent consideration balance was zero and $0.4 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other.</span><i style="font-style:italic;"> </i>Consist of taxes payable and deferred cost related to our technology transfer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470519328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Line of Credit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Line of Credit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (&#8220;Eclipse&#8221;) as agent for the lenders (the &#8220;Eclipse Loan Agreement&#8221;).&#160;Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the &#8220;Revolving Loans&#8221;), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued variable interest through maturity at the one-month Secure Overnight Financing Rate (&#8220;SOFR), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding&#160;month. Interest is payable&#160;monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Avenue Capital Agreement, described in Note 12 &#8211; Long Term Debt, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the &#8220;Eclipse Second Amendment&#8221;). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurred $0.1 million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $0.1 million as of June 30, 2022 was included in other noncurrent assets in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the Eclipse Amendment&#8221;) to the Loan and Security Agreement dated October 2, 2019 (as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, and the Eclipse Amendment (the &#8220;Eclipse Agreement&#8221;). The Eclipse Amendment, among other things, provided for an aggregate increase of $2.0 million to the Eclipse Lender&#8217;s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least five business&#160;days prior notice to Eclipse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The&#160;Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#8217;s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company&#8217;s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Total interest expense on the Revolving Loans, including amortization of deferred financing costs, were $0.7 million and $0.4 million&#160;for the years ended June 30, 2023 and 2022. As of June 30, 2023 and 2022, the outstanding Revolving </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loans under the Eclipse Loan Agreement, as amended, were $1.6&#160;million and $3.8 million, respectively. Unused line of credit amount as of June 30, 2023 was $9.3 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469761728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Long-term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deerfield Debt.</span> Upon closing of the Neos Acquisition, the Company assumed a senior secured term credit facility (the &#8220;Deerfield Facility&#8221;) with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P. (collectively, &#8220;Deerfield&#8221;) with an outstanding balance of $16.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluated and determined&#160;that the&#160;fair value of the remaining outstanding debt was $17.4 million as of the March&#160;19, 2021 acquisition date. Accordingly, the Company recorded a premium&#160;of $0.8 million, which was the difference between carrying amount and the fair value of the debt&#160;and was being amortized into interest expense using the effective interest method over the remaining term of the debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $0.2 million during the year ended June 30, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $0.8 million for the period from July 1, 2021 through full repayment on January 26, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Avenue Capital Loan. </span>On January 26, 2022 (&#8220;Closing Date&#8221;), the Company entered into a Loan and Security Agreement (the &#8220;Avenue Capital Agreement&#8221;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#8220;Avenue Capital Lenders&#8221;), and Avenue Capital Management II, L.P. as administrative agent (the &#8220;Avenue Capital Agent&#8221;), collectively (&#8220;Avenue Capital&#8221;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate and 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the Deerfield Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (&#8220;Interest-only Period&#8221;). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (&#8220;Interest-only Milestone 1&#8221;). The Interest-only Period could further be extended automatically without any action by any party for an additional six months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (&#8220;Final Payment&#8221;). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s obligations under Avenue Capital Agreement are secured by substantially all of the Company&#8217;s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#8217;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company&#8217;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022 (&#8220;Issuance Date&#8221;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 15 &#8211; Stockholders Equity, at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#8220;Avenue&#8221;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company&#8217;s August 2022 equity financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 &#8211; Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. The interest-only period now extends to the January 26, 2025 maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.59%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $2.7 million and $0.9 million for the years ended June 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, due on January 26, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term, final payment fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 638</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (925)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing leases, maturing through May 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,798</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,713</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Future principal payments of long-term debt, including financing leases, are as follows;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,638</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future principal payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,723</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (925)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,713</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477131712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">12. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determine the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 1:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 2:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Level 3:</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:9.5pt;">Unobservable inputs that are supported by little or no market activity.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities</span>,<span style="font-size:10pt;"> contingent consideration liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recurring Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table presents the Company&#8217;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2023 and 2022, by level within the fair value hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_Yi-wD1QAw027O6Gw0MqnzA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_YynIzFLXAkeAX8AGtpTUAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,770</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds, and reflect their fair value at Level 1 in the fair value hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Recurring Fair Value Measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended June 30, 2023 and 2022, were fixed payment arrangements, goodwill and intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4%, and are classified as Level 3 inputs in the fair value hierarchy. In May 2022, the Company recognized a fixed payment arrangement liability of $7.6 million relating to the termination of the License, Development, Manufacturing and Supply Agreement with Tris. See Note 9 &#8211; Other Liabilities for further information on fixed payment arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on the Company&#8217;s impairment analyses for fiscal years 2023 and 2022, the Company recorded an impairment charge of $5.6 million on intangible assets during the year ended June 30, 2023; and an impairment charge of $7.1 million on intangible assets and $65.8<span style="white-space:pre-wrap;"> million on goodwill for the year ended June 30, 2022. Valuation of goodwill and intangible assets involves significant Level 3 inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted EBITDA margins, and the selection of a discount rate. These assumptions may be affected by expectations about future market or economic conditions. See Note 7 -  Goodwill and Other Intangible Assets and Note 2 - Summary of Significant Accounting Policies, for further discussion on the fair value measurement of goodwill and other intangible assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Level 3 Input Changes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the&#160;year ended June 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CVR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Included in earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (391)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,391)</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases, issues, sales and settlements:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,998</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Settlements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Level 3 Inputs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the fair value of contingent liabilities in subsequent periods are recorded as a gain or loss in the consolidated statements of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in valuing the CVRs were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leveraged Beta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market risk premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company specific discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 9,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 8,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in <span style="-sec-ix-hidden:Hidden_iwcBQPje9UyI7pXQKxPUyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">valuing</span></span> the derivative warrant liabilities, marked to market, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">83.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.59-4.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.13-4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">              Expected volatility was based primarily on historical volatility. The Company chose to use a two-year lookback on historical volatility to avoid the effects of COVID-19 and the Innovus acquisition. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term of these warrants, and will not differ materially. If expected volatility by the active market is higher than estimated, the derivative may result in a greater fair value. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479921648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year of 2023, there was no income tax benefit, primarily driven by Section 382 limitation on post-TCJA (&#8220;Tax Cuts and Jobs Act&#8221;) net operating loss (&#8220;NOL&#8221;) utilization, further described below. As of June 30, 2023, the Company had $0.1 million deferred tax asset (DTA) included in other non-current assets, $0.1 million deferred tax liability (DTL) included in other long-term liabilities, and $0.1 million income tax payable in accrued liabilities in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Section 382 Limitation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of the Internal Revenue Code, substantial changes in the Company&#8217;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the Company&#8217;s Section 382 analysis, an ownership change was determined to have occurred in March 2022 at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $12 million) is determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation. The Company also determined that ownership change occurred in June 2023 at a time that the Company was in a net unrealized loss position. As a result of the Section 382 analysis, the Company had estimated $0.3 million of disallowed recognized built-in loss and had carried forward as an operating loss as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had federal net operating losses of approximately $504.0 million as of June 30, 2023, that subject to limitation (as described above), may be available in future tax years to offset taxable income. Of the available federal net operating losses, approximately $172.0 million can be carried forward indefinitely, while the remaining balance will begin to expire in 2024 and completely expire in 2027. As of June 30, 2023, the Company had research and development credits of $3.0 million, which begin to expire in 2024. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2039. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized.  Generally, it is not appropriate to use zero as an applicable tax rate and rather, a deferred tax asset should be recorded at the applicable tax rate and a valuation of an equal amount would be provided.  However, under certain circumstances it may be appropriate to follow an alternative approach and use a zero rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross deferred tax assets disclosed.  The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and not apply a zero rate to NOL carryforwards expected to expire unutilized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In review of the Company&#8217;s consolidated deferred position excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and not utilized against a net DTL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The provision for income taxes consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (91)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax benefit resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and various states) differs from the income tax provision (benefit) in the financial statements. Reconciliation of the U.S. federal statutory income tax rates to our effective tax rate is as follows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of phased-in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on debt extinguishment and interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,443</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,944</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,773</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,423</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,975</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,177</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 799</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 132,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,966)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,686</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,717)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (308)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (788)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,378)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (127)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In fiscal year 2022, the impairment of goodwill decreased net deferred tax liabilities by $0.1 million resulting in an income tax benefit of $0.1 million. As of June 30, 2022, the Company had $0.1 million deferred tax liabilities included in other long-term liabilities in the consolidated balance sheet. The Company had federal net operating losses of approximately $503.2 million as of June 30, 2022, subject to Section 382 limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a valuation allowance of $136.4 million and $129.0 million at June 30, 2023 and 2022, respectively, to reserve its net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not, that it will realize the benefits of these deductible differences, net of the valuation allowance provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#8217;s net operating loss carryforward, interest expense carryover or research and development credit carryover and therefore do not require recognition. As a result of these timing differences, at June 30, 2023 and 2022, the Company had gross unrecognized tax benefits related to uncertain tax positions of $2.9 million and $2.8 million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A tabular roll-forward of the Company&#8217;s gross unrecognized tax benefits is below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from prior period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (120)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (647)</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,822</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The change in the Company&#8217;s gross unrecognized tax benefits relates to the acquisition of Neos, whereby historic tax positions of Neos were inherited in the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to 2004 being subject to examination.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478418672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of June 30, 2023 and 2022, the Company had 5,517,174 and 1,928,941 common shares issued and outstanding, respectively, and no preferred shares issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Included in the common stock outstanding are 40,996 shares of unvested restricted stock issued to executives, directors, and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2020, the Company filed a shelf registration statement (the &#8220;2020 Shelf&#8221;), which was declared effective by the SEC on June 17, 2020, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. On June 4, 2021, the Company entered into an agreement with an agent for the sale of up to $30.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2020 Shelf (the &#8220;ATM Sales Agreement&#8221;). During the year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $3.0 million before deducting underwriting discounts, commissions, and other offering expenses of $0.1 million. The 2020 Shelf expired in June 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 28, 2021, the Company filed a shelf registration statement (the &#8220;2021 Shelf&#8221;), which was declared effective by the SEC on October 7, 2021, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2023, approximately $82.4 million remain available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. The 2021 Shelf expires in October 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock (the &#8220;March 2022 Offering&#8221;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable <span style="-sec-ix-hidden:Hidden_fR7I1KmwmUOKA79OdXpBSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span></span> after the date of issuance and have a term of five years from the date of exercisability. The Company raised gross proceeds of $7.6 million through the March 2022 Offering before commission and other costs of $0.8 million. The pre-funded and common warrants have a combined fair value of approximately $2.8 million at issuance, and are classified as a derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (see Note 16 - Warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August 11, 2022, the Company closed on an underwritten public offering (the &#8220;August 2022 Offering&#8221;) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance, and are classified as derivative warrant liabilities with the offset in additional paid in capital in stockholders&#8217; equity in the Company&#8217;s consolidated financial statements (See Note 16 &#8211; Warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June 8, 2023, the Company entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company&#8217;s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the &#8220;Exchange Warrants&#8221;). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company&#8217;s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company&#8217;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 &#8211; Warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478392816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2023 Equity Incentive Plan.</i><span style="white-space:pre-wrap;"> On May 18, 2023, the Company&#8217;s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the &#8220;2023 Equity Incentive Plan&#8221;). Prior to the Company&#8217;s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (&#8220;Aytu 2015 Plan&#8221;) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (&#8220;the Neos 2015 Plan&#8221;) (collectively the &#8220;2015 Plans&#8221;).  For the 2023 Equity Incentive Plan, the stockholders approved (a) </span>200,000 new shares, (b) 87,155 shares available for grant under the 2015 Plans be &#8220;rolled over&#8221; to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional <span style="-sec-ix-hidden:Hidden_Hl9WG5ycz0COuiafV-9j_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">awards</span></span> will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. As of June 30, 2023 the Company had 287,155 shares that are available for grant under the 2023 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Aytu 2015 Plan.</i> On June&#160;1, 2015, the Company&#8217;s stockholders approved the Aytu 2015 Plan, which, as amended in July&#160;2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">equity awards. On February&#160;13, 2020, the Company&#8217;s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Neos 2015 Plan.</i> Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units (RSUs) previously granted under Neos plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities will stay the same as they were under the previous Neos plan. The Company allocated costs of the replacement awards attributable to pre- and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the fiscal year ended June 30, 2023, 49,212 stock options were granted. The weighted-average grant date fair value of options granted during the year ended June 30, 2023 was $4.00. As of June 30, 2023, there was $0.1 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.2 years. No options were granted during the fiscal year 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 7.77</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 9.06</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercisable at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 6.17</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table details the options outstanding at June 30, 2023 by range of exercise prices:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">123.16 - 290.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, as a result of the change in members of the Company&#8217;s board, the Company accelerated unvested shares for two former members and recorded $1.5 million of non-cash equity compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 19, 2022, the Company entered into a Stipulation of Compromise and Settlement (the &#8220;Stipulation&#8221;). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate 2021 grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation during the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, the Company granted a total of 6,825 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which <span style="-sec-ix-hidden:Hidden_RhAn5e9yTkGo43QiNn8L3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> vest on the grant date and <span style="-sec-ix-hidden:Hidden_76J9aX39Y0KMdQ7sa8ZTdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/12</span></span> <span style="-sec-ix-hidden:Hidden_ZQWV1d3orUOWhJfxpy8Wrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on</span></span> <span style="-sec-ix-hidden:Hidden_Kew6LAzlW0Subej7uXg45g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span></span> <span style="-sec-ix-hidden:Hidden_atRctttF5kGizw3GS0D_sg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">first</span></span> day of <span style="-sec-ix-hidden:Hidden_UM8ORUgeAkeglLMdGPU3ZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each</span></span> <span style="-sec-ix-hidden:Hidden_fyBILllLnk6bWwcWwYApTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarter</span></span> <span style="-sec-ix-hidden:Hidden_Ez33FFSqI0uGMSU9NaITRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereafter</span></span>, <span style="-sec-ix-hidden:Hidden_ZiVqmCiNWEOf8STK7ZK6yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject</span></span> to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $3.31 per-share to $13.4 per-share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock activity under the Aytu 2015 Plan is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148.91</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,825</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.79</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,434)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126.98</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135.66</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142.20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, there was $3.6 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.0 years. The total fair value of restricted stock vested during the year ended June 30, 2023 was $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company previously issued 4 shares of restricted stock outside of the Aytu 2015 Plan, which vest in July&#160;2026. On January 17, 2022, the Company granted 5,000 shares of restricted stock to a member of its management team outside of the Aytu 2015 Plan, of which <span style="-sec-ix-hidden:Hidden_aDjYmXhr_0y36dQjawXmwQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> vest on January 17, 2023 and <span style="-sec-ix-hidden:Hidden_Cdi3hkXdc0OpPArxBtSwhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/12</span></span> <span style="-sec-ix-hidden:Hidden_w_FAzbQnJkiomaZGu2gnqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each</span></span> <span style="-sec-ix-hidden:Hidden_RQWy15Pb2k-QNuwGzup_XQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarter</span></span> <span style="-sec-ix-hidden:Hidden_Pb5UtpvkmEGcCA2EitT1Fg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereafter</span></span>, <span style="-sec-ix-hidden:Hidden_NOkVRpcVoUuTSnoKpinAAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject</span></span> <span style="-sec-ix-hidden:Hidden_pnnHcg3G30GLFzKZerZfyA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span></span> <span style="-sec-ix-hidden:Hidden_Zf0xvLUMsEy4X0ESjua5-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continuing</span></span> <span style="-sec-ix-hidden:Hidden_SjR6CETviEC4J8qxQetREw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employment</span></span> with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $27.00 per-share. As of June 30, 2023, there was $0.4 million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#8217;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.56&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended June 30, 2023, the Company did not grant restricted stock units (&#8220;RSU&#8221;). RSU activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.88</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.26</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.62</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, there was $0.1 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#8217;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.6 years. The total fair value of RSUs vested during the year ended June 30, 2023 was immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 536</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and Administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,657</p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,248</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479947152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_WarrantsOrRightsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liability Classified Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation valuation model, and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2023, the Company entered into a securities purchase agreement (the &#8220;Security Purchase Agreement&#8221;) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company&#8217;s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#8220;Common Warrants&#8221;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the &#8220;Exchange Warrants&#8221;). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company&#8217;s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company&#8217;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Security Purchase Agreement) of $12 million (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August 11, 2022, the Company closed on the August 2022 Offering, pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#8220;Stock Combination Event&#8221;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the associated common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a <span style="-sec-ix-hidden:Hidden_9EV35llWm0G5Ej7R_H5Kdw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span></span> to 1 reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $2.32.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 7, 2022, the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#8217;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable <span style="-sec-ix-hidden:Hidden_u-AypRtbtUiKizPrtwHpzw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span></span> after the date of issuance and have a term of five years from the date of exercisability (see Note 14 &#8211; Stockholders&#8217; Equity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 26, 2022, as consideration for entering into the Avenue Capital Agreement as described in Note 11 &#8211; Long-term Debt, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#8220;Avenue Capital Warrants&#8221;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the issuance (see Note 11 &#8211; Long-term Debt for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 &#8211; Fair Value Considerations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of warrants is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.8</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,028,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant adjusted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,568)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,011.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,538,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.71</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsOrRightsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsOrRightsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478225616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the merger with Neos, Aytu had two 401(k)&#160;plans the (&#8220;Neos Plan&#8221;) and the (&#8220;Aytu Plan&#8217;) both plans allow participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Neos Plan matched 100% of the first 3% contributed by employees and matched 50% on the next 4% and 5% contributed by the employees. The Company&#8217;s match for the Neos Plan was approximately $0.4 million for the year ended June 30, 2022. The Aytu Plan matched 50% of the first 6% contributed to the plan by employees. The Company&#8217;s match for the Aytu Plan was approximately $0.2 million for both years ended June 30, 2023 and 2022. In July 2022, the Company transferred the Neos Plan into the Aytu BioPharma Employee Retirement Plan and in February 2023 the Company transferred the Aytu Plan into the Aytu BioPharma Employee Retirement Plan. The Aytu BioPharma Employee Retirement Plan matches 100% of the first 3% contributed by employees and matches 50% of the next 4% and 5% contributed by the employees. The Company&#8217;s match for the Aytu BioPharma Employee Retirement Plan was approximately $0.7<span style="white-space:pre-wrap;"> million during the year ended June 30, 2023.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715-70/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478259968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric Portfolio Fixed Payments and Product Milestone</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assumed two fixed, periodic payment obligations to an investor (the &#8220;Fixed Obligation&#8221;). Under the first fixed obligation, the Company was to pay monthly payment of $0.1 million beginning November&#160;1, 2019 through January&#160;2021, with a balloon payment of $15.0 million that was to be due in January&#160;2021 (&#8220;Balloon Payment Obligation&#8221;). A second fixed obligation requires the Company pay a minimum of $0.1 million&#160;monthly through February&#160;2026, except for $0.2 million paid in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the &#8220;Early Payment Agreement&#8221;) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the next six quarters commencing September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company acquired a Supply and Distribution Agreement with Tris (the &#8220;Tris Karbinal Agreement&#8221;), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Tris Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial&#160;year that spans from August&#160;1 through July&#160;31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million&#160;each&#160;year. The annual payment is due in August&#160;of each&#160;year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to June 30, 2022, the Company&#8217;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR<i style="font-style:italic;">. </i>The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#8220;Tris&#8221;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#8211; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#8217;s estimated borrowing rate. The Company recognized $0.9 million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product Contingent Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make five additional payments of $0.5 million when certain levels of FlutiCare sales are achieved. In fiscal year 2023, the manufacturer associated with this contingent liability filed for bankruptcy. There were no payments required in fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rumpus Earn Out Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (&#8220;Denovo&#8221;) and Johns Hopkins University (&#8220;JHU&#8221;), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company&#8217;s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, AR101 received Orphan Drug Designation (&#8220;ODD&#8221;) and Fast Track designation from the FDA, resulting in total milestone payments of $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In May 2023, the Company entered into an operating lease agreement to relocate its principal office within Denver, Colorado. The lease has a commencement date of October 1, 2023 with an initial term of <span style="-sec-ix-hidden:Hidden_JDyjzzB8SUiDT9RhDuHhaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five and a half years</span></span>. Undiscounted minimum monthly rent payments average approximately $15,500 over the initial term of the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has one five-year renewal option through March 2034.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-indent:36pt;margin:0pt;">Legal Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Witmer Class-Action Securities Litigation. </i>A shareholder derivative suit was filed on September12, 2022 in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#8217;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint drops Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enrichment and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in as insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#8217; fees. While we believe that this lawsuit is without merit and have vigorously defended against it, we have agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#8217;s attorneys&#8217; fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Sabby Litigation.</i> A complaint was filed on February 22, 2023 in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#8220;Sabby&#8221;) and Walleye Opportunities Master Fund Ltd (&#8220;Walleye&#8221;), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrantholders may receive, and that the Company failed to provide prompt notice to the warrantholders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. While we believe that this lawsuit is without merit and we intend to vigorously defend against it, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Stein Litigation.</i> Cielo Stein (&#8220;Stein&#8221;), a former sales specialist, filed a complaint on February 1, 2023 in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company&#8217;s response to Stein&#8217;s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#8217; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which is pending. Due to the early stage of litigation, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations, and intend to vigorously defend this case in the event it is not dismissed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474831376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicensingAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19. License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Healight</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the Company&#8217;s focus on the revenue growth of its commercial business, the Company had terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NeuRx</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, Neos entered into an Exclusive License Agreement (&#8220;NeuRx License&#8221;) with NeuRx Pharmaceuticals LLC (&#8220;NeuRx&#8221;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx&#8217;s proprietary compound designated as NRX-101, referred to by Neos as NT0502. NT0502 is a new chemical entity that is being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Teva</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (&#8220;Teva&#8221;) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (&#8220;ANDA&#8221;) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Actavis</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shire</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the &#8220;2014 License Agreement&#8221;) with Shire LLC (&#8220;Shire&#8221;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#8217; New Drug Application (the &#8220;NDA&#8221;) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expires May of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2017, Neos entered into a License Agreement (the &#8220;2017 License Agreement&#8221;) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos&#8217; NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicensingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for licensing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicensingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479863120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20. Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Company&#8217;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages and aggregates its&#160;operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#8217;s prescription products. The Consumer Health Segment contains the Company&#8217;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2023, the Rx Segment recognized an impairment loss of $2.6 million due to ceasing active development of the NT0502 product candidate as a result of the Company&#8217;s increased focus on commercial efforts. The Consumer Health Segment recognized an impairment loss of $3.0<span style="white-space:pre-wrap;"> million from intangible assets  (see Note 7 &#8212; Goodwill and Other Intangible Assets) and an inventory write-off of </span>$2.1 million due to the discontinuance of its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended June 30, 2022, the Rx Segment recognized a total impairment loss of $64.6 million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, the Consumer Health Segment recognized $10.8<span style="white-space:pre-wrap;"> million of goodwill and intangible assets write downs (see Note 7 &#8212;  Goodwill and Other Intangible Assets).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Select financial information for these segments is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rx</p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consumer Health</p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2023:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,707)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,065)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,387</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment and write-off expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,824</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,046</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2022:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (92,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (109,906)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,378</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,458</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,248</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478259968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Distribution and Supply Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with a privately-owned pharmaceutical company for Adzenys XR-ODT and Cotempla XR-ODT product lines. The pharmaceutical company will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT; and will focus on distributing and selling these products for patients in Israel and the Palestinian Authority. The Company will commit to product supply based on forecasts and provide product training. Due to the nascency of the collaboration, estimates of its financial effect cannot be made. This agreement represents the Company&#8217;s first international commercial agreement for Adzenys and Cotempla.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468705296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principals of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Principals of Consolidation</span><i style="font-style:italic;">. </i>The Company&#8217;s consolidated financial statements include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span><i style="font-style:italic;">.</i> The Company&#8217;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Prior Period Reclassification and Previously Reported Financial Statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Prior Period Reclassification</span><i style="font-style:italic;">. </i>Certain prior year amounts in the consolidated statements of operations and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of amortization of intellectual property, and a reclassification of fair value adjustment from contingent consideration. Amortization of intellectual property was previously included in research and development expenses and is currently recorded in amortization of intangible assets expenses on the consolidated statements of operations. Gain or loss from the fair value of contingent consideration was previously included in Other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the fiscal years ended June 30, 2023 and 2022 or its financial position as of June 30, 2023 or June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Financial Statements</span><i style="font-style:italic;">. </i>The classification of certain of the Company&#8217;s warrants was previously recorded as equity. These warrants according to U.S. GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the audited financial statements as of June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">SEC Staff Accounting Bulletin No. 99, &#8220;Materiality,&#8221; and the Financial Accounting Standards Board (&#8220;FASB&#8221;), Statement of Financial Accounting Concepts No. 2 &#8220;Qualitative Characteristics of Accounting Information&#8221; indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company&#8217;s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance Sheet data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (288,472)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (287,078)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,784)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,308</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Twelve Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Operation data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">Total other income, net </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,889)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (74.01)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Stockholders' Equity data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,854</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Cash Flow data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (211)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,605)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Includes reclassification of gain or loss from the fair value of contingent consideration. See </span><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Prior Period Reclassification </i><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">in Note 2 &#8211; Summary of Significant Accounting Policies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Previously Reported Segment Information</span><i style="font-style:italic;">. </i>During the year ended June 30, 2023, the Company identified an omission regarding the disclosure of certain key metrics of its reportable segments under ASC 280 related to the year ended June 30, 2022. During the year ended June 30, 2022, the Company inappropriately reported the net income of each of its two segments as opposed to operating income which more closely aligns with the adjusted EBITDA metric that is utilized by its chief operating decision maker. The impact on June 30, 2022 was that $92.4 million and $17.5 million of operating loss relating to the Rx Segment and Consumer Health segment, respectively, should have been reported as a separate line. The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99. The Company concluded that the omission was not material to any of the previously issued consolidated financial statements and began reporting operating results by segment in accordance with ASC 280 on a prospective basis starting with the year ended June 30, 2023</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span><i style="font-style:italic;">.</i> The Company&#8217;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to FDIC (the &#8220;Federal Deposit Insurance Corporation&#8221;) insurance limits, and cash balances in the money market funds are not FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounts Receivable, net</span><i style="font-style:italic;">. </i>Accounts receivable represent amounts due from customers less allowances for doubtful accounts, discounts and pricing chargebacks. An allowance for doubtful accounts, when needed, is based upon the financial condition and payment history of customers; collections experience on other accounts; and economic factors or events expected to affect future collections. The allowance for doubtful accounts was zero for both years ended June 30, 2023 and 2022. The allowance for discounts was $1.8 million and $1.3 million for the years ended June 30, 2023 and 2022, respectively. The allowance for chargebacks was $1.2<span style="white-space:pre-wrap;"> million for both years ended June 30, 2023 and 2022.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below presents the opening and closing balances of receivables from customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accounts Receivable, gross</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,927</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,708</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,325</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Decrease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,106)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Chargeback</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Allowance</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,358</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,592)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,628</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,548)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,145)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,990</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inventories</span><i style="font-style:italic;">.</i> Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_GoingConcernPolicyTextBlock', window );">Going Concern Determination</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern Determination</span><i style="font-style:italic;">.</i> In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the financial statements are issued.<span style="font-size:11pt;"> </span>The evaluation is based on relevant conditions and events that are known and reasonably knowable within one year after the date that the financial statements are issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and equipment, net</span><i style="font-style:italic;">. </i>Property and equipment are recorded at cost less accumulated depreciation. <span style="-sec-ix-hidden:Hidden_ZU0GSZmRRU6mHNeNM31yuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Furniture</span></span> and <span style="-sec-ix-hidden:Hidden_QQYcc8br-EqS2gjQlclZQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">equipment</span></span> are depreciated on a straight-line basis over their estimated useful lives which are generally <span style="-sec-ix-hidden:Hidden_BkyMcFO_ukqYjCCDP1gOew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> to seven years. Leasehold improvements are amortized over the <span style="-sec-ix-hidden:Hidden_6fUhpC-LoUCZ1c2RWfvzow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shorter of the estimated useful life</span></span> or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span><i style="font-style:italic;">.</i> At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#8220;ROU&#8221;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#8217;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#8217;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#8217;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in other liabilities in the Company&#8217;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and Business Combination and Contingent considerations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquisitions</span><b style="font-weight:bold;">. </b>In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does not result in goodwill. Contingent consideration is accounted for Acquired in-process research and development with no alternative future use is charged to expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent consideration</span><i style="font-style:italic;">. </i>The consideration for our acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination and Contingent considerations</span><i style="font-style:italic;">. </i>The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants. </span>The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC 815,including whether the warrants are indexed to the Company&#8217;s own common shares and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability classified warrants are valued using the Monte Carlo simulation model or the Black-Scholes option pricing model at issuance, and for each reporting period. Equity classified warrants are valued using the Black-Scholes model.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue Recognition</span><i style="font-style:italic;">. </i>The Company generates revenue from product sales through its prescription pharmaceutical products segment (&#8220;Rx Segment&#8221;) and its consumer healthcare products segment (&#8220;Consumer Health </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Segment&#8221;). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rx Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#8220;free-on-board&#8221; destination when shipped domestically within the United States and &#8220;free-on-board&#8221; shipping point when shipped internationally consistent with the contractual terms. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rx product revenue is recognized net of consideration paid to the Company&#8217;s customers and other adjustments to the transaction price (known as &#8220;Gross to Net&#8221; adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#8220;Gross to Net&#8221; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gross to Net adjustments include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Savings offers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Prompt payment discounts</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Prompt payment discounts are based on standard provisions of wholesalers&#8217; services.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesale distribution fees </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#8217;s products by wholesalers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Rebates </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Wholesaler chargebacks</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#8217; end customers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Returns</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Wholesalers&#8217; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company&#8217;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consumer Health Segment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized &#8220;free-on-board&#8221; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_CustomerContractCostsPolicyTextBlock', window );">Customer Contract Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Customer Contract Costs</span><i style="font-style:italic;">.</i> The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one&#160;year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span><i style="font-style:italic;">. </i>Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#8217;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#8217;s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company&#8217;s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally <span style="-sec-ix-hidden:Hidden_b9ThaH63FEyijuGZHHcAxg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span> to sixty days. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents customers that contributed more than 10% of gross revenue and accounts receivable<i style="font-style:italic;">: </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of gross revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of accounts receivable</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Costs of Sales</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Costs of Sales</span><i style="font-style:italic;">. </i>Costs of sales consists primarily of manufactured product cost, products acquired from third-party manufacturers, freight, production, and indirect manufacturing overhead costs and FDA fees for commercialized products. Certain of the Company&#8217;s sales activities depend on licensing arrangements that may require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company's third-party logistics companies are included in costs of sales.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span><i style="font-style:italic;">.</i> The Company accounts for share-based payments compensation expense using a fair value based model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#8217;s common stock and recognized ratably over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#8220;simplified method,&#8221; which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn&#8217;t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span>. Research and development costs are expensed as incurred and include salaries and benefits, facilities costs, overhead costs, raw materials, laboratory and clinical supplies, clinical trial costs, contract services, milestone payments and fees paid to regulatory authorities for review and approval of the Company&#8217;s product candidates and other related costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span><i style="font-style:italic;">.</i> The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-lived Assets and Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-lived Assets and Goodwill</span><i style="font-style:italic;">.</i> The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company&#8217;s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry forecasted financial performance indicate that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company&#8217;s industry.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Advertising Costs</span><i style="font-style:italic;">. </i>Advertising costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $11.1 million and $13.6 million of advertising costs for the&#160;years ended June 30, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span><i style="font-style:italic;">.</i> The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of  to be sustained upon an examination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt issuance costs, discounts (premium)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt issuance costs, discounts (premiums)</span><i style="font-style:italic;">. </i>Debt issuance costs reflect fees paid to lenders and third parties directly related to issuing debt. Debt issuance costs and discounts (premiums) related to term loans are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense. Debt issuance costs related to a line of credit facility are classified as assets and subsequently amortized over the term of the line of credit as additional interest expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment information</span><i style="font-style:italic;">. </i>The Company&#8217;s operating segments engage in business activities from which it may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#8217;s chief operating decision maker, who is the Company&#8217;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#8217;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has two reportable segments: the Rx Segment and the Consumer Health Segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Paragraph IV litigation costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Paragraph IV litigation costs</span><i style="font-style:italic;">. </i>Legal costs incurred by the Company in the enforcement of the Company&#8217;s intellectual property rights are charged to expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss Per Common Share</span><i style="font-style:italic;">.</i> Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For the years ended June 30, 2023 and 2022, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets-forth securities excluded from the calculation of diluted earnings per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,538,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 434,328</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,899</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,377</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,500</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,636,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reference Rate Reform.</span> In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (&#8220;ASU&#8221;) 2020-04, <i style="font-style:italic;">Reference Rate Reform (Topic 848)</i>: <i style="font-style:italic;">&#8220;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&#8221;</i>, which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective July 1, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Earnings Per Share.</span> In May 2021, the FASB issued ASU 2021-04,<i style="font-style:italic;"> &#8220;Earnings Per Share (Topic260), Debt &#8211; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718), and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#8221;.</i> The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Debt&#8212;Debt with Conversion and Other Options.</span> In August 2020, the FASB issued ASU No. 2020-06,<i style="font-style:italic;"> Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8212; &#8220;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</i>, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (&#8221;SEC&#8221;), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have any material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial Instruments&#160;</span>&#8211;<span style="font-style:italic;font-weight:bold;"> Credit Losses.</span> In June&#160;2016, the FASB issued <i style="font-style:italic;">ASU 2016-13, &#8220;Financial Instruments&#160;&#8211; Credit Losses&#8221;</i> requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard is effective for smaller reporting companies for fiscal periods beginning after December&#160;15, 2022. In May 2019, the FASB issued ASU 2019-05, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses</i>&#8221;, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, &#8220;<i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures</i>&#8221; which eliminates the accounting guidance for troubled debt restructurings by creditors and adds disclosure requirements for current period gross write-offs by year of origination for financing receivables and net investments in leases. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal&#160;year ended June&#160;30, 2024. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CustomerContractCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for customer contract costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CustomerContractCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern determination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468073184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of the impact of the immaterial correction of an error</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance Sheet data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,174)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331,386</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (288,472)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (287,078)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,784)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,308</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Twelve Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Previously</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As Adjusted</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Operation data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">Total other income, net </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,889)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (74.01)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Stockholders' Equity data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,854</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statement of Cash Flow data</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,779)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on derivative warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (211)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,394)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,605)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Includes reclassification of gain or loss from the fair value of contingent consideration. See </span><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Prior Period Reclassification </i><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">in Note 2 &#8211; Summary of Significant Accounting Policies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of receivables from customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Accounts Receivable, gross</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,927</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,708</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance, June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,325</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance, June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,219</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Decrease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,106)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of allowance for discounts and allowance for chargebacks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Allowance for Chargeback</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Allowance</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,149</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,358</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,592)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,408)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,507</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,628</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,548)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,145)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,990</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of concentration of business risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of gross revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage of accounts receivable</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,538,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 434,328</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,899</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,377</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Note 15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,500</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,636,773</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532,104</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477207968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,121</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consumer Health Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,548</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Consolidated revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenue by product lines</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rx Segment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_g-cbh5-g8Eq9t2stexXsqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADHD </span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,855</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_K8_3hQR_I0yTd3PB8O7Q8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pediatric</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,084</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_3ehiKXD22k2GoV9XNE777Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,182</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,121</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of product revenues by geographic location</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 106,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,606</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">International</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,063</p></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total net revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473053472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:23.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,814</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,838</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,197</p></td></tr><tr><td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,849</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479765152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,487</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 999</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment, furniture and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,128</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets under construction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,446</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,681)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,421)</p></td></tr><tr><td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,025</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475837024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statement of Operations Classification</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease cost:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Amortization of leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (expense), net</p></td></tr><tr><td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total net lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of balance sheet information related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Classification</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_oCFrnX1cZEKlI0YfWFbvaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Property and equipment, net</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total leased assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,227</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_uO7hW3tJ10-9Y4OnbKB2gw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_kiHw9kJlzEqfvdcIxL-40Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current portion of debt</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_unXTBH375Ue8ldFNegISKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other liabilities</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_rmlxlXZlBUmyfb7kJxK3Ag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Debt, net of current portion</span></span></p></td></tr><tr><td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of remaining lease term and discount rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Remaining Lease Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.63</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.87</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.73</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-Average Discount Rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.48</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.54</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.43</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LesseeLeasesCashFlowInformationTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flow classification of lease payments:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,016</p></td></tr><tr><td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows - finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of future minimum lease payments, operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of future minimum lease payments, finance leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td></tr><tr><td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's assets and liabilities related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LesseeLeasesCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for leases of the lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LesseeLeasesCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481027568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of change in carrying amount of goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rx Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consumer Health Segment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,802</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,165)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,802)</p></td></tr><tr><td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite lived intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.49</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.33</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.60</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,004)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite lived intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.49</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,678)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,613)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.67</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net&#160;Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(in years)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Definite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,224)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.33</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired technology right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.75</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired product distribution rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.60</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,004)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indefinite-lived intangibles:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in-process R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indefinite-lived</p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.35</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,518</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,989</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,496</p></td></tr><tr><td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total future amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,970</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475903792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued savings offers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,711</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued program liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,468</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,675</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,765</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued customer and product related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,817</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,770</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,656</p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,187</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ScheduleOfReturnReserveTableTextBlock', window );">Schedule of the return reserve</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Return Reserve</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,367</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,568</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,165)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,770</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charges to expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,346)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,777</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ScheduleOfReturnReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the return reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ScheduleOfReturnReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479775728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Schedule of other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed payment arrangement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,051</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,317</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent value rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 815</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,157</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,090)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,359)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,798</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473467072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, due on January 26, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,000</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term, final payment fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 638</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (925)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing leases, maturing through May 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,798</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,713</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of future principal payments of long term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,638</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future principal payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,723</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less unamortized discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (925)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (85)</p></td></tr><tr><td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-current portion of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,713</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468953984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_Yi-wD1QAw027O6Gw0MqnzA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value at June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CVR liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden_YynIzFLXAkeAX8AGtpTUAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,770</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in Level 3 inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CVR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consideration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liability</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,796</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Included in earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (578)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (391)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,391)</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases, issues, sales and settlements:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,998</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Settlements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant assumptions used in valuation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in valuing the CVRs were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leveraged Beta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market risk premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company specific discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant assumptions used in valuation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">August 9,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">89.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 8,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant assumptions used in <span style="-sec-ix-hidden:Hidden_iwcBQPje9UyI7pXQKxPUyQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">valuing</span></span> the derivative warrant liabilities, marked to market, were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">83.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equivalent term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.59-4.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.13-4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470532800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (109)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (91)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (117)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,159)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">162(m) limitation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of phased-in tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on debt extinguishment and interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (110)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.09)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114,443</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued Rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,944</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,773</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 817</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,423</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,975</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174 Capitalization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,177</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 799</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 137,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 132,652</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,966)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,686</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangibles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,717)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (308)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (483)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (788)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,378)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,813)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (127)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Tabular rollforward of gross unrecognized tax benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,435</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from prior period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease resulting from current period tax positions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (120)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (647)</p></td></tr><tr><td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,822</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473456208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 7.77</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Outstanding at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 9.06</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercisable at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;"> 6.17</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Stock options outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">123.16 - 290.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 225.74</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted stock activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148.91</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,825</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.79</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (42,434)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126.98</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135.66</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142.20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted stock units activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.88</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.26</p></td></tr><tr><td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,963</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.62</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 536</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and Administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,657</p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,248</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474979440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightActivityTableTextBlock', window );">Summary of warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;in&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 434,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.8</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,028,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant adjusted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,568)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,011.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,538,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.71</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475008144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment select financial information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rx</p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consumer Health</p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2023:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,399</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,707)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,065)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,387</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment and write-off expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,824</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,046</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Year Ended June 30, 2022:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,669</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (92,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (109,906)</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,821</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,378</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,458</p></td></tr><tr><td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,248</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477201408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Financial Condition - Segments (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474979440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Financial Condition - Reverse Stock Split (Details)<br></strong></div></th>
<th class="th"><div>Jan. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470600880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Financial Condition - Product Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>item</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfProductPortfolios', window );">Number of product portfolios</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfProductPortfolios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Product Portfolios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfProductPortfolios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469570816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Financial Condition - General Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 22,985<span></span>
</td>
<td class="nump">$ 19,360<span></span>
</td>
<td class="nump">$ 49,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">28,937<span></span>
</td>
<td class="nump">21,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Net Income (Loss) Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,051)<span></span>
</td>
<td class="num">(108,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract', window );"><strong>Retained Earnings (Accumulated Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,129)<span></span>
</td>
<td class="num">(287,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="num">$ (5,129)<span></span>
</td>
<td class="num">$ (28,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474127248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Financial Condition - Going Concern (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear', window );">Substantial Doubt about Going Concern, within One Year</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember', window );">Avenue Capital Loan, Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -SubTopic 40<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479710/205-40-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473415696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 6,403<span></span>
</td>
<td class="nump">$ 1,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">97,106<span></span>
</td>
<td class="nump">93,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">343,485<span></span>
</td>
<td class="nump">331,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(304,129)<span></span>
</td>
<td class="num">(287,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">$ 39,357<span></span>
</td>
<td class="nump">44,308<span></span>
</td>
<td class="nump">$ 137,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469069520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="nump">$ 4,793<span></span>
</td>
<td class="nump">$ 1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(17,051)<span></span>
</td>
<td class="num">(108,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,051)<span></span>
</td>
<td class="num">$ (108,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">$ (5.11)<span></span>
</td>
<td class="num">$ (74.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (5.11)<span></span>
</td>
<td class="num">$ (74.01)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (110,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.00)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470190784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 6,054<span></span>
</td>
<td class="nump">$ 8,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473417792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,051)<span></span>
</td>
<td class="num">$ (108,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="num">$ (4,793)<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468853568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (17,065)<span></span>
</td>
<td class="num">$ (109,906)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,358)<span></span>
</td>
<td class="num">(92,441)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Operating Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (9,707)<span></span>
</td>
<td class="num">$ (17,465)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034480984352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowances</a></td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="nump">$ 2,507<span></span>
</td>
<td class="nump">$ 2,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts', window );">Allowance for discounts</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks', window );">Allowance for chargebacks</a></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Doubtful Accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473100704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Opening balance</a></td>
<td class="nump">$ 24,219<span></span>
</td>
<td class="nump">$ 30,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease', window );">Increase (decrease)</a></td>
<td class="nump">7,708<span></span>
</td>
<td class="num">(6,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Closing balance</a></td>
<td class="nump">$ 31,927<span></span>
</td>
<td class="nump">$ 24,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, before Allowance for Credit Loss, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473416384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts', window );">Allowance for discount, beginning balance</a></td>
<td class="nump">$ 1,301<span></span>
</td>
<td class="nump">$ 1,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal', window );">Allowance for discount, charges to expense</a></td>
<td class="nump">9,074<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery', window );">Allowance for discount, payments</a></td>
<td class="num">(8,597)<span></span>
</td>
<td class="num">(6,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts', window );">Allowance for discount, ending balance</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks', window );">Allowance for chargeback, beginning balance</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal', window );">Allowance for chargeback, charges to expense</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery', window );">Allowance for chargeback, payments</a></td>
<td class="num">(4,548)<span></span>
</td>
<td class="num">(4,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks', window );">Allowance for chargeback, ending balance</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Total allowance, beginning balance</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">2,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Total allowance, charges to expense</a></td>
<td class="nump">13,628<span></span>
</td>
<td class="nump">11,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Total allowance, payments</a></td>
<td class="num">(13,145)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Total allowance, ending balance</a></td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="nump">$ 2,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts, Recovery</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks, Recovery</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Discounts, Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Pricing Chargebacks, Credit Loss Expense (Reversal)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470480912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, plant and equipment, estimated useful lives</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481026160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableCreditTermsLowEndOfRange', window );">Accounts receivable, credit terms, low end of range</a></td>
<td class="text">40 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccountsReceivableCreditTermsHighEndOfRange', window );">Accounts receivable, credit terms, high end of range</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableCreditTermsHighEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Terms, High End of Range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableCreditTermsHighEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccountsReceivableCreditTermsLowEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Terms, Low End of Range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccountsReceivableCreditTermsLowEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473429840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Credit Concentration Risk | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=aytu_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=aytu_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468071024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpenseAbstract', window );"><strong>Marketing and Advertising Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473051248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475870688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,636,773<span></span>
</td>
<td class="nump">532,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">6,538,052<span></span>
</td>
<td class="nump">434,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">52,762<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Employee Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">40,996<span></span>
</td>
<td class="nump">85,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Employee Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475080288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member', window );">Accounting Standards Update 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475818736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - General Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember', window );">Consumer Health Portfolio | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfProducts', window );">Number of products | product</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469473008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Revenues by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 107,399<span></span>
</td>
<td class="nump">$ 96,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">73,799<span></span>
</td>
<td class="nump">61,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 33,600<span></span>
</td>
<td class="nump">$ 35,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474304192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Revenues by Product Portfolio (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 107,399<span></span>
</td>
<td class="nump">$ 96,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_AttentionDeficitHyperactivityDisorderPortfolioMember', window );">ADHD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 46,855<span></span>
</td>
<td class="nump">$ 42,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitNameOfSegmentExtensibleList', window );">Reporting Unit, Name of Segment</a></td>
<td class="text">Rx<span></span>
</td>
<td class="text">Rx<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_PediatricPortfolioMember', window );">Pediatric</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 25,377<span></span>
</td>
<td class="nump">$ 16,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitNameOfSegmentExtensibleList', window );">Reporting Unit, Name of Segment</a></td>
<td class="text">Rx<span></span>
</td>
<td class="text">Rx<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">$ 2,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitNameOfSegmentExtensibleList', window );">Reporting Unit, Name of Segment</a></td>
<td class="text">Rx<span></span>
</td>
<td class="text">Rx<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember', window );">Consumer Health Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitNameOfSegmentExtensibleList', window );">Reporting Unit, Name of Segment</a></td>
<td class="text">Consumer Health Segment<span></span>
</td>
<td class="text">Consumer Health Segment<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 73,799<span></span>
</td>
<td class="nump">$ 61,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitNameOfSegmentExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates business segment in which reporting unit is included.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitNameOfSegmentExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_AttentionDeficitHyperactivityDisorderPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_AttentionDeficitHyperactivityDisorderPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_PediatricPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_PediatricPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_ConsumerHealthPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468073184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Revenues by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 107,399<span></span>
</td>
<td class="nump">$ 96,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">106,918<span></span>
</td>
<td class="nump">94,606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468753264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Tabular Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,301<span></span>
</td>
<td class="nump">$ 1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">1,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,738<span></span>
</td>
<td class="nump">7,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 11,995<span></span>
</td>
<td class="nump">$ 10,849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474893152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Inventory Write-down (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrChargesAbstract', window );"><strong>Production Related Impairments or Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 2,351<span></span>
</td>
<td class="nump">$ 2,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_InventoryWriteDownAndImpairment', window );">Inventory write-down and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_InventoryWriteDownAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Write-down and Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_InventoryWriteDownAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470591776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Tabular Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,496<span></span>
</td>
<td class="nump">$ 5,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(3,681)<span></span>
</td>
<td class="num">(2,421)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember', window );">Office Equipment, Furniture and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">$ 832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Asset under Construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract', window );"><strong>Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_OfficeEquipmentFurnitureAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481007856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Depreciation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationAbstract', window );"><strong>Depreciation, Depletion and Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479911488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Gain (Loss) on Disposal (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract', window );"><strong>Gain (Loss) on Disposition of Property Plant Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain (loss) on sale of equipment</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479812544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Impairment (Details) - Manufacturing Equipment<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract', window );"><strong>Impairment, Long-Lived Asset, Held-for-Use [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charge</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income</a></td>
<td class="text">Impairment expense<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468263328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - General Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">2,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=aytu_ExpansionDateMember', window );">Expansion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RentReceivableFromSubleaseProperty', window );">Rent receivable from sublease property</a></td>
<td class="nump">20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=aytu_ExpirationOfSubleaseMember', window );">Expiration of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RentReceivableFromSubleaseProperty', window );">Rent receivable from sublease property</a></td>
<td class="nump">$ 70,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember', window );">Office Space and Manufacturing Facilities, Grand Prairie, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease, borrowing rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AreaOfSubleaseProperty', window );">Area of Sublease Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_RemainingAreaOfSubleaseProperty', window );">Remaining Area of Sublease Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Lessee, Finance Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance leases, interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aytu_PrincipalOfficeDenverColoradoMember', window );">Principal Office, Denver, Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AreaOfSubleaseProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of sublease property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AreaOfSubleaseProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RemainingAreaOfSubleaseProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Area of Sublease Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RemainingAreaOfSubleaseProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RentReceivableFromSubleaseProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Receivable from Sublease Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RentReceivableFromSubleaseProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_ExpansionDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_ExpansionDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_ExpirationOfSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_ExpirationOfSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aytu_PrincipalOfficeDenverColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aytu_PrincipalOfficeDenverColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473103168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Net Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="nump">$ 1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total net lease cost</a></td>
<td class="nump">$ 1,574<span></span>
</td>
<td class="nump">$ 1,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468809984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Assets and Liabilities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 2,054<span></span>
</td>
<td class="nump">$ 3,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">$ 2,213<span></span>
</td>
<td class="nump">$ 3,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 1,258<span></span>
</td>
<td class="nump">$ 1,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases, current</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position</a></td>
<td class="text">Current portion of debt<span></span>
</td>
<td class="text">Current portion of debt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance leases, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position</a></td>
<td class="text">Debt, net of current portion<span></span>
</td>
<td class="text">Debt, net of current portion<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLeaseAndFinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="nump">$ 3,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents right-of-use asset for operating lease and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470427952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease assets, weighted-average remaining lease term</a></td>
<td class="text">1 year 8 months 19 days<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease assets, weighted-average remaining lease term</a></td>
<td class="text">10 months 13 days<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease assets, weighted-average discount rate</a></td>
<td class="nump">7.78%<span></span>
</td>
<td class="nump">7.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease assets, weighted-average discount rate</a></td>
<td class="nump">6.54%<span></span>
</td>
<td class="nump">6.43%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473011024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows - operating leases</a></td>
<td class="nump">$ 1,436<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Investing Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows - finance leases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Financing Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows - finance leases</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowInvestingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475671776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Leases - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 2,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474235088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Leases - Gross Difference (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Operating Lease Liabilities, Gross Difference, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 2,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="nump">$ 3,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481009248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Finance Leases - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470600880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Finance Leases - Gross Difference (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Finance Lease Liabilities, Gross Difference, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468812800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 65,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(65,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">8,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">(8,637)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx Segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">57,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="num">$ (57,165)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468978224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">$ 81,558<span></span>
</td>
<td class="nump">$ 91,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(19,613)<span></span>
</td>
<td class="num">(16,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Finite-lived intangible assets, accumulated impairment</a></td>
<td class="num">(2,975)<span></span>
</td>
<td class="num">(7,058)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">58,970<span></span>
</td>
<td class="nump">68,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember', window );">Acquired product technology right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">42,176<span></span>
</td>
<td class="nump">45,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(10,881)<span></span>
</td>
<td class="num">(7,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Finite-lived intangible assets, accumulated impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">31,295<span></span>
</td>
<td class="nump">34,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Acquired technology right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">30,200<span></span>
</td>
<td class="nump">30,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,054)<span></span>
</td>
<td class="num">(2,278)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">26,146<span></span>
</td>
<td class="nump">27,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember', window );">Acquired product distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">9,182<span></span>
</td>
<td class="nump">11,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,678)<span></span>
</td>
<td class="num">(3,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Finite-lived intangible assets, accumulated impairment</a></td>
<td class="num">(2,975)<span></span>
</td>
<td class="num">(2,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 1,529<span></span>
</td>
<td class="nump">5,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Finite-lived intangible assets, accumulated impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,662)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469559920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining amortization period</a></td>
<td class="text">12 years 8 months 1 day<span></span>
</td>
<td class="text">13 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember', window );">Acquired product technology right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining amortization period</a></td>
<td class="text">11 years 5 months 26 days<span></span>
</td>
<td class="text">12 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Acquired technology right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining amortization period</a></td>
<td class="text">14 years 9 months<span></span>
</td>
<td class="text">15 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember', window );">Acquired product distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-lived intangible assets, remaining amortization period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductDistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473438896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">$ 81,558<span></span>
</td>
<td class="nump">$ 91,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="nump">84,158<span></span>
</td>
<td class="nump">94,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(19,613)<span></span>
</td>
<td class="num">(16,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Finite-lived intangible assets, accumulated impairment</a></td>
<td class="num">(2,975)<span></span>
</td>
<td class="num">(7,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment', window );">Indefinite-lived intangible assets, accumulated impairment</a></td>
<td class="num">(2,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment', window );">Impairment</a></td>
<td class="num">(5,575)<span></span>
</td>
<td class="num">(7,058)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net carrying amount</a></td>
<td class="nump">$ 58,970<span></span>
</td>
<td class="nump">$ 70,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets (Excluding Goodwill), Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034481098320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 6,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">4,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">32,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 58,970<span></span>
</td>
<td class="nump">$ 68,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475021552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember', window );">Supply and Distribution Agreement, Tris Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementTerm', window );">Supply and distribution agreement, term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469578464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Estimated Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod', window );">Finite-lived intangible asset, useful life, renewable period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod', window );">Finite-lived intangible asset, useful life, renewable period</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember', window );">Product Technology Right | Attention Deficit Hyperactivity Disorder Portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Useful Life, Renewable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ProductTechnologyRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_AttentionDeficitHyperactivityDisorderPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_AttentionDeficitHyperactivityDisorderPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468843680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>product </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember', window );">Innovus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfProductsAcquired', window );">Number of products acquired | product</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired', window );">Number of registered trademarks and or patent rights and customer lists acquired | item</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember', window );">Innovus Pharmaceuticals, Inc | Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfProductsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfProductsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Registered Trademarks and or Patent Rights and Customer Lists Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479921648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortizationAbstract', window );"><strong>Amortization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization expense</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473957424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember', window );">Neos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment | Innovus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_AciphexMember', window );">AcipHex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_ZolpiMistMember', window );">ZolpiMist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_TussionexMember', window );">Tussionex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=aytu_CefaclorMember', window );">Cefaclor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets, finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NeosTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_AciphexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_AciphexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_ZolpiMistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_ZolpiMistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_TussionexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_TussionexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=aytu_CefaclorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=aytu_CefaclorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470347712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 65,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470485440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - General Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedSavingOffers', window );">Accrued savings offers</a></td>
<td class="nump">$ 15,739<span></span>
</td>
<td class="nump">$ 12,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedProgramRelatedLiabilities', window );">Accrued program liabilities</a></td>
<td class="nump">11,012<span></span>
</td>
<td class="nump">9,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">4,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AccruedCustomerAndProductRelatedFeesCurrent', window );">Accrued customer and product related fees</a></td>
<td class="nump">6,579<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReserveCurrent', window );">Return reserve</a></td>
<td class="nump">5,777<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">3,656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 46,799<span></span>
</td>
<td class="nump">$ 44,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedCustomerAndProductRelatedFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Customer and Product Related Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedCustomerAndProductRelatedFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedProgramRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedProgramRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedSavingOffers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information related to accrued saving offers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedSavingOffers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReturnReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReturnReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474224768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities - Return Reserve (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReserve', window );">Return reserve, beginning balance</a></td>
<td class="nump">$ 5,770<span></span>
</td>
<td class="nump">$ 6,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReserveChargesToExpense', window );">Return reserve, charges to expense</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">8,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReservePayments', window );">Return reserve, payments</a></td>
<td class="num">(8,346)<span></span>
</td>
<td class="num">(9,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ReturnReserve', window );">Return reserve, ending balance</a></td>
<td class="nump">$ 5,777<span></span>
</td>
<td class="nump">$ 5,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReturnReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReturnReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReturnReserveChargesToExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Reserve, Charges to Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReturnReserveChargesToExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReturnReservePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return Reserve, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReturnReservePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475815680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesUnclassifiedAbstract', window );"><strong>Other Liabilities, Unclassified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="nump">$ 10,420<span></span>
</td>
<td class="nump">$ 13,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">3,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure', window );">Contingent value rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilities', window );">Other</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total other liabilities</a></td>
<td class="nump">$ 14,065<span></span>
</td>
<td class="nump">$ 18,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesUnclassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesUnclassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474984592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total other liabilities</a></td>
<td class="nump">$ 14,065<span></span>
</td>
<td class="nump">$ 18,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Less: current portion</a></td>
<td class="num">(7,090)<span></span>
</td>
<td class="num">(5,359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other liabilities, noncurrent</a></td>
<td class="nump">$ 6,975<span></span>
</td>
<td class="nump">$ 12,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469221504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities - Fixed Payment Arrangements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 12, 2022 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,420<span></span>
</td>
<td class="nump">$ 13,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber', window );">Fixed payment arrangements, periodic payment obligations, number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount', window );">Fixed payment arrangements, monthly payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount', window );">Fixed payment arrangements, balloon payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid', window );">Fixed payment arrangements, balloon payment amount, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber', window );">Fixed payment arrangements, quarterly payment amount, payments, number | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmount', window );">Fixed payment arrangements, quarterly payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue', window );">Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum', window );">Fixed payment arrangements, monthly variable payment amount, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid', window );">Fixed payment arrangements, monthly variable payment amount, one-time payment, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026', window );">Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPaymentAmountPaid', window );">Fixed payment arrangements, payment amount, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember', window );">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsLiabilityReduction', window );">Fixed payment arrangements, liability, reduction</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsInstallmentPaymentsNumber', window );">Fixed payment arrangements, installment payments, number | payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember', window );">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember', window );">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember', window );">Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsCurrent', window );">Fixed payment arrangements, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsNoncurrent', window );">Fixed payment arrangements, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances', window );">Issues, fixed payment arrangements</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Balloon Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsBalloonPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Balloon Payment Amount, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsInstallmentPaymentsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Installment Payments, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsInstallmentPaymentsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsLiabilityReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Liability, Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsLiabilityReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, Aggregate Payments to Satisfy Obligation if Paid before 12 February 2026</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, Percentage of Net Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Payment Amount, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Periodic Payment Obligations, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Quarterly Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsQuarterlyPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477394240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementTerm', window );">Supply and distribution agreement, term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales', window );">Supply and distribution agreement, royalty, percentage of net sales (as a percent)</a></td>
<td class="nump">23.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits', window );">Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item</a></td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit', window );">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount', window );">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount</a></td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation', window );">Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount', window );">Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Royalty, Percentage of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473935248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities - Contingent Value Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum', window );">Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum', window );">Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts', window );">Contingent Value Rights payouts (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
<td class="nump">6,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure', window );">Contingent value rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod', window );">Contingent value rights, gain (loss) for change in fair value during period</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Shares, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Contingent Value Rights Payouts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475819024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities - Contingent Consideration - Business Combination (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember', window );">Innovus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount', window );">Business combination, contingent consideration, product related, milestone payable, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate', window );">Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469080816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities - Contingent Consideration - Other than Business Combination (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,359,000<span></span>
</td>
<td class="nump">$ 7,090,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember', window );">Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod', window );">Contingent consideration other than from business combination, liability, reversed in period</a></td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod', window );">Contingent consideration other than from business combination, gain (loss) for change in fair value during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember', window );">Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod', window );">Contingent consideration other than from business combination, liability, reversed in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod', window );">Contingent consideration other than from business combination, gain (loss) for change in fair value during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Other than from Business Combination, Liability, Reversed in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469557392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities - Contingent Consideration - Total (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod', window );">Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468162880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>D</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,563<span></span>
</td>
<td class="nump">$ 3,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease', window );">Maximum borrowing capacity, increase (decrease)</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2025<span></span>
</td>
<td class="text">May 11,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock', window );">Availability block</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023', window );">Termination fee before 26 January 2023 (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024', window );">Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024', window );">Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod', window );">Notice period | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense including amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Unused line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentGross', window );">Unamortized deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused capacity commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable', window );">Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Termination, Business Days, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Availability Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2023, but before 26 January 2024</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2024</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, before 26 January 2023</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_EclipseLoanAgreementSecuredRevolvingLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_EclipseLoanAgreementSecuredRevolvingLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468317312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Long-term, final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_DeerfieldFacilityMember', window );">Deerfield Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount of the remaining outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of the remaining outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember', window );">Avenue Capital Loan, Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread', window );">Debt instrument, minimum variable rate before basis spread (as a percent)</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate (as a percent)</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentInterestPaymentTerm', window );">Debt Instrument, Interest Payment Term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentInterestPaymentExtensionTerm', window );">Debt Instrument, Interest Payment Extension Term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_InterestOnlyPeriodFurtherExtensionTerm', window );">Interest Only Period Further Extension Term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentTermOfTrailingMonthsRevenue', window );">Debt Instrument, Term of Trailing Months Revenue</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument Prepayment Fee Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Loan Processing Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense including amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember', window );">Avenue Capital Loan, Term Loan | Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument Prepayment Fee Percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember', window );">Avenue Capital Loan, Term Loan | Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DebtInstrumentPrepaymentFeePercentage', window );">Debt Instrument Prepayment Fee Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentInterestPaymentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest payment extension term in a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentInterestPaymentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentInterestPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest payment term in a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentInterestPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Minimum Variable Rate before Basis Spread</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee percentage in a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentTermOfTrailingMonthsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of trailing months revenue in a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentTermOfTrailingMonthsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_InterestOnlyPeriodFurtherExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Further extension term of interest only period in a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_InterestOnlyPeriodFurtherExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_DeerfieldFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_DeerfieldFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_AvenueCapitalLoanTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470382192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Jun. 29, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">Mar.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475815680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Composition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, due on January 26, 2025</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Long-term, final payment fee</a></td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="num">(925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing leases, maturing through May 2024</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total debt</a></td>
<td class="nump">14,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">$ (96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Non-current portion of debt</a></td>
<td class="nump">$ 14,713<span></span>
</td>
<td class="nump">$ 14,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470387936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Future Principal Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne', window );">2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo', window );">2025</a></td>
<td class="nump">15,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LongTermDebtAndFinanceLeaseLiabilityGross', window );">Future principal payments</a></td>
<td class="nump">15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less unamortized discount and issuance costs</a></td>
<td class="num">(925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">$ (96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Non-current portion of debt</a></td>
<td class="nump">$ 14,713<span></span>
</td>
<td class="nump">$ 14,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LongTermDebtAndFinanceLeaseLiabilityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, and Finance Lease, Liability, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LongTermDebtAndFinanceLeaseLiabilityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, and Finance Lease, Liability, Maturity, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, and Finance Lease, Liability, Maturity, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469540624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure', window );">CVR liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position</a></td>
<td class="text">Derivative warrant liabilities<span></span>
</td>
<td class="text">Derivative warrant liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative warrant liabilities</a></td>
<td class="nump">$ 6,403<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,403<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure', window );">CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative warrant liabilities</a></td>
<td class="nump">6,403<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 6,403<span></span>
</td>
<td class="nump">$ 2,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Value Rights Liabilities, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475652672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in earnings</a></td>
<td class="num">$ (578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</a></td>
<td class="text">Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in earnings</a></td>
<td class="num">$ (391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</a></td>
<td class="text">Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Included in earnings</a></td>
<td class="num">$ (6,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income</a></td>
<td class="text">Gain on derivative warrant liability<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issues</a></td>
<td class="nump">$ 10,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 6,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=aytu_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473834928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>Y</div>
</th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>Y</div>
</th>
<th class="th">
<div>Aug. 09, 2022 </div>
<div>Y</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList', window );">Derivative Liability, Valuation Technique</a></td>
<td class="text">us-gaap:ValuationTechniqueOptionPricingModelMember<span></span>
</td>
<td class="text">us-gaap:ValuationTechniqueOptionPricingModelMember<span></span>
</td>
<td class="text">us-gaap:ValuationTechniqueOptionPricingModelMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputLeveragedBetaMember', window );">Measurement Input, Leveraged Beta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsMeasurementInput', window );">Contingent value rights, measurement input</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputMarketRiskPremiumMember', window );">Measurement Input, Market Risk Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsMeasurementInput', window );">Contingent value rights, measurement input</a></td>
<td class="nump">0.0635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.8342<span></span>
</td>
<td class="nump">0.8326<span></span>
</td>
<td class="nump">0.8989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.01<span></span>
</td>
<td class="nump">4.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsMeasurementInput', window );">Contingent value rights, measurement input</a></td>
<td class="nump">0.0547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0387<span></span>
</td>
<td class="nump">0.0309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsMeasurementInput', window );">Contingent value rights, measurement input</a></td>
<td class="nump">0.2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Measurement Input, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentValueRightsMeasurementInput', window );">Contingent value rights, measurement input</a></td>
<td class="nump">0.1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.0000<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentValueRightsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentValueRightsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates valuation technique for measuring derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputLeveragedBetaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputLeveragedBetaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputMarketRiskPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=aytu_MeasurementInputMarketRiskPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470299648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="nump">$ 10,420<span></span>
</td>
<td class="nump">$ 13,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets excluding goodwill</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed Payment Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Minimum | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMeasurementInput', window );">Fixed payment arrangements, measurement input</a></td>
<td class="nump">0.100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Maximum | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMeasurementInput', window );">Fixed payment arrangements, measurement input</a></td>
<td class="nump">0.154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475017696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470350912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Consolidated Balance Sheet (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAbstract', window );"><strong>Taxes Payable, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Assets, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475017696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Section 382 Limitation (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation', window );">Post-change NOL determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation</a></td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss', window );">Disallowed recognized built-in loss, carried forward as an operating loss</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475062896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Operating Loss Carry Forwards (Details) - Domestic Tax Authority - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 504.0<span></span>
</td>
<td class="nump">$ 503.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="nump">$ 172.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474320496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax Credit Carry Forwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034474126960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469545408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="num">$ (3,581)<span></span>
</td>
<td class="num">$ (23,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationContingentConsideration', window );">Contingent consideration</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount', window );">162(m) limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">3,641<span></span>
</td>
<td class="nump">12,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent', window );">Tax at statutory rate (as a percent)</a></td>
<td class="num">(22.30%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent', window );">State income taxes, net of federal benefit (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration', window );">Contingent consideration (as a percent)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.14%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent', window );">162(m) limitation (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as a percent)</a></td>
<td class="nump">22.68%<span></span>
</td>
<td class="nump">11.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="nump">0.72%<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax provision (benefit) (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.09%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Provision (Benefit), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent consideration, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, State Income Taxes, Net of Federal Benefit, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468558896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred Tax Assets, Net of Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 114,265<span></span>
</td>
<td class="nump">$ 114,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsAccruedRebates', window );">Accrued Rebates</a></td>
<td class="nump">6,994<span></span>
</td>
<td class="nump">5,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,250<span></span>
</td>
<td class="nump">2,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D credits</a></td>
<td class="nump">2,416<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsInterest', window );">Interest</a></td>
<td class="nump">4,188<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Warrant Derivatives</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures', window );">Section 174 Capitalization</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,332<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">137,778<span></span>
</td>
<td class="nump">132,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(136,400)<span></span>
</td>
<td class="num">(128,966)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(845)<span></span>
</td>
<td class="num">(2,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxLiabilitiesRightOfUseAsset', window );">ROU asset</a></td>
<td class="num">(483)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (1,378)<span></span>
</td>
<td class="num">(3,813)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (127)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsAccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsAccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Section 174 Capitalization, Research or Experimental Expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478433680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment', window );">Goodwill impairment, decrease in net deferred tax liabilities</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet', window );">Income tax benefit resulting from decreased net deferred tax liabilities</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Net, Decrease during Period, Goodwill Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Benefit, Decrease in Deferred Tax Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034589462656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract', window );"><strong>Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475662976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits - General Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 2,948<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473457792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,822<span></span>
</td>
<td class="nump">$ 3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase resulting from current period tax positions</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decrease resulting from current period tax positions</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,948<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479514352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity - Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478384496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity - Restricted Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">5,517,174<span></span>
</td>
<td class="nump">1,928,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">40,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475584896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity - Stock Offerings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,575<span></span>
</td>
<td class="nump">$ 11,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfMember', window );">Shelf Registration Statement, 2020 Shelf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ShelfRegistrationAmountAuthorized', window );">Shelf registration, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember', window );">Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AtmSalesAgreementAmountAuthorized', window );">At-the-market sales agreement, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses', window );">Underwriting discounts, commissions, and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfMember', window );">Shelf Registration Statement, 2021 Shelf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ShelfRegistrationAmountAuthorized', window );">Shelf registration, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ShelfRegistrationRemainingAmountAvailableForSale', window );">Shelf registration, remaining amount available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member', window );">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts', window );">Commission and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member', window );">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses', window );">Underwriting discounts, commissions, and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member', window );">Securities Purchase Agreement, 2023, Private Offering, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">1,743,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts', window );">Commission and other costs</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AtmSalesAgreementAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>At-the-market Sales Agreement, Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AtmSalesAgreementAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock and Warrants Issuance Costs, Commissions and Other Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuance Costs, Underwriting Discounts, Commissions, and Other Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock and Warrants, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShelfRegistrationAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized amount of common stock, preferred stock, debt securities, warrants, rights and units under the shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShelfRegistrationAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShelfRegistrationRemainingAmountAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Remaining Amount Available for Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShelfRegistrationRemainingAmountAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034467806032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity - Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jan. 26, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 07, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 11,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightOfferingPrice', window );">Class of warrant or right, offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">Jun.  08,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="nump">430,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">1.5899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock', window );">Class of warrant, term of expiration after closing price of common stock</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock', window );">Class of warrant or right, percentage of exercise price equaling common stock</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares)</a></td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda', window );">Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted earnings before interest, taxes, depreciation, and amortization</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expiration Term on Achievement of
Consolidated Trailing Twelve-Month Adjusted EBITDA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034467967792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - General Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 18, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 19, 2021</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Feb. 13, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">52,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested units outstanding (in shares)</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested units outstanding (in shares)</a></td>
<td class="nump">38,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember', window );">Aytu 2015 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan | Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan | Share-Based Payment Arrangement, Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan | Share-Based Payment Arrangement, Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember', window );">Neos 2015 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">287,155<span></span>
</td>
<td class="nump">87,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Neos2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Neos2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470283888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">49,212<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="num">(172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending balance (in shares)</a></td>
<td class="nump">52,762<span></span>
</td>
<td class="nump">3,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 209.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in dollars per share)</a></td>
<td class="nump">128.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">131.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 18.37<span></span>
</td>
<td class="nump">$ 209.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">9 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price exercisable (in dollars per share)</a></td>
<td class="nump">$ 225.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life in years exercisable</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473810256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Range of Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">52,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">9 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable | shares</a></td>
<td class="nump">3,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted average exercise price</a></td>
<td class="nump">$ 225.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember', window );">Exercise Price Range 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">49,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted average exercise price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">9 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">Exercise Price Range 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">3,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted average exercise price</a></td>
<td class="nump">$ 217.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">6 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable | shares</a></td>
<td class="nump">3,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted average exercise price</a></td>
<td class="nump">$ 225.74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">Exercise Price Range 2 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices</a></td>
<td class="nump">123.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">Exercise Price Range 2 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of exercise prices</a></td>
<td class="nump">$ 290.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473216784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock - General Information (Details) - Restricted Stock - Aytu 2015 Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested units outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,075<span></span>
</td>
<td class="nump">80,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034467804208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock - Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Aytu 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">80,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">6,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(42,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/Cancelled (in shares) | shares</a></td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">38,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 148.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">126.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">135.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 142.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(3,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">4,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">26.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468797632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock - Additional Information (Details) - Restricted Stock - Non-plan - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 17, 2022</div></th>
<th class="th"><div>Jun. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 27.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Management | Tranche Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_NonplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_NonplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=aytu_ShareBasedCompensationAwardTrancheNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477240448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Compensation Costs (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation costs, options</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Aytu 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs, excluding options</a></td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Non-plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs, excluding options</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition</a></td>
<td class="text">1 year 6 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized compensation costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs, excluding options</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_NonplanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_NonplanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470146016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 19, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,046<span></span>
</td>
<td class="nump">$ 5,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,965<span></span>
</td>
<td class="nump">$ 4,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber', window );">Accelerated unvested shares, former board members, number | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded', window );">Stipulation of compromise and settlement, board members, percentage of 2021 grants rescinded (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Accelerated Unvested Shares, Former Board Members, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Percentage of Grants Rescinded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473800592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Stock Issued (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member', window );">Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member', window );">Securities Purchase Agreement, 2023, Private Offering, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">1,743,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034466897680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - General Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 06, 2023</div></th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>D </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 25, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 07, 2022</div></th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  07,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 11,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member', window );">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays', window );">Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days) | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16', window );">Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days) | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne', window );">Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo', window );">Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares', window );">Class of warrant or right, exercise price adjustment, maximum shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice', window );">Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right, date from which warrants or rights exercisable</a></td>
<td class="text">Jun.  08,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="nump">430,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrant or right, number of securities called by each warrant or right (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">1.5899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights', window );">Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock', window );">Class of warrant, term of expiration after closing price of common stock</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock', window );">Class of warrant or right, percentage of exercise price equaling common stock</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member', window );">Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or right (in shares) | shares</a></td>
<td class="nump">2,173,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda', window );">Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted earnings before interest, taxes, depreciation, and amortization | $</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Equity Offering, Common Stock Price Lower than Warrant Exercise Price Prior to Anniversary Two of Stock Combination Event, Adjusted Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Maximum Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, 20 Consecutive Trading Day Period Preceding Trading Day 16, Lowest Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, Consecutive Trading Days Preceding Trading Day 16</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expiration Term on Achievement of
Consolidated Trailing Twelve-Month Adjusted EBITDA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469225168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Warrants Activity (Details) - Warrants to Purchase Common Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, number of warrants (in shares)</a></td>
<td class="nump">434,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Warrants issued (in shares)</a></td>
<td class="nump">6,028,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="num">(87,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightAdjusted', window );">Warrant adjusted (in shares)</a></td>
<td class="nump">181,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Warrants expired (in shares)</a></td>
<td class="num">(18,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, number of warrants (in shares)</a></td>
<td class="nump">6,538,052<span></span>
</td>
<td class="nump">434,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife', window );">Outstanding, weighted average remaining contractual life</a></td>
<td class="text">4 years 8 months 15 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife', window );">Warrants issued, weighted average remaining contractual life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife', window );">Warrants exercised, weighted average remaining contractual life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife', window );">Warrant adjusted, weighted average remaining contractual life</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 92.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice', window );">Warrants issued (in dollars per share)</a></td>
<td class="nump">1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted', window );">Warrant adjusted (in dollars per share)</a></td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired', window );">Warrants expired (in dollars per share)</a></td>
<td class="nump">2,011.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Outstanding, exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 92.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Adjusted, Weighted Average Remaining Contractual Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Adjusted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised, Weighted Average Remaining Contractual Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average period of remaining contractual life of warrants or rights, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average period of remaining contractual life of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469119904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>plan</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_NumberOfEmployeeBenefitPlan', window );">Number of employee benefit plan | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employee benefit plan contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan | First 3% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of employee's contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan | Next 4% and 5% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of employee's contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan | Next 4% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember', window );">Neos Plan | Next 5% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuPlanMember', window );">Aytu Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employee benefit plan contribution</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuPlanMember', window );">Aytu Plan | 6% Contribution By Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of employee's contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember', window );">Aytu Biopharma Employee Retirement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employee benefit plan contribution</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember', window );">Aytu Biopharma Employee Retirement Plan | First 3% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of employee's contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember', window );">Aytu Biopharma Employee Retirement Plan | Next 4% and 5% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of employee's contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember', window );">Aytu Biopharma Employee Retirement Plan | Next 4% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember', window );">Aytu Biopharma Employee Retirement Plan | Next 5% Contribution by Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of employees' salary with employer matching contribution</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Employee Benefit Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=aytu_NeosPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_FirstThreePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_FirstThreePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFourPercentAndFivePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFourPercentAndFivePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFourPercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFourPercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_NextFivePercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_NextFivePercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=aytu_AytuPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=aytu_AytuPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=aytu_SixPercentContributionByEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=aytu_SixPercentContributionByEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=aytu_AytuBiopharmaEmployeeRetirementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468357968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Fixed Payment Arrangements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,420<span></span>
</td>
<td class="nump">$ 13,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber', window );">Fixed payment arrangements, periodic payment obligations, number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount', window );">Fixed payment arrangements, monthly payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount', window );">Fixed payment arrangements, balloon payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid', window );">Fixed payment arrangements, balloon payment amount, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber', window );">Fixed payment arrangements, quarterly payment amount, payments, number | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmount', window );">Fixed payment arrangements, quarterly payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember', window );">Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum', window );">Fixed payment arrangements, monthly variable payment amount, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid', window );">Fixed payment arrangements, monthly variable payment amount, one-time payment, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangementsPaymentAmountPaid', window );">Fixed payment arrangements, payment amount, paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember', window );">Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FixedPaymentArrangements', window );">Fixed payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember', window );">Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances', window );">Issues, fixed payment arrangements</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsBalloonPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Balloon Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsBalloonPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Balloon Payment Amount, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPaymentAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Payment Amount, Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPaymentAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Periodic Payment Obligations, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Quarterly Payment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsQuarterlyPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034477638368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementTerm', window );">Supply and distribution agreement, term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales', window );">Supply and distribution agreement, royalty, percentage of net sales (as a percent)</a></td>
<td class="nump">23.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits', window );">Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item</a></td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit', window );">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount', window );">Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount</a></td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation', window );">Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount', window );">Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Royalty, Percentage of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SupplyAndDistributionAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supply and Distribution Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SupplyAndDistributionAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SupplyAndDistributionAgreementTrisPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034480980432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration Liability (Details) - Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod', window );">Contingent consideration other than from business combination, liability, reversed in period</a></td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod', window );">Contingent consideration other than from business combination, gain (loss) for change in fair value during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Other than from Business Combination, Liability, Reversed in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034475936880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Product Contingent Liability (Details) - Product Contingent Liability, Novalere, FlutiCare<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved', window );">Product contingent liability, additional payments, number, certain sales achieved | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved', window );">Product contingent liability, additional payments, amount, certain sales achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_ProductContingentLiabilityMilestonePayment', window );">Product contingent liability, milestone, payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Contingent Liability, Additional Payments, Amount, Certain Sales Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Contingent Liability, Additional Payments, Number, Certain Sales Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProductContingentLiabilityMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Contingent Liability, Milestone, Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProductContingentLiabilityMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=aytu_ProductContingentLiabilityNovalereFluticareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=aytu_ProductContingentLiabilityNovalereFluticareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469542768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Earn Out Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 12, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementsAr101Member', window );">Commercial Global License Agreements, AR101</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock', window );">License agreement, milestone, maximum earn-out, cash and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock', window );">License agreement, milestone payment paid, cash and common stock</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_StockIssuedDuringPeriodSharesMilestonePayments', window );">Issuance of common stock related to milestone payment (in shares)</a></td>
<td class="nump">109,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementMilestonePaymentPaidCash', window );">License agreement, milestone payment paid, cash</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member', window );">Commercial Global License Agreement, Denovo Biopharma LLC, AR101</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementAnnualMaintenanceFee', window );">License agreement, annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementLicenseOptionFee', window );">License agreement, license option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementEscalatingRoyaltiesMaximum', window );">License agreement, escalating royalties, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member', window );">Commercial Global License Agreement, Johns Hopkins University, AR101</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange', window );">License agreement, minimum annual royalties, low end of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange', window );">License agreement, minimum annual royalties, high end of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales', window );">License agreement, royalties, percentage of net product sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum', window );">License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementAnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Annual Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementAnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementEscalatingRoyaltiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Escalating Royalties, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementEscalatingRoyaltiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementLicenseOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, License Option Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementLicenseOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone, Maximum Earn-out, Cash and Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementMilestonePaymentPaidCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Paid, Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementMilestonePaymentPaidCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payment Paid, Cash and Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Minimum Annual Royalties, High End of Range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Minimum Annual Royalties, Low End of Range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalties, Achievement of Certain Regulatory and Commercial Milestones, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalties, Percentage of Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuedDuringPeriodSharesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuedDuringPeriodSharesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementsAr101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementsAr101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034470390128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease (Details) - Operating Lease Agreement<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AverageUndiscountedMinimumMonthlyRentPayments', window );">Average undiscounted minimum monthly rent payments</a></td>
<td class="nump">$ 15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AverageUndiscountedMinimumMonthlyRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average Undiscounted Minimum Monthly Rent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AverageUndiscountedMinimumMonthlyRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_OperatingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_OperatingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034469765296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Legal Matters (Details) - Sabby Litigation<br></strong></div></th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=aytu_SabbyLitigationMember', window );">Sabby Volatility Warrant Master Fund Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Litigation case, class of warrant or right, number of securities called by warrants or rights</a></td>
<td class="nump">312,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase shares (in shares)</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=aytu_SabbyLitigationMember', window );">Walleye Opportunities Master Fund Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Litigation case, class of warrant or right, number of securities called by warrants or rights</a></td>
<td class="nump">54,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued to purchase shares (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Case, Class of Warrant or Right, Number of Securities Called by Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=aytu_SabbyLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=aytu_SabbyLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_SabbyVolatilityWarrantMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_WalleyeOpportunitiesMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034473141920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember', window );">Licensing Agreement, Cedars-Sinai Medical Center, Healight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry', window );">License agreement, term, after the first bona fide commercial sale of such licensed product in a country</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementInitialLicenseFeePaid', window );">License agreement, initial license fee paid</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementPatentProsecutionFeesPaid', window );">License agreement, patent prosecution fees paid</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember', window );">Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum', window );">License agreement, up-front, non-refundable license fee paid, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember', window );">License Agreement, 2017, Shire LLC, New Drug Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum', window );">License agreement, up-front, non-refundable license fee paid, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementInitialLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementInitialLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementPatentProsecutionFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Patent Prosecution Fees Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementPatentProsecutionFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Term, after First Bona Fide Commercial Sale of Licensed Product in Country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front, Non-refundable License Fee Paid, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034478433680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - General Information (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034479315136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Impairment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">$ 5,705<span></span>
</td>
<td class="nump">$ 75,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrChargesAbstract', window );"><strong>Production Related Impairments or Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">64,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Asset Impairment Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionRelatedImpairmentsOrChargesAbstract', window );"><strong>Production Related Impairments or Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionRelatedImpairmentsOrChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionRelatedImpairmentsOrChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140034468445088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Select Financial Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 107,399<span></span>
</td>
<td class="nump">$ 96,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,065)<span></span>
</td>
<td class="num">(109,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,387<span></span>
</td>
<td class="nump">9,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="nump">7,824<span></span>
</td>
<td class="nump">75,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,046<span></span>
</td>
<td class="nump">5,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember', window );">Rx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">73,799<span></span>
</td>
<td class="nump">61,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,358)<span></span>
</td>
<td class="num">(92,441)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,271<span></span>
</td>
<td class="nump">7,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="nump">2,730<span></span>
</td>
<td class="nump">64,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">5,722<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember', window );">Consumer Health Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,600<span></span>
</td>
<td class="nump">35,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,707)<span></span>
</td>
<td class="num">(17,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aytu_AssetImpairmentAndWriteoffCharges', window );">Impairment and write-off expense</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">10,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AssetImpairmentAndWriteoffCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset impairment and write-off of assets recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AssetImpairmentAndWriteoffCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_RxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>aytu-20230630x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aytu="http://aytubio.com/20230630"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aytu-20230630.xsd" xlink:type="simple"/>
    <context id="As_Of_9_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_1cn0JRM84U6rdzEe3qxCig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-07</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_QByDhdR18kWOtQNXuaKWXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0Kak6DTDzkyr-6pUSkAZgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yekhljvbxU-rrnE2lH9ydw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O4CwaXSKW0-EnAiW9BgQ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_ThApNN5hSEC7yAWt4I3olg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_WlYHSncbxkyESoDclR_i5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_YRN694O3EEKsSKs55s-uVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_se_2_5-8wkmfy3FsWYR-eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_n6ygMXZYX06DicD4TeTCsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_q294pgLXSkiw4_mNpKB8fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_t8eRN6kS_EqT7DiyJIMG7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-19</instant>
        </period>
    </context>
    <context id="As_Of_2_13_2020_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_L2WFGiNHUUeTtcgD-Tt5cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-13</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_8cakf67lD06PgvsYxOk2qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_Hq8jU58mP0yXy0NLI2hCtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_19_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_5bokif2CVU27ubsvFSCIGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_c91ZRffRLEe9Xlg8BIIOcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_VVTadRrGBUuL-6oQmtuGQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_8_2_2021_To_8_2_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_6Su9NkIAvUOaA057CsgVYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7YsSuAEDpU6Jmd-xM6h7wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3m-PBbKuhE65KlFLmBEPew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_rz01dYXMbkqXZMuUYv3ppA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_M8QzGlI3w0ei7UlfZaBHGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_fx_an4UdW0Kqxay6f5AycA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_tWk3vNLTpUG0H2Wvl2eRBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_qA7uEawIfEG6yPQLwo5_4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_cOsjlAaax0iq1gy16Unhnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_3jn_JzaekUCCqwhh5fzJaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SIgXTNQCeUCoZSwIwFVNNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5WcZTEx5b0iBMqbaHODblw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eYzcqI0yOkiPlqcLPWgNGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_l1yBXDDsXkSmrgaCSj0xrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_lAg5efzSNE2sQ24FnyN9IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_FUWMCFz5JEWq94W9ci2zcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_eHsxoU6HEUOy3QGc61-17Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_-w-9won20kO7uoXOtbDR1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_0KUsBxJuTkW5bP-8Li0HvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">aytu:ShareBasedCompensationAwardTrancheEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_-jV0TussHES3Y8yd6y1Z7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_amdkmNT3rEWFjdSSoepO6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_S6HC2MMrH0iNwu4ujLgsNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_bgnuDzVZ90GHs01Kz4agwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_gPGJ0H3cakSZg1nXXAX0Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Neos2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_trxd6492bkmdu5cEs_LDOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_CQLYBsBbXECCphRQy0MWNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_us-gaap_NonUsMember_LkBwlL2700aENO-vthtouA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_ny4Ioj3TaUWAHDoTez-dHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_country_US_eQR9LbH5NkuCUdtmvO2k4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_7PrD9QVnpUeLAEO5GWzdCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_cXbnpjXPukexCAFy3_LFIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_Ei3dfZNp9kKN-0D3nbjFKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_zUCpOHor3EKdIXUHOlnNXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_country_US_rIjPJISGDEi3pzssDPn3HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_YxGJ1VVEdEyw5ny5-XgKFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_-wVTRKUC6ECEuGno8N9RJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_723PZapFN067HORqlV5P5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_ClJODWq5GkytcMX5yJ4VSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_vn_CdUbVbUCIdczuM-TVqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lW0IGwUkb02QvnOBc2Pj2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_opCVDrrQuEy8HCC-ycOUCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_jqeMvRIcF0KKaWLkShVnzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:PediatricPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_tW-XdTep1EiTmzvuYPs2Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_wY87TqPOnkW6ipA7FPw71Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_r6wyCx8FVUSn4nYPEIcZkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_9ibQ5VWhQku-IfGQmqL7sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QrBZlgHdA022QUl02C4sgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_9jIFl-JbSUSy2-E0dwOfCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_5MqaEaeetUGtGEYDAHXg8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_7mJbheQk9E-fPv17qgwvgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_CSjduuCOFUWc6w0vdHoF3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_kQajJzeLJkCdUTJlMSe9iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_bUb-E6CVMEW0AkWN12ZTNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:OfficeEquipmentFurnitureAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_qTHTkenh9EuSbsPXngyU5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_NGXHsoRLLUW-TllyXMODGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_y5gGC1vDBUWYv1EcPoN6Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MBlO3K9Y5E-CNimpZftBwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q2AFXDkUOEyEfmyAK7PljQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Svctda3Et0O2kTjOc-zi0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_Y4i8_JEJe0SvA0HJFtx-NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_gcPJdm_wtE65EZK74cL6oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:PrincipalOfficeDenverColoradoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_4QygS4Rlv0O5YI7SfAsGHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_8Yuqe19JIk2B29trNymR7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_db-vGfL3fUmxvIexRiVKVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_lv1AQVTl0keo4ZlP9CVIgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_NeosTherapeuticsIncMember_jE3g0rsLqEWv2jo6veaozw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NeosTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_ThMW95wZjkCdP_ru56uSmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_ZolpiMistMember_dJH0ndjeUEaT4pdit6AumQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_TussionexMember_zVcKQ1_g1UWXhUn0779uOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:TussionexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_CefaclorMember_mhqlF9Qs0UWCJpWeLPVIJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:CefaclorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AciphexMember_qGDcQ6lLy0ulHTbXHsPakA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AciphexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_17kGrCVmQEOjFdEV5C2_zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_DxeLmfrDLkiqMKsp5HRFVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_g8KZkdeDqk-U60JJxrNmOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_F_kE5Lxwtky7YSEDVzN1hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:AttentionDeficitHyperactivityDisorderPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_JXn5-Xzq2kiOE7uPypp10Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_fwYbk0T1rkuVqkxgYwDegA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_Sbisw7Ka2U-eJeK-plm2KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_96lPa_UH3EC_sxZ01SDNgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_kEPlwQ3Z5EajARrt_81BZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_pvg1LRUhb0W16a7tuQUDyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_i3pgtEL-p0az9jQE1IUGqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_KFT-owhYG0KTW-8HwcgXlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentValueRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_AfRtXHFQ9USFYETLv0hWfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">aytu:ContingentValueRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_4vybuWwiOkecBLkUHT6SMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_N8QRmflkVEK0aXHJHlg2eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:NonplanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UpGaGbRyLEqoaYVRkRx8cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_8_2023_eNIKHDa7GEyCxQqlAVN61w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2022_3F2Ccz3Wck6721wKJ-0A4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wTfWp6Qu5kuUcvqKqDdSvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Z12qpqcVkkK_jr6qZ_cGBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_IsVh2msT0EmhmcrW0JvYbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lzWJ_F-ZrUaSzSfq1TNUiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LRQAfaW_D0auL9YBkk-kXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_3CSXkEWhhkC8dtO67-wH2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_V5QFAOw8DUmhBp4aYi7M0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_psdJZSxrqEyjZhoFMF-3Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_OU6-ZAL7g068xkL0XGt6CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_uyAuyq8iF02T8ekDM7p7Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9VU0MObsYUWsSE7KNqA2LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BwVbhIEKsk-sG7dxwmlpBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lHN7htztVE6wijIYRnB1CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LU7VfbLrpkCDkceqmLfiUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7aP_mPOQnEm0PE5wFOYT_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_RUN5j4oRMUyMIuo84vuTaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentAndFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:SixPercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_x_PrG4pcs06d9XTkn5jk5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_iQ5ElZ-9mkCBPVrJJm9cng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFourPercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_hvi9wwMyG02M4YOpOzDNtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_sWQv2CL_9karqaYLUrXPDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:NextFivePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:FirstThreePercentContributionByEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_-JXzqrvuMU6CA_7Lj0xMKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_BL_kOTzSHEKA4ccnDQIqTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuBiopharmaEmployeeRetirementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7x7PFK5f0kiltq3YkU0RXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:NeosPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_WbJzKLlmzki6AlcwWXPsyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">aytu:AytuPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_1tT0xZNkt0etJpk7fTLLPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_M0-TXPTse0mGHnAuhWTPYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_bt9P46zN4Uul011WiS7arg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:DeerfieldFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gPuRFu8KH0SGqG1C9lGBcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MuRUdcU6WUG7NmDnhiTGRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dmuRzfJ_1EO6Agna7CZtLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_pYyR9VketkCher0rQtHN3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_DezRVWJ-AU2jRVzIgJxVKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dI9JDG4GZ0q2nb3uqscqxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_dyFD-8ah2kCovq17PPt-2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fubd0D8AXkeZ3HKcrke_bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MpUuzivE-kWKg5ULjMW2Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__8vHwioqrU-ElY0VqMElLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_G2AveL47mkeAW3hRAHiUWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">aytu:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TdsGYshoqUijifsxflxvYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U52ccDTbd0SLphyOs_tA1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_bb-F103xJEKObyLwN9P9hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_jJVCcTYbiUaIJ-QiKtx9tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_BMNvc2gmyU2xEU7d2Lo8uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_aUf6uQX8JkCRV6eBvCg8Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_25_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_Y2L8pKkibkq2ytqbielQJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-25</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_ik8BrUrWiUqfXRn4qxLh-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_I38l4DudfUG9B_ywzeXUNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_29_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_hHbd5LNmMkO0y394Oj5L5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_tKH_DOG2x0SbdakkNDfEwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2022_To_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_8BPUJ7pkK0qSQNua439-Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ZXAfman6vk2Sxgjn7SWz_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201613Member__qlcvv9uqkqtL2K0Bw_iFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q9trfMe7pUqct3050BPKPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_uaS8GvqRBE6WifGw2IAIyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j3RI5vFShkKJU2UzYtHHnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember__yHJIt2Q9UOXX-nN6ZJg3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_btNydZdRJUeurgcuPy8Ayw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_sbvAUga0FkCVwaanOZG6qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Z3wjagFy1kWhlKur4kTO9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember_GoexjV6gxkqMDtQcdeO1uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_m2S0-xKuZ06BhQoPKWEIIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_G4vMM4ms7UyTRxItSf21Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lWZtLtuZq0aBxZRyaXV8jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_M9qxYqENEUmjeBlE_Zjf2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_xlpXGmnCE0q9N4hnP11C0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_l930vcslY0aPIpci-ZFhFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AwSMEA2VYkySNlTWV-Mg5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_95MKJo-V6E6JsQfGaBmnxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_vnaTWWbZJUOh5Za0C4EoQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_30_2022_Hh0hfMIawkOJO2Wn8Wo4kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2023_ra_B9a0R50O4AefrE3gZZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2023-09-20</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SupplyAndDistributionAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SupplyAndDistributionAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_6_30_2020_uXBqmTqkjkG4C-vVf43Sxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_t8Ed9oXcc0ahpFotmKPoCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_28_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_biR4fT1tx0yl6OmCteqbJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-28</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2020_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfMember_g5mEjHtQiUyvG-DIxyhSLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_1u8MB_0WKUqOOhFJoTnpRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpirationOfSubleaseMember_qJVnAen4DEKJ5nCT7EWV2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:ExpirationOfSubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpansionDateMember_OStY-vIWGkihjBhiDOXvUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:ExpansionDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_PuGTLMkWzEGYXoqXlmsEWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_qxV92QOxs02EZ-8Z3YXlNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:ProductContingentLiabilityNovalereFluticareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:ProductContingentLiabilityNovalereFluticareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-02-28</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_srt_RangeAxis_srt_MinimumMember_0H_yp89jtUqG89f48FDrpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">aytu:ConsumerHealthPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:WalleyeOpportunitiesMasterFundLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">aytu:SabbyLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:SabbyVolatilityWarrantMasterFundLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_O8YhH2nEYUOb-JVw1s0Yfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-26</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2017_To_10_31_2017_us-gaap_TypeOfArrangementAxis_aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_1wb-z3AmGEG4sOa28Qj_VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LicenseAgreement2017ShireLlcNewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_TypeOfArrangementAxis_aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_eC9Z_MBaeUGsNuYWxQQb7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementsAr101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementsAr101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LicensingAgreementCedarsSinaiMedicalCenterHealightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-12</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_wh8-haFGq0ilyzEd2ep6MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_vUpSuynmCUCGZ3WZlbjUuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_86YG5A0Um0yo8qgGtK-dHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_45L0yjrLA06cm11dTTlAbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_WKARek3HGUePLpa2Lv1yQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_KrFIpmKuVEO1-6ai2hZCKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_7wtjA0AipUW_t_5VDehRxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="As_Of_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_psb5HJRJGUmm-pY27HkHJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_5qxxQfplJUCrdZsaKXc-bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Z0XzDKGO6UGmhcRPSeKd1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_12_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_jDvZD8q0Y0el44FFCfCVRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="As_Of_5_12_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_2wCCGQMMCUmH4iUajN7RIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-21</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_UOFSRPaFi0u7A5wpcioV4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductTechnologyRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ProductDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:EclipseLoanAgreementSecuredRevolvingLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_m0FsqjSjeUaa1vPcTxPTlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_kws3beaygUG87BjJP1LOuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">aytu:EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:AvenueCapitalLoanTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-26</startDate>
            <endDate>2022-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-JITEKUA0GmzvfgKWJObg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_G4Ig525OfkKi6bpvihM7ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_XqoLyaAyJkqUthh4KeWIOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_v1uEDB4Qe0ChX25O408Kdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputMarketRiskPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputLeveragedBetaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6RWMQBcVTkKXBXn5bPIjLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_vlDLGuQ7RU6fpglPTudPkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_z3pQQ5Ly3kepba66l3j4ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_j9upZ0K_wkaSqBsZ35fPUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputMarketRiskPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_32pYQVd-O0683kHB-OxqJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">aytu:MeasurementInputLeveragedBetaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">aytu:LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_umMfg0XoZ0-AYDOK8yZ-LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:InnovusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_4_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_6bo-99QlKEWBnykXi0Nj8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:RxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_LnhBuUfFUU2Q1TN_RRlvNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aytu:OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <unit id="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">
        <measure>aytu:item</measure>
    </unit>
    <unit id="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w">
        <measure>aytu:product</measure>
    </unit>
    <unit id="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw">
        <measure>aytu:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">
        <measure>aytu:segment</measure>
    </unit>
    <unit id="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ">
        <measure>aytu:D</measure>
    </unit>
    <unit id="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">
        <measure>aytu:payment</measure>
    </unit>
    <unit id="Unit_Standard_agreement_JfZ2PWRCJ0apFPM0xMjerg">
        <measure>aytu:agreement</measure>
    </unit>
    <unit id="Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg">
        <measure>aytu:plan</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_mrEuTDctZU6eyaOEDuRFiQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_2-s3_3j2KUSm_aQnUWHO0g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Hidden_rIBeRtWFvEGJfXJe_l62nQ">http://fasb.org/us-gaap/2023#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Hidden_BJqygzVGsUWKb9RG-yTu9g">http://fasb.org/us-gaap/2023#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw"
      id="Hidden_yQ9teocmrEaukVqlK0qQGA">http://aytubio.com/20230630#ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg"
      id="Hidden_ENsPMegNIk2YzYHeCFNu_Q">http://aytubio.com/20230630#ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ"
      id="Hidden_llgInfKn_U2zW9dlBCNJSA">http://fasb.org/us-gaap/2023#DerivativeGainLossOnDerivativeNet</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_FMHpnXdokUSkB93aoVfALQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_IYKQ6G4kC0q2f0Eo8FxG9w">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_l0zNFg108E-x9CeMtWe_cQ">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_uaGaFPSQFEWqA3PDf3QHEg">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_9O13ml59skCUuFb3DYly5g">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_703MTevAkUC44Zd3mOLqdQ_2_1">0001385818</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_RXGs4pIy6k-rOMRza_dEmQ_3_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_jOglyZgiXkS8Q-yZN_UixQ_4_1">false</dei:AmendmentFlag>
    <us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList
      contextRef="As_Of_8_9_2022_3F2Ccz3Wck6721wKJ-0A4Q"
      id="Hidden_lJyJinKATUWpgR-69fgRWA">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList>
    <us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList
      contextRef="As_Of_6_8_2023_eNIKHDa7GEyCxQqlAVN61w"
      id="Hidden_Gk_K9Y9VnUGpM3yHOr25gQ">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_lW0IGwUkb02QvnOBc2Pj2g"
      id="Hidden_3RYmrqdPpkulAM_puxB6GA">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_ClJODWq5GkytcMX5yJ4VSA"
      id="Hidden_uFqyeNkqnUqdeYZoziKJTg">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_723PZapFN067HORqlV5P5w"
      id="Hidden_tV4Cb9jIzEmzHK0NDzFEuA">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_tW-XdTep1EiTmzvuYPs2Tg"
      id="Hidden_yRGseizAxkmA67HfSaHhJA">http://aytubio.com/20230630#ConsumerHealthMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_vn_CdUbVbUCIdczuM-TVqA"
      id="Hidden_z6eyzX-6U0S2IpXwpmIt5w">http://aytubio.com/20230630#ConsumerHealthMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_LYG5MF9ZSUmaFm4UmaMR2g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_GVVL6pelS0SESYOcJDmIMg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Hidden_hVXynGx4zUyImHk6UmwuZQ">http://fasb.org/us-gaap/2023#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Hidden_BSDhkQqovkW5-zz8We4mCQ">http://fasb.org/us-gaap/2023#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w"
      decimals="INF"
      id="Hidden_G-ii9jXEiUerH3aNSGrgcw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_r6wyCx8FVUSn4nYPEIcZkw"
      id="Hidden_ZU0GSZmRRU6mHNeNM31yuQ">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QrBZlgHdA022QUl02C4sgg"
      id="Hidden_QQYcc8br-EqS2gjQlclZQg">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_9ibQ5VWhQku-IfGQmqL7sg"
      id="Hidden_BkyMcFO_ukqYjCCDP1gOew">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw"
      id="Hidden_6fUhpC-LoUCZ1c2RWfvzow">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <aytu:AccountsReceivableCreditTermsLowEndOfRange
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Hidden_b9ThaH63FEyijuGZHHcAxg">P40D</aytu:AccountsReceivableCreditTermsLowEndOfRange>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_wY87TqPOnkW6ipA7FPw71Q"
      id="Hidden_g-cbh5-g8Eq9t2stexXsqA">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_jqeMvRIcF0KKaWLkShVnzg"
      id="Hidden_K8_3hQR_I0yTd3PB8O7Q8Q">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ReportingUnitNameOfSegmentExtensibleList
      contextRef="As_Of_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_opCVDrrQuEy8HCC-ycOUCw"
      id="Hidden_3ehiKXD22k2GoV9XNE777Q">http://aytubio.com/20230630#RxMember</us-gaap:ReportingUnitNameOfSegmentExtensibleList>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw"
      id="Hidden_kMk3CteVXE-sj0ReN6tePA">http://fasb.org/us-gaap/2023#AssetImpairmentCharges</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_oCFrnX1cZEKlI0YfWFbvaQ">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_uO7hW3tJ10-9Y4OnbKB2gw">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_kiHw9kJlzEqfvdcIxL-40Q">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_unXTBH375Ue8ldFNegISKg">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_rmlxlXZlBUmyfb7kJxK3Ag">http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <aytu:SupplyAndDistributionAgreementTerm
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg"
      id="Hidden_jJl8Ok9bXUO0qTue9ytzzw">P20Y</aytu:SupplyAndDistributionAgreementTerm>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Hidden_Ed_wMja5SES4fIWHM8Ndsg">http://fasb.org/us-gaap/2023#AssetImpairmentCharges</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_Yi-wD1QAw027O6Gw0MqnzA">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Hidden_YynIzFLXAkeAX8AGtpTUAQ">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Hidden_iwcBQPje9UyI7pXQKxPUyQ">http://fasb.org/us-gaap/2023#ValuationTechniqueOptionPricingModelMember</us-gaap:DerivativeLiabilityValuationTechniqueExtensibleList>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q"
      id="Hidden_fR7I1KmwmUOKA79OdXpBSQ">2022-09-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_n6ygMXZYX06DicD4TeTCsg"
      decimals="INF"
      id="Hidden_Hl9WG5ycz0COuiafV-9j_g"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_rz01dYXMbkqXZMuUYv3ppA"
      decimals="4"
      id="Hidden_RhAn5e9yTkGo43QiNn8L3A"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_7YsSuAEDpU6Jmd-xM6h7wA"
      decimals="4"
      id="Hidden_76J9aX39Y0KMdQ7sa8ZTdA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3m-PBbKuhE65KlFLmBEPew"
      decimals="4"
      id="Hidden_ZQWV1d3orUOWhJfxpy8Wrw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_qA7uEawIfEG6yPQLwo5_4A"
      decimals="4"
      id="Hidden_Kew6LAzlW0Subej7uXg45g"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_cOsjlAaax0iq1gy16Unhnw"
      decimals="4"
      id="Hidden_atRctttF5kGizw3GS0D_sg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_M8QzGlI3w0ei7UlfZaBHGg"
      decimals="4"
      id="Hidden_UM8ORUgeAkeglLMdGPU3ZQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_fx_an4UdW0Kqxay6f5AycA"
      decimals="4"
      id="Hidden_fyBILllLnk6bWwcWwYApTw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_3jn_JzaekUCCqwhh5fzJaA"
      decimals="4"
      id="Hidden_Ez33FFSqI0uGMSU9NaITRQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_tWk3vNLTpUG0H2Wvl2eRBA"
      decimals="4"
      id="Hidden_ZiVqmCiNWEOf8STK7ZK6yw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_eYzcqI0yOkiPlqcLPWgNGg"
      decimals="4"
      id="Hidden_aDjYmXhr_0y36dQjawXmwQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SIgXTNQCeUCoZSwIwFVNNw"
      decimals="4"
      id="Hidden_Cdi3hkXdc0OpPArxBtSwhA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5WcZTEx5b0iBMqbaHODblw"
      decimals="4"
      id="Hidden_w_FAzbQnJkiomaZGu2gnqw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFourMember_eHsxoU6HEUOy3QGc61-17Q"
      decimals="4"
      id="Hidden_RQWy15Pb2k-QNuwGzup_XQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheFiveMember_-w-9won20kO7uoXOtbDR1w"
      decimals="4"
      id="Hidden_Pb5UtpvkmEGcCA2EitT1Fg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSixMember_l1yBXDDsXkSmrgaCSj0xrw"
      decimals="4"
      id="Hidden_NOkVRpcVoUuTSnoKpinAAQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheSevenMember_lAg5efzSNE2sQ24FnyN9IA"
      decimals="4"
      id="Hidden_pnnHcg3G30GLFzKZerZfyA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheEightMember_0KUsBxJuTkW5bP-8Li0HvA"
      decimals="4"
      id="Hidden_Zf0xvLUMsEy4X0ESjua5-w"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_us-gaap_VestingAxis_aytu_ShareBasedCompensationAwardTrancheNineMember_FUWMCFz5JEWq94W9ci2zcw"
      decimals="4"
      id="Hidden_SjR6CETviEC4J8qxQetREw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0833</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_6_2023_To_1_6_2023_hYeZUFMVr0egm4uUilaK2w"
      decimals="INF"
      id="Hidden_9EV35llWm0G5Ej7R_H5Kdw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_i1YPUiX8G0W0pDyUiLyo3Q"
      id="Hidden_u-AypRtbtUiKizPrtwHpzw">2022-09-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w"
      id="Hidden_JDyjzzB8SUiDT9RhDuHhaw">P5Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:DocumentType
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_ydSwSaK_l0CGsnK35sfYiw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_xz9_IZehKkWAbAbfM-SWTQ_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_F0D7lfQbBEKbXiNDfH3-Jg">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_uerQKjMF5kWskO-7t5g1Rg">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_pZ83pVOZrEGQtDJtiAH5ig">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_thWcF5m650uNbPRFJSOykA_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_kOV_pSMc6km0gZ5lAtaduQ">001-38247</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_9Rv2Yw5Yok2-DNcoF68sAg">AYTU BIOPHARMA,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_M5QOELngpEKNb3MQ1lkBqQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_SamGF8uPV0CsM4nla8u4cA_1_2">47-0883144</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_U66rSZNGNEuJWjDZyYeNMg">7900 East Union Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_JWzYxWuPdUeHgqKqQ-w_xA">Suite&#160;920</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_jBnhrLMSYU29RjpTiRsX9A">Denver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_2ewQ9oRrtkCKYdmdv2l6hw">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_Cus_K2-iUE2JzbcrxVJNNQ_1_2">80237</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_DwNQv4hypUOwn-Skhq5XNQ">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_h7n72GSvOUiqz35HYYGcWQ">437-6580</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_HE2FRogN4ECSq2YP1ReJkg_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:EntityListingParValuePerShare
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_8FAVmQ39Qkylj2JRVowEkA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</dei:EntityListingParValuePerShare>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_fRZEZy_pB0qf5Q_vXc-EEg_2_1">AYTU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_gWLiYz6hPE-GCjY4k_Hv2Q">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_0pVncOb2gUeNY6C1iJQYng">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_ENUspgn5fEKci7ikmDuogQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_GSHL-lDTLEGE6GJWVUk3Gw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_4d7y6gZcgkyvYGEzoeKdaw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_k6YzN7-XmUaVugMZfIr7Ow_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_enzPHWmqqk6PfTKekZJz8w_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_63k51YX0WkihSnILVdhvhw_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_k9BuwhWH2E6oN_B7IgOHow">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_u5Oei-wlkUqBgw2kquw4WQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_12_30_2022_Hh0hfMIawkOJO2Wn8Wo4kA"
      decimals="-5"
      id="Narr_DPYargVTMUqFcd7nvOFMXg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_9_20_2023_ra_B9a0R50O4AefrE3gZZw"
      decimals="INF"
      id="Narr_FGbhoC608Eu52Cc_3aJxAA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5530027</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorLocation
      contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"
      id="Narr_TY185D_aO0SKlSLF09sLFA">Denver, Colorado</dei:AuditorLocation>
    <dei:AuditorLocation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Narr_nlXP349EK0O7HCt66apVyA">Denver, Colorado</dei:AuditorLocation>
    <dei:AuditorLocation
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_pxKbRHW7Mk6OfOkrQQiNkA">Denver, Colorado</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_j9eCIITPCkmhazNWU4tJmg">Grant Thornton, LLP</dei:AuditorName>
    <dei:AuditorName
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_Ol-RsCTtQUWoKI81RCSOTg">Grant Thornton, LLP</dei:AuditorName>
    <dei:AuditorName
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Narr_Jf9baTOy50-KKuiIau7myg">Plante &amp; Moran, PLLC</dei:AuditorName>
    <dei:AuditorName
      contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"
      id="Narr_cmByUOAwbEO32GOkU0Eg1w">Plante &amp; Moran, PLLC</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_G0eqJ4_NGEqyFDuV1uOfJw">248</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_iOTpeBBSqkmPiSf_3i7lrg">248</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      id="Narr_lXT4WL3BU0eJTUwTtUnEuw">166</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"
      id="Narr_mNQei-bDb0WN4OhJ5XW_XA">166</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_jxaFgWU1mUy0lrTMqukEMA_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">22985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_5CeuEphqkk2kZSmKZjhX6A_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">19360000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_cGSHHvIuj0ecoTlf4TX9cQ_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">28937000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_vOKt5b4LSkGt1-hDCoP7Tg_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">21712000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Yhq3hP8gLUaPvGf-x18RaQ_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11995000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_TQJRHAs2CUi_gH3huFRktw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10849000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_u8bOVLmXR0ekGc7WlMYG3g_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8047000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_qbibpmKNzkagLcT9eIcLIg_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7375000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_ymLFc-QeQk-iOvQo3n_m7Q_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">868000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_gAV2EDUIz0i4sPQ9cFa0UQ_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">633000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_wUHKDf_-v0iTaUV2DqEdbg_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">72832000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_k---mgN-VUGsdg_dBho2rw_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">59929000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_4xUKXBUY3k62FW0S5haezw_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1815000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_oe2F7hiHWE23q_nO2Pxr9A_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3025000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_W7F2EPUp9Ue7Bgd3_1SBLA_12_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_3inkJHrtWEmsXlgZ-3rDQw_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3271000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_x3N2JMRFC0mHIQp6XDMo8w_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">58970000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_HIl7f2s1dEWlmuDWF6x4SA_13_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">70632000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_y9aoaBp3N0OcSyhCGeQ_XQ_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">792000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_BEXN3kzaGk2cvMV6sNDtog_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">766000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_JfH7z2ilME6YtcfQy9RRRw_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">63631000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_lMVBr_e0ukCcyPZzxtc9zQ_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">77694000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_lDFhVeezPUmlI5S67yXyCg_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">136463000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_83cf_mo_5UK0wCNQ6WnDPw_16_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">137623000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_eioZYdGLPUGLoXteGI1Aww_20_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">13478000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_MYoS-XAqrUGmNx0HIsMcgA_20_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10987000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_CRk1-vJFWUeN_Db0pXY0mA_21_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_WVxbq3_03kaybeo4_hV2Dw_21_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_lZwH1O52HkyDM4zYC11UPg_22_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1563000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_n7Gv8-VUEESAVp3OrkHO0g_22_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3813000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_rJqcoGyg30We6IU3Ppgmmg_23_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_jNTikVHIlk2SUFyzdmyTXA_23_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Rcf5b2uLc0eppA_xL7druQ_24_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7090000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_x5s5SCdBJ0yaTmAqxW3lhA_24_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5359000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Y_IppyT3VkKgvRZNsXDXQQ_25_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">69015000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_MeMPjRctA02ES2pQU5fLOQ_25_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">64442000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_3II5-YNWFE2bZBPOa6jxhg_27_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14713000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Ho44jxVPd0OeOWMTg3-g9Q_27_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14279000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_HHTboVsxGUKTpNPEtp-xZQ_28_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_aZKNVAp5A06bPyD63Lm--w_28_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_a7aivwG-vEuJFK0YebXkRg_29_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_gXWovIB7kUmt-ghiwU-BZg_29_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12798000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_DkGHxNAV_UqN9xwQzTn_0A_30_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">97106000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_bLU78J1xGUGh5n83ZJHF6g_30_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">93315000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_H3h-6bkjxU2j9W81_n1jcA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_mlpIGW7O6Uyj5TWoWwqzYQ"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_V6oRMiNRS0qBm8Y1r_khjw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_L70UI7W9gEuRky3i3TXsvw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_g78d1nWdukKRf3JMLtPuDw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_pe3kGEwXjkmOJHI75BRUkQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_Liq8un8UJke8D3CqwZWNNQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_bkjwuZzFuk-Mk2X7aICZuw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_uyds8Cb8L0yLZxSNlY8pqA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_RhqjUV4eRUWg-QNhrqvaow"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_iPYn2euFQESGKFW5m3ZQMw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_FH30OJCZtECSwC-7_bFDqQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_tENZx5gqHkKoRosVhccIWQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5517174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_kp33oo2NJ0ST4FhgtHh9rA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5517174</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_yoDeoU95U0-FNYlw-y4s5w"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_cIpesK9j1kGMUQrw1SuHEw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_vCRW8PUzrUGp-ZHx2ejtww_36_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_dGMINa_-gU2u5AeRdiDhzg_37_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">343485000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Q6d3IXjNzEazeQaT9zci-A_37_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">331386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_HFtuDWE7Wk6XbqBxfKw7cg_38_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-304129000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_NP8YNKEeTkSj1UTP7tW2kQ_38_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-287078000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_VsV60TDfF02AY5_w0dyuTg_39_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">39357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_r9zcFYMbEU2m34VWo9GWxQ_39_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44308000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_C1kzlMb6g0ib7-LnJ1GXNw_41_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">136463000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_m84IY9evtEaUhIcxEvQskw_41_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">137623000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_eCLDru7pjkeAnwWOfEbXXw_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_oitzDVCdLUqttoUrhWxmyw_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_LB7QZFr-ZkSx1pT0foJvSg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">40767000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_uavk07mi0EePiLREN2s2WQ_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44386000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_NCDQ4DnpJU-mUG5CQddZ4A_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">66632000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_ewmwibn-rkypmGfadbSMHg_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">52283000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_YSpuCr0DmkazqSzksjpnIQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">41448000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Cg1MQedr9EGoKQoKoctAsQ_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">38713000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_eoz5H9-GUk2zBgg8CnBhZg_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">28630000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_FjMGB_8C7kuFtXM8Pj9uMQ_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">31167000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_3xgM9FfhhUGytwT0eyJXgA_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_QWAbJyxYzEi68D2kUUcwVA_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12662000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_b0nmCqn7ek-mP6J2y4R1Xg_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">65802000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_OT28EWnZi0iOcrUhPBrXkg_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5705000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_DMVxlPYw3k2eOoR8_67f9A_13_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9656000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_fu8WIDXQzk2ygEQJpKT_fQ_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4788000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_zBNubYvT00qEZQ1ZK9I2iA_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5844000</us-gaap:AmortizationOfIntangibleAssets>
    <aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_imZc2JLo40OZDlNM3tixFg_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">969000</aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_W19JwYyo3kOsdzjn_1DIfA_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1655000</aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_a7SG-mRv-UaQwHfIG2syUA_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">83697000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_xxmpz0z_REiSxvZn4i7jFg_16_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">162189000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_8RJ9lFhPb0qxpp2F5lmfnQ_18_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_SB8E720G4UO0YU9jXC5TTg_18_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-109906000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_COgPa6FPk0SQWDo3SGF2Vw_21_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-4779000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_esw74XjBkEKYqn9eRQ5-zg_21_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-757000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_ZoZujx6F4Uab7VoVEd8EFA_22_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">169000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_mUwIMFqqq0mQJLg1J_fgOg_23_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4793000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_IdRyJOHY-EC1wPKuHbfPdw_23_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1605000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_AEGfvDDwqU-USrdkJHCcoQ_24_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_a3v6tt3MkUCXJlNOtd-ifA_24_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1017000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_OFAQ3-tTREC-1IgActXM8A_25_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17051000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_s6E5ZP-ixkKBctaTi5Wh4Q_25_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_UzHGzmO6-kiNGk7m9yU5Eg_26_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_jmqVALIWQEGUVVG4pt1VwA_27_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_tHzi2yFfF0ezGiAk2fSRKg_27_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="0"
      id="Tc_7ar8-RFP_kKgqtHw9Q9T4A_29_3"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3339906</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="0"
      id="Tc_7ar8-RFP_kKgqtHw9Q9T4A_29_3_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3339906</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="0"
      id="Tc_rjo6NH4I2kiwh6TbnG30xg_29_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1469875</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="0"
      id="Tc_rjo6NH4I2kiwh6TbnG30xg_29_6_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1469875</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_yzHKA9Cnz0qeyh3x52hrDg_31_3"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-5.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_yzHKA9Cnz0qeyh3x52hrDg_31_3_2"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-5.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="2"
      id="Tc_59LZ7I_jD0KdR22F3DKdtg_31_6"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-74.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="2"
      id="Tc_59LZ7I_jD0KdR22F3DKdtg_31_6_2"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-74.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ"
      decimals="INF"
      id="Tc_gQaAZGIiikeN4nI6dQI1GA_5_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA"
      decimals="-3"
      id="Tc_e-Lh3LYkpUSqJ1LTvbvSzw_5_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">331386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg"
      decimals="-3"
      id="Tc_tQKGj6lqK0Ov1T0bkOzd6Q_5_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-287078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_1xNXJy9wn0uiQqJ1Bgff_A_5_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44308000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw"
      decimals="INF"
      id="Tc_JnSs312g8k6PPQYqroYKaw_7_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">-18180</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw"
      decimals="-3"
      id="Tc_ytirZT7kq02ODb1OHHJqjg_7_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6046000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_notlcwGH-UibiRfTI5tA5g_7_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6046000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Narr_09TTy0nAY0axDo-Q4AoHDw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1004000</aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw"
      decimals="INF"
      id="Tc_51JL-qaQcE2L8nF4B2A8yQ_8_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3606413</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5xS4D-rEjE2tuL8NTCHZKw"
      decimals="-3"
      id="Tc_-VxUjEnIYE-6YGtIquq2_A_8_10"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wk5fDkh-UEi9f6XIoTrNRw"
      decimals="-3"
      id="Tc_ni3tm6Hw402p_fh2kgHb-w_8_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6053000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_8riVQxjfJEmrS8M4k4e1Fg_8_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6054000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Q2AFXDkUOEyEfmyAK7PljQ"
      decimals="-3"
      id="Tc_Az2JTgMOK0que8JNxT6l4g_9_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_etmgmNBh80OTokOXbf3lSw_9_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17051000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ"
      decimals="INF"
      id="Tc_Er9CQTIVM0-Ncb1R3iewnw_10_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5517174</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O5HeaVg8B0GWgP6y54V7JQ"
      decimals="-3"
      id="Tc_o9jyiV513UG3LoqQOPsjMg_10_10"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yekhljvbxU-rrnE2lH9ydw"
      decimals="-3"
      id="Tc_qACDcG4sjUSo8TUSAT-2aQ_10_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">343485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0Kak6DTDzkyr-6pUSkAZgA"
      decimals="-3"
      id="Tc_j4QYZ_Uy7EOcvXnDa0rSFA_10_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-304129000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_PELp_kvh2UCfg7-j6pHiQQ_10_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">39357000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U52ccDTbd0SLphyOs_tA1Q"
      decimals="INF"
      id="Tc_PsFqxn3odEiAJmxyycsVMQ_5_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1374521</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg"
      decimals="-3"
      id="Tc_eQLHIlKyh0OOu8wiDD7RXQ_5_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">315867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O4CwaXSKW0-EnAiW9BgQ0w"
      decimals="-3"
      id="Tc_jAz-jja0A0egsJ0uBZVtCA_5_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-178299000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_onXUGjUMNkifW4Dr0lDv_Q_5_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">137568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ"
      decimals="INF"
      id="Tc_QXCngTdc1U2TKhtpgyNOzg_7_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">20434</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow"
      decimals="-3"
      id="Tc_fgvp5gHK1k635YCX7GIlMQ_7_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5248000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_BYkkI89bW0iXSukrMu-gqg_7_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5248000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Narr_Up9c7MfqXECoEVPtx_P9rg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1048000</aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ"
      decimals="INF"
      id="Tc_5XN20idhr0aWijzbk74gXw_8_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">424539</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow"
      decimals="-3"
      id="Tc_gReb4xSNN0i58Ukrd92YEQ_8_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8854000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_qGDCoEli8ka0fGne-eyOuw_8_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8854000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <aytu:StockIssuedDuringPeriodSharesMilestonePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_e8AHm5MP5ku_exxhay9IxQ"
      decimals="INF"
      id="Tc_LqMGV3RGHkaIWUexYigEOg_9_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">109447</aytu:StockIssuedDuringPeriodSharesMilestonePayments>
    <aytu:StockIssuedDuringPeriodValueMilestonePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow"
      decimals="-3"
      id="Tc_54hu1ENw-EuyO3SvCiSCdg_9_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1425000</aytu:StockIssuedDuringPeriodValueMilestonePayments>
    <aytu:StockIssuedDuringPeriodValueMilestonePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Y8BIrMdyB0u52lCTNkw4fg_9_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1425000</aytu:StockIssuedDuringPeriodValueMilestonePayments>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_M3sH2gVU20KfEN3vhqh1ow"
      decimals="-3"
      id="Tc_xijFjmXeckmwZPuYvgLimg_10_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_mljM8fHAkEe0cKtajM8h_w_10_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Svctda3Et0O2kTjOc-zi0w"
      decimals="-3"
      id="Tc_stlmFUUk40u9Rj3z-Z2tdw_11_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_XR1FAWbgQUm1HyU7kIiGLQ_11_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hkqGUP8B4E-CT4_XnrE0VQ"
      decimals="INF"
      id="Tc_Ln9mCn6WJUC3R5ZSsir0pw_12_7"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eJoH8VoDEU6SP-L110i7JA"
      decimals="-3"
      id="Tc_w7-pErbdVkCA255sCjreDw_12_13"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">331386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4QAs8xUiMEKEzljNzcRRGg"
      decimals="-3"
      id="Tc_z03D_WPPzkyuysESyQcPCQ_12_16"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-287078000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_5B2X8XBkak66zg3W-XmENg_12_19"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44308000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_-WimGYmArUGz_fyVwH-UcQ_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17051000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_D2q3pVyvAECU2EYgzILghA_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_K5kVlVD5J0WVkJ_k50vRbA_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8815000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_jJUleTGrZ0CSqDpvwPQCkg_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10146000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_yGqfSX8AYUCzYse6gy9s_A_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5705000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_nGusxjVteUO2hBiwEuTVUw_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">75458000</us-gaap:AssetImpairmentCharges>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_92IsAzRr8kqehayaLlaQUw_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2351000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_P2uLWq2MNEGcpz_e-m913Q_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2186000</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_4SoO1cWpT0a2V6K_Do9tNA_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6046000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_gsmtU7xQCEy08Ot8hWO_4g_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5248000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_UwQ3H9XLC0q-N7KD30otwQ_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4793000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_-3go8rfxo0yKVblHB7qupA_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1605000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_WHsp9F9wnEqWCrTd4HJrPg_12_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">969000</aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_4uln7FHU10WA-bK0D_5EVA_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1655000</aytu:ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_uVrGKol3SEqHpiWUVpE0sw_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">559000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_mHBJjmyGX0uQoSWiIITzFg_13_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-126000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <aytu:IssuanceOfStockForMilestonePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_X2kzGBUnfEGWsS9B4RniNg_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1425000</aytu:IssuanceOfStockForMilestonePayments>
    <aytu:WriteOffOfDeferredDebtIssuanceCostNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_fXnD9XBkQ0WTcMCMQzp35w_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-193000</aytu:WriteOffOfDeferredDebtIssuanceCostNet>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_GZ3iRXJHH0KpdSmKfJW0_A_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_QeBqPq7KlUy0j_c_lpSJsQ_16_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-65000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_Kcj5zcSR9UKvrz4kETEN1g_18_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7153000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_IboMADXq8kqt5WSIg9yrbQ_18_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-6533000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_HjUYiqpq70617Wgj266Ncw_19_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3609000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_joLz-Gmwj0ukTJRSdyGRkA_19_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-1299000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_S34nscFr_US3esQqEkDUww_20_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">914000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_ZS5KK8JW_UKG60X_KiiLIw_20_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-2228000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_-Ej2-_xBT06IELL0K2GT4w_21_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2384000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_8iWl1OJFvU2cFtC6mb2prw_21_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-7681000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_LDw-15gqc0O2URwiYnwkZg_22_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3605000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_gKFU6VeGVUqlkz2hHpvIBg_22_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-13292000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_BdEPYkZByky0dphTIa7_zQ_23_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">111000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_0OBeAliXDUCcJOB_I1UybQ_23_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-50000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_DdV3GoQ5_USI0XTP27O4Zw_24_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-5129000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_54OKLD2nUk2UsFlB--0Qsg_24_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-28823000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ao3cVIsdPku0VYuEu0p_0w_26_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_BZV8xlpGoUG4npSnROJa9Q_26_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3178000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_a2NwHXAzgUe4rPR-5HRNdw_27_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">112000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_zPb0ULJlMk2vEjERmjkK5w_27_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">70000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_6deLNnjcXES96Q6VZVuMEQ_28_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-117000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_kSdnVeC-00yBCs0PTnJw9w_28_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-3248000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_2__pYzx3gUuGC_URL47ObQ_30_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_e7okxOJCmk61YW7-QgN18g_30_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11694000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <aytu:PaymentsForFixedPaymentArrangement
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_X4FfL5B-LkiVb_qt4xafuA_31_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4266000</aytu:PaymentsForFixedPaymentArrangement>
    <aytu:PaymentsForFixedPaymentArrangement
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_uucOUvwu3kCgCnMurDhYBA_31_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4409000</aytu:PaymentsForFixedPaymentArrangement>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_rqSAoUJLlEi08LvPaS7FuQ_32_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-2250000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_k5jTTyNLn0GWwFW6iAF6Nw_32_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-4121000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_R0EyVv7nuU6ZqSpEem_aVQ_33_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_s5VVi6E9A06LQCl62JWh-A_33_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16101000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_9yMaRL6Sq0mmUg75VLdxQw_34_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_0lj5N6HMd06nSwMjP9WALQ_35_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">92000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_3TPc5FchckePH4tHwkgyqg_35_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">526000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_VQ9YJe7SYEO-PS3BI_QYeg_36_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-7000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ro5SQrlJ5U-JjG6Bgl0UhA_37_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8871000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_AanWo5PGDkyNkAEL-p7SaA_37_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1530000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ELplbpDBQUG_pkenDQaSGg_38_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_mnXFaCT7TEu7qL80n4yAfQ_38_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-30541000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Cze1VIVGo0-VxQ3LK9VfzQ_39_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">19360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_jdg3AWVDe0GrQsSQIDfQCw_39_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">49901000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_jL3zu54rmkK9amfIPD8wTw_40_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">22985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_VmgmGEXwbUubomEyubpEyA_40_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">19360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_wXagSifDcke_qZY0VgbyEg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3812000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_jIxNHY7M8E21cfs0_CAt2w_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3148000</us-gaap:InterestPaidNet>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_2Yi5BOonAUOYr76oGgYj2Q_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">147000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_w1eC0yV_u0yemwQyDILYzw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">54000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_lLDed2bMo06Zoh4lRF_7vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Nature of Business and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Aytu BioPharma, Inc. (&#x201c;Aytu,&#x201d; or the &#x201c;Company&#x201d;), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the &#x201c;Consumer Health Portfolio&#x201d;). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (&#x201c;Neos&#x201d;) in March 2021, (the &#x201c;Neos Acquisition&#x201d;) the Company changed its name to Aytu BioPharma, Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every &lt;span style="-sec-ix-hidden:Hidden_G-ii9jXEiUerH3aNSGrgcw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty&lt;/span&gt;&lt;/span&gt; shares held (&#x201c;Reverse Stock Split&#x201d;). Where applicable, all share and per share amounts in this annual report have been adjusted to reflect the effect of the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Rx Segment primarily consists of two product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (&#x201c;ADHD&#x201d;) together the &#x201c;ADHD Portfolio&#x201d;, and the &#x201c;Pediatric Portfolio&#x201d; consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Consumer Health Portfolio consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, urological health and general wellness, commercialized through direct mail and e-commerce marketing channels.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s strategy is to continue building its portfolio of revenue-generating products, leveraging its commercial team&#x2019;s expertise to build leading brands within large therapeutic and consumer markets. As a result of focusing on building the portfolio of revenue-generating products, the Company has indefinitely suspended active development of its clinical development program AR101 (enzastaurin), and has terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, the Company had $23.0 million of cash and cash equivalents and $28.9 million in accounts receivable. The Company incurred a net loss of $17.1 million and $108.8 million during the years ended June 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $304.1 million and $287.1 million as of June 30, 2023 and 2022, respectively. Cash used in operations was $5.1 million and $28.8 million during the years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company has non-operating liabilities that are scheduled to, or may become current in the eighteen months following the filing of this 10-K, most notably the maturity of the $15 million Avenue Capital term note (the &#x201c;Avenue Note&#x201d;). The Company expects to refinance the Avenue Note in the event it does not have sufficient cash on hand to retire it. As a result, there exists substantial doubt about the Company&#x2019;s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on i) eliminating expenses for clinical development, ii) winding down or monetizing the Consumer Health Segment, which has generated negative cash flows since its acquisition in 2021, iii) refinancing its $15 million Avenue Note (see Note 11 &#x2013; Long-term Debt) to extend its maturity date, and, if necessary iv) raising additional capital through public or private equity, debt offerings, or monetizing additional assets in order to meet its obligations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_ulzzFY8eV0mnW7Td7VJe7g"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <aytu:NumberOfProductPortfolios
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="INF"
      id="Narr_2Zl-0z9GwUWkspqXg4qMvw"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">2</aytu:NumberOfProductPortfolios>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_IwYYokjKTUuOrt1g1CLJBg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">23000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_fBW9Jb33PEGz5XqVprXPQQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">28900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_g6rkUPg3vU6u5dJyRDi8oA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_fdXC_Zkd_EOrsCEBeSRLgw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108800000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_yiOFmokvyUG9MyyHvem9cA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-304100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_dQQk13dPgkWioGysunDmvA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-287100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_ZCLA537P9kOOwsFxvhiAGw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-5100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_HXTAgZ6vGk2WBAQYqIDPUA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-28800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ"
      decimals="-6"
      id="Narr_55m8hmaRO020GQ_6Zffq1Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_x73fgisUGkKpPN7Nbqsv3g">true</us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ"
      decimals="-6"
      id="Narr_24EbhjzYokGb_42x4OLNQQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_0JCBIz-QSUKv_SmxuW8OXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principals of Consolidation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company&#x2019;s consolidated financial statements include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company&#x2019;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;width:36pt;"&gt;&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/span&gt;&lt;i style="font-style:italic;white-space:pre-wrap;"&gt;.  &lt;/i&gt;The preparation of financial statements and footnotes requires the use of management estimates, judgments and assumptions. Actual results may differ from estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation; revenue recognition, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances; allowance for doubtful accounts; inventory impairment; determination of right-of-use assets and lease liabilities; valuation of financial instruments, derivative warrant liabilities, intangible assets, long-lived assets, and goodwill; purchase price allocations, and the depreciable lives of long-lived assets; accruals for contingent liabilities; and determination of the income tax provision, deferred taxes and valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Prior Period Reclassification&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Certain prior year amounts in the consolidated statements of operations and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of amortization of intellectual property, and a reclassification of fair value adjustment from contingent consideration. Amortization of intellectual property was previously included in research and development expenses and is currently recorded in amortization of intangible assets expenses on the consolidated statements of operations. Gain or loss from the fair value of contingent consideration was previously included in Other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the fiscal years ended June 30, 2023 and 2022 or its financial position as of June 30, 2023 or June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Previously Reported Financial Statements&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The classification of certain of the Company&#x2019;s warrants was previously recorded as equity. These warrants according to U.S. GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the audited financial statements as of June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;SEC Staff Accounting Bulletin No. 99, &#x201c;Materiality,&#x201d; and the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), Statement of Financial Accounting Concepts No. 2 &#x201c;Qualitative Characteristics of Accounting Information&#x201d; indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company&#x2019;s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance Sheet data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (288,472)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,078)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,784)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Twelve Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Operation data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Total other income, net &lt;/span&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,889)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (74.01)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Stockholders' Equity data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of common stock, net of issuance cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Cash Flow data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (211)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,605)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;Includes reclassification of gain or loss from the fair value of contingent consideration. See &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;"&gt;Prior Period Reclassification &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;in Note 2 &#x2013; Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Previously Reported Segment Information&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;During the year ended June 30, 2023, the Company identified an omission regarding the disclosure of certain key metrics of its reportable segments under ASC 280 related to the year ended June 30, 2022. During the year ended June 30, 2022, the Company inappropriately reported the net income of each of its two segments as opposed to operating income which more closely aligns with the adjusted EBITDA metric that is utilized by its chief operating decision maker. The impact on June 30, 2022 was that $92.4 million and $17.5 million of operating loss relating to the Rx Segment and Consumer Health segment, respectively, should have been reported as a separate line. The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99. The Company concluded that the omission was not material to any of the previously issued consolidated financial statements and began reporting operating results by segment in accordance with ASC 280 on a prospective basis starting with the year ended June 30, 2023&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company&#x2019;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to FDIC (the &#x201c;Federal Deposit Insurance Corporation&#x201d;) insurance limits, and cash balances in the money market funds are not FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable, net&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Accounts receivable represent amounts due from customers less allowances for doubtful accounts, discounts and pricing chargebacks. An allowance for doubtful accounts, when needed, is based upon the financial condition and payment history of customers; collections experience on other accounts; and economic factors or events expected to affect future collections. The allowance for doubtful accounts was zero for both years ended June 30, 2023 and 2022. The allowance for discounts was $1.8 million and $1.3 million for the years ended June 30, 2023 and 2022, respectively. The allowance for chargebacks was $1.2&lt;span style="white-space:pre-wrap;"&gt; million for both years ended June 30, 2023 and 2022.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below presents the opening and closing balances of receivables from customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts Receivable, gross&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,927&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Decrease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,106)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Chargeback&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Allowance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,592)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,597)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,548)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,145)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Going Concern Determination&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the financial statements are issued.&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;The evaluation is based on relevant conditions and events that are known and reasonably knowable within one year after the date that the financial statements are issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and equipment, net&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Property and equipment are recorded at cost less accumulated depreciation. &lt;span style="-sec-ix-hidden:Hidden_ZU0GSZmRRU6mHNeNM31yuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Furniture&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_QQYcc8br-EqS2gjQlclZQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;equipment&lt;/span&gt;&lt;/span&gt; are depreciated on a straight-line basis over their estimated useful lives which are generally &lt;span style="-sec-ix-hidden:Hidden_BkyMcFO_ukqYjCCDP1gOew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are amortized over the &lt;span style="-sec-ix-hidden:Hidden_6fUhpC-LoUCZ1c2RWfvzow;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shorter of the estimated useful life&lt;/span&gt;&lt;/span&gt; or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#x201c;ROU&#x201d;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#x2019;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#x2019;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in other liabilities in the Company&#x2019;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;. &lt;/b&gt;In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does not result in goodwill. Contingent consideration is accounted for Acquired in-process research and development with no alternative future use is charged to expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants. &lt;/span&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC 815,including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability classified warrants are valued using the Monte Carlo simulation model or the Black-Scholes option pricing model at issuance, and for each reporting period. Equity classified warrants are valued using the Black-Scholes model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company generates revenue from product sales through its prescription pharmaceutical products segment (&#x201c;Rx Segment&#x201d;) and its consumer healthcare products segment (&#x201c;Consumer Health &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Segment&#x201d;). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Rx Segment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#x201c;free-on-board&#x201d; destination when shipped domestically within the United States and &#x201c;free-on-board&#x201d; shipping point when shipped internationally consistent with the contractual terms. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rx product revenue is recognized net of consideration paid to the Company&#x2019;s customers and other adjustments to the transaction price (known as &#x201c;Gross to Net&#x201d; adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#x201c;Gross to Net&#x201d; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gross to Net adjustments include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Savings offers&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Prompt payment discounts&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Prompt payment discounts are based on standard provisions of wholesalers&#x2019; services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Wholesale distribution fees &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#x2019;s products by wholesalers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Rebates &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Wholesaler chargebacks&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#x2019; end customers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Returns&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Wholesalers&#x2019; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company&#x2019;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Consumer Health Segment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized &#x201c;free-on-board&#x201d; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Customer Contract Costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#x2019;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#x2019;s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company&#x2019;s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally &lt;span style="-sec-ix-hidden:Hidden_b9ThaH63FEyijuGZHHcAxg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;forty&lt;/span&gt;&lt;/span&gt; to sixty days. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents customers that contributed more than 10% of gross revenue and accounts receivable&lt;i style="font-style:italic;"&gt;: &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of gross revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of accounts receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Costs of Sales&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Costs of sales consists primarily of manufactured product cost, products acquired from third-party manufacturers, freight, production, and indirect manufacturing overhead costs and FDA fees for commercialized products. Certain of the Company&#x2019;s sales activities depend on licensing arrangements that may require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company's third-party logistics companies are included in costs of sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company accounts for share-based payments compensation expense using a fair value based model. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#x2019;s common stock and recognized ratably over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#x201c;simplified method,&#x201d; which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn&#x2019;t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;. Research and development costs are expensed as incurred and include salaries and benefits, facilities costs, overhead costs, raw materials, laboratory and clinical supplies, clinical trial costs, contract services, milestone payments and fees paid to regulatory authorities for review and approval of the Company&#x2019;s product candidates and other related costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-lived Assets and Goodwill&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company&#x2019;s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry forecasted financial performance indicate that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company&#x2019;s industry.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The consideration for our acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income&lt;span style="font-size:12pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising Costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Advertising costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $11.1 million and $13.6 million of advertising costs for the&#160;years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of  to be sustained upon an examination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Debt issuance costs, discounts (premiums)&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Debt issuance costs reflect fees paid to lenders and third parties directly related to issuing debt. Debt issuance costs and discounts (premiums) related to term loans are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense. Debt issuance costs related to a line of credit facility are classified as assets and subsequently amortized over the term of the line of credit as additional interest expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment information&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company&#x2019;s operating segments engage in business activities from which it may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#x2019;s chief operating decision maker, who is the Company&#x2019;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#x2019;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has two reportable segments: the Rx Segment and the Consumer Health Segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Paragraph IV litigation costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Legal costs incurred by the Company in the enforcement of the Company&#x2019;s intellectual property rights are charged to expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination and Contingent considerations&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For the years ended June 30, 2023 and 2022, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets-forth securities excluded from the calculation of diluted earnings per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,538,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 434,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,636,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reference Rate Reform.&lt;/span&gt; In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2020-04, &lt;i style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/i&gt;: &lt;i style="font-style:italic;"&gt;&#x201c;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&#x201d;&lt;/i&gt;, which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective July 1, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Earnings Per Share.&lt;/span&gt; In May 2021, the FASB issued ASU 2021-04,&lt;i style="font-style:italic;"&gt; &#x201c;Earnings Per Share (Topic260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#x201d;.&lt;/i&gt; The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Debt&#x2014;Debt with Conversion and Other Options.&lt;/span&gt; In August 2020, the FASB issued ASU No. 2020-06,&lt;i style="font-style:italic;"&gt; Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x2014; &#x201c;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (&#x201d;SEC&#x201d;), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have any material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial Instruments&#160;&lt;/span&gt;&#x2013;&lt;span style="font-style:italic;font-weight:bold;"&gt; Credit Losses.&lt;/span&gt; In June&#160;2016, the FASB issued &lt;i style="font-style:italic;"&gt;ASU 2016-13, &#x201c;Financial Instruments&#160;&#x2013; Credit Losses&#x201d;&lt;/i&gt; requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard is effective for smaller reporting companies for fiscal periods beginning after December&#160;15, 2022. In May 2019, the FASB issued ASU 2019-05, &#x201c;&lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/i&gt;&#x201d;, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, &#x201c;&lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures&lt;/i&gt;&#x201d; which eliminates the accounting guidance for troubled debt restructurings by creditors and adds disclosure requirements for current period gross write-offs by year of origination for financing receivables and net investments in leases. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal&#160;year ended June&#160;30, 2024. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:36pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Nw1ZCKszEE21VEVKnV8M3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Principals of Consolidation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company&#x2019;s consolidated financial statements include the accounts of: Aytu Therapeutics, LLC, Innovus Pharmaceuticals, Inc. and Neos Therapeutics, Inc. and their respective wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_2wE1xyoDF06MJrFa4vKsTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company&#x2019;s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_k0VNfs5H9EKjrFjorTZifw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Prior Period Reclassification&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Certain prior year amounts in the consolidated statements of operations and statements of cash flows have been reclassified to conform to the current year presentation, including a reclassification made in the presentation of amortization of intellectual property, and a reclassification of fair value adjustment from contingent consideration. Amortization of intellectual property was previously included in research and development expenses and is currently recorded in amortization of intangible assets expenses on the consolidated statements of operations. Gain or loss from the fair value of contingent consideration was previously included in Other expense, net, and is currently recorded in operating expenses on the consolidated statements of operations. These reclassifications did not impact operating results or cash flows for the fiscal years ended June 30, 2023 and 2022 or its financial position as of June 30, 2023 or June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Previously Reported Financial Statements&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The classification of certain of the Company&#x2019;s warrants was previously recorded as equity. These warrants according to U.S. GAAP should have been classified as derivative warrant liabilities at fair value and marked to market at each reporting period, with changes in fair value recorded in earnings. The affected filing periods include the audited financial statements as of June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;SEC Staff Accounting Bulletin No. 99, &#x201c;Materiality,&#x201d; and the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), Statement of Financial Accounting Concepts No. 2 &#x201c;Qualitative Characteristics of Accounting Information&#x201d; indicate that quantifying and aggregating adjustments is only the beginning of an analysis of materiality and that both quantitative and qualitative factors must be considered in determining whether individual adjustments are material. The Company evaluated the adjustments and determined that the impact was not material to the consolidated financial statements as of and for the fiscal year ended June 30, 2022. As a result, adjustments for the immaterial adjustments were applied to this period for comparative purposes. The adjustments did not change the Company&#x2019;s reported total assets, cash and cash equivalents, operating expenses, operating losses or cash flows from operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements as of and for the fiscal year ended June 30, 2022 have been adjusted as shown in the following tables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance Sheet data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (288,472)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,078)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,784)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Twelve Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Operation data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Total other income, net &lt;/span&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,889)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (74.01)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Stockholders' Equity data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of common stock, net of issuance cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Cash Flow data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (211)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,605)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;Includes reclassification of gain or loss from the fair value of contingent consideration. See &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;"&gt;Prior Period Reclassification &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;in Note 2 &#x2013; Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Previously Reported Segment Information&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;During the year ended June 30, 2023, the Company identified an omission regarding the disclosure of certain key metrics of its reportable segments under ASC 280 related to the year ended June 30, 2022. During the year ended June 30, 2022, the Company inappropriately reported the net income of each of its two segments as opposed to operating income which more closely aligns with the adjusted EBITDA metric that is utilized by its chief operating decision maker. The impact on June 30, 2022 was that $92.4 million and $17.5 million of operating loss relating to the Rx Segment and Consumer Health segment, respectively, should have been reported as a separate line. The Company assessed the materiality of this omission on the previously issued interim and annual consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99. The Company concluded that the omission was not material to any of the previously issued consolidated financial statements and began reporting operating results by segment in accordance with ASC 280 on a prospective basis starting with the year ended June 30, 2023&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_dr53aXMAz06VkwWQ9zlD2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance Sheet data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid-in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,174)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (288,472)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (287,078)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,784)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Twelve Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Previously&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Adjustment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Adjusted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:47.36%;background:#ffffff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Operation data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Total other income, net &lt;/span&gt;&lt;sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,889)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (74.01)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Stockholders' Equity data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of common stock, net of issuance cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statement of Cash Flow data&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gain on derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (211)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,394)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,605)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;Includes reclassification of gain or loss from the fair value of contingent consideration. See &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;"&gt;Prior Period Reclassification &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;in Note 2 &#x2013; Summary of Significant Accounting Policies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"
      decimals="-3"
      id="Tc_DfARo3xXl0W861xTHM6MeA_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_hRlDgZLtGUSpEwcrF8QoNg_6_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw"
      decimals="-3"
      id="Tc_iaAwqnU0aESfci90rsiM5A_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">91531000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"
      decimals="-3"
      id="Tc__wLpXilUr0-Wzq0K69-rIQ_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1784000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_NIDbJKYdTkGHlcV4GRLHaw_7_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">93315000</us-gaap:Liabilities>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw"
      decimals="-3"
      id="Tc_gPRDDlDYn0-LlHvsNNSZLg_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">334560000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"
      decimals="-3"
      id="Tc_FO8y68xFv0C3YpAm7zG9_w_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-3174000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_GxcbO7DJCE6NKsybkV200g_8_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">331386000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw"
      decimals="-3"
      id="Tc_auhIfS8Ah0udpJTUo_Z-ZQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-288472000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"
      decimals="-3"
      id="Tc_tNFVHpAkV0K8IYwz4EtFOg_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_4w0oUf8Hu06zPYrG981LJg_9_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-287078000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw"
      decimals="-3"
      id="Tc_EWL9yme1pk2IQ9orL6gZyQ_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_vXMdjH1eR0KUpQEesMAmNw"
      decimals="-3"
      id="Tc_dAMogO1Kp0KswgLPC4NUbg_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-1784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_NdWwp9CxrkGCbPrj6QHRng_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44308000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_UoAuahPxpkOvsboZiREMqA_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">211000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_QeoQ-oemkEWy0atiO5847A_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_mGUng9kUEEmXRBFt7gtsXw_7_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1605000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_4IbcAzG5Ik2kaZlZ5FBEXw_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1278000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_u_4HfJ1Jq0mR2gEinKmdkg_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-261000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_6KgV9pvEbU2gMSxH-D8Jvg_8_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1017000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_rSZu5MPy_ECI-wqzPDSQ2Q_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110283000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_OFBy14Dr2EWusoLFQ0oSnA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_-34Fd-zVrEuiDgj3dXgIqA_9_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_jGR3j_HBq0KRoLMrcVROiQ_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_o4EVWspbiE-iAyw-ZT96og_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_jK8xe9A3JkyYPrT7TFbrPQ_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="2"
      id="Tc_UBRBk4bsPEuDny4JQtxs7Q_11_3"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-75.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="2"
      id="Tc_UBRBk4bsPEuDny4JQtxs7Q_11_3_2"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-75.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="2"
      id="Tc_qXgVfDEOoE6_NTEAP_xekg_11_6"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="2"
      id="Tc_qXgVfDEOoE6_NTEAP_xekg_11_6_2"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="2"
      id="Tc_HaimNf7oIE2_5ClgsfRdgQ_11_9"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-74.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="2"
      id="Tc_HaimNf7oIE2_5ClgsfRdgQ_11_9_2"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">-74.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_ClPDFZjy9EmkpIQzG9Z7cQ_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11652000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_Y37fH9yE8UGTnZG_o6X91w_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-2798000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_KHmc3GC-l0yrtK8t7FAceQ_14_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8854000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_UsIemhWy3kan4qz4U2gUYA_17_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110173000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_wDmFvHFs0U-6XwTtYEjihQ_17_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc__nI2WhbllUSHVO8DBR7-Sw_17_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-108779000</us-gaap:ProfitLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ"
      decimals="-3"
      id="Tc_pMduOxIli0Sij-CW8unSMw_18_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">211000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_C_gJ1hiGUkGlYy-ApaoqdA"
      decimals="-3"
      id="Tc_32beKxjbGUKD4seuQq1MXA_18_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1394000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_pzGTwPQwyUulo8V5yWErFw_18_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1605000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="INF"
      id="Narr_3septTjjREmgQyfLAMnvLw"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_kQpeuspLFEKCUjXf9ZCcCw"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-5"
      id="Narr_Q2voKGjeC0KUx0nN6geGhA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-92400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-5"
      id="Narr_-Cq4_zkt106_OasFhbXL2g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_HA8hUeckg0SWpkRFwkO2Kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company&#x2019;s primary objectives for investment of available cash are the preservation of capital and the maintenance of liquidity. The Company invests its available cash balances in bank deposits and money market funds. The cash balances in bank deposits are subject to FDIC (the &#x201c;Federal Deposit Insurance Corporation&#x201d;) insurance limits, and cash balances in the money market funds are not FDIC insured. The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_MnQGfPN3ZEaGsou-N9hAwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounts Receivable, net&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Accounts receivable represent amounts due from customers less allowances for doubtful accounts, discounts and pricing chargebacks. An allowance for doubtful accounts, when needed, is based upon the financial condition and payment history of customers; collections experience on other accounts; and economic factors or events expected to affect future collections. The allowance for doubtful accounts was zero for both years ended June 30, 2023 and 2022. The allowance for discounts was $1.8 million and $1.3 million for the years ended June 30, 2023 and 2022, respectively. The allowance for chargebacks was $1.2&lt;span style="white-space:pre-wrap;"&gt; million for both years ended June 30, 2023 and 2022.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below presents the opening and closing balances of receivables from customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts Receivable, gross&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,927&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Decrease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,106)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below details the change in allowance for discount, and allowance for chargeback for the periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Chargeback&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Allowance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,592)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,597)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,548)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,145)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Narr_1qW2S5EPxU-BUjC4xEvrcQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Narr_HYNLeXTGBU6bWMA07q9lMA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_EZq5dIMX4EyEQ-mXFTGCtQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1800000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_LYrEvsNgBEaHrIVW4Fs1jw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1300000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_3IL-Ux3juEmgGPpeeEzAgg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1200000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr__aXIaaDFBkO4iUNWSYf3gA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1200000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_e1AZ1nmVMUSkZI88tipI9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts Receivable, gross&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,927&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Opening balance, June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing balance, June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Decrease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,106)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc__UtmmxJwGk6_yNjVi6hLLQ_3_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">24219000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_kU1gaj7pz0C4GIMI4Jj3jQ_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">31927000</us-gaap:AccountsReceivableGross>
    <aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_3dWAho8b_UOQpWijCywQVQ_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7708000</aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_-yKoPSaqBEOVAyk_WRYk0Q_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30325000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc__yiWFmYc2EG8EfGUfpBQyQ_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">24219000</us-gaap:AccountsReceivableGross>
    <aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Nx_Y1_jhZkK8YkzUkMXjdg_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-6106000</aytu:AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_SWBxAQBa_E-tQV2AOmroPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for Chargeback&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Allowance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:50.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,592)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,408)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,628&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,597)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,548)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,145)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_xXanAlCNmEi2Ot-U3CmNeA_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1133000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_7Zmky8xk0UOVX9qWTZQ4RA_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1016000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc__8TD4x9RI0ux6wOg8xvxrQ_4_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2149000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_5r_Yl-1TNUCngO5RzxtYPA_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6760000</aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_CpW30nOaS0aYk4uijOjEDA_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4598000</aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_lx-kuZPEYkK0ylzHaDSJNw_5_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11358000</us-gaap:ProvisionForDoubtfulAccounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_b5Ztrg0NuUakrKNI1qCI1Q_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6592000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_1-Y_Gi6nPEqcVz26pfmcVA_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4408000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_ic_G2farSU-ttlIps4cYoA_6_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_-WvzMp7hc0yqkjHFxhFP1g_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1301000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_sfokl32GbEiBFHskPXgGbA_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1206000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_IvcT1SP_oUyuPL4HiAyA2Q_7_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2507000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_dShS2KbwNU-7UJFIKRpWxQ_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9074000</aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal>
    <aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ePr_v-V1V0SjeBWywguWCQ_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4554000</aytu:AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_YkVngKnqqkuwth4p9YyuWg_8_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">13628000</us-gaap:ProvisionForDoubtfulAccounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_us2qu_F2EUydShITxcSedQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8597000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_aS3Ey4ZssEGepoLwy3D2AQ_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4548000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc__55LCZzrNE-jQPn5-vVeCA_9_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">13145000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_RqdayOcF70GxH4rwGGw_Ew_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1778000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts>
    <aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_pNXajGtlNkWOkGM_PLawIQ_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1212000</aytu:AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_iAD0u7P9zkqIu-c4e557OA_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2990000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_kcex6NCQJ0ajZapHjCW1sg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inventories&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Prior to regulatory approval, before economic benefit is probable, pre-launch inventories are expensed as research and development. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If evidence exists that the net realizable value of inventory is lower than its cost, the difference is recognized as a loss in the period the impairment is identified. &lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <aytu:GoingConcernPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_uPk3zQ9itECEI7nts0F_YQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Going Concern Determination&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; In connection with the preparation for each annual and interim financial reporting period, management evaluates whether there are events that, in the aggregate, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the financial statements are issued.&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;The evaluation is based on relevant conditions and events that are known and reasonably knowable within one year after the date that the financial statements are issued. Recurring operating losses or year over year negative cash flows from operating activities are considered negative trends.&lt;/p&gt;</aytu:GoingConcernPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_cOU7r61nCUiS5OBfYdLaGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and equipment, net&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Property and equipment are recorded at cost less accumulated depreciation. &lt;span style="-sec-ix-hidden:Hidden_ZU0GSZmRRU6mHNeNM31yuQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Furniture&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_QQYcc8br-EqS2gjQlclZQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;equipment&lt;/span&gt;&lt;/span&gt; are depreciated on a straight-line basis over their estimated useful lives which are generally &lt;span style="-sec-ix-hidden:Hidden_BkyMcFO_ukqYjCCDP1gOew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; to seven years. Leasehold improvements are amortized over the &lt;span style="-sec-ix-hidden:Hidden_6fUhpC-LoUCZ1c2RWfvzow;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shorter of the estimated useful life&lt;/span&gt;&lt;/span&gt; or remaining lease term. The Company begins depreciating assets when they are placed into service. Maintenance and repairs are expensed as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA"
      id="Narr_y69yBKt-akOWeNQFV5QWCA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_QAwfrtlvkk6Oq10ok9kQKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease. Lease classification, recognition and measurement are determined at the lease commencement date. Lease liabilities and right-of-use (&#x201c;ROU&#x201d;) assets are recorded based on the present value of lease payments over the expected lease term, including options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. In determining the present value of the lease payments, the Company uses the implicit interest rate when readily determinable and uses the Company&#x2019;s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Fixed lease payments, or in substance fixed, are recognized over the expected term of the lease using the effective interest method. Variable lease payments are expensed as incurred. Fixed and variable lease expenses on operating leases are recognized within cost of sales and operating expenses in the Company&#x2019;s consolidated statements of operations. ROU asset amortization and interest costs on financing leases are recorded within cost of sales and interest expense, respectively, in the Company&#x2019;s consolidated statements of operations. The Company has elected to account for payments on short-term leases as lease expense on a straight-line basis over lease terms of 12 months or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in other liabilities in the Company&#x2019;s consolidated balance sheets. Financing leases are included in property and equipment, net, current portion of long-term debt and long-term debt, net of current portion in the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income from subleasing is recognized on a straight-line basis over the sublease term, subject to collectability issues which will limit the income recognized to payment received until collectability is no longer an issue. Any variable payments are recognized as incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Group_ejEQd9vV30WVduYnfaNOhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquisitions&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;. &lt;/b&gt;In an acquisition of a business or a group of assets, the Company uses the acquisition method of accounting which identifies, recognizes, and measures the identifiable assets acquired, liabilities assumed and any non-controlling interest at their acquisition date fair values. Any excess of the purchase consideration over the fair values of the net identifiable assets acquired is recorded as goodwill. If the Company determines the assets acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets, which records the assets acquired at the purchase price and does not result in goodwill. Contingent consideration is accounted for Acquired in-process research and development with no alternative future use is charged to expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The consideration for our acquired businesses and licenses often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income&lt;span style="font-size:12pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Business Combination and Contingent considerations&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company recognizes the identifiable tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of purchase price over the aggregate fair values is recorded as goodwill. The Company calculates the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed to allocate the purchase price at the acquisition date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consideration for our acquisitions and certain licensing agreements often includes future payments that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Management estimates the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. The Company revalues its contingent consideration obligations each reporting period using Monte Carlo simulation. Changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <aytu:WarrantsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Yto7i2Hb2kilJdTEyKM9xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants. &lt;/span&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC480, and whether the warrants meet all of the requirements for equity classification under ASC 815,including whether the warrants are indexed to the Company&#x2019;s own common shares and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability classified warrants are valued using the Monte Carlo simulation model or the Black-Scholes option pricing model at issuance, and for each reporting period. Equity classified warrants are valued using the Black-Scholes model.&lt;/p&gt;</aytu:WarrantsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_6_KEa9LpOEikjv55QWzBIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company generates revenue from product sales through its prescription pharmaceutical products segment (&#x201c;Rx Segment&#x201d;) and its consumer healthcare products segment (&#x201c;Consumer Health &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Segment&#x201d;). The Company evaluates its contracts with customers to determine revenue recognition using the following five-step model: (1)&#160;identify the contract with the customer; (2)&#160;identify the performance obligations; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations; and (5)&#160;recognize revenue when (or as) a performance obligation is satisfied. There is not a recognized financing component related to product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Rx Segment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Net product sales for the Rx Segment (which includes the ADHD Portfolio and the Pediatric Portfolio) consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer in accordance with shipping terms (i.e., upon delivery), which is generally &#x201c;free-on-board&#x201d; destination when shipped domestically within the United States and &#x201c;free-on-board&#x201d; shipping point when shipped internationally consistent with the contractual terms. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rx product revenue is recognized net of consideration paid to the Company&#x2019;s customers and other adjustments to the transaction price (known as &#x201c;Gross to Net&#x201d; adjustments). Estimating adjustments to the transaction price and applying the constraint on variable consideration requires the use of significant management judgment and other market data. Gross to Net adjustments include provisions for product returns, wholesaler distribution fees and chargebacks for discounted pricing to participating entities, managed care rebate programs, savings programs for patients covered under commercial payor plans and other deductions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company makes estimates of the net sales price, including estimates of variable consideration to be incurred on the respective product sales (known as &#x201c;Gross to Net&#x201d; adjustments). Estimating gross to net adjustments and applying the constraint on variable consideration requires the use of significant management judgment and other market data. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gross to Net adjustments include:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Savings offers&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Company offers savings programs for its patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Prompt payment discounts&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Prompt payment discounts are based on standard provisions of wholesalers&#x2019; services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Wholesale distribution fees &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Wholesale distribution fees are based on definitive contractual agreements for the management of the Company&#x2019;s products by wholesalers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Rebates &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Rx Portfolio products are subject to commercial managed care and government (i.e. Medicaid) programs whereby discounts and rebates are provided to participating managed care organizations and federal and/or state governments. Calculations related to rebate accruals are estimated based on historical information from third-party providers. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Wholesaler chargebacks&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Rx Portfolio products are subject to certain programs with wholesalers whereby pricing on products is discounted below wholesaler list price to participating entities. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their acquisition cost and the discounted price back to the Company following the product purchases of the wholesalers&#x2019; end customers.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Returns&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Wholesalers&#x2019; contractual return rights are limited to defective product, product that was shipped in error, product ordered by customer in error, product returned due to overstock, product returned due to dating or product returned due to recall or other changes in regulatory guidelines. The return policy for expired product allows the wholesaler to return such product starting six months prior &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;to expiry date to twelve months post expiry date. The Company analyzes return data available from sales since inception date to determine a reliable return rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Savings offers, rebates and wholesaler chargebacks reflect the terms of underlying agreements, which may vary. Accordingly, actual amounts will depend on the mix of sales by product and contracting entity. Future returns may not follow historical trends. The Company&#x2019;s periodic adjustments of its estimates are subject to time delays between the initial product sale and ultimate reporting and settlement of deductions. The Company continually monitors these provisions and do not believe variances between actual and estimated amounts have been material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Consumer Health Segment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Consumer Health Segment revenue (consisting of the Consumer Health Portfolio) is from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized &#x201c;free-on-board&#x201d; shipping point, as those are the agreed-upon contractual terms. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from a customer are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of sales.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <aytu:CustomerContractCostsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_mCGBMhirFkCF9VMPrQbAWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Customer Contract Costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company expenses the incremental costs to obtain a contract as incurred, since they are satisfied within one&#160;year.&lt;/p&gt;</aytu:CustomerContractCostsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_JGGAzLzJZUaid3oOl7qefQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Financial instruments that potentially subject the Company to credit risk concentrations consist of cash, cash equivalents and accounts receivable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains deposits in financial institutions in excess of federally insured limits. The Company periodically monitors the credit quality of the financial institutions with which it invests and believes that the Company is not exposed to significant credit risk due to the financial position of those institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also subject to credit risk from accounts receivable related to product sales. The Company&#x2019;s customers, sometimes referred to as partners or customers, are primarily large wholesale distributors that resell the Company&#x2019;s products to retailers. The loss of one or more of these large customers could have a material adverse effect on the Company&#x2019;s business, operating results or financial condition. The Company does not charge interest or require collateral related to its accounts receivable. Credit terms are generally &lt;span style="-sec-ix-hidden:Hidden_b9ThaH63FEyijuGZHHcAxg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;forty&lt;/span&gt;&lt;/span&gt; to sixty days. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents customers that contributed more than 10% of gross revenue and accounts receivable&lt;i style="font-style:italic;"&gt;: &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of gross revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of accounts receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <aytu:AccountsReceivableCreditTermsHighEndOfRange
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_ZHq54zwB8kWWTYsdBnsx7Q">P60D</aytu:AccountsReceivableCreditTermsHighEndOfRange>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_0xJtTbrvqkq_rzaQeHatSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of gross revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage of accounts receivable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer C&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA"
      decimals="2"
      id="Tc_3sWZGJwLWkqe1X7WwsXfYQ_4_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember__8vHwioqrU-ElY0VqMElLA"
      decimals="2"
      id="Tc_ep6HrZtjm0uAnjAd9Q2QGQ_4_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_DezRVWJ-AU2jRVzIgJxVKw"
      decimals="2"
      id="Tc_3wPSisoblU2OC1TJGCI1Fg_4_8"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_G2AveL47mkeAW3hRAHiUWA"
      decimals="2"
      id="Tc_k2s3FPaviEKOwyiA5OV4nw_4_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dmuRzfJ_1EO6Agna7CZtLg"
      decimals="2"
      id="Tc_MENtZYpdTkqjuxDwTCYNSg_5_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_fubd0D8AXkeZ3HKcrke_bg"
      decimals="2"
      id="Tc_EYBfI9BRA028yEClvJQCPw_5_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_pYyR9VketkCher0rQtHN3g"
      decimals="2"
      id="Tc_S0cbeTJxMEazLVEVGBAT1A_5_8"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerBMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MpUuzivE-kWKg5ULjMW2Nw"
      decimals="2"
      id="Tc_b1K7IK46eUiG01KIJUALeQ_5_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gPuRFu8KH0SGqG1C9lGBcw"
      decimals="2"
      id="Tc_dE5upl6qzUeUNaH4HqO-mA_6_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_dI9JDG4GZ0q2nb3uqscqxQ"
      decimals="2"
      id="Tc_B8QjfBkhVkuxvbYOQ20yGA_6_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_MuRUdcU6WUG7NmDnhiTGRA"
      decimals="2"
      id="Tc_J8RKKHg-lU26CJJEtIGoFg_6_8"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_MajorCustomersAxis_aytu_CustomerCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_dyFD-8ah2kCovq17PPt-2A"
      decimals="2"
      id="Tc_-ucTuvZ_Vk-fVCxS0Ra34g_6_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_sPk512Dfb0Ce-CdYOBcibw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Costs of Sales&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Costs of sales consists primarily of manufactured product cost, products acquired from third-party manufacturers, freight, production, and indirect manufacturing overhead costs and FDA fees for commercialized products. Certain of the Company&#x2019;s sales activities depend on licensing arrangements that may require periodic milestone payments or royalty payments, which are also included in costs of sales. In addition, distribution, shipping and handling costs invoiced by the Company's third-party logistics companies are included in costs of sales.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_R9n6bWUBdU2EBtDFvNKAAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company accounts for share-based payments compensation expense using a fair value based model. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock and restricted stock unit grants are valued based on the estimated grant date fair value of the Company&#x2019;s common stock and recognized ratably over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock option grants are valued using the Black-Scholes option pricing model and compensation costs are recognized ratably over the period of service using the graded method. The Black-Scholes option pricing model requires the Company to estimate the expected term of the award, the expected volatility, the risk-free interest rate, and the expected dividends. The expected term is determined using the &#x201c;simplified method,&#x201d; which is the midpoint between the vesting date and the end of the contractual term. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company doesn&#x2019;t anticipate paying any dividends in the near future. Forfeitures are recognized as they occur. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_XmzERv2OjkeX7CaDGMtF8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;. Research and development costs are expensed as incurred and include salaries and benefits, facilities costs, overhead costs, raw materials, laboratory and clinical supplies, clinical trial costs, contract services, milestone payments and fees paid to regulatory authorities for review and approval of the Company&#x2019;s product candidates and other related costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_G7F2N8w470eHdMfbOMdeOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company records acquired intangible assets based on fair value on the date of acquisition. Finite-lived intangible assets are recorded at cost and amortized on a straight-line basis over the estimated lives of the assets. Indefinite-lived intangible assets are not subject to amortization.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_QeswFbOM-ESvFSlICrmk3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-lived Assets and Goodwill&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The Company assesses impairment of asset groups, including intangible assets, when events or changes in circumstances indicate that their carrying amount may not be recoverable. Long-lived assets consist of property and equipment, net, right of use assets and other intangible assets, net. Circumstances which could trigger a review include, but are not limited to: (i) changes in Company plans; (ii) competition; (iii) significant adverse changes in the business climate or legal or regulatory factors; (iv) or, expectations that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. If the estimated future undiscounted cash flows, excluding interest charges, from the use of an asset are less than its carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill is reviewed for impairment at least annually or whenever events or changes in circumstances, including a decline in the Company&#x2019;s stock price, indicate that its carrying amount is less than its fair value. If qualitative factors, such as general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry forecasted financial performance indicate that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount, the Company performs a quantitative analysis of fair value. The Company determines the fair value of a reporting unit utilizing a discounted cash flow model. Significant assumptions inherent in the valuation methodologies include, but are not limited to, prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in the Company&#x2019;s industry.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_rd4bfo9mDUi3S0_cvwJwJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Advertising Costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Advertising costs consist of the direct marketing activities related to the Consumer Health Segment. The Company expenses all advertising costs as incurred. The Company incurred $11.1 million and $13.6 million of advertising costs for the&#160;years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_Fp4s9ANJdE-vuuRRK_UB1Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_wRvmVzIMR0GZtAlsV7s-IQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">13600000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_RINByVsHTUGChkIL-PTLTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;balance sheet date. A valuation allowance is recorded to reduce the net deferred tax asset when it is more likely than not that some portion or all of its deferred tax asset will not be utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of  to be sustained upon an examination.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in Income tax (provision) benefit in the consolidated statements of operations.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_5a9l8N2auU6IRxWXfZ4BWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Debt issuance costs, discounts (premiums)&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Debt issuance costs reflect fees paid to lenders and third parties directly related to issuing debt. Debt issuance costs and discounts (premiums) related to term loans are reported as direct deductions (increases) to the outstanding debt and amortized over the term of the debt using the effective interest method as an addition (reduction) to interest expense. Debt issuance costs related to a line of credit facility are classified as assets and subsequently amortized over the term of the line of credit as additional interest expense.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_g0FAgyCZb0yXsX1Z7lt3bA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment information&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The Company&#x2019;s operating segments engage in business activities from which it may earn revenues and incur expenses and for which discrete information is available and regularly reviewed by the Company&#x2019;s chief operating decision maker, who is the Company&#x2019;s Chief Executive Officer, to make decisions about resources to be allocated to the segment and to assess performance. Operating segments are aggregated for reporting purposes when the operating segments are identified as similar in accordance with the basic principles and aggregation criteria in the accounting standards. The Company&#x2019;s reporting segments are based on product lines, which have different lines of management responsibility and marketing strategies. The Company has two reportable segments: the Rx Segment and the Consumer Health Segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="INF"
      id="Narr_xIF_EQ0eOE2W6x1gzd0hGg"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_jUAOnzudo0ehxTwRBUVlKQ"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_vxtNcY32uUmOQ8O4cUsiYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Paragraph IV litigation costs&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Legal costs incurred by the Company in the enforcement of the Company&#x2019;s intellectual property rights are charged to expense.&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_XgmMMSIPAEyNeBG1kRCbYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt; Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. For the years ended June 30, 2023 and 2022, the Company incurred a net loss and did not include common equivalent shares in the computation of diluted net loss per share because the effect would have been anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets-forth securities excluded from the calculation of diluted earnings per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,538,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 434,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,636,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_K9tBrhzgYkuZLYim_7aOCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,538,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 434,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;(Note 15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,636,773&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532,104&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember__yHJIt2Q9UOXX-nN6ZJg3A"
      decimals="0"
      id="Tc_8i4nbpdYAESIwQ5OkFLRiw_3_4"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6538052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aytu_WarrantsToPurchaseCommonStockMember_GoexjV6gxkqMDtQcdeO1uQ"
      decimals="0"
      id="Tc_bs08VeY2yUmh-NX8H25XoA_3_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">434328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_j3RI5vFShkKJU2UzYtHHnQ"
      decimals="0"
      id="Tc_pQ9-mMserUmOJELtVZNS8Q_4_4"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">52762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Z3wjagFy1kWhlKur4kTO9w"
      decimals="0"
      id="Tc_HU40fJVoBUiomcyxffnSMA_4_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_uaS8GvqRBE6WifGw2IAIyQ"
      decimals="0"
      id="Tc_qZKw3_S6hkCjUPzixrntwQ_5_4"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">40996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_sbvAUga0FkCVwaanOZG6qA"
      decimals="0"
      id="Tc_hHGtrfL4g02vZGc5FFCxgQ_5_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">85377</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Q9trfMe7pUqct3050BPKPA"
      decimals="0"
      id="Tc_G2Usblda7kK3mDSFAZf9kg_6_4"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">4963</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_btNydZdRJUeurgcuPy8Ayw"
      decimals="0"
      id="Tc_wwl_dSaFAUutYBtC500yyw_6_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">8500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="0"
      id="Tc_Q1Yw_vVifEurZt8Xm14hxA_7_4"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6636773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="0"
      id="Tc_DT6DzbGiRUe43IhtNXmrHw_7_6"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">532104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_q7p9Omqxj0uIZjaTTjCn5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reference Rate Reform.&lt;/span&gt; In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (&#x201c;ASU&#x201d;) 2020-04, &lt;i style="font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/i&gt;: &lt;i style="font-style:italic;"&gt;&#x201c;Facilitation of the Effects of Reference Rate Reform on Financial Reporting&#x201d;&lt;/i&gt;, which provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued if contract modifications are made on or before December 31, 2022. The Company adopted the guidance effective July 1, 2022 for the accounting of its LIBOR indexed revolving loans by prospectively applying the interest rate. The Company elected not to reassess the discount rate of its leases. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Earnings Per Share.&lt;/span&gt; In May 2021, the FASB issued ASU 2021-04,&lt;i style="font-style:italic;"&gt; &#x201c;Earnings Per Share (Topic260), Debt &#x2013; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&#x201d;.&lt;/i&gt; The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2021-04 and related updates did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Debt&#x2014;Debt with Conversion and Other Options.&lt;/span&gt; In August 2020, the FASB issued ASU No. 2020-06,&lt;i style="font-style:italic;"&gt; Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x2014; &#x201c;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing major separation models currently required. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. The amendments in this update are effective for public entities that are smaller reporting companies, as defined by the Securities and Exchange Commission (&#x201d;SEC&#x201d;), for the fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted through a modified retrospective or full retrospective method. The Company will adopt the guidance on July 1, 2024 and does not expect the adoption of the standard to have any material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial Instruments&#160;&lt;/span&gt;&#x2013;&lt;span style="font-style:italic;font-weight:bold;"&gt; Credit Losses.&lt;/span&gt; In June&#160;2016, the FASB issued &lt;i style="font-style:italic;"&gt;ASU 2016-13, &#x201c;Financial Instruments&#160;&#x2013; Credit Losses&#x201d;&lt;/i&gt; requiring the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide additional information about the expected credit losses on financial instruments and other commitments to extend credit. The standard is effective for smaller reporting companies for fiscal periods beginning after December&#160;15, 2022. In May 2019, the FASB issued ASU 2019-05, &#x201c;&lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/i&gt;&#x201d;, to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;upon adoption of the new credit losses standard. The effective dates and transition for ASU 2019-05 aligns with those of ASU 2016-13. In March 2022, the FASB issued ASU 2022-02, &#x201c;&lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (topic 326) Troubled Debt Restructurings and Vintage Disclosures&lt;/i&gt;&#x201d; which eliminates the accounting guidance for troubled debt restructurings by creditors and adds disclosure requirements for current period gross write-offs by year of origination for financing receivables and net investments in leases. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal&#160;year ended June&#160;30, 2024. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg"
      id="Narr_TEfoD2s_xUyVNRDyUlWsew">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_ZXAfman6vk2Sxgjn7SWz_g"
      id="Narr_BoBl-vV5Jk-jP9arZV8O2A">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201613Member__qlcvv9uqkqtL2K0Bw_iFw"
      id="Narr_NTK1Kv_lXEG58vhq9WBfpg">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_zbb6jCGUKEm5-gf4VfxJIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Revenues from Contracts with Customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company disaggregates its revenue into two segments, the Rx Segment and the Consumer Health Segment. The Rx Segment includes the ADHD Portfolio, comprised of Adzenys XR-ODT and Cotempla XR-ODT; and the Pediatric Portfolio, comprised of Poly-Vi-Flor, Tri-Vi-Flor, and Karbinal ER. The Consumer Health portfolio is comprised of over ten consumer health products competing in large healthcare categories.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Revenues by Segment&lt;/i&gt;: Net revenue disaggregated by segment for the years ended June 30, 2023 and 2022 were as follows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rx Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consumer Health Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,548&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Consolidated revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Revenues by Product Portfolio&lt;/i&gt;: Net revenue disaggregated by significant product portfolios in the Rx Segment for the years ended June 30, 2023 and 2022 were as follows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Rx Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_g-cbh5-g8Eq9t2stexXsqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ADHD &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K8_3hQR_I0yTd3PB8O7Q8Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Pediatric&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3ehiKXD22k2GoV9XNE777Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Revenues by Geographic location. &lt;/i&gt;The following table reflects product revenues by geographic location as determined by the billing address of the Company&#x2019;s customers:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;International&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,063&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total net revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_qhAVrN6m4EOy2xekF-E5hA"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <aytu:NumberOfProducts
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_srt_RangeAxis_srt_MinimumMember_0H_yp89jtUqG89f48FDrpg"
      decimals="INF"
      id="Narr_FXJGhPwr5UaRwDgBK6MrAg"
      unitRef="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w">10</aytu:NumberOfProducts>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_dXUWpVwtzUy1ED8k1-GtcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rx Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consumer Health Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,548&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Consolidated revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_4DOAZ_3bv0amAZTxfHD03A_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_8FXXj2QZ_kSex6KrDHAfDQ_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">61121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_ZJFfZAB_5UKkNH8S40VM2g_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">33600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_ncagX6gZHE2W79vSMm3K7g_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">35548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_yW-Qq9Jmt0igTDVY72ntHw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_HhJXDSi_gE-cxpfZjG_RkQ_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_CYCucMC-2EWWkuIQGk-DLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Rx Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_g-cbh5-g8Eq9t2stexXsqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ADHD &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_K8_3hQR_I0yTd3PB8O7Q8Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Pediatric&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_3ehiKXD22k2GoV9XNE777Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_cXbnpjXPukexCAFy3_LFIA"
      decimals="-3"
      id="Tc_90GX6lWEhEC9pVn7a0iRRQ_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_-wVTRKUC6ECEuGno8N9RJw"
      decimals="-3"
      id="Tc_8zhtwt3oakOodQ9bbGHBmA_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">42855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_7PrD9QVnpUeLAEO5GWzdCQ"
      decimals="-3"
      id="Tc_uzdCbs0HnUK3rn4a-WS8iA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">25377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_PediatricPortfolioMember_YxGJ1VVEdEyw5ny5-XgKFw"
      decimals="-3"
      id="Tc_XRBHABSlwkS22g61QwGw4w_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_ny4Ioj3TaUWAHDoTez-dHg"
      decimals="-3"
      id="Tc_MzpU8574t06cY0HGakMinw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_us-gaap_ManufacturedProductOtherMember_zUCpOHor3EKdIXUHOlnNXA"
      decimals="-3"
      id="Tc_wmtxjlkvQEmsoB0xfZPusQ_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2182000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_Jw6pJXl6zkmi6gHapozHdw_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_JNkGY-QvvEuLcJCEPeBikQ_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">61121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_9HrBp8MjGk-BwBTF-B0jrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 106,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;International&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,063&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total net revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_country_US_eQR9LbH5NkuCUdtmvO2k4Q"
      decimals="-3"
      id="Tc_TrRzpCK170OrxgFIvxstkA_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">106918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_country_US_rIjPJISGDEi3pzssDPn3HA"
      decimals="-3"
      id="Tc_IrFrNGCAo0GOA5vriQZduw_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">94606000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_us-gaap_NonUsMember_LkBwlL2700aENO-vthtouA"
      decimals="-3"
      id="Tc_ueDMjNafXkOwr1LrW32ZRA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_StatementGeographicalAxis_us-gaap_NonUsMember_Ei3dfZNp9kKN-0D3nbjFKQ"
      decimals="-3"
      id="Tc_XzZfiqrM70qhU1MzYeJWcQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2063000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_g9MGZZjslUySnhtjWHgSrQ_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_HENg5CJtAkCr6gPk9FH1pg_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_nO66R__FHkO6NX-l828IMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:23.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,849&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred charges of $2.4 million and $4.2 million to reduce the carrying value of inventory to net realizable value during the years ended June 30, 2023 and 2022, respectively, primarily as a result of unsalable and slow-moving products. &lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_EiBmaBMYN02w7kzSK7n5Xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:23.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,849&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_BLuN2TlVp0quw-FiPjxtjA_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1301000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_2og4V6tS2kShfLBNz_cjTA_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1814000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_SsFqyCOFoka_j3ev4xyifA_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2956000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_NU8maN4BDkOrivAVqK364A_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1838000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_1YwjZGrk9kOjqGn_nf0Rkw_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7738000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_vMO6CtNdm0-W6wnZbbEduA_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7197000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_vnKXT5VpnUegicphLDxaqA_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11995000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Dd0nRXGiGkui4t2waJ91TQ_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10849000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_9Kx_gOp80UWH3jrhvwIMQQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2400000</us-gaap:InventoryWriteDown>
    <aytu:InventoryWriteDownAndImpairment
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_T1Zq0VDKiUuHLZ9bYIdoJg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4200000</aytu:InventoryWriteDownAndImpairment>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_qrGQDah-a06IpVQgRxe6jA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment, furniture and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets under construction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,681)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,421)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense was $1.3 million and $1.6 million for the&#160;years ended June 30, 2023 and 2022, respectively. During the year ended June 30, 2022, the Company recognized a gain of $0.1 million on the disposal of equipment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the year ended June 30, 2022, in connection with the decision to divest Tussionex, the Company recorded a $0.2 million &lt;span style="-sec-ix-hidden:Hidden_kMk3CteVXE-sj0ReN6tePA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;impairment&lt;/span&gt;&lt;/span&gt; charge related to manufacturing equipment associated with this product. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_75VIdKH3REylWC1YYnJsFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment, furniture and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets under construction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,446&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,681)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,421)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_7mJbheQk9E-fPv17qgwvgw"
      decimals="-3"
      id="Tc_Dy5tGLi_t06jn-E66TgrTQ_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2433000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_qTHTkenh9EuSbsPXngyU5w"
      decimals="-3"
      id="Tc_9lx2hJOuWkiZCO8TZ77Xow_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2487000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_ow-g9-556E6RqG6yxLCcLw"
      decimals="-3"
      id="Tc_EAn2hHYqLEumK7V3KbrKRg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">999000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_kQajJzeLJkCdUTJlMSe9iQ"
      decimals="-3"
      id="Tc_9KWp4d9Wgkyp42eyXZn_HQ_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">999000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_5MqaEaeetUGtGEYDAHXg8g"
      decimals="-3"
      id="Tc_3o0K8uVqG0i8yUhk9I_eNA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1125000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_OfficeEquipmentFurnitureAndOtherMember_bUb-E6CVMEW0AkWN12ZTNQ"
      decimals="-3"
      id="Tc_rh47EP2NR0Gbju7crN0zYg_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1128000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_CSjduuCOFUWc6w0vdHoF3g"
      decimals="-3"
      id="Tc_3YrVUD7ZbEWCiig37MNi0A_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">832000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_LabEquipmentMember_NGXHsoRLLUW-TllyXMODGA"
      decimals="-3"
      id="Tc_28N9PI1eOkq-JpttKi2Kjw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">832000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_9jIFl-JbSUSy2-E0dwOfCQ"
      decimals="-3"
      id="Tc_AyyopxAY7EyEnpU2xTLB1A_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">107000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_e1FENN_96EKkFm6wtwimfQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5496000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_lNJCc5kGGEyAaocgJc499Q_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5446000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_xERXY8INZEGcixIwFy4qKA_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3681000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_DqruiKiXikqeOOROeEhbfw_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2421000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_G0lOu_jdVUm9GY5DPlnz4w_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1815000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_aDYlPh2s0kSAkUQhlp23Hw_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3025000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_pvfFCp60h0iXraz0t0TSVA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_EdKZegyPlkyLJqy-0yC6rw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1600000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_4vmo9yJmsUCf4EE7Q6AIOg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw"
      decimals="-5"
      id="Narr_NzeNAbxgU0KxKojnwXrZoQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <aytu:LeaseDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_b9APaADJL06Fa4YQP7oD0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s operating leases are for its offices, manufacturing facilities and equipment, and its finance leases are for equipment. These leases have original lease periods expiring between 2022 and 2027. Most leases include &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;option provisions under which the parties may extend the lease term. Certain non-real estate leases also include options to purchase the leased property. The Company&#x2019;s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Neos Acquisition, Aytu assumed an operating lease ROU asset and lease liability of $3.5 million, which represented the present value of the remaining lease payments as of the acquisition date, for the office space and manufacturing facilities at Grand Prairie, Texas. As the lease agreement does not provide an implicit rate, a borrowing rate of 6.7% was used to determine the present value of future lease payments. The finance leases are related to equipment finance leases with fixed contract terms and an implicit interest rate of approximately 5.9%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2023, the Company entered into an agreement with a manufacturing company to sublease 22,909 square feet of the Company&#x2019;s manufacturing facility in Grand Prairie, Texas (the &#x201c;Sublease Agreement&#x201d;). The sublease commenced in May 2023 and will terminate on December 31, 2024. The Sublease Agreement provides the sublessee an option to expand the subleased property to include the remaining 54,203 square feet of the Company&#x2019;s manufacturing facility. The expansion date may commence as early as April 1, 2024 but no later than December 31, 2024 (the &#x201c;Expansion Date&#x201d;). Under the terms of the Sublease Agreement, the sublessee will pay base rent of approximately $20,500 per month through the Expansion Date. Beginning on the Expansion Date, base rent will be $70,686 per month through the expiration of the sublease. In addition to the base rent, the sublessee will pay the Company certain operating expenses incurred by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the fiscal year ended June 30, 2023, in addition to the sublease mentioned above, the Company entered into an operating lease agreement to relocate its principal office (See Note 18 &#x2013; Commitments and Contingencies). During the fiscal year ended June 30, 2022, the Company commenced a five-year operating lease and recorded an ROU of $0.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease expenses are as follows;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement of Operations Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="9" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization of leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other (expense), net&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total net lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="9" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oCFrnX1cZEKlI0YfWFbvaQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_uO7hW3tJ10-9Y4OnbKB2gw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kiHw9kJlzEqfvdcIxL-40Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_unXTBH375Ue8ldFNegISKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rmlxlXZlBUmyfb7kJxK3Ag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Remaining lease terms and discount rates used are as follows;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-Average Remaining Lease Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-Average Discount Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information related to leases is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash flow classification of lease payments:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, the maturities of the Company&#x2019;s future minimum lease payments were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</aytu:LeaseDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA"
      decimals="-5"
      id="Narr_Uz2BvkIxHUiCW8Xxm8dFTQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA"
      decimals="-5"
      id="Narr_WckY8X4nZ0yQIAA8QILgOA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA"
      decimals="3"
      id="Narr_0IjcUi3KdU-9tB6508Onsw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.067</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="As_Of_3_19_2021_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_JjTuDpl19kaOU7iNgXTXDA"
      decimals="3"
      id="Narr_JmhrR4Ha0kq3BNt7qwJkPQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.059</us-gaap:LesseeFinanceLeaseDiscountRate>
    <aytu:AreaOfSubleaseProperty
      contextRef="As_Of_4_30_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_LnhBuUfFUU2Q1TN_RRlvNw"
      decimals="INF"
      id="Narr_mn-lJefBG0Gizls-WIwrJw"
      unitRef="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A">22909</aytu:AreaOfSubleaseProperty>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Narr_HdkvYzf7dEikeSaxOiXIyQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <aytu:RemainingAreaOfSubleaseProperty
      contextRef="As_Of_5_31_2023_srt_CounterpartyNameAxis_aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember_PuGTLMkWzEGYXoqXlmsEWA"
      decimals="INF"
      id="Narr_R_hfThftwU6lvQIPdlu0Gg"
      unitRef="Unit_Standard_sqft_Yuz7nwo9HEGsuuBZpxmP4A">54203</aytu:RemainingAreaOfSubleaseProperty>
    <aytu:RentReceivableFromSubleaseProperty
      contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpansionDateMember_OStY-vIWGkihjBhiDOXvUQ"
      decimals="0"
      id="Narr_VSZhLaYvskqO29Utrp5ZUA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">20500</aytu:RentReceivableFromSubleaseProperty>
    <aytu:RentReceivableFromSubleaseProperty
      contextRef="As_Of_6_30_2023_srt_StatementScenarioAxis_aytu_ExpirationOfSubleaseMember_qJVnAen4DEKJ5nCT7EWV2g"
      decimals="0"
      id="Narr_1PoCG1Um3Em7wwBwxBzexA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">70686</aytu:RentReceivableFromSubleaseProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg"
      id="Narr_wivHl2P1lUaCWG0R1iFqDw">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_srt_CounterpartyNameAxis_aytu_PrincipalOfficeDenverColoradoMember_NSzc66kl1kSH-WJ1eS6bQg"
      decimals="-5"
      id="Narr_zpDRuwxyPESgw5idCr7btg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_cBRSLFix3UGQUyDf5cAjVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement of Operations Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="9" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease cost:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,299&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Short-term lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Amortization of leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:27.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other (expense), net&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:49.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total net lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_9XyDOetEt0uXHOEvvGpzww_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1402000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_rg6ByUAPzEidh2GCzOKAIQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1299000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_S6PwGJL40USStDsznbT9_A_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">97000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_uU2InoX3B0iii87S-uEDQg_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">152000</us-gaap:ShortTermLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_JmhuFS6pYUaF9p1kHKvMKQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">66000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_qSjZVWywF021hViCYIbjFw_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">73000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_0z_E29ZFR0-UUvJqjA8WYQ_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_B34z6o6GyEG9Sj9JY8SqKQ_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ig-VAd067kagRvlqUZEnpA_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1574000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_oxHJ4WEG40y7gbmUEChXhA_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1538000</us-gaap:LeaseCost>
    <aytu:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_2RIBQxO6bEu-0EFils-cMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="9" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_oCFrnX1cZEKlI0YfWFbvaQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total leased assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,227&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_uO7hW3tJ10-9Y4OnbKB2gw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kiHw9kJlzEqfvdcIxL-40Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current portion of debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 832&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_unXTBH375Ue8ldFNegISKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:30.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rmlxlXZlBUmyfb7kJxK3Ag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:45.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:30.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_gWfMT6nNJk6wB-1vlkAoeA_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_92w77hdz-EykL3RAbJ2yyg_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3271000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_oPVc18wEwkGz7b-Mr1SOag_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">159000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_u3b_qmj0eUyFOBYgehE4Tw_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">256000</us-gaap:FinanceLeaseRightOfUseAsset>
    <aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_yLIwYIxvJEqI6jQU26s6Rw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2213000</aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset>
    <aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_X_D9XzalNEWun4ka--CIzw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3527000</aytu:OperatingLeaseAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_DhKTZxpdeUGlsmFUshwUeA_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1258000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Xq2FeY931EumhHF3xYzQ6Q_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1227000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_zReWlrKuNEW4snuH6KtUgw_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_6mEXers4b0iHgxCRf4gvuQ_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Y9oqriihw0ifT87xtJlzkQ_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">832000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_FBSsXKpoMkKE6BBZF5D-2g_13_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2090000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_YGey-S9tvk2DwlrbmpWsdQ_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">84000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <aytu:OperatingLeaseAndFinanceLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc__6-m1H1ZtEOJIYZVHzjQ-A_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2175000</aytu:OperatingLeaseAndFinanceLeaseLiability>
    <aytu:OperatingLeaseAndFinanceLeaseLiability
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_ElbxzpB590WDw5J3_ZJisw_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3497000</aytu:OperatingLeaseAndFinanceLeaseLiability>
    <aytu:RemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_6AR3TaJNhk6ICvNyb5ZAHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-Average Remaining Lease Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-Average Discount Rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:67.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Finance lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:RemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Tc_2DIFE68cek6OIrB3MH1OQg_4_3">P1Y8M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Tc_1HsvhlR4G0qTxcnZPeqMxw_4_6">P2Y7M17D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      id="Tc_Zc-jgYDUD0Sczl9YFxztIA_5_3">P0Y10M13D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      id="Tc_LiVbjKaPRk-ux7_txiPYPw_5_6">P1Y8M23D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="4"
      id="Tc_ah5P6RORyUqb-1dJidQ8zw_7_3"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0778</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="4"
      id="Tc_PWoYZl_RCkWNcHQMSHltvA_7_6"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0748</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="4"
      id="Tc_NfzTAC7BTEy63L4Cs5Ur0g_8_3"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0654</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="4"
      id="Tc_IrFZMSuuzEOMzHZ-4cVrgA_8_6"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0643</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <aytu:LesseeLeasesCashFlowInformationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_t3utrfuUTkOEPPkzIP3ETw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash flow classification of lease payments:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,016&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows - finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:LesseeLeasesCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_N-lp9_MTKkuSRjm13LwbsA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1436000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_3HXfh3cmnUSGCfm2fOzDxA_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1016000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_hTfiUPeITkOyKSIPvFyK7Q_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_RjXd3eVhWEKmb18WNj0UeQ_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_sq42lPqjCEaCHba-NsEMAg_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_C8V7FYeC-Uub0gMB2X_MAw_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">102000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_CTIwg1Yipk2Y3guACLPUFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_4tfBFwMukUeexMdsfiup5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:70.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_yrZ-jVr1m0W8DeIblIbl2A_3_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_7bT3YxxR806RJ08tR-3iSQ_3_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">88000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_yS8N-9zYw0uyhtu6n1iY7Q_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_EUJM-lNeEEig-CYiC6NWFg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_hDk-sglwrECzS7cYIG_-Yg_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_KwSyrkoaxk6ZSDjm64xrsQ_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2263000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_U2DXgsLn5kaEaGu0bQAafA_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">88000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_aJKu84akFkym2GS-_pJ4rQ_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">173000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_tHXeZ8C2akaxSBLYgFiuvg_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_7Upy1OlO_UGRnVuLnl2ulA_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Ob4t4A76_0WkNwWADqKQgA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:FinanceLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_T7ypsdbv6UeBIuIi5bBfAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Goodwill and Other Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no goodwill carrying amounts in the consolidated balance sheets as of June 30, 2023 and 2022. The carrying amount of goodwill by reportable segment and changes during the year ended June 30, 2022 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rx Segment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consumer Health Segment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consolidated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,802&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Goodwill impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,802)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended June 30, 2022, the Company&#x2019;s market capitalization significantly declined. The decline was considered a qualitative factor that led management to reassess whether an impairment had occurred. Management&#x2019;s evaluation indicated that the goodwill related to its reporting units in both the Rx and Consumer Health segments were potentially impaired. The Company then performed a quantitative impairment test by calculating the fair value of the reporting unit and compared that amount to its carrying value. Significant assumptions inherent in the valuation methodologies include, but were not limited to prospective financial information, growth rates, terminal value, discount rates and comparable multiples from publicly traded companies in our industry. The decline in market capitalization was an indicator of increased risk thereby increasing the discount rates in the valuation models. The Company determined the fair value of the reporting unit utilizing the discounted cash flow model. Using a risk adjusted weighted-average discount rate, the fair value of the reporting units was less than its carrying value. The Company recognized an impairment charge of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$57.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million in the Rx Segment, associated with the Cerecor and Neos acquisition and a &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.6&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million impairment charge in the Consumer Health Segment related to the goodwill associated with the Innovus Acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Intangible Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The tables below provide the summary of the Company&#x2019;s intangible assets as of June 30, 2023 and June 30, 2022, respectively. Carrying amounts are net of any impairment charges from prior periods. Intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,054)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,678)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,004)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the estimated future amortization expense to be recognized over the next&#160;five years and periods thereafter:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total future amortization expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;Acquired Product Technology Rights&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The acquired Product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Karbinal&#xae; ER. &lt;/i&gt;The Company acquired and assumed all rights and obligations pursuant to the Supply and Distribution Agreement, as Amended, with Tris for the exclusive rights to commercialize Karbinal&#xae; ER in the United States (the &#x201c;Tris Karbinal Agreement&#x201d;). The Tris Karbinal Agreement&#x2019;s initial term terminates in August&#160;of 2033, with an optional initial &lt;span style="-sec-ix-hidden:Hidden_jJl8Ok9bXUO0qTue9ytzzw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20-year&lt;/span&gt;&lt;/span&gt; extension.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Poly-Vi-Flor&#160;and Tri-Vi-Flor.&lt;/i&gt; The Company acquired and assumed all rights and obligations pursuant to a Supply and License Agreement and various assignment and release agreements, including a previously agreed to Settlement and License Agreements (the &#x201c;Poly-Tri Agreements&#x201d;) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;ADHD Portfolio.&lt;/i&gt; As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys XR-ODT and Cotempla XR-ODT. The formulations for the ADHD products are protected by patented technology. The estimated economic life of these proprietary technologies is 17 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;Acquired Technology Right&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;TRRP Technology.&lt;/i&gt; As part of the Neos Acquisition, the Company acquired Time Release Resin Particle (&#x201c;TRRP&#x201d;) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;technology underlines each of Neos&#x2019; core products and can potentially be used in future product development initiatives as well.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;Acquired Product Distribution Rights (and customer list)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. As of June 30, 2022, the customer list intangible asset was fully amortized. During the fiscal year ended June 30, 2023, this intangible asset was impaired by $3.0 million due to the discontinuance of products in the Consumer Health Segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;Acquired In-Process R&amp;amp;D&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;IPR&amp;amp;D &#x2013; NT0502.&lt;/i&gt; As part of the Neos Acquisition, the Company acquired in-process research and development associated with NT0502, a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. As this is an indefinite-lived intangible asset, this acquired asset remains an indefinite-lived asset until the completion or abandonment of the associated research and development efforts. If a product using this technology is eventually approved for commercial sale, at that time, the IPR&amp;amp;D will begin amortizing on a straight-line over the life of the product. During the fiscal year ended June 30, 2023, the Company fully impaired the IPR&amp;amp;D of NT0502 due to the termination of its development program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"&gt;Other &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Other intangible assets consist of customer lists, trade names and other technology and licenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain of the Company&#x2019;s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $6.1 million and $7.8 million during the years ended June 30, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team&#x2019;s expertise to build leading brands within large therapeutic and consumer health markets. As a result of focusing on building the portfolio of revenue-generating products, the Company decided to abandon active development of its NT0502 (N-desethyloxybutynin), a new chemical entity that is for the treatment of sialorrhea, which is excessive salivation or drooling. During the year ended June 30, 2023, the Company incurred an impairment charge of $2.6 million related to NT0502 and terminated the licensing agreement. The Company also terminated the license agreement with Cedars-Sinai Medical Center surrounding the Healight technology platform as an additional result of terminating the development of the Healight program. Further, the acquired product distribution rights from Innovus was impaired by $3.0 million due to discontinuance of products in the Consumer Health Segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2022, in connection with the decision to discontinue commercializing or divesting certain products within the Rx Segment that have minimal revenue and gross margin contribution, the Company recorded $4.9 million &lt;span style="-sec-ix-hidden:Hidden_Ed_wMja5SES4fIWHM8Ndsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;impairment&lt;/span&gt;&lt;/span&gt; expense for the write-down of intangible assets consisting of (i) $2.6 million for AcipHex, (ii) $1.4 million for ZolpiMist, (iii) $0.5 million for Tussionex, (iv) $0.2 million for Cefaclor and (v) $0.2 million for the Neos tradename. Additionally, the Company&#x2019;s Consumer Health Segment recorded an impairment of $2.2 million related to products no longer being marketed and products that have been underperforming.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Narr_5hsItURkcUC0EfQvDNBBbg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Narr_5YQa8Io5r0qqt5R8Jk7naA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_tznAQ8bCvEy1mdfPX-Stbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rx Segment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consumer Health Segment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consolidated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,802&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Goodwill impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,165)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,802)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_17kGrCVmQEOjFdEV5C2_zQ"
      decimals="-3"
      id="Tc_97_hvBR8RkqQe2EhmkQonA_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">57165000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_DxeLmfrDLkiqMKsp5HRFVA"
      decimals="-3"
      id="Tc_ivcxCvAu0kS4sj1ZYi-s1w_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8637000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_oQm-u0CZkE2Y4uZfw87ZCQ_4_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">65802000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_OcXr5qGPPEGu6SjbfYnECg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">57165000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_k5V2L5lMakm_T31POfIj3Q_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8637000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_zFiTVNwYbk2Nv5Hfq2AIlA_5_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">65802000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-5"
      id="Narr__uVUsTPe5UaYURJyoZ6ZCQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">57200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-5"
      id="Narr_9vSQqo5sAUuy4BXONrNOKA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_d7o3ZyjumEimiuBY5m6XRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,054)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,678)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,004)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_L5PfZQ9uQEiWLUg67l8_tg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:67.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,054)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,678)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:30.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,613)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net&#160;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Impairment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:66.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Definite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,224)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired technology right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired product distribution rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,354&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,666&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,004)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Indefinite-lived intangibles:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Acquired in-process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Indefinite-lived&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:30.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,632&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA"
      decimals="-3"
      id="Tc_FXVb9lwuDE-GnLe2hO70Xw_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">42176000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA"
      decimals="-3"
      id="Tc_mC_kW24p-065BPc2__Rp0A_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10881000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA"
      decimals="-3"
      id="Tc_cRjqtxmfu0m5PWYy5HNBvQ_8_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">31295000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_fwYbk0T1rkuVqkxgYwDegA"
      id="Tc__zYUKfuDuEKVxJprb4TE8A_8_14">P11Y5M26D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA"
      decimals="-3"
      id="Tc_48U5t-o8S0KsS01brkLXnA_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA"
      decimals="-3"
      id="Tc_WzPdZtkOHUOA4aw5wAv3iA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4054000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_4Vs_vzDQlUiZRr2kCc-wrA"
      decimals="-3"
      id="Tc_VLTwnbnLn0-LPMgSv0CDkg_9_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">26146000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_JXn5-Xzq2kiOE7uPypp10Q"
      id="Tc_nffGe_yCok2Ws78zpapGAQ_9_14">P14Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg"
      decimals="-3"
      id="Tc_7tUsCzeFgE6W0jV69_QGTg_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9182000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg"
      decimals="-3"
      id="Tc_kiQGx8yvLEy11kyF90Mr4g_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4678000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg"
      decimals="-3"
      id="Tc_sDz9Aoyu6kqXnj94ny3LLw_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2975000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_luEkmHGQmUWttImRk3TOOg"
      decimals="-3"
      id="Tc_Xz8OAcIP9kKZI0u_SZsP5g_10_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1529000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_Sbisw7Ka2U-eJeK-plm2KA"
      id="Tc_9VWOJ3OpDUWjx8wj4FURIQ_10_14">P1Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_M9_7-bGnBUuSZYPmN1f68Q_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">81558000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_04yQ6AaZZECQgMNwRnXfEA_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">19613000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_j58iyTnL20WE8aq8rzm-jA_11_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2975000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_FKj-TPAHDEOtJSIt0A0emQ_11_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">58970000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA"
      id="Tc_AXxCxwbeEke0JvoM4O2DCA_11_14">P12Y8M1D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_RxaRw3eo9EqdOu9idOlFNQ_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_5VbDQ_-V_ke__ZAHFuuAbQ_13_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc__pai3Jnm20OBCcHNvulH1Q_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_3REJajl-60WJb8vcjryaEQ_14_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</aytu:IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_jlYtKFQIF02q_s1KSgpT2w_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">84158000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_hJEHWpqxZUSUszoGFzEh1w_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">19613000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_0o4pzEp6kE68zSB-5axSSg_15_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5575000</aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_X7XI21yoEE6d3raobJOz2g_15_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">58970000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA"
      id="Tc_uEv_zrha9UO0Phtyr5BwNQ_15_14">P12Y8M1D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw"
      decimals="-3"
      id="Tc_0mQ62Ku7GkChUywATDd85A_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">45400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw"
      decimals="-3"
      id="Tc_LFaoP2g7sEq1XO15aBGtRQ_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7667000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw"
      decimals="-3"
      id="Tc_b5C7V03tvkuEok1vQ-yBQw_8_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3224000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_gBiXn05Hb0SeTMtkFrIcuw"
      decimals="-3"
      id="Tc_RFTprqVpUU2cTKHaD5Y3gQ_8_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">34509000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_kEPlwQ3Z5EajARrt_81BZw"
      id="Tc_2aW9MnwVpUW4t0MCvqMVSA_8_14">P12Y3M29D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ"
      decimals="-3"
      id="Tc_tT3JSxsDr0WVozFgmtxn7g_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ"
      decimals="-3"
      id="Tc_bJcrknao00eAo9M996ew9w_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2278000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_fvbxHT9ZMk2sknhwQEhgpQ"
      decimals="-3"
      id="Tc_H4j2oJjeU0KQikfzajtDjA_9_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">27922000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_96lPa_UH3EC_sxZ01SDNgw"
      id="Tc_z4R9yHEviUWs-dsuLZ7Zrg_9_14">P15Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw"
      decimals="-3"
      id="Tc_H7H8FUyzIEyuVQF_9QqteQ_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11354000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw"
      decimals="-3"
      id="Tc_OMhj2enZAkGPd2HZIsiW9A_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3581000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw"
      decimals="-3"
      id="Tc_MRxjDv585ke9EjF1iPpr1A_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2172000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_scBDP9fszki3B7tGSUSQGw"
      decimals="-3"
      id="Tc_7q4AmmzdPU-5EIILbHbiqA_10_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5601000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductDistributionRightsMember_pvg1LRUhb0W16a7tuQUDyA"
      id="Tc_K50XtBmGX02UwPEpQjI8Xg_10_14">P7Y7M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ"
      decimals="-3"
      id="Tc_bcsK_VLFCUmzl1ix5KzE7g_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4666000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ"
      decimals="-3"
      id="Tc_OBmD7LxAr0Kf8TSSDCg5gw_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3004000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember_m8qEI98Bmkig0GZ52Ja9PQ"
      decimals="-3"
      id="Tc_KFkKUlm2RE6258lD-Bp9hQ_11_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1662000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_ZlRx7UIK-0GlWJ5W2vtBQw_12_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">91620000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_EyAmMn9g80COz0CcC-r94w_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16530000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_qdaMjoim3UeRJUcGvnYxLg_12_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7058000</aytu:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_R1eq8D6UBkW7jeh4kzSQLg_12_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">68032000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA"
      id="Tc_84ZwRSzXakqgcnasQnALRw_12_14">P13Y4M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_uSw_GyGe6UmQAUT2jvF6mg_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_1b4k0Sgm5U-KJt0cL8yJbg_14_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_TIKgaew6BUu-pCQt_ETP8w_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_FRmpk2NC80S-s9NAAAX90g_15_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_8kya9YJUp0Gt3xnSitiDGg_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">94220000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_EnU5a59CTEiELzPmDIjpJQ_16_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16530000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_A2reA1_LQ06cToz4CV5HXQ_16_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7058000</aytu:IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_SXyjP7DJr0yl6ck5d5WtHA_16_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">70632000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_bjtR06AwIUm1uRVpY4ygCA"
      id="Tc_2OxvXI6ot0moH3h0qoVizA_16_14">P13Y4M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_LNnYlDApI0aJcecWM2MUGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,989&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total future amortization expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_HUCOW20tF0eE7ClK4kn4KA_3_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6518000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_VVpDYNDbOUearS4bExg85A_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_y2HXNQbilE-H-qS7PwkgOg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_rkIW8PzQI0qUQASipWZZYA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_3VrJV4N81Ey3RvobUR4oNw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4989000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_wgScfDfAMUinAGEaYFHkEg_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">32496000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_l7BySZssSkWq6eCNKN_m8g_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">58970000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_F_kE5Lxwtky7YSEDVzN1hA"
      id="Narr_-PCsno29MEejOrsc1lBH7g">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <aytu:NumberOfProductsAcquired
      contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw"
      decimals="INF"
      id="Narr_6J0Y0BQ0yUOdR-pPXZRZhA"
      unitRef="Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w">35</aytu:NumberOfProductsAcquired>
    <aytu:NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired
      contextRef="Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw"
      decimals="INF"
      id="Narr_k78-1D_kK0WeaTsMlATLuQ"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">300</aytu:NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q"
      decimals="-5"
      id="Narr_4Zx8g9aLAU6WMV8l0JF04A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA"
      id="Narr__YSEQWq-PEy9Z_yj-i2Jrw">P1Y</aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod>
    <aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_UOFSRPaFi0u7A5wpcioV4g"
      id="Narr_P0H4qBF8TUOFzSAXvPvEjQ">P20Y</aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_XykXM9XXnEazU_Lj1k8tHw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6100000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_DzCjWlESK02tb5BAMk0IrA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7800000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_NeosTherapeuticsIncMember_jE3g0rsLqEWv2jo6veaozw"
      decimals="-5"
      id="Narr_uV9A2nLLZk2ZjT0aeUs9ow"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_VS3GMYD0Ck-9H-BUAyC34Q"
      decimals="-5"
      id="Narr_piFzsqROiUGHM_CWbra-mQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_Y6CIcUFk30OrmB28acZ6xw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4900000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_AciphexMember_qGDcQ6lLy0ulHTbXHsPakA"
      decimals="-5"
      id="Narr_s72sdyA1dUirQQRxxLtMpw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_ZolpiMistMember_dJH0ndjeUEaT4pdit6AumQ"
      decimals="-5"
      id="Narr_qk5iPZKxdUO4tCWS9Gs76g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1400000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_TussionexMember_zVcKQ1_g1UWXhUn0779uOw"
      decimals="-5"
      id="Narr_XST4vpwgFUSHghz3vgbFNQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">500000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_ProductOrServiceAxis_aytu_CefaclorMember_mhqlF9Qs0UWCJpWeLPVIJw"
      decimals="-5"
      id="Narr_roKihFkX506kW8UVN_GyOQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_ThMW95wZjkCdP_ru56uSmA"
      decimals="-5"
      id="Narr_9O5AIIBwNEmjtkOrIVRbMQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-5"
      id="Narr__6MK8NcMO0eQlmaCvxs_MQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Jw2VE9-mZEeFwBZHyFHOYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Accrued liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued savings offers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,711&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued program liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,765&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued customer and product related fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Return reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table details the change in return reserve for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Return Reserve&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,165)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,346)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Savings offers represent programs for the Company&#x2019;s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Program liabilities include government and commercial rebates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Other accrued liabilities consist of accrued license fees, professional fees, credit card liabilities, taxes payable, legal settlements, and samples expense, none of which individually represent greater than five&#160;percent&lt;span style="font-size:12pt;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_4q8h_ziWZE6KlmZnvxo9uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued savings offers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,711&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued program liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,468&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,675&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,765&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued customer and product related fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,579&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Return reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <aytu:AccruedSavingOffers
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Biv37Sg8l0OX2HQ8NiuPyg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15739000</aytu:AccruedSavingOffers>
    <aytu:AccruedSavingOffers
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_4ChCNSeO2kir23lisjhviA_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12711000</aytu:AccruedSavingOffers>
    <aytu:AccruedProgramRelatedLiabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_tO2DlVMi4EOY7dNd5ln8jw_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">11012000</aytu:AccruedProgramRelatedLiabilities>
    <aytu:AccruedProgramRelatedLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_0coiT-GeWku93xglb-1UmA_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9468000</aytu:AccruedProgramRelatedLiabilities>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_0trivw-JcEWex_Dbskma8Q_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5675000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_3TFJzt1DQUWUXChExVfTBA_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4765000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <aytu:AccruedCustomerAndProductRelatedFeesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_gNe1CQJq2EqwwFAOmfk17g_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6579000</aytu:AccruedCustomerAndProductRelatedFeesCurrent>
    <aytu:AccruedCustomerAndProductRelatedFeesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_LgAn9cHKBUiZodsux8hZaA_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7817000</aytu:AccruedCustomerAndProductRelatedFeesCurrent>
    <aytu:ReturnReserveCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_eSP5DYHhe0Cb1l3ThrJoJQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5777000</aytu:ReturnReserveCurrent>
    <aytu:ReturnReserveCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_7FHhc6VYGkCtlcFx1I4boA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5770000</aytu:ReturnReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_ITDjx6h8ukOqE9tg9lK9cg_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_9U0LNLF-N0eHcncmudTsyA_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3656000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_qGAzwgVKsker1Yx0AvYHsw_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_4zLSW3CCk0aUSSkkyNCDfw_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">44187000</us-gaap:AccruedLiabilitiesCurrent>
    <aytu:ScheduleOfReturnReserveTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_0LTX1jleq0KOlv8oyAJ6jg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Return Reserve&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,165)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charges to expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,346)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</aytu:ScheduleOfReturnReserveTableTextBlock>
    <aytu:ReturnReserve
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_vdv0d_sxlEOkmnlbK-GT7Q_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6367000</aytu:ReturnReserve>
    <aytu:ReturnReserveChargesToExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_OuINFg4oNE6ctnfGtNNbKQ_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8568000</aytu:ReturnReserveChargesToExpense>
    <aytu:ReturnReservePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_KAGjWjEGVE2sWEEu7aZNaA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9165000</aytu:ReturnReservePayments>
    <aytu:ReturnReserve
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_YXeNpUrJz0CIXu-cP7Sksw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5770000</aytu:ReturnReserve>
    <aytu:ReturnReserveChargesToExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_e_gxnzpJzUOspW8iOBAW2A_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8353000</aytu:ReturnReserveChargesToExpense>
    <aytu:ReturnReservePayments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_x5UGaLHjRkCJrlZfxz7KNQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8346000</aytu:ReturnReservePayments>
    <aytu:ReturnReserve
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_RffxJBfUWEqng_q37GmTBA_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5777000</aytu:ReturnReserve>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Hw6whEvvyEGtV9CUMVTETQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed payment arrangement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent value rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,157&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,359)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total other liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fixed payment arrangements.&lt;/span&gt; Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $0.1 million from November 2019 through January 2021 plus $15.0 million due in January 2021, of which $15.0 million was paid down early in March 2020. Monthly variable payments due to the same investor are equal to 15.0% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $0.1 million, except for January 2021, when a one-time payment of $0.2 million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $9.3 million have been made or (ii) February 12, 2026. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"&gt;On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in early satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"&gt;The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of June 30, 2023, the fixed payment arrangement balance was $1.7 million in other current liabilities and $2.1 million in other non-current liabilities on the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 12, 2022, the Company entered into an agreement with Tris to terminate the License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the &#x201c;License Agreement&#x201d;). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $6.0&#160;million to $9.0&#160;million, which reduced our total liability for minimum payments by approximately $8.0&#160;million from the original License Agreement. The settlement payment will be paid in&#160;three&#160;installments from December 2022 through July 2024. As of June 30, 2023, the balance was $6.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent value rights.&lt;/span&gt; Contingent value rights (&#x201c;CVRs&#x201d;) represent contingent consideration related to the Company&#x2019;s 2020 acquisition of Innovus of up to $16.0 million payable upon attainment of future performance milestones. Consideration can be satisfied in up to 470,000 shares of the Company&#x2019;s common stock, or cash either upon the option of the Company or in the event there are insufficient shares available to satisfy such obligations. In the fiscal years ended June 30, 2020 and 2021, the Company issued to the CVR holders 6,191 and 5,160 shares of common stock, respectively, upon achievement of specified revenues. No milestones were met during the fiscal years ended June 30, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;2022 and 2023. As of June 30, 2023, up to $5.0 million of future milestone payments potentially remain. During the years ended June 30, 2023 and 2022, the Company recognized a gain of $0.6 million and $0.8 million, respectively, in the consolidated statements of operations related to the changes in fair values of CVRs. As of June 30, 2023 and 2022, the CVRs balance was zero and $0.6 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Contingent consideration represents the fair value of potential future payments in connection with acquisitions that are contingent upon the occurrence of a particular event or events. The Company records an obligation for such contingent payments at fair value on the acquisition date. Subsequent changes in the fair value of contingent consideration obligations are recognized in the consolidated statements of income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Company&#x2019;s 2020 acquisition of Innovus, the Company recognized approximately $0.2 million in product related contingent consideration. The fair value was based on a discounted value of the future contingent payment using a 30% discount rate based on the estimated risk that the milestones are achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to June 30, 2022, the Company&#x2019;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#x201c;Tris&#x201d;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#x2013; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#x2019;s estimated borrowing rate. The Company recognized $0.9 million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to June 30, 2022, the royalty payments related to licensing agreements with Magna Pharmaceuticals, Inc. (&#x201c;Magna&#x201d;) for ZolpiMist were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing ZolpiMist, the Company concluded that the royalty-based product milestone payments underlying the contingent consideration liability ceased to exist. In 2022, the Company reversed the remaining contingent consideration liabilities of $0.6 million and recorded the $50,000 payment due for termination of the Manga licensing agreements in other current liabilities. The Company recognized a $0.6 million gain from termination of the contingent consideration liability in the consolidated statements of operations for the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2023 and 2022, the Company recognized a gain of $0.4 million and a loss of $0.5 million, respectively, from the changes in fair values of contingent considerations. As of June 30, 2023 and 2022, the contingent consideration balance was zero and $0.4 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other.&lt;/span&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;Consist of taxes payable and deferred cost related to our technology transfer.&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_j8nub6fNxU6KDJZTtS6FxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:46.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed payment arrangement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,317&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent value rights&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,157&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,090)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,359)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total other liabilities, noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_QKeHN_9bpkeikgBvC5LNJw_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10420000</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_YMYPpkGDo0C1smJjVftIBA_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">13051000</aytu:FixedPaymentArrangements>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_l1uctFXRvUqSv8lqMU5YLg_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2090000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_L9sHK35yRkiij_l2tEmROg_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3317000</us-gaap:OperatingLeaseLiability>
    <aytu:ContingentValueRightsLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_05q3Pcl9PEKTsaR8a-2euA_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">578000</aytu:ContingentValueRightsLiabilitiesFairValueDisclosure>
    <aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_SFAoMfecD0SdWuyYAcsPyQ_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">396000</aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability>
    <us-gaap:OtherSundryLiabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_sMS5siaEaEyrWIeH9JkWDQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1555000</us-gaap:OtherSundryLiabilities>
    <us-gaap:OtherSundryLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_m57yABtW9UG5rl5RuonKIg_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">815000</us-gaap:OtherSundryLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_g8qmDnit5EiciwUPFraHHA_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14065000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_173iIK_TQ0yHID2OBsExow_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">18157000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_6ww-8TS9tEelBHXXSJdWAA_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7090000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Hj7Dc7COWUCxbJG2eiru_A_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5359000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_iOhEQ_hxZEugs8N3XJsCtg_12_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_p1XwGZmoMEuU_JVq4jxE8g_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12798000</us-gaap:OtherLiabilitiesNoncurrent>
    <aytu:FixedPaymentArrangementsMonthlyPaymentAmount
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw"
      decimals="-5"
      id="Narr_MTy9cSL0XkqnjQdA53nujw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:FixedPaymentArrangementsMonthlyPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw"
      decimals="-5"
      id="Narr_HlVob6xEQESpZcqkMW6keA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000.0</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid
      contextRef="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw"
      decimals="-5"
      id="Narr_EQjRe7dJvkqFjItzy0TqOg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000.0</aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q"
      decimals="3"
      id="Narr_I8fe6myAC0er2OWOVfkLJQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.150</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q"
      decimals="-5"
      id="Narr_1685SqeCz0CkshOmbNmcOw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_vUpSuynmCUCGZ3WZlbjUuw"
      decimals="-5"
      id="Narr_kTHG6dSySEaBNsEmhy4_6Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q"
      decimals="-5"
      id="Narr_WVkgmO-MqkmPkZnEIuUQjg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9300000</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026>
    <aytu:FixedPaymentArrangementsPaymentAmountPaid
      contextRef="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A"
      decimals="-5"
      id="Narr_CR4MjCyZjE6dgHUZRpD5Uw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2800000</aytu:FixedPaymentArrangementsPaymentAmountPaid>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg"
      decimals="-5"
      id="Narr_TUB46cHwhUqOn7l4VzYczA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="INF"
      id="Narr_VcqmJ1BnWUShZvGqW70hwQ"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">6</aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmount
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="-5"
      id="Narr_0yC0h5_f4EmbXrUIM0mpEw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">500000</aytu:FixedPaymentArrangementsQuarterlyPaymentAmount>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="INF"
      id="Narr_oLDIhGOwgEatEjMlpPVPkg"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">6</aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber>
    <aytu:SupplyAndDistributionAgreementTerm
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg"
      id="Narr_MX637d94yUO5S69r8JN3bw">P20Y</aytu:SupplyAndDistributionAgreementTerm>
    <aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="3"
      id="Narr_SifhmLT3fkaNq5kGOqDVbg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.235</aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="INF"
      id="Narr_gUXFDG0Y_kOPSXU_1JdxZA"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">70000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="0"
      id="Narr_w6AtlU2HXkif_9Q-eT8rPw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="INF"
      id="Narr_ixHqboZfnE-0FNeTZVus0A"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">70000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_sMsiohkqXkKN5YnzeEWk5A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2100000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount>
    <aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_eMZxPNAhQEm_l_mBAvbcTg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation>
    <aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_rEjupwffm0KYJZHcK1a4Yw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">40000000.0</aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount>
    <aytu:FixedPaymentArrangementsCurrent
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow"
      decimals="-5"
      id="Narr_Kvm8iG7Ac0mSlwiQHVUQtw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1700000</aytu:FixedPaymentArrangementsCurrent>
    <aytu:FixedPaymentArrangementsNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_0Ecq4r2a6k65lv0RId8Eow"
      decimals="-5"
      id="Narr_eXv80IgScES4DIz2_ugIvg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2100000</aytu:FixedPaymentArrangementsNoncurrent>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_5_12_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_jDvZD8q0Y0el44FFCfCVRA"
      decimals="-5"
      id="Narr_iOT0uEUP6kSdJ3zkbCfoTw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6000000.0</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_5_12_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_2wCCGQMMCUmH4iUajN7RIg"
      decimals="-5"
      id="Narr_L0ydbeVGVEWF5MhE-NgWkQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9000000.0</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangementsLiabilityReduction
      contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_7wtjA0AipUW_t_5VDehRxw"
      decimals="-5"
      id="Narr_jDM7vFCSrEuwQ0IltZxUBQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8000000.0</aytu:FixedPaymentArrangementsLiabilityReduction>
    <aytu:FixedPaymentArrangementsInstallmentPaymentsNumber
      contextRef="As_Of_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_psb5HJRJGUmm-pY27HkHJg"
      decimals="INF"
      id="Narr_wkLlF7NoeUW5MV5blIUbMg"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">3</aytu:FixedPaymentArrangementsInstallmentPaymentsNumber>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember_5qxxQfplJUCrdZsaKXc-bA"
      decimals="-5"
      id="Narr_0avsFGgvu0yyH8XCtjD3JQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6600000</aytu:FixedPaymentArrangements>
    <aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum
      contextRef="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg"
      decimals="-5"
      id="Narr_2fxOL0AfrUKPptf7ySeCmg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16000000.0</aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum>
    <aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum
      contextRef="As_Of_2_29_2020_PFK4L-DSd0G5-JLt7SBnMg"
      decimals="INF"
      id="Narr_MtYVsD5620KUjrm-2Klw-g"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">470000</aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum>
    <aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts
      contextRef="Duration_7_1_2019_To_6_30_2020_uXBqmTqkjkG4C-vVf43Sxg"
      decimals="INF"
      id="Narr_3tSpedh7nE6RjgyFZbPFwQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6191</aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts>
    <aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts
      contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"
      decimals="INF"
      id="Narr_RNyfuMqqKESVjeTrCMwlww"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5160</aytu:StockIssuedDuringPeriodSharesContingentValueRightsPayouts>
    <aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_AXRWFkYwyEGA-bCJwQw7dg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5000000.0</aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum>
    <aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_O9FJOcTGtUCFRN7aqVKAng"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_CW0akrgCqUWARSJ487H4nw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">800000</aytu:ContingentValueRightsGainLossForChangeInFairValueDuringPeriod>
    <aytu:ContingentValueRightsLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_ABpQCDBdFEODwj7-dIUxjQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</aytu:ContingentValueRightsLiabilitiesFairValueDisclosure>
    <aytu:ContingentValueRightsLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_R0n27RIIRUe953QjlZxBtQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:ContingentValueRightsLiabilitiesFairValueDisclosure>
    <aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount
      contextRef="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ"
      decimals="-5"
      id="Narr_6HH18D7bH0m1QRVefKO8fw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount>
    <aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate
      contextRef="As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ"
      decimals="INF"
      id="Narr_3jhy3_Glp0OvJzgcB-uz6w"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.30</aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod
      contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q"
      decimals="-5"
      id="Narr_tah0LLOT3kGuzpi61kgaGg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8500000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod>
    <aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances
      contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ"
      decimals="-5"
      id="Narr_jJRftOTkg0qD4nV79RfSqw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7600000</aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA"
      decimals="-5"
      id="Narr_H2jGxblBRUSs4BAxMIxEww"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">900000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ"
      decimals="-5"
      id="Narr_dJgZSbir-0moIGmerpieoQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_y5gGC1vDBUWYv1EcPoN6Uw"
      decimals="0"
      id="Narr_qGObHRKSWk2VA8eCYSR64Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">50000</us-gaap:OtherLiabilitiesCurrent>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ"
      decimals="-5"
      id="Narr_fhwSnyYIMEKV_FKQLBR8Dw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod>
    <aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_fHMhOQDwRU-bk-ZP3DQ6rw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod>
    <aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_4QgcIsXp_0exEFNOvwaRAw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-500000</aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_hKAJRc3i4kWCN2bSYhyINA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_yI-1XKuvXkeQyeP1R0YopQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ShortTermDebtTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_DAnpWFqktUqu91B5A6lW_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Line of Credit&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (&#x201c;Eclipse&#x201d;) as agent for the lenders (the &#x201c;Eclipse Loan Agreement&#x201d;).&#160;Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the &#x201c;Revolving Loans&#x201d;), of which up to $2.5 million was available for short-term swingline loans, against 85% of eligible accounts receivable. The Revolving Loans thereunder accrued variable interest through maturity at the one-month Secure Overnight Financing Rate (&#x201c;SOFR), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding&#160;month. Interest is payable&#160;monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Avenue Capital Agreement, described in Note 12 &#x2013; Long Term Debt, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the &#x201c;Eclipse Second Amendment&#x201d;). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurred $0.1 million in legal and other fees related to the Eclipse Second Amendment, all of which were recorded as deferred financing costs and are being amortized on a straight-line basis over the remaining term of the Eclipse Loan Agreement as interest expense. The unamortized cost of $0.1 million as of June 30, 2022 was included in other noncurrent assets in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the Eclipse Amendment&#x201d;) to the Loan and Security Agreement dated October 2, 2019 (as amended by Amendment No. 1, dated March 19, 2021, Amendment No. 2, dated January 26, 2022, Amendment No. 3, dated June 1, 2022, and the Eclipse Amendment (the &#x201c;Eclipse Agreement&#x201d;). The Eclipse Amendment, among other things, provided for an aggregate increase of $2.0 million to the Eclipse Lender&#x2019;s commitment to make revolving loans from time to time under the Eclipse Agreement and increased the maximum amount available under the revolving credit facility provided under the Eclipse Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Agreement remains subject to a borrowing base and reserve, and availability blockage requirements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to&#160;(i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement with at least five business&#160;days prior notice to Eclipse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The&#160;Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company&#x2019;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company&#x2019;s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement as amended.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company&#x2019;s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Total interest expense on the Revolving Loans, including amortization of deferred financing costs, were $0.7 million and $0.4 million&#160;for the years ended June 30, 2023 and 2022. As of June 30, 2023 and 2022, the outstanding Revolving &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loans under the Eclipse Loan Agreement, as amended, were $1.6&#160;million and $3.8 million, respectively. Unused line of credit amount as of June 30, 2023 was $9.3 million.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw"
      decimals="-5"
      id="Narr_-jJh6sgANEmLwmE9hfXLcQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg"
      decimals="-5"
      id="Narr_IJocGHKCpkuqS12GITQfww"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <aytu:LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_rbMg9La7ZUWtVEyE61Dhwg"
      decimals="INF"
      id="Narr_8mvTlATNJ0u1ufkSedhS9w"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.85</aytu:LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA"
      decimals="4"
      id="Narr_2DKLxDqdr06N0vvvIHYuxg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_Y4i8_JEJe0SvA0HJFtx-NQ"
      decimals="4"
      id="Narr_Ham05tgxf0-zIV98-cxCVg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_3_1_2021_To_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember__llAO05PvkiHzBUr6DypoA"
      id="Narr_8J7zG4q4M0ytdoTSmIHoQQ">2022-05-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_M0-TXPTse0mGHnAuhWTPYA"
      id="Narr__uEIVawkL0eQQodqQGUtvg">2025-01-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw"
      decimals="-5"
      id="Narr_enrhqtQMQk6XlM85KBb4mA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag"
      decimals="-5"
      id="Narr_pxYhKHjl70qXmxSE8_eKVA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag"
      decimals="-5"
      id="Narr_oUszNLhUPkqOfcM0Zn2IvQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3500000</aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock>
    <aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock
      contextRef="As_Of_3_31_2021_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ONpBT9_mxk-iRcg8N1EPkw"
      decimals="-5"
      id="Narr_gOaSACDOukuzaK0qfBDaOw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000000.0</aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock>
    <aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag"
      decimals="-5"
      id="Narr_MnNVkJPo2kGwfrkzoGnaag"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3500000</aytu:LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock>
    <us-gaap:DeferredFinanceCostsNoncurrentGross
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_jIHEIYkJZkuAY4SCdaH8Ag"
      decimals="-5"
      id="Narr_tj4989TZd0WDShqcAipcGw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <us-gaap:DeferredFinanceCostsNoncurrentGross
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg"
      decimals="-5"
      id="Narr_GgoRb8DC2EmAe3IW2v_l_Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <aytu:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_O8YhH2nEYUOb-JVw1s0Yfg"
      decimals="-5"
      id="Narr_WdAf5ichIU6CgNjGkkf0Mg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2000000.0</aytu:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_gcPJdm_wtE65EZK74cL6oQ"
      decimals="-5"
      id="Narr_feDoOV7RwU-EZpzW7QpAAQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="3"
      id="Narr_I9tdPQZocEi2wZu5-2YTWA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.020</aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="3"
      id="Narr__Ouvr-8HCkKH68MwRVzAZw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.010</aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024>
    <aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="3"
      id="Narr_fewN9fuvwkyILHERn36lmw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.005</aytu:LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024>
    <aytu:DebtInstrumentTerminationBusinessDaysNoticePeriod
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="INF"
      id="Narr_4Pzg_-0zkkCsuSOPgWIADA"
      unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ">5</aytu:DebtInstrumentTerminationBusinessDaysNoticePeriod>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_8Yuqe19JIk2B29trNymR7w"
      decimals="-5"
      id="Narr_OY7D6fi6nE6HYRZCBwkOUw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_db-vGfL3fUmxvIexRiVKVw"
      decimals="-5"
      id="Narr_jay4gFNX90CiOBtSNW6sIA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</us-gaap:InterestExpenseDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="-5"
      id="Narr_JCx9TRwkEEqbvlntn95f1A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1600000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_UbIjXJIZ2k2j8SWhsQoFfg"
      decimals="-5"
      id="Narr_2BZvtR0jR0-5Ahej9Jxq9w"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3800000</us-gaap:ShortTermBorrowings>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_ps8fZa5LhEeZSDGoEOvE2A"
      decimals="-5"
      id="Narr_-rx869EdSUO_iRP0Us4RHQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9300000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_K-2nfJoreEm7CCdJ211PQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Long-term Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Deerfield Debt.&lt;/span&gt; Upon closing of the Neos Acquisition, the Company assumed a senior secured term credit facility (the &#x201c;Deerfield Facility&#x201d;) with Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P. (collectively, &#x201c;Deerfield&#x201d;) with an outstanding balance of $16.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluated and determined&#160;that the&#160;fair value of the remaining outstanding debt was $17.4 million as of the March&#160;19, 2021 acquisition date. Accordingly, the Company recorded a premium&#160;of $0.8 million, which was the difference between carrying amount and the fair value of the debt&#160;and was being amortized into interest expense using the effective interest method over the remaining term of the debt.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2022, the Company repaid the remaining principal outstanding in full, plus exit fees and accrued interest under the Deerfield Facility. The Company recognized a gain of $0.2 million during the year ended June 30, 2022 related to the extinguishment of the Deerfield Facility. Total interest expense on the facility, net of premium amortization, was $0.8 million for the period from July 1, 2021 through full repayment on January 26, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Avenue Capital Loan. &lt;/span&gt;On January 26, 2022 (&#x201c;Closing Date&#x201d;), the Company entered into a Loan and Security Agreement (the &#x201c;Avenue Capital Agreement&#x201d;) with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders (the &#x201c;Avenue Capital Lenders&#x201d;), and Avenue Capital Management II, L.P. as administrative agent (the &#x201c;Avenue Capital Agent&#x201d;), collectively (&#x201c;Avenue Capital&#x201d;), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate and 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used towards the repayment of the Deerfield Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (&#x201c;Interest-only Period&#x201d;). The Interest-only Period could be extended automatically without any action by any party for six months provided as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (&#x201c;Interest-only Milestone 1&#x201d;). The Interest-only Period could further be extended automatically without any action by any party for an additional six months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue as of the date of determination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (&#x201c;Final Payment&#x201d;). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s obligations under Avenue Capital Agreement are secured by substantially all of the Company&#x2019;s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company&#x2019;s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company&#x2019;s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of June 30, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2022 (&#x201c;Issuance Date&#x201d;), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#x201c;Avenue Capital Warrants&#x201d;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants, as described in Note 15 &#x2013; Stockholders Equity, at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022 and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the shares of common stock issuable upon exercise of the Avenue Capital Warrants were set at an exercise price of $24.20. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 25, 2022, the Company entered into an agreement with Avenue Venture Opportunities Fund, L.P (&#x201c;Avenue&#x201d;) to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company&#x2019;s August 2022 equity financing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 &#x2013; Warrants, the interest-only period of the Avenue Capital Agreement was extended further upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. The interest-only period now extends to the January 26, 2025 maturity date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the debt discounts discussed above, the Company also incurred $0.4 million loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 16.59%. Total interest expense on the Avenue Capital loan including debt discount amortization, were $2.7 million and $0.9 million for the years ended June 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-term debt consists of the following;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt, due on January 26, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term, final payment fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (925)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing leases, maturing through May 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-current portion of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Future principal payments of long-term debt, including financing leases, are as follows;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future principal payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (925)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current portion of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw"
      decimals="-5"
      id="Narr_DG1iuhq1pkyYKkGSV8ylFQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw"
      decimals="-5"
      id="Narr_SRkP8S6N00edGDCFMEnmOQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">17400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw"
      decimals="-5"
      id="Narr_SxvAjCDptEm84ehiNJ2VrQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">800000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_g8KZkdeDqk-U60JJxrNmOQ"
      decimals="-5"
      id="Narr_-Bjqd6K0UUqbTQRXinhieA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_7_1_2021_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_4QygS4Rlv0O5YI7SfAsGHA"
      decimals="-5"
      id="Narr_Sp3pWEVBVEu80knRrACSTA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">800000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_or32U-oD-E2fJCWtre3ZHQ"
      decimals="-5"
      id="Narr_VG5CX8zXlU23NZ3iKfvHMg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <aytu:DebtInstrumentMinimumVariableRateBeforeBasisSpread
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      decimals="4"
      id="Narr_7u8R_E5Fn0SSMbI85Vu_Eg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0325</aytu:DebtInstrumentMinimumVariableRateBeforeBasisSpread>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      decimals="3"
      id="Narr_rl9dLvE1Zk2nbxz2BkifRQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.074</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <aytu:DebtInstrumentInterestPaymentTerm
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      id="Narr_oIw4p6yKk0mETQ82v2-9eg">P18M</aytu:DebtInstrumentInterestPaymentTerm>
    <aytu:DebtInstrumentInterestPaymentExtensionTerm
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      id="Narr_rFGTHI0Tx06LJmNYL7C2Ow">P6M</aytu:DebtInstrumentInterestPaymentExtensionTerm>
    <aytu:InterestOnlyPeriodFurtherExtensionTerm
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      id="Narr_0sl7doU5kUWpxngGbe_bbg">P6M</aytu:InterestOnlyPeriodFurtherExtensionTerm>
    <aytu:DebtInstrumentTermOfTrailingMonthsRevenue
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      id="Narr_jAwLrMjFuke0Tg56aD9OWg">P12M</aytu:DebtInstrumentTermOfTrailingMonthsRevenue>
    <aytu:DebtInstrumentPrepaymentFeePercentage
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_NB8QefbM6E6bitJQMv2ekA"
      decimals="3"
      id="Narr_owA6mN01UE2W8MRG8KI0ZA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.030</aytu:DebtInstrumentPrepaymentFeePercentage>
    <aytu:DebtInstrumentPrepaymentFeePercentage
      contextRef="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_kws3beaygUG87BjJP1LOuQ"
      decimals="3"
      id="Narr_gZFSXCpugkyn6r0Ia0q81A"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.020</aytu:DebtInstrumentPrepaymentFeePercentage>
    <aytu:DebtInstrumentPrepaymentFeePercentage
      contextRef="Duration_1_26_2022_To_1_26_2022_srt_StatementScenarioAxis_aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_m0FsqjSjeUaa1vPcTxPTlA"
      decimals="3"
      id="Narr_BWLSfoyAJUi6bHuVVhlmdQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.010</aytu:DebtInstrumentPrepaymentFeePercentage>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"
      decimals="-5"
      id="Narr_6av_ngfYxU2gEfqwhwoB_A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_1_26_2022_To_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_8BPUJ7pkK0qSQNua439-Bg"
      id="Narr_zvxlTTXXoUa7OClHJdUU4Q">2022-01-26</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"
      decimals="INF"
      id="Narr_o1yFif9FI0Svb8iezicq0g"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">24.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_29_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_hHbd5LNmMkO0y394Oj5L5w"
      decimals="INF"
      id="Narr_iIGnoLx3WECfd2tERxz7iA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">24.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"
      decimals="-5"
      id="Narr_a1p_1XuT7EGBwNeNtEFSPA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_tKH_DOG2x0SbdakkNDfEwA"
      id="Narr_RhXEyDdY-0Kq2Pi6iKzfFg">2022-03-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:SharePrice
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg"
      decimals="2"
      id="Narr_Ibqu0Ue0V0CPHBTOf6tOhA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">25.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg"
      decimals="INF"
      id="Narr_q6ZY16eGNUK9vboJa4yrAg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">24.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_25_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_Y2L8pKkibkq2ytqbielQJA"
      decimals="INF"
      id="Narr_qDwDgTFoUUmVKTPBMSz9-Q"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LoanProcessingFee
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA"
      decimals="-5"
      id="Narr_jvM9XE01XUio9DyRXBZydA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</us-gaap:LoanProcessingFee>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_bt9P46zN4Uul011WiS7arg"
      decimals="4"
      id="Narr_8NJFd-pSMU6ZkUrzgcE1bA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.1659</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_p-uqAUyYr0uaoNKsPlpdDA"
      decimals="-5"
      id="Narr_wly_pBvKnkK2hJgq5kcyOg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_DebtInstrumentAxis_aytu_AvenueCapitalLoanTermLoanMember_lv1AQVTl0keo4ZlP9CVIgA"
      decimals="-5"
      id="Narr_A4W5_QoB40uDV_O508W7UQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_L0WOECD2Nk6e5USgzFUEAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt, due on January 26, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term, final payment fee&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (925)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financing leases, maturing through May 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Non-current portion of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_hIwOOubZDUiVkmnloXgmtA_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_5BWjWyNuhkOZcRL0UnWv0A_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">638000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_X4FHmihnek-AobFfEAKGbA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">925000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_iYOfwuWDwEex1Tb25SmumA_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_R8xL3jmS-0S570wd2BNs1Q_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14798000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_4MP8Qp89sUWZw3P4Tpn1wA_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_gnsy8EPmaEier7y9ozKuJw_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14713000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_kEu4cO8CqkaJfW-oA31pQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future principal payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less unamortized discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (925)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-current portion of debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_lJuUa4gsHU6mkkEEbsi2Dg_3_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne>
    <aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_3lDbQCY3KEONY3r4YgZl_Q_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15638000</aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo>
    <aytu:LongTermDebtAndFinanceLeaseLiabilityGross
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_TNMCtW29c0WpwDnEo9TGXQ_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15723000</aytu:LongTermDebtAndFinanceLeaseLiabilityGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_U3bq9t-vxUCNo4QeeOS7Zw_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">925000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_yR9r2JykRUWKMkXnnokhAw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">85000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_mlT1e9sNfE6gR-VhowsOdg_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">14713000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_xE0VuuBj8kutHU4XH7Gk3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:9.5pt;font-weight:bold;"&gt;12. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We determine the fair value of financial and non-financial assets using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Level 1:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Level 2:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Level 3:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities&lt;/span&gt;,&lt;span style="font-size:10pt;"&gt; contingent consideration liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, accounts receivable, accounts payable&#160;and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company&#x2019;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recurring Fair Value Measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2023 and 2022, by level within the fair value hierarchy:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Yi-wD1QAw027O6Gw0MqnzA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CVR liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YynIzFLXAkeAX8AGtpTUAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents in the consolidated balance sheets include bank deposits and money market funds, and reflect their fair value at Level 1 in the fair value hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Recurring Fair Value Measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial assets and liabilities that were accounted for at fair value on a non-recurring basis during the years ended June 30, 2023 and 2022, were fixed payment arrangements, goodwill and intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Fixed payment arrangements are recognized at their amortized cost basis using market appropriate discount rates and are accreted up to their notional face value over time. Significant assumptions used in valuing the fixed payment arrangements were discount rates from 10.0% to 15.4%, and are classified as Level 3 inputs in the fair value hierarchy. In May 2022, the Company recognized a fixed payment arrangement liability of $7.6 million relating to the termination of the License, Development, Manufacturing and Supply Agreement with Tris. See Note 9 &#x2013; Other Liabilities for further information on fixed payment arrangements. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Based on the Company&#x2019;s impairment analyses for fiscal years 2023 and 2022, the Company recorded an impairment charge of $5.6 million on intangible assets during the year ended June 30, 2023; and an impairment charge of $7.1 million on intangible assets and $65.8&lt;span style="white-space:pre-wrap;"&gt; million on goodwill for the year ended June 30, 2022. Valuation of goodwill and intangible assets involves significant Level 3 inputs in estimating their fair values. These input assumptions included revenue growth rates, forecasted EBITDA margins, and the selection of a discount rate. These assumptions may be affected by expectations about future market or economic conditions. See Note 7 -  Goodwill and Other Intangible Assets and Note 2 - Summary of Significant Accounting Policies, for further discussion on the fair value measurement of goodwill and other intangible assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Summary of Level 3 Input Changes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the&#160;year ended June 30, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CVR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consideration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Included in earnings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (578)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (391)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,391)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Purchases, issues, sales and settlements:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Issues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Settlements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3 Inputs&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Changes in the fair value of contingent liabilities in subsequent periods are recorded as a gain or loss in the consolidated statements of operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant assumptions used in valuing the CVRs were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leveraged Beta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Market risk premium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;20.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Company specific discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;August 9,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 8,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant assumptions used in &lt;span style="-sec-ix-hidden:Hidden_iwcBQPje9UyI7pXQKxPUyQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;valuing&lt;/span&gt;&lt;/span&gt; the derivative warrant liabilities, marked to market, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;83.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.59-4.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.13-4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;              Expected volatility was based primarily on historical volatility. The Company chose to use a two-year lookback on historical volatility to avoid the effects of COVID-19 and the Innovus acquisition. The Company believes this method produced an estimate that was representative of the Company&#x2019;s expectations of future volatility over the expected term of these warrants, and will not differ materially. If expected volatility by the active market is higher than estimated, the derivative may result in a greater fair value. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_0fQuHK8GzEKd155MIjpOFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Yi-wD1QAw027O6Gw0MqnzA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value at June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CVR liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YynIzFLXAkeAX8AGtpTUAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg"
      decimals="-3"
      id="Tc_OagLZFhYJ0etkdeK0ruIqg_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg"
      decimals="-3"
      id="Tc_iu4xgb2F1EOxpRBxCTYiRw_6_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cwNRITAiPkukl10bayVdpg"
      decimals="-3"
      id="Tc_6mLCpyVGgkyyifgXVPDzRQ_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Zb1hu8tssE69fl5YLVAcVg"
      decimals="-3"
      id="Tc_Fr70Bfbo7UyOE-Cm0f4zTg_7_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A"
      decimals="-3"
      id="Tc_D47XN0c61EWvXskUVSNEIA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">396000</aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability>
    <aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg"
      decimals="-3"
      id="Tc_STEJEQ04LU6uFt8kuqGkJQ_6_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">396000</aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability>
    <aytu:ContingentValueRightsLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A"
      decimals="-3"
      id="Tc_bf2NChayy0m-eGlSdm2Xgw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">578000</aytu:ContingentValueRightsLiabilitiesFairValueDisclosure>
    <aytu:ContingentValueRightsLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg"
      decimals="-3"
      id="Tc_nBkzOOv4ckOZyT0n6WuQag_7_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">578000</aytu:ContingentValueRightsLiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A"
      decimals="-3"
      id="Tc_oB70SXezh02hJ6fjQl1vcw_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg"
      decimals="-3"
      id="Tc_9r48odMk1UShmkN2hLcYNw_8_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A"
      decimals="-3"
      id="Tc_iClno79Yl0-xp17NCP070A_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2770000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_gRaIptCZZkiKOcmup747sg"
      decimals="-3"
      id="Tc_LOebDGcsg0CZemIWRFe-aQ_9_12"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2770000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <aytu:FixedPaymentArrangementsMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_WKARek3HGUePLpa2Lv1yQw"
      decimals="3"
      id="Narr_K187N8DzkEm5BHkAZ1PAPw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.100</aytu:FixedPaymentArrangementsMeasurementInput>
    <aytu:FixedPaymentArrangementsMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_KrFIpmKuVEO1-6ai2hZCKQ"
      decimals="3"
      id="Narr_svdMiSP530aTLMCdhdkTqg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.154</aytu:FixedPaymentArrangementsMeasurementInput>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_5_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Z0XzDKGO6UGmhcRPSeKd1g"
      decimals="-5"
      id="Narr_GF1g1X4ZI0GWcvBW9pxi9g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7600000</aytu:FixedPaymentArrangements>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_xvSqIJNyCkWCNpBxc58Ayg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5600000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_Gjw2uEHuPUG5RDO4G0ro6A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7100000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-5"
      id="Narr_-PwKd-5qEUmlvfLtogUjpg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">65800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_rwYMkNUfOEqq5g9bJrW_lw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CVR&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consideration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liability&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="10" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Included in earnings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (578)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (391)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,391)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Purchases, issues, sales and settlements:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Issues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Settlements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA"
      decimals="-3"
      id="Tc_pREYRHxAC02w7LKKoGWLhw_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">578000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_AfRtXHFQ9USFYETLv0hWfw"
      decimals="-3"
      id="Tc_xgJZWAdAykeVZyVSwKhuGg_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">396000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_KFT-owhYG0KTW-8HwcgXlQ"
      decimals="-3"
      id="Tc_KEQaDa4ldUCZrG19iD-p0A_4_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1796000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw"
      decimals="-3"
      id="Tc_ZFpgwZhkqUyRl3zlMAqdiw_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">578000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg"
      decimals="-3"
      id="Tc_cXnfGMkH6EyXv-Fz8sqpEw_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ"
      decimals="-3"
      id="Tc_Wf-8xld3FUS6QvmVZbVqvA_5_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6391000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ"
      decimals="-3"
      id="Tc_tdxxPEX1e0uf4NzO0Pesnw_7_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10998000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentConsiderationMember_srbVVwRjQkipICt7LXsyTg"
      decimals="-3"
      id="Tc_wM3pmftTB0ygGEduaXmRnQ_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_i3pgtEL-p0az9jQE1IUGqw"
      decimals="-3"
      id="Tc_RRCPbu8y90yBCsaliGqc5Q_9_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6403000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_IHXx_69-2k6xSeLjf9Zxuw"
      id="Tb_9T5Pro5tD0yyXwNzqFFJug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant assumptions used in valuing the CVRs were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leveraged Beta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Market risk premium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;20.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Company specific discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ"
      decimals="2"
      id="Tc_dshqxwsz9UGkqLEQv96ncg_3_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.84</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_32pYQVd-O0683kHB-OxqJw"
      decimals="2"
      id="Tc_mwSjWMkq2ECt5aQ0CeFI_A_3_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.85</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_v1uEDB4Qe0ChX25O408Kdg"
      decimals="4"
      id="Tc_y51y1A5viEOBAM11NMGDCQ_4_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0635</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputMarketRiskPremiumMember_j9upZ0K_wkaSqBsZ35fPUA"
      decimals="4"
      id="Tc_2fWEwDSpGUmsnBRuTEIrqA_4_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0622</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_t-JITEKUA0GmzvfgKWJObg"
      decimals="4"
      id="Tc_ZrkfroQAH0qZ_Pw06W-SNw_5_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0547</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_6RWMQBcVTkKXBXn5bPIjLQ"
      decimals="4"
      id="Tc_ZW8t7n6Hp0-sTJwXwQEGZQ_5_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0286</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_G4Ig525OfkKi6bpvihM7ow"
      decimals="4"
      id="Tc_TpCmS5Lokk-1FXP-SgR1nw_6_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.2200</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_vlDLGuQ7RU6fpglPTudPkA"
      decimals="4"
      id="Tc_WzE49ZmVkESc_wMzf9STCw_6_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.2050</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_XqoLyaAyJkqUthh4KeWIOQ"
      decimals="4"
      id="Tc_9V-e_ia6skWcWqq-vCAM4Q_7_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.1000</aytu:ContingentValueRightsMeasurementInput>
    <aytu:ContingentValueRightsMeasurementInput
      contextRef="As_Of_6_30_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_z3pQQ5Ly3kepba66l3j4ig"
      decimals="4"
      id="Tc_cDMES5KkPkuEsgHy6E5P8g_7_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.1000</aytu:ContingentValueRightsMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_uDrFgqv7o0qW8bWsea15KQ"
      id="Tb__kF3gv0r2U6suYK6GyS6Kg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Significant assumptions used in valuing the derivative warrant liabilities at issuance date were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;August 9,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;89.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 8,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;83.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant assumptions used in &lt;span style="-sec-ix-hidden:Hidden_iwcBQPje9UyI7pXQKxPUyQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;valuing&lt;/span&gt;&lt;/span&gt; the derivative warrant liabilities, marked to market, were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;83.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equivalent term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.59-4.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.13-4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_BwVbhIEKsk-sG7dxwmlpBg"
      decimals="4"
      id="Tc_1FyOmwd0MUyMGPhTgLFPOw_3_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.8989</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lHN7htztVE6wijIYRnB1CQ"
      decimals="2"
      id="Tc_jx0jZ1oLs0qhVYWJJRnzJA_4_2"
      unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw">4.11</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_9VU0MObsYUWsSE7KNqA2LQ"
      decimals="4"
      id="Tc_bsi_l92ld0GiZrJsUK9Mew_5_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0309</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_8_9_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_LU7VfbLrpkCDkceqmLfiUg"
      decimals="4"
      id="Tc_f5nDLccMwE2aZZJCsJaqhg_6_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0000</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_psdJZSxrqEyjZhoFMF-3Bg"
      decimals="4"
      id="Tc_-0NTYcg9cEWJ3P1t1rExYw_3_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.8326</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_OU6-ZAL7g068xkL0XGt6CA"
      decimals="2"
      id="Tc_qY3XN_iAzEiiz0uqMRfasA_4_2"
      unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw">5.01</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_V5QFAOw8DUmhBp4aYi7M0Q"
      decimals="4"
      id="Tc_rqRistxa90KkrjPTsRwoDA_5_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0387</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_8_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_uyAuyq8iF02T8ekDM7p7Ig"
      decimals="2"
      id="Tc_lwA3U4zbmkerxG3nWZCKFQ_6_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.00</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_LRQAfaW_D0auL9YBkk-kXw"
      decimals="4"
      id="Tc_z9WsiKOjbUiIzjzdrrKoMQ_3_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.8342</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_Z12qpqcVkkK_jr6qZ_cGBA"
      decimals="2"
      id="Narr_n5TOuB2JXUKERCwunA9NqQ"
      unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw">3.59</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_lzWJ_F-ZrUaSzSfq1TNUiA"
      decimals="2"
      id="Narr_5bKZ-Iz_b0qhWCN6kcIWzA"
      unitRef="Unit_Standard_Y_g5EHe1fv50OMs7g4KHIqYw">4.95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_wTfWp6Qu5kuUcvqKqDdSvA"
      decimals="4"
      id="Narr_XC0szhTIuUmojD7ah7a2GQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0413</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_IsVh2msT0EmhmcrW0JvYbQ"
      decimals="4"
      id="Narr_8_7NkBpvOEWVnLsRgfDDsw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0440</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_3CSXkEWhhkC8dtO67-wH2A"
      decimals="4"
      id="Tc_QeFxWp4Z8EiJF8r0TYcMhg_6_2"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0000</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_dVnRG1a2Skak1Geepo5a8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the fiscal year of 2023, there was no income tax benefit, primarily driven by Section 382 limitation on post-TCJA (&#x201c;Tax Cuts and Jobs Act&#x201d;) net operating loss (&#x201c;NOL&#x201d;) utilization, further described below. As of June 30, 2023, the Company had $0.1 million deferred tax asset (DTA) included in other non-current assets, $0.1 million deferred tax liability (DTL) included in other long-term liabilities, and $0.1 million income tax payable in accrued liabilities in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Section 382 Limitation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the provisions of the Internal Revenue Code, substantial changes in the Company&#x2019;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. NOL carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the Company&#x2019;s Section 382 analysis, an ownership change was determined to have occurred in March 2022 at a point in time when the Company had a net unrealized built-in gain. As such, the NOL generated during that period has been allocated and the post-change NOL (approximately $12 million) is determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation. The Company also determined that ownership change occurred in June 2023 at a time that the Company was in a net unrealized loss position. As a result of the Section 382 analysis, the Company had estimated $0.3 million of disallowed recognized built-in loss and had carried forward as an operating loss as of June 30, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had federal net operating losses of approximately $504.0 million as of June 30, 2023, that subject to limitation (as described above), may be available in future tax years to offset taxable income. Of the available federal net operating losses, approximately $172.0 million can be carried forward indefinitely, while the remaining balance will begin to expire in 2024 and completely expire in 2027. As of June 30, 2023, the Company had research and development credits of $3.0 million, which begin to expire in 2024. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2039. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, the Company had various state NOL carryforwards. The determination of the state NOL carryforwards is dependent on apportionment percentages and state laws that can change from year to year and impact the amount of such carryforwards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company notes there is diversity in practice regarding the treatment of deductions or loss carryforwards that are expected to expire unutilized.  Generally, it is not appropriate to use zero as an applicable tax rate and rather, a deferred tax asset should be recorded at the applicable tax rate and a valuation of an equal amount would be provided.  However, under certain circumstances it may be appropriate to follow an alternative approach and use a zero rate to write off the asset against the valuation allowance, reducing the valuation allowance and gross deferred tax assets disclosed.  The Company considered both accounting viewpoints and determined it would present its NOL carryforwards gross with a full valuation allowance and not apply a zero rate to NOL carryforwards expected to expire unutilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In review of the Company&#x2019;s consolidated deferred position excluding NOLs and other tax attributes, the Company is in a net DTA position and therefore all NOLs are being fully valued and not utilized against a net DTL. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The provision for income taxes consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (109)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (117)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax benefit resulting from applying statutory rates in jurisdictions in which the Company is taxed (Federal and various states) differs from the income tax provision (benefit) in the financial statements. Reconciliation of the U.S. federal statutory income tax rates to our effective tax rate is as follows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent difference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;162(m) limitation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Goodwill impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remeasurement of deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of phased-in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on debt extinguishment and interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.09)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued Rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174 Capitalization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 836&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 132,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,966)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (845)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (308)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,378)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (127)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In fiscal year 2022, the impairment of goodwill decreased net deferred tax liabilities by $0.1 million resulting in an income tax benefit of $0.1 million. As of June 30, 2022, the Company had $0.1 million deferred tax liabilities included in other long-term liabilities in the consolidated balance sheet. The Company had federal net operating losses of approximately $503.2 million as of June 30, 2022, subject to Section 382 limitation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has recorded a valuation allowance of $136.4 million and $129.0 million at June 30, 2023 and 2022, respectively, to reserve its net deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not, that it will realize the benefits of these deductible differences, net of the valuation allowance provided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. The Company has no accrued interest related to its uncertain tax positions as they all relate to timing differences that would adjust the Company&#x2019;s net operating loss carryforward, interest expense carryover or research and development credit carryover and therefore do not require recognition. As a result of these timing differences, at June 30, 2023 and 2022, the Company had gross unrecognized tax benefits related to uncertain tax positions of $2.9 million and $2.8 million, respectively. Changes in unrecognized benefits in any given year are recorded as a component of deferred tax expense. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A tabular roll-forward of the Company&#x2019;s gross unrecognized tax benefits is below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase resulting from prior period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase resulting from current period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decrease resulting from current period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (120)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (647)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The change in the Company&#x2019;s gross unrecognized tax benefits relates to the acquisition of Neos, whereby historic tax positions of Neos were inherited in the acquisition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Additionally, Neos pre-acquisition tax years are subject to the same general statute of limitations, resulting in its tax years back to 2004 being subject to examination.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_Hz4nRry6PEKxKZkLXrpYaA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_1tT0xZNkt0etJpk7fTLLPg"
      decimals="-5"
      id="Narr_QurA6XKqrUGSrdGkhRXvAg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg"
      decimals="-5"
      id="Narr_-atlxU1Gd0CMcy3q4Q5kjw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_AKPEG3Pb6kq5eJ4MAe6TNw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:AccruedIncomeTaxesCurrent>
    <aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-6"
      id="Narr_HGEfR3fBSkW-kIRterpt_Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12000000</aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation>
    <aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_6ui3hPEfukqbOxTDTGixIw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">300000</aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ"
      decimals="-5"
      id="Narr_xUNKi9L0qkeWVmaa3mtIBg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">504000000.0</us-gaap:OperatingLossCarryforwards>
    <aytu:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ"
      decimals="-5"
      id="Narr_PcP-Lq9S1061U6uuOAncvQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">172000000.0</aytu:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w"
      decimals="-5"
      id="Narr_o8xXzGVuRkuQ739dJAopiA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_nGAwGj7mDUizmofVdGqGjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (109)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (91)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (117)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_DEPGXwkuNEG_Z7JPfN-uww_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">80000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_D0l-UutydkGhYn0m4fqQPQ_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">46000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_oVrmDNspkUeD7svrQiM9sQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_HOaPGdkd3EysY0-Rp95Rxw_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">126000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Zt22Yieb1Uiku3DlpBIzMw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_Xuz2bKGQM0mpN1n3kmmsGw_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-109000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Rkum4b-UO02PMNSuvD5wSA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-91000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_ONrGF_sMN0mC0nWozo7ONw_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_tnQahNnDrECmrIpM5aph2w_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-26000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_7iWvqELPkEa6ENm1Ezwn9Q_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-126000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_3qKMKzBHiEOlXnZuVKIPYQ_11_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-117000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_9JENLb4gP06vVVwCaHgthw_12_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_1ATgvjyrfUm8S__kcj2rsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="13" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,159)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent difference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.14)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;162(m) limitation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Goodwill impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remeasurement of deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of phased-in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on debt extinguishment and interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (110)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.09)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_mOrsxZwNmU2zY5Uy5VFOzQ_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-3581000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_Ny5iKXGeIEGbHFdcepNRJg_4_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">-0.2230</aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_pcUxmGWp6EmU-LqXWQZjOQ_4_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-23159000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_3rf-NMpfPU2-UD1t21BPiQ_4_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">-0.2100</aytu:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_7NpCzkRXw0ShKLOjdn1Yig_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">16000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_hYQf2EGQwkCgOICe43N9lQ_5_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0010</aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_N492SKHJ2kyk7EdMV9phEg_5_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">601000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_D_R6A_e5ZEisfVH5--273w_5_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0055</aytu:EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_irU92--3JUmiVzwxuINgZQ_7_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">273000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_ryXkfrod7U2P6gUVbpbU5w_7_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0027</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <aytu:IncomeTaxReconciliationContingentConsideration
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_jesCxAUj-kCZOe51SRYuCA_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-193000</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_TCJBWymQFka0jonopWQRHg_8_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">-0.0120</aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration>
    <aytu:IncomeTaxReconciliationContingentConsideration
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_lXXuXJcN7UmKPwsQPmNlDw_8_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-155000</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_wN4OMTTj40KvixLRqKqgmA_8_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">-0.0014</aytu:EffectiveIncomeTaxRateReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_gSHJZ3NpSkqhbl5R8FVc5w_9_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">76000</aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount>
    <aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_EZfR-daUj0inLEhWdxM3iA_9_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0008</aytu:EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_0S_liwaUG0WYOv8ogEGwfg_10_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9733000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_SjMlqGV83USD3j61QxLbXw_10_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0883</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_O0CsLdM6nUaEAsJn4tgxxQ_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3641000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_QgnwKTRJC0uVFzCFRmkQBw_16_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.2268</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_wn3M7KseAEi6b2roebnPPQ_16_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12472000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_Xp2ARINILkKWeKqK7RG7mQ_16_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.1131</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_F0bvqNWkuUS4skPfO2nGsg_18_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">117000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_n4FdCNnSAk-wZzczMTtsYw_18_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0072</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_VNDIhl_rYUSgjRtd2cZj-w_18_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">49000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_RDA_zpXRkkuSW-XSdIq3CA_18_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="4"
      id="Tc_yUkShCc21k-2p_d-qBgJ2w_19_5"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Ude9sxTfx06jnzcEEKU3mw_19_9"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-110000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="4"
      id="Tc_kFBzyxv4AUWRp9G-xPxDtw_19_11"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">-0.0009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_5R6b5SIDXk2JyLkltqb8bQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 114,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued Rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,773&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 758&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,423&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174 Capitalization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 836&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 137,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 132,652&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,966)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (845)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,717)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (308)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (483)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (788)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,378)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,813)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (127)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_I3_BfWX1LE-jfjNGku9EYg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">114265000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_YySYEJNfQUuqcQffRWX58w_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">114443000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <aytu:DeferredTaxAssetsAccruedRebates
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_Zua6k96kGEWeJUXXBp9qtQ_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6994000</aytu:DeferredTaxAssetsAccruedRebates>
    <aytu:DeferredTaxAssetsAccruedRebates
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_CcP0CpYrAEuLWdmX_oNHvQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5944000</aytu:DeferredTaxAssetsAccruedRebates>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_ycQUsyUo7EKoIUpnOhYagA_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4250000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_SOWtCQ_Oaka8zorbKHDQMw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2773000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_A5eAlkYaEEW2v28ATbz7lA_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">758000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_PajtVnPBPk2vBPuqKNx4LA_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">817000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_lIfyVqGwcUGEGii372NnmQ_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2416000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_Renrsfxt60SCDOZkMR4Jaw_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2423000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <aytu:DeferredTaxAssetsInterest
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_mE4EbTx_HEiuzOEORT-tag_10_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4188000</aytu:DeferredTaxAssetsInterest>
    <aytu:DeferredTaxAssetsInterest
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_JiVs2oDrw0aEkUEyc0n0nQ_10_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2975000</aytu:DeferredTaxAssetsInterest>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_GgiqeaArcUCI8hMCmmYhxg_11_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1504000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <aytu:DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_FOE5hVtymEi-4lTO2jR0aQ_12_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">836000</aytu:DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_6xU8zWaPe0GznpSkIgkW2w_13_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">743000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_D3zRloraPUKY37_cZt60YA_13_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1177000</us-gaap:DeferredTaxAssetsInventory>
    <aytu:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_ReUNN-vFI0Kr-EYCudI1cA_14_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">492000</aytu:DeferredTaxAssetsLeaseLiability>
    <aytu:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_mbyJXI8LbEKwJuOkD8a_QQ_14_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">799000</aytu:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_wYACH3EYpUWF1XR7JqAxtg_15_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1332000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_c8z6NALaH0uEmOwOe_p9Fg_15_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1301000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_b_OPMSvm8ki10vNqFUniMQ_16_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">137778000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_vtSzJ87t9kymxbuX2kt6LA_16_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">132652000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_4uQLZwpU4UyKkSMKmi_bMA_17_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">136400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_R1zm5UicGkCvhDj-YZUW4Q_17_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">128966000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_zGsgTVmpmkqzSpRPezMrMg_18_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1378000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_z432LUx-10uFWRyoW0-38w_18_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3686000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_6-ssxNpR7UiMWW7KzSn1Wg_20_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">845000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_HPjAOCUrIEKztjY4-zDEAg_20_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2717000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_9U67NEqITUmsnMgUy0vBZw_21_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">50000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_mfsZTExzHE-y8f_UHwDHgg_21_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">308000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <aytu:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_huk88KhnXEuGEKbivxle7g_22_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">483000</aytu:DeferredTaxLiabilitiesRightOfUseAsset>
    <aytu:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_AoLppWwgZ0qUk-AGIQyXlQ_22_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">788000</aytu:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_ipmcDWc9iEiF6CDgt9sMjQ_23_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1378000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_WnTJtQYPWEyqFtUpKRT9rg_23_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3813000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_RwdOHhiVZ0SeXpR2deRQHw_24_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">127000</us-gaap:DeferredTaxLiabilities>
    <aytu:DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_dovBdmKCGUSW_ygJkhEIfw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment>
    <aytu:IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-5"
      id="Narr_mV1rNYrK8EGmst-FoeihXA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg"
      decimals="-5"
      id="Narr_e4DBSh5kTEqMT2r-m0cZaw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_6_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_MBlO3K9Y5E-CNimpZftBwA"
      decimals="-5"
      id="Narr_1DbaP_MKI0SnciYiimOEEg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">503200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_3yM3ByFDYEa6yI1CHnUJ2g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">136400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_Iwg-8a7u_U-k1DPd4AgMnQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">129000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr__mYQmGaEgkuw4wYPVyq3MQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_UeHPbuQhlUmuhV1U1TR61g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_bYYoqHwQPU-tJHIMISvylw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase resulting from prior period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increase resulting from current period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 246&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decrease resulting from current period tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (120)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (647)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_mkQ0zv49GUCxUUWdckWSow_4_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2822000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg"
      decimals="-3"
      id="Tc_DcxP_RGPK0uxePVIff_OLw_4_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3435000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_uPot53ItE0mH_7Y7g_8ueA_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">246000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_thkEsFB9JUqD9fyR3klajQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">34000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_wSGdzj1NLEmOIBWMwpPXtQ_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">120000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_zKbLXLa4wUGxPLCNSxIDpA_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">647000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-3"
      id="Tc_yjx2mtp_P0mhZogoGcLXqQ_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2948000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-3"
      id="Tc_yi306P61NEOrBJywxNxd9w_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2822000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_qQQw_6nLjUiAKYLpp-U1RQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has 200.0 million shares of common stock authorized with a par value of $0.0001 per share and 50.0 million shares of preferred stock authorized with a par value of $0.0001 per share. As of June 30, 2023 and 2022, the Company had 5,517,174 and 1,928,941 common shares issued and outstanding, respectively, and no preferred shares issued and outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Included in the common stock outstanding are 40,996 shares of unvested restricted stock issued to executives, directors, and employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 8, 2020, the Company filed a shelf registration statement (the &#x201c;2020 Shelf&#x201d;), which was declared effective by the SEC on June 17, 2020, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. On June 4, 2021, the Company entered into an agreement with an agent for the sale of up to $30.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the 2020 Shelf (the &#x201c;ATM Sales Agreement&#x201d;). During the year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total gross proceeds of approximately $3.0 million before deducting underwriting discounts, commissions, and other offering expenses of $0.1 million. The 2020 Shelf expired in June 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 28, 2021, the Company filed a shelf registration statement (the &#x201c;2021 Shelf&#x201d;), which was declared effective by the SEC on October 7, 2021, covering up to $100.0 million of its common stock, preferred stock, debt securities, warrants, rights, and units. As of June 30, 2023, approximately $82.4 million remain available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. The 2021 Shelf expires in October 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 7, 2022, the Company closed on an underwritten public offering utilizing the 2021 Shelf, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common stock purchase warrants to purchase up to 333,300 shares of common stock (the &#x201c;March 2022 Offering&#x201d;). The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable &lt;span style="-sec-ix-hidden:Hidden_fR7I1KmwmUOKA79OdXpBSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six months&lt;/span&gt;&lt;/span&gt; after the date of issuance and have a term of five years from the date of exercisability. The Company raised gross proceeds of $7.6 million through the March 2022 Offering before commission and other costs of $0.8 million. The pre-funded and common warrants have a combined fair value of approximately $2.8 million at issuance, and are classified as a derivative warrant liabilities with the offset in additional paid in capital in stockholders&#x2019; equity in the Company&#x2019;s consolidated financial statements (see Note 16 - Warrants).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On August 11, 2022, the Company closed on an underwritten public offering (the &#x201c;August 2022 Offering&#x201d;) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance, and are classified as derivative warrant liabilities with the offset in additional paid in capital in stockholders&#x2019; equity in the Company&#x2019;s consolidated financial statements (See Note 16 &#x2013; Warrants).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On June 8, 2023, the Company entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#x201c;Common Warrants&#x201d;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the &#x201c;Exchange Warrants&#x201d;). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company&#x2019;s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company&#x2019;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 &#x2013; Warrants).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_9_VzCTVtZUe_BY4C2oqPPQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_AuMZhG0Bq02W3TE7v4m8TA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_FSSgZbDcIk2zWuST0x5jKw"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_vLtWntjLskOsH0lzwFKc7g"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="-5"
      id="Narr_ey0MIKy6pUGnp2vHUSeWJQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">50000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="-5"
      id="Narr_EOkG_E2G8kWu09VBYgy3yQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">50000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_Rx3IQpJCrEmOtyrniMgwNg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_Zj_dPmSkC0eVXRVHrHNwdg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_apxGfm4LWku_3-j0CGjUWg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5517174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_z1qe5EoP7U6lCNdGXyIvqA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5517174</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_z-cqLgvOpEiG02wRuAV3hQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_lS57SBx50UKbHnfLborsKg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1928941</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_ge_CWWasykSQ75IqYWhYJg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_F75a8ifL3EqzAjCpDAKIsw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Narr_oQAccj4dvkSX1CUOLPZhuQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Narr_6S818-YZY0muWmq5954NsA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TdsGYshoqUijifsxflxvYA"
      decimals="INF"
      id="Narr_R--OjroIkE-nEm3gQ5x1xA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">40996</us-gaap:CommonStockSharesOutstanding>
    <aytu:ShelfRegistrationAmountAuthorized
      contextRef="As_Of_6_17_2020_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfMember_g5mEjHtQiUyvG-DIxyhSLA"
      decimals="-5"
      id="Narr_A3ebeaE-rkyWcL-2KHjL1w"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000000.0</aytu:ShelfRegistrationAmountAuthorized>
    <aytu:AtmSalesAgreementAmountAuthorized
      contextRef="As_Of_6_4_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_6bo-99QlKEWBnykXi0Nj8w"
      decimals="-5"
      id="Narr_wWCNeotl702fk2MuWKVAzQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30000000.0</aytu:AtmSalesAgreementAmountAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A"
      decimals="INF"
      id="Narr_ze6ZSJWgA0KnI_-dMdd42g"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">699929</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A"
      decimals="-5"
      id="Narr__od4kflCtUm3wxjY1te-2w"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember_WO_s8jJs40OI6fA-sN1S5A"
      decimals="-5"
      id="Narr_PdwMHqxqxkKorRlsvdXE_Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses>
    <aytu:ShelfRegistrationAmountAuthorized
      contextRef="As_Of_9_28_2021_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_biR4fT1tx0yl6OmCteqbJw"
      decimals="-5"
      id="Narr_T57JElUAwEKY3U1fra_vJA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000000.0</aytu:ShelfRegistrationAmountAuthorized>
    <aytu:ShelfRegistrationRemainingAmountAvailableForSale
      contextRef="As_Of_6_30_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfMember_t8Ed9oXcc0ahpFotmKPoCw"
      decimals="-5"
      id="Narr_0WqzyCvkgUasB9TWACnENA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">82400000</aytu:ShelfRegistrationRemainingAmountAvailableForSale>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA"
      decimals="INF"
      id="Narr_t5IWsTWUe06II53YZRBf3g"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">151500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg"
      decimals="INF"
      id="Narr_KyVLLDBRykuK9nfZvX9jDw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">151500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_1CHTv40zdkK3YS7uoe7Z8w"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">333300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_1czrUMCo2U6i7MU7buKz0Q"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1.1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg"
      decimals="INF"
      id="Narr_o9VmgfFSUEiXatjNkOi0vg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_CAwpursoU0qpGQR5oQh8WA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">26.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      id="Narr_9u7YqFng-kCVTA6JqhESHg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA"
      decimals="-5"
      id="Narr_rbx_aD2ev0iH0N6XxWsfpg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7600000</aytu:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA"
      decimals="-5"
      id="Narr_el8GYwKeNkGWg8LlYT6DfA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">800000</aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg"
      decimals="-5"
      id="Narr_bAadN-Ex1EW_8qD9_Q9QAA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA"
      id="Narr_FQ-7_5jVYEOW0V9xTQzqgw">2022-08-11</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA"
      decimals="INF"
      id="Narr_M3X9oG45kkSLnt29N-cBOA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1075290</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"
      decimals="INF"
      id="Narr_fGeqUiuEok6jlRXP4uY0RA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">87500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_YHyrFgDghkqz-hzG1rrPEQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1265547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"
      decimals="INF"
      id="Narr_9gverrxbKUK9oYHeXUrkaQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_YHsl-ggX1EeVYlFjYgd-3Q"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_1c-ygVpo4EypcsU4CkVa0Q"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightOfferingPrice
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw"
      decimals="INF"
      id="Narr_zpL9LAwFgEWkyzaL3EgtHA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.58</aytu:ClassOfWarrantOrRightOfferingPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_31_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_ik8BrUrWiUqfXRn4qxLh-g"
      decimals="INF"
      id="Narr_mtq_QBFKCE2CHe1McTWa5A"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_15YFYDxNtUyzsB00zTEIRg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      id="Narr_3k35P_CB-kqDhMvTpDPyVQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA"
      decimals="-5"
      id="Narr_C9GA9eA2n0Ce62RWRbQSHg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10000000.0</aytu:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses
      contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member_JpjGQwpiVkWXBY6hGEhkZA"
      decimals="-5"
      id="Narr_DyizO_kNREajBZnsLJHANA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">900000</aytu:CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_be7MR4B5u0GtQAxY595aXw"
      decimals="-5"
      id="Narr_oxD6_ah7TkWS9YeM_bj2Hw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6000000.0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ"
      id="Narr_WKAf8oEmU0a1hF7jdibpNw">2023-06-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"
      decimals="INF"
      id="Narr_iyiG3Egjd0SwGOQUwt26OQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1743695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_l347MGO4HUapGRyzMJxwlw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">430217</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      decimals="INF"
      id="Narr_TL1iizNZa0OPs8BRWHFklA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A"
      decimals="INF"
      id="Narr_Dx-Rw7bmCk-fw79wNUAAew"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q"
      decimals="INF"
      id="Narr_ADLK7Xhw2Eqcw02LX3tiwg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_80dVEL80M06emJg-qEzWag"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_TBcydqPWNUizj0YiY9Ya7A"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q"
      decimals="2"
      id="Narr_z9IX80Xr3kC5lBvtIK562Q"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">1.59</aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="4"
      id="Narr_rWvbkZEBp0WHR61t2LxWjw"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">1.5899</aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      id="Narr_1MJaSgshBU2H9zP1-S7ywg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q"
      id="Narr_1swSRuMuC0KpHNn19h9Szw">P30D</aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock>
    <aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      decimals="INF"
      id="Narr_K_Xa-1a8UEGRzIIhw9W2bA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">2</aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A"
      id="Narr_9JHEPMy8zkaJKdK1rIXEsQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA"
      id="Narr_1OAzFbCXq0eu3zQmCMVMMA">P30D</aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda>
    <aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA"
      decimals="-6"
      id="Narr_vItENKF_sUKk4LvK1E6NvA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12000000</aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"
      decimals="-5"
      id="Narr_BLltnzEieki3Xlb2G_xf3Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4000000.0</aytu:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <aytu:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"
      decimals="-5"
      id="Narr_NQo5Ok_7xUCXRiQzMQouxw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3400000</aytu:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_QByDhdR18kWOtQNXuaKWXg"
      decimals="-5"
      id="Narr_8DorV8Q5TkajnchYXDJMGA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5000000.0</us-gaap:WarrantsAndRightsOutstanding>
    <aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"
      decimals="-5"
      id="Narr_wdY71VAp-E-02C9s4zQn0w"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Pg8hqGz--UmWV1_lwbwGKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2023 Equity Incentive Plan.&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt; On May 18, 2023, the Company&#x2019;s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the &#x201c;2023 Equity Incentive Plan&#x201d;). Prior to the Company&#x2019;s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (&#x201c;Aytu 2015 Plan&#x201d;) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (&#x201c;the Neos 2015 Plan&#x201d;) (collectively the &#x201c;2015 Plans&#x201d;).  For the 2023 Equity Incentive Plan, the stockholders approved (a) &lt;/span&gt;200,000 new shares, (b) 87,155 shares available for grant under the 2015 Plans be &#x201c;rolled over&#x201d; to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional &lt;span style="-sec-ix-hidden:Hidden_Hl9WG5ycz0COuiafV-9j_g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;awards&lt;/span&gt;&lt;/span&gt; will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. As of June 30, 2023 the Company had 287,155 shares that are available for grant under the 2023 Equity Incentive Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Aytu 2015 Plan.&lt;/i&gt; On June&#160;1, 2015, the Company&#x2019;s stockholders approved the Aytu 2015 Plan, which, as amended in July&#160;2017, provides for the award of stock options, stock appreciation rights, restricted stock, and other &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;equity awards. On February&#160;13, 2020, the Company&#x2019;s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, and the restricted stock units have a vesting period of 4 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Neos 2015 Plan.&lt;/i&gt; Pursuant to the Neos Acquisition, the Company assumed 3,486 stock options and 1,786 restricted stock units (RSUs) previously granted under Neos plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities will stay the same as they were under the previous Neos plan. The Company allocated costs of the replacement awards attributable to pre- and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the fiscal year ended June 30, 2023, 49,212 stock options were granted. The weighted-average grant date fair value of options granted during the year ended June 30, 2023 was $4.00. As of June 30, 2023, there was $0.1 million of total unrecognized compensation cost adjusted for estimated forfeitures, related to non-vested stock options granted under the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.2 years. No options were granted during the fiscal year 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock option activity is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Outstanding June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 7.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (177)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Outstanding at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Exercisable at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 6.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table details the options outstanding at June 30, 2023 by range of exercise prices:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;123.16 - 290.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2023, as a result of the change in members of the Company&#x2019;s board, the Company accelerated unvested shares for two former members and recorded $1.5 million of non-cash equity compensation expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 19, 2022, the Company entered into a Stipulation of Compromise and Settlement (the &#x201c;Stipulation&#x201d;). As a part of the terms of the Stipulation, the Company agreed to rescind 25% of the aggregate 2021 grants to board members. As a result of the recission of the shares, the Company recorded $0.6 million in non-cash compensation during the year ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2023, the Company granted a total of 6,825 shares of restricted stock, with certain accelerated vesting conditions, to members of its management team pursuant to the Aytu 2015 Plan, of which &lt;span style="-sec-ix-hidden:Hidden_RhAn5e9yTkGo43QiNn8L3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/3&lt;/span&gt;&lt;/span&gt; vest on the grant date and &lt;span style="-sec-ix-hidden:Hidden_76J9aX39Y0KMdQ7sa8ZTdA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/12&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_ZQWV1d3orUOWhJfxpy8Wrw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;on&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Kew6LAzlW0Subej7uXg45g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_atRctttF5kGizw3GS0D_sg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;first&lt;/span&gt;&lt;/span&gt; day of &lt;span style="-sec-ix-hidden:Hidden_UM8ORUgeAkeglLMdGPU3ZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;each&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_fyBILllLnk6bWwcWwYApTw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;quarter&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Ez33FFSqI0uGMSU9NaITRQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thereafter&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:Hidden_ZiVqmCiNWEOf8STK7ZK6yw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;subject&lt;/span&gt;&lt;/span&gt; to continuing employment with the Company through each vesting date. These restricted stock grants have a grant date fair value ranging from $3.31 per-share to $13.4 per-share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock activity under the Aytu 2015 Plan is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,825&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,434)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,689)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, there was $3.6 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested restricted stock granted under the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.0 years. The total fair value of restricted stock vested during the year ended June 30, 2023 was $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company previously issued 4 shares of restricted stock outside of the Aytu 2015 Plan, which vest in July&#160;2026. On January 17, 2022, the Company granted 5,000 shares of restricted stock to a member of its management team outside of the Aytu 2015 Plan, of which &lt;span style="-sec-ix-hidden:Hidden_aDjYmXhr_0y36dQjawXmwQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/3&lt;/span&gt;&lt;/span&gt; vest on January 17, 2023 and &lt;span style="-sec-ix-hidden:Hidden_Cdi3hkXdc0OpPArxBtSwhA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/12&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_w_FAzbQnJkiomaZGu2gnqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;each&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_RQWy15Pb2k-QNuwGzup_XQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;quarter&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Pb5UtpvkmEGcCA2EitT1Fg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thereafter&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:Hidden_NOkVRpcVoUuTSnoKpinAAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;subject&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_pnnHcg3G30GLFzKZerZfyA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;to&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_Zf0xvLUMsEy4X0ESjua5-w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;continuing&lt;/span&gt;&lt;/span&gt; &lt;span style="-sec-ix-hidden:Hidden_SjR6CETviEC4J8qxQetREw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;employment&lt;/span&gt;&lt;/span&gt; with the Company through each vesting date until January 17, 2025. This restricted stock grant has a grant date fair value of $27.00 per-share. As of June 30, 2023, there was $0.4 million total unrecognized costs adjusted for estimated forfeitures, related to non-vested restricted stock outside of the Company&#x2019;s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.56&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended June 30, 2023, the Company did not grant restricted stock units (&#x201c;RSU&#x201d;). RSU activity is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, there was $0.1 million of total unrecognized compensation costs adjusted for estimated forfeitures, related to non-vested RSUs granted under the Company&#x2019;s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.6 years. The total fair value of RSUs vested during the year ended June 30, 2023 was immaterial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense related to the fair value of stock options, restricted stock and RSUs was included in the consolidated statements of operations as set forth in the below table:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 536&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and Administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A"
      decimals="INF"
      id="Narr_gVKcaUJ1CECD_fzk8wUn2Q"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_qbxZzqX92U6beZgSNWhe_A"
      decimals="INF"
      id="Narr_n0rO3WOrfk6Pemz7ClLddg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">87155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_18_2023_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_q294pgLXSkiw4_mNpKB8fg"
      decimals="INF"
      id="Narr_wfMLQhCXU0iptJnSOffSSw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_6_30_2023_us-gaap_PlanNameAxis_aytu_TwoThousandTwentyThreeEquityIncentivePlanMember_se_2_5-8wkmfy3FsWYR-eQ"
      decimals="INF"
      id="Narr_GgQ6HngVLU6KZEjP1zLtnA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">287155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_13_2020_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_L2WFGiNHUUeTtcgD-Tt5cQ"
      decimals="INF"
      id="Narr_Nmtr81akKkK56wGSvh11bg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_Hq8jU58mP0yXy0NLI2hCtg"
      id="Narr_R2PmUspq6U6jgY86bsNAFg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_S6HC2MMrH0iNwu4ujLgsNA"
      id="Narr_fjrEZtpkc0OZPz93klhDiQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_trxd6492bkmdu5cEs_LDOQ"
      id="Narr_asrubAa0tUqqVXoC_daDpA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_-jV0TussHES3Y8yd6y1Z7g"
      id="Narr_Dskadpd_R06WW2e6PVlEHw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_bgnuDzVZ90GHs01Kz4agwg"
      id="Narr_5snPOueX70eHaExI2beQFA">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_CQLYBsBbXECCphRQy0MWNg"
      id="Narr_fyiIY54YokC2cD3lNn7XWw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_YRN694O3EEKsSKs55s-uVw"
      decimals="INF"
      id="Narr_uQI604C_TkeYiO_sz_I92w"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_3_19_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_5bokif2CVU27ubsvFSCIGg"
      decimals="INF"
      id="Narr_1zS6sAZT2k2LR4MrWSxYaQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_4_19_2021_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_t8eRN6kS_EqT7DiyJIMG7w"
      decimals="INF"
      id="Narr_E5gE3D45xE2Rx35QRVQOBw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_8cakf67lD06PgvsYxOk2qA"
      id="Narr_92pSw_z9OUmsIinEuYfMPw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_amdkmNT3rEWFjdSSoepO6g"
      id="Narr_WMd7pMp29k6gCn-ZqhjCYA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_aytu_Neos2015PlanMember_gPGJ0H3cakSZg1nXXAX0Cw"
      id="Narr_ND7fYs_6EUeL766wpVWijA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_nBwUQDCSfkSj3yLRlNJtVQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">49212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Narr_lMdwQe1_JkyaWgGXXc9TMQ"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg"
      decimals="-5"
      id="Narr_Mi_pfHqtFEmzsLK2pBeTXw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UpGaGbRyLEqoaYVRkRx8cg"
      id="Narr_6QB6wNGmekycm9ucFueYrA">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="INF"
      id="Narr_MdKa1movyUWCm5QC_RPPCg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_gBpj7yXvA0uZ8ANagrf3LQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Outstanding June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 7.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (172)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (177)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Outstanding at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Exercisable at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt; 6.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="INF"
      id="Tc_kCgy_M0jJUK2jnXUyhVaXA_6_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w"
      decimals="2"
      id="Tc_V7EJLKiMHUGdz2f9Lva4hw_6_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">209.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2020_To_6_30_2021_0uZAJr7SNUWxUfK_8xoiLQ"
      id="Tc_TXCBuMgAXkWf8RiTiVucuQ_6_7">P7Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Tc_Dk85phsw90aLN29XxrBFTQ_7_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">49212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_phnx6LJWekedBSNVnEOqvA_7_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Tc_o-AGRrE69UanSY3yK8hKSg_8_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_6Sx9BbLNA0GbqGHTzJEvlQ_8_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">128.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Tc_4pUcl346gUWdYVUvufLfQA_9_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_e5lX1_vXQkWGiE3O-SQp9g_9_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">131.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Tc_GwXSAFgLuEy4P8jE3N0WiQ_10_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">52762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="2"
      id="Tc_0GuEJERaxECj5A8oBEJ4JQ_10_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">18.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_a7fRJljo8kyzZGUP_mALEg_10_7">P9Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Tc_5ysC1AilDEixEzsQPxeA0g_12_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="2"
      id="Tc_kZfjSwpVtUGw0BzSo_ARjg_12_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">225.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_cAIbx4D4CEyrM_TOuYWJtQ_12_7">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_3HvAr78fFESSuShpsSvzqA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:44.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;123.16 - 290.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 225.74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw"
      decimals="2"
      id="Tc_wYfOGVOEkE6R_whPigkyBg_8_1"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">4.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_S6o_hJV1h0q-bvakpXYVnw"
      decimals="INF"
      id="Tc__n4OMu58u0COQ7iGY9TmtQ_8_3"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">49212</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw"
      decimals="2"
      id="Tc_NjgXz0YB1UyPdiQk9CD2Ww_8_6"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">4.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeOneMember_dV81JNwbkU6w6_KcXLEOQw"
      id="Tc_5yM4PQVgnUGKwvtcrGkWFQ_8_8">P9Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_ThApNN5hSEC7yAWt4I3olg"
      decimals="2"
      id="Narr_72VrYP2pKkiM1h0_z-Di5g"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">123.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_WlYHSncbxkyESoDclR_i5g"
      decimals="2"
      id="Narr_rct_7xD5FUOa4dbLI5B3gQ"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">290.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw"
      decimals="INF"
      id="Tc_NjHCOnGqNEW_r7c3dXPguA_9_3"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3550</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg"
      decimals="2"
      id="Tc_f4dom1HmNkaRqz6P2v_MNw_9_6"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">217.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg"
      id="Tc_R0AplVHYPE256NcvwZAgUQ_9_8">P6Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3VdFkuort0CYQiJ3pWmzFw"
      decimals="INF"
      id="Tc_oJyHTvDdX02LyjTYi268Sg_9_10"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3022</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_aytu_ExercisePriceRangeTwoMember_3Ai6yWqDLkKuwnBiCGAIyg"
      decimals="2"
      id="Tc_zTBqu3TSkE2DBxsBUinPtg_9_13"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">225.74</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Tc_pIg8Yy8BKEeeazQx4mKM_Q_10_3"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">52762</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_QyJaQjIzWUC60_gCyUGDXg_10_6"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">18.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tc_KCcIDrlYDEyDE9YbfRbaOQ_10_8">P9Y21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw"
      decimals="INF"
      id="Tc_WscpoTD1gUqRN-70faLYxQ_10_10"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3022</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="2"
      id="Tc_-9U7atAj0kKrbN8chUvJlw_10_13"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">225.74</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_1u8MB_0WKUqOOhFJoTnpRQ"
      decimals="INF"
      id="Narr_qOL2DHNPmU-nmhQ34QjLBg"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">2</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember_m2S0-xKuZ06BhQoPKWEIIg"
      decimals="-5"
      id="Narr_JR105v7VHkyNfZkwS64oCQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded
      contextRef="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ"
      decimals="INF"
      id="Narr_mNQAjAQKRUScPl2KxXy-IA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.25</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_12_19_2022_To_12_19_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember_tmiP1xTj8UC_3wVmb7MXRQ"
      decimals="-5"
      id="Narr_k0LRZr6SIU22bwLF2nri4A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_2_2021_To_8_2_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_6Su9NkIAvUOaA057CsgVYQ"
      decimals="INF"
      id="Narr_W8SPtPtkt0qX3W8o-gGssQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_c91ZRffRLEe9Xlg8BIIOcQ"
      decimals="2"
      id="Narr_29pFoY08jk6I6sIstLuYog"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_VVTadRrGBUuL-6oQmtuGQg"
      decimals="2"
      id="Narr_PCu0GjFosEe6BFI-a6IRUg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">13.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_IwOCWfvFhkinZ4ur6dWlVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,825&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (42,434)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,689)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135.66&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A"
      decimals="INF"
      id="Tc_mtMIfcJgOkmi7ZryXuvtXg_5_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">80373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A"
      decimals="2"
      id="Tc_TCCfk10TxEG5ZG862v1qdg_5_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">148.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="INF"
      id="Tc_gaPkLrfcsEOcx0MuxrV-jQ_6_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="2"
      id="Tc_FPML5s2Uc0WNB1JEcTGjDA_6_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="INF"
      id="Tc_EL4jHeHBpEm1kzdN9fS2fA_7_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">42434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="2"
      id="Tc_A7EQi8wYR0ijwPm3pMpVbw_7_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">126.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="INF"
      id="Tc_qKHLy8sMU0aVRAU8KRBHJQ_8_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="2"
      id="Tc_zd4iUBhxNki_ZW9fGa7trA_8_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">135.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ"
      decimals="INF"
      id="Tc_-R0j_avDvkivZwXFdx0o5w_9_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">38075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ"
      decimals="2"
      id="Tc_LLgTuBN-3UimVt6uxfkF_Q_9_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">142.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ"
      decimals="-5"
      id="Narr_o7uJh5pXqkKwxiF0v1DPYA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      id="Narr_ZaGAMXoutkWZbqSmR8QHfA">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ"
      decimals="-5"
      id="Narr_23nvJXDXLkuXBhoG4e-x3g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ"
      decimals="INF"
      id="Narr_F2hovHPtGEavzcSlfSHVYA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA"
      decimals="INF"
      id="Narr_HJzqFgT2yk2YpqE--Tq1AQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_17_2022_To_1_17_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_Z4aLVgpa-kuI0CJE3moimA"
      decimals="2"
      id="Narr_o-sEaFANTUuOWHw2NkSUHQ"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">27.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_4vybuWwiOkecBLkUHT6SMA"
      decimals="-5"
      id="Narr_Wfdh4BN4KEOR7mcXsgtWUw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_N8QRmflkVEK0aXHJHlg2eQ"
      id="Narr_gbOhtH7RQ0G988VflExXDg">P1Y6M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_XeWi9L6vHUyAEdsppsu6eA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ"
      decimals="INF"
      id="Tc_77OPaXYOVE-QYXLQE3fEGQ_6_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">8500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_UCzkQaKuSUK7GUygwAZIXQ"
      decimals="2"
      id="Tc_C6L8joOvFk-zltZpd7_D6w_6_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">25.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw"
      decimals="INF"
      id="Tc_aQKKw3Ipm0Gf2Qr7ameJRA_7_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">3537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw"
      decimals="2"
      id="Tc_z-RaxzHie06qVjm_niF-Qw_7_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">26.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA"
      decimals="INF"
      id="Tc_eQPtgqhtNkekUyv-xBXcAg_8_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">4963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA"
      decimals="2"
      id="Tc_Nck03Jxf2E-qE9zFKLPL4w_8_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">25.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yyyYpdhwYUa5RT3qbDM0uA"
      decimals="-5"
      id="Narr_xV6yLhjZ00-rgDo5smqhqw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dtERgCcS9E-lLDBBku9Ziw"
      id="Narr_I8_JoPgwBkGOqw4paOPDhQ">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_CCKVPkiDGUCVIxlMV-dD8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 536&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:72.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and Administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-indent:0pt;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_xlpXGmnCE0q9N4hnP11C0A"
      decimals="-3"
      id="Tc_wHniP4IAvEiqZ9ZiwcX2lg_5_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_vnaTWWbZJUOh5Za0C4EoQw"
      decimals="-3"
      id="Tc_ejmRkBXGcUadmZF_vX_O0A_5_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">31000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lWZtLtuZq0aBxZRyaXV8jw"
      decimals="-3"
      id="Tc_FlNsYSjS8Eu02N3FcklJAQ_6_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_AwSMEA2VYkySNlTWV-Mg5g"
      decimals="-3"
      id="Tc_CObVIUIbIkei6NH1RnTgAQ_6_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_G4vMM4ms7UyTRxItSf21Ag"
      decimals="-3"
      id="Tc_nGXvfv3RxE2OVpFHf2QYMg_7_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">23000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_l930vcslY0aPIpci-ZFhFg"
      decimals="-3"
      id="Tc_uwXRydtHYEGmpHVTNMO_Mw_7_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_M9qxYqENEUmjeBlE_Zjf2g"
      decimals="-3"
      id="Tc_GxRPWdmh40S2J7NKsSpRtg_8_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5965000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_95MKJo-V6E6JsQfGaBmnxQ"
      decimals="-3"
      id="Tc_giBiMzvU90enecHxB6FUCw_8_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_3ynmSVfO40OmLENH14bGzw_9_3"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6046000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_2axJkolD9EeNFZkMcy_cvA_9_6"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <aytu:WarrantsOrRightsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_rjrj-z_qAk6uRXIw0W-e-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16. Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liability Classified Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for liability classified warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of liability classified derivative financial instruments was calculated using either the Black-Scholes option pricing model or the Monte Carlo simulation valuation model, and is revalued every quarter. Changes in the fair value of liability classified derivative financial instruments in subsequent periods are recorded as unrealized derivative gain or loss in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 8, 2023, the Company entered into a securities purchase agreement (the &#x201c;Security Purchase Agreement&#x201d;) pursuant to which the Company agreed to issue and sell an aggregate of (i) 1,743,695 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the &#x201c;Common Warrants&#x201d;). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the &#x201c;Exchange Warrants&#x201d;). Each Pre-Funded Warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will be immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company&#x2019;s common stock equaling 200% of the exercise price for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company&#x2019;s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Security Purchase Agreement) of $12 million (see Note 14 &#x2013; Stockholders&#x2019; Equity).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On August 11, 2022, the Company closed on the August 2022 Offering, pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a &#x201c;Stock Combination Event&#x201d;), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32 and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 &#x2013; Stockholders&#x2019; Equity).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current exercise price of $8.60. As a result, the associated common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a &lt;span style="-sec-ix-hidden:Hidden_9EV35llWm0G5Ej7R_H5Kdw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&lt;/span&gt;&lt;/span&gt; to 1 reverse stock split. Pursuant to the aforementioned warrant agreement, the Company triggered a Stock Combination Event and the warrant exercise price and number to be issued was adjusted based on the average of each of the lowest five trading days during the twenty-day consecutive trading day period beginning on December 30, 2022. Subsequently, as a result of the Securities Purchase Agreement in June 2023, the common warrants from the August 2022 Offering had an adjusted exercise price of $2.32.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 7, 2022, the Company closed on an underwriting agreement, pursuant to which, the Company sold, (i) 151,500 shares of the Company&#x2019;s common stock, (ii) pre-funded warrants to purchase up to 151,500 shares of common stock, and (iii) common warrants to purchase up to 333,300 shares of common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase 1.1 shares of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants have an exercise price of $0.002 per share of common stock and were exercised in full in April 2022. The common warrants have an exercise price of $26.00 per share of common stock and are exercisable &lt;span style="-sec-ix-hidden:Hidden_u-AypRtbtUiKizPrtwHpzw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six months&lt;/span&gt;&lt;/span&gt; after the date of issuance and have a term of five years from the date of exercisability (see Note 14 &#x2013; Stockholders&#x2019; Equity).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2022, as consideration for entering into the Avenue Capital Agreement as described in Note 11 &#x2013; Long-term Debt, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the &#x201c;Avenue Capital Warrants&#x201d;). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants were immediately exercisable and expire on January 31, 2027. At inception, the Company accounted for the Avenue Capital Warrants as a derivative warrant liability as the number of warrants was not fixed at the issuance (see Note 11 &#x2013; Long-term Debt for further details).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 &#x2013; Fair Value Considerations).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of warrants is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 434,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,028,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (87,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant adjusted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,568)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,011.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,538,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</aytu:WarrantsOrRightsDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member_fbLuMsMHE0qXd0zT-e_CpQ"
      id="Narr_5YRQvHTdVkqMabm3tRUsNw">2023-06-08</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_SubsidiarySaleOfStockAxis_aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member_PCjj1daxC02g6tuBIRDViQ"
      decimals="INF"
      id="Narr_0RBmHp2Uw0OOa4M1A4u_0Q"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1743695</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_Fgz0rN7wGk2fcxTPEqaCzQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">430217</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      decimals="INF"
      id="Narr_oE6Vur2X9U-Y4JjQIhW-GA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A"
      decimals="INF"
      id="Narr_CdUxa4E8H0yT35xydlOIKA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">2173912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q"
      decimals="INF"
      id="Narr_GWlJoVu3MkyEu-vTQLAF0g"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_lbAgpVHhWUG8h-6KGjZojQ"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member_4SZ_GWRF40O82xykfa5F6Q"
      decimals="INF"
      id="Narr_zwyyy4DEg0KPqPqkhigYpA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">1.59</aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member_MO6LdXMe5UKqTSi4IebShA"
      decimals="INF"
      id="Narr_566DdUFrG0CK_pFGw1ibcw"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">1.5899</aytu:ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      id="Narr_4i7GfGIHhES2neYNNfqSxA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_TQP2-LMazkeoQX0gryQj2Q"
      id="Narr_s34h3acVVEq2jD3j4rr-UQ">P30D</aytu:ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock>
    <aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member_M-pCUYoNe0ykxRDeHskaBw"
      decimals="INF"
      id="Narr_T4cCuUu8OEe3kpfb7FVF2Q"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">2</aytu:ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_Va2RshkrmEKrthn-JOlV8A"
      id="Narr_54nFkxRZF0GcbsIOYVSraw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA"
      id="Narr_InUZnx2QXEGVzjBqszyDyA">P30D</aytu:ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda>
    <aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="Duration_6_8_2023_To_6_8_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member_kxRM06WYgUSYv3joAjE8bA"
      decimals="-6"
      id="Narr_zKv3iNkqxUKHpXR-RTP7Rw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">12000000</aytu:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="Duration_8_11_2022_To_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member_Pa3QR864s0WrmhuF05catA"
      id="Narr_iZGrfOCMykufN4CaI03JSA">2022-08-11</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"
      decimals="INF"
      id="Narr_Dw9b6q8otEWR1BSf0ScZyQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">87500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_pC922mw5YUGKn4U_dZGAfQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1265547</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"
      decimals="INF"
      id="Narr_NIqMM-l6o0engU-QPuU5KA"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_aWuWpiTXy0aGfhcl_QLDyw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member_BQWQH8qPVkiA0uQIcCEYEw"
      decimals="INF"
      id="Narr_vW6JO9r8YkWxu0LCe7yS-Q"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_0jIlk3KreEayH748-wms4Q"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      id="Narr_3QVrTmKSG0iG_eAf3oV4Lw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_yTr7ahOmqkiP5O75iSCXRQ"
      unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ">5</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_exFpJRTVAkOPXppGvAZHmA"
      unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ">20</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_xevQ7rePkUmnj8FNSDZpqg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">5</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_ip3C37vVLE6hW7JaWdUJwg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">2.32</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_bgcTfWqX3UWn4dxBrgbrPQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">2325581</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_MZoGvqd0-EWEOPDdlD-Jcg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">2.32</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A"
      decimals="INF"
      id="Narr_nloDuUge50CFnuMzgZuDDg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">8.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg"
      decimals="INF"
      id="Narr_X5m1-383nU2pNiIPZ7Z52g"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">3.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_8ln2O5nxeUqhFXf2qqKxOg"
      decimals="INF"
      id="Narr_cAX_BPxc6Uqak8pSVZ4BkA"
      unitRef="Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ">5</aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_aUf6uQX8JkCRV6eBvCg8Kg"
      decimals="INF"
      id="Narr_TBfoAypBm0Simi7yu5IX1w"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA"
      decimals="INF"
      id="Narr_SaDgg6Qq5E2r4cu2QPofHw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">151500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg"
      decimals="INF"
      id="Narr_hja6sBKjTk2ySbal5PtYlQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">151500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_IOE35FvSiU65Rox2o42YLQ"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">333300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_5n_jf809wUSZRkBdUi244g"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">1.1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg"
      decimals="INF"
      id="Narr_405GdyEFWUW4ausAedY58A"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.002</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_ql6fEi4HTUO3IJyNv1P8ig"
      decimals="INF"
      id="Narr_BvM6GuCUoUuhOJ_tKZnWDg"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">26.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member_1cn0JRM84U6rdzEe3qxCig"
      id="Narr_draYYP28eU2LmR6eO4wvEQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"
      decimals="INF"
      id="Narr_4KgesRw2i0-1kF7uBkeatA"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">24.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_26_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member_OBherfzm0Eyu1LmAad-jRw"
      decimals="INF"
      id="Narr_WI8r53mWSkuzomIzqSqd4A"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">24.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightActivityTableTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_GOBxCT94X0aBUr8KSQWKoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding June&#160;30,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 434,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,028,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (87,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant adjusted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrants expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,568)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,011.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,538,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</aytu:ClassOfWarrantOrRightActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_jJVCcTYbiUaIJ-QiKtx9tQ"
      decimals="INF"
      id="Tc_rKTE6eucqEK5QxlPZhR3KA_6_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">434328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_I38l4DudfUG9B_ywzeXUNA"
      decimals="2"
      id="Tc_9KTn_FOOW0KVQ4Oge1pKVA_6_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">92.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_umMfg0XoZ0-AYDOK8yZ-LA"
      id="Tc_osSpHnqOHkS-3NEBNS4Q-g_6_7">P4Y9M18D</aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <aytu:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      decimals="INF"
      id="Tc_aXTtoPnaQE2yjLhhmkLQxQ_7_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6028331</aytu:ClassOfWarrantOrRightIssuedDuringPeriod>
    <aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig"
      decimals="2"
      id="Tc_8f8bOVu6QUedh2__W1OvBw_7_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">1.61</aytu:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <aytu:ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      id="Tc_Pd6xLpEXgEW94oRCrAijGQ_7_7">P5Y</aytu:ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife>
    <aytu:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      decimals="INF"
      id="Tc_Jrd8YVzQDUKNPWYMXdOUzg_8_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">87500</aytu:ClassOfWarrantOrRightExercisedDuringPeriod>
    <aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig"
      decimals="2"
      id="Tc_5bUk4Fbyf0O_4suFDsn8Zw_8_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">0.02</aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
    <aytu:ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      id="Tc_jk2UhLEZCEu6nWDVG2GY4w_8_7">P5Y</aytu:ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife>
    <aytu:ClassOfWarrantOrRightAdjusted
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      decimals="INF"
      id="Tc_KLOhqu3Dx0mVN9Synwvbfw_9_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">181461</aytu:ClassOfWarrantOrRightAdjusted>
    <aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig"
      decimals="2"
      id="Tc_RD-HBzO68UeG5aEUEslt-g_9_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">5.04</aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted>
    <aytu:ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      id="Tc_U-nHE1XskUKzGN_Z5PNX6Q_9_7">P3Y10M24D</aytu:ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife>
    <aytu:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      decimals="INF"
      id="Tc_cxoR3DSqcUimXqL2LZSWPA_10_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">18568</aytu:ClassOfWarrantOrRightExpiredDuringPeriod>
    <aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_594Uovs1gEiMe4yK48hRig"
      decimals="2"
      id="Tc_UQTub2H15Eu4Ij7laHhVKg_10_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">2011.56</aytu:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_bb-F103xJEKObyLwN9P9hg"
      decimals="INF"
      id="Tc_WABu2D6s10ONQSgatHs6qg_11_2"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">6538052</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_BMNvc2gmyU2xEU7d2Lo8uw"
      decimals="2"
      id="Tc_PI8G8Zlp10uA2cwp7NMPDA_11_5"
      unitRef="Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA">4.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw"
      id="Tc_7-62lKfWv0e-B9kauOgs0w_11_7">P4Y8M15D</aytu:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_bN60I1qwZkCKCdgwmvA7uQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17. Employee Benefit Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to the merger with Neos, Aytu had two 401(k)&#160;plans the (&#x201c;Neos Plan&#x201d;) and the (&#x201c;Aytu Plan&#x2019;) both plans allow participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Neos Plan matched 100% of the first 3% contributed by employees and matched 50% on the next 4% and 5% contributed by the employees. The Company&#x2019;s match for the Neos Plan was approximately $0.4 million for the year ended June 30, 2022. The Aytu Plan matched 50% of the first 6% contributed to the plan by employees. The Company&#x2019;s match for the Aytu Plan was approximately $0.2 million for both years ended June 30, 2023 and 2022. In July 2022, the Company transferred the Neos Plan into the Aytu BioPharma Employee Retirement Plan and in February 2023 the Company transferred the Aytu Plan into the Aytu BioPharma Employee Retirement Plan. The Aytu BioPharma Employee Retirement Plan matches 100% of the first 3% contributed by employees and matches 50% of the next 4% and 5% contributed by the employees. The Company&#x2019;s match for the Aytu BioPharma Employee Retirement Plan was approximately $0.7&lt;span style="white-space:pre-wrap;"&gt; million during the year ended June 30, 2023.  &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <aytu:NumberOfEmployeeBenefitPlan
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_xko3OSBjrU6wxRF381eExA"
      unitRef="Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg">2</aytu:NumberOfEmployeeBenefitPlan>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg"
      decimals="INF"
      id="Narr_etSVEI1u90m3Rja62GDizQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_46yIvNkqh0iWfT0ASeJuZg"
      decimals="2"
      id="Narr_pyz_4HmoL0CArxy0ldN2ag"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7aP_mPOQnEm0PE5wFOYT_A"
      decimals="INF"
      id="Narr_ukvnM_48nEGhg1ASJwyh6Q"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_x_PrG4pcs06d9XTkn5jk5Q"
      decimals="INF"
      id="Narr_7JQ7DwZaEki0o6tD24xmOQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_hvi9wwMyG02M4YOpOzDNtQ"
      decimals="INF"
      id="Narr_OKg7_lpWnUiW31Jrf_8Cfg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_NeosPlanMember_7x7PFK5f0kiltq3YkU0RXQ"
      decimals="-5"
      id="Narr_sm2nesUTWUGpsf3g5x1i3A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w"
      decimals="INF"
      id="Narr_joJYichnT0aw60wR-HPr4A"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_SixPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_QID3lexWzEOGE-DNQbi09w"
      decimals="INF"
      id="Narr_zC4d3OxdGkS0Ebx4498-ww"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_WbJzKLlmzki6AlcwWXPsyg"
      decimals="-5"
      id="Narr_j9PGM3rps0GAm7q9pY5zfA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuPlanMember_-JXzqrvuMU6CA_7Lj0xMKg"
      decimals="-5"
      id="Narr_30n6aYcAEU-Dtx071s5W3Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g"
      decimals="INF"
      id="Narr_TAio2oAoNEOWjsZ2z8jL7w"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_FirstThreePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_z_FLnLV6402ArtafMfvP7g"
      decimals="INF"
      id="Narr_3h2lIeryIkm0aKNJofBhlA"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentAndFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_RUN5j4oRMUyMIuo84vuTaw"
      decimals="INF"
      id="Narr_r5eoR2I4Y0WDgSTnNHB17A"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFourPercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_iQ5ElZ-9mkCBPVrJJm9cng"
      decimals="INF"
      id="Narr_I_M62FD7b0assrWbXNZdvQ"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_StatementScenarioAxis_aytu_NextFivePercentContributionByEmployeesMember_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_sWQv2CL_9karqaYLUrXPDw"
      decimals="INF"
      id="Narr_H4RSmUPP6UyZYWkySK9xLg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_RetirementPlanNameAxis_aytu_AytuBiopharmaEmployeeRetirementPlanMember_BL_kOTzSHEKA4ccnDQIqTA"
      decimals="-5"
      id="Narr_i91xEzwhyEGBSg3HM_EI8g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_8vJuHKURM0q014nem4TrSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;18. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pediatric Portfolio Fixed Payments and Product Milestone&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company assumed two fixed, periodic payment obligations to an investor (the &#x201c;Fixed Obligation&#x201d;). Under the first fixed obligation, the Company was to pay monthly payment of $0.1 million beginning November&#160;1, 2019 through January&#160;2021, with a balloon payment of $15.0 million that was to be due in January&#160;2021 (&#x201c;Balloon Payment Obligation&#x201d;). A second fixed obligation requires the Company pay a minimum of $0.1 million&#160;monthly through February&#160;2026, except for $0.2 million paid in January&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;29, 2020, the Company entered into an Early Payment Agreement and Escrow Instruction (the &#x201c;Early Payment Agreement&#x201d;) pursuant to which the Company agreed to pay $15.0 million to the investor in satisfaction of the Balloon Payment Obligation. The parties to the Early Payment Agreement acknowledged and agreed that the remaining fixed payments other than the Balloon Payment Obligation remained due and payable pursuant to the terms of the Agreement, and that nothing in the Early Payment Agreement alters, amends, or waives any provisions or obligations in the Waiver or the Investor agreement other than as expressly set forth therein. The first fixed obligation was fully paid as of January 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in satisfaction of the second fixed obligation. The company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million over the next six quarters commencing September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company acquired a Supply and Distribution Agreement with Tris (the &#x201c;Tris Karbinal Agreement&#x201d;), under which the Company is granted the exclusive right to distribute and sell the product in the United States. The initial term of the Tris Karbinal Agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial&#160;year that spans from August&#160;1 through July&#160;31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Karbinal Agreement make-whole payment is capped at $2.1 million&#160;each&#160;year. The annual payment is due in August&#160;of each&#160;year. The Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to June 30, 2022, the Company&#x2019;s contingent consideration liabilities included obligations under licensing arrangements for Tuzistra XR&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The royalty and make-whole milestone payments related to licensing agreements with TRIS Pharma, Inc. (&#x201c;Tris&#x201d;) for Tuzistra XR were being accounted for as contingent consideration and revalued at each reporting period. As a result of the discontinuation of commercializing Tuzistra (see Note 3 &#x2013; Revenue from Contracts with Customers) and a settlement agreement with Tris, the Company concluded that the product milestone payments underlying the contingent consideration liability ceased to exist. The Company reversed the remaining contingent consideration liabilities of $8.5 million and recorded a liability of $7.6 million related to the settlement payments payable to Tris for termination of the Tuzistra licensing agreement. The settlement payments are included in fixed payment arrangements at their present value using the Company&#x2019;s estimated borrowing rate. The Company recognized $0.9 million gain on settlement of the Tris contingent consideration liabilities in the consolidated statements of operations for the year ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Product Contingent Liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make five additional payments of $0.5 million when certain levels of FlutiCare sales are achieved. In fiscal year 2023, the manufacturer associated with this contingent liability filed for bankruptcy. There were no payments required in fiscal 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rumpus Earn Out Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (&#x201c;Denovo&#x201d;) and Johns Hopkins University (&#x201c;JHU&#x201d;), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company&#x2019;s option, are payable to Rumpus. Under the license agreement with Denovo, the Company assumed the responsibility for paying annual maintenance fees of $25,000, a license option fee of $0.6 million payable in April 2022, and upon the achievement of certain regulatory and commercial milestones, up to $101.7 million, and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for paying minimum annual royalties escalating from $5,000 to $20,000 beginning in calendar year 2022, royalties of 3.0% of net product sales, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2022, AR101 received Orphan Drug Designation (&#x201c;ODD&#x201d;) and Fast Track designation from the FDA, resulting in total milestone payments of $4.0 million, which were paid in 109,447 shares of common stock and $2.6 million in cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating Lease&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In May 2023, the Company entered into an operating lease agreement to relocate its principal office within Denver, Colorado. The lease has a commencement date of October 1, 2023 with an initial term of &lt;span style="-sec-ix-hidden:Hidden_JDyjzzB8SUiDT9RhDuHhaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five and a half years&lt;/span&gt;&lt;/span&gt;. Undiscounted minimum monthly rent payments average approximately $15,500 over the initial term of the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Variable lease payments will be expensed as incurred. Under the lease agreement, the Company has one five-year renewal option through March 2034.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;text-indent:36pt;margin:0pt;"&gt;Legal Matters&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Witmer Class-Action Securities Litigation. &lt;/i&gt;A shareholder derivative suit was filed on September12, 2022 in the Delaware Chancery Court by Paul Witmer, derivatively and on behalf of all Aytu stockholders, against Armistice Capital, LLC, Armistice Capital Master Fund, Ltd., Steve Boyd (Armistice&#x2019;s Chief Investment Officer and Managing Partner, and a former director of Aytu), and certain other current and former directors of Aytu, Joshua Disbrow, Gary Cantrell, John Donofrio, Jr., Michael Macaluso, Carl Dockery and Ketan B. Mehta. Plaintiff amended the complaint on April 5, 2023. The Amended Complaint drops Mr. Macaluso as a defendant and alleges that (i) Armistice facilitated the sale of assets of Cerecor in 2019 and Innovus in 2020 to Aytu in exchange for convertible securities which it subsequently converted and sold at a profit on the open market; (ii) the Armistice defendants breached their fiduciary duties, were unjustly enrichment and wasted corporate assets in connection with these acquisitions; (iii) the Armistice defendants breached their fiduciary duties by engaging in as insider trading; and (iv) the other directors breached their fiduciary duties, and aided and abetted the Armistice defendants breaches of fiduciary duties, in connection with these acquisitions. The Amended Complaint seeks unspecified damages, equitable relief, restitution, disgorgement of profits, enhanced governance and internal procedures, and attorneys&#x2019; fees. While we believe that this lawsuit is without merit and have vigorously defended against it, we have agreed to settle the matter for various corporate governance modifications and the payment of plaintiff&#x2019;s attorneys&#x2019; fees. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sabby Litigation.&lt;/i&gt; A complaint was filed on February 22, 2023 in the Supreme Court of the State of New York by Sabby Volatility Warrant Master Fund LTD (&#x201c;Sabby&#x201d;) and Walleye Opportunities Master Fund Ltd (&#x201c;Walleye&#x201d;), holders of certain warrants to purchase common stock, against the Company. The complaint alleges that the Company improperly adjusted the exercise price of the warrants and miscalculated the number of shares the warrantholders may receive, and that the Company failed to provide prompt notice to the warrantholders of such adjustment. The complaint seeks a declaratory judgment of the warrant share calculation, that 575,000 warrant shares be due to Sabby on exercise of its warrants rather than 312,908 shares, and that 100,000 warrant shares be due to Walleye on exercise of its warrants rather than 54,146 shares. While we believe that this lawsuit is without merit and we intend to vigorously defend against it, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stein Litigation.&lt;/i&gt; Cielo Stein (&#x201c;Stein&#x201d;), a former sales specialist, filed a complaint on February 1, 2023 in Jefferson County Circuit Court in Kentucky against the Company and its wholly-owned subsidiary Neos Therapeutics. The complaint alleges that Aytu retaliated against Stein in violation of the Kentucky Civil Rights Act after she opposed what she contends was unwelcome behavior by her supervisor. The complaint also alleges that the Company&#x2019;s response to Stein&#x2019;s subsequent complaint to human resources was inadequate. The complaint seeks an award of unspecified compensatory damages, emotional-distress damages, and attorneys&#x2019; fees and costs. The Company removed the lawsuit to the United States District Court for the Western District of Kentucky and filed a motion to dismiss the complaint, which is pending. Due to the early stage of litigation, we are not able to predict at this time whether this proceeding will have a material impact on our financial condition or results of operations, and intend to vigorously defend this case in the event it is not dismissed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember_wh8-haFGq0ilyzEd2ep6MQ"
      decimals="INF"
      id="Narr_ZZvBBitf10W0nE5pzA8biQ"
      unitRef="Unit_Standard_agreement_JfZ2PWRCJ0apFPM0xMjerg">2</aytu:FixedPaymentArrangementsPeriodicPaymentObligationsNumber>
    <aytu:FixedPaymentArrangementsMonthlyPaymentAmount
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw"
      decimals="-5"
      id="Narr_jTOMpvcOiUGi52hKHcs6Hw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:FixedPaymentArrangementsMonthlyPaymentAmount>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmount
      contextRef="As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_iJ4AvQy2w06Vcin2CWuDVw"
      decimals="-5"
      id="Narr_iKYxVc0oqEK15IVuVc24_g"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000.0</aytu:FixedPaymentArrangementsBalloonPaymentAmount>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_45L0yjrLA06cm11dTTlAbg"
      decimals="-5"
      id="Narr_fYAeHQf8hEKvd7lgCuD4OA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum>
    <aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_86YG5A0Um0yo8qgGtK-dHg"
      decimals="-5"
      id="Narr_x9Sd2tJGhEiCVP4qPs1xzQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">200000</aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid>
    <aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid
      contextRef="Duration_5_29_2020_To_5_29_2020_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_aXb6lQlXfUul0Lpi5MKIMw"
      decimals="-5"
      id="Narr_M6anEiW0q02SCrP7m-qLtw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15000000.0</aytu:FixedPaymentArrangementsBalloonPaymentAmountPaid>
    <aytu:FixedPaymentArrangementsPaymentAmountPaid
      contextRef="Duration_6_21_2021_To_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_bUqFOuZjx0iOaoVadRu1-A"
      decimals="-5"
      id="Narr_tHMQO3Lo_06crOaBPaZyOA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2800000</aytu:FixedPaymentArrangementsPaymentAmountPaid>
    <aytu:FixedPaymentArrangements
      contextRef="As_Of_6_21_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_gnsD7qTzWkm1zvvleaiOtg"
      decimals="-5"
      id="Narr_fWdtSh-vokO3ROru15LHaA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</aytu:FixedPaymentArrangements>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="INF"
      id="Narr_xui9x2jLuEqFAFXISXcrHQ"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">6</aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmount
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="-5"
      id="Narr_8sdkuI-sVEibU8OSA0x0_A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">500000</aytu:FixedPaymentArrangementsQuarterlyPaymentAmount>
    <aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber
      contextRef="As_Of_9_30_2021_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember_5_PDmNBYb066P7iEOJgkEA"
      decimals="INF"
      id="Narr_4gxoyPElnkGxcJQ2d2xwBQ"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">6</aytu:FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber>
    <aytu:SupplyAndDistributionAgreementTerm
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_N_53DiWYEkq5a8aEFqlwWg"
      id="Narr_fKlih06XxEWLOyGyCHMtrw">P20Y</aytu:SupplyAndDistributionAgreementTerm>
    <aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="3"
      id="Narr_8JMwGTJO4EuOY-R3t2jVbw"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.235</aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="INF"
      id="Narr_xv9JaA04r069-O9Jpkzs4g"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">70000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="INF"
      id="Narr_di7cglqOH0OitT4_iw23zQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">30</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="INF"
      id="Narr_dqDxdOx5kEGZ7hmBMzFQcg"
      unitRef="Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg">70000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits>
    <aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_bEb5OErYb0SclMJZK74CjA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2100000</aytu:SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount>
    <aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_4voELNJipkmBqeNV3fRXug"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation>
    <aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount
      contextRef="As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw"
      decimals="-5"
      id="Narr_gI9iALEjdkKwu5oJor2sCQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">40000000.0</aytu:SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod
      contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q"
      decimals="-5"
      id="Narr_Am_eoXtdW0Sby-iqnghKrw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">8500000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod>
    <aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances
      contextRef="Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qyhPxNP3pkq8ChGuKuxobQ"
      decimals="-5"
      id="Narr_L7bkW2s8ckGEcZdOtmr2nw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7600000</aytu:FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances>
    <aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_DVDTdZpqwEqkuVvwVz1RiA"
      decimals="-5"
      id="Narr_vHnV5Kegh0e9n-9ZpTQKfw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">900000</aytu:ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod>
    <aytu:ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved
      contextRef="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw"
      decimals="INF"
      id="Narr_GRHx97hEN0-GewB1bmyTPQ"
      unitRef="Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg">5</aytu:ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved>
    <aytu:ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved
      contextRef="As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw"
      decimals="-5"
      id="Narr_LCWbz09Ock-GOEOtWoF9qw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">500000</aytu:ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved>
    <aytu:ProductContingentLiabilityMilestonePayment
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_qxV92QOxs02EZ-8Z3YXlNA"
      decimals="-3"
      id="Narr_rGoc0Ps-rEqpIVsxx4tgNw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">0</aytu:ProductContingentLiabilityMilestonePayment>
    <aytu:LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ"
      decimals="-5"
      id="Narr_GnFCaBnWakGjtdIH_EfcLQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">67500000</aytu:LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock>
    <aytu:LicenseAgreementAnnualMaintenanceFee
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ"
      decimals="-3"
      id="Narr_jGgoHTrZ6UaOELqDVbAr-A"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">25000</aytu:LicenseAgreementAnnualMaintenanceFee>
    <aytu:LicenseAgreementLicenseOptionFee
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ"
      decimals="-5"
      id="Narr_Uyk8xuwp-EiW9lEG5hJKFQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">600000</aytu:LicenseAgreementLicenseOptionFee>
    <aytu:LicenseAgreementEscalatingRoyaltiesMaximum
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member_w3zwsjEZnE2ch4mAqdWPlQ"
      decimals="-5"
      id="Narr_zrDN0drfh06YKVMjtqWQVQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">101700000</aytu:LicenseAgreementEscalatingRoyaltiesMaximum>
    <aytu:LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ"
      decimals="-3"
      id="Narr_iO0z4KmipUygwJrTsa9CRw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5000</aytu:LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange>
    <aytu:LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ"
      decimals="-3"
      id="Narr_qhfA4kqlo02Rm1FCZIZEIQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">20000</aytu:LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange>
    <aytu:LicenseAgreementRoyaltiesPercentageOfNetProductSales
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ"
      decimals="INF"
      id="Narr__xGwZP-fy0aQhb8neVzqHg"
      unitRef="Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA">0.030</aytu:LicenseAgreementRoyaltiesPercentageOfNetProductSales>
    <aytu:LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum
      contextRef="As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member_qyHWbbUNPk6GoMc3gBTwDQ"
      decimals="-5"
      id="Narr_KO_Db7DyJUaKPHfXJp5NoA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1600000</aytu:LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum>
    <aytu:LicenseAgreementMilestonePaymentPaidCashAndCommonStock
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w"
      decimals="-5"
      id="Narr_Dn4Hed91gUy47UMp_WY4Rw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">4000000.0</aytu:LicenseAgreementMilestonePaymentPaidCashAndCommonStock>
    <aytu:StockIssuedDuringPeriodSharesMilestonePayments
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w"
      decimals="INF"
      id="Narr_Yl0hQcJ3Pka7DFG6dFtNyw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">109447</aytu:StockIssuedDuringPeriodSharesMilestonePayments>
    <aytu:LicenseAgreementMilestonePaymentPaidCash
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_hgaS86rKiE2bTJVPggUi-w"
      decimals="-5"
      id="Narr_ZoYT_K80cUaCNIh0HZWTQA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</aytu:LicenseAgreementMilestonePaymentPaidCash>
    <aytu:AverageUndiscountedMinimumMonthlyRentPayments
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw"
      decimals="0"
      id="Narr_-YkIWZmzuE-t8-QlNGpasg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">15500</aytu:AverageUndiscountedMinimumMonthlyRentPayments>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_C_RumQh2pkOaSIHG6ONp6w"
      id="Narr_sXznGw8oeEC13_w3exEjhg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg"
      decimals="INF"
      id="Narr_Frm2bQ0htkKBpEuFVgDY8A"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">575000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg"
      decimals="INF"
      id="Narr_a1wzoDEgf06sSpbd1Qh9eg"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">312908</aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA"
      decimals="INF"
      id="Narr_V1MIjbgcuE6OXafBxrzfuw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_22_2023_dei_LegalEntityAxis_aytu_WalleyeOpportunitiesMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_E80hfNAS8UOlFMunCVGutA"
      decimals="INF"
      id="Narr_j4SdMPOyOkmQB1wluVfjAw"
      unitRef="Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw">54146</aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <aytu:LicensingAgreementsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_NhdSKw9Y_0aJ1CiYHrwGfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19. License Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Healight&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device platform technology. The agreement with Cedars-Sinai grants the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. The term of the agreement is on a country-by-country basis and will expire on the latest of the date upon which the last to expire valid claim shall expire, ten years after the first bona fide commercial sale of such licensed product in a country, or the expiration of any market exclusivity period granted by a regulatory agency. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the terms of the agreement, the Company paid an initial $0.3 million license fee and approximately $0.1 million in earlier patent prosecution fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the Company&#x2019;s focus on the revenue growth of its commercial business, the Company had terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;NeuRx&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2018, Neos entered into an Exclusive License Agreement (&#x201c;NeuRx License&#x201d;) with NeuRx Pharmaceuticals LLC (&#x201c;NeuRx&#x201d;), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx&#x2019;s proprietary compound designated as NRX-101, referred to by Neos as NT0502. NT0502 is a new chemical entity that is being developed by Neos for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i)&#160;the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii)&#160;expiration of regulatory exclusivity of such licensed product in such country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for, and to receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Teva&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (&#x201c;Teva&#x201d;) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Actavis&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Shire&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the &#x201c;2014 License Agreement&#x201d;) with Shire LLC (&#x201c;Shire&#x201d;) for a non-exclusive license to certain patents for certain activities with respect to Neos&#x2019; New Drug Application (the &#x201c;NDA&#x201d;) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid a lump sum, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos is paying a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expires May of 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2017, Neos entered into a License Agreement (the &#x201c;2017 License Agreement&#x201d;) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos&#x2019; NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos is paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents.&lt;/p&gt;</aytu:LicensingAgreementsTextBlock>
    <aytu:LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw"
      id="Narr_uADRIr7iU0moUQex6jaNEw">P10Y</aytu:LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry>
    <aytu:LicenseAgreementInitialLicenseFeePaid
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw"
      decimals="-5"
      id="Narr_r_R8lClrhUuE6JSWu9ptSw"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">300000</aytu:LicenseAgreementInitialLicenseFeePaid>
    <aytu:LicenseAgreementPatentProsecutionFeesPaid
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw"
      decimals="-5"
      id="Narr_73fFvwG1mE6Jml_sgVwzzA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">100000</aytu:LicenseAgreementPatentProsecutionFeesPaid>
    <aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum
      contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_TypeOfArrangementAxis_aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember_eC9Z_MBaeUGsNuYWxQQb7w"
      decimals="-5"
      id="Narr__OTM38tUq0C5VWh9TlF9pg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000000.0</aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum>
    <aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum
      contextRef="Duration_10_1_2017_To_10_31_2017_us-gaap_TypeOfArrangementAxis_aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember_1wb-z3AmGEG4sOa28Qj_VA"
      decimals="-5"
      id="Narr_FpkWKYtnXkG080NfqhHvNQ"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1000000.0</aytu:LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_ipo8m4jKIEqHP9X-_u4W8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;20. Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Company&#x2019;s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages and aggregates its&#160;operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company&#x2019;s prescription products. The Consumer Health Segment contains the Company&#x2019;s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2023, the Rx Segment recognized an impairment loss of $2.6 million due to ceasing active development of the NT0502 product candidate as a result of the Company&#x2019;s increased focus on commercial efforts. The Consumer Health Segment recognized an impairment loss of $3.0&lt;span style="white-space:pre-wrap;"&gt; million from intangible assets  (see Note 7 &#x2014; Goodwill and Other Intangible Assets) and an inventory write-off of &lt;/span&gt;$2.1 million due to the discontinuance of its products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended June 30, 2022, the Rx Segment recognized a total impairment loss of $64.6 million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, the Consumer Health Segment recognized $10.8&lt;span style="white-space:pre-wrap;"&gt; million of goodwill and intangible assets write downs (see Note 7 &#x2014;  Goodwill and Other Intangible Assets).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Select financial information for these segments is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Consumer Health&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Year Ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,707)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,065)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,387&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment and write-off expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,824&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,046&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Year Ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (92,441)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,465)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (109,906)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="INF"
      id="Narr_eQ6VniBnDkaFJkNA8oFKxg"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="INF"
      id="Narr_AqJ_LheuAUiLGFwBlkdfkg"
      unitRef="Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-5"
      id="Narr_7wD0JB03EkGB-VLeOwHsSg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-5"
      id="Narr_DbmCjF1DFUmzjmAnhyhOSA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">3000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-5"
      id="Narr__TJAvx4e2k-n0g3ODQBxvA"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2100000</us-gaap:InventoryWriteDown>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-5"
      id="Narr_V94qmKJbh0ynmEeDSxHV2Q"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">64600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-5"
      id="Narr_772gIuyHOUaqBSRYkyYUzg"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_tM4nQgRop0OvztR26hcM-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Consumer Health&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Year Ended June 30, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,707)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,065)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,387&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment and write-off expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,094&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,824&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,046&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Year Ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Product revenue, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,548&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (92,441)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,465)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (109,906)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,821&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Impairment expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,649&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,248&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_418TiD4Nl0SX-8hhvDTSww_5_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">73799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_K-52NcA0yEGpUMYw9w-Qcg_5_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">33600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_rc4IaK7j6EyOVLG7PGBgfw_5_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">107399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_SMvWtKTy70-hvOR_lbGGBQ_6_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-7358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_5axHKRmulUmVPVXgDgPq8A_6_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-9707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_gUZY9PMPIUKBl30LH953MA_6_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17065000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_3e3f5s5SoEuLZZikBedx9Q_8_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6271000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_uIRWD2swOEGfyr9HQRS0tQ_8_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1116000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_wq6yK_oGSEanExsr1jXDnw_8_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7387000</us-gaap:DepreciationAndAmortization>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_dvvWLxXKG0iuqnmbUv4c3A_9_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">2730000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_yO6avAYh2kiJxNv2nFKKnQ_9_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5094000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_NTFrpkpXZU6g-kGns0po0g_9_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7824000</aytu:AssetImpairmentAndWriteoffCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g"
      decimals="-3"
      id="Tc_4ByAYsqi0kqs0wXT6gRS3Q_10_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5722000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_gpT8R5fdAEqN4aigXSlHKQ"
      decimals="-3"
      id="Tc_qFCbwf2sKUi9yeqmLiPsEA_10_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">324000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      decimals="-3"
      id="Tc_b7Te6RfRHUagMgB02PWpbQ_10_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">6046000</us-gaap:ShareBasedCompensation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_5RyzjyyOI0qRKPda4DmrkQ_14_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">61121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_pmV4XhAXCEqvbfXI2Dgw4g_14_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">35548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_v3qXR0yQZ0KVPiIvoshjiw_14_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">96669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_zfl_ViY_hkm0Gn7cEHCK6w_15_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-92441000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_CLksWEYiPUiXq3B9fQhZCA_15_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-17465000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_dkmHreii4UO8OtH7t8PQYQ_15_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">-109906000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_iw0II8EaSU-VhB4-m0J1kQ_17_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">7821000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_hV6u3U1BtkKHQnYuaFoGCQ_17_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">1557000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_YdYOqScem021Fr8n85nWCA_17_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">9378000</us-gaap:DepreciationAndAmortization>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_Vv-hi233f02PU_ZZxhgpsA_18_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">64649000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_uaQl9tf5bk2RpvfzARsP5A_18_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">10809000</aytu:AssetImpairmentAndWriteoffCharges>
    <aytu:AssetImpairmentAndWriteoffCharges
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_EBilxIQsqkaVQJFVgvHSzA_18_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">75458000</aytu:AssetImpairmentAndWriteoffCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_ibb6LOogSEWEqcu26w8PZg"
      decimals="-3"
      id="Tc_OOu0W5mxoEW8EJ5VXZvHbg_19_2"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5190000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_Gnm6sUwJL0a5JPZXNzJnNQ"
      decimals="-3"
      id="Tc_q1YtC4StBEOZYtaDRYO9ig_19_5"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">58000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg"
      decimals="-3"
      id="Tc_Qn4g4k5vM0qAQsDCdPWv6w_19_8"
      unitRef="Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ">5248000</us-gaap:ShareBasedCompensation>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ"
      id="Tb_Dyr68U9KxEqJYBid-VkKQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;21. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Distribution and Supply Agreement &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In July 2023, the Company entered into an exclusive collaboration, distribution and supply agreement with a privately-owned pharmaceutical company for Adzenys XR-ODT and Cotempla XR-ODT product lines. The pharmaceutical company will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT; and will focus on distributing and selling these products for patients in Israel and the Palestinian Authority. The Company will commit to product supply based on forecasts and provide product training. Due to the nascency of the collaboration, estimates of its financial effect cannot be made. This agreement represents the Company&#x2019;s first international commercial agreement for Adzenys and Cotempla.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>181
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVGR*V=P8N>Z^9MQ)8^2JNUP*#K"M +Q?2&#=[8W]0++[(#;_#U!+ P04
M" !4=DQ7>'Z8;.H"   I"P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;*V6:V^;,!2&_XK%IJF5NF!("$F7(*V9IFW2I*C5ML\NG 2KQF:V2;K]^ME
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M9VR2ADWB]/2.,R' CK,UM:9\,@BA2F4?]0(]M H12GQ[H-,&6NJL2W7Q*3>
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M3:?3YRHCAB<BMKB%QE[+&.K9/=7O=<Q6KL;4MCOS\$*>V]B.5XH6JD)KU^5
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M1=U^W3-HWZ01@/_OA- O%^8!_;LSZ[\ 4$L#!!0    ( %1V3%=B&S)H$ H
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MX.6H F!N-'#D@[U%0D(203BJTKZ@;:AFM0HX@H!$ ,*JS7EE4@H.*;7A\BW
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MB4BE71.E]$']4FM@-\),!+@)A@5*/8#'  O'S_(2( "?#,]<@B\ Q)IRX\<
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MZ9.:"))9X _Z]T[UY66Q8LYD:E'1K/:C$+X>3OX]Z+_E+ 9YXW"FD0:DI:W
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M!\#[90EVU7W!!<*/9;[\7U!+ P04    " !4=DQ7)3["CPD$  !<"P  &0
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M^.NSGWCYIB"- NZO!/Y4FH5QT [4L[\ 4$L#!!0    ( %1V3%<H(KER%0,
M "X'   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*U5;4_;,!#^*Z>
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M!?_#I@+71D6C'<+!5\BT 71-_%P;7POGU]6A1WA3HY^A8M6CF^4TQ+E8 3/
MW"&-0>>WD88)[\5!#?U2GRJU<(ZH&!0O/2'P5J>$6S.L0KH#-ZG=3]I(VXZS
M3ML]!F?M#'PV;U^2&[I"+@T(G!$TZA\?!J#;Z=P*5M5^(DZ5I?GJMR4]:*B=
M 9W/E+(;P3GHGLC)7U!+ P04    " !4=DQ7;D3Q8(T#  #*"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6RE5EMOVSP,_2N"5PP;8,2W)$W;)$ O
M&[Y]6+%@UX=A#XI-V\)DR9/DIMFO'R7'KHNDV8:]1!+-<W1(46+F&ZF^ZQ+
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M([36E$1@\="@#'<L<HE)!J/9801K\@^))SY)"D #'I_9$S0WLE -2%31@9
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M#C0Q@90Q,QDX)=5=#)_X[G#BNMAE2(+3"O"0(E_;,KBODD-N&'0FXUB,2N?
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MT2VZ:)!LVX>B#S0UMHA0I$I2=OSW'5*R+,>.D7;[8HF7.7,[,QK/-DH_F0+
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M-;IL, A+T*8[?D^B29@E%_V-.,RBJ!.LM%II6AY$]*62* I'T;$+%^$XG79
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M='@V'\11I+D)MN3OU L;@LWY<J,DS*(%>+^R&"[J&]J@_<?%]7\!4$L#!!0
M   ( %1V3%=D-OE]@0H  %L=   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;*U967,;-Q+^*RC&2<E5-"])/F))5;(<5Y+R5;*]>=C:!W &)!'/#"8
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MPU.F=_H O;=JZ<5;[9+,N,HJ\<_KI?,6T?"O0]H&6F>':5&&_.Q*F:C+$5+
M*;M5HZN??I@_G[T^(NE9(^G9,>I_PQ?'S\]G$]&G(;Z5B'S27!=K6O8;)3XJ
MX\1U\E>EG>;,T(7X(&VR(8O/Q[SGQN2E+'9".F2K2H599GHM:;<3%1QM>9=3
M"2R:BB0PDVNK%!+6XZ7T@<]&I@(KBK;IPAN$M]^(7Y),ETZ)-Q4$4\Z)&UEJ
M+S/Q_OV-.%E-OT\EXBG1A>QL829CVO)4G/STP\O%8O8Z$N*G^>NGD!=2D 2
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MO'(^$C9\R@L/WI3\^6QI/"HT_]PH":O1!KQ?&>/K!V+0?$^]^@]02P,$%
M  @ 5'9,5R17UB__"P  CB,  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&ULM5K;DMLV$OT5E#))V56R1M)<[;&G:FS'E:3L>"K.Y6%K'R 2DA!3! .
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MD!!"O\(\X5'ZCTJLC29QY1#"Q3.95/,))+L6EK-.-.PW$W S:&[>^>H,X/%
M!TBY+//FV5'4&["7P2T(OV0?,/5@3*\74 2AHO'[Q+*_BOK'P:HX&A[A]K;>
M4YKQ..ITPGF=:$#W-8@PV$_(W,O=B* BS:A_FX+['8YYXK@:>)LRT46W.R+\
M83Z\*B<E+'727O73&[=M0D[@ XCERMCP)!J>0+\W34?GD"9[Y8#7,AW[4;?;
MW"R]LN*,7M0Y<=9_I/<K*5M(D:5!)*P8\@_%XW M'+=JUHOBHV=H-H@ZS]!L
M>/QLS9X;(C\F$W>HWH^?H7HO&IP<]*.3P5/ZP_L]3.QW?IA[MXD]1^R/7*^
MUA*@1-+[K0+MEK%*N[=UR\DK1_= +@17@%M* H_,SM6!@R*94@\CGCSL)$-K
M^*.2'IH*AS%=,;[Y_?/=[4'WI(&M=T6A'DMD;0*C&@<H5V48B4R*1W= @'8Y
M%P #I(A*R\1W)Q7@%M4) J=W.]4QNB\255NWWB&MH%UZV^"A;J"$;Z%)@=JJ
MSMV>GFFJ3P7"';I$)XYB!WTUO?Q!H>)91OWL>$DC8 #,[=Y'AF\OZ07)5$ZF
MCG6@7MI>+WZ$X*%GF5GWZ@0M@R"6P6;K+=EPSN18!-%08>;ERR+:E^D5?PE?
M!IHV>E8OEU9C>8/>I^@>$[4#M@L_QWD&6SBDG2D'8ZON>YMA W955&_[2. P
M^)@C%V@8Z9,5>E>)7<9_U]&,-E_%7/F/09;3_2<U[WPKQ3(QQM).=#QH04GW
MF8J_L6KF/@T9*6M5[BZG@L,3- '/QPJ=3'5##)IOA2[_ U!+ P04    " !4
M=DQ7H51C=.X.  #>,   &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6S5
M6^MOVS@2_U>(;'>1 *IC27ZE+R!-]Y%%7TC;6QP.]X&6:9M;6?225%SO7W\S
M0TJB+#EIN^V' Q:-)9'#><]O2.Z3G=(?S5H(RSYM\L(\/5E;NWUT?FZRM=AP
M,U!;4<"7I=(;;N%1K\[-5@N^H$F;_#P9#B?G&RZ+DV=/Z-U;_>R)*FTN"_%6
M,U-N-ESOGXM<[9Z>Q"?5BQNY6EM\<?[LR9:OQ#MA/VS?:G@ZKZDLY$841JJ"
M:;%\>G(9/WH^PO$TX%]2[$SPFZ$D<Z4^XL/UXNG)$!D2N<@L4N#PYU9<B3Q'
M0L#&7Y[F2;TD3@Q_5]1_(=E!ECDWXDKE?\B%73\]F9VPA5CR,K<W:O>;\/*,
MD5ZF<D/_LIT;FZ8G+"N-51L_&3C8R,+]Y9^\'H()L^&1"8F?D!#?;B'B\@6W
M_-D3K79,XVB@AC](5)H-S,D"C?+.:O@J89Y]=EUD:B/8>_Y)F"?G%BCB^_/,
MSW[N9B='9L<)>Z4*NS;LYV(A%FT"Y\!*S4]2\?,\N9/B[V4Q8.DP8LDP2>^@
ME];RI40OO5<^]D*:+%>FU(+]YW)NK :/^&^?S([BJ)\B1LDCL^69>'H"86"$
MOA4GSW[Z(9X,']_![ZCF=W07]7OM<??L.!VPD (#SV5V+=@29.<YVPNNF5J2
M<B/\ +K8<<,*Q:2;9D%1<U&(I;01VVH)D2KS/5MHB)V"S??LG0^G=):P7&ZD
MY?0(_VV5L0_?7_U^R4Y_^F&6),/'J/6KTAK&BP7[7<T-N\PL?8L?G[$"4@XD
M%PT$BA4#RYAZXNLW+^MAI96Y_)M6B=BRU,@UQ)W)M)R+!3 +>67 +@W*!=XC
M:N\A =F5VFQYL6=KOF /AH,8@BC/D6,(7:$U4$"1N3' S>F+]Y=GJ(F\!&^&
M'TS1:H4J'F8E#"ZL&VFB.VCEDL^!9;M'>B_[Z.6J6#VT0F_JL5( 2=12BVQ@
MDRW?\WDND ;/,ET"N6 NOD9A,U48E<L%MZ@9GO,B$XR2PZ!EN)>-X3Y X#H?
MV6IU*S'9DBKQS74!3!;@-S<"K%^B,A<B@@0.T<,+*^%+MN;%JF' :QN-%T\?
M Z%=(;19RRWDK#TD<0/)$L<VGF/0=7 JWZ@2] M+@_59QK7>0\W9<;TP\)U;
M> 4.*+P_.'4N2XOAC&YM!CWS.'P$;O\$T9E53'SBD$*=W)YAB@CXL:>Q-6TM
M5D @%X9TL5L+LAM.0&/0)""P6\MLW<Q>0=QH4OT:8FHN(& PX: I]@PT9DLK
M!NQ](VO VD(:GH,GD\6D<0I"AU*T*HI6,0?.GF5*+R!J\GW;R5')\Z,B@UHP
MI.%?(&<"=H%;4X(D]#K4 \75EFM;><2A?4.GXN I>R/)D0/#.P^A-+,0Z/20
MLTBN-;\53&446&3-5UP#$Q"Z0 L"#1**+,A;+,  -$+1B6A.6:0L (\XP\U+
MF=N',&<%@(381\FB6HF-T(M28]XAUX(L)%5@-C1%YE0#,4G!@<G-BX)T3OD6
MXN43Y$<K(#\^@$KHH_8,S=>6%$RR+',8QF^YS"F.X:U:+C'I^-2,&0NL(ZI%
M?.P'ID0V9L,?@]AQSE3I@^=&M19&R3IV"!5.Z9(6)GV3FFE6J&8T'&:=0TU3
MP@:U2,<):)I7 >Z=I=\Y#DTHC"4M4NY+Z]P'-*J8H'C,U*IH6Y@80/L@%8Q[
M"5]]Z*-+HQ>VRPOO%HFV"I'24D!"!(-TRY.@Z0>&'P]'@V'-=<\*D5-I8,B@
M;)Y25%2UC,_5K3B+JC!NO*5)=57Z,8$'P3L_"EUFP-XX]3?3[Q(I.A0HGB:!
M0#[I'JI70M58RD+BE CS(+HTK*D%-@)(O:H^.R $%%88QIB.ME*3/*":$5D/
M>-[F@M9N?9U^9E%'#$:) XDMH%#E:KO!2IV!ETM+)!ZDC4B13]M'>/()NM8=
MYFUQ1'-R"=# -E7CF$D"^[E, W/OT,L89-2J7&$N3"\^4PVW -14:3R_G5+H
MQ*JR@\=LSD^.S'!I#)J_!2H3?7N[51HGDG9!D S^<BS^J'E')>>[H%K[E+/4
M:N,+K7)_<8($WC-[4/JI#/4P7DD*ZA;& U?D#U"I-@BU0'-;!/0R$[YXN^0.
M;@D9RQ++F%+$HLP\[- N*?0@#2R!8!$(5V=4;YVR:.KBKU1'<O1^:9$5= 2*
M)*BPJ F85AK!_A9:^60$7W.9N>P/48Q5B!0!/T >B,,^2&K6JLP1Y5(*U @C
M?7X^1HZ#*^1E;6%86/Q50O![)>\J>@3W%BC+;Y!B;Y&#DK!@)K2%(&:9U%FY
M0:27(<"S=5IJ2[E4F*-)P)S@(K;9;A#W48F*X$X5VL_::<@=&"U.%I*58\TV
M3KI&AAH61: "L%YEUYX1M-A*HU6[JD1O,0Z/M7T*03,H @?/ 9\COD9-X3JW
M4NP(A1B?7>KB*BM-4@^(, 7&=&/(,;.32)8PP%&VO?\@2&AKJDOT'M>\QMT2
MY/P8:&MU";6BJE(.)+%?0?$='@3F7-M"JK06:A4 V8-*+@.0 %U40\T#*"V
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M(!X&*U9_)\,X&#(>PY"W4-YX@;'O/$U@=>I3;!@KU7-WA>,CWUF5?:3M=-<
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M33VZ7&ARE@K1RW>@ =4-8H!'[Q#KETX.L/H5XM$[06?%]U&=:3_5^2ZFX^R
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MGYJ@?,GFLH3N0OS01*;W-9$)JH-3H;<IALX,(L_Q/ ^^:IH2A?5#8<S$(LO
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MKAB%VH  \'PAA*XOD$'SULO%?P%02P,$%     @ 5'9,5TQ,S?ZY"@  [2$
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MCGIDN>IQA18IBE7FHJ[03S38E' T)TQ^PD-8-,_+'A65>$5P!J[*]1C&H.$
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MH"5EF.998Q$8U$K[LE:%H^749YB@KG)*[27[FTK> 5#P%<^XX'9##>2IZ1+
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M;"]W;W)K<VAE971S+W-H965T,C<N>&ULS5AM;]LV$/XKA!<4":#:LBQ+=MZ
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M9_A\8WUB^O#.^\1MT? S077&^7.'Z+P3NF&50FYS@ QN+AWG-CP[(;5'[>?
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MA[ E:CZ_+S$Y26__T,P$#Z&'<8ZW0I@X\-DS-Y/>4>&CZN:*F/[SKYWP))M
M2D'LDE/OLZ'>O7K$53]U.B#39<<PPK[G.IXD47)8%9FE\CC$,BF@=KIPI8;
M_MR_@PEX1Z>6!W80/-<9,.T &)^.@G^SG)9KFQ\_S_=3DU\8<<>@Q*0_J<5*
M1T\'SV!;S2[P50^Z%:O/OBOEBE/S<ENS' P_Z$:L3FT4^^;RN+NY'%0"K)[J
MFWIOP6[F)?5(MFFCKP*JB:=O'X^[&[[?@_DNU@)M]16]OZ,5P2^$T1ELQ;[;
M.^YNVG[O^_]!,G[$AM&<VB7-*LB/[\LRP\18*]I?#SPH>?>1BN]X.\,$SL$U
M!9!W;!E%"379)WB./0 <]9MNXF-E(PV;"IG66]UWKL*2:0(:(:6^U#,]L%K;
MNU)K^"H?ZCQ*I-1G@Y)5=#T#@S]W.\.;%;KYT?(.GDCG<1.7Y6%P:(IR*U+O
MFJNH%3E\YUU9:F-DRIN-'IYV.P94@'<ER>GF::*:KW<) 1S3B^21KTWM?@=-
M)<8(.EL39!'1#+L% ]-ZPI\C!C;HM+A@SN3H;4;^!4@A@QO*S&KZMJ;*8U19
MC>;F=R,1OH+B7I&CS5R_<>$Y[)H4!9:=3'_.AH>-F&1*RKQ<ZQ8@RO!$$)[I
M]!9RS]= J KA2O%AH._*;'3!=0^A/EH*E M]VR77Q$4.>_W<>0B)I%!ABQG?
MG;N+NZN7N4AQ)[75IY%%1T>[E9U.W>/[G>-'.H\QDJV$TO=WSJ2BNF&<N0%]
M#+C;_XU]/V;<W8]INMXI/=J*[-.G TJ-GGI3>[D*9,??B36]2#*SA=JL3KGK
M!\E<@B-Y,%="J"?JL1.+*1)_@T RJF+I&D,;2-3+.H]OS@L_<B"<N5?!Y1S?
M$DNP;,[(O-],V,R1_YU>*=:&,^HS:E]1((.)=N)VE&@&%R>Q=[[.HN1\+&K+
MXW!FJ( ;9"[JPM:7FYC"#^\]!1>NNG$)R!1\)=RQ?]J]ERY)]*VW<7?3[%N\
MX]%X]X>*@FX"0))O1;UM?7-F-^CV(_7$]=3E(T?-9ZOC[ARS+=L$NJ^5EF>\
MUK %]"-8^]QUW)V[O@5%"][W;L/>_\+P=M Z",Q:\7]&\KISD4<H\6F)N#LM
M@5U1]*J@6\KS4^Q[AR_A::7B&1F*LPN8_/MQ)A#]Q1XF"C?P$8((W7_1+/G0
M(?3=+52^-"\5 O>^T#U:L!R]3>C/?X% =R:.\FRF(Y_RV[:5I)%IN*#7KPR#
MES%,H\EH'@TF,1N/QM$HGK-W$+F6!X@C59!<4'9J\%::21S-IC$;1?/%PL^J
MJ5C 6](IIQ#&@VBQF++Y)!K-9D\!@?Z5O[;> C!:3'WN<1Y-!@/S8H1S7)U&
MT]$TFLU&;#**H^%@W"GP/K<5=^>V\"4B104&YRH#!F*($KS11H)+CN;!]R_J
MX1V#@%+V7R#C!ESKL7E&BNP+T/S(;?/01_3B/^([O[;]]I_9Q:=R!S''W+XT
M -^>FJ1"ARNVQL/9.S+J9-+:X<!0_VK5C];-MJF4=_84XJ&_\Z<05CM]9'"*
MIX/+B)$!(D<4P/Q49NX517H[WCW@,K50&TW[Q5V]K(BB\6S0FR"$1D+10M+I
MN,8CPXG9<'X9F7R ?4F47NL'GJV1W1;&C;M_ G[ .VH#<1[SAWUAWPOF49H/
M)[WQX/(5O=V+2S<XV$IZ=8CQ1IK4PH-W#S:XQ1?92LZI6Q.GZ:5Z-^8E3B >
MOX*BQ'MS-^C=?=":P>Q&_XN%F':!T(U?TX90U1'HQY*4O0OX@;J@S%+]+Y]R
MM'?QX+)K%PSH9V^"G6^D\'@+",^*\B[OL4>Y]AJ@L6+2L:@5?G\N0E"F+/8C
MO9@5 H"[G\$R#*>]X<B]#[E]HA._$$#W6JU3C!>=F<RN:S3?VPJM>6>L;0DV
MN55W]3YSD2:U0@AW1=*0LN@-)A!;0.BL[!V,4G=O![3BC6+V$Z7@T"[J1 "^
MOEE?R<W,V#CN#6+'ER^B\D)O^R@&4_I)EGCQ6,NS+BW4:04^!>H?I.07H4MN
M^)(?()\RFL&-3;JM[EYPK-O^I%7,!N'$2]+NU'RX^JKMBM(YE.+@R\%'LRC^
M,L7@L$QO7IN,.U?+I[RUETH7YE6GGKQVM_%E\*+_+9=K^N<,J#)=5/J=_^Y7
M]T\F7.E_*, /U__> FSN&KLH<KZ"J8/^#*(0J?\) _T%]H?^V8!E657EECYN
M>))QB0/@^:H$W\%\P07</R3QYG\!4$L#!!0    ( %1V3%>FNFX&^08   $;
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;-4967.;1OBO[*B7/$.D
MY8;$UHR/I$VG23U1VCQT^K""E;0UL,KNXN/?]UM :+$0=B=VT[X(%K[[_L3Q
M#1=7<DVI0K=Y5LB3T5JIS<OI5"9KFA,YX1M:P)LE%SE1<!2KJ=P(2M(**<^F
M#L;!-">L&,V.JV>78G;,2Y6Q@EX*),L\)^+NC&;\YF1DC[8//K#56ND'T]GQ
MAJSHG*K?-I<"3M.62LIR6DC&"R3H\F1T:K\\BS1\!? [HS?2N$=:DP7G5_KP
M-CT982T0S6BB- 4"EVMZ3K-,$P(Q/C<T1RU+C6C>;ZF_J70'719$TG.>?6*I
M6I^,HA%*Z9*4F?K ;WZBC3Z^II?P3%:_Z*:&#8,12DJI>-X@@P0Y*^HKN6WL
M8"!$^ ""TR XE=PUHTK*"Z+([%CP&R0T-%#3-Y6J%38(QPKME+D2\)8!GIK-
M:V<@OD1SMBK8DB6D4.@T27A9*%:LT"7/6,*H1../9)%1>70\5<!8HT^3ALE9
MS<0YP,1VT#M>J+5$KXN4IET"4Y"X%=O9BGWF#%+\N2PFR,46<K#C#M!S6S.X
M%3WW +T^??\X74@E(&S^[-.XIN?UT].I]%)N2$)/1I KDHIK.II]_XT=X%<#
MTGJMM-X0]=D<4C,M,ZJ]IM84L1Q8J=T)@I4*1C*4<"&:\(>7I$!4""[ZU!ED
M>$B=R,'N*_3<UU.IA0>/TZW'G3Z82T&O&2]E=O?%'#_0#1>*ICORZ5^0BE"+
ME,FQ?FJ ;:]C5H G0!92I/((G9&,% E%\ZK*II"F3V:;"_#S-=&%#=T0(73J
M9HPL6,:4#N$MV+?HA7%O6V$<[)T_<@41TX\=VY;OVEV4R#,!7,NU?;!(RG2T
M :$-8>D+L$-"-DP3WL&ZKF?Y 3:>C%W+#KVC#HQMN5&@ZU"9EQG15H9:"XFI
M3#PGBBPO=(XZDKFQUX4)+1Q&1XV"4%&3JS7/4BJDAK+#5XA^+IFZ,Y"\P,*Q
M8U*I%#;Y>)[EXNC9@W][_7A#,W"R64;W8/['*3)7X.(*&5+]UPT5I"I:3YHK
M/\*(@C31PSECQH!C=P.^&U:V%6"_"2D.55<@5B0\IQ8J(,?'=C<DG3 RSF,G
MN/<>VR'ZA4N)%A3F+-K00HK<=F+0QI83N8/1;N/(BJ+X"+T',3)-\AX!.WR8
M0!C&NFI)ED#/@,1C6:E]6&Q)@G^@M>0Y&%.N"<AKX(?^!&.3 Y[$<0? FV!#
M_:>Z=B)H;B3Y#^AUG=Y/&DQOI2RKH@[<MJ;03&O_PT.V!4BX-&N6#9'C=TJ+
M ^4W,BT&'O2]YS70.9%K] 8F\J>URA<'W3_,T3$DZ5&'D*9\[PDDZM.'&[!]
M6R19F4*?A!$K(U)6L_-VUEI5BHC:&DO!\VHT6Q(FT#7)RB9NJHE3NP1N)4N;
MLC=!<TJA6#/ OP1#\!3*[3T60/T]5Q35D63;X-]'3_(3-#"#^NT,ZC]Z!@4#
M4'"7W@YJ7>O%!9*O;]0<I/L\HV9C!*GMV$AJH94P(_6!!@4]J= V7-2SG'6@
MV4+;\"S'CM$Y./X@O+O'#<:=V EU2,%F+<V"&EKA(\:,0?',/@:/7,<?%F]_
M=FB4NJ![XHT#R\;!P_DU$'%!&W'!HR..9%"[JO(*_1(:E&S\J]M5]UT"#6I%
M%R2YZ@W&099?=^]I@[>CST6CZP-@YZW:>X#UT+(#?V0&_%OJGCT4PK9ENV[G
MC&USG7$LVXL; TBD.**WD!UR7]' "HTU9'N%Y23>3SAHVZX?H4MRIUOH?MF
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M:0!XO^2@=7/0#-JO7K._ 5!+ P04    " !4=DQ7&L<]0U4#  #4"0  &0
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M<867D!GF^.P"H15P?<^YZB;:0?^0V_P 4$L#!!0    ( %1V3%<]$LYEA@(
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MA?+/L=!;X/@XL&F>2[6E.<P=[ X%\AZ<Q<L_@M1_-4([[FC'8^B+.VS&HF%
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M8R?;WQ(?5B"- JZOA="'B7'0/=46_P)02P,$%     @ 5'9,5R;Z)@OH @
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MH1 6 K,EV'D3\0$%OML+_:XC<OTX0'<E"*P(6R(*^KYW]WJCW?5'&VCD1L$
M7>BSKU%FD1=,*T#"= 2Y4V,0;FN.!\,N1\IUY\NL%-V]WDL2C?JH/N5__PG<
M.(ZWO,,@1D]<8;I]L+89>J[?WZ8(AFX0#] -2#G6+4L(H[[D8J?NXX'9N>W"
M'L=N%(].]FEQ$>.LX=Y4K.^.!G&W@J$[& UWW3BOTR(+$$O[$$B]R153=;=L
MO>U;<UZWV$UX_5#=8K$D3.K3L=!0_W00.W6I&T/QTC;<.5>Z?=MIKM]+$"9
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M3TY@G_18[M66>WWHDQO)XCO$EMMXAKUK,[(7ILO("-ON"?JO_C_K_ "7_UN
MTWO*@2:^?J)KJL@I+>9[HG^4^91RQ&:=DYQ#**M0*$FVI_U![X.H^Q</E,>I
M@!3B:;R%^#V=4906Z$]*N$ ?2BDD*1)E#@0VW00V1JX1#8>UUAL8')JAC4(S
M#-$[B$ZU)&]H8$BPIY9XIFTC(*D934'*.B>0S5D&\@=.B _WQ!T<F3#5Q<,R
MY950V"+D.J8[W+&7R!V37>1C(PQPPV8G,MT0#4T[^.9X67M3T=#^Q*ZA/-;P
M%?;-T$.!Z82H)\_\.L_\%^>90&SK@K9<ZX5ZG5Q[M1S]UMS]7O_=*?_=7=3'
M$)WFJ5K3I)WGB4BS2*]&;5G-0\\259? T_[&&$UL#;$&-VS&=KFO3:*9V!W4
M^:9BM"=LMQX=FKAB%P>?-+YM1H"$L&LZ 3I">&@K!=?P?;M)%DYH^AC( G Z
MB.3IAO4170=$#PT%-0T%O31T3>$<DL9J3X5FI+Z2WPOU8VGHQ32RB2M=WEY0
MG>&$2]%;DO(]67VFVT;F+<E*BCX5]^!!L.-)_< HL@TW=)O[Z4%)=.HZ&Q@1
M]O<F<<UPB&XKR ,/&Y[KM177P!Q&K=5X(W(0&$$T;"NYOAD$G69#V8L,._1W
MS,8FMOMB+:QC+?RZ6"N+5(K>B.L'_-_6KM<+.L.W=WC(-Z.HCB=@*;?E&(8U
M376'A&<, W<7-, ]\1#5\1 ]?P0ZFNI+4LSR)5S#B;YVT ?5IFT!T8OX8RA(
M';*KB^?>I]IO>RY6?L1-$J\3];) <L%* 25,'$*I%U)%AB!98]O!YU&CXSIP
M^A!@1KQ H(82>D\SMM0WRSU"L?>&?#= -T 7^KP-ZCGA=U2VG62PNS_DH7>T
M@/#.M.YIDL,A2-UE]<V^G@)"9DLBGA'X(?K()"B)9S:]L<S L+V@T?<-[$6M
M1&0U'B=RRN?Z"48 ?EG(ZIVB'JU?>4ZKQXVM>/5$])[P>0KGDHS.0-4V0SA[
M\^K9I>I(MM1/'5,F)<MU<T%)0KD2@.\SQN2FHR:HW[XF_P!02P,$%     @
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MJ0KR^892\510[_/+#SZ+_P!02P,$%     @ 5'9,5U*WV!'@!   <1@  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULQ5E=;]LV%/TKA%8,*9!:(OTA
M.[,-)$Z[=6@W(VZVAV$/C$3;7"71)6D[^?>[E!S)'Q1A#1[:AUJB><\]YU+F
M/6*&6R&_JB5C&CVG2:9&WE+KU8WOJVC)4JI:8L4R^&8N9$HUW,J%KU:2T3@/
M2A.?!$'/3RG/O/$P'YO*\5"L=<(S-I5(K=.4RI<[EHCMR,/>Z\ #7RRU&?#'
MPQ5=L!G3CZNIA#N_1(EYRC+%188DFX^\6WPS(5T3D,_X@[.MVKM&1LJ3$%_-
MS<=XY 6&$4M8I T$A8\-F[ D,4C X]L.U"MSFL#]ZU?T#[EX$/-$%9N(Y$\>
MZ^7(ZWLH9G.Z3O2#V/["=H)R@I%(5/X_VN[F!AZ*UDJ+=!<,#%*>%9_T>5>(
MO0#<JPD@NP!R'-"I"6CO MJYT()9+NN>:CH>2K%%TLP&-'.1UR:/!C4\,\LX
MTQ*^Y1"GQ[-B^9"8HQE?9'S.(YII=!M%8IUIGBW05"0\XDRA=V@JV8:+M4I>
MT -;":E9C#[PC&81IPF:::H9K+ V4\L;@_S[BDEJ5DVAJWNF*4_46YCS.+M'
M5V_>HC?(1VI))>3@&7K,N%;7, C77Y:0C6:Q&OH:Q!K*?K03=E<((S7",$&?
M1::7"KW/8A8? OA0I;)4Y+54=\2)^.LZ:Z%V<(U(0-H60I/SPXF#3KM<N7:.
MUZ[!>R^ED&@BI"Q^$0I!H6").(Q.&7S$Z#;^!YZ@8DD>F"J7Y*]/@(4^PIWZ
MVU;9(G''GMAL+#=J12,V\F#G4$QNF#?^\0?<"WZR5>5"8 <UZI0UZKC0QS_#
M/H9@LXBA'AMJ-@RTI5*:)SSA](DG7+_8"E"@]G-4LQ%NQIUP &N^V1=V.@E8
M=\M)!X2[)>&ND_ 7H>&7)/2227C^(Y&R:Y0Q;>-8 (7[Z3M'#"U3 AS:&?9*
MACTGPT]"*?3$H(&P'4.DZ;.-8.\D^SL<!EU\1-(V+>CW^P,[S[#D&3IY_@8M
M, &N-F;AR<I9F=FF!?TPK&'6+YGUG<SNJ.*16=6<'X*]$4$94WA,\TT07<$S
M&XLDH;+X,A]]:]-1Y!GL$^RV\+$,RZRPTPIP4/W#=D6#4M' J>B>)VO3"RZA
M:7"6)LNL,S7AH.J,@5.5I=M9VY 3I>EN>2FT0\U[;@!_KZ:RRWRI.ET([;!.
MI*H3^5\:BQNV<1'(R0Y%<-US7_D*[&S)37J0&ZFQG/9IOR)AOT9/Y0&PVP2<
MW['<0(WE="R=#0>DWZY15)D$['8)KM[F#FVLH6OI@<9$U&FH; 1V^XC+=4%W
MHL:*>Z>*PQI7ARLS@MUNY)(=TIVJL5Z+RZG56UD<[/8X#] Z\S=]>/O;[Q[7
MZ+C#7.\U%*M:9Z+&:B^$=EB6RB?AP7=KKTZ+UKA.%T([?-&NK!=Q6Z__VE[=
ML$V+L$,[>,-K#SKVWP:I/!9Q>I,F_=6-U%@//FU(I%?C%TCEA8C;"YW?7]U
MC>604[M0OSR5_2%N^^-JKN[0Q@+:39ZORN\0M]^Y7&=U)VHLMW/RTA:T!C4O
MTZ0R0\1MAB[96MVI&@ONGB/8WSN\39E<Y&?:"N7GK\7A9#E:GIO?YJ?%1^-W
M^&92G'Y7,,5A_&<J%QR:3<+F !FT0B FB_/MXD:+57Y$_"2T%FE^N604=E\S
M ;Z?"Z%?;TR"\J\,XW\!4$L#!!0    ( %1V3%<+RP#@40,  &@,   9
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MHY\"J*P!?5]):0X+&Z#^<1'_"U!+ P04    " !4=DQ7CG0M/>P#   @$@
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M>P,/)71%MMP\R/U/M"#4M7BQY-K]1?MB;N"A>*N-S IC\"!C(O\EGPHAC@R
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M0/EZY/C.9N"6+ IE!MQXN,0+F(&Z6TZ%[KF=2D9*8))PA@3D(V?L7R61P=>
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M" /0\SGG:M,Q=U/W[1+_!5!+ P04    " !4=DQ7CRK.#-8"  !0!P  &0
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M$@G>'V8E>"8IH3N\8.0&_*6UIF\Q+0C,4VWW]I$H3)E\IZ<_SQ_!VS?OP!M
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M6I^\2&$,]/VE$.HP, ]HSG+3_P!02P,$%     @ 5'9,5V^L=;X< P  B@T
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M, OT]Y1SM9F8_KVZ?@W_ E!+ P04    " !4=DQ7V=5GZV "  # !0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6REE-]OTS 0Q_^54Y 02&-)TZZ@
MT49J.WX,:5*U"GA /+C.);'FV,&^KMM_C^VDH4AM>."E\=EWW_N<W;O97IL'
M6R$2/-52V7E4$377<6QYA36SE[I!Y4X*;6I&SC1E;!N#+ ]!M8S3))G&-1,J
MRF9A;VVRF=Z1% K7!NRNKIEY7J+4^WDTB@X;]Z*LR&_$V:QA)6Z0OC9KXZRX
M5\E%C<H*K<!@,8\6H^OEE?</#M\$[NW1&GPE6ZT?O'&;SZ/$ Z%$3EZ!N<\C
MKE!*+^0P?G6:49_2!QZO#^H?0^VNEBVSN-+RN\BIFD?O(LBQ8#M)]WK_&;MZ
M B#7TH9?V'>^201\9TG77; CJ(5JO^RINX>C@-'T3$#:!:2!NTT4*&\8L6QF
M]!Z,]W9J?A%*#=$.3BC_*!LR[E2X.,HV[6. +F C2B4*P9DB6'"N=XJ$*F&M
MI> "+;R!E58<%1D6+M2%K SF@N!>V =W_ D5&B;A5K5_%N_TZ@:)"6E?SV)R
MN#YIS#NT98N6GD$;I7"G%546/J@<\[\%8E=G7VQZ*':9#BI^V:E+&"<7D";I
M>$!OW%_>..B-S^B=NJ4?BZUU-\3IYZF*6[W):3W?@->V81SGD>LPB^81H^SE
MB]$T>3] .^EI)T/J!UKK>HFC>&1;B1? VQ<D-+6] ->B@"KW3VN8*O%4"<-)
M)@GD[-D.X%[UN%?_BUNYEOLG[W"6Z7G>^*BK:C1EF!T6 E7;8/UN/YX6;5?^
M<6]GVQTSI5 6)!8N-+E\ZZ!,.R]:@W03>G2KR75\6%9NQ*+Q#NZ\T)H.AD_0
M#^WL-U!+ P04    " !4=DQ7B]U8A=D#  !7%0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6S%6%UOVS84_2N$!@P=L$6B_)G,-A [&]:B!0)G6Q^*
M/=#2M45$(CV2MCN@/[XDI4B60 MS2J OB43=>WC/O<?$ 6<G+IYE!J#0YR)G
M<AYD2NWOPE F&11$WO ],/UERT5!E'X5NU#N!9#4)A5Y&$?1."P(9<%B9M<>
MQ6+&#RJG#!X%DH>B(.*_)>3\- ]P\+*PIKM,F85P,=N3'3R!^FO_*/1;6*.D
MM  F*6=(P'8>W..[51R9!!OQ-X63/'M&ALJ&\V?S\C:=!Y&I"')(E($@^M\1
M5I#G!DG7\6\%&M1[FL3SYQ?TWRUY369#)*QX_I&F*IL'TP"EL"6'7*WYZ0^H
M"(T,7L)S:?^B4Q4;!2@Y2,6+*EE74%!6_B>?JT:<)>#QA82X2HB["<,+"8,J
M86")EI596@]$D<5,\!,2)EJCF0?;&YNMV5!FQOBDA/Y*=9Y:/)7C0WR+GNB.
MT2U-"%/H/DGX@2G*=NB1YS2A(-$O:,59 DP)8B>@4U8"4JK0FLIG_?E/LCGD
M1* '*I.<RX, ].8!%*&Y_&D6*EVMV3-,JLJ6967QA<IPC#YPIC*)?F,II&V
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M;"]W;W)K<VAE971S+W-H965T-C$N>&ULK53);MLP$/T5@@6Z &DD2XY3N+8
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M"FWJW0U+TY%!V@"SGPNA]Q-[0-_CD[]02P,$%     @ 5'9,5Q+CE'"Y P
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M$X%MZ1_V^H?_J6"'3YF")P+;2L&H3\'H@07;72>V2O??+-/1/S4XB.Z5Z<&
MCY43;MS_6*FE:XN:9+(5QE^@_6K?><]<P[FW/L6.[!OH7QC?SJ^H*IG0A$.!
MD-'1"$M2^1;I)T8VKLLLI,&>X885_E6 L@;XO9#2K"<V0/^?DOX!4$L#!!0
M   ( %1V3%</U/_3 @,  "D+   9    >&PO=V]R:W-H965T<R]S:&5E=#8U
M+GAM;+5676_:,!3]*U9639VT-5\0H .D IO::96JLFX/TQY,<DFB)C:S'6C_
M_:Z=D (-:)7@!6+[WN-SKD^<VU]Q\2@3 $6>\HS)@94HM;BT;1DFD%-YP1?
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M6:!X+()8,AXC :N)<8=OYX0D"6G$OPQV\N 8)5*>.?^6G'SR)H:5,((07)5
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M3B;:GV@;:#M1O&QZT)HKW=&:8:[_.2!,@-[?<*Z>)Z:M]7^QY"]02P,$%
M  @ 5'9,5T%CAJV, @  H08  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN
M>&ULK55M3]LP$/XK5H8FD 9Y:PMB::2V;())2!4=X\.T#VYR;2P2.[.=!O[]
MSDX:"DNK(>U+XK/OGGN>R_D2U4(^J@Q DZ<BYVKL9%J7EZZKD@P*JLY$"1Q/
M5D(65*,IUZXJ)=#4!A6Y&WC>R"THXTX<V;VYC"-1Z9QQF$NBJJ*@\GD*N:C'
MCN]L-^[8.M-FPXVCDJYA ?J^G$NTW XE905PQ00G$E9C9^)?SH;&WSK\8%"K
MG34Q2I9"/!KC)AT[GB$$.23:(%!\;6 &>6Z D,;O%M/I4IK W?46_:O5CEJ6
M5,%,Y \LU=G8N7!("BM:Y?I.U-?0ZK$$$Y$K^R1UXWON.22IE!9%&XP,"L:;
M-WUJZ[ 3X(_V! 1M0/ V8+ G(&P#0BNT869E75%-XTB*FDCCC6AF86MCHU$-
MX^8K+K3$4X9Q.K[A&^!:2 :*G)*M]4P>)--PFHJ:D^,KT)3EZ@0=[A=7Y/CH
MA!P1QLGW3%2*\E1%KD8J!M!-VK33)FVP)ZT?D%O!=:;(%YY"^AK 10V=D& K
M9!H<1/Q6\3,2>I](X 5A#Z'9OX<'!^B$75U#BQ?NP9M+D59-I]Y!3C6DY*8H
M*9-X [0B0I)91N4:J_YSLE1:8CO_ZBMCDV70G\5<\4M5T@3&#MYA!7(#3OSQ
M@S_R/O>5X#^!O2K(H"O(X!!Z_-):===:?8(;E N+8D;0)@["H1^YFUTA/4[^
MQ:AS>D5PV!$<OIL@P>XFK/MN?7P/@K[W PW_TC7 <?Q&E[MSVPO 'C)#4)%$
M5%PW]Z7;[>;LQ(Z7-_M3G+_-N'R!:8;W+;8FXXKDL$)([^P<B<EF(#:&%J6=
M*4NA<4+998;_$)#& <]70NBM81)T?Z7X#U!+ P04    " !4=DQ7GV^EW@T$
M   <%@  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6S56%V/FS@4_2L6
M6ZU::6; D 0RFR"E24?M:JI&G<[NPVH?'#")5;!3VR3M_OJU@>$K#--4O.1E
M!L.]Q^=^62>>'1G_*G882_ ]B:F8&SLI][>F*8(=3I"X87M,U9>(\01)M>1;
M4^PY1F'FE,2F;5D3,T&$&OXL>[?F_HRE,B84KSD0:9(@_N,MCMEQ;D#CZ<5G
MLMU)_<+T9WNTQ0]8/N[77*W,$B4D"::", HXCN;& MXN;4L[9!9_$7P4M6>@
M0]DP]E4O/H1SP]*,<(P#J2&0^G? 2QS'&DGQ^%: &N6>VK'^_(1^EP6O@MD@
M@9<L_IN$<C<W/ .$.$)I+#^SXWM<!#36> &+1?87' M;RP!!*B1+"F?%("$T
M_X^^%XFH.<#1,PYVX6#_K(-3.#A9H#FS+*P5DLB?<78$7%LK-/V0Y2;S5M$0
MJLOX(+GZ2I2?]-=<=027/P"B(7CW+25[52,)KL$7M$ECQ,&*B"!F(N48O%YA
MB4@LWJC/CP\K\/K5&_ *$ J^[%@J%("8F5)QTLAF4.S_-M_??F;_/U-Z QSK
M"MB6[72X+W_>W6ZZFRH393KL,AUVAN>\D(XKL(X1E5>MM.C5':&(!AC<8]4]
M(.O[:Q9=/ZK%0@BL?2*).5@$09JH%$H<@A56,Q80E'>N EDDC$OR7_[BG\5&
M2*X:^M^N_.6$1]V$]93?BCT*\-Q06PC,#]CP?_\-3JP_NK(Y$%@CMTZ96Z</
MO=EJ^"FG5V#+F>CLG!S.R^#T<73PQZ/I9&8>ZA%U&8TJHP;34<ETU,OT'@NA
M#IBJ?F&[?JA6OR[J.;Y;8W7M3#S8XMYA98]LV$U^7)(?_U*:*99=3,<G'* '
MQRVBIT:.98^[>4Y*GI->GA\132/5]"DG=%O-6!?'7J!S1V @L$;,;AFS>VG'
MBSMD;@<":^36*W/K#7N\>"=-;8\<I]7Y74:>V]WYTY+I](7C195VQ^(0?$CV
MG!VP)MI)L1?GW.(,!-8(&5J5SK NK?4+Q@.E=RBT9GYK.@X.V_X%7KVUI]-I
MJ_U?,&IRK406[-49_J<H(JK.[RJ6=RFG1&J1J>E_DCO,.SD/*H:&0FMFH9)#
MT+FXB>A5<&?G=R"T9GXK$0?[5=SY$W&JQR"TVUJHV\I[9B8JU0;[9=L]VO2+
MH'[_LVLS$%HSVDK[P<G%]?Z@*G,HM&9^*YT)>Z76+_2^>]+5GF.W6]\]^;%5
M-VIRK70;[!=N635!2D-5S"6CJD1I\-SOJGZHLXLT$%HS\$H&PNG%#<&@BG,H
MM.953B4Y[5[)=?X0%'CU_H:6VQJ"_DW/#<JL7=WI>]./B&\)%2#&D8*W;EQU
M3O/\*C)?2+;/;O,V3$J69(\[C-3L: /U/6),/BWT!6%Y(>S_#U!+ P04
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M081J.DG)3M(T>9/Q6R-[)(W/21(GZ8&$9O\.3]Y()^T<3CU?>H1OW\AS9ZN
M4,!H^*12VO+?P>2?DZ6Q&NOZUR$7PR&#PX>XMWYI:I;#F.)I!O0&:/;^77\8
M?S[DP'\B>^''H/-C\!;["S\(A,(Z)#BP##V+ZT6;K-_#Z]SLZS@4,^QB0GK1
MWN.H0*]]SS D5XVTH:BZU:XM3?QK?+4^Q785NLM?FM#K;IA><VF(@!52QKV/
M%Y3HT#_"Q*K:/\&ELOB@_;#$E@O:!>#^2BF[F[@#NB:>_0%02P,$%     @
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MO#\6M&11NP"Z7RIEMX8KT*WM]"]02P,$%     @ 5'9,5^M);+#Z!0  WR\
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M8V;->L *1Q/!]T@8:8UF'JQOK+:VAC 3QH42^BO1>BIZ!.T#B;IHL4M3"CI
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M"".@OZ\Y5Z\+<ULK;N?1OU!+ P04    " !4=DQ7U+V;T[ "   W"   &0
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M.A/=A'C3IIJ)9*7YTJ^85'W###/5V8'K /5\S9C<373SZ/XKQ/\ 4$L#!!0
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M=\#NKZ4T^\ U?/>[2OX"4$L#!!0    ( %1V3%<C7/?W3P(  $,%   9
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M<R]S:&5E=#@T+GAM;+U96V_;-AC]*X16#"U01R)USVP#:8)N'78)FG9[&/9
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MOOF?J>H24750+EWAGDLTUP#7S,S%"Y1=8.93*7'=L0Z:J]SH#U!+ P04
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MJYXTW'K>4[F=W>TMUQ*M*3<XRPW^]\P(HGJ4/-TWZIOI5FFA+5I3\GG!XK_
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M\;0XC$&_APIS@3Z_Y%P]-LP-ZJW@^?]02P,$%     @ 5'9,5WE5K']( @
M$ 8  !D   !X;"]W;W)K<VAE971S+W-H965T.3,N>&ULK95=;],P%(;_BF4F
MM$G0I$E;JI)$ZAH!0T)4*X,+Q(6;G#;6'#O83C/^/;:31IV602]VT_CC/*_/
M>=/C1(V0]ZH T.BA9%S%N-"Z6GB>R@HHB1J)"KC9V0E9$FVF<N^I2@+)'50R
M+_#]F5<2RG$2N;6U3")1:T8YK"52=5D2^><:F&AB/,;'A5NZ+[1=\)*H(GO8
M@+ZKUM+,O%XEIR5P105'$G8Q7HX7:6CC7<!W"HTZ&2-;R5:(>SNYR6/LVX2
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M:I'S[NKM&I*MVMMKP:1:H.UCH;Y6@.L U9\S)I\:^D(<OG^2/U!+ P04
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MB9#>:8Q'+9O>T4RTJ&SY70B-Q=P.<VRW((T![B^%T-N)"= U\.0/4$L#!!0
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M2,Q%8A2)>4C,1V(,B04@K%%*PVTI#<&+I"&R*I"8@\1<)$:1F(?$?"3&D%@
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MM$Z@52"VBVD7;G+:6#AVL)T6_OUL)V3I%"J8HMVTMG/>M^<\CMTSW7'Q(%,
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MJ*D#2G-!:5Y!:TZW1M.F]$"YUJ6O/"!L-X'^X)(%5&O&>(B^=9K!EW9&;]5
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M-A2&_XHU7559*9L!SV?29*1-P&U623=*=MN+52\\C)E!"WAJFWQ4_?&U@<!
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M1.GD_(XEV[<2\QA\O)+P%CXCSE$B!5SX6")"Q:4Z^;CTX>+-);P!&T2$.!9
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M JXGJ.\I8_*UHV_QYM$6_0-02P,$%     @ 5'9,5V$@00#8 @  VP@  !H
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M(VY^N06BU[>9H)^O.5?/ W/.K?[7B/X%4$L#!!0    ( %1V3%?CS(!]  0
M  D1   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6S56%MOVS84_BN$
M5@P)D$:B?,]L ;6];!D:($B:[F'8 RW1-E&*]$C*;O_]#BE9LFM)";(%:%YL
MD2*_\YT[J?%.JB]Z3:E!7U,N],1;&[.Y\GT=KVE*]*7<4 %OEE*EQ,!0K7R]
M490D;E/*_3 (^GY*F/"BL9N[4]%89H8S0>\4TEF:$O5M2KG<33SL[2?NV6IM
M[(0?C3=D11^H>=S<*1CY)4K"4BHTDP(INIQX'_#5- SL!K?B,Z,[??",K"H+
M*;_8P4TR\0++B'(:&PM!X&]+9Y1SBP0\_BE O5*FW7CXO$>_=LJ#,@NBZ4SR
M/UEBUA-OZ*&$+DG&S;W<_4X+A7H6+Y9<NU^T*]8&'HHS;61:; 8&*1/Y/_E:
M&.(Y&\)B0^AXYX(<RSDQ)!HKN4/*K@8T^^!4=;N!'!/6*P]&P5L&^TQT39A"
MGPG/*+JE1&>*@LF-1N_1HY +3=66+#A%-V*3P>P]C:6(&6?$FO3"CC.EF%BA
M*=%,7Z"/C"S@M6%4H[,Y-81Q?8[>(2;0I[7,-!&)'OL&B%OQ?ER0G.8DPP:2
M.$2W4IBU1K^*A";' #YH7*H=[M6>AJV(?V3B$G6""Q0&80<]/LS1V;OS%MQ.
M:<Z.P^TVX,Z )I@#3%@8U85YK<JM0#89K_2&Q'3B0;99/U O^ODGW ]^::'9
M+6EV'7KG2:\?NZP(@01!OISX]C0@3N)A1GB<<3= ?]U+SA&DSHZHY.\Z"W1?
MP0*]T@*]5D=-Z8H)8;5;$$Y$3.L(YA!#!V'+VS;J#89C?ULCMU_*[;?*O1$Q
MSR"&;490HBR#VNCHGXA^WRA[4,H>M,JN\_JWFB1^AJ-_@WJ/SCY*K<\OT(,A
MQI4-))>P/I8I15*AF4S!<6M;P;>TF*]3M9WT04;!HV8)57E\02E!#>EVQ \M
M+9<U@676Z <%;YXYK>^H8K*MJ Q+^PY?1+5.Z5:D%\;^J.0Y>@/9/WH%"^"@
M:GO!?\__ N,P"SNC?GT2XH..B_^7$E# '-6 S@@WB \K\>%;K )/L/X!R@"N
M#@&X_10 9UG#\X-4K:J=FN+>X-:JH^/6=AG-@?Z6V",NNF8"(IH1#N;61F6.
MR%&JU[)ZC7:,JWZ,>V^@*.'64\-+C5 =#G#[Z>!Y52G'&!R$#QXTEJ7J<(#;
M&^VSR]+@-'K[S76I:IZXO7O^J'6IG;43!:&55.D'P:4(B.-[)=I"H^K9N+4A
M1C=:9PV).SIQ" Y&HX;#8EBUR+"]1<)=ZXE(#$_[8[\;=+X3[!_<3E.J5NX.
MKE$L,V'RBVHY6][S/^2WVVIY_I'@EBA($(TX7<+6X'( Z:KR>W<^,'+C[KH+
M:>#F[![7E(!S[ )XOY32[ =60/GU(_H74$L#!!0    ( %1V3%>\B2/-KP8
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MAZ;/Z!&YT7#B>'M4#"W9HC*NJ8S[\Z(N0D?H,Z,<PIQS]4)TH>E5.A2-2;'
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M'!.0[4!I-UI4KB?G0IL.=\O<S&"4-L!\7PBA-QN;H)_JR1]02P,$%     @
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MIBS-FU^6],"A=@&T7RAEMX8;NO[)3/\ 4$L#!!0    ( %1V3%?Q(Q(*<0(
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M"5P;J/4Y8W(WT!L4G6OP%U!+ P04    " !4=DQ7YKB&HJ$$   7%   &@
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M9HTM$)(5WD7RD1U^([F@D<8+6"323W#(;1T+!#LA69P[*P8Q3;)O_)('HN(
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M1-4]K+@V<D"+75L!@67)AN^KV>>0OV@-S]$:$I'?(K&LY/!]I?P<B=W(/3A
M;5ORA*<S@,/N'5DV ?"-7< YPB[:%>1HC7?GC%O>7=D<P#=W!^>HNVBWD*/5
MU8W'+1T#*CL&]#\ZAC-TYO U9@AYXUK^,!M"Z+9T_*CL(M 97<0Y5*%YBU3Z
MF)QJBV';GQ-4=A>HN[OX0V7I,F^#;3EG6!9SAM,ZLC4@[.@Z3O!09]^9F,^^
M71FQQ(2OT\F34&E+_3W/YA#%TV*Z=9O.=&K/[^#-(IM1E3#9R.PSYFN:"!"1
ME8)T!KXJ+3R;0F4WDFW30<Z22<GB]')#L$J:VD#]OF),OM[H!8I9X/P_4$L#
M!!0    ( %1V3%<SG4>=J00  %02   :    >&PO=V]R:W-H965T<R]S:&5E
M=#$R,"YX;6RM6-MNVS@0_15"6Q0M$$<B)>N2V@;2&,5FD;9!+NW#8A]HF;:)
M2J*7I.UDOWY)29$<D5+3(B^V+C/#,T<S/"--#HS_$!M")'C(LT),G8V4VS/7
M%>F&Y%B<LBTIU)T5XSF6ZI2O7;'E!"]+ISQSD>>%;HYIX<PFY;5K/INPG<QH
M0:XY$+L\Q_SQ(\G88>I Y^G"#5UOI+[@SB9;O":W1-YOK[DZ<YLH2YJ30E!6
M $Y64^<<GET@I!U*BV^4',31,="I+!C[H4\NEU/'TXA(1E*I0V#UMR<7),MT
M)(7CWSJHTZRI'8^/GZ)_*I-7R2RP(!<L^TZ7<C-U8@<LR0KO,GG##G^2.J&Q
MCI>R3)2_X%#;>@Y(=T*RO'96"'):5/_XH2;BR $&/0ZH=D O=?!K![],M$)6
MIC7'$L\FG!T U]8JFCXHN2F]53:TT(_Q5G)UERH_.;LL4I83<(<?B  C,"<K
MPCE9Z@O@7 @B!<#%$EQ1O* 9E;2TNL.+788YF%.19DSL. 'OYD1BFHGWZO;]
M[1R\>_,>O &T '<;MA,JA)BX4N'5J[IIC>UCA0WU8/MK5YP"WSL!R$.^Q?WB
MY>[HN;NK6&JH0@U5J(SG]\2S<',"OJA.8ROP#6<[7-;E>:8Z Q<I 7^?+X3D
MJD[_L:5>K178U]+->R:V."531W6G('Q/G-G;/V#H?; 1\4K!GM'B-[3X0]%G
M)0-;PE7ZQ1JH<A @Q9P_ K7''#!?VI*O(L9E1+W1[&<0!B@<3]S]<5I6LR#P
M&[-G@(,&<# (^#Q-^4X]QANRP))8Z[(*$!TM'"9)T$%G&HV3(+!C&S?8QH/8
M;C>8DY'>EY9 -:;:K$595C:08V/] (V]#DC3"$51#X%A S)\$8'D0>.S,Q@:
MZT;CN(/-M(EA9(<6-="B06@W;W&^_3 'J>I3*JW((I.1 (8=:#8CU$-;W&"+
M![%=%I*H]I,V4+'Y+&'<Y<LT0DDTMH-*&E#)(*COJE5Q(=7&S^D>:TFUDI88
M2\.QUVV(P95^<Q>"7BMDWG#KU(,!C )P@;=4XHS^U]L\=;!GQ>=WJV!XQ=_-
MZ$B:X4\*9D\*R?BC-0%H=MC1SE@G8!I!&/7T&&R%$ X*RNR*J T*9/5,8(>'
MS(I.4!>>:10E20^Z5H_@L"!]E1O"K9A\DPW?-T#9K#S8@ZH5'3BL.G=,%:0>
M,*L90JH9 I<SA!6IJ2W0CZ*HNR-8[92.HAZTK0S!81VZ(D*<@7TSU>"GJ<:*
MUA29$?3#P.N*D=40Q4D8]N!M%0D.2]+<Y/4$%-5L]M(L3#E2G!N,FU9^&/?A
M;V4+1B^?+8^&[6K ')XDX: D_NHH^5K1GA/1:B3\J4CB8DT7F5V'H*F!HSCH
MSHTV*Q3US1:PU4HX+):?Z(-Z1 -M:\KDR)C(;$:^%]NQH5;^T+#\W7R]KY!9
M7S9,M1L%<5<M;%91W(>LE3$T+&.6G2]K*]P*%QJ#_\C2B\A4MY$?PYXQ#1V]
MYPW+FVZY7X+[NN]RR)(\ZM:N>_3*K[^W?,9\30L!,K)2;MYII+9:7GW"J$XD
MVY9? 19,2I:7AQN"EX1K W5_Q9A\.M$?%IH/2;/_ 5!+ P04    " !4=DQ7
M$"^7/X<"  "X!0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,C$N>&ULE51M
M;],P$/XKIS"A31I-FJX#C312N_(RQ*1I8_ !\<%-+HTUQPZVTXQ_S]E)LR)U
M!;XD]OGNN>?.?BYIE7XP):*%QTI(,PM*:^N+,#19B14S(U6CI)-"Z8I9VNIU
M:&J-+/=!E0CC*#H/*\9ED";>=J/31#56<(DW&DQ354S_6J!0[2P8!UO#+5^7
MUAG"-*G9&N_0WM<WFG;A@)+S"J7A2H+&8A;,QQ>+J?/W#E\YMF9G#:Z2E5(/
M;G.5SX+($4*!F74(C'X;O$0A'!#1^-EC!D-*%[B[WJ*_][53+2MF\%*);SRW
MY2QX$T".!6N$O57M1^SK\00S)8S_0MO[1@%DC;&JZH.)0<5E]V>/?1]V N+X
MF8"X#X@][RZ19[EDEJ6)5BUHYTUH;N%+]=%$CDMW*7=6TRFG.)M>R4Q5"%_8
M(QIX!4LL4&O,G0'FQJ UP&0.GSE;<<$M]U[S/.>NITS E>P>ANOP\1(MX\*<
MP!%P"==<"#*;)+1$U*4+LY[4HB,5/T-J',.UDK8T\$[FF/\)$%*%0YGQMLQ%
M?!#Q4R-',(E.(8[B"=S?+>'XZ.0 [F1HW\3C3O[:/EARDPEE&HWP?;XR5M.#
M^[&O]@[Q;#^B$^&%J5F&LX!49E!O,$A?OAB?1V\/\#T;^)X=0D\_*)6W="_
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MR4U4V);N"4/C ]SY6FMZ,?Q8=8]B]A=02P,$%     @ 5'9,5R*]S6I3 @
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M965T,3(T+GAM;*U646_:,!#^*U963:W4-B%)H>L@4H%.ZZ1*B+;;P[0'-SG
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M'VB W[8A *L<X%:.,[+=(+YU3P!61<"M(MV]14?E7J<\+_-.,D[(,ZL7K,S
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M*6!<<VE*1I1V@9F?"Z&W';M!4X2._@502P,$%     @ 5'9,5\_P_0TX!0
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M>J%_T>V[V"'L>CW]L:F-ZDW:Z#8(()*QK2X])WMY7]U30G*TH@P]'2A2G_V
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M&R!+8*J!O+^B5!Q/U /R?R28_@=02P,$%     @ 5'9,5Y^@K4?. @  8 D
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M3.-D\6?TJ?Y"K P8;!O0JP?TU@9T!UL&].L!_;4!_6T#!O6 P?J WI8!=CW
M7AO0L[<,&-8#ANL#+K8,N*@'7.Q[A,MZP.6^ Z[J 5?[?EF[G9?O7&??8W27
MW^S%#]WBIV3^(^9$173])DN?K:QZ?.E5;\Q_3N?CRY^L.*DB];'(RK^-RW'%
M]2]1ED5)D5O?6;Y*5!9-+)$LDEK]Q'_KJ"**)_E?K&^L<RM_B#*56W%B_9S$
M17Y:?K!\^\=X,BD?F[\Y+\H)5>SYJ#[X^\7!>UL.+F?)F=6Y/+5ZG5[?^OFC
M8WW[C7:DQ1\;X)L=<%3!PP6\8;AC'OYN=G]F=;OSX3W+V6M&KIG\,<K*&5W4
MY#Z@M\>GV!N^ C=(_A[?A7ZG_BXX9BLP6W]+GY;6CED)L_3W45%^?O8^DC1+
M']5C\Z7?,#S<XX>AW]TQD?,R=\OP]9;AZ\WI_A;Z9A+EN97>674*K32SYB<U
MZU\_E ^U1*&F^;\WY6KA#C:[U6GX^_PQ&JFW)^5Y-E?9DSJY_O.?NL/.7S=E
MB<0<$G-)S",QG\0"$A,D)DDLA# M:OUEU/HF_?ICD8Y^M?+'25R<6J,T>5+9
MXJJP.L]M2IB1:YNP!5:=[DNMNLI]NNZ<=>PWYT^KT2$/Z9*81V(^B04D)DA,
MDE@(85IT!LOH#(S165XB%JGU89:-'LH[&.LFG4[+^,QC=6JYO\WBXK,U/Y_%
M=[$:GUH?,O7=W2P9J_'+V:V\7BRO@D8/V\[#[XW3:!LY$G-(S"4QC\1\$@M(
M3)"8)+$0PK1DVLMDVD>Z?K3)J)&80V(NB7DDYI-80&*"Q"2)A1"F16VXC-K0
M>!)<1NVYB5I61>W42F;36Y55?Y>KT2R+B[B\K1]%DTEYZKO]_#(@7XZPOHV3
M^A[R+];_MM_6OC?.J&U(2<PA,7>!7:Q<&W?MKMWIZ%?''GE,G\0"$A,D)DDL
MA# M?A?+^%T<&C_U266CN+PD?<SBD5IY3).X?!ZY<3J91%EN/99AG8>N2I]Q
M8>F]<5)M$TAB#HFY"ZP[U&]/.[VU!)+']$DL(#%!8I+$0@C3$GBY3.#E$>X"
MZP?L>P=HG$+;O)&80V(NB7DDYI-80&*"Q"2)A1"FI?)JF<JK(]T!7I%1(S&'
MQ%P2\TC,)[& Q 2)21(+(4R+6K?3/%7>^>KN <U3:IM35'-0S:VUU?O ?OG?
MJ_M ]*@^J@6H)E!-HEI(:7H45UHKW2-%447E]>?ZJ/WC:)Q6ZSB2FH-J;JUU
M^ZOK,F?=]3"2Q_11+4 U@6H2U4)*T\/8M%BZQF?NO]3BC'E6K;.(MF!0S:VU
MRY4H]H;K243K+:@6H)I -8EJ(:7I26Q*+EUSR\60Q'%4*.LN2Z?6\T/<G )7
M<UB'-;J=J(UY0RLQJ.:@FKOCJSPO%,X;A=L6LCQT/CZJ!:@F4$VB6DAI>AJ;
MWDQWS^),E(Q?,I;.BKPHWX^3^U.K4-ET8]+0)@RJ.:CF[O@*VM9G55X5;$P8
MVGQ!M0#5!*K)@[_B(34//4U-UZ5K?'[_P"<@WCVI9%8^+GJ,BVBR\D2$C))9
ME'W>^E2$>3:M,XAV9%#-134/U7Q4"U!-H)I$M9#2]*PV99GN\$A/2W31T@NJ
M.:CFHIJ':CZJ!:@F4$VB6DAI>NR:DDSWJVS)F&?5.K-H3P;5W%J[6EV(&9RM
M]V308_JH%J":V/#UN#Q;6YF2Z"%#2M,CUK1@NN8:S'%76-#^"ZHYJ.;N^"K/
M?UMVQPH+VGM!M0#5!*I)5 LI34]CTW[I&I_QW^>>\(<XNHTGW&TAVIM!-0?5
M7%3S4,U'M0#5!*I)5 LI3?]M]Z9 T^L<Z;:PA]9@4,U!-1?5/%3S42U -8%J
M$M5"2M-CUY1E>@>798YY6VB>5>O,HET95'-1S:LU\TVFCQXS0#6!:A+50DK3
ML]AT97H'=V5^__VC^=BM$\?N"\-N#,/N#&/^GBVW6MIV5^"CTPE03:":1+60
MTO0P-G69GKG(<?CMX^Q^EA=;;Q+-AVV=0[0I@VHNJGFHYJ-:@&H"U22JA92F
MA[)IS?0&Q[I)1&LSJ.:@FHMJ'JKYJ!:@FD UB6HAI>FQ:^HU/7.]YK@7IFB9
M!M6<'5^7Y5Z@V\[V+CH=#]5\5 M03:":1+60TO0P-OV9GGFWF8,O3#]LVG5M
MU]4J6KE!-0?57%3S4,U'M0#5!*I)5 LI34]J4[GI71SK:A5MS:":@VHNJGFH
MYJ-:@&H"U22JA92FQZZIX?0.KN$<[5?QS5-J'5BTG5-KJ[\\?WGQ:@\U%SVH
MAVH^J@6H)E!-HEI(:7H2FPI.SUS!^5*_B6^>5NLTHD6<6M.V-%Q/(MJN034?
MU0)4$Z@F42VD-'V#^Z9=TS]X>YIC/LUOGE7;(**:4VNK3Z5WSM;W-7318WJH
MYJ-:@&H"U22JA;7V:D_+YM]A/65-F:9O+M,<O#3S:BO$'<LRYGFTSA5:GT$U
M%]4\5/-1+4 U@6H2U4)*TU/:U&SZQWIEI3[:H4$U!]5<5/-0S4>U -4$JDE4
M"RE-C]W*BRP=O/_,T99ES%-J'5BT;%-KVHU@;VC;@XOU2U#VY9K8UVMB7[")
M?<4F]B6;V-=L.D:/IM_T:/K&PL 76Y@Q3ZMU'M$63JV9%F;0 WJHYJ-:@&H"
MU22JA92F)[&IUO0/KM8<=6$&+=V@FE-KQE\<=]%#>JCF;_@$^F=]_1,(-CRH
M=]9?6WX2Z,0DJH64IB>GZ<'T]^S!M-U!S>RV_ME'.RT[/N?M.W"YZ#P\5/-1
M+4 U@6H2U4)*TQ/6]%?ZU)8QT?@_L[R8JJ3\J]]F:7G-6+TUCI_B/,VJU]2=
M+V_FBR70IW0RFZKOGE5%E5>5T9/*HON:JEY*NWH-WNKBLXB?E%5D415G:QQ]
MKDYP<3HN'ZA&:O[![K!X6'W$J35)GU5>K'ZL/D>6;U2G16?COPAHW0;5G%I;
MO2RUU\^%:(<&U?S=TP_0 PI4DZ@64IJ>YZ88TS^X&'/$/&\)<VZ(\1Z)1?LV
MJ.;T7_=M>NME&_2('JKYJ!:@FD UB6HAI>GI;LHV_8/+-GNG>ZR2\:F5CU02
ME6=:*TTV_L:&>2*MPX?6:_JOZS6O3I=HO0;5?%0+4$V@FD2UD-*T[ V:>LV
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M>,QM"&2ES&^7\J#4!J6FMX;B-A<(W%Q0<H-2TUTK=G/-\':IJ7]0._5[U0$
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MW<$PVXCY*KU7W2./8QZD#Y>,SIA(#I#[YYS'FXVD@^(^DI-_ %!+ P04
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M35H-NM2J([ =K8:55L/6.;.9(6PS0WI8 &+ DB"@E]< GF0) 5R@[[ ^]TC
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M7+"\G<DG@JYT1W!/A>PO]#"2+2 P)2#W%Y2*[40=4#:5P3]02P,$%     @
M5'9,5R^"30A;!   $!,  !H   !X;"]W;W)K<VAE971S+W-H965T,34Q+GAM
M;+68:V_;-A2&_PJA%4,++!%)W:S,-I X*YIA!8)XW3X,^\!8M"U4$CV2CM/]
M^I&2HBM%-('WQ=;E\-5S*/*\%.<GQK^*/:42/.=9(1;.7LK#E>N*S9[F1%RR
M RW4G2WC.9'JE.]<<>"4)&6C/',QA*&;D[1PEO/RVCU?SME19FE![SD0QSPG
M_-L-S=AIX2#GY<)#NMM+?<%=S@]D1]=4?CG<<W7F-BI)FM-"I*P G&X7SC6Z
M6F&L&Y01?Z3T)#K'0*?RR-A7?7*7+!RHB6A&-U)+$/7W1%<TR[22XOBG%G6:
M9^J&W>,7]8]E\BJ91R+HBF5_IHG<+YR9 Q*Z)<=,/K#3)UHG%&B]#<M$^0M.
M=2QTP.8H),OKQHH@3XOJGSS7'=%I@,*)!KAN@(<-_(D&7MW *Q.MR,JT;HDD
MRSEG)\!UM%+3!V7?E*U5-FFA7^-:<G4W5>WD<DUWZJ5(<%=40T)W[058E]T,
M/J8%*38IR7JWW]]22=),?%"!7]:WX/V[#^ =2 OP^YX=!2D2,7>E0M,/<#<U
MQDV%@2<P$ :?62'W OQ2)#3I"[@JIR8Q_)+8#;8J_GHL+H$'?P(88L\ M/K^
MYMB"XS7][)5ZWH3> WVBQ9$*\-?UHY!<C=Z_3;U4B?AF$3VEK\2!;.C"47-6
M4/Y$G>6//Z 0_FS*\$QBO7S])E_?IOZ2+]AREH.->K4Z936VY;X>U92;\J]$
M9Z6HKD!/2P0C+X[G[E,WLW%8'(9A&]5##AKDP(K\&Q.BXE5%DI=CW3B2*Y6H
M\_ +%,$P&#":PF <P]!,&3:4H97REJJWI>9D502+!)"<<9G^6UXPX88CCLB;
M10/8<5#L13,S:=201E;2N_Q 4EY6%\UYXJFD%VR[!?19F9"@)MAH##O#_@#6
M$!3XP03MK*&=66G7DFV^7FA'2-1XS35AU<<6VMD()(1^.* =!P78GX"-&]C8
M/KN>33C6-J\M'F<2ZZ6'8.M*\!SELE8Y4\KG4NOGW'%B]'^4S%JU/\&C4<DT
MA(4(860>B BWU/@L5;.6Z=7#R.O,VAK3$!9CWY_B;/T76>WN]76SUNMU&([0
MD'<<I2K6%&WKGLANGV^IG;5D%P5''AP"CZ-"/_0GO!.UYHGL[OF6^HG&'AE$
M>KG5)S9$H1A. +<^BNQ&NE(#]:CF%/A$2:;F6+T2-G):E5Y=9LZDUL^[=644
MG:6T6LW]U3F?2:V?<^OMR&[N;RVM8^_VO!".II0A+ BF/!ZU)H_L+O_=I34V
MU,P(#M=XIC 4^9V%:_]#JS5K;#7&UY?66J]+@A :+IQ,44$03="V-HOM-ON6
MTHK'YAG >+@N-40A.(,3I16W%HOM%ON6TEI+=C^1O-%"VA T6D:[G;T%-4UV
MY9:+4!S'0E9?X\W59EOGNMS,&%R_05>K:G.FE:GVBCX3ODL+ 3*Z59+P,E(%
MGU?;+]6)9(=R!^.12357R\,])0GE.D#=WS(F7T[T YI-L.5_4$L#!!0    (
M %1V3%=J=XC;:P,  )47   -    >&PO<W1Y;&5S+GAM;-U846_:,!#^*U&Z
M3JTT-82L@:R M"%5FK1-E=J'O56&.,&2XV2.Z6"_?KXX)('Z$.W#"@LJL>_\
M???Y?$Y,1Z5:<WJ_H%0YJXR+<NPNE"H^>5XY7]",E%=Y087V)+G,B-)=F7IE
M(2F)2P!EW.OW>J&7$2;<R4@LL]M,E<X\7PHU=OU>8W/,[6NLK>%'US%\TSRF
M8_?QXOVO9:YNWCGF?O;A[*QWU=/7X^7-KO.B]5ZZGI7^^B#Z/=P8<7@ ,4J+
MD0X.2\:^5&#4PVWJ:OBY)C+ <PP666 Z2HN$#@(>]*S@#A0#^O:HO2X67_1!
M'X%OH3%P<&!![JW'BMRKM\!DE.2BW0F!:PPZ.LFH\T3XV)T2SF:2 2HA&>-K
M8^Z#89[S7#I*;T$MQP=+^<>X?=.#W5GS9$SDLHIM(ICO63U\Q['I@4#&>2.P
M[QK#9%00I:@4M[I3#:Z,SUQ.W7Y8%UIA*LG:[U^[+:"ZZ2"S7,94MD\$=V.:
MC#A-0(YDZ0+N*B\\<"J59[H1,Y+F@E0:-HBZH6GGE/-[>'3]3+:X5TEG7:M2
M%$U3"ZJ;AL9T@+_+9KB[M(-7\3H%>\K5EZ6>CJCZ4"WT3M*$K:K^*FD$8.P^
MSDZ*@J\_<Y:*C)K)'QQP,B(;G+/()?NCHT&IS+6!2M=YHE*Q>=?R6Y+B@:[4
MIIQ6":ZY?X*:_VV>4RJH)+PK6M?^,6?YU8KK5_U;:*X>*[N*$9'7QR\R&!R_
MQOJ =.PB3R"3073\&NOCY;&+/(5,#M[LR?X2D?XIB.R?@LC@*$5Z]<&W<[K>
M.ELW5@=^PXS='_"+B;=!G=F2<<5$W5NP.*;BV1%;TRLRXW2;7X^/:4*67#TT
MSK';MK_3F"VSJ!EU!XFH1[7M;S ]/VQ^0.E83,1T1>-IW97IK&HZNJ&CUA<
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 5'9,5YJB&+*L"0  +F,   \
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M,R)V$0:=!*!P V=$79D+MOGM*EW!6CX>P;V;$751+ER4>\*^M&LCN[6;+6T
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MX<!.S%TI/ "%9J*.2C@(NCW[/BC,2N#480D'06]%M9(A*#03=5S"8=#NQ@]
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M2P$"% ,4    " !4=DQ7-ZL(3^\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !4=DQ7F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( %1V3%<8J_^W] @  *5+   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !4=DQ7J=Z'^44&   <&P
M&               @($X$0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 5'9,5WA^F&SJ @  *0L  !@              ("!LQ<  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %1V3%=B78&S\@4
M /(8   8              " @=,:  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !4=DQ7AMP3PU@%   ,(0  &               @('[
M(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 5'9,5\L/
MCJ&! @  _ 4  !@              ("!B28  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( %1V3%=^!\NKK0<  $<C   8
M  " @4 I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !4
M=DQ78ALR:! *  #1&   &               @($C,0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 5'9,5U%#:>8Y&@  .%,  !@
M         ("!:3L  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( %1V3%<E/L*/"00  %P+   9              " @=A5  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 5'9,5R@BN7(5 P  +@<
M !D              ("!&%H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !4=DQ7;D3Q8(T#  #*"   &0              @(%D70
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %1V3%<:AY"Z
MNP@  !\=   9              " @2AA  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 5'9,5X]R&T1A#   !BH  !D
M ("!&FH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !4
M=DQ7U4,!;XH$  !E#   &0              @(&R=@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %1V3%>]92.1K0@  ,08   9
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M970R,"YX;6Q02P$"% ,4    " !4=DQ7E\+$/7,)  #X'@  &0
M    @(&1M0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M %1V3%?J <\4YPD   $C   9              " @3N_  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 5'9,5TQ,S?ZY"@  [2$  !D
M             ("!6<D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !4=DQ7JO,OIY4#  ")"0  &0              @(%)U   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %1V3%=+*_DZ( H
M (X:   9              " @178  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 5'9,5V[^2G@D"0  WQ@  !D              ("!
M;.(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !4=DQ7
M;34'C#$&   C$@  &0              @(''ZP  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( %1V3%>?4D#.;0,  *\'   9
M      " @2_R  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 5'9,5\.+B1+I&P  5&(  !D              ("!T_4  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !4=DQ7IKIN!OD&   !&P
M&0              @('S$0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( %1V3%<:QSU#50,  -0)   9              " @2,9 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 5'9,5ST2SF6&
M @  _04  !D              ("!KQP! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !4=DQ7 NE<^_8"   <!P  &0
M@(%L'P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %1V
M3%>.U@/*804  )<7   9              " @9DB 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 5'9,5WY8KL*%!0  VB4  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !4=DQ7V/9
M?DH%  "<%@  &0              @('=-P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( %1V3%=/J[;W= 8  +P7   9
M  " @5X] 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M5'9,5\ZX)$SS!   !Q,  !D              ("!"40! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !4=DQ7]4%:4?$"  !K!P  &0
M            @($S20$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( %1V3%<OF*!@;P,  &4*   9              " @5M, 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 5'9,5^P?-))P @
MY 4  !D              ("! 5 ! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !4=DQ7Z#\"SB\"  !L!   &0              @(&H
M4@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %1V3%?'
M7LN15 (  &(%   9              " @0Y5 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ 5'9,5UW3':\A!   91   !D
M     ("!F5<! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1V3%>.="T][ ,  " 2   9              "
M@7AL 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 5'9,
M5UD:@M@> P  )PL  !D              ("!FW ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !4=DQ7J1H]W=H"  #'"   &0
M        @('P<P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( %1V3%>/*LX,U@(  % '   9              " @0%W 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 5'9,5X!/&NO( P  UPT
M !D              ("!#GH! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !4=DQ7;ZQUOAP#  "*#0  &0              @($-?@$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %1V3%?9U6?K
M8 (  , %   9              " @6"! 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ 5'9,5XO=6(79 P  5Q4  !D
M ("!]X,! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !4
M=DQ7[F/A_W$"  #9!0  &0              @($'B $ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %1V3%<6^R\X=0(  .\%   9
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M970V-2YX;6Q02P$"% ,4    " !4=DQ7?]]=;!8$  #+%0  &0
M    @(%/F@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M %1V3%=@Z1*9"P,  "T+   9              " @9R> 0!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ 5'9,5T^+!ZV) @  T08  !D
M             ("!WJ$! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !4=DQ706.&K8P"  "A!@  &0              @(&>I $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %1V3%>?;Z7>#00
M !P6   9              " @6&G 0!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ 5'9,5[E<R[9J @  T 4  !D              ("!
MI:L! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !4=DQ7
M79YAZ$H"  #R!   &0              @(%&K@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( %1V3%=K\WCT?P(  ,(%   9
M      " @<>P 0!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ 5'9,5^M);+#Z!0  WR\  !D              ("!?;,! 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !4=DQ7^( )!N "   K"
M&0              @(&NN0$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( %1V3%<Z.SW0V0,  *D/   9              " @<6\ 0!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 5'9,5]2]F].P
M @  -P@  !D              ("!U< ! 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !4=DQ7E&+9J]8"  !0"0  &0
M@(&\PP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( %1V
M3%<V>#/I; (   D&   9              " @<G& 0!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ 5'9,5RQ\TKV# @  RP8  !D
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M=#@T+GAM;%!+ 0(4 Q0    ( %1V3%>6K\:+-P,  .(.   9
M  " @5#9 0!X;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @
M5'9,5\JM?ETB P  =@H  !D              ("!OMP! 'AL+W=O<FMS:&5E
M=',O<VAE970X-BYX;6Q02P$"% ,4    " !4=DQ78()D^N\"  #@"0  &0
M            @($7X $ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4
M Q0    ( %1V3%>Y-+H)9P(  .(%   9              " @3WC 0!X;"]W
M;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @ 5'9,5RF:^Z/L @
MU@D  !D              ("!V^4! 'AL+W=O<FMS:&5E=',O<VAE970X.2YX
M;6Q02P$"% ,4    " !4=DQ7R32*HOT#   ]%   &0              @('^
MZ $ >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    ( %1V3%>0
M$L8O9 (  ,(%   9              " @3+M 0!X;"]W;W)K<VAE971S+W-H
M965T.3$N>&UL4$L! A0#%     @ 5'9,5Q;8XVZS!   %AX  !D
M     ("!S>\! 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4
M" !4=DQ7>56L?T@"   0!@  &0              @(&W] $ >&PO=V]R:W-H
M965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( %1V3%=H[3K4^ (   L)   9
M              " @3;W 0!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L!
M A0#%     @ 5'9,5]/H:.#( @  S <  !D              ("!9?H! 'AL
M+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4    " !4=DQ7:6^E0=<"
M  !I"   &0              @(%D_0$ >&PO=V]R:W-H965T<R]S:&5E=#DV
M+GAM;%!+ 0(4 Q0    ( %1V3%?4@Q?V;P(  &8&   9              "
M@7(  @!X;"]W;W)K<VAE971S+W-H965T.3<N>&UL4$L! A0#%     @ 5'9,
M5Y/VC^"O"0  "'@  !D              ("!& ," 'AL+W=O<FMS:&5E=',O
M<VAE970Y."YX;6Q02P$"% ,4    " !4=DQ7R0%#S&8#  !U"@  &0
M        @('^# ( >&PO=V]R:W-H965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0
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M965T,3 S+GAM;%!+ 0(4 Q0    ( %1V3%?<+O%#N 8  $(Q   :
M      " @=@> @!X;"]W;W)K<VAE971S+W-H965T,3 T+GAM;%!+ 0(4 Q0
M   ( %1V3%<(\K=%.0<  "4[   :              " @<@E @!X;"]W;W)K
M<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    ( %1V3%<JV&8M(00  -D9
M   :              " @3DM @!X;"]W;W)K<VAE971S+W-H965T,3 V+GAM
M;%!+ 0(4 Q0    ( %1V3%>I:*$X$ ,  , )   :              " @9(Q
M @!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;%!+ 0(4 Q0    ( %1V3%=A
M($$ V (  -L(   :              " @=HT @!X;"]W;W)K<VAE971S+W-H
M965T,3 X+GAM;%!+ 0(4 Q0    ( %1V3%>DM<H/F@,  .,0   :
M      " @>HW @!X;"]W;W)K<VAE971S+W-H965T,3 Y+GAM;%!+ 0(4 Q0
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M965T,3$S+GAM;%!+ 0(4 Q0    ( %1V3%=/]<CDG@(  /<'   :
M      " @;5- @!X;"]W;W)K<VAE971S+W-H965T,3$T+GAM;%!+ 0(4 Q0
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M965T,3$X+GAM;%!+ 0(4 Q0    ( %1V3%?FN(:BH00  !<4   :
M      " @;); @!X;"]W;W)K<VAE971S+W-H965T,3$Y+GAM;%!+ 0(4 Q0
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M965T,3(S+GAM;%!+ 0(4 Q0    ( %1V3%<56BZ; 0,  #$(   :
M      " @35M @!X;"]W;W)K<VAE971S+W-H965T,3(T+GAM;%!+ 0(4 Q0
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M965T,3(X+GAM;%!+ 0(4 Q0    ( %1V3%=#VLA'8@D  !IW   :
M      " @0^, @!X;"]W;W)K<VAE971S+W-H965T,3(Y+GAM;%!+ 0(4 Q0
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M965T,3,S+GAM;%!+ 0(4 Q0    ( %1V3%>[L-3=T@0   \D   :
M      " @3.J @!X;"]W;W)K<VAE971S+W-H965T,3,T+GAM;%!+ 0(4 Q0
M   ( %1V3%>@D$)F= ,  ) .   :              " @3VO @!X;"]W;W)K
M<VAE971S+W-H965T,3,U+GAM;%!+ 0(4 Q0    ( %1V3%?/\/T-. 4  %0@
M   :              " @>FR @!X;"]W;W)K<VAE971S+W-H965T,3,V+GAM
M;%!+ 0(4 Q0    ( %1V3%>?H*U'S@(  & )   :              " @5FX
M @!X;"]W;W)K<VAE971S+W-H965T,3,W+GAM;%!+ 0(4 Q0    ( %1V3%=U
M1P =\@\  ,?P   :              " @5^[ @!X;"]W;W)K<VAE971S+W-H
M965T,3,X+GAM;%!+ 0(4 Q0    ( %1V3%='7$&E:@0  *85   :
M      " @8G+ @!X;"]W;W)K<VAE971S+W-H965T,3,Y+GAM;%!+ 0(4 Q0
M   ( %1V3%>2UEIT=@4  "<L   :              " @2O0 @!X;"]W;W)K
M<VAE971S+W-H965T,30P+GAM;%!+ 0(4 Q0    ( %1V3%?XS*.R< <  %-2
M   :              " @=G5 @!X;"]W;W)K<VAE971S+W-H965T,30Q+GAM
M;%!+ 0(4 Q0    ( %1V3%?=%ZVH:@,  ($*   :              " @8'=
M @!X;"]W;W)K<VAE971S+W-H965T,30R+GAM;%!+ 0(4 Q0    ( %1V3%<E
M%G1[\0(  )<'   :              " @2/A @!X;"]W;W)K<VAE971S+W-H
M965T,30S+GAM;%!+ 0(4 Q0    ( %1V3%=382H#M (  +T'   :
M      " @4SD @!X;"]W;W)K<VAE971S+W-H965T,30T+GAM;%!+ 0(4 Q0
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M965T,30X+GAM;%!+ 0(4 Q0    ( %1V3%=H"%#>8@(  -@%   :
M      " @7'V @!X;"]W;W)K<VAE971S+W-H965T,30Y+GAM;%!+ 0(4 Q0
M   ( %1V3%>2_4Y-60,  & .   :              " @0OY @!X;"]W;W)K
M<VAE971S+W-H965T,34P+GAM;%!+ 0(4 Q0    ( %1V3%<O@DT(6P0  ! 3
M   :              " @9S\ @!X;"]W;W)K<VAE971S+W-H965T,34Q+GAM
M;%!+ 0(4 Q0    ( %1V3%=J=XC;:P,  )47   -              "  2\!
M P!X;"]S='EL97,N>&UL4$L! A0#%     @ 5'9,5Y>*NQS     $P(   L
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64$L%!@    "? )\ !"P  /(6 P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>350</ContextCount>
  <ElementCount>581</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>150</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition</Role>
      <ShortName>Nature of Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Revenues from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers</Role>
      <ShortName>Revenues from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Line of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLineOfCredit</Role>
      <ShortName>Line of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>11901 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Revenues from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables</Role>
      <ShortName>Revenues from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureInventories</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesTables</Role>
      <ShortName>Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureOtherLiabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureWarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureWarrants</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>32003 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Business and Financial Condition - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails</Role>
      <ShortName>Nature of Business and Financial Condition - Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Nature of Business and Financial Condition - Reverse Stock Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails</Role>
      <ShortName>Nature of Business and Financial Condition - Reverse Stock Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40103 - Disclosure - Nature of Business and Financial Condition - Product Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails</Role>
      <ShortName>Nature of Business and Financial Condition - Product Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40104 - Disclosure - Nature of Business and Financial Condition - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails</Role>
      <ShortName>Nature of Business and Financial Condition - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40105 - Disclosure - Nature of Business and Financial Condition - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails</Role>
      <ShortName>Nature of Business and Financial Condition - Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40205 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40206 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40207 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40208 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40209 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40210 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40211 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40212 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Advertising Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40213 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40214 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40215 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Revenues from Contracts with Customers - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails</Role>
      <ShortName>Revenues from Contracts with Customers - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Revenues from Contracts with Customers - Revenues by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Revenues by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Revenues from Contracts with Customers - Revenues by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Revenues by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Inventories - Tabular Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails</Role>
      <ShortName>Inventories - Tabular Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Inventories - Inventory Write-down (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails</Role>
      <ShortName>Inventories - Inventory Write-down (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails</Role>
      <ShortName>Property and Equipment - Tabular Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Property and Equipment - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Property and Equipment - Gain (Loss) on Disposal (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails</Role>
      <ShortName>Property and Equipment - Gain (Loss) on Disposal (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Property and Equipment - Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails</Role>
      <ShortName>Property and Equipment - Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Leases - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails</Role>
      <ShortName>Leases - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Leases - Net Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails</Role>
      <ShortName>Leases - Net Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails</Role>
      <ShortName>Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>40605 - Disclosure - Leases - Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails</Role>
      <ShortName>Leases - Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>40606 - Disclosure - Leases - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>40607 - Disclosure - Leases - Operating Leases - Gross Difference (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails</Role>
      <ShortName>Leases - Operating Leases - Gross Difference (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>40608 - Disclosure - Leases - Finance Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Finance Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>40609 - Disclosure - Leases - Finance Leases - Gross Difference (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails</Role>
      <ShortName>Leases - Finance Leases - Gross Difference (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>40707 - Disclosure - Goodwill and Other Intangible Assets - Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>40708 - Disclosure - Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>40709 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>40710 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>40711 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accrued Liabilities - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails</Role>
      <ShortName>Accrued Liabilities - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Accrued Liabilities - Return Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails</Role>
      <ShortName>Accrued Liabilities - Return Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Other Liabilities - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails</Role>
      <ShortName>Other Liabilities - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Other Liabilities - Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails</Role>
      <ShortName>Other Liabilities - Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Other Liabilities - Fixed Payment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails</Role>
      <ShortName>Other Liabilities - Fixed Payment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Other Liabilities - Supply and Distribution Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails</Role>
      <ShortName>Other Liabilities - Supply and Distribution Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Other Liabilities - Contingent Value Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails</Role>
      <ShortName>Other Liabilities - Contingent Value Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Other Liabilities - Contingent Consideration - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails</Role>
      <ShortName>Other Liabilities - Contingent Consideration - Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>40907 - Disclosure - Other Liabilities - Contingent Consideration - Other than Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails</Role>
      <ShortName>Other Liabilities - Contingent Consideration - Other than Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>40908 - Disclosure - Other Liabilities - Contingent Consideration - Total (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails</Role>
      <ShortName>Other Liabilities - Contingent Consideration - Total (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Line of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLineOfCreditDetails</Role>
      <ShortName>Line of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureLineOfCredit</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Long-term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails</Role>
      <ShortName>Long-term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Long-term Debt - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails</Role>
      <ShortName>Long-term Debt - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Long-term Debt - Composition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails</Role>
      <ShortName>Long-term Debt - Composition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Long-term Debt - Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Long-term Debt - Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Fair Value Measurements - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income Taxes - Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails</Role>
      <ShortName>Income Taxes - Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income Taxes - Section 382 Limitation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails</Role>
      <ShortName>Income Taxes - Section 382 Limitation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Income Taxes - Operating Loss Carry Forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails</Role>
      <ShortName>Income Taxes - Operating Loss Carry Forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>41305 - Disclosure - Income Taxes - Tax Credit Carry Forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails</Role>
      <ShortName>Income Taxes - Tax Credit Carry Forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>41306 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>41307 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>41308 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>41309 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>41310 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>41311 - Disclosure - Income Taxes - Unrecognized Tax Benefits - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>41312 - Disclosure - Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Stockholders Equity - Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails</Role>
      <ShortName>Stockholders Equity - Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Stockholders Equity - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails</Role>
      <ShortName>Stockholders Equity - Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Stockholders Equity - Stock Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails</Role>
      <ShortName>Stockholders Equity - Stock Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>41404 - Disclosure - Stockholders Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Equity Incentive Plans - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails</Role>
      <ShortName>Equity Incentive Plans - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Equity Incentive Plans - Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails</Role>
      <ShortName>Equity Incentive Plans - Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>41504 - Disclosure - Equity Incentive Plans - Restricted Stock - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>41505 - Disclosure - Equity Incentive Plans - Restricted Stock - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>41506 - Disclosure - Equity Incentive Plans - Restricted Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>41507 - Disclosure - Equity Incentive Plans - Unrecognized Compensation Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Compensation Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>41508 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Warrants - Stock Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails</Role>
      <ShortName>Warrants - Stock Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Warrants - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails</Role>
      <ShortName>Warrants - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>41604 - Disclosure - Warrants - Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails</Role>
      <ShortName>Warrants - Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>140</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Commitments and Contingencies - Fixed Payment Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails</Role>
      <ShortName>Commitments and Contingencies - Fixed Payment Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Commitments and Contingencies - Supply and Distribution Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Supply and Distribution Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>41803 - Disclosure - Commitments and Contingencies - Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>41804 - Disclosure - Commitments and Contingencies - Product Contingent Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails</Role>
      <ShortName>Commitments and Contingencies - Product Contingent Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>41805 - Disclosure - Commitments and Contingencies - Earn Out Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Earn Out Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>41806 - Disclosure - Commitments and Contingencies - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>41807 - Disclosure - Commitments and Contingencies - Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails</Role>
      <ShortName>Commitments and Contingencies - Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>41901 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureLicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/DisclosureLicenseAgreements</ParentRole>
      <Position>148</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Segment Information - General Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails</Role>
      <ShortName>Segment Information - General Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>42002 - Disclosure - Segment Information - Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails</Role>
      <ShortName>Segment Information - Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="aytu-20230630x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>42003 - Disclosure - Segment Information - Select Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails</Role>
      <ShortName>Segment Information - Select Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>151</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aytu-20230630.xsd</File>
    <File>aytu-20230630_cal.xml</File>
    <File>aytu-20230630_def.xml</File>
    <File>aytu-20230630_lab.xml</File>
    <File>aytu-20230630_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="aytu-20230630x10k.htm">aytu-20230630x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>aytu-20230630x10k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1024">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>187
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aytu-20230630x10k.htm": {
   "nsprefix": "aytu",
   "nsuri": "http://aytubio.com/20230630",
   "dts": {
    "schema": {
     "local": [
      "aytu-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aytu-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aytu-20230630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aytu-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aytu-20230630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aytu-20230630x10k.htm"
     ]
    }
   },
   "keyStandard": 409,
   "keyCustom": 172,
   "axisStandard": 39,
   "axisCustom": 0,
   "memberStandard": 52,
   "memberCustom": 94,
   "hidden": {
    "total": 69,
    "http://fasb.org/us-gaap/2023": 64,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://aytubio.com/20230630": 2
   },
   "contextCount": 350,
   "entityCount": 1,
   "segmentCount": 150,
   "elementCount": 980,
   "unitCount": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1024,
    "http://xbrl.sec.gov/dei/2023": 46
   },
   "report": {
    "R1": {
     "role": "http://aytubio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aytubio.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity",
     "longName": "00300 - Statement - Consolidated Statement of Stockholders' Equity",
     "shortName": "Consolidated Statement of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XKQWlwX_K0uZwDpPIQO9Fg",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical",
     "longName": "00305 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:StockIssuedDuringPeriodValueNewIssuesIssuanceCosts",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition",
     "longName": "10101 - Disclosure - Nature of Business and Financial Condition",
     "shortName": "Nature of Business and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers",
     "longName": "10301 - Disclosure - Revenues from Contracts with Customers",
     "shortName": "Revenues from Contracts with Customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aytubio.com/role/DisclosureInventories",
     "longName": "10401 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipment",
     "longName": "10501 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aytubio.com/role/DisclosureLeases",
     "longName": "10601 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets",
     "longName": "10701 - Disclosure - Goodwill and Other Intangible Assets",
     "shortName": "Goodwill and Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aytubio.com/role/DisclosureAccruedLiabilities",
     "longName": "10801 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilities",
     "longName": "10901 - Disclosure - Other Liabilities",
     "shortName": "Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aytubio.com/role/DisclosureLineOfCredit",
     "longName": "11001 - Disclosure - Line of Credit",
     "shortName": "Line of Credit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebt",
     "longName": "11101 - Disclosure - Long-term Debt",
     "shortName": "Long-term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurements",
     "longName": "11201 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxes",
     "longName": "11301 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aytubio.com/role/DisclosureStockholdersEquity",
     "longName": "11401 - Disclosure - Stockholders Equity",
     "shortName": "Stockholders Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlans",
     "longName": "11501 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aytubio.com/role/DisclosureWarrants",
     "longName": "11601 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:WarrantsOrRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:WarrantsOrRightsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aytubio.com/role/DisclosureEmployeeBenefitPlan",
     "longName": "11701 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11801 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aytubio.com/role/DisclosureLicenseAgreements",
     "longName": "11901 - Disclosure - License Agreements",
     "shortName": "License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:LicensingAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aytubio.com/role/DisclosureSegmentInformation",
     "longName": "12001 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aytubio.com/role/DisclosureSubsequentEvents",
     "longName": "12101 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables",
     "longName": "30303 - Disclosure - Revenues from Contracts with Customers (Tables)",
     "shortName": "Revenues from Contracts with Customers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aytubio.com/role/DisclosureInventoriesTables",
     "longName": "30403 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "30503 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aytubio.com/role/DisclosureLeasesTables",
     "longName": "30603 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables",
     "longName": "30703 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aytubio.com/role/DisclosureAccruedLiabilitiesTables",
     "longName": "30803 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesTables",
     "longName": "30903 - Disclosure - Other Liabilities (Tables)",
     "shortName": "Other Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebtTables",
     "longName": "31103 - Disclosure - Long-term Debt (Tables)",
     "shortName": "Long-term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "31203 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesTables",
     "longName": "31303 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansTables",
     "longName": "31503 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aytubio.com/role/DisclosureWarrantsTables",
     "longName": "31603 - Disclosure - Warrants (Tables)",
     "shortName": "Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:ClassOfWarrantOrRightActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:ClassOfWarrantOrRightActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aytubio.com/role/DisclosureSegmentInformationTables",
     "longName": "32003 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails",
     "longName": "40101 - Disclosure - Nature of Business and Financial Condition - Segments (Details)",
     "shortName": "Nature of Business and Financial Condition - Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails",
     "longName": "40102 - Disclosure - Nature of Business and Financial Condition - Reverse Stock Split (Details)",
     "shortName": "Nature of Business and Financial Condition - Reverse Stock Split (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
     "longName": "40103 - Disclosure - Nature of Business and Financial Condition - Product Information (Details)",
     "shortName": "Nature of Business and Financial Condition - Product Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g",
      "name": "aytu:NumberOfProductPortfolios",
      "unitRef": "Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g",
      "name": "aytu:NumberOfProductPortfolios",
      "unitRef": "Unit_Standard_item_U4Ap8H8xnE-53s7wNRiGEg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
     "longName": "40104 - Disclosure - Nature of Business and Financial Condition - General Information (Details)",
     "shortName": "Nature of Business and Financial Condition - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails",
     "longName": "40105 - Disclosure - Nature of Business and Financial Condition - Going Concern (Details)",
     "shortName": "Nature of Business and Financial Condition - Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)",
     "shortName": "Summary of Significant Accounting Policies - Previously Reported Financial Statements - Balance Sheet and Statement of Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_X786OEV-Uk2MFNoPqbMvjw",
      "name": "us-gaap:Liabilities",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)",
     "shortName": "Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)",
     "shortName": "Summary of Significant Accounting Policies - Previously Reported Financial Statements - Statement of Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Previously Reported Financial Statements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_KSzsOe5vVU-_q8vV072-YQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails",
     "longName": "40205 - Disclosure - Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)",
     "shortName": "Summary of Significant Accounting Policies - Previously Reported Financial Statements - Operating Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails",
     "longName": "40206 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable, Net - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails",
     "longName": "40207 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable, Net - Receivables from Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails",
     "longName": "40208 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable, Net - Allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "aytu:AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "40209 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_Zk-eXjgEJU6UH5o4VKNVCA",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails",
     "longName": "40210 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:AccountsReceivableCreditTermsHighEndOfRange",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:AccountsReceivableCreditTermsHighEndOfRange",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails",
     "longName": "40211 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk - Tabular Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_MajorCustomersAxis_aytu_CustomerAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_IYqHyo3ceEWV3fyhlI0aoA",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails",
     "longName": "40212 - Disclosure - Summary of Significant Accounting Policies - Advertising Costs (Details)",
     "shortName": "Summary of Significant Accounting Policies - Advertising Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AdvertisingExpense",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "longName": "40213 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails",
     "longName": "40214 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
     "longName": "40215 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "shortName": "Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202104Member_n28plwEDMUm6Eohx-3AnMg",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
     "longName": "40301 - Disclosure - Revenues from Contracts with Customers - General Information (Details)",
     "shortName": "Revenues from Contracts with Customers - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_ConsumerHealthPortfolioMember_srt_RangeAxis_srt_MinimumMember_0H_yp89jtUqG89f48FDrpg",
      "name": "aytu:NumberOfProducts",
      "unitRef": "Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
     "longName": "40302 - Disclosure - Revenues from Contracts with Customers - Revenues by Segment (Details)",
     "shortName": "Revenues from Contracts with Customers - Revenues by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
     "longName": "40303 - Disclosure - Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)",
     "shortName": "Revenues from Contracts with Customers - Revenues by Product Portfolio (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_ProductOrServiceAxis_aytu_AttentionDeficitHyperactivityDisorderPortfolioMember_cXbnpjXPukexCAFy3_LFIA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails",
     "longName": "40304 - Disclosure - Revenues from Contracts with Customers - Revenues by Geographic Location (Details)",
     "shortName": "Revenues from Contracts with Customers - Revenues by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_StatementGeographicalAxis_country_US_eQR9LbH5NkuCUdtmvO2k4Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails",
     "longName": "40401 - Disclosure - Inventories - Tabular Disclosure (Details)",
     "shortName": "Inventories - Tabular Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails",
     "longName": "40402 - Disclosure - Inventories - Inventory Write-down (Details)",
     "shortName": "Inventories - Inventory Write-down (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg",
      "name": "aytu:InventoryWriteDownAndImpairment",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
     "longName": "40501 - Disclosure - Property and Equipment - Tabular Disclosure (Details)",
     "shortName": "Property and Equipment - Tabular Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails",
     "longName": "40502 - Disclosure - Property and Equipment - Depreciation Expense (Details)",
     "shortName": "Property and Equipment - Depreciation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails",
     "longName": "40503 - Disclosure - Property and Equipment - Gain (Loss) on Disposal (Details)",
     "shortName": "Property and Equipment - Gain (Loss) on Disposal (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
     "longName": "40504 - Disclosure - Property and Equipment - Impairment (Details)",
     "shortName": "Property and Equipment - Impairment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_aytu_ManufacturingEquipmentMember_hTmUHxELE02AcoWXWW0Nvw",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails",
     "longName": "40601 - Disclosure - Leases - General Information (Details)",
     "shortName": "Leases - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails",
     "longName": "40602 - Disclosure - Leases - Net Lease Cost (Details)",
     "shortName": "Leases - Net Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
     "longName": "40603 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
     "longName": "40604 - Disclosure - Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)",
     "shortName": "Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:RemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:RemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails",
     "longName": "40605 - Disclosure - Leases - Cash Flow Information (Details)",
     "shortName": "Leases - Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:LesseeLeasesCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:LesseeLeasesCashFlowInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "40606 - Disclosure - Leases - Operating Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Leases - Operating Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails",
     "longName": "40607 - Disclosure - Leases - Operating Leases - Gross Difference (Details)",
     "shortName": "Leases - Operating Leases - Gross Difference (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "40608 - Disclosure - Leases - Finance Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Leases - Finance Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails",
     "longName": "40609 - Disclosure - Leases - Finance Leases - Gross Difference (Details)",
     "shortName": "Leases - Finance Leases - Gross Difference (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
     "longName": "40701 - Disclosure - Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Change in Carrying Amount of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementBusinessSegmentsAxis_aytu_ConsumerHealthMember_DxeLmfrDLkiqMKsp5HRFVA",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
     "longName": "40702 - Disclosure - Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aytu_ProductTechnologyRightMember_iw5WUoKyrUuRgi2LPKbXgA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails",
     "longName": "40703 - Disclosure - Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Weighted-average Remaining Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_srt_RangeAxis_srt_WeightedAverageMember_qlFeewmn0EazUiJW4YjynA",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails",
     "longName": "40704 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
     "longName": "40705 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
     "longName": "40706 - Disclosure - Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Supply and Distribution Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
     "longName": "40707 - Disclosure - Goodwill and Other Intangible Assets - Estimated Useful Life (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Estimated Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA",
      "name": "aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_srt_RangeAxis_srt_MinimumMember_DiHClXzqAUOLDLK2Tv46fA",
      "name": "aytu:FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
     "longName": "40708 - Disclosure - Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Product Distribution Rights and Customer List (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_1_2020_To_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_txJsFIjzhES6zLhDWIxkPw",
      "name": "aytu:NumberOfProductsAcquired",
      "unitRef": "Unit_Standard_product_NSGT5DHdqUOAMbZSg_as5w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails",
     "longName": "40709 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AmortizationOfDeferredCharges",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AmortizationOfDeferredCharges",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
     "longName": "40710 - Disclosure - Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Intangible Assets Impairment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_i-hD5_AmZkSLZL8vPpgbTg",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_BusinessAcquisitionAxis_aytu_NeosTherapeuticsIncMember_jE3g0rsLqEWv2jo6veaozw",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails",
     "longName": "40711 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)",
     "shortName": "Goodwill and Other Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:Goodwill",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:Goodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:Goodwill",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails",
     "longName": "40801 - Disclosure - Accrued Liabilities - General Information (Details)",
     "shortName": "Accrued Liabilities - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:AccruedSavingOffers",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:AccruedSavingOffers",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails",
     "longName": "40802 - Disclosure - Accrued Liabilities - Return Reserve (Details)",
     "shortName": "Accrued Liabilities - Return Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "aytu:ReturnReserve",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:ScheduleOfReturnReserveTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_s7bzdFRHAEqT1R3MrP4wOg",
      "name": "aytu:ReturnReserve",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:ScheduleOfReturnReserveTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails",
     "longName": "40901 - Disclosure - Other Liabilities - Components (Details)",
     "shortName": "Other Liabilities - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:OtherSundryLiabilities",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails",
     "longName": "40902 - Disclosure - Other Liabilities - Classification (Details)",
     "shortName": "Other Liabilities - Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:OtherLiabilities",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails",
     "longName": "40903 - Disclosure - Other Liabilities - Fixed Payment Arrangements (Details)",
     "shortName": "Other Liabilities - Fixed Payment Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_1_2019_us-gaap_OtherCommitmentsAxis_aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember_n0Ic1SZidUi2mCx8_oNe5Q",
      "name": "aytu:FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails",
     "longName": "40904 - Disclosure - Other Liabilities - Supply and Distribution Agreement (Details)",
     "shortName": "Other Liabilities - Supply and Distribution Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw",
      "name": "aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails",
     "longName": "40905 - Disclosure - Other Liabilities - Contingent Value Rights (Details)",
     "shortName": "Other Liabilities - Contingent Value Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails",
     "longName": "40906 - Disclosure - Other Liabilities - Contingent Consideration - Business Combination (Details)",
     "shortName": "Other Liabilities - Contingent Consideration - Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_29_2020_us-gaap_BusinessAcquisitionAxis_aytu_InnovusPharmaceuticalsIncMember_OfRjQvoUa0C8wYaMVk2SKQ",
      "name": "aytu:BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
     "longName": "40907 - Disclosure - Other Liabilities - Contingent Consideration - Other than Business Combination (Details)",
     "shortName": "Other Liabilities - Contingent Consideration - Other than Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2021_To_6_30_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember_9OVvG8G6q0mbGffoqxRyrQ",
      "name": "aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails",
     "longName": "40908 - Disclosure - Other Liabilities - Contingent Consideration - Total (Details)",
     "shortName": "Other Liabilities - Contingent Consideration - Total (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://aytubio.com/role/DisclosureLineOfCreditDetails",
     "longName": "41001 - Disclosure - Line of Credit (Details)",
     "shortName": "Line of Credit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_aytu_EclipseLoanAgreementSecuredRevolvingLoansMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_SecuredDebtMember_O8YhH2nEYUOb-JVw1s0Yfg",
      "name": "aytu:LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
     "longName": "41101 - Disclosure - Long-term Debt - Narrative (Details)",
     "shortName": "Long-term Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:DebtInstrumentFeeAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_19_2021_us-gaap_DebtInstrumentAxis_aytu_DeerfieldFacilityMember_zO1XP0i2NUaBmJwgu4GfYw",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
     "longName": "41102 - Disclosure - Long-term Debt - Warrants (Details)",
     "shortName": "Long-term Debt - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "Duration_3_7_2022_To_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_tKH_DOG2x0SbdakkNDfEwA",
      "name": "us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member_cJjtWOain0GY9HJF3j80Sg",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_beKI9HXnQkeZMPJBEWt1SA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails",
     "longName": "41103 - Disclosure - Long-term Debt - Composition (Details)",
     "shortName": "Long-term Debt - Composition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails",
     "longName": "41104 - Disclosure - Long-term Debt - Future Principal Payments (Details)",
     "shortName": "Long-term Debt - Future Principal Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
     "longName": "41201 - Disclosure - Fair Value Measurements - Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MNH1y0Je9UqbdsWLBzlA5A",
      "name": "aytu:BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails",
     "longName": "41202 - Disclosure - Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)",
     "shortName": "Fair Value Measurements - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_FairValueByLiabilityClassAxis_aytu_ContingentValueRightsMember_CZttNuBZcEOgRaMVO7_lQA",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
     "longName": "41203 - Disclosure - Fair Value Measurements - Valuation Assumptions (Details)",
     "shortName": "Fair Value Measurements - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ",
      "name": "aytu:ContingentValueRightsMeasurementInput",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_aytu_MeasurementInputLeveragedBetaMember_NVzg-GO5uU2Gk2ttTP5jpQ",
      "name": "aytu:ContingentValueRightsMeasurementInput",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
     "longName": "41204 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails",
     "longName": "41301 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R114": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
     "longName": "41302 - Disclosure - Income Taxes - Consolidated Balance Sheet (Details)",
     "shortName": "Income Taxes - Consolidated Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails",
     "longName": "41303 - Disclosure - Income Taxes - Section 382 Limitation (Details)",
     "shortName": "Income Taxes - Section 382 Limitation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails",
     "longName": "41304 - Disclosure - Income Taxes - Operating Loss Carry Forwards (Details)",
     "shortName": "Income Taxes - Operating Loss Carry Forwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_trKbOzoSE0SVM-96nTcDWQ",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R117": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails",
     "longName": "41305 - Disclosure - Income Taxes - Tax Credit Carry Forwards (Details)",
     "shortName": "Income Taxes - Tax Credit Carry Forwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_JDsRSkWnL0iOAV8cl3Xh7w",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
     "longName": "41306 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R119": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails",
     "longName": "41307 - Disclosure - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails",
     "longName": "41308 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities - Tabular Disclosure (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R121": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails",
     "longName": "41309 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R122": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails",
     "longName": "41310 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities - Balance Sheet Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_NHMolewghUaWseVoKPRuTg",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R123": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails",
     "longName": "41311 - Disclosure - Income Taxes - Unrecognized Tax Benefits - General Information (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R124": {
     "role": "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "41312 - Disclosure - Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits - Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R125": {
     "role": "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
     "longName": "41401 - Disclosure - Stockholders Equity - Common and Preferred Stock (Details)",
     "shortName": "Stockholders Equity - Common and Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R126": {
     "role": "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails",
     "longName": "41402 - Disclosure - Stockholders Equity - Restricted Stock (Details)",
     "shortName": "Stockholders Equity - Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TdsGYshoqUijifsxflxvYA",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R127": {
     "role": "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
     "longName": "41403 - Disclosure - Stockholders Equity - Stock Offerings (Details)",
     "shortName": "Stockholders Equity - Stock Offerings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_17_2020_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2020ShelfMember_g5mEjHtQiUyvG-DIxyhSLA",
      "name": "aytu:ShelfRegistrationAmountAuthorized",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R128": {
     "role": "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "longName": "41404 - Disclosure - Stockholders Equity - Warrants (Details)",
     "shortName": "Stockholders Equity - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "128",
     "firstAnchor": {
      "contextRef": "As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member_nyAPQPBdxkKmZjxggCk6eg",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R129": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
     "longName": "41501 - Disclosure - Equity Incentive Plans - General Information (Details)",
     "shortName": "Equity Incentive Plans - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "129",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_13_2020_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_L2WFGiNHUUeTtcgD-Tt5cQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R130": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails",
     "longName": "41502 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "130",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_V8-DWr8xh0GXcNZoThiv_w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R131": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
     "longName": "41503 - Disclosure - Equity Incentive Plans - Range of Exercise Prices (Details)",
     "shortName": "Equity Incentive Plans - Range of Exercise Prices (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "131",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R132": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
     "longName": "41504 - Disclosure - Equity Incentive Plans - Restricted Stock - General Information (Details)",
     "shortName": "Equity Incentive Plans - Restricted Stock - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "132",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_AInkh90QjEiG3ysawFPxZQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_2_2021_To_8_2_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_6Su9NkIAvUOaA057CsgVYQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R133": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
     "longName": "41505 - Disclosure - Equity Incentive Plans - Restricted Stock - Activity (Details)",
     "shortName": "Equity Incentive Plans - Restricted Stock - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "133",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_fkvkP0tVBEed2GhGzxQL8A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_Aytu2015PlanMember_12zSQmmNzk6CrPdbL6chxQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R134": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
     "longName": "41506 - Disclosure - Equity Incentive Plans - Restricted Stock - Additional Information (Details)",
     "shortName": "Equity Incentive Plans - Restricted Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "134",
     "firstAnchor": {
      "contextRef": "Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_1_2015_To_6_1_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_aytu_NonplanMember_KLNZKNyM-0qvSTdUN_2yfQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R135": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
     "longName": "41507 - Disclosure - Equity Incentive Plans - Unrecognized Compensation Costs (Details)",
     "shortName": "Equity Incentive Plans - Unrecognized Compensation Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "135",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_SvT4VOHf50CBvJIjb4hAPg",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R136": {
     "role": "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
     "longName": "41508 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense (Details)",
     "shortName": "Equity Incentive Plans - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "136",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R137": {
     "role": "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails",
     "longName": "41601 - Disclosure - Warrants - Stock Issued (Details)",
     "shortName": "Warrants - Stock Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "137",
     "firstAnchor": {
      "contextRef": "Duration_3_7_2022_To_3_7_2022_us-gaap_SubsidiarySaleOfStockAxis_aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member_68IxWTINIk2DIWeurG29KA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R138": {
     "role": "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
     "longName": "41602 - Disclosure - Warrants - General Information (Details)",
     "shortName": "Warrants - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "138",
     "firstAnchor": {
      "contextRef": "As_Of_3_7_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member_vVITWxSXOE2uUtOMkd6Oyg",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_11_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member_KQmo6mLJJk2lVae0W5KK3A",
      "name": "aytu:ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays",
      "unitRef": "Unit_Standard_D_FNxIIhcnCE2AGqsVcU-rBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R139": {
     "role": "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails",
     "longName": "41604 - Disclosure - Warrants - Warrants Activity (Details)",
     "shortName": "Warrants - Warrants Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "139",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_jJVCcTYbiUaIJ-QiKtx9tQ",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:ClassOfWarrantOrRightActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_aytu_WarrantsToPurchaseCommonStockMember_epG8OeOnIk-3NTlmjd_yfw",
      "name": "aytu:ClassOfWarrantOrRightIssuedDuringPeriod",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "aytu:ClassOfWarrantOrRightActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R140": {
     "role": "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails",
     "longName": "41701 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "140",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:NumberOfEmployeeBenefitPlan",
      "unitRef": "Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "aytu:NumberOfEmployeeBenefitPlan",
      "unitRef": "Unit_Standard_plan_XJquu7dlmEWI8Yt0bpcaKg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R141": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
     "longName": "41801 - Disclosure - Commitments and Contingencies - Fixed Payment Arrangements (Details)",
     "shortName": "Commitments and Contingencies - Fixed Payment Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "141",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_qbfr3vPRk0WdLNKiitdxRw",
      "name": "aytu:FixedPaymentArrangements",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R142": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
     "longName": "41802 - Disclosure - Commitments and Contingencies - Supply and Distribution Agreement (Details)",
     "shortName": "Commitments and Contingencies - Supply and Distribution Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "142",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2023_us-gaap_TypeOfArrangementAxis_aytu_SupplyAndDistributionAgreementTrisPharmaIncMember_O-gJ7YgZwUCvEJZRq5u1bw",
      "name": "aytu:SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales",
      "unitRef": "Unit_Standard_pure_IYvNWdp2oU-MBAh5JdwWQA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R143": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
     "longName": "41803 - Disclosure - Commitments and Contingencies - Contingent Consideration Liability (Details)",
     "shortName": "Commitments and Contingencies - Contingent Consideration Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "143",
     "firstAnchor": {
      "contextRef": "Duration_5_12_2022_To_5_12_2022_us-gaap_OtherCommitmentsAxis_aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember_qFtKQKgKKkqA1nAdDFVR7Q",
      "name": "aytu:ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R144": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails",
     "longName": "41804 - Disclosure - Commitments and Contingencies - Product Contingent Liability (Details)",
     "shortName": "Commitments and Contingencies - Product Contingent Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "144",
     "firstAnchor": {
      "contextRef": "As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw",
      "name": "aytu:ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved",
      "unitRef": "Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_28_2015_us-gaap_OtherCommitmentsAxis_aytu_ProductContingentLiabilityNovalereFluticareMember_r5KiqqqT50GkX7SkJ8JEMw",
      "name": "aytu:ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved",
      "unitRef": "Unit_Standard_payment_KR7KlnjAs0uPxEfRtJPwWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R145": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
     "longName": "41805 - Disclosure - Commitments and Contingencies - Earn Out Payments (Details)",
     "shortName": "Commitments and Contingencies - Earn Out Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "145",
     "firstAnchor": {
      "contextRef": "As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ",
      "name": "aytu:LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_12_2021_us-gaap_TypeOfArrangementAxis_aytu_CommercialGlobalLicenseAgreementsAr101Member_JLfW1cgrokuW7cPfvz9bhQ",
      "name": "aytu:LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R146": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
     "longName": "41806 - Disclosure - Commitments and Contingencies - Operating Lease (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "146",
     "firstAnchor": {
      "contextRef": "Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw",
      "name": "aytu:AverageUndiscountedMinimumMonthlyRentPayments",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_1_2023_To_5_31_2023_us-gaap_TypeOfArrangementAxis_aytu_OperatingLeaseAgreementMember_4ooYTlBP5kiCOSfKkwzxaw",
      "name": "aytu:AverageUndiscountedMinimumMonthlyRentPayments",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R147": {
     "role": "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails",
     "longName": "41807 - Disclosure - Commitments and Contingencies - Legal Matters (Details)",
     "shortName": "Commitments and Contingencies - Legal Matters (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "147",
     "firstAnchor": {
      "contextRef": "As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg",
      "name": "aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_2_22_2023_dei_LegalEntityAxis_aytu_SabbyVolatilityWarrantMasterFundLtdMember_srt_LitigationCaseAxis_aytu_SabbyLitigationMember_rGJC9fxXNEGrdvSl_TxeJg",
      "name": "aytu:LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_w4aqCR3c6063a-WXcgAkKw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R148": {
     "role": "http://aytubio.com/role/DisclosureLicenseAgreementsDetails",
     "longName": "41901 - Disclosure - License Agreements (Details)",
     "shortName": "License Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "148",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw",
      "name": "aytu:LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "aytu:LicensingAgreementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_TypeOfArrangementAxis_aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember_AlfpnDBkska3bX3hfnyBDw",
      "name": "aytu:LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "aytu:LicensingAgreementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R149": {
     "role": "http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails",
     "longName": "42001 - Disclosure - Segment Information - General Information (Details)",
     "shortName": "Segment Information - General Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "149",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_00OIbjBxhUaw4WusXGUEFA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R150": {
     "role": "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
     "longName": "42002 - Disclosure - Segment Information - Impairment (Details)",
     "shortName": "Segment Information - Impairment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "150",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_StatementBusinessSegmentsAxis_aytu_RxMember_5mQwwKJmBEel5yTZfoLA2g",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    },
    "R151": {
     "role": "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
     "longName": "42003 - Disclosure - Segment Information - Select Financial Information (Details)",
     "shortName": "Segment Information - Select Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "151",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_eJOHBX9-8EOzyVJd7wHTNQ",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_mgfUv57BHUG7LV-lcawDwQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aytu-20230630x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paragraph IV litigation costs",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r171",
      "r665",
      "r697",
      "r702",
      "r708",
      "r733",
      "r856"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficitAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r514",
      "r522",
      "r525",
      "r531",
      "r538",
      "r542",
      "r543",
      "r544",
      "r709"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r1042",
      "r1043"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r516",
      "r517",
      "r525",
      "r526",
      "r530",
      "r532",
      "r706"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r141",
      "r187",
      "r289",
      "r309",
      "r315",
      "r318",
      "r657",
      "r668",
      "r825"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r176",
      "r203",
      "r540",
      "r541",
      "r911"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r372"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCredit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Text Block]",
        "terseLabel": "Line of Credit",
        "documentation": "The entire disclosure for short-term debt."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r183",
      "r527"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Outstanding, exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, exercise price (in dollars per share)",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-term Debt",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2023ButBefore26January2024",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2023, but before 26 January 2024",
        "label": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2023, but before 26 January 2024",
        "terseLabel": "Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestAfter26January2024",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2024",
        "label": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, after 26 January 2024",
        "terseLabel": "Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r267",
      "r274",
      "r283",
      "r331",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r378",
      "r503",
      "r504",
      "r505",
      "r534",
      "r535",
      "r536",
      "r537",
      "r546",
      "r547",
      "r548",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r651",
      "r652",
      "r653",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r324",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r377",
      "r380",
      "r381",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r828",
      "r894",
      "r1071"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment",
        "label": "Intangible Assets, Net (Excluding Goodwill), Accumulated Impairment",
        "negatedTotalLabel": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Acquired technology right",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsAugust2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r468",
      "r499",
      "r500",
      "r502",
      "r848"
     ]
    },
    "aytu_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Three Equity Incentive Plan [Member]",
        "terseLabel": "2023 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r324"
     ]
    },
    "aytu_ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightTermOfExpirationAfterClosingPriceOfCommonStock",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock",
        "label": "Class of Warrant or Right, Term of Expiration after Closing Price of Common Stock",
        "terseLabel": "Class of warrant, term of expiration after closing price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExpirationTermOnAchievementOfConsolidatedTrailingTwelveMonthAdjustedEbitda",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Expiration Term on Achievement of\nConsolidated Trailing Twelve-Month Adjusted EBITDA",
        "label": "Class of Warrant or Right, Expiration Term on Achievement of Consolidated Trailing Twelve-Month Adjusted EBITDA",
        "terseLabel": "Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "aytu_AytuBiopharmaEmployeeRetirementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AytuBiopharmaEmployeeRetirementPlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aytu Biopharma Employee Retirement Plan [Member]",
        "label": "Aytu Biopharma Employee Retirement Plan [Member]",
        "terseLabel": "Aytu Biopharma Employee Retirement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Liabilities",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "aytu_SabbyLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SabbyLitigationMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sabby Litigation [Member]",
        "label": "Sabby Litigation [Member]",
        "terseLabel": "Sabby Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "aytu_AverageUndiscountedMinimumMonthlyRentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AverageUndiscountedMinimumMonthlyRentPayments",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average Undiscounted Minimum Monthly Rent Payments",
        "label": "Average Undiscounted Minimum Monthly Rent Payments",
        "terseLabel": "Average undiscounted minimum monthly rent payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ProductionRelatedImpairmentsOrChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductionRelatedImpairmentsOrChargesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Production Related Impairments or Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLeaseAgreementMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Agreement [Member]",
        "label": "Operating Lease Agreement [Member]",
        "terseLabel": "Operating Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortization",
        "terseLabel": "Adjusted earnings before interest, taxes, depreciation, and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative Financial Instruments, Liabilities",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Accumulated Impairment",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Accumulated Impairment",
        "negatedLabel": "Indefinite-lived intangible assets, accumulated impairment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "aytu_ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightPercentageOfExercisePriceEqualingCommonStock",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock",
        "label": "Class of Warrant or Right, Percentage of Exercise Price Equaling Common Stock",
        "terseLabel": "Class of warrant or right, percentage of exercise price equaling common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r883",
      "r905"
     ]
    },
    "aytu_FixedPaymentArrangementsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Current",
        "label": "Fixed Payment Arrangements, Current",
        "terseLabel": "Fixed payment arrangements, current"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedAugust2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, August 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, August 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, August 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentChargesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoanProcessingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoanProcessingFee",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Processing Fee",
        "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of receivables from customers",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "aytu_ClassOfWarrantOrRightActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrant activity.",
        "label": "Class of Warrant or Right, Activity [Table Text Block]",
        "terseLabel": "Summary of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsAugust2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of product revenues by geographic location",
        "terseLabel": "Schedule of product revenues by geographic location",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "aytu_ExpirationOfSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ExpirationOfSubleaseMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration of Sublease [Member]",
        "label": "Expiration of Sublease [Member]",
        "terseLabel": "Expiration of sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "aytu_ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightAdjustedWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Adjusted, Weighted Average Remaining Contractual Life",
        "label": "Class of Warrant or Right, Adjusted, Weighted Average Remaining Contractual Life",
        "terseLabel": "Warrant adjusted, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesUnclassifiedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesUnclassifiedAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Unclassified [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Increase (Decrease)",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Increase (Decrease)",
        "terseLabel": "Maximum borrowing capacity, increase (decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "aytu_PrincipalOfficeDenverColoradoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "PrincipalOfficeDenverColoradoMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Office, Denver, Colorado [Member]",
        "label": "Principal Office, Denver, Colorado [Member]",
        "terseLabel": "Principal Office, Denver, Colorado"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExpansionDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ExpansionDateMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expansion Date [Member]",
        "label": "Expansion Date [Member]",
        "terseLabel": "Expansion date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from the computation of earnings per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life in years outstanding, ending balance",
        "terseLabel": "Outstanding, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "aytu_RentReceivableFromSubleaseProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "RentReceivableFromSubleaseProperty",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent Receivable from Sublease Property",
        "label": "Rent Receivable from Sublease Property",
        "terseLabel": "Rent receivable from sublease property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdjusted",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Adjusted",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Adjusted",
        "terseLabel": "Warrant adjusted (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life in years exercisable",
        "terseLabel": "Weighted average remaining contractual life in years exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Total allowance, charges to expense",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r348"
     ]
    },
    "aytu_RemainingAreaOfSubleaseProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "RemainingAreaOfSubleaseProperty",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Area of Sublease Property",
        "label": "Remaining Area of Sublease Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r198",
      "r201",
      "r667"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "aytu_AreaOfSubleaseProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AreaOfSubleaseProperty",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of sublease property.",
        "label": "Area of Sublease Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt.",
        "verboseLabel": "Long-term debt, due on January 26, 2025",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r185",
      "r405",
      "r417",
      "r830",
      "r831",
      "r1069"
     ]
    },
    "aytu_ClassOfWarrantOrRightAdjusted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightAdjusted",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Adjusted",
        "label": "Class of Warrant or Right, Adjusted",
        "terseLabel": "Warrant adjusted (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r860",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt issuance costs, discounts (premium)",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "terseLabel": "Measurement Input, Discount for Lack of Marketability",
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Measurement Input, Expected Dividend Rate",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2023 and June 30, 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r663",
      "r856"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited/cancelled",
        "terseLabel": "Forfeited/cancelled (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r76"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r649"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails": {
       "parentTag": "aytu_InventoryWriteDownAndImpairment",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Cost, Gross, Noncurrent",
        "terseLabel": "Unamortized deferred financing costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract]",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r281"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r281"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r284",
      "r649",
      "r705",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r732",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r751",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r862"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r355",
      "r356",
      "r813"
     ]
    },
    "us-gaap_OtherSundryLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Sundry Liabilities",
        "terseLabel": "Other",
        "documentation": "The aggregate carrying amount, as of the balance sheets date, of obligations not otherwise itemized or categorized in the footnotes to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r184"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r847",
      "r887",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r1042",
      "r1043"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r1061",
      "r1063",
      "r1066"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Finite-lived intangible assets, remaining amortization period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r643",
      "r644",
      "r645",
      "r830",
      "r831",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r847",
      "r887",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expenses",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r250",
      "r289",
      "r309",
      "r315",
      "r318",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r597",
      "r825",
      "r945"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r284",
      "r649",
      "r705",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r732",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r751",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r862"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Net payments made on short-term line of credit",
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Warrant Derivatives",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r828"
     ]
    },
    "us-gaap_CashFlowInvestingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowInvestingActivitiesLesseeAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Investing Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_ReportingUnitNameOfSegmentExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitNameOfSegmentExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Unit, Name of Segment [Extensible Enumeration]",
        "terseLabel": "Reporting Unit, Name of Segment",
        "documentation": "Indicates business segment in which reporting unit is included."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r828"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Employee Unvested Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage employer matches of employee's contribution",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Financing Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising costs",
        "terseLabel": "Advertising costs",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r81",
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other intangible assets",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "R&amp;D credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock activity",
        "terseLabel": "Restricted stock activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r593"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforward",
        "terseLabel": "Net operating loss carry forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r195",
      "r196",
      "r199",
      "r200"
     ]
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment expense",
        "verboseLabel": "Impairment loss",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r322",
      "r826"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Discount Rate",
        "terseLabel": "Finance leases, interest rate (as a percent)",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease, borrowing rate (as a percent)",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r260",
      "r261",
      "r262",
      "r263",
      "r274",
      "r331",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r378",
      "r503",
      "r504",
      "r505",
      "r534",
      "r535",
      "r536",
      "r537",
      "r546",
      "r547",
      "r548",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r651",
      "r652",
      "r653",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "srt_ManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ManagementMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1058"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r255",
      "r257",
      "r260",
      "r261",
      "r264",
      "r265",
      "r273",
      "r283",
      "r537",
      "r576",
      "r580",
      "r581",
      "r616",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704",
      "r892",
      "r895",
      "r896",
      "r897",
      "r916",
      "r921",
      "r922",
      "r1048",
      "r1056",
      "r1057"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r716",
      "r718",
      "r720",
      "r776",
      "r778",
      "r781",
      "r790",
      "r794",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r810",
      "r836",
      "r861",
      "r949",
      "r1071"
     ]
    },
    "aytu_ReturnReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ReturnReserve",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return Reserve",
        "label": "Return Reserve",
        "periodEndLabel": "Return reserve, ending balance",
        "periodStartLabel": "Return reserve, beginning balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r275",
      "r277",
      "r279",
      "r280",
      "r281",
      "r283",
      "r581",
      "r582",
      "r656",
      "r671",
      "r823"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShareBasedCompensationAwardTrancheSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheSixMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Six"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets lease liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Gain on derivative warrant liability",
        "terseLabel": "Gain on derivative warrant liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionReverseStockSplitDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "aytu_EffectiveIncomeTaxRateReconciliationContingentConsideration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationContingentConsideration",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to contingent consideration, percentage.",
        "label": "Effective Income Tax Rate Reconciliation, Contingent Consideration",
        "terseLabel": "Contingent consideration (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NonplanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NonplanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonplan [Member]",
        "label": "Nonplan [Member]",
        "terseLabel": "Non-plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r104",
      "r549"
     ]
    },
    "aytu_Neos2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "Neos2015PlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neos 2015 Plan [Member]",
        "label": "Neos 2015 Plan [Member]",
        "terseLabel": "Neos 2015 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875"
     ]
    },
    "aytu_PaymentsForFixedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "PaymentsForFixedPaymentArrangement",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Fixed Payment Arrangement",
        "label": "Payments for Fixed Payment Arrangement",
        "negatedLabel": "Payment made to fixed payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShareBasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875"
     ]
    },
    "aytu_NeosTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NeosTherapeuticsIncMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neos Therapeutics, Inc [Member]",
        "label": "Neos Therapeutics, Inc [Member]",
        "terseLabel": "Neos Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_StockIssuedDuringPeriodSharesContingentValueRightsPayouts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesContingentValueRightsPayouts",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Contingent Value Rights Payouts",
        "label": "Stock Issued During Period, Shares, Contingent Value Rights Payouts",
        "terseLabel": "Contingent Value Rights payouts (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r716",
      "r718",
      "r720",
      "r776",
      "r778",
      "r781",
      "r790",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r810",
      "r836",
      "r861",
      "r949",
      "r1071"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875"
     ]
    },
    "aytu_IncomeTaxReconciliationContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "IncomeTaxReconciliationContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation, Contingent Consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-use Asset",
        "label": "Deferred Tax Liabilities, Right-of-use Asset",
        "negatedLabel": "ROU asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "aytu_CustomerContractCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CustomerContractCostsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for customer contract costs.",
        "label": "Customer Contract Costs [Policy Text Block]",
        "terseLabel": "Customer Contract Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "aytu_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject to Expiration",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards not subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ZolpiMistMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ZolpiMistMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZolpiMist [Member]",
        "label": "ZolpiMist [Member]",
        "terseLabel": "ZolpiMist"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CustomerAMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab Equipment [Member]",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CustomerBMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B [Member]",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentLongLivedAssetHeldForUseAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of senior debt (premium) discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r611",
      "r832",
      "r833",
      "r908"
     ]
    },
    "aytu_LicensingAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicensingAgreementsTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for licensing agreements.",
        "label": "Licensing Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CustomerCMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C [Member]",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r220",
      "r811"
     ]
    },
    "aytu_ConsumerHealthPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ConsumerHealthPortfolioMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Health Portfolio [Member]",
        "label": "Consumer Health Portfolio [Member]",
        "terseLabel": "Consumer Health Portfolio"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r837",
      "r949",
      "r1071",
      "r1072"
     ]
    },
    "aytu_ProductDistributionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductDistributionRightsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Distribution Rights [Member]",
        "label": "Product Distribution Rights [Member]",
        "verboseLabel": "Acquired product distribution rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "aytu_PediatricPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "PediatricPortfolioMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Portfolio [Member]",
        "label": "Pediatric"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percentage of employees' salary with employer matching contribution",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of allowance for discounts and allowance for chargebacks",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "aytu_MeasurementInputMarketRiskPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "MeasurementInputMarketRiskPremiumMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Market Risk Premium [Member]",
        "label": "Measurement Input, Market Risk Premium [Member]",
        "terseLabel": "Measurement Input, Market Risk Premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentForAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortizationAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Tabular rollforward of gross unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r1039"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r612",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r909"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r126",
      "r127",
      "r181",
      "r185",
      "r254",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r612",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r909"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r79",
      "r80",
      "r115",
      "r116",
      "r118",
      "r121",
      "r169",
      "r170",
      "r254",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r612",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r909"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r552",
      "r556",
      "r597",
      "r945",
      "r946",
      "r1059"
     ]
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Decrease resulting from current period tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment for debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior secured credit facility, due on May 11, 2022",
        "verboseLabel": "Carrying amount of the remaining outstanding debt",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r185",
      "r415"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r301",
      "r312",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r264",
      "r265",
      "r267",
      "r268",
      "r270",
      "r277",
      "r279",
      "r280",
      "r281",
      "r283",
      "r581",
      "r582",
      "r656",
      "r671",
      "r823"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase resulting from current period tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment select financial information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r68"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fair Value",
        "verboseLabel": "Fair value of the remaining outstanding debt",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r68"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "aytu_DeferredTaxAssetsAccruedRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxAssetsAccruedRebates",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Accrued Rebates",
        "label": "Deferred Tax Assets, Accrued Rebates",
        "terseLabel": "Accrued Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less unamortized discount and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r404",
      "r416",
      "r830",
      "r831"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r118",
      "r398",
      "r612",
      "r830",
      "r831"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519"
     ]
    },
    "aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Amount",
        "terseLabel": "162(m) limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted stock units activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Selling and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingAndAdvertisingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketingAndAdvertisingExpenseAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and Advertising Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r379",
      "r755"
     ]
    },
    "us-gaap_SellingAndMarketingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "negatedLabel": "Contingent consideration payment",
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Long-term, final payment fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principals of Consolidation",
        "terseLabel": "Principals of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r820"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of concentration risk",
        "terseLabel": "Concentration risk (as a percent)",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r113",
      "r114",
      "r324"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipmentAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdvertisingCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option activity",
        "terseLabel": "Stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r87"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r755"
     ]
    },
    "aytu_ShareBasedCompensationAwardTrancheSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheSevenMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Seven"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Selling and Marketing Expense",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r814"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r628",
      "r855"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows - finance leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r631"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r815"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r816"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r628",
      "r855"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r234",
      "r235",
      "r243",
      "r250",
      "r260",
      "r272",
      "r273",
      "r289",
      "r309",
      "r315",
      "r318",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r551",
      "r554",
      "r555",
      "r582",
      "r597",
      "r657",
      "r669",
      "r711",
      "r752",
      "r768",
      "r769",
      "r825",
      "r852",
      "r853",
      "r868",
      "r903",
      "r945"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing leases, maturing through May 2024",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Granted, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested outstanding, ending balance (in shares)",
        "periodStartLabel": "Unvested outstanding, beginning balance (in shares)",
        "terseLabel": "Unvested units outstanding (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Range of exercise prices",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "verboseLabel": "Finance leases, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r859",
      "r860",
      "r861",
      "r863",
      "r864",
      "r865",
      "r866",
      "r913",
      "r914",
      "r1047",
      "r1073",
      "r1076"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested",
        "terseLabel": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails",
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r182"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Number of options exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r120",
      "r662",
      "r731"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number of options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance leases, long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Weighted average exercise price",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r260",
      "r261",
      "r262",
      "r263",
      "r274",
      "r331",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r378",
      "r503",
      "r504",
      "r505",
      "r534",
      "r535",
      "r536",
      "r537",
      "r546",
      "r547",
      "r548",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r651",
      "r652",
      "r653",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "aytu_NumberOfProductsAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NumberOfProductsAcquired",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products Acquired",
        "label": "Number of Products Acquired",
        "terseLabel": "Number of products acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Number of shares authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Number of shares available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r283"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r198",
      "r201",
      "r202"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of options outstanding, beginning balance (in shares)",
        "terseLabel": "Number of options outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of future minimum lease payments, finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r283"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r654"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding, number of warrants (in shares)",
        "periodStartLabel": "Outstanding, number of warrants (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r650"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net",
        "terseLabel": "Proceeds from borrowings",
        "documentation": "Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "verboseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r357",
      "r655",
      "r828",
      "r856",
      "r925",
      "r932"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Option",
        "verboseLabel": "Employee Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued to purchase shares (in shares)",
        "verboseLabel": "Class of warrant or right, number of securities called by warrants or right (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Product",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r249",
      "r420",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r571",
      "r773",
      "r774",
      "r793"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Other than Long-term Debt, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Tax withholding for stock-based compensation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails",
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails",
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails",
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails",
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails",
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails",
      "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short-term line of credit",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r181",
      "r856",
      "r1068"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202104Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202104Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2021-04 [Member]",
        "terseLabel": "Accounting Standards Update 2021-04",
        "documentation": "Accounting Standards Update 2021-04 Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r401",
      "r423",
      "r640",
      "r818",
      "r819"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r904"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r649",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r809",
      "r835",
      "r857",
      "r894",
      "r943",
      "r944",
      "r949",
      "r1071"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r649",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r809",
      "r835",
      "r857",
      "r894",
      "r943",
      "r944",
      "r949",
      "r1071"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "terseLabel": "Non-US",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1079",
      "r1080",
      "r1081"
     ]
    },
    "aytu_ShareBasedCompensationAwardTrancheNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheNineMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ninth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Nine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r248"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r231",
      "r250",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r552",
      "r556",
      "r597",
      "r856",
      "r945",
      "r946",
      "r1059"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r283",
      "r340",
      "r341",
      "r537",
      "r576",
      "r580",
      "r581",
      "r582",
      "r616",
      "r638",
      "r639",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r283",
      "r340",
      "r341",
      "r537",
      "r576",
      "r580",
      "r581",
      "r582",
      "r616",
      "r638",
      "r639",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities",
        "totalLabel": "Total other liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r658",
      "r726",
      "r727",
      "r869",
      "r1075"
     ]
    },
    "aytu_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for going concern determination.",
        "label": "Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern Determination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "terseLabel": "Cost, Product and Service",
        "documentation": "Indicates type of cost from product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Goodwill impairment",
        "terseLabel": "Goodwill impairment",
        "verboseLabel": "Impairment of goodwill",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r358",
      "r364",
      "r369",
      "r828"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": "aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-lived Assets and Goodwill",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "aytu_OperatingLeaseAndFinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLeaseAndFinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents right-of-use asset for operating lease and finance lease.",
        "label": "Operating Lease and Finance Lease, Right-of-use Asset",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionSegmentsDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r154",
      "r188",
      "r216",
      "r234",
      "r235",
      "r239",
      "r250",
      "r260",
      "r264",
      "r265",
      "r267",
      "r268",
      "r272",
      "r273",
      "r278",
      "r289",
      "r309",
      "r315",
      "r318",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r582",
      "r597",
      "r670",
      "r752",
      "r768",
      "r769",
      "r825",
      "r867",
      "r945"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities, Gross Difference, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets excluding goodwill",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "aytu_MeasurementInputLeveragedBetaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "MeasurementInputLeveragedBetaMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Leveraged Beta [Member]",
        "label": "Measurement Input, Leveraged Beta [Member]",
        "terseLabel": "Measurement Input, Leveraged Beta"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from contract with customer",
        "verboseLabel": "Product revenue, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r308",
      "r313",
      "r314",
      "r320",
      "r322",
      "r324",
      "r444",
      "r445",
      "r649"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Goodwill impairment (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1044"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issues",
        "terseLabel": "Issues",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Prior Period Reclassification and Previously Reported Financial Statements",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock based compensation (as a percent)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1044"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1044"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentrations",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r197"
     ]
    },
    "aytu_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average period of remaining contractual life of warrants or rights.",
        "label": "Class of Warrant or Right, Weighted Average Remaining Contractual Life",
        "terseLabel": "Outstanding, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets, finite-lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r935"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Provision for income taxes",
        "verboseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r207",
      "r272",
      "r273",
      "r297",
      "r520",
      "r539",
      "r672"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Class of warrant or right, number of securities called by each warrant or right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r890"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt instrument, basis spread on variable rate (as a percent)",
        "verboseLabel": "Basis spread on variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues from Contracts with Customers",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r446"
     ]
    },
    "aytu_ClassOfWarrantOrRightExpiredDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights expired during the period.",
        "label": "Class of Warrant or Right, Expired During Period",
        "negatedLabel": "Warrants expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r267",
      "r274",
      "r283",
      "r331",
      "r332",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r378",
      "r503",
      "r504",
      "r505",
      "r534",
      "r535",
      "r536",
      "r537",
      "r546",
      "r547",
      "r548",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r609",
      "r610",
      "r613",
      "r614",
      "r615",
      "r616",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r651",
      "r652",
      "r653",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704"
     ]
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationAmountAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationAmountAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized amount of common stock, preferred stock, debt securities, warrants, rights and units under the shelf registration.",
        "label": "Shelf Registration, Amount Authorized",
        "terseLabel": "Shelf registration, amount authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Unused line of credit",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r70",
      "r74"
     ]
    },
    "aytu_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average period of remaining contractual life of warrants or rights, issued.",
        "label": "Class of Warrant or Right, Issued, Weighted Average Remaining Contractual Life",
        "terseLabel": "Warrants issued, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentInterestPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentInterestPaymentTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payment term in a debt instrument.",
        "label": "Debt Instrument, Interest Payment Term"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SecuritiesPurchaseAgreement2023PrivateOfferingJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, 2023, Private Offering, June 2023 [Member]",
        "label": "Securities Purchase Agreement, 2023, Private Offering, June 2023 [Member]",
        "terseLabel": "Securities Purchase Agreement, 2023, Private Offering, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LitigationCaseClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Case, Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "label": "Litigation Case, Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Litigation case, class of warrant or right, number of securities called by warrants or rights"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DeerfieldFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeerfieldFacilityMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Deerfield Facility.",
        "label": "Deerfield Facility"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_InterestOnlyPeriodFurtherExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "InterestOnlyPeriodFurtherExtensionTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Further extension term of interest only period in a debt instrument.",
        "label": "Interest Only Period Further Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentGainLossOnDisposalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Gain (loss) on sale of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationRemainingAmountAvailableForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationRemainingAmountAvailableForSale",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Remaining Amount Available for Sale",
        "label": "Shelf Registration, Remaining Amount Available for Sale",
        "terseLabel": "Shelf registration, remaining amount available for sale"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AciphexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AciphexMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AcipHex [Member]",
        "label": "AcipHex [Member]",
        "terseLabel": "AcipHex"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain on extinguishment of debt",
        "verboseLabel": "Gain (Loss) on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r77",
      "r78"
     ]
    },
    "aytu_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's assets and liabilities related to leases.",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of balance sheet information related to leases"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NumberOfProductPortfolios": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NumberOfProductPortfolios",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Portfolios",
        "label": "Number of Product Portfolios",
        "terseLabel": "Number of product portfolios"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "Class of Warrant or Right, Issued During Period",
        "verboseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LesseeLeasesCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LesseeLeasesCashFlowInformationTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for leases of the lessee.",
        "label": "Lessee, Leases, Cash Flow Information [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r754"
     ]
    },
    "aytu_DebtInstrumentInterestPaymentExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentInterestPaymentExtensionTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payment extension term in a debt instrument.",
        "label": "Debt Instrument, Interest Payment Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r808",
      "r822"
     ]
    },
    "aytu_AssetImpairmentAndWriteoffCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AssetImpairmentAndWriteoffCharges",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset impairment and write-off of assets recognized in the income statement.",
        "label": "Asset Impairment And Writeoff Charges",
        "terseLabel": "Impairment and write-off expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, par value $.0001; 200,000,000 shares authorized; shares issued and outstanding 5,517,174 and 1,928,941, respectively, as of June 30, 2023 and June 30, 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r664",
      "r856"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "aytu_AccruedProgramRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccruedProgramRelatedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for program related liabilities.",
        "label": "Accrued Program Related Liabilities",
        "terseLabel": "Accrued program liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SecuritiesPurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SecuritiesPurchaseAgreement2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, 2023 [Member]",
        "label": "Securities Purchase Agreement, 2023 [Member]",
        "terseLabel": "Securities Purchase Agreement, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total share-based compensation expense",
        "verboseLabel": "Total share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r510"
     ]
    },
    "aytu_WarrantsOrRightsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsOrRightsDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for warrants or rights.",
        "label": "Warrants or Rights Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SabbyVolatilityWarrantMasterFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SabbyVolatilityWarrantMasterFundLtdMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sabby Volatility Warrant Master Fund Ltd [Member]",
        "label": "Sabby Volatility Warrant Master Fund Ltd [Member]",
        "terseLabel": "Sabby Volatility Warrant Master Fund Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r732"
     ]
    },
    "aytu_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails",
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment [Member]",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, June 2023 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, June 2023 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r132",
      "r732",
      "r750",
      "r1076",
      "r1077"
     ]
    },
    "aytu_AccruedSavingOffers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccruedSavingOffers",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to accrued saving offers.",
        "label": "Accrued Saving Offers",
        "terseLabel": "Accrued savings offers"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedCommonWarrantsJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Net proceeds from issuance of stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "aytu_OfficeEquipmentFurnitureAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OfficeEquipmentFurnitureAndOtherMember",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Equipment, Furniture and Other [Member]",
        "label": "Office Equipment, Furniture and Other [Member]",
        "terseLabel": "Office Equipment, Furniture and Other"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WalleyeOpportunitiesMasterFundLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WalleyeOpportunitiesMasterFundLtdMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Walleye Opportunities Master Fund Ltd [Member]",
        "label": "Walleye Opportunities Master Fund Ltd [Member]",
        "terseLabel": "Walleye Opportunities Master Fund Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedPreFundedWarrantsJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ConsumerHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ConsumerHealthMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Health [Member]",
        "label": "Consumer Health [Member]",
        "terseLabel": "Consumer Health Segment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheWarrantsJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedTrancheBWarrantsJune2023Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Exercisable, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable, net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r327",
      "r328",
      "r330"
     ]
    },
    "aytu_CefaclorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CefaclorMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cefaclor [Member]",
        "label": "Cefaclor [Member]",
        "terseLabel": "Cefaclor"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLeaseAndFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLeaseAndFinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating and finance lease liability.",
        "label": "Operating Lease and Finance Lease Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossFullyAvailableToOffsetCurrentFiscalYearPreChangeIncomeSubjectToLimitation",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation",
        "label": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Fully Available to Offset Current Fiscal Year Pre-Change Income Subject to Limitation",
        "terseLabel": "Post-change NOL determined to be fully available to offset fiscal 2023 pre-change income subject to the 80% limitation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash and non-cash investing and financing transactions",
        "terseLabel": "Supplemental cash flow data"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Expired",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Expired",
        "terseLabel": "Warrants expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OperatingLossCarryforwardsLimitationsOnUseOwnershipChangePostChangeNetOperatingLossDisallowedRecognizedBuiltInLossCarriedForwardAsOperatingLoss",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesSection382LimitationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss",
        "label": "Operating Loss Carryforwards, Limitations on Use, Ownership Change, Post-change Net Operating Loss, Disallowed Recognized Built-in Loss, Carried Forward as Operating Loss",
        "terseLabel": "Disallowed recognized built-in loss, carried forward as an operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForCreditLossAllowanceForDiscounts",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails": {
       "parentTag": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts",
        "periodEndLabel": "Allowance for discount, ending balance",
        "periodStartLabel": "Allowance for discount, beginning balance",
        "terseLabel": "Allowance for discounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Class of warrant or right, date from which warrants or rights exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "negatedLabel": "Payments made to borrowings",
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "aytu_ContingentValueRightsLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Liabilities, Fair Value Disclosure",
        "label": "Contingent Value Rights Liabilities, Fair Value Disclosure",
        "terseLabel": "CVR liability",
        "verboseLabel": "Contingent value rights"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForCreditLossAllowanceForDiscountsRecovery",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts, Recovery",
        "label": "Accounts Receivable, Allowance for Credit Loss, Allowance for Discounts, Recovery",
        "negatedLabel": "Allowance for discount, payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForDiscountsCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Discounts, Credit Loss Expense (Reversal)",
        "label": "Accounts Receivable, Allowance for Discounts, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for discount, charges to expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenue by product lines",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacks",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails": {
       "parentTag": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks",
        "label": "Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks",
        "periodEndLabel": "Allowance for chargeback, ending balance",
        "periodStartLabel": "Allowance for chargeback, beginning balance",
        "terseLabel": "Allowance for chargebacks"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentPrepaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment fee percentage in a debt instrument.",
        "label": "Debt Instrument Prepayment Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r447",
      "r459",
      "r494",
      "r495",
      "r496",
      "r646",
      "r647",
      "r690",
      "r722",
      "r723",
      "r775",
      "r777",
      "r779",
      "r780",
      "r789",
      "r806",
      "r807",
      "r827",
      "r834",
      "r847",
      "r858",
      "r861",
      "r941",
      "r947",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r113",
      "r114",
      "r324",
      "r795"
     ]
    },
    "aytu_AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForPricingChargebacksCreditLossExpenseReversal",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Pricing Chargebacks, Credit Loss Expense (Reversal)",
        "label": "Accounts Receivable, Allowance for Pricing Chargebacks, Credit Loss Expense (Reversal)",
        "terseLabel": "Allowance for chargeback, charges to expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentValueRightsMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsMeasurementInput",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent value rights.",
        "label": "Contingent Value Rights, Measurement Input",
        "terseLabel": "Contingent value rights, measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForCreditLossAllowanceForPricingChargebacksRecovery",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks, Recovery",
        "label": "Accounts Receivable, Allowance for Credit Loss, Allowance for Pricing Chargebacks, Recovery",
        "negatedLabel": "Allowance for chargeback, payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableAllowanceForCreditLossAllowanceForDoubtfulAccounts",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails": {
       "parentTag": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Allowance for Doubtful Accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ReturnReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ReturnReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return Reserve, Current",
        "label": "Return Reserve, Current",
        "terseLabel": "Return reserve"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EventOccursAfterJanuary262024ButOnOrBeforeJanuary262025Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]",
        "label": "Event Occurs after January 26, 2024, but on or before January 26, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "aytu_DebtInstrumentTermOfTrailingMonthsRevenue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentTermOfTrailingMonthsRevenue",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of trailing months revenue in a debt instrument.",
        "label": "Debt Instrument, Term of Trailing Months Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableBeforeAllowanceForCreditLossPeriodIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, before Allowance for Credit Loss, Period Increase (Decrease)",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r459",
      "r647",
      "r690",
      "r722",
      "r723",
      "r775",
      "r777",
      "r779",
      "r780",
      "r789",
      "r806",
      "r807",
      "r827",
      "r834",
      "r847",
      "r858",
      "r947",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentMinimumVariableRateBeforeBasisSpread": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentMinimumVariableRateBeforeBasisSpread",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Minimum Variable Rate before Basis Spread",
        "label": "Debt Instrument, Minimum Variable Rate before Basis Spread",
        "terseLabel": "Debt instrument, minimum variable rate before basis spread (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ReturnReservePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ReturnReservePayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return Reserve, Payments",
        "label": "Return Reserve, Payments",
        "negatedLabel": "Return reserve, payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r447",
      "r459",
      "r494",
      "r495",
      "r496",
      "r646",
      "r647",
      "r690",
      "r722",
      "r723",
      "r775",
      "r777",
      "r779",
      "r780",
      "r789",
      "r806",
      "r807",
      "r827",
      "r834",
      "r847",
      "r858",
      "r861",
      "r941",
      "r947",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "aytu_DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxAssetsSection174CapitalizationResearchOrExperimentalExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Section 174 Capitalization, Research or Experimental Expenditures",
        "label": "Deferred Tax Assets, Section 174 Capitalization, Research or Experimental Expenditures",
        "terseLabel": "Section 174 Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_PrimaryCarePortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "PrimaryCarePortfolioMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Care Portfolio [Member]",
        "label": "Primary Care Portfolio [Member]",
        "terseLabel": "Primary Care Portfolio"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ReturnReserveChargesToExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ReturnReserveChargesToExpense",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesReturnReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return Reserve, Charges to Expense",
        "label": "Return Reserve, Charges to Expense",
        "terseLabel": "Return reserve, charges to expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
        "terseLabel": "Unrecognized compensation costs, excluding options",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r459",
      "r647",
      "r690",
      "r722",
      "r723",
      "r775",
      "r777",
      "r779",
      "r780",
      "r789",
      "r806",
      "r807",
      "r827",
      "r834",
      "r847",
      "r858",
      "r947",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Unrecognized compensation costs, options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "aytu_AvenueCapitalLoanTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AvenueCapitalLoanTermLoanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avenue Capital Loan, Term Loan [Member]",
        "label": "Avenue Capital Loan, Term Loan",
        "terseLabel": "Avenue Capital Loan, Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ScheduleOfReturnReserveTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ScheduleOfReturnReserveTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the return reserve.",
        "label": "Schedule of Return Reserve [Table Text Block]",
        "terseLabel": "Schedule of the return reserve"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EventOccursAfterJanuary262023ButOnOrBeforeJanuary262024Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]",
        "label": "Event Occurs after January 26, 2023, but on or before January 26, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation, amortization and accretion",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r294"
     ]
    },
    "aytu_TussionexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "TussionexMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tussionex [Member]",
        "label": "Tussionex [Member]",
        "terseLabel": "Tussionex"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails",
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r464",
      "r879",
      "r880",
      "r917"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other noncash adjustments",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails",
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r464",
      "r879",
      "r917"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease assets, weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r855"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r131",
      "r132",
      "r171",
      "r707",
      "r770",
      "r791"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "negatedLabel": "Total allowance, payments",
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73",
      "r650"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease assets, weighted-average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r855"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r131",
      "r132",
      "r171"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite lived intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r162"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite lived intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails",
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesGrossDifferenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r660"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "verboseLabel": "Interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r412",
      "r832",
      "r833"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesOperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of future minimum lease payments, operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NumberOfProducts",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products",
        "label": "Number of Products",
        "terseLabel": "Number of products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r259",
      "r331",
      "r332",
      "r335",
      "r336",
      "r337",
      "r342",
      "r343",
      "r378",
      "r534",
      "r546",
      "r547",
      "r559",
      "r560",
      "r561",
      "r572",
      "r573",
      "r583",
      "r594",
      "r595",
      "r598",
      "r599",
      "r600",
      "r609",
      "r613",
      "r614",
      "r615",
      "r635",
      "r651",
      "r652",
      "r691",
      "r692"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "terseLabel": "Derivative warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r596",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r745",
      "r747",
      "r748",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r819",
      "r1074"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern, within One Year [true false]",
        "terseLabel": "Substantial Doubt about Going Concern, within One Year",
        "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r324",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r380",
      "r381",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r828",
      "r894",
      "r1071"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Financial Condition",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r155",
      "r156"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_RemainingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "RemainingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted average lease term and discount rate.",
        "label": "Remaining Lease Term And Discount Rate [Table Text Block]",
        "terseLabel": "Schedule of remaining lease term and discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r76"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r178"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r712",
      "r913",
      "r914",
      "r915",
      "r1047",
      "r1076"
     ]
    },
    "us-gaap_DepreciationAndAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortizationAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentDepreciationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r586",
      "r643",
      "r644",
      "r645",
      "r830",
      "r831",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of future principal payments of long term debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "verboseLabel": "Cash used in operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r588",
      "r589",
      "r593"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r586",
      "r645",
      "r830",
      "r831",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r212",
      "r237",
      "r238",
      "r239",
      "r255",
      "r256",
      "r257",
      "r261",
      "r271",
      "r273",
      "r284",
      "r339",
      "r345",
      "r435",
      "r503",
      "r504",
      "r505",
      "r536",
      "r537",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r580",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r639",
      "r693",
      "r694",
      "r695",
      "r712",
      "r770"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r902",
      "r938"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of business risk",
        "terseLabel": "Schedule of concentration of business risk",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r57",
      "r58",
      "r113",
      "r179"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r893",
      "r939"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r255",
      "r256",
      "r257",
      "r261",
      "r271",
      "r273",
      "r339",
      "r345",
      "r503",
      "r504",
      "r505",
      "r536",
      "r537",
      "r563",
      "r566",
      "r567",
      "r570",
      "r580",
      "r693",
      "r695",
      "r712",
      "r1076"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r937"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and rights outstanding, term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Effective income tax rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r245",
      "r246"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r212",
      "r237",
      "r238",
      "r239",
      "r255",
      "r256",
      "r257",
      "r261",
      "r271",
      "r273",
      "r284",
      "r339",
      "r345",
      "r435",
      "r503",
      "r504",
      "r505",
      "r536",
      "r537",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r580",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r639",
      "r693",
      "r694",
      "r695",
      "r712",
      "r770"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs of Sales",
        "terseLabel": "Costs of Sales",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Weighted average exercise price",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of long term debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r79",
      "r80",
      "r115",
      "r116",
      "r118",
      "r121",
      "r169",
      "r170",
      "r830",
      "r832",
      "r912"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities",
        "terseLabel": "Schedule of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDeferredCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDeferredCharges",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Deferred Charges",
        "terseLabel": "Amortization expense",
        "documentation": "The amount of amortization of deferred charges applied against earnings during the period."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory balances",
        "terseLabel": "Schedule of Inventory balances",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r138",
      "r139",
      "r140"
     ]
    },
    "aytu_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock and Warrants, Net of Issuance Costs",
        "label": "Proceeds from Issuance of Common Stock and Warrants, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock and warrants, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price outstanding, beginning balance (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474"
     ]
    },
    "aytu_NeosPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NeosPlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to Neos Plan.",
        "label": "Neos Plan [Member]",
        "terseLabel": "Neos Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of the impact of the immaterial correction of an error",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "aytu_StockIssuedDuringPeriodSharesMilestonePayments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "StockIssuedDuringPeriodSharesMilestonePayments",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Milestone Payments",
        "label": "Stock Issued During Period, Shares, Milestone Payments",
        "terseLabel": "Issuance of common stock related to milestone payment (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options exercisable",
        "terseLabel": "Number of options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r218",
      "r250",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r553",
      "r556",
      "r557",
      "r597",
      "r856",
      "r945",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of significant assumptions used in valuation",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "aytu_NextFourPercentAndFivePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NextFourPercentAndFivePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Next Four percent And Five Percent Contribution By Employees [Member]",
        "label": "Next Four percent And Five Percent Contribution By Employees [Member]",
        "terseLabel": "Next 4% and 5% Contribution by Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price exercisable",
        "terseLabel": "Weighted average exercise price exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "aytu_NextFivePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NextFivePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Next Five Percent Contribution By Employees [Member]",
        "label": "Next Five Percent Contribution By Employees [Member]",
        "terseLabel": "Next 5% Contribution by Employees"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FirstThreePercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FirstThreePercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Three Percent Contribution By Employees [Member]",
        "label": "First Three Percent Contribution By Employees [Member]",
        "terseLabel": "First 3% Contribution by Employees"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShareBasedCompensationAwardTrancheEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheEightMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eighth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Eight"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r911",
      "r1043"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r533",
      "r541",
      "r911"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of change in carrying amount of goodwill",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934"
     ]
    },
    "aytu_SixPercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SixPercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 6% contribution by employees.",
        "label": "Six Percent Contribution By Employees [Member]",
        "terseLabel": "6% Contribution By Employees"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Exercise Price Range One [Member]",
        "terseLabel": "Exercise Price Range 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails",
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "aytu_NextFourPercentContributionByEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NextFourPercentContributionByEmployeesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Next Four percent Contribution By Employees [Member]",
        "label": "Next Four percent Contribution By Employees [Member]",
        "terseLabel": "Next 4% Contribution by Employees"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_NumberOfEmployeeBenefitPlan": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NumberOfEmployeeBenefitPlan",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Employee Benefit Plan",
        "label": "Number of Employee Benefit Plan",
        "terseLabel": "Number of employee benefit plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r116",
      "r418",
      "r612"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "aytu_DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxLiabilitiesNetDecreaseDuringPeriodGoodwillImpairment",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Net, Decrease during Period, Goodwill Impairment",
        "label": "Deferred Tax Liabilities, Net, Decrease during Period, Goodwill Impairment",
        "terseLabel": "Goodwill impairment, decrease in net deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Incentive Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative warrant liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options outstanding",
        "terseLabel": "Stock options outstanding",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "aytu_WriteOffOfDeferredDebtIssuanceCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WriteOffOfDeferredDebtIssuanceCostNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of Deferred Debt Issuance Cost, Net",
        "label": "Write-off of Deferred Debt Issuance Cost, Net",
        "terseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease assets, weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r855"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "aytu_AytuPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AytuPlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to Aytu Plan.",
        "label": "Aytu Plan [Member]",
        "terseLabel": "Aytu Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r250",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r553",
      "r556",
      "r557",
      "r597",
      "r730",
      "r824",
      "r869",
      "r945",
      "r1059",
      "r1060"
     ]
    },
    "aytu_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock and Warrants",
        "label": "Proceeds from Issuance of Common Stock and Warrants",
        "terseLabel": "Proceeds from issuance of common stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights issued during period.",
        "label": "Class of Warrant or Right, Issued During Period, Exercise Price",
        "verboseLabel": "Warrants issued (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesBalanceSheetLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument, maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r829",
      "r1050"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Debt, net of current portion",
        "verboseLabel": "Non-current portion of debt",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r661"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_TaxesPayableCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_StockIssuedDuringPeriodValueNewIssuesIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "StockIssuedDuringPeriodValueNewIssuesIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, Value, New Issues, Issuance Costs",
        "terseLabel": "Stock issued during period, value, new issues, issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt and Lease Obligation, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Current portion of debt",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "aytu_AccountsReceivableCreditTermsHighEndOfRange": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableCreditTermsHighEndOfRange",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Terms, High End of Range",
        "label": "Accounts Receivable, Credit Terms, High End of Range",
        "terseLabel": "Accounts receivable, credit terms, high end of range"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "aytu_StockIssuedDuringPeriodValueMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "StockIssuedDuringPeriodValueMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Milestone Payments",
        "label": "Stock Issued During Period, Value, Milestone Payments",
        "terseLabel": "Issuance of common stock related to milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityValuationTechniqueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityValuationTechniqueExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Valuation Technique [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Valuation Technique",
        "documentation": "Indicates valuation technique for measuring derivative liability."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "aytu_AccountsReceivableCreditTermsLowEndOfRange": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccountsReceivableCreditTermsLowEndOfRange",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Credit Terms, Low End of Range",
        "label": "Accounts Receivable, Credit Terms, Low End of Range",
        "terseLabel": "Accounts receivable, credit terms, low end of range"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock [Member]",
        "label": "Warrants to Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockEquityClassifiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockEquityClassifiedMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Equity Classified [Member]",
        "label": "Warrants to Purchase Common Stock, Equity Classified [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Equity Classified"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_AttentionDeficitHyperactivityDisorderPortfolioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AttentionDeficitHyperactivityDisorderPortfolioMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Attention Deficit Hyperactivity Disorder Portfolio [Member]",
        "label": "ADHD",
        "terseLabel": "Attention Deficit Hyperactivity Disorder Portfolio"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockEquityClassifiedCommonWarrantsMarch2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Equity Classified, Common Warrants, March 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockEquityClassifiedPreFundedWarrantsMarch2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Equity Classified, Pre-funded Warrants, March 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r254",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r612",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r909"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockLiabilityClassifiedAvenueCapitalWarrantsJanuary2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockEquityClassifiedAvenueCapitalWarrantsJanuary2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r186",
      "r666",
      "r856",
      "r910",
      "r920",
      "r1051"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Exercised",
        "terseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r911",
      "r1043"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r592"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationStatement2021ShelfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationStatement2021ShelfMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, 2021 Shelf [Member]",
        "label": "Shelf Registration Statement, 2021 Shelf [Member]",
        "terseLabel": "Shelf Registration Statement, 2021 Shelf"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationStatement2020ShelfMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationStatement2020ShelfMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, 2020 Shelf [Member]",
        "label": "Shelf Registration Statement, 2020 Shelf [Member]",
        "terseLabel": "Shelf Registration Statement, 2020 Shelf"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingMarch2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureWarrantsStockIssuedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022 [Member]",
        "label": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022 [Member]",
        "terseLabel": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, March 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CommonStockAndWarrantsIssuanceCostsCommissionsAndOtherCosts",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock and Warrants Issuance Costs, Commissions and Other Costs",
        "label": "Common Stock and Warrants Issuance Costs, Commissions and Other Costs",
        "terseLabel": "Commission and other costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r472",
      "r491",
      "r492",
      "r493",
      "r494",
      "r497",
      "r506",
      "r507",
      "r508",
      "r509"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized premium",
        "terseLabel": "Unamortized premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118",
      "r948"
     ]
    },
    "aytu_WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "WarrantsToPurchaseCommonStockEquityClassifiedMarch2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to Purchase Common Stock, Equity Classified, March 2022 [Member]",
        "label": "Warrants to Purchase Common Stock, Equity Classified, March 2022 [Member]",
        "terseLabel": "Warrants to Purchase Common Stock, Equity Classified, March 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CommonStockIssuanceCostsUnderwritingDiscountsCommissionsAndOtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuance Costs, Underwriting Discounts, Commissions, and Other Offering Expenses",
        "label": "Common Stock Issuance Costs, Underwriting Discounts, Commissions, and Other Offering Expenses",
        "terseLabel": "Underwriting discounts, commissions, and other offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "aytu_FixedPaymentArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangements",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements",
        "label": "Fixed Payment Arrangements",
        "terseLabel": "Fixed payment arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net carrying amount",
        "verboseLabel": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails": {
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118",
      "r948"
     ]
    },
    "aytu_AccruedCustomerAndProductRelatedFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AccruedCustomerAndProductRelatedFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Customer and Product Related Fees, Current",
        "label": "Accrued Customer and Product Related Fees, Current",
        "terseLabel": "Accrued customer and product related fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "IncomeTaxBenefitDecreaseInDeferredTaxLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Benefit, Decrease in Deferred Tax Liabilities, Net",
        "label": "Income Tax Benefit, Decrease in Deferred Tax Liabilities, Net",
        "terseLabel": "Income tax benefit resulting from decreased net deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "aytu_FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationNonRecurringBasisLiabilityIssuances",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Non-recurring Basis, Liability, Issuances",
        "terseLabel": "Issues, fixed payment arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationStateIncomeTaxesNetOfFederalBenefitPercent",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, State Income Taxes, Net of Federal Benefit, Percent",
        "label": "Effective Income Tax Rate Reconciliation, State Income Taxes, Net of Federal Benefit, Percent",
        "terseLabel": "State income taxes, net of federal benefit (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMeasurementInput",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Measurement Input",
        "label": "Fixed Payment Arrangements, Measurement Input",
        "terseLabel": "Fixed payment arrangements, measurement input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r219",
      "r227",
      "r351",
      "r352",
      "r354",
      "r648",
      "r821"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r855"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1058"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employee benefit plan contribution",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows - finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r631"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total net lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r855"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r890"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesFinanceLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesNetLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r855"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other operating assets and liabilities, net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in Level 3 inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r112"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r112"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r224",
      "r250",
      "r289",
      "r310",
      "r316",
      "r333",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r552",
      "r556",
      "r597",
      "r659",
      "r744",
      "r856",
      "r869",
      "r945",
      "r946",
      "r1059"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Included in earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r856"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of disaggregation of revenue",
        "terseLabel": "Schedule of disaggregation of revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrentAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesClassificationDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Total other liabilities, noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1038",
      "r1044"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r421"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtWarrantsDetails",
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r812",
      "r856"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r108",
      "r212",
      "r213",
      "r238",
      "r255",
      "r256",
      "r257",
      "r261",
      "r271",
      "r339",
      "r345",
      "r435",
      "r503",
      "r504",
      "r505",
      "r536",
      "r537",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r580",
      "r603",
      "r604",
      "r608",
      "r639",
      "r694",
      "r695",
      "r710",
      "r734",
      "r750",
      "r771",
      "r772",
      "r792",
      "r868",
      "r910",
      "r920",
      "r1051",
      "r1076"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNetAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r136",
      "r157",
      "r734",
      "r750",
      "r771",
      "r772",
      "r856",
      "r869",
      "r910",
      "r920",
      "r1051",
      "r1076"
     ]
    },
    "aytu_ProductTechnologyRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductTechnologyRightMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Technology Right [Member]",
        "label": "Product Technology Right [Member]",
        "terseLabel": "Product Technology Right",
        "verboseLabel": "Acquired product technology right"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r837",
      "r949",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r732"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r545",
      "r845",
      "r846"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r732",
      "r750",
      "r1076",
      "r1077"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r270",
      "r271",
      "r283",
      "r580",
      "r581",
      "r885",
      "r886",
      "r888",
      "r889",
      "r892",
      "r897",
      "r898"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByGeographicLocationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r113",
      "r114",
      "r324",
      "r795"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r845",
      "r846"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetAllowancesDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Total allowance, ending balance",
        "periodStartLabel": "Total allowance, beginning balance",
        "totalLabel": "Allowances",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r329",
      "r346",
      "r347",
      "r350",
      "r1070"
     ]
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableNetReceivablesFromCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "periodEndLabel": "Closing balance",
        "periodStartLabel": "Opening balance",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r325",
      "r1070"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r113",
      "r114",
      "r324",
      "r703",
      "r795"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r545"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r856"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r421"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r131",
      "r132",
      "r171"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Net income tax provision (benefit) (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r131",
      "r132",
      "r171",
      "r712",
      "r770",
      "r791",
      "r868"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total other income, net",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions and Business Combination and Contingent considerations",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementCommercialMilestoneObligationsNetRevenueTriggerAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount",
        "label": "Supply and Distribution Agreement, Commercial Milestone Obligations, Net Revenue Trigger Amount",
        "terseLabel": "Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentChargesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Impairment Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment of other assets",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r940"
     ]
    },
    "aytu_Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "Aytu2015PlanRestrictedStockAcceleratedUnvestedSharesForTwoFormerBoardMembersMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members [Member]",
        "label": "Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members [Member]",
        "terseLabel": "Aytu 2015 Plan, Restricted Stock, Accelerated Unvested Shares for Two Former Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsAnnualUnitSalesUnits",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units",
        "label": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Annual Unit Sales, Units",
        "terseLabel": "Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r588",
      "r589",
      "r591",
      "r593"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails",
      "http://aytubio.com/role/DisclosureLongTermDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense including amortization of deferred financing costs",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r411",
      "r419",
      "r832",
      "r833"
     ]
    },
    "aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersPercentageOfGrantsRescinded",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Percentage of Grants Rescinded",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Percentage of Grants Rescinded",
        "terseLabel": "Stipulation of compromise and settlement, board members, percentage of 2021 grants rescinded (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails": {
       "parentTag": "aytu_IntangibleAssetsNetExcludingGoodwillAccumulatedImpairment",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Accumulated Impairment",
        "label": "Finite-Lived Intangible Assets, Accumulated Impairment",
        "negatedLabel": "Finite-lived intangible assets, accumulated impairment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Noncurrent",
        "label": "Fixed Payment Arrangements, Noncurrent",
        "terseLabel": "Fixed payment arrangements, noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShareBasedCompensationAwardTrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationAwardTrancheFiveMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Five"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EclipseLoanAgreementSecuredRevolvingLoansShortTermSwinglineLoansMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans [Member]",
        "label": "Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans [Member]",
        "terseLabel": "Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAvailabilityBlock",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Availability Block",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Availability Block",
        "terseLabel": "Availability block"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityTerminationFeePercentageOfOutstandingPrincipalAndUnpaidAccruedInterestBefore26January2023",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, before 26 January 2023",
        "label": "Line of Credit Facility, Termination, Fee, Percentage of Outstanding Principal and Unpaid Accrued Interest, before 26 January 2023",
        "terseLabel": "Termination fee before 26 January 2023 (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DebtInstrumentTerminationBusinessDaysNoticePeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DebtInstrumentTerminationBusinessDaysNoticePeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Termination, Business Days, Notice Period",
        "label": "Debt Instrument, Termination, Business Days, Notice Period",
        "terseLabel": "Notice period"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityPercentageOfEligibleAccountsReceivable",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Percentage of Eligible Accounts Receivable",
        "terseLabel": "Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EclipseLoanAgreementSecuredRevolvingLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EclipseLoanAgreementSecuredRevolvingLoansMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eclipse Loan Agreement, Secured Revolving Loans [Member]",
        "label": "Eclipse Loan Agreement, Secured Revolving Loans [Member]",
        "terseLabel": "Eclipse Loan Agreement, Secured Revolving Loans"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockAcceleratedUnvestedSharesFormerBoardMembersNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Accelerated Unvested Shares, Former Board Members, Number",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock, Accelerated Unvested Shares, Former Board Members, Number",
        "terseLabel": "Accelerated unvested shares, former board members, number"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationCoveredEmployeesDeductionLimitationPercent",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Covered Employees Deduction Limitation, Percent",
        "terseLabel": "162(m) limitation (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "Aytu2015PlanRestrictedStockStipulationOfCompromiseAndSettlementBoardMembersRescindAggregate2021GrantsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants [Member]",
        "label": "Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants [Member]",
        "terseLabel": "Aytu 2015 Plan, Restricted Stock, Stipulation of Compromise and Settlement, Board Members, Rescind Aggregate 2021 Grants"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementRoyaltyPercentageOfNetSales",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Royalty, Percentage of Net Sales",
        "label": "Supply and Distribution Agreement, Royalty, Percentage of Net Sales",
        "terseLabel": "Supply and distribution agreement, royalty, percentage of net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r152"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentEquityOfferingCommonStockPriceLowerThanWarrantExercisePricePriorToAnniversaryTwoOfStockCombinationEventAdjustedExercisePrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Equity Offering, Common Stock Price Lower than Warrant Exercise Price Prior to Anniversary Two of Stock Combination Event, Adjusted Exercise Price",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Equity Offering, Common Stock Price Lower than Warrant Exercise Price Prior to Anniversary Two of Stock Combination Event, Adjusted Exercise Price",
        "terseLabel": "Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtCompositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total debt",
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "aytu_SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementCommercialMilestoneObligationsCumulativeNetSalesMaximumObligation",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation",
        "label": "Supply and Distribution Agreement, Commercial Milestone Obligations, Cumulative Net Sales, Maximum Obligation",
        "terseLabel": "Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Abstract]",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePrice20ConsecutiveTradingDayPeriodPrecedingTradingDay16LowestTradingDays",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, 20 Consecutive Trading Day Period Preceding Trading Day 16, Lowest Trading Days",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, 20 Consecutive Trading Day Period Preceding Trading Day 16, Lowest Trading Days",
        "terseLabel": "Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionGeneralInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "verboseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r152",
      "r247"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDivisorCommonStockVolumeWeightedAveragePriceConsecutiveTradingDaysPrecedingTradingDay16",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, Consecutive Trading Days Preceding Trading Day 16",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Divisor, Common Stock, Volume-weighted Average Price, Consecutive Trading Days Preceding Trading Day 16",
        "terseLabel": "Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentPerUnit",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit",
        "label": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Per Unit",
        "terseLabel": "Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementMinimumUnitSalesCommitmentsRoyaltyMakeWholePaymentUnderAnnualMinimumSalesCommitmentMaximumAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount",
        "label": "Supply and Distribution Agreement, Minimum Unit Sales Commitments, Royalty Make Whole Payment under Annual Minimum Sales Commitment, Maximum Annual Amount",
        "terseLabel": "Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicensingAgreementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]",
        "label": "Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]",
        "terseLabel": "Licensing Agreements, TRIS Pharma, Inc, Royalty and Make Whole Payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsInstallmentPaymentsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsInstallmentPaymentsNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Installment Payments, Number",
        "label": "Fixed Payment Arrangements, Installment Payments, Number",
        "terseLabel": "Fixed payment arrangements, installment payments, number"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "Class of Warrant or Right, Exercised During Period",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373",
      "r650",
      "r654"
     ]
    },
    "aytu_FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsTrisPharmaIncRoyaltyAndMakeWholePaymentsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]",
        "label": "Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments [Member]",
        "terseLabel": "Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsLiabilityReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsLiabilityReduction",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Liability, Reduction",
        "label": "Fixed Payment Arrangements, Liability, Reduction",
        "terseLabel": "Fixed payment arrangements, liability, reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "aytu_ContingentValueRightsGainLossForChangeInFairValueDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsGainLossForChangeInFairValueDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period",
        "label": "Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period",
        "terseLabel": "Contingent value rights, gain (loss) for change in fair value during period"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableAmountMaximum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Amount, Maximum",
        "label": "Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Amount, Maximum",
        "terseLabel": "Contingent value rights, business combination, contingent consideration, milestone payable, amount, maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsFiniteLivedIntangibleAssetsDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsWeightedAverageRemainingLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r73"
     ]
    },
    "aytu_ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsBusinessCombinationContingentConsiderationMilestonePayableSharesMaximum",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentValueRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Shares, Maximum",
        "label": "Contingent Value Rights, Business Combination, Contingent Consideration, Milestone Payable, Shares, Maximum",
        "terseLabel": "Contingent value rights, business combination, contingent consideration, milestone payable, shares, maximum (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureAccruedLiabilitiesGeneralInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued liabilities",
        "verboseLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "aytu_ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentConsiderationAndContingentValueRightsGainLossForChangeInFairValueDuringPeriod",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 7.0
      },
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period",
        "label": "Contingent Consideration and Contingent Value Rights, Gain (Loss) for Change in Fair Value During Period",
        "negatedLabel": "Gain from contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease assets, weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r855"
     ]
    },
    "aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationLiability",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability",
        "label": "Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_IssuanceOfStockForMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "IssuanceOfStockForMilestonePayments",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Stock for Milestone Payments",
        "label": "Issuance of Stock for Milestone Payments",
        "terseLabel": "Shares issuance related to milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "BusinessCombinationContingentConsiderationAndContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationTotalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period",
        "label": "Business Combination, Contingent Consideration, and Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period",
        "terseLabel": "Business combination, contingent consideration, and contingent consideration other than from business combination, gain (loss) for change in fair value during period"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_Aytu2015PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "Aytu2015PlanMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aytu 2015 Plan [Member]",
        "label": "Aytu 2015 Plan [Member]",
        "terseLabel": "Aytu 2015 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_InnovusPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "InnovusPharmaceuticalsIncMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsIntangibleAssetsImpairmentDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovus Pharmaceuticals, Inc [Member]",
        "label": "Innovus Pharmaceuticals, Inc [Member]",
        "terseLabel": "Innovus Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentConsiderationOtherThanFromBusinessCombinationLiabilityReversedInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Other than from Business Combination, Liability, Reversed in Period",
        "label": "Contingent Consideration Other than from Business Combination, Liability, Reversed in Period",
        "terseLabel": "Contingent consideration other than from business combination, liability, reversed in period"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentConsiderationOtherThanFromBusinessCombinationGainLossForChangeInFairValueDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationLiabilityDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period",
        "label": "Contingent Consideration Other than from Business Combination, Gain (Loss) for Change in Fair Value During Period",
        "terseLabel": "Contingent consideration other than from business combination, gain (loss) for change in fair value during period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset under Construction [Member]",
        "terseLabel": "Asset under Construction",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount",
        "label": "Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount",
        "terseLabel": "Business combination, contingent consideration, product related, milestone payable, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "aytu_LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicensingAgreementsMagnaPharmaceuticalsIncZolpimistRoyaltyPaymentsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationOtherThanBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]",
        "label": "Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments [Member]",
        "terseLabel": "Licensing Agreements, Magna Pharmaceuticals, Inc, ZolpiMist, Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateProvisionBenefitPercent",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Provision (Benefit), Percent",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Provision (Benefit), Percent",
        "terseLabel": "Tax at statutory rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "aytu_InventoryWriteDownAndImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "InventoryWriteDownAndImpairment",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureInventoriesInventoryWriteDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Write-down and Impairment",
        "label": "Inventory Write-down and Impairment",
        "totalLabel": "Inventory write-down and impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "aytu_OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "OfficeSpaceAndManufacturingFacilitiesGrandPrairieTexasMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space and Manufacturing Facilities, Grand Prairie, Texas [Member]",
        "label": "Office Space and Manufacturing Facilities, Grand Prairie, Texas [Member]",
        "terseLabel": "Office Space and Manufacturing Facilities, Grand Prairie, Texas"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationStatement2021ShelfUnderwrittenPublicOfferingAugust2022Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022 [Member]",
        "label": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022 [Member]",
        "terseLabel": "Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesContingentConsiderationBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate",
        "label": "Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate",
        "terseLabel": "Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne": {
     "xbrltype": "pureItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioOne",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario One",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario One",
        "terseLabel": "Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FiniteLivedIntangibleAssetUsefulLifeRenewablePeriod",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Useful Life, Renewable Period",
        "label": "Finite-Lived Intangible Asset, Useful Life, Renewable Period",
        "terseLabel": "Finite-lived intangible asset, useful life, renewable period"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightOfferingPrice",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Offering Price",
        "label": "Class of Warrant or Right, Offering Price",
        "terseLabel": "Class of warrant or right, offering price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosurePropertyAndEquipmentImpairmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charge",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r75",
      "r165"
     ]
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentQuotientDividendScenarioTwo",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario Two",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Quotient, Dividend, Scenario Two",
        "terseLabel": "Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualLife",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised, Weighted Average Remaining Contractual Life",
        "label": "Class of Warrant or Right, Exercised, Weighted Average Remaining Contractual Life",
        "terseLabel": "Warrants exercised, weighted average remaining contractual life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Significant Noncash Transaction, Value of Consideration Given",
        "terseLabel": "Other noncash investing and financing activities",
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "aytu_RxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "RxMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsChangeInCarryingAmountOfGoodwillDetails",
      "http://aytubio.com/role/DisclosureNatureOfBusinessAndFinancialConditionProductInformationDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails",
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesBySegmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationImpairmentDetails",
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rx [Member]",
        "label": "Rx [Member]",
        "terseLabel": "Rx",
        "verboseLabel": "Rx Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows - operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r631"
     ]
    },
    "aytu_NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "NumberOfRegisteredTrademarksAndOrPatentRightsAndCustomerListsAcquired",
     "presentation": [
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsProductDistributionRightsAndCustomerListDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Registered Trademarks and or Patent Rights and Customer Lists Acquired",
        "label": "Number of Registered Trademarks and or Patent Rights and Customer Lists Acquired",
        "terseLabel": "Number of registered trademarks and or patent rights and customer lists acquired"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentMaximumShares",
     "presentation": [
      "http://aytubio.com/role/DisclosureWarrantsGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price Adjustment, Maximum Shares",
        "label": "Class of Warrant or Right, Exercise Price Adjustment, Maximum Shares",
        "terseLabel": "Class of warrant or right, exercise price adjustment, maximum shares (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_DeferredTaxAssetsInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "DeferredTaxAssetsInterest",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest",
        "label": "Deferred Tax Assets, Interest",
        "terseLabel": "Interest"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementMilestoneMaximumEarnOutCashAndCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone, Maximum Earn-out, Cash and Common Stock",
        "label": "License Agreement, Milestone, Maximum Earn-out, Cash and Common Stock",
        "terseLabel": "License agreement, milestone, maximum earn-out, cash and common stock"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementLicenseOptionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementLicenseOptionFee",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, License Option Fee",
        "label": "License Agreement, License Option Fee",
        "terseLabel": "License agreement, license option fee"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ContingentValueRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ContingentValueRightsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsUnobservableInputsReconciliationRecurringBasisLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights [Member]",
        "label": "Contingent Value Rights [Member]",
        "terseLabel": "Contingent Value Rights"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesLegalMattersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://aytubio.com/role/DisclosureLineOfCreditDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
        "verboseLabel": "Unused capacity commitment fee (as a percent)",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "Exercise Price Range 2"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementMinimumAnnualRoyaltiesLowEndOfRange",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Minimum Annual Royalties, Low End of Range",
        "label": "License Agreement, Minimum Annual Royalties, Low End of Range",
        "terseLabel": "License agreement, minimum annual royalties, low end of range"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementRoyaltiesPercentageOfNetProductSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementRoyaltiesPercentageOfNetProductSales",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalties, Percentage of Net Product Sales",
        "label": "License Agreement, Royalties, Percentage of Net Product Sales",
        "terseLabel": "License agreement, royalties, percentage of net product sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "terseLabel": "Property, plant and equipment, estimated useful lives",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "aytu_ProductContingentLiabilityNovalereFluticareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductContingentLiabilityNovalereFluticareMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Contingent Liability, Novalere, FlutiCare [Member]",
        "label": "Product Contingent Liability, Novalere, FlutiCare [Member]",
        "terseLabel": "Product Contingent Liability, Novalere, FlutiCare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "aytu_ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductContingentLiabilityAdditionalPaymentsNumberCertainSalesAchieved",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Contingent Liability, Additional Payments, Number, Certain Sales Achieved",
        "label": "Product Contingent Liability, Additional Payments, Number, Certain Sales Achieved",
        "terseLabel": "Product contingent liability, additional payments, number, certain sales achieved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "aytu_SupplyAndDistributionAgreementTrisPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementTrisPharmaIncMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Tris Pharma, Inc [Member]",
        "label": "Supply and Distribution Agreement, Tris Pharma, Inc [Member]",
        "terseLabel": "Supply and Distribution Agreement, Tris Pharma, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SupplyAndDistributionAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SupplyAndDistributionAgreementTerm",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsSupplyAndDistributionAgreementDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesSupplyAndDistributionAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and Distribution Agreement, Term",
        "label": "Supply and Distribution Agreement, Term",
        "terseLabel": "Supply and distribution agreement, term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Unrecognized compensation costs, period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "aytu_ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductContingentLiabilityAdditionalPaymentsAmountCertainSalesAchieved",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Contingent Liability, Additional Payments, Amount, Certain Sales Achieved",
        "label": "Product Contingent Liability, Additional Payments, Amount, Certain Sales Achieved",
        "terseLabel": "Product contingent liability, additional payments, amount, certain sales achieved"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ProductContingentLiabilityMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ProductContingentLiabilityMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesProductContingentLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Contingent Liability, Milestone, Payment",
        "label": "Product Contingent Liability, Milestone, Payment",
        "terseLabel": "Product contingent liability, milestone, payment"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementRoyaltiesAchievementOfCertainRegulatoryAndCommercialMilestonesMaximum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalties, Achievement of Certain Regulatory and Commercial Milestones, Maximum",
        "label": "License Agreement, Royalties, Achievement of Certain Regulatory and Commercial Milestones, Maximum",
        "terseLabel": "License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementAnnualMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementAnnualMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Annual Maintenance Fee",
        "label": "License Agreement, Annual Maintenance Fee",
        "terseLabel": "License agreement, annual maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesTableTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other liabilities",
        "documentation": "Tabular disclosure of other liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementMinimumAnnualRoyaltiesHighEndOfRange",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Minimum Annual Royalties, High End of Range",
        "label": "License Agreement, Minimum Annual Royalties, High End of Range",
        "terseLabel": "License agreement, minimum annual royalties, high end of range"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementEscalatingRoyaltiesMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementEscalatingRoyaltiesMaximum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Escalating Royalties, Maximum",
        "label": "License Agreement, Escalating Royalties, Maximum",
        "terseLabel": "License agreement, escalating royalties, maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRangeOfExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life of options outstanding",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangibles",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r1041"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1040"
     ]
    },
    "aytu_FixedPaymentArrangementsBalloonPaymentAmountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsBalloonPaymentAmountPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Balloon Payment Amount, Paid",
        "label": "Fixed Payment Arrangements, Balloon Payment Amount, Paid",
        "terseLabel": "Fixed payment arrangements, balloon payment amount, paid"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsAdditionalInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsBalanceSheetAndStatementOfStockholdersEquityDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfOperationsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsStatementOfStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Error Correction, Adjustment"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsAndLiabilitiesTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "terseLabel": "Net operating losses",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "aytu_FixedPaymentArrangementsQuarterlyPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsQuarterlyPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Quarterly Payment Amount",
        "label": "Fixed Payment Arrangements, Quarterly Payment Amount",
        "terseLabel": "Fixed payment arrangements, quarterly payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMonthlyPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMonthlyPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Monthly Payment Amount",
        "label": "Fixed Payment Arrangements, Monthly Payment Amount",
        "terseLabel": "Fixed payment arrangements, monthly payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r382",
      "r383",
      "r796",
      "r942"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMonthlyVariablePaymentAmountMinimum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum",
        "label": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Minimum",
        "terseLabel": "Fixed payment arrangements, monthly variable payment amount, minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityCommonAndPreferredStockDetails",
      "http://aytubio.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r309",
      "r315",
      "r318",
      "r825"
     ]
    },
    "aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMonthlyVariablePaymentAmountOneTimePaymentPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid",
        "label": "Fixed Payment Arrangements, Monthly Variable Payment Amount, One-time Payment, Paid",
        "terseLabel": "Fixed payment arrangements, monthly variable payment amount, one-time payment, paid"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsPeriodicPaymentObligationsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsPeriodicPaymentObligationsNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Periodic Payment Obligations, Number",
        "label": "Fixed Payment Arrangements, Periodic Payment Obligations, Number",
        "terseLabel": "Fixed payment arrangements, periodic payment obligations, number"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsBalloonPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsBalloonPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Balloon Payment Amount",
        "label": "Fixed Payment Arrangements, Balloon Payment Amount",
        "terseLabel": "Fixed payment arrangements, balloon payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturedProductOtherMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureRevenuesFromContractsWithCustomersRevenuesByProductPortfolioDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Article or substance produced by labor or machinery, classified as other."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLossAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPreviouslyReportedFinancialStatementsOperatingIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://aytubio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc [Member]",
        "label": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc [Member]",
        "terseLabel": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationFixedPaymentsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments [Member]",
        "label": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments [Member]",
        "terseLabel": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsInvestorAssumedProductAcquisitionFromCerecorIncPeriodicPaymentObligationVariablePaymentsMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments [Member]",
        "label": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments [Member]",
        "terseLabel": "Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r513",
      "r1067"
     ]
    },
    "aytu_FixedPaymentArrangementsPaymentAmountPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsPaymentAmountPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Payment Amount, Paid",
        "label": "Fixed Payment Arrangements, Payment Amount, Paid",
        "terseLabel": "Fixed payment arrangements, payment amount, paid"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsQuarterlyPaymentAmountPaymentsNumber",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number",
        "label": "Fixed Payment Arrangements, Quarterly Payment Amount, Payments, Number",
        "terseLabel": "Fixed payment arrangements, quarterly payment amount, payments, number"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMonthlyVariablePaymentAmountPercentageOfNetRevenue",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Percentage of Net Revenue",
        "label": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Percentage of Net Revenue",
        "terseLabel": "Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsMonthlyVariablePaymentAmountAggregatePaymentsToSatisfyObligationIfPaidBefore12February2026",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Aggregate Payments to Satisfy Obligation if Paid before 12 February 2026",
        "label": "Fixed Payment Arrangements, Monthly Variable Payment Amount, Aggregate Payments to Satisfy Obligation if Paid before 12 February 2026",
        "terseLabel": "Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "aytu_AtmSalesAgreementAmountAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "AtmSalesAgreementAmountAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market Sales Agreement, Amount Authorized",
        "label": "ATM Sales Agreement, Amount Authorized",
        "terseLabel": "At-the-market sales agreement, amount authorized"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "ShelfRegistrationStatement2020ShelfAtmSalesAgreementMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureStockholdersEquityStockOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement [Member]",
        "label": "Shelf Registration Statement, 2020 Shelf, ATM Sales Agreement [Member]",
        "terseLabel": "Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LongTermDebtAndFinanceLeaseLiabilityMaturityYearOne",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "aytu_LongTermDebtAndFinanceLeaseLiabilityGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, and Finance Lease, Liability, Maturity, Year One",
        "label": "Long-Term Debt, and Finance Lease, Liability, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://aytubio.com/role/DisclosureSegmentInformationSelectFinancialInformationDetails",
      "http://aytubio.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "aytu_LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LongTermDebtAndFinanceLeaseLiabilityMaturityYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": "aytu_LongTermDebtAndFinanceLeaseLiabilityGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, and Finance Lease, Liability, Maturity, Year Two",
        "label": "Long-Term Debt, and Finance Lease, Liability, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LongTermDebtAndFinanceLeaseLiabilityGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LongTermDebtAndFinanceLeaseLiabilityGross",
     "crdr": "credit",
     "calculation": {
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aytubio.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, and Finance Lease, Liability, Gross",
        "label": "Long-Term Debt, and Finance Lease, Liability, Gross",
        "totalLabel": "Future principal payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk By Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r113",
      "r114",
      "r324",
      "r795",
      "r891"
     ]
    },
    "aytu_FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "FixedPaymentArrangementsTerminationOfOriginalLicenseAgreementTrisPharmaIncMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesFixedPaymentArrangementsDetails",
      "http://aytubio.com/role/DisclosureOtherLiabilitiesFixedPaymentArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc [Member]",
        "label": "Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc [Member]",
        "terseLabel": "Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicensingAgreementCedarsSinaiMedicalCenterHealightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicensingAgreementCedarsSinaiMedicalCenterHealightMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement, Cedars-Sinai Medical Center, Healight [Member]",
        "label": "Licensing Agreement, Cedars-Sinai Medical Center, Healight [Member]",
        "terseLabel": "Licensing Agreement, Cedars-Sinai Medical Center, Healight"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureEquityIncentivePlansGeneralInformationDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansRestrictedStockActivityDetails",
      "http://aytubio.com/role/DisclosureEquityIncentivePlansUnrecognizedCompensationCostsDetails",
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Employee Unvested Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "SettlementAgreementAndAssociatedLicenseAgreement2014ShireLlcNewDrugApplicationMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application [Member]",
        "label": "Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application [Member]",
        "terseLabel": "Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875"
     ]
    },
    "aytu_LicenseAgreement2017ShireLlcNewDrugApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreement2017ShireLlcNewDrugApplicationMember",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, 2017, Shire LLC, New Drug Application [Member]",
        "label": "License Agreement, 2017, Shire LLC, New Drug Application [Member]",
        "terseLabel": "License Agreement, 2017, Shire LLC, New Drug Application"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskTabularDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r57",
      "r58",
      "r113",
      "r179",
      "r795"
     ]
    },
    "aytu_LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementUpFrontNonRefundableLicenseFeePaidMaximum",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front, Non-refundable License Fee Paid, Maximum",
        "label": "License Agreement, Up-front, Non-refundable License Fee Paid, Maximum",
        "terseLabel": "License agreement, up-front, non-refundable license fee paid, maximum"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementInitialLicenseFeePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementInitialLicenseFeePaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial License Fee Paid",
        "label": "License Agreement, Initial License Fee Paid",
        "terseLabel": "License agreement, initial license fee paid"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementPatentProsecutionFeesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementPatentProsecutionFeesPaid",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Patent Prosecution Fees Paid",
        "label": "License Agreement, Patent Prosecution Fees Paid",
        "terseLabel": "License agreement, patent prosecution fees paid"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementTermAfterFirstBonaFideCommercialSaleOfLicensedProductInCountry",
     "presentation": [
      "http://aytubio.com/role/DisclosureLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Term, after First Bona Fide Commercial Sale of Licensed Product in Country",
        "label": "License Agreement, Term, after First Bona Fide Commercial Sale of Licensed Product in Country",
        "terseLabel": "License agreement, term, after the first bona fide commercial sale of such licensed product in a country"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_LicenseAgreementMilestonePaymentPaidCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementMilestonePaymentPaidCash",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Paid, Cash",
        "label": "License Agreement, Milestone Payment Paid, Cash",
        "terseLabel": "License agreement, milestone payment paid, cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "aytu_LicenseAgreementMilestonePaymentPaidCashAndCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "LicenseAgreementMilestonePaymentPaidCashAndCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payment Paid, Cash and Common Stock",
        "label": "License Agreement, Milestone Payment Paid, Cash and Common Stock",
        "terseLabel": "License agreement, milestone payment paid, cash and common stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aytubio.com/role/DisclosureLeasesGeneralInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r401",
      "r423",
      "r640",
      "r817",
      "r819"
     ]
    },
    "aytu_CommercialGlobalLicenseAgreementsAr101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CommercialGlobalLicenseAgreementsAr101Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Global License Agreements, AR101 [Member]",
        "label": "Commercial Global License Agreements, AR101 [Member]",
        "terseLabel": "Commercial Global License Agreements, AR101"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://aytubio.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
      "http://aytubio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r592"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CommercialGlobalLicenseAgreementDenovoBiopharmaLlcAr101Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Global License Agreement, Denovo Biopharma LLC, AR101 [Member]",
        "label": "Commercial Global License Agreement, Denovo Biopharma LLC, AR101 [Member]",
        "terseLabel": "Commercial Global License Agreement, Denovo Biopharma LLC, AR101"
       }
      }
     },
     "auth_ref": []
    },
    "aytu_CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aytubio.com/20230630",
     "localname": "CommercialGlobalLicenseAgreementJohnsHopkinsUniversityAr101Member",
     "presentation": [
      "http://aytubio.com/role/DisclosureCommitmentsAndContingenciesEarnOutPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Global License Agreement, Johns Hopkins University, AR101 [Member]",
        "label": "Commercial Global License Agreement, Johns Hopkins University, AR101 [Member]",
        "terseLabel": "Commercial Global License Agreement, Johns Hopkins University, AR101"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "SubTopic": "40",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479710/205-40-50-13"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a),(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-70/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>188
<FILENAME>0001558370-23-016393-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-016393-xbrl.zip
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M'Z'5/$]K4!>3(DKTWQT<5M$OT(1?"=EBE@E"$PC3/U^_<AJ2,_;<U.6-RFA
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M-J.QL/"S%\4GP5<%'RLD3#S *7TBMS ,23-A;1XE$#6>E#$1*Z-B"3(3(%5
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MEG_9?PG<3_9F0V'LPD_)!]]G<0<0W_ 3\,YX:/GVF@0;V\G;)'@*B/-VR9Z
M&[J/TGAC!<Z*K.TKY@@R<>Z@*3O^(:3X%JI*&J>N598F]8,0/5WKJZXM@K_V
MTG)[^&GO\&CO^+!;*]R0[Z.B($='>T#K^+!9#+J2XG?061P?8^7RR1+#WYN)
MQ..\5 H%\A$%<OC!N!T+.W@4Q*)@#VD%)MI0++2T[4VL$L0+@XQ,.^6H)=BK
M$?BE71M*>B[<(/AKFZY1+)+^Z"B%@(>M))#FC[F'7QTX3_3PO?CEAL:=,BV
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M'<9TT"G(1N1#_10KZ816B0C\P_@#F_GQO6E8!H']DVRV%U;;Y[B>BBLD;HE
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MU9^V]X'=1MQ9P;JZL!V;N5F)S5VZH,15');U)S7"-49;IFXYN8APER<M.*#
M#&C_ !*,4[<@/AWA$<JN:5_GU'@'Z'37MG]JSY%F3DB?T*;!1M0-NZU*C70H
M;K."OO1!CJ#Q9R3^O^-"7"8S&M]([3;ARX8FSL*+^P@JA>;7O$?>G&F$W1V:
M:_L!%#D# ZF.&3EUA%S<P9_YKA=Z<*>BO^4,2)?NR9ED'LO0I7'7G4$7RM6L
MAM>F#%4,;<CW71=3F8.;EB5MSM'QEJUXYXL%=6#D\Y\(/V4>X[;+:B)0&N0>
M81]\>&8/*Q8%L,I_>(;/KP\K3DCL=P&#/GR!52V>6$L<MRXY0N[KK8'$&T1K
M-63YBN/.X#ZO0_EREIQ;LL0@20U,N38F\PV\9X823=KH@=R!6Y,KZL^(O8%Q
MHW"^R$TEL>5WZK$@=?H5#@\U#PL,0FU'A%0ZXBOV%1@9;:_LQ:8343M:8]QM
M;1A"4LR%#OCE^-;,#YA'7=SY>^ V139A?O&>B'B5-W/5 PO+M?6#U7 UC4__
MLA;:'(>5(#[\2#?D'^P7$IR1#2?X<A\5U_)G:\9#^D<U%%Y?0CNS%D07O.Q]
MI//UQF.O!,;ED'*1J];.:5%FA!;.?"-NROI+\8AJ\Y/%FGPCY"R95;_X;G(7
M'6^IBWB8R?/=N&*LB172LMQH=%NSJ+RW'Q]?KVB8Q$Z4;ZC4IX\06-'2OS/T
MH<0MJ61$O[8#? LO\MVKT*WGSJS,"#G^:GL>>27SS09&U0@?BL185"I^C4N,
MD-M<"4]Q*[YNWHY]+><+X7\FF#M%AMV3U^IZH[2?.2C=K2[J.MQ<RYJ<'F(4
MWIX].JYYR-<H_PCU0]-R,("?P&1++X7\+?))%P%HR(Q0+FV/L1HETY?0#R ;
MZ81T,&%I*?\ TBL?D XF.C79'T!NL,KTG1497' :NC^.Y$ZV);I&PB.4G6I;
M%NO2[- :;O :4?H&>[SM+:5\*<L"L.\X?UTPCG=_@BNZIJ&0=C#WOP1D_NP3
M'JSH)@[ =<N",/[KAH0E*A>1YZ7.Z!YY8& U!"1,7"8N*+X.^=_$YC#VIZ&\
M'+8F]]'C/XD3/K"\WMH5]QB;N2-'J5L0XAGHON>Q9[SVXK"E3_^ ]4%$O?#2
M3RN!<>,BKF86E,IN%]Y^+=L11.7K,#/D63RVRWCLK8(,%;^FT0A+VSS]Z(Q%
M6MH=S3YLHAH]$?XZE-AR>J/9->LGOXRSG/'S%[QN2N)X@K9G+#H34J.1VA;Z
M*-H0>&(%YL&2/-K.[WT[:QW!'Z/7RISU5[]6-/^]]'"@45!%>#0"W<ITPJ+'
M<!%Y:=F^LXE$;E=Z]1T)(XZA/0A_(K+G=7WR;C(GE!P6V<G0T<BEE&\T/4$S
MM)38J#E%;$@?#7O:1]^<%7$C#U;U)4X:_>8-\U<W!$;B,7]&%@3ZF_M@O\17
MSNZ)>//I\.=WI_8&5F->XLN ;-G<6<TY:BRG2,/VA/:".*-RE,Q!J8YE'-!-
MN<AH?B-OYKLB>#);+)*^7AS]]7E'TU]:6QJQCTS]=!9?RE=<O1B&W B%]\L^
MRBZ P6)M__;_ 5!+ P04    " !4=DQ7%+Q\4VP;  !DN $ %0   &%Y='4M
M,C R,S V,S!?8V%L+GAM;.U=6V_C.I)^7V#_@S;S,@-L.K83Y](X/8-<&P$Z
M[2#IGLO3@2)3"??(DH>2<IE?OT7J8LD2)9*2+4KNP<%T;)-%?E5%LE@L%G_[
MV_O",5X1\;'G?MD;?QKM&<BUO#EVG[_LA?Z^Z5L8[_WMK__]7[_]S_[^/R\>
MOAESSPH7R T,BR S0'/C#0<OQ@]ON31=XPX1@AW'N"!X_HP,8SSZ=/1I]&E\
M:.SOQT0N3!\J>:[!J$T^C=-?+F."GOL9*AZ,)P>3T>30F'Z>G'P^.C+N[]*2
M=]!#&]<7=;#[QV?Z?T_0J %87?_SNX^_[+T$P?+SP<';V]NGM\-/'GF&^J/Q
MP3_OOCU:+VAA[F/7#TS70GM)+4JEK-[X[.SL@/V:%"V4?'\B3M+&X4'2G90R
M_(HKRF=ZXN///NO>-\\R R:RVF8,;@GZ:3\IMD^_VA]/]@_'G][]^1YPSS!^
M(YZ#'I!M,'R?@X\E^K+GX\72H;UAW[T09'_9,S^"<)]*8'1\.*+U__08@"BI
MFEQZKN\Y>$XE>V$Z%,GC"T*!OV=0ZC\?;E,0E,H3]CY9WN* _G8@0H0Q48C=
M!QO!E'[IS^S9$A$F%V5P/&HZH;PT_9<;QWMK!62&V!8Q7F'?<CP_).@Q7"Q,
M\C&S'_&S"W.*9;K!N65YH1O ''@/7;8P\N-O_ =D(?QJ/CGH.PJ^(A<$Y-RZ
MMD<63%!7*#"Q(\*737>@$U[>NJ\@5(] ?W^83Z%CDM5O*JP1HM<UTN3/CW\0
M'* K[TU)"\0(=H+UGG@P$04?Y^[\^M\A7M*!VXIXY0AW@OT; HH^##7VQZ7G
M!RI *ZATB.HQ7$(MRG33R:ZI#><S>>(=\B!>8MWGZ.--&,!/=]C%BW#!OKHW
M/]A"I<X)^2;TX<=7XOG^%;9M1&!7H#3(I>AVB/P&NU1)-Z<'L@WHPHO6=$"(
M:B>HOWK>_ UVK; 0S8(71&YAUG*?,1A9Y[X/FPSH.:S$W_ KFJ__I,*.-IK3
MDD_;8$Z_.'+M!WA!MSS1@#]?>"3 _V'+W_7[$KF^TGAJL=5.N :;&1*B^3=L
M/F$'!V#SMK.5DJ+;"7(FKDS_+KW%TG-5%Q8!:GJ@=$S?9UM;5<D*4NQFS?3<
MYQ^(+*[04\ DX&-EV[F&5.?XH@GEGF#7PDO3:60529#M!/>-B<G?32=$=V"Q
MP&?6I0=DA03Z^7QA^E@)MPS9CGP;T&OTPWQ'/NS07S$]&KCQ2.9K-0>',-6N
M48,P/%!$![/)96:G/Z4=OX!EQ<9*OH!&[73-F2L$]CI!<_@061I@@61FY9:<
M?LV;D^:393H6T*)R^ :_Q;RA/6MX.)'A.WH/D#M'\_1;'%#RH]%X-#+VC90<
M_)VE:,0D#>D##P8-P#F>E>N(0P^//)+7 $K.!WJ,EFWZ3XQ@Z.\_F^:2':X=
M("?PDV^8LC!%B;_X/9)00M0QGY##3A S/_Y^?'@R/9N.1]/)\03^-QI-$@EL
MN9N7,-L"JRM[&Y>!3I\>3DXFIT?3TZ/Q\?3H["S3Z8SBG)-\_TUB)?3ASYPN
M%846ESCPZ6D I;8/6\!%4M\FWD*(F7'[G@P6C\P1^;(WWC-"'[KH+6GSIK-G
MO"'\_!*P7[8MI++3CAJ955315815W2N1I"Q"#05+3_M@$J?_4)?_J^E0Z^<\
MN#0)^0#SAQE&' D+U1V&J-6AQC*?:"1SMG<3F7:+!8<A34%<L>@.-1)=>A0)
M,PU':-DBPQ!7+:)84$<:">J>H*6)Y[%WKWJ8E98=ANC$H<4RG%;)<$FP1W#P
MP:;33LS4[[ _%+!45\5T%:.4L5H#1\,E;MT!#S/'];OEA#2,,G'6<^?/^JJZ
M2K5&4&53JR)8#4W9)'KEWJ$!6YD0%O@[>]3Y0#LXLW_Z$>9S.P!CP++"!949
MFE^A)4%6Y *"FMFS&N[\O>F&\R(XZ:^^=<0J#6>H? #&&EZ>/5Y59S Z(H]2
M0T,]L\6HM1E*RPY'G,+H-#3C,\YMF&<> \_ZX\5SH)L^G;F"#XY$ZZKEK:_#
MR>'X:.O0A,&4=E\SW51B>%%7!:%J:/P\T),6%\VO3>+"U.GG%DL;6Y@W^=17
MU$_:@F(JRE<1K(;R/I_/<=2+>]A?W[J7YA('IG/I+1:>R_C#VZ#65AR0O!7!
M:F@NWI/XZ)7UNLHK7U)R0!(51:>A29C1NLI3E;5B>7BG .^XK\(3@J:W%5AO
M\.DGKY:,HSJ,&LZ:V0#%RBU8L:#68BSM7*7$JE#I:-[$1^OWY@<]5T_BJHOQ
MQ&(Q"*)DM!9Z51_YP0F-H.NI&;(JL NREA>J3O/TXXM' AI[?.$1XKW1K1G/
M&5$L.2!!BJ+3T+K-1H^S2!FVTV(NW-F3@Y^CO DUJ[ ,C0&)O3EN$:.YR]/S
MPG61>H=X'3?/ /EI7R4N@U D,D++P=YHE&LM[%;'=970*Q?I+@?T%2+X%?K_
MBC)LJ3WIJJDU!)FK0-1P.5^?H,0.,0<K54ETXCZLWP[6;KJT?/V%F[XJPV?N
M/9A)]3V8%6W#LPVEY%C;5>KO--T)O<STS?-YJ]-:F:W'K25-WX#& K<#[(:P
M#5@Q]P+97NY.UO5[0$Q0..R:Y.,6!,*4$VJ"4D#7GF_= !'D\\.%-]:B?@._
M5 'R\7#;Y8:(@Z53NSV)Q:D=-R4E]9/_ML5;LI (LDE.,;9O'[!T,??$L[F!
M!9D2.823D09;=5$Q% 58!TM.<(<=!(J\(C=$B?X3TPK^@8.7R] /@!$DC?ZE
M$5OP'[WJRXT<D::DGR+4B;,LAJ0=V+J/<)H5;V;3('!V:HC(*[:0_^@Y<XX^
M\"L,0>R2Z&KW[_L=AAS'UW%JE_*DG'[R4Y^_Q<#I*+Y'Q P.T+X[D_R!,AAX
M9R7<"AH+M%(L)2<F<AAUM[?C]%CT3L-\@5WL!X3YDJH%75-K.-)6 :J[)_4!
M^0AX1Z^77X%IX7CL/DRUP"OK#$?<\C U]*0FU^AN%TL3$PJ@8A==7G@X$I7
MIV$<X.HJRZK_ER\F>>:;4OP:>=!C#8)R584J"U+# \WL#4*:]RM_*Y876E19
M:3CR5< 9B_AX0XMN,3L:_>;WR*'W'!^!X'GLU*-'K^DO+/"872KTOYK89;Y
MCX"ZPJ^W;IH+\"JDR?_N$?1Q?;^[R:;ZKS1;YTZL:B<Z;=6^>ZZ7WZ%6VW/<
M\OKI0_<N=#EFR9G_'=D4LOI274D_I9'K*L?"4)*[MNY5.N?Y=!@A?^;"" %0
M(?9?J.TTLVG $&^'4%=O>-)7@ZQAF/,J-BA9\6;NZCM^2J_:>L.3N1ID#;?_
MZ3H8XX\S"%=&8Q1*:RA?L4@*,21"WO:2[<(V@Z>RS^)E&,R-G3J2B9VBQ W9
M1_>VGRAT+?WE ]AL!%L )TZ/F?\B4S(RWT$E"(U]O4+1O_ Y.BJ]?K>8V?\
M/+FV;63QAL>V.['M;0,*:)]9MG'0J8N/GSY]<2;=@IU;,/E574,5)Y ?AQ,8
MAR<=SRC=*%AN8]&,>QI>EHM.N"O\S:L"^BE$0W$4Y5L#5O>SP6S2,_C;0;%+
M12!#G4C5'5  939HN)>0.H80<<X/4N(2P+7<.ZP_/,O=-JP7W '9"H+6\!SQ
M$=0078"!,J=O2L'NJ&KN+B^\ _*5 *[AB>*6?#V#E+P:#VK/'.4/@G;DG/%P
M.AUW?36C-27:.MMT/(#,']E'F94!!0UBIN'+](4NEAU&*+*!7WW :M0**V+5
M.&UO7>+,2+>^']+DV3.;I?<"/;[##O(#STW?L2Z;702J#5C$C5@0B_9LXZ)E
MUNW,MNE15Y3ZD!YY)=VF>E@T)L0K#EV\ZDQ(W$$CC8Q*=@Y>PHGD<"(]5:B*
M&Q"I/V"U:(<7B79HZRTL^L*+S]7Q#R%KJ^Z @BBS(=$-K6X/%=$D_A/^<5)E
MG9W4@#K\B>CY7D0M1!\_RY4LB?$1?9HCLBKH68W83BJ+,F,2+>+[++70HK44
MH]*K25POSX*CZ?1H-'S=$.%!H@8ZN35+D:PE'Y51A+6JNZH+(FQ(U*'R4D7G
MZI WJ^.4=U6OE8H2V$G5D&)&HB#5GL@NDX]P.$:M*K])@%,) ?W41=L )U'N
M:1@%$;OHJ-^^W..?3*H?XCK6B*9^:M=0Z"5A5*WSIS;RJ@-S-W'^ DQ@G870
MG%UX8A.RM"Z)4MD=[6G$$=5X\:[7N?3T2'6=*R&@G\IHN\Z)<J_]2##.T4YF
M+-S@=S2//Y\30C&6^/$%:^513:?3D[&>TXBH1-8.=10YH.4RDYD#'] R!C:S
MOV$7T5LG!,VYEX6$Z@Y8%YKS04>+-@-F=39=GDG^$5DAB?)1<S?8RO1V3'&:
M\T9DV>C2*+E/!\;Z$7B=]5I28Q>T0Q)];:!Q!\M+;CJLT6N.$LB0V &M:,R.
MVECEKC<OY;-B_<O"M?5V0#O4>""2+:E#)<B8VVR;+KZ-E:2R8PJBRI':@..-
MWY:G4:^.YX<$/5(FDH^9_8B?76QCRX1]6'2V2:.F/0=;]-G90N ,,#9.YGGK
MVAY9Q'?R A,[8C?LCT:3T;&Q;ZRZ0J_;1[VA5^HS_3%6'3*2'D'AI%/&JE?_
M:T"_X*>X:T:F;\:?X][]94_7*_KGCN.]T1D'%.K*"Y\".W2$@[Y$*[?B^"@2
MSC8?;=AH/'Y5I\I<(VW0S0^YX^ET<M3Q)"0GU]1+LC%FM'_1O4TUX5QM:$YP
MMQ6CD@OM^U%:U(A[@MF-#7;W]\FT_FA--8J4=UI'!-DA[E[?B,62">'\83X!
M';+Z3<X .1J-UPV0#''X%-//%M'?BDBO55<%[:R*@(A/3D;'I]/#Z3'\>W(Z
M'G40A13WYX;FA']!<_9,!W1N9M,4XN2U(B:MMJ9^0[J6_66116HX=<^)LLH!
MX)$_:,0M[*Y\.<GS:PY+\I(X=7\V(<7U8+[=F0$BV'3D!,^MF.?'"?"C:S=$
M$[G+P50\Q-CT2EW,]2&[5$^JE^JT 8.UL#^')C:_6/-N\Q;0GKOS51:;,O.U
MMDI?4]=T.?QDA"&3F28_U@3VT1L97K 4+!$)/@ .#<!A;ZLTM(BG18LX:<4P
MW;F1MM-7XSA!<^]0/V>&<?!WY+Y%['EWEE9B9O_THT<2SFV8@&%+%2ZHN.@=
MY%4B,K$,;MMH>/M'#"J0HO3R73!3IF5])K'MJ^[:>4<GK-8S&:>2 +J8-G[I
M^.9UO+EVBUPPWXCIP.#0W03[@X;$R-D)QT5S/"()?] 3./;!H'1[8!.D/.",
MP<SO73WX6M?%8D']QG8!0^FKKM4 -%P5'E]@K-,@HCH9%0OF(9YJ<*F^4D:"
M #2,R:V:Q.O78,':/9-F$U0:IMK-PDG>HZI^@ZFB1H]%*8)$/*/N!HV/QW"Y
M=-A=#].Y,!T*X/$%T5=)%,.)CD>'7)LDVY@1MV:PYK8;(L3Q%^97OS6K,[V-
M6>8V%*W9J>&2]N,R)*0BN5EE)7W&I(+(^*:.$$P-S9Y2N-7RK:HR&.E*@]30
M7.)H*'WT464 K^H-1LIJ2#4WF\0%75-K,&)6P=G^<P4J1L.:12]M.A3J=SH%
M5:,1JM,GG>3 Y4] (E@UMR'$1%Q1(P_ZK.\"ED4J;D9L<$^7!^W?A '\=(==
MO @CIU%R8T9V9U>X*)+N[-(F5U]%S1IQN[$O.FFY%_YHD#+BF!@I!T.>7T.\
M^I:'NVC'OH,B_'A#SBNZ\]S@A1<'IDI.GXE"5>#9>:)5+FBX1HCB^Q<RR8\W
MKZ&NQ%1V4T6JP&NX2Y6"!6TVG2]3.CNL'5SX&FYM98#=>"%I03THF=W5#BYZ
M+<X;UFS3K\3S_2MLVPAV\I9DF.3QZ$3&(&5M&:O&?MF@2?7?-9L6?KKS^)XD
M3?=.+UJ<+^@G%9@\6OV=(*BT)*<(*29H:'YR8,DYP'-@#T?3Z:3K%Q^;25P&
MIA9^B:PSI46OQ"EW$8@;'(Y/HM037K\.U%?3X;Q#WO<@2T:_&4!4H+7'(;*H
M.[XT4S(A-#0%S\1G@1X:@AL:^!T8?J5=DC3XI&CT;]"7+_?-06MHV(E$6%66
M';1T=33E:,:#-^PXR?M;MVY@NL^89C9A+W'1S @!0'BE"=[R/\E-Z2?%RPU)
MV^P2)&O=6+5A1(U$$SZ]>^S0/I04Z,5LS^,A/YM(7:7MCVQ>=]CZ*X^"5=-R
MO L(:VVLRV/4/85(!:C,#2VQ.'])0GE^C36X9-.J3LB@WO23'IP@*+'>5Z=>
MD*719ZFW![CVQ(<C\$YL@Z8&P9&B0=!'&Z!$@\# CYYO26!S9E"QJEO/9%*R
MTJDB*J^LWXP@(\1\YA-EO#VV$]JS"W64O80,FYJ,/5&%6YCF;3XP\<E!CLS
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MW73"*)^RG^G=C8D)^V5E_I1-C ID^B7#5E&*;X&V8Q<[IN]C&UL*3ONS8D:
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M\KI,G_D:=9ZDK!)==G0J0-,]B4<,Z091J\*1E#&OEGY"5I <5_Q2J'LB_\?
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M=2WEWN!(0A!OK>]2E[.G](A9W/-35D5KH0L>* KCZI%C.@/EJ^?-W[#CG+N
M-##=9QI9E>Y-<Y^ESKXEZ.JK)<*RKYPB6N1*CPXX,ZCOB0<[E>#CWC%=^N[!
M];]#+.CQ$Z&2Y]31D/5'C@<;GI'J]P69GK,,XS/[IQ^I=\WN@%]Q4,)N"%OQ
MS*DL*.VW@T@<.(JU^NO_ U!+ P04    " !4=DQ7-C<J- 5O  "&_P< %0
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MU0A; RC@.SCO2F2/QN??/8E\KT+'*+[_*65\B@),48 I"C!% :8HP!0%F*(
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MS/@N++5J>7A>K28B=R@NGX@J35%%=1.C(6 ??U)),$,4CC-'@B]%0<%=W<X
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M15?Z.QB@Y"<J5@4BW"0+G5X <@Z'$@QM&@QMN\EAR*]T-!)['IV [W3I,!B
M5$6+O):2QJX(Y/D^SY0I*3S5*_-AF#A!^87]HX58&$\ (%G2HJ@8DPNL^.1"
MW[PL]AQ2RF>HY)T;'>DJ8</U*FF=80&0W E3*#M3]NCD-[_LDS41AZ=@P 4@
MG_6XY)I+9;LRSH"CFH?/0 [87?\05:[&7"3K)$B)6Z@D.0J[-N;BV\.4 +)O
M+4IF#P2$+'2[ZP-/Q%\NZ9)JN4^VG 9 +BY8X1(2#4"XZ@*'L4\IP7 ((]_+
MBQ,698TI8B]Y@0K3T-4O.J&KW?2SVOST4P'"K +#(06R=-\15X2I=(>Q7[K^
M()X74 :BS-@V/3)@/9@$_I&!0Z]\W]N# [ KW^L\9JY>(Q"",SJ8\(,MNIL?
ME% *1TT1*#1Y%;8'1+5\Y)5:&C5"&49B9;GO&0"$:'3%8Q#\A[:A^H*7::X,
MX@?Z<4BYJ,\#(*AC13KJ5(!3E%\?OS*-5'%4&(T$('!C>I:TPA.N'9PV>UHY
M?1C$OW8TB+/F,07F0&WCJ8;^5$-_JJ$/K(9^5FV6;CFE,[.'@J\]# K PM6L
M]=H#LN/P];.S#)U]Z_O_XF#CK_VH3*IIP]Z68P,PA]ISN27.H#93E8MC*E8Y
MK =#I7>R6O$<W;-R:^T5D8@]<I?5:N0MU_[G +ALQ49J_^C#,5#WS!ANO01E
M:P!^!_-%S4-D:/=22UGZ1.EPBZ/H&I.+%0L\WX3E)>/+A-T7[GWUZD\)P,LP
M^&+6IX8%7P3#=KZX(,CSS2Z(GIZ<G#:="FRP&5[,LN'@.P5VP8?'%29I$O\E
M>HGU@N.\+N-NP'4(Z$02'X&@+1@G@0XK:G$C/CY6#\0]F*3> F%K&.X"J7!)
M.=&'PZ [+U@Q#.0QF*2W6#GM %C_"DFJD7\? :N$9X"P*@DD4=P/YS4$\[2+
MZ7;$0P80&^Z<M7PS$C>'L1N)I4K,A2H6 ZCC5V[@;R)TBYU=+F:^&*G5AH-7
MJMBQCQ)?EO$0 +8FE6"5VK(Q<C9Y5*[RQV_T)SHPZHMUBI%M/Z?94HK-N:R@
M@]7-LBB S%( )"?6?K/QSRN!!\/TO-I'!0P#I.<4KR&,$THD0R*J0]*2YZ^(
MA/YR%5_[H1.Z='TR"!_Q@I1?;D(/O3U^<S;LBXY&W79, $><6!HYBG=;/.%8
MJJHPC*BQM1B,''I^=BEO6X02AZGZX*X=-W7\YU? SC$AF!V8%\Z&?HFW-Z%+
MD!.A2Y3]/S]$VF4\ /$5-8-[P!-.(,4$#\$:-1L"0,A%?PV;H39T$,8$FFJ%
MD*O 7_HL%]E-DTU9]5;DOW(<S8/- B#4,L"ZUL4>SFJO&]!IK=['#=V3O'E8
M53Q.!2M=OSN *A?ZJUP?+3B<Y,GI<TA!\@KIW(45KQ':B:K!)JXY'H#*#]UV
M=$T\X3"_+K"?G3AA<%WN7]G0Z0"@/$+;I5I'!-+Q>_;J^$&>1W-.)_G:]:3E
M# B@],  ARH'41N,94CE.12U;6"^F"=Q%#NAQW(GB$^M[HT3G(7><[AQ?(\>
M_]0T\VZH&4=0%&?/DWWXY9].F+].]E%7$ 8$ ,!#8AT$9T#"'*Z@G2WH_]>P
M.4\X./XTKO3I0P7AT33K,JE/KB,25-LB.;;PM?8K6B#,T&)6U^8J>!29C)?.
M-KK#L>\B<9YHBT$@O%.GR? 6V,&Q4PK9NGK;H)#Y/U]$&=K<EA!>L=,W3;@H
MP.%%B4BI<2MC+M66$%ZD,XB]\%" PPO>+OZ &"G8"UH=W.ZR02"\2M?-3R/#
M#@YS+]$"$0IW%I-%%SBJOF3YB>!(G)6HT1/"DW(F_AH-E&Q</<#ALD#@CCWN
MP8HCFMU!..7<0:"COJ.GP'K&QJ4_E$/#OX_04#0DUQ"X+:=$7_-[!Q*23_F]
MWW5^[R5"9.&CP"N]I<)D4&%3 ,E,VOFZ0B0&H.U96I&6:@Y^[ 0L#Y2= ^S_
MQ316=@&0MZ)-:R4R_>\M$8DK^PK]:[>GT#_^>(R=.$O>=5'H4&6 LZ%+VH&Y
MN*'8SR4HC$_R?/KG,-H@UZ=KS^/NX8JV=C=PI>R45!=C,$3B/UU@\=RE.FZ4
M.M4*E]HON4=W'LY)YM6M?OE)DN_?;4"+!X&6J.WR^;OA.3(K?Q)"]',[5FH,
M:/&<Z8^5&G@"4F_WS%NI=EMI;2U%60&_6*FUE9K<,\<NJ-&]906+>,5M];J
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MI2\.:N U]*ZH!.$L]+ZPMZT%[X:8]1^32[_VLE>:X3<TMRKS%L!<X"B.2C<
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M=/6&B.M'ACE )H,"N*C6CUR8( TG89B+^UW"R#9?[&[+7M#EA;SS;1,KDRW
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M?G>"1/JDG05@ -R>!";!'0D*1[XKB=%YZ>EL43Z@")%7Y-$U>9W$"4%%KK1
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MRP9T&$(0D)O0N7T4W2=T-JJ6G"T)*B#\*.&P7D< 7H8VBU,/N?'Y<4_\5RI
MA83\,PE1)S8IQK.^\$RD4Y=["ISMJBZ\<UWEW59ULE=50@L;ODK9A\IZ@$4C
M*J9JPJ0S,\,S;^,=^I9^$LJ!9F<(>[*Y9&@B9]'/D,?;;L(%)NLL-F?H;O@@
M<3?DH\\JP\/W.EP$3A3-%SD:<Y+6$I?Y$&0=1DZ:X4$B\0A(VH/Q"*C94<NC
M$6.T6V4?;><V\8"46OG2'C#,>Z7L*=DTH%U?[$E/N%"O+O!ZS4P;T1T8_6X
M;'D-@2HU32V<QF9!I@JE:/@+'WDM62(:QK9-8"!^>GP2(6J=;VHW2[?Q0'-2
M+L4M.3N"0\4(H'N"KA.F"Q:]^N:Y>H+#$@(^>=I)@YHVML4C^S24;"A&MV@E
M6A8,!6%L2\79*PH3=.%L_-@)BI[_=,*$6M,]BH?N-(<E)SV(ARYAQI:36]]Y
M\8,^5#_)2*"YW8:[$EP!,'"@M=YA)M#Z@G()M):) UKT9\DRB>*>I6-O3- ;
MP8!RL$<( !S?TV2'$ &-20YM;Q"1J;5T:- (@+C4]=LA9$4UPZ%M'KT+BHI
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MS/TS\:.4?NSMG@M$D(O)3>C*/.>]3@ @9BT7R(IGO5?$X?(^NU/CN_E(\Y?
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MR3JX0VT9OV.6J,?N/7])G5'Q9R>B^M!U$GJWL:?81O0Z6]Q:1%)1WT[TT!B
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M$.1FFSU+-EZS_>3?Z9\"9DA[ / HZ3!%BL/@)>;JKD@Z?^H)P8L%WQ^KVPE
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MSQ120MXH/H$O#HK SM<^/.W\;'\.-Q][K30^;E )6Z'/1T$V3T,Y"9X0'[:
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MJOFNQG 7'HEI8J:WF/ %?[W05=>"'<":J-MAK*@"-YAU#3<-Z4H^NZ05<0T
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M-]$TODII[AZQG 3.;%GAO<JSXN!SP%G1AZ3.BO:'0+.BUT3C,"JD.<R**>"
M6D>X5KRTJE419CX-QZZUB' -_V'4 ;9/M#9\/>J!T^G"_:<4;_+H.MR(]DCH
MU5QHP!^CUXKXIMH"0[['^$EB?H4*38BI<K6K<D87[&L7X,8%>>&"Z-@%4-+^
M'*<^"?<9?Z_] 9/=Q6N&XY0M@5[$[/75OI,64\A?/(4,\^1 HM$3OF@Z&@C1
M$FFM)*RU0LR,%6I9AKXT5J&666[FG2%ZM9<'<9J%.[:7M6'$YVF?BBLVZ3+
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MH#0@%;[Z)"L+/@S%" ]B\;@@Z("4F&LU*ATNP93V2*=;#LO C$<IHG:7JE,
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M.EE_%O0^W^^C-PJ__5+.>DMPZ84PO7WRR,Z[BGWQ U@F0F#FR3B?U,<Z!DL
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M*\SYYM. 1?5R)K/8U).H+V!C;O;X<;_;!?3X]"L_26/_>4_CJ;CQ(CO-_.!
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M'&;>4<5!+%QEV\(M6GM[H!HW?15:J59'0X/-._J%IAEZIKI0PI2A*$2O^<?
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MQD;EDZBI*$[Y5@)3NRL]J&>4R,E991ZN.*T(C-F 24<3V-$EXZ\8;VW/PXU
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M:.S07!6BNE"F# :A31B#?LQF%P@(PXK[V%_BWR*Z-8'=P]MVHK1L6YA<J(1
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MWFN:[(:\)?^#TG^H 7]<\TD=EJ0FR3E"D$6G@R"ZQ#A%&-+.Z"60FM$!K&.
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M.5O]FL/CER%.:#AA^) V2I6HHM,$(;SB^#EJ.41J9%0$UY<MK@\(_(*]*P/
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M1!',O&0>V^[9CVDNT3;H*]SUVC9X%3#@3:NWK=;K/59V#Q,'D_%TX=1S=2;
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M"?<Z.UV.*9]C1_738XXRR2B*$1,]0]P*=@%>>0LD-P0]?Y1G!.8MQCU6"@J
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M,C%\?"(2/RF2,$V<ZZ7'(^6*44 TUT^' )CY& NY%L;^_? <L<(()%B!J!E
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M-4E^ QZVK?=QU^A?.^&"Y.?!_R$I*]\=#Y",/>FS,]"?)Q%E%#8(U;63'2)
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M]P\'9*=)Y*2\_HP]G_X_:U1#N[#1IDW;N*:(*%4&JM?2 /Q1^>$FU@K6N O
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MSJEFR_!N"D+-S-Q$XAZ[Q,G#(C!*%RS^=/W*F_AEZ,.:X*]"HTG Z':SMIH
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M)F?0;A?J.M -?YV$=PG-PI3299*>&SN99NN]'-4F+HA5>9,I.0C2"Q[8@CQ
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MG8,6<$8)!?0Y#-5RS,CJNE;*C1*RA[B>P3M>BA&19!G';W-/NJ9*LFJ5K</
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M3EN)(^X9;]9DUCB%:L.F2R/I->3K;,X;RD;W$@%GLZ/+XQ#K-KGU)8<)NZS
MBM)OMHYUHX#\#,@VG[Q>+8PVI\J 86\B>8;_J;7X8RL%7 #?R=:>O'$N1@%>
MK4&SH)'P&1'.AK'MJ-/G*T#+R>PZ\&4=(N6*9>T=CL='AP.@3DOY,_:<#XD]
MQ11@LAXU3ET[.:3&G]9$=%TIG0UM44HJ$-V@T"K9R94F* LQAB>Y5O=8GLM
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M340R#=YU)3$<8.;@S19B1&^42@P(-0'!%-T_L_+FHN[$;>87/<IVF:ITT>>
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M\LKQO"#P&[.CKOY.L$-8< W[ZJYMQY9O-!46&U*7 #D'D]DCB)[!._#CVLN
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MDMCM-<XSYGT##KE?2F3Z :/%=S]X(SF8R;;]WE_%4?@,7&QCH0<3#+&]Q?^
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M"<F59X3UG#J3]ZH2N*_;NDIH$U^S!@]NXJJ5=C#W,DO(9(C,DGB#._,WHCE
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M:MZYW;XZ;DC^47:^.16;;_8-3-.,]JB7PQZ55''YD?\H%M8B7%/51+"%G%V
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M_XJW=U]\5]0&%-3=5=4#$<\*BHAZXT!8PI+S2<5?WV \)B8QB49,K%'CW4E
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M]^CJJ''OZ'A!YL]$Q$=J E<6Z$?Y%C,#B_EQ)M\.;_T\WU[SG>>I3A<$$K2
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MC\;#*WZO#"T8@":< Z5F!9*EPHD!UGMX_&+4DF:V1QN2?[P^WO,D!23EH&U
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M4/%AYES36*!7< SKHP$E2WWR_<EO(D@8!!1J#CQ)?5%K^KI1*;;:<QE7S4C
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MX7FVL.%OSUZXO]1<<7_SRB*8%>U!59H$7J?_6# :KJL/V<=Z;KB,SG;Z[="
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MF(%5<S&5()RR:62#LN#Z4^*>DA4U.J5BR7@KO)]F&)G 8KUW::J"?CWH%:/
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MF8(?&,Y02Q,&@8&^\]CCC'^5*GCK4"B5%&PR5Z7YIU$0F?8JK:F'2T%C1EX
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MC.XIZ#YC,Q292S+5YG& #TO /Y$#$M 0IFU2V,&E&/(2PTO1XVP'<>@54*?
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M%0=3\?(<A< UTZ)&!M49#9=7*('T=X1KXQ68K(<9?>-K-D("8\H)GR.>6X"
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MRG4N)6@$+CFB\[H*DQ+(3[8U2C: \\^U\<P-XGU&0(W=3(0WX3L#:H_N$4C
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M09GSW<FELJXZ<W?T E(OKV,=GE4%#\]+E^(2VG2<:0MZ3IQK$EXH)8CJ8:<
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M.9@S,'H%7=R9]7=6)@#01Y+?00!#=HHO#S"#S(!]8[),FJ:7@[@LPUN2$\#
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M#Q\<(%K<@U.K&T[<@/IP.FU6S,?+OA!M#,*.,(=6L5B8O&"D"0X/RM%E:T;
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M(&/8=OV#*2*EML]'S CA!NI=Q6Y-VIGP=Z%+R[T^$". *<A7VHC:S_*X;%]
M:QKOR9&=EW)16JJ"96%FY".@M8\=AKQH3^M&(=(SD4TG3E5)6K/L+^?HJMP'
M7)1;RU=>5? #-^VX'[TO;:3L9'YV!^78F.1M9F/.%VGRPBZ;Y/YN\I)ZY-_B
M=4U.-)8S=1["-F".4EOCG8-K8_\-'H+2DCF"ZZY7391I:H,.5J'X%?PT-ZG"
M]0+9#19G0(VJOJ5K5#@76,T[DKYCRH*@WN":!_I<!)QG)O_,/O:=2Z!@(0O"
MZ((+O&SZ3UG2AHXJ[G4CSH(>VUC(/DIH_MPL*N1I1W;W!D_T?%YS7:<)HP;M
M^L8)2-RB[%?>I4Q0?XO'ZR?4B@IS+.!/]<JLNL^5LIB>_O=5Y4F:Q1/6!DII
MUT"-RZAS:^<F*YE+F=/GW.719I6V1"![B*I/2(XJJJ'44AE+D'H70XNG:2 \
MQI6#D&55Y&5[Z3$7%LD;^#6]66FQ,>R"\6K&BP:XBC*SXS+7VM= <)WU+R2?
M/V'274VJ!U=1$AI4U@".W$T.IE/:(Z?4U&-' @">!7^EK44ZUY65%]APRE'M
MU7'TSQ?W:&X29[MR-!@'@PPO=<46ZDI2+>Q3/2!E>*G U&1,YO<YI%X'X?IF
MHW?TXOBGX^3H\.7!R>&SY.1-\O3-JU>'1T]?'+Q\\:^#DQ=O7E]7?R=,PMQD
M9P7XN%U*5'9,T HG/2\C37*Z,'>3$^N;VP61ND( B<HZ3J2@;"U+4XPX]<BI
MX"\O0J?V0H )[DWBLU]7>I#PK@PE9^5K9. \I,G_9"LMYJ!%@;G0@T!&JM1N
M=#&<FXR+A]S%<QF)5J->-VV*I=_8U)MF)\LNN9(@H33-"9+@L[HL:J AYT7I
M=> I=P(U7-K6,'DV*EA1V. 7R8R:Y0B:H=!%_;UJX 0+-F!7T0N'CC+**:LE
MG<SCMTMQ92Y2V$WCU_?XHG9C057?!G06^MC6.!**#F<G!\-9,!1PLE];YY9B
M@WM[^T_XD%>OY^#9C\\^Y%(<N"/$WK67K=QS,3, :A_A9#F^A<%<24ZKFZ_L
MBV9-\/XZF;P$W&C8!RG1H]M&S DDFT:[NQO;J;^.6A <1_$HQ_=4E@%V&N2C
M*1C<89=:/DTZM5)1[VKD#?;[)[ZZ6N^OHYV]OC%4B8N5LHX;?,,AY&;?OC<=
MNC4Q:)@()_PBDKDJ9NZ3].*IU0(TS@-I";?N&B$GEW8."389PQWXT.#5%R*J
MQE?QIG/H1BV-+ZU,]VA;IMN6Z;Z0SLDQ^ O(V4Q#,7H71VE\.DUL;$E$*<WJ
M5#22!=] 9QJXNZTYRY:(9\F'$?G$#M3;HJ_#N!AX$\^?'?AZSQ!.3[P]JVY>
M-\)[P(8S#&3UKMZ[AD4D^L3.*%AF'<C[B;_3<P)[= -AI,H,2WIY1W!TG5PG
M-]D7_]63A=1N'C21&Z\>FIV<E@]./J4_"=KZ!*X<32>GKW3>A1H721\],97K
MHBYS01?;L)N.6#">)0=EYVA-(IPMEL31^^2M=S%I@>OUHIV1C^T&0;=O>#H^
M^JMU3 XO,J3Z[@:'=C85Y@W^L%BH(V$M!3<E*-PP31"PD),8\)"ZTC=6O/P&
M+'1 ]JC )4F8#CP)9M8.7I0390JE]$D?(=]2,Z;$1+$M4>\B=*+Z%Q_(KC,O
M#5[1CA5+#?*3$T<D-1'(8F*K04//.2 O'[4>7C?R=LRB6"UH02@F=V+B;9_'
M)N'B;7]SW*7/TE0*3\3N*ESOF1W]Y( --\WG'>DW??WL0!N3(T6&Y.'>PSN3
MNW?NW55[+\"\-G"+.5%SQO@U<5XYJ$<54^X 7)UL/6UFQ1H. ;",#YX60E_M
MD\]L4!B&2;XR+S'M2S_+2A4)G4R YJ<=3_*)>-_HP>TZ.[ ORVC>Y\^>'J2^
M78#+MKXSS&?*@[,..58'^$3,6\$?$.7Y:@6VO%4C8G:BW;VH<ZHYI79;5G:B
M9@B0<3.L34Y"SX">P<-"6S";8N5H7TCO%?'T@T/8[4VU9%0&0 W+..WQ^.D6
M.(TX?]#+GKLT>*+.#M4KN#Y!%42B@,(I/*_/7<]#X8.B>=9*\F$A(L$8J=,&
M:?.JN]/:)9;7;<9RJ0OBV335:3=/$VM!NXWV,1 I!^]YR[Q!9893@;&P@07Q
MD9G8>>G,Z#D@6,B3HL;KVR&6\@#HDJ"$DE$G&QO>;-+6S<0X^-.DMF.@[%IX
MS\;=JO9_A&AVU6U\-)T:?2C_&+X<L+*FTT%>Z:+_7F7D!Y$R''<H\W@'6PR_
MWR#)S*(NX-?"J%!^C1;KI)%86@X+;8"QHZ#1K;9=CCPOG25!<[J<*3754*+E
MP?D8?\1_?;F-DSD PA0A<K<0@+D8&N45#1P2-7PINJZ"@WEICSYT.)TZ&LLH
M :6>CHQY*K6U=N@U>1];[&]9MYTN8GT.,52]0HX^G>/V'5L7??%T+IZ$?%#C
M52K.>J0C.7</U./BOJ]XJN+X@+9@PL  )<.0X@+CX$7^5?)-BRQW$'A?5XB4
MZNVO_[&RM[KW$&B)_6]3;N9'1P_QC&2H:6;6;5O.DQ>_4*'/]T[2.!U,N^P,
M1@6U5@$A+7B+Z4>,SE![KYXT16#L)/>F!A-_D/]AJG6;_._1SIMG)[O)FRIY
M,^UJ0G807@K_GYZ5\B(LD@H!TV/3=7P$)@=.!9D\N^2E4XSRG[!4KCSH';93
M1&5W3DWS='B?F+/,VOEET-++7Z3[$^#*?E$O0G!^.I'B8U0PBV2/4-?$+5RB
M[M(1"$1C:12)0:82<'^ >B'0RT-6F\\:D#_++UW#;M%,5PNL,IBK<%SO[T?C
M^@%K  ,TM@#H[W]F]I]:=\DNT"R<_F?V>3A[S\_Y^./-/YYS;'YU(^D4T_M\
MK/GMO>.%$TQ[E.?VVRO/[8WN@?CLQ5FM@_D,P7D!2(?=Y0P/KDRGZ("G6JSY
MD8LUQ^:42=Z9[F7T0T9<M:[\BTF>*(- +T7$'!RT=;*X4@0#KVV]*KVCP;@=
M8VP:YT-+OZ,*#Y?96LA' E)L=HV#FKZ'#MA3E_!,55C;'WVU;79)*[V;YAY1
M@O"']I2DSZE=U&4JH\GFU U9&!5A9/K01I<I13'I%1;,CIW;'5DPN\F/!5KB
MD-4IU\[8XAGG=F1!"#QM0+Y*N0;B5Q5G/HS K"M"# $4!+363,+G<M^4<F'\
M("L[.$ND2E#([C\5T=>()+:JV'"#&,>O*MY)U+.9X_<]>K_3U3MO3I[*,P N
MV1+;4M-E+L39-#$.]B:P&^8FWDV.#+3D=.EC='!V2(IW[)85A> ^Z.G,:4UT
MLI$Z(^UNX3_V(MU7W7T;WN$V-ME_&,5B#SEP ?2!>VEX&E6;111?B'O"<R_T
M,NW8OV56P>%#/J+2!GLS:S*\&A*,(H]*]^?MN36,>-!?' .?CFBH?J TUNHG
M41NHR#!0!X\/E((HQV&.D >R&^I"7,R5EP>'\$#U[B:OZL; 1@W!+5]D\??Q
MMOB[+?[>G.+O""JL%=&6$!WFS/8I.KTEMQ9RVP7:23Y_YPA+V&MR'C$!G7";
MCAY=J;\IS"3K3A[8JF&FQIA"19F44-YJY]H@H>2B+:%9$/6FKF V-'(QG";2
M\R " <JM$Q*',6U"4H+_=?!O=HD"-6X!6ZLWZ!ZX=1HXE!"WT8WU^2I)D6N]
M2=]C(87H_I<5<5ZO.O K!7$ M==3"TA$=J=U+*\5'ERLN.*QJ566#>BEZ"PG
M/1\;VHP2N-MOH@E&2G?C[;!R$9P1("PZYJ89<HW=H(_(G*[AJYX5UI%W24DG
MI8W2YY04+D+1+]#!]&'4AL8OG#T>F>2TSH09"M5-&=7\HVMTW\"0_0.>*R]:
MNVW7WQ454*0[D[*>OANT@K-QHRM=0VN::YB38:+_(5_&42%-A6[#]=I\OYWE
MVS++-ISS/BN3Q99$3MS42WO\=411A6LYTBXU;MM%<#L709@0)MAWV^V$86?X
M^78]W/[UH-RQ-/6N%JW]'CVD?;]?9[LH;L6BH.RO$VZ4WC[RM]DR.#W*=Z!=
M4R('YP83RB$W;=' G_B8:^(SR6R[3,$&-@2:K!['0(^!X(/)#<:N^3$'[0)R
MB& 5+ <O<EV/-#1,'4L4<^0DF(+V75&6!$!D5%IGLH7*G0HAW&S&2 4R7,1Y
M%]!Q!MIH0M5+)D\1D:-]*5&Z3VWD%!(HE!SOHRF#4?T$\M=1)HK64&A?=L:Z
M\?%_8^;F3RH+;[?4%[NE6C.5WGOMYI(*V41R-J.'/!(-F@^KJ<OSC').JY9$
MNF?A8;!=_-O%?T,7?QCDD+[*C"@^[8-.T;<;%X @%F!,;F+C#]"S2BU$S?)+
MZ%YL\(ZWFV&[&:Y[,S2F6$R@2^O 9J!5H2[WNBRF:Z<-Y'3G!W2/;.2I*:2/
M$ZTC@@CK0QD&T&]HJ/\>#[#=&MNM<2.VQH7G1"0J0B/<;VPG2J6*'"$I46&C
M0*$ME3)@<'4Z(<  ;C<6%US<KT&VD4E]RC6(A/6[: N'Y3PM+H8GEN$^L\V$
M+@YM?<OWX350[#2&P96*UE ",Y1$V5'H1XR>=C<OVF:U5,$Y*D+.A=Q/?AL@
M4I:^C\$'O(-F7@;Q ]OF$9A2^0U4WEVALT>/$B>$\R%9E0^5MWP[]*#' 8K
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M12)>G0I41<F"X%#S84#D./)3';Q]T;([CG,?E!09U%J9-#VX2@GRQ:RM.97
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M()?[M9Y2\8< O>VH6U<G9=;&;IXWV;E4:7N_=KN_S6:&]R323(&I$0<KATW
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MP<];8K_$01]T*0W;<Z@2C^8EYQ^$") !,!3M25=X(6KZT=S*Q#A>37U.NF'
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MX#I;:61K#7HW&F>\DP19Z7DG3%=NFVI)A.5D#0[Z".MK37E)ZW5G+&Y+>E^
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MF5JEX;>A;@990SJ]L:!3;LII)F/&>-57S(A2A:J*I3B'RK6T>M0;6-LB0LI
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M(U^T(98/<P\-:=0CTU(*7HA-!4;5&6%'"@ UY9>D-=1C"?'Q#7N"+^]ES]+
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MC1-XO'-+^*ZTI2,?&9I8=II9+/@V@3K$5S66^[.,EP1_C_(B0=YX(\$DK^!
M6C;ZKQ9N4747ID6Y+*A8-T1(HSXYF@NQF-RW.TC>A5A1;J906:O&]-AP$17X
MW-DY/$ %$I+G+7!K<' D(?Z[)8@-BIU=S(M(0^+VH2/!CI[B) L!$(KU%D>
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MFR-$(I%..E]0W^TDZ+#VU\V$:^?33/T9[-[0P"8,+SX[,RCWNO@TPPYX$#O
MX/'/8X><)SY:"$%). 53Q+,10"+LS3.6Z"20#'<^PS=8;_?%>K/V$C5G)N>4
M)$*@C39>"8HO0;8FIP'_30A;7H=,#\1607BKW+1;<<R+T=,I/"7-B=R@W"S1
MPPI-*3D!WYAG]'&84AV_C]J6RX81RGS0$,(WA&5:+.M*;>2VJ"H-"..ID5Y=
M3$IY\/T^(.B$H @I$M?KXJY[\(((YVQ$I1^='4UZHD>GAB\"<R:W>;DL$+E1
M)&[K46YP+?8SBT%LV\M.9(/#>FD&TGKPOT@AQYX7('B#7CT/2Y++#!,VATV
M02!WMQ]6(-?"Y&?QF7 EK$MK>MC'BXD]B@QCDULH=W6BY QQ'('!S?@CD/N
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MYD$3HEM:(9U(Z(YZ3-Z('P6";ASM.W!K0XPN%0,DSSRPL#LG3QV(X3IE0 -
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MI4G#0]HZ+YVT^-?.(_\3'P2C*A=Q%J1XY4=_^I_#.BJY)J>*ZKF)+A3L-F;
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M65#X5_L@49L*)3_(^=T\SE956A6SUW+3'Y[I5Y<JZ%8)8-O*;E$JG!Z\Y7K
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M%FDU'POU4W%),2IPWNUFTP7> \P\7H2B($'A'N %.(<48TI(1E)8;<3\0(6
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MF(?7P$N;)O&<WEFQ'UP#%A(,(EZ_?0S3( 5^C]#0=6"'E\()X_@;/C6/8?N
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MYUQ$(B'DA,%,7<]I#/BRS*E@.7F"BS>[E,@5 ![-RX5 &?LMYELH7VI-_FC
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M]H-[$>"#3:M%(3?-XF=TDTDY>[%UFVDJM0K2@!L!"J0*MJSVE-RG3?=*T_B
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M*R'NAKT2$"RYH4!_.'2'[:$%1(7EK55?73X=[M!84(K0GEPDX9:^O(+F7Z(
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M[&DJL*ZX,P85N&74GV"A/M:&\A;(7."BN8(*IQQQF1XX=9*+R=*M.!J*/'Z
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MP;_?_EO:*HQ"L ?\!IOD%,6X"C<_B^)%.6 1HUD[8&&^Y):&5<SR.7)[-,D
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MN8@S'4VO%E1<SQS$:[ETP7)QPG8;9<RQ]T)09K:2D5M(+BH"23"8:L(4Q5G
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MM@/;@>WLVW;R6"DL5I_DLW98K#Z![>Q+4RY6G^2C,A>K3\IM.[NH-&*];,J
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MJ6L]QVL3X(#X@; "9  90 :0411D%(V*7OD1==?PT<V%OG6]D6A_ S\8LN!
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M+PP#-Z('/C:N2^[\X$:,Q8"*OHZG8LS&W,QXXV<74-\<\'OZ(7](YC$.%+'
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M[WSI' 7]$\M1XGX"]<(1BY\)F[0#X:$4:^5HX; 3*TP"&^36\=T$,@%_]%%
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M]WQC9[IBZB,<Z*URTD^+_T^Y =VG!QS=,S=_K%:)]N.V3K/T?M5H/4GY%];
ME-$^;I9X.^;SB!D_(]S>Q.C7I(@1<!_&ANJ3FF+>$HE9*L?#GNA!^1^QBLY#
M')\'#-CLG216CN)(0%#-/A)K39H3JOG$C#FZ#Y([RAL.&"<DO ON18&S4!AV
MG?!N$3JE>-!:=@*1!"E^[REUAOM@WDM/)BCX N7^?L8MS/'Q..YL'K-$I/<S
MA=DO2WC<NPN,X5 AU^9A1^I9J8M/NF2^UBRM-CR43=ELE] +[X.1#W'@T@=.
M? ]'SCT;9E7Y=&5!J;2+FY34UV3OO5K:U?-=3[V+[4__^*'?Z?;?/K/;:&D-
M8 <1YZD%! $&;LLLG?Z*Z4@\""/N%!TQVU%O)NI=&*X*_B(2B4F(V&:H=#L:
M.M)Y\J;$7BH>"JE8<0D..#X'$-.<F<2_M(&H:&ML?:RQ88UMRS4VN-W*N5T^
MI66<E 2"P/K!-?6<OV93K;DOE:M<&8E]/IT:\QF#8*2+OGA&N/D8"A<N99);
M7\J;4S[S"A0YSGRHV'26TJI%/'XSM9&-L^,PF9P.?3F1]>\\*37]1PI8LPG:
MM]U1[-&3'#U9?G/D.F4XCRYJ^B=U61&1;)M/=&>A@[P62@'_LOB*F+X+(JE6
ME4:9B?J;A8;%8LXD9$.7I=/.QTU<'XY@HI4ST25FI("9X'>1 ZWF.K44KARM
M(OA/4UV&"+@I!9,;.Y]:1D^3H=S19P!\>XX/,SDMZX$=+ZNHW7G;1(!O]_41
MX71&Z!R;._W5^N"2&W_&/<NY>^:ALNKQLD1(;1Y*%+N2OIWQJ:]:<!E*%97?
M8Q3XDX5-*.M-3I-]3Y0XPW^^^MKI#T>=7G_PM34:C;ZV[,'P*QTR^ZO1888U
M&O:;0T9?*4*J?G$:L8EI7:H^>#B34!D[4W]TS$V&.MX[YK&18SO)C[Z[M?VG
M=U,M'O+*G&I9<1SN].KDLUJD-JVZ/.2U^EB,F=JO^&KVW[3_ON6FER?'OU^<
M7OT?.?OSR\G%Y:^GY^3L SD^N;@Z.OU"WIU\.?EP>GQZ]"GYG!Q]>4\^'WTY
M^M?)YY,O5_+/BY-/1U<G[\DEGVC\]NO9I_<G%_PK5U?\Z[.C:KEK15<+6D\2
M1\0D7JRUC1=$_D?+-M).!@E,J)NX&R&WKSI21*4C.HJOXS!2H]!,MJ&).T%=
M*E$8R]C0\W%,KK$\1I& RL272_+\<4SCIQ12V7B2A==;C:@10*4'J!+(#),5
M4CG/]*A8[V?W/.P);66V<"-7"33"$.CUOB&43.BR" HEA);!H[BFG+\]P1=7
MBZ!I<4JE$.8>_=^M"M_.PAH8GU)0V^;PDMM)9BOI0>RR4 7R=!/.R;'<LQTN
M?#C;%<6G"5'@#.)H/6G(,'*Q#5-.D4,^H>&O_3 4&QE"WY4[$^2QYN&C*878
M&R+66^6"I'IOF;+X(<O>1XRHXXF]86R1K\@-2S8'W2"9. 3SU>B.H=HFMU6L
M836R*]1;V>7#>2=GB%4X%M.H9'%3^9ID%76H9CWM6KMIU RKJQH>JF.?V0/;
MF;BXGFGM:3GR1&VRH\F>]#LG%(N20^XX(C:L+4@GJG4!&[G,SJRYJSX1Z[QK
MVB^WXO/KI)AQG5"N,S'.:\F8<F.5R$GPH@;]6:C,[C;'*X>Q&,)T97A2$VMA
M_TE^D=D )!XN]L0,5NR886*_BTOO0G6F(3OTR=X?CXEY+PWX4*1=HSS,:EL9
M+>ZG43O6<AI=M9U#S,/C*%WR]N+)0+&V->.SN@=INN0G!B1ZTES2! .I;G8W
MV[RW(!VOOGMFC))M(6KO  W4GH\Q<Y,1G=U!O1:(RTH0F=T;<IDR\^<WN88_
M^=,[0SGRHA6B[>$<V_,&U0CW#$QN8!PE&]V3P4[:.!^#I_LN Q;9O#I9Z?D#
M-N5/(+07?E%7.%Q%P']2,8$_;^($Y4FA4.R*"V_(Z_]YLP+8&<L-$T,4W3E(
M<U1DOWSC"0?(AT=MZ*>AK40(!1/^IM1EIO& VQ<9.2Y_O)!,Q'ZS9(>&'.=D
MR:-.GG0XBSZEB,<U>P:6DK&4O,U2<C8UD9DDC7F93LF$?VG[-;&?C/N6S,;J
ME%;75E+JV61M*0 JK\Q#$%7[4H\>HIB\<_QS[CXGM*8<X:EGUVNDVS<,<B*D
MZ=\]X6>.;ID7LQJYC/G\1'VQ;QFUY5WB/>ZFN_5O%:54;P@D)ITL!D3M>YY-
MYR3L17J1] V%>?G.@FD8\YE2\IUEWQ,%Z8-ETD.]VK1V2;=5[YH_/9'O*X.R
MS/7%L841'])4ED[_ENFW#I4CN>/]]*P!9^:ZLZ_2 2=J?(Z0A^%NDK).-'C3
M#'69;%K?EZ?-JF-8-!R6ODQ\C7'1;5Q@+EH.2[_>[V%<]!L7SHPMC,N+C<LW
M%I![EH3MK1-ZW] )+^F_O[L#>L^T?WF#0+I-X+N;]AQEV$G;UFH'JT?[J4S#
M7Z20E\KZ:3?L)/GPOD?YR7:OA\!.VOY<*-0-!N<S&?%%H/!<!-*M.U8U'FY>
M-P>@?0<4+1A<RO6(0@6![\' 4@_D!(IBA887  7"@6:6@'" <+ ,^W>9-?Q"
M!84=S PJ.@]XL2%_<9>_-R* 0*";^6O? ?U]%U3=L=<0AXF&B U;Q0:@ .'B
M^7 QW^%U^(-M,S8:[;=SGL)!^R>92TN<YLGL.50'#G?I)#3KDQTO(>RA==]4
M87O'ZR8E'U'IZ:LUHLJ%:S:DVQRXUI/EK^<QG:?B5W)$^@OU(CJF+E4Y=+E_
M_CQ+;EPCGSX=DZ0'9%U$[4E=WLYYGW;;?!+3ZRJDFC6CUZGU3*M$T[@=^^<"
M#FJ_WMW=>.Z?<_]4-IJ\;;0I%8W*OQ?VQJ#UZ@: 8:_D6Z]N !W?LY[TY"X\
MWSM(:P?,,_P71%&M$OG.108IR5CMFU/G(W!4R'UJ$SR4PG%, Y<<U\E[W[YA
MP<-K:V=*A38-?1'_J9D.N=W4MU=K&;O6,LH[[!K*STO#_C\@N04FN<HE?_3'
M'CD2+MGS1X'CDX]!_743"K)>)'8[C]OO0#O6DN>^H">MD-O4)F@H3_J'<^OP
MYO]:)Y^<^'6KK-2V0MKP[CURI]:SVN7FP!62BT&6*T.6C0T489D*ZRS)CE46
M)7A?[EXK&7)/"X%5&_=]TW(-.@$D?K\D_J,?CF-*+F9U?E^WRTKDH5$O\_.N
M6>MW.N4FZ!43J3?;EE=O&B7?N/'=._7VZ98_T^"&_*9*G+_NE$*=KB*QWE+&
MKK6-'5IG)4=^W]0:BG<)R?*_ G9-SA_"O^R_'B;Q#26ONV4ERU"]O\.!6U;-
M;#7+S:HA>T/V+JOL?>2ZWU)@K994ZU)5;T0A'%4E@@Y\_H/74C1/JT"](:][
MI:#SE=]L8O:-6K]MEHBGEWG#R49#VJRW=KA8O7^V_E@"65'V<?M[U^=W7Z@0
MFBGG4S?[;+(B^?IB1O5-JD1EDKXO7TY6(ZUW6!I!K'9]7GW4\STVZR0B2MH0
M@QCBOMDLZ9L5U)E5G'KU3$#;JNCH3@&1#LF\3MZL:.L:CK*OA[E(Z[N%:VMP
M9JN^U==@NK0C:*SJM#6I$_I)_2R9$F&M']/TH:]6%6UTDCI[E(3VF UC/L9F
M\WWC2%3<4Y7XGLH3,2\->WER+ K\?8P]?H%.6O/P75KX+XSM<5+$K_;T%46!
MKZ3*(W<ELHRGN'ZFBN?0"96/XA^M+N,YRW2PICAD?<4CI'=R C(-.-]TIOS-
M01PZGC .Q4H)C7CO&/QQ'8]<1G4RVPX;QM/ECN_69:5?WF@V<]G")Z<C]M@D
M?!$D94GJ>/K<8)(/KB_*J/&&\"9XE'HU<GQ%C$ZO9=173Q%@R:LLV2J@)1_S
MB8X31A+7KYTWI%6SVOTU6*_Q;_"O-&N]?I/$L@ N-RW^Q2AP9+E=];.:-"W^
M5?Y=RS#6555UPC"6\)$EBH5A)O50956^Y.))O55QY]LWBO2VUUXQK<-ZY$['
ME/S!74#,/4!JE><TB$2@JI%/]7/R.:BKRR7GO83W$L]PSB_LB+JU:9G!I  U
MF:J?RXJ!3U]?79??I)X6I@W82.0OF] '40YZ[I(>E[5]OFCPQK>&W6YNM\T2
MV&VW8SUIDJ^WML;ALCD^@Z[O[J/^'"Q)G==9<LFDJ/2!N9BQZKD.6S.-?-UZ
M0PC)]J7<!?U$3RXT'6:4-:-V"<RHW:ZUK-[3\8]S4K/S= !4P:_9;>\B^(D#
M<$S5>5?B):?%9N>Y(,A;[00!N_551?DHB,-(5@'GUZ81I[LN]3S!@SG_Y'CC
MG)J'Q'1GF8B&=!Z"@H?ZPJ?#]'DDT^77E,_"KR0>7%)O4;4V\/G<D$,\&]7F
MI=*31ZH]OJVX[.Q3QM(PK)[_M<=O)I[->R 3ELX_,E<0PK;9?1O.RZX3!:XW
M,A9OT A9)%U.!7B %OUWP^8/4"='H9R U/CP<Z,F%W*6TZ&D]WJ@;B&E#H$*
M_DE8>^*.JV?0C_IK&@?V6,Y\Q+67>@]A_AO\4Z<$_JE3:_>:3[LGJ]8WNYFO
M;!C+"AW&NX_#^&O)=FI6I_N,+Z_UNIUO[RP85M:P>@4TK%-/5)27ZK1P],*C
MJC5 &1V',E(NKBNFJXGI$B)_8&F1S5J_9:Y%63(5Y@2]9BV(2/LS2]/X;KO<
M<$V9$F?XSU=?^V9O..Q9G:\=<S3ZVAJV^E][C-*OG5YOV![9(]KMVT+DI^DO
M3B,V,9O'W$BHXUW(M0-NVSP^AA<JNEX%U MI^J.=.*I'BS-";EM]LBH#HQ4G
MK4ZO3CZK6;C9K,N#5JMQ:&;7\585CE2]^"VW/CZYN#HZ_4(N3CX=79V>?;G\
M]?3\LJ;^/'E/KBZ.OEP>'<M/:N3HRWOR_O3BY/CJ[(*<?GE_<G["__ER?#([
M'+8;G"T]Y_I^3L96JAD/)!EB.?([?)XLRIN=)\?]3R'5A';@# 19<SF!HZ[+
M>=?\N:1UB_LHDPX=_DPT6/A*C?A" %)+(MPU3!G_2'H=&O"O*:6:?VL8!VI/
M B,N#04%#CCY'3DACQ(*$@^,"N?#G96BZW>,_Q\GK%1*4P^"P=XY_ $'L[=J
M,VY_^ U1:X>.66K6CSRS?(@#ES[X<70X<N[9,+O&F(9,97B+05-]K9DDI'X4
M9K[KJ7<1CO_Q0[_3[;]])OPM.8-MO-7< <@K\4<+)M1=,+7DK5>_R, V\6.Q
M9L?G9[Y[R\06&9NQH9AA)IA1;Y ?3<Z9Q!JN /;,D6\YK7C9  \8Y0HC,>'F
M'LZ/,ZRHMFJK%4?4F+MY^7*DRG9(UR?*>*C?VXEHG1 D_H/%V;Q [./9>_J^
MD-&O?>$HDSU:-3Z7GL-8SJMI\H3B7>[HU>L)OU8@IMJ.J$K#LC/GI[9<9$ G
M?=FCK0B9;]HN=\]BG\GX$7:;8LA>HB[]VEH[5BO=8#(+93WS<;'YO_]MH\T<
MF68ERXZ6A.PU.Q@$C-X<T!&_\R%U[^A#F.X*[->;<Q-,GZHIHZM1;W(D9%[/
MNW2AV^\/,EVVR%75S]+W@F0M5+VYM-_DU;KAM,RZC/[S+3 ML]YMO]!8/2(9
MG3FWI(0'^M$_7_UP=7:\<M+RK&E>26_,#83/?R-!)F;(IK]D1GT=5A=[>E4'
MYDZ\/G)JQ**(7,VDLYJT?OY*<BG>UJ6SL#7I6X['#AN1DYE;2C(>U(1FF&3$
ME0):+/>$JF^_2Q?FDR]+4C=;!JQ)62&>\/=_9=2-QG7RJU@J](4+HYX7"T]&
M.>M[4)-$^8 V#<>+9.].;$&=3@/_WA&NB'NT'UM65\3:6D+G[(QZ\6.STQ:?
MD0$-67KYJ<N?^L>.)3^0=QCX'G\KPQP%123,$Y%=[IYH&FKW1"U1#_E<TV:\
M7]+517ZWY+:S#1BJ 6GVX%"PV]M$)9:R))TPX<&IS>=^]7W-$VX=Q@?\2/3G
MK9!/ W+!NYF/GNILWH/9V8-JV&QVH0+'?J84)Z,1CT8"F5+W%P- ATKF%SW\
M,>; L RQZ64:!V%,O2@5)X[BH1-Q+$XF3B1D\>,Q9_@"V:L^Y  56UC$T K?
M(+2,0'9:NN]%0E&.JYC2I)*UFD<L3G XOCA0Q.JS$KS%U)RTC);HY MV':NY
M.;D\^(V#3,2"S)T8Y;B6VW4RUY1/,_4%XD0\YO@;N8ZM<)\&YS!C2\Z$/^J4
M3[$B/LNJD[-8_)K_0LRYQ+?XIS;C-L#_G+<STTB!C]%BHY(]/DFC%1Z(6L @
M=X$3)7B7#L4?IKYU&',>(:Y[$G&#Y3^XI7RV)WVO^NX=&W#O*7?VC*-H>MAH
MW-W=U>E#% \<O\[=0=*%8L2$6&(9;T^E""3PFXH<<@'#>GOL!U,_$ 3H7V))
MP*.>S>1OS+>$TY1=6MXWP/<\</Q@)I>EP$VXV5J$RHU6,4M_%TX$YL3]9XR0
M>TK. 6MB2CMTAO,E$BJ&E']=C@I'C!KY!SYVUS08IEXO&7)^L?5 KJ5K,X[:
M1"9N^\[G%Q$_FZ5(3Y9\I'=1Z)$+0X%P+@]+2%;XDU%"?*S R&Z3Y:]E5"OP
MKKBKNJ5<XUF^BT"B*X\E)/TL&N?8L1 :Z$CL@TOD!/$LR9W$5\6U9A.^E+/7
M4J(NFK7HZN4*F*#DBKZ+Z_&P.1+]P%LB<%Z;/Y\RFMEB6_H<3/+_)?*NN'VX
MIW"1]C,YY1B?BNC(;6D_]G.FP)Y=!N9CJ]9Z57S]<G3Y_NC?F<V,P0WCP+E*
M]Q!)&YF(I5!A-+QO9[LF^11^+/0DM?"H)*.YG:0 $#.B62?4EVPV&2EU!T%=
MPI%:;<S^C-C<&L5LBI,#N:3,GX"#5"R%)LJG<730S#B[2T['A%OEW7J2/N61
M+5%J]INMFCR?,Y&\I2:=>-(GRB](MW_*3388JD79 5.LA?^9;J/*/)]:Y.;A
MDW-9)<L]>C!^N\QLD]-M*CO!GG6">'?Q$1[DUBWNEA;4/-[FL:-FO)+S*5*D
M#ALM3F<?W2%ALZDCF"\S)'-A=0_U^>Q'A^2UF>R H[;-IOQ9U _=A^Q,UWU0
M9BIZ*'8CN4F6#F^=T \>YD8_XZ;BW9$0&L7&72D^+K8[?:*1Y"IAS",<-VTA
M>+X5G[VVDD<2HJ,W]P-I6$T[8..K[BFP?1#Q((E&(T'/,DL_P2*ZYK"6Q,A)
M0Z"RW+J<F3S>S[#\>^;(<<A<(HF0 Z8XVK*VDC[?L>K$^@9S._UT" LZ!'2(
M;72([%DE,UG#3=<7V\T!L[M#^VMSV&%?6_UN[ROW1.97N]LW>LT^LWL]NKR^
MV#I/]^8?V;80R/ELZP.?\G+B<RDFO38+7V9]\3N6%%OUQ47"P;==Z?SB],OQ
MZ?G1)W)T?'SV^Y>KHR]7Y,/)R:5<#KP\N?CC]/CD<L<K@%DW;"QU1!9H*Q:/
M-EQHSCU@_.S<B^-J7X0PY-ARNQO_\86PH/=Q(!GYU^Y7\ZME6-;7*_]KYVO3
M$'\TO[*/9[^^^]_^0>_D[*^'/SX.NW>_7GWY]RMY#OF?KX;,.92DS ]$SLY7
M$JY?:!!\_4^?'9^>7IT?WTS&]*\O?_[>BCY.KO?Q)&?NP45X?!7]^_<__=].
M>^;%\>79U;5(N2'TBJNQ'WB1[XFZK^<_-Q:>[I?'?TOY?_%W?.:G5"<Q'PIE
MQ,N&3ZH>B<\?!1-]SVQ%M$3KE,A%A;C%IXI\WN*+^9#4^\15'G-='FQ%9SD>
M#[Q/W$BP2;GT\&@I5NAL(E0O"&U[HB_?@ $SBP'KJW,P?M_^>C3Y?S>7G_[?
MI][M^?1ZP,?R60Q\'/4'].KLH6T<_/9;[)S2N#MY^#8T&MDG,;\:\?\[^AAT
M+[_\_N?][Z/?OO;N?>?3!FBT)^\>?C\[NAN<G#6M?YW=_&Z<7)MWW->Y'%6,
M_(-.IF_)9S\0IYK./WTZW@B2R8_ESS8$) \@CKL(R#VAX4HNE+FN+T4XM5@[
M.[=)KZ_%K%!,SEDBF4T#?\3"D ^-T+*3T$<"T;Y@;C[SDVS9UO-K"6HOOC>-
M!RX?<JJ"J;CUR DF8>VQ?2\:U#.:]<) I+]<\Q.K-ON&FG EA#E1Z3G3II[<
M;BNW>,E]%W7RK1LCU(B( 4C8B& NMF(\BP0QN\M*L<-E!AX%Z5TSIZ9?;9Q^
MHR/9YOICZQFNE;F^$!1''!UI1$W_EKLI#Q6=ON.=\"R-S:S.S[Y*!Z'OQM'C
M@^,YYSS)_&YS$I%=V?WN]! 8%PW'Q82]:#DN/3%1Q[#H-BS<C74P+OJ-"]R8
MGN,"-_:2P_*MN>F>(\=[ZX3>*G$NK\H=^G;)-_8 GY:)-__YJOUJV]XPZZW^
MBW;'[%C-JN61U?WS5!6?_Q/SWA,Y[UTLX0/3@&F\A&DD4D@JR$_O"0\GSI"D
MJW+%,1VA$RGMMFG4,JLG,*$"F5#OF1Y9?YANE7%8VQI'O][IE,DVA-JZNY)P
M3\X8"^E% 90Y4*R57O/1M,98T]D+O=J=]>JC5L,=%\0=%Y'1%,?87I^*':%^
M+/:CA&]V058T2U*OUN/%*N3.P*Y9"_=1HE'#@?YQ!PV3TIKN]20VJQC5VFV]
MJ(YVXPW8 _9+L&^WNM]=;63_)$_%K/28D8A=NZ@AHQE3R]-D]S<WRJ_$1F^^
M#7U_+=V]12<G%7<=S& &>IE!_GU24GMI6CL*@)KQG"N9"@'SN%P([:)9-+E9
M#/U8;%[5P56\)./=>\,Q$X3AP'"T,)QVM_]TBE0437O[*%-9:1,6KTHQN7;E
M(4W^^S_[S5>\U3-+Z>$@*SW(TR[B]&SV*$TH#\_(LS/R3)Q,$2K.W0=I*0_Y
MT_0Z,N&).,*CSF:1^=&8;*74RP.SQO]1E[T\Z"7EMT*5="MS!L@?C5B@/I$9
M>#A(QNQ@(K-8D-='5Y_?S+\BSMZ\?)[C)P[-9?M;% )SZ<.AX\D26P/7MV^6
M3JXFF2.M>BM9J52/_VRBZ>2+2_FFD[2<,N]TC?QHU$W"&^DF25]6'\L2B<2R
M1[,6#D@EQ]-6']5:/M"X?!XJ36T]3/,???"#"3$-.=<WW_Y;CJII'/R[<93-
M._;,4:[DE-4>\LE_5RKG]TXX<<)0)9 ZS?3DQ1SPY^K0V_P$>5C?\?'IO0/X
MS)N?:C2M]*3=JHQ/2;*/%1F.1-&LAR@F[QS_?$R#":WQ#K7KY'4F%U:2UR+)
M<O5&U.83W<]FAP"7CG*2U\E/LT:0_EYFE1&7SUQ750;YEN.+"[G82S*@5S)G
MUM0/5'JJ!0^2I"%ZW&<BFXR07U3L6>4X5ISJ#%>=T4PCDSG+]"4.3XHBB"(C
M#!URHB%JX$P=3^95$>EF0]NESB1)@*(^4.%%QC9QB?_&G):,')70>.(/U6LJ
M\WG%GJWRR(M\V.I<:&C[4YGO*C/8B<^4-5M$-N2IRB/T&%FR-U3GI7WU9'>L
M/ZHZR_HHGDWF_N+W%45Y5%*>*0WH-:=38_%N(.( ?TB1*4<X&7$SP>(C$3OB
M:.604377>GS,G1*5/Y>_Q_O%*R.^WZ\,3$^CL9:4ZN/<_%KETQ)8?VP>L\X=
MIJ&AILK[*2B*<A">G_HS_AT^@DP!(LW=]UHZ)<J'C/' ZLRS*W(#D*D5FT;K
M-7WSVGPC"AXN)UE,*PK.")SC<>X6JWQT;\B 17<B^4$&$,O'J'UE:Q,:14D.
MK%5F0.3)<)&#SA8VL0+ERC3],!9IR80U">.2,$WM:Y:;,8&[3"@G#)8#6B6F
M2W,"RE1C2<*[QS[ISH_=H4H(:-,X$Q#4Q_P2$WHC>H032YF?++UH//A/DOLY
MFN?BR@Z+Z'5N"!Y3-Y:YU$1&JIEW_!YO*!/E*>3-BH#,T:%N(6=E,F7@#"&;
M V05/A:<EWCV6>+K.T9O9)I;9W6C9.Y 3V7DG)?NFK=./;#""+MU_#AT'Y(W
MU=.)L@WD]+2F'K-_-(_K\GIADE<WS=:9MG?-XQRI0_L7,U>;,%%N L_X5C.;
M3ZZ,_NTJ8]S"C2O"+D'C1#(?.ET][$[T+<.<F2+*V0K_T4/HS$-;EBDE;SG\
MH3AI2JJGNK[@Z8[*FQ&RQ2GEM>\/9<[V3*970:"O9<9:]7V9]W#6U"D+1#;0
M4"::XY^'H;P1?[PA$\;">UGFJ_2>>PR9T,.W[3@(9-P50%-)].[&W'?:3F#'
M$Q%GQ7Q+Y-6S12A8O*[(!ZCJQB77$<\J"M/-'TS,U+BI\$"N9FJSGN>7'HW2
M3+RSW)])63>5D_K#;#R2I-1U<J3"_ +2'T^\:@( =S)G;](C"2ZR\4 EU&4!
M;_(L&<B0)"0I[2+9$TF/JV"ZT+BDM=R,8S<Q?YD0T?8#F6Y?P3*4DUUQ?^[W
M,ITG4_8O]MM0EL+CWOMAQ@O5Q>6E92^%26Q(,@>N<AH9SR0*+*[QSG7RJW_'
MG6XP"T=\3BDHED@_F2;V2Q[&GL>>A<;.#4SP@%E$3)S9*!;E>676RB0/<Y+S
M<38&HJ=4@M\AB2/.U/Z:I:[F71T,#U0*6YFE6193F&6F54FC>>LFTWD26B'P
MQ)'*(+S6P<\'8,&692)1CA?I):1J(X:&V@^+YC<0N7-%ZO#$T82I!U$I$CU1
MWY"%SK7 W!Q@PKCY2RK=!$NS7[L/BS6N"I;$L(DDA@Q)#%=A-:]B"EIPD&6.
M(4,/#TFQE&UFJ8D?Z42+?D4$8QI'8S_@UU^F]LI_<D<>BQC-WW"\_\9.6G'K
M46JI3Y_.9YK0XD=S56B5:^14G<?Z<*X(B)_*,*K*?PU5_:]:.FM.IY=+/?"H
M>%_1%,\3[YJJBF0RHRU_0LB>S\N>\TR#*^"X"Q%RTY1I99SL;"[FF/-%KU0D
M$7H9^V^LF)DPU8G@M(X_5WI6#+&7Y&;.\C5/9:SV/5GL09"? 1M3=R2]5Y)J
M._5XCT"0%)L(IX(7<_^57%UH17(6I=+KI^1OM13#?T:)N((2-C/5 6KI]5(6
M-TQT%Y']?"AE&5DL^F&J\IJKO'B)NBJ9W$36%ABP^:K2MJJ'TM#2[J.SH@V)
M7"KZD'MU5Z8CMUDR/Y+\=C;)3/M;/MFCCIQ/=64Q'3D=$Q**R/A.96[[3%;X
M=#8UX]O\*:@]EK,N[M9M-9M0"K$4R6;]7IOK6/[JB;&<6JCTYT+3R6AI\K'%
MTV4@E*I0,JO\@OCTFNY6_A-M22^R_-,W4J(CCW6G9YYBU4.\>5$_LW(E?)O#
MDP6;5+0PJ<"D8LM)19('W>I8]K#9-+^.FJWVUU:3-K_V!J/AU\' -HWAD+:;
M[=ZK7S)YT,^/+JY.__AJ-LV>82:?O%!]EF=/QF;+#/''4J<O3O_(U)&66=O;
M)_=C;OZ1.!9[G(E(,\7L,MI50UZF*G0[YZK0)__[Z^F[TRN5XOWX[,OEV:?3
M][(@](?3+T=?CD^//I'+*_[&YY,O5^3R^->3][]_VF42^&>Z<5L:V5HU"B]4
M!C4]DBUCHNJ9;Q^(N:9[.:-,+YAJ_YN21 ]].U8K5T++&SFN6CX7(F0B289R
M 28MHR.KO869^C\)9Q33Q?LYF<L0QE6MY[^-/<DW1;A2U_YP8-91K/JIIRYQ
ME>&+^:Z4C80' =T/(LFX1K6J :.]PVC!\;RCKEC)(Y=CQN3*B2P?FY5-9KH!
M4 04K4%1)FAQ^)RI)2TQY\YN1EBE2@%=0-<WHNMR7H4S3-0W<O+?6&SF ]J
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M8)+*C]2+:?! .E*@;$*@A$"I:^S0A/-N(E":#:O=L#:IQ(;1VO=@0: $!85
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M'C*^E>3;;I@M2+XZTNIMTSI@*$&.M27'&@18T.I*-!=<L4Q>#*%,%Y:I?Q<
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M==8@OH)S5Z*YH(IE\F((9;JP3/V[ "B ( P0@-7J)@BW04XU)Z?%%80M+38
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M#XPZI\8=H]/OMQ\-<,9O)*.[;$':S($UH+F8/%>BN9BQE8E,@%'J,MG3OPN
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M\M!WJ,2E(N+;JL1MC"7XM+9\6H,("R)>B>:"+);)BR&4Z4(S]>\"H  J,4
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ME?1DF9NK;RIT?HQWWF0GRR@G:RM4T6P'=3MONWU;4S3)TH!-,I($L%ZKIR.
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M8)F_[E$=J,YO_VNKSRP\J=6'IHV/&ORV +HH9 K0TU\]%Z\,!#N_6:A."(?
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M:(+Z63,=0#&)7U]L0TA0_1FO]#\P:C\?*E_3<N".3$3^B/Q]2_Y(4$0@((&
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M'*4C@5-H+SP^0V 57.-WV:F4S<.P.:RY.\S=G7TGT)VLFJ?9U$-,G-'*PNU
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M$G:MVH((I5AHKVL *1PA,6]Y7J4\SW! 3VRZ(\6LLM3D-Q09>NQ!BS5]$#_
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M-E&:JKIL04CQ5&?Z\BR?UE I;WS"5$0+O52/<&WT07!GX0-5B%@^.\%UV L
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M/UT>TW23*VP3@V5O80V:K18D6^I[^GVR0601=V_:.63H5:\]?:A6T'N1HV<
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MN?V6^P[,!#_VCWWV/''XAN\A[-+'#X9]Q)Z:KBX?P=H1J,&'?6Q+1$3G%:1
MKL#)^1@/_31]- 3?BO1OZ&'O R-]U'=4_'NA&*&/GG0L'&"7\.8?B(O[FYB[
MU!3_86]<?@BN[_I/0;Z\%AMVN"QB'44YCDAE7 BM\*=(W?P>2:>C^_2.&ER
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MR6;$]U.##H8ROB(W^)L""D?RWV[UO(8/E&:]I*@WI(XHW4Y2CGK?N"^?(!\
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M KB=!.N8%D(MPG\R'%L82+#1F !*"DQH&S#?R-$DO&=!FL$F8=*(,"# M8@
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M";)JRLZ4>P0,Q\8;<Z&PQ31 ,1A!>Q=]3W17@<2-G8!"U%"M &[X$H!NEHD
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MHCDE)G6+S:05CM,D/8@3"L&3T8#^_I\03J4)+.,F$H;B%XQ74_P)9C"%QNY
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MZ5%851V-S11X4(2_]M^-X9*!9*,0'KL\$O/T /%5FC1I4Q].('C(GN]2" P
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M_V6-U=F,[D['%L2ZHN$_V 2J/C=@]XHP6(5/G<S_M$+7HADCF%65\=)Q#((
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M!%-J5SZ <0,XCPY,5!@Z:$/$A(IA#HF*/V\@H42A!T@HRXX94#'"*L4[JZS
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M!69"DTOAH+OT13B% U)[A7 E@*#TXE4=/D&--CC!^GGQ>%NIB_X=N<H,13.
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MQ6Z-5@=V?:7<*>VS+G',D>PT5[G"ZN#<<XN%UE<Z4J70=>S;HEU*B^)JM0"
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M ^\P1%?A,LZ[&!#7#PX@(HAK5U57/#020%V>$=_$<>^&GI[)%@:KYZ95;2:
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MJG&^VU!'*+.76N1G5X2/);/7,Q&^);-E+CH1RF0BI59,91YOS0H$3<;7P 3
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M.#M8P'(V7'UE6/&<EZ;!>G[0'EVSHCKOKH:,R"JJU! 6%:636]9V[A74Y@M
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ML;=TC:$"-_N]K W"R]HXWI:=>0'Y".9I .>E;\RECPW5XPC7F^$*O@?NDS&
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M<[RTLRM+ZX4LWZG,339SKHQUE:F*=PG9B2>+52Y=.ZG,O?+,UU7%AW&ZKZZ
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M@HF1=_EI'<]JKQC[J@^'*X%,K.B.L.:'H&RQAQ6Q!X$QT"3!A)IIM'GX3LG
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M524T/S=*9 5/);T#:QT/PU]IYM'R W.Z> .@=K]7^:R)@;[%S0)5X^]7*#@
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MAL&=;O7;& ;G!,,9&=![VL[;Z4+5)+8J+2B42(WL,H-D /)NI8D'.BI;<8O
MF[MFC:]7MX)L;59/%=JP"<TH)V?$TAC*.Y<-WENWXM\V#]]Y"60<4VDX,A(N
M 8%;UAW>9<5/][K7F7 _, -_?"=+7I#^91V^Q?Z1I ]6B6D_008,T)\!2)FJ
M:JPA7<4PXF.6H\$'X&Q6S(8_ \N&8AK2>6SJV(X)8GR(_&)@LP"Z!6*V$9N
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MWO)J4/."<[:F'L8MGP0"YR814N?H*O%,Y#K$=M 2N_%%^VG<'4/]\9]]J9C
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MYP[-_P^P^U_ \Z_:.B5=HZW!NEHG>*K:'C\U=U7]-SRPOX-:CF[4,DVAT2)
M1]7X_&IC<0BUY&NH#1G^@1JO&S'5T"6(M0E *I3K^?)R<X)1>[5^@BZ$< CC
M IAHJ\@E]&7"E*DH3#D*4_ZP,&44>'S*-3Q^DJ,GR30@Q2272HII+D5/>"Z3
M(6B.IZ;3+ U2J702/\_[3_0%KI[)\/2"M[<$:"Y4*DM-\BFZ@V3A\<A"I;&9
MY5;I'!LOIP:EK3Q<2-4U'$D=C^S4QZ7$TA'Y =W+ZAH[7*?[>0E%-QZ/G/'I
MM#PI[[J$7)L(PQV@"^:0@2-/YFPG&HU&_YD;L$LMEUQT%&9J-B0N>3IG&:Z^
MW-KR/=;)]<=YK9>TUJ##41QQ/#)>Z3PGC5F>0UF<BM09B\^,PL"1I^LD1_.R
MW5HX"F %9E8UG6=50W.>K+-2V=E:<JP @B9G):UFT':6E^")<O+V=#LU*E-V
MK\BV>GIKQAGD0(+K3)^.')/2RJZ4:KK2HC?9;#IEL8S&<)G3D;4>$'?TBGDB
MMN!Y-;,FY6=[R7#9TY%Y?N7TUGFSQ=:Z'7VTM!>I!81G@C@=JF7KJSH[XBD%
M/%?BUK8U,I\Z$,B)TZ%FHK^T:LM,02F9J]&&*=$U8L:@H2<@M0QV\;PBE#)1
M4DL5@RDI8%[%0P]ARHD3,3-- YI+3$6:2TTH@N/YU(1+IC-9GDI/DD#('$\^
M'#0*<GS:70TTNM&KYU?#2;D)=\>=T+^3;5OER41M#.+6O$.HS]02FK:0 D]&
MTE,SW:Q6"B(Q2N=M)<ME.MW$FDN=0F%0ZW12DIF8$_D%:"V%N9J,\QTX\@0(
MCI9--%+/$X5H-65+6CXGI\W:65H5J='3BLJOLP0]Z.2VVR=!5WJ=<W0U-.5B
M;C0;3 DP&\CE.27-'4LZ1U>9YV(]'U]F=X/\.MW2V&VRL:N@D2?KE'I2F9E-
M\S11:W7M\M/J^:G7.TN!!7/1[&3H=)^MC7:][-JJF:/"60ILD?)":6S8OB*#
M7,TQ5#D)M9RS%#BLI,U<1BF7%(>KKU/-O,&D.3S47^F5&RPR;M2!U>:WZ$Q@
M=!%^8SI K,L\+DTA ZL@6] B06$'I[T4JVMRR&;CVI@%Q75N7-X6RZUGZ4J]
M%$]BM5[V"6>@DNYN)*;N=W(;__29A83CM.QP6\\/[:K9FIXB^X6>F:EE9L;M
MY-&8I6NJ-M97&R/KK*.>F??6,Y-\I+YIJT;7>'DDJ+VB?$<- Z$MFHWP<G]X
M2;S1<"O"RVWPDGVDOVGOW_O&2R3'[A,OD1R[4[P0C^0W[13\(8CYV<JT;^G'
M-P/"A[58?4N"WQ0")Q;^Q[=@33PF;EO5^JT6K6< ^EMMB2-*NAHEI;\5(46R
M..*@2!:_QD+(1_L=A&\D:W^?4,BSPO7(5GC)Z7T U70 U:-=1U+[Z['>Q:0V
M]:N\2%)8:G\>9ONS@E(W#,="N9%_13I-Q!V7;I3TAG/NRN%]GP-(;WG\(R!]
M&'-]<B!%['8)Q_17@M+;I[@&IU#!X2E^!_W+PL#QPX@L?@7?B\H]3H%I74RH
MW-EN;]#.$(N-.P/#)9J6N2?K/3:6#>_TD[0EP\6E/%;L84YL83X\TX@L)Z^2
MZ9Z448G6$UGN9)JRT]Y*'(4B<!/40SKY6MO8B)LC;G[MX/[>[$QRPTR\,#(S
MFQE1>A*:8Z,_DU?<5=DYE9_EFSW0(A79)).J;,UG*QDE5="0G<F'=.*T\M=G
M]B/XZH97(.8DC/HS&#+W*)*^UYX_W*J_M62ZBJ+1=GFPZ^:LAJ+USX@INT46
MU&%#3K&MY[38%"E5S\S7:'U03"4>B,1I4FS$SQ$_WZW;X-8,?155XV<8FA ,
MN1\O@9'B9),;29W$$P.-@>N#>D?V(46?UM'\7;7CSK1F7Q-!A=F!;N'\I\A0
M^O2&TFL\?@=PB;PF5VCFSFH+U=@"<"KX\J@JJGZNGSMAF_)J':\*[ ALN,+$
M4C0^@]+)43_W!SI]6L H$@Z1</@0->C. /-9-:/?D0[)?K&ZLQ.%SF T>,K/
MV,UPVL\Q4#I [2CUD*9?DPZ?URD3]/8(528*2AI-0>2BN6N3[LZ%6^2SN83/
MQF\3R.BB5\#0$VM%\)H\DYH@D>]4ER2[7*^+3$N;*HFTQ&60MD,_4.DKWAE%
MK/[M6#URYUS$G?.+O%Z7&#TKE&NY@3PV1,O99&9C'A4?@KI+^B&32']USTX7
MV(ZIXRYZY@I$9MOW,MO\'++(57-W.HS+F%V7+U\68*#7I@K/Y1D@\I.$FNS/
MS*I1[7!9US633K\FP"(>CW@\\KC<4GEY)Y.GB^690 ^?2TK>5H7B)E%)30Q4
M^)!VF?RTH<QG]K"XC57Y%VH'?BDSZR["T%TI=KO$S3N*4O]=_>=^@'AK.7GQ
M>RLL%4Z+9;XL-"O]PGQ#SS*.TEJR65O*JK6L@ N[0M6(?"!>M>WN7,!\<FZ)
M1,X%U;'[@>*M9<[%;\-^6N9D!T2]62_&FP0H"[J@.6+?VC)(YD!-+?E 4Z>]
MK+Z,/XG&K^@;-J]>57F[FPW?G=EY* J24!2(AH/J+'^4++A9&M7-=WY'4O#B
MFM?/",!EB=FMI6'-4H"9>-X0S.JY;*U1YP6H=*7HAW0VRKB*),-'IF3=?.MW
M)!HNKB#]C&A([>J]43*?5PA^T.LIRK:9+TRQ:$!Q0JF'1.;-R[9_X[8!ET",
MCQ>O?<0AB1XY30]:05R>(7Y14GQX#XU^N$E&S&W@( *;EU4+-] 09KPN =3E
MV3RX4PQ:^"W@"@S1BBW0#Y!$Q:MVVL#^U7V;C0-/ZPL=-HAZ_RDQ5\&2J+74
M5<;8,E5Z?JU.*I^EP\;'M<]X2;:GDH]TU%'C>@6<?QDQ]"-%1GBY/[RDHDKT
M]XD7ZC$9(>9ZB'F_ ^V7CYJ;>YX_Q(Y\2[!_#RB\)4:_"11<H?5U"OMZ$8]=
M/^+QUVJ-1A(DDB"1!+F,VG-O$N(RU8@C"1%)B$A"W(F$N&S QV4+G[Y38-S9
M[5:.5WE=  ^Q,TUI2(),7$Q$W-F^;R4C[@P,E[BT\TV+;QU0GN"L]&0G%KME
MAEWV$]UDPVRGUBWI @'E9R[A5N**$#EKH[(M1=/522U>ZJ<[7,K-;4W2E\EW
MN['J\QK=YF?P1SB;;<3 !M4RND3.V\?H,O<HE;[9GC]<3_EXZ71\Z9H(7[J2
MG!R?%2B.T<9*KSZN9U;MA33I7T)8>8S9-UB7+<\(KY93:1:EE-%D:<'6IR6[
MV9S4.FXUY\P#=:$R;)]+#6OS6PWJLI<(KXS4K?M5MV[G]WTKHNJ^(LY/ !?[
M\XO(1Y_1S\C%&E.:C^9L:<B2UHAEG30_;O*,6V\V^Y X4X#IKR^FU;UAC)*1
MCO=)=;Q+FIE1(.A'9#&?D4_/3Z"Y&)C5'9&O/#EQH9WN*=;:+Q]YJ?3ESZ6W
M7=$.O;.=1AK<W6EP7UK2_6+4\$<8L("3-OIN4=T-6M9BE)%;.69$,FYEN<Q#
MDDI^=>_;Q:W5;\;1-]?'OF/\T1T:G1\ETUXQ.C?4H,37R_.NDJ^:ZGBZV:5K
M3:_P%)1EJ=-,YVL8G7=VR+]AAR8C'>]+ZWC7O12-#-@/J;5W1M9UI]---3<=
MC-BE+G'+9+JDH0KG;BF9MZKL?;7,Q9](&7PAA";[_A":#U]R[Z"U;\P$7K:B
MWX3/"M(9\X8&E[E%BTZD_[9B"WA"H[,24BUD>2!"@H?LBEKF0/ +,J_"$5OX
M[ (>$19*DX0B0)BYJ9.&9<,WQGB<&RF8\@)SC&W$+ <."6:6K9@H6P*4"C80
M'V\#H/9I,T*X&4%U1!"3T,YUI#'@JOBAK9M@PMO NM&:WUVS/]B)7\#$\\U8
M^ D1H <@9EPB\/;T !%IJ,"",L-$2;#0"$3"VWT$3?J /QFXJIWWTOC!2P_G
M?HS=%DC :P%QT.S)!XP50_NT,&IERT+K?8BM>,$=!'A3!Z*[7Q^"D.A-0U4_
M"/-_OU(^$!TGENQQ6O"S@/#KX0EB9PKPKB#)NE\)D)-E.R; HRH\UT/,YC<
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M:0-1YFW4-*]MF/;4@(3W@(;,@6![6@PO22: P 2!SJ#)NJPY&IKCZY\COTQ
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MC$4X[0T[[=K5]GHDG<-4UG..WRNF**Y=T)JYYPE!T^VTS+:JDL(><':E63Q
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M':*BVN/-( <1GGF3,[&W&0E?P]MY[$2$N[:I!6Q;=<\!7Q?%]QD3X%^J>?W
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MZPJ_8Q/M2B]HOAL20/JWNX0C']#Q:\[7(PT?.<=/[!U!J%6OX&[%=<0R\-3
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M09+!WD.]=S6R?[3@9)#DH#4-_PUDE&;@&)/4"DD:$ZOYH64(^*3\^ZKJ?!M
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MA!J/GAOQQ)\2P0'IY G.2T5TCHY2DPI2&G*;W#"K;Z4LP'GZ.7P_E !*48&
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MPDA!X,I/DKT6F/7GDYWE-GU$5/LB?VM_XW1R21)</O$M]9!HDH.9!(RJS0"
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MDO=2*OT+ZA,%8/D ]@L[SH*WZ<^5M7NGZ>A8VM9",X!?<>93%< ? ==P>6A
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M$ZHHCQ$56Z%%O!^L\\KA$"Q,_UNN"; -@T#>8=!A>9C697G'>SK$(5_O <
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M7%$T\L(W\!TA^!M:[C38CJP[ *K-I>3M)O26W;)*=TX+!*[$B24GQE>Y684
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M&]QR@;=O*T;76'*S*DL;*X/8.JQ;:;;!W1A8V5UB[>18'118IZ.R&]>0S<6
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M\'=('D CAT=D"D4.CSO06CH2@,E:@J6ZB(7!2WQ6/JK<#9%V5%*B5&7$,\R
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M?L*WN'JUC'5U01[)LM9DF!E,/"(?@PV7#CCGPUC/<B8+2;!CMA';#WHD,P1
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M-3N3XA-P=2EQ?@K>_9M777YK[0-WV4=R'ZC]?7#IDNB2P![)Y+]B1S]#B 3
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M)@(MO>"ZF M6@6V Q;+M-:-]]L0O:D\'X$(!_H5OY%78_!'M;FE*\>/3P3/
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M2P-OMYL)P<494F3CX 8V*G%BW<+ARL#;QV+962RK%H/%YYS()2RKVQG/P,K
MVXUU;5ZCAM,5ULPYNSC7&NO%Q S<^]CSE>4FGBOR\]R +<9G5G9!M;*9,5P9
M>+LVL,"#ALL)&V<F%2V7U5UL37'IX#-[&#M0[65>4>*C=+E+#W2YWYIQF>#*
M48;<&KO*D&6*VZ*;JRO&8%QL<]G@RE6';BTF;C6O#-9CS28D3%$Z@.JPX%+6
MV.;I21&7,;[!U9)I11BM-VAIX$RI>0)CJ*E=QKI"D\2'^HBC2F I$7SJALM8
M";;0-QB-GB3B[01M*PT7+CU]*I>4,HD,)J4Y(@O8*4'P/,<+&9%+"8*4%4G
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M&31W[;I=)!.-)%H:./U&SPZTH=YJL-LZK=1-L5))5V=ADB+)5J9,LS[M8;1
M3G):9[9C11>L#)Q>'*[2:B>[Z"ATD6I4M\ZF+A!P9>#TU=VNSW5VB1U+*^;
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MR1>\_[8!VQ:]7%0=M+]?;96.W!7JUG-A[>GER<,!H#659&!//\0$&,%0X4^
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M?#%^/#X/YKWZPW/ )6P]M68/6^2]%NU:U@75$9^*AF$)BRP>2E1L@#EK*IF
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M]/] Z<&;.>%O;"U_-5YU0WO ]?:^@M<1.VS9%=)LL:W;UJ35[<_KTUJTFAG
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MO95K__*#G#=<I$"9W!U^?&8%;B,P=]#9Z@%6Z5LSSC=H!/-.3?V8O0 #/'T
MI CP],<SSL_#TT=O*Q@@ZP-@QL,%0[Y%#\( .:_*(X_<H3! S<=!S3ON4/=.
MB7GH=H8/B:;?AW>^1[/#XTG_F-Z'QU/_WD7ZW0)&N_.]MVZ(**6S5N>]=&<^
ML9Y4A;Q=Y_.1-+\:.FPWV[[+P]VOUU*+1,H5H=TI-[E0M=,N5#EJP*6];D+1
MI_")<Q??5<CNJ++:+9?A>W=!? ?*W* 1XKMQYC[.?GVJ"%J"*43'>GF1FH36
MJM6=29%>DG'<!D)D^#GZR&7SCZ7KPMV#OI51<K_E\8\G?^_5\@^01+*XVC A
MUF-<2"TDX_&)'>LJSCU:+*\V#!*J^;Q#96=3/#T@JT8$C"M7\QH&44]A*O(M
MJN#?CWGRL^9\)S7RKVZFW!1K[L-J^7S+GW6H)BS7&47&F7ES/.UI2BI4]5K^
MD,PS^<UJX'\D)/--2N+?)"1S_T6GOS1F\SE46JU6G9DT<CJ\$*XUJ'D_6<3M
MNRR-]GK,1JY6K.%\9)4F\H1?+4++>%MDAVXC(/HIQE!!S.9'5\/_XJ#.S6=^
M>W/J:Y'J/NRG3T5]2N($IW++ <F%YEQLG<H7*@7:<?L'D>%GYKAT[9G*][<K
M3O^>(W)@D%Z5,,&;##HNMW,H4%1EP8 R./)>OI$G.(AKG H\N^5(TCZ$;(0F
M%:*)P\-^__L_>X<:-[@ :S_HQF]?^'<FYAVF)!$.#.60>V825>#[+:B.L#)]
M:Q=@C1\0^KW!#[@2&#"7@!["=OZ&*W*TG+"NQ,ZB[966\&[;KR[A?_G*V4V/
M-I8^^TT2SZ@BRK:Z!DT\1\)7HM8!NC-;%2A@(P-BT+\:Y<1)9H5_OUCZ#14I
M@=6%$CJJQ&%N>%?8/>)YCEOW5_K4 @I(['N2+--]G.GW!GV<[-$#G.X)A"#V
M^A+@GC#PHFB*^.6^5?"!@NY15J(ZH:9X66O&HCFQ6XKF6>BT'EZYHA8VV9CS
M-7X::]MV6^$ZQ2C;(X^OM*PFH;1*5@RW(U9IS(9#9"DS[%''5U):*-./%]D1
MSB3P-:<D2U*KYX KPX=7ZCDRY.! GB;3<*A9KB2+5*5;!<,_>F:J/<LR@T9;
MX/*9K)0-CWIIB1GVPCW\\$J6S \6!M]D)_5!I)GJTV4ME*V"*X_G[I2<H512
M:Y/$N#VRR*J9H;,LN/)HG(5$S1X4*7TV2:>L<EE6AX;*PW#[T=N30KK&UZ1P
M&4^83A$O+D:SZ@)ZM\?CI(4ETR<S^8D=M]H=O:=V4G'8#.[HRG4U1SMJ7#&Y
M?+.OKJS%,#JKP,Y-1U=.ZN'$>)8PECPS"9%%Q;#+RP+K]GC:OW)!1TE:RQ?D
MR0KHR\*D5>F0.=;MHH*N/ !?OP9/91@=S=/K4(B?MII$3W7Z3CH_[,%+J<N"
M[/=K*/)ND^6!:]0MF\RJ,!IW<3QD#)-ZV)S.1W-4HXZX::\0L/SF1_N#F-^H
M5MT;PX_W7HLN&^WE],K0B4_2Y;E#SP2@0T956(ONJ!3=:[T_$&>\L]^',H6,
M9RB">J/>$(B6H3Y<ZGU6A"RHF?*N%,#9[$_9J]KHBO'3<4$Y6-\<+0N:JR:J
M-EP&14./ IR)MAH%]WKP/^3PP.?J@)W1,%"A.5.V(!]9(__.OJSJ#H9<D2^N
M/G?(;H"QCOVXK9=GLJJJB^CJ\N T4\.GF/$5K/5XIFI=(I%O5B9*,LTGFMFE
M6FR&I&1T&%2MNW+5NBF8A>I7AHF0SQ'BAL5KCBO60%\H#*9F 68S(<K^1G]!
M8?T+?PJ!G_[^#E5M/A$X)6-!M:'[HPOQ3#,!7>Z/+K'G&!W0Y?[H$N#8?=(E
MP+'[I$OL.7I+0^V[T^6]"32OV<W?<;/Z-<C^'B?_PA\]^4?2S[&'.DC=@1$<
M#D5P/G? +Q"&F\_Y3H7A^YR#/9&0& A-(#27/3L.C._O)#-NQNZ%J@Y<F7.^
MIHSM17B$_%; ZIZT/X&D!^[,N6#\WK)&-LMZ,.L HN]%T.X"HG^.D?]7%NXM
MZK8I:)+Y]WM-EE.;17>6M TW&M&>K:#*YL4$X,XF>9/,=.;NEN$RB>=P0^#!
MJPF\.S_KC2DR64W4IW+=3UHH>)O\>PDS4.#*@SH4-R])9JG.VNFIEN#P>:Q$
MC[0*023P_80MZAT)6UYRP6Z"U6YF >=F<&RRJZA-&KB3T90*G647G#+OPCP=
ML4VJ,!>2 F;&2R?_ [ (P.*%J/M/!PMB%RS(3X+%0A,:K5:_F^/+HW!7P!,T
MIU>=KP<+>3RM3>+MM,@+TK2;ZBW:O3(.DYR97W^HXUS,SUI-MY2$FFS*@B&.
M4-Z:)"]D59^YK=F_F[OPA6CWL^;\6AK%-T2]3YA(OL"QFI3<BIN'11X.JJVN
M5;#L[AP7XLMN;26TF]'Q#7 PI9;,3GU<CW(V3I:HE#A1<RPLV0:,)NI*]=H"
MS/@)<WXM9>$;8L8G+*6W8 ;KU(L<2S8[DU6]I#9:S5!Q&!Y^/68DROUFEL_V
MLQ-984H9HJ8UA@@S@.T4ICY7J.0!0DYU657A,0AH3H'K)K(%/@7>Y+?V)F]E
M<OUTW_,35I@GI@!0B[Z0[L-IFEX4B_34C/"K1FV9M>H#DF!O *=:NKT8+*C:
MDB/+S5DJ,R"KG>(0K ",6UVI_$J - '2!%&N"]ENKR*-&J/PA6BJ'5RH9&>B
M$NJF1JD;((WMM&LKR<ITN/1TEFDV2L5RKPA/X0/#C:2_5= K+6NR(:C(2&.E
MJ:(IIF6@U.; A?T,6-ZXKNZ75-'S3*\[+B'\2':8)XD '??E<!\BB['YLC/G
M2AP_'<MQE>MUQP/R!A"97M8J+6DZHO$ZF8N4\F9]5K-@.3Q@C(6?8DPX"(D%
M>/(Q RO DXM86V_#DUBXF,_IH2;#,3FS.D@+\:FVK'X]G@R5N%)<+_@8#H8M
M9I9Q)L4G8&TZ!I;79,+'%<8_FU-^9_X,JF>"F:\4Y B<VJL[M3>OK'FSU*Z;
MS_RNH/>-M6*^&BBIE3:M-P=E&B]/"UPI0]#]]!I6<P.&%_.$TR]M*P28$6#&
MA6-?-Y_Y76'&@;FFA$;)<(^==B?U0K<0751FPW[C!LX:*2QS$UU-QCBYE.I.
MBN*J)RY@M4:X$?E$TJ^V>_(+_WZ>9+/]^F3[O'O@3%R\RO [7O[E,]TO57SM
MBLIOA,LK55835I;]NR7 2FF6639J4&[-I&**JF[:QHDB:,;8&(?6O3D[8>Q:
M.^O@K9 <\F01+)HLL=8+UZ'RHL252J8='28Y7VV/8)XQ?]:WJ??W7V7_Q!#\
M^[<"' ]%!+\6%,'E"2RA"J:I#!3@A6P'K/RYS: ;VP*;F""*0/U8)JK<J6[&
M*V['ZWCCQ?HK5#G3D/Q2C/O%"V5!A!4%_4KKL+B@ NZ"]3H-&3P2!L1?NA]^
MX[T+X+FA+)!SO1V36RER_YZ3 ]ZY>:!H@B8JP _<#LRMG@@07;3=4HRV"0<D
M*[",*AI%7 5J.5071[H*2."68\1F0&#A=5-=DE5,=Z\L0@'&$H*AZIBI3.$#
MX;5P?.Y?Z.HG-'?%!--'(Y<P&5@+*VQN"X8E&\]88@0K')I^/<9+S!$\RK3[
MICRW(2W<<J8F!K2<1P-8Z]1$I5,!KZ[WGS@4P-V0'733?%=UR1L5W2QK;ZK2
MRL#>(A!+$;!&]P/*2$#+ T\X/0A%X1^(K3U?:!MZQ3;$$; 4@ !-=0W5^]R(
M^5;*X;%]^'PO*#3H%^RB6<QP^+PMX>M&2.XE9M5]2P4N+7BB-9*$%2QR*FN'
MYLJI,9INDP)#G[9&BC@ZU '<4C9$Q83&QDZ5UG"G5EUD&E)S,B\*_2EEU7BS
MY+C%!K"H6T_UT%IXVJW+BZ'3@:CVJ*5C F;*HFTHE@(H///6!Q.&AHR8!/L+
MW@F5(8G_4W>O7&'^.F*L?QVZ@OCG;_@(TX8P )[MP%GMO1H]%Q5054P3B B4
M+5-6X8X;^ W\. 0+ OGR+^7O*[3S>1L[U8'L*9(B&"MX!J$\0'RR9:?Z9KW\
M9=BL GQ,!8DBN&T@P[JW!\Q428S'A"0L$S@Y9"P[GJTEF\IG&C?#L67A6DI)
M5&?7+?*+;&(3""SZR3QL?X$8":_%IYD9R3MXN2S018*E[1X.R_T^16CJB8D=
M;UI@[E+[@']8YUE$4N5&[9X !0$)9X8<&MBH7,Q&%0%04A791N<OW><!=MAP
MWO5Z.%T7-"J&G$(3]6\\('RQS!2D=E$.\_EYHZ[06;E?'WVB^]/)X;O]F@#'
M;E@T(:BJ+,57A]ARDB-2PS5NE").>D(.Q&6CPLV%Q!IP!$WA3X#$+_'#+NWW
M, .L2\A=F(WQY&,%XA' )-",09P$570#7"*"V]G-Y=^"/;QIG6..T"S!=_22
MC*\FRUI2SI@3(?Z)YJC78 Z=8YJV0;9C?*A#Y\;5[*@52K.__I!/1(1ZBA''
M_7+.L <D^^)O!/TG*1__EI2/GR%]4R!KYFAB3+F\88VT4*ZL-J-WA@L)B5\*
M-!?-X*L&%5ZN)+6<S7^$]!#[!:POFU9('L RYO *5T^ZH'&2!X8RLNX=8.1C
MNQ=M(<*U;SS$<<EQA#:N"W+P(S855K"K@.R:6GX3!->=.#,'<,$IM;;+JWO7
M"Q:8\\"&G10V[T$>"3)T7FFJ\;EF8-?E;/?7,WQ-U[N]=*N6HO%RE%RN)@,A
MG&(^8>B<'+MG(<L5N)J;'S?,3)SDYG1+S>E-FRI.5IP=6C2J!3:%#V$W#1S'
M3S34F/FLX+M3)A@8&CCTPN 7QSIN3P5R2Q'YB"=8DH-^]XG;'078Q%N^1(7B
M(6?JP,9WQW+(E9#+M._%7W=A4GV(Q=0^.YPU,Z,6GXZ.0DP^/>[JX^H;6,P%
MJ1,VTX8CE.E4!KZ)):NK/>YPSY4<@!EBBA5F 6<=T-U2@)\%GN*9[Z?>(AB[
MMP-^']BJ>AHY7QT0A+WOP(9? G,H"/P2 \(U?8473[+BVEFM5G22&^+YRKPR
MGXR486?&PJ8NX=A+6/<70)L')MI78<?5Z!9FF*3$IXPTGLCW9JFT0RA]T4%T
MB\;.4.Y0T7@VSPF7"@FOO)PI@-+V3'?UFBP8P#$W#L(OI\)R]^PSG>BR!*M5
MF\<A.?_!K":YA"C;E@G]"&".-F1CND,-6HFD!^EL9L3524WNE$J#>7T)I&@
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M\2V-EI9Q8]@W*C 7ZHDBPT_AZ(D<<W?Y3[O;8#+ZOL_M$=\UFW?W4U',#'"
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M]2=&GNI-\UV!YH)*F;I_*7M'60%BMZS 156M/2T.AGA;[^(AMI,LYZ.K;JC
MGJS5"(LIOEZZX$"(-]M&.^$O:&!ON%\WZ[.,-B]G)O405>+BI3I=#0W!9",
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MDL^7*JU.L2V5^?6P%X66=C1RLM?7WX&L?>N0]=<OPP\.</\\2_Z58/<&N$Z
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MIQ;PH!S*R\D"?A+ .U(&R,L*Q0<VKT6T?0 \9JQNSV; "H$ E%3,39+)3B@
M;58U#( JN\$W]$5>,/J*!LR9H^#;$]!Y<(OTV&D%MPUA]1X/YN2EJ )86P#
M@U2&/HODC\-%2U,&*(5.JWA9 %Z, >I2\!"4+N:E+0$/QU+ <& 4Q'>8S@P4
M >'G"R(U5C.Y/-A13CO'DM#*LIJTNZZ;]\-AN?E3VVWW4B],)956AYO,PT)4
MX%)S%=D!)THCG5*7K[P0K,FN#Y)7E1'.M)=<JU!>I5>)3-$R'."CXNZQAD,5
ML*_G'&#V(-\2K:Z &?I*4*V59]P"&EXZ;_#<UM-%U[\<&N8BG6'7X1,++M>M
MS<,VT=\+?U)OM4-??GG-72XOH0_HEO*@)%MU8*^8I[/[HKFBDV[DRC1GESNA
M&F61XV8?4HLZ892BU%Q-MF!M$R 9M\N5.2=Z8"G=LBR"HIF;#4O((NZ0D<7E
MV;-/'H2 )_6!_23!8_V":Y(9(I!U=Z\!):6A^";4!,#^ 28LQMI#V[2\3?GM
M=KRM>AL4%/$$5^J-K K 9MKC:786S427&A<*4V;$*=64-'?24K\YJ[ZC*O[+
MK_<V,^%J( [=2[6#Q7 VO\ _S-,>\B*6$UB<-G F%BK'<K/)VJ2'O_Y$\"?\
MQ($21 /3J[6SL^,)UC.\#T2 +;R]\$VXZP"2IL)$!CRDPV#YM?,L?@31/? J
M@G5MP67U_"Z4$N4RA'?SP8T [>#C3O*'I$3$H3HO9_"R8C7HGN*0%-S\I$[P
M!O2L9 %  @(,>Y.)%<CQ]>58FB>74GD9GG#I;F0TC1?7J:IX7HY#B$1>R2P?
MYP\A_H1TG] 94(Q#^V(,Q%P49C-HQEK?5:#?'OGZ<GDN"DOXK7O)"_&T/M</
MESFCT\?KHEK,=?,1.C%&NR&O);Q *=_J=Y<U/&;:X0$OU6I7VP. /W7O.5-D
M!%R!J:U:RDR5=TP+.!@WW7@_812:&<(0/ )\(V/V#"J>@/U>?'MBLZB;%.Z=
M=-^$#58?>=^^%>SQUO::DYQ%+W2N4,HIL\DT/I=+36I0:]O#5_91-E:DN'GK
MUEA^VLGI!4RT,3W!C(9#M&D;0,WG: TH7),7LF;+#7=-7T".83:FL 5N+$WR
MCAW6<[I!F@EX6 U_B<">\V.X;[F5_U,Q%!@!UO=+X^PE FQ.5XG^60T+_FDJ
M 'C=P--N[%?11-66]K9N3<_Z417@1KJAX9TH.3*4&O8:TDC VK7_*B?B;-X9
MCE_ OP<KBKPVWW!VC_5NM.X6##<[5GZ(&LQR9P@^'YA>Y*B6K6,N-SYA@!^?
M-RFPD$TWR5H'@\4<(&U87T9/W NJ"R^LEQM&7PBJ[4HJ,A,-&17]! ]RSP$\
M8RSR#V030+X?)4(1]9V0'_AZJPB4-;Q[,[J_3%G&2CK ?LKMRD+\@WD\[3J>
M?N5I;P420"_IX%&F6\Y4@$DNENKIG^,PVWZR"!B51_=-/I$?!SM!$<0/ZLH_
MJ_4J8X'GRP@/8=E3@"[6OG<%9<@P-QL2?@K!F_CU"D[63E(=06Z"<ML/K^^)
M%7PVW:"5N0>6GBT$H.W0'/)WN.8I*U_-#_/YR9PE-%9*IIJUR/MK>KGES#?K
MF-A=1C3\QDA &W%QN.<CF]#N@K8+_+W@$Z_FD2>K'72MVP51=MJ3];8EM?!Z
M?Q52YMIPE(>!ONA+VYFN((EP1P,R[)9=[I*JY_8)WTO:U:BR+%6HV60>38S2
M=MY>ZOT/DC8E*$83XE#1W=.#[VD!"><UO0]TRP)N862UF0W,;YC0(X+518M0
MTC7PA6W XY9QP53,#;&S)LP$$^73*26%2'_2(LVH.$ES8E<J6U.#U "5(\_'
MI: V5-[!;S>U: -+&T#Q\PS!)2BN@K8U96/JL>(FR.YCXPD]X$+*J8<+AKQ5
M:W _\MRNI8FYT*<8&$P4A+\BD/<V1$_I5(",Z-"QA/5UP] =>!W@,_D0X$1]
MJ ']?L4\NI=+5UT3JY+-9$/JSN8.-Y_8S8737!,UY8.)%1_$JC10&07=-%.Z
MD1A!<F:UC6B<;+BYR]2+C-8,Y^7A")=C6BC6G36J^0$ZEA4[S]1#\$9HWN\P
MW.Y.T!MM+5]]HK:NB(U,ORP!4FWZS+O/?+T<XOV>OO4,B2UML0W<W,9JSFI'
MIUJ(,#0;-7UAF]M]RY(.Y!]8B)O=@:V1Y&TDFO"$K@ZL-T@[9%MMMA4A%*14
M\/\$ "!D#<),;Y]+BJBL__:=@&<\B]M%2A1/OEJ"#]!Y47A2+_P&@/#(MZ7>
MAGC^\J!9BF"6'B 8X;PRG\\;83P]:4?JDUPTQQ5?C#:^E)YS_OVL)*%==4'=
M3\I)R ;<\T$N/BN.%&"_'/6Y1)*?KF66L<B(*^&AM.S$B?YTU:@ SV\ O/5C
MT1<VK_N";+I;4^CMD/T>^KA>^(OTV3,W$JW^&H^5Q4DH7>;*5DM/Q>;.*SER
MSDC6@+^!7H&IX-DJ(M-&%+W(,/Q+\%Z.ZN<-%#@"%U]A@,1UD #RV# W&AA7
MQI&L6Z-]J-\:L /@-+F.9%_0)H8]L\05L@G 6Y'/>?,SD^]GFOFR&2.K_[^]
M+^U-'.G"_7ZE^Q^L?N\KS4B0,3OTO!J)Q>QA)Q"^(&,;XV!LXX4EO_[6J2HO
M+$DG/220;H]FICNAL&LY>YWSG/;.8N/<))J=)![':NM0SR<NP-5>.(<2S5G.
M-2NZP':LJ,FMC=J#M=LE;;F%*$,[4YX?""10N:YXI^WGHMVBYNPY*P/I!HXW
M-:;MV!Y:Q=7*3?*&J:CH=^?J33RM:3DSZ$,)*3*0\J.JKLY#[",1F4D6%OE1
M[9S[1)>;796+W$92V4.>&*&*&33N4MH'8^NRJL_0'\1?D&BDI"0AG:LS'AP/
MTVP6O7 1^?"@,TQ=7R #K*H;2T@D0 P*_C!PN?N=>G7H9R21%"_P%W0FWXNQ
ML3MF:- N 53@N.:BMRY)AABQ;I)PV+F[ ;3(C[P"2%(_./:6L+ ?>JW@[24N
MA.0[$'D3+9M*C7IS/HH)LJDOG5%&Z,PWS[G9XB?=W>,7>:*"!O*!41"?%'EK
M@>%YO*9P9[5+12L7^8(VXI>5)UNL5:?<7&@B[9_.O*9>T'$A#:%%=<=W,5W[
M$'2*Z\JB<3AI%JD TD?2#?:!TP!SBC!(["'S'C.)?=:[U V"\A%\+B(!PCU!
M>!!*W\=Q/D++1VQ*$65(K,TRP#MQE1::*WH-=JOI92JB3EO2("# S*6/";=]
M  &2=7O\W52%($5N$\];ZXF;:%Q<6"17^;4XZJC=5_38.RB2WF3ZVU:6I+,*
M[*DBZ]6!.4D/^3;77)<>9GDS"M>5J;-7W!&&]PZ94 6<Q^]R'#\M(.C/;;QC
MP:,(RH'A?IG=.5LCRBFCG,I54HMZHXQ+XE\):@78G"A%<N\"XMOYO:3]]4Z7
M@\/$NI8$J13O1O?L.3^;I18KFO,%FWYL/-P_V>M1]P'WY(J= :YS3YJ<J>2]
MBEY<0?S&N^.%BT#WNH1X%["/M/[9\-(OR;4-EM?ZEK$E2?.JOA?(LB&_N6/*
MD#R@[B.!I*,7Y/N!8?(S8MY-EJ'BWE]:8+UXTE^ #O%FT+WP;;0@+:[WU=%L
M-FQUENF*?B\DY,)@6[J0X*?)*T3^>^38U+><)K;GN!7T63V@M-GG9&.E&,.]
MO*V; XO/%7O(D3FO!KZ(2+C%HZ@B#OO!6:P7\WQRN59U-MY;Q<K%26W"U;J0
MK'[^,'QH+FSLJ1)LO!= 0-K YZ>W)P"_,U?]YL[M'8F$QZ_WSNHH8YW&"EY)
M7)_N*MM))SK?LWQW,<MJTL/SNOI"BHZ7MWX@L7]+U7T1/OUI]>T==][?[/:<
M!@=[WDY33^XHU^=53=]H3TNS3&E?'_*-3G4^KANIEHZ,Z]@K%MV5$GA*/X2\
M17($AQ'@%E%"9R0R;=, 1).2Z<C(Q;,4F=Z2NN&(=JET$+\H\Y;-#-""E^C<
M_.&>-5(NY2,T4<7%;-'M@\3$CXQWO_$&\U+QB(7,][-ILZ%P\=F@_M"1Y:$2
M_<G0]XOQB  *UQN#$24M697$7$P>[I.9X;TQ'3TFP0Y(OI*#YH8=<$#9K;9]
MX^F0F,1TF^37Q5Y"2+/I!!\=C04YOVQL;_R WI.K#AL..0V2&+P'[N/5'Q_7
M^63T1Y5==(5ZHK/D,Z5R)2V6[=8>MRC)19+),X[#^7 /YL20=][-.V>Y9:(_
M#J:-+"L,^6*KMF"KD]&@BY.]7W'9:43N=L/];7+;CT1P$]+E/D<AD>OP>WX?
MN/1Z"45/]R9(408\=Q1];DJJ+D"J.M14&8C7H#DZQ/[GZ*2QOXH.H"1I&*>@
M"-7PO*B3/!GRM 4&*J P".2QD!,!C-06;!W@$&*T\15!MM5.*G$/ZKSA^BFJ
M[*(+140+_U[%?TSKI?W3\W,AVQ\JI4&NMR@YU06__?M<C?@%J.*U G.X9::I
MF@M>G;L%L;3('/^!8[P^"H/KKKL0G>9AGA/:68@R?%(OA!01.0F21I>(O3FK
MW"-S3.6^ *"@JCKB;;7022V58KL_;RRWS[O#'C;L6T5,GFQ(< NI;TB!-'N2
MC^=Q5O9''Y>UT63U['!1.QOMJJV*P5L8I#>2.N<1>O@LYTK$,95# C1%O@AF
M G]%[(M4B'T18E]\&O;%Y= L7E; +N0?54B>9,4X!#- D3# 9L$0D$B_.=#H
M\. :[E K'BI34&_@2[V"!D%<_ L*T^*TYZRZB[BQ;//]6K62;K>,]/8M4 ]N
MQY.F9%F2=/@6)#:E+:\>03U8XV>MLLWJ$E>,):;;A+3CGA8R47-1T&W'6 ^@
MON Y[H666Z!YSYL"E&DFDI]LJKG\3^4L$,8/+*>F)*/YW_,V(#A]I+WF"]/O
M_YGC?PXG\GK5S0BR?TRFJ/*6%<T3,Z /^=\D#[6)_G#Q':$\)T]<F 7:$_0M
M])^R(05LEJ,01!.2WH2?0I&J:$Y(W$UJ+2%FW\*]->3C"I*Y1WS@F#;@0'5X
M1V7(E"*!IU-X&-SR -M#2/Q \@AN X5=*#(A"-5!]JUE,WESI5@VF)=%WH#5
M1B"5(W+Z>W1$%CHBIHPV$(VQQ;L(T[<EM*2"OA>9/[PO>%?OQ84BS2FD+#9%
MV]B.-?$<[WF-Q]<['=ZT-5@&,>. K6#'%%,2 %P3K0!F_R?YW TBDM05+#TH
M O71]RSWBQ&FKEL+AP?,G)FI;R-,!0"TBKQF(V&J1O %$%/2-7V.O%KTHXG6
M=:\("UZ")2-[QK'0KXN\J:)1PE*B<<N&A*P^IG#'W$L+F[^#-EK(Q%?F<P+$
M2Z^- .83?P!G0BXY4VX3)MR=E8XM>N-$4S<LYMZ\\U[N@H_-(39.5XL.59(E
M6N'ZA_)GX+CF/)0HV+P+VP.A64P'7N8018P#,L/M+^"!7@ZMAI' <>(-$ VD
M:NP$G ^.+[V0J$7VF:V A+=\\J>YO39.7)+6#CH5=>\.IF#+%B(]R-+@(6H\
M5_"6P 211P3M9\VE9/^-UH(6@Q&1O05Y*[<8L&UP@WI283!71 >YW>A$1 >F
M$2%A'$=[<BQXOZ0A&;E8N22R!0*&B+-IZ%!@X&X).+6ZIDF$J6E6H@1:R$?:
ML_#4_L7<<"-.3>;=*TVL_G!2.[3\!9GY-Y[D'\J&O(20N$_//UP[I@M%=*&M
M9Y+MDL!K\\44<?JP-^W)2S2,M-T2*MPL WD4<P7 L/D5LDW1<R%]T,;V >(^
M)!YPT-16;(=DZ2 O0]9-V;LT()0"W].P#!09&?P#DDU#>BG;\*,*(]''CNGM
M!-(_IB;M+2J.<.[-'3-:(+&+R 0)2!4"YFZMGF(Q2-ABX:R0%#=(3@(E2VAG
M@3Q#9J.@R>D.H%^3C82]IG)4L8'ZR#@?U)>4-M L6-!PF(DVT"O1L0*4&%C5
M2A?1G@FT9(&@@1\ HABNI/$$[0MKO:HR#5K,@$!.+LZ_DT "&@!391-_!QO1
MW:3>[_,SQ+D!]0[:G<D')/N!,O<;>\=IG(4J\[YC0&T95>'4G<6(:/ #+.]1
M-Y<@)<@;'W2P]'&RP0C75]E!!<PT!R7OK@)_X>"V8@3Z82\Q;0,*:B%: 1+H
MX/NVZ'V?CO;3+ZF1$+RUVY(YD.Y8#C(NP4H_3,5S.2%@L/M8UV2K#M36 =3<
M"O&O@5%V>1&DMX<Y!X%5\"-,$%]TV[S)X,)GG(4L.*JG\31<P0"#:1@Y\!UW
M:2M^[UX&!2#W@U.:\_A,8;V H2_B:MZ5@7'Y82XTZ^3HN?!2!](8\2K\HCKA
M2#B"0A=4WB07H4^.* ?KG^A#R?P9=WD*Z5;&OQFU]AT7%%[%1)RX3:*D3+%E
MSB%18^\#> 9 ;#YQ4MHDI 64A0C+[<-JVE.?;XK@6AT^Q?_0+:FHU(NY^6[<
MXBJFN.FKT\%.JO^+EKS86&_/Z1S;9@_\%%+?TI[[QGL1R%(LN&NQZ,#SX:RR
MN8K/NNS"7C8*!N>4'^328Q8:+V=>2#<Y.$O+[3B%J(?PN:[Y1(Y.'P*_'GDC
MZO!Z+X1'_I;[D."K/^+T^=CV62]Q\IQ-6WUC)L:ZBYP$21+(=\NQ9WH&D/,(
MB)@KGB.5\P=*X3*GR&79Q;R5[V>';;5\[VC%AXICOPHF_?F,^Q"[KSW-9,'A
MTNTQ/R_LS.>Y@^\@7TA->I%Q7>WZ!5CW]H_\DQCW*=D7[SOM?7NYZA9B6]5Y
MF#_E(4<P&8DESUQXDL/X>7]A*V'71,,&Q(G?<.PU@)9'9@7C5B<@4U%4!)MQ
M7V4CBQ>*\BA-*19Q=R1<KH,CJ\3O "<#30&Y0\B@0DL!$D7V)C)/P;> WT-+
M$H7@ 9@T7^6H2OI#DWA^'[?!EI#5?.PV%!5)U1GRF6>]PT^^[>U%P$@2-':A
MT3,M1"C$R> /@TJ>PQ'S_8VZ-)\C8Q1]6H0KNSUZKRD J1+G XUHH&4ZPG)_
MSF@G?C4(,V34JONHOM5H19HBXAA!2](M7(?)&Q*4-UJOFODXC&1*L#'80G??
M2'8!_;M1=/4 HL*;7%'9*"I#N)K) S_ K1;B30@:&3K<(FPQDBP%T($&6-@=
M<[2MI*+Y2#@.N@%\)V1J ?-8#B)T1%BZ>3II"+6]X*!XKC;- R<&G'MR^!,_
M\A5X*!JU<!#YP??0W@L2F1]B1Q$ F%V0BQ/O0&,@\BO"C@3#*#!.TBSB-/@Q
ME95.2H2CN'!>LBS_LQ=#(33YTK*M8YR-E;ZACI0KX:BK<P#C33'(!9>HO"X*
M$F@7S?\8+<&G-MP/B5 QF31%$4=.G'48, V@":,E@Z"[8TJ.YW9)N!N:A4L"
MT!M4C]%N3IY&O#C52\J E$"#0TUC!8!0!;H!%@_+H!LDB5].-I_>T?\TCKM4
M;U<+XUPTR[6?]P]U,;.M#EK=,_E0AS@LZ.D%%6<,TOO1UD+L-[:YQRG+UV-%
MY;%J;BOS[FE7@//CW!X"4-QAH/?:IB-=[%;UY#;MY6O66.Z.H>E?/D;FE8J:
M7]>$50G2(18V*,#/3,?R2LI>;6MZ#@:)8L%)R"JWHGW$Z@IS#_(#L7L1?YM$
M=I$=BH2(;JKB%J)#M+ :.)R&=PT=[OU!2B#A;RR0J$)_!6&@\?AG<Z_A7SD6
MB<*[.Q7QV]Q3H0:)Q'0&HK2!Z!,2DC88"HPM"0M-5W69!MM>6X5,0WA!7>_5
M1=E8^S$&;[OW)2( /^@&?I@'0.6]SEVP*_@50-*+DI VK,KV#018(59E*AH"
MZEX"G ?H(4$%'E)N*E9V2!SJ ,BW>&&K>,-0W=@X66\P.\A?.T#!$/1Y9/^8
M^^AL'Z5_A8HSA6@_+.BEG:&8DGL7!8NT?*A!@AJ+ 3'<PGH5$L$Q!A_^W@8=
M&=*C2&6MP&?P'AAY4\>*9* _<Y)*.O8M*0NGDHX<-#YG2JR$5EVBHFY;7IT;
M6JFPM)9\8C9.+.;:OE!Z4S;#V8Q3R%_(@U%6!B#6 J+4,N(%/R$6ZDW:<_HM
MMX%532N2LPCX9TZ^U*N9&67(KO1A5]JEG_@6A_PS1(SGNUQ06] '@9VAE\-%
MU@$NL'OYB6.RE-+%8'L2CT0B;@M4?'Z>/0H\0NXFO?XG$)(G^)1>>Y39'L-4
M^H4MLJ0!6,DOTJ$I'6:IA5EJE\U2>]VZ>H<M]ADY;9W76C>_D*I&VAS[Z=4?
MED-\.SKD$B4,-;)=]-=E27JQ=:\Y[675HFHNA@Z7KO='3LZP^QC8*O%R_8)K
M[ #P W:-/R?/^]<ZHPXV$9$R!QN8HD)8+YY3)C$O;[:5V J=TDJ=6O+#]OD9
M-^E\N:D 18A1%<ET#5+#?QU);[B.KW,&D/HX1#37!<=R#4J*;8XL!7V+S'%Z
M31"P4&84B?,XT57TP%O=8,Q/."H1!B*! DX\A/*47.3B:%T7\Q-;DM/;?9Z3
M> ;/TJV0B;.Q;(1$.8^K=SBO!]Z)\^T%=/%"W,^]M Q\5.0C@@LK8-<(L>(!
M=!8>X4>#3\&]R"-<PQ-/DM?\WGP1WR-U:^>1]X-X"5<<^:X>8/-"CG#$]?(B
M09B^R%%I-MI0+Q/$.)B]:TM;;I<P>(^W",P/D-EA*I(-H6,([X&AZ!71DD3P
M5F\<C;$Q2 :;2R;M$#6CD6;X?,"FV/@=_9/!7:,T1 7(3USA64CXWHN$;:'_
M&$:CIRLC]CE^E.NKVLCZM-V$"PLM4#=-Y'(&8HYH0Q%3XH1=M/P-[X;X1%/7
M51R,# 9-(9MD)AWTM\+@H^Z>!3UIDK-R4A6,<;Q/85$HJDB@[07:#E&:*QK!
MX(/5'!#<'>/5A.,P*&PDK6Q]R2.&5Q_[1O#YB;^$76=$,7Z]-?6#0!(J.-KN
MHCGH6L U>X]#AC\(SHS:@O!0]$M%]?QTR/#Y#LFO!'_VU'=SW75DLD?/N.O@
M_:&S\R=!%,WQ'#!-"9"?9[UMUCB/\R]$*Y#+2MOC',PKX"@&?<JW[LJ5I'<P
MI'94XVA*2&AH5$]1'O7#880\CQ*):4:$[B9A!=K P0=^Z.Q< 3TZ. R":OGU
M_,#9<P=DEZ]R,32<[;(_3.(/Z$KACJ/[+/T)#Z02YA85XT#:\-?3BVTH.!5(
M)^TXOF/TE",<%$SN1*$-^_GC!B)HF*<*CY6J;\]@M88[>,!CD8S7M:C?=C:@
MOCQEA'D6D02^HW3%//J3"'+\&"@:\L"FB6CV%!UMG8+C.V"889I1! ;#>!!N
M+2)2A#LI9MR+MDL#BBB%IIV?S1"ID4M-V'J,)9'W Y3>XO.M4M[OGH*OO] ,
M\=P.!";TNZ37N&D<CG)-8/)*=\T"7.:N !Y4N)H9_#K%Y@6;WRC658G6*W?.
M8)K-O&#0G:$].OL+D)_[I'])@7GQ6=+VUB$!PE@@K$,2\KO>$SI*?6DZZB^0
MSKZJ2X!9$I%/\BSYH.WV.A<$&M5I./ 3 +H^XRO8?G]N>/SID$/' >_$@:.
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MFFC]^;^_9G3E%_!9J /L9E,;.^A/J(B,6X7S@7MPF63T]_L+UU[RB_53Y"V
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M&:;0AAS^6W/XA:SEG^;0UJ!L&DMC/!FFY>BRHEFLH;,RXE!L,&?CKW'HUPR
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MI86IM=?6P)>VJG\:./5A$UTH\41BSL8[P^EDLEO(AH48F[062D;2R=<R9,)
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MGM<YO]\_OS]^YWSNZ[_K<U^OS_MUO^Z+]Y4W!T#M;>QL ! ? ( .#L";!"X
M8#Z^GW4@_H,2$!80X.<7@ @)"0J+0<3$1"&BHN(2TE!Q"2D)45&H/%1*1E9.
M3DY,4D%17E916E9.]N<0$/C@#K^ B(" B*RXJ+CL?RQ>)R E#)P$<&"0.L G
M!0)+@7CO =A!3@'07P+^)1#?049!(6$1B.B!H0$*\(' 8#Y^\,_4!]WH@S[
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MG,IZHG!P0-5N&W")_2[ KJTNF7L?CE6L"&2L,*O4@-E ZP%L;1<>N NL=6*
M,:'L(H,E@?7,2V3[(BJ#G[*2V"$('8UG#(:%S*R:@( -F#6/U!IBP8!1$#.3
M :X)1%Z3OH5D-,E-VN#5]#Q=]\CBSK*NLLA@H45)(-:-*OR?+6SSD S$N::7
MHYZ(7J,&EV:89$0&Y':"S_;3D-;,TM$0?KF H;'67_FAHD57)*!A1)8D&QXJ
MN]!53>]41:.F90$'!K9 3H [:>C)\AXH7)VR7L @:OYI H*A  ,V#T8#5Y&4
MN33\?+O%]I&P#S6*D@H]-,!)60*9>OULX0EX-_!,XEYN"T+76+@E-"DRHG",
M"EA)#C8V,+L$/=I?V\.._W_T\$I1(I$RBGKM7U^TK$33HK@7/1+^!@6,XV]!
M&.PK!+UB5_+#8 %8:AT$0^;_G55V"-[]L)NBZ_/X+_OTWTDPH?B'&4NY0W@T
M6,%Z5S[O]\T[7%V.'\HW84BQ&ZQ< $?:'5=:?=PE[_ZQRB_5LI9%?/QX='C_
MKR=C\L-(?'&_$X3\[PEM?E.B_K9*W+UG3F]W*C9QI[HFO@&\T=0E2+LQ"ECB
M+NP3]MXXXH5C#7>AO$OF>CY&Z3$!B>*D 1DL*%K*R:@K:VD &0BGRC2@IP#G
MJ].\!*U;AQQ8%S6KW?!ACA?J#J=SZG*/WJ#(&"55I#N?HCL?(**:M2KT,+G1
MA3R5F*X=+@@P(W80\.:#?<^),S@OH:'#(D]\5O":I"QDC9T^U!G>*'E3K#>;
MK&O3&4Y#T-VF<%\>R $XP2AAQ.:<A4];T7K,?*XSE X@=@:\ @V;X?".LE*%
M+EL;N=R!)]? ]V@&F5WIF5G XI6DL-9.^@5J'LFW2/DAO5!\?QVAY:25,T.]
M,*6UI!MQ(W!11;B+>VEK&&WVW1V-HF,UNE/1_^Z@@.4L<K4\-@4)TW%>IA\C
M3[E7'RSCE\'=UA0=J)TD29XKH.CW*@>SXN9&:.B($\ZJ0G=;,L:WU/06Y [_
M]\&3_2'H$JB$PG$K6C"#X XUSC6" D#.@MY,#BG40HN8UY++!KA-"T^C]Z1+
MD,S$9M!:03\5,30MKZ\C;ULP7^]J._M$7GPT:4"K-A/QF?DC+ZPX$] !.U2"
M1Q$[H4 "(M%J"E;" \;H=P/IA!&YCO]NDUAA,4(1/+AB8N!QPF'6W8=^R+GZ
M-]B"C8M:(/TL-!&12,8Z>L&=9%,_R-$;P]$[!;H',GVG+XR^O-W9"RF1S]\8
MQ2\^F&$VY$4N2#4AK^X$%!UX]Q(46CX=$U/5$L;B^U!1*-.TK3JWAW=B%/YN
MN@%_$#)*@8S._FSQT*]*U)L0DV?9J0M$L^8$#+JMZE85Y#.9D>K-&(_$3N?S
M7]B+!<G(U=^%@R )_D)$2D@XNE)T] U/6<6+$-A'8XCOLQX4H4L"[178NP9[
M+TLT;P/#+NJF,BG>!H>QPB _2)9+C38 FBDE4 FY]5)5SZQ;'M7)W.@6SUB@
ME?-C0Z^=#4V171$[J@3)!/2'*#QTZUSHY&VNV--,WK!+,CU\E*/_:K!_IB6!
M\ISDX5!1(X;4]LQ_MS.?P9E_0Z8-;NJI)Y4OPP'>M^.:0SR@-RF."B"?46,@
MB 0H&Y0T4\]6;<$T5$VRCC>6#5T?,8-78KA*!^H.^<H1R4=!K$!WG,&:P&RM
M]LCVV;@LVIKMO)I(N%S0F(?1Z>-?K"F(;N>Z]WSQ>QW6#]T E0[U-1YB=U88
ML8.QL&._)YP!0ECGP"3'HI[2022A[]^@*IE,,K@*T"H*+%YL55<VDU72 *5J
M&,V\; MRE-?F4T-1@92B@P_W_[KSM[\</-P_L1/R&L-G4R8B_ZX&7-3M^-]
M2.1P:("*: $UXB%=T 4'CS8X+"H!H5AOWJ#H.F*S(19E/>_ KTJ@(05/9#[/
M3VMM"'V%7-&Q#2H];@8H1$9?"+R#\!]LR421"IH,<$CRZ"!P1_BBN'RJ#:,>
MLNN*P^!1$&"&41XM>E?X.F!70,8@*%PPS9T\F-6D[#SG<\;262MRZA=UFW.H
MV'OUW<.O29=O@^'_[H;O;2P\'_W7L+<+#HNC@%17A*?C^!9NE@2WAQ1Y1PY"
MT6T:Q[!_@\/EM(*_ZZ_S<1.\HH1;E(T.^KOCHQWX^O#0RL&S,_ Z-YWS?"D
MX24'>_[=UHT7J=?8+MP>#)YX?C$,;-'R$LBV&K)GBY\8C G?RE8HC@L.GCT/
M*U.Q_D0D!,),1+QL#H,F5L9?N".:660IOQ6QV<A%F3:ZK,]=-TP"QM#%-01
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MK4<G9G!AUJS&&MKR!$'PLRLD\.A."M@?1#"@$>"-/B<=;FSV<GJM?R)_%EL
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M[@1DAVIF)X')?/-P_:M8V]%%5ON\:&2^- XZJT&M!*S:Q1FMA8O7=H.5$T(
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M82%F'J&[9W5N84NR(&3N3J1K[D<2+6R^<HWC= CZX^!P9WT0<F.!%W(INKC
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MEZ_>/W_WYL-=9-4;21",7%-=EG-5^%ALD,,$'ZB:G/[,#3Q\,KK_X+I[**/
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MF-I7U'!#1CW;0>,-H'&X!=#X7JQ4!!BO&V0?MP?.UTU)P@S !@(%,R4G*S&
MHE"IC++\:J+5*/H>P \T$."K[Y#C :_L$Y?X]4F,(S4S%$TKLW"$Z++((N#*
M)7T!(MD,F2O+(2@DT7AIO#BHBP/XQRDKQ,!'HUB756O:[JS ?YF7SXJY*OG=
MM&&>6X&2 S.5Q32J]92D0/IWB/BCJJ340\ PX-MNW^YHS+Z-9>#5Y3N#4IVS
M(&Q$DTP]B45>-&LH1::H:B0(%G^[DKTQ3H*2:'=4B51)PZ*H ]N9@&C<W9/0
MH?;-@@97 (E!JC1JX/.\*#\1/."K>%1JA-(J"<N!OKC\"F"FMT6-&ZEJ>,I
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MEC=QRY5;(%N^93 '&+J7H,C+S]2QA.(5/%*&I59F*M$CS67[ C7F]@B!"M#
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M&:JFBAOL%C,T:%XQ3U1BPJ!&\AQ02>FUJ>4%;#,U612AR&7W'V=HG87G?BU
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MF@<*H5A":]8)_::@3D&@L@$AZN!J&\W%B4NU).A\=%PN;P_9)3!&E0=T3:G
M;:F$0SL5.;!RTF^K[!+=>&(OT%24>N-ZQ@PDC('&4BI-KD$_%."'Y138F0LG
MN(ZSIFVBZ">55VA!08V\?4J^ -1')D%$&?@Q<EBE@*8@_/6T4#0CV.I1%&M%
M5AM26 ="Z#.)Q3.?!L9]QQK;M%)(/4M+&P*/D$O^#&M;6A+M2I0K$P%F"R[P
MRZJ$NP'P6BO<8:RZ-I&H7-4<EX4EMB=:"'"487L&M""Y5-E]V%$^CL?DD,T7
M<SP!$['^EF)!+J9P8DG<"<1?TCG\@^L6 "=?:N"5"V?_$*1QNQP9VX^8"ZAB
M<XE0I'^GZA4%I:9CX'HI74@BG-(&FR';SB.IMS6) 7H3U=04[>;;H)B/ "F=
MT:\ 12PX4@YP#2<K6;QLT$,W1>H:5:# RK:N$4!PA>4TRNARDL$U'[R.\ZRH
MHH^+/"T1<??^=?GZXSY/B;:'(C%F'";OZ$G65058 &14*KH%P&//)HAZ;-6G
MY @'D.;%[L149D"EX-B*YZ*=X34X3-4B"STL/\3!J*$CM27PO?NV31Q<-<[8
M2OSPZ=>F7+21?(]HD#9G3IIR56-/'8O)U.- P"A$C; R@<1_]V,"R')&OF*D
M]1&8XBE**6A'WMH6ICIS("40@+[N%*0";PKM40-.U^74T@$)+O0M&20C='XU
M)7Z&@TX1_EOH3P9>W/Z*=9J(+H2,"BO>FE+Y?8N.#H)%&Q%U(((K_#&-\YCR
MY*FIXC4"WL#*;@-&!C:.P77&U <DI:>"I>^W:LJ1.DBI/4@U=.X,DA,]U&WJ
M3&(U7SY08=P5.M+Q/+DS&4!40=91+#LQ+VPVR-[IWVPZ1I"Y;U*FR7>7Q95I
M "J'PKB#L8#-,-,)B[&X]*J(4%VDB*-@A1@^EQ>1].;U^D>X,D,>X=H2W\77
MZ")\OG,1[ER$V^4B?/2=Z&/EK# U/'UM%XM-<M&K&@-NI P>?DGDJ0%J-14"
M/.-F*T"34"OT ODM<>%;<>8-SSOD^?"PRHQ.04?0K!8GU/DMI6*>=JB.?4#&
MX-IS9@21<NF7.38C1_P<&5&0WC=K(F>,Z:AL1UJWP>[6VNV73?^EUL)>4.*:
MWOBD#5/K.;J6>(,)#,K4;^+7EIQWOT=N,;CEH?7MNN.6M;_8#9%R@L%:XBL*
MA3P6XGWQ8#XI*$<&.>+R0^F;W/,Y&E4 =27ND.+*J=*QP$K8GH1":1U_4MA%
M*=DEJSU41/AFQHK0O4,:.@I8RW1:5R+3_,;.^;+VG>L#BJ/DJ\>BE9PWXOHT
MP(N9_H0><6-2)<SB?"F ,1+YI7 I=XG $.:QT=-]S3?X7*I94R^CARVLX7<U
M2MBV>9QGHQ2!N!HX.^[ TJ[*$2_Z4PHX"2I6$I:V1A'/,1-+6AY*J/"0 H$-
MPCCAW9(1W -+Z!PG;4+A9@604&G+?D3>$LK"(_/(VU9/0#P66\OY%H(YGE<A
M[04Q@\0UT.,0:U$]R.O/]1YSU#X7K,W0US;1I&W)Q!?'&"](7GC2$.E=#A6$
M\<9R>*"]:C4'Y0,.N&;_4)$HQ:=-R6]PNIGW+1UC%NNIBSR@^9L259@2]FJZ
MZ/EJC%$:0)MM2JE5Z2<F6\5Z"#/&\QTM>[ @[3>C0=NNI'+J3&W,+?=91OK9
M@.KL 7!062C/AA@T?23BEAK4P8@=+,%E;?Z2*:++I)FR7BY^(!,%)2DID@_!
M@6!A6H0K)YPVI<!^E10SXNEC58QAO1,R8<'L<=29G$6N8 76JT6U!RG.Q!FP
M9$>F_9^=BD8/[+Q\.G:P&-U5;&%"W!272'!::*#C L=R8!3K<BWA*\OV2205
M9Y\A2ZAKAVQ1]%(EU,!YC=V9+\;:F8=];Y%*'Q,AEQB<S6S?2XQC+AIN]0U/
M"PPG2N-IC-X"EHVD% 0:!5-LK5CC.4Y5NK"V8]0@,>1I=&_PW@U="PWK04\I
MLA";->#MD9N>>N7T+ZQG^$$?>_8XJ9BS@)&B^9 ;3DJ&C/,IDHIKDG(P<QE3
MITV$(2\9&/PHOBXX*7)I>UP'D/7$59D94,2FY6@,\5S_<:8HJOS7IM15R@#.
MI1VYMDMBHN+(&"=,&:V=>6*R0L0KBDT@I-T4B!.C(*%(")R$/UR;:B[7NC#I
M1RCDUWY6&\,85@8Q(@<H\!SK%@VQBZ&=N0+ Q])SNY3,FS"MT5WB<3J.P=;5
MW3<3(\+'4A:5VMDX$*(_1L'+4!NC-1Z_0R\=@6\X1[RNQD2O%L*]3_H.:0D?
MT?>6J/C,)$3!=UPRID?R!:TV9U3"D-%,3PKDD3EJ*$0X%C[[7T@U(D_FKSJ]
M'YR+UN6/X2P\!<RU.J34N@?M0?GNLC5.&^.-Q02O)N%0=(JV0*J![_;YYP:>
M*:M-3:W\0/T?'(=$ZH5!6K/8!,BL7]W LSATU31S&NS[-$J;Y_H,3QF]B90C
MB^$5LM-V&V)MTOGL"9)Q7]>B5?&/%MP[5BJ.\A$;"!7!@%.%\UML=JH2$J/O
M7'9)VEFO:B2"ZIL842DM*X1TR9T%!H@@3D>Y=OW4X8(:0)5^/:/-XQ#<H<LC
MP;%N$%=-E+2H16!#YV[;JRAKPE(5+<7A_F2HIB:&4;%QK7<Y7F8HV]+\Q0P7
M5DAH::(;'D$HSB9 _UDGIQ3W=H8I 745C>'QW#S;HN.R:"*_0')KU\6F6\."
M0Y4Z4U!J.ID&I,2 Y.\S5G.*-E(^HX&T8J8X:!7_J95MAW)7Z3RPA\,Q!FDI
M%-B\);Z$K]%E=W*\\]GM?';;Y;-;0M)=LIGIL$@I:QL08^X9A4%MUZI<. +J
M=[[MUO#P:!])X"+S4$%Q-(8,/.L(#MXQ .VR>S;7Y9YO07;/A6]X'D6OX="P
MKM;MDW<N.#N]QK"TLEHXJS?PNHH87$,RCTD=)0&O4T[&^%78FB/NQ-"+V!IO
MK49I N3:$?F(*^ZI38(7:3\5NXFR>(Y"BS<"IC:6VLYA4S9C:;V'KL_0Q$\F
MS($1=5!000^%5"=J&QT'9#A5-=7'Q:!T[P+%P0O21V/#2*>LVXJ\),'<QAQ8
ME-:P%@\K)9(S^Y!S?I%-92[)+VZJ&=DT31] #KG,(Q^2+B26D (N37.PBPL3
M6[FLPM>E.T4!1!3VBXQ[P7^@^C=FVHN+P+]E.H[379$5F-4*5S2'/#% O?!C
M4'"0M$;J;B8P88ZT*"ONB.L,CZY65"=LEFZYIT>WP)VK[\*5A22'0*CL&#-2
MQ<HGP1M=%!HL_RFPJ0N\X'#>G;2[_O:'_SI5R;.5_'>3CKE"J)&YXSDNF$,#
M78Z .SBS39+$I+R7-6!*V&-@NA04)\9VGP8H=RYB%R6_L:@\" 'K_9-=B]@S
MK\:F-=?XM9+86D/ELMA<PQN/G9F6@(XB-KD.%I%$:K_(+V"\2$&%Q@WGMEV5
MN3G+#,VU4XY4]U0V-+8%SA8;F2NMGMG&6W'D,*@LH 2WV^^Z^%YYW"6FX8Z<
MG8:(A =BGK.S4RHL.,#G.S%A<S'AY'@+Y(17G(R.U_G?'M[>(<FWOP9?@"@8
M$&O9']D%JMH:AXO 0W%/!./Y,C^1[T ;+DQNOF$? 2DSG2<UFZF \HO7YC7@
M3!97^$6.X=NO\'KBM+#Q93_GQ+L^UF0>;0U@J(;]&D8T(Z#<1?P44 ^#9-JR
MN\=6W/&V[6Y[L2GE3BS$IJ\QBP#YOKU+-V+U(MH;FK;D4K: &(T)#1\Q;:@J
MZ29NFF?/8S*B^A2'XAE8%K-Q$DYE0?-N@ZV/D;&S)88"*$*)JKW_)5LH>Q:X
MHTPWH$PG6T"9L*;8^.XE!Y96&"8J!;)1J9Q,%,1'&M+0!CIB\2)T33$"M#2N
M4>[ @$"I4E5):CSFKM@)JMX9.-"-) $3>NJ-/FBQ<98ZE]1 0'<U9J]:TRB3
M43(84!3<#@]N@ >G6X 'OP#X8:@00,<=M'>_UJQ?W,CK\Q=RC=5- Z0K.;T9
M?_;JP$O+"S\O;,B:(*6HMV;E23RU[<%#W;XR #W; @#]:-N,MH'HWNBVR;G#
MJEXRB2FT+F27=%*K_'62VZWZ:R4&OPSK-3HKV?=+T;A>[PGZC XEBM=%"6T(
MW$-Q[4B02<0(D5'S ]6Q*RPU8%&[&BE,A7M=6H>!+" N W(2=%QLM^P8A46E
MTT9A@G O+H=A4GS I@9/J^[\TG('? <))6]PS4PI&1?-2^TL@&X:NP]<"A_!
MGOM"D8^?.FZU8B1BG=$R*/A;6OOP=)@^O*,8-Z 8C[> 8EP:3"77S>VIA/1Z
MPGJL-AYD>:GW34S RX8B'%&>'NB/+)9>HY")ZDO579*,2@OIC*/&8=@F;]&I
M>%WXGVF^1BYL%.Y2T[8UQ.>BMT,4HW+?MCHFI<#4B;8K]J=+$BOYD:IB_:8&
M8>,Q;E9CZE$.)22%[/]F66+&77IS5NRX!FE7^AYYA[B9@7W7BO8^7>TG.U?[
M5^YJW_6BO1=^^V0+^.U':NZ-%<7O4KIQ95<!)M'<15SU.V3; 5Q'RSRW:QR^
M81>FH!4'FS@:[FMIRD:VLT-VXN(-P'<;>BG_@L;D\O; ^Q:3D'$((\DY64,,
M=U; 8 !B^T>&8:,FG] H-&3BXQI]HGSAT.09HV8JC"JHL*"N:N8CWR$E,)%9
MQ)C?;1Z',:5@\1FTI0PSR4=<(>?)EJ1^'4\AX[ADF?:[@7_3YGU@U"+F3\+'
M5@0K28]]RRJ]ZH5QZWB]X7@E?RC&?8%(M@TM/-X6E-9[MP"AG 81HQ^'_ZZV
M([8P2TIF<YX@V6DX&;R2&&9*X*4BU*@S:265ZL>FVQB&32C0*:A;(*A*V8"R
ME# TA\J\ZG0@M5>QG*S2L]I5$4>S3UH"SKNRK(Q48IU'0&?CNSQ'*>L)EZA7
M63$?B.O2B\(P3U(+/>NLYV$=EF0</8+G94[0G<OY ZHM7VMTY9L1WH,5(LZC
M*.IS'?=2!J8$IT\/GS[GZ6_0_])<M^O#KHVC9X$%Y$P-XU;T>$ >.6>/59'_
M>G3\"  ZRT2UL)]QQ_(9WBCA?ZD5VQ'^DS@318Z0'M2@X*CR@@[*:!O/2$&B
M&0Q4W..=&N7MQ.7KD5ZV2;T;ODCOJ )L.*I3?^?;N86+1=U$+W7QGNH"#J(W
M>7(XB,Z^.8._D)HAO+R/RT]SS$7]V, E1:?'3P?193[.U)SRP&P\P;/CDY/3
MS@D<(0 <$=S\T10"MN>H_C+BW4NWVQ60F5E(%!JUO'##F3(T,H]A!O=&]]>O
M!8?$#L\[S6%SH68;>AQ<8&L*E#CNS1,5-I"D5C%%RG!''7C)H(NL&Y13KX5'
M2V?P ORYR4$<I0W6.FGJ25'"JM*6?VH5Q]@!XFI W(9P_!^8 H*8^V,\OR,P
M8I"GXPFF#4(4=!J@0)<20SK%Q<XN4JZ (W&[)(]05$MEX#*+YU8X^6@2;LU4
MSFLR9HU7RBJYV@:C3.+7:!S)S97@;F[OB&/"/G[IB6-+)47!CX89*4P8S#@^
MGOU^YBF/:-M>EDO"S^%M=&7HVM6MU5S66-6&O5#-)8N?8<">#?2[F,U4G%6K
M0_9VJ+DQ:IYN1P1L0\  2MD=M-]^-L$Q!2Y./F^F0[:3)-ZL@\B8:UA)I [K
M5>'>#E5C"_E8ZBX793M&FXP&L("#I9 !$\1I9[%.RC$'7WK-H+"RGHE5K8"U
MV7X".V"^ 3!O0]!D$(LCPL+=K/[MOA1LP)3 8YG+M5SK5)$>($F=-64RH;+I
M4U52#6@$/EQR7V4TY =9QFWHANB;QB!'%(ZH#4H4%J.@8CX]M<359Q2?*JFQ
M4U4 SDSHN4)289O+M2Q3)KX3L<"/80]*.O15/S?CH9\<2TF;XR$K<YP*LG)A
MRBCZWAF(6U%XG"PBA=L;Z9O<XS^1VG1>7)"U79LR'=XE:;\MO5<G?9FE>.<L
MOT]G^>G.6;YSEN]8Z'H6N@WQUC]0\F/T5C6@5]W!9?X+^A;1*T8]+-CU/* $
MOR('=#>FX2GU\H!E8>.ZU+>,F8(IB@J;A!6(1HJ*V-J7Q%LI>AAN,")LP6)1
MXJ7PJHL^)'7?2I\"+FJX9$4^) Z+C%)/WD:_O+EZ>_GQ8_3+/R\_7+[[?O#M
MT7"-);233F8J$%LQOLW"K=!"-L:1+JO:FH[B(:CJNWM:?4\7_[[Z.7KYYMW[
M?UY\^.EB$+UY^^JP<U$KO#PG3PZ/GR[U\JQX\>S/>^L&QW/Y_RY?_7SUYE^7
M=";_23!T<X+]<G$>1?]_Z7]1_W_+7\#__KQ-/OKN+2@PY]&_WOSKS<7;Z,<W
M/]\0Z$Z>'IY]88AQ][<V@Q0^V>BGBP__$[W[GS?_B21Z)>2]FL2ZG!?3."B2
MIO**=7WX0&'9ZH;W=OK\\/&3S3WRM I< W6OGF"U ^=T><<E^/_,4^)>]529
M1YH ?+GJ[=D?JM[>59>]+D#,7Z/*'@V+= '_3.II]MW_ E!+ P04    " !4
M=DQ7S+FJ[GDZ  "=B@( &0   &%Y='4M,C R,S V,S!X97@Q,&0T-RYH=&WM
M?6M7XSC6[E_1J7ZG7U@K";D0KCVU3H!010^7'!*FIC_-4FR%N''LC"] YM>?
MO;=D6W8<+M55$%>IUPP%B2UM25N/]EV__9]ZO>]-N6<)FWT>79PSV[?BF? B
M9@6"1_#I@Q--V<B?S[G'+D00.*[+C@+'OA6,M9J-[4:KV6TTZ_6/OT%;Q^HE
MWSN +[=:[:UVL]UAS>Y!>_>@U62#"[9Q,SK>I,=/KHY'?PSZLM_!S='YV3'[
M4-_:^M(YWMHZ&9W(+[8;S18;!=P+G<CQ/>YN;?4O/[ /TRB:'VQM/3P\-!XZ
M#3^XW1I=;TVCF;N]Y?I^*!IV9'_X^!M^ C\%MS_^-A,19]:4!Z&(_O[A9G1:
MWX,G(B=RQ<??MI)_Y;-CWUY\_,UV[ED8+5SQ]P\S'MPZ7CWRYP>=YCPZA#>W
MX.O",X_U!\>.IC#6YM\.Y]RV'>^V[HI)=-!M[.UE'P7.[33]S)=#.PB$RR/G
M7F#;6JN6*WAP,/:CZ6&Q@[(WY\E[$]^+ZA,^<]S%P?^.G)D(V:5X8-?^C'O_
M6Y.?P+^A")S)_Q[2TZ'S7P%-P_ B\1C5N>O<0N-(ZZ$<_P%\Q_#_._)?['"<
MZU VT8*OZ,\'02,=^ZX-S_8?I\[8B8AQ=G_;&L,<SK\#Q18PL B>(!E?74$U
M-6,+RP\X3FW==3QQ$'NV"/"WI:^ID8/0=QW[\-X)872N$RT.IHYM"P^Z^O67
MO7:S<_C;%G;S7L.-7SA6RW?]X."7)OWW5V;BP\<A[.=^;]C_;2O^YJ-V@ 8O
M.NC "+]NC=]KH?Z,P\B9++[1*#Y\''T^&[)DIME&-'5"AN-H-P^'\1A@(Q3T
M9^MPD\%7-F'SQ ]8("8B$(#Z;!X'@"(P(!XR?\(N^(*UNC6&L%UCW+/QO1FW
M!1LOZ,^QB!Z$\&#\?LA&4Q'PN8@CQPIK['P ;["1>(2F7&?F8&=S'D2>",*I
M,V<;.FEAZ <);;*CWL4(NO?B";>B. "09$/?C9&UL.WS8VS\!'#N@0<B;=]U
MN%Q(9ODS.*(6Q5Y$.@,-F)K6CM8]]9H^QF L @=Y&\ ?,(2)[[K^0WBPSAQA
M.^'<Y8L#Q\,M61^[OG6G-X\G3ZYM;$,>(-1+&8-]S:A2N)<@X/G!C+NY T!]
M].%CJY%.J/SG'<#I6EA.Q-V0P.G)'7:@F&:$6RO94^F>(-DHVTN1SZ*I8,C
M\ N/V#4<R4'HP)-'<0ADA2'[!-SE)7MEB9VU[5)#'CP'%H51V_1'&%L6,2XL
M)OP/(%^$$7;Z!882.6-HM3%HI!O@@H?P"#LOV6KI%GBZW0&(2C-^RJ'E,\]J
MT,.1\+@7U1@=.4 Q/._+P5HBB+CCL6-_-A.!Y7 7^L;9ZN&.0IFRIA!(0LWO
ML2=8>[_&6OO[^]0VAX=L^!YV8:[%4R< @GKX+8FFT*-L66]N*.:1F(UAQ"V$
MKV8;\5 D<%AH(IN.7$=G."AG]O*NMJFK3JZK(7 =PMDS?0%'!?9S/5U9D9\-
M*=]/H8$5W9SZ<0!,6M*/F$R$A4*C#OW4SWY^Z@HMK.K(F93WHX^G-P?]@='Y
M MI ?H$FY9T@O^8Z&CJ/+^@HO@5D92U:H%9A@?(-J*X.H:%; 8\%<EOC"U<@
M^CI>PLBU(B/66'&M:\5EK2TM@!Q18;@UIM&7;ESM^*XE6!/.A45CG@=BYN#!
M#12$#NQ_.#!AX'P^#_Q'9P9SX2[8_FZMO=>&U[R(PY9GX7]BA)N)$!$^',ZY
M!<."4T-.7<3:V_M-=ME@GP&T'X A.CO-&F 6DCP(N!,X\+@\X?49'2A:4F'C
M*9IV=VNMU@J:<'EC0,(0-(0F312P8W[QEK]>ZAV_R/?9;M9:N\WR/I/1)WVS
M[68S%19Z,)3Y @>!-.@K@X< CR)N3>%=E!U@36!:WO%42Y2KWO/'6L,(-=]4
MJ&FO@5"3;(,7"#5OOOJ[[1]Y]7O%U7]R]DD^\BS"1H]@17U",A([ 3"J91):
MHI:$2O8,$?M3I:56KL-D#T\"?Y83]]C<#Y!Y$D@;O.08:;=K^R 5/'F,+.,H
M8G.QEPVD$([4">!H[M!+9&M["<X;J0@NV/)3# F9^? #96?'BET> ,6V"*W
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M>"IF- WCF0$%,>9Q @>1X/Z=@_U_PDB*CHFD,)$4)I+B^^@QZU#NO$]:,9X
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MQ/<C+22PM%(+?5.\G]-GN_N-]F[)N'9VT5-1.JY.M['?636N!KLAKH!%LIP
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M/&0]UV7#.+@5;,3'KL$<@SD&<ZI!.6!.=[MJF/,28_6YSVUF"=<-01W#HLX
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MJ"3\?*DL_/R_'COG8^&RK6OQI[ BQ_>J!D;'_!:=X!$\R"M7S?FK6?Z]T0<
MDSWP0$S].!0%(-JBPI/PK^W<?X.^6]AC)!ZCNN/9PHL..CM%:G)A$]J;;?CV
MW@D=:?0[F#HV- #/__K+7KO9.=1C)GXJ,E]$52L9CRTL/^"(#777\<1!#.,+
M\+>EKZF1@]!W'?NE Y), C\2"BQ7\.!@[$=3168=?H_\V4$'R54;H-G\VS?A
MZVS1Y!ZS8.%$D,S/CMI'ZO\8>_,XA4%%[%BC7?Z<IJ?OF%MWMX$/LU2W?-</
M#GYITG^'VLCR7ZCS&MD I[6N_FZ638#ZR!63Z*#;V$MAH![0.[F/ #'D2W/
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M0?[!.QXEZ'$0).'3)IR!\?4*$Q)>76<O YGLQ)26(LM!D=UN#U1#&JMI)CU
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M8E239]H5+=?+(%]E/M9EP"4,E.E4DV ;2J%FIL6T[QC,2(Y180M-2"ES9<T
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M&1EV9_5(T(;D#):2ZM;)R+_#HJ4BXMJE&VGTH<X 2;H;/0@G@^3D+9<(@EJ
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MLQ43-/'4=^SI56RKH?$EPM7X2C@$,!M2ZT*Y0D+FY AGM@G .24 ]]H$8)L
M7(($X#UPG%E6"!!B?^J*5N46:%2;$^^1JE+P&98E%<$E&4%9*7UT)1>679:"
M'W@93B.!A\CO6^2O>8:D%U1\CO5. >ZX6^]$U30:'\% 'P14UVI ,64,QLR8
M$MEP" 0!CJ0VMNKEMB&6_&89PV/D(X06V-C=Y&+>3KD'K1%%PB[4+&]FD*N"
M0_-BF IMENSI6;+=QR-X*8)S_.!=2E=VFQV;JRC:74QV3,@J)1HR>T!&!^A>
MX=A$"^S(>4&A:0ILT%<$[:,$ 30V[IGC#^C685F!CF"^;X,&+Y6)HX:]/LCV
M)-9UG\WUUA]:&KQ4K/"3,UK%GVH\X1Q.D2;)1]2OEY0#=#H?+D6Q.D'Z) X;
M&D]M)J:$-T6TUFK>05 RJGY$N'8$I\3E+<U >A+9^&!2N%5H3]^3 ZUA/37:
M7R1C2=SA,=6D*()J9X3]+#DV0@YL7 GAU<DW8)98L*_*:YKBLIS33U/=_O2,
M?:Z%4'#C2SN(ZXUG;-WL0:XH_*E0.G;> \7NQO8F;II/. Y.D Y!%]OHZHM%
M5WN>"2!:J[;<C8+=E\:?T\T^3M\PI\J3-&MEZ=S(%#3H,YSXQ1D_W[M-HB+.
ML8=VHG+N&X4C#PKO&PY''TSO(2'W-SUP,\:>=_/F]9_IBSO.#2A+;/[9H?N
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M-"QD1L6<3X9'1[^4K@GW@UL./]"P$KDG#GSFF3AZN%0<:&L!/!EUYT<9[D3
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MPG8NP%REX(*&V8D-_1D8!(WWL@1T_09B+[:E8T0>U0ALS5#E0:)TK(A:-.7
ML@F..*E.UZ,II-6+&<MB:D=/T.PJTYGD+%"34S6[FF7%6"9AF*/*Z5+3,94F
M>7,S4<?X"BC?I5^H)*:MM##):!.Q [&NB\K20..PMT=FGD=F(=@MEU9'5=L%
M67VIK-P0R%XKE^WZF43KRL(:4YN9[74K&Q=\Y@BK37,I<-- 1:"<)VAB5%HT
M[$.X@6^2X:!Z'OEGPEWD,R,6G<5^*[AML)J(:D3IL]J%6RUB&RG+9LZJ=O$
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M)!7ZXY%T*TA1PY:*YH06?#=/+>C1"WWEAL#W0-NP'?65TGG2@,4.\M+]0Z#
MW'+%RPID'&^08NL9<T8%/IP!IR]\DYL7B>$8F4X!&!%*UY?B)V/00ZERX? +
MGH*?%J%OIM8.YGU "I\"7=F <DL$=_)H=9 &HQG?A1@CR,%N=00!/(W)&\+X
M UE,(K.7T)^:\6"5;29=+1V63Z/ D_UX!MX/_ 64*089Z,H3'%U"(+>G%'GP
M/LP5*GQK\R<H672YB4+.B+0%@.+"B7H1PTI(?:[A1Z*W! M,B*WZ DA-)A+P
M%\</8\2@#!\57<0PRO'AR4 JA9A4> -I5SKK]"G]ZD7R%LDI@IR(A/F>T*\&
M,\X6.G,@$+P   3V4]&8-0TV8 ^3O)Z!<FZ!:3!3<!L' I<,QMGA.F9[[G-O
MI)"ZUS[;!9B&.DX:%QT 8)CQ5-,QAA6BE&8#(,GG)0KTB$6&%[J.,,?NCMX<
M^ P4:@@CEJ4F=R5%(PSS 3,*EA+LD4=>F (C>Y&3CF*RPV1 $7-%16 N [8Y
MQ+D@'B+I4IO19E"!4 D$Y04&IV),RJ$7D3P?N*^"*OA]#L@LJJ6W&1<&UT(J
MH9@]ISF*J;=@JGR/4@J.>"4?AY.O@Z27Q^4(4?"4SR?X)8R,8$$(&/$ _A )
M$>=Q #5\40(9!!-)_T%$&'GUIX;_\,I._'J-T%4+?9Z<\V>J?F:R*AMJ11]8
M*]I:T74J RHW@:Y,I4^'772O.M\Z=UUV=7E]V>M>L-O.7>^F>W?_Q^7M6Y?]
M:%Y_;M67-Q=?[WMWEYTK=OWUJG?Y2Z][T[GIL:MNY[Y;S5JE#SIX>CE"?T@6
MK61%8+9":8UAZW:S&+4N^3J8X0.#RI$F"CD#0\ 0\TS$E'-U.T8MQU7VBHG+
MS#Y&$RSMH[&98#Z9.P[,31% "K8!- ,9EXW'PO$&GJ/BEN84M_B087&C%V/X
MQN!4DKW$QS2_:_K%IH.2FV9/97$F'D %R%#PQY"RNV3&L72LK-C/7@#[H"51
M-  $*Z6A>,#^E@9"#MQN-5C[]/1T;N:UCZG2>(RI58P-ZQ2FC/YB;AMCXUDT
MW)R/S-7,*^:1@R5_#ACF"-D DX08 \CBR#0-IKN4[3P?56Q'0E2^A7:NSF?+
M=.E0URZP#H9J$7=4WR'M6&D/NV* D8%=FVU:%]ONE=BV,TA4FEV20D[_&=G/
MI_5&.;J!O3A%XJ$Y $S3]V1MVY]A7U9T85G"2!:Z)4.D_)W]788U7,"<,(F^
M>PZC01%WDC"*<T=EJB/\2-<%9W@QZV5BB(:34H%$44AE5/G,?;2)(DI,D'<J
MF4!^BO2(R51D55?RZGQH%.3*>;8'+5P:,N=OBL0%3%,2B6<RKN=B2&D(*W_$
ME<K\^\#<#H)[9V8'2RQ\%_<W"BGV J+F!NB8_0%F/94\@,\=XZ,7H>]S0,C.
M_YRV6@VPYG<;<X$@81X)L#B%05,DJV%=0 0\"*142S+9A!21@49+IP70B<1
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MOSQN#71PCZHK"UAB]#*9_M*;A/-BE\>G>Q2[5)X;Q;GR"$5V/.#IX)IY2J!
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MP6AI%!.Q((6DCFX)9 IOV5FIQ  &)<++,0>UH.@7RX^S^74GHYZY(5P@CV-
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MX&+U!L#OH+[>JH%Z0<O57HN]Z-JO2GDV9@3[Y]TVZ])4@1SKY-(L<T&M=6E
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MSW<R>PP]]YE&9K_V0W<*/X;)R/_K_P=02P,$%     @ 5'9,5Z-=/=(020
MCHP" !D   !A>71U+3(P,C,P-C,P>&5X,3!D-#DN:'1M[7T)<]I8NNA?T>M[
MYXY=10C@/>GI*MLA:<]-')=-3^[4JU=3!^E@U!$2H\68^^O?MYQS="0$Q@DV
M8*N7Q ;IK-^^_OI_WKSIAD,1NM)S?N]]^>QXD9N-9)@Z;BQ%"I]._'3H]*+Q
M6(3.%QG'?A X9['OW4K':;>:^\UVZZ#9>O/FMU]AK'/U4A2^@R_?MCMO.ZW.
MGM,Z>-<Y>K?7<JZ^.#M_],YWZ?$/7\][_[SJ\KQ7?YQ]OCAW?GGS]NVWO?.W
M;S_T/O 7^\U6V^G%(DS\U(]"$;Q]V[W\Q?EEF*;C=V_?3B:3YF2O&<6W;WO7
M;X?I*-A_&T11(IM>ZOWRVZ_X"?PIA??;KR.9"L<=BCB1Z=]^^:/W\<TQ/)'Z
M:2!_^_6M_IN?[4?>]+=?/?_.2=)I(/_VRTC$MW[X)HW&L)%Q^A[>? M?EYZY
M?S/QO73XKMUJ_>7]6'B>']Z^">0@?7?0/#[./XK]VZ'Y+.*MO8ME(%+_3N+8
MUJAN($7\KA^EP_?E":K>'.OW!E&8OAF(D1],W_VUYX]DXES*B7,=C43XUP9_
M G\G,O8'?WU/3R?^_TH8&K:7ROOTC0C\6Q@<U_J>]_\.OG/P_W:'?\ 9^X49
M)Y+VUH\"#[[LW@_]OI\2J)S\^K8/IS9^@C6Z +(R7K#(CQ?7-SWG]$OW\@/\
MWW-Z7YW/W=.;[M,LY\\L2?W!E#_R0P]6]V[O<+SH%'M#/W$^^G&2.J> @!XA
M81HYGZ5(I+.3XM?_]1_'G4[KO?F>?F^_WW7@NY'P)#[?EXX<#*2+X."(Q(D&
MSHT<IW+4E_%__4?[L/6^W>"_.ZU6I^'TIXX(/7@MG4@9.M]./]_T+LX:SN?F
M5;/A".<#@-9$Q-()_)&/N#T6<1K*.!GZ8V='K>@S#!%$L:<7U* QKSZ>XD!7
M.$Q/WL-B%HW1DZ'(M]1<$YPL!.;K[OE%#P[HZ>#X!P#G5QQ-K\/SDW$@IN_\
M,/!#^:8?1.YW>WPD187!<0RF*#1-:;B?VA;_B@.]"Z-X)(+W]I&JCW[Y[12N
M&K_X3?VE88E!"*CU2'P4_89S$;K-')+<*!Y'L4#J9R#(/)R#(5TW )P? FJD
M0P%\3<:I\$/G/!J-9.SZ(E H=GH;2TE8YRD>YD2Q(_I1ECI_ST*ID.9$84_[
MY.2$P7PH[H"DP\IH2&"E-,@'&$3AWU<WC0SV=0ZL 9P=>"(1(PGH.\6!)" B
M8*% #)=\!"))X.:DUX#U2TT":,D&_6-Y*V+D*V9WXUB._ 2N:\=ZZ4I]:-X#
MZ*"MPK'L';:<:R 9<>(#'3G+$@"?)''.Z0#A^&CR<S^=XH8^Q70WL?!C7S:<
MGHCA@Q3VGX7IM,$WU,#-CR(@'(CLOIL%(@ZFCB<3-_;[="4T)NWDB;#]%6+3
M60F;KK(XR02SD@+\GQ)8$:C"C3(*5 .^ S#O,+A7\Y>_9\&TR%KX:8./!H8=
M/TT<DB=@+)2W",)]0E)@?#9(X%S,$FK@6!5PG"\+')\R@1@]S4'#IB-?X09]
MD,3-8SF]/8LS5SK_W72^P/BW$5!8%B\^ /)+ *4O3>=Z"IK$+;\I 21PX*@/
M1T;$G "*[]W)X-SB'"(:3I+U_P3(P^7JE9)$H=X$L=X91#'H*_!%(GS/F5EI
M#4NK@J4/B]BVND!B: +YJH=W1ES-PG"@'D- ?+B@ 3(9<WV-2I 9PN/Y6/)>
MNAER6">$G=U:\)K+D>VC]TD!M$H -7<!FP,EEU^_ 3_]O7O=_?CUNMM P'9A
M)\"CE>P#&\;]:'X/XG;%/="QX6X'41!$D^3=QNQOV[&@7<*"7S,].ZW3DZX2
M4M^X$=S*N_]HT3_OR]_BAM\1>.)/,U_S0I(H\%$-^2 '/C+3GHQ'R:]OL]^:
M#K/=TR!P7#$&@AC 1@!/\ $GC$"D5:\PN#O)4,"CA)X(/2,I0I >;0H*?P*Y
M=8=JC%I8>PKHZ:P#>KKW8S2F,>W0*H$-1?,I",D(" ?Z-05(*!/BJ![39C]T
M@\QCT$K& @0"-QJ-8WC!PSG%>!Q']_X(A$U0" Y:#=@2J#!A*OH@$";_SM#:
M,)"2Y,&SS ](LSG5I.XB] !28E3<E'9"R_(3 '( =19@G^DDR;:E< ^/$#2I
M5+A#A6C(\N (R3(C2 VBCV$?.Z0W,B[&<B#CF$YN%VFT)6CE5W6#QZC$+'U/
M^FK<[V$T":1W*Q,^"L-]$6^3,4A,2LPJC<?J)=YL0NS9=>4XK7P0EJF6A&-J
M!1)9D4<&R)HDK(HD[*V#)" C>20%  CQE0A"E@Z%G,@M],\L8QD*<1G=D1'2
MV6LUG$ZKW7)V8( AXV^HC23.7AN_;1T^E07P%<+4_CI@Z@PO_QH.  'KW?*
M9=[+(:<LN%J^D8*+Y:B#Y^O0/?SM%_P(W3O,5?CQ/LPM8]QF(,:)?*=_L \6
M+VG()XCN%J!Q*:RFZ,S!PR^Z<O);/FK]!2\YC>%_3T]\)]$&)@(%)/TH3:.1
M>F'_N'EX]!<+_O30[Q3XK08'BD?5[%0:QFW ?<,/E?""<&,6CI5[S)S.G9\
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M,%+B9$DISKN1.XE5/(&.[] A!>STHY@(C$FPPC_096A^/5O.54U!Z *&2[*
MXIP9.2MC'"@&-@]M:51N$,-,ML4=25.] <".LO2=R-+H1_7'@V:GO7D,JN2-
MW!&[CZ+<>\UVYYD9T<K\AZWFX7.OW8JZNA+Q]U=SU$?-D^=>^_Y>\_@O/RQ.
M;@>R]C<>69_:-+\&',Z9Z6L__'5@]4GSX*5CM5MC]1JQ^NRU'_X:L'KON'E4
MQNI:Z7ZA2O?A.I3N:SG(XKZ?#$GO/D6]$\NUV)KVU]#Y(-WJ"@\'5D88Z];C
M.+KS/2N_%E1G4%+5N(5$SSESF_QQS+:;1,[OL!=,8/CH#]*ITQM&64()?*C-
MQHFS\Y\=3O+85?G#9!;H3_7T\*$G,3^8='A,;TOCS$T=?X1+I6QZDX"DM?/W
M>AM>PQE&$PETH<$QQ*7=4HY3&%EI@#B?.8,AQFI5;M+Q!Y@7SSE0 #T.*)AZ
MQ3YG:>AT5+0K.'T1?H^S<>I.<7172J+)F$@=3IV(XMS]$"[U3H:%1QKX#,C#
MUM@^WN= 9$':T .X?NQFHR2EE<E[/X$CF0Q]=]C@ CVXG%N?ZA# :L((B*3$
M=RDW4"2)N.40?=@(C8FN<'@UR@)UXG[*V91J8CNCK' /YGIT::!%1V@BN*W$
M7<Y6C)!LJ6S?/%?@%J:)0RJF$*0JPS&9-<S #3><+ RP0,%$^'=L9)K$?HJO
M F!I&&A@X:#12,(BSN-HXGR Y8C$^1C%J?.-TMQVX"PP)YT!4,I=M6:@$YS>
MCC.;/2/T #V!PXSS!#G[>$QJSC*'0F@0A<&4QAJ+J4[&QSG9PH3,2PVYX^_"
M0N#>&RJ_"O<*,P_@%*@N$J9,P9?J??03^2F>.2(5PY^%94!Z0SIH&E*EE8:2
MM\CWJL!QWN7/(.2.#RODX\(A81V!Z!/X8@H47"?:#@ 4(]<7!>@I'*_)(YF=
M?69&'!EFA6D%;MZ1_\Y@"@"7093!@<H8;>7.SOY?=O6P24;9*7@!?!B-_"0*
MQ >7POM8X8H-T!H:A2E:LQ",[\2P&3_F4B*<U/5X2-8P7 6_E$I,%,0!X@F3
M (W$,S30"435FS&REO)&R=:(!ZY6J\RM)BV,LLJ >@&O[V=Q(C6 XV=C6+5U
M?/.P!4>626HSC$8ARTV3<K-&-QK[DN#/#^\BH(,)7NU;1%<?Q ,1PX;A!1S<
M))WDLQ26ZB>$FE%H\IO&63R.*/'1KC7 "!O+VXA0*A 9E5[Q=QN,%4CA$4[U
M>5Z$>-Q\[GRD%D3@G2'+*#"LD?@N*X]RN;/C_/8\VN80KC^%6R:X5SGU>!8J
M#Q[)FD?U:V#&+"1"M>1]&?CQL)B.A\<RD'[A_O0I= 5,4R)[#PY+R92(B'3L
M?@P"Q\X>2!:>F"9J^07LBD$P(OP2^CAPGECBO:;1K23"2(B-$R@ZJ6K@X=LB
M =K:!QJM0-RS^4N=HK8JT?IH+:(UD2^ /"Z[]G4PD+$M5RL*8Q$]H4@>O#.@
M=R)\A^$GEI1JJ\651"?.6BZL!$35<#WIR6>/2D^VB[W@#N$-.P-YMV&5TC"2
MBBH5H/@H<X"-*#51!=1;B"/DX;*1Y&:15'VCA+FC'6\7""=<44.I-$C42:/Q
MLEB+&[-YN_A40#\-E Y2X@ %P%!((C$K6!5U&N2$& L\A5["C"S^+M.* 5@K
M(Q1BKLN3*YG+C[EH('+V';'A@=KS H]G8JRM..15FZ<Z^Y9YEC<TM[@DN;C;
M[YTKU!([=<3Y2RC:J@GD GIHJ@)&*-)Z3K$ IY*%*#??TF_@1Z  KIN-IT@[
M2%1D5J<5$#$8 ** ])CLSMB>F&F2L<E8?VP]PJX<4B0/1N3+U:E-D+Y>"FOI
MS[ 6N%<6;HJBMR7]6A9$N!E!ZBM B;8^[=BEM5P80Q4AL>4*YY*>-3#'"JD:
M@"=F?1:5D5RJ8L4E4@""W$99;8![P-49CI;D5IH2LRE8"BWVE&3]D9_:S C+
M'#+LDSX/V" 'J/@M8F8E 1)K>UK%5=2QEA5(^T#PF#T98#U.XM"17=8+9"\C
M7Z%)A49FVVW%D<]4UZ5@IM*Y TM/\AM7N#; K>\<@/2@JX%:2I9:W;0 $+9D
MH'>2EW'4AX*B1VYFX%=@=-+(JR3IW*Y9N0FC5)NZ@5XDN>J5.G2D3 /A!VQ*
MA.D#?1^[>)R\Z1GH'A>*(Q;$*R4F5RVV"&<&>+VJ6YXACV@4)+D:C3%93 38
ML@-, &J3"&W=]JPY";;,"\3PZ%M=<F_.Q.:L0E58CPWF\A8>Y-JPMB!&8J I
MY^J46 < "@/["(X@4/5L/8F82,7'U!:<ODC0RIW"F+#I11)A:8*DC%A JMDT
MPI8OE^YGB7O!4M01VCYH&24[ 9>H'6M9E\[7&#!!V0JCD>\R?:E9T.I8D%MB
M0?8=*T1&'"E>I.8!-N(J%0>M=J3F@";BIX2*<:'0%3TTJ&(/K!9/"2_D/5:)
M3F1>NG8&OLB&3_JS'JZ,CBA (CPU"FJ1M23&,2J73!(70D U2M"V"@35C(=+
M9F*6<^8R%6.VJ @8\<Q<@F/N.W=Y#3O&EJYE]FQX:"9BY6,JS68?LA\"14B1
M0# >LCU>;09Y>/5YU.BW.O3S2NB7L]."R4"ZN*6$/GD0%74,]8Q56/,9/X[E
M7>22@57Y04A-4+Q/@92V-0'3.$7=V\M&#(NS['- D=\:GRH1"%=>9ERY1PW-
M[80BC P(H# L>6T&XBZ**7S;EL>4@A1AJ;-%(ET-JZN#55G-*A@*D)X8#U5?
MAG+@6UY5[:2IM./Z@THOO*.\1(0!,P*NGZBP!A"UV&%?CAQ8IP,?/=%C..S(
MTZ^7I>C*DU!PKPF\9YTM?9QR?P)8B Q!$KQEO&=W286D#CH)6\]4Z6;F&G1"
M/'U?NN@TR\L9%P,$X(R!OXK;6(PWJ#CSMN/1\3J<+E_'VJ?9)2@J.%PP<$%1
M>"VPL(G2%?1:KL^6AU&@9AB$SB?R62)A?5HJ10S%%;@"D&[2Z8P4I1Z_C4GE
MSR4I4MW')B2%<:!D/(?9/AN;>6I0K]B&0RW]BK\R.OA.>Q?85S2:&\O5;N&\
M.OV2/]UKY5\?,%/<Z3PTSL'"<3JMY;T[FX"++X6IE;T[MA9O2"8*Q0;R&00;
M!9'\%HTV)4N<UDH  5S];B%O+M<@< BE"K.]#7O3]%%(=P*1&GOP1&*Q?0RS
MJ5TQ3^>*V:M=,:_$%;/3V=\%[1_K1X+LXU-L"N$?1>'8S..S ,#I:G* I9<-
M S'13&(\#GR7-)4"KS'B(K>I:I"]CFP< CAW[NS)HVKF+NFQ<UE&6I#MQF3B
MA$.!-VV7LB%S%".F*9W/!DJD;*$.Y=+FNH:R6_.3+*1BJNM(4)H J)7LDK8E
MC!AT@HD(##,GLPF:< H"+PK5V&($9@F,D/!1^$$6RWDDF0R=Z/GB\U$?4Y5U
MLGWT$PQ!"O4W97/F;"7WDECLC] '3RJ$3<+A6WP1F72)3J/\- ,PH'=PV%-$
MMZ#9!QECS:YR:8=SM@=JYWEW'E@!W:%E>>M/YTZ)@\.1@IJ=T(GB88\Q+WM$
M'IR<-^5QX;@V^Z#S)>ES^V,<A0L QV*1B/TF@$#'*J@.,JK=FB;$N="IX@3S
MD$R&FU1;S]#O)%,*V62U'Y_"=C1Y#6OL[V99P&UKG [0.-YQ58#&;NGZB$!C
M.[B=]O$J<;$6VI[,;SH;,@97:MS;%30#P[KGF!TTE'/T*#UF1^Q,9(#^N79'
M@896\WVX9<_GYAICI).FXH&-)47\1JO9SAX%JI(-6JT@X2V@NY\Z5+!-; +@
M3\@)GZJH:'*,3FT S"T8H$BY6A%:8)50P_ 4^?D\BR$BGV[+[! O!8W*OI^+
M2C*.Z&$ H<$!NWG;B;)N6M+(E6P $#IMP"C*&P^4$S&P9$A6T&5"?F$%9 Y@
M(#=!R1$E&0#I'[&!?"8#  AO_'TV"T#E+>R2E4!B%'2!7#<J>R!0[175^XSR
M'( CQ]IYBMUS3,H.^><+QT><JW1Z5853U.ZU\Q=7?AL!CL)4R-VBG)4YQ58-
MVMPQCP-9XI\P;59=$9J#YJC4.7'=#8XZFK]B?+U18IZ)?X]C'!9CPPW3!."8
M1PXYUCZ/_<Y]V 5AM7S^>"7J&$Q[I(?.A64(CCGAJ'M[IH:5%$*]-T7<]U/5
M=05)KNO"<0@3-U&TU^2T:Q-B<+D8SF^ ; \3*U4I[+!YH.@1$X7+POV&\#Q>
M\,GL!?\HX!,J)B2)(O[X><D3="=1;ED<?6>+C,!G$A(>U:5$L<W=TDED?0,R
M9X1 $&&HD:(R!8#%H#K JJ'*I%0&%F#NC]V=7KZ*F1UE:49JD(H20@A<:E_J
M?6MSFP1$CX"BO>;1L0U%=#DD\%C7T\!]J^1! 4C]9P18!WQ"LX-Y]S2@C->=
M]L%CKZE(2&'R*HJ^B*)4DE?<FXF"H:Q4O94\+= "2<U;^G#NVO<YE%I-L@>M
M6-D,3<S5T=BHE"3,P<[= ).FC'I5,5Q13U**9.5JJSE/\3QJJ^33627W:ZOD
M2[)*/I+P/H+RMFVR"Y*?]-GJ-+"I3!Z8J=ACD:7:<=]*8;03\4HQ(46:84(]
MBWSW02'VR4C)3Y_^W2,.OR0\(15GER?E-1N?D"U2&A([QM[9B@;C/4V!DF.
M2P7=)N&5,M"UG98E$+D1)_=2].-R<%:5&3N//E*-1;%<)>!,0E'BQH_=L/0N
MD5"N.)M/C(4%9:!P2DG/>0J(*16B2A8 :P]DT6PUR+"Z2)0D7)% ([H17?!=
M1.<H8W,EA=U;&A70:%9=:56J>@; 5\ VUDV IY<1]W&RCKB/3ZI%NQWO<1Z%
M9%D,4X0HK<*R81[A@@WMI2A"-M"5N\/;+>%#3Z<G%#W=>9OX/&>? C>>/QWW
M_!'IN TE1ZL<EPQQ6NHD*1 Y?,1O?;PUEJP*2]JM=:#)>332_/146\H*597+
M().L 7H_$/3Z7.MC;)3+JK7KG"0T@'!&TJY&5. T,IU(R[)']4-TE-0DE'%#
MAW$A9GR,^LC2<!9D52*P'S^]Q>A+$_554<]&N_5LO;9RQ;H$]4CXH>%K0"I4
MS+H<#&#<H@VY<CX438TN11V_2Y\A(]4E<T9C&28LAI'T!5=+6RITP<U9_%IJ
M"'2KB-9#QTF7-(H\?^#K$CJ%U)R9$]'$&5 YY*)%;NSWU]76G?;<F E@5XFJ
M'MO*C*FUY',@L!B- S^WT2JO+P]^V&FV.AV-/CUY#Z-=47@$\*CSR-L(5^T+
MH>;M]5#S#+LU(#-/RH&N6@%&#Z<674KHH-RJ84;]-@!,7&N\G*Q1D!Z3)<IH
MX\0>/?XLE@T%J,(L^)O7=<V;&N)6!G&=M8C9IH3>9S$I@YSJP8 T:\1^<PYV
MMN@;E^!36=6J<!@'35=YFP(Q,27\;E+E5R,Z5L/1RN!H;SV4"U3S$*^^2X1E
M>5 "4H,C$KM70#3PXU$A4=]5H\\5KVH+_A-:\ ]J"_ZKL^ S?%Q<.M\N>I?=
MFQOGV^_=Z^[7C]7^<,[<SX)IKJN59 A.>6-D];G,I.(#'E:[@*&F<#JZX$L_
MRK,2FJ9ISIK[J&JD5%7X88ID+& ]^[\\6#Q]_Z39>H9Z_ N#R'&:?F$:Q3GZ
M48 47-_KKV_[O[U[7(^V#=_9_.8N_6+1^$==Z7'SY'C#-\[86;I0NY/$-L+P
MC_#@+0+DG]C>-H+OCVYWRZ'XV^GGF][%&7#3YE6SAM&-AM&KCZ<S%[7EX(=I
M_Z"+HWD\\$=4;AG-/Z&,DZ$_KN%QH^%1*,OOPIO;<@"MN?Q+@MB5</F']KK7
MW-M;_U;/IN^J;VMOB=LZ:!YNP&V=?CDS7J77)Z \#&:;@%$_!V;K7__54,0C
M\5'TF9<!F'T^;VPSWJ^$HF\/C:@%R.VB%\\'GNO?:UD^#GR=PXO!%2*<UG1F
M:^C,18JI<(%T;B70%A%H*E-3F)K"K!<J/RF O"H#9$U3-IRFU+:%FM1L#:EY
M1::3IP7<O?WU[W"NUMY9 A@[M 45Z*""9-KC>X<BL!P=7;/N+=;$]143UR6P
M< /N\*>PL-T\/'K!6/BZN,86"J^78B1UB^\/47;K?'$_88WZ6B.N*>E6[?#'
MJ2X&^FX>R2TE&#><+]PXO::M6T-;T:SS#ZQ">17+!$NYIC51?4E$]57J_G7P
MSTM"TM<:_/,8U&UO .I^4+F-75V;Y'$9%7O[A(@O5LU\18BZ#,#N-X\W8+L_
M#[.(>2\69HD<O:6L,YT&N>I\TQ]<WK.FO?Y$EO#KR9@]K#-FMS9C=F/P8.7T
MT)58#*1$;YZQ0HYSBE4!GFEO,Y?W/!L%GD^%?:A][#-N%W?HCVZ=)';_]HN8
MIMF;3JNSUSK<:]W+^W;+VS]IM=K-/\>WOS@B2/_VRR=L2>&[1CBI+'2A"<_1
M8?-HSY#:@\.]IJ[5^@3<IV:"+X0)'M5,L&:"-1,L,\&SE\X$"QW4-XP%=GZ4
M!1Z#CHX%1+A*2([)BNRT0/=%&C*#D4A><@)]<+!?,\Z:<3[ .(]KQKFUC'/C
MJ+%F.^?K9#N+BM1\^N/T^O2R]T_GZT?G<_?TIFO*\FQ"!:P>EK'2Q;*I;0WA
MZPZ5MU*UA/77IK.NGW!9[NJB5S=RG%8V6F]U&EA,_\/I]>?N99<B"?YY>NGL
M%*>)8C./[D#1EZ$<^-2DH5!8I.$LSM,S0^O:3WKDNAKC@]OB7PG5%E5C/"T5
M8RQ43S-9L WG(G3INCAU#7!YK-#9W)%Y6%]2PR&\HVJ;5+15I(XKXQ3+4.=%
MKQ7 YN6JL9T=%4<&X!%];*[P]RR43N>DX;1/3DZXW>!0W&%-4,$#A2Z_2AX"
M!N*O;AH9$.X<*!C& :B'+=6(Q4JU5!FNCT6[==U':F^L&DEP"Q9=P5O7IJ<5
M&R"/Y:V(J=^4WMQ8=XB ^Z?-".S<T7*NL80_!FXX9UD" )(DSCD=D2X1?:XZ
M6X'DAZ<?"S_V9</IB9BZ-5+UW6E#IR13'>I8%=YULT#$P=0J+ZW&+*ZZ1IQ5
M(<Y9"7&NK%;(!5 _)5CB<N":/%?#N +6$PM8&W-H]-^S8%HDS_QTGK=N>J'X
M:<(=>V$L/PVX*JE/F)FDU5""DUX1VG^^RI%^$8'.V]+6Y'F54':^+)15B@"S
MI*LL"C2<LSASI?/?3><+C'\; 56>FEO-/S+4#H'','K=@$2JRMM1'\Y1F&ZU
MJO@F28(54(:][OM_JL+Y>A\$9*+< 0C[+6 7@;H]R)-!VH=Y@@ W6\<.2\0K
MK0*J,V3#']A05 05+-*.@YCWK;8VY=$,,%OM;NJ;7M5-=Q>)?';!W/GBVUP[
M ;8AO@-ABGH28P5M*JUNDZ+2JX:P4,\)$J, Y8'IC")LF*4:=L''W#49P$=[
ML$Q+<R5L>?0WM?LR.S)=PG@)9?IC5?M6W>%*JP-]1^*25,^76 YDK!IHP[O6
MK@HB80VJJP+5CR50O:CN@S-S:SG9V9D,(R>:A EW0,ZE'H:+78#TA'MX>TOT
MW&+EPX!7\5UN2=S@RM*&A%%#E5C"R2LE1<'M#+%K@*2FP(TX9I)BJW)".S.A
M:DDX\8, G[,67'$,2([S@_ BF=@$N+C%PI(WDNI>?OWF]+#&]\>OU]V&ZE"$
MRE1<Z&*>-UM3'Y0/Q28/K.I16V$ #%1&L9>TNB>[U=KB@]Z$?N0O ]_+36TL
M\8&Z,0!FP*U[9!SE-N"HRP!)OHNP&_TT%T@3Q1RB$1S.6$SUW2MV$'%/&6S5
MQXT<\3?F-DDV2O -*M^>OY%+L<SIN/\5]1!-AX,LH _T?#+&5GS46Z0P)W5D
MIZX0=R@A44]*!E-LX0HLSNPN4;TF[NA=4XS>J&>@$W['=ETT*T_'7(PGVQR\
MW7:0+'>]Z>G+*E[)2  !M[N!(G52Y![ %P@O)N[ Q1F01MDB;R16)DL:9F)N
MX>Y&H/A);IF$)"IU3/\U0[:Y%8G! -UCV$ BMLA%)4K!+Q8N,O//M$(AXYC=
M4M5>(%HMPJG^3A:ZI>LS,/NOW'S=#^4)_7,GM7]N:_USJP7FF@'\/ ,HMZOJ
M51!=U7\:P &Q$=0$0]>15)+M-M<QL4-\%DO\"N1O@6* Z4Q>(*4H=8:ZDY3I
M2DH@G.#;,;9NQ)9XFA/I%TNR"C;<E23;C OF0\W(4N[+2VM-L0<:_@0"-C:F
MKTULJX.D_1(D74::-<+A>W(@LB!U0DF-9)U;'^TH!9YI\6C3^5E=/6N,RN#/
M?6RI(QEJB>99!@MNOFQ@!?D\B*TN3NN/$*! %T+)^E;X(3";O%'Z6X0/]6DN
MF ^B((@FY(P#&$4R#J,3:/-^+/DW-@YA!=9:'\8W%5A7K(YL4:7EY!!>(8O5
M</RT<'PPSX#(Q)#NRU J!&$-7[/0@Y2'[W)Y.-(2)O?B4F/3BS,@:YX=@XKH
M1UEBR:(T]@@?RL9 @:5/%#*'U2>155\WX!P^I-Y/!%"]Q-D1NQ9E9+N:5F$*
M.D_#V>GOZFN$+Y6BW\#[1NV#34-*,T]E M_LN+LYO4$XB)$\Q++ =LL FT,%
M,6+FI4!PV8,+$Z'C'NOX!K)H+MSQEIA-C,<!6=WP20WO^',BW2S&H3U)(B=.
MIHP4^AOXD&AD%%2P_1WYB+WRV_G^2+J85I#BOAQ0V,$LXEFZ+9[YSL">'M7/
MK!]'[""LD6I52'4T%ZG(Y*LP2Q^])$N7O/?AG-#! H0W2U$:Q?WT04JEL)3<
M>0L DF1 B?-1E>A8\/5.V (^3P"=-5;4U[^JZS\NNTB 8%JW1:%^<>RC4E*Z
M2'F/5#(A62]FBRF(3;%4MB9E $*_K<9OO$$FUD" 0%U!<!KK_NXHVY$5=3 #
M'X;+U]>^JFL_J3!+/A1^88S'52X@8([1>"P#\O&"[HJ1:VR$'O@P#H7J)=@2
M>T0V<]-@V\.P/69C09)SF *]\"+-@^\P^DTW::^A865^D]8<*[53'4#+GNR$
M90Y@[5*$2=&$$(I1'D.8$W&Z8WNP]M'[! F+"Y0DBA,K>C+1^NI-Y 3HS!?)
M[)OE.#0EN% O=C*EY/Y]I3J2RP:[<B>9@D\ JP$&N9$98Q!'(Y ^  *MX"(4
M0D91G-ZB=93D?DGB8AH#J)!4E\?H(1G3TE4#I% 0/P&BV=Z'2D@.V"6KR^R>
M&$?8_*-] EHISW&5 C[-H!I;;1L3Z\3*TH2>(Q@K0#;]8-OQJ@AL_%4?AFRH
M;P"]8]@N'8B4^9%(95I@WJ%?:RP\0>49\^-Y<%&C_:K0ONPO+:-](2QS+M(K
M1K$(Y?.!%B%\?;&KNMBRU_&";P5CJU@U%!P" PP8Y/H,]2L4\LF]9]R("ZPM
MEFFY**P5J9%YH:&LC.KBT=^-YNHI168B:5#K82(%:KA6$]#P(GR*5N$74A5+
MA4$Q A1HTIE%"K.%<FH ; "$QR9[L,^!?Y_;T%%&K9W<JX.WLI/CBD4U*QXP
M42&@Z)[&,(P,X^ ^:&-%,IMXD,?8S4W'X)0B8O:F!U(U_.5@H*/0%7PEV0A?
M^<^CPU:CU6HUX3\E=H B!-R[O%+<2.3"9[&L4%,7KW6?UAH6N7/MR'XZ1W:[
M57NRM]:3O;#061G &;U1= %E,Y4&AU/R9JD02S1/^ /*&61D)D1.9M"8&8<6
MCA.@&M-(16O)^[&?!PP2(QV/ ]\E+G0;"Y=D7R09:-_U(Z]1-(":^"Q*JRE:
MIG$T>I,LG; "6B8(W>1?^"[EF&(V"Z(]>J=(4J]YV<IX6=G-6N6P3S(TWTME
MC)A-//#Y@M&R'\M";&XREBZ91P)M.%.0:64^Z*  TGMEK#R8X=1B<Q1V>CNC
M2VY6CE[7Y'I4)J'ABBG0'W6 *9 8Y9(3_0B>F8 &G4IEZ$=B1,OXVR\(,@ 6
M5*C0T'*FB4"N S%.Y#O]@[T=7*JBV$C$$+UA"T42R438)I"SK&WINL/,#G1E
MC-:S5+0OW07=!XVO%+IE,M6_7F.&NE+ZEBB16=CG_@F5LG^^??ZH=//X.M+K
MO<^?V6=]=157M^Y"KFNXVGE;3H&+P FB:71+MKVRZU]/LXVY9+K49>/UH?#<
M;BF%?;9;S<-U<E,CV(CTL;VV"OO8.VEN0+>MN=LL7*VMT>);-95:0;>QPOX/
MFT?/T,]@[FV?>A[Z\^< ]-PZ[\4KW&L>/$-CGPV#V*V"1OVJTH4.FL<'/.Y6
M .DJ+_C'8+NFUC6UKA%A;U,EZ)H#U!!>0W@-X8^_\^-F>YTZY4WOM-?%(J&]
M[O^<WCSVECK-Y^VP1-;QXJ6AR^WH%1J,-Q2\GMZJ6,-<#7,+2=KYUS]4X>/>
MZ36ZEFH(>\ZEUZW@GJYD-D9&QAG%'DW0%^]^#Z-)(+U;RKZF!+>1Q,S\T^P6
M0YS_]2]G7@'LY_5P-P]R8-0^;OJLTLM=#>IY4\2#UCP@=VA4Q_RT:63UD2W:
M<:,_9OEYCH-@$&W]7+S?8WNXO\:[?XPJ^$RG<!FE(IXZ5UD_\%WGC7.3JCZG
M5'6YOMH7NM%J:WZ[TSQ\P)J_09O_OS=2!/_O<6V3]YKS^U\_T[*_3*EM@)]0
M'=DNAH3*Y''-A#N'S>/]3>8H9=!\AL9&KT'R7#)LMFXCM4QT?[N.[M_:Z/Z-
M0807WA;KPTOOQG@>C2GIR^+(IA?0,S=G7!1;??[URY>+FYN+KY?.Z:?K;O=+
M][+GG'5[W[K=RZ=K"/;H99;::YTZ'[J?3[^=7G>=SQ=?+GK=#\[5Z77OLGM]
M\_O%U0:M^_3RPS.NYE']WSY^/</S0P#H7I]?G'[>J/YO"Y?>^_WB!A9^V;L^
M/>^A&=> +NZAU)^KS]6T^S*=8#NLQ6 F EAI?[DN;CB7ZJ! ?+/<1D'WJ)G
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MH26MV:U<,N;X$1)N$0RPEAJBE;.S_Z;]MO.77=/U,DI!?KC6EB^V;BG;ENK
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M9@21 Q9)#V(YXI1@UU\&74.G[(=-;QKZECP$(0M! /#^P'?-?DC$X9;0ML]
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MJX=*K;SM1]X4_AJFH^"W_P]02P,$%     @ 5'9,5Y'35NS\$0  4*<  !D
M  !A>71U+3(P,C,P-C,P>&5X,3!D-3 N:'1M[5U[4QLYMO\J6G;G#JDR?@$)
M&"95QC@3=GD5.)6=/^5NV=9-OU;JQGCK?OA[SI&ZW6XP$ C!GE&J"+@?DHYT
M?N<M^?!O6UO]:,(C3_CL\^#LE/FQEX4B2IFG!$_AZE2F$S:(DX1'[$PH)8.
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MJQ:+I)&W*ZK6QN3I$;T4DP0UJ7(#M7O-3JYK["M&KN"OW$XM3$03IBJ"KA.
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M\SQ"80^(4/ 4G;S@\3USG7GD?)21[$I/QN.3@73A9+5L;3>-$(UKF@@L*82
MY&D?A:+DZ-AKQ'\4(;:QI_=HO\ 6U?\'H6$7<'O], #YJ10_D#N XA<#A1Z(
MLQA)L*/_MJ>=D_XH%XZC/\E'XY3C?$:\+W:ZH>!?=XANG7#OB8\C?>A'1[7&
M7LH^=&B.78K?J4144)49^*\O:-;G<?#D[=CW*P;JM/F(; C_)U L"(<1ANJ\
MN722>OQ;GL><W(I05HYRG,(/8L5]GB0:*45/HH5=B2@@7G-XG7RLR$.&@OMH
M^,B$EKRMG3Q.J9R. W3'&UFZFIC86 ],O!?D884OEHN"42KYA2(::?/_A7$$
M8*Q#E,.I+JSZ20EM95,C* : CUU2!+3O&-2&QO&>S6YJ[!-,#UP9?<E6SI!M
M:2/KGFTO.: E6T<U#*<D70/FPBG!!14MUPW;JA_.<!J@Z+W@H3=@L\]-TVQ:
M]7IC^C15N*Q&92X+U20.X [KGCS&_:;5.)I^C%53?5->,4U9(E*-0<ZIM8#P
M'5FV]'5$E#:X3E"&_Q;?' %#4*:""O?!9SW)20]!U<]-%.@""XMB^(7BK@QM
MRI"S2)J*D;9:0-C^G[S5@U:9DB1EB9BZ1KWV$AE 2UYFA3M65CCMYYD L^^F
M-,7-O$UH[P)7_&4$NW[DR)W@@*:=EI6>KA+"HB0,!5G4HP1$-^.]Y XP/Q=S
M5]35XU!*QLO;?T@V0YM2?Y"S10VXBXY3&:89+IH_S0*RE*'IA4G@6H&'Z(?O
M(9%#D8[P%(7.((II$1HP<)R9H+&\BWA(NO_,;3F"A48][N3M-4"_8^'WR<I2
M$'WO>,C[(&@-6-U6#\.1&%.SE7/V[S,7U&6F< C'1.,S>X!UQ9^Y]"QV?=T&
M>O_#X)X.-!%/3^LGT$$S.5T;1AT8VEYP>5L*(N&TLP=> @\;\_#0*GKT%<1W
M41T10R7CI.[EC'X8SI1"Y:6R@+JY4YXUO670Y,>W-CV*<-K:*3NA2/R,Z]Z:
MMB/:Q31*^2P//#Z<R0,MPL@T(+"7>(5(0(#T9\RMKRB?M^*8.P-RR[30DDM:
M8QS4-MD,2]<0F^NA(:)]9JFZ8><9ZXFF)8I#(Y;>!(]*2&K:*"75[0I$PUS@
MZI1[8Y*PO[V:L+$X59.>[*T'/3E#L?H>&!KWEDI62+UX3JNS0!3PXP'( 6;)
M*,^/^)BPI. ?_!GU>9V1+H<,[SZ6P7_I&,G7 R-+(O12L?(R57]GVEKB06AT
M=%(11Z$,2KK#-'7F\P0RHZHP384 )']?/[:.#@YK>_LS%C8Y TO\6'KL,Q]K
M \V>Q7*T[KG9>!?MU#EY)Q2DH$U9])R!7HHFO8R9H>#!;M3KM</4]J"C17;2
M#TO6!_QWJ!:TOWN\:^^Q';:WV[1W[>,"9+HR&@$E.I$^^?2[7N!\U>A\N%]K
MU/66Z"3>UP^L?7N_=GCT@H:4E]EA?==NP@[K==QBW5YXB_;$%H^LP\.]VG']
M52)6?C""H\K\[=6UU&HSN.XZ,;A&%1G<%#[R/(/KR5X\8-SW*1.6AV/\-!1!
M;Q%FT2CPN$;=.F@V:_7#9\R#D],5?"%SEE_2?)4E[[N7V;0.[48-N/%&<5T]
M$N.L$XFI5X+$S$>P>H6%QK6.D&UL8EZ7$/.:>[.P "6@,[J[W]_A1R9 =B'^
MH6  ::(^>5R,<I665(>\+J$V.L$F>!('ALS6F@>_37*"$KU6UZO?.3BJU?=^
MRTOS)3K\"MK"L=%L[-TF_+JGH+O(#IY;=+->.]I_XT6_;QQ9QTV[9MO9:HD4
M5ONL07FL*T59'_;^2AQV<]^J-PY N%O!P][/Z^PK<=@'UOYQL]9LE@X[9?*O
MP\9_D',O(])E:EHE90.!]B6^"2>)5>2!*SQ4B!AG0S$,L-90,L3 %Q7"HY+5
M!IAC%"<@?+D4,(+OA4H:"^F# ".2*%1)/Q!B2(0*91-N]5W\O[Q';G\]=)?;
M$67/ >2"OB[\2"PW':,0T]<5%)^I@^:RXJ/UP].(/0P09;  WL0.Z''! ;=&
M@(VY2#430:6]?WPT\@!.<(:2(0-'(.S4(UAYU]\H#!ZE6ZX15MC!PLLL5?&X
MX^%75; BC3H#)2VC"RJK>X11CCJ,*0ABG=K='3,@X=)- R;]A&(A,,:I6%.D
M<!);&#*5'4-Z8-JNM(VC4BP8Q50].V1Y%S!PN@D5O&%F>7U_CZ'E HC.D CL
M=]Q+Q93B^6S,SKC8?/]!;CA4/PH>BTP-GC;<6Q""+;YMSIQ^E,!J4?_(WE'M
M:"_O'VD<UX[MWY8F7:S\O71+]Y+B]L(.JV;^-O8/:GO'R[N-4OS'*Y.0-]SD
MAA+,IP1[^Z %;2A!12C!T7[M8.^WRNL[OWY(\\%Z*#SW. ]2;57&\5[TDFA9
MT8BKZ=-<\[B)N8&!;PU&5SWF)F&J]JG4-0S<3W-LFQ.E.]'Q]\BE9W1K538)
M]<Y,[$%O5:3;N, #<:PT/TD>#)4/QS&E*U2-1\;,">!X*6G2\U*-6T01/(TL
M6R7=;2% *CG+&U>@_'R'UG]'ZZ=B%,L.T%<Y3#Z%6N0R&9>?R% @E]7(>2;X
M\3.055:CS#SK!X#LN1K7E3O%&UK@LH\10*VG$!<3HE59<#BG*1>>.\JL>N4$
M"E7@F.]O+^^K@<^Y(A=)E)H,@?YFN;$'+/!36D@IE]-(,Y:6B50E[5EW X/Z
M0J+A[B3M9B.W@8:8_%VD*N1?UKG/*>7&W'?Q35=@R!+>R=XV)6M7I9J256]:
M';Y1*!YED$3>F/6QT![L.9NT1^M6>&FIHM01FAO5$_@),)?")\$(AXT,:%K,
ME(.;.9,%,X1L2Q:W'PI?/,%I=<=4(+^8]0N\$C8@@.EC><&!H E@$"S_0V0X
M?7NRAJ9:H9FAF *-,WEI8<-G#W9%A<'U#G";&T/[UO1&4V=L_2,\#?C/D_2,
MD&=$DWP)BHVJYD.:DU: L*M*"J(JK!/+Y:;B!U)#0/E]UDW;TTPK:J!OB,I4
M/HIHRKVHK:6, Z1[I.-F%C> EY LZ1'4U16/)5T*?E5<#OJ.9."RE#[JA\KO
MZT42"*G9?@B.M("6U</(DOZ?.*[=="J9/W[.*S_@N"930E:SEW0!1>::'B-L
M# _%%'8I%1H=!$_B$9-N9&_*4=,N3 B 7FCJO9NV6)RJ"JZCM8ZG;&[B*7^%
MSL+/F=1U%A5*MCE+A*5I@7 "/QA*1]L>@&10?0^0HH%*_\9<B7H/)0,J1W0
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MK^P2/C:\RULQ3"^_H/M/U957&1[2>S:V"2<885URT]D'!W;G'55NHE>JVKT
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M2MWK4=F_3. 8CD]6P%#TT"NAY+DH<0:F<:P*E5/=7\D4$?.OPL_,A!O 7T7
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MKOK+3J[Z"V:8I1A"(?$(0)YGW).I'U5'%2BWH-8W8?2(RVEH;8+'+C@<VRB
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ML(9+=2:K+9C6E:H.#+Z"6L,=C#YE&]7R)J-R'U0GR!7>.#']5.8"RBFP]D@
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MOBK3G:1*+:O#DEV["V*=#)S/Z]#4"7F1^2__P<7R:68M>.\_H4=I='P\QM]
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M"[MI_5RLVK.;MUU*LUKFR/?RCA "+_:+\URX^U\M:AZ&RCHP/70B*,&#<E5
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MF-M2=:]8JJY2MK7JEM>J^_G"=+>AI_G[HKITV]VP-X4?PV3D?_H_4$L#!!0
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MV%R^^MH%=I(C@PY0L 1H9JN@_4)& &F6M<?W>9 O0_10S&+AXXW81+:^T=J
M=I:&T+=(?D( $\Z4[<C=XLS32XO= 3HP<3_C>G4A((;C)2AZ%.[+HP;=EWA
M6M9??77F;\ V_H4#+]#X;[@:H9?B'8MGLB-A2>^CQ!'L'W7V"5K?A,"NS-D=
M;":(W+C/+IM$H<]0^/H DX4=F5NR4^'F*L@_WWK<3&5'IA+'$<( KF:<#'F'
M8TXQ. '(CNAM=?!KM[7[\QQ\2I4G200'&ZVCSL!8<*:F803D4$0^&W,%]"!/
M(GD Y G>27\UK<YH\R'1YH,-Z-=0@/CAEHAS!7ZK#O?BEP2_E<S!:"HC=S7
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MIV1JP=\67E.?IRKT)*)6A\]D#"/_GW")&JFW^\F[5/YJ>QYS<A^@UE[EH*Y
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M98%S2R%1JE2;>_F$:[1UQ4$%JB18&-AF"X,^6U' 3<2 _-QG7)<W;(-83-(
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M3]ZB:<3CC'Q:3?_D[VTT5,+5CO^H?O.UY+AB^+' .XW@N2065@#[1]!J ]!
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M,S V,S!X97@Q,&0U-"YH=&WM/6M3VTBV?Z4O.W,'JH3Q"TP@DRH"SH2MA%!
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MX;&I$H$ <I+$B@%P2>1"(M%TV8"C1\3G$@2/"7_#H>5YY#?N:Z@IG,>(I0&
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M@L-SLPA4#J2=JOF%!3'-!A49Y(H+ZL#1QJAS+[$W.X] )M.0SX]D%,*.[@Z
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M#)D+C@(P'JQPM^F<3*J=I5/5<Q?:=!J"3&* %MO!Z%ACP-:<J(%V74![\!A
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MR,:!:#+298$1-T<H+,1 9?""'D;5UM%UZM9>U18NS1!"/CLNBK$2\2.CAET
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M^\,L3E2DD\4L5H/@@T[38I5<JS16,"5T+.%5I6M=E*:FDB#]T2JW/(&,VT1
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M0:URCS5)&3?/)!))X:%8T_G=1DZEB=_,36X/*A5J,H$-PD1N^AD8 W$6>DC
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MC84*"#,/ECN/@7.OK!%/[H>;X\083L562M6(<CPX\9\$CI<13A.F$N52J3G
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MIK)TESYXI4-5-5UE3=L[[XJUM8^[WB'=1Q$SD9BYS:S_/59$%PN[?GOG&<8
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M6&3N[;J;T]Y0K%N2BN-486Q #,< EI!BKTTNM.W%QD]..9O9)6M2F123[%V
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MV2)Y ZE[LA Q<'PL#8-C*69T *ZN^EN'0&>R%$X@QQ4 5 #P<@"P=A  !D'
MYG$$1C[D,VFD.!55PL @\/2MPX$AGD,$*Q2H4.#E*-#80108XUG((097T%65
M-^,$9Q"P=0A050(5!KP> YJ[B %Q&%*<OIIP&0>BJ@"J[-_1[&_M8/;+=5-
M,.*R!QC#N9P\ GT:N]M9!50H4*' :U'@< =18(A9M/9SX%96 =4NH$* UR/
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M4!K;)A9/X>8L#W!+^4;UU1[U8<427?4_++G8JQF@_0XI%[7I694Q$%8Y^^W
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MC!+/VV;8(+B!S. ?@F!&QKP C"#<;C'1!?B".%2K5CTO(++ECIKP(A$51C;
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M$;D 8A[#MM'KNPLQBTM@S^C0+[V>CUW!9W26=9K2/P&(+[M<&P!N +@!X :
M&P"^XHR.Y]%7@JK.,IL4N[PA0 -Y2MZ$]N=UIQ'HX/ZE[PVT?H#85L,0CW6^
M,08_R]-7@#/>Q+X? :#K@\$'7GTB6Y?N4@H5]RNW5^"T.7ET:?2Z+$PKL\\6
M!XHQ3:XG2E9%BL>A4D5-9&B]TKA<49^:X#M[@A?,JY^;6-)^E7+I;'2I:/&.
M9DDGS'/G*W1LF(KH5/*T!LC^OM_?640P5Q;:DW[W[J=]F?3P?U!+ P04
M" !4=DQ7<^: =,\(  "#-@  &    &%Y='4M,C R,S V,S!X97@S,60R+FAT
M;>U;;6_;.!+^*[P4MTT R_)+TF;M-$#>BLW=I@FZ+@[[D9+&%A%*U)*4'>^O
MOQE2LN7$;9/>IO7F7*!)1 [)&?*9X3,4=?2/(+C(4Y['D+!?1E>_LD3%90:Y
M9;$&;K%T)FS*1JHH>,ZN0&LA)3O5(ID 8]U.>[_=[1RT.T%P?(1]G56-5#[
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MNH?@_A2"V,VZ8<DU'<0=>KU7K8@V2+W;^^XJ@XI2%^@\QK&Q.$98.P4<O9]
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M_[(2TJHK(=6HA#PU0-2ED?K N"Z-O'Z7UZ61NC12ET8JOW.I#PGK37--O6H
MJZE7=4@U]>K2R--*(^6A3<VE*H2QIQY>O-H2R1T]Z\I(-2CZ2E;:[U=&1ILC
MST<J(U\*U6GHG;SO>3R-)(*H3NGD"3O\8'.DZ!+O>B$0DZ\.1+FPREBQ]8#;
M?4%Q>J)VWB&+J%;\+Z/+]H-U]TY'[S5MGMB+R8)J^3D+F4LJ+'+#F5\PJ-O5
M6X>;F):WF0J^D3\)F#U:>/(O4$L! A0#%     @ 5'9,5^]5*SI#+@  .E("
M !$              ( !     &%Y='4M,C R,S V,S N>'-D4$L! A0#%
M  @ 5'9,5Q2\?%-L&P  9+@! !4              ( !<BX  &%Y='4M,C R
M,S V,S!?8V%L+GAM;%!+ 0(4 Q0    ( %1V3%<V-RHT!6\  (;_!P 5
M          "  1%*  !A>71U+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4
M" !4=DQ7(S'4)4_>   _8Q  %0              @ %)N0  87ET=2TR,#(S
M,#8S,%]L86(N>&UL4$L! A0#%     @ 5'9,5V^] &A5N   2H,. !4
M         ( !RY<! &%Y='4M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    (
M %1V3%<U,^&?4&<% "F//0 5              "  5-0 @!A>71U+3(P,C,P
M-C,P>#$P:RYH=&U02P$"% ,4    " !4=DQ7:_!S?J@-  !##@  &
M        @ '6MP< 87ET=2TR,#(S,#8S,'@Q,&LP,#$N:G!G4$L! A0#%
M  @ 5'9,5Z#W18F ,P  -R@! !D              ( !M,4' &%Y='4M,C R
M,S V,S!X97@Q,&0T-2YH=&U02P$"% ,4    " !4=DQ7Z*ZI"/0^   X>0$
M&0              @ %K^0< 87ET=2TR,#(S,#8S,'AE>#$P9#0V+FAT;5!+
M 0(4 Q0    ( %1V3%?,N:KN>3H  )V* @ 9              "  98X" !A
M>71U+3(P,C,P-C,P>&5X,3!D-#<N:'1M4$L! A0#%     @ 5'9,5P!%A'K8
MK@  $D4' !D              ( !1G,( &%Y='4M,C R,S V,S!X97@Q,&0T
M."YH=&U02P$"% ,4    " !4=DQ7HUT]TA!)  ".C ( &0
M@ %5(@D 87ET=2TR,#(S,#8S,'AE>#$P9#0Y+FAT;5!+ 0(4 Q0    ( %1V
M3%>1TU;L_!$  %"G   9              "  9QK"0!A>71U+3(P,C,P-C,P
M>&5X,3!D-3 N:'1M4$L! A0#%     @ 5'9,5P/^Z@NT)P  BV$! !D
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M9#4U+FAT;5!+ 0(4 Q0    ( %1V3%>+N4/B" 4  /TV   8
M  "  15?"@!A>71U+3(P,C,P-C,P>&5X,C%D,2YH=&U02P$"% ,4    " !4
M=DQ72PRNL@H$   A"@  &               @ %39 H 87ET=2TR,#(S,#8S
M,'AE>#(S9#$N:'1M4$L! A0#%     @ 5'9,5[R T2>' P  @0@  !@
M         ( !DV@* &%Y='4M,C R,S V,S!X97@R,V0R+FAT;5!+ 0(4 Q0
M   ( %1V3%=B_)"<'PD  "([   8              "  5!L"@!A>71U+3(P
M,C,P-C,P>&5X,S%D,2YH=&U02P$"% ,4    " !4=DQ7<^: =,\(  "#-@
M&               @ &E=0H 87ET=2TR,#(S,#8S,'AE>#,Q9#(N:'1M4$L!
M A0#%     @ 5'9,5^C#NGK0!0  ,#D  !@              ( !JGX* &%Y
L='4M,C R,S V,S!X97@S,F0Q+FAT;5!+!08     &  8 (4&  "PA H    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
